FN Clarivate Analytics Web of Science
VR 1.0
PT B
AU Pan, J
   Karlen, C
   Ulfvin, C
AF Pan, J
   Karlen, C
   Ulfvin, C
BE Kelley, RG
   Frankel, GS
   Natishan, PM
   Newman, RC
TI Electrochemical study of resistance against localized corrosion of
   stainless steels for biomaterial application
SO PROCEEDINGS OF THE SYMPOSIUM ON CRITICAL FACTORS IN LOCALIZED CORROSION
   III: A SYMPOSIUM IN HONOR OF THE 70TH BIRTHDAY OF JEROME KRUGER
SE ELECTROCHEMICAL SOCIETY SERIES
LA English
DT Proceedings Paper
CT Critical Factors in Localized Corrosion III - A Symposium in Honor of
   Jerome Kurgers 70th Birthday
CY NOV   01, 1998
CL BOSTON, MA
ID OSTEOSYNTHESIS DEVICES; NITROGEN; PASSIVATION; FILMS
AB The resistance of Sandvik Bioline High-N and 316 LVM against localized corrosion was investigated by electrochemical methods including cyclic potentiodynamic polarization and potentiostatic polarization measurements in a phosphate-buffered saline solution and a simulated crevice solution. The measurements were also performed for SAF 2507 (a high-performance duplex stainless steel) for comparison. High-N is a higher alloyed austenitic stainless steel compared to 316 LVM, the results demonstrate that High-N has a high resistance to pitting initiation and strong tendency for repassivation. Its localized corrosion resistance is even slightly better than that of SAF 2507. While 316 LVM may have a risk for crevice corrosion in implant applications, the risk seems to be negligible for High-N. Considering the fact that also the mechanical properties are superior to 316 LVM, High-N is believed to be an excellent implant material. It seems that the stable Z-phase, enriched in nitrogen and niobium does not have a negative effect on the localized corrosion resistance of High-N.
C1 Royal Inst Technol, Dept Mat Sci & Engn, S-10044 Stockholm, Sweden.
RP Pan, J (reprint author), Royal Inst Technol, Dept Mat Sci & Engn, Drottning Kristinas Vag 51, S-10044 Stockholm, Sweden.
CR Baroux Bernard, 1995, CORROSION MECH THEOR, P265
   BLACK J, 1994, ELECTROCHEMICAL SOC, P35
   CIGADA A, 1989, J BIOMED MATER RES, V23, P1087, DOI 10.1002/jbm.820230908
   CLAYTON CR, 1995, MAT SCI ENG A-STRUCT, V198, P135, DOI 10.1016/0921-5093(95)80068-6
   CLAYTON CR, 1995, CORROSION MECH THEOR, P175
   Fraker A. C., 1987, METALS HDB, V13, P1324
   GREENE ND, 1985, STP, V859, P5
   Halada GP, 1996, CORROSION, V52, P36, DOI 10.5006/1.3292093
   *INT ORG STAND, 1992, 58321 ISO INT ORG ST
   *ISO, 1992, 58329 ISO INT ORG ST
   JONES DA, 1992, PRINCIPLES PREVENTIO, P198
   KOHN DH, 1992, MAT SCI TECHNOLOGY, V14, P29
   Kruger J., 1979, ASTM SPEC TECH PUBL, P107
   MATTSSON E, 1978, BRIT CORROS J, V13, P5, DOI 10.1179/000705978798358626
   Nielsen K., 1987, British Corrosion Journal, V22, P272
   OLDFIELD JW, 1978, BRIT CORROS J, V13, P104, DOI 10.1179/000705978798276258
   Olefjord I, 1996, CORROS SCI, V38, P1203, DOI 10.1016/0010-938X(96)00018-2
   Ornhagen C, 1996, J BIOMED MATER RES, V31, P97, DOI 10.1002/(SICI)1097-4636(199605)31:1<97::AID-JBM12>3.0.CO;2-J
   ORNHAGEN C, 1995, THESIS AB SANDVIK ST
   SHREIR LL, 1994, CORROSION METAL ENV, V1, P164
   SIVAKUMAR M, 1994, J MATER ENG PERFORM, V3, P744, DOI 10.1007/BF02818375
   Wegrelius L, 1995, MATER SCI FORUM, V185-, P347, DOI 10.4028/www.scientific.net/MSF.185-188.347
   WILLIAMS DF, 1976, ANNU REV MATER SCI, V6, P237, DOI 10.1146/annurev.ms.06.080176.001321
NR 23
TC 1
Z9 1
U1 0
U2 2
PU ELECTROCHEMICAL SOCIETY INC
PI PENNINGTON
PA 65 S MAIN ST, PENNINGTON, NJ 08534-2839 USA
BN 1-56677-211-7
J9 ELEC SOC S
PY 1999
VL 98
IS 17
BP 383
EP 394
PG 8
WC Electrochemistry; Materials Science, Multidisciplinary; Metallurgy &
   Metallurgical Engineering
SC Electrochemistry; Materials Science; Metallurgy & Metallurgical
   Engineering
GA BM76C
UT WOS:000079705400036
DA 2018-10-19
ER

PT J
AU Pletnev, MA
   Dorfman, AM
   Povstugar, VI
   Mikhailik, OM
   Lyakhovich, AM
AF Pletnev, MA
   Dorfman, AM
   Povstugar, VI
   Mikhailik, OM
   Lyakhovich, AM
TI Determination of the corrosion resistance of finely dispersed materials
   based on metallic iron
SO PROTECTION OF METALS
LA English
DT Article
ID SURFACE-STRUCTURE; POWDERS
AB A method to determine the corrosion resistance of materials based on finely dispersed iron, including those with modifying coatings, is suggested. The method is implemented by measuring the difference in the volumes of hydrogen (equivalent to the masses of non-oxidized metal) evolved upon the acid dissolution of the control and exposed specimens of the material. The method was used to study the corrosion mechanism of a magnetic biomaterial, namely, finely dispersed iron powder with surface oxides modified by a copolymer of oleic acid with oxygen, in stagnant and laminarly flowing physiological solutions at 37.0 +/- 0.2 degrees C.
C1 Udmurt State Univ, Izhevsk 426037, Russia.
   Russian Acad Sci, Inst Physicotech, Ural Div, Izhevsk 42600, Russia.
   Ukrainian Acad Sci, SONAR, UA-252601 Kiev, Ukraine.
RP Pletnev, MA (reprint author), Udmurt State Univ, Ul Krasnogeroyskaya 71, Izhevsk 426037, Russia.
OI Pletnev, Mikhail/0000-0003-3275-2699
CR AKIMOV GV, 1946, OSNOVY UCHENIYA KORR
   BABKO AK, 1968, PHYSICOCHEMICAL METH
   Karyakina M.I., 1988, ISPYTANIE LAKOKRASOC
   MAOZ R, 1988, J CHIM PHYS PHYS CHI, V85, P1060
   MIKHAILIK OM, 1991, COLLOID SURFACE, V52, P315, DOI 10.1016/0166-6622(91)80024-I
   MIKHAILIK OM, 1991, COLLOID SURFACE, V52, P331, DOI 10.1016/0166-6622(91)80026-K
   MIKHAILIK OM, 1988, ZH PRIKL KHIM, P2414
   NATANSON EM, 1959, KOLLOIDNYE METALLY
   RESHETNIKOV SM, 1987, ZASHCH MET, V23, P499
   Rozenfel'd I.L., 1969, KORROZIYA ZASHCHITA
   Rozenfeld I. L., 1966, USKORENNYE METODY KO
   SUKHOVICH EP, 1983, IZV AKAD NAUK LATV S, P63
   TAPEROVA AA, 1976, LAB PRAKTIKUM OBSHCH, P31
   1997, SCI CLIN APPL MAGNET
   1983, FIZICHESKII ENTSIKLO, P343
NR 15
TC 0
Z9 0
U1 0
U2 1
PU MAIK NAUKA/INTERPERIODICA
PI NEW YORK
PA C/O PLENUM/CONSULTANTS BUREAU 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0033-1732
J9 PROT MET+
JI Protect. Met.
PD JAN-FEB
PY 1999
VL 35
IS 1
BP 32
EP 35
PG 4
WC Metallurgy & Metallurgical Engineering
SC Metallurgy & Metallurgical Engineering
GA 169XE
UT WOS:000078774100007
DA 2018-10-19
ER

PT J
AU Duconseille, E
   Cressant, A
   Kelche, C
   Woerly, S
   Will, B
   Poucet, B
   Cassel, JC
AF Duconseille, E
   Cressant, A
   Kelche, C
   Woerly, S
   Will, B
   Poucet, B
   Cassel, JC
TI Homotopic septal grafts combined with a hydrogel bridge promote
   functional recovery in rats with fimbria-fornix lesions: A unit
   recording study
SO RESTORATIVE NEUROLOGY AND NEUROSCIENCE
LA English
DT Article
DE biomaterial; hippocampus; intraseptal grafts; place cells; regeneration;
   septo-hippocampal system; theta rhythm; polymer
ID SUBCORTICALLY DENERVATED HIPPOCAMPUS; COMPLEX-SPIKE CELLS; CHOLINERGIC
   NEURONS; PLACE CELLS; INTRAHIPPOCAMPAL GRAFTS; THETA-RHYTHM; PATHWAYS;
   TRANSPLANTATION; BUNDLE; FIELDS
AB Fimbria-fornix lesions abolish the hippocampal electrophysiological activity time-locked to the theta rhythm and alter some functional characteristics of place cells. The present experiment investigated whether homotopic grafts of fetal septal cells can alleviate some of these alterations when combined with a polymeric hydrogel bridging a fimbria-fornix lesion-cavity. Eleven months after grafting surgery, unit recordings were obtained from hippocampal neurons of seven rats [two sham-operated (S), two lesion-only (L) and three grafted (G)] while they explored a radial maze. The lesions induced dramatic loss of hippocampal acetylcholinesterase(AChE)-positive reaction products. Surviving grafts were found in the three grafted rats and several AChE-positive processes could be observed in the polymeric hydrogel, as well as in the most dorsal portion of the hippocampal parenchyma. Of 168 recorded units, 132 were hippocampal interneurons (i.e., fired rapidly everywhere in the maze), and 36 were pyramidal place cells (i.e., fired only when the rat was in a specific location in the maze, the place field). The overall firing characteristics of either cell type were similar in S, L and G rats. However, while none of the interneurons recorded from L rats was found to fire rhythmically, a significant proportion of interneurons recorded from S and G rats had an activity pattern time-locked to the theta rhythm [S: 16/19 (84 %); G : 22/70 (31 %)]. In addition, the increase in firing activity observed in interneurons recorded from S rats when they were moving was disrupted in cells from L rats, but partially restored in cells from G rats. Concerning place cells, most (93 %) place fields in S rats were stable relative to extra-maze cues when the radial maze was rotated, while they followed the maze rotation in both L and G rats. Because of the low number of rats used, the present results should be considered with caution. Nevertheless, they indicate graft-induced recovery of some properties of hippocampal function following fimbria-fornix damage, and suggest that homotopic transplants of projection neurons may foster some functional recovery when provided with a biomaterial allowing the host or grafted neurons to cross the lesion cavity.
C1 Univ Strasbourg, CNRS, UMR 7521, Lab Neurosci Comportementales & Cognit, F-6700 Strasbourg, France.
   CNRS, Ctr Rech Neurosci Cognit, Marseille, France.
   Organogel Canada Ltee, Quebec City, PQ, Canada.
RP Cassel, JC (reprint author), Univ Strasbourg, CNRS, UMR 7521, Lab Neurosci Comportementales & Cognit, 12 Rue Goethe, F-6700 Strasbourg, France.
EM christophe.cassel@psycho-ulp.u.strasbg.fr
RI Cressant, Arnaud/S-9527-2018; Poucet, Bruno/B-4019-2010
OI Poucet, Bruno/0000-0003-2704-804X
CR BASSANT MH, 1995, NEURODEGENERATION, V4, P61, DOI 10.1006/neur.1995.0007
   BEGOVAC PC, 1990, J CELL BIOL, V110, P461, DOI 10.1083/jcb.110.2.461
   BEST PJ, 1989, PSYCHOBIOLOGY, V17, P230
   Bland BH, 1996, EXP NEUROL, V138, P286, DOI 10.1006/exnr.1996.0067
   BUZSAKI G, 1987, NEUROSCIENCE, V22, P871, DOI 10.1016/0306-4522(87)92966-6
   BUZSAKI G, 1992, RESTOR NEUROL NEUROS, V4, P369, DOI 10.3233/RNN-1992-4602
   BUZSAKI G, 1987, BRAIN RES, V400, P334, DOI 10.1016/0006-8993(87)90632-9
   CASSEL JC, 1991, RESTOR NEUROL NEUROS, V3, P55, DOI 10.3233/RNN-1991-3202
   Cassel JC, 1997, PROG NEUROBIOL, V51, P663, DOI 10.1016/S0301-0082(97)00009-9
   Cressant A, 1997, J NEUROSCI, V17, P2531
   Duconseille E, 1998, RESTOR NEUROL NEUROS, V13, P193
   Dunnett S B, 1989, Restor Neurol Neurosci, V1, P83, DOI 10.3233/RNN-1989-1109
   FOX SE, 1981, EXP BRAIN RES, V41, P399
   GRAY JA, 1983, NEUROSCI BIOBEHAV R, V7, P119, DOI 10.1016/0149-7634(83)90014-3
   GREEN JD, 1954, J NEUROPHYSIOL, V17, P533
   Hofferer E, 1996, BEHAV BRAIN RES, V74, P175, DOI 10.1016/0166-4328(95)00158-1
   Hofferer E, 1996, EXP BRAIN RES, V111, P187
   JUNG MW, 1993, HIPPOCAMPUS, V3, P165, DOI 10.1002/hipo.450030209
   KOELLE GB, 1954, J COMP NEUROL, V100, P211, DOI 10.1002/cne.901000108
   KUBIE JL, 1984, PHYSIOL BEHAV, V32, P115, DOI 10.1016/0031-9384(84)90080-5
   LEE MG, 1994, NEUROSCIENCE, V62, P1033, DOI 10.1016/0306-4522(94)90341-7
   MCNAUGHTON BL, 1989, EXP BRAIN RES, V76, P485, DOI 10.1007/BF00248904
   MILLER VM, 1980, BRAIN RES, V194, P311, DOI 10.1016/0006-8993(80)91214-7
   Muller RU, 1996, CURR OPIN NEUROBIOL, V6, P196, DOI 10.1016/S0959-4388(96)80073-0
   MULLER RU, 1994, J NEUROSCI, V14, P7235
   MULLER RU, 1987, J NEUROSCI, V7, P1935
   OKEEFE J, 1979, BEHAV BRAIN SCI, V2, P487, DOI 10.1017/S0140525X00063949
   OKEEFE J, 1978, EXP BRAIN RES, V31, P573
   OLTON DS, 1990, ACTA NEUROBIOL EXP, V50, P125
   POUCET B, 1993, PSYCHOL REV, V100, P163, DOI 10.1037/0033-295X.100.2.163
   POUCET B, 1994, NEUROREPORT, V5, P2045, DOI 10.1097/00001756-199410270-00014
   Poucet B, 1997, BEHAV BRAIN RES, V84, P151, DOI 10.1016/S0166-4328(96)00144-1
   RANCK JB, 1973, EXP NEUROL, V41, P462, DOI 10.1016/0014-4886(73)90290-2
   ROSEMAN S, 1970, CHEM PHYS LIPIDS, V5, P270, DOI 10.1016/0009-3084(70)90024-1
   SEGAL M, 1981, NEUROSCI LETT, V27, P7, DOI 10.1016/0304-3940(81)90197-X
   SHAPIRO ML, 1989, NEUROSCIENCE, V32, P1, DOI 10.1016/0306-4522(89)90103-6
   SHAPIRO ML, 1983, SOC NEUR ABSTR, V9, P647
   SINDEN JD, 1995, BEHAV BRAIN SCI, V18, P10, DOI 10.1017/S0140525X00037249
   SIRKIN DW, 1983, STAIN TECHNOL, V58, P121, DOI 10.3109/10520298309066769
   SMYTHE JW, 1992, NEUROSCI BIOBEHAV R, V16, P289, DOI 10.1016/S0149-7634(05)80203-9
   STEWART M, 1992, BRAIN RES, V591, P122, DOI 10.1016/0006-8993(92)90986-J
   STEWART M, 1990, TRENDS NEUROSCI, V13, P163, DOI 10.1016/0166-2236(90)90040-H
   SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111
   Tarricone BJ, 1996, BEHAV BRAIN RES, V74, P25, DOI 10.1016/0166-4328(95)00144-1
   VANDERWOLF CH, 1969, ELECTROEN CLIN NEURO, V26, P407, DOI 10.1016/0013-4694(69)90092-3
   VINOGRADOVA OS, 1995, PROG NEUROBIOL, V45, P523, DOI 10.1016/0301-0082(94)00051-I
   WAINER BH, 1985, NEUROSCI LETT, V54, P45, DOI 10.1016/S0304-3940(85)80116-6
   WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1
   WEIL SM, 1991, RESTOR NEUROL NEUROS, V3, P167, DOI 10.3233/RNN-1991-3401
   Wiener SI, 1996, PROG NEUROBIOL, V49, P335, DOI 10.1016/0301-0082(96)00019-6
   WIENER SI, 1995, EUR J NEUROSCI, V7, P2206, DOI 10.1111/j.1460-9568.1995.tb00642.x
   Will B, 1998, CELLULAR AND MOLECULAR BASIS OF REGENERATION: FROM INVERTEBRATES TO HUMANS, P379
   Winer B.J., 1971, STAT PRINCIPLES EXPT
   WOERLY S, 1994, J NEURAL TRANSP PLAS, V5, P245
   Woerly S, 1996, BIOMATERIALS, V17, P301, DOI 10.1016/0142-9612(96)85568-2
   Woerly S, 1998, J BIOMAT SCI-POLYM E, V9, P681, DOI 10.1163/156856298X00091
NR 56
TC 11
Z9 11
U1 0
U2 3
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 0922-6028
EI 1878-3627
J9 RESTOR NEUROL NEUROS
JI Restor. Neurol. Neurosci.
PY 1999
VL 15
IS 4
BP 305
EP 317
PG 13
WC Neurosciences
SC Neurosciences & Neurology
GA 282DZ
UT WOS:000085202700004
DA 2018-10-19
ER

PT S
AU Kirkpatrick, SJ
AF Kirkpatrick, SJ
BE Tuchin, VV
   Ryabukho, VP
   Zimnyakov, DA
TI Transform method for laser speckle strain rate measurements in
   biological tissues and biomaterials
SO SARATOV FALL MEETING '98: LIGHT SCATTERING TECHNOLOGIES FOR MECHANICS,
   BIOMEDICINE, AND MATERIAL SCIENCE
SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
   (SPIE)
LA English
DT Proceedings Paper
CT Saratov Fall Meeting 98 on Light Scattering Technologies for Mechanics,
   Biomedicine, and Material Science
CY OCT 06-09, 1998
CL SARATOV, RUSSIA
SP Chernyshevsky Saratov State Univ, Russian Acad Sci, Inst Precis Mech & Control, Saratov Educ & Res Ctr Opt, Laser Phys, & Biophys, Saratov Reg Minist Youth, Sport & Tourism, Volga Reg Ctr New Informat Technologies, State Med Univ, Ophthalm Clin, Russian Acad Nat Sci, Saratov Div, Russian Fed Program Integrat, SPIE Russian Chapter, Russian Fdn Basic Res, Almus Ltd, Rian Ltd
DE laser speckle; strain rate; biological tissue; biomaterials
ID BONE
AB Laser speckle strain measurements in biological tissues and some synthetic biomaterials, such as translucent dental composites and ceramics, are often complicated by the physical properties of the materials. For example, speckles generated by illuminating soft biological tissue with laser light are subject to rapid decorrelation due to the Brownian movement of water and scattering particles in the tissues and to cellular motions. In addition, the penetration of the laser beam into the tissue or translucent biomaterial results in multiple scattering and a complete depolarization of the speckle field. This may complicate the evaluation of the strain field when a force is applied to the material because the speckle pattern shift is providing information from the surface of the material as well as from the bulk sample, where the strains may or may not be the same as on the surface. This paper presents a variation of a speckle processing scheme originally called the 'Transform Method' for evaluating both surface and bulk strain rates and total strains in biological tissues and translucent biomaterials. The method is not a correlation based technique, but instead relies upon two-dimensional frequency transforms of time series of one-dimensional speckle pattern records stacked into two dimensional arrays. The method is insensitive to speckle field depolarization and, compared to correlation-based techniques, is relatively insensitive to speckle decorrelation. Strain rates and total in-plane strains were measured in both hard (cortical bone) and soft (artery segments) biological tissues and in translucent biomaterials (dental ceramics), Potential applications to medical diagnostics and biomaterials science are also discussed.
C1 Oregon Hlth Sci Univ, Dept Biomat & Biomech, Portland, OR 97201 USA.
CR Ashman R B, 1987, Adv Dent Res, V1, P64
   DECHOW PC, 1993, AM J PHYS ANTHROPOL, V90, P291, DOI 10.1002/ajpa.1330900304
   DUNCAN DD, 1992, OPT ENG, V31, P1583, DOI 10.1117/12.57679
   DUNCAN DD, 1994, APPL OPTICS, V33, P5177, DOI 10.1364/AO.33.005177
   DUNCAN DD, 1995, MEAS SCI TECHNOL, V6, P335
   KIRKPATRICK SJ, 1995, J BIOMED MATER RES, V29, P1437, DOI 10.1002/jbm.820291115
   Kirkpatrick SJ, 1998, J BIOMED MATER RES, V39, P373, DOI 10.1002/(SICI)1097-4636(19980305)39:3<373::AID-JBM5>3.0.CO;2-G
   YAMAGUCHI I, 1981, OPT ACTA, V28, P1359, DOI 10.1080/713820454
   YAMAGUCHI I, 1982, OPT ENG, V21, P436, DOI 10.1117/12.7972927
NR 9
TC 0
Z9 0
U1 0
U2 0
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 0-8194-3200-8
J9 P SOC PHOTO-OPT INS
PY 1999
VL 3726
BP 504
EP 511
DI 10.1117/12.341432
PG 8
WC Materials Science, Multidisciplinary; Mechanics; Medical Laboratory
   Technology; Optics
SC Materials Science; Mechanics; Medical Laboratory Technology; Optics
GA BM94U
UT WOS:000080215700063
DA 2018-10-19
ER

PT S
AU Nishijima, S
   Okada, T
   Niihara, K
AF Nishijima, S
   Okada, T
   Niihara, K
BE Niihara, K
   Sekino, T
   Yasuda, E
   Sasa, T
TI Design of ceramics with warm feeling
SO SCIENCE OF ENGINEERING CERAMICS II
SE KEY ENGINEERING MATERIALS
LA English
DT Article; Proceedings Paper
CT 2nd International Symposium on Science of Engineering Ceramics (EnCera
   98)
CY SEP 06-09, 1998
CL OSAKA, JAPAN
SP Ceram Soc Japan, Amer Ceram Soc, European Ceram Soc, Fine Ceram Res Assoc
DE ceramics with warm feeling; semantic differential method; heat flow;
   material parameters
ID BIOMATERIAL; SURFACES
AB It has been clarified that the design of ceramics with appeal to perception, especially "warm feeling" is possible. The material parameters were derived by assuming that the heat flow across the contact surfaces between human hands and the ceramics controls the warm feeling. The heat flow was found to be proportional to the material parameter: a square root of the product of the thermal conductivity, specific heat and density. By means of the Semantic Differential Method bricks were evaluated from the "warm feeling" point of view to quantify the perception. The relationship between the quantified perception and the material parameter was studied and a strong correlation was found to exist indication that the design standard for "the ceramics with warm feeling" can be derived. Using the obtained standard, several materials were evaluated and the results agreed well with the conventional feeling. The obtained standard was applied to the design of the ceramics with warm feeling.
C1 Osaka Univ, ISIR, Osaka 5670047, Japan.
RP Nishijima, S (reprint author), Osaka Univ, ISIR, 8-1 Mihogaoka, Osaka 5670047, Japan.
CR BARLAZ MA, 1993, J ENVIRON ENG-ASCE, V119, P798, DOI 10.1061/(ASCE)0733-9372(1993)119:5(798)
   BERTHOD F, 1994, CLIN MATER, V15, P259, DOI 10.1016/0267-6605(94)90055-8
   BOBJER O, 1993, APPL ERGON, V24, P190, DOI 10.1016/0003-6870(93)90007-V
   GATTI AM, 1994, J MATER SCI-MATER M, V5, P190, DOI 10.1007/BF00121087
   GOONETILLEKE RS, 1992, P HUM FACT SOC, V1, P519
   GRUEN R, 1993, SURF COAT TECH, V60, P613
   ISHIHARA S, 1993, P INT JOINT C NEUR N, V3, P2512
   KALERT RE, 1994, P STRUCT C, V94, P520
   KAWABATA S, 1989, J TEXT I, V80, P19, DOI 10.1080/00405008908659184
   KAWASHIMA A, 1992, J ANTIBIOT, V45, P207, DOI 10.7164/antibiotics.45.207
   KUMAR G, 1993, POLYM INT, V31, P289
   SHEU MS, 1993, J ADHES SCI TECHNOL, V7, P1065, DOI 10.1163/156856193X00583
NR 12
TC 3
Z9 3
U1 0
U2 1
PU TRANS TECH PUBLICATIONS LTD
PI ZURICH-UETIKON
PA BRANDRAIN 6, CH-8707 ZURICH-UETIKON, SWITZERLAND
SN 1013-9826
BN 0-87849-817-6
J9 KEY ENG MAT
PY 1999
VL 2
BP 535
EP 538
DI 10.4028/www.scientific.net/KEM.161-163.535
PG 4
WC Materials Science, Ceramics; Materials Science, Composites
SC Materials Science
GA BV70B
UT WOS:000179851900117
DA 2018-10-19
ER

PT B
AU Thierry, B
   Tabrizian, M
   Yahia, LH
   Savadogo, O
AF Thierry, B
   Tabrizian, M
   Yahia, LH
   Savadogo, O
BE Trochu, F
   Brailovski, V
   Galibois, A
TI Effect of sterilization processes on the ions release of NiTi alloy
SO SHAPE MEMORY ALLOYS: FUNDAMENTALS, MODELING AND INDUSTRIAL APPLICATIONS
LA English
DT Proceedings Paper
CT International Symposium on Shape Memory Alloys: Fundamentals, Modeling
   and Industrial Applications held at the 38th Annual Conference of
   Metallurgists of CIM
CY AUG 22-26, 1999
CL QUEBEC CITY, CANADA
SP Canadian Inst Min, Met & Petr, Met Fabricat & Proc Sect, Met Soc, Canadian Inst Min, Met & Petr, Mat Sci & Engn Sect, Met Soc, Commerce Sci & Technol, Minist Ind
ID TITANIUM; MODEL; METAL
AB Using cyclic polarization in physiological solution, the effects of sterilization processes on the corrosion behavior of NiTi were monitored. The breakdown potentials of electropolished NiTi discs were greater than that of commonly used biomaterial 316L even after sterilization (0.5-1.1 V/SCE for NiTi vs 0.4 V/SCE for 316L). The passive release of nickel and chromium ions were determined using atomic absorption. NiTi alloy and 316L released similar amount of nickel after few days of immersion in bank's physiological solution. The amount of released nickel were under the level considered as toxic in the human body. SEM observations did not showed any trace of pitting corrosion and AES observations indicated surface contamination by Ca and P on NiTi alloy.
C1 Ecole Polytech, Inst Biomed Engn, Montreal, PQ, Canada.
RP Thierry, B (reprint author), Ecole Polytech, Inst Biomed Engn, Montreal, PQ, Canada.
RI Thierry, benjamin/B-2785-2009
OI Thierry, benjamin/0000-0002-6757-2842
CR ASTM - American Society for Testing and Materials, 1996, ANN BOOK ASTM STAND
   BROWN SA, 1988, J BIOMED MATER RES, V22, P321, DOI 10.1002/jbm.820220406
   Carter AJ, 1998, CATHETER CARDIO DIAG, V44, P193, DOI 10.1002/(SICI)1097-0304(199806)44:2<193::AID-CCD13>3.0.CO;2-O
   DAVIS LE, HDB AUGER ELECT SPEC
   HEALY KE, 1992, J BIOMED MATER RES, V26, P319, DOI 10.1002/jbm.820260305
   MOORLEGHEM WV, 1998, BIOMED MAT RES, V8, P55
   REVIE RW, 1969, CORROS SCI, V9, P755, DOI 10.1016/S0010-938X(69)80081-8
   Ryhanen J, 1997, J BIOMED MATER RES, V35, P451
   Sheth S, 1996, CIRCULATION, V94, P1733, DOI 10.1161/01.CIR.94.7.1733
   TREPANIER C, 1998, J BIOMED MATER RES, V43, P423
   Vezeau PJ, 1996, J ORAL MAXIL SURG, V54, P738, DOI 10.1016/S0278-2391(96)90694-1
   Wever DJ, 1998, BIOMATERIALS, V19, P761, DOI 10.1016/S0142-9612(97)00210-X
NR 12
TC 0
Z9 0
U1 0
U2 0
PU CANADIAN INST MINING, METALLURGY AND PETROLEUM
PI MONTREAL
PA XEROX TOWER, 1 PLACE ALEXIS NIHON, 1210-3400 DE MAISONNEUVE BLVD,
   MONTREAL, PQ H3Z 3B8, CANADA
BN 0-919086-93-4
PY 1999
BP 373
EP 382
PG 10
WC Metallurgy & Metallurgical Engineering
SC Metallurgy & Metallurgical Engineering
GA BR12W
UT WOS:000165711800030
DA 2018-10-19
ER

PT B
AU Chan, SP
   Toh, KK
   Bobyn, JD
   Hacking, SA
   Tanzer, M
   Krygier, JJ
AF Chan, SP
   Toh, KK
   Bobyn, JD
   Hacking, SA
   Tanzer, M
   Krygier, JJ
BE Stein, H
   Suk, SI
   Leung, PC
   Thorngren, KG
   Akeson, W
TI The osseous response to a new porous tantalum biomaterial
SO SIROT 99
LA English
DT Proceedings Paper
CT International Meeting of the
   International-Research-Society-of-Orthopaedic-Surgery-and-Traumatology
CY APR 16-19, 1999
CL SYDNEY, AUSTRALIA
SP Int Res Soc Orthopaed Surg & Traumatol
C1 McGill Univ, Montreal Gen Hosp, Dept Surg, Div Orthopaed, Montreal, PQ H3G 1A4, Canada.
RP Chan, SP (reprint author), McGill Univ, Montreal Gen Hosp, Dept Surg, Div Orthopaed, Montreal, PQ H3G 1A4, Canada.
CR Black Jonathan, 1994, Clinical Materials, V16, P167, DOI 10.1016/0267-6605(94)90113-9
   BOBYN JD, 1980, CLIN ORTHOP RELAT R, P263
   BOBYN JD, 1997, T ORTHOP RES SOC, P758
   BOBYN JD, 1999, IN PRESS J ARTHROPLA
   KRYGIER JJ, P SIROT SYDN AUSTR 1
   STACKPOOL GJ, 1995, T COMBINED ORTHOP RE, P45
   Turner TM, 1995, P 21 ANN M SOC BIOM, P125
NR 7
TC 0
Z9 0
U1 0
U2 1
PU FREUND PUBL HOUSE LTD
PI LONDON
PA SUITE 500, CHESHAM HOUSE, 150 REGENT ST, LONDON W1R 5FA, ENGLAND
BN 965-294-135-2
PY 1999
BP 39
EP 43
PG 5
WC Orthopedics
SC Orthopedics
GA BP99M
UT WOS:000086844900004
DA 2018-10-19
ER

PT B
AU Toh, KK
   Chan, SP
   Bobyn, JD
   Hacking, SA
   Plank, PA
   Tanzer, M
   Krygier, JJ
AF Toh, KK
   Chan, SP
   Bobyn, JD
   Hacking, SA
   Plank, PA
   Tanzer, M
   Krygier, JJ
BE Stein, H
   Suk, SI
   Leung, PC
   Thorngren, KG
   Akeson, W
TI Bone growth into a porous tantalum biomaterial with calcium phosphate
   coating
SO SIROT 99
LA English
DT Proceedings Paper
CT International Meeting of the
   International-Research-Society-of-Orthopaedic-Surgery-and-Traumatology
CY APR 16-19, 1999
CL SYDNEY, AUSTRALIA
SP Int Res Soc Orthopaed Surg & Traumatol
C1 McGill Univ, Montreal Gen Hosp, Dept Surg, Div Orthopaed, Montreal, PQ H3G 1A4, Canada.
RP Toh, KK (reprint author), McGill Univ, Montreal Gen Hosp, Dept Surg, Div Orthopaed, Montreal, PQ H3G 1A4, Canada.
CR Black Jonathan, 1994, Clinical Materials, V16, P167, DOI 10.1016/0267-6605(94)90113-9
   BOBYN JD, 1980, CLIN ORTHOP RELAT R, P263
   BOBYN JD, 1997, T ORTHOP RES SOC, P758
   BOBYN JD, 1999, IN PRESS J ARTHROPLA
   KRYGIER JJ, 1999, P SIROT SYDN AUSTR
   LAYROLLE P, 1998, P EUR SOC BIOM, P5
   STACKPOOL GJ, 1995, T COMBINED ORTHOP RE, P45
NR 7
TC 2
Z9 2
U1 0
U2 1
PU FREUND PUBL HOUSE LTD
PI LONDON
PA SUITE 500, CHESHAM HOUSE, 150 REGENT ST, LONDON W1R 5FA, ENGLAND
BN 965-294-135-2
PY 1999
BP 354
EP 358
PG 3
WC Orthopedics
SC Orthopedics
GA BP99M
UT WOS:000086844900059
DA 2018-10-19
ER

PT S
AU Tabrizian, M
   Thierry, B
   Savadogo, O
   Yahia, L'H
AF Tabrizian, M
   Thierry, B
   Savadogo, O
   Yahia, L'H
BE Claus, RO
   Spillman, WB
TI Surface characteristics of sterilized electropolished NiTi shape memory
   alloy as biomaterials
SO SMART STRUCTURES AND MATERIALS 1999: SENSORY PHENOMENA AND MEASUREMENT
   INSTRUMENTATION FOR SMART STRUCTURES AND MATERIALS
SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
   (SPIE)
LA English
DT Proceedings Paper
CT Smart Structures and Materials 1999 Conference
CY MAR 01-04, 1999
CL NEWPORT BEACH, CA
SP SPIE, Soc Exptl Mech, Amer Soc Mech Engineers, BFGoodrich Aerosp, Def Adv Res Projects Agcy, US Army Res Off, USAF Res Lab, Ceram Soc Japan, Intelligent Mat Forum, Japan
DE NiTi; shape memory; electropolishing; sterilization; ethylene oxide;
   surface characterization; corrosion
ID NICKEL-TITANIUM ALLOY; IN-VITRO; RESPONSES
AB As a potential biomaterial for many medical applications, NiTi alloy derives its good biocompatibility and corrosion resistance from a homogeneous and protective oxide layer, mainly composed of TiO2, with little concentration of nickel. However, during corrosion testing at high potential, NiTi is suscesptible to pitting corrosion, which may affect the amount of ions (nickel and titanium) released by the alloy and thus, may affect its biocompatibility. As a passivating treatment, electropolishing (EP) was demonstrated to decrease the amount of nickel on the surface and to remarkably improve the corrosion behavior of the alloy. After sterilization by ethylene oxide (EO), no modification of the promising corrosion behavior of electropolished NiTi were observed, although some surface modifications were reported. The corrosion resistance of ethylene oxide sterilized and electropolished samples ranked between that of the commonly used Ti6Al4V and 316L (0.4<1<1.4 mV/SCE) implant alloys.
C1 Ecole Polytech, Inst Biomed Engn, Biomat Biomech Res Grp, Dept Engn Mech, Montreal, PQ H3C 3A7, Canada.
RP Tabrizian, M (reprint author), Ecole Polytech, Inst Biomed Engn, Biomat Biomech Res Grp, Dept Engn Mech, CP 6079,Succ Ctr Ville, Montreal, PQ H3C 3A7, Canada.
RI Thierry, benjamin/B-2785-2009
OI Thierry, benjamin/0000-0002-6757-2842
CR Assad M, 1998, J BIOMED MATER RES, V41, P154, DOI 10.1002/(SICI)1097-4636(199807)41:1<154::AID-JBM18>3.3.CO;2-0
   ASTM - American Society for Testing and Materials, 1996, ANN BOOK ASTM STAND
   BergerGorbet M, 1996, J BIOMED MATER RES, V32, P243, DOI 10.1002/(SICI)1097-4636(199610)32:2<243::AID-JBM14>3.0.CO;2-K
   Dai KR, 1996, BIO-MED MATER ENG, V6, P233
   DAVIS LE, HDB AUGER ELECT SPEC
   NAKAYAMA Y, 1989, BIOMATERIALS, V10, P420, DOI 10.1016/0142-9612(89)90134-8
   Rondelli G, 1996, BIOMATERIALS, V17, P2003, DOI 10.1016/0142-9612(95)00352-5
   Ryhanen J, 1998, J BIOMED MATER RES, V41, P481, DOI 10.1002/(SICI)1097-4636(19980905)41:3<481::AID-JBM19>3.0.CO;2-L
   SHABALOVSKAYA S, 1994, P INT C SHAP MEM SUP
   SHABALOVSKAYA S, 1995, J VAC SCI TECHNOL A, V13
   Takeshita F, 1997, BIOMATERIALS, V18, P21, DOI 10.1016/S0142-9612(96)00051-8
   THIERRY B, 1998, UNPUB J BIOMED MAT R
   Trepanier C, 1997, MATER RES SOC SYMP P, V459, P363
   TREPANIER C, IN PRESS J BIOMED MA
   TREPANIER C, 1998, J BIOMED MATER RES, V43, P423
   TRIGWELL S, 1997, P 2 INT C SHAP MEM S, P383
   Vezeau PJ, 1996, J ORAL MAXIL SURG, V54, P738, DOI 10.1016/S0278-2391(96)90694-1
   WALIVAARA B, 1994, BIOMATERIALS, V15, P827, DOI 10.1016/0142-9612(94)90038-8
   Wever DJ, 1998, BIOMATERIALS, V19, P761, DOI 10.1016/S0142-9612(97)00210-X
   Wever DJ, 1997, BIOMATERIALS, V18, P1115, DOI 10.1016/S0142-9612(97)00041-0
NR 20
TC 6
Z9 6
U1 0
U2 3
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 0-8194-3144-3
J9 P SOC PHOTO-OPT INS
PY 1999
VL 3670
BP 106
EP 114
DI 10.1117/12.349719
PG 9
WC Instruments & Instrumentation; Materials Science, Multidisciplinary;
   Optics
SC Instruments & Instrumentation; Materials Science; Optics
GA BN29P
UT WOS:000081456200012
DA 2018-10-19
ER

PT S
AU Myers, N
   Wessling, F
   Deuser, M
   Anderson, CD
   Lewis, M
AF Myers, N
   Wessling, F
   Deuser, M
   Anderson, CD
   Lewis, M
BE ElGenk, MS
TI The BioDyn Facility on ISS: Advancing biomaterial production in
   microgravity for commercial applications
SO SPACE TECHNOLOGY AND APPLICATIONS INTERNATIONAL FORUM - 1999, PTS ONE
   AND TWO
SE AIP Conference Proceedings
LA English
DT Proceedings Paper
CT 1999 Space Technology and Applications International Forum (STAIF-99) -
   Opportunities and Challenges for the New Millennium
CY JAN 31-FEB 04, 1999
CL ALBUQUERQUE, NM
SP Boeing Co, Lockheed Martin Astronaut, NASA, USAF, Air Force Res Lab, US DOE, IAF 99, Amsterdam, Amer Inst Chem Engineers, AIAA, Amer Astronaut Soc, ASME Int, Amer Inst Aeronaut & Astronaut, Amer Inst Chem Engineers, Heat Transfer & Energ Convers Div, Amer Nucl Soc, Trin Sect, Amer Soc Mech Engineers, Nucl Engn Div & Heat Transfer Div, Inst Elect & Electr Engineers Inc, Nucl & Plasma Sci Soc, NASA Natl Space Grant Coll & Fellowship Program, New Mexico Space Grant Consortium, Profess Aerosp Contractors Assoc
AB The primary goals of the BioDyn program are to foster use of the microgravity environment for commercial production of bio-materials from cells, and to develop services and processes for obtaining these materials through space processing. The scope of products includes commercial bio-molecules such as cytokines, other cell growth regulatory proteins, hormones, monoclonal antibodies and enzymes; transplantable cells or tissues which can be improved by low-G processes, or which cannot be obtained through standard processes in earth gravity; agriculture biotechnology products from plant cells; microencapsulation for diabetes treatment. and factors regulating cellular aging. To facilitate BioDyn's commercial science driven goals: hardware designed for ISS incorporates the flexibility for interchange between the different ISS facilities including the glovebox, various thermal units and centrifuges. By providing a permanent research facility, ISS is the critical space-based platform required by scientists for carrying out the long-term experiments necessary for developing bio-molecules and tissues using several cell culture modalities including suspension and anchorage-dependent cell types.
C1 Univ Alabama, Consortium Mat Dev Space, Huntsville, AL 35899 USA.
RP Myers, N (reprint author), Univ Alabama, Consortium Mat Dev Space, Huntsville, AL 35899 USA.
EM myersn@email.uah.edu
CR Deuser MS, 1998, AIP CONF PROC, P793
   Lewis M.L., 1994, EARTH SPACE REV, V03, P22
   Lewis ML, 1998, FASEB J, V12, P1007
NR 3
TC 0
Z9 0
U1 1
U2 1
PU AMER INST PHYSICS
PI MELVILLE
PA 2 HUNTINGTON QUADRANGLE, STE 1NO1, MELVILLE, NY 11747-4501 USA
SN 0094-243X
BN 1-56396-846-0
J9 AIP CONF PROC
PY 1999
VL 458
BP 453
EP 458
PG 6
WC Engineering, Aerospace; Thermodynamics; Engineering, Multidisciplinary;
   Geosciences, Multidisciplinary; Multidisciplinary Sciences; Nuclear
   Science & Technology; Remote Sensing; Physics, Applied; Physics,
   Multidisciplinary
SC Engineering; Thermodynamics; Geology; Science & Technology - Other
   Topics; Nuclear Science & Technology; Remote Sensing; Physics
GA BM78K
UT WOS:000079755200076
DA 2018-10-19
ER

PT J
AU Cobb, MA
   Badylak, SF
   Janas, W
   Simmons-Byrd, A
   Boop, FA
AF Cobb, MA
   Badylak, SF
   Janas, W
   Simmons-Byrd, A
   Boop, FA
TI Porcine small intestinal submucosa as a dural substitute
SO SURGICAL NEUROLOGY
LA English
DT Article
DE dura substitute; xenograft; small intestinal submucosa
ID CREUTZFELDT-JAKOB-DISEASE; ADULT CASE-REPORTS; MATER GRAFT; HEMORRHAGIC
   COMPLICATIONS; VASCULAR GRAFT; DOG-MODEL; REPAIR; ASSOCIATION;
   PERICARDIUM; COLLAGEN
AB BACKGROUND The continuing search for the ideal dural substitute is currently directed toward collagen preparations. Xenogeneic porcine small intestinal submucosa (SIS), a naturally occurring extracellular matrix rich in collagen, has been successfully used as a soft tissue graft in several body organ systems, including preliminary studies as a dural substitute in the rat.
   METHODS Eight dogs underwent temporoparietal craniotomy and dural resection with replacement by SIS. Five dogs had contralateral procedures without SIS grafting. Three dogs had contralateral SIS grafts placed 2 months after the initial procedure. Histologic assessment was obtained at 7, 30, 60, 90, and 120 days. Cerebrospinal fluid (CSF) cytological examination and routine serum chemistry preceded sacrifice.
   RESULTS Histologic evaluation showed initial graft infiltration by mononuclear round cells, spindle-shaped cells within an eosinophilic staining extracellular matrix, and neovascularity. Complete resorption of the graft was evident by 60 days. This pattern is consistent with the previously described incorporation and remodeling of the SIS graft at other sites. CSF cytology and routine serum chemistry at the time of sacrifice were normal. Response to repeat grafting was identical to that of initial exposure. There was no clinical or histologic evidence of sensitization or graft rejection. No evidence of adverse effect on the underlying cerebral cortex was observed.
   CONCLUSIONS Porcine small intestinal submucosa demonstrates a favorable biologic response as a dural substitute in the canine model. It is a promising biomaterial for dural replacement. (C) 1999 by Elsevier Science Inc.
C1 Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT 06520 USA.
   Arkansas Childrens Hosp, Dept Neurosurg, Little Rock, AR 72202 USA.
   Purdue Univ, Hillenbrand Biomed Engn Ctr, W Lafayette, IN 47907 USA.
RP Cobb, MA (reprint author), Yale Univ, Sch Med, Dept Neurosurg, 333 Cedar St,POB 208039, New Haven, CT 06520 USA.
OI Badylak, Stephen/0000-0003-3555-0689
CR ADEGBITE AB, 1983, J NEUROSURG, V58, P295, DOI 10.3171/jns.1983.58.2.0295
   AIKEN SW, 1994, VET COMP ORTHOPAED, V7, P124
   AlMefty O, 1997, NEUROSURGERY, V40, P206
   Anson JA, 1996, NEUROSURGERY, V39, P764, DOI 10.1097/00006123-199610000-00025
   BADYLAK SF, 1995, J BIOMED MATER RES, V29, P977, DOI 10.1002/jbm.820290809
   BADYLAK SF, 1993, TISSUE ENGINEERING, P179
   BADYLAK SF, 1989, J SURG RES, V47, P74, DOI 10.1016/0022-4804(89)90050-4
   BADYLAK SF, 1994, J VASC SURG, V19, P465, DOI 10.1016/S0741-5214(94)70073-7
   BHATIA S, 1995, J NEUROSURG, V83, P897, DOI 10.3171/jns.1995.83.5.0897
   BROWN MH, 1948, SURG GYNECOL OBSTET, V86, P663
   Clarke KM, 1996, J SURG RES, V60, P107, DOI 10.1006/jsre.1996.0018
   Cobb MA, 1996, SURG NEUROL, V46, P389, DOI 10.1016/S0090-3019(96)00202-9
   Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0
   COLLINS RLL, 1991, J BIOMED MATER RES, V25, P267, DOI 10.1002/jbm.820250212
   DOILLON CJ, 1984, SCANNING ELECTRON MI, V3, P1313
   DUNN MG, 1983, CONNECT TISSUE RES, V12, P59, DOI 10.3109/03008208309005612
   FERRAND BK, 1993, J BIOMED MATER RES, V27, P1235, DOI 10.1002/jbm.820271004
   HILES MC, 1995, J BIOMED MATER RES, V29, P883, DOI 10.1002/jbm.820290714
   HILES MC, 1993, J BIOMED MATER RES, V27, P139, DOI 10.1002/jbm.820270202
   Hodde J P, 1996, Tissue Eng, V2, P209, DOI 10.1089/ten.1996.2.209
   KNAPP PM, 1994, J ENDOUROL, V8, P125, DOI 10.1089/end.1994.8.125
   Kropp B P, 1995, Urology, V46, P396, DOI 10.1016/S0090-4295(99)80227-1
   Kropp BP, 1996, J UROLOGY, V155, P2098, DOI 10.1016/S0022-5347(01)66117-2
   LANE KL, 1994, NEUROSURGERY, V34, P737, DOI 10.1227/00006123-199404000-00026
   Lantz G C, 1990, J Invest Surg, V3, P217, DOI 10.3109/08941939009140351
   Lantz G C, 1993, J Invest Surg, V6, P297, DOI 10.3109/08941939309141619
   LANTZ GC, 1992, J SURG RES, V53, P175, DOI 10.1016/0022-4804(92)90031-T
   LAQUERRIERE A, 1993, J NEUROSURG, V78, P487, DOI 10.3171/jns.1993.78.3.0487
   MARTINEZLAGE JF, 1994, J NEUROL NEUROSUR PS, V57, P1091, DOI 10.1136/jnnp.57.9.1091
   MAURER PK, 1985, J NEUROSURG, V63, P448, DOI 10.3171/jns.1985.63.3.0448
   MIYASHITA K, 1991, NEUROLOGY, V41, P940, DOI 10.1212/WNL.41.6.940
   NISBET TJ, 1989, MMWR-MORBID MORTAL W, V38, P24
   ONEILL P, 1984, J NEUROSURG, V61, P351, DOI 10.3171/jns.1984.61.2.0351
   Parizek J, 1996, J NEUROSURG, V84, P508, DOI 10.3171/jns.1996.84.3.0508
   PREVEL CD, 1995, ANN PLAS SURG, V35, P374, DOI 10.1097/00000637-199510000-00008
   PREVEL CD, 1995, ANN PLAS SURG, V35, P381, DOI 10.1097/00000637-199510000-00009
   PREVEL CD, 1994, MICROSURG, V15, P586, DOI 10.1002/micr.1920150812
   Robertson SC, 1997, NEUROSURGERY, V40, P201, DOI 10.1097/00006123-199701000-00046
   SANDUSKY GE, 1992, AM J PATHOL, V140, P317
   Takayama Shoukei, 1993, Neurological Surgery, V21, P167
   THADANI V, 1988, J NEUROSURG, V69, P766, DOI 10.3171/jns.1988.69.5.0766
   THAMMAVARAM KV, 1990, SOUTHERN MED J, V83, P634, DOI 10.1097/00007611-199006000-00009
   *US DHEW, 1985, 8523 NIH DHHS
   Vaught JD, 1996, J UROLOGY, V155, P374, DOI 10.1016/S0022-5347(01)66663-1
   VoytikHarbin SL, 1997, J CELL BIOCHEM, V67, P478, DOI 10.1002/(SICI)1097-4644(19971215)67:4<478::AID-JCB6>3.0.CO;2-P
   XU BZ, 1988, J NEUROSURG, V69, P707
   YAMADA S, 1994, NEUROSURGERY, V34, P740, DOI 10.1227/00006123-199404000-00027
NR 47
TC 78
Z9 84
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA
SN 0090-3019
J9 SURG NEUROL
JI Surg. Neurol.
PD JAN
PY 1999
VL 51
IS 1
BP 99
EP 104
DI 10.1016/S0090-3019(97)00475-8
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 160PW
UT WOS:000078241000035
PM 9952131
DA 2018-10-19
ER

PT J
AU Scudiero, L
   Langford, SC
   Dickinson, JT
AF Scudiero, L
   Langford, SC
   Dickinson, JT
TI Scanning force microscope observations of corrosive wear on
   single-crystal brushite (CaHPO4 center dot 2H(2)O) in aqueous solution
SO TRIBOLOGY LETTERS
LA English
DT Article
DE tribology; corrosive wear; tribochemistry; scanning force microscopy;
   atomic force microscopy; chemical mechanical polishing; dissolution;
   stress-enhanced dissolution; brushite; phosphate
ID DISSOLUTION; MORPHOLOGY; SURFACE
AB We examine nanometer-scale corrosive wear on a model biomaterial, single-crystal brushite (CaHPO4. 2H(2)O) in aqueous solution. Wear was produced by using the tip of a scanning force microscope (SFM) to provide mechanical stimulation. Monolayer deep, triangular etch pits form spontaneously on brushite {010} surfaces in undersaturated aqueous solution, providing three crystallographically distinct steps for study. Pronounced, localized wear is readily produced by drawing the SFM tip back and forth across the edges of these pits. The wear rate depends strongly on the contact force and the crystallographic orientation of the step. We analyze the length of the wear track in terms of the rate of mechanically enhanced double-kink nucleation (the removal of ions from initially complete or intact steps). The rate of subsequent material removal (after linear scanning) also depends strongly on the contact force due to mechanically enhanced rates of kink propagation. Models of the bonding geometries for steps and various kinks explain several strong asymmetries in step stability and vulnerability to dissolution and corrosive wear.
C1 Washington State Univ, Dept Phys, Pullman, WA 99164 USA.
   Washington State Univ, Mat Sci Program, Pullman, WA 99164 USA.
RP Dickinson, JT (reprint author), Washington State Univ, Dept Phys, Pullman, WA 99164 USA.
CR BEEVERS CA, 1958, ACTA CRYSTALLOGR, V11, P273, DOI 10.1107/S0365110X58000670
   CURRY NA, 1971, CHEM SOC LONDON A, P3725
   Dickinson JT, 1997, TRIBOL LETT, V3, P69, DOI 10.1023/A:1019135828336
   Hall C, 1996, AICHE J, V42, P232, DOI 10.1002/aic.690420119
   HEIJNEN WMM, 1991, J CRYST GROWTH, V108, P290, DOI 10.1016/0022-0248(91)90376-G
   HILLIG WB, 1965, HIGH STRENGTH MATERI, P682
   LeGeros R. Z., 1972, Journal of Crystal Growth, V13-14, P476, DOI 10.1016/0022-0248(72)90284-9
   Liang Y, 1996, SURF SCI, V351, P172, DOI 10.1016/0039-6028(95)01298-2
   Liang Y, 1997, SURF SCI, V373, P275, DOI 10.1016/S0039-6028(96)01155-7
   Liang Y, 1996, J VAC SCI TECHNOL A, V14, P1368, DOI 10.1116/1.579956
   Nakahara S, 1995, TRIBOL LETT, V1, P277
   OHTA M, 1982, J CRYST GROWTH, V56, P652, DOI 10.1016/0022-0248(82)90050-1
   OHTA M, 1979, J CRYST GROWTH, V47, P135, DOI 10.1016/0022-0248(79)90171-4
   Park NS, 1996, LANGMUIR, V12, P4599, DOI 10.1021/la950904b
   Park NS, 1996, J APPL PHYS, V80, P2680, DOI 10.1063/1.363185
   SIMON PB, 1965, ACTA CRYSTALLOGR, V19, P750
   TIMOSHENKO SP, 1970, THEORY ELASTICITY
NR 17
TC 34
Z9 34
U1 3
U2 7
PU BALTZER SCI PUBL BV
PI BUSSUM
PA PO BOX 221, 1400 AE BUSSUM, NETHERLANDS
SN 1023-8883
J9 TRIBOL LETT
JI Tribol. Lett.
PY 1999
VL 6
IS 1
BP 41
EP 55
DI 10.1023/A:1019134901387
PG 15
WC Engineering, Chemical; Engineering, Mechanical
SC Engineering
GA 163BW
UT WOS:000078383200006
DA 2018-10-19
ER

PT J
AU Sung, HW
   Huang, RN
   Huang, LLH
   Tsai, CC
   Chiu, CT
AF Sung, HW
   Huang, RN
   Huang, LLH
   Tsai, CC
   Chiu, CT
TI Feasibility study of a natural crosslinking reagent for biological
   tissue fixation
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE biological tissue; crosslinking reagent; genipin; cytotoxicity;
   enzymatic degradation
ID IN-VITRO; COLLAGEN; DEGRADATION; GENIPOSIDE; TEMPERATURE; BIOMATERIAL;
   GENIPIN
AB Bioprostheses derived from biological tissues must be chemically modified and subsequently sterilized before they can be implanted in humans. Various crosslinking reagents, including formaldehyde, glutaraldehyde,dialdehyde starch, and epoxy compound, have been used to chemically modify biological tissues. However, these synthetic crosslinking reagents are all highly (or relatively highly) cytotoxic. It is therefore desirable to provide a crosslinking reagent suitable for use in biomedical applications that is of low cytotoxicity and that forms stable and biocompatible crosslinked products. This study evaluates the feasibility of using a naturally occurring crosslinking reagent-genipin-to chemically modify biological tissues. Genipin and ifs related iridoid compounds, extracted from gardenia fruits, have been used in traditional Chinese medicine for the treatments of jaundice and various inflammatory and hepatic diseases, In this feasibility study, the cytotoxicity of genipin and the crosslinking characteristics of genipin-fixed biological tissues were investigated. Fresh porcine pericardia procured from a slaughterhouse were used as raw materials. Glutaraldehyde and an epoxy compound (ethylene glycol diglycidyl ether), which has been used extensively in developing bioprostheses, were used as controls. It was found that the cytotoxicity of genipin was significantly lower than that of glutaraldehyde and the epoxy compound. The amino acid residues in the porcine pericardium that may react with genipin were lysine, hydroxylysine, and arginine. Additionally, the genipin-fixed tissue had a mechanical strength and resistance against enzymatic degradation comparable to the glutaraldehyde-fixed tissue. This suggests that genipin can form stable crosslinked products. The results of this in vitro study demonstrate that genipin is an effective crosslinking reagent for biological tissue fixation. (C) 1998 John Wiley & Sons, Inc.
C1 Natl Cent Univ, Dept Chem Engn, Chungli 32054, Taiwan.
   Natl Cent Univ, Inst Life Sci, Chungli 32054, Taiwan.
   Natl Taiwan Univ, Coll Med, Ctr Biomed Engn, Taipei, Taiwan.
RP Sung, HW (reprint author), Natl Cent Univ, Dept Chem Engn, Chungli 32054, Taiwan.
RI Huang, Lynn/J-9237-2016
OI Huang, Lynn/0000-0002-6602-7578; Huang, Rong Nan/0000-0002-5117-8672
CR ABURADA M, 1980, PHARMACOMETRICS, V19, P259
   AKAO T, 1994, BIOL PHARM BULL, V17, P1573
   BUCHI G, 1967, J AM CHEM SOC, V89, P2776
   DAMINK LHHO, 1995, J BIOMED MATER RES, V29, P139, DOI 10.1002/jbm.820290202
   FUJIKAWA S, 1987, TETRAHEDRON LETT, V28, P4699, DOI 10.1016/S0040-4039(00)96601-2
   FUJIKAWA S, 1987, BIOTECHNOL LETT, V9, P697, DOI 10.1007/BF01024600
   HARPER E, 1972, BIOPOLYMERS, V11, P1607, DOI 10.1002/bip.1972.360110807
   LEE JM, 1995, MED ENG PHYS, V17, P115, DOI 10.1016/1350-4533(95)91882-H
   Lohre J M, 1993, ASAIO J, V39, P106, DOI 10.1097/00002480-199304000-00007
   LOHRE JM, 1992, ARTIF ORGANS, V16, P630
   MCCLAIN PE, 1972, J BIOL CHEM, V247, P692
   Nimni ME, 1988, COLLAGEN, VIII, P1
   NISHI C, 1995, J BIOMED MATER RES, V29, P829, DOI 10.1002/jbm.820290707
   NOISHIKI Y, 1993, INT J ARTIF ORGANS, V16, P192
   NOISHIKI Y, 1986, T AM SOC ART INT ORG, V32, P114
   Noishiki Y., 1989, U. S. Patent, Patent No. [4,806,599, 4806599]
   Rosenberg D., 1978, VASCULAR GRAFTS, P261
   STENZEL KH, 1974, ANNU REV BIOPHYS BIO, V3, P231, DOI 10.1146/annurev.bb.03.060174.001311
   Sung H. W., 1993, ASIAN CARDIOVASC THO, V1, P104
   Sung HW, 1996, J BIOMED MATER RES, V31, P511, DOI 10.1002/(SICI)1097-4636(199608)31:4<511::AID-JBM11>3.0.CO;2-J
   Sung HW, 1997, ARTIF ORGANS, V21, P50
   Sung HW, 1997, J BIOMED MATER RES, V35, P147
   TOUYAMA R, 1994, CHEM PHARM BULL, V42, P668
   TSAI TH, 1994, J LIQ CHROMATOGR, V17, P2199
   TU R, 1994, J BIOMED MATER RES, V28, P677, DOI 10.1002/jbm.820280604
   YAMANO T, 1990, FOOD CHEM TOXICOL, V28, P515, DOI 10.1016/0278-6915(90)90122-4
   Yamazaki M, 1996, BIOL PHARM BULL, V19, P791
   YANNAS IV, 1975, J BIOMED MATER RES, V9, P623, DOI 10.1002/jbm.820090608
NR 28
TC 207
Z9 220
U1 4
U2 68
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD DEC 15
PY 1998
VL 42
IS 4
BP 560
EP 567
DI 10.1002/(SICI)1097-4636(19981215)42:4<560::AID-JBM12>3.0.CO;2-I
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 135HJ
UT WOS:000076795500012
PM 9827680
DA 2018-10-19
ER

PT J
AU Serre, CM
   Papillard, M
   Chavassieux, P
   Voegel, JC
   Boivin, G
AF Serre, CM
   Papillard, M
   Chavassieux, P
   Voegel, JC
   Boivin, G
TI Influence of magnesium substitution on a collagen-apatite biomaterial on
   the production of a calcifying matrix by human osteoblasts
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE magnesium; calcifying matrix; osteoblast-like cell culture; apatite;
   collagen sponge
ID BIODEGRADATION BEHAVIOR; HYDROXYAPATITE CERAMICS; BONE TISSUE;
   INTERFACE; MINERALIZATION; FLUORAPATITE; SULFATE; CELLS; DOGS
AB The induction of a calcifying matrix is of great interest in the restoration of bone defects. In a previous in vitro study we demonstrated that a collagen sponge constituted of type I collagen fibrils, chondroitin sulfates, and hydroxyapatite crystals induces an earlier and a more abundant synthesis of a new extracellular calcifying matrix than do other biomaterials such as collagen or hydroxyapatite alone. Bone mineral contains various amounts of magnesium ions, either adsorbed at the surface of apatite crystals or incorporated inside the crystal structure. Magnesium is known to reduce the degradation rate of tricalcium phosphate ceramics and to influence the crystallization of mineral substance. Thus we evaluated two sponges modified with different substituted apatites. The substituted low magnesium-containing apatite sample decreased the osteoinductive properties of the sponge whereas the substituted high magnesium-containing apatite sample had a toxic effect on bone cells and prevented the formation of any extracellular matrix. Such a toxic effect can be explained by the presence of large numbers of magnesium ions released into the culture medium even though at physiological level magnesium is able to promote bone mineralization and to control the growth of hydroxyapatite crystals. Thus collagen sponges containing hydroxyapatite remain one of the most appropriately evaluated biomaterials used for the restoration of periodontal pockets and bone defects. (C) 1998 John Wiley & Sons, Inc.
C1 Fac Med RTH Laennec, INSERM, U403, F-69372 Lyon 08, France.
   Fac Odontol, F-69372 Lyon 08, France.
   Federat Rech Odontol, INSERM, U424, F-67085 Strasbourg, France.
RP Serre, CM (reprint author), Fac Med RTH Laennec, INSERM, U403, 8 Rue G Paradin, F-69372 Lyon 08, France.
RI Chavassieux, Pascale/L-9071-2018
CR ALTHOFF J, 1982, HISTOCHEMISTRY, V74, P541, DOI 10.1007/BF00496668
   AMJAD Z, 1984, J COLLOID INTERF SCI, V101, P250, DOI 10.1016/0021-9797(84)90025-0
   BIGI A, 1992, CALCIFIED TISSUE INT, V50, P439, DOI 10.1007/BF00296775
   BLUMENTHAL N, 1986, J PERIODONTOL, V57, P84, DOI 10.1902/jop.1986.57.2.84
   BLUMENTHAL NC, 1992, MATER RES SOC SYMP P, V252, P29
   BOSKEY AL, 1992, J ORTHOP RES, V10, P774, DOI 10.1002/jor.1100100605
   BOUVIER M, 1990, ARCH ORAL BIOL, V35, P301, DOI 10.1016/0003-9969(90)90047-E
   BOUVIER M, 1990, DIFFERENTIATION, V45, P128, DOI 10.1111/j.1432-0436.1990.tb00466.x
   BRAUTBAR N, 1986, NEPHRON, V44, P1, DOI 10.1159/000183902
   CHAVASSIEUX PM, 1990, J BONE MINER RES, V5, P337, DOI 10.1002/jbmr.5650050406
   CHIRANJEEVIRAO SV, 1982, INORG CHIM A-BIOINOR, V67, P183, DOI 10.1016/S0020-1693(00)85062-8
   DEBRUIJN JD, 1993, CELL MATER, V3, P407
   DELANGE GL, 1990, J BIOMED MATER RES, V24, P829, DOI 10.1002/jbm.820240704
   DELANGE GL, 1989, BIOMATERIALS, V10, P121, DOI 10.1016/0142-9612(89)90044-6
   DHERT WJA, 1993, J BIOMED MATER RES, V27, P127, DOI 10.1002/jbm.820270116
   GARCIA R, 1992, J MATER SCI-MATER M, V3, P154, DOI 10.1007/BF00705285
   Irigaray JL, 1996, J BIOMAT SCI-POLYM E, V7, P741, DOI 10.1163/156856296X00507
   IRIGARAY JL, 1993, J RADIOAN NUCL CH AR, V174, P93, DOI 10.1007/BF02040337
   JOHNSSON MSA, 1991, BONE-BIOMATERIAL INTERFACE, P68
   JONES JE, 1980, CALCIFIED TISSUE INT, V31, P231, DOI 10.1007/BF02407186
   KLEIN CPAT, 1983, J BIOMED MATER RES, V17, P769, DOI 10.1002/jbm.820170505
   KLEIN CPAT, 1986, BIOMATERIALS, V7, P144
   KUHNE JH, 1994, ACTA ORTHOP SCAND, V65, P246, DOI 10.3109/17453679408995448
   LEGEROS RZ, 1989, MAGNETISUM HLTHD IS
   MARIE PJ, 1983, CALCIFIED TISSUE INT, V35, P755, DOI 10.1007/BF02405119
   OGUCHI H, 1995, BIOMATERIALS, V16, P33, DOI 10.1016/0142-9612(95)91093-E
   POSNER AS, 1969, PHYSIOL REV, V49, P760
   SERRE CM, 1993, BIOMATERIALS, V14, P97, DOI 10.1016/0142-9612(93)90217-P
   Tsuboi S, 1992, CALCIFIED TISSUE INT, V50, P34
   WANG JS, 1994, CLIN ORTHOP RELAT R, P272
   Wiesmann HP, 1997, J BONE MINER RES, V12, P380, DOI 10.1359/jbmr.1997.12.3.380
   WUTHIER RE, 1971, CALC TISS RES, V8, P24, DOI 10.1007/BF02010120
   YAFFE A, 1984, J PERIODONTOL, V55, P623, DOI 10.1902/jop.1984.55.11.623
   YAMASAKI H, 1992, BIOMATERIALS, V13, P308, DOI 10.1016/0142-9612(92)90054-R
NR 34
TC 155
Z9 180
U1 0
U2 44
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD DEC 15
PY 1998
VL 42
IS 4
BP 626
EP 633
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 135HJ
UT WOS:000076795500020
PM 9827688
DA 2018-10-19
ER

PT J
AU Lu, JX
   Gallur, A
   Flautre, B
   Anselme, K
   Descamps, M
   Thierry, B
   Hardouin, P
AF Lu, JX
   Gallur, A
   Flautre, B
   Anselme, K
   Descamps, M
   Thierry, B
   Hardouin, P
TI Comparative study of tissue reactions to calcium phosphate ceramics
   among cancellous, cortical, and medullar bone sites in rabbits
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE tissue reactions; bone sites; histomorphometry; bioceramics; porosity
ID POROUS HYDROXYAPATITE; MARROW; INTERFACE; IMPLANTS; CULTURE; CELLS
AB In order to understand the influence of the implantation site on bone biomaterial evaluation, we implanted cylinders of HA and beta-TCP ceramics in the femoral diaphysis and condyle of rabbits. After 3, 8, 12, and 24 weeks of implantation, histological investigation and histomorphometry were performed on undecalcified samples. Our results show that spontaneous bone healing in the empty cavities is significantly different (p < 0.05) between cortical (SBH > 80%) and cancellous bone sites (SBH < 31%) and that no new bone is formed in marrow tissue. For both porous ceramics, the highest osteogenesis was obtained in the cortical site. Osteogenesis was intermediate in the cancellous site and weak in the medullar site. The material biodegradation was the strongest in the medullar site and higher in the cancellous site than in the cortical site. Both activities were better in the beta-TCP than in the HA (p > 0.05). The marrow tissue presents a foreign-body reaction more reliable, sensitive, and durable than other bone tissues. Therefore, the cancellous bone site is a good site for evaluation of the biofunctionality of biomaterials because of the equilibrium of the osteogenesis and the biodegradation activities, but marrow tissue seems to be better for testing material biocompatibility in vivo. (C) 1998 John Wiley & Sons, Inc.
C1 IRMS, F-62608 Berck Sur Mer, France.
   CRITT, Maubeuge, France.
RP Lu, JX (reprint author), IRMS, Rue Docteur Calot, F-62608 Berck Sur Mer, France.
EM irms@wanadoo.fr
OI Anselme, Karine/0000-0002-6669-205X
CR *AFNOR, 1995, 309936 EN AFNOR
   DACULSI G, 1989, REV CHIR ORTHOP, V75, P65
   Delesse MA, 1847, CR HEBD ACAD SCI, V25, P544
   EGGLI PS, 1988, CLIN ORTHOP RELAT R, P127
   GREEN E, 1986, CLIN ORTHOP RELAT R, P292
   HERNIGOU P, 1995, INNOV TECH BIOL MED, V16, P194
   JARCHO M, 1981, CLIN ORTHOP RELAT R, P259
   KITSUGI T, 1993, BIOMATERIALS, V14, P216, DOI 10.1016/0142-9612(93)90026-X
   KRAMER IRH, 1968, ARCH ORAL BIOL, V13, P1095, DOI 10.1016/0003-9969(68)90063-0
   Lu J. X., 1997, BIOCERAMICS, V10, P583
   MAXIAN SH, 1993, J BIOMED MATER RES, V27, P717, DOI 10.1002/jbm.820270604
   OHASHI H, 1994, J MATER SCI-MATER M, V5, P237, DOI 10.1007/BF00121095
   OHGUSHI H, 1990, J BIOMED MATER RES, V24, P1563, DOI 10.1002/jbm.820241202
   Ohgushi H, 1996, J BIOMED MATER RES, V32, P333, DOI 10.1002/(SICI)1097-4636(199611)32:3<333::AID-JBM5>3.0.CO;2-T
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   PETITE H, 1994, J MATER SCI-MATER M, V5, P368, DOI 10.1007/BF00058965
   RADDER AM, 1994, J BIOMED MATER RES, V28, P141, DOI 10.1002/jbm.820280202
   RENOOIJ W, 1985, CLIN ORTHOP RELAT R, P272
   SCHWARTZ Z, 1994, J CELL BIOCHEM, V56, P340, DOI 10.1002/jcb.240560310
   SIMMONS DJ, 1985, CLIN ORTHOP RELAT R, P100
NR 20
TC 138
Z9 152
U1 4
U2 9
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD DEC 5
PY 1998
VL 42
IS 3
BP 357
EP 367
DI 10.1002/(SICI)1097-4636(19981205)42:3<357::AID-JBM3>3.0.CO;2-I
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 125XK
UT WOS:000076262200002
PM 9788497
DA 2018-10-19
ER

PT J
AU Christoforou, C
   Lin, XH
   Bennett, S
   Connors, D
   Skalla, W
   Mustoe, TA
   Linehan, J
   Arnold, F
   Gruskin, EA
AF Christoforou, C
   Lin, XH
   Bennett, S
   Connors, D
   Skalla, W
   Mustoe, TA
   Linehan, J
   Arnold, F
   Gruskin, EA
TI Biodegradable positively charged ion exchange beads: A novel biomaterial
   for enhancing soft tissue repair
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE charged beads; soft tissue repair; degradable; wound healing;
   crosslinked diethylaminoethanol dextran
ID SURFACE-CHARGE; DEAE-DEXTRAN
AB Previous work in the area of vulnerary agents is extensive. One material of focus has been positively charged ion exchange beads, which have been shown to promote a variety of wound-healing responses in several models. The goal of this work was to improve upon the clinical utility of positively charged dextran beads by creating a biodegradable version that maintains the material's inherent efficacy. A chemical method consisting of a sodium periodate oxidation was used to create a degradable diethylaminoethanol crosslinked dextran bead. The ability of this process to create a degradable bead was verified in vitro and in vivo. Furthermore, efficacy was shown in a rat linear incision model for a variety of beads exhibiting different degradation rates. The results show that efficacy is maintained by a degradable bead, but there is a diminution of the magnitude of the response as the mass loss rate is increased. Efficacy also was investigated for a moderate but completely degrading bead material over time and dose. Wound breaking strength was evaluated at days 7, 10, 14, 21, and 28 for degradable beads at doses of 10 mg/mL and 50 mg/mL. Although little difference in efficacy was noted for the increased dose, statistically significant increases over control were seen at days 7, 10, and 14 for the 10 mg/mL dose and at days 10 and 14 for the 50 mg/mL dose. At days 21 and 28 there were no differences between treated and control wounds. (C) 1998 John Wiley & Sons, Inc.
C1 US Surg Corp, N Haven, CT 06473 USA.
   Northwestern Univ, Sch Med, Chicago, IL USA.
   Oxford Brookes Univ, Oxford OX3 0BP, England.
RP Christoforou, C (reprint author), US Surg Corp, PDF Bldg,195 McDermott Rd, N Haven, CT 06473 USA.
RI Linehan, John/B-7627-2009
CR BOTTENBERG P, 1991, J PHARM PHARMACOL, V43, P457, DOI 10.1111/j.2042-7158.1991.tb03514.x
   DAI L, 1995, POLYM REPRINTS, V36, P82
   DUNSTAN CR, 1988, METABOLISM, V37, P815, DOI 10.1016/0026-0495(88)90113-8
   EPPLEY BL, 1994, ANN PLAS SURG, V32, P463, DOI 10.1097/00000637-199405000-00004
   FRIMAN S, 1993, J HEPATOL, V17, P48, DOI 10.1016/S0168-8278(05)80520-3
   Galiano RD, 1996, ANN PLAS SURG, V36, P608, DOI 10.1097/00000637-199606000-00008
   Gilman A. G., 1990, PHARM BASIS THERAPEU
   Godin C, 1996, EUR BIOPHYS J BIOPHY, V25, P25, DOI 10.1007/s002490050012
   Greisler H P, 1990, Ann Vasc Surg, V4, P98, DOI 10.1007/BF02042699
   Hunt JA, 1996, J BIOMED MATER RES, V31, P139, DOI 10.1002/(SICI)1097-4636(199605)31:1<139::AID-JBM15>3.0.CO;2-I
   KLOTZ U, 1987, CLIN PHARMACOKINET, V12, P123, DOI 10.2165/00003088-198712020-00003
   KRUKOWSKI M, 1990, J ORAL MAXIL SURG, V48, P468, DOI 10.1016/0278-2391(90)90233-R
   *MERCK CO, 1989, MERCK IND
   MUSTOE TA, 1992, PLAST RECONSTR SURG, V89, P891, DOI 10.1097/00006534-199205000-00018
   NIKKILA EA, 1976, ATHEROSCLEROSIS, V24, P407, DOI 10.1016/0021-9150(76)90133-7
   OREDSSON SU, 1986, SURGERY, V94, P453
   PUPITA F, 1983, INT J CLIN PHARM RES, V3, P287
   RYAN CM, 1992, J PHARM SCI, V81, P350, DOI 10.1002/jps.2600810412
   SAIFER MGP, 1994, ADV EXP MED BIOL, V366, P377
   SHAH FH, 1994, ASIA-PAC J MOL BIOL, V2, P107
   SIMONS LA, 1976, CLIN EXP PHARMACOL P, V3, P99, DOI 10.1111/j.1440-1681.1976.tb00595.x
   SOMACK R, 1991, FREE RADICAL RES COM, V12-3, P553
   TOUFIK J, 1995, BIOMATERIALS, V16, P1081, DOI 10.1016/0142-9612(95)98904-S
   VARANI J, 1995, J BIOMED MATER RES, V29, P993, DOI 10.1002/jbm.820290811
   WU L, IN PRESS J SURG RES
NR 25
TC 9
Z9 9
U1 0
U2 6
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD DEC 5
PY 1998
VL 42
IS 3
BP 376
EP 386
DI 10.1002/(SICI)1097-4636(19981205)42:3<376::AID-JBM5>3.0.CO;2-G
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 125XK
UT WOS:000076262200004
PM 9788499
DA 2018-10-19
ER

PT J
AU Gao, JM
   Niklason, L
   Langer, R
AF Gao, JM
   Niklason, L
   Langer, R
TI Surface hydrolysis of poly(glycolic acid) meshes increases the seeding
   density of vascular smooth muscle cells
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE surface modification; poly(glycolic acid); cell seeding density;
   vascular smooth muscle cells; tissue engineering; biomaterials
ID BLOOD-VESSEL; POLYMERS; ADHESION; SERUM; ASSAY; VEIN; DNA
AB A procedure for surface hydrolysis of poly(glycolic acid) (PGA) meshes was developed to increase cell seeding density and improve attachment of vascular smooth muscle cells. Hydrolysis of PGA in 1N NaOH transformed ester groups on the surface of PGA fibers to carboxylic acid and hydroxyl groups. After hydrolysis, the polymer scaffold retained its original gross appearance and dimensions while the fiber diameter decreased. A plot of fiber diameter versus the hydrolysis time showed a linear relationship, with a rate of decrease in fiber diameter of 0.65 mu m/min. The molecular weight and thermal properties of the polymer did not change significantly following surface hydrolysis. In cell seeding experiments, surface-hydrolyzed mesh was seeded with more than twice as many cells as unmodified PGA mesh. Vascular smooth muscle cells attached to the surface-hydrolyzed PGA mesh both as individual cells and as cell aggregates while only cell aggregates were observed on the unmodified mesh. Control experiments indicated that adsorption of serum proteins onto the surface-hydrolyzed PGA fibers was correlated with the increase in cell seeding density. These results demonstrate that optimization of biomaterial-cell interactions provides a strategy for increasing the initial cell seeding density for the engineering of tissues of high cell density. (C) 1998 John Wiley & Sons, Inc.
C1 MIT, Dept Chem Engn, Cambridge, MA 02139 USA.
   Massachusetts Gen Hosp, Dept Anesthesia, Boston, MA 02114 USA.
RP Langer, R (reprint author), MIT, Dept Chem Engn, Cambridge, MA 02139 USA.
FU NHLBI NIH HHS [HL03492-02]
CR CIMA LG, 1991, J BIOMECH ENG-T ASME, V113, P143, DOI 10.1115/1.2891228
   COHN D, 1987, POLYMER, V28, P2018, DOI 10.1016/0032-3861(87)90035-8
   COX JL, 1991, PROG CARDIOVASC DIS, V34, P45, DOI 10.1016/0033-0620(91)90019-I
   CURTIS ASG, 1984, J CELL SCI, V71, P17
   DAVIES MG, 1994, CRYOBIOLOGY, V31, P63, DOI 10.1006/cryo.1994.1008
   FRAZZA E J, 1971, Journal of Biomedical Materials Research Biomedical Materials Symposium, V1, P43
   FREED LE, 1994, BIO-TECHNOL, V12, P689, DOI 10.1038/nbt0794-689
   FREED LE, 1993, J CELL BIOCHEM, V51, P257, DOI 10.1002/jcb.240510304
   FRESHNEY RI, 1994, CULTURE ANIMAL CELLS, P127
   Gao J., UNPUB
   KIM YJ, 1988, ANAL BIOCHEM, V174, P168, DOI 10.1016/0003-2697(88)90532-5
   KOWALCZYNSKA HM, 1991, J CELL SCI, V99, P587
   LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7
   LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529
   Lanza R. P., 1997, PRINCIPLES TISSUE EN
   LEE RMK, 1979, SCANNING ELECTRON MI, V3, P439
   LEE RMKW, 1982, J MICROSC-OXFORD, V125, P77, DOI 10.1111/j.1365-2818.1982.tb00324.x
   LHEUREUX N, 1993, J VASC SURG, V17, P499, DOI 10.1016/0741-5214(93)90150-K
   MIKOS AG, 1993, J BIOMED MATER RES, V27, P183, DOI 10.1002/jbm.820270207
   Mooney DT, 1996, BIOMATERIALS, V17, P115, DOI 10.1016/0142-9612(96)85756-5
   Nerem R M, 1995, Tissue Eng, V1, P3, DOI 10.1089/ten.1995.1.3
   NETTER J, 1988, APPL STAT, P329
   Rhodin J.A.G, 1980, HDB PHYSL 2, P1
   SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787
   VACANTI CA, 1991, PLAST RECONSTR SURG, V88, P753, DOI 10.1097/00006534-199111000-00001
   VANDERLEI B, 1987, SURGERY, V101, P459
   WEINBERG CB, 1986, SCIENCE, V231, P397, DOI 10.1126/science.2934816
   WYATT PJ, 1993, ANAL CHIM ACTA, V272, P1, DOI 10.1016/0003-2670(93)80373-S
NR 28
TC 252
Z9 265
U1 3
U2 47
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD DEC 5
PY 1998
VL 42
IS 3
BP 417
EP 424
DI 10.1002/(SICI)1097-4636(19981205)42:3<417::AID-JBM11>3.3.CO;2-N
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 125XK
UT WOS:000076262200010
PM 9788505
DA 2018-10-19
ER

PT J
AU Vacheethasanee, K
   Temenoff, JS
   Higashi, JM
   Gary, A
   Anderson, JM
   Bayston, R
   Marchant, RE
AF Vacheethasanee, K
   Temenoff, JS
   Higashi, JM
   Gary, A
   Anderson, JM
   Bayston, R
   Marchant, RE
TI Bacterial surface properties of clinically isolated Staphylococcus
   epidermidis strains determine adhesion on polyethylene
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE Staphylococcus epidermidis; bacterial adhesion; polyethylene; rotating
   disk system; microbial adhesion to hydrocarbon; electrostatic
   chromatography
ID COAGULASE-NEGATIVE STAPHYLOCOCCI; INTRAVASCULAR CATHETERS; HYDROPHOBIC
   BIOMATERIAL; PLASMA-PROTEINS; IN-VITRO; ADHERENCE; THERMODYNAMICS;
   ENUMERATION; POLYMERS
AB The role of surface physiochemical properties of Staphylococcus epidermidis strains in adhesion to polyethylene (PE) was investigated under physiological flow conditions in phosphate buffered saline (PBS) and 1% platelet poor plasma (PPP). Four clinically isolated strains were divided into two groups: low and high relative hydrophobicity, and the F1198 and RP62A strains showing significantly greater hydrophobicity than the F21 and F1018 strains. In PBS, adhesion of all S. epidermidis strains was shear dependent from 0 to 15 dyn/cm, after which adhesion becomes shear independent. Strains with higher surface hydrophobicity showed higher adhesion to PE, demonstrating the influence of bacterial surface hydrophobicity in nonspecific adhesion. Bacterial adhesion correlated well with bacterial surface hydrophobicity at low shear stresses (0-8 dyn/cm(2)). In 1% PPP, adhesion of all strains dramatically decreased and we found no correlation between bacterial surface hydrophobicity and adhesion. The presence of plasma proteins reduced nonspecific adhesion. S. epidermidis surface charge did not correlate with bacterial adhesion in either test media. The results suggested that S. epidermidis surface hydrophobicity may mediate nonspecific adhesion to PE at low shear stresses in protein-free media. (C) 1998 John Wiley & Sons, Inc.
C1 Case Western Reserve Univ, Dept Macromol Sci, Cleveland, OH 44106 USA.
   Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA.
   Univ Nottingham, Div Microbiol & Infect Dis, Nottingham NG7 2RD, England.
   Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA.
RP Marchant, RE (reprint author), Case Western Reserve Univ, Dept Macromol Sci, Cleveland, OH 44106 USA.
EM rxm4@po.cwru.edu
FU NHLBI NIH HHS [HL47300]
CR ABSOLOM DR, 1983, APPL ENVIRON MICROB, V46, P90
   ABSOLOM DR, 1988, CAN J MICROBIOL, V34, P287, DOI 10.1139/m88-054
   BAYSTON R, 1972, DEV MED CHILD NEUROL, V14, P25
   Brydon HL, 1996, J NEUROL NEUROSUR PS, V60, P671, DOI 10.1136/jnnp.60.6.671
   CARBALLO J, 1991, MED MICROBIOL IMMUN, V180, P149
   CHRISTENSEN GD, 1993, HOSP PRACT, V28, P27, DOI 10.1080/21548331.1993.11442920
   CHRISTENSEN GD, 1987, J AM GERIATR SOC, V35, P469, DOI 10.1111/j.1532-5415.1987.tb04673.x
   COTTONARO CN, 1981, ASAIO T, V27, P391
   DOYLE RJ, 1995, METHOD ENZYMOL, V253, P542
   ESPERSEN F, 1994, J MED MICROBIOL, V40, P37, DOI 10.1099/00222615-40-1-37
   EVANSHURRELL JA, 1993, FEMS MICROBIOL LETT, V107, P77
   Galliani S, 1996, J LAB CLIN MED, V127, P71, DOI 10.1016/S0022-2143(96)90168-7
   GALLIANI S, 1994, J LAB CLIN MED, V123, P685
   GILBERT P, 1991, J APPL BACTERIOL, V71, P72
   GRAY ED, 1984, LANCET, V1, P367
   GRISTINA AG, 1990, PATHOGENESIS OF WOUND AND BIOMATERIAL-ASSOCIATED INFECTIONS, P193
   Gristina Anthony G., 1994, P131
   HERRMANN M, 1988, J INFECT DIS, V158, P693, DOI 10.1093/infdis/158.4.693
   HIGASHI JM, HDB BIOMATERIALS EVA
   HOGT AH, 1985, J GEN MICROBIOL, V131, P2485
   HOGT AH, 1986, INFECT IMMUN, V51, P294
   HOGT AH, 1985, A VAN LEEUW J MICROB, V51, P510, DOI 10.1007/BF00404506
   KRISTINSSON KG, 1989, J MED MICROBIOL, V28, P249, DOI 10.1099/00222615-28-4-249
   KRONVALL G, 1977, ACTA PATH MICRO IM B, V85, P249
   LAMMLER C, 1988, CAN J MICROBIOL, V34, P1
   Maniatis T., 1982, MOL CLONING LAB MANU
   PASCUAL A, 1986, EUR J CLIN MICROBIOL, V5, P518, DOI 10.1007/BF02017694
   PEDERSEN K, 1980, FEMS MICROBIOLOGY LE, V12, P365
   REIFSTECK F, 1987, J MED MICROBIOL, V24, P65, DOI 10.1099/00222615-24-1-65
   ROSENBERG M, 1980, FEMS MICROBIOL LETT, V9, P29, DOI 10.1111/j.1574-6968.1980.tb05599.x
   ROZALSKA B, 1995, FEMS IMMUNOL MED MIC, V11, P307, DOI 10.1111/j.1574-695X.1995.tb00161.x
   SIERACKI ME, 1985, APPL ENVIRON MICROB, V49, P799
   Sugarman B, 1989, Infect Dis Clin North Am, V3, P187
   VAUDAUX PE, 1995, INFECT IMMUN, V63, P585
   WANG I, 1993, J BIOMED MATER RES, V27, P1119, DOI 10.1002/jbm.820270902
   WANG IW, 1993, J INFECT DIS, V167, P329, DOI 10.1093/infdis/167.2.329
   WANG IW, 1995, J BIOMED MATER RES, V29, P485, DOI 10.1002/jbm.820290408
NR 37
TC 55
Z9 57
U1 0
U2 16
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD DEC 5
PY 1998
VL 42
IS 3
BP 425
EP 432
DI 10.1002/(SICI)1097-4636(19981205)42:3<425::AID-JBM12>3.0.CO;2-F
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 125XK
UT WOS:000076262200011
PM 9788506
DA 2018-10-19
ER

PT J
AU Kitano, T
   Ohashi, H
   Kadoya, Y
   Kobayashi, A
   Yutani, Y
   Yamano, Y
AF Kitano, T
   Ohashi, H
   Kadoya, Y
   Kobayashi, A
   Yutani, Y
   Yamano, Y
TI Measurements of zeta potentials of particulate biomaterials in
   protein-rich hyaluronan solution with changes in pH and protein
   constituents
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE zeta potential; wear particles; inflammatory synovial fluid; polymethyl
   methacrylate (PMMA); ultrahigh molecular weight polyethylene (UHMWPE)
ID RABBIT TIBIA; LUBRICATION; PARTICLES; FLUID
AB This study was undertaken to determine the zeta potentials of particulate biomaterials in three types of protein-rich hyaluronan solution with changes in pH; a microelectrophoretic method was used. For the purpose of determining the pH value of synovial fluid in various inflammatory conditions, we collected synovial fluid samples from joints with osteoarthritis (OA), rheumatoid arthritis (RA), and those undergoing revisions arthroplasties. The mean values of the pH in the synovial fluid from joints with OA, RA, and revision arthroplasty were shown to be 7.9, 7.5, and 8.1, respectively. The pH-zeta potential curves obtained differed, depending on the biomaterial and the medium. Addition of gamma-globulin to the medium reduced the absolute value of the zeta potentials of some of the biomaterials. The findings of this study suggest that the electrophoretic behaviors of the particulate biomaterials tested in this study are affected by the protein constituents of and pH changes in protein-rich synovial fluid. The values we obtained will be useful as reference standards and will also aid in the study of the surface phenomena of biomaterials. (C) 1998 John Wiley & Sons, Inc.
C1 Osaka City Univ, Sch Med, Dept Orthopaed Surg, Abeno Ku, Osaka 5450051, Japan.
RP Kitano, T (reprint author), Osaka City Univ, Sch Med, Dept Orthopaed Surg, Abeno Ku, 1-5-7 Asahimachi, Osaka 5450051, Japan.
EM tkitano@med.osaka-cu.ac.jp
CR CHARNLEY J, 1979, LOW FRICTION ARTHROP
   CUMMINGS NA, 1966, ARTHRITIS RHEUM, V9, P47, DOI 10.1002/art.1780090106
   DELECRIN J, 1994, CLIN ORTHOP RELAT R, P240
   FALCHUK KH, 1970, AM J MED, V49, P223, DOI 10.1016/S0002-9343(70)80078-X
   GOLDIE I, 1969, ACTA ORTHOP SCAND, V40, P634, DOI 10.3109/17453676908989529
   GOODMAN SB, 1988, CLIN ORTHOP RELAT R, P255
   GOODMAN SB, 1990, J BIOMED MATER RES, V24, P517, DOI 10.1002/jbm.820240408
   GOODMAN SB, 1993, BIOMATERIALS, V14, P723, DOI 10.1016/0142-9612(93)90035-Z
   GRISTINA AG, 1994, CLIN ORTHOP RELAT R, P106
   HANNIG K, 1990, FREE FLOW ELECTROPHO, P13
   HIGAKI H, 1995, J JPN SOC TRIBOLOGIS, V40, P598
   HILLS BA, 1989, J RHEUMATOL, V16, P82
   KOFOED H, 1986, INJURY, V17, P391, DOI 10.1016/0020-1383(86)90078-1
   KOWALCHUK RM, 1995, J BIOMED MATER RES, V29, P47, DOI 10.1002/jbm.820290108
   MANGIONE P, 1990, INT ORTHOP, V14, P393
   MCCARTY DJ, 1989, ARTHRITIS ALLIED CON, P69
   Ropes MW, 1940, J CLIN INVEST, V19, P795, DOI 10.1172/JCI101182
   SHANBHAG AS, 1994, J BIOMED MATER RES, V28, P81, DOI 10.1002/jbm.820280111
   WALKER PS, 1973, ACTA ORTHOP BELG, V1, P43
   WIERSEMA PH, 1966, J COLLOID INTERF SCI, V22, P78, DOI 10.1016/0021-9797(66)90069-5
NR 20
TC 17
Z9 17
U1 1
U2 3
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD DEC 5
PY 1998
VL 42
IS 3
BP 453
EP 457
DI 10.1002/(SICI)1097-4636(19981205)42:3<453::AID-JBM15>3.0.CO;2-H
PG 5
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 125XK
UT WOS:000076262200014
PM 9788509
DA 2018-10-19
ER

PT J
AU Skarja, GA
   Brash, JL
   Bishop, P
   Woodhouse, KA
AF Skarja, GA
   Brash, JL
   Bishop, P
   Woodhouse, KA
TI Protein and platelet interactions with thermally denatured fibrinogen
   and cross-linked fibrin coated surfaces
SO BIOMATERIALS
LA English
DT Article
DE fibrin; protein adsorption; platelets; blood compatibility; surface
   coating
ID WHOLE-BLOOD; ADSORPTION; THROMBIN; POLYETHYLENE; ACTIVATION; PLASMA;
   POLYURETHANES; ACCUMULATION; ALBUMIN; BINDING
AB In this work the hypothesis that a mature, cross-linked fibrin clot, pre-formed on a biomaterial, may be relatively nonthrombogenic was investigated. A cross-linked fibrin layer was formed on polyethylene which had been precoated with thermally denatured fibrinogen. Plasma protein adsorption and platelet interactions with the cross-linked fibrin and denatured fibrinogen surfaces were investigated. The adsorption of albumin, fibrinogen, and fibronectin from plasma was measured. For all three proteins, the cross-linked fibrin surface exhibited much higher levels of adsorption than either the thermally denatured fibrinogen or the polyethylene surface. Vroman peaks were observed for fibrinogen and fibronectin on polyethylene but not on the cross-linked fibrin and thermally denatured fibrinogen materials. In dilute plasma the thermally denatured fibrinogen surface showed considerable resistance to protein adsorption. However, at plasma concentrations greater than about 5% normal, this protein resistance was apparently lost. Platelet interactions (adhesion and release of granule constituents from adherent platelets) using suspensions of washed platelets in the presence of red cells were investigated at shear rates of 50, 300, and 525 s(-1) using a cone and plate apparatus. The levels of platelet adhesion on the different surfaces were in the order: adsorbed fibrinogen > cross-linked fibrin > thermally denatured fibrinogen = polyethylene. Platelets on the cross-linked fibrin surface also showed high levels of release indicating significant platelet activation. Scanning electron microscopic observations were in agreement with the platelet adhesion and release data, showing only a few (but well-spread) adherent platelets on the cross-linked fibrin surface. (C) 1998 Elsevier Science Ltd. All rights reserved.
C1 McMaster Univ, Dept Chem Engn, Hamilton, ON L8S 4L7, Canada.
   Zymogenet Inc, Seattle, WA 98105 USA.
RP Woodhouse, KA (reprint author), Univ Toronto, Dept Chem Engn & Appl Chem, Toronto, ON M5S 3E5, Canada.
CR ANDRADE J D, 1991, Journal of Biomaterials Science Polymer Edition, V2, P161
   BRASH JL, 1989, J BIOMED MATER RES, V23, P157, DOI 10.1002/jbm.820230203
   BRASH JL, 1979, J POLYM SCI POL SYM, P377
   BRASH JL, 1992, BLOOD COMPATIBLE MAT, P3
   BURKEL WE, 1989, MED PROG TECHNOL, V14, P165
   CHIU YL, 1988, BLOOD CELLS, V13, P437
   EBERHART RC, 1987, ANN NY ACAD SCI, V516, P78, DOI 10.1111/j.1749-6632.1987.tb33032.x
   ELAM JH, 1992, BIOMATERIALS, V13, P3, DOI 10.1016/0142-9612(92)90086-4
   GOLDSMITH HL, 1986, THROMB HAEMOSTASIS, V55, P415
   HAMAGUCHI M, 1993, BLOOD, V81, P2348
   HORBETT TA, 1984, THROMB HAEMOSTASIS, V51, P174
   ITO Y, 1992, J BIOMED MATER RES, V26, P1065, DOI 10.1002/jbm.820260808
   JEN CJ, 1991, AM J PHYSIOL, V261, pH1457
   KUMAR R, 1994, THROMB HAEMOSTASIS, V72, P713
   MARTAKOS P, 1995, ASAIO J, V41, pM735, DOI 10.1097/00002480-199507000-00110
   MARTINEZSALES V, 1995, HAEMOSTASIS, V25, P158
   MCMANAMA G, 1986, BLOOD, V68, P363
   MULVIHILL JN, 1990, J BIOMED MATER RES, V24, P155, DOI 10.1002/jbm.820240203
   MUSTARD JF, 1972, BRIT J HAEMATOL, V22, P193, DOI 10.1111/j.1365-2141.1972.tb08800.x
   NIEVELSTEIN PFEM, 1988, ARTERIOSCLEROSIS, V8, P200, DOI 10.1161/01.ATV.8.2.200
   NIEWIAROWSKI S, 1972, J CLIN INVEST, V51, P685, DOI 10.1172/JCI106857
   OKKEMA AZ, 1991, J BIOMED MATER RES, V25, P1371, DOI 10.1002/jbm.820251106
   PACKHAM MA, 1969, J LAB CLIN MED, V73, P686
   RUBENS F, 1992, J BIOMED MATER RES, V26, P1651, DOI 10.1002/jbm.820261209
   RUBENS FD, 1993, THROMB HAEMOSTASIS, V69, P130
   RUBENS FD, 1995, THROMB HAEMOSTASIS, V73, P850
   SCOTT C F, 1991, Journal of Biomaterials Science Polymer Edition, V2, P173
   Skarja GA, 1997, J BIOMED MATER RES, V34, P439, DOI 10.1002/(SICI)1097-4636(19970315)34:4<439::AID-JBM5>3.0.CO;2-L
   Skarja GA, 1997, J BIOMED MATER RES, V34, P427, DOI 10.1002/(SICI)1097-4636(19970315)34:4<427::AID-JBM4>3.3.CO;2-R
   VOEGEL JC, 1987, COLLOID SURFACE, V25, P139, DOI 10.1016/0166-6622(87)80297-4
   WHICHER SJ, 1978, J BIOMED MATER RES, V12, P181, DOI 10.1002/jbm.820120205
   WOODHOUSE KA, 1992, J COLLOID INTERF SCI, V152, P60, DOI 10.1016/0021-9797(92)90008-A
NR 32
TC 22
Z9 23
U1 1
U2 12
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD DEC
PY 1998
VL 19
IS 23
BP 2129
EP 2138
DI 10.1016/S0142-9612(98)00045-3
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 146QE
UT WOS:000077441200002
PM 9884053
DA 2018-10-19
ER

PT J
AU Imai, T
   Watari, F
   Yamagata, S
   Kobayashi, M
   Nagayama, K
   Toyoizumi, Y
   Nakamura, S
AF Imai, T
   Watari, F
   Yamagata, S
   Kobayashi, M
   Nagayama, K
   Toyoizumi, Y
   Nakamura, S
TI Mechanical properties and aesthetics of FRP orthodontic wire fabricated
   by hot drawing
SO BIOMATERIALS
LA English
DT Article
DE orthodontic wire; composite; FRP; glass fiber; Young's modulus;
   biomaterial
AB The FRP wires 0.5 mm in diameter with a multiple fiber structure were fabricated by drawing the fiber-polymer complex at 250 degrees C for an esthetic, transparent orthodontic wire. Biocompatible CaO-P2O5-SiO2-Al2O3 (CPSA) glass fibers of 8-20 mu m in diameter were oriented unidirectionally in the longitudinal direction in PMMA matrix. The mechanical properties were investigated by 3-point flexural test. The FRP wire showed sufficient strength and a very good elastic recovery after deformation. Young's modulus and the flexural load at deflection 1 mm were nearly independent of the fiber diameter and linearly increased with the fiber fraction. The dependence on fiber fraction obeys well the rule of mixture. This FRP wire could cover the range of strength corresponding to the conventional metal orthodontic wires from Ni-Ti used in the initial stage of orthodontic treatments to Co-Cr used in the final stage by changing the volume ratio of glass fibers with the same external diameter. The estheticity in external appearance was excellent. Thus the new FRP wire can satisfy both mechanical properties necessary for an orthodontic wire and enough estheticity, which was not possible for the conventional metal wire. (C) 1998 Published by Elsevier Science Ltd. All rights reserved.
C1 Hokkaido Univ, Sch Dent, Sapporo, Hokkaido 060, Japan.
   Chiba Inst Technol, Narashino, Chiba 275, Japan.
RP Watari, F (reprint author), Hokkaido Univ, Sch Dent, Sapporo, Hokkaido 060, Japan.
CR ANDREASEN GF, 1971, J AM DENT ASSOC, V82, P1373, DOI 10.14219/jada.archive.1971.0209
   Anusavice KJ., 1996, PHILLIPS SCI DENT MA, P237
   CRAIG RG, 1997, RESTORATIVE DENT MAT, P247
   Graber TM, 1985, ORTHODONTICS CURRENT
   KAPILA S, 1989, AM J ORTHOD DENTOFAC, V96, P100, DOI 10.1016/0889-5406(89)90251-5
   KOBAYASHI M, 1984, ORTHO CERAMIC IMPLAN, V4, P79
   MORISHITA M, 1987, BIOMATERIALS CLIN AP, V7, P275
   NEWMAN GV, 1965, AMER J ORTHODONTICS, V51, P901, DOI 10.1016/0002-9416(65)90203-4
   Swartz M L, 1988, J Clin Orthod, V22, P82
   THUROW RC, 1982, EDGEWISE ORTHODONTIC
   WATARI F, 1996, P 9 INT S CER MED OX, V9, P469
   WATARI F, 1996, P INT C MICR FUNCT M, P141
NR 12
TC 24
Z9 25
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD DEC
PY 1998
VL 19
IS 23
BP 2195
EP 2200
DI 10.1016/S0142-9612(98)00127-6
PG 6
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 146QE
UT WOS:000077441200009
PM 9884060
DA 2018-10-19
ER

PT J
AU Lincks, J
   Boyan, BD
   Blanchard, CR
   Lohmann, CH
   Liu, Y
   Cochran, DL
   Dean, DD
   Schwartz, Z
AF Lincks, J
   Boyan, BD
   Blanchard, CR
   Lohmann, CH
   Liu, Y
   Cochran, DL
   Dean, DD
   Schwartz, Z
TI Response of MG63 osteoblast-like cells to titanium and titanium alloy is
   dependent on surface roughness and composition
SO BIOMATERIALS
LA English
DT Article
DE osteoblasts; titanium; titanium alloy; surface roughness; PGE(2);
   TGF-beta; in vitro
ID GROWTH-FACTOR-BETA; EXTRACELLULAR-MATRIX; ALKALINE-PHOSPHATASE;
   CARTILAGE CELLS; TGF-BETA; BONE; DIFFERENTIATION; INVITRO;
   PROLIFERATION; IMPLANTS
AB The success of an implant is determined by its integration into the tissue surrounding the biomaterial. Surface roughness and composition are considered to influence the properties of adherent cells. The aim of this study was to determine the effect of chemical composition and surface roughness of commercially pure titanium (Ti) and Ti-6Al-4V alloy (Ti-A) on MG63 osteoblast-like cells. Unalloyed and alloyed Ti disks were machined and either fine-polished or wet-ground, resulting in smooth (S) and rough (R) finishes, respectively. Standard tissue culture plastic was used as a control. Surface topography and profile were evaluated by cold field emission scanning electron microscopy and profilometry, while chemical composition was determined using Auger electron spectroscopy and Fourier transform infrared spectroscopy. The effect on the cells was evaluated 24 h postconfluence by measuring cell number, [H-3]-thymidine incorporation into DNA, cell and cell layer alkaline phosphatase specific activity (ALPase), osteocalcin and collagen production, [S-35]-sulfate incorporation into proteoglycan, and prostaglandin E-2 (PGE(2)) and transforming growth factor-beta (TGF-beta) production. When compared to plastic, the number of cells was reduced on the pure Ti surfaces, while it was equivalent on the Ti-A surfaces; [H-3]-thymidine incorporation was reduced on all surfaces. The stimulatory effect of surface roughness on ALPase in isolated cells and the cell layer was more pronounced on the rougher surfaces, with enzyme activity on TI-R being greater than on TfA-R. Osteocalcin production was increased only on the TI-R surface. Collagen production was decreased on Ti surfaces except Ti-R; [S-35]-sulfate incorporation was reduced on all surfaces. Surface roughness affected local factor production (TGF-beta, PGE(2)). The stimulatory effect of the rougher surfaces on PGE(2) and TGF-beta was greater on Ti than Ti-A. In summary, cell proliferation, differentiation, protein synthesis and local factor production were affected by surface roughness and composition. Enhanced differentiation of cells grown on rough vs. smooth surfaces for both Ti and Ti-A surfaces was indicated by decreased proliferation and increased ALPase and osteocalcin production. Local factor production was also enhanced on rough surfaces, supporting the contention that these cells are more differentiated. Surface composition also played a role in cell differentiation, since cells cultured on Ti-R surfaces produced more ALPase than those cultured on Ti-A-R. While it is still unknown which material properties induce which cellular responses, this study suggests that surface roughness and composition may play a major role and that the best design for an orthopaedic implant is a pure titanium surface with a rough microtopography. (C) 1998 Published by Elsevier Science Ltd. All rights reserved.
C1 Univ Texas, Hlth Sci Ctr, Dept Periodont, San Antonio, TX 78284 USA.
   Wilford Hall USAF Med Ctr, Lackland AFB, TX 78236 USA.
   Univ Texas, Hlth Sci Ctr, Dept Orthopaed, San Antonio, TX 78284 USA.
   Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA.
   SW Res Inst, San Antonio, TX USA.
   Hebrew Univ Jerusalem, Hadassah Fac Dent Med, Dept Periodont, Jerusalem, Israel.
RP Boyan, BD (reprint author), Univ Texas, Hlth Sci Ctr, Dept Periodont, San Antonio, TX 78284 USA.
EM BoyanB@uthscsa.edu
OI lohmann, christoph/0000-0002-2962-2183; Dean, David/0000-0002-4512-9065
CR AKATSU T, 1991, J BONE MINER RES, V6, P183
   ALI SY, 1984, SCI FDN ORTHOPAEDICS, P175
   ANDERSON HC, 1984, BONE MINERAL RES, P109
   ARAI T, 1989, T SOC BIOMET ANN M
   BONEWALD LF, 1992, J BIOL CHEM, V267, P8943
   BONEWALD LF, 1990, CLIN ORTHOP RELAT R, P261
   Bordji K, 1996, BIOMATERIALS, V17, P929, DOI 10.1016/0142-9612(96)83289-3
   Bowers K T, 1992, Int J Oral Maxillofac Implants, V7, P302
   Boyan B D, 1993, J Oral Implantol, V19, P116
   BOYAN BD, 1989, J BIOL CHEM, V264, P11879
   Boyan BD, 1998, J BIOMED MATER RES, V39, P77, DOI 10.1002/(SICI)1097-4636(199801)39:1<77::AID-JBM10>3.0.CO;2-L
   BOYAN BD, 1994, J BIOL CHEM, V269, P28374
   BRAUN G, 1995, CLIN ORAL IMPLAN RES, V6, P1, DOI 10.1034/j.1600-0501.1995.060101.x
   Bretaudiere J. P., 1984, METHOD ENZYMAT AN, P75
   Brunette D M, 1988, Int J Oral Maxillofac Implants, V3, P231
   BUSER D, 1991, J BIOMED MATER RES, V25, P889, DOI 10.1002/jbm.820250708
   CHEROUDI B, 1989, J BIOMED MATER RES, V23, P1067
   Cheroudi B, 1990, J BIOMED MATER RES, V24, P1203
   Choi JY, 1996, J CELL BIOCHEM, V61, P609, DOI 10.1002/(SICI)1097-4644(19960616)61:4<609::AID-JCB15>3.0.CO;2-A
   Cochran David, 1994, Int J Oral Maxillofac Implants, V9, P289
   DALLAS SL, 1995, J CELL BIOL, V131, P539, DOI 10.1083/jcb.131.2.539
   DEAN DD, 1994, CALCIFIED TISSUE INT, V54, P399, DOI 10.1007/BF00305527
   Eisenbarth E, 1996, BIOMATERIALS, V17, P1399, DOI 10.1016/0142-9612(96)87281-4
   EVANS EJ, 1987, BIOMATERIALS, V8, P377, DOI 10.1016/0142-9612(87)90009-3
   FRANCESCHI RT, 1985, J CELL PHYSIOL, V123, P401, DOI 10.1002/jcp.1041230316
   GOLIJANIN G, 1989, J DENT RES, V68, P307
   GOLIJANIN L, 1988, Journal of Dental Research, V67, P367
   GRABOWSKY KS, 1989, MATER RES SOC S P, V110, P697
   GROESSNERSCHREIBER B, 1992, J CELL SCI, V101, P209
   Hale L V, 1986, J Bone Miner Res, V1, P489
   HAMBLETON J, 1994, J ORTHOPAED RES, V12, P542, DOI 10.1002/jor.1100120411
   HENCH LL, 1973, J BIOMED MATER RES, V7, P25, DOI 10.1002/jbm.820070304
   JARCHO M, 1977, J BIOENG, V1, P79
   Kieswetter K, 1996, J BIOMED MATER RES, V32, P55, DOI 10.1002/(SICI)1097-4636(199609)32:1<55::AID-JBM7>3.0.CO;2-O
   Lausmaa J, 1986, MATER RES SOC S P, V55, P351
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MARTIN JY, 1995, J BIOMED MATER RES, V29, P389, DOI 10.1002/jbm.820290314
   Merritt K, 1985, ASTM STP, P195
   MICHAELS C M, 1989, Journal of Dental Research, V68, P276
   NORDE W, 1992, Clinical Materials, V11, P85, DOI 10.1016/0267-6605(92)90032-O
   NOWLIN P, 1989, Journal of Dental Research, V68, P275
   OKEEFE RJ, 1988, ENDOCRINOLOGY, V122, P2953, DOI 10.1210/endo-122-6-2953
   Ong J L, 1996, Implant Dent, V5, P83, DOI 10.1097/00008505-199600520-00002
   OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304
   PETERKOFSKY B, 1971, BIOCHEMISTRY-US, V10, P988, DOI 10.1021/bi00782a009
   RAISZ LG, 1990, ENDOCRINOLOGY, V126, P1654, DOI 10.1210/endo-126-3-1654
   RICH A, 1981, J CELL SCI, V50, P1
   RICKARD DJ, 1993, CALCIFIED TISSUE INT, V52, P227, DOI 10.1007/BF00298724
   ROSTOKER W, 1979, J BIOMECH ENG-T ASME, V101, P2
   SCHROEDER A, 1981, J MAXILLOFAC SURG, V9, P15, DOI 10.1016/S0301-0503(81)80007-0
   SCHWARTZ Z, 1989, J BONE MINER RES, V4, P199
   SCHWARTZ Z, 1991, CALCIFIED TISSUE INT, V49, P359, DOI 10.1007/BF02556260
   THOMAS KA, 1985, J BIOMED MATER RES, V19, P875, DOI 10.1002/jbm.820190802
   Thompson GJ, 1996, BIOMATERIALS, V17, P1949, DOI 10.1016/0142-9612(96)00009-9
   VANNOORT R, 1987, J MATER SCI, V22, P3801, DOI 10.1007/BF01133326
   VROUWENVELDER WCA, 1994, BIOMATERIALS, V15, P97, DOI 10.1016/0142-9612(94)90257-7
   WINDELER AS, 1991, BONE-BIOMATERIAL INTERFACE, P205
NR 57
TC 486
Z9 493
U1 4
U2 102
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD DEC
PY 1998
VL 19
IS 23
BP 2219
EP 2232
DI 10.1016/S0142-9612(98)00144-6
PG 14
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 146QE
UT WOS:000077441200012
PM 9884063
DA 2018-10-19
ER

PT J
AU van Susante, JLC
   Buma, P
   Homminga, GN
   van den Berg, WB
   Veth, RPH
AF van Susante, JLC
   Buma, P
   Homminga, GN
   van den Berg, WB
   Veth, RPH
TI Chondrocyte-seeded hydroxyapatite for repair of large articular
   cartilage defects. A pilot study in the goat
SO BIOMATERIALS
LA English
DT Article
DE cartilage repair; hydroxyapatite; chondrocyte; transplantation
ID MEDIAL FEMORAL CONDYLE; IN-VITRO; OSTEOCHONDRAL DEFECTS; CANINE
   CHONDROCYTES; COLLAGEN GEL; IMPLANTS; RABBIT; BONE; BEHAVIOR; KNEE
AB The aim of this study was to evaluate the potential for restoration of a large cartilage defect in the goat knee with hydroxyapatite (HA) loaded with chondrocytes. Isolated chondrocytes were suspended in fibrin glue, seeded on top of the HA, and then the composite graft was implanted in the defect. After transplantation, cell behaviour, newly synthesised matrix and the HA-glue interface were assessed histologically after 2, 4, 12, 26 and 52 weeks. Special attention was paid to the incorporation process of HA in the subchondral bone and interactions between this biomaterial and the fibrin-glue-chondrocyte suspension.
   Chondrocytes in the glue proved to survive the transplantation procedure and produced new metachromatically stained matrix two weeks after implantation. The glue-cell suspension had penetrated the superficial porous structure of the HA. Four weeks after surgery, islands of hyaline-like cartilage were observed at the HA-glue interface. A layer of fibrous tissue was formed surrounding the HA graft, resulting in a relatively instable fixation of the HA in the defect. This instability of the graft in the defect, possibly together with early weight bearing, resulted in a gradual loss of the newly formed hyaline cartilage-like repair tissue. Progressive resorption of the HA occurred without any sign of active bone remodelling from the host site. One year after surgery part of the defect which extended down to the cancellous bone had been predominantly restored with newly formed lamellar bone. Only small HA remnants were still present at the bottom of the original defect. Resurfacing of the joint had occurred with fibrocartilaginous repair tissue.
   The absence of adequate fixation capacity of the Hd near the joint space resulted in a relative instability of the graft with progressive resorption. Therefore, HA is not a suitable biomaterial to facilitate the repair of large articular cartilage defects. (C) 1998 Elsevier Science Ltd. All rights reserved.
C1 Univ Nijmegen Hosp, Dept Orthoped, Orthopaed Res Lab, NL-6500 HB Nijmegen, Netherlands.
   Priveklin Klein Rosendaal, Rozendaal, Netherlands.
   Univ Nijmegen Hosp, Lab Expt Rheumatol, NL-6500 HB Nijmegen, Netherlands.
RP van Susante, JLC (reprint author), Univ Nijmegen Hosp, Dept Orthoped, Orthopaed Res Lab, POB 9101, NL-6500 HB Nijmegen, Netherlands.
RI Berg, W.B./H-8010-2014; Buma, Pieter/C-9828-2013; Buma, P./H-8019-2014
CR BRITTBERG M, 1994, NEW ENGL J MED, V331, P889, DOI 10.1056/NEJM199410063311401
   BUCKWALTER JA, 1997, INSTR COURSE LECT, V46
   Chen F S, 1997, Am J Orthop (Belle Mead NJ), V26, P396
   Curl WW, 1997, ARTHROSCOPY, V13, P456, DOI 10.1016/S0749-8063(97)90124-9
   HOMMINGA GN, 1993, ACTA ORTHOP SCAND, V64, P441, DOI 10.3109/17453679308993663
   HOMMINGA GN, 1990, J BONE JOINT SURG BR, V72, P1003
   HOMMINGA GN, 1991, ACTA ORTHOP SCAND, V62, P415, DOI 10.3109/17453679108996635
   ITAY S, 1987, CLIN ORTHOP RELAT R, P284
   IYODA K, 1993, CLIN ORTHOP RELAT R, P287
   Kandel R A, 1997, In Vitro Cell Dev Biol Anim, V33, P174
   KLOMPMAKER J, 1992, BIOMATERIALS, V13, P625, DOI 10.1016/0142-9612(92)90031-I
   Kuboki Y, 1995, CONNECT TISSUE RES, V32, P219, DOI 10.3109/03008209509013726
   Lee D A, 1993, Osteoarthritis Cartilage, V1, P137, DOI 10.1016/S1063-4584(05)80029-9
   LINDHOLM TC, 1993, ANN CHIR GYNAECOL S, V207, P91
   MANKIN HJ, 1982, J BONE JOINT SURG AM, V64, P460, DOI 10.2106/00004623-198264030-00022
   MESSNER K, 1993, BIOMATERIALS, V14, P513, DOI 10.1016/0142-9612(93)90240-3
   MESSNER K, 1994, BIOMATERIALS, V15, P657, DOI 10.1016/0142-9612(94)90163-5
   Minas T, 1997, ORTHOPEDICS, V20, P525
   Nehrer S, 1997, J BIOMED MATER RES, V38, P95
   Nehrer S, 1997, BIOMATERIALS, V18, P769, DOI 10.1016/S0142-9612(97)00001-X
   ODRISCOLL SW, 1994, J BONE JOINT SURG AM, V76A, P1042, DOI 10.2106/00004623-199407000-00013
   ODRISCOLL SW, 1988, J BONE JOINT SURG AM, V70A, P595, DOI 10.2106/00004623-198870040-00017
   Peterson RL, 1996, BOT REV, V62, P1, DOI 10.1007/BF02868919
   REDDI AH, 1994, J CELL BIOCHEM, V56, P192, DOI 10.1002/jcb.240560213
   SCHUMAN L, 1995, BIOMATERIALS, V16, P809, DOI 10.1016/0142-9612(95)99644-2
   Suominen E, 1996, J BIOMED MATER RES, V32, P543, DOI 10.1002/(SICI)1097-4636(199612)32:4<543::AID-JBM7>3.0.CO;2-R
   TRIGLIA JM, 1993, ARCH OTOLARYNGOL, V119, P87
   VACANTI CA, 1991, PLAST RECONSTR SURG, V88, P753, DOI 10.1097/00006534-199111000-00001
   vanSusante JLC, 1995, ACTA ORTHOP SCAND, V66, P549, DOI 10.3109/17453679509002314
   VANSUSANTE JLC, 1998, IN PRESS BIOMATERIAL
   WAKITANI S, 1989, J BONE JOINT SURG BR, V71, P74
   WANG JS, 1996, ACTA ORTHOP SCAND S, V269
   Yoshikawa T, 1996, BIO-MED MATER ENG, V6, P345
NR 33
TC 66
Z9 66
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD DEC
PY 1998
VL 19
IS 24
BP 2367
EP 2374
DI 10.1016/S0142-9612(98)00158-6
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 150BU
UT WOS:000077643200016
PM 9884051
DA 2018-10-19
ER

PT J
AU Friedman, CD
   Costantino, PD
   Takagi, S
   Chow, LC
AF Friedman, CD
   Costantino, PD
   Takagi, S
   Chow, LC
TI BoneSource (TM) hydroxyapatite cement: A novel biomaterial for
   craniofacial skeletal tissue engineering and reconstruction
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article; Proceedings Paper
CT Portland Bone Symposium
CY 1997
CL PORTLAND, OREGON
DE BoneSource (TM); hydroxyapatite cement; biomaterial; craniofacial
   skeletal
ID BONE-GRAFT SUBSTITUTE; POROUS HYDROXYAPATITE; SURGERY
AB BoneSource(TM)-hydroxyapatite cement is a new self-setting calcium phosphate cement biomaterial, Its unique and innovative physical chemistry coupled with enhanced biocompatibility make it useful for craniofacial skeletal reconstruction. The general properties and clinical use guidelines are reviewed. The biomaterial and surgical applications offer insight into improved outcomes and potential new uses for hydroxyapatite cement systems. (C) 1998 John Wiley & Sons, Inc.
C1 Fox Chase Canc Ctr, Dept Surg Oncol, Philadelphia, PA 19111 USA.
   Natl Inst Stand & Technol, Amer Dent Assoc Hlth Fdn, Paffenbarger Res Ctr, Gaithersburg, MD 20899 USA.
   Mt Sinai Med Ctr, Dept Otolaryngol Head & Neck Surg, New York, NY 10029 USA.
RP Friedman, CD (reprint author), Fox Chase Canc Ctr, Dept Surg Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA.
EM C-Friedman@FCCC.edu
FU NIDCR NIH HHS [DE11789]
CR Brown P.W., 1986, CEMENTS RES PROGR, V99, P352
   CHARNLEY J, 1960, J BONE JOINT SURG BR, V42, P28
   CHOW LC, 1991, MATER RES SOC SYMP P, V179, P3
   COSTANTINO PD, 1991, ARCH OTOLARYNGOL, V117, P379
   COSTANTINO PD, IN PRESS OTOLARYNGOL
   FRIEDMAN CD, 1991, ARCH OTOLARYNGOL, V117, P384
   HOLMES RE, 1988, PLAST RECONSTR SURG, V81, P662, DOI 10.1097/00006534-198805000-00003
   HOLMES RE, 1996, COMMUNICATION    APR
   JARCHO M, 1981, CLIN ORTHOP RELAT R, P259
   KVETON JF, 1995, AM J OTOL, V16, P465
   MANSON PN, 1986, PLAST RECONSTR SURG, V77, P888, DOI 10.1097/00006534-198606000-00003
   SALYER KE, 1989, PLAST RECONSTR SURG, V84, P236, DOI 10.1097/00006534-198908000-00008
   Stelnicki EJ, 1997, J CRANIOFAC SURG, V8, P367, DOI 10.1097/00001665-199708050-00007
NR 13
TC 311
Z9 324
U1 2
U2 43
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD WIN
PY 1998
VL 43
IS 4
BP 428
EP 432
DI 10.1002/(SICI)1097-4636(199824)43:4<428::AID-JBM10>3.0.CO;2-0
PG 5
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 143MM
UT WOS:000077259500010
PM 9855201
DA 2018-10-19
ER

PT J
AU Denstedt, JD
   Wollin, TA
   Reid, G
AF Denstedt, JD
   Wollin, TA
   Reid, G
TI Biomaterials used in urology: Current issues of biocompatibility,
   infection, and encrustation
SO JOURNAL OF ENDOUROLOGY
LA English
DT Review
ID URINARY-TRACT INFECTION; SHOCK-WAVE LITHOTRIPSY; URETERAL STENTS;
   SURFACE-PROPERTIES; CATHETER ENCRUSTATION; BACTERIAL BIOFILMS; URETHRAL
   STRICTURE; CARDIAC-SURGERY; PSEUDOMONAS-AERUGINOSA; MICROBIAL ADHESION
AB This review focuses on the biomaterials used in urology, in particular, the properties of urethral catheters and ureteral stents currently being used in clinical practice. The importance of biomaterial type, biocompatibility, and encrustations are discussed and explained. Current management of bacterial infection and the importance of biofilms are presented, with recommendations based on published information.
C1 St Josephs Hlth Ctr, Lawson Res Inst, London, ON N6A 4V2, Canada.
   Univ Western Ontario, Div Urol, London, ON, Canada.
   Univ Western Ontario, Dept Immunol & Microbiol, London, ON, Canada.
RP Reid, G (reprint author), St Josephs Hlth Ctr, Lawson Res Inst, H414,268 Grosvenor St, London, ON N6A 4V2, Canada.
CR ABDELHAKIM A, 1984, J UROLOGY, V131, P1077, DOI 10.1016/S0022-5347(17)50813-7
   ABSOLOM DR, 1983, APPL ENVIRON MICROB, V46, P90
   BAIER RE, 1984, J BIOMED MATER RES, V18, P337, DOI 10.1002/jbm.820180404
   BIERKENS AF, 1991, J UROLOGY, V145, P699, DOI 10.1016/S0022-5347(17)38428-8
   Bitschay J., 1956, HIST UROLOGY EGYPT, P76
   BREGG K, 1989, J UROLOGY, V141, P510, DOI 10.1016/S0022-5347(17)40875-5
   BROWN MRW, 1988, J ANTIMICROB CHEMOTH, V22, P777, DOI 10.1093/jac/22.6.777
   BRUCE AW, 1974, CAN MED ASSOC J, V111, P238
   Candela JV, 1997, J ENDOUROL, V11, P45, DOI 10.1089/end.1997.11.45
   Characklis W., 1990, BIOFILMS, P3
   CHOONG S, 1997, J ENDOUROL S1, V11, pS50
   CHRISTENSEN GD, 1989, INFECT ASS INDWELLIN, P27
   Compan V, 1996, BIOMATERIALS, V17, P1243, DOI 10.1016/0142-9612(96)84945-3
   CORMIO L, 1995, J UROLOGY, V153, P494, DOI 10.1097/00005392-199502000-00069
   COSTERTON JW, 1987, ANNU REV MICROBIOL, V41, P435, DOI 10.1146/annurev.mi.41.100187.002251
   COX AJ, 1989, UROL RES, V17, P353, DOI 10.1007/BF00510524
   COX AJ, 1988, BRIT J UROL, V61, P156, DOI 10.1111/j.1464-410X.1988.tb05067.x
   COX AJ, 1987, BRIT J UROL, V59, P159, DOI 10.1111/j.1464-410X.1987.tb04810.x
   COX AJ, 1989, UROL RES, V17, P349, DOI 10.1007/BF00510523
   CULKIN DJ, 1992, UROLOGY, V40, P385, DOI 10.1016/0090-4295(92)90397-F
   ELFAQIH SR, 1991, J UROLOGY, V146, P1487, DOI 10.1016/S0022-5347(17)38146-6
   FERRIE BG, 1986, BRIT J UROL, V58, P549, DOI 10.1111/j.1464-410X.1986.tb05465.x
   GRAHAM DT, 1984, J BIOMED MATER RES, V18, P1125, DOI 10.1002/jbm.820180914
   GRAHAM DT, 1983, MED J AUSTRALIA, V1, P456
   GRIFFITH DP, 1976, INVEST UROL, V13, P346
   GRISTINA AG, 1987, SCIENCE, V237, P1588, DOI 10.1126/science.3629258
   HOLMES SAV, 1992, BRIT J UROL, V69, P651, DOI 10.1111/j.1464-410X.1992.tb15640.x
   HUKINS DWL, 1983, BRIT J UROL, V55, P304, DOI 10.1111/j.1464-410X.1983.tb03304.x
   JOHNSON JR, 1990, J INFECT DIS, V162, P1145, DOI 10.1093/infdis/162.5.1145
   KEANE PF, 1994, BRIT J UROL, V73, P687, DOI 10.1111/j.1464-410X.1994.tb07557.x
   KORHONEN P, 1991, UROL RES, V19, P127, DOI 10.1007/BF00368190
   Kulik E, 1996, J BIOMED MATER RES, V30, P295, DOI 10.1002/(SICI)1097-4636(199603)30:3<295::AID-JBM4>3.0.CO;2-L
   KUNIN CM, 1966, NEW ENGL J MED, V274, P1155, DOI 10.1056/NEJM196605262742101
   LIEDBERG H, 1989, UROL RES, V17, P357, DOI 10.1007/BF00510525
   MARDIS HK, 1988, UROL CLIN N AM, V15, P471
   MARX M, 1988, J UROLOGY, V139, P180, DOI 10.1016/S0022-5347(17)42349-4
   MCENTEE G, 1984, BRIT J UROL, V56, P506
   NACEY JN, 1991, NEW ZEAL MED J, V104, P355
   NACEY JN, 1985, J UROLOGY, V134, P623, DOI 10.1016/S0022-5347(17)47315-0
   NACEY JN, 1986, J UROLOGY, V136, P706, DOI 10.1016/S0022-5347(17)45032-4
   NICKEL JC, 1989, UROLOGY, V34, P284
   NICKEL JC, 1994, J ANTIMICROB CHEMOTH, V33, P31, DOI 10.1093/jac/33.suppl_A.31
   OHKAWA M, 1990, J UROLOGY, V143, P717, DOI 10.1016/S0022-5347(17)40071-1
   OSULLIVAN DC, 1991, UROL CLIN N AM, V18, P677
   Pearle MS, 1997, UROLOGY, V49, P679, DOI 10.1016/S0090-4295(96)00626-7
   PRATTTERPSTRA I, 1989, J COLLOID INTERF SCI, V129, P586
   PRINTZEN G, 1996, INJURY S3, V27, pSC9
   RAMSAY JWA, 1987, BR J UROL, V66, P66
   RATNER BD, 1980, J BIOMED MATER RES, V14, P665, DOI 10.1002/jbm.820140512
   REID G, 1994, ANTIMICROB AGENTS CH, V38, P1490, DOI 10.1128/AAC.38.7.1490
   REID G, 1992, INT BIODETER BIODEGR, V30, P105, DOI 10.1016/0964-8305(92)90057-U
   REID G, 1995, SURF SCI REP, V21, P251, DOI 10.1016/0167-5729(94)00006-9
   REID G, 1994, SURF INTERFACE ANAL, V21, P581, DOI 10.1002/sia.740210812
   REID G, 1995, COLLOID SURFACE B, V5, P171, DOI 10.1016/0927-7765(95)01208-Z
   Reid G, 1998, URINARY TRACT INFECT, P111
   REID G, 1994, COLLOID SURFACE B, V2, P377
   Reid KA, 1995, ENVIRON CHEM, V1, P269
   ROBERTS JA, 1990, J UROLOGY, V144, P264, DOI 10.1016/S0022-5347(17)39428-4
   RUUTU M, 1985, BRIT J UROL, V57, P82, DOI 10.1111/j.1464-410X.1985.tb08992.x
   RUUTU M, 1982, LANCET, V1, P218
   Ruutu M L, 1991, Scand J Urol Nephrol Suppl, V138, P235
   SALTZMAN B, 1988, UROL CLIN N AM, V15, P481
   SIEMSSEN PA, 1991, BRIT J UROL, V67, P83, DOI 10.1111/j.1464-410X.1991.tb15075.x
   STAMM WE, 1991, AM J MED S3, V3, pS65
   SUTHERLAND PD, 1983, BRIT J UROL, V55, P413, DOI 10.1111/j.1464-410X.1983.tb03334.x
   Tieszer C, 1998, J UROLOGY, V160, P876, DOI 10.1016/S0022-5347(01)62825-8
   TIESZER C, 1998, APPL BIOMATER, V43, P321
   UYEN HMW, 1989, BIOMATER ARTIF CELL, V17, P385, DOI 10.3109/10731198909118853
   VANDERWALL E, 1992, LANCET, V339, P946
   WELCH RA, 1985, GYNECOL ONCOL, V22, P356, DOI 10.1016/0090-8258(85)90051-4
   WILCOX MH, 1992, LANCET, V339, P1421, DOI 10.1016/0140-6736(92)91247-6
   WOLLIN TA, IN PRESS J ENDOUROL
   ZHANEL GG, 1990, ARCH INTERN MED, V150, P1389, DOI 10.1001/archinte.150.7.1389
NR 73
TC 79
Z9 82
U1 2
U2 18
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA
SN 0892-7790
J9 J ENDOUROL
JI J. Endourol.
PD DEC
PY 1998
VL 12
IS 6
BP 493
EP 500
DI 10.1089/end.1998.12.493
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA 155LN
UT WOS:000077948600002
PM 9895250
DA 2018-10-19
ER

PT J
AU Den Dunnen, WFA
   Meek, MF
   Robinson, PH
   Schakernraad, JM
AF Den Dunnen, WFA
   Meek, MF
   Robinson, PH
   Schakernraad, JM
TI Peripheral nerve regeneration through P(DLLA-epsilon-CL) nerve guides
SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE
LA English
DT Article
ID POLY(DL-LACTIDE-EPSILON-CAPROLACTONE)
AB P(DLLA-epsilon-CL) nerve guides can be used perfectly for short nerve gaps in rats, and are even better than short autologous nerve grafts. The tube dimensions, such as the internal diameter and wall thickness, are very important for the final outcome of peripheral nerve regeneration, as well as the recovery of nerve function. Before using biodegradable nerve guides in patients, it will be necessary to control the swelling the biomaterial during degradation. (C) 1998 Kluwer Academic Publishers.
C1 Acad Hosp Groningen, Dept Neurosurg, NL-9713 GZ Groningen, Netherlands.
   Acad Hosp Groningen, Dept Plast & Reconstruct Surg, NL-9713 GZ Groningen, Netherlands.
   BioScan, NL-3723 MB Bilthoven, Netherlands.
RP Den Dunnen, WFA (reprint author), Acad Hosp Groningen, Dept Neurosurg, Hanzeplein 1, NL-9713 GZ Groningen, Netherlands.
RI den Dunnen, Wilfred/A-4034-2009
CR DenDunnen WFA, 1996, MICROSURG, V17, P348, DOI 10.1002/(SICI)1098-2752(1996)17:7<348::AID-MICR2>3.0.CO;2-C
   denDunnen WFA, 1997, J BIOMED MATER RES, V36, P337, DOI 10.1002/(SICI)1097-4636(19970905)36:3<337::AID-JBM9>3.3.CO;2-8
   DENDUNNEN WFA, 1995, J BIOMED MATER RES, V29, P757, DOI 10.1002/jbm.820290612
   LUNDBORG G, 1980, J HAND SURG, V5, P35
   Meek MF, 1996, MICROSURG, V17, P555, DOI 10.1002/(SICI)1098-2752(1996)17:10<555::AID-MICR5>3.0.CO;2-P
NR 5
TC 27
Z9 27
U1 0
U2 3
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0957-4530
J9 J MATER SCI-MATER M
JI J. Mater. Sci.-Mater. Med.
PD DEC
PY 1998
VL 9
IS 12
BP 811
EP 814
DI 10.1023/A:1008987910224
PG 4
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 161CK
UT WOS:000078270600027
PM 15348945
DA 2018-10-19
ER

PT J
AU Hutcheon, GA
   Downes, S
   Davies, MC
AF Hutcheon, GA
   Downes, S
   Davies, MC
TI Interactions of chondrocytes with methacrylate copolymers
SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE
LA English
DT Article
ID ARTICULAR CHONDROCYTES; ADSORPTION; SYSTEM
AB Copolymers of poly (ethylmethacrylate) (PEMA) and tetrahydrofurfuryl methacrylate (THFMA) have been shown to exhibit potential as a biomaterial for use in cartilage repair. However, the interactions of chondrocytes with the polymer surface is not well understood. A series of novel methacrylate copolymers containing PEMA, THFMA and hydroxyethyl methacrylate (HEMA) were prepared and the ability of these various copolymers to support chondrocytes attachment in vitro has been assessed by the Alamar blue assay for cell number and environmental scanning electron microscopy (ESEM). As the mole fraction of HEMA in PEMA/THFMA/HEMA copolymers increased, chondrocyte attachment to the polymer surface in 24 h decreased. Chondrocytes maintained a rounded morphology and were strongly attached on the THFMA/PEMA polymer surface, but as the mole fraction of HEMA increased the cells present became much smaller with fewer cell to cell interactions. The effect of pre-adsorbing fibronectin on to the polymer surface on cell attachment was assessed both in the presence and absence of serum. Chondrocyte attachment was significantly reduced in serum-free medium. Pre-adsorption of fibronectin on to the copolymer surface substantially increased cell attachment in all cases. In conclusion, chondrocyte attachment and proliferation on these copolymers may be controlled by changes in the polymer surface chemistry and is highly sensitive to the presence of proteins either in the culture media or pre-adsorbed on to the copolymer surface. (C) 1998 Kluwer Academic Publishers.
C1 Queens Med Ctr, Sch Biomed Sci, Dept Mol & Cell Biol, Nottingham NG7 2UH, England.
   Univ Nottingham, Dept Pharmaceut Sci, Lab Biophys & Surface Anal, Nottingham NG7 2RD, England.
RP Hutcheon, GA (reprint author), Queens Med Ctr, Sch Biomed Sci, Dept Mol & Cell Biol, Nottingham NG7 2UH, England.
EM gillian.hutcheon@nottingham.ac.uk
OI Davies, Martyn/0000-0001-7695-0596; Hutcheon,
   Gillian/0000-0002-9786-2074
CR ANDRADE JD, 1986, ADV POLYM SCI, V79, P1
   ARCHER CW, 1990, J CELL SCI, V97, P361
   DOWNES S, 1994, J MATER SCI-MATER M, V5, P88, DOI 10.1007/BF00121696
   HEWITT AT, 1980, P NATL ACAD SCI-BIOL, V77, P385, DOI 10.1073/pnas.77.1.385
   HORBETT TA, 1988, J BIOMED MATER RES, V22, P763, DOI 10.1002/jbm.820220903
   KIRKPATRICK CJ, 1992, ADV BIOMAT, V10, P31
   LOESER RF, 1993, ARTHRITIS RHEUM, V36, P1103, DOI 10.1002/art.1780360811
   MCFARLAND CE, IN PRESS J BIOMED MA
   RESSISS N, 1994, J MAT SCI MAT MED, V5, P793
   SAWTELL R, 1997, THESIS U NOTTINGHAM
   Sawtell RM, 1995, J MATER SCI-MATER M, V6, P676, DOI 10.1007/BF00134299
   SAWTELL RM, 1995, CELL MATER, V5, P63
   SOMMARIN Y, 1989, EXP CELL RES, V184, P181, DOI 10.1016/0014-4827(89)90376-5
NR 13
TC 9
Z9 10
U1 0
U2 2
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0957-4530
J9 J MATER SCI-MATER M
JI J. Mater. Sci.-Mater. Med.
PD DEC
PY 1998
VL 9
IS 12
BP 815
EP 818
DI 10.1023/A:1008940027063
PG 4
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 161CK
UT WOS:000078270600028
PM 15348946
DA 2018-10-19
ER

PT J
AU Di Silvio, L
   Dalby, M
   Bonfield, W
AF Di Silvio, L
   Dalby, M
   Bonfield, W
TI In vitro response of osteoblasts to hydroxyapatite-reinforced
   polyethylene composites
SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE
LA English
DT Article
ID BONE-REPLACEMENT
AB A primary human cell culture model was used to investigate a range of hydroxyapaptite (HA)-reinforced high-density polyethylene (HDPE) composites (HAPEX(TM)). These materials are being developed as potential bone-substitute materials. When designing and optimizing a second-generation biomaterial, it is important to achieve a balance between mechanical and biological properties without compromising either. Biochemical and histological parameters have been used to compare the biological response of 20% and 40% volume HA in HDPE. Cellular DNA and incorporation of tritiated thymidine was measured to assess cell proliferation. Alkaline phosphatase (ALP) production was used as a marker of osteoblast phenotype expression. In this preliminary study, osteoblasts cultured on the 20% HAPEX(TM) showed a greater increase in the rate of proliferation and osteoblast expression as indicated by an increase in ALP activity compared to the 40% HAPEX(TM) over the time period studied. Osteoblast-like cells showed a flattened morphology on both composites and in some cases a greater covering was observed on the 20% HAPEX(TM). These results indicate that the composites may not be identical in terms of bioactivity and that further research on surface topography and physico-chemical properties is required to assess fully the biological response of these composites. (C) 1998 Kluwer Academic Publishers.
C1 Univ Catholique Louvain, Inst Orthopaed, IRC Biomed Mat, Stanmore HA7 4LP, Middx, England.
   Univ London Queen Mary & Westfield Coll, IRC Biomed Mat, London E1 4NS, England.
RP Di Silvio, L (reprint author), Univ Catholique Louvain, Inst Orthopaed, IRC Biomed Mat, Stanmore HA7 4LP, Middx, England.
OI Dalby, Matthew/0000-0002-0528-3359; Di Silvio, Lucy/0000-0003-2554-2052
CR ABRAM J, 1984, PLAST RUB PROC APPL, V4, P261
   BONFIELD W, 1988, J BIOMED ENG, V10, P522, DOI 10.1016/0141-5425(88)90110-0
   BONFIELD W, 1981, BIOMATERIALS, V2, P185, DOI 10.1016/0142-9612(81)90050-8
   BONFIELD W, 1986, BIOL BIOMECHANICAL P, P153
   DISILVIO L, 1995, THESIS U LONDON
   Downes RN, 1991, BIOCERAMICS, V4, P239
   Huang J., 1997, J MATER SCI-MATER M, V8, P1
   TANNER KE, 1994, BRIT CERAM T, V93, P104
   WANG M, 1994, BRIT CERAM T, V93, P91
NR 9
TC 45
Z9 45
U1 0
U2 11
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0957-4530
J9 J MATER SCI-MATER M
JI J. Mater. Sci.-Mater. Med.
PD DEC
PY 1998
VL 9
IS 12
BP 845
EP 848
DI 10.1023/A:1008900312950
PG 4
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 161CK
UT WOS:000078270600033
PM 15348951
DA 2018-10-19
ER

PT J
AU Al-Saffar, N
   Iwaki, H
   Revell, PA
AF Al-Saffar, N
   Iwaki, H
   Revell, PA
TI Direct activation of mast cells by prosthetic biomaterial particles
SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE
LA English
DT Article
ID STIMULATORY FACTOR-I; ORTHOPEDIC IMPLANTS; MEDIATOR RELEASE;
   FOREIGN-BODY; T-CELL; INTERLEUKIN-4; MACROPHAGES; IL-4; MASTOCYTOSIS;
   EXPRESSION
AB IL-4 is a mast cell and T cell produced immune cytokine that is important in the regulation of macrophage function. IL-4 has also been implicated in the induction of foreign body giant cell formation. In patients with long-term joint prostheses, a localized granulomatous inflammation develops in periarticular tissues and other organs where phagocytosis of particulate material from various prosthetic components takes place. In this study we used the inflammatory lesions of the bone-implant interface as a model to investigate the possible production, the frequency and the cellular source of IL-4. 40 samples of the interface membrane obtained from 25 patients undergoing revision of clinically failed implants were analyzed by immunohistochemistry. Cryostat sections were labeled with specific monoclonal antibodies to mast cell products: IL-4, tryptase and the receptor c-kit (CD117). The study has identified a significant level of production of IL-4 by mast cells in all the cases analyzed. There was an apparent difference in the number of mast cells in relation to the histological variants of the interface. The increase in the number of mast cells and IL-4 production was more pronounced in cases with heavy macrophage infiltrate than those exhibiting a predominance of giant cells. The findings imply that the recruitment of mast cell and IL-4 expression precede the granulomatous reaction and may have a role in the induction of a number of immunopathological changes related to mast cell activation by biomaterial particles. (C) 1998 Kluwer Academic Publishers.
C1 Royal Free Hosp, Sch Med, Dept Histopathol, London NW3 2PF, England.
   Royal Free Hosp, Sch Med, Interdisciplinary Res Ctr IRC Biomed Mat, London NW3 2PF, England.
RP Al-Saffar, N (reprint author), Royal Free Hosp, Sch Med, Dept Histopathol, Rowland Hill St, London NW3 2PF, England.
CR ALSAFFAR N, 1994, BRIT J RHEUMATOL, V33, P309
   ALSAFFAR N, 1995, ANN RHEUM DIS, V54, P201, DOI 10.1136/ard.54.3.201
   Asherson GL, 1996, CLIN EXP IMMUNOL, V103, P1, DOI 10.1046/j.1365-2249.1996.845537.x
   Baghestanian M, 1997, BLOOD, V90, P4438
   CRISP AJ, 1984, ARTHRITIS RHEUM, V27, P845, DOI 10.1002/art.1780270802
   FALLON MD, 1983, CALCIFIED TISSUE INT, V35, P29, DOI 10.1007/BF02405002
   GOLDRING SR, 1983, J BONE JOINT SURG AM, V65, P575, DOI 10.2106/00004623-198365050-00001
   GRAVES L, 1990, J BONE MINER RES, V5, P1113
   Haddad FS, 1996, J BONE JOINT SURG BR, V78B, P546
   HART PH, 1989, P NATL ACAD SCI USA, V86, P3807
   HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914
   KUPPER T, 1987, J IMMUNOL, V138, P4080
   LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921
   MALONEY WJ, 1990, J BONE JOINT SURG AM, V72A, P1025, DOI 10.2106/00004623-199072070-00011
   MCNALLY AK, 1995, AM J PATHOL, V147, P1487
   MCNNES A, 1988, J EXP MED, V167, P598
   MOSMANN TR, 1986, P NATL ACAD SCI USA, V83, P5654, DOI 10.1073/pnas.83.15.5654
   OLIVEIRA DBG, 1995, EUR J IMMUNOL, V25, P2259, DOI 10.1002/eji.1830250822
   PARK LS, 1987, J EXP MED, V166, P476, DOI 10.1084/jem.166.2.476
   Peoch M, 1996, NEW ENGL J MED, V335, P133, DOI 10.1056/NEJM199607113350214
   POSTLETHWAITE AE, 1992, J CLIN INVEST, V90, P1479, DOI 10.1172/JCI116015
   ROTHE MJ, 1990, J AM ACAD DERMATOL, V23, P615, DOI 10.1016/0190-9622(90)70264-I
   SCHULMAN ES, 1993, CRIT REV IMMUNOL, V13, P35
   SWAIN SL, 1990, J IMMUNOL, V145, P3796
   TALLROTH K, 1989, J BONE JOINT SURG BR, V71, P571
   Yamamoto M, 1996, AM J PATHOL, V148, P331
NR 26
TC 15
Z9 15
U1 0
U2 3
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0957-4530
J9 J MATER SCI-MATER M
JI J. Mater. Sci.-Mater. Med.
PD DEC
PY 1998
VL 9
IS 12
BP 849
EP 853
DI 10.1023/A:1008952329788
PG 5
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 161CK
UT WOS:000078270600034
PM 15348952
DA 2018-10-19
ER

PT J
AU Schwarz, K
   Epple, M
AF Schwarz, K
   Epple, M
TI Hierarchically structured polyglycolide - a biomaterial mimicking
   natural bone
SO MACROMOLECULAR RAPID COMMUNICATIONS
LA English
DT Article
ID BIODEGRADABLE IMPLANTS; PHASE-SEPARATION; ACID) FOAMS; TRANSPLANTATION
AB Polyglycolide (poly(hydroxyacetic acid)) with wide variability of pore size can be prepared by combination of a solid-state polymerization reaction and addition of sodium chloride crystals. The solid state reaction leads to a composite of polyglycolide and NaCl. The latter can be washed out with water leaving behind porous polyglycolide with interconnected pores in the micrometer range. To achieve a higher porosity and to induce larger pores, additional coarse sodium chloride was added before polymerization. This opens a way to functionally graded polyglycolide resembling natural bone that should have a potential as bone substituting material.
C1 Univ Hamburg, Inst Inorgan & Appl Chem, D-20146 Hamburg, Germany.
RP Epple, M (reprint author), Univ Hamburg, Inst Inorgan & Appl Chem, Martin Luther King Pl 6, D-20146 Hamburg, Germany.
CR Ashammakhi N, 1997, BIOMATERIALS, V18, P3, DOI 10.1016/S0142-9612(96)00107-X
   Breuer CK, 1996, BIOTECHNOL BIOENG, V50, P562, DOI 10.1002/(SICI)1097-0290(19960605)50:5<562::AID-BIT11>3.0.CO;2-L
   Chiellini E, 1996, ADV MATER, V8, P305, DOI 10.1002/adma.19960080406
   deGroot JH, 1996, BIOMATERIALS, V17, P163, DOI 10.1016/0142-9612(96)85761-9
   Edwards DA, 1997, SCIENCE, V276, P1868, DOI 10.1126/science.276.5320.1868
   Epple M, 1998, J BIOMED MATER RES, V43, P83
   Epple M, 1997, J MATER CHEM, V7, P1037, DOI 10.1039/a700275k
   Epple M, 1996, CHEM BER, V129, P1123, DOI 10.1002/cber.19961290923
   Hocker H, 1998, MACROMOL SYMP, V130, P161, DOI 10.1002/masy.19981300115
   HOFMANN GO, 1995, ARCH ORTHOP TRAUM SU, V114, P123, DOI 10.1007/BF00443385
   IshaugRiley SL, 1997, J BIOMED MATER RES, V36, P1, DOI 10.1002/(SICI)1097-4636(199707)36:1<1::AID-JBM1>3.0.CO;2-P
   Kapur R, 1996, J BIOMED MATER RES, V33, P205, DOI 10.1002/(SICI)1097-4636(199624)33:4<205::AID-JBM1>3.0.CO;2-T
   KENLEY RA, 1987, MACROMOLECULES, V20, P2398, DOI 10.1021/ma00176a012
   Kiefer J, 1996, MACROMOLECULES, V29, P8546, DOI 10.1021/ma960960z
   Langer R, 1998, NATURE, V392, P5
   MIKOS AG, 1994, POLYMER, V35, P1068, DOI 10.1016/0032-3861(94)90953-9
   NIHANT N, 1995, J COLLOID INTERF SCI, V173, P55, DOI 10.1006/jcis.1995.1296
   OSTHER PJ, 1995, BRIT J SURG, V82, P1080, DOI 10.1002/bjs.1800820824
   PENNINGS AJ, 1990, COLLOID POLYM SCI, V268, P2, DOI 10.1007/BF01410416
   RITTER SK, 1997, CHEM ENG NEWS, P27
   Rueger JM, 1998, ORTHOPADE, V27, P72
   Schugens C, 1996, J BIOMED MATER RES, V30, P449, DOI 10.1002/(SICI)1097-4636(199604)30:4<449::AID-JBM3>3.0.CO;2-P
   Schugens C, 1996, POLYMER, V37, P1027, DOI 10.1016/0032-3861(96)87287-9
   Wintermantel E, 1996, BIOMATERIALS, V17, P83, DOI 10.1016/0142-9612(96)85753-X
NR 24
TC 32
Z9 32
U1 2
U2 8
PU WILEY-V C H VERLAG GMBH
PI BERLIN
PA MUHLENSTRASSE 33-34, D-13187 BERLIN, GERMANY
SN 1022-1336
J9 MACROMOL RAPID COMM
JI Macromol. Rapid Commun.
PD DEC
PY 1998
VL 19
IS 12
BP 613
EP 617
DI 10.1002/(SICI)1521-3927(19981201)19:12<613::AID-MARC613>3.3.CO;2-D
PG 5
WC Polymer Science
SC Polymer Science
GA 147MZ
UT WOS:000077572400004
DA 2018-10-19
ER

PT J
AU Scott-Burden, T
   Tock, CL
   Bosely, JP
   Clubb, FJ
   Parnis, SM
   Schwarz, JJ
   Engler, DA
   Frazier, OH
   Casscells, SW
AF Scott-Burden, T
   Tock, CL
   Bosely, JP
   Clubb, FJ
   Parnis, SM
   Schwarz, JJ
   Engler, DA
   Frazier, OH
   Casscells, SW
TI Nonthrombogenic, adhesive cellular lining for left ventricular assist
   devices
SO CIRCULATION
LA English
DT Article
DE muscle, smooth; cells; heart-assist device; nitric oxide
ID SMOOTH-MUSCLE CELLS; NITRIC-OXIDE; GROWTH; ENDOTHELIALIZATION;
   COAGULATION; ENDOTHELIUM; PROSTHESES; ACTIVATION; DISEASE; GRAFTS
AB Background-The textured, blood-contacting surfaces of the Thermocardiosystems HeartMate left ventricular assist device (LVAD) promote the passivation of the biomaterial caused by the accumulation of an integral coagulum. Commonly, acute, postimplantation thrombocytopenia causes significant bleeding, requiring surgery or blood transfusions. Chronic complications include thromboembolic microevents that can affect central nervous system function. Pumps, explanted during donor organ transplantation, are often found to have an extensive cellular panus associated with the blood-contacting surfaces of the device. This natural cellular lining suggests a possible strategy for improving the blood biocompatibility of the HeartMate. Therefore, seeding of LVADs with cells genetically engineered to enhance their antithrombotic properties before implantation was investigated as a means to improve biocompatibility for long-term use.
   Methods and Results-Bovine vascular smooth muscle cells genetically engineered to produce nitric oxide were seeded on LVAD biomaterials and exposed to elevated shear stresses to determine cell-adhesive capabilities. Comparative studies were performed with vascular endothelial cells isolated from the same vessel. To assess the thrombogenic potential of the genetically engineered smooth muscle cells, monolayers were exposed to whole blood in parallel plate flow chambers and were platelet-adhesion quantified. This procedure used scanning electron microscopy and computer image-capture software. Endothelial cell monolayers and mock-transduced smooth muscle cells were assayed in a comparative manner. LVADs were seeded with genetically engineered smooth muscle cells and maintained under cell culture conditions for 96 hours. Thereafter, seeded LVADs were incorporated into in vitro flow loops. Cell retention within the pump was determined by sampling the effluent culture medium downstream of the pump and cell counting in a Coulter counter. After 18 hours of in vitro flow, a seeded pump was implanted into the abdominal cavity of a calf and anastomosed to the apex of the heart and to the descending aorta, More genetically engineered smooth muscle cells were retained on the surface of LVAD biomaterials when they were subjected to shear stresses up to 75 dyne/cm than endothelial cells assayed in the identical manner. Adherence of platelets to the surface of smooth muscle cells was significantly reduced after their transduction with nitric oxide synthase with GTP cyclohydrolase genes. Platelet deposition on the genetically modified myocyte layers was similar to that associated with endothelial cell layers. Cell loss from cell-seeded LVADs incorporated into in vitro flow loops remained <5% of the total cell number seeded regardless of the duration of flow.
   Conclusions-LVADs seeded with smooth muscle cells, transduced with the genes to optimize nitric oxide production, adhered well to the pump surface under in vitro and in vivo flow conditions.
C1 Texas Heart Inst, Vasc Cell Biol Lab, Texas Med Ctr, Houston, TX 77225 USA.
   Texas Heart Inst, Texas Med Ctr, Dept Cardiovasc Pathol, Houston, TX 77225 USA.
   Texas Heart Inst, Texas Med Ctr, Dept Cardiovasc Surg Res, Houston, TX 77225 USA.
RP Scott-Burden, T (reprint author), Texas Heart Inst, Vasc Cell Biol Lab, Texas Med Ctr, POB 20345, Houston, TX 77225 USA.
FU NHLBI NIH HHS [HL-53233]
CR BERNHARD WF, 1969, SURGERY, V66, P284
   DIDISHEIM P, 1993, CARDIOVASC PATHOL, V2, pS1
   FRAZIER OH, 1995, ANN SURG, V222, P327, DOI 10.1097/00000658-199509000-00010
   FRAZIER OH, 1992, ANN THORAC SURG, V53, P1080, DOI 10.1016/0003-4975(92)90393-I
   GOLDSMITH HL, 1986, THROMB HAEMOSTASIS, V55, P415
   IGO SR, 1984, T AM SOC ART INT ORG, V30, P81
   JONES PA, 1979, P NATL ACAD SCI USA, V76, P1882, DOI 10.1073/pnas.76.4.1882
   LELKES PI, 1991, J BIOMECH ENG-T ASME, V113, P132, DOI 10.1115/1.2891227
   Livingston ER, 1996, CIRCULATION, V94, P227
   MCCRAY DR, 1981, P NATL ACAD SCI USA, V78, P4975
   Rose EA, 1996, ANN THORAC SURG, V61, P399, DOI 10.1016/0003-4975(95)01003-3
   SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4
   ScottBurden T, 1996, CIRCULATION, V94, P235
   ScottBurden T, 1995, ANN THORAC SURG, V60, P1561, DOI 10.1016/0003-4975(95)00834-9
   SCOTTBURDEN T, 1992, CIRC RES, V71, P1088, DOI 10.1161/01.RES.71.5.1088
   SCOTTBURDEN T, 1989, HYPERTENSION, V13, P295, DOI 10.1161/01.HYP.13.4.295
   SHI Q, 1994, J VASC SURG, V20, P546, DOI 10.1016/0741-5214(94)90279-8
   Spanier T, 1996, J THORAC CARDIOV SUR, V112, P1090, DOI 10.1016/S0022-5223(96)70111-3
   TRANSONTOY R, 1993, PHYSICAL FORCES MAMM, P60
   VANHOUTTE PM, 1994, TEX HEART I J, V21, P62
   Visweswaran P, 1997, ASAIO J, V43, pM753
   VONDELEYDEN HE, 1992, P NATL ACAD SCI USA, P1637
   WECHEZAK AR, 1984, SCANNING ELECTRON MI, V3, P1353
   YAO SK, 1992, CIRCULATION, V86, P1302, DOI 10.1161/01.CIR.86.4.1302
   YUE X, 1988, SURGERY, V103, P206
NR 25
TC 1
Z9 1
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 10
PY 1998
VL 98
IS 19
SU S
BP II339
EP II345
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 136YF
UT WOS:000076886100088
PM 9852924
DA 2018-10-19
ER

PT J
AU Nacul, AM
   Nacul, AP
   de Born, AG
AF Nacul, AM
   Nacul, AP
   de Born, AG
TI Bioplastique as a complement in conventional plastic surgery
SO AESTHETIC PLASTIC SURGERY
LA English
DT Article
DE bioplastique; rhytidoplasty; rhinoplasty
ID SOFT-TISSUE AUGMENTATION; SUBDERMAL IMPLANTATION; TEXTURED
   MICROIMPLANTS; FAT; COLLAGEN; FIBREL; RABBIT
AB This research presents reports of cases where a biocompatible and alloplastic biomaterial-Bioplastique-was used, associated with conventional plastic surgery or as a complement to it, with the aim of achieving a better final aesthetic result. Four cases are presented where Bioplastique was used in association with rhytidoplasty, rhinoplasty, and other surgical techniques. This material has shown itself to be appropriate to complement surgery; achieving a final result which would not be possible without any resort to a complement or any other hard procedure by the surgeon and is not more traumatic for the patient.
C1 Clin Nacul Cirurgia Plast, Porto Alegre, RS, Brazil.
RP Nacul, AM (reprint author), Clin Nacul Cirurgia Plast, Quintino Bocaiuva 1086,Moinhos de Vento, Porto Alegre, RS, Brazil.
CR ALLEN O, 1992, AESTHET PLAST SURG, V16, P227, DOI 10.1007/BF00190068
   BEISANG AA, 1992, AESTHET PLAST SURG, V16, P83, DOI 10.1007/BF00455154
   COLEMAN WP, 1993, J DERMATOL SURG ONC, V19, P1032, DOI 10.1111/j.1524-4725.1993.tb00996.x
   DAVIS RE, 1995, ARCH OTOLARYNGOL, V121, P95
   ERSEK RA, 1991, PLAST RECONSTR SURG, V87, P693, DOI 10.1097/00006534-199104000-00014
   ERSEK RA, 1992, AESTHET PLAST SURG, V16, P67, DOI 10.1007/BF00455151
   ERSEK RA, 1991, PLAST RECONSTR SURG, V87, P219, DOI 10.1097/00006534-199102000-00001
   GOLD MH, 1994, J DERMATOL SURG ONC, V20, P586, DOI 10.1111/j.1524-4725.1994.tb00151.x
   GOLD MH, 1995, DERMATOL CLIN, V13, P353, DOI 10.1016/S0733-8635(18)30087-1
   KONONAS TC, 1993, PLAST RECONSTR SURG, V91, P763, DOI 10.1097/00006534-199304001-00001
   LEMPERLE G, 1995, PLAST RECONSTR SURG, V96, P627, DOI 10.1097/00006534-199509000-00015
   LIU B, 1994, CHUNG KUO HSUEK KO H, V16, P197
   Lodde J P, 1995, Ann Chir Plast Esthet, V40, P676
   MLADICK RA, 1992, AESTHET PLAST SURG, V16, P69, DOI 10.1007/BF00455152
   MOSCONA R, 1989, PLAST RECONSTR SURG, V84, P501, DOI 10.1097/00006534-198909000-00020
   MUHLING J, 1994, J CRANIO MAXILL SURG, V22, P200, DOI 10.1016/S1010-5182(05)80558-X
   NACUL AM, 1996, 2 AT CIR PLAST SBPC, P625
   NACUL AM, 1994, ARQ CATARINENSES MED, V23, P114
   Nacul AM, 1995, REV SOC BRAS CIR PLA, V10, P15
   NORDSTROM MR, 1993, ARCH OTOLARYNGOL, V119, P208
   Sherris DA, 1996, LARYNGOSCOPE, V106, P658, DOI 10.1097/00005537-199605000-00027
   SIMONS G, 1992, AESTHET PLAST SURG, V16, P77, DOI 10.1007/BF00455153
   SPIRA M, 1994, J BIOMED MATER RES, V28, P91, DOI 10.1002/jbm.820280112
   XU Z, 1995, CHUNG KUO HSUEH KO H, V17, P188
NR 24
TC 4
Z9 4
U1 0
U2 1
PU SPRINGER VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010 USA
SN 0364-216X
J9 AESTHET PLAST SURG
JI Aesthet. Plast. Surg.
PD NOV-DEC
PY 1998
VL 22
IS 6
BP 444
EP 450
DI 10.1007/s002669900232
PG 7
WC Surgery
SC Surgery
GA 146QD
UT WOS:000077441100012
PM 9852179
DA 2018-10-19
ER

PT J
AU Baufreton, C
   Kirsch, M
   Loisance, DY
AF Baufreton, C
   Kirsch, M
   Loisance, DY
TI Measures to control blood activation during assisted circulation
SO ANNALS OF THORACIC SURGERY
LA English
DT Review
ID SYSTEMIC INFLAMMATORY RESPONSE; ENDOTHELIAL-CELL INJURY; CARDIOPULMONARY
   BYPASS; CARDIOVASCULAR-SURGERY; HEART-TRANSPLANTATION; COMPLEMENT
   ACTIVATION; CYTOKINE RELEASE; IN-VITRO; HEPARIN; APROTININ
AB Major improvements in heart assist devices have allowed prolonged mechanical circulatory support with successful subsequent weaning or heart transplantation. The contact of blood with biomaterials used in life-sustaining devices and numerous biomaterial-independent factors elicit a systemic inflammatory response, which involves activation of various plasma protein systems and blood cells, prolonged mechanical circulatory support elicits a systemic inflammatory response and hemostatic perturbations similar to that reported during cardiopulmonary bypass. However, in the setting of prolonged assistance, time has a complex and ill-known influence on blood activation. Methods to reduce blood activation during prolonged assisted circulation are derived from cardiopulmonary bypass investigations. Improving the biocompatibility of artificial devices can be achieved either by biomaterial surface modifications, by inhibition of biologic cascades leading to blood activation, or by controlling end points of biologic cascades. However, the necessity to respect the integrity of the organism during prolonged assistance precludes most systemic interventions and limits the control of blood activation to the area of the device. (C) 1998 by The Society of Thoracic Surgeons.
C1 Hop Henri Mondor, Dept Thorac & Cardiovasc Surg, F-94010 Creteil, France.
   Hop Henri Mondor, Ctr Rech Chirurg, F-94010 Creteil, France.
RP Loisance, DY (reprint author), Fac Med, Ctr Rech Chirurg, 8 Rue Gen Sarrail, F-94000 Creteil, France.
EM loisance@univ-paris12.fr
CR ANDERSON JM, 1990, INT J ARTIF ORGANS, V13, P375
   Ashraf S, 1997, ANN THORAC SURG, V63, P68
   Barstad RM, 1996, BRIT J HAEMATOL, V94, P517, DOI 10.1111/j.1365-2141.1996.tb08989.x
   Barstad RM, 1996, THROMB HAEMOSTASIS, V75, P827
   Baufreton C, 1997, ANN THORAC SURG, V63, P50
   Baufreton C, 1996, ASAIO J, V42, pM417, DOI 10.1097/00002480-199609000-00023
   BIDSTRUP BP, 1989, J THORAC CARDIOV SUR, V97, P364
   Boyle EM, 1997, ANN THORAC SURG, V63, P277
   Boyle EM, 1996, ANN THORAC SURG, V62, P1549, DOI 10.1016/0003-4975(96)00836-3
   BUTLER J, 1993, ANN THORAC SURG, V55, P552, DOI 10.1016/0003-4975(93)91048-R
   Clowes AW, 1996, CIRCULATION, V93, P1319, DOI 10.1161/01.CIR.93.7.1319
   COPELAND J, 1995, MECH CIRCULATORY SUP, P26
   Dunn PF, 1996, CIRCULATION, V93, P1439, DOI 10.1161/01.CIR.93.7.1439
   Edmunds L H Jr, 1995, ASAIO J, V41, P824, DOI 10.1097/00002480-199510000-00002
   EDMUNDS LH, 1993, J CARDIAC SURG, V8, P404, DOI 10.1111/j.1540-8191.1993.tb00384.x
   FRAZIER OH, 1993, TEX HEART I J, V20, P78
   FRAZIER OH, 1995, MECH CIRCULATORY SUP, P237
   Gikakis N, 1996, CIRCULATION, V94, P341
   GILLINOV AM, 1994, ANN THORAC SURG, V57, P126, DOI 10.1016/0003-4975(94)90380-8
   GOLDSTEIN DJ, 1995, ANN THORAC SURG, V59, P1063, DOI 10.1016/0003-4975(95)00086-Z
   Goldstein DJ, 1997, ANN THORAC SURG, V63, P971, DOI 10.1016/S0003-4975(96)01117-4
   Gorman RC, 1996, J THORAC CARDIOV SUR, V111, P1, DOI 10.1016/S0022-5223(96)70395-1
   GRAHAM TR, 1990, EUR J CARDIO-THORAC, V4, P182, DOI 10.1016/1010-7940(90)90002-H
   Hasper D, 1996, INT J ARTIF ORGANS, V19, P590
   HETZER R, 1992, J HEART LUNG TRANSPL, V11, P175
   HIMMELREICH G, 1995, ASAIO J, V41, pM790, DOI 10.1097/00002480-199507000-00122
   Hornick P, 1996, PERFUSION-UK, V11, P3, DOI 10.1177/026765919601100102
   HSU L-C, 1991, Perfusion (London), V6, P209, DOI 10.1177/026765919100600310
   HUMMEL M, 1994, CRIT CARE MED, V22, P448, DOI 10.1097/00003246-199403000-00015
   ITESCU S, 1996, CIRCULATION S1, V96, P689
   JANSEN PGM, 1994, EUR J CARDIO-THORAC, V8, P125, DOI 10.1016/1010-7940(94)90167-8
   Kaufmann f, 1996, CARDIOVASC ENG, V1, P40
   KIRKLIN JK, 1983, J THORAC CARDIOV SUR, V86, P845
   KLUFT C, 1991, BLOOD USE IN CARDIAC SURGERY, P10
   Kuitunen AH, 1997, ANN THORAC SURG, V63, P438
   Livingston ER, 1996, CIRCULATION, V94, P227
   LOISANCE DY, 1995, MECH CIRCULATORY SUP, P332
   MANN DL, 1994, CHEST, V105, P897, DOI 10.1378/chest.105.3.897
   MARCUM JA, 1985, BIOCHEM BIOPH RES CO, V126, P365, DOI 10.1016/0006-291X(85)90615-1
   MCKELLAR SH, 1997, ASAIO J, V43, P38
   MENASCHE P, 1995, CIRCULATION, V92, P334, DOI 10.1161/01.CIR.92.9.334
   MENCONI MJ, 1992, J CARDIAC SURG, V7, P177, DOI 10.1111/j.1540-8191.1992.tb00794.x
   MENCONI MJ, 1995, J CELL BIOCHEM, V57, P557, DOI 10.1002/jcb.240570320
   Miyamoto Y1, 1989, T AM SOC ART INT ORG, V31, P508
   MOORE FD, 1988, ANN SURG, V208, P95, DOI 10.1097/00000658-198807000-00014
   MOSQUERA DA, 1991, BRIT J SURG, V78, P656, DOI 10.1002/bjs.1800780608
   PAE WE, 1994, J HEART LUNG TRANSPL, V13, P811
   PEKNA M, 1994, ANN THORAC SURG, V58, P421, DOI 10.1016/0003-4975(94)92219-5
   POIRIER VL, 1995, MECH CIRCULATORY SUP, P229
   Rafii S, 1995, ANN THORAC SURG, V60, P1627, DOI 10.1016/0003-4975(95)00807-1
   ROSE EA, 1994, CIRCULATION, V90, P87
   Ryu G, 1992, ASAIO J, V38, pM644
   SALAMA A, 1988, NEW ENGL J MED, V318, P408, DOI 10.1056/NEJM198802183180704
   Salih V, 1993, Am J Cardiovasc Pathol, V4, P317
   ScottBurden T, 1996, CIRCULATION, V94, P235
   SHENKAR R, 1994, AM J RESP CELL MOL, V10, P290, DOI 10.1165/ajrcmb.10.3.8117448
   Spanier T, 1996, J THORAC CARDIOV SUR, V112, P1090, DOI 10.1016/S0022-5223(96)70111-3
   Spanier T. B., 1997, Journal of Heart and Lung Transplantation, V16, P102
   SPANIER TB, 1996, CIRCULATION S1, V96, P695
   SPANIER TB, 1996, CIRCULATION S1, V96, P293
   STEINBERG BM, 1995, ANN THORAC SURG, V60, P525, DOI 10.1016/0003-4975(95)00482-Z
   TABUCHI N, 1994, EUR J CARDIO-THORAC, V8, P87, DOI 10.1016/1010-7940(94)90098-1
   Te Velthuis Henk, 1997, Journal of Thoracic and Cardiovascular Surgery, V114, P117, DOI 10.1016/S0022-5223(97)70124-7
   TEVELTHUIS H, 1995, THESIS FREE U AMSTER
   TOCK CL, 1997, ASAIO J, V43, P17
   Usui A, 1996, ANN THORAC SURG, V62, P1404, DOI 10.1016/0003-4975(96)00634-0
   VIDEM V, 1992, J THORAC CARDIOV SUR, V103, P806
   von Segesser L K, 1991, ASAIO Trans, V37, pM278
   von Segesser LK, 1996, PERFUSION-UK, V11, P241, DOI 10.1177/026765919601100309
   VONSEGESSER LK, 1992, INT J ARTIF ORGANS, V15, P301
   VONSEGESSER LK, 1994, INT J ARTIF ORGANS, V17, P294
   VROMAN L, 1988, B NEW YORK ACAD MED, V64, P352
   Wagner W R, 1992, ASAIO J, V38, pM634, DOI 10.1097/00002480-199207000-00114
   WALENGA JM, 1992, ANN THORAC SURG, V53, P844, DOI 10.1016/0003-4975(92)91448-I
   WEERWIND PW, 1995, J THORAC CARDIOV SUR, V110, P1633, DOI 10.1016/S0022-5223(95)70024-2
   WILHELM CR, 1996, CIRCULATION S1, V96, P293
   Williams M. R., 1997, Journal of Heart and Lung Transplantation, V16, P105
   ZILLA P, 1991, J THORAC CARDIOV SUR, V101, P671
NR 78
TC 13
Z9 14
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA
SN 0003-4975
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD NOV
PY 1998
VL 66
IS 5
BP 1837
EP 1844
DI 10.1016/S0003-4975(98)00726-7
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 151CN
UT WOS:000077703300100
PM 9875814
DA 2018-10-19
ER

PT J
AU Rhee, PH
   Friedman, CD
   Ridge, JA
   Kusiak, J
AF Rhee, PH
   Friedman, CD
   Ridge, JA
   Kusiak, J
TI The use of processed allograft dermal matrix for intraoral resurfacing -
   An alternative to split-thickness skin grafts
SO ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY
LA English
DT Article; Proceedings Paper
CT 44th Annual Meeting of the Society-of-Head-and-Neck-Surgeons
CY MAY 14-16, 1998
CL PALM BEACH, FLORIDA
SP Soc Head & Neck Surgeons
AB Background: The standard reconstruction of significant mucosal defects in head and neck surgery has been split-thickness skin grafting (STSG). Objective: To examine the use of a commercially available acellular dermal matrix as an alternative to STSG to reduce the scarring and contracture inherent to meshed split-thickness autografting and avoid the additional donor site morbidity.
   Patients and Methods: Twenty-nine patients with full-thickness defects of the oral cavity were included in this retrospective chart review. Candidate patients had their operative procedure performed at a tertiary care center during a 24-month period. Allograft dermal matrix, an acellular tissue-processed biomaterial, was applied to these intraoral defects. The defects were reconstructed with an acellular dermal graft matrix in the same technical fashion as with an autologous skin graft. Patients were evaluated for rate of "take," functional return time to reepithelialization, average surface area of graft, associated pain and discomfort, evidence of restrictive graft contracture, patient diagnosis, and graft location within the oral cavity. Any evidence of incomplete graft reepithelialization was considered grounds for graft failure, either complete or incomplete. Epithelialization and contracture were assessed during outpatient clinical examinations. Patient complaints with regard to discomfort at the graft bed were considered evidence of pain.
   Results: Graft locations included 9 in the tongue (32%), 5 in the maxillary oral vestibule (17%), 4 in the mandible (14%), 4 in the floor of mouth (14%), 3 in the hard and/or soft palate (10%), 3 in the tonsil (10%), and 1 in the lip (3%). The overall rate of take was 90% with complete epithelialization noted on clinical evaluation within 4 week. Patients were followed up for an average of 8.6 months. The average grafted surface area was 25 cm(2). Pain or discomfort was noted in 3 patients (12%). One patient (4%) was noted to have clinical evidence of graft contracture.
   Conclusions: Allograft dermal matrix was successful as a substitute to autologous STSG for resurfacing of intraoral defects. Allograft dermal matrix may be considered a useful reconstructive option for patients with oral mucosal defects.
C1 Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
RP Friedman, CD (reprint author), Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA.
CR Alvi A, 1996, HEAD NECK-J SCI SPEC, V18, P538, DOI 10.1002/(SICI)1097-0347(199611/12)18:6<538::AID-HED8>3.0.CO;2-3
   HOFFMAN DK, 1994, ANN PLAS SURG, V33, P295, DOI 10.1097/00000637-199409000-00010
   Lattari Vincent, 1997, Journal of Burn Care and Rehabilitation, V18, P147, DOI 10.1097/00004630-199703000-00010
   LVESE SA, 1995, TRANSPLANTATION, V60, P1
   MCCARTHY JG, 1990, PLASTIC SURG, P221
   Omi T, 1996, BURNS, V22, P206, DOI 10.1016/0305-4179(95)00110-7
   Wainwright David, 1996, Journal of Burn Care and Rehabilitation, V17, P124, DOI 10.1097/00004630-199603000-00006
   WAINWRIGHT DJ, 1995, BURNS, V21, P243, DOI 10.1016/0305-4179(95)93866-I
NR 8
TC 58
Z9 75
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610 USA
SN 0886-4470
J9 ARCH OTOLARYNGOL
JI Arch. Otolaryngol. Head Neck Surg.
PD NOV
PY 1998
VL 124
IS 11
BP 1201
EP 1204
DI 10.1001/archotol.124.11.1201
PG 4
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA 136VR
UT WOS:000076880300002
PM 9821920
OA Bronze
DA 2018-10-19
ER

PT J
AU Su, SH
   Eaton, JW
   Venezia, RA
   Tang, LP
AF Su, SH
   Eaton, JW
   Venezia, RA
   Tang, LP
TI Interactions of vancomycin resistant enterococci with biomaterial
   surfaces
SO ASAIO JOURNAL
LA English
DT Article
ID URINARY-TRACT INFECTION; GLYCOPEPTIDE RESISTANCE; INFLAMMATORY
   RESPONSES; CATHETER CULTURES; BACTEREMIA; FAECALIS; FAECIUM;
   MICROBIOLOGY; ENDOCARDITIS; TEICOPLANIN
AB Enterococci are a frequent cause of nosocomial infections and are often found adherent to indwelling catheters. Concern about such device associated infections has increased with the appearance of vancomycin resistant (VR) enterococci. However, the possible influence of vancomycin resistance in the pathogenesis of biomaterial centered infection has not yet been assessed. Using polyethylene terephthalate (PET) disks as model surfaces, the authors evaluated possible differences in the adherence and persistence of vancomycin sensitive (VS) and VR strains of Enterococcus faecium and Enterococcus faecalis on biomaterial surfaces in vitro and in vivo. The results indicate that: 1) as expected, the clearance of free VR and VS organisms after intraperitoneal injection into normal mice is equally efficient. 2) In vitro, VR bacteria are roughly twice as adherent to plasma coated PET surfaces as are VS organisms. 3) However, in vivo persistence of VS organisms preadherent to biomaterial implants is 5- to 10-fold better than that of preadherent VR organisms. The authors now believe that a discrete change in bacterial cell wall composition between VR and VS enterococci may contribute to the substantial differences in bacterial adhesion and survival of adherent organisms.
C1 Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.
   Albany Med Coll, Dept Pathol, Albany, NY 12208 USA.
RP Tang, LP (reprint author), Baylor Coll Med, Dept Pediat, 1 Baylor Plaza, Houston, TX 77030 USA.
CR ARDUINO RC, 1994, INFECT IMMUN, V62, P987
   Arthur M, 1996, J INFECTION, V32, P11, DOI 10.1016/S0163-4453(96)80003-X
   BAND JD, 1979, AM J MED, V67, P735, DOI 10.1016/0002-9343(79)90727-7
   BARRALL DT, 1985, ARCH SURG-CHICAGO, V120, P57
   BOULANGER JM, 1991, REV INFECT DIS, V13, P847
   BRYAN CS, 1985, SURG GYNECOL OBSTET, V160, P557
   Dooley DP, 1996, J CLIN MICROBIOL, V34, P409
   DOUGHERTY SH, 1988, REV INFECT DIS, V10, P1102
   DRYDEN MS, 1992, J HOSP INFECT, V20, P185, DOI 10.1016/0195-6701(92)90086-2
   DUMA RJ, 1969, MEDICINE, V48, P87, DOI 10.1097/00005792-196903000-00001
   DUTKAMALEN S, 1990, ANTIMICROB AGENTS CH, V34, P1875, DOI 10.1128/AAC.34.10.1875
   EATON JW, 1982, SCIENCE, V215, P691, DOI 10.1126/science.7036344
   ELIOPOULOS GM, 1992, INFECT ENDOCARDITIS, P209
   EMORI TG, 1993, CLIN MICROBIOL REV, V6, P428
   FACKLAM RR, 1989, J CLIN MICROBIOL, V27, P731
   FELMINGHAM D, 1992, CLIN INFECT DIS, V15, P295, DOI 10.1093/clinids/15.2.295
   GRANINGER W, 1992, CLIN INFECT DIS, V15, P49, DOI 10.1093/clinids/15.1.49
   GRISTINA A G, 1988, Medical Progress Through Technology, V14, P205
   GRISTINA AG, 1987, SCIENCE, V237, P1588, DOI 10.1126/science.3629258
   GULLBERG RM, 1989, REV INFECT DIS, V11, P74
   HALL LMC, 1992, J CLIN MICROBIOL, V30, P1953
   HANDWERGER S, 1995, ANTIMICROB AGENTS CH, V39, P2446, DOI 10.1128/AAC.39.11.2446
   HARVEY BS, 1992, INFECT IMMUN, V60, P3635
   HASLETT TM, 1988, J CLIN MICROBIOL, V26, P696
   HITCHINS VM, 1992, P INF CONTR S INFL M, P1
   HUNG KY, 1995, NEPHROL DIAL TRANSPL, V10, P247
   JETT BD, 1994, CLIN MICROBIOL REV, V7, P462
   JOHNSON AP, 1990, CLIN MICROBIOL REV, V3, P280
   JONES WG, 1986, ARCH SURG-CHICAGO, V121, P649
   KAPLAN AH, 1988, J CLIN MICROBIOL, V26, P1216
   KHARDORI N, 1991, REV INFECT DIS, V13, P587
   LECLERCQ R, 1989, ANTIMICROB AGENTS CH, V33, P10, DOI 10.1128/AAC.33.1.10
   LECLERCQ R, 1988, NEW ENGL J MED, V319, P157, DOI 10.1056/NEJM198807213190307
   MAKI DG, 1973, ANN INTERN MED, V79, P867, DOI 10.7326/0003-4819-79-6-867
   MAKI DG, 1988, MEDICINE, V67, P248, DOI 10.1097/00005792-198807000-00005
   MOELLERING RC, 1992, CLIN INFECT DIS, V14, P1173, DOI 10.1093/clinids/14.6.1173
   MORENO F, 1994, DIAGN MICR INFEC DIS, V20, P41, DOI 10.1016/0732-8893(94)90017-5
   MURRAY BE, 1990, CLIN MICROBIOL REV, V3, P46
   Rantz LA, 1943, ARCH INTERN MED, V71, P516, DOI 10.1001/archinte.1943.00210040075008
   RICHET H, 1990, J CLIN MICROBIOL, V28, P2520
   RUOFF KL, 1990, J CLIN MICROBIOL, V28, P435
   SCHABERG DR, 1991, AM J MED, V91, pS72, DOI 10.1016/0002-9343(91)90346-Y
   SHERERTZ RJ, 1990, J CLIN MICROBIOL, V28, P76
   SHLAES DM, 1989, ANTIMICROB AGENTS CH, V33, P198, DOI 10.1128/AAC.33.2.198
   STAMM WE, 1978, ANN INTERN MED, V89, P764, DOI 10.7326/0003-4819-89-5-764
   TAILOR SAN, 1993, ANN PHARMACOTHER, V27, P1231, DOI 10.1177/106002809302701014
   TANG LP, 1993, J LAB CLIN MED, V122, P292
   TANG LP, 1993, J EXP MED, V178, P2147, DOI 10.1084/jem.178.6.2147
   Tang LP, 1996, J CLIN INVEST, V97, P1329, DOI 10.1172/JCI118549
   UTTLEY AHC, 1988, LANCET, V1, P57
   VENDITTI M, 1993, CLIN INFECT DIS, V17, P524, DOI 10.1093/clinids/17.3.524
   WELLS CL, 1990, J INFECT DIS, V162, P82, DOI 10.1093/infdis/162.1.82
NR 52
TC 7
Z9 7
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA
SN 1058-2916
J9 ASAIO J
JI Asaio J.
PD NOV-DEC
PY 1998
VL 44
IS 6
BP 770
EP 775
DI 10.1097/00002480-199811000-00003
PG 6
WC Engineering, Biomedical; Transplantation
SC Engineering; Transplantation
GA 136WG
UT WOS:000076881700003
PM 9831084
DA 2018-10-19
ER

PT J
AU Thomson, RC
   Yaszemski, MJ
   Powers, JM
   Mikos, AG
AF Thomson, RC
   Yaszemski, MJ
   Powers, JM
   Mikos, AG
TI Hydroxyapatite fiber reinforced poly(alpha-hydroxy ester) foams for bone
   regeneration
SO BIOMATERIALS
LA English
DT Article
DE polymer processing; foam scaffold; orthopaedic biomaterial;
   hydroxyapatite fiber; poly(lactic-co-glycolic acid); PLGA; bone
   regeneration; tissue engineering
ID BIODEGRADABLE POLYMER SCAFFOLDS; PARTICULATE COMPOSITE;
   MECHANICAL-PROPERTIES; TRABECULAR BONE; INVIVO; INVITRO; CELLS;
   RESORPTION; INGROWTH; DEVICES
AB A process has been developed to manufacture biodegradable composite foams of poly(DL-lactic-co-glycolic acid) (PLGA) and hydroxyapatite short fibers for use in bone regeneration. The processing technique allows the manufacture of three-dimensional foam scaffolds and involves the formation of a composite material consisting of a porogen material (either gelatin microspheres or salt particles) and hydroxyapatite short fibers embedded in a PLGA matrix. After the porogen is leached out, an open-cell composite foam remains which has a pore size and morphology defined by the porogen. By changing the weight fraction of the leachable component it was possible to produce composite foams with controlled porosities ranging from 0.47 +/- 0.02 to 0.85 +/- 0.01 (n = 3). Up to a polymer:fiber ratio of 7:6, short hydroxyapatite fibers served to reinforce low-porosity PLGA foams manufactured using gelatin microspheres as a porogen. Foams with a compressive yield strength up to 2.82 +/- 0.63 MPa (n = 3) and a porosity of 0.47 +/- 0.02 (n = 3) were manufactured using a polymer:fiber weight ratio of 7:6. In contrast, high-porosity composite foams (up to 0.81 +/- 0.02, n = 3) suitable for cell seeding were not reinforced by the introduction of increasing quantities of hydroxyapatite short fibers. We were therefore able to manufacture high-porosity foams which may be seeded with cells but which have minimal compressive yield strength, or low porosity foams with enhanced osteoconductivity and compressive yield strength. (C) 1998 Published by Elsevier Science Ltd. All rights reserved.
C1 Rice Univ, Cox Lab Biomed Engn, Inst Biosci & Bioengn, Houston, TX 77005 USA.
   Rice Univ, Dept Chem Engn, Houston, TX 77005 USA.
   Mayo Clin & Mayo Fdn, Dept Orthoped Surg, Rochester, MN 55905 USA.
   Univ Texas, Hlth Sci Ctr, Dept Oral Biomat, Houston, TX 77030 USA.
RP Mikos, AG (reprint author), Rice Univ, Cox Lab Biomed Engn, Inst Biosci & Bioengn, 6100 S Main St, Houston, TX 77005 USA.
EM mikos@rice.edu
FU NIAMS NIH HHS [R29-AR42639]
CR AMLER MH, 1990, J BIOMED MATER RES, V24, P1079, DOI 10.1002/jbm.820240810
   ANDRIANO KP, 1993, J APPL BIOMATER, V4, P1, DOI 10.1002/jab.770040102
   ATALA A, 1992, J UROLOGY, V148, P658, DOI 10.1016/S0022-5347(17)36685-5
   BURR DB, 1993, J BIOMED MATER RES, V27, P645, DOI 10.1002/jbm.820270512
   CRAIG RG, 1993, RESTORATIVE DENTAL M
   FREED LE, 1993, J BIOMED MATER RES, V27, P11, DOI 10.1002/jbm.820270104
   FRICKE J, 1988, J NON-CRYST SOLIDS, V100, P169, DOI 10.1016/0022-3093(88)90014-2
   GERHART TN, 1988, J BIOMED MATER RES, V22, P1071, DOI 10.1002/jbm.820221110
   GERHART TN, 1989, J BIOMED MATER RES, V23, P1, DOI 10.1002/jbm.820230102
   GERHART TN, 1986, J ORTHOPAED RES, V4, P76, DOI 10.1002/jor.1100040109
   GILLETT N, 1985, BIOMATERIALS, V6, P113, DOI 10.1016/0142-9612(85)90074-2
   GOLDSTEIN SA, 1987, J BIOMECH, V20, P1055, DOI 10.1016/0021-9290(87)90023-6
   GOMI K, 1993, BIOMATERIALS, V14, P91, DOI 10.1016/0142-9612(93)90216-O
   Habal M B, 1991, J Craniofac Surg, V2, P27
   HOLMES R, 1984, CLIN ORTHOP RELAT R, P252
   Ishaug SL, 1997, J BIOMED MATER RES, V36, P17
   IshaugRiley SL, 1997, J BIOMED MATER RES, V36, P1, DOI 10.1002/(SICI)1097-4636(199707)36:1<1::AID-JBM1>3.0.CO;2-P
   JASTY M, 1993, J BIOMED MATER RES, V27, P639, DOI 10.1002/jbm.820270511
   KNOWLES JC, 1992, BIOMATERIALS, V13, P491, DOI 10.1016/0142-9612(92)90099-A
   MAROM G, 1993, BIOMATERIALS, V14, P127, DOI 10.1016/0142-9612(93)90224-P
   MIKOS AG, 1993, BIOMATERIALS, V14, P323, DOI 10.1016/0142-9612(93)90049-8
   NILSSON K, 1980, FEBS LETT, V118, P145, DOI 10.1016/0014-5793(80)81238-5
   POURDEYHIMI B, 1986, J MATER SCI, V21, P4468, DOI 10.1007/BF01106573
   Ripamonti U, 1992, J Craniofac Surg, V3, P149, DOI 10.1097/00001665-199211000-00007
   ROSEN HM, 1989, PLAST RECONSTR SURG, P955
   ROUDIER M, 1995, J BIOMED MATER RES, V29, P909, DOI 10.1002/jbm.820290802
   SCHMITZ JP, 1988, CLIN ORTHOP RELAT R, P245
   SUMNER DR, 1995, J BONE JOINT SURG AM, V77A, P1135, DOI 10.2106/00004623-199508000-00001
   THOMSON RC, 1995, J BIOMAT SCI-POLYM E, V7, P23, DOI 10.1163/156856295X00805
   Toriumi D M, 1993, Facial Plast Surg, V9, P29, DOI 10.1055/s-2008-1064593
   UYAMA S, 1993, TRANSPLANTATION, V55, P932
   VERHEYEN CCPM, 1992, J BIOMED MATER RES, V26, P1277, DOI 10.1002/jbm.820261003
   VERT M, 1984, MACROMOLECULAR BIOMA, P119
   WALD HL, 1993, BIOMATERIALS, V14, P270, DOI 10.1016/0142-9612(93)90117-K
NR 34
TC 302
Z9 329
U1 6
U2 87
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD NOV
PY 1998
VL 19
IS 21
BP 1935
EP 1943
DI 10.1016/S0142-9612(98)00097-0
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 142HB
UT WOS:000077193500004
PM 9863527
DA 2018-10-19
ER

PT J
AU Barcellos, IO
   Carobrez, SG
   Pires, ATN
   Alvarez-Silva, M
AF Barcellos, IO
   Carobrez, SG
   Pires, ATN
   Alvarez-Silva, M
TI In vivo and in vitro responses to poly(ethylene
   terephthalate-co-diethylene glycol terephthalate) and polyethylene oxide
   blends
SO BIOMATERIALS
LA English
DT Article
DE biopolymer; blends; PET-co-DEGT; PEG; implants; inflammation
ID POLY(ETHYLENE-TEREPHTHALATE) COPOLYMERS; POLYMERIC BIOMATERIALS;
   INFLAMMATORY RESPONSES; NETWORKS; SURFACES; INVITRO; PROTEIN
AB Although biocompatible polymeric compounds are generally nontoxic, nonimmunogenic, and chemically inert, implants made from these materials may trigger acute and chronic inflammatory responses. These inflammatory reactions may induce degeneration of implanted biopolymer. Interactions between implanted biomaterial and inflammatory cells are mediated by many cellular events involving cellular adhesion and activation. We studied the inflammatory responses in vivo and in vitro to samples of biopolymers composed of poly(ethylene terephthalate-cn-diethylene glycol terephthalate) plus 0, 5, 25% of polyethylene oxide. We observed that these biopolymers did not induce inflammatory responses when implanted in the peritoneal cavity of mice for 28 days. However we observed deposition of hyaluronic acid at the surface of implanted biomaterial, suggesting that tolerance to biomaterial occurred after surgical implantation. No significant adhesion of inflammatory cells such as mononuclear phagocytes and peripheral leukocytes were observed in vitro, when poly(ethylene terephthalate-co-diethylene glycol terephthalate) blends were used as substratum to cellular adhesion. These results suggest that blends composed of poly(ethylene terephthalate-co-diethylene glycol terephthalate) induce low inflammatory cell adhesion, since no rejection of biopolymer was observed when implanted in experimental animal models. (C) 1998 Published by Elsevier Science Ltd. All rights reserved.
C1 Univ Fed Santa Catarina, Div Imunol, Dept MIP, BR-88040900 Florianopolis, SC, Brazil.
   Univ Reg Blumenau, Dept Quim, Blumenau, SC, Brazil.
RP Alvarez-Silva, M (reprint author), Univ Fed Santa Catarina, Div Imunol, Dept MIP, BR-88040900 Florianopolis, SC, Brazil.
RI Alvarez-Silva, Marcio/K-2432-2012
OI Alvarez-Silva, Marcio/0000-0003-0708-7017
CR ALVAREZSILVA M, 1993, J CELL SCI, V104, P477
   BARCELLOS IO, IN PRESS POLYM
   Cenni Elisabetta, 1993, Clinical Materials, V14, P191, DOI 10.1016/0267-6605(93)90002-O
   DESAI NP, 1992, MACROMOLECULES, V25, P226, DOI 10.1021/ma00027a038
   DESAI NP, 1991, BIOMATERIALS, V12, P144, DOI 10.1016/0142-9612(91)90193-E
   DESAI NP, 1992, BIOMATERIALS, V13, P505, DOI 10.1016/0142-9612(92)90101-S
   DESAI NP, 1992, BIOMATERIALS, V13, P420
   GALLAGHER G, 1993, TUMOR IMMUNOBIOLOGY, P414
   GRAINGER DW, 1989, J BIOMED MATER RES, V23, P979, DOI 10.1002/jbm.820230903
   KIYOTSUKURI T, 1995, POLYMER, V36, P2629, DOI 10.1016/0032-3861(95)91211-O
   LAURENT TC, 1992, FASEB J, V6, P2397
   LEE JH, 1989, J BIOMED MATER RES, V23, P351, DOI 10.1002/jbm.820230306
   MAECHLINGSTRASSER C, 1989, J BIOMED MATER RES, V23, P1385, DOI 10.1002/jbm.820231202
   MARTINEZ JM, 1994, J APPL POLYM SCI, V51, P223, DOI 10.1002/app.1994.070510203
   MCKENZIE SB, 1996, TXB HEMATOLOGY, P733
   MUKAE K, 1990, POLYM J, V22, P250, DOI 10.1295/polymj.22.250
   Nagata M, 1996, POLYM INT, V39, P83
   Pomposo JA, 1996, MACROMOLECULES, V29, P7038, DOI 10.1021/ma9518969
   ROMAN JS, 1997, AN QUIM-INT ED, V93, pS22
   SCOTT JE, 1992, FASEB J, V6, P2639
   SEFTON MV, 1990, P ACS DIV POLYM MATE, V62, P741
   Sotele JJ, 1997, POLYMER, V38, P1179, DOI 10.1016/S0032-3861(96)00619-2
   SUNG C, 1990, POLYMER, V31, P556, DOI 10.1016/0032-3861(90)90402-K
   TANG LP, 1993, J LAB CLIN MED, V122, P292
   TANG LP, 1993, J EXP MED, V178, P2147, DOI 10.1084/jem.178.6.2147
   TIBERG F, 1992, COLLOID POLYM SCI, V270, P1188, DOI 10.1007/BF01095059
   WON HJ, 1994, POLYM B, V33, P113
   1975, POLYM HDB, pV77
NR 28
TC 6
Z9 8
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD NOV
PY 1998
VL 19
IS 22
BP 2075
EP 2082
DI 10.1016/S0142-9612(98)00119-7
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 145ZC
UT WOS:000077401900008
PM 9870759
DA 2018-10-19
ER

PT J
AU Patel, N
   Padera, R
   Sanders, GHW
   Cannizzaro, SM
   Davies, MC
   Langer, R
   Roberts, CJ
   Tendler, SJB
   Williams, PM
   Shakesheff, KM
AF Patel, N
   Padera, R
   Sanders, GHW
   Cannizzaro, SM
   Davies, MC
   Langer, R
   Roberts, CJ
   Tendler, SJB
   Williams, PM
   Shakesheff, KM
TI Spatially controlled cell engineering on biodegradable polymer surfaces
SO FASEB JOURNAL
LA English
DT Article
DE tissue engineering; neurite extension; integrins; patterning
ID PERIPHERAL-NERVE REGENERATION; SELF-ASSEMBLED MONOLAYERS; RECOGNITION
   SEQUENCES; AXONAL REGENERATION; SIGNAL-TRANSDUCTION; LIGAND-BINDING;
   ADHESION; ATTACHMENT; NETWORKS; RGD
AB Controlling receptor-mediated interactions between cells and template surfaces is a central principle in many tissue engineering procedures (1-3). Biomaterial surfaces engineered to present cell adhesion ligands undergo integrin-mediated molecular interactions with cells (1, 4, 5), stimulating cell spreading, and differentiation (6-8). This provides a mechanism for mimicking natural cell-to-matrix interactions. Further sophistication in the control of cell interactions can be achieved by fabricating surfaces on which the spatial distribution of ligands is restricted to micron-scale pattern features (9-14). Patterning technology promises to facilitate spatially controlled tissue engineering with applications in the regeneration of highly organized tissues. These new applications require the formation of ligand patterns on biocompatible and biodegradable templates, which control tissue regeneration processes, before removal by metabolism. We have developed a method of generating micron-scale patterns of any biotinylated ligand on the surface of a biodegradable block copolymer, polylactide-poly(ethylene glycol). The technique achieves control of biomolecule deposition with nanometer precision. Spatial control over cell development has been observed when using these templates to culture bovine aortic endothelial cells and PC12 nerve cells. Furthermore, neurite extension on the biodegradable polymer surface is: directed by pattern features composed of peptides containing the IKVAV sequence (15, 16), suggesting that directional control over nerve regeneration on biodegradable biomaterials can be achieved.
C1 Univ Nottingham, Sch Pharmaceut Sci, Lab Biophys & Surface Anal, Nottingham NG7 2RD, England.
   MIT, Dept Chem Engn, Cambridge, MA 02139 USA.
RP Shakesheff, KM (reprint author), Univ Nottingham, Sch Pharmaceut Sci, Lab Biophys & Surface Anal, Nottingham NG7 2RD, England.
EM kevin.shakesheff@nottingham.ac.uk
RI Roberts, Clive/C-6970-2009; Williams, Philip/C-6947-2009
OI Roberts, Clive/0000-0001-9443-3445; Williams,
   Philip/0000-0002-1822-2133; Davies, Martyn/0000-0001-7695-0596;
   Shakesheff, Kevin/0000-0003-3236-2439
CR BENZEEV A, 1988, P NATL ACAD SCI USA, V85, P2161, DOI 10.1073/pnas.85.7.2161
   Brecknell JE, 1996, BIOL REV, V71, P227, DOI 10.1111/j.1469-185X.1996.tb00748.x
   CANNIZZARO SM, 1998, IN PRESS BIOTECHNOL
   Cao YL, 1997, PLAST RECONSTR SURG, V100, P297, DOI 10.1097/00006534-199708000-00001
   Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425
   CIMA LG, 1993, CHEM ENG PROG    JUN, P46
   Cook AD, 1997, J BIOMED MATER RES, V35, P513
   Decherchi P, 1996, BRAIN RES, V726, P181, DOI 10.1016/0006-8993(96)00331-9
   Delamarche E, 1997, ADV MATER, V9, P741, DOI 10.1002/adma.19970090914
   DEROSE JA, 1991, SURF SCI, V256, P102, DOI 10.1016/0039-6028(91)91204-B
   DRUMHELLER PD, 1994, ANAL BIOCHEM, V222, P380, DOI 10.1006/abio.1994.1506
   EVANS PJ, 1994, PROG NEUROBIOL, V43, P187, DOI 10.1016/0301-0082(94)90001-9
   GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515
   Han DK, 1996, MACROMOLECULES, V29, P5233, DOI 10.1021/ma9601070
   HICKMAN JJ, 1994, J VAC SCI TECHNOL A, V12, P607, DOI 10.1116/1.578844
   HO SP, 1994, ADV MATER, V6, P130, DOI 10.1002/adma.19940060205
   HUBBELL JA, 1995, BIO-TECHNOL, V13, P565, DOI 10.1038/nbt0695-565
   Humphries MJ, 1996, CURR OPIN CELL BIOL, V8, P632, DOI 10.1016/S0955-0674(96)80104-9
   Ide C, 1996, NEUROSCI RES, V25, P101
   KIM E, 1995, NATURE, V376, P581, DOI 10.1038/376581a0
   KUMAR A, 1994, LANGMUIR, V10, P1498, DOI 10.1021/la00017a030
   LANGER R, 1995, ANN BIOMED ENG, V23, P101, DOI 10.1007/BF02368317
   LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529
   Larue L, 1996, DEVELOPMENT, V122, P3185
   LEE JS, 1993, BIOMATERIALS, V14, P958, DOI 10.1016/0142-9612(93)90139-S
   Lhoest JB, 1996, J BIOMAT SCI-POLYM E, V7, P1039, DOI 10.1163/156856296X00534
   Li SM, 1996, MACROMOLECULES, V29, P57, DOI 10.1021/ma950531l
   Lopina ST, 1996, BIOMATERIALS, V17, P559, DOI 10.1016/0142-9612(96)88706-0
   MASSIA SP, 1991, J CELL BIOL, V114, P1089, DOI 10.1083/jcb.114.5.1089
   Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60
   Minuth WW, 1998, CELL TISSUE RES, V291, P1
   Mooney DJ, 1997, J BIOMED MATER RES, V37, P413, DOI 10.1002/(SICI)1097-4636(19971205)37:3<413::AID-JBM12>3.0.CO;2-C
   Mrksich M, 1996, P NATL ACAD SCI USA, V93, P10775, DOI 10.1073/pnas.93.20.10775
   Nicholls J, 1996, TRENDS NEUROSCI, V19, P229, DOI 10.1016/0166-2236(96)10021-7
   OCHI M, 1994, EXP NEUROL, V128, P216, DOI 10.1006/exnr.1994.1130
   Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0
   Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0
   POLLOCK M, 1995, CURR OPIN NEUROL, V8, P354, DOI 10.1097/00019052-199510000-00005
   PUGLIESE L, 1993, J MOL BIOL, V231, P698, DOI 10.1006/jmbi.1993.1321
   RANIERI JP, 1994, INT J DEV NEUROSCI, V12, P725, DOI 10.1016/0736-5748(94)90052-3
   RANIERI JP, 1995, J BIOMED MATER RES, V29, P779, DOI 10.1002/jbm.820290614
   Ratner BD, 1996, J MOL RECOGNIT, V9, P617, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<617::AID-JMR310>3.0.CO;2-D
   Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697
   SCHLAEPFER DD, 1994, NATURE, V372, P786
   SHIBUYA Y, 1995, NEUROSCIENCE, V67, P253, DOI 10.1016/0306-4522(95)00015-B
   SPARGO BJ, 1994, P NATL ACAD SCI USA, V91, P11070, DOI 10.1073/pnas.91.23.11070
   Tamayo J, 1996, LANGMUIR, V12, P4430, DOI 10.1021/la960189l
   TASKINEN HS, 1995, ACTA NEUROPATHOL, V89, P144
   YAMADA KM, 1991, J BIOL CHEM, V266, P12809
   Zhao XM, 1997, J MATER CHEM, V7, P1069, DOI 10.1039/a700145b
   1996, J VACUUM SCI TECHNOL, V7
NR 51
TC 199
Z9 203
U1 2
U2 25
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD NOV
PY 1998
VL 12
IS 14
BP 1447
EP 1454
PG 8
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 134NM
UT WOS:000076749500003
PM 9806753
DA 2018-10-19
ER

PT J
AU Aigner, J
   Tegeler, J
   Hutzler, P
   Campoccia, D
   Pavesio, A
   Hammer, C
   Kastenbauer, E
   Naumann, A
AF Aigner, J
   Tegeler, J
   Hutzler, P
   Campoccia, D
   Pavesio, A
   Hammer, C
   Kastenbauer, E
   Naumann, A
TI Cartilage tissue engineering with novel nonwoven structured biomaterial
   based on hyaluronic acid benzyl ester
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE cartilage; tissue engineering; confocal laser scanning microscopy;
   hyaluronic acid; bioresorbable materials
ID LASER-SCANNING MICROSCOPY; RECONSTRUCTIVE SURGERY; BIODEGRADABLE
   POLYMERS; ARTICULAR-CARTILAGE; PERFUSION CULTURE; FIBRIN GLUE; IN-VITRO;
   CHONDROCYTES; ALGINATE; EXPRESSION
AB The aim of this study was to investigate the possibility of using the benzyl ester of hyaluronic acid (HYAFF(R) 11), a recently developed semisynthetic resorbable material, as a scaffold for the culture of human nasoseptal chondrocytes in tissue-engineering procedures of cartilage reconstruction. Different techniques such as immunohistochemistry, scanning electron microscopy, and confocal laser scanning microscopy were used to study the behavior, morphology, and phenotype expression of the chondrocytes, which were initially expanded and then seeded on the material. The nonwoven cell carrier allowed good viability and adhesivity of the cells without any surface treatment with additional substances. Furthermore, the cultured cells expressed cartilage-specific collagen type II, indicating that they were able to redifferentiate within the scaffold of HYAFF(R) 11 and were able to retain a chondrocyte phenotype even after a long period of in vitro conditions. Nevertheless, the expression of collagen type I, which was produced by dedifferentiated or incompletely redifferentiated chondrocytes, was noticeable. Additional data were obtained by subcutaneous implantation of samples seeded with human cells in the in vivo model of the athymic nude mouse. The results after 1 month revealed the development of tissue similar to hyaline cartilage. This study is promising for the use of this scaffold for tissue engineering of cartilage replacements. (C) 1998 John Wiley & Sons.
C1 Univ Munich, Dept Otorhinolaryngol, Munich, Germany.
   GSF Neuherberg, Dept Pathol, Oberschleissheim, Germany.
   Fidia Adv Biopolymers Srl, Abano Terme, Italy.
   Univ Munich, Inst Surg Res, D-8000 Munich, Germany.
RP Aigner, J (reprint author), Univ Munich, Dept Otorhinolaryngol, Marchioninistr 15, Munich, Germany.
EM Joachim.Aigner@hno.med.uni-muenchen.de
RI Campoccia, Davide/K-5348-2018
OI Campoccia, Davide/0000-0002-3336-0219
CR Aigner J, 1997, IN VITRO CELL DEV-AN, V33, P407, DOI 10.1007/s11626-997-0054-x
   ANDREASSI L, 1991, WOUNDS, V3, P116
   ATTAWIA MA, 1995, J BIOMED MATER RES, V29, P843, DOI 10.1002/jbm.820290709
   AYDELOTTE MB, 1988, CONNECT TISSUE RES, V18, P205, DOI 10.3109/03008208809016808
   BENEDETTI L, 1993, BIOMATERIALS, V14, P1154, DOI 10.1016/0142-9612(93)90160-4
   BENEDETTI LM, 1990, J CONTROL RELEASE, V13, P33, DOI 10.1016/0168-3659(90)90072-2
   BENYA PD, 1978, CELL, V15, P1313, DOI 10.1016/0092-8674(78)90056-9
   BENYA PD, 1982, CELL, V30, P215, DOI 10.1016/0092-8674(82)90027-7
   BUJIA J, 1995, ACTA OTO-LARYNGOL, V115, P307, DOI 10.3109/00016489509139316
   BUJIA J, 1995, LARYNGO RHINO OTOL, V74, P205, DOI 10.1055/s-2007-997721
   BUSCHMANN MD, 1995, J CELL SCI, V108, P1497
   ButnariuEphrat M, 1996, CLIN ORTHOP RELAT R, P234
   Campoccia D, 1996, BIOMATERIALS, V17, P963, DOI 10.1016/0142-9612(96)84670-9
   CAMPOCCIA D, 1993, BIOMATERIALS, V14, P1135, DOI 10.1016/0142-9612(93)90156-V
   CAMPOCCIA D, IN PRESS BIOMATERIAL
   CIMA LG, 1991, J BIOMECH ENG-T ASME, V113, P143, DOI 10.1115/1.2891228
   CORTIVO R, 1990, CELL BIOL INT REP, V14, P111
   CORTIVO R, 1991, BIOMATERIALS, V12, P727, DOI 10.1016/0142-9612(91)90020-B
   DONATI L, 1995, WOUND REPAIR REGEN, V3, P363
   Freed LE, 1997, IN VITRO CELL DEV-AN, V33, P381
   FREED LE, 1993, J BIOMED MATER RES, V27, P11, DOI 10.1002/jbm.820270104
   FREED LE, 1995, BIOMEDICAL ENG HDB, P1788
   Fukuda K, 1996, J PHARMACOL EXP THER, V277, P1672
   Grande DA, 1997, J BIOMED MATER RES, V34, P211, DOI 10.1002/(SICI)1097-4636(199702)34:2<211::AID-JBM10>3.0.CO;2-L
   GRANDOLFO M, 1993, CALCIFIED TISSUE INT, V52, P42, DOI 10.1007/BF00675625
   GUO JF, 1989, CONNECT TISSUE RES, V19, P277, DOI 10.3109/03008208909043901
   Haisch A, 1996, HNO, V44, P624, DOI 10.1007/s001060050067
   Hanthamrongwit M, 1996, J BIOMED MATER RES, V30, P331
   HOMMINGA GN, 1993, ACTA ORTHOP SCAND, V64, P441, DOI 10.3109/17453679308993663
   Ishizeki K, 1996, ANAT EMBRYOL, V193, P61
   ITAY S, 1987, CLIN ORTHOP RELAT R, P284
   KUIAWA MJ, 1986, DEV BIOL, V114, P519
   Mooney DT, 1996, BIOMATERIALS, V17, P115, DOI 10.1016/0142-9612(96)85756-5
   Paige KT, 1996, PLAST RECONSTR SURG, V97, P168, DOI 10.1097/00006534-199601000-00027
   Park S S, 1995, Facial Plast Surg, V11, P278, DOI 10.1055/s-2008-1064544
   PUELACHER WC, 1994, BIOMATERIALS, V15, P774, DOI 10.1016/0142-9612(94)90031-0
   RASTRELLI A, 1990, CLIN IMPLANT MAT, V9, P199
   ROBINSON D, 1990, CALCIFIED TISSUE INT, V46, P246, DOI 10.1007/BF02555003
   Sims CD, 1996, PLAST RECONSTR SURG, V98, P843, DOI 10.1097/00006534-199610000-00015
   SITTINGER M, 1994, BIOMATERIALS, V15, P451, DOI 10.1016/0142-9612(94)90224-0
   TOLLE BP, 1989, CIBA F SYMP, V143, P138
   VACANTI CA, 1991, PLAST RECONSTR SURG, V88, P753, DOI 10.1097/00006534-199111000-00001
   vanSusante JLC, 1995, ACTA ORTHOP SCAND, V66, P549, DOI 10.3109/17453679509002314
   VONDERMARK K, 1977, NATURE, V267, P531, DOI 10.1038/267531a0
   WAKITANI S, 1989, J BONE JOINT SURG BR, V71, P74
   WEST DC, 1989, EXP CELL RES, V183, P179, DOI 10.1016/0014-4827(89)90428-X
   WILLIAMS DF, 1995, P 21 ANN M SOC BIOM, V18, P180
   YOO TJ, 1988, ANN OTO RHINOL LARYN, V97, P318
NR 48
TC 244
Z9 257
U1 1
U2 35
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD NOV
PY 1998
VL 42
IS 2
BP 172
EP 181
DI 10.1002/(SICI)1097-4636(199811)42:2<172::AID-JBM2>3.0.CO;2-M
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 122FC
UT WOS:000076060400002
PM 9773813
DA 2018-10-19
ER

PT J
AU Loty, S
   Sautier, JM
   Loty, C
   Boulekbache, H
   Kokubo, T
   Forest, N
AF Loty, S
   Sautier, JM
   Loty, C
   Boulekbache, H
   Kokubo, T
   Forest, N
TI Cartilage formation by fetal rat chondrocytes cultured in alginate
   beads: A proposed model for investigating tissue-biomaterial
   interactions
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE alginate beads; in vitro; chondrocytes; differentiation; biomaterials
ID HYDROXYAPATITE INTERFACE; CHICK CHONDROCYTES; CELL-SHAPE;
   DIFFERENTIATION; COLLAGEN; BONE; ULTRASTRUCTURE; MATRIX; CHONDROGENESIS;
   DEPOSITION
AB Chondrocytes from 21-day-old rat fetal nasal cartilage were cultured in alginate beads for up to 20 days. It was found that chondrocytes retained their spherical shape and typical chondrocytic appearance. During the culture time, chondrocytes underwent differentiation, as demonstrated by the alkaline phosphatase-specific activity and rate of proteoglycan synthesis. Morphological data confirmed chondrocyte differentiation with the appearance of hypertrophic chondrocytes scattered in the alginate gel and a dense extracellular matrix containing filamentous structures and matrix resides. In addition, Northern blot analysis performed on day 8 of culture showed that chondrocytes cultured in alginate beads expressed type II collagen mRNA. The alginate bead method also appeared to be suitable for testing biomaterials, and the ready dissolution of the alginate beads by chelating agents provided a simple means for the rapid recovery of encapsulated chondrocytes. Powdered glass-ceramic particles entrapped in the alginate gel were colonized by chondrocytes, which then proliferated and formed a tissue similar to a true calcified cartilaginous structure. These results indicate that the alginate system represents a relevant model for studies of chondrogenesis and endochondral ossification. Furthermore, the encapsulation method could prove useful for studies of tissue-biomaterial interactions in an in vitro environment which more closely mirrors the cartilage matrix than other culture methods. (C) 1998 John Wiley & Sons, Inc.
C1 Univ Paris 07, Lab Bol Odontol, Inst Biomed Cordeliers, F-75270 Paris 06, France.
   Univ Paris 07, Dev Biol Lab, F-75251 Paris, France.
   Kyoto Univ, Fac Engn, Sakyo Ku, Kyoto 60601, Japan.
RP Loty, S (reprint author), Univ Paris 07, Lab Bol Odontol, Inst Biomed Cordeliers, 15-21 Rue Ecole Med, F-75270 Paris 06, France.
CR ANDERSON HC, 1967, J CELL BIOL, V35, P81, DOI 10.1083/jcb.35.1.81
   ARCHER CW, 1982, CELL DIFFER DEV, V11, P245, DOI 10.1016/0045-6039(82)90072-0
   BENYA PD, 1982, CELL, V30, P215, DOI 10.1016/0092-8674(82)90027-7
   BONAVENTURE J, 1994, EXP CELL RES, V212, P97, DOI 10.1006/excr.1994.1123
   BONUCCI E, 1967, J ULTRA MOL STRUCT R, V20, P33, DOI 10.1016/S0022-5320(67)80034-0
   CHACKO S, 1969, J EXP MED, V130, P417, DOI 10.1084/jem.130.2.417
   DEBRUIJN JD, 1992, J BIOMED MATER RES, V26, P1365, DOI 10.1002/jbm.820261008
   GANELES J, 1986, J PERIODONTOL, V57, P133, DOI 10.1902/jop.1986.57.3.133
   GERSTENFELD LC, 1991, J CELL BIOL, V112, P501, DOI 10.1083/jcb.112.3.501
   GRANDOLFO M, 1993, CALCIFIED TISSUE INT, V52, P42, DOI 10.1007/BF00675625
   GUO JF, 1989, CONNECT TISSUE RES, V19, P277, DOI 10.3109/03008208909043901
   Hauselmann H. J., 1996, AM J PHYSIOL, V271, P742
   HAUSELMANN HJ, 1992, MATRIX, V12, P116
   HINEK A, 1987, J CELL BIOL, V104, P1435, DOI 10.1083/jcb.104.5.1435
   Kokubo T., 1982, Bulletin of the Institute for Chemical Research, Kyoto University, V60, P260
   LEBOY PS, 1989, J BIOL CHEM, V264, P17281
   LIVECCHI AB, 1994, J BIOMED MATER RES, V28, P839, DOI 10.1002/jbm.820280802
   LOTY S, 1995, BIOL CELL, V83, P149, DOI 10.1016/0248-4900(96)81303-7
   MAOR G, 1987, COLLAGEN REL RES, V7, P351
   MAYNE R, 1976, P NATL ACAD SCI USA, V73, P1674, DOI 10.1073/pnas.73.5.1674
   NEO M, 1992, J BIOMED MATER RES, V26, P1419, DOI 10.1002/jbm.820261103
   POLLESELLO P, 1990, EXP CELL RES, V188, P214, DOI 10.1016/0014-4827(90)90162-4
   POOLE AR, 1991, CARTILAGE MOL ASPECT, P179
   PRECIOUS DS, 1994, BONE, V9, P145
   RAMDI H, 1993, EXP CELL RES, V207, P449, DOI 10.1006/excr.1993.1214
   ROZEN V, 1992, TRENDS GENETIC, V8, P97
   SAUTIER JM, 1994, CALCIFIED TISSUE INT, V55, P458, DOI 10.1007/BF00298560
   SAUTIER JM, 1993, BIOL CELL, V78, P181, DOI 10.1016/0248-4900(93)90128-2
   SAUTIER JM, 1991, CELL MATER, V1, P209
   SMITH MM, 1990, BIOL REV, V65, P277, DOI 10.1111/j.1469-185X.1990.tb01427.x
   SOLURSH M, 1982, DEV BIOL, V94, P259, DOI 10.1016/0012-1606(82)90090-2
   SOLURSH M, 1975, CELL DIFFER DEV, V4, P131, DOI 10.1016/0045-6039(75)90034-2
   VANBLITTERSWIJK CA, 1985, BIOMATERIALS, V6, P243, DOI 10.1016/0142-9612(85)90020-1
   VINKKAPUHAKKA H, 1993, ARCH ORAL BIOL, V38, P49, DOI 10.1016/0003-9969(93)90154-E
   WU LNY, 1989, J BIOL CHEM, V264, P2134
NR 35
TC 55
Z9 57
U1 0
U2 4
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD NOV
PY 1998
VL 42
IS 2
BP 213
EP 222
DI 10.1002/(SICI)1097-4636(199811)42:2<213::AID-JBM6>3.0.CO;2-S
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 122FC
UT WOS:000076060400006
PM 9773817
DA 2018-10-19
ER

PT J
AU van Dijk, K
   Maree, CHM
   Verhoeven, J
   Habraken, FHPM
   Jansen, JA
AF van Dijk, K
   Maree, CHM
   Verhoeven, J
   Habraken, FHPM
   Jansen, JA
TI A complete characterization of Ca-5(PO4)(3)OH sputter-deposited films by
   ion beam analysis: RBS and ERD
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE calcium phosphate; ion beam analysis; coating; Rutherford
   backscattering; elastic recoil detection; biomaterial
ID ELASTIC RECOIL DETECTION; RF; HYDROXYAPATITE; IMPLANTS; LAYERS
AB RF magnetron sputter deposition was used to deposit thin calcium phosphate (hydroxyapatite) lavers on titanium alloy substrate material. We determined the precise amount of calcium, phosphorus, oxygen, and hydrogen in these films by combining two ion-beam analysis techniques: Rutherford backscattering spectrometry (RBS) and elastic recoil detection (ERD). Variables were Fewer level partial oxygen pressure, or additional water vapor. Also examined was the influence of additional bias power to the substrates during deposition and the effect of annealing on the final composition of the deposited layers. Measurements showed that the Ca/P ratio decreased with increasing oxygen pressure or decreasing sputtering Fewer. Ln addition, the Ca/P ratio increased when a bias was applied to the substrates. The O/P ratio of the films decreased with additional oxygen pressure but increased when additional water vapor was applied during deposition. AU as-deposited films showed a higher hydrogen content than stoichiometric HA. The hydrogen content in the films deposited with water vapor was more than 7 times higher than in the films deposited under pure argon conditions. After annealing, the hydrogen content decreased to about 3.5 at % whereas in stoichiometric HA the hydrogen content amounts to 4.5 at %. After annealing, the oxygen concentration in the film also decreased. We assume that hydrogen disappears out of the film as H2O during annealing. For the targets used in these experiments, sputter deposition at 400 W, with additional water vapor and annealing at 500 degrees C, produced films with a stoichiometry closest to that of hydroxyapatite. (C) 1998 John Wiley & Sons, Inc.
C1 Catholic Univ Nijmegen, Dept Biomat, Sch Dent, NL-6500 HB Nijmegen, Netherlands.
   Univ Utrecht, Dept Atom & Interface Phys, NL-3508 TA Utrecht, Netherlands.
   FOM, Inst Atom & Mol Phys, NL-1098 Amsterdam, Netherlands.
RP Jansen, JA (reprint author), Catholic Univ Nijmegen, Dept Biomat, Sch Dent, POB 9101, NL-6500 HB Nijmegen, Netherlands.
EM Jansen@dent.kun.nl
RI Institute (DINS), Debye/G-7730-2014; Jansen, John/H-8055-2014
CR AOKI H, 1991, SCI MED APPL HYDROXY
   BIK WMA, 1992, NUCL INSTRUM METH B, V64, P832, DOI 10.1016/0168-583X(92)95587-H
   BIK WMA, 1993, REP PROG PHYS, V56, P859, DOI 10.1088/0034-4885/56/7/002
   Callahan Thomas J., 1994, V1196, P185
   COOK SD, 1988, CLIN ORTHOP RELAT R, V232, P225
   De Groot K, 1981, BIOCOMPATIBILITY CLI, V1, P199
   DELANGE GL, 1989, BIOMATERIALS, V10, P121, DOI 10.1016/0142-9612(89)90044-6
   Flohr Keith W., 1994, V1196, P16
   GEESINK RGT, 1987, CLIN ORTHOP RELAT R, P147
   HOROWITZ E, 1994, ASTM STANDARDS
   KASEMO B, 1988, J BIOMED MATER RES-A, V22, P145, DOI 10.1002/jbm.820221307
   Lucchini JP, 1996, CLIN ORAL IMPLAN RES, V7, P397, DOI 10.1034/j.1600-0501.1996.070414.x
   Maree CHM, 1996, MATER CHEM PHYS, V46, P198, DOI 10.1016/S0254-0584(97)80014-4
   Russell SW, 1996, J BIOMED MATER RES, V30, P165
   Van Dijk K., 1995, Journal of Biomedical Materials Research, V29, P269
   vanDijk K, 1997, THIN SOLID FILMS, V304, P191, DOI 10.1016/S0040-6090(97)00104-1
   vanDijk K, 1995, SURF COAT TECH, V76, P206, DOI 10.1016/02578-9729(50)25901-
   vanDijk K, 1996, BIOMATERIALS, V17, P405, DOI 10.1016/0142-9612(96)89656-6
NR 18
TC 11
Z9 11
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD NOV
PY 1998
VL 42
IS 2
BP 266
EP 271
DI 10.1002/(SICI)1097-4636(199811)42:2<266::AID-JBM11>3.3.CO;2-U
PG 6
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 122FC
UT WOS:000076060400011
PM 9773822
DA 2018-10-19
ER

PT J
AU Takebe, T
   Itoh, S
   Ariake, T
   Shioji, H
   Shioyama, T
   Ishibashi, K
   Ishizawa, H
AF Takebe, T
   Itoh, S
   Ariake, T
   Shioji, H
   Shioyama, T
   Ishibashi, K
   Ishizawa, H
TI The effect on immunocytes of anodic oxide titanium after hydrothermal
   treatment
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE anodic oxide titanium; hydrothermal treatment; SA-treated titanium;
   biomaterial; immunocyte
ID IMPLANTS; FILMS; BONE; CA
AB All dental root implants come in contact with the oral epithelium, and many complex factors are found to arise in this region. In order to perform a successful dental root implantation, it is necessary to clarify the interaction of the dental root implant material with the host defense mechanisms involved in the specific and nonspecific immuno responses to many antigens in oral bacteria and their components. Recently, focusing on developing the dental root implant, the Nikon Corporation improved the surface characteristics of pure titanium even further by developing a hydroxyapatite (HA) layer formed on an anodic titanium oxide film containing Ca and P via hydrothermal treatment (SA treatment). However, since little is known about the effect of SA-treated pure titanium (HA/Ti) on the defense mechanisms of the oral membrane epithelium, we investigated (1) the in vitro proliferation of murine splenic B lymphotocytes on the surface of HA/Ti in the presence of three lipopolysaccharide (LPS) concentrations and (2) interleukin-(1 alpha) (IL-1 alpha) production hi the reaction of human peripheral blood mononuclear cells (PBM cells) on the surface of HA/Ti under the same concentrations. After culture, murine splenic lymphocytes were measured by uptake of H-3-thymidine, and cytokine release (IL-1 alpha) from PBM cells was measured by ELISA. Results showed that HA/Ti had hardly any effect on the LPS-induced proliferation of B lymphocytes and IL-la: production. In vitro investigations of the effects of HA/Ti on the LPS-induced proliferation of murine splenic B lymphocytes and IL-1 alpha from PBM cells might be a useful way of elucidating the defense mechanism between implants and the oral epithelium. (C) 1998 John Wiley & Sons, Inc.
C1 Iwate Med Univ, Sch Dent, Dept Fixed Prosthodont, Morioka, Iwate 0200021, Japan.
   Nikon Inc, Optoelect Mat Lab, Sagamihara, Kanagawa 228, Japan.
RP Takebe, T (reprint author), Iwate Med Univ, Sch Dent, Dept Fixed Prosthodont, 1-3-27 Chuodori, Morioka, Iwate 0200021, Japan.
EM takebej@cap.iwate-med.ac.jp
CR ALBREKTSSON T, 1983, ANN BIOMED ENG, V11, P1, DOI 10.1007/BF02363944
   ARIAKE T, 1996, P 9 INT S CER MED OT, P333
   Cook S D, 1987, Int J Oral Maxillofac Implants, V2, P15
   DEBRUIJN JD, 1994, J BIOMED MATER RES, V28, P105, DOI 10.1002/jbm.820280114
   DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI 10.1016/S0065-2776(08)60642-2
   ILFELD DN, 1981, CELL IMMUNOL, V57, P400, DOI 10.1016/0008-8749(81)90098-8
   ISHIZAWA H, 1995, J BIOMED MATER RES, V29, P65, DOI 10.1002/jbm.820290110
   ISHIZAWA H, 1995, J BIOMED MATER RES, V29, P1071, DOI 10.1002/jbm.820290907
   ISHIZAWA H, 1995, J BIOMED MATER RES, V29, P1459, DOI 10.1002/jbm.820291118
   Ishizawa H, 1997, J BIOMED MATER RES, V35, P199
   ITOH S, 1990, HDB BIOACTIVE CERAMI, V1, P227
   KAJIMURA K, 1996, J JPN PROSTHODONT SO, V40, P946
   MERGENHAGEN S, 1961, J INFECT DIS, V108, P304, DOI 10.1093/infdis/108.3.304
   MORONI A, 1994, BIOMATERIALS, V15, P926, DOI 10.1016/0142-9612(94)90119-8
   MORRISON DC, 1978, AM J PATHOL, V93, P526
   PERALA DG, 1992, J PERIODONTOL, V63, P426, DOI 10.1902/jop.1992.63.5.426
   SCHROEDER A, 1991, ORAL IMPLANTOLOGY, P37
   TAKEBE J, 1994, J JPN PROSTHODONT SO, V38, P315
   Williams D.F, 1981, BIOCOMPATIBILITY CLI, V1, P9
NR 19
TC 13
Z9 13
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD NOV
PY 1998
VL 42
IS 2
BP 272
EP 277
DI 10.1002/(SICI)1097-4636(199811)42:2<272::AID-JBM12>3.0.CO;2-L
PG 6
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 122FC
UT WOS:000076060400012
PM 9773823
DA 2018-10-19
ER

PT J
AU Matsuoka, H
   Nakamura, T
   Takadama, H
   Yamada, S
   Tamura, J
   Okada, Y
   Oka, M
   Kokubo, T
AF Matsuoka, H
   Nakamura, T
   Takadama, H
   Yamada, S
   Tamura, J
   Okada, Y
   Oka, M
   Kokubo, T
TI Osteoclastic resorption of bone-like apatite formed on a plastic disk as
   an in vitro assay system
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE apatite; assay; biomaterial; biomimetic; osteoclast
ID GROWTH-FACTOR-BETA; BIOACTIVE GLASS; MARROW CULTURES; CELL-FORMATION;
   IN-VITRO; SYNTHETIC HYDROXYAPATITE; EXTRACELLULAR-MATRIX; STIMULATING
   ACTIVITY; RESORBING-ACTIVITY; OSTEOCALCIN
AB WE have investigated the applicability of a simple and inexpensive osteoclastic assay system using bone-like apatite-coated polyethyleneterephthalate (PET) disks. A 1 mu m thick apatite layer, uniform and homogeneous bone-mineral-like with no organic components, was made on PET disks using a biomimetic process. As substrates for an osteoclastic assay, these coated disks were compared with dentine as well as with bone-like or heat-treat ed apatite of various thicknesses on apatite- and wollastonite-containing glass ceramic (A-W GC) disks. The unfractionated bone cells, including osteoclasts, of a neonatal rabbit were seeded onto these substrates. By scanning electron microscopic examination, the resorption lacunae of the thick bone-like apatite clearly showed track-like shapes at various depths, similar to those of dentine although the border between the A-W CC and the apatite was unclear. In contrast, those of heat-treated apatite showed small and shallow shapes with irregular margins, quite different from those of dentine. By reducing the thickness of bone-like apatite to 1 mu m as well as using PET as its substrate, the margins of the resorption lacunae became quite clear, and with the use of phase-contrast microscopy during culture, osteoclasts and resorption Fits could be precisely observed. The resorbed area, easily measured with the aid of bright-field microscopy and an image analyzer, was found to have increased in a time-dependent manner and at the end of 4 days of culture was not statistically different from that of dentine. (C) 1998 John Wiley & Sons, Inc.
C1 Kyoto Univ, Fac Med, Dept Orthopaed Surg, Sakyo Ku, Kyoto 60601, Japan.
   Kyoto Univ, Fac Engn, Dept Chem Mat, Sakyo Ku, Kyoto 60601, Japan.
   Kyoto Univ, Biomed Engn Res Ctr, Sakyo Ku, Kyoto 60601, Japan.
RP Matsuoka, H (reprint author), Kyoto Univ, Fac Med, Dept Orthopaed Surg, Sakyo Ku, 54 Kawahara Cho, Kyoto 60601, Japan.
CR BASLE MF, 1993, CALCIFIED TISSUE INT, V53, P348, DOI 10.1007/BF01351842
   Benahmed M, 1997, J BIOMED MATER RES, V34, P115, DOI 10.1002/(SICI)1097-4636(199701)34:1<115::AID-JBM15>3.0.CO;2-J
   BLAIR HC, 1986, J CELL BIOL, V102, P1164, DOI 10.1083/jcb.102.4.1164
   BOYDE A, 1991, CALCIFIED TISSUE INT, V49, P65, DOI 10.1007/BF02565123
   CHENU C, 1994, J CELL BIOL, V127, P1149, DOI 10.1083/jcb.127.4.1149
   COLLIN P, 1992, ENDOCRINOLOGY, V131, P1181, DOI 10.1210/en.131.3.1181
   DAVIES JE, 1993, CELL MATER, V3, P245
   DEBRUIJN JD, 1994, J BIOMED MATER RES, V28, P105, DOI 10.1002/jbm.820280114
   ElGhannam A, 1997, J BIOMED MATER RES, V36, P167, DOI 10.1002/(SICI)1097-4636(199708)36:2<167::AID-JBM5>3.0.CO;2-I
   FISCHER LW, 1983, J BIOL CHEM, V258, P12723
   FRANCHIMONT N, 1995, ENDOCRINOLOGY, V136, P5469, DOI 10.1210/en.136.12.5469
   FUJISAWA R, 1993, J DENT RES, V72, P1222, DOI 10.1177/00220345930720081001
   FULLER K, 1991, BIOCHEM BIOPH RES CO, V181, P67, DOI 10.1016/S0006-291X(05)81382-8
   GLOWACKI J, 1991, J CELL BIOCHEM, V45, P292, DOI 10.1002/jcb.240450312
   GOMI K, 1993, BIOMATERIALS, V14, P91, DOI 10.1016/0142-9612(93)90216-O
   HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665
   HILL PA, 1995, ENDOCRINOLOGY, V136, P124, DOI 10.1210/en.136.1.124
   HORTON MA, 1991, EXP CELL RES, V195, P368, DOI 10.1016/0014-4827(91)90386-9
   INGRAM RT, 1994, J CLIN INVEST, V93, P989, DOI 10.1172/JCI117106
   Jimi E, 1996, J CELL PHYSIOL, V168, P395, DOI 10.1002/(SICI)1097-4652(199608)168:2<395::AID-JCP18>3.0.CO;2-2
   Jimi E, 1996, ENDOCRINOLOGY, V137, P2187
   Kakudo S, 1996, J BONE MINER METAB, V14, P129, DOI 10.1007/BF02239480
   KANATANI M, 1995, J BONE MINER RES, V10, P1681, DOI 10.1002/jbmr.5650101110
   KATOH M, 1995, BONE, V16, P97, DOI 10.1016/S8756-3282(94)00015-8
   KOKUBO T, 1986, J MATER SCI, V21, P536, DOI 10.1007/BF01145520
   KOKUBO T, 1990, J BIOMED MATER RES, V24, P331, DOI 10.1002/jbm.820240306
   Kokubo T, 1991, BIOCERAMICS, V4, P113
   KOKUBO T, 1996, 5 WORLD BIOM C TOR C
   LIAN JB, 1984, J CLIN INVEST, V73, P1223, DOI 10.1172/JCI111308
   LIGGETT WH, 1994, J CELL BIOCHEM, V55, P190, DOI 10.1002/jcb.240550206
   MCKEE MD, 1993, J BONE MINER RES, V8, P485
   MULLERMAI CM, 1990, SCANNING MICROSCOPY, V4, P613
   Ohgushi H, 1996, J BIOMED MATER RES, V32, P341, DOI 10.1002/(SICI)1097-4636(199611)32:3<341::AID-JBM6>3.0.CO;2-S
   OLDBERG A, 1988, J BIOL CHEM, V263, P19430
   OURSLER MJ, 1994, J BONE MINER RES, V9, P443
   PRICE PA, 1976, P NATL ACAD SCI USA, V73, P1447, DOI 10.1073/pnas.73.5.1447
   Raynal C, 1996, ENDOCRINOLOGY, V137, P2347, DOI 10.1210/en.137.6.2347
   REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473
   ROSS FP, 1993, J BIOL CHEM, V268, P9901
   SHINAR DM, 1990, ENDOCRINOLOGY, V126, P3153, DOI 10.1210/endo-126-6-3153
   STEELE JG, 1993, J BIOMAT SCI-POLYM E, V5, P245
   TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo-122-4-1373
   TAKESHITA N, 1992, J ELECTRON MICROSC, V41, P141
   TANAHASHI M, 1994, J AM CERAM SOC, V77, P2805, DOI 10.1111/j.1151-2916.1994.tb04508.x
   TETI A, 1991, BIOCHEM BIOPH RES CO, V179, P634, DOI 10.1016/0006-291X(91)91419-D
   TEZUKA K, 1992, BIOCHEM BIOPH RES CO, V186, P911, DOI 10.1016/0006-291X(92)90832-6
   UDAGAWA N, 1989, ENDOCRINOLOGY, V125, P1805, DOI 10.1210/endo-125-4-1805
   WALSH CA, 1991, J BONE MINER RES, V6, P661
   YAMADA S, 1994, J BIOMED MATER RES, V28, P1357, DOI 10.1002/jbm.820281114
   YAMADA S, 1994, CELL MATER, V4, P347
NR 50
TC 9
Z9 9
U1 0
U2 2
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD NOV
PY 1998
VL 42
IS 2
BP 278
EP 285
DI 10.1002/(SICI)1097-4636(199811)42:2<278::AID-JBM13>3.0.CO;2-F
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 122FC
UT WOS:000076060400013
PM 9773824
DA 2018-10-19
ER

PT J
AU Suggs, LJ
   Krishnan, RS
   Garcia, CA
   Peter, SJ
   Anderson, JM
   Mikos, AG
AF Suggs, LJ
   Krishnan, RS
   Garcia, CA
   Peter, SJ
   Anderson, JM
   Mikos, AG
TI In vitro and in vivo degradation of poly(propylene fumarate-co-ethylene
   glycol) hydrogels
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE cardiovascular stents; hydrogels; poly(ethylene glycol); poly(propylene
   fumarate); biodegradation; tissue engineered implants
ID CORONARY ANGIOPLASTY; RESTENOSIS
AB The degradation of poly(propylene fumarate-co-ethylene glycol) hydrogels was examined in vitro in phosphate-buffered saline at pH 7.4 and in vivo in a subcutaneous rat model. These hydrogels have potential application as biodegradable, injectable cardiovascular stents, and, as such, their mass loss, dimensional changes, mechanical properties, morphology, and biocompatiblity over a 12-week time course were evaluated. Three formulations were fabricated: one base formulation consisting of 25% (w/w) PEG, molecular weight 4,600; one high weight percent PEG formulation with 50%; (w/w) PEG; and one high molecular weight PEG formulation, molecular weight 10,500. All three formulations showed significant weight loss (between 40 and 60%) on the first day due to leaching of the uncrosslinked fraction. Further weight loss was observed only for the low weight percent PEG copolymers in the in vivo case, and a slight increase in volume was observed due to degradative swelling. The mechanical properties of the P(PF-co-EC) hydrogels decreased significantly in the first 3 weeks, showing the biphasic pattern typical of bulk degradation. In vitro, the hydrogels showed at least a 20% retention of their initial ultimate tensile stress after 3 weeks. The dynamic mechanical properties showed similar retention, with the in vivo mechanical properties differing from the iri vitro properties only after 6 weeks of degradation. Differences in PEC molecular weight appeared to have little effect, but increasing the weight percent PEG decreased the rate of degradation both in vitro and in vivo. The morphology of the copolymer films, based on scanning electron microscopy observation, was not significantly different either among the three formulations or on the time course of the study, suggesting tl,ere were no macroscopic structural changes during this time period. The P(PF-co-EG) hydrogels demonstrated good initial biocompatibility, showing responses characteristic of biomaterial implants. (C) 1998 John Wiley & Sons, Inc.
C1 Rice Univ, Inst Biosci & Bioengn, Cox Lab Biomed Engn, Houston, TX 77251 USA.
   Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA.
   Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA.
   Case Western Reserve Univ, Dept Macromol Sci, Cleveland, OH 44106 USA.
RP Mikos, AG (reprint author), Rice Univ, Inst Biosci & Bioengn, Cox Lab Biomed Engn, 6100 S Main St, Houston, TX 77251 USA.
FU NIAMS NIH HHS [R01-AR44381]; NIGMS NIH HHS [5T32GM08362]
CR Anderson James M., 1996, P165
   CHU CC, 1981, J BIOMED MATER RES, V15, P795, DOI 10.1002/jbm.820150604
   FRANKLIN SM, 1993, CORONARY ARTERY DIS, V4, P232, DOI 10.1097/00019501-199303000-00003
   GottsaunerWolf M, 1996, CLIN CARDIOL, V19, P347, DOI 10.1002/clc.4960190505
   HEROLD DA, 1989, BIOCHEM PHARMACOL, V38, P73, DOI 10.1016/0006-2952(89)90151-2
   HILLWEST JL, 1994, P NATL ACAD SCI USA, V91, P5967, DOI 10.1073/pnas.91.13.5967
   HOLMES DR, 1984, AM J CARDIOL, V53, pC77, DOI 10.1016/0002-9149(84)90752-5
   MERRILL EW, 1982, J AM SOC ARTIF INT O, V6, P60
   Peter SJ, 1998, J BIOMED MATER RES, V41, P1
   Peter SJ, 1997, TISSUE ENG, V3, P207, DOI 10.1089/ten.1997.3.207
   Peter SJ, 1997, J BIOMAT SCI-POLYM E, V8, P893, DOI 10.1163/156856297X00074
   Suggs LJ, 1997, MACROMOLECULES, V30, P4318, DOI 10.1021/ma970312v
   SUGGS LJ, 1996, PHYSICAL PROPERTIES, P615
   SUGGS LJ, IN PRESS J BIOMATER
   Yaszemski MJ, 1996, BIOMATERIALS, V17, P2127, DOI 10.1016/0142-9612(96)00008-7
NR 15
TC 59
Z9 60
U1 1
U2 7
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD NOV
PY 1998
VL 42
IS 2
BP 312
EP 320
DI 10.1002/(SICI)1097-4636(199811)42:2<312::AID-JBM17>3.0.CO;2-K
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 122FC
UT WOS:000076060400017
PM 9773828
DA 2018-10-19
ER

PT J
AU Li, TT
   Akao, M
   Takagi, M
AF Li, TT
   Akao, M
   Takagi, M
TI Tissue reaction of hydroxyapatite sol to rat molar pulp
SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE
LA English
DT Article
ID BONE; MICROCRYSTALS
AB Hydroxyapatite sol was prepared by dispersing unheated hydroxyapatite microcrystals into distilled water. A suspension of hydroxyapatite heated at 800 degrees C (HAp-800 degrees C) in distilled water was used as a comparative material. These were characterized by X-ray diffractometry, SEM and electroconductivity measurements. 0.001 ml of each material was injected into the upper first molar pulp of rats. After 7-14 days post-operatively, the group with hydroxyapatite sol showed slight inflammation in the pulp cavities and a highly calcified tubular dentine bridge was observed. Osteodentine had developed and adhered to the surface of the hydroxyapatite microcrystals. Matrix vesicles were observed in the extracellular matrix between collagen fibrils and electron-dense granules. After 28 days, the inflammation completely disappeared and tubular dentine was observed below the osteodentine. Acid phosphates (ACPase) activity was detected along all biosynthesizing pathways in odontoblast-like cells. Localized dehydrogenate (LDH) activity indicated phagocytosis of hydroxyapatite microcrystals by odontoblasts. In the group with HAp-800 degrees C after 7-14 days post-operatively, the inflammation was moderate. After 28 days, relatively fewer calcified dentine tubules were observed. ACPase activity was detected only along the membranes bounding cytoplasmatic vacuoles. It was concluded that hydroxyapatite sol is a safe biomaterial for use as dental pulp and induces early formation of dentine-bridge more so than HAp-800 degrees C. (C) 1998 Kluwer Academic Publishers.
C1 Tokyo Med & Dent Univ, Fac Dent, Dept Oral Pathol, Tokyo 113, Japan.
RP Li, TT (reprint author), Tokyo Med & Dent Univ, Fac Dent, Dept Oral Pathol, Tokyo 113, Japan.
CR AKAO M, 1981, J MATER SCI, V16, P809, DOI 10.1007/BF00552220
   AOKI H, 1994, T MRS JAP, V15, P3
   AOKI H, 1975, JPN CERAM SOC, V10, P469
   AOKI H, 1992, REP I MED DENT ENG, V26, P15
   AOKI H, 1994, MED APPL HYDROXYAPAT, P176
   AOKI H, 1977, J DENT ENG, V18, P86
   AOKI H, 1995, REP I MED DENT ENG, V29, P32
   Best S, 1997, J MATER SCI-MATER M, V8, P97, DOI 10.1023/A:1018558816871
   BONFIELD W, 1981, BIOMATERIALS, V2, P185, DOI 10.1016/0142-9612(81)90050-8
   BONFIELD W, 1988, J BIOMED ENG, V93, P91
   DUCHEYNE P, 1986, BIOMATERIALS, V7, P97, DOI 10.1016/0142-9612(86)90063-3
   Fukuchi N, 1995, BIO-MED MATER ENG, V5, P219
   FUKUCHI N, 1996, JPN J DENT MAT, V15, P20
   FURUSAWA M, 1987, J TOKYO DENT COLL SO, V87, P701
   GITELMAN HJ, 1967, ANAL BIOCHEM, V18, P531
   IMAI M, 1993, J ORAL PATHOL MED, V22, P411, DOI 10.1111/j.1600-0714.1993.tb00132.x
   JARCHO M, 1976, J MATER SCI, V11, P2027, DOI 10.1007/BF02403350
   KITASAKO Y, 1996, JPN J CONSERV DENT, V40, P1
   KLEIN CPAT, 1984, BIOMATERIALS, V5, P362, DOI 10.1016/0142-9612(84)90036-X
   KOBAYASH T, 1995, T 10 S AP, V10, P15
   KOMORIYA T, 1986, JPN J CONSERV DENT, V29, P214
   LI TT, 1995, BIO-MED MATER ENG, V5, P83
   Li TT, 1996, J MATER SCI-MATER M, V7, P355, DOI 10.1007/BF00154548
   MATSUZAWA T, 1971, J HISTOCHEM CYTOCHEM, V19, P801, DOI 10.1177/19.12.801
   MURAL M, 1981, JPN J CONSERV DENT, V24, P58
   NEGM MM, 1981, ORAL SURG ORAL MED O, V51, P190, DOI 10.1016/0030-4220(81)90039-6
   OSBORN JF, 1985, IMPLANTATWERKSTOFF H, P1
   SCHRODER U, 1985, J DENT RES, V64, P541, DOI 10.1177/002203458506400407
   SEINO E, 1992, JPN J CONSERV DENT, V35, P1374
   SEKINE N, 1953, SHIKA GAKUHO, V53, P666
   SHOJI S, 1984, JPN J CONSERV DENT, V27, P204
   TAKIKAWA K, 1995, J JPN SOC BIOMATER, V13, P217
   TOUW JJA, 1980, CELL TISSUE RES, V209, P111
   YOSHIKI S, 1971, ARCH ORAL BIOL, V16, P1143, DOI 10.1016/0003-9969(71)90043-4
NR 34
TC 7
Z9 8
U1 1
U2 4
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0957-4530
J9 J MATER SCI-MATER M
JI J. Mater. Sci.-Mater. Med.
PD NOV
PY 1998
VL 9
IS 11
BP 631
EP 642
DI 10.1023/A:1008979424395
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 170YR
UT WOS:000078835300004
PM 15348681
DA 2018-10-19
ER

PT J
AU De La Cruz, C
   Haimovich, B
   Greco, RS
AF De La Cruz, C
   Haimovich, B
   Greco, RS
TI Immobilized IgG and fibrinogen differentially affect the cytoskeletal
   organization and bactericidal function of adherent neutrophils
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
ID ACTIVATION; ADHESION; BIOMATERIALS; LEUKOCYTES; INTEGRINS; SURFACES
AB The infection of a vascular prosthesis is a dreaded clinical outcome. Since fibrinogen (FBGN) and immunoglobulin (IgG) coat the implanted biomaterial surface, it is with these immobilized proteins that the neutrophil (PMN) interacts. This study tests the hypothesis that PMN are impaired in their ability to kill bacteria when bound to immobilized IgG or FBGN. Isolated human PMN were bound to FBGN or IgG: and then left untreated or exposed to phorbol myristate acetate (PMA; 10(-7) M). PMN adhered loosely, but did not spread, onto FBGN. In contrast, PMN spread fully onto IgG, exhibiting polarized pseudopodia. PMA treatment induced spreading of the FBGN bound cells. Suspended and adherent PMN were incubated 1 h with C-14-labeled Staphylococcus aureus; then, phagocytosis was assessed by radioactive uptake or bacterial kill. was determined by plating recovered bacteria and colony counting. Data were analyzed by unpaired t test. We observed that both the phagocytic and the killing ability of FBGN-bound PMN were similar to that of suspended PMN. Conversely, IgG-bound PMN displayed a 62 +/- 6% (P < 0.01) decrease in phagocytosis and 33 +/- 7% (P < 0.05) reduction in bill vs suspended cells. PMA induced a 74 +/- 6% (P < 0.01) reduction in phagocytosis and 68 +/- 5% (P < 0.01) reduction in kill of bacteria for PMN bound to FBGN with no further effect on IgG-bound PMN. Using fluorescent vital dyes and confocal microscopy we determined that 33% fewer PMN were engaged in phagocytosis when bound to IgG vs FBGN. We conclude that Fc receptor ligation by immobilized IgG or PMA treatment of the FBGN-adherent PMN triggers cell spreading and reduced bactericidal activity. These results indicate that excessive cytoskeletal organization may impair the ability of PMN to kill bacteria and result in vascular graft infections. (C) 1998 Academic Press.
C1 Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, New Brunswick, NJ 08903 USA.
RP De La Cruz, C (reprint author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, 1 Robert Wood Pl,MEB Room 594, New Brunswick, NJ 08903 USA.
CR DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545
   FABIAN I, 1992, BRIT J HAEMATOL, V80, P137, DOI 10.1111/j.1365-2141.1992.tb08890.x
   GERSHAM HD, 1991, J CLIN INVEST, V88, P588
   GOLDSTEIN IM, 1979, SEMIN HEMATOL, V16, P175
   HENSON PM, 1971, J IMMUNOL, V107, P1547
   HENSON PM, 1992, INFLAMMATION BASIC P, P511
   HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9
   HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S
   Kaplan S S, 1990, ASAIO Trans, V36, pM172
   KATZ DA, 1994, SURGERY, V116, P446
   KLOCK JC, 1976, BLOOD, V48, P149
   NATHAN CF, 1987, J CLIN INVEST, V80, P1550, DOI 10.1172/JCI113241
   OMANN GM, 1987, PHYSIOL REV, V67, P285
   PANKOWSKY DA, 1990, J VASC SURG, V11, P599, DOI 10.1067/mva.1990.18272
   ROLIDIES E, 1991, J INFECT DIS, V163, P579
   SANDOR M, 1993, J CLIN IMMUNOL, V13, P32768
   TANG LP, 1993, J LAB CLIN MED, V122, P292
   WRIGHT DG, 1979, J IMMUNOL, V123, P285
   ZIMMERLI W, 1984, J CLIN INVEST, V73, P1191, DOI 10.1172/JCI111305
NR 19
TC 9
Z9 9
U1 0
U2 0
PU ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
J9 J SURG RES
JI J. Surg. Res.
PD NOV
PY 1998
VL 80
IS 1
BP 28
EP 34
DI 10.1006/jsre.1998.5262
PG 7
WC Surgery
SC Surgery
GA 134HK
UT WOS:000076737300005
PM 9790811
DA 2018-10-19
ER

PT J
AU Malaisrie, SC
   Malekzadeh, S
   Biedlingmaier, JF
AF Malaisrie, SC
   Malekzadeh, S
   Biedlingmaier, JF
TI In vivo analysis of bacterial biofilm formation on facial plastic
   bioimplants
SO LARYNGOSCOPE
LA English
DT Article
DE biofilm; biomaterial; bioimplant
ID POLYTETRAFLUOROETHYLENE GORE-TEX; SILVER-OXIDE; INFECTION
AB Objectives: This study examines the formation of biofilm on biomaterials commonly used in facial plastics and reconstruction including titanium, silicone, ion-bombarded silicone (Ultrasil), e-PTFE (Gore-Tex), and PHDPE (Medpor). Methods: These biomaterials were implanted subcutaneously in the dorsum of 11 guinea pigs after contamination with Staphylococcus aureus and examined with scanning electron microscopy after 7 days. Wounds were also inspected for infection and extrusion rates. Results: Results show biofilm formation on titanium, silicone, ion-bombarded silicone, e-PTFE, and PHDPE associated with high rates of extrusion and infection. Implants of e-PTFE with silver/chlorhexidine, on the other hand, appeared resistant to biofilm formation and demonstrated significantly lower rates of extrusion and infection. Conclusions: contamination of bioimplants in vivo leads to formation of bacterial biofilm on the surface of the biomaterial, causing infection, pus formation, and extrusion. The authors hypothesize that the antiseptic agents impregnated in the biomaterial form a protective coat of silver, chlorhexidine, and inflammatory cells that inhibits initial bacterial adhesion to the biomaterial surface.
C1 Univ Maryland, Med Syst, Dept Surg, Div Otolaryngol Head & Neck Surg, Baltimore, MD 21201 USA.
   Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
RP Biedlingmaier, JF (reprint author), Maryland Gen Hosp, Head Serv, 827 Linden Ave, Baltimore, MD 21201 USA.
CR ADAMS JS, 1991, APPL BIOMATERIALS FA, P271
   BROWN MRW, 1993, J APPL BACTERIOL, V74, pS87, DOI 10.1111/j.1365-2672.1993.tb04345.x
   Choi J C, 1995, J Craniomaxillofac Trauma, V1, P42
   CHOLE RA, 1995, ARCH OTOLARYNGOL, V121, P562
   COSTERTON JW, 1995, ANNU REV MICROBIOL, V49, P711, DOI 10.1146/annurev.mi.49.100195.003431
   COSTERTON JW, 1987, ANNU REV MICROBIOL, V41, P435, DOI 10.1146/annurev.mi.41.100187.002251
   Dougherty W R, 1994, J Craniofac Surg, V5, P26, DOI 10.1097/00001665-199402000-00007
   FULEIHAN NS, 1993, OTOLARYNGOLOGY HEAD, P612
   Gander S, 1996, J ANTIMICROB CHEMOTH, V37, P1047, DOI 10.1093/jac/37.6.1047
   GODIN MS, 1995, ARCH OTOLARYNGOL, V121, P1131
   GOLSHANI S, 1994, AM J COSMET SURG, V11, P105
   JOHNSON JR, 1990, J INFECT DIS, V162, P1145, DOI 10.1093/infdis/162.5.1145
   MAAS CS, 1993, ARCH OTOLARYNGOL, V119, P1008
   PICHA GJ, 1997, PLASTIC MAXILLOFACIA, P75
   Romano J J, 1993, J Craniofac Surg, V4, P142, DOI 10.1097/00001665-199307000-00007
   RUSSELL AD, 1993, J HOSP INFECT, V25, P229, DOI 10.1016/0195-6701(93)90109-D
   SAIDI IS, 1998, IN PRESS OTOLARYNGOL
   SAMARANAYAKE R, 1998, OTOLARYNGOL HEAD NEC, V118, P444
   SCHERRIS DA, 1996, LARYNGOSCOPE, V106, P658
   Sclafani AP, 1997, ARCH OTOLARYNGOL, V123, P328
   WALTER C, 1991, APPL BIOMATERIALS FA, P323
NR 21
TC 22
Z9 23
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA
SN 0023-852X
J9 LARYNGOSCOPE
JI Laryngoscope
PD NOV
PY 1998
VL 108
IS 11
BP 1733
EP 1738
DI 10.1097/00005537-199811000-00026
PN 1
PG 6
WC Medicine, Research & Experimental; Otorhinolaryngology
SC Research & Experimental Medicine; Otorhinolaryngology
GA 136NY
UT WOS:000076867000026
PM 9818835
DA 2018-10-19
ER

PT J
AU Bescher, E
   Mackenzie, JD
AF Bescher, E
   Mackenzie, JD
TI Hybrid organic-inorganic sensors
SO MATERIALS SCIENCE & ENGINEERING C-BIOMIMETIC AND SUPRAMOLECULAR SYSTEMS
LA English
DT Article
DE organic-inorganic sensors; second order bonding; covalent bonding
ID SOL-GEL GLASS; RUTHENIUM COMPLEXES; HYDROGEN-PEROXIDE; GLUCOSE
   BIOSENSOR; CYTOCHROME-C; WAVE; BIOMATERIAL; COATINGS; ENZYMES
AB Using the sol-gel process, it is possible to combine organic and inorganic components within the same matrix. Many new hybrid materials with unique mechanical, chemical or physical properties have been synthesized using this low-temperature, 'soft chemistry' route. Optics and sensing technology probably stand to benefit the most from the current research effort on these new materials. Since they combine the features of gel-derived oxides (mechanical strength, transparency in the visible, high porosity and surface area) with the characteristics of organic molecules (wide range of reactivity and specificity, optical properties), organic-inorganic hybrids are materials that often cannot be fabricated by other means. This report describes some recent work in the authors' laboratory and briefly summarizes other recent advances in the field. According to a recent trend, it distinguishes between two different types of hybrids. In type I hybrids, the interaction between organic and inorganic constituents is weak and due to second order (Van der Waals or hydrogen) bonding. In Type II hybrids, the interaction between the organic and the inorganic constituents is strong and due to covalent or iono-covalent bonding. (C) 1998 Elsevier Science S.A. All rights reserved.
C1 Univ Calif Los Angeles, Dept Mat Sci & Engn, Los Angeles, CA 90004 USA.
EM bescher@ucla.edu
CR AHARONSON N, 1994, BETTER CERAMICS CHEM, V346, P329
   Audebert P, 1994, J SOL-GEL SCI TECHN, V2, P809, DOI 10.1007/BF00486355
   AVNIR D, ACS S SERIES, V499, pCH27
   BenDavid O, 1997, P SOC PHOTO-OPT INS, V3136, P104, DOI 10.1117/12.279156
   Bescher EP, 1997, P SOC PHOTO-OPT INS, V3136, P397, DOI 10.1117/12.284135
   BLITH D, 1995, ANALYST, V120, P2725
   BRAUN S, 1990, MATER LETT, V10, P1, DOI 10.1016/0167-577X(90)90002-4
   BRAUN S, 1992, ANAL CHIM ACTA, V256, P65
   BRINKER CJ, 1990, SOL GEL SCI PHYSICS
   CHEN ZP, 1995, CHEM MATER, V7, P1779, DOI 10.1021/cm00058a005
   CHERNYAK V, 1991, CHEM PHYS LETT, V181, P39, DOI 10.1016/0009-2614(91)90218-X
   CHERNYAK V, 1990, SENSOR MATER, V2, P117
   Chut SL, 1997, ANALYST, V122, P1431, DOI 10.1039/a703383d
   CocheGuerente L, 1997, CHEM MATER, V9, P1348, DOI 10.1021/cm960498x
   COLLINO LR, 1994, J SOL-GEL SCI TECHN, V2, P823
   Collinson MM, 1997, LANGMUIR, V13, P7245, DOI 10.1021/la9701485
   Costello BPJD, 1996, J MATER CHEM, V6, P289
   DAVE B, 1994, ANAL CHEM, V66
   DAVE BC, 1995, CHEM MATER, V7, P1431, DOI 10.1021/cm00056a003
   DUNUWILLA D, 1995, ANAL CHEM, V67, P1307
   ELLERBY L, 1993, SCIENCE, V255, P113
   GLAZER AN, 1984, TRENDS BIOCHEM SCI, V9, P423, DOI 10.1016/0968-0004(84)90146-4
   GLEZER V, 1993, J AM CHEM SOC, V115, P2533, DOI 10.1021/ja00059a072
   Grant SA, 1997, SENSOR ACTUAT B-CHEM, V45, P35, DOI 10.1016/S0925-4005(97)00263-3
   Grate JW, 1997, CHEM MATER, V9, P1201, DOI 10.1021/cm960590t
   Hong E, 1996, MATER RES SOC SYMP P, V435, P449, DOI 10.1557/PROC-435-449
   Inoue H, 1998, J SOL-GEL SCI TECHN, V11, P67, DOI 10.1023/A:1008688917552
   Ji Q, 1998, J AM CHEM SOC, V120, P221, DOI 10.1021/ja962477+
   JWAN JLH, 1997, J NONCRYST SOLIDS, V220, P316
   KUYAVSKAYA BI, 1992, J NONCRYST SOLIDS, V147, P808
   Lee SK, 1997, ANALYST, V122, P81, DOI 10.1039/a604885d
   LEV O, 1992, FRESEN J ANAL CHEM, V343, P370, DOI 10.1007/BF00322873
   Li J, 1996, ANAL CHIM ACTA, V335, P137, DOI 10.1016/S0003-2670(96)00337-6
   LIN J, 1991, SENSOR ACTUAT B-CHEM, V5, P219, DOI 10.1016/0925-4005(91)80250-N
   LIVAGE J, 1994, SOL GEL OPTICS, V3, P493
   MACCRAITH BD, 1993, ANALYST, V118, P385, DOI 10.1039/an9931800385
   McEvoy AK, 1996, ANALYST, V121, P785, DOI 10.1039/an9962100785
   Miller JM, 1996, J NON-CRYST SOLIDS, V202, P279, DOI 10.1016/0022-3093(96)00191-3
   MURAMATSU H, 1987, ANAL CHEM, V59, P2760, DOI 10.1021/ac00150a007
   NARANG U, 1994, ANAL CHEM, V66, P3139, DOI 10.1021/ac00091a023
   OKA K, THESIS UCLA
   PANKRATOV I, 1995, J ELECTROANAL CHEM, V393, P35, DOI 10.1016/0022-0728(95)04020-O
   Panusa A, 1996, CHEM MATER, V8, P1202, DOI 10.1021/cm9504706
   Park TM, 1997, ELECTROANAL, V9, P1120, DOI 10.1002/elan.1140091416
   PARKASH R, 1991, TALANTA, V38, P1116
   Roux C, 1997, J SOL-GEL SCI TECHN, V8, P663, DOI 10.1023/A:1018380512509
   SANCHEZ C, 1994, NEW J CHEM, V18, P1007
   Wallington SA, 1997, J SOL-GEL SCI TECHN, V8, P1127, DOI 10.1023/A:1018396005125
   Wang J, 1997, ELECTROANAL, V9, P689, DOI 10.1002/elan.1140090907
   Wang J, 1997, ELECTROANAL, V9, P908, DOI 10.1002/elan.1140091208
   Wang J, 1997, ELECTROANAL, V9, P52, DOI 10.1002/elan.1140090112
   WANG R, 1993, ANAL CHEM, V65, P2671, DOI 10.1021/ac00067a020
   WATSON J, 1994, STANNIC OXIDE GAS SE
   WONG P, 1995, THESIS UCLA
   WONG PW, 1994, MATER RES SOC SYMP P, V346, P329
   WU SG, 1994, APPL BIOCHEM BIOTECH, V47, P11, DOI 10.1007/BF02788671
   WU SG, 1993, CHEM MATER, V5, P115, DOI 10.1021/cm00025a022
   YANG L, 1995, ANAL CHEM, V67, P1307, DOI 10.1021/ac00104a002
   ZINK JI, 1994, NEW J CHEM, V18, P1109
   1996, MRS S P
NR 60
TC 50
Z9 52
U1 0
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928-4931
J9 MAT SCI ENG C-BIO S
JI Mater. Sci. Eng. C-Biomimetic Supramol. Syst.
PD NOV
PY 1998
VL 6
IS 2-3
BP 145
EP 154
DI 10.1016/S0928-4931(98)00039-3
PG 10
WC Materials Science, Multidisciplinary
SC Materials Science
GA 150AB
UT WOS:000077638700008
DA 2018-10-19
ER

PT J
AU Won, CY
   Chu, CC
AF Won, CY
   Chu, CC
TI Inulin polysaccharide having pendant amino acids: Synthesis and
   characterization
SO JOURNAL OF APPLIED POLYMER SCIENCE
LA English
DT Article
DE inulin; amino acids; dicyclohexylcarbodiimide (DCC); esterification of
   inulin; biomaterials
ID HYDROGELS; COPOLYMERIZATION; ESTERIFICATION; POLYESTER
AB Inulin polysaccharide was esterified with N-protected alpha-amino acids (N,N'-di-benzylocarbonyl-L-lysine and N-benzylocarbonyl-glycine) under a mild condition (room temperature) and within short reaction times (6 h). The esterification reactions were conducted in the presence of dicyclohexylcarbodiimide and 4-(dimethylamino)pyridine as a catalyst. The optimal reaction time (6 h) was determined by monitoring the concentration of free carboxylic acid of the N-protected amino acids during the reaction. The degree of substitution per fructose unit was 0.95 for inulin-lysine and 1.01 for inulin-glycine. The resulting biopolymer was deprotected by catalytic transfer hydrogenation method using 1,4-cyclohexadiene as an effective hydrogen donor. The structures, molecular weight, and thermal properties of the amino acid esters of inulin were determined by Fourier transform infrared spectroscopy, H-1 and C-13 NMR, UV, viscosity, and dicyclohexylcarbodiimide. This new modified inulin polysaccharide mould have the potential as a biomaterial for biomedical applications. (C) 1998 John Wiley & Sons, Inc.
C1 Cornell Univ, Fiber & Polymer Sci Program, Ithaca, NY 14853 USA.
   Cornell Univ, Biomed Engn Program, Ithaca, NY 14853 USA.
RP Chu, CC (reprint author), Cornell Univ, Fiber & Polymer Sci Program, Ithaca, NY 14853 USA.
CR ANDERSON GW, 1952, J AM CHEM SOC, V74, P5309, DOI 10.1021/ja01141a024
   ARNOLD SC, 1986, POLYM REPRINT, V27, P42
   BARRERA DA, 1993, J AM CHEM SOC, V115, P11010, DOI 10.1021/ja00076a077
   BARRERA DA, 1995, MACROMOLECULES, V28, P425, DOI 10.1021/ma00106a004
   CALUB TM, 1990, CARBOHYD RES, V199, P11, DOI 10.1016/0008-6215(90)84088-C
   CASTELLANO A, 1987, J POLYM SCI POL CHEM, V25, P1419, DOI 10.1002/pola.1987.080250518
   CHAVES MS, 1989, MAKROMOL CHEM, V190, P2391
   DE SMEDT SC, 1995, MACROMOLECULES, V28, P5082, DOI 10.1021/ma00118a042
   DHAON MK, 1982, J ORG CHEM, V47, P1962, DOI 10.1021/jo00349a028
   ELAMIN B, 1979, J ORG CHEM, V44, P3442, DOI 10.1021/jo01333a048
   FERRUTI P, 1979, MAKROMOL CHEM, V180, P375
   Franssen O, 1997, J CONTROL RELEASE, V44, P237, DOI 10.1016/S0168-3659(96)01527-1
   FUCHS A, 1987, STARCH-STARKE, V39, P335, DOI 10.1002/star.19870391002
   Greenstein J. P., 1961, CHEM AMINO ACIDS
   GROSSE OM, 1995, J POLYM SCI POL CHEM, V33, P815
   Gruber JV, 1997, MACROMOLECULES, V30, P5361, DOI 10.1021/ma970554v
   IDELSON M, 1958, J AM CHEM SOC, V80, P4631, DOI 10.1021/ja01550a056
   KALUZYNSKI K, 1994, MACROMOL CHEM PHYSIC, V195, P3855, DOI 10.1002/macp.1994.021951211
   KIM SH, UNPUB CARBOHYD POLYM
   LEE KH, 1997, Patent No. 5610241
   MOLTENI L, 1982, OPTIMIZATION DRUG DE, P285
   MUTTER M, 1973, PEPTIDES, P285
   NATHAN A, 1992, MACROMOLECULES, V25, P4476, DOI 10.1021/ma00044a004
   NEISES B, 1978, ANGEW CHEM INT EDIT, V17, P552
   NGO TT, 1986, Patent No. 4582875
   OPHOFF MG, 1995, J POLYM SCI POL CHEM, V33, P815
   Schacht E., 1984, J CONTROL RELEASE, V1, P33
   SEIKH MI, 1972, ARCH INT PHYSL BIOCH, V80, P489
   SHEEHAN JC, 1956, J AM CHEM SOC, V78, P1367, DOI 10.1021/ja01588a029
   SILVERSTEIN RM, 1991, SPECTROMETRIC IDENTI, P293
   Uryu T, 1997, MACROMOL SYMP, V120, P147, DOI 10.1002/masy.19971200116
   VERMEERSCH J, 1986, MAKROMOL CHEM, V187, P125
   WANG C, 1994, J POLYM SCI POL CHEM, V32, P413, DOI 10.1002/pola.1994.080320302
   WIRTH PC, 1974, Patent No. 3836433
   Won CY, 1997, CARBOHYD POLYM, V32, P239, DOI 10.1016/S0144-8617(96)00169-5
   Won CY, 1996, MACROMOL RAPID COMM, V17, P653, DOI 10.1002/marc.1996.030170907
   WON CY, IN PRESS
   WON CY, UNPUB POLYMER
   WON CY, IN PRESS CARBOHYD PO
   YALPANI M, 1988, POLYSACCHARIDES STUD, P36
NR 40
TC 8
Z9 8
U1 0
U2 9
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-8995
J9 J APPL POLYM SCI
JI J. Appl. Polym. Sci.
PD OCT 31
PY 1998
VL 70
IS 5
BP 953
EP 963
DI 10.1002/(SICI)1097-4628(19981031)70:5<953::AID-APP16>3.0.CO;2-U
PG 11
WC Polymer Science
SC Polymer Science
GA 122FG
UT WOS:000076060800016
DA 2018-10-19
ER

PT J
AU Yu, YC
   Tirrell, M
   Fields, GB
AF Yu, YC
   Tirrell, M
   Fields, GB
TI Minimal lipidation stabilizes protein-like molecular architecture
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID MACROPHAGE SCAVENGER RECEPTOR; TRIPLE-HELICAL PEPTIDES; PULMONARY
   SURFACTANT APOPROTEIN; COLLAGEN-BASED STRUCTURES; MELANOMA
   CELL-ADHESION; N-ISOBUTYLGLYCINE NLEU; SOLID-PHASE SYNTHESIS;
   AMINO-ACID-SEQUENCE; CIRCULAR-DICHROISM; LIGAND-BINDING
AB Peptide-amphiphiles with collagen-model head groups and dialkyl chain tails have been shown previously to self-assemble into highly ordered polyPro II-like triple-helical structures when dissolved in aqueous subphases. In the present study, we have examined peptide-amphiphiles containing monoalkyl chain tails for similar self-assembly behaviors. The structure of a collagen-model peptide has been characterized with and without an N-terminal hexanoic acid (C-6) modification. Evidence for a self-assembly process of both the peptide and peptide-amphiphile has been obtained from (a) circular dichroism spectra and melting curves characteristic of triple-helices, (b) one-dimensional NMR spectra indicative of stable triple-helical structure at low temperatures and melted triple helices at high temperatures, and (c) pulsed-field gradient NMR experiments demonstrating different self-diffusion coefficients between proposed triple-helical and non-triple-helical species. The peptide-amphiphile appeared to form monomeric triple helices. The thermal stability of the collagen-like structure:in the peptide-amphiphile was found to-increase as the monoalkyl tail chain length is increased over a range of C-6 to C-16 The assembly process driven by the hydrophobic tail, albeit monoalkyl or dialkyl, may provide a general method for creating well-defined protein molecular architecture. Peptide-amphiphile-structures possessing these alkyl moieties have the potential to be used for biomaterial surface modification td improve biocompatibility or, by mimicing fusion of viral envelopes with cellular membranes; as drug delivery vehicles.
C1 Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA.
   Univ Minnesota, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA.
   Florida Atlantic Univ, Dept Chem & Biochem, Boca Raton, FL 33431 USA.
RP Fields, GB (reprint author), Univ Minnesota, Dept Lab Med & Pathol, 420 Delaware St SE, Minneapolis, MN 55455 USA.
CR ANACHI RB, 1995, FEBS LETT, V368, P551, DOI 10.1016/0014-5793(95)00738-U
   ASHKENAS J, 1993, J LIPID RES, V34, P983
   Barany G, 1979, PEPTIDES           A, V2, P1
   BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699
   BENSON B, 1985, P NATL ACAD SCI USA, V82, P6379, DOI 10.1073/pnas.82.19.6379
   BERNDT P, 1995, J AM CHEM SOC, V117, P9515, DOI 10.1021/ja00142a019
   Brodsky B, 1995, FASEB J, V9, P1537
   BRODSKY B, 1992, BIOPOLYMERS, V32, P447, DOI 10.1002/bip.360320423
   BRODSKYDOYLE B, 1976, BIOCHEM J, V159, P279, DOI 10.1042/bj1590279
   Bulleid NJ, 1997, EMBO J, V16, P6694, DOI 10.1093/emboj/16.22.6694
   Cha X, 1996, B CHEM SOC JPN, V69, P163, DOI 10.1246/bcsj.69.163
   CHELBERG MK, 1990, J CELL BIOL, V111, P261, DOI 10.1083/jcb.111.1.261
   DARAGAN VA, 1993, BIOPOLYMERS, V33, P521, DOI 10.1002/bip.360330403
   DRICKAMER K, 1986, J BIOL CHEM, V261, P6878
   ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6
   FAN P, 1993, BIOCHEMISTRY-US, V32, P13299, DOI 10.1021/bi00211a043
   Feng YB, 1997, BIOCHEMISTRY-US, V36, P8716, DOI 10.1021/bi962980z
   Feng YB, 1996, J AM CHEM SOC, V118, P10351, DOI 10.1021/ja961260c
   FIELDS C G, 1991, Peptide Research, V4, P95
   FIELDS CG, 1993, PEPTIDE RES, V6, P39
   Fields CG, 1996, LETT PEPT SCI, V3, P3, DOI 10.1007/BF00131080
   FIELDS CG, 1993, J BIOL CHEM, V268, P14153
   FIELDS CG, 1993, BIOPOLYMERS, V33, P1695, DOI 10.1002/bip.360331107
   Fields GB, 1995, CONNECT TISSUE RES, V31, P235, DOI 10.3109/03008209509010815
   FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x
   Fields GB, 1998, BIOPOLYMERS, V47, P143, DOI 10.1002/(SICI)1097-0282(1998)47:2<143::AID-BIP3>3.3.CO;2-P
   FRASER RDB, 1979, J MOL BIOL, V129, P463, DOI 10.1016/0022-2836(79)90507-2
   GERMANN HP, 1988, BIOPOLYMERS, V27, P157, DOI 10.1002/bip.360270112
   GIBBS SJ, 1991, J MAGN RESON, V93, P395, DOI 10.1016/0022-2364(91)90014-K
   Goodman M, 1996, J AM CHEM SOC, V118, P5156, DOI 10.1021/ja954132h
   Goodman M, 1996, J AM CHEM SOC, V118, P10928, DOI 10.1021/ja961717i
   HEIDEMANN E, 1982, ADV POLYM SCI, V43, P143
   Hojo H, 1997, TETRAHEDRON, V53, P14263, DOI 10.1016/S0040-4020(97)00994-0
   Holmgren SK, 1998, NATURE, V392, P666, DOI 10.1038/33573
   KING DS, 1990, INT J PEPT PROT RES, V36, P255
   KOBAYASHI Y, 1973, J MOL BIOL, V81, P337, DOI 10.1016/0022-2836(73)90145-9
   KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0
   LI MH, 1993, BIOCHEMISTRY-US, V32, P7377, DOI 10.1021/bi00080a007
   LONG CG, 1992, J MOL BIOL, V225, P1, DOI 10.1016/0022-2836(92)91020-P
   MACQUAIRE F, 1992, BIOCHEMISTRY-US, V31, P2576, DOI 10.1021/bi00124a018
   MAYO KH, 1991, BIOCHEMISTRY-US, V30, P8251, DOI 10.1021/bi00247a022
   MAYO KH, 1997, PROTEIN STRUCTURAL B, P567
   Melacini G, 1996, J AM CHEM SOC, V118, P10725, DOI 10.1021/ja9617193
   OHNISHI SI, 1988, CURR TOP MEMBR TRANS, V32, P257
   OKUYAMA K, 1981, J MOL BIOL, V152, P427, DOI 10.1016/0022-2836(81)90252-7
   PRIVALOV PL, 1982, ADV PROTEIN CHEM, V35, P1, DOI 10.1016/S0065-3233(08)60468-4
   PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191
   ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0
   ROTH W, 1979, MAKROMOL CHEM, V180, P905
   ROTH W, 1980, BIOPOLYMERS, V19, P1909, DOI 10.1002/bip.1980.360191017
   SCHUMACHER M, 1986, NATURE, V319, P407, DOI 10.1038/319407a0
   SHAW BR, 1975, BIOPOLYMERS, V14, P1951, DOI 10.1002/bip.1975.360140913
   SHIMIZU T, 1989, CHEM LETT, P1341, DOI 10.1246/cl.1989.1341
   Tanaka T, 1996, PROTEIN ENG, V9, P307, DOI 10.1093/protein/9.3.307
   TANAKA T, 1993, FEBS LETT, V334, P272, DOI 10.1016/0014-5793(93)80693-O
   Tanaka Y, 1998, J PEPT RES, V51, P413
   TANFORD C, 1961, PHYSICAL CHEM MACROM, P358
   THAKUR S, 1986, BIOPOLYMERS, V25, P1081, DOI 10.1002/bip.360250608
   TORCHIA DA, 1975, BIOCHEMISTRY-US, V14, P887, DOI 10.1021/bi00676a004
   VENUGOPAL MG, 1994, BIOCHEMISTRY-US, V33, P7948, DOI 10.1021/bi00191a023
   Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15
   WUTHRICH K, 1983, NMR PROTEINS NUCL AC, P14
   Yang W, 1997, BIOCHEMISTRY-US, V36, P6930, DOI 10.1021/bi970051h
   Yu YC, 1997, METHOD ENZYMOL, V289, P571
   Yu YC, 1996, J AM CHEM SOC, V118, P12515, DOI 10.1021/ja9627656
   YU YC, 1997, THESIS U MINNESOTA M, P59
NR 66
TC 129
Z9 135
U1 0
U2 31
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD OCT 7
PY 1998
VL 120
IS 39
BP 9979
EP 9987
DI 10.1021/ja981654z
PG 9
WC Chemistry, Multidisciplinary
SC Chemistry
GA 127ZP
UT WOS:000076381000001
DA 2018-10-19
ER

PT J
AU Sabokbar, A
   Fujikawa, Y
   Murray, DW
   Athanasou, NA
AF Sabokbar, A
   Fujikawa, Y
   Murray, DW
   Athanasou, NA
TI Bisphosphonates in bone cement inhibit PMMA particle induced bone
   resorption
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Article
ID ISOLATED RABBIT OSTEOCLASTS; RESORBING CELLS; MACROPHAGES; INVITRO;
   DIFFERENTIATION; ARTHROPLASTY; PHOSPHATASE; OSTEOBLASTS
AB Objective - Wear particle induced bone resorption is thought to be one of the mechanisms that contribute to implant loosening. It has previously been shown that macrophages, in response to polymethylmethacrylate (PMMA) particles, differentiate into bone resorbing osteoclasts, and that this process is inhibited by a bisphosphonate, etidronate (EHDP). The aim of this study was to determine whether incorporating EHDP in bone cement could reduce PMMA associated bone resorption.
   Methods - Two concentrations of EHDP were mixed with PMMA monomer before polymerisation, Particles of PMMA (1-10 mu m) were generated then added to mouse monocytes cocultured with UMR106 rat osteoblast-like cells and the extent of osteoclast differentiation was determined by assessing the extent of tartrate resistant acid phosphatase (TRAP) staining and measuring the amount of lacunar bone resorption.
   Results - The addition of PMMA to monocyte-UMR106 cocultures resulted in a marked increase in the number of TRAP positive osteoclast-like cells and a significant increase in the number of lacunar resorption pits compared with control cultures to which no particles had been added. After the addition of particles of PMMA + 20 mg EHDP, significantly fewer lacunar pits (p = 0.00006) and fewer TRAP positive cells were noted compared with cocultures containing PMMA particles alone.
   Conclusions - These results indicate that by mixing a bisphosphonate with bone cement, it is possible to inhibit PRIMA particle induced bone resorption. This bisphosphonate inhibition of PMMA biomaterial wear particle containing macrophage-osteoclast differentiation and bone resorption may provide a possible therapeutic strategy to prevent or to control the osteolysis of aseptic loosening.
C1 Univ Oxford, Nuffield Orthopaed Ctr, Dept Pathol, Oxford OX3 7LD, England.
RP Athanasou, NA (reprint author), Univ Oxford, Nuffield Orthopaed Ctr, Dept Pathol, Oxford OX3 7LD, England.
RI Murray, David/D-7117-2011
FU Wellcome Trust
CR ALFARO J, IN PRESS J BONE JOIN
   Athanasou NA, 1996, J BONE JOINT SURG AM, V78A, P1096, DOI 10.2106/00004623-199607000-00016
   ATHANASOU NA, 1984, MICRON MICROSC ACTA, V15, P47, DOI 10.1016/0739-6260(84)90030-3
   AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013
   BULLOUGH PG, 1988, ORTHOP CLIN N AM, V19, P611
   CARANO A, 1990, J CLIN INVEST, V85, P456, DOI 10.1172/JCI114459
   CECCHINI MG, 1990, J BONE MINER RES, V5, P1019
   CHAMBERS TJ, 1984, J CELL SCI, V66, P383
   CHAMBERS TJ, 1980, J PATHOL, V132, P255, DOI 10.1002/path.1711320307
   FLANAGAN AM, 1991, CALCIFIED TISSUE INT, V49, P407, DOI 10.1007/BF02555852
   Fleisch H, 1983, BONE MINERAL RES ANN, P319
   Horowitz SM, 1996, J BIOMED MATER RES, V31, P91, DOI 10.1002/(SICI)1097-4636(199605)31:1<91::AID-JBM11>3.0.CO;2-P
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   JIRANEK WA, 1993, J BONE JOINT SURG AM, V75A, P863, DOI 10.2106/00004623-199306000-00007
   KIM KJ, 1993, CLIN ORTHOP RELAT R, P142
   LENNOX DW, 1987, CLIN ORTHOP RELAT R, P171
   LINDER L, 1986, ACTA ORTHOP SCAND, V57, P495, DOI 10.3109/17453678609014777
   MALCOLM AJ, 1988, J BONE JOINT SURG BR, V70, P153
   MALONEY WJ, 1989, CLIN ORTHOP RELAT R, P129
   MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252
   MJOBERG B, 1994, ACTA ORTHOP SCAND, V65, P361, DOI 10.3109/17453679408995473
   MURRAY DW, 1990, J BONE JOINT SURG BR, V72, P988
   NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815
   Pandey R, 1996, ANN RHEUM DIS, V55, P388, DOI 10.1136/ard.55.6.388
   Pandey R, 1996, ACTA ORTHOP SCAND, V67, P221, DOI 10.3109/17453679608994677
   Passeri G, 1994, J BONE MINER RES  S1, V9, pS230
   QUINN J, 1992, J BONE JOINT SURG BR, V74, P652
   QUINN JMW, 1994, ENDOCRINOLOGY, V134, P2416, DOI 10.1210/en.134.6.2416
   REVELL PA, 1982, CURRENT TRENDS PATHO, P73
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Sabokbar A, 1996, ACTA ORTHOP SCAND, V67, P593, DOI 10.3109/17453679608997763
   Sabokbar A, 1997, J BONE JOINT SURG BR, V79B, P129, DOI 10.1302/0301-620X.79B1.6966
   SAHNI M, 1993, J CLIN INVEST, V91, P2004, DOI 10.1172/JCI116422
   SATO M, 1990, J BONE MINER RES, V5, P35
   Schmidt A, 1996, P NATL ACAD SCI USA, V93, P3068, DOI 10.1073/pnas.93.7.3068
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   Vitte C, 1996, ENDOCRINOLOGY, V137, P2324, DOI 10.1210/en.137.6.2324
   WAHLIG H, 1983, REVISION ARTHROPLAST, V2, P56
NR 38
TC 39
Z9 43
U1 0
U2 1
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD OCT
PY 1998
VL 57
IS 10
BP 614
EP 618
DI 10.1136/ard.57.10.614
PG 5
WC Rheumatology
SC Rheumatology
GA 137VJ
UT WOS:000076937100009
PM 9893573
OA Bronze, Green Published
DA 2018-10-19
ER

PT J
AU Elcin, YM
   Dixit, V
   Gitnick, G
AF Elcin, YM
   Dixit, V
   Gitnick, G
TI Hepatocyte attachment on biodegradable modified chitosan membranes: In
   vitro evaluation for the development of liver organoids
SO ARTIFICIAL ORGANS
LA English
DT Article
DE biodegradable polymers; chitosan membranes; hepatocyte attachment; cell
   attachment kinetics; hepatocyte transplantation; bioartificial liver;
   tissue engineering
ID N-ACETYLATION; TRANSPLANTATION; SUPPORT; SYSTEM
AB Extracellular matrix structures including glycosaminoglycans play a critical role in cell attachment, differentiation, and morphogenesis. We evaluated chitosan ([1 --> 4] linked 2-amino-2-deoxy-beta-D-glucan) as a biomaterial for hepatocyte attachment because of its structural similarity to glycosaminoglycans. Freshly isolated rat and fetal porcine hepatocytes were seeded on chitosan membranes that had been previously blended with collagen, gelatin, or albumin to improve biocompatibility and surface roughness. The optimal cell density and attachment kinetics were quantified. The metabolic activity was investigated by measuring daily urea and total protein secretion by the cells for 2 weeks. While collagen blended-chitosan membranes provided a good attachment surface for rat hepatocytes, albumin and gelatin blended chitosan membranes were superior for fetal porcine hepatocyte attachment. The optimal attachment was maintained with membranes of medium molecular weight (M(r) = 750,000 daltons) chitosan, at 3-4 x 10(3) cells/cm(2) after 3 h of incubation. In vitro experiments demonstrated that fetal porcine hepatocytes survived at least 14 days when seeded on the chitosan-albumin matrix, demonstrating that this biomaterial can provide suitable cell attachment scaffolds for creating liver tissue organoids.
C1 Univ Calif Los Angeles, Sch Med, Dept Med, Liver Biosupport & Hepatitis Res Lab, Los Angeles, CA 90095 USA.
   Ankara Univ, Dept Chem, TR-06100 Ankara, Turkey.
RP Dixit, V (reprint author), Univ Calif Los Angeles, Sch Med, Dept Med, Liver Biosupport & Hepatitis Res Lab, 675 Circle Dr S,MRL Room 1240, Los Angeles, CA 90095 USA.
OI Elcin, Yasar Murat/0000-0003-1037-0825
CR AKIYAMA SK, 1990, BIOCHIM BIOPHYS ACTA, V1031, P91, DOI 10.1016/0304-4157(90)90004-V
   ANTHONSEN MW, 1993, CARBOHYD POLYM, V22, P193, DOI 10.1016/0144-8617(93)90140-Y
   BALASSA LL, 1971, Patent No. 252373
   BENZEEV A, 1987, J CELL SCI, P293
   CHANDY T, 1989, J COLLOID INTERF SCI, V130, P331, DOI 10.1016/0021-9797(89)90112-4
   CIMA LG, 1991, BIOTECHNOL BIOENG, V38, P145, DOI 10.1002/bit.260380207
   DIXIT V, 1992, ARTIF ORGANS, V16, P336
   DIXIT V, 1994, ARTIF ORGANS, V18, P371, DOI 10.1111/j.1525-1594.1994.tb02219.x
   Dixit V, 1992, Cell Transplant, V1, P391
   DIXIT V, 1995, ARTIF ORGANS, V23, P809
   DRAGET KI, 1992, BIOMATERIALS, V13, P635, DOI 10.1016/0142-9612(92)90032-J
   Elcin YM, 1996, ARTIF CELL BLOOD SUB, V24, P257, DOI 10.3109/10731199609117438
   ELCIN YM, 1995, J ECON ENTOMOL, V88, P830
   ELCIN YM, 1995, ENZYME MICROB TECH, V17, P587, DOI 10.1016/0141-0229(94)00026-N
   FULLER BJ, 1988, J HEPATOL, V7, P368, DOI 10.1016/S0168-8278(88)80010-2
   HIRANO S, 1989, BIOMATERIALS, V10, P574, DOI 10.1016/0142-9612(89)90066-5
   HONG HL, 1987, J CELL SCI, V87, P259
   Inouye K, 1988, Drug Des Deliv, V2, P165
   JOHNSON LB, 1994, CELL TRANSPLANT, V3, P273, DOI 10.1177/096368979400300403
   MA XJ, 1994, ARTIF CELL BLOOD SUB, V22, P43, DOI 10.3109/10731199409117399
   Markwald RR, 1984, ROLE EXTRACELLULAR M, P323
   MUZZARELLI R, 1988, BIOMATERIALS, V9, P247, DOI 10.1016/0142-9612(88)90092-0
   NAKAJIMA M, 1986, JPN J SURG, V16, P418, DOI 10.1007/BF02470609
   Reid LM, 1990, CURR OPIN CELL BIOL, V2, P121, DOI 10.1016/S0955-0674(05)80042-0
   RIVAS PA, 1992, TRANSPLANT P, V24, P2833
   SANDBICHLER P, 1992, GASTROENTEROLOGY, V102, P605, DOI 10.1016/0016-5085(92)90109-C
   SEGLEN PO, 1976, METHOD CELL BIOL, P13
   Sheehan DC, 1980, THEORY PRACTICE HIST
   SKEHAN P, 1985, IN VITRO CELL DEV B, V21, P288
   SUGANO M, 1978, NUTR REP INT, V18, P531
   TOOLE BP, 1984, ROLE EXTRACELLULAR M, P43
NR 31
TC 62
Z9 65
U1 2
U2 10
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0160-564X
J9 ARTIF ORGANS
JI Artif. Organs
PD OCT
PY 1998
VL 22
IS 10
BP 837
EP 846
PG 10
WC Engineering, Biomedical; Transplantation
SC Engineering; Transplantation
GA 126MR
UT WOS:000076297700006
PM 9790081
DA 2018-10-19
ER

PT J
AU Lundberg, F
   Gouda, I
   Larm, O
   Galin, MA
   Ljungh, A
AF Lundberg, F
   Gouda, I
   Larm, O
   Galin, MA
   Ljungh, A
TI A new model to assess staphylococcal adhesion to intraocular lenses
   under in vitro flow conditions
SO BIOMATERIALS
LA English
DT Article
DE cerebrospinal fluid; heparinization IOLs; perfusion; staphylococci
ID EXTRACAPSULAR CATARACT-EXTRACTION; COAGULASE-NEGATIVE STAPHYLOCOCCI;
   IN-VITRO; POLY(METHYL METHACRYLATE); POLYMER SURFACES; HEPARIN;
   ADHERENCE; ENDOPHTHALMITIS; IMPLANTATION; FIBRONECTIN
AB Adhesion of staphylococcal cells to intraocular lenses coated with heparin was studied under in vitro flow conditions (280 mu l min(-1)) at 37 degrees C, The intraocular lenses were incubated with human cerebrospinal fluid for Ih or with cerebrospinal fluid including 0.50% plasma for 12 h, prior to bacterial challenge. Two strains of Staphylococcus epidermidis selected for this study, were isolated from biomaterial-associated infections. Bacterial adhesion was quantitated by bioluminescence and visualized by fluorescence microscopy of acridine orange stained bacteria. Surface coating with heparin significantly decreased bacterial adhesion of both strains after incubation with cerebrospinal fluid including 0.50% plasma for 12 h (p = 0.0209). However, no difference in bacterial adhesion was obtained between intraocular lenses with and without heparin, after incubation with cerebrospinal fluid for Ih (p = 0.327), Microscopy showed that more bacteria were present on intraocular lenses without heparin than on intraocular lenses with heparin, The results show that preincubation with a proteinaceous fluid influences subsequent bacterial adhesion to the polymer surface. The results suggest that IOLs with heparin coating may be less prone to bacterial adhesion under perfusion conditions after surface conditioning in human CSF with 0.50% plasma and a preincubation period of 12 h. Heparin coating might be a valuable tool to decrease implant-associated bacterial endophthalmitis. (C) 1998 Published by Elsevier Science Ltd, All rights reserved.
C1 Univ Lund, Dept Med Microbiol, S-22362 Lund, Sweden.
   Medicarb AB, S-16865 Bromma, Sweden.
   Karolinska Inst, Dept Expt Surg, S-10401 Stockholm, Sweden.
RP Ljungh, A (reprint author), Univ Lund, Dept Med Microbiol, Solvegatan 23, S-22362 Lund, Sweden.
CR Appelgren P, 1996, CRIT CARE MED, V24, P1482, DOI 10.1097/00003246-199609000-00009
   ARCIOLA CR, 1994, J CATARACT REFR SURG, V20, P158, DOI 10.1016/S0886-3350(13)80157-5
   BAKER AS, 1994, INFECT ASS INDWELLIN, P113
   CHEUNG AL, 1991, J CLIN INVEST, V87, P2236, DOI 10.1172/JCI115259
   CHRISTENSEN GD, 1983, INFECT IMMUN, V40, P407
   Davson H, 1956, PHYSL OCULAR CEREBRO
   DICKINSON RB, 1995, INFECT IMMUN, V63, P3143
   FROMAN G, 1987, J BIOL CHEM, V262, P6564
   GALIN MA, 1976, T OPHTHAL SOC UK, V96, P166
   HERRMANN M, 1991, INFECT IMMUN, V59, P279
   HERRMANN M, 1988, J INFECT DIS, V158, P693, DOI 10.1093/infdis/158.4.693
   HOPEN G, 1982, AM J OPHTHALMOL, V94, P402, DOI 10.1016/0002-9394(82)90369-5
   LARM O, 1987, THROMB HAEMOSTASIS, V58, P84
   Leaming DV, 1996, J CATARACT REFR SURG, V22, P931, DOI 10.1016/S0886-3350(96)80194-5
   Leroux les Jardins S, 1995, J Fr Ophtalmol, V18, P45
   LUDWICKA A, 1985, J MICROBIOL METH, V4, P169, DOI 10.1016/0167-7012(85)90033-8
   Lundberg F, 1997, J MED MICROBIOL, V46, P285, DOI 10.1099/00222615-46-4-285
   MEISLER DM, 1986, AM J OPHTHALMOL, V102, P733, DOI 10.1016/0002-9394(86)90401-0
   MENIKOFF JA, 1991, OPHTHALMOLOGY, V98, P1761
   Mukai M, 1970, Nippon Ganka Gakkai Zasshi, V74, P1269
   PANDE M, 1995, J CATARACT REFR SURG, V21, P326, DOI 10.1016/S0886-3350(13)80142-3
   PAULSSON M, 1994, J BIOMED MATER RES, V28, P311, DOI 10.1002/jbm.820280305
   PAULSSON M, 1993, BIOMATERIALS, V14, P845, DOI 10.1016/0142-9612(93)90006-N
   PAULSSON M, 1992, J CLIN MICROBIOL, V30, P2006
   PEKNA M, 1993, BIOMATERIALS, V14, P189, DOI 10.1016/0142-9612(93)90022-T
   POWER WJ, 1994, J CATARACT REFR SURG, V20, P440, DOI 10.1016/S0886-3350(13)80181-2
   Rattigan SM, 1996, J CATARACT REFR SURG, V22, P243, DOI 10.1016/S0886-3350(96)80226-4
   RIESENFELD J, 1990, ANAL BIOCHEM, V188, P383, DOI 10.1016/0003-2697(90)90624-I
   ROZALSKA B, 1995, FEMS IMMUNOL MED MIC, V11, P307, DOI 10.1111/j.1574-695X.1995.tb00161.x
   SPANGBERG M, 1990, J CATARACT REFR SURG, V16, P170, DOI 10.1016/S0886-3350(13)80726-2
   STARK WJ, 1983, OPHTHALMOLOGY, V90, P311
   STOLLENWERK M, 1998, IN PRESS ZENTRALBL B
   TSAI TS, 1986, P SOC EXP BIOL MED, V183, P74
   VROMAN L, 1986, J COLLOID INTERF SCI, V111, P391, DOI 10.1016/0021-9797(86)90042-1
   WEBER DJ, 1986, REV INFECT DIS, V8, P12
   WEBSTER JJ, 1988, J BIOLUM CHEMILUM, V2, P129, DOI 10.1002/bio.1170020304
   ZDANOWSKI Z, 1993, APMIS, V101, P926, DOI 10.1111/j.1699-0463.1993.tb00203.x
NR 37
TC 14
Z9 15
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD OCT
PY 1998
VL 19
IS 19
BP 1727
EP 1733
DI 10.1016/S0142-9612(98)00081-7
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 140KG
UT WOS:000077086000002
PM 9856583
DA 2018-10-19
ER

PT J
AU Josset, Y
   Oum'hamed, Z
   Zarrinpour, A
   Lorenzato, M
   Adnet, JJ
   Laurent-Maquin, D
AF Josset, Y
   Oum'hamed, Z
   Zarrinpour, A
   Lorenzato, M
   Adnet, JJ
   Laurent-Maquin, D
TI DNA image cytometry and Ag-NORs-staining application in biocompatibility
   studies on human osteoblast cells in vitro
SO BIOMATERIALS
LA English
DT Article
DE osteoblasts; biocompatibility; DNA image cytometry; Ag-NORs; Pyrost (R);
   biomaterial
ID NON-HODGKINS LYMPHOMA; BONE-FORMATION; IN-VITRO; INVITRO; CULTURE;
   HYDROXYAPATITE; PROLIFERATION; ATTACHMENT; GLASS; BIOMATERIALS
AB We report here the study of the biocompatibility of a bone graft material, the Pyrost(R), using a previously established in vitro model of human osteoblasts, The effect of this material on cell proliferation was evaluated by the MTS assay. Results indicated the absolute absence of cytotoxic or cytostatic effect of Pyrost(R) on cultured osteoblasts. Viability rate was more than 90% in cells cultured with the material compared to the control. Morphological analysis, undertaken by scanning electron microscopy showed a good adhesion and a spreading of osteoblasts in contact with the material that was colonized by cultured cells. In the second part of this work, we have introduced two methods as complementary biocompatibility tests: DNA image cytometry and interphase Ag-NORs quantification. DNA content was measured in cells cultured with or without Pyrost(R) for 3, 9, 15 and 30 days. The determination of DNA indicated that the majority of osteoblasts population was diploid without aneuploidy. The DNA index and cell distribution profile in DNA histograms were similar in all cell populations. The Ag-NORs amount was used as a parameter for cell kinetic evaluation. We have measured the Ag-NORs index like DNA quantification. The proliferation rate, evaluated by Ag-NORs counts in osteoblasts cultured with or without the material, was identical. However, a decrease in Ag-NORs index was observed from day 3 to day 15 of incubation. These results showed a satisfactory biocompatibility of the Pyrost(R) in human osteoblasts culture, The material did not alter cell viability and had no inducing effect either on proliferation rate or on cell ploidy as demonstrated by DNA image cytometry and Ag-NORs proteins staining. (C) 1998 Published by Elsevier Science Ltd. All rights reserved.
C1 UFR Odontol, IFR 53, EA 2068, Ctr Etud Biomat & Interfaces, F-51100 Reims, France.
   CHU Maison Blanche, Lab Pol Bouin, F-51095 Reims, France.
   CHU Maison Blanche, Inserm U314, F-51095 Reims, France.
RP Josset, Y (reprint author), UFR Odontol, IFR 53, EA 2068, Ctr Etud Biomat & Interfaces, 2 Rue Gal Koenig, F-51100 Reims, France.
CR ALLIOTLICHT B, 1991, BIOMATERIALS, V12, P752, DOI 10.1016/0142-9612(91)90025-6
   BEGLEY CT, 1993, BONE, V14, P661, DOI 10.1016/8756-3282(93)90089-S
   BROOK IM, 1992, BIOMATERIALS, V13, P721, DOI 10.1016/0142-9612(92)90134-A
   BROOK IM, 1991, BIOMATERIALS, V12, P179, DOI 10.1016/0142-9612(91)90197-I
   CAREY FA, 1994, J PATHOL, V172, P307, DOI 10.1002/path.1711720404
   CHEUNG HS, 1989, BIOMATERIALS, V10, P63, DOI 10.1016/0142-9612(89)90012-4
   CROCKER J, 1988, J PATHOL, V154, P151, DOI 10.1002/path.1711540207
   DEBRUIJN JD, 1992, J BIOMED MATER RES, V26, P1365, DOI 10.1002/jbm.820261008
   Dee KC, 1996, BIOMATERIALS, V17, P209, DOI 10.1016/0142-9612(96)85765-6
   DERENZINI M, 1989, ACTA CYTOL, V33, P491
   DOGLIOLI P, 1991, CYTOTECHNOLOGY, V7, P39, DOI 10.1007/BF00135637
   DOGLIOLI P, 1994, REV ACTUAL ODONTO ST, V185, P109
   HALL PA, 1988, HISTOPATHOLOGY, V12, P373, DOI 10.1111/j.1365-2559.1988.tb01952.x
   HIDDEMANN W, 1984, CYTOMETRY, V5, P445, DOI 10.1002/cyto.990050502
   HOLDEREGGER C, 1992, ANAL CELL PATHOL, V4, P87
   HOWLETT CR, 1994, BIOMATERIALS, V15, P213, DOI 10.1016/0142-9612(94)90070-1
   HUNTER A, 1995, BIOMATERIALS, V16, P287, DOI 10.1016/0142-9612(95)93256-D
   JANMOHAMED RM, 1989, J PATHOL, V158, P3, DOI 10.1002/path.1711580103
   Jonsson KB, 1997, CALCIFIED TISSUE INT, V60, P30, DOI 10.1007/s002239900182
   Karaca Inci, 1994, Journal of Nihon University School of Dentistry, V36, P95
   LANG H, 1990, J ORAL MAXIL SURG, V48, P606, DOI 10.1016/S0278-2391(10)80475-6
   LAURENTMAQUIN D, 1997, IITT INT, P225
   LORENZATO M, 1994, ANN PATHOL, V14, P257
   LORENZATO M, 1993, PATHOL RES PRACT, V189, P1161, DOI 10.1016/S0344-0338(11)80839-3
   MALIK MA, 1992, BIOMATERIALS, V13, P123, DOI 10.1016/0142-9612(92)90008-C
   MEYER U, 1993, BIOMATERIALS, V14, P917, DOI 10.1016/0142-9612(93)90133-M
   MORRISON C, 1995, BIOMATERIALS, V16, P987, DOI 10.1016/0142-9612(95)94906-2
   NOLAN PC, 1992, J BONE JOINT SURG BR, V74, P284
   OFNER D, 1994, PATHOLOGE, V15, P226, DOI 10.1007/s002920050049
   PULEO DA, 1991, J BIOMED MATER RES, V25, P711, DOI 10.1002/jbm.820250603
   SAUTIER JM, 1991, CELL MATER, V1, P209
   SAUTIER JM, 1990, IN VITRO CELL DEV B, V26, P1079
   SAUTIER JM, 1992, BIOMATERIALS, V13, P400, DOI 10.1016/0142-9612(92)90046-Q
   SHTEYER A, 1990, INT J ORAL MAX SURG, V19, P370, DOI 10.1016/S0901-5027(05)80085-2
   SURESH UR, 1990, J PATHOL, V160, P213, DOI 10.1002/path.1711600306
   TRERE D, 1995, ANAL CELL PATHOL, V8, P57
   VROUWENVELDER WCA, 1992, BIOMATERIALS, V13, P382, DOI 10.1016/0142-9612(92)90044-O
   Yliheikkila P K, 1995, Int J Oral Maxillofac Implants, V10, P655
   Zarrinpour A., 1995, Bone (New York), V17, P596, DOI 10.1016/8756-3282(96)87939-7
NR 39
TC 8
Z9 8
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD OCT
PY 1998
VL 19
IS 19
BP 1791
EP 1798
DI 10.1016/S0142-9612(98)00090-8
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 140KG
UT WOS:000077086000009
PM 9856590
DA 2018-10-19
ER

PT J
AU Deible, CR
   Petrosko, P
   Johnson, PC
   Beckman, EJ
   Russell, AJ
   Wagner, WR
AF Deible, CR
   Petrosko, P
   Johnson, PC
   Beckman, EJ
   Russell, AJ
   Wagner, WR
TI Molecular barriers to biomaterial thrombosis by modification of surface
   proteins with polyethylene glycol
SO BIOMATERIALS
LA English
DT Article
DE platelet; polyethylene glycol; fibrinogen; surface modification;
   adsorbed proteins
ID FIBRINOGEN ADSORPTION; MURAL THROMBOGENESIS; PLATELET-ADHESION;
   COLLAGEN; IMMOBILIZATION; POLYURETHANES; VISUALIZATION; DEPOSITION
AB For cardiovascular biomaterials, thrombosis, thromboembolism and vascular graft occlusion are believed to be precipitated by the adsorption of proteins containing adhesive ligands for platelets. Polyethylene-glycol-diisocyanate (PEG-diisocyanate, 3400 MW) may potentially react with protein amines to form molecular barriers on adsorbed proteins on biomaterials, thereby masking adhesive ligands and preventing acute surface thrombosis. To test this notion, PE, PTFE, and glass microconduits were pre-adsorbed with fibrinogen and treated with PEG-diisocyanate, non-reactive PEG-dihydroxyl, or remained untreated. Following perfusion of In-111-labeled platelets in whole human blood for 1 min (wall shear rate = 312 s(-1)), PEG-diisocyanate treated surfaces experienced 96% (PE), 97% (PTFE) and 94% (glass) less platelet deposition than untreated surfaces. Similar reductions were seen for PEG-diisocyanate versus PEG-dihydroxyl treatment. Low shear perfusions of plasma for 1 h prior to blood contact did not reduce the inhibitory effect of PEG-diisocyanate. Platelet adhesion onto collagen-coated glass coverslips and platelet deposition onto preclotted Dacron were also reduced by treatment with PEG-diisocyanate(93 and 91%, respectively). Protein-reactive PEG may thus have utility in forming molecular barriers on surface-associated proteins to inhibit acute thrombosis on cardiovascular biomaterials. (C) 1998 Published by Elsevier Science Ltd. All rights reserved.
C1 Univ Pittsburgh, Med Ctr, Dept Surg, Pittsburgh, PA 15213 USA.
   Univ Pittsburgh, Med Ctr, Dept Bioengn, Pittsburgh, PA 15213 USA.
   Univ Pittsburgh, Dept Chem Engn, Pittsburgh, PA 15261 USA.
RP Wagner, WR (reprint author), Univ Pittsburgh, Med Ctr, Dept Surg, 328 Scaife Hall,200 Lothrop St, Pittsburgh, PA 15213 USA.
EM wagner@pittsurg.nb.upmc.edu
OI Russell, Alan/0000-0001-5101-4371
CR ABUCHOWSKI A, 1984, CANCER BIOCHEM BIOPH, V7, P175
   ADAMS GA, 1983, BLOOD, V62, P69
   ANDRADE JD, 1986, ADV POLYM SCI, V79, P1
   BADIMON L, 1987, J LAB CLIN MED, V110, P706
   BERGSTROM K, 1992, J BIOMED MATER RES, V26, P779, DOI 10.1002/jbm.820260607
   BERGSTROM K, 1994, J BIOMAT SCI-POLYM E, V6, P123
   BROWN WE, 1973, BIOCHEMISTRY-US, V12, P828, DOI 10.1021/bi00729a007
   CHINN JA, 1991, THROMB HAEMOSTASIS, V65, P608
   Deible CR, 1996, CIRCULATION, V94, P3600
   FOLIE BJ, 1988, BLOOD, V72, P1393
   HAN DK, 1989, J BIOMED MATER RES-A, V23, P87, DOI 10.1002/jbm.820231309
   HARRIS J, 1992, PROCEEDINGS OF THE SIXTH NORTH AMERICAN CRANE WORKSHOP, P1
   Hepburn C., 1992, POLYURETHANE ELASTOM, P107
   HUBBELL JA, 1986, BIOMATERIALS, V7, P354, DOI 10.1016/0142-9612(86)90006-2
   HUBBELL JA, 1986, REV SCI INSTRUM, V57, P892, DOI 10.1063/1.1138830
   JOHNSON PC, 1992, PLAST RECONSTR SURG, V90, P650, DOI 10.1097/00006534-199210000-00015
   LLANOS GR, 1993, J BIOMED MATER RES, V27, P1383, DOI 10.1002/jbm.820271105
   MAECHLINGSTRASSER C, 1989, J BIOMED MATER RES, V23, P1395, DOI 10.1002/jbm.820231203
   Merrill EW, 1983, AM SOC ARTIF INTERN, V6, P60
   RANUCCI E, 1994, J BIOMAT SCI-POLYM E, V6, P133
   SALZMAN EW, 1987, ANN NY ACAD SCI, V516, P184, DOI 10.1111/j.1749-6632.1987.tb33040.x
   SHEU MS, 1993, J ADHES SCI TECHNOL, V7, P1065, DOI 10.1163/156856193X00583
   SLACK SM, 1992, J BIOMED MATER RES, V26, P1633, DOI 10.1002/jbm.820261208
   Wagner W R, 1992, ASAIO J, V38, pM634, DOI 10.1097/00002480-199207000-00114
   WAGNER WR, 1990, J LAB CLIN MED, V116, P636
   WAGNER WR, 1994, T SOC BIOMATERIALS, V17, P3
   WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723
   Zalipsky S, 1992, POLYETHYLENE GLYCOL, P347
NR 28
TC 51
Z9 53
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD OCT
PY 1998
VL 19
IS 20
BP 1885
EP 1893
DI 10.1016/S0142-9612(98)00098-2
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 140KJ
UT WOS:000077086200009
PM 9855190
DA 2018-10-19
ER

PT J
AU Bohic, S
   Heymann, D
   Pouezat, JA
   Gauthier, O
   Daculsi, G
AF Bohic, S
   Heymann, D
   Pouezat, JA
   Gauthier, O
   Daculsi, G
TI Transmission FT-IR microspectroscopy of mineral phases in calcified
   tissues
SO COMPTES RENDUS DE L ACADEMIE DES SCIENCES SERIE III-SCIENCES DE LA
   VIE-LIFE SCIENCES
LA English
DT Article
DE infrared; FT-IR; microspectroscopy; bone mineral; enamel; apatite;
   carbonate; mapping; biomaterial
ID CALCIUM-PHOSPHATE CERAMICS; RESOLUTION; BONE
AB Fourier-transform infrared microspectroscopy (FT-IRM) was used to study bone mineralization processes in an in vivo model and in enamel in osteogenesis imperfecta. Finally, the ability of FT-IRM to map new bone formed in implanted macroporous calcium phosphate biomaterial from sections was reported for the first time. FT-IRM allowed the correlation of the microstructure of bone formation in the in vivo model with modifications in carbonate and phosphate environments of the mineral phases during maturation. FT-IRM analysis on enamel sections revealed changes in the mineral environment of carbonate and phosphate ions and probably in the size of enamel crystals. These modifications contributed to the fragility of enamel in osteogenesis imperfecta. The infrared functional group imaging of a part of implanted biomaterial and the bone ingrowth provided the visualization of chemical modifications occurring in biomaterial implants at 20 mu m spatial resolution. The use of FT-IRM, in conjunction with appropriate sampling methods and data analysis should provide further insight into the molecular structure of mineral phases of calcified tissues and help to elucidate mineralization processes, skeletal disorders and properties of the biomaterials used as bone substitute. (C) Academie des sciences / Elsevier, Paris.
C1 Fac Chirurg Dent, UPRES EA 2159, Ctr Rech Mat Internet Biol, F-44042 Nantes 1, France.
RP Bohic, S (reprint author), Fac Chirurg Dent, UPRES EA 2159, Ctr Rech Mat Internet Biol, 1 Pl A Ricordeau, F-44042 Nantes 1, France.
EM sbohic@sante.univ-nantes.fr
RI Gauthier, Olivier/A-4639-2015; BOHIC, Sylvain/F-6464-2013; Daculsi,
   Guy/P-1320-2014
OI BOHIC, Sylvain/0000-0001-6355-7592; Daculsi, Guy/0000-0003-1030-3446
CR DACULSI G, 1989, J BIOMED MATER RES, V23, P883, DOI 10.1002/jbm.820230806
   Daculsi G, 1997, INT REV CYTOL, V172, P129, DOI 10.1016/S0074-7696(08)62360-8
   DONG AC, 1988, BIOCHEM BIOPH RES CO, V156, P752, DOI 10.1016/S0006-291X(88)80907-0
   Elliot JC, 1994, STUDIES INORGANIC CH, V18
   FRIEDENSTEIN AJ, 1968, TRANSPLANTATION, V6, P230, DOI 10.1097/00007890-196803000-00009
   HEYMANN D, 1998, IN PRESS CONNECTIVE
   HILL SH, 1989, FOURIER TRANSFORM SP, V1145, P400
   KAUPPINEN JK, 1981, APPL SPECTROSC, V35, P271, DOI 10.1366/0003702814732634
   Legeros R.Z., 1991, MONOGRAPHS ORAL SCI, V15
   Legeros Racquel Z., 1993, Clinical Materials, V14, P65, DOI 10.1016/0267-6605(93)90049-D
   MENDELSOHN R, 1989, CALCIFIED TISSUE INT, V45, P62, DOI 10.1007/BF02556664
   MENDELSOHN R, 1989, CALCIFIED TISSUE INT, V44, P20, DOI 10.1007/BF02556236
   OLEARY TJ, 1989, APPL SPECTROSC, V43, P1095, DOI 10.1366/0003702894203994
   Paschalis EP, 1996, CALCIFIED TISSUE INT, V59, P480, DOI 10.1007/BF00369214
   REFFNER JA, 1988, MICROBEAM ANAL, V23, P227
   REY C, 1992, INT CONGR SER, V1002, P5
   REY C, 1991, CALCIFIED TISSUE INT, V49, P251, DOI 10.1007/BF02556214
   REY C, 1991, J BONE MINER RES, V6, P515
   SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0
NR 19
TC 23
Z9 23
U1 0
U2 1
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0764-4469
J9 CR ACAD SCI III-VIE
JI Comptes Rendus Acad. Sci. Ser. III-Sci. Vie-Life Sci.
PD OCT
PY 1998
VL 321
IS 10
BP 865
EP 876
DI 10.1016/S0764-4469(99)80027-4
PG 12
WC Biology; Multidisciplinary Sciences
SC Life Sciences & Biomedicine - Other Topics; Science & Technology - Other
   Topics
GA 140EJ
UT WOS:000077073900008
PM 9835023
DA 2018-10-19
ER

PT J
AU Kasemo, B
AF Kasemo, B
TI Biological surface science
SO CURRENT OPINION IN SOLID STATE & MATERIALS SCIENCE
LA English
DT Review
ID SOLID-SURFACES; PROTEIN ADSORPTION; BIOMATERIALS; BILAYERS; STABILITY;
   CELLS; WATER
AB Biological surface science will be as important in the future of surface science as semiconductors, catalysis and materials science have been in the past. There are three important research directions: firstly, studies of simple molecules such as water, amino acids, small peptides, and self-assembled monolayers of molecules both in UHV (ultrahigh vacuum) and in water. Secondly, studies of protein, DNA and membrane adsorption (kinetics, dynamics, structure and function) in the liquid phase. Thirdly, advanced preparation of biomaterial and biosensor surfaces, by making surface patterns with controlled chemical, topographic and micromechanical (viscoelastic) properties, for basic studies and applications such as, medical implants, biosensors, bioelectronics and tissue engineering.
C1 Chalmers Univ Technol, Dept Appl Phys, S-41296 Gothenburg, Sweden.
RP Kasemo, B (reprint author), Chalmers Univ Technol, Dept Appl Phys, S-41296 Gothenburg, Sweden.
EM kasemo@fy.chalmers.se
CR Arwin H, 1998, THIN SOLID FILMS, V313, P764, DOI 10.1016/S0040-6090(97)00993-0
   Barlow SM, 1998, SURF SCI, V401, P322, DOI 10.1016/S0039-6028(97)01086-8
   BRASH JL, 1996, INTERFACIAL PHENOMEN
   Caruso F, 1997, J COLLOID INTERF SCI, V186, P129, DOI 10.1006/jcis.1996.4625
   CHEHROUDI B, 1990, J BIOMED MATER RES, V24, P1203, DOI 10.1002/jbm.820240906
   Collings AF, 1997, REP PROG PHYS, V60, P1397, DOI 10.1088/0034-4885/60/11/005
   CONNOLLY P, 1994, TRENDS BIOTECHNOL, V12, P123, DOI 10.1016/0167-7799(94)90089-2
   Curtis A, 1997, BIOMATERIALS, V18, P1573, DOI 10.1016/S0142-9612(97)00144-0
   Davis SS, 1997, TRENDS BIOTECHNOL, V15, P217, DOI 10.1016/S0167-7799(97)01036-6
   DUKE CB, 1994, SURF SCI, V299, P1
   Elwing H, 1998, BIOMATERIALS, V19, P397, DOI 10.1016/S0142-9612(97)00112-9
   Fairlie DP, 1998, CURR MED CHEM, V5, P29
   Fishman HA, 1998, ANNU REV BIOPH BIOM, V27, P165, DOI 10.1146/annurev.biophys.27.1.165
   Fredriksson C, 1998, LANGMUIR, V14, P248, DOI 10.1021/la971005l
   Garrison MD, 1997, ANN NY ACAD SCI, V831, P101
   GOLD J, 1995, J VAC SCI TECHNOL A, V13, P2638, DOI 10.1116/1.579463
   HANSMAA HG, 1997, J STRUCT BIOL, V2, P99
   Harder P, 1998, J PHYS CHEM B, V102, P426, DOI 10.1021/jp972635z
   HLADY V, 1990, BIOSENS BIOELECTRON, V5, P291, DOI 10.1016/0956-5663(90)85002-T
   Hlady V, 1996, CURR OPIN BIOTECH, V7, P72, DOI 10.1016/S0958-1669(96)80098-X
   HOCH HC, 1996, NANOFABRICATION BIOS, P201
   Hook F, 1998, LANGMUIR, V14, P729, DOI 10.1021/la970815u
   HOOK F, 1998, IN PRESS P NATL ACAD
   Horbett TA, 1995, ACS S SERIES, V602
   HUBBELL JA, 1995, BIO-TECHNOL, V13, P565, DOI 10.1038/nbt0695-565
   HUI SW, 1995, BIOPHYS J, V68, P171, DOI 10.1016/S0006-3495(95)80172-4
   Israelachvili J, 1996, NATURE, V379, P219, DOI 10.1038/379219a0
   KASEMO B, 1994, ENVIRON HEALTH PERSP, V102, P41, DOI 10.2307/3432057
   KASEMO B, 1986, CRIT REV BIOCOMPAT, V2, P335
   KASEMO B, 1993, OSSEOINTEGRATION ORA
   KASEMO B, 1998, IN PRESS P 15 INT C
   KASEMO B, 1997, SURFACE CHARACTERIZA
   Keller CA, 1998, BIOPHYS J, V75, P1397, DOI 10.1016/S0006-3495(98)74057-3
   KING DA, 1981, CHEM PHYSICS SOLID S, P1
   Lofgren P, 1997, SURF SCI, V370, P277, DOI 10.1016/S0039-6028(96)00961-2
   LUNDSTROM I, 1985, PROG COLL POL SCI S, V70, P76
   Mrksich M, 1996, ANNU REV BIOPH BIOM, V25, P55, DOI 10.1146/annurev.bb.25.060196.000415
   Naert I, 1993, OSSEOINTEGRATION ORA
   NIMERI G, 1998, IN PRESS COLLOIDS B
   NOLLERT P, 1995, BIOPHYS J, V69, P1447, DOI 10.1016/S0006-3495(95)80014-7
   Norde W, 1996, MACROMOL SYMP, V103, P5, DOI 10.1002/masy.19961030104
   Persson B, 1997, SLIDING FRICTION PHY
   Ratner BD, 1996, J MOL RECOGNIT, V9, P617, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<617::AID-JMR310>3.0.CO;2-D
   RATNER BD, 1995, BIOSENS BIOELECTRON, V10, P797, DOI 10.1016/0956-5663(95)99218-A
   Rodahl M, 1997, FARADAY DISCUSS, V107, P229, DOI 10.1039/a703137h
   Sackmann E, 1996, SCIENCE, V271, P43, DOI 10.1126/science.271.5245.43
   Salafsky J, 1996, BIOCHEMISTRY-US, V35, P14773, DOI 10.1021/bi961432i
   Sleytr UB, 1997, TRENDS BIOTECHNOL, V15, P20, DOI 10.1016/S0167-7799(96)10063-9
   Stupp SI, 1997, SCIENCE, V277, P1242, DOI 10.1126/science.277.5330.1242
   TAMPE R, 1996, NANOFABRICATION BIOS, P201
   Tengvall P, 1998, BIOMATERIALS, V19, P407, DOI 10.1016/S0142-9612(97)00110-5
   THIEL PA, 1987, SURF SCI REP, V7, P211, DOI 10.1016/0167-5729(87)90001-X
   Vogler EA, 1998, ADV COLLOID INTERFAC, V74, P69, DOI 10.1016/S0001-8686(97)00040-7
   WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191
   Wintermantel E, 1996, BIOKOMPATIBLE WERKST
   Wong JY, 1997, SCIENCE, V275, P820, DOI 10.1126/science.275.5301.820
   Zhdanov VP, 1998, SURF REV LETT, V5, P615, DOI 10.1142/S0218625X98001006
   Zoungrana T, 1997, J COLLOID INTERF SCI, V190, P437, DOI 10.1006/jcis.1997.4895
NR 58
TC 137
Z9 137
U1 0
U2 47
PU CURRENT CHEMISTRY LTD
PI LONDON
PA 34-42 CLEVELAND STREET, LONDON W1P 6LE, ENGLAND
SN 1359-0286
J9 CURR OPIN SOLID ST M
JI Curr. Opin. Solid State Mat. Sci.
PD OCT
PY 1998
VL 3
IS 5
BP 451
EP 459
DI 10.1016/S1359-0286(98)80006-5
PG 9
WC Materials Science, Multidisciplinary; Physics, Applied; Physics,
   Condensed Matter
SC Materials Science; Physics
GA 131RD
UT WOS:000076588300006
DA 2018-10-19
ER

PT J
AU Aravind, S
   Paul, W
   Vasudev, SC
   Sharma, CP
AF Aravind, S
   Paul, W
   Vasudev, SC
   Sharma, CP
TI Polyethylene glycol (PEG) modified bovine pericardium as a biomaterial:
   A comparative study on immunogenicity
SO JOURNAL OF BIOMATERIALS APPLICATIONS
LA English
DT Article
ID COMPLEMENT ACTIVATION; DRUG-DELIVERY; BIOPROSTHESES; SURFACES; TISSUES;
   HEPARIN; BLOOD
AB Bioprosthetic heart valves made from glutaraldehyde (GA)-fixed porcine aortic valves or bovine pericardium (BP) are having some advantages over mechanical valves. However, their durability is low due to the calcification and immunological rejection. Study on immunogenicity is an important part in understanding the biocompatibility of materials. Polyethylene glycol (PEG) on pericardium can control biodegradation and calcification. Also, PEG exhibits low immunogenicity. We have studied the complement activation potential and the contribution of complement factors (biologic factors) on the calcification of PEG grafted pericardium samples and compared with standard (control) glutaraldehyde-treated pericardium samples. PEG-grafted BP activated using GA and carbodiimide (EDC) could be selected for further studies since complement activation and calcification observed on these samples has been relatively low.
C1 Sree Chitra Tirunal Inst Med Sci & Technol, Biomed Technol Wing, Div Biosurface Technol, Trivandrum 695012, Kerala, India.
RI Paul, Willi/D-2438-2009; Sharma, Chandra/A-4140-2009
OI Paul, Willi/0000-0002-0398-4258; Sharma, Chandra/0000-0002-6982-0926
CR Burkel WE, 1982, BIOL SYNTHETIC VASCU, P221
   CARRENO MP, 1988, BIOMATERIALS, V9, P514, DOI 10.1016/0142-9612(88)90047-6
   Chandy T, 1996, BIOMATERIALS, V17, P577, DOI 10.1016/0142-9612(96)88708-4
   COURTNEY JM, 1992, CARDIOVASCULAR BIOMA, P43
   HAN DK, 1989, J BIOMED MATER RES-A, V23, P211
   HARRIS JR, 1990, BLOOD CELL BIOCH, V1, P92
   Jayakrishnan A, 1996, BIOMATERIALS, V17, P471, DOI 10.1016/0142-9612(96)82721-9
   Khor E, 1997, BIOMATERIALS, V18, P95, DOI 10.1016/S0142-9612(96)00106-8
   LABARRE D, 1993, J APPL BIOMATER, V4, P231, DOI 10.1002/jab.770040304
   Levy R J, 1994, J Heart Valve Dis, V3, P101
   LEVY RJ, 1986, CRC CRITICAL REV BIO, P147
   LEVY RJ, 1983, AM J PATHOL, V113, P142
   LIU L, 1994, J BIOMED MATER RES, V28, P767, DOI 10.1002/jbm.820280703
   McConell I, 1981, IMMUNE SYSTEM, P40
   Moczar M, 1996, ASAIO J, V42, pM375, DOI 10.1097/00002480-199609000-00015
   MOLLNES TE, 1995, ARTIF ORGANS, V19, P909, DOI 10.1111/j.1525-1594.1995.tb02450.x
   ROSS D, 1992, CARDIOLOGY CARDIAC S, P203
   Schoen F J, 1984, Cardiol Clin, V2, P717
   SINDHU CV, 1997, J BIOMED MATER RES, V35, P357
   WALPORT M, 1989, IMMUNOLOGY
NR 20
TC 9
Z9 11
U1 1
U2 5
PU TECHNOMIC PUBL CO INC
PI LANCASTER
PA 851 NEW HOLLAND AVE, BOX 3535, LANCASTER, PA 17604 USA
SN 0885-3282
J9 J BIOMATER APPL
JI J. Biomater. Appl.
PD OCT
PY 1998
VL 13
IS 2
BP 158
EP 165
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 122FN
UT WOS:000076061400003
PM 9777465
DA 2018-10-19
ER

PT J
AU Brocchini, S
   James, K
   Tangpasuthadol, V
   Kohn, J
AF Brocchini, S
   James, K
   Tangpasuthadol, V
   Kohn, J
TI Structure-property correlations in a combinatorial library of degradable
   biomaterials
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE combinatorial design; fibroblast proliferation; tyrosine;
   pseudo-poly(amino acid); degradable polymer; cell-polymer interactions;
   polyarylate; tissue engineering; biomaterial
ID ENDOTHELIAL-CELL GROWTH; OXYGEN-CONTAINING FILMS; RADIOFREQUENCY
   PLASMAS; TYROSINE; SURFACES; ATTACHMENT; DESIGN
AB A combinatorial library of degradable polyarylates was prepared. These polymers are A-B-type copolymers consisting of an alternating sequence of a diphenol and a diacid. The library was prepared by copolymerizing, in all possible combinations, 14 different tyrosine-derived diphenols and eight different aliphatic diacids, resulting in 8 x 14 = 112 distinct polymers. This approach (a) increases the number of available polymeric candidate materials for medical applications, and (b) facilitates the identification of correlations between polymer structure and glass transition temperature, air-water contact angle, mechanical properties, and fibroblast proliferation. The pendent chain and backbone structures were systematically varied by (a) simple homologative variations in the number of methylene groups, (b) substitution of oxygen for methylene groups, and (c) introduction of branched and aromatic structures. The polymers contained within the library exhibited incremental variations in T-g (from 2 degrees C to 91 degrees C) and air-water contact angle (from 64 degrees to 101 degrees). Fibroblast proliferation (in vitro, serum-containing media) ranged from approximating that measured on tissue culture polystyrene to complete absence of proliferation. Generally, decreased proliferation correlated linearly with increased surface hydrophobicity, except in those polymers derived from oxygen-containing diacids in their backbone which were uniformly good growth substrates even if their surfaces were very hydrophobic. In a selected subgroup of polymers, tensile strength of thin solvent cast films ranged from about 6 to 45 MPa, while Young's modulus (stiffness) ranged from about 0.3 to 1.7 Cpa. Combinatorial biomaterial libraries such as these tyrosine-derived polyarylates permit the systematic study of material-dependent biological responses and provide the medical device designer with the option to choose a suitable material from a library of related polymers that encompasses a broad range of properties. (C) 1998 John Wiley & Sons, Inc.
C1 Rutgers State Univ, Dept Chem, New Brunswick, NJ 08903 USA.
RP Kohn, J (reprint author), Rutgers State Univ, Dept Chem, 610 Taylor Rd, Piscataway, NJ 08854 USA.
RI Tangpasuthadol, Varawut/F-9260-2010
FU NIGMS NIH HHS [GM49894]
CR Brocchini S, 1997, J AM CHEM SOC, V119, P4553, DOI 10.1021/ja970389z
   CHASIN M, 1990, BIODEGRADABLE POLYM, P43
   ERTEL SI, 1990, J BIOMED MATER RES, V24, P1637, DOI 10.1002/jbm.820241207
   ERTEL SI, 1994, J BIOMED MATER RES, V28, P919, DOI 10.1002/jbm.820280811
   ERTEL SI, 1991, J BIOMAT SCI-POLYM E, V3, P163, DOI 10.1163/156856291X00269
   FIORDELISO J, 1994, J BIOMAT SCI-POLYM E, V5, P497
   Hooper KA, 1995, J BIOACT COMPAT POL, V10, P327, DOI 10.1177/088391159501000404
   Hooper KA, 1998, J BIOMED MATER RES, V41, P443, DOI 10.1002/(SICI)1097-4636(19980905)41:3<443::AID-JBM14>3.0.CO;2-J
   HUBBELL JA, 1995, BIO-TECHNOL, V13, P565, DOI 10.1038/nbt0695-565
   KANG IK, 1989, J BIOMED MATER RES, V23, P223, DOI 10.1002/jbm.820230207
   KULKARNI RK, 1966, ARCH SURG-CHICAGO, V93, P839
   LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529
   LOWE G, 1995, JCS REV, P309
   MITSCHER LA, 1995, CHEMTRACTS ORG CHEM, V8, P19
   RATNER BD, 1990, J VAC SCI TECHNOL A, V8, P2306, DOI 10.1116/1.576755
   RAY JA, 1981, SURG GYNECOL OBSTET, V153, P497
   STEELE JG, 1994, J BIOMAT SCI-POLYM E, V6, P511, DOI 10.1163/156856294X00473
   TAMADA Y, 1994, J BIOMED MATER RES, V28, P783, DOI 10.1002/jbm.820280705
   TORMALA P, 1991, J BIOMED MATER RES, V25, P1, DOI 10.1002/jbm.820250102
NR 19
TC 143
Z9 145
U1 4
U2 38
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD OCT
PY 1998
VL 42
IS 1
BP 66
EP 75
DI 10.1002/(SICI)1097-4636(199810)42:1<66::AID-JBM9>3.0.CO;2-M
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 114ZD
UT WOS:000075638300009
PM 9740008
DA 2018-10-19
ER

PT J
AU Hsiue, GH
   Lee, SD
   Chang, PCT
   Kao, CY
AF Hsiue, GH
   Lee, SD
   Chang, PCT
   Kao, CY
TI Surface characterization and biological properties study of silicone
   rubber membrane grafted with phospholipid as biomaterial via plasma
   induced graft copolymerization
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE phospholipid; 2-methacryloyloxyethyl phosphorylcholine; silicone rubber
   membrane; plasma induced grafted polymerization; protein adsorption;
   platelet adhesion; epithelial cells interaction
ID EPITHELIAL-CELL ATTACHMENT; BRILLIANT BLUE G250; ACRYLIC-ACID;
   POLYETHYLENE SURFACE; PROTEIN ADSORPTION; GLOW-DISCHARGE;
   POLYMERIZATION; POLYMERS; FILM; HEMOCOMPATIBILITY
AB Poly(2-methacryloyloxyethyl phosphorylcholine) (pMPC) was grafted onto the surface of a silicon rubber (SR) membrane (pMPC-SR) by plasma induced grafted copolymerization (PIP). Argon plasma was used to activate the SR surfaces. Determination was also made of the influences of grafted copolymerization reaction time, reaction temperature, and monomer concentration on polymerization yield. The surface properties of SR were characterized by ATR-FTIR, ESCA, and SEM. In those analyses the ATR-FTIR spectra indicated that the pMPC grafted onto the SR surface at 1720 and 3300 cm(-1). The elemental composition and different carbon bindings on the surface of the SR were examined by ESCA. An increasing P1s/C1s value g was obtained in the grafted polymerization yield with a concentration of 0.05-0.5M of MPC in the isolated ethanol solution. The surface morphologies of pMPC-SR differed more than those of control and Ar plasma treated surfaces. The difference could have been caused by the homogeneous graft polymerization of pMPC onto the SR membrane. In the biological analyses, protein adsorption on pMPC-SR surfaces was reduced. The reduced level increased with an increase in the pMPC grafted amount. The epithelial cell attachment and growth onto these samples were suppressed. The blood compatibility for a series of pMPC-SR surfaces was examined by platelet adhesion. Blood platelet morphologies in contact with the high ratio of pMPC-SR surfaces were maintained, meaning that in this case the release reaction for platelets never occurred. Consequently, the high amount of pMPC-SR surface had excellent blood compatibility, further suggesting that prevention of adhesion, activation of platelets, and adsorption of blood protein could be achieved. (C) 1998 John Wiley & Sons, Inc.
C1 Natl Tsing Hua Univ, Dept Chem Engn, Hsinchu, Taiwan.
   Taichung Vet Gen Hosp, Dept Ophthalmol, Taichung, Taiwan.
RP Hsiue, GH (reprint author), Natl Tsing Hua Univ, Dept Chem Engn, Hsinchu, Taiwan.
CR Aeschlimann A, 1991, Schweiz Rundsch Med Prax, V80, P1190
   ALLIEU Y, 1990, REV CHIR ORTHOP, V76, P437
   ALLMER K, 1988, J POLYM SCI POL CHEM, V26, P2099, DOI 10.1002/pola.1988.080260809
   ANDRADE JD, 1986, ADV POLYM SCI, V79, P1
   BASZKIN A, 1984, BIOMATERIALS, V5, P175, DOI 10.1016/0142-9612(84)90054-1
   BOLZ A, 1992, BIOMED TECH, V37, P244, DOI 10.1515/bmte.1992.37.11.244
   BOLZ A, 1993, MED BIOL ENG COMPUT, V31, pS123, DOI 10.1007/BF02446660
   BONFIELD TL, 1991, J BIOMED MATER RES, V25, P165, DOI 10.1002/jbm.820250204
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   BRASH JL, 1979, J POLYM SCI POL SYM, P377
   Brash JL, 1991, BLOOD COMPATIBLE MAT, P3
   BREWIS DM, 1982, SURFACE PRETREATMENT, P199
   CAMERON JD, 1988, CURR EYE RES, V7, P293, DOI 10.3109/02713688809047035
   CHAPMAN D, 1968, BIOL MEMBRANE
   CLARK DT, 1978, J POLYM SCI POL CHEM, V16, P791, DOI 10.1002/pol.1978.170160407
   FAZAKES DS, 1963, BIOCHIM BIOPHYS ACTA, V71, P377
   GREGORIADIS G, 1980, LIPOSOMES BIOL SYSTE
   HARAGUCHI C, 1990, J APPL POLYM SCI APP, V46, P385
   HARRIS PI, 1990, HORIZONS MEMBRANE BI, P1
   HAYAT U, 1992, BIOMATERIALS, V13, P801, DOI 10.1016/0142-9612(92)90022-G
   HAYWARD JA, 1984, BIOMATERIALS, V5, P135, DOI 10.1016/0142-9612(84)90047-4
   HSIUE GH, 1993, J POLYM SCI POL CHEM, V31, P3327, DOI 10.1002/pola.1993.080311321
   HSIUE GH, 1989, ANGEW MAKROMOL CHEM, V173, P195, DOI 10.1002/apmc.1989.051730115
   HSIUE GH, 1990, J APPL POLYM SCI, V40, P235, DOI 10.1002/app.1990.070400119
   HSIUE GH, 1994, BIOMATERIALS, V15, P163
   HSIUE GH, 1993, BIOMATERIALS, V14, P591
   HUB HH, 1980, ANGEW CHEM INT EDIT, V19, P938, DOI 10.1002/anie.198009381
   ICHIJIMA H, 1991, MAKROMOL CHEM, V192, P1213
   ISHIHARA K, 1990, J JPN SOC BIOMATER, V8, P231
   Karube I, 1991, Rinsho Byori, V39, P237
   KIM SW, 1974, T AM SOC ART INT ORG, V20, P4449
   KOJIMA M, 1991, BIOMATERIALS, V12, P121, DOI 10.1016/0142-9612(91)90189-H
   Lee SD, 1996, BIOMATERIALS, V17, P587, DOI 10.1016/0142-9612(96)88709-6
   LEE SD, 1994, J APPL POLYM SCI, V54, P1279, DOI 10.1002/app.1994.070540909
   Lee SD, 1996, J POLYM SCI POL CHEM, V34, P141, DOI 10.1002/(SICI)1099-0518(19960115)34:1<141::AID-POLA15>3.0.CO;2-L
   LIN HB, 1992, BIOMATERIALS, V13, P905, DOI 10.1016/0142-9612(92)90113-3
   LINDEMAN RD, 1989, J AM COLL NUTR, V8, P285
   LIVSHIYS VS, 1989, LITERARY REV, V19, P49
   LOPEZ GP, 1993, MACROMOLECULES, V26, P3247, DOI 10.1021/ma00065a001
   LYMAN DJ, 1975, T AM SOC ART INT ORG, V21, P49
   MADOU M, 1993, APPL BIOCHEM BIOTECH, V41, P109, DOI 10.1007/BF02918537
   NAKAI S, 1977, MAKROMOL CHEM, V178, P2963
   OSADA Y, 1982, CHEM LETT, P171, DOI 10.1246/cl.1982.171
   OSADA Y, 1984, J APPL POLYM SCI APP, V38, P45
   PETTIT DK, 1990, INVEST OPHTH VIS SCI, V31, P2269
   PIGLOWSKI J, 1994, BIOMATERIALS, V15, P909, DOI 10.1016/0142-9612(94)90116-3
   RASMUSSEN JR, 1977, J AM CHEM SOC, V99, P4736, DOI 10.1021/ja00456a035
   REISNER AH, 1975, ANAL BIOCHEM, V64, P509, DOI 10.1016/0003-2697(75)90461-3
   SCHEULE RK, 1991, EXP LUNG RES, V17, P661, DOI 10.3109/01902149109062872
   SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6
   SUZUKI M, 1986, MACROMOLECULES, V19, P1804, DOI 10.1021/ma00161a005
   UYAMA Y, 1988, J APPL POLYM SCI, V36, P1087, DOI 10.1002/app.1988.070360509
   VONDRACEK P, 1984, BIOMATERIALS, V5, P209, DOI 10.1016/0142-9612(84)90017-6
   WANG CC, 1993, J POLYM SCI POL CHEM, V31, P1307, DOI 10.1002/pola.1993.080310526
   ZHAO Q, 1990, J BIOMED MATER RES, V24, P621, DOI 10.1002/jbm.820240508
NR 55
TC 48
Z9 49
U1 1
U2 23
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD OCT
PY 1998
VL 42
IS 1
BP 134
EP 147
DI 10.1002/(SICI)1097-4636(199810)42:1<134::AID-JBM17>3.0.CO;2-L
PG 14
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 114ZD
UT WOS:000075638300017
PM 9740016
DA 2018-10-19
ER

PT J
AU Tang, LP
   Wu, YL
   Timmons, RB
AF Tang, LP
   Wu, YL
   Timmons, RB
TI Fibrinogen adsorption and host tissue responses to plasma functionalized
   surfaces
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE radio frequency glow discharge plasma polymerization; functionality;
   fibrinogen; inflammation; fibrosis
ID COMPLEMENT ACTIVATION; INVIVO BIOCOMPATIBILITY; POLYMERIC BIOMATERIALS;
   INFLAMMATORY RESPONSES; ARTERIAL PROSTHESES; PROTEIN ADSORPTION;
   PLATELET-ADHESION; HYDROXYL-GROUPS; CELL-ADHESION; POLYETHYLENE
AB The physical and chemical characteristics of material surfaces are thought to play important roles in biomaterial-mediated tissue responses. To understand the importance of discrete biomaterial chemical characteristics in modifying host tissue responses, we constructed surfaces bearing different functional groups using radio frequency glow discharge plasma polymerization. Surfaces evaluated included those having high concentrations of -OH, -NH2, -CF3, and siloxyl groups. These surfaces and polyethylene terephthalate controls were used to assess the importance of particular physicochemical characteristics in surface:protein:cell interactions both in vitro and in vivo. The results obtained show that surface functionalities do significantly affect both the adsorption and "denaturation" of adsorbed fibrinogen (which is an important mediator of inflammatory responses to biomaterial implants). In addition, these surfaces provoke different degrees of acute inflammatory responses. Interestingly, the amounts of "denatured" fibrinogen that spontaneously accumulate on the individual surfaces correlate closely with the extent of biomaterial-mediated inflammation. These results suggest that surfaces that tend to "irreversibly" bind fibrinogen prompt greater acute inflammatory responses. Unexpectedly, all test surfaces except those bearing a siloxyl group engender relatively similar biomaterial-mediated fibrotic responses. Thus surface functionalities alone may not be sufficient to affect subsequent fibrotic responses. (C) 1998 John Wiley Rr Sons, Inc.
C1 Baylor Coll Med, Texas Med Ctr, Dept Pediat, Houston, TX 77030 USA.
   Univ Texas, Dept Chem & Biochem, Arlington, TX 76019 USA.
RP Tang, LP (reprint author), Baylor Coll Med, Texas Med Ctr, Dept Pediat, 1 Baylor Plaza, Houston, TX 77030 USA.
FU NHLBI NIH HHS [R01-HL56187, R01-HL53637]
CR ANDERSON JM, 1990, INT J ARTIF ORGANS, V13, P375
   Baier R E, 1969, J Biomed Mater Res, V3, P191, DOI 10.1002/jbm.820030115
   BEAMSON G, 1992, HIGH RESOLUTIONS XPS
   BERGMAN I, 1963, ANAL CHEM, V35, P1961, DOI 10.1021/ac60205a053
   BOHNERT J L, 1990, Journal of Biomaterials Science Polymer Edition, V1, P279
   BOHNERT JL, 1986, J COLLOID INTERF SCI, V111, P363, DOI 10.1016/0021-9797(86)90040-8
   CAPPELLI G, 1989, BLOOD PURIFICAT, V7, P293, DOI 10.1159/000169604
   CHINN JA, 1992, J BIOMED MATER RES, V26, P757, DOI 10.1002/jbm.820260606
   CHRISTENSON L, 1989, J BIOMED MATER RES, V23, P705, DOI 10.1002/jbm.820230704
   COLMAN RW, 1984, J CLIN INVEST, V73, P1249, DOI 10.1172/JCI111326
   CRADDOCK PR, 1977, J CLIN INVEST, V59, P879, DOI 10.1172/JCI108710
   DEKKER A, 1991, BIOMATERIALS, V12, P130, DOI 10.1016/0142-9612(91)90191-C
   DESAI NP, 1992, BIOMATERIALS, V13, P505, DOI 10.1016/0142-9612(92)90101-S
   EKDAHL KN, 1993, J COLLOID INTERF SCI, V158, P121, DOI 10.1006/jcis.1993.1236
   FREYRIA AM, 1991, BIOMATERIALS, V12, P111, DOI 10.1016/0142-9612(91)90187-F
   GOBEL RJ, 1987, BIOMATERIALS, V8, P285, DOI 10.1016/0142-9612(87)90116-5
   GRISTINA AG, 1987, SCIENCE, V237, P1588, DOI 10.1126/science.3629258
   Jansen B, 1988, J Biomater Appl, V2, P520
   JEFFREY JJ, 1981, COLLAGEN REL RES, V1, P257
   KO TM, 1993, BIOMATERIALS, V14, P657
   KO TM, 1993, J APPL POLYM SCI, V47, P1601, DOI 10.1002/app.1993.070470908
   KOTTKEMARCHANT K, 1987, J BIOMED MATER RES, V21, P379, DOI 10.1002/jbm.820210310
   LEE JH, 1991, BIOMATERIALS, V12, P443
   LEE JH, 1994, BIOMATERIALS, V15, P705, DOI 10.1016/0142-9612(94)90169-4
   LEE RG, 1974, J BIOMED MATER RES, V8, P251, DOI 10.1002/jbm.820080507
   LEININGER RI, 1987, ANN NY ACAD SCI, V516, P173, DOI 10.1111/j.1749-6632.1987.tb33039.x
   LENK TJ, 1991, LANGMUIR, V7, P1755, DOI 10.1021/la00056a030
   LEW DP, 1989, EUR J CANCER CLIN ON, V25, P1379, DOI 10.1016/0277-5379(89)90091-6
   LINDSAY RM, 1980, T AM SOC ART INT ORG, V26, P603
   Lu HF, 1997, J CLIN INVEST, V99, P1340, DOI 10.1172/JCI119293
   MARCHANT R, 1983, J BIOMED MATER RES, V17, P301, DOI 10.1002/jbm.820170209
   MARCHANT RE, 1984, J BIOMED MATER RES, V18, P309, DOI 10.1002/jbm.820180307
   MARCHANT RE, 1986, J BIOMED MATER RES, V20, P37, DOI 10.1002/jbm.820200105
   MCRITCHIE DI, 1991, J LAB CLIN MED, V118, P48
   MERHI Y, 1989, BIOMATERIALS, V10, P56, DOI 10.1016/0142-9612(89)90010-0
   NUSBACHER J, 1978, BLOOD, V51, P359
   PANCHALINGAM V, 1993, J BIOMAT SCI-POLYM E, V5, P131
   Panchalingam V, 1993, ASAIO J, V39, pM305
   PITT WG, 1986, J COLLOID INTERF SCI, V111, P343, DOI 10.1016/0021-9797(86)90039-1
   RAPOZA R J, 1989, Journal of Biomaterials Science Polymer Edition, V1, P99, DOI 10.1163/156856289X00091
   RATNER BD, 1990, J VAC SCI TECHNOL A, V8, P2306, DOI 10.1116/1.576755
   Rinsch CL, 1996, LANGMUIR, V12, P2995, DOI 10.1021/la950685u
   RINSCH CL, 1994, THESIS U TEXAS HLTH
   SANO S, 1993, BIOMATERIALS, V14, P817, DOI 10.1016/0142-9612(93)90003-K
   SAVAGE CR, 1993, ADV CHEM SER, V236, P745
   SEVASTIANOV VI, 1988, CRIT REV BIOCOMPAT, V4, P109
   SHEPARD AD, 1984, J VASC SURG, V1, P829, DOI 10.1067/mva.1984.avs0010829
   TANG LP, 1993, J LAB CLIN MED, V122, P292
   TANG LP, 1993, J EXP MED, V178, P2147, DOI 10.1084/jem.178.6.2147
   Tang LP, 1996, J CLIN INVEST, V97, P1329, DOI 10.1172/JCI118549
   UENOYAMA K, 1988, J CATARACT REFR SURG, V14, P187, DOI 10.1016/S0886-3350(88)80094-4
   WANG JH, IN PRESS PLASMA SYNT
   YATES SG, 1973, SURG GYNECOL OBSTET, V136, P12
NR 53
TC 83
Z9 84
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD OCT
PY 1998
VL 42
IS 1
BP 156
EP 163
DI 10.1002/(SICI)1097-4636(199810)42:1<156::AID-JBM19>3.3.CO;2-E
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 114ZD
UT WOS:000075638300019
PM 9740018
DA 2018-10-19
ER

PT J
AU Montanaro, L
   Arciola, CR
   Borsetti, E
   Brigotti, M
   Baldassarri, L
AF Montanaro, L
   Arciola, CR
   Borsetti, E
   Brigotti, M
   Baldassarri, L
TI A polymerase chain reaction (PCR) method for the identification of
   collagen adhesin gene (CNA) in Staphylo coccus-induced prosthesis
   infections
SO MICROBIOLOGICA
LA English
DT Article
DE collagen adhesin gene (cna); polymerase chain reaction (PCR); bacterial
   adhesion; biomaterial-associated infection; Staphylococcus aureus;
   Staphylococcus epidermidis
ID AUREUS; FIBRONECTIN; EXPRESSION; SLIME
AB Staphylococci are well-recognized pathogens of foreign body-associated infections. The pathogenesis of such infections involves an initial step of contact between the colonizing bacterium and the biomaterial, with subsequent colony formation. Several studies have been devoted to identify adhesion mechanisms for these bacteria. Slime in particular has been extensively investigated. Recently,considerable attention has been given to the host protein receptors that have been shown in in vitro assays to serve as substrates for bacterial adherence. To determine the importance of the collagen adhesin as virulence factor in Staphylococcus-induced prosthesis infection, a simple and reliable method using a polymerase chain reaction (PCR) was devised to identify collagen adhesin gene (cna).
   By using lysates of ten strains from orthopedic prostheses (5 Staphylococcus aureus and 5 Staphylococcus epidermidis) and two 20-oligonucleotides as primers, a 192-bp region of the cna gene was amplified by PCR and detected by agarose gel electrophoresis. Results obtained by this method were in accordance with those obtained by the in vitro phenotypic characterization of binding ability to collagen of Staphylococcus strains.
C1 Ist Ortoped Rizzoli, Lab Biocompatibil Mat Impianto, I-40136 Bologna, Italy.
RP Montanaro, L (reprint author), Ist Ortoped Rizzoli, Lab Biocompatibil Mat Impianto, Via Barbiano 1-10, I-40136 Bologna, Italy.
RI Baldassarri, Lucilla/B-1042-2013
CR ARCIOLA CR, 1994, J CATARACT REFR SURG, V3, P195
   Baldassarri L, 1997, INFECT IMMUN, V65, P1522
   Baldassarri L, 1995, MICROECOL T, V25, P103
   DELMI M, 1994, J ORTHOPAED RES, V12, P432, DOI 10.1002/jor.1100120316
   Francois P, 1996, BIOMATERIALS, V17, P667, DOI 10.1016/0142-9612(96)86736-6
   GATERMANN S, 1994, INFECT IMMUN, V62, P4556
   Gillaspy AF, 1997, GENE, V196, P239, DOI 10.1016/S0378-1119(97)00256-4
   KREISWIRTH B, 1993, SCIENCE, V259, P227, DOI 10.1126/science.8093647
   LECH MS, 1989, J BIOL CHEM, V264, P21080
   LEE CY, 1995, GENE, V167, P227
   Nomura S, 1997, J BIOMED MATER RES, V38, P35
   PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101
   PATTI JM, 1992, J BIOL CHEM, V267, P4766
   PATTI JM, 1994, INFECT IMMUN, V62, P152
   PAULSSON M, 1993, BIOMATERIALS, V14, P845, DOI 10.1016/0142-9612(93)90006-N
   Rozen S, 1997, PRIMER 3
   Smeltzer MS, 1997, GENE, V196, P249, DOI 10.1016/S0378-1119(97)00237-0
   Vaudaux P, 1990, J Biomater Appl, V5, P134, DOI 10.1177/088532829000500204
NR 18
TC 12
Z9 12
U1 0
U2 2
PU LUIGI PONZIO E FIGLIO
PI PAVIA
PA VIA D DA CATALOGNA 1/3, 27100 PAVIA, ITALY
SN 1121-7138
J9 MICROBIOLOGICA
JI Microbiologica
PD OCT
PY 1998
VL 21
IS 4
BP 359
EP 363
PG 5
WC Microbiology
SC Microbiology
GA 134LZ
UT WOS:000076745700007
DA 2018-10-19
ER

PT J
AU Eidhin, DN
   Perkins, S
   Francois, P
   Vaudaux, P
   Hook, M
   Foster, TJ
AF Eidhin, DN
   Perkins, S
   Francois, P
   Vaudaux, P
   Hook, M
   Foster, TJ
TI Clumping factor B (ClfB), a new surface-located fibrinogen-binding
   adhesin of Staphylococcus aureus
SO MOLECULAR MICROBIOLOGY
LA English
DT Article
ID TOXIC SHOCK SYNDROME; ESCHERICHIA-COLI; REPEAT REGION; GAMMA-CHAIN;
   PROTEINS; RECEPTOR; DOMAIN; IDENTIFICATION; FIBRONECTIN; CLEAVAGE
AB The surface-located fibrinogen-binding protein (clumping factor; ClfA) of Staphylococcus aureus has an unusual dipeptide repeat linking the ligand binding domain to the wall-anchored region. Southern blotting experiments revealed several other loci in the S. aureus Newman genome that hybridized to a probe comprising DNA encoding the dipeptide repeat. One of these loci is analysed here. It also encodes a fibrinogen-binding protein, which we have called ClfB. The overall organization of ClfB is very similar to that of ClfA, and the proteins have considerable sequence identity in the signal sequence and wall attachment domains. However, the A regions are only 26% identical. Recombinant biotinylated ClfB protein bound to fibrinogen in Western ligand blots, ClfB reacted with the alpha- and beta-chains of fibrinogen in the ligand blots in contrast to ClfA, which binds exclusively to the gamma-chain, Analysis of proteins released from the cell wall of S, aureus Newman by Western immunoblotting using antibody raised against the recombinant A region of ClfB identified a 124 kDa protein as the clfB gene product. This protein was detectable only on cells that were grown to the early exponential phase. It was absent from cells from late exponential phase or stationary phase cultures. Using a clfB mutant isolated by allelic replacement alone and in combination with a clfA mutation, the ClfB protein was shown to promote (i) clumping of exponential-phase cells in a solution of fibrinogen, (ii) adherence of exponential-phase bacteria to immobilized fibrinogen in vitro, and (iii) bacterial adherence to ex vivo human haemodialysis tubing, suggesting that it could contribute to the pathogenicity of biomaterial-related infections. However, in wild-type exponential-phase S. aureus Newman cultures, ClfB activity was masked by the ClfA protein, and it did not contribute at all to interactions of cells from stationary-phase cultures with fibrinogen. ClfB-dependent bacterial adherence to immobilized fibrinogen was inhibited by millimolar concentrations of Ca2+ and Mn2+, which indicates that, like ClfA, ligand binding by ClfB is regulated by a low-affinity inhibitory cation binding site.
C1 Univ Dublin Trinity Coll, Moyne Inst Prevent Med, Dept Microbiol, Dublin 2, Ireland.
   Texas Med Ctr, Inst Biosci & Technol, Houston, TX 77030 USA.
   Univ Hosp, Div Infect Dis, CH-1211 Geneva 4, Switzerland.
RP Foster, TJ (reprint author), Univ Dublin Trinity Coll, Moyne Inst Prevent Med, Dept Microbiol, Dublin 2, Ireland.
EM tfoster@tcd.ie
FU NIAID NIH HHS [AI20624]; Wellcome Trust
CR ALTIERI DC, 1993, J BIOL CHEM, V268, P1847
   ANDERSON RO, 1976, FISHERIES, V1, P5
   APPLEYARD RK, 1954, GENETICS, V39, P440
   AUGUSTIN J, 1992, EUR J BIOCHEM, V204, P1149, DOI 10.1111/j.1432-1033.1992.tb16740.x
   Ausubel F., 1987, CURRENT PROTOCOLS MO
   BJORKLIND A, 1974, BIOCHIM BIOPHYS ACTA, V370, P524, DOI 10.1016/0005-2744(74)90113-2
   BROWN EM, 1995, CELL, V83, P679, DOI 10.1016/0092-8674(95)90180-9
   DUTHIE ES, 1952, J GEN MICROBIOL, V6, P95, DOI 10.1099/00221287-6-1-2-95
   FELICIELLO I, 1993, ANAL BIOCHEM, V212, P394, DOI 10.1006/abio.1993.1346
   GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z
   HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8
   Hartford O, 1997, MOL MICROBIOL, V25, P1065, DOI 10.1046/j.1365-2958.1997.5291896.x
   HAWIGER J, 1982, BIOCHEMISTRY-US, V21, P1407, DOI 10.1021/bi00535a047
   HERRMANN M, 1993, J INFECT DIS, V167, P312, DOI 10.1093/infdis/167.2.312
   Hu DD, 1996, J BIOL CHEM, V271, P21745, DOI 10.1074/jbc.271.36.21745
   KERNODLE DS, 1997, STAPHYLOCOCCI HUMAN, P355
   KHAN SA, 1983, PLASMID, V10, P251, DOI 10.1016/0147-619X(83)90039-2
   KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028
   KREISWIRTH BN, 1983, NATURE, V305, P709, DOI 10.1038/305709a0
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0
   LOFDAHL S, 1983, P NATL ACAD SCI-BIOL, V80, P697, DOI 10.1073/pnas.80.3.697
   MCDEVITT D, 1995, MICROBIOL-UK, V141, P937, DOI 10.1099/13500872-141-4-937
   McDevitt D, 1997, EUR J BIOCHEM, V247, P416, DOI 10.1111/j.1432-1033.1997.00416.x
   MCDEVITT D, 1995, MOL MICROBIOL, V16, P895, DOI 10.1111/j.1365-2958.1995.tb02316.x
   MCDEVITT D, 1994, MOL MICROBIOL, V11, P237, DOI 10.1111/j.1365-2958.1994.tb00304.x
   McGavin MJ, 1997, INFECT IMMUN, V65, P2621
   MOREILLON P, 1995, INFECT IMMUN, V63, P4738
   MULLER E, 1993, INFECT IMMUN, V61, P551
   Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1
   NOVICK R, 1967, VIROLOGY, V33, P155, DOI 10.1016/0042-6822(67)90105-5
   O'Connell DP, 1998, J BIOL CHEM, V273, P6821, DOI 10.1074/jbc.273.12.6821
   OREILLY M, 1990, MOL MICROBIOL, V4, P1947, DOI 10.1111/j.1365-2958.1990.tb02044.x
   PATTI JM, 1994, INFECT IMMUN, V62, P152
   POSTON SM, 1991, J MED MICROBIOL, V34, P193, DOI 10.1099/00222615-34-4-193
   RUPP ME, 1979, STAPHYLOCOCCI HUMAN, P379
   Sambrook J, 1989, MOL CLONING LAB MANU
   SaraviaOtten P, 1997, J BACTERIOL, V179, P5259, DOI 10.1128/jb.179.17.5259-5263.1997
   SCHENK S, 1992, FEMS MICROBIOL LETT, V94, P133
   SCHNEEWIND O, 1995, SCIENCE, V268, P103, DOI 10.1126/science.7701329
   SHERERTZ RJ, 1993, J INFECT DIS, V167, P98, DOI 10.1093/infdis/167.1.98
   SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583
   SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0
   VANDYKE MW, 1992, GENE, V111, P99, DOI 10.1016/0378-1119(92)90608-R
   VAUDAUX P, 1989, J INFECT DIS, V160, P865, DOI 10.1093/infdis/160.5.865
   VAUDAUX PE, 1995, INFECT IMMUN, V63, P585
   Vaudaux Pierre E., 1994, P1
   WALDVOGEL FA, 1995, PRINCIPLES PRACTICE, P1754
   Wolz C, 1996, INFECT IMMUN, V64, P3142
NR 49
TC 99
Z9 102
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0950-382X
EI 1365-2958
J9 MOL MICROBIOL
JI Mol. Microbiol.
PD OCT
PY 1998
VL 30
IS 2
BP 245
EP 257
PG 13
WC Biochemistry & Molecular Biology; Microbiology
SC Biochemistry & Molecular Biology; Microbiology
GA 131BE
UT WOS:000076555200003
PM 9791170
DA 2018-10-19
ER

PT J
AU Maniker, A
   Cantrell, S
   Vaicys, C
AF Maniker, A
   Cantrell, S
   Vaicys, C
TI Failure of hydroxyapatite cement to set in repair of a cranial defect:
   Case report
SO NEUROSURGERY
LA English
DT Article
DE cranial fracture; depressed cranial fracture; depressed skull fracture;
   hydroxyapatite
ID RECONSTRUCTION; SURGERY
AB OBJECTIVE AND IMPORTANCE: Hydroxyapatite cement, a new biomaterial that is being marketed as a method for reconstructing cranial defects, offers many advantages. We document, herein, the complete dissolution and failure of this material to set in a surgically dry field, under optimal conditions, an occurrence that has not been previously reported.
   CLINICAL PRESENTATION: Hydroxyapatite cement was used for reconstruction of a frontal bone defect secondary to a traumatic depressed cranial fracture in a 9-year-old male patient. At the time of suture removal on postoperative Day 6, we observed serous discharge from the wound, a reappearance of the cranial defect, and brain pulsations visible subcutaneously.
   INTERVENTION: The patient was returned to the operating room, at which time we learned that the hydroxyapatite cement had migrated out of the defect; small concretions of the cement were scattered throughout the subgaleal space. The concretions of cement in the subgaleal space and the small amount of cement remaining in the defect were removed, and titanium mesh was used. An excellent cosmetic result was achieved.
   CONCLUSION: Although offering many advantages, hydroxyapatite cement does carry a risk of failure to set, despite optimal technique. Causes for failure to set, as well as possible modifications in the use of material and technique, are discussed.
C1 Univ Med & Dent New Jersey, New Jersey Med Sch, Div Neurosurg, Newark, NJ 07103 USA.
   Univ Med & Dent New Jersey, New Jersey Med Sch, Div Oral & Maxillofacial Surg, Newark, NJ 07103 USA.
RP Maniker, A (reprint author), Univ Med & Dent New Jersey, New Jersey Med Sch, Div Neurosurg, 90 Bergen St,No 7300, Newark, NJ 07103 USA.
CR Brown P.W., 1986, CEMENTS RES PROGR, V99, P352
   COSTANTINO PD, 1992, PLAST RECONSTR SURG, V90, P174, DOI 10.1097/00006534-199290020-00003
   KAMERER DB, 1994, AM J OTOL, V15, P47
   Kurashina K, 1997, BIOMATERIALS, V18, P539, DOI 10.1016/S0142-9612(96)00162-7
   KVETON JF, 1995, LARYNGOSCOPE, V105, P156, DOI 10.1288/00005537-199502000-00008
   KVETON JF, 1995, AM J OTOL, V16, P465
   Miyamato Y, 1996, BIOMATERIALS, V17, P1429, DOI 10.1016/0142-9612(96)87286-3
   SHINDO ML, 1993, ARCH OTOLARYNGOL, V119, P185
NR 8
TC 32
Z9 32
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA
SN 0148-396X
J9 NEUROSURGERY
JI Neurosurgery
PD OCT
PY 1998
VL 43
IS 4
BP 953
EP 954
DI 10.1097/00006123-199810000-00134
PG 2
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 121MT
UT WOS:000076018200120
PM 9766327
DA 2018-10-19
ER

PT J
AU Misch, CM
   Jolly, RL
   Williams, DR
   Chorazy, CJ
AF Misch, CM
   Jolly, RL
   Williams, DR
   Chorazy, CJ
TI Maxillary implant surgery on a patient with thalassemia - A case report
SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS
LA English
DT Article
ID BETA-THALASSEMIA; SINUS HYPOPLASIA; BONE; HYPERPLASIA
AB This case report describes the successful maxillary rehabilitation of. partially edentulous patient with thalassemia minor. This rather common genetic disorder presented clinical implications for the placement of maxillary dental implants. The diagnostic evaluation for thalassemia and clinical manifestations are discussed. The surgical technique, implant biomaterial, and prosthetic phase of therapy were modified to accommodate the poor osseous architecture.
C1 St Francis Med Ctr, Dept Oral & Maxillofacial Surg, Pittsburgh, PA 15201 USA.
RP Misch, CM (reprint author), St Francis Med Ctr, Dept Oral & Maxillofacial Surg, 400 45th St, Pittsburgh, PA 15201 USA.
CR ANDREOU J, 1984, J COMPUT ASSIST TOMO, V8, P180, DOI 10.1097/00004728-198402000-00048
   ASBELL MB, 1964, ANN NY ACAD SCI, V119, P662
   BLOCK M S, 1992, Dental Clinics of North America, V36, P27
   BOLGER WE, 1990, OTOLARYNG HEAD NECK, V103, P759, DOI 10.1177/019459989010300516
   CARLSSON L, 1988, ACTA ORTHOP SCAND, V59, P272, DOI 10.3109/17453678809149361
   FICARRA G, 1987, INT J ORAL MAX SURG, V16, P227, DOI 10.1016/S0901-5027(87)80136-4
   FINSTERBUSH A, 1985, CLIN ORTHOP RELAT R, P132
   FRIBERG B, 1991, International Journal of Oral and Maxillofacial Implants, V6, P142
   GOLEC T S, 1992, Dental Clinics of North America, V36, P39
   HES J, 1990, ORAL SURG ORAL MED O, V69, P185, DOI 10.1016/0030-4220(90)90326-N
   JAFFIN RA, 1991, J PERIODONTOL, V62, P2, DOI 10.1902/jop.1991.62.1.2
   JURKIEWICZ MJ, 1967, PLAST RECONSTR SURG, V5, P459
   KARMODY CS, 1977, T AM ACAD OPHTHALMOL, V84, P723
   Lavelle C L, 1993, Int J Oral Maxillofac Implants, V8, P179
   LEE GR, 1993, WINTROBES CLIN HEMAT, P791
   Lekholm U, 1985, TISSUE INTEGRATED PR, P199, DOI DOI 10.1111/J.1708-8208.2002.TB00174.X
   Lewis S, 1995, Int J Oral Maxillofac Implants, V10, P319
   Lukens John N., 1993, P1102
   MARSH JL, 1994, COMPLICATIONS ORTHOP, P191
   MCgowan DA, 1993, MAXILLARY SINUS ITS, P137
   Misch CE, 1990, PRACTICAL PERIODONTI, V2, P27
   MODIC MT, 1980, RADIOLOGY, V135, P383, DOI 10.1148/radiology.135.2.7367631
   MOSELEY JE, 1974, SEMIN ROENTGENOL, V9, P169, DOI 10.1016/0037-198X(74)90015-7
   PALING MR, 1982, RADIOLOGY, V144, P539, DOI 10.1148/radiology.144.3.7100468
   PEREZ CA, 1988, ORAL SURG ORAL MED O, V66, P507, DOI 10.1016/0030-4220(88)90279-4
   POOTRAKUL P, 1981, NEW ENGL J MED, V304, P1470, DOI 10.1056/NEJM198106113042406
   RADECKI CA, 1990, INT J ORAL MAX SURG, V19, P158, DOI 10.1016/S0901-5027(05)80134-1
   Rotter B E, 1996, Implant Dent, V5, P28, DOI 10.1097/00008505-199600510-00006
   SAADOUN AP, 1992, INT J PERIODONT REST, V12, P487
   SFIKAKIS P, 1963, ACTA HAEMATOL-BASEL, V29, P193, DOI 10.1159/000207344
   SILLING G, 1978, AM J ORTHOD DENTOFAC, V74, P444, DOI 10.1016/0002-9416(78)90067-2
   SOMM PM, 1984, RADIOLOGY, V152, P463
   TATUM H, 1986, DENT CLIN N AM, V30, P207
   van Steenberghe D, 1990, Int J Oral Maxillofac Implants, V5, P272
   VANDIS ML, 1986, ORAL SURG ORAL MED O, V62, P229, DOI 10.1016/0030-4220(86)90055-1
   WAKE M, 1993, ARCH OTOLARYNGOL, V119, P1353
   WEATHERALL DJ, 1995, WILLIAMS HEMATOLOGY, P581
   WEEL F, 1987, BRIT J ORAL MAX SURG, V25, P348, DOI 10.1016/0266-4356(87)90076-3
NR 38
TC 2
Z9 3
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA
SN 1079-2104
J9 ORAL SURG ORAL MED O
JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.
PD OCT
PY 1998
VL 86
IS 4
BP 401
EP 405
DI 10.1016/S1079-2104(98)90363-8
PG 5
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 129RN
UT WOS:000076476900006
PM 9798221
DA 2018-10-19
ER

PT J
AU Tsimoyiannis, EC
   Tassis, A
   Glantzounis, G
   Jabarin, M
   Siakas, P
   Tzourou, H
AF Tsimoyiannis, EC
   Tassis, A
   Glantzounis, G
   Jabarin, M
   Siakas, P
   Tzourou, H
TI Laparoscopic intraperitoneal onlay mesh repair of incisional hernia
SO SURGICAL LAPAROSCOPY & ENDOSCOPY
LA English
DT Article
DE expanded polytef; hernioplasty; laparoscopy; prosthetic material;
   ventral hernia
ID EXPANDED POLYTETRAFLUOROETHYLENE
AB Improvements in laparoscopic techniques and equipment have engendered many new intraabdominal procedures. Laparoscopic hemioplasty was used in 11 patients with 12 incisional abdominal hernias. All repairs were made with an intraperitoneal onlay patch of expanded polytef Gore Tex DualMesh Biomaterial. The patch was secured by whole-thickness sutures, tied subcutaneously through stab holes, and staples between the sutures to cover the hernia defect without excision of the hernia sac. There were three postoperative complications: one seroma, one hematoma, and one infection. These complications successfully healed without reoperation. No recurrence was observed during a follow-up of 8-21 months (average 15 months). It is concluded that laparoscopic incisional hernioplasty using the new Gore-Tex DualMesh Biomaterial, which is securely sutured and stapled on the abdominal wall, is a promising minimally invasive procedure. Continued follow-up is necessary to determine the long-term results.
C1 G Htzikosta Gen Hosp, Dept Surg, Ioannina, Greece.
   G Htzikosta Gen Hosp, Dept Anaesthesia, Ioannina, Greece.
RP Tsimoyiannis, EC (reprint author), 3 Hippocratus, GR-45332 Ioannina, Greece.
CR ADAMSONS RJ, 1963, SURG GYNECOL OBSTET, V117, P396
   Arabamson J, 1997, MAINGOTS ABDOMINAL O, P479
   ARREGUI ME, 1993, SURG CLIN N AM, V73, P513
   DEBORD JR, 1995, HERNIA, P328
   DEBORD JR, 1992, POSTGRAD GEN SURG, V4, P156
   DEYSINE M, 1992, AM J SURG, V163, P422, DOI 10.1016/0002-9610(92)90045-S
   Lanzafame R J, 1993, J Laparoendosc Surg, V3, P193, DOI 10.1089/lps.1993.3.193
   LEBLANC KA, 1993, SURG LAPAROSC ENDOSC, V3, P39
   LEBLANC KA, 1994, INGUINAL HERNIA ADV, P541
   Lopez-Martinez R A, 1993, J Laparoendosc Surg, V3, P561, DOI 10.1089/lps.1993.3.561
   SARLI L, 1997, SURG LAPARO ENDO PER, V6, P472
   STOPPA RE, 1989, WORLD J SURG, V13, P545, DOI 10.1007/BF01658869
   Toy F K, 1991, Surg Laparosc Endosc, V1, P151
   TSIMOYIANNIS EC, 1994, SURG LAPAROSC ENDOSC, V4, P367
   WOOL NL, 1985, P I MED CHICAGO, V38, P33
NR 15
TC 25
Z9 25
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA
SN 1051-7200
J9 SURG LAPAROSC ENDOSC
JI Surg. Laparoscopy Endosc.
PD OCT
PY 1998
VL 8
IS 5
BP 360
EP 362
DI 10.1097/00019509-199810000-00008
PG 3
WC Surgery
SC Surgery
GA 125DD
UT WOS:000076221400008
PM 9799145
DA 2018-10-19
ER

PT J
AU Tong, J
   Arnell, RD
   Ren, LQ
AF Tong, J
   Arnell, RD
   Ren, LQ
TI Dry sliding wear behaviour of bamboo
SO WEAR
LA English
DT Article
DE bamboo; natural biomaterial; composite material; sliding wear; adhesion
AB Dry sliding wear behaviour of bamboo (Phyllostachys pubescens) against a grey iron (HT200) was examined on a block-on-ring machine. The wear volume of bamboo was a function of the normal load the sliding velocity and the relative orientation of bamboo fibres with respect to the rubbing surface. The wear volume increased with the normal load and sliding velocity. The normal-oriented specimens (N-type) gave better wear resistance than the parallel-oriented ones (P-S- and P-I-type), and the outside surface layer (P-S-type) gave better resistance than the inner later (P-I-type). Material transfer from bamboo to the counterface took place during the rubbing process for the three types of specimens. The predominant wear mechanisms were adhesion, microcracking and microploughing-microcutting for the P-S- and P-I-type, and adhesion and microcracking for the N-type. (C) 1998 Elsevier Science S.A. All rights reserved.
C1 Univ Salford, Dept Aeronaut Mech & Mfg Engn, Salford M5 4WT, Lancs, England.
   Jilin Univ Technol, Sch Agr Machinery Engn, Changchun 130025, Peoples R China.
RP Arnell, RD (reprint author), Univ Salford, Dept Aeronaut Mech & Mfg Engn, Salford M5 4WT, Lancs, England.
CR GODBOLE VS, 1986, J MATER SCI LETT, V5, P303, DOI 10.1007/BF01748085
   LAKKAD C, 1981, FIBRE SCI TECHNOL, V14, P319
   LI S, 1991, MAT SCI PROGR, V5, P542
   TONG J, 1995, TRIBOL INT, V28, P323, DOI 10.1016/0301-679X(95)00084-H
   YAKOU T, 1993, JPN J TRIBOL, V38, P491
NR 5
TC 38
Z9 48
U1 0
U2 5
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0043-1648
J9 WEAR
JI Wear
PD OCT
PY 1998
VL 221
IS 1
BP 37
EP 46
DI 10.1016/S0043-1648(98)00261-0
PG 10
WC Engineering, Mechanical; Materials Science, Multidisciplinary
SC Engineering; Materials Science
GA 146VQ
UT WOS:000077453200005
DA 2018-10-19
ER

PT J
AU Rozalska, B
   Sadowska, B
   Ljungh, A
   Rudnicka, W
AF Rozalska, B
   Sadowska, B
   Ljungh, A
   Rudnicka, W
TI Granulocyte-macrophage colony-stimulating factor (GM-CSF)-coated
   implants and their potential for reducing biomaterial-associated
   infection in neutropenic hosts
SO ZENTRALBLATT FUR BAKTERIOLOGIE-INTERNATIONAL JOURNAL OF MEDICAL
   MICROBIOLOGY VIROLOGY PARASITOLOGY AND INFECTIOUS DISEASES
LA English
DT Article
ID HUMAN-NEUTROPHILS; STAPHYLOCOCCUS-EPIDERMIDIS; GM-CSF; MICE; BLOOD;
   CATHETER; TRIAL; COLONIZATION; PHAGOCYTOSIS; ANTIBIOTICS
AB The incidence of infections associated with the use of medical biomaterials is high for skin-penetrating devices, when microbes of the normal skin flora like coagulase-positive and coagulase-negative staphylococci dominate as causative organisms. The most serious ones are infections in immunocompromised individuals. A mouse model of subcutaneous staphylococcal infection yielding abscesses in cyclophosphamide-induced neutropenic mice implanted with heparinized polyethylene (H-PE) was used. The present study addresses the question of the effects of implant modification with recombinant granulocyte-macrophage stimulating factor (rGM-CSF) on the course of infection. Our findings demonstrate that such modification reduces the proliferation of bacteria within the abscess and as a consequence limits the dissemination of bacteria from the local infection induced in the neutropenic host.
C1 Univ Lodz, Dept Infect Biol, Inst Microbiol & Immunol, PL-90237 Lodz, Poland.
   Univ Lund, Dept Med Microbiol, S-22362 Lund, Sweden.
RP Rozalska, B (reprint author), Univ Lodz, Dept Infect Biol, Inst Microbiol & Immunol, Banacha 12, PL-90237 Lodz, Poland.
CR BONILLA MA, 1994, BRIT J HAEMATOL, V88, P723, DOI 10.1111/j.1365-2141.1994.tb05110.x
   DEVALON ML, 1987, INFECT IMMUN, V55, P2398
   Fontt EO, 1996, INFECT IMMUN, V64, P3429
   GRAY ED, 1984, LANCET, V1, P365
   Jansen B, 1989, J Invest Surg, V2, P361, DOI 10.3109/08941938909018262
   JANSEN B, 1992, J HOSP INFECT, V22, P93, DOI 10.1016/0195-6701(92)90093-2
   JASWON MS, 1994, PEDIATR RES, V36, P623, DOI 10.1203/00006450-199411000-00016
   JOHNSON GM, 1986, INFECT IMMUN, V54, P13
   Kaplan S S, 1990, ASAIO Trans, V36, pM172
   KARP JE, 1994, CURR OPIN INFECT DIS, V7, P430, DOI 10.1097/00001432-199408000-00003
   KAYASHIMA S, 1993, IMMUNOLOGY, V80, P471
   KRAFT WG, 1986, INFECT IMMUN, V52, P707
   Kumaratilake LM, 1996, PARASITE IMMUNOL, V18, P115, DOI 10.1046/j.1365-3024.1996.d01-64.x
   LARM O, 1983, BIOMATER ARTIF CELL, V11, P161, DOI 10.3109/10731198309118804
   LEYDEN JJ, 1979, J INVEST DERMATOL, V72, P165, DOI 10.1111/1523-1747.ep12676347
   LUCAS R, 1994, LECTINS BIOL BIOCH C, V10, P244
   Maki DG, 1997, ANN INTERN MED, V127, P257, DOI 10.7326/0003-4819-127-4-199708150-00001
   MATSUMOTO M, 1990, MICROBIOL IMMUNOL, V34, P765, DOI 10.1111/j.1348-0421.1990.tb01054.x
   MAYER P, 1991, J INFECT DIS, V163, P584, DOI 10.1093/infdis/163.3.584
   Pascu C, 1996, CURR MICROBIOL, V32, P201, DOI 10.1007/s002849900036
   PAULSSON M, 1993, BIOMATERIALS, V14, P845, DOI 10.1016/0142-9612(93)90006-N
   PIGUET D, 1994, ACTA ONCOL, V33, P639, DOI 10.3109/02841869409121775
   Raad I, 1997, ANN INTERN MED, V127, P267, DOI 10.7326/0003-4819-127-4-199708150-00002
   RIBER U, 1993, APMIS, V101, P55, DOI 10.1111/j.1699-0463.1993.tb00081.x
   ROBERTS PJ, 1990, J LEUKOCYTE BIOL, V48, P247
   ROILIDES E, 1991, J INFECT DIS, V163, P579, DOI 10.1093/infdis/163.3.579
   Rozalska B, 1996, IMMUNOL LETT, V49, P99, DOI 10.1016/0165-2478(95)02489-1
   Rozalska B, 1996, MICROBIOL IMMUNOL, V40, P931, DOI 10.1111/j.1348-0421.1996.tb01162.x
   ROZALSKA B, 1995, FEMS IMMUNOL MED MIC, V11, P307, DOI 10.1111/j.1574-695X.1995.tb00161.x
   Rozalska Barbara, 1995, Acta Microbiologica Polonica, V44, P243
   Schierholz JM, 1997, BIOMATERIALS, V18, P839, DOI 10.1016/S0142-9612(96)00199-8
   SHIMONO N, 1994, CLIN DIAGN LAB IMMUN, V1, P556
   SMITH PD, 1990, J INFECT DIS, V161, P999, DOI 10.1093/infdis/161.5.999
   WHITEOWEN C, 1993, CLIN EXP IMMUNOL, V92, P477
   YASUDA H, 1990, INFECT IMMUN, V58, P2502
NR 35
TC 1
Z9 1
U1 0
U2 0
PU GUSTAV FISCHER VERLAG
PI JENA
PA VILLENGANG 2, D-07745 JENA, GERMANY
SN 0934-8840
J9 ZBL BAKT-INT J MED M
JI Zent.bl. Bakteriol.-Int. J. Med. Microbiol. Virol. Parasitol. Infect.
   Dis.
PD OCT
PY 1998
VL 288
IS 2
BP 237
EP 251
PG 15
WC Microbiology; Virology
SC Microbiology; Virology
GA 131GN
UT WOS:000076568000009
PM 9809405
DA 2018-10-19
ER

PT J
AU Xia, HY
   Rayson, GD
AF Xia, HY
   Rayson, GD
TI Investigation of aluminum binding to a Datura innoxia material using
   Al-27 NMR
SO ENVIRONMENTAL SCIENCE & TECHNOLOGY
LA English
DT Article
ID METAL-ION-BINDING; NUCLEAR MAGNETIC-RESONANCE; CHEMICAL MODIFICATION;
   EU(III) LUMINESCENCE; BIOMASS; REMOVAL; URANIUM; SITES; SPECTROSCOPY;
   BIOMATERIAL
AB Al binding to biomaterial derived from cell wall fragments of the plant Datura innoxia has been investigated using solid-state Al-27 NMR spectroscopy. Carboxylate groups have been determined to be the responsible functionalities for Al3+ binding to this material at pH 3.5. The binding of Al3+ directly to the polysilicate structure of the immobilized biomaterial was also observed. At pH 5.0, direct binding of the Al-13(7+) polymer ion to the biomaterial was discovered. Carboxylate groups were also determined to be involved in the binding of Al3+ at pH 5.0. The presence of an additional octahedral Al-binding site was also suggested at the higher pH.
C1 New Mexico State Univ, Dept Chem & Biochem, Las Cruces, NM 88003 USA.
RP Rayson, GD (reprint author), New Mexico State Univ, Dept Chem & Biochem, Box 30001 MSC 3C, Las Cruces, NM 88003 USA.
CR AKITT JW, 1981, J CHEM SOC DALTON, P1617, DOI 10.1039/dt9810001617
   Bedell G. W., 1990, BIOSORPTION HEAVY ME, P313
   BERTSCH PM, 1986, SOIL SCI SOC AM J, V50, P825, DOI 10.2136/sssaj1986.03615995005000030051x
   COTTON FA, 1988, ADV INORGANIC CHEM, pCH7
   CRIST RH, 1981, ENVIRON SCI TECHNOL, V15, P1212, DOI 10.1021/es00092a010
   DARNALL DW, 1986, ENVIRON SCI TECHNOL, V20, P206, DOI 10.1021/es00144a018
   DELHAIZE E, 1995, PLANT PHYSIOL, V107, P315, DOI 10.1104/pp.107.2.315
   Drake LR, 1996, ENVIRON SCI TECHNOL, V30, P110, DOI 10.1021/es950131d
   Drake LR, 1996, ANAL CHEM, V68, pA22, DOI 10.1021/ac9618029
   Drake LR, 1997, APPL SPECTROSC, V51, P1476, DOI 10.1366/0003702971939253
   GALUN M, 1984, WATER AIR SOIL POLL, V21, P411, DOI 10.1007/BF00163640
   GARDEATORRESDEY JL, 1990, ENVIRON SCI TECHNOL, V24, P1372, DOI 10.1021/es00079a011
   Good N E, 1972, Methods Enzymol, V24, P53
   GOOD NE, 1966, BIOCHEMISTRY-US, V5, P467, DOI 10.1021/bi00866a011
   GRAY GA, 1995, MAGN MOMENTS, V7, P30
   HINTON JF, 1978, NMR PERIOD TABLE, P279
   Kaim W., 1994, BIOINORGANIC CHEM IN, P330
   KE HYD, 1992, ENVIRON SCI TECHNOL, V26, P782, DOI 10.1021/es00028a018
   KE HYD, 1993, ENVIRON SCI TECHNOL, V27, P2466, DOI 10.1021/es00048a024
   KE HYD, 1992, APPL SPECTROSC, V46, P479, DOI 10.1366/0003702924125258
   KE HYD, 1994, ENVIRON SCI TECHNOL, V28, P586, DOI 10.1021/es00053a009
   Kuyucak N., 1990, BIOSORPTION HEAVY ME, P173
   LUJAN JR, 1994, SOLVENT EXTR ION EXC, V12, P803, DOI 10.1080/07366299408918239
   MACFALL JS, 1995, APPL SPECTROSC, V49, P156, DOI 10.1366/0003702953963805
   Mann H, 1990, BIOSORPTION HEAVY ME, P93137
   MONCRIEF RM, 1995, SEPAR SCI TECHNOL, V30, P2421, DOI 10.1080/01496399508013120
   NAKAJIMA A, 1990, BIOMASS, V21, P55, DOI 10.1016/0144-4565(90)90047-N
   SCOTT CD, 1992, BIOTECHNOL BIOENG, V39, P1064, DOI 10.1002/bit.260391011
   SIMERAL LS, 1993, APPL SPECTROSC, V47, P1954, DOI 10.1366/0003702934065966
   TREENSEARS ME, 1984, BIOTECHNOL BIOENG, V26, P1323, DOI 10.1002/bit.260261109
   TSEZOS M, 1981, BIOTECHNOL BIOENG, V23, P583, DOI 10.1002/bit.260230309
   Volesky B., 1990, BIOSORPTION HEAVY ME, P139
   WANG HK, 1984, ENVIRON SCI TECHNOL, V18, P106, DOI 10.1021/es00120a011
   XIA HA, 1997, THESIS NEW MEXICO ST
NR 34
TC 20
Z9 21
U1 0
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0013-936X
J9 ENVIRON SCI TECHNOL
JI Environ. Sci. Technol.
PD SEP 15
PY 1998
VL 32
IS 18
BP 2688
EP 2692
DI 10.1021/es980171s
PG 5
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA 120NX
UT WOS:000075963400005
DA 2018-10-19
ER

PT J
AU Jakubiec, B
   Marois, Y
   Zhang, Z
   Roy, R
   Sigot-Luizard, MF
   Dugre, FJ
   King, MW
   Dao, L
   Laroche, G
   Guidoin, R
AF Jakubiec, B
   Marois, Y
   Zhang, Z
   Roy, R
   Sigot-Luizard, MF
   Dugre, FJ
   King, MW
   Dao, L
   Laroche, G
   Guidoin, R
TI In vitro cellular response to polypyrrole-coated woven polyester
   fabrics: Potential benefits of electrical conductivity
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE polypyrrole; polyester; conductivity; in vitro; cell culture; cell
   activation; interleukin expression
ID SYNTHETIC VASCULAR PROSTHESES; BIOMEDICAL POLYMERS; MONOCYTES
   MACROPHAGES; CYTOKINE PRODUCTION; IN-VITRO; ELECTRODES;
   POLYDIMETHYLSILOXANE; ADHESION; GLUCOSE; CELLS
AB Electrically conducting polypyrrole-treated films have recently been shown to influence the morphology and function of mammalian cells in vitro. This type of polymer represents a possible alternative biomaterial for use in vascular implantation. The present study compared the in vitro biocompatibility of five different polyester woven fabrics having increasing levels of electrical conductivity ranging from 4.5 x 10(4) to 123 Ohm/square with that of low density polyethylene and polydimethylsiloxane primary reference materials. Biocompatibility was measured in terms of four different types of in vitro cellular response, including (a) an indirect and (b) a direct control organotypic culture assay using endothelial cells, (c) a polymorphonuclear (PMN) cell activation study using flow-cytometric measurements of CD11/CD18 integrin molecule expression and (d) a semiquantification of interleukin (IL)-6 mRNA expression on monotytes/macrophages using reverse-transcriptase polymerase chain reaction. The organotypic culture study revealed that the fabrics with high levels of conductivity exhibited lower cell migration, proliferation, and viability. The PMN activation study of blood from 10 healthy adult donors demonstrated that the two most conductive fabrics were able to identify the more reactive donors. The levels of IL-6 mRNA expression by monocytes/macrophages decreased as the conductivity level of the fabrics increased. The results of the present study therefore indicate that high levels of conductivity (<200 Ohm/square) on polyester fabrics are detrimental to the growth, migration, and viability of endothelial cells; induce elevated PMN activation; and affect the intracellular metabolism of monocytes. They also point to a specific range of conductivity (10(3) < 10(4) Ohm n/square) which is associated with an optimum in vitro cellular response. (C) 1998 John Wiley & Sons, Inc. J Biomed Mater Res, 41, 519-526, 1998.
C1 CHU Quebec, Ctr Rech Rhumatol & Immunol, Quebec City, PQ, Canada.
   CHU Quebec, Inst Biomat Quebec Inc, Quebec City, PQ, Canada.
   Univ Laval, Fac Med, Dept Chirurg, Quebec City, PQ G1K 7P4, Canada.
   Univ Technol Compiegne, Dept Genie Biol, Compiegne, France.
   Univ Manitoba, Dept Clothing & Text, Winnipeg, MB, Canada.
   INRS Energie & Mat, Varennes, PQ, Canada.
RP Guidoin, R (reprint author), Univ Laval, Expt Surg Lab, Room 1701,Serv Bldg, St Foy, PQ G1K 7P4, Canada.
RI Zhang, Ze/A-7902-2008
CR ANDERSON JM, 1988, T AM SOC ART INT ORG, V34, P101
   BONFIELD TL, 1991, J BIOMED MATER RES, V25, P165, DOI 10.1002/jbm.820250204
   BONFIELD TL, 1992, J BIOMED MATER RES, V26, P837, DOI 10.1002/jbm.820260702
   BONFIELD TL, 1993, J BIOMED MATER RES, V27, P1195, DOI 10.1002/jbm.820270910
   BORDENAVE L, 1992, J BIOMAT SCI-POLYM E, V3, P509, DOI 10.1163/156856292X00475
   DEFIFE KM, 1995, J BIOMED MATER RES, V29, P431, DOI 10.1002/jbm.820290403
   DUVAL JL, 1988, BIOMATERIALS, V9, P155, DOI 10.1016/0142-9612(88)90115-9
   ERTEL SI, 1994, J BIOMED MATER RES, V28, P667, DOI 10.1002/jbm.820280603
   FORTIER G, 1990, BIOSENS BIOELECTRON, V5, P473, DOI 10.1016/0956-5663(90)80036-D
   GAO ZQ, 1994, ANALYST, V119, P459, DOI 10.1039/an9941900459
   GREGORY RL, 1991, PERCEPTION, V20, P1
   HORII Y, 1988, J IMMUNOL, V141, P1529
   Jakubiec B, 1994, ASAIO J, V40, pM616, DOI 10.1097/00002480-199407000-00072
   KAO WYJ, 1994, J BIOMED MATER RES, V28, P73, DOI 10.1002/jbm.820280110
   KUHN HH, 1991, TECH PAP SOC PLAST E, V37, P760
   LAGOODEENADAYALAN S, 1993, LYMPHOKINE CYTOK RES, V12, P59
   LIAN A, IN PRESS CONDUCTING
   Marois Y, 1996, BIOMATERIALS, V17, P1835, DOI 10.1016/0142-9612(95)00245-6
   MCFAUL SJ, 1990, J IMMUNOL METHODS, V130, P15, DOI 10.1016/0022-1759(90)90293-5
   MILLER KM, 1988, J BIOMED MATER RES, V22, P713, DOI 10.1002/jbm.820220805
   PETILLO O, 1994, J BIOMED MATER RES, V28, P635, DOI 10.1002/jbm.820280514
   ROITT Y, 1991, ESSENTIAL IMMUNOLOGY
   ROTH S, 1993, SYNTHETIC MET, V57, P3623, DOI 10.1016/0379-6779(93)90487-H
   SALTHOUSE TN, 1984, J BIOMED MATER RES, V18, P395, DOI 10.1002/jbm.820180407
   Selampinar F, 1997, BIOMATERIALS, V18, P1163, DOI 10.1016/S0142-9612(97)00056-2
   SPILIZEWSKI KL, 1987, BIOMATERIALS, V8, P12, DOI 10.1016/0142-9612(87)90021-4
   SUN ZS, 1992, ANAL CHEM, V64, P1112, DOI 10.1021/ac00034a008
   TROJANOWICZ M, 1990, BIOSENS BIOELECTRON, V5, P149, DOI 10.1016/0956-5663(90)80005-X
   VONRECUM AF, 1995, J BIOMAT SCI-POLYM E, V7, P181, DOI 10.1163/156856295X00698
   WITKOWSKI A, 1992, ANAL CHEM, V64, P635, DOI 10.1021/ac00030a012
   WITKOWSKI A, 1991, ANAL CHEM, V63, P622, DOI 10.1021/ac00006a013
   WONG JY, 1994, P NATL ACAD SCI USA, V91, P3201, DOI 10.1073/pnas.91.8.3201
   WONG JY, 1993, MATER RES SOC SYMP P, V293, P179
   YUN JK, 1995, J BIOMED MATER RES, V29, P257, DOI 10.1002/jbm.820290217
   ZHANG WB, 1990, J INORG BIOCHEM, V40, P189, DOI 10.1016/0162-0134(90)80052-Y
NR 35
TC 48
Z9 50
U1 0
U2 12
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD SEP 15
PY 1998
VL 41
IS 4
BP 519
EP 526
DI 10.1002/(SICI)1097-4636(19980915)41:4<519::AID-JBM2>3.0.CO;2-F
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 104KM
UT WOS:000075013600002
PM 9697023
DA 2018-10-19
ER

PT J
AU Razatos, A
   Ong, YL
   Sharma, MM
   Georgiou, G
AF Razatos, A
   Ong, YL
   Sharma, MM
   Georgiou, G
TI Molecular determinants of bacterial adhesion monitored by atomic force
   microscopy
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; OUTER-MEMBRANE; SURFACES;
   BINDING; LIPOPOLYSACCHARIDES; BIOFILMS; PROTEIN; MUCOIDY; MDCK
AB Bacterial adhesion and the subsequent formation of biofilm are major concerns in biotechnology and medicine. The initial step in bacterial adhesion is the interaction of cells with a surface, a process governed by long-range forces, primarily van der Waals and electrostatic interactions. The precise manner in which the force of interaction is affected by cell surface components and by the physiochemical properties of materials is not well understood. Here, we show that atomic force microscopy can be used to analyze the initial events in bacterial adhesion with unprecedented resolution. Interactions between the cantilever tip and confluent monolayers of isogenic strains of Escherichia coli mutants exhibiting subtle differences in cell surface composition were measured. It was shown that the adhesion force is affected by the length of core lipopolysaccharide molecules on the E. coli cell surface and by the production of the capsular polysaccharide, colanic acid. Furthermore, by modifying the atomic force microscope tip we developed a method for determining whether bacteria are attracted or repelled by virtually any biomaterial elf interest. This information will be critical for the design of materials that are resistant to bacterial adhesion.
C1 Univ Texas, Dept Chem Engn, Austin, TX 78712 USA.
   Univ Texas, Dept Petr Engn, Austin, TX 78712 USA.
   Univ Texas, Inst Mol & Cell Biol, Austin, TX 78712 USA.
RP Georgiou, G (reprint author), Univ Texas, Dept Chem Engn, Austin, TX 78712 USA.
EM gg@che.utexas.edu
CR Basu S, 1996, J COLLOID INTERF SCI, V181, P443, DOI 10.1006/jcis.1996.0401
   BIGGS S, 1995, LANGMUIR, V11, P156, DOI 10.1021/la00001a028
   BOLAND T, 1995, P NATL ACAD SCI USA, V92, P5297, DOI 10.1073/pnas.92.12.5297
   BOMAN HG, 1975, J BACTERIOL, V121, P455
   Brock T.D., 1994, BIOL MICROORGANISMS
   BrowningKelley ME, 1997, LANGMUIR, V13, P343, DOI 10.1021/la960918x
   BRYERS JD, 1987, BIOTECHNOL PROGR, V3, P57, DOI 10.1002/btpr.5420030202
   BUSSCHER HJ, 1984, APPL ENVIRON MICROB, V48, P980
   BUTT HJ, 1995, BIOELECTROCH BIOENER, V38, P191, DOI 10.1016/0302-4598(95)01800-T
   Chilkoti A, 1995, BIOPHYS J, V69, P2125, DOI 10.1016/S0006-3495(95)80083-4
   CHRISTENSEN GD, 1995, METHOD ENZYMOL, V253, P477
   COSTERTON JW, 1995, ANNU REV MICROBIOL, V49, P711, DOI 10.1146/annurev.mi.49.100195.003431
   CURTIS FC, 1996, ESCHERICHIA COLI SAL
   DERETIC V, 1993, BIO-TECHNOL, V11, P1133, DOI 10.1038/nbt1093-1133
   DUCKER WA, 1994, LANGMUIR, V10, P3279, DOI 10.1021/la00021a061
   ELGAVISH A, 1993, INFECT IMMUN, V61, P3304
   ERIKSSON.KG, 1971, J BACTERIOL, V108, P1210
   FILIP C, 1973, J BACTERIOL, V115, P717
   FLETCHER M, 1985, J COLLOID INTERF SCI, V140, P5
   FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628
   Freeman A, 1996, BIOTECHNOL BIOENG, V52, P625, DOI 10.1002/(SICI)1097-0290(19961205)52:5<625::AID-BIT10>3.3.CO;2-O
   GOLDMANN WH, 1996, EXP CELL RES, V226, P226
   GOTTESMAN S, 1991, MOL MICROBIOL, V5, P1599, DOI 10.1111/j.1365-2958.1991.tb01906.x
   GRISTINA AG, 1987, SCIENCE, V237, P1588, DOI 10.1126/science.3629258
   HANSMA HG, 1994, ANNU REV BIOPH BIOM, V23, P115, DOI 10.1146/annurev.bb.23.060194.000555
   HAVEKES L, 1977, J BACTERIOL, V129, P1
   HOH JH, 1994, J CELL SCI, V107, P1105
   INOUYE M, 1969, P NATL ACAD SCI USA, V64, P957, DOI 10.1073/pnas.64.3.957
   Klein NJ, 1996, J INFECT DIS, V173, P172, DOI 10.1093/infdis/173.1.172
   Klotz SA, 1990, MICROBIAL CELL SURFA, P107
   LEE GU, 1994, SCIENCE, V266, P771, DOI 10.1126/science.7973628
   Lee H. B., 1995, BIOMEDICAL ENG HDB, P581
   Loosdrecht M. C. M. V., 1987, APPL ENVIRON MICROB, V53, P1898
   LUGTENBERG B, 1983, BIOCHIM BIOPHYS ACTA, V737, P51, DOI 10.1016/0304-4157(83)90014-X
   LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9
   MOZCS N, 1987, BIOTECHNOL BIOENG, V30, P439
   MULHERN PJ, 1992, ULTRAMICROSCOPY, V42, P1214, DOI 10.1016/0304-3991(92)90426-K
   NIKAIDO H, 1987, ESCHERICHIA COLI SAL, P7
   OFCK I, 1994, BACTERIAL ADHESION C
   RADMACHER M, 1994, LANGMUIR, V10, P3809, DOI 10.1021/la00022a068
   Raetz C. R. H., 1987, ESCHERICHIA COLI SAL, P498
   Rick P. D., 1987, ESCHERICHIA COLI SAL, P648
   Roberts IS, 1996, ANNU REV MICROBIOL, V50, P285, DOI 10.1146/annurev.micro.50.1.285
   ROONEY SA, 1972, J BACTERIOL, V111, P531
   SCHOENENBERGER CA, 1994, BIOPHYS J, V67, P929, DOI 10.1016/S0006-3495(94)80556-9
   SCHURR MJ, 1995, J BACTERIOL, V177, P5670, DOI 10.1128/jb.177.19.5670-5679.1995
   SENDEN TJ, 1995, COLLOID SURFACE A, V94, P29, DOI 10.1016/0927-7757(94)02954-Q
   STICKLER DJ, 1995, CELL MATER, V5, P167
   STOUT V, 1990, J BACTERIOL, V172, P659, DOI 10.1128/jb.172.2.659-669.1990
   VALKONEN KH, 1991, MOL MICROBIOL, V5, P2133, DOI 10.1111/j.1365-2958.1991.tb02143.x
   VONOSS CJ, 1991, BIOFOULING, V4, P25
   Yoon RH, 1997, J COLLOID INTERF SCI, V185, P363, DOI 10.1006/jcis.1996.4583
NR 52
TC 278
Z9 285
U1 5
U2 84
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 15
PY 1998
VL 95
IS 19
BP 11059
EP 11064
DI 10.1073/pnas.95.19.11059
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 120LD
UT WOS:000075957100012
PM 9736689
OA Bronze, Green Published
DA 2018-10-19
ER

PT J
AU Li, PJ
   Ducheyne, P
AF Li, PJ
   Ducheyne, P
TI Quasi-biological apatite film induced by titanium in a simulated body
   fluid
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE apatite; titanium; biomimetic coating; bioactivity; bioactive surface
ID CALCIUM-PHOSPHATE FORMATION; HYDROGEN-PEROXIDE; STAINLESS-STEEL;
   IN-VIVO; INTERFACE; IMPLANTS; BONE; ENVIRONMENT; BIOMATERIAL; CERAMICS
AB Commercially pure titanium (c.p.Ti) is capable of inducing the formation of a carbonated apatite onto its surface in a simulated body fluid (SBF) comprised of calcium ions, phosphate ions, and other inorganic species present in the body fluid. Ln addition to the incorporation of carbonate ions, such formed apatite has other important characteristics of the bone mineral phase, such as a small crystal size and ionic substitution by Mg2+ and Cl-. Thus, we call this apatite a quasi-biological apatite. The formation of the quasi-biological apatite is proposed to be related to TiOH groups that develop on the titanium surface through interaction with the SBF. The results suggest that titanium implants may be activated such that they can form a strong bond with bone tissue through the in vivo formation of apatite. Since the solution can reach any open space, the process discussed in this study is very suitable for coating porous titanium implants with a quasi-biological apatite film. (C) 1998 John Wiley & Sons, Inc.
C1 Univ Penn, Dept Bioengn, Philadelphia, PA 19108 USA.
RP Li, PJ (reprint author), Johnson & Johnson Profess Inc, Dept Appl Res, 325 Paramount Dr, Raynham, MA 02767 USA.
FU NIAMS NIH HHS [AR-40194]
CR ALBREKTSSON T, 1986, BIOMATERIALS, V7, P201, DOI 10.1016/0142-9612(86)90103-1
   ALBREKTSSON T, 1983, ANN BIOMED ENG, V11, P1, DOI 10.1007/BF02363944
   ALBREKTSSON T, 1982, CLIN APPL BIOMATERIA, P167
   BRANEMARK PI, 1983, J PROSTHET DENT, V50, P399, DOI 10.1016/S0022-3913(83)80101-2
   Campbell AA, 1996, J BIOMED MATER RES, V32, P111, DOI 10.1002/(SICI)1097-4636(199609)32:1<111::AID-JBM13>3.0.CO;2-P
   DACULSI G, 1990, CALCIFIED TISSUE INT, V46, P20, DOI 10.1007/BF02555820
   DUCHEYNE P, 1986, BIOMATERIALS, V7, P97, DOI 10.1016/0142-9612(86)90063-3
   Ducheyne P., 1992, BONE BONDING BIOMATE, P13
   DUCHEYNE P, 1992, BONE BONDING BIOMATE, P13
   FOWLER BO, 1974, INORG CHEM, V13, P194, DOI 10.1021/ic50131a039
   HANAWA T, 1992, APPL SURF SCI, V55, P269, DOI 10.1016/0169-4332(92)90178-Z
   HANAWA T, 1991, BIOMATERIALS, V12, P767, DOI 10.1016/0142-9612(91)90028-9
   HANSSON HA, 1983, J PROSTHET DENT, V50, P108, DOI 10.1016/0022-3913(83)90175-0
   HEALY KE, 1992, J BIOMED MATER RES, V26, P319, DOI 10.1002/jbm.820260305
   Hench L.L., 1991, J AM CERAM SOC, V74, P1482
   KASEMO B, 1983, J PROSTHET DENT, V49, P832, DOI 10.1016/0022-3913(83)90359-1
   KOKUBO T, 1991, BIOMATERIALS, V12, P155, DOI 10.1016/0142-9612(91)90194-F
   Kokubo T, 1996, J AM CERAM SOC, V79, P1127, DOI 10.1111/j.1151-2916.1996.tb08561.x
   KOKUBO T, 1990, J BIOMED MATER RES, V24, P721, DOI 10.1002/jbm.820240607
   LEITAO E, 1995, MAT MED, V6, P849
   Li P, 1997, J BIOMED MATER RES, V34, P79, DOI 10.1002/(SICI)1097-4636(199701)34:1<79::AID-JBM11>3.0.CO;2-K
   LI PJ, 1994, J BIOMED MATER RES, V28, P7, DOI 10.1002/jbm.820280103
   LI PJ, 1995, J BIOMED MATER RES, V29, P325, DOI 10.1002/jbm.820290307
   LI PJ, 1993, J BIOMED MATER RES, V27, P1495, DOI 10.1002/jbm.820271205
   Murai K, 1996, J BIOMED MATER RES, V30, P523, DOI 10.1002/(SICI)1097-4636(199604)30:4<523::AID-JBM11>3.3.CO;2-6
   Pan J, 1996, J BIOMED MATER RES, V30, P393
   PAN J, 1994, J BIOMED MATER RES, V28, P113, DOI 10.1002/jbm.820280115
   REY C, 1991, CALCIFIED TISSUE INT, V49, P259, DOI 10.1007/BF02556215
   SENNERBY L, 1992, J MATER SCI-MATER M, V3, P262, DOI 10.1007/BF00705291
   STEFLIK DE, 1993, J BIOMED MATER RES, V27, P791, DOI 10.1002/jbm.820270612
   SUNDGREN JE, 1986, J COLLOID INTERF SCI, V110, P9, DOI 10.1016/0021-9797(86)90348-6
   TAKATSUKA K, 1995, J BIOMED MATER RES, V29, P157, DOI 10.1002/jbm.820290204
   TENGVALL P, 1992, Clinical Materials, V9, P115, DOI 10.1016/0267-6605(92)90056-Y
NR 33
TC 122
Z9 125
U1 0
U2 7
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD SEP 5
PY 1998
VL 41
IS 3
BP 341
EP 348
DI 10.1002/(SICI)1097-4636(19980905)41:3<341::AID-JBM1>3.0.CO;2-C
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA ZX504
UT WOS:000074523300001
PM 9659601
DA 2018-10-19
ER

PT J
AU Rad, AY
   Ayhan, H
   Piskin, E
AF Rad, AY
   Ayhan, H
   Piskin, E
TI Adhesion of different bacterial strains to low-temperature
   plasma-treated sutures
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE contact angles, adherence to rho-xylene; zeta potentials and surface
   charges of bacteria, sutures, low-temperature plasma treatment;
   bacterial attachment
ID COAGULASE-NEGATIVE STAPHYLOCOCCI; CELL-SURFACE HYDROPHOBICITY;
   ADHERENCE; INVITRO; EPIDERMIDIS; BIOMATERIAL; INFECTIONS; PREVENTION;
   ENERGY
AB In this study, five different bacteria with their different strains were isolated and characterized. Contact angles were measured by a captive-bubble technique. Surface-free energies were calculated from the contact angles. Hydrophobicities also were evaluated by rho-xylene adhesion. The zeta potentials and surface charges of the bacteria were obtained. The contact angles of the gram-positive bacteria and gram-negative bacteria were within the range of 48 degrees-69 degrees and 43.5 degrees-55 degrees, respectively, while corresponding surface-free energies were in the limits of 45.4-51.6 erg/cm(-2) and 51.7-61.8 erg/cm-2 respectively. The p-xylene adhesions were parallel to hydrophobicities defined by contact angles, and 32.2-80.3% and 2.3-36.6% for the gram-positive bacteria and,gram-negative bacteria, respectively. The zeta potentials for these bacteria were from -650.2 to +17.5 mV and from -159.6 to -6.0 mV, respectively. Most of the bacteria were negatively charged, except the CNS-2 and CPS-1 strains. In the second part of the study, attachment of these bacteria to Vicryl(R) sutures and their DMAEMA and AAc plasma-treated forms were investigated. Hydrophobic bacteria attached more to hydrophobic Vicryl(R) sutures. Both plasma treatments caused significant drops in bacterial attachment in most cases. Effects of AAc plasma treatment were more pronounced. (C) 1998 John Wiley & Sons, Inc.
C1 Hacettepe Univ, Dept Chem Engn, TR-06532 Ankara, Turkey.
   TUBITAK, Ctr Excellence Polymer Biomat, TR-06532 Ankara, Turkey.
RP Piskin, E (reprint author), Hacettepe Univ, Dept Chem Engn, TR-06532 Ankara, Turkey.
CR ALSOLOM DR, 1983, APPL MICROBOL, V46, P90
   ANDRADE JD, 1979, J POLYM SCI POL SYM, P313
   BAILEY J, 1990, DIAGNOSTIC MICROBIOL, pA37
   CHU CC, 1984, AM J SURG, V147, P197, DOI 10.1016/0002-9610(84)90088-6
   FATTOM A, 1984, APPL ENVIRON MICROB, V47, P135
   GEMMELL CG, 1988, UROL RES, V16, P381
   GOLOMB G, 1991, J BIOMED MATER RES, V25, P937, DOI 10.1002/jbm.820250803
   GORDON AS, 1984, APPL ENVIRON MICROB, V47, P495
   GRISTINA AG, 1993, INT J ARTIF ORGANS, V16, P755
   GRISTINA AG, 1987, BIOMATERIALS CLIN AP, P661
   HARKES G, 1991, BIOMATERIALS, V12, P853, DOI 10.1016/0142-9612(91)90074-K
   HOGT AH, 1986, J BIOMED MATER RES, V20, P533, DOI 10.1002/jbm.820200409
   HOGT AH, 1985, J GEN MICROBIOL, V131, P2485
   HOGT AH, 1986, INFECT IMMUN, V51, P294
   JAMES AM, 1979, SURF COLLOID SCI, V11, P174
   JANSEN B, 1990, ADV BIOMAT, V9, P117
   JOHNSON JR, 1990, J INFECT DIS, V162, P1145, DOI 10.1093/infdis/162.5.1145
   MERRITT K, 1987, BIOMATERIALS CLIN AP, P705
   MINAGI S, 1985, INFECT IMMUN, V47, P11
   MINAGI S, 1986, J GEN MICROBIOL, V132, P1111
   MOZES N, 1987, J MICROBIOL METH, V6, P99, DOI 10.1016/0167-7012(87)90058-3
   NEUMANN AW, 1974, J COLLOID INTERF SCI, V49, P291, DOI 10.1016/0021-9797(74)90365-8
   PASCUAL A, 1986, EUR J CLIN MICROBIOL, V5, P518, DOI 10.1007/BF02017694
   PERRY RH, 1985, PERRYS CHEM ENG HDB, P289
   RAD AY, 1997, THESIS U HACETTEPE A
   ROSENBERG M, 1980, FEMS MICROBIOL LETT, V9, P29, DOI 10.1111/j.1574-6968.1980.tb05599.x
   Rozalska B, 1994, Postepy Hig Med Dosw, V48, P143
   SAMUEL RF, 1990, CAN J MICROBIOL, V37, P445
   SENNETT P, 1965, Patent No. 3208919
   SHENSTROM TA, 1989, APPL ENVIRON MICROB, V55, P142
   SINGHAL JP, 1991, BIOMAT ARTIF CELL IM, V19, P631, DOI 10.3109/10731199109117841
   TANG LP, 1995, AM J CLIN PATHOL, V103, P466
   VANDERMEI HC, 1987, J MICROBIOL METH, V6, P277, DOI 10.1016/0167-7012(87)90065-0
   VANDERMEI HC, 1988, J BACTERIOL, V170, P246
   VANETTA LL, 1982, J INFECT DIS, V146, P423, DOI 10.1093/infdis/146.3.423
   VANLOOSDERCHT MCM, 1987, APPL ENVIRON MICROB, V55, P1898
   VANLOOSDRECHT MCM, 1987, APPL ENVIRON MICROB, V53, P1898
   Veenstra GJC, 1996, J BACTERIOL, V178, P537, DOI 10.1128/jb.178.2.537-541.1996
   WADSTROM T, 1987, ZBL BAKT-INT J MED M, V266, P191
   WEERKAMP AH, 1988, J DENT RES, V67, P1483, DOI 10.1177/00220345880670120801
NR 40
TC 22
Z9 22
U1 3
U2 8
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD SEP 5
PY 1998
VL 41
IS 3
BP 349
EP 358
DI 10.1002/(SICI)1097-4636(19980905)41:3<349::AID-JBM2>3.0.CO;2-C
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA ZX504
UT WOS:000074523300002
DA 2018-10-19
ER

PT J
AU Maloney, WJ
   Sun, DH
   Nakashima, Y
   James, R
   Smith, RL
AF Maloney, WJ
   Sun, DH
   Nakashima, Y
   James, R
   Smith, RL
TI Effects of serum protein opsonization on cytokine release by
   titanium-alloy particles
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE titanium alloy; particulate debris; total joint arthroplasty;
   monocytes/macrophages; cytokines; SDS-PAGE
ID WEAR; INTERFACE; BIOLOGY; BONE
AB This study tested whether macrophages respond differently to retrieved titanium-alloy particles than they do to machined titanium-alloy particles and assessed whether pretreatment of machined titanium-alloy particles with human serum would influence macrophage activation and cytokine release in vitro. Human monocyte/macrophages were isolated from normal healthy donors and exposed to increasing concentrations of machined and retrieved titanium-alloy particles. The profile of cytokine release was determined by commercially available ELISA kits. Machined titanium-alloy particles were opsonized with human serum and added to macrophage cultures. Serum protein binding was confirmed by SDS-PAGE analysis. The results showed that machined titanium-alloy particles and retrieved titanium-alloy particles stimulate a similar level of cytokine release when tested at comparable concentrations. Opsonization of the machined particles with human serum increased the macrophage release of cytokines in the first 12 h after exposure compared to nonopsonized particles. At 24 h, the opsonized particles stimulated significantly higher levels of cytokine release, but only at the greatest particle concentrations. This study demonstrates that machined titanium alloy induces a metabolic response in macrophages similar to that of titanium-alloy particles retrieved from failed total hip arthroplasty. In addition, these data show that serum protein binding to orthopedic biomaterial debris alters the macrophage reaction to the particles. (C) 1998 John Wiley & Sons, Inc.
C1 Stanford Univ, Sch Med, Orthopaed Res Lab, Stanford, CA 94305 USA.
RP Smith, RL (reprint author), Stanford Univ, Sch Med, Orthopaed Res Lab, R144,300 Pasteur Dr, Stanford, CA 94305 USA.
CR AGINS HJ, 1988, J BONE JOINT SURG AM, V70A, P347, DOI 10.2106/00004623-198870030-00005
   AKIRA S, 1990, FASEB J, V4, P2860
   ALBERT K, 1994, BIO-MED MATER ENG, V4, P199
   AMSTUTZ HC, 1976, P 4 OP SCI M HIP SOC, P102
   ANTHONY PP, 1991, J BONE JOINT SURG BR, V72, P971
   BECKENBAUGH RD, 1978, J BONE JOINT SURG AM, V60, P306, DOI 10.2106/00004623-197860030-00005
   BOUER TW, 1992, P 38 ANN M ORTH RES, V17, P354
   BRIEN WW, 1992, CLIN ORTHOP RELAT R, P66
   BUCHERT PK, 1986, J BONE JOINT SURG AM, V68A, P606, DOI 10.2106/00004623-198668040-00020
   CARLSSON AS, 1980, CLIN ORTHOP RELAT R, P262
   CHARNLEY J, 1979, LOW FRICTION ARTHROP
   CHIBA J, 1992, T ORTHOP RES SOC, V17, P350
   DEVINE TM, 1974, THESIS MIT CAMBRIDGE
   DORR LD, 1990, CLIN ORTHOP RELAT R, P82
   FREEMAN MAR, 1982, J BONE JOINT SURG BR, V64, P489
   HOROWITZ SM, 1993, J BONE JOINT SURG AM, V75A, P802, DOI 10.2106/00004623-199306000-00002
   HOWIE DW, 1988, J BONE JOINT SURG AM, V70A, P257, DOI 10.2106/00004623-198870020-00015
   Jacobs J J, 1992, Instr Course Lect, V41, P119
   JIRANEK WA, 1993, J BONE JOINT SURG AM, V75A, P863, DOI 10.2106/00004623-199306000-00007
   JOHANSON NA, 1987, CLIN ORTHOP RELAT R, P123
   KIM KJ, 1993, CLIN ORTHOP RELAT R, P142
   KISHIMOTO T, 1989, BLOOD, V74, P1
   KOBZIK L, 1993, J IMMUNOL, V151, P2753
   KOVACS P, 1992, P 38 ANN M ORTH RES, V17, P358
   KOZZIN SC, 1986, J ARTHROPLASTY, V1, P249
   Maloney WJ, 1996, CLIN ORTHOP RELAT R, P268
   MALONEY WJ, 1996, AM ACAD ORTHOP SURG, V45, P1448
   MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035
   PAROD RJ, 1986, J IMMUNOL, V136, P2041
   RIMNAC CM, 1994, J BONE JOINT SURG AM, V76A, P1052, DOI 10.2106/00004623-199407000-00014
   TAKATA K, 1988, J BIOL CHEM, V263, P14819
   WILLERT HG, 1977, J BIOMED MATER RES, V11, P157, DOI 10.1002/jbm.820110202
   WITT JD, 1991, J BONE JOINT SURG BR, V73, P559
NR 33
TC 25
Z9 25
U1 1
U2 1
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD SEP 5
PY 1998
VL 41
IS 3
BP 371
EP 376
DI 10.1002/(SICI)1097-4636(19980905)41:3<371::AID-JBM5>3.3.CO;2-A
PG 6
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA ZX504
UT WOS:000074523300005
PM 9659605
DA 2018-10-19
ER

PT J
AU Schwager, K
AF Schwager, K
TI Titanium as an ossicular replacement material - Results after 336 days
   of implantation in the rabbit
SO AMERICAN JOURNAL OF OTOLOGY
LA English
DT Article
DE titanium; middle ear; ossicular replacement; biomaterial; animal
   experiment
ID MIDDLE-EAR; CALCIUM-PHOSPHATE; OTOLOGIC SURGERY; HYDROXYLAPATITE;
   OSSICULOPLASTY; RECONSTRUCTION; TYMPANOPLASTY; PROSTHESES
AB Objective: Titanium in other parts of the body, well known for its biocompatibility, was examined in an animal model for its use as an ossicular replacement material.
   Study Design: The biocompatibility of titanium was studied in the middle ear of rabbits using light and scanning electron microscopy. Titanium pins were placed as middle ear prostheses or as free implants and were examined after 28, 84, 168, and 336 days.
   Results: After 28 days, the prostheses were covered by regular mucosa. The free implants took up to 336 days to be totally epithelialized. There were no inflammatory cells observed on the surface of the material nor were unusual amounts of fibrous tissue seen. In addition, the titanium material exhibited an affinity toward bone.
   Conclusions: The results of this animal experiment indicate that titanium is a useful material for ossicular replacement prostheses.
C1 Univ Wurzburg, Klin & Poliklin Hals Nasen & Ohrenkranke, D-97080 Wurzburg, Germany.
RP Schwager, K (reprint author), Univ Wurzburg, Klin & Poliklin Hals Nasen & Ohrenkranke, Josef Schneider Str 11, D-97080 Wurzburg, Germany.
CR ALBREKTSSON T, 1992, CLIN APP BIOMATER, P167
   COLETTI V, 1984, ACTA OTORHINOL ITAL, V4, P689
   COUSINS VC, 1987, CLIN OTOLARYNGOL, V12, P183, DOI 10.1111/j.1365-2273.1987.tb00185.x
   DARC MB, 1996, KNOCHENERSATZ MITTEL, V1, P47
   FUNASAKA S, 1984, BIOMATERIALS OTOLOGY, P281
   Geyer G, 1997, HNO, V45, P222, DOI 10.1007/s001060050108
   GEYER G, 1993, EUR ARCH OTO-RHINO-L, V250, P253
   GEYER G, 1990, THESIS WURZBURG
   GJURIC M, 1987, LARYNGO RHINO OTOL, V66, P522, DOI 10.1055/s-2007-998723
   GROTE JJ, 1984, ARCH OTOLARYNGOL, V110, P197
   GROTE JJ, 1981, ORL J OTO-RHINO-LARY, V43, P248, DOI 10.1159/000275544
   GROTE JJ, 1985, AM J OTOL, V6, P269
   GROTE JJ, 1986, ANN OTO RHINOL LARYN, V95, P1
   HOMSY CA, 1984, BIOMATERIALS OTOLOGY, P9
   HOPPE F, 1996, KNOCHENERSATZ MITTEL, V1, P104
   JAEHNE M, 1996, KNOCHENERSATZ MITTEL, V1, P63
   JAHNKE K, 1987, HNO, V35, P1
   JAHNKE K, 1980, ARCH OTO-RHINO-LARYN, V227, P624, DOI 10.1007/BF00467629
   JAHNKE K, 1979, ARCH OTO-RHINO-LARYN, V223, P373, DOI 10.1007/BF01109587
   JAHNKE K, 1984, BIOMATERIALIEN NAHTM, P66
   KERR AG, 1981, CLIN OTOLARYNGOL, V6, P187, DOI 10.1111/j.1365-2273.1981.tb01530.x
   KERR AIG, 1984, CLIN OTOLARYNGOL, V9, P361, DOI 10.1111/j.1365-2273.1984.tb01522.x
   KRUMMEL FJ, 1987, LARYNGO RHINO OTOL, V66, P409, DOI 10.1055/s-2007-998691
   KUIJPERS W, 1984, BIOMATERIALS OTOLOGY, P18
   MCELVEEN JT, 1994, OTOLARYNG CLIN N AM, V27, P777
   MCELVEEN JT, 1995, OTOLARYNG HEAD NECK, V113, P420, DOI 10.1016/S0194-5998(95)70079-X
   PLESTER D, 1981, AM J OTOL, V3, P104
   PUSALKAR A, 1991, TRANSPLANTS IMPLANTS, P104
   PUSALKAR A, 1996, KNOCHENERSATZ MITTEL, V1, P55
   RECK R, 1987, LARYNGO RHINO OTOL, V66, P373, DOI 10.1055/s-2007-998679
   Reck R, 1988, Ann N Y Acad Sci, V523, P100, DOI 10.1111/j.1749-6632.1988.tb38504.x
   RECK R, 1981, CLIN OTOLARYNGOL, V6, P63, DOI 10.1111/j.1365-2273.1981.tb01786.x
   SPECTOR M, 1984, BIOMATERIALS OTOLOGY, P29
   STEINBACH E, 1996, KNOCHENERSATZ MITTEL, V1, P58
   Stupp CH, 1996, LARYNGO RHINO OTOL, V75, P335, DOI 10.1055/s-2007-997590
   TEICHGRAEBER JF, 1983, AM J OTOL, V5, P127
   VANBLITTERSWIJK CA, 1984, BIOMATERIALS OTOLOGY, P94
   WEHRS RE, 1989, AM J OTOL, V10, P181
NR 38
TC 39
Z9 39
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0192-9763
J9 AM J OTOL
JI Am. J. Otol.
PD SEP
PY 1998
VL 19
IS 5
BP 569
EP 573
PG 5
WC Otorhinolaryngology
SC Otorhinolaryngology
GA 188RV
UT WOS:000079863000007
PM 9752962
DA 2018-10-19
ER

PT J
AU Schierholz, JM
   Rump, AFE
   Pulverer, G
   Beuth, J
AF Schierholz, JM
   Rump, AFE
   Pulverer, G
   Beuth, J
TI Anti-infective catheters: Novel strategies to prevent nosocomial
   infections in oncology
SO ANTICANCER RESEARCH
LA English
DT Review
DE oncology; catheters; antimicrobial catheters
ID CENTRAL VENOUS CATHETER; PROSPECTIVE RANDOMIZED TRIAL; EXTRACORPOREAL
   DETOXIFICATION METHODS; SILVER-IMPREGNATED CUFF; FOREIGN-BODY
   INFECTIONS; BLOOD-STREAM INFECTION; BRAIDED NYLON SUTURES;
   BACTERIAL-COLONIZATION; CANCER-PATIENTS; RISK-FACTORS
AB Intravenous access contributes significantly to the therapeutical success and to the comfort of oncologic patients. The highest risk for bloodstream infections, however, is vascular catheter-mediated. In oncology high mortality is associated with Pseudomonas aeruginosa, Candida albicans and Staphylococcus aureus sepsis. Besides established hygienic measures, the coupling or incorporation of antimicrobial substances to or into catheter materials may be a suitable way to prevent the development of catheter-associated infections. Here we present a risk- benefit evaluation of different models of antimicrobial catheter coated with silver, antiseptics or antibiotics. The controversial reports on clinical efficacy and the potential of adverse reactions due to silver and antiseptic coated catheters are discussed. The microbiological, pharmaceutical and physicochemical backgrounds of different types of coating are discussed in detail. Incorporation of antimicrobial agents into long-term silicon catheters providing a slow release of those substances through the external and internal surfaces of catheters may be the most effective technological innovation for reducing biomaterial-mediated nosocomial infections.
C1 Univ Cologne, Inst Med Microbiol & Hyg, D-50935 Cologne, Germany.
   Rhein Westfal TH Aachen, Aachen Tech Univ, Dept Anesthesiol, D-52074 Aachen, Germany.
RP Schierholz, JM (reprint author), Univ Cologne, Inst Med Microbiol, Goldenfelsstr 19-21, D-50935 Cologne, Germany.
CR ANCONA A, 1990, DERMATOL CLIN, V8, P95
   ANTHONY GG, 1987, BIOMATERIALS, V8, P423
   ARROW PM, 1993, CLIN INFECT DIS, V16, P778
   BABYCOS CR, 1993, JPEN-PARENTER ENTER, V17, P61, DOI 10.1177/014860719301700161
   Bach A, 1996, INTENS CARE MED, V22, P1066, DOI 10.1007/BF01699229
   BACH A, 1994, J ANTIMICROB CHEMOTH, V33, P969
   BAMBAUER R, 1995, INT J ARTIF ORGANS, V18, P326
   BAMBAUER R, 1995, DIALYSIS TRANSPLANT, V24, P228
   BARZA M, 1993, J ANTIMICROB CHEMOTH, V31, P17, DOI 10.1093/jac/31.suppl_D.17
   BECKER RO, 1978, J BONE JOINT SURG AM, V60, P871, DOI 10.2106/00004623-197860070-00001
   BENVENISTY AI, 1988, J SURG RES, V44, P1, DOI 10.1016/0022-4804(88)90116-3
   BERGERON MG, 1993, J ANTIMICROB CHEMOTH, V31, P113, DOI 10.1093/jac/31.suppl_D.113
   Bertoglio S, 1996, Minerva Chir, V51, P427
   BOCK SN, 1990, J CLIN ONCOL, V8, P161, DOI 10.1200/JCO.1990.8.1.161
   CARDE P, 1989, EUR J CANCER CLIN ON, V25, P939, DOI 10.1016/0277-5379(89)90151-X
   CHEUNG J, 1985, ANAESTH INTENS CARE, V13, P429
   CHRISTENSEN GD, 1993, HOSP PRACT, V30, P27
   CHU CC, 1987, J BIOMED MATER RES, V21, P1281, DOI 10.1002/jbm.820211102
   CHUANG JH, 1991, JPEN-PARENTER ENTER, V15, P173, DOI 10.1177/0148607191015002173
   Ciresi DL, 1996, AM SURGEON, V62, P641
   CIVETTA JM, 1996, CRIT CARE MED, V24
   CLARKE DE, 1990, CHEST, V97, P966, DOI 10.1378/chest.97.4.966
   *COLL MACM CAN INC, 1985, GOODM GILM PHARM BAS, P963
   COLMANO G, 1980, AM J VET RES, V41, P964
   COSTERTON JW, 1987, ANNU REV MICROBIOL, V41, P435, DOI 10.1146/annurev.mi.41.100187.002251
   DAHLBERG PJ, 1995, INFECT CONT HOSP EP, V16, P506
   DEITCH EA, 1983, ANTIMICROB AGENTS CH, V23, P356, DOI 10.1128/AAC.23.3.356
   DUMITRIU S, 1989, COLLOID POLYM SCI, V267, P595, DOI 10.1007/BF01410436
   EARLY TF, 1990, SOUTHERN MED J, V83, P34, DOI 10.1097/00007611-199001000-00010
   ELLIS M, 1988, J INFECT DIS, V158, P1268, DOI 10.1093/infdis/158.6.1268
   Ellis ME, 1996, SCAND J INFECT DIS, V28, P91, DOI 10.3109/00365549609027157
   FALONE AE, 1983, PLAST RECONSTRUC SUR, V77, P455
   FISHER AA, 1989, CUTIS, V43, P17
   FLOWERS RH, 1989, JAMA-J AM MED ASSOC, V261, P878, DOI 10.1001/jama.261.6.878
   FURR JR, 1994, J HOSP INFECT, V27, P201, DOI 10.1016/0195-6701(94)90128-7
   Gabler W L, 1987, J Oreg Dent Assoc, V56, P24
   GABLER WL, 1987, J PERIODONTAL RES, V22, P150, DOI 10.1111/j.1600-0765.1987.tb01555.x
   GABLER WL, 1987, J PERIODONTAL RES, V22, P445, DOI 10.1111/j.1600-0765.1987.tb02053.x
   GIRVENT M, 1995, ANN SURG, V221, P115
   GLEESON NC, 1993, GYNECOL ONCOL, V51, P372, DOI 10.1006/gyno.1993.1306
   GUGGENBICHLER JP, 1992, EUR J CLIN MICROBIOL, V11, P408, DOI 10.1007/BF01961855
   GUTSCHIK E, 1993, J ANTIMICROB CHEMOTH, V31, P87, DOI 10.1093/jac/31.suppl_D.87
   HAMPL J, 1995, ACTA NEUROCHIR, V133, P147, DOI 10.1007/BF01420065
   HARLE DG, 1985, BRIT J ANAESTH, V57, P1073, DOI 10.1093/bja/57.11.1073
   HEARD SO, 1997, CRIT CARE MED, V25
   HOWELL PB, 1995, CANCER, V75, P1367, DOI 10.1002/1097-0142(19950315)75:6<1367::AID-CNCR2820750620>3.0.CO;2-Z
   JANSEN B, 1992, J ANTIMICROB CHEMOTH, V30, P135, DOI 10.1093/jac/30.2.135
   JANSEN B, 1992, J HOSP INFECT, V22, P93, DOI 10.1016/0195-6701(92)90093-2
   Jarvis WR, 1991, AM J MED, V91, P1855
   KAMAL GD, 1991, JAMA-J AM MED ASSOC, V265, P2364, DOI 10.1001/jama.265.18.2364
   KINGSTON D, 1992, J HOSP INFECT, V20, P257, DOI 10.1016/0195-6701(92)90004-6
   KINGSTON D, 1990, J HOSP INFECT, V16, P271, DOI 10.1016/0195-6701(90)90116-6
   KLEMPNER MS, 1990, NEW ENGL J MED, V322, P959, DOI 10.1056/NEJM199004053221404
   Kohnen W, 1996, BIOTECHNOLOGY BIOACT, P317
   KROHANE PP, 1983, LANCET, V2, P1388
   Kruse J A, 1993, Nutr Clin Pract, V8, P163, DOI 10.1177/0115426593008004163
   KURKCHUBASCHE AG, 1992, ARCH SURG-CHICAGO, V127, P21
   LAWES EG, 1993, ANAESTHESIA, V48, P446, DOI 10.1111/j.1365-2044.1993.tb07037.x
   Laxenaire M C, 1985, Ann Fr Anesth Reanim, V4, P158, DOI 10.1016/S0750-7658(85)80192-1
   LAXENAIRE MC, 1982, KLIN WOCHENSCHR, V60, P1006, DOI 10.1007/BF01716963
   LAYTON GT, 1989, CLIN EXP ALLERGY, V19, P307, DOI 10.1111/j.1365-2222.1989.tb02388.x
   Lemmers NWM, 1996, J CLIN ONCOL, V14, P2916, DOI 10.1200/JCO.1996.14.11.2916
   LIEDBERG H, 1990, BRIT J UROL, V65, P379, DOI 10.1111/j.1464-410X.1990.tb14760.x
   Logghe C, 1997, J HOSP INFECT, V37, P145, DOI 10.1016/S0195-6701(97)90184-5
   MAKI DG, 1981, AM J MED, V70, P719, DOI 10.1016/0002-9343(81)90603-3
   MAKI DG, 1988, AM J MED, V85, P307, DOI 10.1016/0002-9343(88)90579-7
   Maki DG, 1997, ANN INTERN MED, V127, P257, DOI 10.7326/0003-4819-127-4-199708150-00001
   Maki DG, 1989, INFECT ASS INDWELLIN, P161
   MCLEAN RJC, 1993, CAN J MICROBIOL, V39, P895, DOI 10.1139/m93-134
   MERMEL LA, 1991, AM J MED, V91, pS197, DOI 10.1016/0002-9343(91)90369-9
   MERMEL LA, 1993, J INFECT DIS, V167, P920, DOI 10.1093/infdis/167.4.920
   MIRRO J, 1990, J PEDIATR SURG, V25, P122
   MITCHELL DJ, 1993, BRIT J UROL, V71, P613, DOI 10.1111/j.1464-410X.1993.tb16038.x
   MODAK SM, 1992, COMPLICATION SURG, V11, P23
   MORO ML, 1994, INFECT CONT HOSP EP, V15, P253
   MUELLER BU, 1992, J CLIN ONCOL, V10, P1943, DOI 10.1200/JCO.1992.10.12.1943
   MURPHY PM, 1988, J INFECT DIS, V158, P627, DOI 10.1093/infdis/158.3.627
   NOSHER JL, 1990, CARDIOVASC INTER RAD, V13, P102, DOI 10.1007/BF02577362
   NYSTROM B, 1983, J HOSP INFECT, V4, P338, DOI 10.1016/0195-6701(83)90004-X
   OKEEFE SJD, 1994, JPEN-PARENTER ENTER, V18, P256, DOI 10.1177/0148607194018003256
   OLANOFF LS, 1979, T AM SOC ART INT ORG, V25, P334
   Pemberton LB, 1996, ARCH SURG-CHICAGO, V131, P986
   PETERS G, 1982, J INFECT DIS, V146, P479, DOI 10.1093/infdis/146.4.479
   Pittet D, 1994, JAMA-J AM MED ASSOC, V272, P1819
   PRESS OW, 1984, MEDICINE, V63, P189, DOI 10.1097/00005792-198407000-00001
   Raad I, 1996, J INFECT DIS, V173, P495, DOI 10.1093/infdis/173.2.495
   Raad I, 1996, J INFECT DIS, V173, P418, DOI 10.1093/infdis/173.2.418
   RAAD I, 1995, ANTIMICROB AGENTS CH, V39, P2397, DOI 10.1128/AAC.39.11.2397
   RAAD I, 1997, ANN INTERN MED, V15, P1
   RAMSELAAR CG, 1992, BRIT J UROL, V70, P451, DOI 10.1111/j.1464-410X.1992.tb15813.x
   REYNOLDS JEF, 1993, MARTINDALE EXTRA PHA, V1412, P788
   RILEY DM, 1995, AM J MED, V98, P349, DOI 10.1016/S0002-9343(99)80313-1
   ROTSTEIN C, 1995, INFECT CONT HOSP EP, V16, P451
   RUNGBY J, 1990, DAN MED BULL, V37, P442
   RUNGBY J, 1987, ARCH TOXICOL, V61, P40, DOI 10.1007/BF00324546
   RUNGBY J, 1987, ARCH TOXICOL, V59, P408, DOI 10.1007/BF00316206
   RUNGBY J, 1986, EXP MOL PATHOL, V45, P22, DOI 10.1016/0014-4800(86)90003-1
   SALZMAN MB, 1993, J INFECT DIS, V167, P487, DOI 10.1093/infdis/167.2.487
   SAMPATH LA, 1995, J HOSP INFECT, V30, P201, DOI 10.1016/S0195-6701(95)90315-1
   SCHAEFFER AJ, 1988, J UROLOGY, V139, P69, DOI 10.1016/S0022-5347(17)42295-6
   SCHIERHOLZ J, 1994, BIOMATERIALS, V15, P996, DOI 10.1016/0142-9612(94)90080-9
   Schierholz JM, 1997, BIOMATERIALS, V18, P839, DOI 10.1016/S0142-9612(96)00199-8
   Schierholz JM, 1998, ZBL BAKT-INT J MED M, V287, P411
   Schierholz JM, 1997, ZBL BAKT-INT J MED M, V286, P107
   Schierholz JM, 1996, ZBL BAKT-INT J MED M, V284, P390
   Schierholz JM, 1997, ARZNEIMITTEL-FORSCH, V47, P70
   Schierholz JM, 1990, NEW POLYMER MAT, V3, P61
   SEAL DV, 1990, PATHOGENESIS OF WOUND AND BIOMATERIAL-ASSOCIATED INFECTIONS, P501
   SEGURA M, 1989, J CLIN MICROBIOL, V27, P2656
   Segura M, 1996, ANN SURG, V223, P363, DOI 10.1097/00000658-199604000-00004
   SHERERTZ RJ, 1989, ANTIMICROB AGENTS CH, V33, P1174, DOI 10.1128/AAC.33.8.1174
   Sherertz RJ, 1997, J CLIN MICROBIOL, V35, P641
   SHERERTZ RJ, 1993, J INFECT DIS, V167, P98, DOI 10.1093/infdis/167.1.98
   SHETH NK, 1985, LANCET, V2, P1266
   Simionescu C. I., 1985, MAKROMOL CHEM S, V9, P179
   SIOSHANSI P, 1994, ARTIF ORGANS, V18, P266, DOI 10.1111/j.1525-1594.1994.tb02193.x
   SITGESSERRA A, 1995, AM J INFECT CONTROL, V23, P310, DOI 10.1016/0196-6553(95)90062-4
   SITGESSERRA A, 1985, SURGERY, V97, P355
   Solomon DD, 1987, J CONTROL RELEASE, P343
   SOLOVSKIJ MV, 1983, BIOMATERIALS, V4, P44, DOI 10.1016/0142-9612(83)90069-8
   SPADARO JA, 1986, J BIOMED MATER RES, V20, P565, DOI 10.1002/jbm.820200504
   Spanik S, 1997, SUPPORT CARE CANCER, V5, P330, DOI 10.1007/s005200050083
   SUDMANN E, 1985, ACTA ORTHOP SCAND, V56, P534
   TEBBS SE, 1994, EUR J CLIN MICROBIOL, V13, P111, DOI 10.1007/BF01982182
   TEBBS SE, 1993, J ANTIMICROB CHEMOTH, V31, P261, DOI 10.1093/jac/31.2.261
   Tennenberg S, 1997, ARCH SURG-CHICAGO, V132, P1348
   TROOSKIN SZ, 1985, SURGERY, V97, P547
   TROOSKIN SZ, 1990, PERITON DIALYSIS INT, V10, P57
   TSAI WC, 1987, SURG GYNECOL OBSTET, V165, P207
   Velasco E, 1997, AM J INFECT CONTROL, V25, P458, DOI 10.1016/S0196-6553(97)90067-5
   Vlasveld L T, 1994, Eur J Surg Oncol, V20, P122
   WIDMER AF, 1993, PREVENTION CONTROL N, P556
   WILLIAMS RL, 1988, BIOMATERIALS, V9, P206, DOI 10.1016/0142-9612(88)90085-3
NR 133
TC 16
Z9 18
U1 0
U2 1
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDNTIOU-KALAMOU RD KAPANDRITI, POB 22,
   ATHENS 19014, GREECE
SN 0250-7005
J9 ANTICANCER RES
JI Anticancer Res.
PD SEP-OCT
PY 1998
VL 18
IS 5B
BP 3629
EP 3638
PG 10
WC Oncology
SC Oncology
GA 148KN
UT WOS:000077504500001
PM 9854469
DA 2018-10-19
ER

PT J
AU Corry, DC
   DeLucia, A
   Zhu, H
   Radcliffe, RR
   Brevetti, GR
   El-Khatib, H
   Vance, SJ
   Moyer, BR
   Cotts, WG
   Richenbacher, WE
AF Corry, DC
   DeLucia, A
   Zhu, H
   Radcliffe, RR
   Brevetti, GR
   El-Khatib, H
   Vance, SJ
   Moyer, BR
   Cotts, WG
   Richenbacher, WE
TI Time course of cytokine release and complement activation after
   implantation of the HeartMate left ventricular assist device
SO ASAIO JOURNAL
LA English
DT Article; Proceedings Paper
CT 44th Annual Conference of the
   American-Society-for-Artificial-Internal-Organs
CY APR 23-25, 1998
CL NEW YORK, NY
SP Amer Soc Artificial Internal Organs
ID SYSTEMIC INFLAMMATORY RESPONSE; ENDOTHELIAL-CELL INJURY; CARDIOPULMONARY
   BYPASS; CARDIOVASCULAR-SURGERY; INTERLEUKIN-6; SEPSIS; DYSFUNCTION; C3A;
   TRANSPLANTATION; STRATEGIES
AB Pro-inflammatory mediators, including interleukin-6 (IL-6), IL-8, and complement C3a, are released after cardiac surgery as part of the inflammatory response related to blood-biomaterial interaction in the cardiopulmonary bypass circuit. Post operative time course data for these mediators are not fully defined in patients receiving left ventricular assist device (LVAD) support. The authors performed enzyme linked immunosorbent assays for concentrations of IL-6, IL-8, and C3a in plasma in six HeartMate(R) LVAD recipients at the following times: pre operatively; 4, 8, 16, 24, 36, and 48 hr post operatively; daily through the first week; and weekly thereafter for 6 weeks. All patients survived without major complications during the study. Pre operative concentrations of IL-6 and C3a in plasma were significantly increased compared with age matched controls. Post operatively, the concentrations of IL-6 and IL-8 in plasma took longer to return to baseline values after insertion of the LVAD than the trends reported in the literature after routine cardiopulmonary bypass alone. Concentrations of IL-6 and complement C3a continued to decrease to lower than baseline post operatively, reaching statistical significance after 6 weeks of LVAD support. The authors conclude that the presence of the HeartMate LVAD delays the return of pro-inflammatory mediator concentrations back to baseline values compared with routine cardiopulmonary bypass alone, but the device does not appear to be an ongoing source of cytokine release or complement activation.
C1 Univ Iowa Hosp & Clin, Dept Surg, Div Cardiothorac Surg, Iowa City, IA 52242 USA.
   Univ Iowa Hosp & Clin, Dept Surg, Div Cardiol, Iowa City, IA 52242 USA.
RP Richenbacher, WE (reprint author), Univ Iowa Hosp & Clin, Dept Surg, Div Cardiothorac Surg, 200 Hawkins Dr, Iowa City, IA 52242 USA.
FU NHLBI NIH HHS [HL07121]
CR BERGER D, 1995, CLIN CHIM ACTA, V239, P121, DOI 10.1016/0009-8981(95)06105-M
   Biffl WL, 1996, ANN SURG, V224, P647, DOI 10.1097/00000658-199611000-00009
   BOCCI V, 1991, CLIN PHARMACOKINET, V21, P274, DOI 10.2165/00003088-199121040-00004
   Boyle EM, 1997, ANN THORAC SURG, V63, P277
   BUTLER J, 1993, ANN THORAC SURG, V55, P552, DOI 10.1016/0003-4975(93)91048-R
   CASTELL JV, 1988, EUR J BIOCHEM, V177, P357, DOI 10.1111/j.1432-1033.1988.tb14384.x
   CHENOWETH DE, 1981, NEW ENGL J MED, V304, P497, DOI 10.1056/NEJM198102263040901
   CRUICKSHANK AM, 1990, CLIN SCI, V79, P161, DOI 10.1042/cs0790161
   DAFFERN PJ, 1995, J EXP MED, V181, P2119, DOI 10.1084/jem.181.6.2119
   Damas P, 1997, CRIT CARE MED, V25, P405, DOI 10.1097/00003246-199703000-00006
   DeRose JJ, 1997, ANN THORAC SURG, V64, P1757, DOI 10.1016/S0003-4975(97)01107-7
   DeRose JJ, 1997, ANN SURG, V226, P461, DOI 10.1097/00000658-199710000-00007
   DINARELLO CA, 1993, JAMA-J AM MED ASSOC, V269, P1829, DOI 10.1001/jama.269.14.1829
   FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560
   GOLDSTEIN DJ, 1995, ANN THORAC SURG, V59, P1063, DOI 10.1016/0003-4975(95)00086-Z
   Goldstein DJ, 1997, ANN THORAC SURG, V63, P971, DOI 10.1016/S0003-4975(96)01117-4
   HARADA A, 1994, J LEUKOCYTE BIOL, V56, P559
   Hasper D, 1996, INT J ARTIF ORGANS, V19, P590
   Hecke F, 1997, CRIT CARE MED, V25, P2015, DOI 10.1097/00003246-199712000-00019
   HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621
   Hoch RC, 1996, J LAB CLIN MED, V128, P134, DOI 10.1016/S0022-2143(96)90005-0
   HUGLI TE, 1990, CURR TOP MICROBIOL, V153, P181
   HUMMEL M, 1994, CRIT CARE MED, V22, P448, DOI 10.1097/00003246-199403000-00015
   JORENS PG, 1993, AM REV RESPIR DIS, V148, P890, DOI 10.1164/ajrccm/148.4_Pt_1.890
   KARAKURUM M, 1994, J CLIN INVEST, V93, P1564, DOI 10.1172/JCI117135
   KAWAHITO K, 1995, J THORAC CARDIOV SUR, V110, P99, DOI 10.1016/S0022-5223(05)80014-5
   KIRKLIN JK, 1991, ANN THORAC SURG, V51, P529, DOI 10.1016/0003-4975(91)90302-7
   KIRKLIN JK, 1983, J THORAC CARDIOV SUR, V86, P845
   KISHIMOTO T, 1989, BLOOD, V74, P1
   LEFER AM, 1990, SCIENCE, V249, P61, DOI 10.1126/science.2164258
   LEONARD EJ, 1990, AM J RESP CELL MOL, V2, P479, DOI 10.1165/ajrcmb/2.6.479
   Naldini A, 1997, J CELL PHYSIOL, V173, P335, DOI 10.1002/(SICI)1097-4652(199712)173:3<335::AID-JCP5>3.0.CO;2-O
   Presterl E, 1997, AM J RESP CRIT CARE, V156, P825, DOI 10.1164/ajrccm.156.3.9607131
   RAASVELD MHM, 1993, TRANSPLANT INT, V6, P89, DOI 10.1007/BF00336651
   Rafii S, 1995, ANN THORAC SURG, V60, P1627, DOI 10.1016/0003-4975(95)00807-1
   Salih V, 1993, Am J Cardiovasc Pathol, V4, P317
   STEINBERG JB, 1993, J THORAC CARDIOV SUR, V106, P1008
   Stove S, 1996, CLIN DIAGN LAB IMMUN, V3, P175
   Tonnesen E, 1996, INT J CARDIOL, V53, pS1, DOI 10.1016/0167-5273(96)02568-5
   TorreAmione G, 1996, J AM COLL CARDIOL, V27, P1201, DOI 10.1016/0735-1097(95)00589-7
   Tsutamoto T, 1998, J AM COLL CARDIOL, V31, P391, DOI 10.1016/S0735-1097(97)00494-4
   Verrier ED, 1996, ANN THORAC SURG, V62, P915
   Wan S, 1996, J THORAC CARDIOV SUR, V111, P469, DOI 10.1016/S0022-5223(96)70458-0
   Wan S, 1997, CHEST, V112, P676, DOI 10.1378/chest.112.3.676
   Wan S, 1997, ANN THORAC SURG, V63, P269
   WESTABY S, 1987, INTENS CARE MED, V13, P89
   Yamada H, 1996, ACTA ANAESTH SCAND, V40, P311, DOI 10.1111/j.1399-6576.1996.tb04438.x
   Yamaguchi T, 1997, ASAIO J, V43, pM449
   YAMAWAKI S, 1995, ELS APPL ELECT MAT, V6, P91
NR 49
TC 24
Z9 24
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1058-2916
EI 1538-943X
J9 ASAIO J
JI Asaio J.
PD SEP-OCT
PY 1998
VL 44
IS 5
BP M347
EP M351
DI 10.1097/00002480-199809000-00005
PG 5
WC Engineering, Biomedical; Transplantation
SC Engineering; Transplantation
GA 128NJ
UT WOS:000076412600005
PM 9804450
OA Bronze
DA 2018-10-19
ER

PT J
AU Love, C
   Zelenovic, T
   Dahl, T
   Breznock, E
   Lirtzman, R
AF Love, C
   Zelenovic, T
   Dahl, T
   Breznock, E
   Lirtzman, R
TI Rapid intraoperative construction of autologous small caliber blood
   vessels
SO ASAIO JOURNAL
LA English
DT Article; Proceedings Paper
CT 44th Annual Conference of the
   American-Society-for-Artificial-Internal-Organs
CY APR 23-25, 1998
CL NEW YORK, NEW YORK
SP Amer Soc Artificial Internal Organs
ID INTERNAL MAMMARY ARTERY; TISSUE CARDIAC-VALVE; BYPASS GRAFTS; VEIN
   GRAFTS; REPLACEMENT; OPERATION
AB Autologous pericardium, briefly tanned in glutaraldehyde, is an excellent biomaterial when used in various cardiac procedures, including repair and replacement of heart valves. A generalized lack of calcification and an absence of inflammatory response in these combined experiences has led the authors to consider the use of treated autologous pericardium for the construction of substitute small caliber blood vessels. Rapid, intraoperative construction of a vascular graft from autologous pericardium, briefly treated in 0.62% glutaraldehyde, is accomplished through the use of two concentric, mating helical stents that support a rectangular pattern of tissue into a cylindrical, nonkinking, compliant conduit. A disposable automated assembly tool provides for precise assembly of the tissue and stents. The tools and methods for construction of vascular grafts from nonvascular tissue are known as the Rapidgraft(TM) (Ramus Medical Technologies, Santa Barbara, CA). The technique can be used with any suitable tissue. Accelerated fatigue test studies have confirmed that stent supported pericardial grafts are capable of withstanding physiologic pressures and flows beyond 7 equivalent years. Six autologous pericardial grafts measuring 5 mm in diameter by 5.5 cm in length showed 100% patency beyond 5 months in a growing calf carotid artery model. Pathological examination of explanted grafts confirm the presence of a continuous endothelial lined surface, infiltration of the tissue by fibrous connective tissue such that the individual layers of the pericardial vessel wall could not be identified, and there was no inflammatory response. Based on the encouraging results in animal studies, a small multicenter clinical trial has been initiated to evaluate the performance of the Rapidgraft as a replacement conduit for the radial artery in cases in which the radial artery has been harvested as a coronary artery bypass conduit. Results from the radial artery trial will be used as an indication to evaluate the Rapidgraft as a coronary artery substitute. We conclude that the material properties, including the biological origin of a vessel wall, may be significant determinants of graft patency, and that the Rapidgraft may be an answer to the need for small caliber arterial graft with the potential for long-term patency and durability.
C1 Ramus Med Technol, Goleta, CA 93117 USA.
RP Love, C (reprint author), Ramus Med Technol, 346B Bollay Dr, Goleta, CA 93117 USA.
CR ALLEN RG, 1977, J PEDIATR SURG, V12, P287, DOI 10.1016/0022-3468(77)90003-3
   ANGELINI GD, 1987, CARDIOVASC RES, V21, P902, DOI 10.1093/cvr/21.12.902
   AUGELLI NV, 1991, TRANSPLANTATION, V52, P466, DOI 10.1097/00007890-199109000-00014
   BERGER K, 1972, ANN SURG, V175, P118, DOI 10.1097/00000658-197201000-00018
   BJORK VO, 1964, J THORAC CARDIOV SUR, V47, P693
   BROCKBANK KGM, 1995, PRINCIPLES AUTOLOGOU
   CHAVAUD S, 1991, J THORAC CARDIOVASC, V102, P171
   DURAN CMG, 1997, IN PRESS 7 INT S CAR
   Edwards W S, 1971, Ann Thorac Surg, V12, P385
   EDWARDS WS, 1969, J THORAC CARDIOV SUR, V58, P854
   FABIANI JN, 1995, ANN THORAC SURG, V60, pS189, DOI 10.1016/0003-4975(95)00247-I
   FITZGIBBON GM, 1986, J THORAC CARDIOV SUR, V91, P773
   Greisler H. P., 1991, NEW BIOL SYNTHETIC V
   GRONDIN CM, 1984, CIRCULATION, V70, P208
   Gross C, 1996, ANN THORAC SURG, V61, P1759, DOI 10.1016/0003-4975(96)00144-0
   IONESCU MI, 1970, THORAX, V25, P46, DOI 10.1136/thx.25.1.46
   JONES EL, 1993, ANN THORAC SURG, V55, P194, DOI 10.1016/0003-4975(93)90509-G
   KEMPEZINSKI RF, 1995, VASCULAR SURG
   KOUCHOUKOS NT, 1990, ANN THORAC SURG, V49, P210, DOI 10.1016/0003-4975(90)90140-2
   LOVE JW, 1992, J HEART VALVE DIS, P1232
   LOVE JW, 1997, AUTOLOGOUS TISSUE HE
   Love JW, 1986, P 3 INT S CARD BIOPR, P691
   LYTLE BW, 1985, J THORAC CARDIOV SUR, V89, P248
   MCENANY MT, 1972, J THORAC CARDIOV SUR, V63, P199
   OSCHNER JL, 1984, J VASC SURG, V1, P306
   PRINCE MR, 1988, INVEST RADIOL, V23, P294, DOI 10.1097/00004424-198804000-00009
   Reardon MJ, 1997, J CARDIOVASC SURG, V38, P201
   REDINA EA, 1995, J THORAC CARDIOVASC, V110, P867
   REVEL CD, 1987, ANN THORAC SURG, V44, P425
   Ross D N, 1972, Ann Thorac Surg, V13, P97
   SAKO Y, 1951, SURGERY, V30, P149
   SENNING A, 1967, J THORAC CARDIOV SUR, V54, P465
   SENNING A, 1984, P 2 INT S CARD BIOPR, P140
   WOODROOF EA, 1985, Patent No. 4502159
   ZARGE JI, 1997, PRINCIPLES TISSUE EN
NR 35
TC 3
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA
SN 1058-2916
J9 ASAIO J
JI Asaio J.
PD SEP-OCT
PY 1998
VL 44
IS 5
BP M648
EP M652
DI 10.1097/00002480-199809000-00070
PG 5
WC Engineering, Biomedical; Transplantation
SC Engineering; Transplantation
GA 128NJ
UT WOS:000076412600070
PM 9804515
DA 2018-10-19
ER

PT J
AU Nilsson, B
   Larsson, R
   Hong, J
   Elgue, G
   Ekdahl, KN
   Sahu, A
   Lambris, JD
AF Nilsson, B
   Larsson, R
   Hong, J
   Elgue, G
   Ekdahl, KN
   Sahu, A
   Lambris, JD
TI Compstatin inhibits complement and cellular activation in whole blood in
   two models of extracorporeal circulation
SO BLOOD
LA English
DT Article
ID CARDIOPULMONARY BYPASS; DYSFUNCTION; COMPONENTS; NEUTROPHIL; GENERATION;
   PLATELET; PATHWAY; HEPARIN; SYSTEM; C5A
AB Recently, a C3-binding cyclic synthetic peptide (Compstatin) has been identified that binds to complement component C3 and inhibits complement activation. Here we have examined the influence of Compstatin on complement activation and its indirect effects on cellular responses in whole blood in two models for extracorporeal circulation. Compstatin effectively inhibited the generation of C3a and sC5b-9 and the binding of C3/C3 fragments to the polymer surface. As a result of the inhibition of complement activation, the activation of polymorphonuclear leukocytes (PMNs; as assessed by the expression of CD11b) and the binding of these cells (CD16(+)) to the polymer surface were almost completely lost. In contrast, blood cell counts were not affected. Using surface plasmon resonance technology, we have confirmed that Compstatin exerts its inhibitory effect on complement activation by binding to native C3. These data show that complement activation, leading to activation and binding of PMNs to the biomaterial surface, can be abolished by the addition of Compstatin. The properties of Compstatin make Compstatin a promising drug for use in extracorporeal circuits to avoid bioincompatibility reactions, eg, during cardiopulmonary bypass, but also a favorable precursor peptide for the development of an anticomplement drug for oral use. (C) 1998 by The American Society of Hematology.
C1 Univ Penn, Dept Pathol & Lab Med, Prot Chem Lab, Philadelphia, PA 19104 USA.
   Univ Uppsala Hosp, Dept Clin Immunol & Transfus Med, S-75185 Uppsala, Sweden.
   Univ Kalmar, Dept Nat Sci, Kalmar, Sweden.
RP Lambris, JD (reprint author), Univ Penn, Dept Pathol & Lab Med, Prot Chem Lab, 410 Johnson Pavil, Philadelphia, PA 19104 USA.
EM lambris@mail.med.upenn.edu
RI Nilsson, Bo/B-3102-2012; Nilsson Ekdahl, Kristina/B-5301-2012; Sahu,
   Arvind/C-2178-2012
OI Nilsson, Bo/0000-0003-0057-2730; Lambris, John/0000-0002-9370-5776
FU NIDDK NIH HHS [DK 19525]; NIAID NIH HHS [AI 30040]; NCI NIH HHS [CA
   16520]
CR ANGELETTI RH, 1996, FORMATION DISULFIDE, P261
   BOKISCH VA, 1969, J EXP MED, V129, P1109, DOI 10.1084/jem.129.5.1109
   CATANA E, 1991, J IMMUNOL METHODS, V138, P265, DOI 10.1016/0022-1759(91)90175-F
   CHENOWETH DE, 1986, T AM SOC ART INT ORG, V32, P226
   EKDAHL KN, 1992, SCAND J IMMUNOL, V35, P85, DOI 10.1111/j.1365-3083.1992.tb02837.x
   FEARON D T, 1991, Clinical and Experimental Immunology, V86, P43
   FISHELSON Z, 1983, J BIOL CHEM, V258, P7411
   GILLINOV AM, 1993, ANN THORAC SURG, V55, P619, DOI 10.1016/0003-4975(93)90264-I
   GONG J, 1996, J CLIN IMMUNOL, V16, P223
   GREELEY WJ, 1991, ANN THORAC SURG, V52, P417, DOI 10.1016/0003-4975(91)90900-B
   HAMMER CH, 1981, J BIOL CHEM, V256, P3995
   INO Y, 1987, INT J IMMUNOPHARMACO, V9, P533, DOI 10.1016/0192-0561(87)90120-2
   Johnson R J, 1990, Prog Clin Biol Res, V337, P507
   KAZATCHKINE MD, 1988, BIOMATERIALS, V9, P30, DOI 10.1016/0142-9612(88)90066-X
   Kirklin JK, 1989, CARDIOPULMONARY BYPA, P131
   KIRSCHFINK M, 1994, INFUSIONSTHERAPIE, V21, P405
   LAMBRIS JD, 1984, J BIOL CHEM, V259, P2685
   Larsson R, 1997, IMMUNOPHARMACOLOGY, V38, P119, DOI 10.1016/S0162-3109(97)00064-7
   MAYER MM, 1961, EXPT IMMUNOCHEMISTRY, P133
   MOLLNES T, 1985, SCAND J IMMUNOL, V22, P703
   MOLLNES TE, 1991, ANN THORAC SURG, V52, P92, DOI 10.1016/0003-4975(91)91426-V
   MOORE WT, 1993, BIOL MASS SPECTROM, V22, P149, DOI 10.1002/bms.1200220303
   MORGAN BP, 1995, IMMUNOL TODAY, V16, P257, DOI 10.1016/0167-5699(95)80175-8
   Morikis D, 1998, PROTEIN SCI, V7, P619, DOI 10.1002/pro.5560070311
   MULLIGAN MS, 1992, J IMMUNOL, V148, P1479
   NILSSON B, 1994, ANN RHEUM DIS, V53, P691, DOI 10.1136/ard.53.10.691
   NILSSON L, 1990, ARTIF ORGANS, V14, P46
   NILSSON UR, 1992, ARTHRITIS RHEUM, V35, P580, DOI 10.1002/art.1780350516
   OEVEREN W, 1985, J THORAC CARDIOVASC, V89, P888
   PEKNA M, 1993, CLIN EXP IMMUNOL, V91, P404
   RINDER CS, 1995, J CLIN INVEST, V96, P1564, DOI 10.1172/JCI118195
   Rosse WF, 1997, MEDICINE, V76, P63, DOI 10.1097/00005792-199703000-00001
   Sahu A, 1996, J IMMUNOL, V157, P884
   SIMS PJ, 1991, IMMUNOL TODAY, V12, P338, DOI 10.1016/0167-5699(91)90012-I
   Sundaram S, 1996, THROMB HAEMOSTASIS, V75, P76
   VIDEM V, 1992, J THORAC CARDIOV SUR, V103, P806
   WACHTFOGEL YT, 1989, BLOOD, V73, P468
   WESTABY S, 1987, INTENS CARE MED, V13, P89
NR 38
TC 111
Z9 112
U1 0
U2 5
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD SEP 1
PY 1998
VL 92
IS 5
BP 1661
EP 1667
PG 7
WC Hematology
SC Hematology
GA 113NP
UT WOS:000075558400022
PM 9716594
DA 2018-10-19
ER

PT J
AU Schwager, K
AF Schwager, K
TI Titanium as a biomaterial for ossicular replacement: results after
   implantation in the middle ear of the rabbit
SO EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
LA English
DT Article
DE hearing loss; biomaterial; ossicular replacements; middle ear titanium;
   animal experiments
ID CHAIN RECONSTRUCTION; HYDROXYLAPATITE; OSSICULOPLASTY; PROSTHESES;
   SURGERY
AB The middle ear poses unique challenges when finding suitable materials for ossicular reconstruction, primarily because of its link to the external environment via the eustachian tube and, hence, its greater exposure to infectious agents. In this study, the biocompatability of titanium was examined in the middle ear of rabbits by using light and scanning electron microscopy. Implants were placed as middle ear prostheses or as free implants. These were inspected at 28 days, 84 days, 168 days, 336 days and 504 days following implantation for mucosal coverage, percent epithelization and any sign of foreign-body reaction. After 28 days, the prostheses were covered by regular mucosa. Although a majority of the free implants took up to 336 days for complete epithelialization, some of the free implants were not epithelialized even at day 504. There were no inflammatory cells observed on the surface of the material, nor were unusual amounts of fibrous tissue seen. In addition, the titanium material exhibited an affinity toward bone. The results of this animal experiment indicate that titanium is a favorable material for ossicular replacement prostheses.
C1 Univ Wurzburg, Klin & Poliklin Hals Nasen & Ohrenkranke, D-97080 Wurzburg, Germany.
RP Schwager, K (reprint author), Univ Wurzburg, Klin & Poliklin Hals Nasen & Ohrenkranke, Josef Schneider Str 11, D-97080 Wurzburg, Germany.
CR ALBREKTSSON T, 1982, CLIN APPL BIOMATERIA, P167
   AUSTIN DF, 1982, OTOLARYNG CLIN N AM, V15, P763
   BELEITES E, 1992, HNO PRAXIS HEUTE, P169
   BERNECKER F, 1993, HNO, V41, P250
   COLETTI V, 1984, ACTA OTORHINOL ITAL, V4, P689
   COUSINS VC, 1987, CLIN OTOLARYNGOL, V12, P183, DOI 10.1111/j.1365-2273.1987.tb00185.x
   DARC MB, 1996, KNOCHENERSATZ MITTEL, V1, P47
   FROOTKO NJ, 1984, BIOMATERIALS OTOLOGY, P169
   FUNASAKA S, 1984, BIOMATERIALS OTOLOGY, P281
   GEYER G, 1993, EUR ARCH OTO-RHINO-L, V250, P253
   GEYER G, 1990, THESIS U WURZBURG
   GJURIC M, 1987, LARYNGO RHINO OTOL, V66, P522, DOI 10.1055/s-2007-998723
   GROTE JJ, 1981, ORL J OTO-RHINO-LARY, V43, P248, DOI 10.1159/000275544
   GROTE JJ, 1986, ANN OTO RHINOL LARYN, V95, P10
   GROTE JJ, 1985, AM J OTOL, V6, P269
   GROTE JJ, 1986, ANN OTO RHINOL LARYN, V95, P1
   HOPPE F, 1996, KNOCHENERSATZ MITTEL, V1, P104
   JAEHNE M, 1996, KNOCHENERSATZ MITTEL, V1, P63
   JAHNKE K, 1987, HNO, V35, P1
   JAHNKE K, 1979, ARCH OTO-RHINO-LARYN, V223, P373, DOI 10.1007/BF01109587
   JAHNKE K, 1984, BIOMATERIALIEN NAHTM, P66
   JAHNKE K, 1982, ADV BIOMATERIALS
   KERR AG, 1981, CLIN OTOLARYNGOL, V6, P187, DOI 10.1111/j.1365-2273.1981.tb01530.x
   KERR AG, 1984, BIOMATERIALS OTOLOGY, P161
   KRUMMEL FJ, 1987, LARYNGO RHINO OTOL, V66, P409, DOI 10.1055/s-2007-998691
   KUIJPERS W, 1984, BIOMATERIALS OTOLOGY, P18
   MCELVEEN JT, 1994, OTOLARYNG CLIN N AM, V27, P777
   MCELVEEN JT, 1995, OTOLARYNG HEAD NECK, V113, P420, DOI 10.1016/S0194-5998(95)70079-X
   PUSALKAR A, 1991, TRANSPLANTS IMPLANTS, P104
   PUSALKAR A, 1996, KNOCHENERSATZ MITTEL, V1, P55
   RECK R, 1987, LARYNGO RHINO OTOL, V66, P373, DOI 10.1055/s-2007-998679
   Reck R, 1988, Ann N Y Acad Sci, V523, P100, DOI 10.1111/j.1749-6632.1988.tb38504.x
   RECK R, 1981, CLIN OTOLARYNGOL, V6, P63, DOI 10.1111/j.1365-2273.1981.tb01786.x
   SPECTOR M, 1984, BIOMATERIALS OTOLOGY, P29
   STEINBACH E, 1986, KNOCHENERSATZ MITTEL, P58
   Stupp CH, 1996, LARYNGO RHINO OTOL, V75, P335, DOI 10.1055/s-2007-997590
   TEICHGRAEBER JF, 1983, AM J OTOL, V5, P127
   VANBLITTERSWIJK CA, 1984, BIOMATERIALS OTOLOGY, P94
   WEHRS RE, 1989, AM J OTOL, V10, P181
NR 39
TC 25
Z9 29
U1 2
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0937-4477
EI 1434-4726
J9 EUR ARCH OTO-RHINO-L
JI Eur. Arch. Oto-Rhino-Laryn.
PD SEP
PY 1998
VL 255
IS 8
BP 396
EP 401
DI 10.1007/s004050050086
PG 6
WC Otorhinolaryngology
SC Otorhinolaryngology
GA 128EJ
UT WOS:000076392500003
PM 9801858
DA 2018-10-19
ER

PT J
AU Furusawa, T
   Mizunuma, K
   Yamashita, S
   Takahashi, T
AF Furusawa, T
   Mizunuma, K
   Yamashita, S
   Takahashi, T
TI Investigation of early bone formation using resorbable bioactive glass
   in the rat mandible
SO INTERNATIONAL JOURNAL OF ORAL & MAXILLOFACIAL IMPLANTS
LA English
DT Article
DE localized osseous defects; osteostimulation; resorbable bioactive glass
ID PERIODONTAL OSSEOUS DEFECTS; IMPLANTS
AB Recent advances in biomaterial technology have made alloplastic bone substitutes more predictable when used with the proper clinical methodology in carefully selected patients. In this animal study, early bone formation using a novel resorbable bioactive glass in the repair of surgically created bony defects in the rat mandible was investigated. Biopsies taken from the implanted sites after 1, 2, 3, 4, 8, and 16 weeks were examined histologically by means of standard cell-staining techniques. In addition, an electron probe microanalyzer was used to determine the presence and distribution of specific elements in samples taken after 16 weeks. Results indicated the early stage of osteoconductive bone growth after approximately 4 weeks. After 16 weeks, electron probe microanalyzer scans indicated the formation of a calcium-phosphate shell formed in situ and the resorption of silica to background levels.
C1 Furusawa Implant Res Inst, Taihaku Ku, Sendai, Miyagi 982, Japan.
   Tohoku Univ, Sch Dent, Dept Oral Bacteriol, Sendai, Miyagi, Japan.
   Showa Univ, Sch Dent, Dept Oral Biomat & Technol, Tokyo, Japan.
   Yamashita Dent Clin, Sendai, Miyagi, Japan.
   Kanagawa Dent Coll, Dept Oral Anat, Yokosuka, Kanagawa, Japan.
RP Furusawa, T (reprint author), Furusawa Implant Res Inst, Taihaku Ku, 1-7-42 Hachihonmatsu, Sendai, Miyagi 982, Japan.
CR BALDOCK WT, 1985, J PERIODONTOL, V56, P1, DOI 10.1902/jop.1985.56.1.1
   Furusawa T, 1997, Implant Dent, V6, P93, DOI 10.1097/00008505-199700620-00003
   GATTI AM, 1993, BIOCERAMICS, V6, P396
   Hench LL, 1971, J BIOMED MATER RES S, V2, P117, DOI DOI 10.1002/JBM.820050611
   Misch C E, 1993, Implant Dent, V2, P158, DOI 10.1097/00008505-199309000-00003
   NERY EB, 1978, J PERIODONTOL, V49, P523, DOI 10.1902/jop.1978.49.10.523
   NERY EB, 1975, J PERIODONTOL, V46, P328, DOI 10.1902/jop.1975.46.6.328
   SCHEPERS E, 1991, J ORAL REHABIL, V18, P439, DOI 10.1111/j.1365-2842.1991.tb01689.x
   Schepers E J, 1993, Implant Dent, V2, P151, DOI 10.1097/00008505-199309000-00002
   SHIMIZU Y, 1997, J JPN SOC BIOMATERIA, V15, P103
NR 10
TC 24
Z9 25
U1 0
U2 0
PU QUINTESSENCE PUBL CO INC
PI CAROL STREAM
PA 551 NORTH KIMBERLY DR, CAROL STREAM, IL 60188-1881 USA
SN 0882-2786
J9 INT J ORAL MAX IMPL
JI Int. J. Oral Maxillofac. Implants
PD SEP-OCT
PY 1998
VL 13
IS 5
BP 672
EP 676
PG 5
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 129TJ
UT WOS:000076478800010
PM 9796151
DA 2018-10-19
ER

PT J
AU Whitson, BA
   Cheng, BC
   Kokini, K
   Badylak, SF
   Patel, U
   Morff, R
   O'Keefe, CR
AF Whitson, BA
   Cheng, BC
   Kokini, K
   Badylak, SF
   Patel, U
   Morff, R
   O'Keefe, CR
TI Multilaminate resorbable biomedical device under biaxial loading
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE multilaminate sheet; biaxial testing; ball burst test; rehydration
   effects; small intestinal submucosa
ID SMALL-INTESTINAL SUBMUCOSA; PRESSURE; GRAFT; DOG
AB The design and test of a multilaminate sheet developed for a hernia repair application is presented. As biomaterial applications become more complex, characterization of uniaxial properties becomes insufficient and biaxial testing becomes necessary. A measure of the in-plane biaxial strength of the device is inferred from a ball burst test. The results of this test for different thicknesses of the device are correlated with the uniaxial strength of the material, A biaxial test such as the ball burst test is more indicative of the properties of a planar material than would be a uniaxial test. The interactions in the biaxial mode of failure are of value and can be related hack to a classical uniaxial tensile test from the ball burst test, The material used in this study to fabricate the device was a resorbable biomaterial called small intestinal submucosa (SIS), The effects of rehydration on the stiffness and associated hall burst properties of the SIS device were also measured, It is shown that at a rehydration time of 5 min from a reference dry state, steady-state mechanical properties are reached. (C) 1998 John Wiley & Sons, Inc.
C1 Purdue Univ, W Lafayette, IN 47907 USA.
   Univ Wisconsin, Madison, WI 53706 USA.
RP Kokini, K (reprint author), Purdue Univ, W Lafayette, IN 47907 USA.
OI Badylak, Stephen/0000-0003-3555-0689
CR ASPDEN RM, 1987, CLIN BIOMECH, V2, P168, DOI 10.1016/0268-0033(87)90010-6
   BADYLAK SF, 1993, TISSUE ENGINEERING, P179
   BADYLAK SF, 1989, J SURG RES, V47, P74, DOI 10.1016/0022-4804(89)90050-4
   BADYLAK SF, 1993, IN PRESS J BIOMED MA, P179
   BADYLAK SF, INPRESS J BIOMED MAT
   CLARKE KM, IN PRESS J SURG RES
   HILES MC, 1995, J BIOMED MATER RES, V29, P883, DOI 10.1002/jbm.820290714
   Lantz G C, 1990, J Invest Surg, V3, P217, DOI 10.3109/08941939009140351
   Lantz G C, 1993, J Invest Surg, V6, P297, DOI 10.3109/08941939309141619
   MCGILL SM, 1990, ERGONOMICS, V33, P147, DOI 10.1080/00140139008927106
   PHEASANT S, 1986, ANTHROPOMETRY ERGONO
   SANDUSKY GE, 1992, AM J PATHOL, V140, P317
   SHIGLEY JE, 1989, MECH ENG DESIGN, P60
NR 13
TC 30
Z9 33
U1 0
U2 4
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD FAL
PY 1998
VL 43
IS 3
BP 277
EP 281
DI 10.1002/(SICI)1097-4636(199823)43:3<277::AID-JBM8>3.3.CO;2-M
PG 5
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 112JN
UT WOS:000075490900008
PM 9730065
DA 2018-10-19
ER

PT J
AU An, YH
   Friedman, RJ
AF An, YH
   Friedman, RJ
TI Concise review of mechanisms of bacterial adhesion to biomaterial
   surfaces
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Review
DE bacteria; bacterial adhesion; biomaterials; material surfaces;
   bacteria-surface interaction
ID COAGULASE-NEGATIVE STAPHYLOCOCCI; SALIVA-COATED HYDROXYAPATITE;
   FIBRONECTIN-BINDING PROTEIN; FIMBRIATED ESCHERICHIA-COLI; CELL-SURFACE;
   SOLID-SURFACES; CATHETERS INVITRO; ORAL STREPTOCOCCI; IN-VITRO;
   INTRAVASCULAR CATHETERS
AB This article review the mechanisms of bacterial adhesion to biomaterial surfaces and the factors affecting the adhesion. The process of bacterial adhesion includes an initial physicochemical interaction phase (phase one) and a late molecular and cellular interaction phase (phase two), which is a complicated process affected by many factors, including the characteristics of the bacteria themselves, the target material surface, and the environmental factors, such as the presence of serum proteins or bactericidal substances. (C) 1998 John Wiley & Sons, Inc.
C1 Med Univ S Carolina, Dept Orthopaed Surg, Orthoped Res Lab, Charleston, SC 29425 USA.
RP An, YH (reprint author), Med Univ S Carolina, Dept Orthopaed Surg, Orthoped Res Lab, Charleston, SC 29425 USA.
EM anh@musc.edu
CR ABBOTT A, 1983, J GEN MICROBIOL, V129, P439
   An YH, 1996, J HOSP INFECT, V33, P93, DOI 10.1016/S0195-6701(96)90094-8
   An YH, 1995, J MICROBIOL METH, V24, P29, DOI 10.1016/0167-7012(95)00051-8
   An YH, 1997, J BONE JOINT SURG BR, V79B, P816, DOI 10.1302/0301-620X.79B5.7228
   An YH, 1996, J ORTHOPAED RES, V14, P846, DOI 10.1002/jor.1100140526
   AN YH, 1993, T SOC BIOMATER, V16, P148
   BAKER AS, 1988, J BONE JOINT SURG AM, V70A, P1551, DOI 10.2106/00004623-198870100-00015
   BARTH E, 1989, BIOMATERIALS, V10, P325, DOI 10.1016/0142-9612(89)90073-2
   BAYER EA, 1983, J BACTERIOL, V156, P818
   Beveridge T J, 1981, Int Rev Cytol, V72, P229, DOI 10.1016/S0074-7696(08)61198-5
   BOZZINI S, 1992, EUR J BIOCHEM, V207, P327, DOI 10.1111/j.1432-1033.1992.tb17054.x
   BRIDGETT MJ, 1992, BIOMATERIALS, V13, P411, DOI 10.1016/0142-9612(92)90159-L
   BRINTON CC, 1965, T NEW YORK ACAD SCI, V27, P1003, DOI 10.1111/j.2164-0947.1965.tb02342.x
   Brokke P, 1991, J Biomater Appl, V5, P204, DOI 10.1177/088532829100500305
   BUSSCHER HJ, 1984, APPL ENVIRON MICROB, V48, P980
   CHEUNG AL, 1990, J INFECT DIS, V161, P1177, DOI 10.1093/infdis/161.6.1177
   CHRISTENSEN GD, 1983, INFECT IMMUN, V40, P407
   CHRISTENSEN GD, 1982, INFECT IMMUN, V37, P318
   CHU CC, 1984, AM J SURG, V147, P197, DOI 10.1016/0002-9610(84)90088-6
   Costerton J. W., 1989, ASM News (Washington), V55, P650
   COURTNEY HS, 1985, INFECT IMMUN, V47, P341
   DANKERT J, 1986, CRIT REV BIOCOMPAT, V2, P219
   DAVENPORT DS, 1986, J INFECT DIS, V153, P332, DOI 10.1093/infdis/153.2.332
   DEGRAAF FK, 1988, A VAN LEEUW J MICROB, V54, P395, DOI 10.1007/BF00461857
   DENYER SP, 1990, J CLIN MICROBIOL, V28, P1813
   Dougherty S H, 1989, Infect Dis Clin North Am, V3, P199
   DOUGHERTY SH, 1988, REV INFECT DIS, V10, P1102
   DUGUID JP, 1951, J PATHOL BACTERIOL, V63, P673, DOI 10.1002/path.1700630413
   DUGUID JP, 1955, J PATHOL BACTERIOL, V70, P335, DOI 10.1002/path.1700700210
   DURAN LW, 1993, T SOC BIOMATER, V16, P35
   ESPERSEN F, 1982, INFECT IMMUN, V37, P526
   ESPERSEN F, 1990, APMIS, V98, P471, DOI 10.1111/j.1699-0463.1990.tb01059.x
   FARBER BF, 1992, J INFECT DIS, V166, P861, DOI 10.1093/infdis/166.4.861
   Fitzgerald R H Jr, 1989, Infect Dis Clin North Am, V3, P329
   FLEMMING RG, 1993, T SOC BIOMATER, V16, P153
   FLETCHER M, 1973, J GEN MICROBIOL, V74, P325, DOI 10.1099/00221287-74-2-325
   FLETCHER M, 1982, APPL ENVIRON MICROB, V44, P184
   FLETCHER M, 1976, J GEN MICROBIOL, V94, P400, DOI 10.1099/00221287-94-2-400
   FLETCHER M, 1979, APPL ENVIRON MICROB, V37, P67
   FLOCK JI, 1987, EMBO J, V6, P2351, DOI 10.1002/j.1460-2075.1987.tb02511.x
   FRANSON TR, 1984, J INFECT DIS, V149, P116, DOI 10.1093/infdis/149.1.116
   FROMAN G, 1987, J BIOL CHEM, V262, P6564
   GERSON DF, 1980, BIOCHIM BIOPHYS ACTA, V602, P506, DOI 10.1016/0005-2736(80)90329-6
   GIBBONS RJ, 1983, INFECT IMMUN, V41, P1190
   GILBERT P, 1991, J APPL BACTERIOL, V71, P72
   GORDON AS, 1981, CAN J MICROBIOL, V27, P698, DOI 10.1139/m81-108
   GRAY ED, 1984, LANCET, V1, P365
   GRISTINA AG, 1987, SCIENCE, V237, P1588, DOI 10.1126/science.3629258
   GRISTINA AG, 1983, J BONE JOINT SURG AM, V65, P128, DOI 10.2106/00004623-198365010-00021
   GRISTINA AG, 1989, ANTIMICROB AGENTS CH, V33, P813, DOI 10.1128/AAC.33.6.813
   GRISTINA AG, 1987, BIOMATERIALS, V8, P423, DOI 10.1016/0142-9612(87)90077-9
   GRISTINA AG, 1991, ORTHOP CLIN N AM, V22, P363
   GRISTINA AG, 1990, INFECT DIS CLIN N AM, V4, P392
   Gristina AG, 1987, PATHOGENICITY CLIN S, P143
   HACKER J, 1992, CAN J MICROBIOL, V38, P720, DOI 10.1139/m92-118
   HARBER MJ, 1983, J GEN MICROBIOL, V129, P621
   HARDEN VP, 1953, J BACTERIOL, V65, P198
   HARKES G, 1991, BIOMATERIALS, V12, P853, DOI 10.1016/0142-9612(91)90074-K
   HASTY DL, 1992, INFECT IMMUN, V60, P2147
   HAWTHORN L, 1990, J BIOMED MATER RES, V24, P1325, DOI 10.1002/jbm.820241005
   HERRMANN M, 1991, INFECT IMMUN, V59, P279
   HERRMANN M, 1993, J INFECT DIS, V167, P312, DOI 10.1093/infdis/167.2.312
   HERRMANN M, 1988, J INFECT DIS, V158, P693, DOI 10.1093/infdis/158.4.693
   HOGT AH, 1983, J GEN MICROBIOL, V129, P2959
   HOGT AH, 1985, J GEN MICROBIOL, V131, P2485
   HOGT AH, 1986, INFECT IMMUN, V51, P294
   HOSCHUTZKY H, 1989, INFECT IMMUN, V57, P76
   HUSSAIN M, 1993, FEMS MICROBIOL LETT, V104, P191, DOI 10.1016/0378-1097(93)90596-T
   HUSSAIN M, 1992, J MED MICROBIOL, V37, P62, DOI 10.1099/00222615-37-1-62
   HUSSAIN M, 1991, J INFECT DIS, V163, P534, DOI 10.1093/infdis/163.3.534
   ICHIMAN Y, 1981, J APPL BACTERIOL, V51, P229, DOI 10.1111/j.1365-2672.1981.tb01237.x
   JANN K, 1992, CAN J MICROBIOL, V38, P705, DOI 10.1139/m92-116
   JONES GW, 1983, CRC CR REV MICROBIOL, V10, P229
   KHARDORI N, 1987, CLIN RES, V35, pA20
   KREKELER C, 1989, EXPERIENTIA, V45, P1047, DOI 10.1007/BF01950157
   KROGFELT KA, 1991, REV INFECT DIS, V13, P721
   KRONCKE KD, 1990, INFECT IMMUN, V58, P2710
   KUUSELA P, 1985, INFECT IMMUN, V50, P77
   KUUSELA P, 1978, NATURE, V276, P718, DOI 10.1038/276718a0
   LILJEMARK WF, 1981, INFECT IMMUN, V34, P428
   LINDAHL M, 1981, BIOCHIM BIOPHYS ACTA, V677, P471, DOI 10.1016/0304-4165(81)90261-0
   LOCCI R, 1981, ZBL BAKT MIK HYG B, V173, P285
   LOPES JD, 1985, SCIENCE, V229, P275, DOI 10.1126/science.3160113
   LUDWICKA A, 1984, ZBL BAKT-INT J MED M, V256, P479, DOI 10.1016/S0174-3031(84)80024-4
   MAFU AA, 1991, APPL ENVIRON MICROB, V57, P1969
   MARRIE TJ, 1983, APPL ENVIRON MICROB, V45, P1018
   Marshall K.C., 1985, BACTERIAL ADHESION M, P133
   MARSHALL KC, 1971, J GEN MICROBIOL, V68, P337, DOI 10.1099/00221287-68-3-337
   MAXE I, 1986, INFECT IMMUN, V54, P695
   MCALLISTER EW, 1993, GASTROINTEST ENDOSC, V39, P422, DOI 10.1016/S0016-5107(93)70120-0
   MCDOWELL SG, 1995, LETT APPL MICROBIOL, V21, P1, DOI 10.1111/j.1472-765X.1995.tb00992.x
   MERRITT K, 1979, J BIOMED MATER RES, V13, P101, DOI 10.1002/jbm.820130111
   METT H, 1983, J BACTERIOL, V153, P1038
   MIORNER H, 1980, INFECT IMMUN, V29, P879
   MOCH T, 1987, P NATL ACAD SCI USA, V84, P3462, DOI 10.1073/pnas.84.10.3462
   MORRIS EJ, 1984, INFECT IMMUN, V43, P656
   MOSHER DF, 1980, SCIENCE, V209, P927, DOI 10.1126/science.7403857
   MOZES N, 1987, J MICROBIOL METH, V6, P99, DOI 10.1016/0167-7012(87)90058-3
   MULLER E, 1991, INFECT IMMUN, V59, P3323
   Naylor P T, 1990, Clin Orthop Relat Res, P126
   NAYLOR PT, 1989, T ORTHOP RES SOC, V14, P108
   NAYLOR PT, 1989, T ORTHOP RES SOC, V14, P561
   NODA Y, 1984, PHYSIOL CHEM PHYS, V16, P29
   OFEK I, 1983, J BACTERIOL, V154, P139
   OGA M, 1988, BIOMATERIALS, V9, P285, DOI 10.1016/0142-9612(88)90100-7
   OGA M, 1993, ACTA ORTHOP SCAND, V64, P273, DOI 10.3109/17453679308993623
   OLSSON J, 1976, SCAND J DENT RES, V84, P20
   OLSSON J, 1976, SCAND J DENT RES, V84, P240
   ORSKOV I, 1990, CURR TOP MICROBIOL, V151, P71
   ORSTAVIK D, 1977, ACTA PATH MICRO IM B, V85, P38
   PASCUAL A, 1986, EUR J CLIN MICROBIOL, V5, P518, DOI 10.1007/BF02017694
   PASCUAL A, 1993, J HOSP INFECT, V24, P211, DOI 10.1016/0195-6701(93)90050-A
   PAULSSON M, 1993, BIOMATERIALS, V14, P845, DOI 10.1016/0142-9612(93)90006-N
   PEDERSEN K, 1981, FEMS MICROBIOL LETT, V12, P365
   PHILLIPS GN, 1981, P NATL ACAD SCI-BIOL, V78, P4689, DOI 10.1073/pnas.78.8.4689
   PRATTTERPSTRA IH, 1987, J GEN MICROBIOL, V133, P3199
   PREWETT AB, 1991, T SOC BIOMATER, V14, P105
   PRINGLE JH, 1986, APPL ENVIRON MICROB, V51, P1321
   QUIRYNEN M, 1993, J DENT RES, V72, P1304, DOI 10.1177/00220345930720090801
   REYNOLDS EC, 1983, INFECT IMMUN, V39, P1285
   Richmond D V, 1973, Adv Microb Physiol, V9, P1, DOI 10.1016/S0065-2911(08)60375-6
   ROSENBERG M, 1980, FEMS MICROBIOL LETT, V9, P29, DOI 10.1111/j.1574-6968.1980.tb05599.x
   ROSENBERG M, 1981, APPL ENVIRON MICROB, V42, P375
   RUTTER P R, 1984, P5
   RYDEN C, 1983, J BIOL CHEM, V258, P3396
   SATOU N, 1988, J GEN MICROBIOL, V134, P1299
   SCHELD WM, 1985, P SOC EXP BIOL MED, V180, P474
   SHERBET GV, 1973, BIOCHIM BIOPHYS ACTA, V298, P50, DOI 10.1016/0005-2736(73)90008-4
   SHETH NK, 1985, LANCET, V2, P1266
   SMITH H, 1977, BACTERIOL REV, V41, P475
   SOKATCH JR, 1979, BACTERIA TREATISE ST, P229
   SPEIER JL, 1982, J COLLOID INTERF SCI, V89, P68, DOI 10.1016/0021-9797(82)90121-7
   Sugarman B, 1989, Infect Dis Clin North Am, V3, P187
   SUGARMAN B, 1981, P SOC EXP BIOL MED, V167, P156
   SUTHERLAND IW, 1983, CRC CR REV MICROBIOL, V10, P173
   SWITALSKI LM, 1984, J BIOL CHEM, V259, P3734
   TIMMERMAN CP, 1991, INFECT IMMUN, V59, P4187
   TOJO M, 1988, J INFECT DIS, V157, P713, DOI 10.1093/infdis/157.4.713
   TROY FA, 1979, ANNU REV MICROBIOL, V33, P519, DOI 10.1146/annurev.mi.33.100179.002511
   VANLOOSDRECHT MCM, 1987, APPL ENVIRON MICROB, V53, P1893
   VANLOOSDRECHT MCM, 1987, APPL ENVIRON MICROB, V53, P1898
   VAUDAUX P, 1984, J INFECT DIS, V150, P546, DOI 10.1093/infdis/150.4.546
   VAUDAUX PE, 1984, INFECT IMMUN, V45, P768
   VERHEYEN CCPM, 1993, J BIOMED MATER RES, V27, P775, DOI 10.1002/jbm.820270610
   WANG IW, 1993, J INFECT DIS, V167, P329, DOI 10.1093/infdis/167.2.329
   WESTERGREN G, 1983, INFECT IMMUN, V40, P432
   WICKEN AJ, 1985, BACTERIAL ADHESION M, P45
   YOSHIDA K, 1970, Infection and Immunity, V2, P528
   Zobell CE, 1943, J BACTERIOL, V46, P39
NR 149
TC 638
Z9 653
U1 11
U2 200
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD FAL
PY 1998
VL 43
IS 3
BP 338
EP 348
DI 10.1002/(SICI)1097-4636(199823)43:3<338::AID-JBM16>3.0.CO;2-B
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 112JN
UT WOS:000075490900016
PM 9730073
DA 2018-10-19
ER

PT J
AU Zioupos, P
AF Zioupos, P
TI Recent developments in the study of failure of solid biomaterials and
   bone: 'fracture' and 'pre-fracture' toughness
SO MATERIALS SCIENCE & ENGINEERING C-BIOMIMETIC MATERIALS SENSORS AND
   SYSTEMS
LA English
DT Article
DE biomaterial(s); bone(s); failure; damage; fracture; toughness
ID WALLABY TAIL TENDONS; EQUINE HOOF WALL; MECHANICAL-PROPERTIES; CORTICAL
   BONE; DAMAGE; MICROCRACKING; RUPTURE; ANTLER; NACRE; TESTS
AB Our understanding of the stress and energy requirements for the fracture of solid bio(logical)-materials has improved lately as a result of a number of investigations which highlighted some important new aspects of the failure process. The present short review article shows that under normal circumstances structural 'damage' precedes the creation of a fatal macrocrack and the onset of 'failure'. The externally perceived material 'toughness' is a function of both: (i) the degree of prefailure accumulation of damage and (ii) of the properties of the final fracture surface. These two situations can be distinguished as 'pre-fracture' toughness and 'fracture toughness' and the relative contribution of each one in the overall toughness of the tissue is crucial for the final outcome of the failure process. Inevitably, materials which show remarkable toughness have to enhance their performance with respect to both the previous two defined quantities. (C) 1998 Elsevier Science S.A. All rights reserved.
C1 Cranfield Univ, RMCS, Dept Mat & Med Sci, Shrivenham SN6 8LA, England.
OI ZIOUPOS, PETER/0000-0002-0123-2706
CR BONFIELD W, 1967, J APPL PHYS, V38, P2450, DOI 10.1063/1.1709926
   CARTER DR, 1977, J BIOMECH, V10, P325, DOI 10.1016/0021-9290(77)90005-7
   Currey JD, 1996, J BIOMECH, V29, P257, DOI 10.1016/0021-9290(95)00048-8
   CURREY JD, 1979, J BIOMECH, V12, P313, DOI 10.1016/0021-9290(79)90073-3
   CURREY JD, 1965, J EXP BIOL, V43, P279
   CURREY JD, 1996, 10 C EUR SOC BIOM LE
   FONDRK M, 1988, J BIOMECH, V21, P623, DOI 10.1016/0021-9290(88)90200-X
   Harris B., 1986, ENG COMPOSITE MAT
   JACKSON AP, 1989, COMPOS SCI TECHNOL, V36, P255, DOI 10.1016/0266-3538(89)90024-9
   Kachanov LM, 1958, IZV AKAD NAUK USS TN, V8, P26, DOI DOI 10.1023/A:1018671022008
   Kasapi MA, 1996, J EXP BIOL, V199, P1133
   Kasapi MA, 1997, J EXP BIOL, V200, P1639
   KER RF, 1997, COMMENTS THEOR BIOL, V4, P151
   KITCHENER A, 1987, J ZOOL, V213, P621, DOI 10.1111/j.1469-7998.1987.tb03730.x
   KRAJCINOVIC D, 1995, MECH MATER, V21, P217, DOI 10.1016/0167-6636(95)00010-0
   KRAJCINOVIC D., 1984, APPL MECH REV, V37, P1
   MELVIN JW, 1993, J BIOMECH ENG-T ASME, V115, P549, DOI 10.1115/1.2895538
   MOYLE DD, 1984, J BIOMECH, V17, P203, DOI 10.1016/0021-9290(84)90011-3
   Pattin CA, 1996, J BIOMECH, V29, P69, DOI 10.1016/0021-9290(94)00156-1
   PETERLIK H, COMMUNICATION
   PIEKARSKI K, 1984, NATURAL LIVING BIOMA, P99
   ROBERTSON DM, 1978, J BIOMECH, V11, P359, DOI 10.1016/0021-9290(78)90070-2
   ROGERS LL, 1988, J BIOMECH, V21, P919, DOI 10.1016/0021-9290(88)90130-3
   STOVER SM, 1995, 41 ANN M ORS ORL FL
   Tattersall HG, 1966, J MATER SCI, V1, P296, DOI 10.1007/BF00550177
   VASHISHTH D, 1996, 4I ANN M ORS ATL GA
   WANG RZ, 1995, J MATER SCI, V30, P2299, DOI 10.1007/BF01184577
   WANG XT, 1995, J EXP BIOL, V198, P831
   WANG XT, 1995, J EXP BIOL, V198, P847
   Zioupos P, 1996, J MATER SCI LETT, V15, P991
   ZIOUPOS P, 1994, J MATER SCI, V29, P978, DOI 10.1007/BF00351420
   ZIOUPOS P, 1994, MED ENG PHYS, V16, P203, DOI 10.1016/1350-4533(94)90039-6
   Zioupos P, 1996, J BIOMECH, V29, P989, DOI 10.1016/0021-9290(96)00001-2
   Zioupos P, 1996, CLIN BIOMECH, V11, P365, DOI 10.1016/0268-0033(96)00010-1
NR 34
TC 43
Z9 43
U1 0
U2 8
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0928-4931
J9 MAT SCI ENG C-BIOMIM
JI Mater. Sci. Eng. C-Biomimetic Mater. Sens. Syst.
PD SEP
PY 1998
VL 6
IS 1
BP 33
EP 40
DI 10.1016/S0928-4931(98)00033-2
PG 8
WC Materials Science, Multidisciplinary
SC Materials Science
GA 133GL
UT WOS:000076678700006
DA 2018-10-19
ER

PT J
AU Nzihou, A
   Attias, L
   Sharrock, P
   Ricard, A
AF Nzihou, A
   Attias, L
   Sharrock, P
   Ricard, A
TI A rheological, thermal and mechanical study of bone cement - from a
   suspension to a solid biomaterial
SO POWDER TECHNOLOGY
LA English
DT Article
DE suspension; radiopaque powders; acrylic bone cement; rheology;
   differential scanning calorimetry; mechanical strength
ID PARTICLES; VISCOSITY; BEHAVIOR; COMPOSITES; KINETICS; MODEL
AB Surgical bone cements are mainly based on acrylic (co)polymers, poly(methyl methacrylate) (PMMA) being the most representative. The curing process is the result of free radical polymerization of a suspension of PMMA powder and methyl methacrylate. The fundamental characteristic of the suspensions before polymerization is the viscosity. Therefore, in this paper, the rheological study of a suspension evolving to hard cement by polymerization is discussed. The effect of concentration (volume fraction) of solids, temperature and nature of inorganic compounds used as filler and opaque substances to X-ray radiations on the viscosity of the suspension are examined. Experimental data and models are discussed. The rheological behaviour corresponds to a shear-thickening model typical for concentrated suspension and data fit to a modified Chong equation. Bone cements obtained by polymerization of the suspension were characterized by differential scanning calorimetry to determine the heat released during the polymerization, the degree of reaction and the glass transition temperature. Mechanical properties are also reported and compared with results for existing commercial sources for bone cement. (C) 1998 Elsevier Science S.A. All rights reserved.
C1 ENSIGC, Lab Genie Chim, CNRS, UMR 5503, F-31078 Toulouse, France.
   Univ Toulouse 3, IUT Castres, Chim Inorgan Lab, F-31062 Toulouse, France.
RP Ricard, A (reprint author), ENSIGC, Lab Genie Chim, CNRS, UMR 5503, 18 Chemin Loge, F-31078 Toulouse, France.
CR ACKERMANN NL, 1979, AICHE J, V25, P327, DOI 10.1002/aic.690250216
   *ASTM, F45186 ASTM
   BARNES HA, 1989, J RHEOL, V33, P329, DOI 10.1122/1.550017
   CHARNLEY J, 1965, J Bone Joint Surg Br, V47, P354
   CHARNLEY J, 1964, J BONE JOINT SURG BR, V46, P518
   CHONG JS, 1971, J APPL POLYM SCI, V15, P369, DOI 10.1002/app.1971.070150210
   CHONG JS, 1971, J APPL POLYM SCI, V15, P2007, DOI 10.1002/app.1971.070150818
   Eilers H, 1943, KOLLOID Z, V102, P154
   Einstein A, 1906, ANN PHYS-BERLIN, V19, P289
   FRANKEL NA, 1967, CHEM ENG SCI, V22, P847, DOI 10.1016/0009-2509(67)80149-0
   Ginebra MP, 1996, J MATER SCI-MATER M, V7, P375, DOI 10.1007/BF00154553
   GIUSTI P, 1994, J MATER SCI-MATER M, V5, P858, DOI 10.1007/BF01172025
   JEFFREY DJ, 1976, AICHE J, V22, P417, DOI 10.1002/aic.690220303
   JINESCU VV, 1974, INT CHEM ENG, V14, P397
   KENNY JM, 1990, COMPOS SCI TECHNOL, V38, P339, DOI 10.1016/0266-3538(90)90020-6
   KENNY JM, 1991, POLYM ENG SCI, V31, P1426, DOI 10.1002/pen.760311909
   KUSY RP, 1978, J BIOMED MATER RES, V12, P271, DOI 10.1002/jbm.820120304
   LEONOV AI, 1990, J RHEOL, V34, P1039, DOI 10.1122/1.550109
   MAFFEZZOLI A, 1995, J MATER SCI-MATER M, V6, P155, DOI 10.1007/BF00120292
   Maffezzoli A, 1997, J MATER SCI-MATER M, V8, P75, DOI 10.1023/A:1018502731892
   MARTIN RI, 1995, J MATER SCI-MATER M, V6, P138, DOI 10.1007/BF00120289
   MOONEY M, 1951, J COLLOID SCI, V6, P6
   NOBLE PC, 1983, BIOMATERIALS, V4, P94, DOI 10.1016/0142-9612(83)90047-9
   PAPACHRISTODOULOU G, 1984, POWDER TECHNOL, V40, P353, DOI 10.1016/0032-5910(84)85081-0
   PARK JB, 1992, BIOMATERIALS INTRO, P154
   PEREK J, 1992, J MATER SCI-MATER M, V3, P333, DOI 10.1007/BF00705365
   REYNOLDS CF, 1985, SLEEP, V8, P20, DOI 10.1093/sleep/8.1.20
   ROSCOE R, 1952, BRIT J APPL PHYS, V3, P267, DOI 10.1088/0508-3443/3/8/306
   Rudnick A., 1963, MATER RES STAND, V3, P283
   STORMS RF, 1990, POWDER TECHNOL, V63, P247, DOI 10.1016/0032-5910(90)80050-9
   STRIVENS TA, 1994, ULLMANNS ENCY IND B, V6, P279
   SUDDUTH RD, 1993, J APPL POLYM SCI, V48, P25, DOI 10.1002/app.1993.070480104
   THOMAS DG, 1965, J COLL SCI IMP U TOK, V20, P267, DOI 10.1016/0095-8522(65)90016-4
   THOMAS DG, 1962, AICHE J, V8, P266, DOI 10.1002/aic.690080227
   TSENOGLOU C, 1990, J RHEOL, V34, P15, DOI 10.1122/1.550120
   TSUTSUMI A, 1994, POWDER TECHNOL, V78, P165, DOI 10.1016/0032-5910(93)02800-P
   TURNER RC, 1981, J BIOMED MATER RES, V15, P425, DOI 10.1002/jbm.820150312
NR 37
TC 23
Z9 23
U1 0
U2 4
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0032-5910
J9 POWDER TECHNOL
JI Powder Technol.
PD SEP 1
PY 1998
VL 99
IS 1
BP 60
EP 69
DI 10.1016/S0032-5910(98)00091-6
PG 10
WC Engineering, Chemical
SC Engineering
GA 108TN
UT WOS:000075281700009
DA 2018-10-19
ER

PT J
AU Omstead, DR
   Baird, LG
   Christenson, L
   Du Moulin, G
   Tubo, R
   Maxted, DD
   Davis, J
   Gentile, FT
AF Omstead, DR
   Baird, LG
   Christenson, L
   Du Moulin, G
   Tubo, R
   Maxted, DD
   Davis, J
   Gentile, FT
TI Voluntary guidance for the development of tissue-engineered products
SO TISSUE ENGINEERING
LA English
DT Article
ID CELL; BIODEGRADATION; THERAPIES; IMPLANTS; INVITRO
AB Tissue Engineering is an emerging field of medical research in which there is tremendous activity. Many of these products rely on the use of a cellular component co-formulated with a natural or synthetic biomaterial. At this time, though, there are no consensus safety or efficacy standards for tissue-engineered products. We describe general approaches for assessment of the safety and efficacy of cell-based tissue-engineered products which will lead to reliable medical products for human use. This article provides a general summary of the factors that should be considered in the design and development of cell- and tissue-based products. Seven areas are considered: cell and tissue sourcing; cell and tissue characterization; biomaterials testing; quality assurance; quality control; and nonclinical testing and clinical evaluation. Factors relevant to these areas have been discussed to provide a set of recommendations on which development of products can be standardized. Where relevant, the discussion has been separated in each area to issues that are independent or dependent on cell source. Also, examples are provided of how these guidelines would be applied to two product types that represent somewhat extreme ends of the spectrum for tissue engineering applications. The first example is a product whose mechanism of action is to provide locally-acting structural repair or enhancement in vivo. The second example is a product whose mechanism of action involves systemically distributed physiologically or pharmacologically active products. In general, we have limited the discussion of product types to those that are implanted into the patient for relatively long periods of time. We believe that adoption of these voluntary guidelines would lead to products that are more consistent in quality and performance as well as more rapidly developed.
C1 Reprogenesis Inc, Cambridge, MA 01239 USA.
   CytoTherapeut Inc, Lincoln, RI USA.
   Med Commun, New Haven, CT USA.
   Genzyme Tissue Repair, Cambridge, MA USA.
   IPS, Bridgewater, NJ USA.
CR *ASTM, 1998, ANN M AM SOC TEST MA
   ATALA A, 1994, J UROLOGY, V152, P641, DOI 10.1016/S0022-5347(17)32671-X
   BAKKER D, 1988, BIOMATERIALS, V9, P14, DOI 10.1016/0142-9612(88)90064-6
   BEHLING CA, 1986, J BIOMED MATER RES, V20, P653, DOI 10.1002/jbm.820200509
   BENYA PD, 1982, CELL, V30, P215, DOI 10.1016/0092-8674(82)90027-7
   BINETTE F, IN PRESS J ORTHOP RE
   BOCH B, 1967, PLASTICS SURG
   BRITTBERG M, 1994, NEW ENGL J MED, V331, P889, DOI 10.1056/NEJM199410063311401
   BURGESS FW, 1996, APS ABSTR, V54
   CHRISTENSON L, 1989, J BIOMED MATER RES, V23, P705, DOI 10.1002/jbm.820230704
   CHRISTENSON L, 1988, T AM SOC ART INT ORG, V34, P681
   *CTR BIOL EV RES, 1989, POINTS CONS COLL PRO
   *CTR BIOL EV RES, 1991, POINTS CONS HUM SOM
   Davila J C, 1968, Ann N Y Acad Sci, V146, P138, DOI 10.1111/j.1749-6632.1968.tb20278.x
   DUMOULIN GC, 1994, CYTOTECHNOLOGY, V15, P365, DOI 10.1007/BF00762411
   DUMOULIN GC, 1992, BIOPHARM-APPL T BIO, V5, P32
   FRESJNEY RI, 1994, CULTURE ANIMAL CELLS
   HANSON DJ, 1983, HISTOPATHOLOGICAL EV
   HENCH LL, 1982, BIOMATERIALS INTERFA
   HERZENBERG LA, 1976, SCI AM, V234, P108, DOI 10.1038/scientificamerican0376-108
   INOUE T, 1987, J BIOMED MATER RES, V21, P107, DOI 10.1002/jbm.820210114
   *ISO, 10993 ISO INT ORG ST
   KLEIN CPAT, 1986, BIOMATERIALS, V7, P144
   KORDAN HA, 1967, J THEOR BIOL, V17, P1, DOI 10.1016/0022-5193(67)90014-8
   MARCHANT RE, 1984, J BIOMED MATER RES, V18, P309, DOI 10.1002/jbm.820180307
   MATHIEU M, 1993, BIOL DEV REGULATORY
   MENDENHALL HV, 1986, HDB BIOMATERIALS EVA, P252
   MORELLO JA, 1994, J CLIN MICROBIOL, V32, P811
   OLSON ME, 1995, ENCY HDB BIOMATERI A, V1, P433
   Ostrovski S, 1995, BIOPHARM-TECHNOL BUS, V8, P20
   PEPPAS NA, 1983, STRUCTURE TESTING AP, P199
   PICIOLO GL, 1998, TISSUE ENG, V4, P5
   POLLACK R, 1975, READINGS MAMMALIAN C
   REES DA, 1981, CELLULAR CONTROLS DI
   SCHARP DW, 1994, DIABETES, V43, P1167, DOI 10.2337/diabetes.43.9.1167
   Spilker B., 1990, INSIDE DRUG IND
   STOKES K, 1982, BIOMATERIALS, V3, P25
   Trask B J, 1991, Curr Opin Genet Dev, V1, P82, DOI 10.1016/0959-437X(91)80046-O
   U. S. Food and Drug Administration, 1998, GUID HUM SOM CELL TH
   *US FOOD DRUG ADM, 1993, POINTS CONS SOM CELL
   *US FOOD DRUG ADM, 1996, GUID APPL PROD COMPR
   *US FOOD DRUG ADM, 1997, PROP APPR REG CELL T
   *US FOOD DRUG ADM, 1996, DRAFT PUBL HLTH SERV
   *US FOOD DRUG ADM, 1987, GUID STER DRUG PROD
   *US FOOD DRUG ADM, 1993, POINTS CONS CHAR CEL
   *US FOOD DRUG ADM, 1995, DRAFT DOC CONC SCREE
   *US FOOD DRUG ADM, 1989, POINTS CONS COLL PRO
   *US FOOD DRUG ADM, 1997, DRAFT GUID SUBM CHEM
   *US PHARM CONV, 1995, PHARMACOPEIAL FORUM, V21, P440
   VISSCHER GE, 1986, J BIOMED MATER RES, V20, P667, DOI 10.1002/jbm.820200510
   WALLIN RF, 1995, ENCY HDB BIOMATERI A, V1, P399
   WOOD N K, 1970, Journal of Biomedical Materials Research, V4, P1, DOI 10.1002/jbm.820040102
   Yaeger PC, 1997, EXP CELL RES, V237, P318, DOI 10.1006/excr.1997.3781
   ZIATS NP, 1988, BIOMATERIALS, V9, P5, DOI 10.1016/0142-9612(88)90063-4
NR 54
TC 24
Z9 24
U1 0
U2 3
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA
SN 1076-3279
J9 TISSUE ENG
JI Tissue Eng.
PD FAL
PY 1998
VL 4
IS 3
BP 239
EP 266
DI 10.1089/ten.1998.4.239
PG 28
WC Cell & Tissue Engineering
SC Cell Biology
GA 126ZC
UT WOS:000076324400002
PM 9836789
DA 2018-10-19
ER

PT J
AU Gray, C
AF Gray, C
TI Advanced bone formation in grooves in vitro is not restricted to
   calcified biological materials
SO TISSUE ENGINEERING
LA English
DT Article
ID IN-VITRO; RAT CALVARIA; INVITRO; OSTEOBLASTS; IMPLANTS; TISSUE; CELLS
AB The aim of this in vitro study was to investigate whether the phenomenon of advanced bone formation in grooves (Bone 18, 115, 1995) is restricted to calcified biological materials. Osteoblasts were released from neonatal rat calvaria by enzyme digestion and cultured in EMEM and 10% FCS. At confluence, they were seeded on to dentine, bone, plastic, titanium, or silicon, which had been grooved using a water-cooled, diamond-edged, slow-speed or high-speed circular saw or reciprocating wire saw, or a rotating dental burr. Cultures were continued for 14-21 days, with a few extended for up to 7 weeks. Osteoblasts were also cultured on grooved dentine and plastic with or without added Stanozolol for 18 days, and bone formation assayed by measuring the total length of bone formed in the grooves in each specimen. Bone formation always occurred first within the grooves and was appositional. It formed on both calcified biological and nonbiological substrates, but developed consistently earlier on the biological substrates, and conformed to both the main grooves and the secondary finer grooving within them. Surface features at scales ranging from the millimeter to nanometer therefore influence the development of bone in vitro and possibly in vivo. The described site-induced bone formation system is valuable as an in vitro assay for biomaterial and pharmaceutical research.
C1 Univ London Univ Coll, Dept Anat & Dev Biol, Hard Tissue Res Unit, London WC1E 6BT, England.
CR BELLOWS CG, 1986, CALCIFIED TISSUE INT, V38, P143, DOI 10.1007/BF02556874
   Chehroudi B, 1997, J BIOMED MATER RES, V34, P279
   CHEHROUDI B, 1992, CELL MATER, V2, P89
   CLARK P, 1990, DEVELOPMENT, V108, P635
   GOMI K, 1993, J BIOMED MATER RES, V27, P429, DOI 10.1002/jbm.820270403
   Gray C, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 1, P142
   Gray C, 1996, BONE, V18, P115, DOI 10.1016/8756-3282(95)00456-4
   JONES SJ, 1993, ANAT EMBRYOL, V187, P343
   Jones SJ, 1997, BONE, V21, P393, DOI 10.1016/S8756-3282(97)00174-9
   JONES SJ, 1994, ANAT EMBRYOL, V190, P339
   JONES SJ, 1975, CELL TISSUE RES, V159, P73
   JONES SJ, 1979, SCANNING ELECTRON MI, V2, P529
   MALAVAL L, 1994, J CELL PHYSIOL, V158, P555, DOI 10.1002/jcp.1041580322
   NEFUSSI JR, 1985, DIFFERENTIATION, V29, P160, DOI 10.1111/j.1432-0436.1985.tb00310.x
   Qu J, 1996, Oral Dis, V2, P102
   SILVE C, 1992, CALCIFIED TISSUE INT, V51, P363, DOI 10.1007/BF00316881
   WojciakStothard B, 1996, EXP CELL RES, V223, P426, DOI 10.1006/excr.1996.0098
NR 17
TC 7
Z9 7
U1 0
U2 1
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA
SN 1076-3279
J9 TISSUE ENG
JI Tissue Eng.
PD FAL
PY 1998
VL 4
IS 3
BP 315
EP 323
DI 10.1089/ten.1998.4.315
PG 9
WC Cell & Tissue Engineering
SC Cell Biology
GA 126ZC
UT WOS:000076324400007
PM 9836794
DA 2018-10-19
ER

PT J
AU Shi, X
   Datta, AK
   Throop, JA
AF Shi, X
   Datta, AK
   Throop, JA
TI Mechanical property changes during freezing of a biomaterlal
SO TRANSACTIONS OF THE ASAE
LA English
DT Article
DE biomaterials; freezing; thermal stress; fracture analysis;
   viscoelasticity; failure strength; failure strain
ID STRESS; ICE
AB Biomaterials freeze over a temperature range, during which their mechanical properties change dramatically. Young's modulus of the tested biomaterial (potato tissue) increases almost three orders of magnitude as temperature is decreased below freezing. This change is not proportional to the fraction of ice formed. The relaxation of the material is initially faster as more ice is formed, an effect attributed to faster relaxation of ice. When the ice formation is complete, further lowering of temperature makes the relaxation slower; art effect attributed to temperature itself as distinct from change of phase. As the temperature lowers, more ice forms and the material behaves more brittle, decreasing the failure strains. The compressive and tensile failure strength increases with drop in temperature. The energy to failure drops significantly with decrease in temperature and increase in strain rate.
C1 Cornell Univ, Dept Agr & Biol Engn, Ithaca, NY 14853 USA.
RP Datta, AK (reprint author), Cornell Univ, Dept Agr & Biol Engn, Riley Robb Hall, Ithaca, NY 14853 USA.
RI Datta, Ashim/K-2294-2012
OI Datta, Ashim/0000-0002-1397-6892
CR Christensen R. M., 1971, THEORY VISCOELASTICI
   CHUMA Y, 1983, T ASAE, V26, P1258
   FINNEY E. E., 1967, Transactions of the American Society of Agricultural Engineers, V10, P4
   FUJIKAWA S, 1992, PHYSICS CHEM ICE
   Fung Y. C., 1990, BIOMECHANICS MOTION
   HELDMAN DR, 1974, T ASAE, V17, P63
   Higashi A., 1964, Japanese Journal of Applied Physics, V3, P610, DOI 10.1143/JJAP.3.610
   HUNT CJ, 1994, CRYOBIOLOGY, V31, P506, DOI 10.1006/cryo.1994.1061
   KHAN AA, 1989, THESIS U READING REA
   Kim N.K, 1993, THESIS U GEORGIA ATH
   KIM NK, 1994, J FOOD SCI, V59, P669, DOI 10.1111/j.1365-2621.1994.tb05590.x
   LAVERTY J, 1991, FOOD FREEZING TODAY
   MELLOR M, 1982, COLD REG SCI TECHNOL, V5, P201, DOI 10.1016/0165-232X(82)90015-5
   MELLOR M, 1980, PHYSICS MECH ICE
   MICHEL B, 1978, ICE MECH 98
   MORROW CT, 1981, J FOOD SCI, V31, P689
   Mott L. F., 1964, AUST REFRIG AIR COND, V18, P16
   Niklas K.J., 1992, PLANT BIOMECHANICS E
   Pitt R. E., 1992, VISCOELASTIC PROPERT
   POUNDER ER, 1965, PHYSICS ICE
   Rahman S., 1995, FOOD PROPERTIES HDB
   RICE RW, 1991, MATER RES SOC SYMP P, V207, P229
   RUBINSKY B, 1980, CRYOBIOLOGY, V17, P66, DOI 10.1016/0011-2240(80)90009-7
   SHANLEY FR, 1957, STRENGTH MAT, P123
   SHI X, 1996, THESIS CORNELL U ITH
   SHI X, 1998, IN PRESS J THERMAL S
   SHI X, 1998, IN PRESS T ASME
   *USDA, 1976, USDA AGR HDB, V8
   Ward IM, 1993, INTRO MECH PROPERTIE
   WATANABE H, 1995, J FOOD ENG, V24, P113, DOI 10.1016/0260-8774(94)P1612-2
NR 30
TC 12
Z9 18
U1 1
U2 2
PU AMER SOC AGRICULTURAL ENGINEERS
PI ST JOSEPH
PA 2950 NILES RD, ST JOSEPH, MI 49085-9659 USA
SN 0001-2351
J9 T ASAE
JI Trans. ASAE
PD SEP-OCT
PY 1998
VL 41
IS 5
BP 1407
EP 1414
PG 8
WC Agricultural Engineering
SC Agriculture
GA 131CR
UT WOS:000076558600023
DA 2018-10-19
ER

PT J
AU Papkovsky, DB
   Ovchinnikov, AN
   Ogurtsov, VI
   Ponomarev, GV
   Korpela, T
AF Papkovsky, DB
   Ovchinnikov, AN
   Ogurtsov, VI
   Ponomarev, GV
   Korpela, T
TI Biosensors on the basis of luminescent oxygen sensor: the use of
   microporous light-scattering support materials
SO SENSORS AND ACTUATORS B-CHEMICAL
LA English
DT Article; Proceedings Paper
CT 4th European Conference on Optical Chemical Sensors and Biosensors
CY MAR 29-APR 01, 1998
CL MUNSTER, GERMANY
DE oxygen sensor; luminescent; sensor membrane
ID OPTICAL SENSORS
AB New sensor technology and materials for luminescence-based oxygen sensors are described, which utilise microporous light-scattering support in sensor fabrication. Such materials display a number of new features and advantages over conventional oxygen sensor membranes, such as, significantly increased levels of luminescent signals obtainable from the sensor, better mechanical, physical and optical properties and a high capacity for loading biomaterial. The new oxygen sensor technology enables simple and robust procedures of sensor fabrication, as well as saving of the sensing materials, bringing down sensor photobleaching, and improvement in reliability of measurements and signal resolution. Biosensors developed on the basis of the above luminescent oxygen-sensitive materials used as chemical transducers, are described. Direct immobilisation of oxidase enzymes of the oxygen sensor membranes allows simple assays of metabolites. In particular, new batch-type enzyme biosensor for glucose has been investigated, using a new heterogeneous assay format. The latter allows simple, fast and highly reproducible analysis of important metabolites. (C) 1998 Elsevier Science S.A. All rights reserved.
C1 Natl Univ Ireland Univ Coll Cork, Dept Biochem, Cork, Ireland.
   Minist Hlth, Mol Diagnost Res Ctr, Dept Biosensors, Moscow 113149, Russia.
   Univ Turku, Joint Biotechnol Lab, FIN-20520 Turku, Finland.
RP Papkovsky, DB (reprint author), Natl Univ Ireland Univ Coll Cork, Dept Biochem, Lee Maltings,Prospect Row, Cork, Ireland.
EM dbp@ucc.ie
OI Papkovsky, Dmitri/0000-0003-1556-1145
CR BESWICK RB, 1988, CHEM PHYS LETT, V143, P589, DOI 10.1016/0009-2614(88)87072-6
   Brandrup J., 1989, POLYM HDB
   Hartmann P, 1996, ANAL CHEM, V68, P2615, DOI 10.1021/ac960008k
   HE HR, 1995, SENSOR ACTUAT B-CHEM, V29, P246, DOI 10.1016/0925-4005(95)01690-2
   JONES TP, 1988, ANAL CHEM, V60, P404, DOI 10.1021/ac00156a006
   MACCRAITH BD, 1995, SENSOR ACTUAT B-CHEM, V29, P51, DOI 10.1016/0925-4005(95)01662-7
   MEIR B, 1995, SENSOR ACTUAT B-CHEM, V29, P240
   *MILL LAB, 1996, MILL LAB CAT
   MOHR GJ, 1994, ANAL CHIM ACTA, V292, P41, DOI 10.1016/0003-2670(94)00096-4
   MORENOBONDI MC, 1990, ANAL CHEM, V62, P2377, DOI 10.1021/ac00220a021
   MUNKHOLM C, 1988, TALANTA, V35, P109, DOI 10.1016/0039-9140(88)80047-X
   PAPKOVSKY DB, 1993, SENSOR ACTUAT B-CHEM, V11, P525, DOI 10.1016/0925-4005(93)85298-O
   PAPKOVSKY DB, 1995, ANAL CHEM, V67, P4112, DOI 10.1021/ac00118a013
   TAN WH, 1992, SCIENCE, V258, P778, DOI 10.1126/science.1439785
   Trettnak W., 1993, FLUORESCENCE SPECTRO, P79
   WEIGL BH, 1994, ANAL CHEM, V66, P3323, DOI 10.1021/ac00092a007
   WOLFBEIS OS, 1988, ANAL CHEM, V60, P2028, DOI 10.1021/ac00170a009
   WOLFBEIS OS, 1991, FIBRE OPTICS CHEM SE
   WOLFBEIS OS, 1996, P AACC S BLOOD GAS B, P68
NR 19
TC 40
Z9 40
U1 0
U2 10
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0925-4005
J9 SENSOR ACTUAT B-CHEM
JI Sens. Actuator B-Chem.
PD AUG 31
PY 1998
VL 51
IS 1-3
BP 137
EP 145
DI 10.1016/S0925-4005(98)00171-3
PG 9
WC Chemistry, Analytical; Electrochemistry; Instruments & Instrumentation
SC Chemistry; Electrochemistry; Instruments & Instrumentation
GA 156WD
UT WOS:000078024400019
DA 2018-10-19
ER

PT J
AU Brown, GL
   Maheshwari, G
   Lauffenburger, DA
   Griffith, LG
AF Brown, GL
   Maheshwari, G
   Lauffenburger, DA
   Griffith, LG
TI Nanoscale control of receptor-ligand interactions at biomaterial
   surfaces.
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
C1 MIT, Dept Chem Engn, Cambridge, MA 02139 USA.
   MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA.
   MIT, Ctr Biomed Engn, Cambridge, MA 02139 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD AUG 23
PY 1998
VL 216
MA 089-BTEC
BP U269
EP U270
PN 3
PG 2
WC Chemistry, Multidisciplinary
SC Chemistry
GA 107WZ
UT WOS:000075235100826
DA 2018-10-19
ER

PT J
AU Razatos, AP
   Ong, YL
   Sharma, MM
   Georgiou, G
AF Razatos, AP
   Ong, YL
   Sharma, MM
   Georgiou, G
TI Evaluating the interaction between bacteria and biomaterial surfaces
   using Atomic Force Microscopy.
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
C1 Univ Texas, Dept Chem Engn, Austin, TX 78712 USA.
   Univ Texas, Dept Petr Engn, Austin, TX 78712 USA.
NR 0
TC 2
Z9 2
U1 0
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD AUG 23
PY 1998
VL 216
MA 093-BTEC
BP U271
EP U271
PN 3
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA 107WZ
UT WOS:000075235100830
DA 2018-10-19
ER

PT J
AU Szleifer, I
AF Szleifer, I
TI Molecular design of biomaterial: Prevention of protein adsorption by
   grafted polymer layers.
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
C1 Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.
RI Szleifer, Igal/B-6920-2009
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD AUG 23
PY 1998
VL 216
MA 463-PHYS
BP U794
EP U794
PN 2
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA 107WY
UT WOS:000075235002392
DA 2018-10-19
ER

PT J
AU Babensee, JE
   Anderson, JM
   McIntire, LV
   Mikos, AG
AF Babensee, JE
   Anderson, JM
   McIntire, LV
   Mikos, AG
TI Host response to tissue engineered devices
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE biocompatibility; biomaterials; cell transplantation; immune response;
   immunoisolation; inflammatory response
ID BIODEGRADABLE POLYMER SCAFFOLDS; HEPATOMA HEPG2 CELLS; NERVE
   GROWTH-FACTOR; DIABETIC NOD MICE; BIOHYBRID ARTIFICIAL PANCREAS; INITIAL
   CLINICAL-EXPERIENCE; IN-SITU PHOTOPOLYMERIZATION; FRACTURE FIXATION
   IMPLANTS; CTLA4-IG PROLONGS SURVIVAL; CULTURED ISLET ALLOGRAFTS
AB The two main components of a tissue engineered device are the transplanted cells and the biomaterial, creating a device for the restoration or modification of tissue or organ function. The implantation of polymer/cell constructs combines concepts of biomaterials and cell transplantation. The interconnections between the host responses to the biomaterial and transplanted cells determines the biocompatibility of the device. This review describes the inflammatory response to the biomaterial component and immune response towards transplanted cells. Emphasis is on how the presence of the transplanted cell construct affects the host response. The inflammatory response towards a biomaterial can impact the immune response towards transplanted cells and vice versa. Immune rejection is the most important host response towards the cellular component of tissue engineered devices containing allogeneic, xenogeneic or immunogenic ex vivo manipulated autologous cells. The immune mechanisms towards allografts and xenografts are outlined to provide a basis for the mechanistic hypotheses of the immune response towards encapsulated cells, with antigen shedding and the indirect pathway of antigen presentation predominating. A review of experimental evidence illustrates examples of the inflammatory response towards biodegradable polymer scaffold materials, examples of devices appropriately integrated as assessed morphologically with the host for various applications including bone, nerve, and skin regeneration, and of the immune response towards encapsulated allogeneic and xenogeneic cells. (C) 1998 Elsevier Science B.V. All rights reserved.
C1 Rice Univ, Inst Biosci & Bioengn, Cox Lab Biomed Engn, Houston, TX 77005 USA.
   Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA.
RP Mikos, AG (reprint author), Rice Univ, Inst Biosci & Bioengn, Cox Lab Biomed Engn, 6100 S Main, Houston, TX 77005 USA.
CR Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0
   ABBAS AK, 1991, CELLULAR MOL IMMUNOL
   ABLAMUNITS V, 1994, CELL TRANSPLANT, V3, P55
   Aebischer P, 1996, NAT MED, V2, P696, DOI 10.1038/nm0696-696
   AEBISCHER P, 1991, BRAIN RES, V560, P43, DOI 10.1016/0006-8993(91)91212-J
   AEBISCHER P, 1994, EXP NEUROL, V126, P151, DOI 10.1006/exnr.1994.1053
   ALHENDY A, 1995, HUM GENE THER, V6, P165, DOI 10.1089/hum.1995.6.2-165
   ALTER BJ, 1990, J EXP MED, V171, P333, DOI 10.1084/jem.171.1.333
   Anderson J. M., 1998, FRONTIERS TISSUE ENG, P152
   Anderson James M., 1995, P223
   ANDERSON JM, 1993, CARDIOVASC PATHOL, V2, pS33
   ANDERSON JM, 1981, J BIOMED MATER RES, V15, P889, DOI 10.1002/jbm.820150613
   ANDERSON JM, 1998, T AM SOC INTERN ORGA, V34, P101
   ANDERSON JM, 1988, T AM SOC ART INT ORG, V34, P101
   ARNAOUT WS, 1990, J SURG RES, V48, P379, DOI 10.1016/0022-4804(90)90079-H
   ATALA A, 1992, J UROLOGY, V148, P658, DOI 10.1016/S0022-5347(17)36685-5
   AUCHINCLOSS H, 1990, TRANSPL P, V22, P1
   BABENSEE JE, 1992, J BIOMED MATER RES, V26, P1401, DOI 10.1002/jbm.820261102
   Bach FH, 1997, NAT MED, V3, P196, DOI 10.1038/nm0297-196
   BARRERA DA, 1993, J AM CHEM SOC, V115, P11010, DOI 10.1021/ja00076a077
   BENHAMOU PY, 1995, HORM METAB RES, V27, P113, DOI 10.1055/s-2007-979921
   BERGMANN L, 1992, FEBS LETT, V299, P103, DOI 10.1016/0014-5793(92)80110-3
   Beumer G. J., 1993, Clinical Materials, V14, P21, DOI 10.1016/0267-6605(93)90043-7
   BEUMER GJ, 1994, BIOMATERIALS, V15, P551, DOI 10.1016/0142-9612(94)90022-1
   BEUMER GJ, 1993, BIOMATERIALS, V14, P598, DOI 10.1016/0142-9612(93)90178-5
   Block GD, 1996, J CELL BIOL, V132, P1133, DOI 10.1083/jcb.132.6.1133
   BODZIONY J, 1992, RES EXP MED, V192, P305, DOI 10.1007/BF02576287
   BOSTMAN O, 1990, J BONE JOINT SURG BR, V72, P592
   BOSTMAN O, 1992, ACTA ORTHOP SCAND, V63, P173, DOI 10.3109/17453679209154817
   BOSTMAN OM, 1991, J BONE JOINT SURG BR, V73, P679
   BOSTMAN OM, 1992, CLIN ORTHOP RELAT R, P193
   Brauker J, 1996, TRANSPLANTATION, V61, P1671, DOI 10.1097/00007890-199606270-00002
   BRAUKER J, 1992, CELL TRANSPLANT, V1, P163
   BRAUKER J, 1992, CELL TRANSPLANT, V1, P164
   BRAUKER JH, 1995, J BIOMED MATER RES, V29, P1517, DOI 10.1002/jbm.820291208
   BRUNI S, 1989, BIOMATER ARTIF CELL, V17, P403, DOI 10.3109/10731198909118855
   Buchser E, 1996, ANESTHESIOLOGY, V85, P1005, DOI 10.1097/00000542-199611000-00007
   BYRNE DJ, 1991, BRIT J SURG, V78, P841, DOI 10.1002/bjs.1800780723
   Byrne G, 1997, TRANSPLANTATION, V63, P149, DOI 10.1097/00007890-199701150-00027
   CAI ZH, 1989, HEPATOLOGY, V10, P855, DOI 10.1002/hep.1840100518
   CAO Y, 1994, TRANSPLANT P, V26, P3390
   Carr-Brendel V E, 1997, Methods Mol Biol, V63, P373
   CAVALLARO JF, 1994, BIOTECHNOL BIOENG, V43, P781, DOI 10.1002/bit.260430813
   CHANDLER C, 1993, ARCH SURG-CHICAGO, V128, P279
   CLAYTON HA, 1993, ACTA DIABETOL, V30, P181, DOI 10.1007/BF00569928
   Clement JD, 1996, TRANSPLANTATION, V62, P388, DOI 10.1097/00007890-199608150-00015
   COLE DR, 1992, DIABETOLOGIA, V35, P231, DOI 10.1007/BF00400922
   Colten H R, 1979, Ann N Y Acad Sci, V332, P482, DOI 10.1111/j.1749-6632.1979.tb47142.x
   COLTON CK, 1991, T ASME, V113, P152
   Cook AD, 1997, J BIOMED MATER RES, V35, P513
   Cooper NR, 1983, HEMATOLOGY
   COULOMBE M, 1994, TRANSPLANTATION, V57, P1201, DOI 10.1097/00007890-199404270-00011
   COULOMBE M, 1994, TRANSPLANTATION, V57, P1195, DOI 10.1097/00007890-199404270-00010
   CROOKS CA, 1990, J BIOMED MATER RES, V24, P1241, DOI 10.1002/jbm.820240908
   CUNNINGHAM AC, 1994, IMMUNOLOGY, V81, P268
   DeFife KM, 1997, J IMMUNOL, V158, P3385
   DEFRANCO AL, 1987, ANNU REV CELL BIOL, V3, P143
   deGroot JH, 1997, BIOMATERIALS, V18, P613, DOI 10.1016/S0142-9612(96)00169-X
   denDunnen WFA, 1996, J BIOMED MATER RES, V31, P105, DOI 10.1002/(SICI)1097-4636(199605)31:1<105::AID-JBM13>3.0.CO;2-M
   denDunnen WFA, 1997, J BIOMED MATER RES, V36, P337, DOI 10.1002/(SICI)1097-4636(19970905)36:3<337::AID-JBM9>3.3.CO;2-8
   DeVos P, 1997, TRANSPLANTATION, V63, P824, DOI 10.1097/00007890-199703270-00006
   DIXIT V, 1995, J BIOMAT SCI-POLYM E, V7, P343
   DORLING A, 1996, XENO, V4, P68
   Ellis DL, 1996, BIOMATERIALS, V17, P291, DOI 10.1016/0142-9612(96)85567-0
   EMERICH DF, 1994, EXP NEUROL, V130, P141, DOI 10.1006/exnr.1994.1193
   EMERICH DF, 1994, J COMP NEUROL, V349, P148, DOI 10.1002/cne.903490110
   EMERICH DF, 1994, PROG NEURO-PSYCHOPH, V18, P935, DOI 10.1016/0278-5846(94)90109-0
   FALUS A, 1990, MOL IMMUNOL, V27, P197, DOI 10.1016/0161-5890(90)90115-G
   FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664
   FONTAINE M, 1995, J PEDIATR SURG, V30, P56, DOI 10.1016/0022-3468(95)90610-X
   FRASER RB, 1995, CELL TRANSPLANT, V4, P529, DOI 10.1016/0963-6897(95)00012-M
   FREED LE, 1993, J BIOMED MATER RES, V27, P11, DOI 10.1002/jbm.820270104
   FREED LE, 1994, J BIOMED MATER RES, V28, P891, DOI 10.1002/jbm.820280808
   FRYER JP, 1995, TRANSPLANTATION, V59, P171, DOI 10.1097/00007890-199501270-00003
   FU XW, 1989, TRANSPLANTATION, V47, P432, DOI 10.1097/00007890-198903000-00006
   GILBERT JC, 1993, TRANSPLANTATION, V56, P423, DOI 10.1097/00007890-199308000-00033
   GILL RG, 1995, CELL TRANSPLANT, V4, P361, DOI 10.1016/0963-6897(95)00019-T
   Grande D A, 1995, Tissue Eng, V1, P345, DOI 10.1089/ten.1995.1.345
   GREEN H, 1979, P NATL ACAD SCI USA, V76, P5665, DOI 10.1073/pnas.76.11.5665
   Greisler HP, 1996, BIOMATERIALS, V17, P329, DOI 10.1016/0142-9612(96)85571-2
   GUENARD V, 1992, J NEUROSCI, V12, P3310
   HABIBULLAH CM, 1995, TRANSPLANTATION, V59, P1495, DOI 10.1097/00007890-199505270-00027
   HAMMANG JP, 1995, CELL TRANSPLANT, V4, pS27, DOI 10.1016/0963-6897(94)00069-V
   HASSE C, 1994, WORLD J SURG, V18, P630, DOI 10.1007/BF00353783
   HILL RS, 1994, PANCREATIC ISLET TRA, V3, P147
   HILLWEST JL, 1994, P NATL ACAD SCI USA, V91, P5967, DOI 10.1073/pnas.91.13.5967
   HILLWEST JL, 1994, OBSTET GYNECOL, V83, P59
   HOFFMAN D, 1993, EXP NEUROL, V122, P100, DOI 10.1006/exnr.1993.1111
   Holder WD, 1997, TISSUE ENG, V3, P149, DOI 10.1089/ten.1997.3.149
   Hollinger JO, 1996, BIOMATERIALS, V17, P187, DOI 10.1016/0142-9612(96)85763-2
   HUBBELL JA, 1995, BIO-TECHNOL, V13, P565, DOI 10.1038/nbt0695-565
   HUGHES M, 1994, HUM GENE THER, V5, P1445, DOI 10.1089/hum.1994.5.12-1445
   HUOT AE, 1992, BIOCHEM BIOPH RES CO, V182, P151, DOI 10.1016/S0006-291X(05)80124-X
   INTVELD PJA, 1994, J POLYM SCI POL CHEM, V32, P1063, DOI 10.1002/pola.1994.080320608
   IRWIN MJ, 1989, J EXP MED, V170, P1091, DOI 10.1084/jem.170.4.1091
   Ishaug SL, 1997, J BIOMED MATER RES, V36, P17
   ISHAUG SL, 1994, J BIOMED MATER RES, V28, P1445, DOI 10.1002/jbm.820281210
   IshaugRiley SL, 1997, J BIOMED MATER RES, V36, P1, DOI 10.1002/(SICI)1097-4636(199707)36:1<1::AID-JBM1>3.0.CO;2-P
   IWATA H, 1989, DIABETES, V38, P224, DOI 10.2337/diab.38.1.S224
   IWATA H, 1992, J BIOMED MATER RES, V26, P967, DOI 10.1002/jbm.820260711
   JOHNSON LB, 1994, CELL TRANSPLANT, V3, P273, DOI 10.1177/096368979400300403
   JOSEPH JM, 1994, CELL TRANSPLANT, V3, P355, DOI 10.1177/096368979400300502
   Juang JH, 1996, TRANSPLANTATION, V61, P1557, DOI 10.1097/00007890-199606150-00001
   KAHAN BD, 1992, CURR OPIN IMMUNOL, V4, P553, DOI 10.1016/0952-7915(92)90025-A
   KAN M, 1989, P NATL ACAD SCI USA, V86, P7432, DOI 10.1073/pnas.86.19.7432
   KAO WYJ, 1995, J BIOMED MATER RES, V29, P1267, DOI 10.1002/jbm.820291014
   Kaufmann PM, 1997, CELL TRANSPLANT, V6, P463, DOI 10.1016/S0963-6897(97)00052-3
   Kessler L, 1996, J LEUKOCYTE BIOL, V60, P729
   Kim TH, 1997, TISSUE ENG, V3, P303, DOI 10.1089/ten.1997.3.303
   KORDOWER JH, 1994, P NATL ACAD SCI USA, V91, P10898, DOI 10.1073/pnas.91.23.10898
   KORDOWER JH, 1995, CELL TRANSPLANT, V4, P155, DOI 10.1016/0963-6897(95)90031-4
   KRONCKE KD, 1991, DIABETOLOGIA, V34, P232, DOI 10.1007/BF00405081
   KVALE D, 1993, J HEPATOL, V17, P347, DOI 10.1016/S0168-8278(05)80216-8
   LACY PE, 1991, SCIENCE, V254, P1782, DOI 10.1126/science.1763328
   LAFFERTY KJ, 1978, BLOOD CELLS, V4, P395
   LAM KH, 1995, J BIOMED MATER RES, V29, P929, DOI 10.1002/jbm.820290804
   LAM KH, 1994, J MATER SCI-MATER M, V5, P181, DOI 10.1007/BF00121086
   LAM KH, 1993, J BIOMED MATER RES, V27, P1569, DOI 10.1002/jbm.820271214
   LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529
   LANGONE F, 1995, BIOMATERIALS, V16, P347, DOI 10.1016/0142-9612(95)93851-4
   LANZA RP, 1993, TRANSPLANT P, V25, P978
   LANZA RP, 1994, TRANSPLANTATION, V57, P1371, DOI 10.1097/00007890-199405150-00015
   LANZA RP, 1991, P NATL ACAD SCI USA, V88, P11100, DOI 10.1073/pnas.88.24.11100
   LANZA RP, 1992, ENDOCRINOLOGY, V131, P637, DOI 10.1210/en.131.2.637
   Laurencin CT, 1996, J BIOMED MATER RES, V30, P133, DOI 10.1002/(SICI)1097-4636(199602)30:2<133::AID-JBM1>3.0.CO;2-S
   LEE RS, 1994, J EXP MED, V179, P865, DOI 10.1084/jem.179.3.865
   LEE SC, 1994, J BIOMED MATER RES, V28, P1149, DOI 10.1002/jbm.820281005
   LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143
   LIEBERGALL M, 1994, BONE FORMATION REPAI
   LINDNER MD, 1995, EXP NEUROL, V132, P62, DOI 10.1016/0014-4886(95)90059-4
   LIU HW, 1993, HUM GENE THER, V4, P291, DOI 10.1089/hum.1993.4.3-291
   Loudovaris T., 1994, Cell Transplantation, V3, P247
   Loudovaris T, 1996, TRANSPLANTATION, V61, P1678, DOI 10.1097/00007890-199606270-00003
   Louie LK, 1997, TISSUE ENG, V3, P187, DOI 10.1089/ten.1997.3.187
   LU CY, 1994, FASEB J, V8, P1122
   MAKI T, 1993, TRANSPLANTATION, V55, P713, DOI 10.1097/00007890-199304000-00005
   MAKI T, 1991, TRANSPLANTATION, V51, P43, DOI 10.1097/00007890-199101000-00006
   Martin C, 1996, BIOMATERIALS, V17, P2373, DOI 10.1016/S0142-9612(96)00075-0
   MARTINEZ OM, 1992, TRANSPLANTATION, V53, P449, DOI 10.1097/00007890-199202010-00035
   MARTINSON L, 1995, CELL TRANSPLANT, V3, P249
   MARTINSON LA, 1992, CELL TRANSPLANT, V1, P171
   MCDIARMID SV, 1994, TRANSPLANTATION, V58, P690
   McNally AK, 1996, AM J PATHOL, V149, P975
   MCNALLY AK, 1995, AM J PATHOL, V147, P1487
   MEISER BM, 1994, TRANSPLANT P, V26, P3181
   MERLE M, 1989, MICROSURG, V10, P130, DOI 10.1002/micr.1920100213
   MIKOS AG, 1993, BIOTECHNOL BIOENG, V42, P716, DOI 10.1002/bit.260420606
   MIKOS AG, 1994, POLYMER, V35, P1068, DOI 10.1016/0032-3861(94)90953-9
   Miller M J, 1996, Tissue Eng, V2, P51, DOI 10.1089/ten.1996.2.51
   MONCADA S, 1991, PHARMACOL REV, V43, P109
   MOONEY DJ, 1995, J BIOMED MATER RES, V29, P959, DOI 10.1002/jbm.820290807
   MOONEY DJ, 1994, CELL TRANSPLANT, V3, P203, DOI 10.1177/096368979400300209
   Mooney DT, 1996, BIOMATERIALS, V17, P115, DOI 10.1016/0142-9612(96)85756-5
   MORRIS CF, 1995, J IMMUNOL, V154, P2470
   MOSES RD, 1992, TRANSPLANTATION, V53, P203, DOI 10.1097/00007890-199201000-00039
   MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5
   MULLER W, 1978, J IMMUNOL, V121, P1578
   Murphy B, 1996, TRANSPLANTATION, V61, P1133, DOI 10.1097/00007890-199604270-00001
   Nakaoka R, 1996, BIOMATERIALS, V17, P2253, DOI 10.1016/0142-9612(96)00034-8
   NAVE M, 1992, Journal of Burn Care and Rehabilitation, V13, P147, DOI 10.1097/00004630-199201000-00033
   Nehrer S, 1997, BIOMATERIALS, V18, P769, DOI 10.1016/S0142-9612(97)00001-X
   NEWGARD CB, 1994, DIABETES, V43, P341, DOI 10.2337/diabetes.43.3.341
   NYBERG SL, 1993, CELL TRANSPLANT, V2, P441, DOI 10.1177/096368979300200602
   OCONNELL PJ, 1993, J IMMUNOL, V150, P1093
   OLUWOLE SF, 1994, TRANSPLANTATION, V58, P1077, DOI 10.1097/00007890-199411270-00004
   ORGAN GM, 1993, TRANSPLANT P, V25, P998
   Pachence JM, 1996, J BIOMED MATER RES, V33, P35, DOI 10.1002/(SICI)1097-4636(199621)33:1<35::AID-JBM6>3.0.CO;2-N
   PANIS Y, 1994, GASTROEN CLIN BIOL, V18, P262
   PEPPAS NA, 1994, SCIENCE, V263, P1715, DOI 10.1126/science.8134835
   PERLMUTTER DH, 1989, J BIOL CHEM, V264, P7669
   PERLMUTTER DH, 1989, J CLIN INVEST, V84, P138, DOI 10.1172/JCI114133
   Peter SJ, 1998, J BIOMED MATER RES, V41, P1
   Picha GJ, 1996, J BIOMED MATER RES, V30, P305
   Platt J L, 1992, ASAIO J, V38, P8, DOI 10.1097/00002480-199201000-00005
   PUKEL C, 1988, DIABETES, V37, P133, DOI 10.2337/diabetes.37.1.133
   RABINOVITCH A, 1990, J CLIN ENDOCR METAB, V71, P152, DOI 10.1210/jcem-71-1-152
   Reddi A. Hari, 1994, Current Opinion in Genetics and Development, V4, P737, DOI 10.1016/0959-437X(94)90141-O
   REID KBM, 1977, BIOCHEM J, V167, P647, DOI 10.1042/bj1670647
   Roberts T, 1996, BIOMATERIALS, V17, P267, DOI 10.1016/0142-9612(96)85564-5
   ROZEMA FR, 1994, J MATER SCI-MATER M, V5, P575, DOI 10.1007/BF00120333
   ROZEMA FR, 1990, J ORAL MAXIL SURG, V48, P1305, DOI 10.1016/0278-2391(90)90487-M
   Sabolinski ML, 1996, BIOMATERIALS, V17, P311, DOI 10.1016/0142-9612(96)85569-4
   Sagen J, 1992, ASAIO J, V38, P24, DOI 10.1097/00002480-199201000-00007
   Salzmann DL, 1997, J BIOMED MATER RES, V34, P463, DOI 10.1002/(SICI)1097-4636(19970315)34:4<463::AID-JBM7>3.0.CO;2-I
   SATO GH, 1997, PRINCIPLES TISSUE EN, P101
   SAVELKOUL HFJ, 1994, J IMMUNOL METHODS, V170, P185, DOI 10.1016/0022-1759(94)90394-8
   SAYEGH MH, 1994, TRANSPLANTATION, V57, P1295, DOI 10.1097/00007890-199405150-00001
   SCHUMAKER VN, 1987, ANNU REV IMMUNOL, V5, P21, DOI 10.1146/annurev.iy.05.040187.000321
   ScottBurden T, 1997, BIOCHEM BIOPH RES CO, V231, P780, DOI 10.1006/bbrc.1997.6194
   ScottBurden T, 1996, CIRCULATION, V94, P235
   SECKEL BR, 1995, J NEUROSCI RES, V40, P318, DOI 10.1002/jnr.490400305
   SEFTON MV, 1994, PANCREATIC ISLET TRA, V3, P107
   SEFTON MV, 1998, FRONTIERS TISSUE ENG, P248
   Shibata H, 1997, J BIOMAT SCI-POLYM E, V8, P601, DOI 10.1163/156856297X00209
   SHIRWAN H, 1995, TRANSPLANTATION, V59, P401, DOI 10.1097/00007890-199502150-00016
   SIEBERS U, 1994, TRANSPLANT P, V26, P787
   SIEBERS U, 1990, METHODS ISLET TRANSP, P206
   Simeonovic CJ, 1997, J IMMUNOL, V158, P2490
   Spilker MH, 1997, TISSUE ENG, V3, P309, DOI 10.1089/ten.1997.3.309
   Suggs LJ, 1997, MACROMOLECULES, V30, P4318, DOI 10.1021/ma970312v
   SUSSMAN NL, 1994, ARTIF ORGANS, V18, P390, DOI 10.1111/j.1525-1594.1994.tb02221.x
   SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x
   TAI IT, 1993, FASEB J, V7, P1061
   TARANTA A, 1961, SCIENCE, V134, P1981, DOI 10.1126/science.134.3494.1981
   THAI NL, 1993, TRANSPLANT P, V25, P444
   THOMSON RC, 1995, J BIOMAT SCI-POLYM E, V7, P23, DOI 10.1163/156856295X00805
   TONG XJ, 1994, BRAIN RES, V663, P155, DOI 10.1016/0006-8993(94)90473-1
   Tse M, 1996, BIOTECHNOL BIOENG, V51, P271, DOI 10.1002/(SICI)1097-0290(19960805)51:3<271::AID-BIT3>3.3.CO;2-T
   TSUKUI T, 1994, EXP CELL RES, V210, P172, DOI 10.1006/excr.1994.1026
   ULUDAG H, 1993, J BIOMED MATER RES, V27, P1213, DOI 10.1002/jbm.820271002
   ULUDAG H, 1994, BIOTECHNOL BIOENG, V44, P1199, DOI 10.1002/bit.260441007
   ULUDAG H, 1995, J CONTROL RELEASE, V33, P273, DOI 10.1016/0168-3659(94)00094-B
   Vacanti C A, 1995, Tissue Eng, V1, P301, DOI 10.1089/ten.1995.1.301
   VACANTI CA, 1991, PLAST RECONSTR SURG, V88, P753, DOI 10.1097/00006534-199111000-00001
   VANLUYN MJA, 1995, J BIOMED MATER RES, V29, P1425, DOI 10.1002/jbm.820291114
   Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410
   Wake MC, 1996, CELL TRANSPLANT, V5, P465, DOI 10.1016/0963-6897(96)00025-5
   WAKE MC, 1994, CELL TRANSPLANT, V3, P339, DOI 10.1177/096368979400300411
   WAKE MC, 1995, CELL TRANSPLANT, V4, P275, DOI 10.1177/096368979500400305
   WAKE MC, IN PRESS BIOMATERIAL
   WALLGREN AC, 1995, TRANSPLANTATION, V60, P594, DOI 10.1097/00007890-199509270-00013
   WEBER C, 1993, TRANSPLANT P, V25, P462
   WEBER C, 1991, TRANSPLANT P, V23, P764
   WEBER C, 1994, TRANSPLANT P, V26, P1116
   WEBER CJ, 1990, TRANSPLANTATION, V49, P396, DOI 10.1097/00007890-199002000-00034
   Weber CJ, 1996, TRANSPLANT P, V28, P821
   Weber CJ, 1997, CELL TRANSPLANT, V6, P505, DOI 10.1016/S0963-6897(97)00045-6
   WELLS GDM, 1993, BIOMATERIALS, V14, P615, DOI 10.1016/0142-9612(93)90181-Z
   WENNMALM A, 1992, BRIT J PHARMACOL, V106, P507, DOI 10.1111/j.1476-5381.1992.tb14365.x
   West J, 1997, SYNTHETIC BIODEGRADA, P83
   WIDNER H, 1993, BASIC CLIN ASPECTS N, V5, P63
   WIEGAND F, 1993, TRANSPLANTATION, V56, P1206, DOI 10.1097/00007890-199311000-00030
   WILKINS LM, 1994, BIOTECHNOL BIOENG, V43, P747, DOI 10.1002/bit.260430809
   WILLIAMS SK, 1994, J BIOMED MATER RES, V28, P203, DOI 10.1002/jbm.820280210
   Winet H, 1997, J BIOMAT SCI-POLYM E, V8, P517, DOI 10.1163/156856297X00425
   WINN SR, 1991, EXP NEUROL, V113, P322, DOI 10.1016/0014-4886(91)90022-5
   WINN SR, 1994, P NATL ACAD SCI USA, V91, P2324, DOI 10.1073/pnas.91.6.2324
   WOLF LA, 1995, TRANSPLANTATION, V60, P1164, DOI 10.1097/00007890-199511270-00018
   WOOD RC, 1995, BIOMATERIALS, V16, P957, DOI 10.1016/0142-9612(95)93122-T
   YANNAS IV, 1989, P NATL ACAD SCI USA, V86, P933, DOI 10.1073/pnas.86.3.933
   YANNAS IV, 1988, COLLAGEN, V3, P87
   YASKO AW, 1992, J BONE JOINT SURG AM, V74A, P659, DOI 10.2106/00004623-199274050-00005
   Yaszemski M J, 1995, Tissue Eng, V1, P41, DOI 10.1089/ten.1995.1.41
   YUKNA RA, 1990, J PERIODONTOL, V61, P633, DOI 10.1902/jop.1990.61.10.633
   ZEKORN T, 1993, ACTA DIABETOL, V30, P238, DOI 10.1007/BF00569935
   ZEKORN T, 1990, TRANSPLANTATION, V50, P391, DOI 10.1097/00007890-199009000-00007
NR 246
TC 260
Z9 264
U1 2
U2 67
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
EI 1872-8294
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD AUG 3
PY 1998
VL 33
IS 1-2
BP 111
EP 139
DI 10.1016/S0169-409X(98)00023-4
PG 29
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 126VH
UT WOS:000076314800009
DA 2018-10-19
ER

PT J
AU Phaneuf, MD
   Szycher, M
   Berceli, SA
   Dempsey, DJ
   Quist, WC
   LoGerfo, FW
AF Phaneuf, MD
   Szycher, M
   Berceli, SA
   Dempsey, DJ
   Quist, WC
   LoGerfo, FW
TI Covalent linkage of recombinant hirudin to a novel ionic poly(carbonate)
   urethane polymer with protein binding sites: Determination of surface
   antithrombin activity
SO ARTIFICIAL ORGANS
LA English
DT Article
DE polyurethane; recombinant hirudin; antithrombin; albumin;
   immobilization; biomaterial
ID THROMBIN; HEPARIN; IMMOBILIZATION; AGGREGATION; CHEMOTAXIS; PLATELETS;
   ALBUMIN; PLASMA
AB Surface thrombus formation on implantable biomaterials such as polyurethane is a major concern when utilizing these materials in the clinical setting. Thrombin, which is responsible for thrombus formation and smooth muscle cell activation, has been the target of numerous surface modification strategies in an effort to prevent this phenomenon from occurring. The purpose of this study was to covalently immobilize the potent, specific antithrombin agent recombinant hirudin (rHir) onto a novel polyurethane polymer synthesized with carboxylic acid groups which served as protein attachment sites. The in vitro efficacy of thrombin inhibition by this novel biomaterial surface was then evaluated. Bovine serum albumin (BSA), which was selected as the basecoat protein, was reacted with sulfo-SMCC in a 1:50 molar ratio. This BSA-SMCC complex was then covalently linked to the carboxylated polyurethane (cPU) surface via the crosslinker EDC (cPU-BSA-SMCC). This cPU-BSA-SMCC surface was then reacted with Traut's-modified I-125-rHir, a procedure which created free sulfhydryl groups on rHir (cPU-BSA-SMCC-S-I-125-rHir). Using these crosslinking procedures, the cPU-BSA-SMCC-S-I-125-rHir segments bound 188 +/- 40 ng/cm(2) (n = 60) whereas the controls with non-specifically bound I-125-rHir (Mitrathan + EDC + BSA + I-125-rHir-SH and cPU-BSA + I-125-rHir-SH) bound 13 +/- 8 ng/cm(2) and 4 +/- 8 ng/cm(2), respectively. Evaluation of these cPU-BSA-SMCC-S-I-125-rHir segments for I-131-thrombin inhibition using a chromogenic assay for thrombin showed that a maximum of 2.64 NIHU thrombin was inhibited in contrast to the controls which inhibited 0.76 and 0.70 NIHU. Controls with nonspecifically bound I-125-rHir also had 0.31 and 0.76 NIHU I-131-thrombin adherent to their respective surfaces whereas the maximum I-131-thrombin binding to the cPU-BSA-SMCC-S-rHir segments was 1.51 NIHU. Exposure to I-131-thrombin did not result in any release of covalently bound I-125-rHir from the cPU-BSA-SMCC-S-I-125-rHir segments. Thus, these results demonstrate that rHir can be covalently bound to this novel polyurethane surface and still maintain potent antithrombin activity.
C1 Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02115 USA.
   CardioTech Int Inc, Woburn, MA 01801 USA.
   Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA USA.
   Harvard Univ, Sch Med, Childrens Hosp, Dept Cardiovasc Surg, Boston, MA USA.
RP Phaneuf, MD (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Surg, W Campus,4 Blackfan Circle,Harvard Inst Med Bldg, Boston, MA 02115 USA.
OI Berceli, Scott/0000-0003-2257-0111
FU NHLBI NIH HHS [1 R43 HL53856-01A1]
CR BARBUCCI R, 1994, BIOMATERIALS, V15, P955, DOI 10.1016/0142-9612(94)90075-2
   BARSHAVIT R, 1983, SCIENCE, V220, P728, DOI 10.1126/science.6836310
   BIZIOS R, 1986, J CELL PHYSIOL, V128, P485, DOI 10.1002/jcp.1041280318
   FENTON JW, 1988, SEMIN THROMB HEMOST, V14, P234, DOI 10.1055/s-2007-1002783
   GRAINGER DW, 1989, J COLLOID INTERF SCI, V132, P161, DOI 10.1016/0021-9797(89)90226-9
   HENNINK WE, 1983, THROMB RES, V29, P1, DOI 10.1016/0049-3848(83)90120-2
   KAPLAN JE, 1989, AM J PHYSIOL, V257, pH423
   KISHIDA A, 1994, BIOMATERIALS, V15, P848, DOI 10.1016/0142-9612(94)90041-8
   MARKWARDT F, 1985, BIOMED BIOCHIM ACTA, V44, P1007
   Nojiri C, 1996, ASAIO J, V42, pM468, DOI 10.1097/00002480-199609000-00032
   OOSTA GM, 1982, J BIOL CHEM, V257, P1249
   PARK KD, 1988, J BIOMED MATER RES, V22, P977, DOI 10.1002/jbm.820221103
   Phaneuf MD, 1997, BIOMATERIALS, V18, P755, DOI 10.1016/S0142-9612(96)00193-7
   PHANEUF MD, 1994, BLOOD COAGUL FIBRIN, V5, P641
   Phaneuf MD, 1997, J BIOMATER APPL, V12, P100, DOI 10.1177/088532829701200202
   PHANEUF MD, 1995, J APPL BIOMATER, V6, P289, DOI 10.1002/jab.770060410
   RUMISEK JD, 1989, SURGERY, V105, P654
   SALZMAN EW, 1980, J CLIN INVEST, V65, P64, DOI 10.1172/JCI109661
   SILVER JH, 1992, BIOMATERIALS, V13, P339, DOI 10.1016/0142-9612(92)90037-O
   SLIMANE S B, 1988, European Surgical Research, V20, P66
   TOLLEFSEN DM, 1974, J BIOL CHEM, V249, P2646
   WALZ DA, 1986, ANN NY ACAD SCI, V485, P323, DOI 10.1111/j.1749-6632.1986.tb34594.x
   WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723
   ZHENG J, 1994, BIOMATERIALS, V15, P963, DOI 10.1016/0142-9612(94)90076-0
NR 24
TC 31
Z9 31
U1 2
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0160-564X
EI 1525-1594
J9 ARTIF ORGANS
JI Artif. Organs
PD AUG
PY 1998
VL 22
IS 8
BP 657
EP 665
DI 10.1046/j.1525-1594.1998.05091.x
PG 9
WC Engineering, Biomedical; Transplantation
SC Engineering; Transplantation
GA 104ZZ
UT WOS:000075048500007
PM 9702317
DA 2018-10-19
ER

PT J
AU Trafny, EA
AF Trafny, EA
TI Susceptibility of adherent organisms from Pseudomonas aeruginosa and
   Staphylococcus aureus strains isolated from burn wounds to antimicrobial
   agents
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
DE antimicrobial resistance; sessile bacteria; collagen dressing
ID BACTERIA; PHARMACOKINETICS; CIPROFLOXACIN; ANTIBIOTICS; COLLAGEN;
   BIOFILMS; INVITRO; THERAPY
AB To assess the bactericidal effects of ciprofloxacin, netilymicin, and polymyxin B on adherent Pseudomonas aeruginosa organisms and also the bactericidal effects of ciprofloxacin, vancomycin and teicoplanin on adherent Staphylococcus aureus cells, a simple end-point microplate assay, based on the method described by Miyake et al. was used in the present study. As results of the assay, the minimal inhibitory concentration (MICADH) values are taken, which express the susceptibility of the bacterial cells spontaneously released from the surface of adherent microcolonies to antimicrobial agents. Also, a minimal bactericidal concentration (MBCADH) value was read, which is defined as the lowest antibiotic concentration required to kill the sessile bacterial cells. For twenty P. aeruginosa strains and nineteen S. aureus strains isolated from burn wounds, an enhanced resistance against bactericidal action of the applied antibiotics was observed when bacterial cells were attached to polystyrene surface. The MICADH values were comparable with the conventional MIC Values only for ciprofloxacin and netilmicin for P. aeruginosa strains. The MBCADH values exceeded many times the conventional MBC values for the majority of strains. The validity of the assay was estimated in the experiment designed to determine the concentration of ciprofloxacin that should be released topically from the collagen dressing to prevent the biomaterial from microbial colonization and allow the decontamination of the wound. (C) 1998 Elsevier Science B.V. All rights reserved.
C1 Mil Int Hyg & Epidemiol, Dept Microbiol & Epidemiol, Warsaw, Poland.
RP Trafny, EA (reprint author), Mil Int Hyg & Epidemiol, Dept Microbiol & Epidemiol, Warsaw, Poland.
OI Trafny, Elzbieta/0000-0003-0318-1698
CR ARIZONO T, 1992, ACTA ORTHOP SCAND, V63, P661
   BOYCE ST, 1993, ANTIMICROB AGENTS CH, V37, P1890, DOI 10.1128/AAC.37.9.1890
   BOYCE ST, 1995, ANTIMICROB AGENTS CH, V39, P1324, DOI 10.1128/AAC.39.6.1324
   BOYCE ST, 1994, J BURN CARE REHABIL, V15, P1
   CHUARD C, 1993, ANTIMICROB AGENTS CH, V37, P625, DOI 10.1128/AAC.37.4.625
   COSTERTON JW, 1995, ANNU REV MICROBIOL, V49, P711, DOI 10.1146/annurev.mi.49.100195.003431
   DOMINGUE G, 1994, J CLIN MICROBIOL, V32, P2564
   EVANS DJ, 1991, J ANTIMICROB CHEMOTH, V27, P177, DOI 10.1093/jac/27.2.177
   Garrelts JC, 1996, ANTIMICROB AGENTS CH, V40, P1153, DOI 10.1128/AAC.40.5.1153
   Grzybowski J, 1997, J BIOMED MATER RES, V36, P163, DOI 10.1002/(SICI)1097-4636(199708)36:2<163::AID-JBM4>3.0.CO;2-I
   ISENBERG HD, 1988, J ANTIMICROB CHEMOTH, V22, P73, DOI 10.1093/jac/22.Supplement_A.73
   JONES JW, 1995, J INFECTION, V31, P80, DOI 10.1016/S0163-4453(95)91736-5
   KOBAYASHI H, 1997, CHEMOTHERAPY, V1, P6
   LEADER WG, 1995, CLIN PHARMACOKINET, V28, P327, DOI 10.2165/00003088-199528040-00005
   Lewis WJ, 1997, NUTRITION, V13, pS5, DOI 10.1016/S0899-9007(97)00215-3
   MIYAKE Y, 1992, CHEMOTHERAPY, V38, P286, DOI 10.1159/000239015
   Steer JA, 1996, J ANTIMICROB CHEMOTH, V37, P545, DOI 10.1093/jac/37.3.545
   TRAFNY EA, 1995, ANTIMICROB AGENTS CH, V39, P2645, DOI 10.1128/AAC.39.12.2645
   TRAFNY EA, 1988, IN PRESS J BIOMED MA
   vanLoosdrecht MCM, 1995, WATER SCI TECHNOL, V32, P35, DOI 10.1016/0273-1223(96)00005-4
   WALTON M A, 1991, Journal of Burn Care and Rehabilitation, V12, P116, DOI 10.1097/00004630-199103000-00005
   WIDMER AF, 1990, J INFECT DIS, V162, P96, DOI 10.1093/infdis/162.1.96
   WIDMER AF, 1990, SCAND J INFECT DIS, V22, P611, DOI 10.3109/00365549009027105
NR 23
TC 22
Z9 22
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0924-8579
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD AUG
PY 1998
VL 10
IS 3
BP 223
EP 228
DI 10.1016/S0924-8579(98)00042-9
PG 6
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA 129XC
UT WOS:000076488500006
PM 9832283
DA 2018-10-19
ER

PT J
AU Jozwiak, A
   Karlik, W
   Wiechetek, M
   Werynski, A
AF Jozwiak, A
   Karlik, W
   Wiechetek, M
   Werynski, A
TI Attachment and metabolic activity of hepatocytes cultivated on selected
   polymeric membranes
SO INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS
LA English
DT Article
DE hepatocytes; membrane; hepatocyte immobilization; liver support system;
   ureagenesis
ID RAT HEPATOCYTES; LIVER SUPPORT; SUBSTRATA; NITRITE
AB Plasma or hormones added to hepatocyte incubation media mask the function of membranes as substrata per se for hepatocyte adhesion. This hypothesis was verified with hepatocyte cultures on various membranes in serum and hormone free medium. Freshly isolated rat hepatocytes were seeded on flat sheet membranes made of Cellulose Acetate (CA), aminated Cellulose Acetate (aCA), polysulfone (PSf) and sulfonated polysulfone (sPSf) and incubated in Hank's Balanced Salts Solutions (HBSS) as well as in William's E medium supplemented with newborn calf serum. It was found that PSf promoted hepatocyte adhesion most effectively. Good properties of PSf as a biomaterial for hepatocyte culture were confirmed in both media cultures. Urea synthesis and ammonia utilization measured in hepatocytes cultured on PSf were higher compared with other membrane cultures. PSf secured longer viability for a higher number of cells seeded on membrane compared with other investigated membranes, which is the reason for higher metabolic activity in PSf culture.
C1 PAS, Inst Biocybernet & Biomed Engn, PL-02109 Warsaw, Poland.
   Agr Univ Warsaw, Dept Pharmacol & Toxicol, Warsaw, Poland.
RP Jozwiak, A (reprint author), PAS, Inst Biocybernet & Biomed Engn, Ul Ksiecia Trojdena 4, PL-02109 Warsaw, Poland.
OI Karlik, Wojciech/0000-0002-6856-3585
CR BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506
   BLAAUBOER BJ, 1979, BIOCH BIOPHYSICAL RE, V90, P36
   BRILL S, 1994, LIVER BIOL PATHOBIOL, P878
   Butler A, 1997, BRIT MED BULL, V53, P719
   DEBARTOLO L, 1997, ARTIF ORGANS, V21, P526
   DIEGELMANN RF, 1986, RES ISOLATED CULTURE, P209
   GARWACKI S, 1990, INT J BIOCHEM, V22, P1185, DOI 10.1016/0020-711X(90)90119-N
   GERLACH J, 1990, INT J ARTIF ORGANS, V7, P436
   Gerlach JC, 1996, INT J ARTIF ORGANS, V19, P610
   KARLIK W, 1995, TOXICOL IN VITRO, V9, P711, DOI 10.1016/0887-2333(95)00058-G
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MAROUDAS NG, 1977, J CELL PHYSIOL, V90, P511, DOI 10.1002/jcp.1040900314
   MICHALOPOULOS GK, 1990, FASEB J, V4, P176
   Okuda H, 1965, Tokushima J Exp Med, V12, P11
   Qiang S, 1997, INT J ARTIF ORGANS, V20, P119
   SEGLEN PO, 1978, EXP CELL RES, V116, P199, DOI 10.1016/0014-4827(78)90076-9
   VANTKLOOSTER GAE, 1992, XENOBIOTICA, V22, P523, DOI 10.3109/00498259209053115
   WIECHETEK M, 1993, ARCH ENVIRON CON TOX, V24, P375, DOI 10.1007/BF01128737
   WIECHETEK M, 1989, INT J BIOCHEM, V1, P653
NR 19
TC 18
Z9 19
U1 0
U2 0
PU WICHTIG PUBL
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 0391-3988
EI 1724-6040
J9 INT J ARTIF ORGANS
JI Int. J. Artif. Organs
PD AUG
PY 1998
VL 21
IS 8
BP 460
EP 466
PG 7
WC Engineering, Biomedical; Transplantation
SC Engineering; Transplantation
GA 129WG
UT WOS:000076486600007
PM 9803348
DA 2018-10-19
ER

PT J
AU Andreassi, L
   Pianigiani, E
   Andreassi, A
   Taddeucci, P
   Biagioli, M
AF Andreassi, L
   Pianigiani, E
   Andreassi, A
   Taddeucci, P
   Biagioli, M
TI A new model of epidermal culture for the surgical treatment of vitiligo
SO INTERNATIONAL JOURNAL OF DERMATOLOGY
LA English
DT Article
ID STABLE VITILIGO; MELANOCYTES; TRANSPLANTATION; REPIGMENTATION;
   GUIDELINES
AB Background Vitiligo can be successfully treated with grafts of autologous cultured epidermal cells.
   Objective To evaluate the efficacy of autologous grafting of epidermal cells, cultured by an original method, in the treatment of localized vitiligo refractory to other therapies.
   Methods Autologous normally pigmented skin was used to culture keratinocytes and melanocytes on a supporting layer of biomaterial (Laserskin), which was grafted directly onto achromatic skin after de-epithelialization with liquid carbon dioxide. The percentage area of repigmentation was calculated by image analysis.
   Results Initial repigmentation of the treated areas was observed 1 month after treatment. Repigmentation continued to increase for 3 months after grafting. Follow-up at 3, 6, 12, and 18 months showed almost complete repigmentation in six out of 11 cases. In four other patients, 40-71% of the grafted achromatic area was repigmented. In one patient, repigmentation was impeded by sepsis.
   Conclusions The method was found to be effective in the treatment of localized vitiligo refractory to other treatments. The therapeutic procedure was simple, reproducible, and easy to use.
C1 Univ Siena, Policlin Le Scotte, Dept Dermatol, I-53100 Siena, Italy.
RP Andreassi, L (reprint author), Univ Siena, Policlin Le Scotte, Dept Dermatol, Viale Bracci, I-53100 Siena, Italy.
CR ANDREASSI L, 1991, WOUNDS, V3, P116
   ANTONIOU C, 1992, DRUGS, V43, P490, DOI 10.2165/00003495-199243040-00005
   Behl PN, 1964, CURR MED PRACT, V8, P218
   BOERSMA BR, 1995, J AM ACAD DERMATOL, V33, P990, DOI 10.1016/0190-9622(95)90292-9
   DAVIDSON J M, 1991, Clinical Materials, V8, P171, DOI 10.1016/0267-6605(91)90027-D
   Drake LA, 1996, J AM ACAD DERMATOL, V35, P620
   FALABELLA R, 1992, J AM ACAD DERMATOL, V26, P230, DOI 10.1016/0190-9622(92)70032-B
   FALABELLA R, 1983, J AM ACAD DERMATOL, V9, P514, DOI 10.1016/S0190-9622(83)70162-3
   GAUTHIER Y, 1992, J AM ACAD DERMATOL, V26, P191, DOI 10.1016/0190-9622(92)70024-A
   HANN SK, 1995, J AM ACAD DERMATOL, V32, P943, DOI 10.1016/0190-9622(95)91329-7
   KAHN AM, 1995, J AM ACAD DERMATOL, V33, P646, DOI 10.1016/0190-9622(95)91287-8
   KOGA M, 1988, ARCH DERMATOL, V124, P1656, DOI 10.1001/archderm.124.11.1656
   NA GY, 1996, ANN DERMATOL, V8, P9
   OLSSON MJ, 1995, BRIT J DERMATOL, V132, P587
   OLSSON MJ, 1993, ACTA DERM-VENEREOL, V73, P49
   Rennekampff HO, 1996, J SURG RES, V62, P288, DOI 10.1006/jsre.1996.0210
   RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8
   Schallreuter KU, 1996, ARCH DERMATOL RES, V288, P14, DOI 10.1007/BF02505037
   ZACHARIAE H, 1993, ACTA DERM-VENEREOL, V73, P46
NR 19
TC 37
Z9 42
U1 0
U2 1
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 0011-9059
J9 INT J DERMATOL
JI Int. J. Dermatol.
PD AUG
PY 1998
VL 37
IS 8
BP 595
EP 598
DI 10.1046/j.1365-4362.1998.00411.x
PG 4
WC Dermatology
SC Dermatology
GA 111VC
UT WOS:000075458200010
PM 9732005
DA 2018-10-19
ER

PT J
AU Levine, RA
   Rose, L
   Salama, H
AF Levine, RA
   Rose, L
   Salama, H
TI Immediate loading of root-form implants: Two case reports 3 years after
   loading
SO INTERNATIONAL JOURNAL OF PERIODONTICS & RESTORATIVE DENTISTRY
LA English
DT Article
ID TITANIUM IMPLANTS; BEAGLE DOGS; BONE; INTERFACE; TISSUE
AB This study examines a protocol for achieving successful osseointegration in immediately loaded implants. With an atraumatic surgical technique and an acceptable biomaterial for implant placement in certain cases adequate splinting of implants may sufficiently shield the bone-implant interface from functional overload and prevent micromovement from exceeding the allowable limits for successful osseointegration. Two successful cases are presented in which titanium root-form implants were immediately loaded for the support of fixed restorations in the maxilla and the mandible. The authors conclude that for a distinct patient population, immediate loading of multiple, splinted implants may prove to be a valuable adjunct to therapy.
C1 Albert Einstein Med Ctr, Philadelphia, PA 19141 USA.
   Univ Penn, Sch Dent Med, Philadelphia, PA 19104 USA.
   Allegheny Univ Hlth Sci, Div Dent Med, Philadelphia, PA 19102 USA.
RP Levine, RA (reprint author), 9880 Bustleton Ave,Suite 211, Philadelphia, PA 19115 USA.
EM ralperio35@aol.com
CR ADELL R, 1981, INT J ORAL MAXILLOF, V10, P387, DOI 10.1016/S0300-9785(81)80077-4
   ASPENBERG P, 1992, ACTA ORTHOP SCAND, V63, P141, DOI 10.3109/17453679209154809
   BABBUSH CA, 1986, J ORAL MAXIL SURG, V44, P274, DOI 10.1016/0278-2391(86)90078-9
   Bidez M W, 1992, Implant Dent, V1, P289, DOI 10.1097/00008505-199200140-00011
   Branemark P I, 1977, Scand J Plast Reconstr Surg Suppl, V16, P1
   BRANEMARK P I, 1969, Scandinavian Journal of Plastic and Reconstructive Surgery, V3, P81
   BRANEMARK PI, 1983, J PROSTHET DENT, V50, P399, DOI 10.1016/S0022-3913(83)80101-2
   BRANEMARK PI, 1985, TISSUE INTEGRATED PR
   Brunski J B, 1993, Dent Implantol Update, V4, P77
   BRUNSKI J B, 1992, Clinical Materials, V10, P153, DOI 10.1016/0267-6605(92)90049-Y
   Buser D, 1990, CLIN ORAL IMPLAN RES, V1, P33, DOI 10.1034/j.1600-0501.1990.010105.x
   Buser D A, 1988, Int J Oral Maxillofac Implants, V3, P173
   HANSSON HA, 1983, J PROSTHET DENT, V50, P108, DOI 10.1016/0022-3913(83)90175-0
   LEVINE RA, 1997, INT J ORAL MAXILLOF, V12, P80
   Lum L B, 1991, Int J Oral Maxillofac Implants, V6, P456
   Roberts WE, 1993, OSSEOINTEGRATION ORA, P157
   Rosenlicht J L, 1993, J Dent Symp, V1, P16
   SAGARA M, 1993, J PROSTHET DENT, V69, P281, DOI 10.1016/0022-3913(93)90107-Y
   SALAMA H, 1995, INT J PERIODONT REST, V15, P345
   SCHNITMAN P A, 1990, Journal of Oral Implantology, V16, P96
   Schroeder A, 1976, SSO Schweiz Monatsschr Zahnheilkd, V86, P713
   SCHROEDER A, 1981, J MAXILLOFAC SURG, V9, P15, DOI 10.1016/S0301-0503(81)80007-0
   Spector M., 1988, NONCEMENTED TOTAL HI, P69
   Weber HP, 1996, CLIN ORAL IMPLAN RES, V7, P11, DOI 10.1034/j.1600-0501.1996.070102.x
   Wohrle PS, 1992, J ORAL IMPLANTOL, V18, P382
NR 25
TC 14
Z9 15
U1 0
U2 0
PU QUINTESSENCE PUBL CO INC
PI CAROL STREAM
PA 551 NORTH KIMBERLY DR, CAROL STREAM, IL 60188-1881 USA
SN 0198-7569
J9 INT J PERIODONT REST
JI Int. J. Periodontics Restor. Dent.
PD AUG
PY 1998
VL 18
IS 4
BP 333
EP 343
PG 11
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 114WB
UT WOS:000075631200003
PM 12693420
DA 2018-10-19
ER

PT J
AU Pereiro, IR
   Wasik, A
   Lobinski, R
AF Pereiro, IR
   Wasik, A
   Lobinski, R
TI Determination of mercury species in fish reference materials by
   isothermal multicapillary gas chromatography with atomic emission
   detection after microwave-assisted solubilization and solvent extraction
SO JOURNAL OF ANALYTICAL ATOMIC SPECTROMETRY
LA English
DT Article
DE methylmercury; mercury; multicapillary column gas chromatography;
   microwave-induced plasma atomic emission spectrometry; fish certified
   reference materials
ID BIOLOGICAL SAMPLES; BUTYLTIN COMPOUNDS; SODIUM TETRAETHYLBORATE;
   ABSORPTION SPECTROMETRY; ENVIRONMENTAL-SAMPLES; SPECIATION ANALYSIS;
   INORGANIC MERCURY; METHYLMERCURY; DERIVATIZATION; BIOMATERIALS
AB A simple and rapid procedure for the simultaneous determination of methylmercury and Hg2+ in fish reference materials was developed. The procedure was based on a rapid (2.5 min) microwave-assisted solubilization of biomaterial with tetramethylammonium hydroxide, simultaneous quantitative ethylation-extraction of the mercury species into hexane (15 min) and flash isothermal separation (15-30 s) using a multicapillary regular column (100 cm) or a minicolumn (22 cm). The chromatographic hardware necessary for sample introduction into a microwave induced plasma was downscaled to a split injection port and a 20 x 20 x 10 cm compartment (housing the 1 m column) or a 22 cm x 1 cm od thermally insulated tube (housing the minicolumn) maintained at a constant temperature and connected directly to the detector. No dilution of the GC eluent (60-120 ml min(-1)) with make-up gas was necessary to achieve optimum sensitivity, Detection limits (as Hg) were 0.5 pg mu l(-1) (20 ng g(-1) dry mass) and 2 pg mu l(-1) (80 ng g-l dry mass)for MeHg+ and Hg2+, respectively. The method was validated for speciation analysis for mercury in BCR 463, BCR 464 (Tuna Fish) and NRCC DORM-1 (Dogfish Mussel) certified reference materials.
C1 CNRS, EP 132, F-64000 Pau, France.
RP Lobinski, R (reprint author), CNRS, EP 132, 2 Av Pr Angot, F-64000 Pau, France.
RI Wasik, Andrzej/B-9045-2018; Rodriguez Pereiro, Isaac/H-4771-2015
OI Wasik, Andrzej/0000-0002-1758-3893; Rodriguez Pereiro,
   Isaac/0000-0002-9693-2042
CR *AOAC, 1995, OFF METH AN ASS OFF, P22
   BULSKA E, 1991, ANAL CHIM ACTA, V249, P545, DOI 10.1016/S0003-2670(00)83032-9
   CEULEMANS M, 1994, APPL ORGANOMET CHEM, V8, P451, DOI 10.1002/aoc.590080505
   Chau YK, 1997, ANAL CHIM ACTA, V338, P51, DOI 10.1016/S0003-2670(96)00427-8
   COOKE WS, 1996, TODAYS CHEM WORK JAN, P16
   DHaese PC, 1997, CLIN CHEM, V43, P121
   EMTEBORG H, 1994, J ANAL ATOM SPECTROM, V9, P297, DOI 10.1039/ja9940900297
   FILIPPELLI M, 1992, ENVIRON SCI TECHNOL, V26, P1457, DOI 10.1021/es00031a025
   FISCHER R, 1993, ANAL CHEM, V65, P763, DOI 10.1021/ac00054a019
   Forstner U., 1983, METAL POLLUTION AQUA, P18
   Gerbersmann C, 1997, ANAL CHIM ACTA, V350, P273, DOI 10.1016/S0003-2670(97)00281-X
   HOLAK W, 1989, J ASSOC OFF ANA CHEM, V72, P926
   JANTZEN E, 1995, FRESEN J ANAL CHEM, V353, P28, DOI 10.1007/BF00322886
   Jimenez MS, 1997, J ANAL ATOM SPECTROM, V12, P597, DOI 10.1039/a607729c
   KUBALLA J, 1995, ANALYST, V120, P667, DOI 10.1039/an9952000667
   Liang L, 1996, TALANTA, V43, P1883, DOI 10.1016/0039-9140(96)01964-9
   MAGOS L, 1971, ANALYST, V96, P847, DOI 10.1039/an9719600847
   MALAKHOV VV, 1993, DOKL AKAD NAUK+, V329, P749
   MAY K, 1987, TOXICOL ENVIRON CHEM, V13, P153, DOI 10.1080/02772248709357178
   Mikac N, 1996, ANAL CHIM ACTA, V326, P57, DOI 10.1016/0003-2670(96)00051-7
   MINGANTI V, 1995, FRESEN J ANAL CHEM, V351, P471, DOI 10.1007/BF00322922
   Pereiro IR, 1997, J ANAL ATOM SPECTROM, V12, P1381, DOI 10.1039/a704050d
   Pereiro IR, 1997, ANAL CHEM, V69, P4799, DOI 10.1021/ac970410e
   RAPSOMANIKIS S, 1994, ANALYST, V119, P1429, DOI 10.1039/an9941901429
   REISINGER K, 1983, FRESEN Z ANAL CHEM, V316, P612, DOI 10.1007/BF00492274
   Schmitt VO, 1997, ANAL COMMUN, V34, P141, DOI 10.1039/a701229b
   Szpunar J, 1996, J ANAL ATOM SPECTROM, V11, P193, DOI 10.1039/ja9961100193
   Szpunar J, 1996, ANAL CHIM ACTA, V332, P225, DOI 10.1016/0003-2670(96)00257-7
   Tseng CM, 1997, J ANAL ATOM SPECTROM, V12, P743, DOI 10.1039/a700956i
   WESTOO G, 1967, ACTA CHEM SCAND, V21, P1790, DOI 10.3891/acta.chem.scand.21-1790
   Zhou CY, 1996, TALANTA, V43, P1061, DOI 10.1016/0039-9140(96)01860-7
NR 31
TC 26
Z9 26
U1 1
U2 4
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON ROAD, CAMBRIDGE CB4 4WF,
   CAMBS, ENGLAND
SN 0267-9477
J9 J ANAL ATOM SPECTROM
JI J. Anal. At. Spectrom.
PD AUG
PY 1998
VL 13
IS 8
BP 743
EP 747
DI 10.1039/a802154f
PG 5
WC Chemistry, Analytical; Spectroscopy
SC Chemistry; Spectroscopy
GA 110MV
UT WOS:000075385700009
DA 2018-10-19
ER

PT J
AU Sacks, MS
   Hamann, MCJ
   Otano-Lata, SE
   Malinin, TI
AF Sacks, MS
   Hamann, MCJ
   Otano-Lata, SE
   Malinin, TI
TI Local mechanical anisotropy in human cranial dura mater allografts
SO JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME
LA English
DT Article
ID DIAPHRAGMATIC CENTRAL TENDON; GLYCEROL
AB Human cranial dura mater (CDM) allograft's success as a repair biomaterial is partly due to its high mechanical strength, which facilitates its ability to form water-tight barriers and resist high in-vivo mechanical lends. Previous studies on CDM allograft mechanical behavior used large test specimens and concluded that the allograft was mechanically isotropic. However, we have quantified CDM microstructure using small angle light scattering (SALS) and found regions of well-aligned fibers displaying structural symmetry between the right and left halves (Jimenez et al., 1998). The high degree of fiber alignment in these regions suggests that they are mechanically anisotropic. However, identification of these regions using SALS requires irreversible tissue dehydration, which may affect mechanical propel-ties. Instead, we utilized CDM structural symmetry to estimate the fiber architecture of one half of the CDM using computer graphics to flip the SALS fiber architecture map of the corresponding half about the plane of symmetry. Test specimens (20 mm x 4 mm) were selected parallel and perpendicular to the preferred fiber directions and subjected to uniaxial mechanical failure testing. CDM allografts were found to be locally anisotropic, having an ultimate tensile strength (UTS) parallel to the fibers of 12.76 +/- 1.65 MPa, and perpendicular to the fibers of 5.21 +/- 1.01 MPa (mean +/- sem). These results indicate that uniaxial mechanical tests on large samples used in previous studies tended to mask the local anisotropic nature of the smaller constituent sections. The testing methods established in this study can be used in the evaluation of new CDM processing methods and post-implant allograft mechanical integrity.
C1 Univ Miami, Dept Biomed Engn, Coral Gables, FL 33124 USA.
   Univ Miami, Dept Orthopaed & Rehabil, Coral Gables, FL 33124 USA.
RP Sacks, MS (reprint author), Univ Miami, Dept Biomed Engn, Coral Gables, FL 33124 USA.
CR CAMPBELL JB, 1958, J NEUROSURG, V15, P207, DOI 10.3171/jns.1958.15.2.0207
   CHUONG CJ, 1991, J BIOMECH, V24, P563, DOI 10.1016/0021-9290(91)90289-Y
   FIORICA JV, 1991, GYNECOL ONCOL, V42, P217, DOI 10.1016/0090-8258(91)90348-9
   GARRETT S, 1990, J CLIN PERIODONTOL, V17, P179, DOI 10.1111/j.1600-051X.1990.tb01083.x
   Jimenez Hamann Maria C., 1998, Journal of Anatomy, V192, P99, DOI 10.1046/j.1469-7580.1998.19210099.x
   KELAMI A, 1971, J UROLOGY, V105, P518, DOI 10.1016/S0022-5347(17)61563-5
   LEHMAN RAW, 1967, J NEUROSURG, V26, P92, DOI 10.3171/jns.1967.26.1part1.0092
   MCGARVEY KA, 1984, BIOMATERIALS, V5, P109, DOI 10.1016/0142-9612(84)90011-5
   MELVIN JW, 1970, P 14 STAPP CAR CRASH, V17, P221
   OTANO SE, 1995, P 1995 BIOENG C, V29, P329
   PARKER R, 1978, THORAX, V33, P638, DOI 10.1136/thx.33.5.638
   PLANCHE CL, 1987, J BIOMED MATER RES, V21, P509, DOI 10.1002/jbm.820210410
   ROOT M, 1992, J UROLOGY, V148, P858, DOI 10.1016/S0022-5347(17)36744-7
   ROYCE PL, 1988, UROL RES, V16, P37
   Sacks MS, 1997, ANN BIOMED ENG, V25, P678, DOI 10.1007/BF02684845
   SACKS MS, 1992, J BIOMECH ENG-T ASME, V114, P183, DOI 10.1115/1.2891370
   *U MIAM, 1995, TISS BANK TECHN MAN
   USHER FC, 1958, ARCH SURG-CHICAGO, V76, P58
   VANNOORT R, 1981, BIOMATERIALS, V2, P41, DOI 10.1016/0142-9612(81)90086-7
   WOLFINBARGER L, 1994, J APPL BIOMATER, V5, P265, DOI 10.1002/jab.770050313
   ZANER DJ, 1989, J PERIODONTOL, V60, P617, DOI 10.1902/jop.1989.60.11.617
NR 21
TC 10
Z9 10
U1 0
U2 3
PU ASME-AMER SOC MECHANICAL ENG
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
SN 0148-0731
J9 J BIOMECH ENG-T ASME
JI J. Biomech. Eng.-Trans. ASME
PD AUG
PY 1998
VL 120
IS 4
BP 541
EP 544
DI 10.1115/1.2798027
PG 4
WC Biophysics; Engineering, Biomedical
SC Biophysics; Engineering
GA 117AC
UT WOS:000075756700016
PM 10412428
DA 2018-10-19
ER

PT J
AU Jenney, CR
   DeFife, KM
   Colton, E
   Anderson, JM
AF Jenney, CR
   DeFife, KM
   Colton, E
   Anderson, JM
TI Human monocyte/macrophage adhesion, macrophage motility, and
   IL-4-induced foreign body giant cell formation on silane-modified
   surfaces in vitro
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article; Proceedings Paper
CT Society-for-Biomaterials 24th Annual Meeting
CY APR 22-26, 1998
CL SAN DIEGO, CALIFORNIA
SP Soc Biomat
DE macrophage; foreign body giant cell; silane; interleukin-4; adhesion
ID COLONY-STIMULATING FACTOR; THEORETICAL-ANALYSIS; SIGNAL-TRANSDUCTION;
   BLOOD MONOCYTES; IN-VIVO; MONOLAYERS; INTERLEUKIN-4; EXPRESSION; FUSION;
   DIFFERENTIATION
AB A cytokine-based, in vitro model of foreign body giant cell (FBGC) formation was utilized to examine the effect of biomaterial surface chemistry on the adhesion, motility, and fusion of monocytes and macrophages. Human monocytes were cultured for 10 days on 14 different silane-modified glass surfaces, during which time the cells assumed the macrophage phenotype. The adhesion of monocytes and macrophages during the culture period decreased by an average of similar to 50%, with the majority of cell loss observed during days 1-3. Most important, the adhesion of monocytes and macrophages was surface independent except for two surfaces containing terminal methyl groups, which decreased adhesion levels. Interleukin-4 (IL-4) and granulocyte-macrophage colony-stimulating factor (GMCSF) were added to the medium to induce FBGC formation and enhance macrophage adhesion, respectively. Surprisingly, GM-CSF decreased long-term monocyte/macrophage adhesion. IL-4-induced FBGC density was strongly influenced by the surface carbon content, as determined by X-ray photoelectron spectroscopy (XPS). In contrast, contact angle and surface energy displayed no correlation with FBGC formation. The motility of adherent macrophages, as measured by time-lapse confocal microscopy, was not affected significantly by differences in surface chemistry or the addition of cytokines. The surface dependence of FBGC formation is hypothesized to be the result of varying levels of silane-derived surface carbon. (C) 1998 John Wiley & Sons, Inc.
C1 Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA.
   Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA.
RP Anderson, JM (reprint author), Case Western Reserve Univ, Inst Pathol, 2085 Adelbert Rd, Cleveland, OH 44106 USA.
FU NHLBI NIH HHS [HL33849, HL55714]
CR ABRAMSON SL, 1990, J IMMUNOL, V144, P625
   ADAMS DO, 1992, INFLAMMATION BASIC P, P637
   Anderson J.M., 1994, PROB GEN SURG, V11, P147
   ANDREESEN R, 1988, CELL TISSUE RES, V253, P271
   ARKLES B, 1991, SILICON COMPOUNDS RE, P59
   Audran R, 1996, CLIN EXP IMMUNOL, V103, P155, DOI 10.1046/j.1365-2249.1996.d01-4.x
   BAIER RE, 1980, ADSORPTION MICROORGA, P59
   BRITLAND S, 1992, EXP CELL RES, V198, P124, DOI 10.1016/0014-4827(92)90157-4
   CRAMER AD, 1973, AM J CLIN PATHOL, V60, P148
   DeFife KM, 1997, J IMMUNOL, V158, P3385
   Dugast C, 1997, J LEUKOCYTE BIOL, V61, P517
   ELLIOTT MJ, 1989, BLOOD, V74, P2349
   GAMBLE JR, 1989, P NATL ACAD SCI USA, V86, P7169, DOI 10.1073/pnas.86.18.7169
   Garratt AN, 1995, ACTA ANAT, V154, P34
   GOLDE DW, 1992, INFLAMMATION BASIC P, P291
   HEALY KE, 1994, BIOTECHNOL BIOENG, V43, P792, DOI 10.1002/bit.260430814
   HORBETT TA, 1993, CARDIOVASC PATHOL, V2, pS137
   IMHOF BA, 1995, ADV IMMUNOL, V58, P345, DOI 10.1016/S0065-2776(08)60623-9
   JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577
   KAELBLE DH, 1970, J ADHESION, V2, P66, DOI 10.1080/0021846708544582
   KAO WYJ, 1994, J BIOMED MATER RES, V28, P819, DOI 10.1002/jbm.820280709
   KAO WYJ, 1995, J BIOMED MATER RES, V29, P1267, DOI 10.1002/jbm.820291014
   KASEMO B, 1988, J BIOMED MATER RES-A, V22, P145, DOI 10.1002/jbm.820221307
   KAZAZI F, 1994, J GEN VIROL, V75, P2795, DOI 10.1099/0022-1317-75-10-2795
   Malmsten M, 1996, J COLLOID INTERF SCI, V178, P123, DOI 10.1006/jcis.1996.0100
   MARGEL S, 1993, J BIOMED MATER RES, V27, P1463, DOI 10.1002/jbm.820271202
   MARIANO M, 1974, J PATHOL, V113, P1, DOI 10.1002/path.1711130102
   McNally AK, 1996, AM J PATHOL, V149, P975
   MCNALLY AK, 1995, AM J PATHOL, V147, P1487
   MCNALLY AK, 1994, P NATL ACAD SCI USA, V91, P10119, DOI 10.1073/pnas.91.21.10119
   MOST J, 1990, EUR J IMMUNOL, V20, P1661, DOI 10.1002/eji.1830200807
   Naif HM, 1997, J IMMUNOL, V158, P501
   PORTER MD, 1987, J AM CHEM SOC, V109, P3559, DOI 10.1021/ja00246a011
   ROSALES C, 1995, J LEUKOCYTE BIOL, V57, P189
   RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619
   Shankar Ravi, 1994, P67
   SMETANA K, 1987, EXP MOL PATHOL, V46, P258, DOI 10.1016/0014-4800(87)90048-7
   SPARGO BJ, 1994, P NATL ACAD SCI USA, V91, P11070, DOI 10.1073/pnas.91.23.11070
   SUKENIK CN, 1990, J BIOMED MATER RES, V24, P1307, DOI 10.1002/jbm.820241004
   Takahara A, 1996, J VAC SCI TECHNOL A, V14, P1747, DOI 10.1116/1.580331
   TAKASHIMA T, 1993, J IMMUNOL, V150, P3002
   TANAKA H, 1991, EXP CELL RES, V192, P165, DOI 10.1016/0014-4827(91)90171-P
   TRUSKEY GA, 1993, BIOMATERIALS, V14, P243, DOI 10.1016/0142-9612(93)90114-H
   Ulman A, 1991, INTRO ULTRATHIN ORGA, P237
   VISSERS MCM, 1988, J IMMUNOL METHODS, V110, P203, DOI 10.1016/0022-1759(88)90104-4
   WASSERMAN SR, 1989, LANGMUIR, V5, P1074, DOI 10.1021/la00088a035
   YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3
   Zardeneta G, 1996, J ORAL MAXIL SURG, V54, P873, DOI 10.1016/S0278-2391(96)90540-6
   ZHAO Q, 1990, J BIOMED MATER RES, V24, P621, DOI 10.1002/jbm.820240508
   ZHAO QH, 1992, J BIOMED MATER RES, V26, P1019, DOI 10.1002/jbm.820260805
NR 50
TC 73
Z9 74
U1 0
U2 12
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD AUG
PY 1998
VL 41
IS 2
BP 171
EP 184
DI 10.1002/(SICI)1097-4636(199808)41:2<171::AID-JBM1>3.0.CO;2-F
PG 14
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA ZU647
UT WOS:000074219000001
PM 9638521
DA 2018-10-19
ER

PT J
AU Khouw, IMSL
   van Wachem, PB
   de Leij, LFMH
   van Luyn, MJA
AF Khouw, IMSL
   van Wachem, PB
   de Leij, LFMH
   van Luyn, MJA
TI Inhibition of the tissue reaction to a biodegradable biomaterial by
   monoclonal antibodies to IFN-gamma
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE IFN-gamma; macrophages; giant cells; inflammatory reactions;
   biomaterials
ID MULTINUCLEATED GIANT-CELLS; DERMAL SHEEP COLLAGEN; INTERFERON-GAMMA;
   HUMAN-MONOCYTES; T-CELL; MONONUCLEAR PHAGOCYTES; IMMUNE-RESPONSE;
   MACROPHAGES; BIOCOMPATIBILITY; INTERLEUKIN-2
AB Biomaterials are increasingly used for clinical applications. However, loss of function may occur owing to tissue reactions, which are mainly caused by a variety of inflammatory reactions. Recently, we demonstrated that macrophages (MO) and T cells play key roles in these reactions. Since immunological studies showed that the T cell-derived cytokine interferon-gamma (IFN-gamma) activates MO, the aim of this study was to investigate the possibility of modulating tissue reactions to biodegradable biomaterials by inactivating IFN-gamma. Dermal sheep collagen (DSC) was used as a test biomaterial. DSC impregnated with anti-IFN-gamma or phosphate-buffered saline (control) was implanted in rats. The results showed that cellular ingrowth and formation and function of giant cells were strongly delayed by anti-IFN-gamma. Also, MHC class II expression was strongly inhibited. In the treated DSC, some huge giant cells were formed at the interface but association with the DSC bundles did not occur. Finally, in both the control and treated DSC, T cells and NK cells were rarely detected. This study demonstrates that IFN-gamma plays an important role in the inflammatory reaction to biomaterials. This reaction can be modulated by anti-IFN-gamma, which warrants further studies of anti-IFN-gamma for clinical application to prevent unwanted tissue reactions to biomaterials. (C) 1998 John Wiley & Sons, Inc.
C1 Univ Groningen, NL-9712 KZ Groningen, Netherlands.
   Univ Groningen Hosp, Clin Immunol, NL-9713 GZ Groningen, Netherlands.
RP Khouw, IMSL (reprint author), Univ Groningen, Bloemsingel 10, NL-9712 KZ Groningen, Netherlands.
CR ANDERSON JM, 1988, T AM SOC ART INT ORG, V34, P101
   ARENZANASEISDEDOS F, 1985, J IMMUNOL, V134, P2444
   BELOSEVIC M, 1989, J IMMUNOL, V143, P266
   BILLIAU A, 1987, EUR J IMMUNOL, V17, P1851, DOI 10.1002/eji.1830171228
   BILLIAU A, 1990, BIOCHEM PHARMACOL, V40, P1433, DOI 10.1016/0006-2952(90)90437-P
   CARDONA MA, 1992, J BIOMED MATER RES, V26, P851, DOI 10.1002/jbm.820260703
   CHAMBERS TJ, 1982, IMMUNOBIOLOGY, V161, P283, DOI 10.1016/S0171-2985(82)80084-3
   DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300
   DAMAS J, 1990, EUR J PHARMACOL, V175, P341, DOI 10.1016/0014-2999(90)90573-O
   DAMINK LHHO, 1995, J MATER SCI-MATER M, V6, P429
   DIJKSTRA CD, 1993, PROG HISTOCHEM CYTOC, V27, P1
   DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589
   FAIS S, 1994, LAB INVEST, V71, P737
   HARTUNG HP, 1990, ANN NEUROL, V27, P247, DOI 10.1002/ana.410270306
   HEREMANS H, 1987, J IMMUNOL, V138, P4175
   HUNIG T, 1989, J EXP MED, V169, P73, DOI 10.1084/jem.169.1.73
   KAO WYJ, 1995, J BIOMED MATER RES, V29, P1267, DOI 10.1002/jbm.820291014
   KELLER R, 1987, J IMMUNOL, V138, P2366
   MCINNES A, 1988, J EXP MED, V167, P598, DOI 10.1084/jem.167.2.598
   MCNALLY AK, 1995, AM J PATHOL, V147, P1487
   MOST J, 1990, EUR J IMMUNOL, V20, P1661, DOI 10.1002/eji.1830200807
   MURRAY HW, 1985, J IMMUNOL, V134, P1619
   NEDWIN GE, 1985, J IMMUNOL, V135, P2492
   PAINEAU J, 1991, J HEART LUNG TRANSPL, V10, P424
   PUTZ D, 1992, INT J ARTIF ORGANS, V15, P456
   REMES A, 1992, BIOMATERIALS, V13, P731, DOI 10.1016/0142-9612(92)90010-L
   ROZEMA FR, 1992, ADV BIOMAT, V10, P349
   STRIGARD K, 1989, ACTA NEUROL SCAND, V80, P201, DOI 10.1111/j.1600-0404.1989.tb03863.x
   STUEHR DJ, 1987, J IMMUNOL, V139, P518
   TANG LP, 1995, AM J CLIN PATHOL, V103, P466
   THOMPSON RC, 1992, INT J IMMUNOPHARMACO, V14, P475, DOI 10.1016/0192-0561(92)90178-N
   van Luyn MJA, 1998, J BIOMED MATER RES, V39, P398
   VANGULIK TM, 1987, NETH J SURG, V39, P90
   VANLUYN MJA, 1994, J MATER SCI-MATER M, V5, P671, DOI 10.1007/BF00120354
   VANOTTERLOO JCAD, 1992, J VASC SURG, V16, P774
   VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83
   VANWACHEM PB, 1991, CELL MATER, V1, P251
   VANWACHEM PB, 1994, J BIOMED MATER RES, V28, P353, DOI 10.1002/jbm.820280310
   Wang JY, 1996, J BIOMED MATER RES, V32, P655, DOI 10.1002/(SICI)1097-4636(199612)32:4<655::AID-JBM19>3.0.CO;2-C
   WEINBERG JB, 1984, P NATL ACAD SCI-BIOL, V81, P4554, DOI 10.1073/pnas.81.14.4554
   WOLFF SM, 1991, NEW ENGL J MED, V324, P486, DOI 10.1056/NEJM199102143240709
   ZAOUI P, 1991, KIDNEY INT, V39, P1020, DOI 10.1038/ki.1991.129
NR 42
TC 46
Z9 46
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD AUG
PY 1998
VL 41
IS 2
BP 202
EP 210
DI 10.1002/(SICI)1097-4636(199808)41:2<202::AID-JBM4>3.0.CO;2-M
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA ZU647
UT WOS:000074219000004
PM 9638524
DA 2018-10-19
ER

PT J
AU Tang, LP
   Liu, L
   Elwing, HB
AF Tang, LP
   Liu, L
   Elwing, HB
TI Complement activation and inflammation triggered by model biomaterial
   surfaces
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE inflammatory responses; complement activation; gold surfaces; thiols
ID SELF-ASSEMBLED MONOLAYERS; GOLD SURFACES; CARDIOPULMONARY BYPASS;
   POLYMERIC BIOMATERIALS; PROTEIN ADSORPTION; LEUKOCYTE COUNTS;
   IMMUNOGLOBULIN-G; COBRA VENOM; L-CYSTEINE; HEMODIALYSIS
AB Biomaterial-mediated complement activation repeatedly has been invoked as a trigger of phagocyte reactions and inflammation. However, a direct correlation between complement activation and inflammatory responses to biomaterial surfaces has yet to be established. Using an animal implantation model and gold surfaces bearing various thiol-linked functionalities, we investigated the potency of different surface groups in prompting complement activation in vitro and surface-mediated accumulation of inflammatory cells in vivo. Among the surfaces tested, mercaptoglycerol- and mercaptoethanol-bearing surfaces engendered the strongest inflammatory responses, as reflected by the accumulation of large numbers of adherent neutrophils and monocytes/macrophages. In contrast, L-cysteine-coated surfaces caused only minor inflammatory responses, and both glutathione-modified and untreated gold implants attracted minimal numbers of inflammatory cells. The accumulation of inflammatory cells on mercaptoglycerol surfaces appears to arise from surface-mediated complement activation because complement-depleted animals failed to exhibit inflammatory responses to mercaptoglycerol-modified implants. Furthermore, there is a close relationship between surface-mediated complement activation (as measured by in vitro iC3b/C5b-9 generation and C3 deposition) and in vivo inflammatory responses. At least in this animal model and with these model surfaces, our results indicate that surface-mediated complement activation can be responsible for the subsequent accumulation of inflammatory cells on implant surfaces. (C) 1998 John Wiley & Sons, Inc.
C1 Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.
   Univ Goteborg, Dept Gen & Marine Microbiol, Biointerface & Biofouling Lab, S-41390 Gothenburg, Sweden.
RP Tang, LP (reprint author), Baylor Coll Med, Dept Pediat, 1 Baylor Plaza, Houston, TX 77030 USA.
FU NHLBI NIH HHS [R01HL53637]
CR ANDERSON JM, 1990, INT J ARTIF ORGANS, V13, P375
   Baier R E, 1969, J Biomed Mater Res, V3, P191, DOI 10.1002/jbm.820030115
   BOHLER J, 1983, CONTRIB NEPHROL, V36, P15
   BOHNERT JL, 1986, J COLLOID INTERF SCI, V111, P363, DOI 10.1016/0021-9797(86)90040-8
   BURHOP KE, 1993, J LAB CLIN MED, V121, P276
   CHENOWETH DE, 1984, ARTIF ORGANS, V8, P281, DOI 10.1111/j.1525-1594.1984.tb04291.x
   CHENOWETH DE, 1987, ARTIF ORGANS, V11, P155, DOI 10.1111/j.1525-1594.1987.tb02649.x
   CHENOWETH DE, 1987, ANN NY ACAD SCI, V516, P306, DOI 10.1111/j.1749-6632.1987.tb33051.x
   CHENOWETH DE, 1988, ARTIF ORGANS, V12, P508, DOI 10.1111/j.1525-1594.1988.tb02815.x
   CHENOWETH DE, 1986, T AM SOC ART INT ORG, V32, P226
   COCHRANE CG, 1970, J IMMUNOL, V105, P55
   CRADDOCK PR, 1977, J CLIN INVEST, V59, P879, DOI 10.1172/JCI108710
   CRADDOCK PR, 1977, J CLIN INVEST, V60, P260, DOI 10.1172/JCI108763
   CUMMING RD, 1980, T AM SOC ART INT ORG, V26, P304
   DAHLGREN C, 1984, INFLAMMATION, V8, P201, DOI 10.1007/BF00916095
   DEFEIJTER JA, 1978, BIOPOLYMERS, V17, P1759, DOI 10.1002/bip.1978.360170711
   HALLGREN R, 1982, NEPHRON, V32, P329, DOI 10.1159/000182874
   HAMMERSCHMIDT DE, 1981, J THORAC CARDIOV SUR, V81, P370
   HAMMERSCHMIDT DE, 1978, BLOOD, V51, P721
   HERZLINGER GA, 1980, T AM SOC ART INT ORG, V26, P165
   HIMMELHOCH SR, 1969, BIOCHEMISTRY-US, V8, P914, DOI 10.1021/bi00831a022
   IHS A, 1991, J COLLOID INTERF SCI, V144, P282, DOI 10.1016/0021-9797(91)90259-B
   JANATOVA J, 1991, COMPLEMENT INFLAMMAT, V8, P61, DOI 10.1159/000463181
   JANATOVA J, 1988, METHOD ENZYMOL, V162, P579
   Johnson FE, 1996, SURG ONCOL, V5, P127, DOI 10.1016/S0960-7404(96)80012-0
   JONSSON U, 1985, J COLLOID INTERF SCI, V103, P360, DOI 10.1016/0021-9797(85)90115-8
   KAZATCHKINE MD, 1988, BIOMATERIALS, V9, P30, DOI 10.1016/0142-9612(88)90066-X
   Liu L, 1996, J BIOMED MATER RES, V30, P535, DOI 10.1002/(SICI)1097-4636(199604)30:4<535::AID-JBM12>3.0.CO;2-G
   LONG J, 1983, BIOMATER ARTIF CELL, V11, P63, DOI 10.3109/10731198309118795
   Moczar M, 1996, J HEART VALVE DIS, V5, pS276
   Moczar M, 1996, ASAIO J, V42, pM375, DOI 10.1097/00002480-199609000-00015
   Mrksich M, 1996, P NATL ACAD SCI USA, V93, P10775, DOI 10.1073/pnas.93.20.10775
   Mrksich M, 1996, ANNU REV BIOPH BIOM, V25, P55, DOI 10.1146/annurev.bb.25.060196.000415
   NUZZO RG, 1983, J AM CHEM SOC, V105, P4481, DOI 10.1021/ja00351a063
   OFLAHERTY JT, 1978, AM J PATHOL, V90, P537
   PITT WG, 1986, J COLLOID INTERF SCI, V111, P343, DOI 10.1016/0021-9797(86)90039-1
   PRIME KL, 1991, SCIENCE, V252, P1164, DOI 10.1126/science.252.5009.1164
   REINISCH BW, 1989, WORLD IONOSPHERE THE, V2, P1
   RYHANEN P, 1979, J THORAC CARDIOV SUR, V77, P259
   SEVASTIANOV VI, 1988, CRIT REV BIOCOMPAT, V4, P109
   SHEPARD AD, 1984, J VASC SURG, V1, P829, DOI 10.1067/mva.1984.avs0010829
   SPAGNUOLO PJ, 1982, BLOOD, V60, P924
   STEWART GJ, 1977, ANN NY ACAD SCI, V283, P179, DOI 10.1111/j.1749-6632.1977.tb41765.x
   TAMIYA T, 1988, ANN THORAC SURG, V46, P47, DOI 10.1016/S0003-4975(10)65851-1
   TANG LP, 1993, J LAB CLIN MED, V122, P292
   TANG LP, 1993, J EXP MED, V178, P2147, DOI 10.1084/jem.178.6.2147
   Tang LP, 1996, J CLIN INVEST, V97, P1329, DOI 10.1172/JCI118549
   TENGVALL P, 1992, LANGMUIR, V8, P1236, DOI 10.1021/la00041a001
   Tengvall P, 1996, BIOMATERIALS, V17, P1001, DOI 10.1016/0142-9612(96)84675-8
   TORRES JL, 1988, ARCH BIOCHEM BIOPHYS, V267, P271, DOI 10.1016/0003-9861(88)90032-X
   VANDENBERG CW, 1991, J IMMUNOL METHODS, V136, P287, DOI 10.1016/0022-1759(91)90015-8
   Ward R. A., 1988, T AM SOC ART INT ORG, V34, P334
   WIENER S, 1973, AM J PATHOL, V73, P807
   WRIGHT DG, 1979, EXP HEMATOL, V7, P11
   YAM LT, 1971, AM J CLIN PATHOL, V55, P283
   ZIMMERMAN GA, 1982, AM REV RESPIR DIS, V126, P1097
NR 56
TC 69
Z9 70
U1 1
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD AUG
PY 1998
VL 41
IS 2
BP 333
EP 340
DI 10.1002/(SICI)1097-4636(199808)41:2<333::AID-JBM19>3.0.CO;2-L
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA ZU647
UT WOS:000074219000019
PM 9638539
DA 2018-10-19
ER

PT J
AU Kaciulis, S
   Mattogno, G
   Napoli, A
   Bemporad, E
   Ferrari, F
   Montenero, A
   Gnappi, G
AF Kaciulis, S
   Mattogno, G
   Napoli, A
   Bemporad, E
   Ferrari, F
   Montenero, A
   Gnappi, G
TI Surface analysis of biocompatible coatings on titanium
SO JOURNAL OF ELECTRON SPECTROSCOPY AND RELATED PHENOMENA
LA English
DT Article
DE biomaterial; hydroxyapatite; titanium; sol-gel; surface analysis
ID SPECTROSCOPIC CHARACTERIZATION; IMPLANT MATERIALS; TIO2(110); TI
AB The coatings of hydroxyapatite, which is widely used for orthopaedic and dental prothesis, were deposited by using the dip-coating method. The layers of hydroxyapatite were grown on commercial Ti substrates. In order to improve the adhesion of hydroxyapatite, the substrate was a priori covered with titania or calcium titanate by using the sol-gel technique. For comparison, commercial samples of hydroxyapatite coating (manufactured by means of plasma-spray apparatus) were analysed. The chemical composition and the structure of the coatings (TiO2, CaTiO3 and hydroxyapatite) were studied by using X-ray photoelectron spectroscopy (XPS), scanning Auger microscopy (SAM), X-ray diffraction (XRD) and secondary electron microscopy (SEM) techniques. The data of quantitative XPS analysis and the surface images (SAM and SEM) displayed the superior quality (cleanness, homogeneity, etc.) of hydroxyapatite deposited by sol-gel in comparison with commercial samples investigated. (C) 1998 Elsevier Science B.V. All rights reserved.
C1 CNR, Inst Mat Chem, I-00016 Monterotondo, Italy.
   Univ Rome 3, Dept Mech & Ind Engn, I-00146 Rome, Italy.
   Univ Parma, Dept Chem, I-43100 Parma, Italy.
   Consorzio Ric Innovaz Vetro, I-43100 Parma, Italy.
RP Napoli, A (reprint author), CNR, Inst Mat Chem, POB 10, I-00016 Monterotondo, Italy.
RI Bemporad, Edoardo/D-4251-2012; Kaciulis, Saulius/G-5252-2010
OI Bemporad, Edoardo/0000-0001-6282-1929; Kaciulis,
   Saulius/0000-0002-9868-7626
CR Battistoni C, 1995, J ELECTRON SPECTROSC, V76, P399, DOI 10.1016/0368-2048(95)02511-1
   Brinker C. J., 1990, SOL GEL SCI
   CIRILLI F, 1997, P ECASIA 97, P1063
   Demri B, 1997, APPL SURF SCI, V108, P245, DOI 10.1016/S0169-4332(96)00576-4
   ELGOMATI MM, 1985, APPL SURF SCI, V24, P147, DOI 10.1016/0169-4332(85)90220-X
   Gardella JA, 1996, J ELECTRON SPECTROSC, V81, P227, DOI 10.1016/0368-2048(96)03054-X
   GOPEL W, 1984, SURF SCI, V139, P333, DOI 10.1016/0039-6028(84)90054-2
   HANAWA T, 1991, BONE-BIOMATERIAL INTERFACE, P49
   Hench L. L., 1993, INTRO BIOCERAMICS, P1
   HUAXIA JI, 1992, J MATER SCI-MATER M, V3, P283
   Kim HM, 1996, J BIOMED MATER RES, V32, P409, DOI 10.1002/(SICI)1097-4636(199611)32:3<409::AID-JBM14>3.0.CO;2-B
   KURTZ RL, 1989, SURF SCI, V218, P178, DOI 10.1016/0039-6028(89)90626-2
   LAUSMAA J, 1990, SURF INTERFACE ANAL, V15, P328, DOI 10.1002/sia.740150506
   Lausmaa J, 1996, J ELECTRON SPECTROSC, V81, P343, DOI 10.1016/0368-2048(95)02530-8
   LAUSMAA J, 1990, APPL SURF SCI, V44, P133, DOI 10.1016/0169-4332(90)90100-E
   LAUSMAA J, 1988, SURFACE CHARACTERIZA, P161
   LEGEROS RZ, 1993, INTRO BIOCERAMICS, P139
   MENG LJ, 1995, P ECASIA 95, P815
   MONTENERO A, IN PRESS INORGANIC C
   Moulder J. F., 1995, HDB XRAY PHOTOELECTR
   PIVETEAU LD, IN PRESS J MAT SCI M
   RATNER BD, 1993, J BIOMED MATER RES, V27, P837, DOI 10.1002/jbm.820270702
   Vogler EA, 1996, J ELECTRON SPECTROSC, V81, P237, DOI 10.1016/0368-2048(96)02526-1
   WAGNER CD, 1986, SURF INTERFACE ANAL, V2, P53
   WILSON J, 1994, BIOCERAMICS, V8
NR 25
TC 63
Z9 64
U1 0
U2 19
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0368-2048
J9 J ELECTRON SPECTROSC
JI J. Electron Spectrosc. Relat. Phenom.
PD AUG
PY 1998
VL 95
IS 1
BP 61
EP 69
PG 9
WC Spectroscopy
SC Spectroscopy
GA 115WL
UT WOS:000075689300006
DA 2018-10-19
ER

PT J
AU Cook, SD
   Salkeld, SL
   Brinker, MR
   Wolfe, MW
   Rueger, DC
AF Cook, SD
   Salkeld, SL
   Brinker, MR
   Wolfe, MW
   Rueger, DC
TI Use of an osteoinductive biomaterial (rhOP-1) in healing large segmental
   bone defects
SO JOURNAL OF ORTHOPAEDIC TRAUMA
LA English
DT Article
DE osteoinductive; bone morphogenic proteins; rhOP-1; bone graft
   substitutes; segmental bone defects
ID MORPHOGENETIC PROTEIN; EXTRACELLULAR-MATRIX; OSTEOGENIC PROTEIN;
   DELIVERY SYSTEMS; GROWTH-FACTOR; DIFFERENTIATION; RHBMP-2; BOVINE; OP-1
AB Objective: To assess the radiographic, histologic, and mechanical characteristics of new bone formation in large segmental bone defects treated with a new osteoconductive material, recombinant human osteogenic protein-1 (rhOP-1).
   Design: In vivo animal study.
   Intervention: Sixteen dogs (thirty-two limbs) with an ulna segmental defect (2.5 centimeters) were randomized to three treatment groups: rhOP-1, collagen alone, and no implant.
   Main Outcome Measurements: Radiographic evidence of defect healing, mechanical testing (torsional strength) as compared with thirty-one control intact dog ulnas, and histologic analysis.
   Results: At twelve weeks, complete radiographic healing was observed in twenty-five of twenty-eight defects (89 percent) treated with rhOP-1. The mechanical strength of the rhOP-1-treated defects at twelve weeks was 65 percent of that of intact ulnas. Histologic analysis revealed that defects treated with rhOP-1 were bridged with lamellar and woven bone that was in continuity with the host bone.
   Conclusions: The results indicate that osteoinductive materials, which have the ability to quickly fill and heal large defects, may have advantages over osteoconductive materials, which are typically used to fill smaller non-load-bearing bone voids.
C1 Texas Orthoped Hosp, Fondren Orthoped Grp LLP, Houston, TX 77030 USA.
   Tulane Univ, Sch Med, Dept Orthopaed Surg, New Orleans, LA 70112 USA.
   Creat Biomol Inc, Hopkinton, MA USA.
RP Brinker, MR (reprint author), Texas Orthoped Hosp, Fondren Orthoped Grp LLP, 7401 S Main, Houston, TX 77030 USA.
CR BOS GD, 1983, J BONE JOINT SURG AM, V65, P239, DOI 10.2106/00004623-198365020-00015
   *CDC, 1988, MMWR-MORBID MORTAL W, V37, P597
   COCKIN J, 1971, J BONE JOINT SURG BR, V53, P153
   COOK SD, 1995, J BONE JOINT SURG AM, V77A, P734, DOI 10.2106/00004623-199505000-00010
   COOK SD, 1994, CLIN ORTHOP RELAT R, P302
   COOK SD, 1994, J BONE JOINT SURG AM, V76A, P827, DOI 10.2106/00004623-199406000-00006
   COOK SD, 1995, 62 ANN M AM AC ORTH
   DRIVDAHL RH, 1982, BIOCHIM BIOPHYS ACTA, V714, P26, DOI 10.1016/0304-4165(82)90123-4
   ENGSTROM A, 1972, BIOCH PHYSL BONE, V2, P237
   GERHART TN, 1993, CLIN ORTHOP RELAT R, P317
   GOLDBERG VM, 1991, BONE AND CARTILAGE ALLOGRAFTS : BIOLOGY AND CLINICAL APPLICATIONS, P3
   HAMMONDS RG, 1991, MOL ENDOCRINOL, V5, P149, DOI 10.1210/mend-5-1-149
   HECKMAN JD, 1991, J BONE JOINT SURG AM, V73A, P750, DOI 10.2106/00004623-199173050-00015
   HORISAKA Y, 1991, CLIN ORTHOP RELAT R, P303
   HOROWITZ MC, 1991, BONE AND CARTILAGE ALLOGRAFTS : BIOLOGY AND CLINICAL APPLICATIONS, P85
   JARCHO M, 1981, CLIN ORTHOP RELAT R, P259
   JARCHO M, 1986, DENT CLIN N AM, V30, P25
   Kamegai Akihide, 1994, Bio-Medical Materials and Engineering, V4, P291
   KENLEY R, 1994, J BIOMED MATER RES, V28, P1139, DOI 10.1002/jbm.820281004
   LAPAN P, 1991, J BONE MINER RES, V6, pS153
   Lavender G, 1938, SURG GYNECOL OBSTET, V67, P705
   LEE SC, 1994, J BIOMED MATER RES, V28, P1149, DOI 10.1002/jbm.820281005
   LEVANDER G, 1934, ACTA CHIR SCAND, V74, P425
   LUYTEN FP, 1989, J BIOL CHEM, V264, P13377
   NILSSON OS, 1986, J BONE JOINT SURG BR, V68, P635
   OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x
   POSNER AS, 1985, CLIN ORTHOP RELAT R, P87
   REDDI AH, 1987, ORTHOP CLIN N AM, V18, P207
   RIPAMONTI U, 1993, ANN CHIR GYNAECOL, V82, P13
   SAMPATH TK, 1987, P NATL ACAD SCI USA, V84, P7109, DOI 10.1073/pnas.84.20.7109
   SAMPATH TK, 1981, P NATL ACAD SCI-BIOL, V78, P7599, DOI 10.1073/pnas.78.12.7599
   SAMPATH TK, 1983, P NATL ACAD SCI-BIOL, V80, P6591, DOI 10.1073/pnas.80.21.6591
   SAMPATH TK, 1990, J BIOL CHEM, V265, P13198
   SAMPATH TK, 1982, EXP CELL RES, V142, P460, DOI 10.1016/0014-4827(82)90389-5
   SAMPATH TK, 1991, T ORTHOP RES SOC, V18, P368
   SATO T, 1991, CLIN ORTHOP RELAT R, P254
   STEVENSON S, 1994, J BONE JOINT SURG AM, V76A, P1676, DOI 10.2106/00004623-199411000-00011
   SUMMERS BN, 1989, J BONE JOINT SURG BR, V71, P677
   TAKAOKA K, 1988, CLIN ORTHOP RELAT R, P250
   TAKAOKA K, 1989, CLIN ORTHOP RELAT R, P258
   TORIUMI DM, 1991, ARCH OTOLARYNGOL, V117, P1101
   TRACY BM, 1984, J BIOMED MATER RES, V18, P719, DOI 10.1002/jbm.820180702
   TSUDA T, 1989, BONE, V10, P195, DOI 10.1016/8756-3282(89)90053-7
   URIST MR, 1983, SCIENCE, V220, P680, DOI 10.1126/science.6403986
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   URIST MR, 1979, P NATL ACAD SCI USA, V76, P1828, DOI 10.1073/pnas.76.4.1828
   URIST MR, 1989, BONE MINERAL RES, V6, P57
   WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220
   WILLESTAEDT H, 1950, Acta Orthop Scand, V19, P419
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   YAMAZAKI Y, 1988, CLIN ORTHOP RELAT R, P240
   YASKO AW, 1992, J BONE JOINT SURG AM, V74A, P659, DOI 10.2106/00004623-199274050-00005
   YASKO AW, 1991, J BONE MINER RES  S1, V6, P155
   Younger E M, 1989, J Orthop Trauma, V3, P192, DOI 10.1097/00005131-198909000-00002
NR 54
TC 58
Z9 63
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA
SN 0890-5339
J9 J ORTHOP TRAUMA
JI J. Orthop. Trauma
PD AUG
PY 1998
VL 12
IS 6
BP 407
EP 412
DI 10.1097/00005131-199808000-00007
PG 6
WC Orthopedics; Sport Sciences
SC Orthopedics; Sport Sciences
GA 109BJ
UT WOS:000075301100007
PM 9715448
DA 2018-10-19
ER

PT J
AU Chen, TM
   Yao, CH
   Wang, HJ
   Chou, GH
   Lee, TW
   Lin, FH
AF Chen, TM
   Yao, CH
   Wang, HJ
   Chou, GH
   Lee, TW
   Lin, FH
TI Evaluation of a novel malleable, biodegradable osteoconductive composite
   in a rabbit cranial defect model
SO MATERIALS CHEMISTRY AND PHYSICS
LA English
DT Article
DE biodegradable composite; osteoconductive composite; rabbit cranial
   defect model
ID BONE MORPHOGENETIC PROTEIN-2; TRICALCIUM PHOSPHATE; AUTOGENOUS BONE;
   SKULL DEFECTS; HYDROXYAPATITE; CRANIOPLASTY; SUBSTITUTE; SURGERY;
   GRAFTS; RECONSTRUCTION
AB The ceramic form of calcium phosphate osteoconductive material such as hydroxyapatite is brittle, non-malleable and non-degradable, and these mechanical properties limit its clinical application in calvarium reconstruction. To improve these properties, we developed a malleable, biodegradable osteoconductive composite composed of tricalcium phosphate particles bound by a gelatin which is set by glutaraldehyde mediated cross-linking. The composite was implanted into a 15 X 15 mm full-thickness, calvarial defect in 20 rabbits For up to 3 months. Twelve rabbits were left unreconstructed as controls. Specimens were retrieved at 2 weeks, 1, 2 and 3 months. Five reconstructed and 3 unreconstructed rabbits were examined for each time period. The assessment included a series of post operative gross examinations, radiographs and histologic evaluations. We are able to demonstrate that this composite is ( 1) biocompatible, with little tissue reaction; (2) osteoconductive, with progressive growth of new bone into the calvarial defect; (3) biodegradable, with progressive replacement of the composite by new bone, a cellular matrix and bone-like material. Replacement of this composite by new bone is postulated to occur by a combination of osteoconduction and biodegradation. These results indicate that further experimental research to combine this malleable, biodegradable, osteoconductive composite with an osteoinductive agent such as bone morphogenetic protein may generate new biomaterial for full-thickness calvarial defect reconstruction. (C) 1998 Elsevier Science S,A, All rights reserved.
C1 Natl Taiwan Univ, Coll Med, Ctr Biomed Engn, Taipei 10018, Taiwan.
   TriServ Gen Hosp, Natl Def Med Ctr, Dept Surg, Burn Ctr, Taipei, Taiwan.
RP Lin, FH (reprint author), Natl Taiwan Univ, Coll Med, Ctr Biomed Engn, Taipei 10018, Taiwan.
EM double@ha.mc.ntu.edu.tw
CR Ashby ER, 1996, PLAST RECONSTR SURG, V98, P420, DOI 10.1097/00006534-199609000-00006
   BUCHOLZ RW, 1987, ORTHOP CLIN N AM, V18, P323
   CAMERON HU, 1977, J BIOMED MATER RES, V11, P179, DOI 10.1002/jbm.820110204
   Constantino PD, 1992, PLAST RECONSTR SURG, V90, P174
   DAMIEN CJ, 1990, J BIOMED MATER RES, V24, P639, DOI 10.1002/jbm.820240602
   DAMIEN CJ, 1994, J BIOMED MATER RES, V28, P553, DOI 10.1002/jbm.820280505
   EDWARDS MSB, 1987, NEUROSURGERY, V20, P273, DOI 10.1227/00006123-198702000-00013
   FERRARO JW, 1979, PLAST RECONSTR SURG, V63, P634, DOI 10.1097/00006534-197905000-00005
   FLATLEY TJ, 1983, CLIN ORTHOP RELAT R, P246
   FRAME JW, 1980, J ORAL SURG, V38, P176
   GEORGIADE NG, 1993, AESTHET PLAST SURG, V17, P85, DOI 10.1007/BF02274726
   GERHART TN, 1989, J BIOMED MATER RES, V23, P1, DOI 10.1002/jbm.820230102
   HARVEY WK, 1985, J ORAL MAXIL SURG, V43, P277, DOI 10.1016/0278-2391(85)90287-3
   HOLLINGER JO, 1986, CLIN ORTHOP RELAT R, P290
   HOLMES RE, 1988, PLAST RECONSTR SURG, V81, P662, DOI 10.1097/00006534-198805000-00003
   HOOGENDOOM HA, 1984, CLIN ORTHO RELAT RES, V187, P261
   JARCHO M, 1981, CLIN ORTHOP RELAT R, P259
   KENLEY R, 1994, J BIOMED MATER RES, V28, P1139, DOI 10.1002/jbm.820281004
   LUCAS PA, 1989, J BIOMED MATER RES-A, V23, P23, DOI 10.1002/jbm.820231306
   Lynn L. H., 1990, J BIOMED MATER RES, V24, P1185
   MANSON PN, 1986, PLAST RECONSTR SURG, V77, P888, DOI 10.1097/00006534-198606000-00003
   MARDEN LJ, 1994, J BIOMED MATER RES, V28, P1127, DOI 10.1002/jbm.820281003
   MARK DE, 1990, PLAST RECONSTR SURG, V86, P623, DOI 10.1097/00006534-199010000-00001
   MORS WA, 1975, ARCH ORAL BIOL, V20, P365, DOI 10.1016/0003-9969(75)90028-X
   NICKELL WB, 1972, ARCH SURG-CHICAGO, V105, P431
   PETTIS GY, 1990, J ORAL MAXIL SURG, V48, P1068, DOI 10.1016/0278-2391(90)90291-9
   PIECUCH JF, 1984, J BIOMED MATER RES, V18, P39, DOI 10.1002/jbm.820180106
   PROLO DJ, 1979, NEUROSURGERY, V4, P18, DOI 10.1227/00006123-197901000-00005
   RAWLINGS CE, 1988, J NEUROSURG, V69, P269, DOI 10.3171/jns.1988.69.2.0269
   RENOOIJ W, 1985, CLIN ORTHOP RELAT R, P272
   SAILER HF, 1994, J CRANIO MAXILL SURG, V22, P191, DOI 10.1016/S1010-5182(05)80557-8
   SALYER KE, 1995, PLAST RECONSTR SURG, V96, P770, DOI 10.1097/00006534-199509001-00002
   SCHMITZ JP, 1975, CLIN ORTHOP RELAT R, V20, P365
   SHIMA T, 1979, J NEUROSURG, V51, P533, DOI 10.3171/jns.1979.51.4.0533
   SIVERBERG B, 1986, J TRAUMA, V26, P128
   SPEER DP, 1980, J BIOMED MATER RES, V14, P753, DOI 10.1002/jbm.820140607
   TURK AE, 1993, PLAST RECONSTR SURG, V92, P593, DOI 10.1097/00006534-199309001-00006
   UCHIDA A, 1984, J BONE JOINT SURG BR, V66, P269
   URIST MR, 1987, CLIN ORTHOP RELAT R, P295
   URIST MR, 1984, CLIN ORTHOP RELAT R, V187, P227
   WOLFE SA, 1982, CLIN PLAST SURG, V9, P539
NR 41
TC 25
Z9 26
U1 0
U2 3
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0254-0584
J9 MATER CHEM PHYS
JI Mater. Chem. Phys.
PD AUG
PY 1998
VL 55
IS 1
BP 44
EP 50
DI 10.1016/S0254-0584(98)00049-2
PG 7
WC Materials Science, Multidisciplinary
SC Materials Science
GA ZR695
UT WOS:000074004500004
DA 2018-10-19
ER

PT J
AU Zhang, F
   Chen, Y
   Zheng, ZH
   Huang, N
   Liu, XH
   Chen, AQ
   Jiang, ZB
AF Zhang, F
   Chen, Y
   Zheng, ZH
   Huang, N
   Liu, XH
   Chen, AQ
   Jiang, ZB
TI Synthesis and blood compatibility of rutile-type titanium oxide coated
   LTI-carbon
SO SCIENCE IN CHINA SERIES C-LIFE SCIENCES
LA English
DT Article
DE titanium oxide film; blood compatibility; in vitro investigation; in
   vivo investigation
AB Titanium oxide films were synthesized by ion beam enhanced deposition, where the films were prepared by depositing titanium atoms and simultaneously bombarding with Xe+ ions at an energy of 40 keV in an O-2 environment. The titanium oxide films exhibit rutile-type structure with (100) orientation and the O/Ti ratio is about 2:1. Ti2+, Ti3+ and Ti4+ coexist in the films. In vitro and in vivo investigations were used to investigate the blood compatibility of titanium oxide films. The results show that the blood compatibility of rutile-type titanium oxide films is better than that of low temperature isotropic pyrolytic carbon (LTI-carbon), which is widely used to fabricate artificial heart valve. It is thought that rutile-type titanium oxide coated LTI-carbon most probably becomes new biomaterial to fabricate artificial heart valves.
C1 Acad Sinica, Shanghai Inst Met, Ion Beam Lab, Shanghai 200050, Peoples R China.
   Zhongshan Hosp, Shanghai Cardiovasc Inst, Shanghai 200032, Peoples R China.
RP Zhang, F (reprint author), Acad Sinica, Shanghai Inst Met, Ion Beam Lab, Shanghai 200050, Peoples R China.
CR BOLZ A, 1990, ARTIF ORGANS, V144, P260
   Dion I., 1993, Bio-Medical Materials and Engineering, V3, P51
   EBERT R, 1982, P WORLD C MED PHYS B
   IMAI Y, 1972, J BIOMED MATER RES, V6, P165, DOI 10.1002/jbm.820060305
   Mitamura Y, 1989, J Biomater Appl, V4, P33, DOI 10.1177/088532828900400103
   PARK K, 1990, BIOMATERIALS, V11, P24, DOI 10.1016/0142-9612(90)90047-T
   WISBEY A, 1991, BIOMATERIALS, V12, P470, DOI 10.1016/0142-9612(91)90144-Y
   Zhang F, 1997, THIN SOLID FILMS, V310, P29, DOI 10.1016/S0040-6090(97)00338-6
   Zhang F, 1997, J VAC SCI TECHNOL A, V15, P1824, DOI 10.1116/1.580798
NR 9
TC 5
Z9 6
U1 0
U2 0
PU SCIENCE PRESS
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA
SN 1006-9305
J9 SCI CHINA SER C
JI Sci. China Ser. C-Life Sci.
PD AUG
PY 1998
VL 41
IS 4
BP 400
EP 405
DI 10.1007/BF02882740
PG 6
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 109DV
UT WOS:000075306700010
PM 18726257
DA 2018-10-19
ER

PT J
AU Tang, LP
   Jennings, TA
   Eaton, JW
AF Tang, LP
   Jennings, TA
   Eaton, JW
TI Mast cells mediate acute inflammatory responses to implanted
   biomaterials
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE histamine; phagocytes
ID COMPLEX-INDUCED PERITONITIS; IMMEDIATE HYPERSENSITIVITY; NEUTROPHIL
   RECRUITMENT; VASCULAR-PERMEABILITY; ARTERIAL PROSTHESES; TISSUE
   REACTION; P-SELECTIN; HISTAMINE; SILICONE; INVIVO
AB Implanted biomaterials trigger acute and chronic inflammatory responses. The mechanisms involved in such acute inflammatory responses can be arbitrarily divided into phagocyte transmigration, chemotaxis, and adhesion to implant surfaces. We earlier observed that two chemokines-macrophage inflammatory protein 1 alpha/monocyte chemoattractant protein 1-and the phagocyte integrin Mac-1 (CD11b/CD18)/surface fibrinogen interaction are, respectively, required for phagocyte chemotaxis and adherence to biomaterial surfaces, However, it is still not clear how the initial transmigration of phagocytes through the endothelial barrier into the area of the implant is triggered, Because implanted biomaterials elicit histaminic responses in the surrounding tissue, and histamine release is known to promote rapid diapedesis of inflammatory cells, we evaluated the possible role of histamine and mast cells in the recruitment of phagocytes to biomaterial implants. Using i.p. and s.c. implantation of polyethylene terephthalate disks in mice,ve find: (i) Extensive degranulation of mast cells, accompanied by histamine release, occurs adjacent to short-term i.p. implants. (ii) Simultaneous administration of H1 and H2 histamine receptor antagonists (pyrilamine and famotidine, respectively) greatly diminishes recruitment and adhesion of both neutrophils (<20% of control) and monocytes/macrophages (<30% of control) to implants. (iii) Congenitally mast cell-deficient mice also exhibit markedly reduced accumulation of phagocytes on both i.p. and s.c. implants, (iv) Finally, mast cell reconstitution of mast cell-deficient mice restores "normal" inflammatory responses to biomaterial implants. We conclude that mast cells and their granular products, especially histamine, are important in recruitment of inflammatory cells to biomaterial implants. Improved knowledge of such responses map permit purposeful modulation of both acute and chronic inflammation affecting implanted biomaterials.
C1 Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.
   Albany Med Coll, Dept Pathol & Lab Med, Albany, NY 12208 USA.
RP Tang, LP (reprint author), Baylor Coll Med, Dept Pediat, 1 Baylor Plaza, Houston, TX 77030 USA.
EM ltang@neo.bcm.tmc.edu
CR AKERSTROM G, 1994, ACTA ANAESTH SCAND, V38, P569, DOI 10.1111/j.1399-6576.1994.tb03953.x
   ASAKO H, 1994, J CLIN INVEST, V93, P1508, DOI 10.1172/JCI117129
   ATHANASOU NA, 1992, J BONE JOINT SURG BR, V74, P57
   Atkinson TP, 1992, INFLAMMATION BASIC P, P193
   BEAVEN MA, 1982, KLIN WOCHENSCHR, V60, P873, DOI 10.1007/BF01716943
   BEHLING CA, 1986, J BIOMED MATER RES, V20, P653, DOI 10.1002/jbm.820200509
   BOYD JF, 1959, J PATHOL BACTERIOL, V78, P379, DOI 10.1002/path.1700780205
   CHAN SC, 1991, CLIN CHEM, V37, P756
   CHERVENI.PA, 1969, J CELL PHYSIOL, V73, P25, DOI 10.1002/jcp.1040730104
   CHRISTENSON L, 1989, J BIOMED MATER RES, V23, P705, DOI 10.1002/jbm.820230704
   CHRISTENSON L, 1991, J BIOMED MATER RES, V25, P1119, DOI 10.1002/jbm.820250906
   COOK PD, 1995, AM J SURG PATHOL, V19, P712, DOI 10.1097/00000478-199506000-00012
   COPELAND M, 1993, PLAST RECONSTR SURG, V92, P1179, DOI 10.1097/00006534-199311000-00030
   DOOLITTLE RF, 1967, ARCH BIOCHEM BIOPHYS, V118, P456, DOI 10.1016/0003-9861(67)90374-8
   EBBE S, 1973, BLOOD, V42, P857
   FALUS A, 1992, IMMUNOL TODAY, V13, P154
   FERREIRA SH, 1973, BRIT J PHARMACOL, V49, P543, DOI 10.1111/j.1476-5381.1973.tb17265.x
   FRANZEN L, 1981, ACTA PATH MICRO IM A, V89, P57
   FUJITA J, 1988, J CELL PHYSIOL, V134, P78, DOI 10.1002/jcp.1041340109
   GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0
   Gilman A G, 1990, GOODMAN GILMANS PHAR, P1811
   GINSBURG H, 1979, NATURE, V280, P151, DOI 10.1038/280151a0
   GREGA GJ, 1991, MICROCIRC ENDOTH LYM, V7, P267
   GUO W, 1993, INT J ARTIF ORGANS, V16, P276
   HAMLIN GW, 1978, BRIT J SURG, V65, P272, DOI 10.1002/bjs.1800650416
   HATTORI R, 1989, J BIOL CHEM, V264, P7768
   HIMMELHOCH SR, 1969, BIOCHEMISTRY-US, V8, P914, DOI 10.1021/bi00831a022
   HOLTROP ME, 1982, CALCIFIED TISSUE INT, V34, P488, DOI 10.1007/BF02411290
   IRMANFLORJANC T, 1994, AGENTS ACTIONS, V41, pC129, DOI 10.1007/BF02007797
   ISSEKUTZ AC, 1981, LAB INVEST, V45, P234
   JIRANEK WA, 1993, J BONE JOINT SURG AM, V75A, P863, DOI 10.2106/00004623-199306000-00007
   JONES DA, 1993, BIOPHYS J, V112, P749
   KANETA S, 1993, RES COMMUN CHEM PATH, V79, P167
   KAPLAN AP, 1976, J INVEST DERMATOL, V67, P327, DOI 10.1111/1523-1747.ep12514352
   KITAMURA Y, 1978, BLOOD, V52, P447
   KOSSOVSKY N, 1983, PLAST RECONSTR SURG, V71, P795, DOI 10.1097/00006534-198306000-00008
   KOTTKEMARCHANT K, 1989, BIOMATERIALS, V10, P147, DOI 10.1016/0142-9612(89)90017-3
   KUBES P, 1994, J IMMUNOL, V152, P3570
   MARCHANT RE, 1984, J BIOMED MATER RES, V18, P1169, DOI 10.1002/jbm.820180917
   MARKS R, 1977, BRIT J CLIN PHARMACO, V4, P367, DOI 10.1111/j.1365-2125.1977.tb00725.x
   MASLINSKI C, 1975, AGENTS ACTIONS, V5, P89, DOI 10.1007/BF02027348
   METCALFE DD, 1992, INFLAMMATION BASIC P, P709
   MORTILLARO NA, 1981, AM J PHYSIOL, V240, pG381
   MURRAY DW, 1990, J BONE JOINT SURG BR, V72, P988
   OKAMOTO H, 1990, IMMUNOLOGY, V69, P162
   OWEN D A A, 1980, Biochemical Society Transactions, V8, P150
   OWEN DAA, 1980, BRIT J PHARMACOL, V69, P615, DOI 10.1111/j.1476-5381.1980.tb07912.x
   PATERSON IS, 1989, MICROVASC RES, V38, P49, DOI 10.1016/0026-2862(89)90016-2
   PICHA GJ, 1990, PLAST RECONSTR SURG, V85, P903, DOI 10.1097/00006534-199006000-00011
   RAMOS BF, 1992, J PHARMACOL EXP THER, V262, P559
   RAMOS BF, 1991, J IMMUNOL, V147, P1636
   RAMOS BF, 1990, J IMMUNOL, V145, P1868
   REINER E, 1989, ENZYMES HYDROLYSING, P266
   RILEY JF, 1953, J PHYSIOL-LONDON, V120, P528, DOI 10.1113/jphysiol.1953.sp004915
   SANTAVIRTA S, 1990, J BONE JOINT SURG AM, V72A, P252, DOI 10.2106/00004623-199072020-00014
   STARK GB, 1990, ANN PLAS SURG, V24, P156, DOI 10.1097/00000637-199002000-00009
   SUTHERLAND K, 1993, J CLIN INVEST, V92, P2360, DOI 10.1172/JCI116841
   TANG L, 1998, IN PRESS TISSUE ENG
   TANG LP, 1993, J EXP MED, V178, P2147, DOI 10.1084/jem.178.6.2147
   Tang LP, 1996, J CLIN INVEST, V97, P1329, DOI 10.1172/JCI118549
   TODA N, 1987, CIRC RES, V61, P280, DOI 10.1161/01.RES.61.2.280
   TORRES JL, 1988, ARCH BIOCHEM BIOPHYS, V267, P271, DOI 10.1016/0003-9861(88)90032-X
   VISTNES LM, 1978, PLAST RECONSTR SURG, V62, P580, DOI 10.1097/00006534-197810000-00015
   WARD R, 1989, BIOMATERIALS, V10, P425, DOI 10.1016/0142-9612(89)90135-X
   WEI YF, 1986, J IMMUNOL, V137, P1993
   WERSHIL BK, 1988, J IMMUNOL, V140, P2356
   WHITTINGHAM S, 1988, MOL CELL PROBE, V2, P169, DOI 10.1016/0890-8508(88)90001-1
   YAM LT, 1971, AM J CLIN PATHOL, V55, P283
   YATES SG, 1973, SURG GYNECOL OBSTET, V136, P12
   YOSHIHARA S, 1995, AM J RESP CRIT CARE, V151, P1011
   ZHANG Y, 1992, SCIENCE, V258, P1957, DOI 10.1126/science.1470922
   ZHAO Q, 1990, J BIOMED MATER RES, V24, P621, DOI 10.1002/jbm.820240508
   ZWADLOKLARWASSER G, 1994, AGENTS ACTIONS, V41, pC99, DOI 10.1007/BF02007785
NR 73
TC 139
Z9 144
U1 2
U2 9
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 21
PY 1998
VL 95
IS 15
BP 8841
EP 8846
DI 10.1073/pnas.95.15.8841
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 103EA
UT WOS:000075143900077
PM 9671766
OA Green Published, Bronze
DA 2018-10-19
ER

PT J
AU Gursel, I
   Balcik, C
   Arica, Y
   Akkus, O
   Akkas, N
   Hasirci, V
AF Gursel, I
   Balcik, C
   Arica, Y
   Akkus, O
   Akkas, N
   Hasirci, V
TI Synthesis and mechanical properties of interpenetrating networks of
   polyhydroxybutyrate-co-hydroxyvalerate and polyhydroxyethyl methacrylate
SO BIOMATERIALS
LA English
DT Article
DE polyhydroxyalkanoates; poly-2-hydroxyethyl methacrylate;
   interpenetrating networks; biomaterial; mechanical properties
ID DELIVERY SYSTEMS; COMPOSITE; POLYMER
AB Naturally occurring, biocompatible, and biodegradable polyhydroxybutyrate-co-hydroxyvalerate (PHBV), and synthetic, non-degrading polyhydroxyethylmethacrylate (PHEMA) membranes were prepared and their mechanical properties were studied. Their performances were compared with the interpenetrating networks (IPN) prepared by photopolymerization of HEMA in the presence of PHBV. The modulus of elasticity, failure stress and failure strain indicated that the IPNs are viscoelastic with properties closer to PHEMA but much stronger than PHEMA homopolymers. Incorporation of PHBV (7, 14 and 22% I-IV) affected the mechanical properties positively. Increasing the PHBV content increased the modulus of elasticity and failure stress nearly in all samples tested. PHBV (7, 14, and 22% HV, 300 mg) samples showed an approximately 17-30 fold increase in terms of modulus of elasticity and 7-10 fold increase in terms of failure stress. The scanning electron micrographs of the membranes showed that the PHEMA membranes are more porous than the PHBV membranes but the IPN structure displayed channels on the membrane surface indicating that HEMA polymerization was achieved by using the PHBV as a scaffold. With the use of the present technique, it is possible to synthesize supramolecular structures from molecules that are not compatible and miscible with each other. (C) 1998 Published by Elsevier Science Ltd. All rights reserved.
C1 Middle E Tech Univ, Dept Sci Biol, Biotechnol Res Unit, Biomat Res Lab, TR-06531 Ankara, Turkey.
   Kirikkale Univ, Dept Biol, Kirikkale, Turkey.
   Middle E Tech Univ, Dept Engn Sci, TR-06531 Ankara, Turkey.
RP Hasirci, V (reprint author), Middle E Tech Univ, Dept Sci Biol, Biotechnol Res Unit, Biomat Res Lab, TR-06531 Ankara, Turkey.
RI Akkus, Ozan/C-2320-2008
OI Gursel, Ihsan/0000-0003-3761-1166; Akkus, Ozan/0000-0003-3523-3421
CR ARICA MY, 1993, POLYM INT, V32, P177, DOI 10.1002/pi.4990320211
   BAUER H, 1988, COLLOID POLYM SCI, V266, P241, DOI 10.1007/BF01452586
   BOEREE NR, 1993, BIOMATERIALS, V14, P793, DOI 10.1016/0142-9612(93)90046-5
   CHIRILA TV, 1994, J BIOMED MATER RES, V28, P745, DOI 10.1002/jbm.820280612
   Doi Y., 1990, MICROBIAL POLYESTERS
   ENGELBERG I, 1991, BIOMATERIALS, V12, P292, DOI 10.1016/0142-9612(91)90037-B
   GURSEL I, 1995, J MICROENCAPSUL, V12, P185, DOI 10.3109/02652049509015289
   JANACEK J, 1973, J MACROMOL SCI R M C, VC  9, P1
   LANGER R, 1981, J BIOMED MATER RES, V15, P267, DOI 10.1002/jbm.820150212
   Lee SY, 1996, BIOTECHNOL BIOENG, V49, P1
   MULLER HM, 1993, ANGEW CHEM INT EDIT, V32, P477, DOI 10.1002/anie.199304771
   OWEN AJ, 1985, COLLOID POLYM SCI, V263, P799, DOI 10.1007/BF01412956
   PEPPAS NA, 1987, HYDROGELS MED PHARM, V2, P49
   RAO JK, 1994, BIOMATERIALS, V15, P383, DOI 10.1016/0142-9612(94)90251-8
   Santin M, 1996, BIOMATERIALS, V17, P1459, DOI 10.1016/0142-9612(96)89769-9
   SMETANA K, 1992, BIOMATERIALS, V13, P639, DOI 10.1016/0142-9612(92)90033-K
   WICHTERLE O, 1960, NATURE, V185, P117, DOI 10.1038/185117a0
   WOOD JM, 1983, DRUG DEV IND PHARM, V9, P93, DOI 10.3109/03639048309048547
NR 18
TC 49
Z9 51
U1 0
U2 23
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD JUL
PY 1998
VL 19
IS 13
BP 1137
EP 1143
DI 10.1016/S0142-9612(98)00009-X
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 108AQ
UT WOS:000075244000002
PM 9720897
DA 2018-10-19
ER

PT J
AU Nageswari, K
   Banerjee, R
   Gupte, RV
   Puniyani, RR
AF Nageswari, K
   Banerjee, R
   Gupte, RV
   Puniyani, RR
TI Hemorheological parameters for biocompatibility evaluation
SO JOURNAL OF BIOMATERIALS APPLICATIONS
LA English
DT Article
DE biomaterials; biocompatibility; hemorheology
ID VISCOSITY; PLASMA; BLOOD
AB Biomaterials have been extensively used for various clinical applications. Since blood is very sensitive to the presence of any foreign substances, testing for hemocompatibility is a major part of biocompatibility evaluation. At present, blood viscosity parameters are being used as screening tests for biomaterial compatibility. Successful use of these parameters will help eliminate many incompatible materials from being subjected to extensive testing. In this study, we evaluated the blood viscosity parameters (n = 10)-whole blood viscosity, plasma viscosity, red cell rigidity, hematocrit, and biochemical parameters (total proteins and albumin). A significant increase in hemorheological parameters after incubation with material was found to be an indicator of incompatibility.
C1 Indian Inst Technol, Sch Biomed Engn, Bombay 400076, Maharashtra, India.
CR BERGER M, 1994, J MATER SCI-MATER M, V5, P622, DOI 10.1007/BF00120343
   BHOWMICK UN, 1989, CGCRI B, V36, P50
   BORETOS JOHN W., 1968, J BIOMED MAT RES, V2, P121, DOI 10.1002/jbm.820020109
   CAZENAVE JP, 1985, P RHON POUL SANT INS
   CHIU TH, 1976, T AM SOC ART INT ORG, V22, P498
   CHIU TH, 1978, T AM SOC ART INT ORG, V24, P389
   CIAPETTI G, 1994, J MATER SCI-MATER M, V5, P640, DOI 10.1007/BF00120346
   DINTENFASS L, 1966, NATURE, V632, P211
   HUSSAIN MA, 1995, CLIN HEMORHEOL, V15, P61
   KULKARNI MV, 1994, CLIN HEMORHEOL, V142, P271
   LOWE GDO, 1976, THROMB RES, V14, P337
   LYMAN DJ, 1975, T AM SOC ART INT ORG, V21, P49
   OFFEMAN RD, 1976, BIOMATER ARTIF CELL, V4, P49, DOI 10.3109/10731197609118644
   PUNIYANI RR, 1994, J ASSOC PHYS INDIA, V8, P42
   PUNIYANI RR, 1989, J GEN MED, V11, P5
   PUNIYANI RR, 1995, TRENDS BIOMATERIALS, V9, P19
   RANADE GG, 1995, CLIN HEMORHEOL, V15, P755
   RANJEET SA, 1995, CLIN HEMORHEOL, V15, P46
   Willows D. M., 1987, PROGR BIOMEDICAL ENG, V1
   YOSHIKAWA S, 1988, IMPLANT MAT BIOFUNCT, P187
NR 20
TC 6
Z9 7
U1 0
U2 0
PU TECHNOMIC PUBL CO INC
PI LANCASTER
PA 851 NEW HOLLAND AVE, BOX 3535, LANCASTER, PA 17604 USA
SN 0885-3282
J9 J BIOMATER APPL
JI J. Biomater. Appl.
PD JUL
PY 1998
VL 13
IS 1
BP 74
EP 80
DI 10.1177/088532829801300105
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 102EQ
UT WOS:000074911700004
PM 9689581
DA 2018-10-19
ER

PT J
AU Peter, SJ
   Miller, ST
   Zhu, GM
   Yasko, AW
   Mikos, AG
AF Peter, SJ
   Miller, ST
   Zhu, GM
   Yasko, AW
   Mikos, AG
TI In vivo degradation of a poly(propylene fumarate) beta-tricalcium
   phosphate injectable composite scaffold
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article; Proceedings Paper
CT Society-for-Biomaterials 24th Annual Meeting
CY APR 22-26, 1998
CL SAN DIEGO, CALIFORNIA
SP Soc Biomat
DE bone tissue engineering; poly(propylene fumarate); biodegradable
   polymer; unsaturated polymer; in situ polymerizable biomaterials
AB This study was designed to investigate the in vivo biodegration and biocompatibility of a poly(propylene fumarate) (PPF)-based orthopedic biomaterial. The effects of varying the PPF to N-vinyl pyrrolidinone ratio and PPF to beta-tricalcium phosphate content were studied. The composite mechanical properties and local tissue interactions were analyzed over 12 weeks. An initial increase in both compressive modulus and strength was seen for composite formulations that incorporated beta-tricalcium phosphate. The samples incorporating a higher PPF to N-vinyl pyrrolidinone ratio reached a maximal compressive strength of 7.7 MPa and a maximal compressive modulus of 191.4 MPa at 3 weeks. The lower PPF to N-vinyl pyrrolidinone ratio samples gained a maximum compressive strength of 7.5 MPa initially and a compressive modulus of 134.0 MPa at 1 week. At 6 weeks, all samples for formulations incorporating beta-tricalcium phosphate crumbled upon removal and were not mechanically tested. Samples that did not incorporate beta-tricalcium phosphate were very weak and insufficient for bone replacement at the 4-day time point and beyond. Tissue interactions resulted in a mild inflammatory response at the initial time points and mature fibrous encapsulation by 12 weeks. (C) 1998 John Wiley & Sons, Inc.
C1 Rice Univ, Inst Biosci & Bioengn, Cox Lab Biomed Engn, Houston, TX 77005 USA.
   Rice Univ, Dept Chem Engn, Houston, TX 77005 USA.
   Univ Texas, MD Anderson Cancer Ctr, Dept Orthopaed Surg, Houston, TX 77030 USA.
RP Mikos, AG (reprint author), Rice Univ, Inst Biosci & Bioengn, Cox Lab Biomed Engn, 6100 S Main, Houston, TX 77005 USA.
FU NIGMS NIH HHS [5T32GM08362]; NIAMS NIH HHS [R01-AR44381]
CR Anderson James M., 1996, P165
   Bajpai P. K., 1983, BIOMATERIALS RECONST, P312
   BOBYN JD, 1992, CLIN ORTHOP RELAT R, P79
   BUCK BE, 1989, CLIN ORTHOP RELAT R, P129
   FRAZIER DD, 1995, MRS P, V349, P5
   GOLDSTEIN SA, 1983, J BIOMECH, V16, P965, DOI 10.1016/0021-9290(83)90097-0
   LIGHT M, 1991, Journal of Foot Surgery, V30, P472
   MADRI JA, 1990, ANDERSONS PATHOLOGY, P98
   Peter SJ, 1997, TISSUE ENG, V3, P207, DOI 10.1089/ten.1997.3.207
   Peter SJ, 1997, J BIOMAT SCI-POLYM E, V8, P893, DOI 10.1163/156856297X00074
   PETTY W, 1985, J BONE JOINT SURG AM, V67A, P1236, DOI 10.2106/00004623-198567080-00015
   PETTY W, 1988, J BONE JOINT SURG AM, V70A, P536, DOI 10.2106/00004623-198870040-00009
   Yaszemski M J, 1995, Tissue Eng, V1, P41, DOI 10.1089/ten.1995.1.41
   Yaszemski MJ, 1996, BIOMATERIALS, V17, P2127, DOI 10.1016/0142-9612(96)00008-7
NR 14
TC 156
Z9 160
U1 2
U2 12
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD JUL
PY 1998
VL 41
IS 1
BP 1
EP 7
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA ZR804
UT WOS:000074015500001
PM 9641618
DA 2018-10-19
ER

PT J
AU Weiss, P
   Bohic, S
   Lapkowski, M
   Daculsi, G
AF Weiss, P
   Bohic, S
   Lapkowski, M
   Daculsi, G
TI Application of FT-IR microspectroscopy to the study of an injectable
   composite for bone and dental surgery
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE FT-IR; microspectroscopy; infrared; injectable biomaterial; calcium
   phosphate; bone substitute
AB Hydroxypropylmethylcellulose (HPMC) of high-viscosity grade is used as a ligand for a bioactive calcium phosphate ceramic (the filler) in a ready-to-use injectable sterilized biomaterial for bone and dental surgery. Application of physico-chemical methods such as XPS, NMR, or Raman spectroscopy encounters difficulties when used to study such a multiphased material. This paper reports on the application of FT-IX microspectroscopy (FT-IRM) for the investigation of inorganic and organic phases of the rough composite and separated phases obtained by mechanical or chemical extraction methods. A comparison of FT-IRM with the conventional KBr pellet method was made and indicates that the macro and micro FT-IR methods are complementary: the former revealed new chemical groups not visualized with the KBr method whereas the latter detected the major compound of the blend. FT-IR microspectroscopy was revealed to be a powerful method of analysis that is complementary to other existing spectroscopic methods. Moreover, it is expected to be a useful tool in the study of biomaterials in biological samples. (C) 1998 John Wiley & Sons, Inc.
C1 Fac Chirurg Dent, UPRES EA 2159, Ctr Rech Mat Interet Biol, F-44042 Nantes 1, France.
   Silesian Tech Univ, Fac Chem, PL-44101 Gliwice, Poland.
RP Bohic, S (reprint author), Fac Chirurg Dent, UPRES EA 2159, Ctr Rech Mat Interet Biol, 1 Pl Alexis Ricordeau,BP 84215, F-44042 Nantes 1, France.
RI BOHIC, Sylvain/F-6464-2013; Daculsi, Guy/P-1320-2014; Lapkowski,
   Mieczyslaw/D-5242-2014; Weiss, Pierre/P-1372-2014
OI BOHIC, Sylvain/0000-0001-6355-7592; Daculsi, Guy/0000-0003-1030-3446;
   Lapkowski, Mieczyslaw/0000-0001-7099-3982; Weiss,
   Pierre/0000-0002-6159-8590
CR DACULSI G, 1995, Patent No. 21634
   FENGEL D, 1991, PAPIER, V45, P45
   Grimandi G, 1998, J BIOMED MATER RES, V39, P660, DOI 10.1002/(SICI)1097-4636(19980315)39:4<660::AID-JBM22>3.0.CO;2-9
   HARTHCOCK MA, 1986, APPL SPECTROSC, V40, P210, DOI 10.1366/0003702864509529
   Legeros R.Z., 1991, MONOGRAPHS ORAL SCI, V15
   LEGEROS RZ, 1986, J DENT RES, V65, P292
   LEGEROS RZ, 1986, J DENT RES, V65, P110
   Nevell TP, 1985, CELLULOSE CHEM ITS A, P243
   NEVELL TP, 1985, CELLULOSE CHEM ITS A, P242
   OCONNOR RT, 1957, ANAL CHEM, V29, P998, DOI 10.1021/ac60127a003
   Paschalis EP, 1996, BONE, V19, P151, DOI 10.1016/8756-3282(96)00164-0
   REY C, 1995, J BONE MINER RES, V10, P1577
   REY C, 1989, CONNECT TISSUE RES, V21, P597, DOI 10.3109/03008208909050016
   Weiss P, 1997, J MATER SCI-MATER M, V8, P621, DOI 10.1023/A:1018519419539
NR 14
TC 23
Z9 25
U1 0
U2 2
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD JUL
PY 1998
VL 41
IS 1
BP 167
EP 170
DI 10.1002/(SICI)1097-4636(199807)41:1<167::AID-JBM20>3.0.CO;2-J
PG 4
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA ZR804
UT WOS:000074015500020
PM 9641637
DA 2018-10-19
ER

PT J
AU Teraoka, K
   Ito, A
   Maekawa, K
   Onuma, K
   Tateishi, T
   Tsutsumi, S
AF Teraoka, K
   Ito, A
   Maekawa, K
   Onuma, K
   Tateishi, T
   Tsutsumi, S
TI Mechanical properties of hydroxyapatite and OH-carbonated hydroxyapatite
   single crystals
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE hydroxyapatite; single crystal; three-point bending test; bending
   strength; Young's modulus
ID HYDROXYLAPATITE; PHOSPHATE; FLUORAPATITE; BEHAVIOR
AB Single-crystal hydroxyapatite and OH-carbonated hydroxyapatite have bending strength much higher than that of dense hydroxyapatite ceramic, indicating potential applicability to a load-bearing biomaterial. However, the effects of carbonate on the strength are less clear. The objective of the present study was to determine the bending strength and Young's modulus of these single crystals with carbonate contents from 0 to 0.62 in CO2 wt%. Three-point bending tests were performed by means of a modified ultramicrohardness tester with a span of 380 mu m and a bending direction <210> of the single crystals. The crystals were broken in air, water, and air after immersion in a cell culture medium for 3 wks. The average Young's modulus of the single crystals was from 54 to 79 GPa. The average bending strength of the single crystals in air was 500 +/- 184, 468 +/- 205, 513 +/- 151, and 450 +/- 162 MPa for those with 0, 0.09, 0.37, and 0.62 wt% carbonate, respectively. No significant decrease in strength was found for hydroxyapatite single crystals both in water and after the immersion in the medium. However, the strength of OH-carbonated hydroxyapatite single crystals decreased significantly by 23 to 43% in water in proportion to the carbonate content. The strength of single crystals with 0.37 and 0.62 wt% carbonate decreased significantly, even after the immersion in the medium. Therefore, hydroxyapatite single crystals are superior to OH-carbonated hydroxyapatite single crystals as a biomaterial for a load-bearing purpose.
C1 Natl Inst Adv Interdisciplinary Res, Bion Design Grp, Tsukuba, Ibaraki 305, Japan.
   Waseda Univ, Sch Educ, Inst Earth Sci, Tokyo, Japan.
RP Ito, A (reprint author), Natl Inst Adv Interdisciplinary Res, Bion Design Grp, 1-1-4 Higashi, Tsukuba, Ibaraki 305, Japan.
RI Ito, Atsuo/M-6785-2018
OI Ito, Atsuo/0000-0003-3318-040X
CR AKAO M, 1981, J MATER SCI, V16, P809, DOI 10.1007/BF00552220
   BROWN WE, 1983, J DENT RES, V62, P672
   DEGROOT K, 1989, J INVEST SURG, V2, P343
   DEPUTTER C, 1986, BIOL BIOMECHANICAL P, P111
   DEWITH G, 1981, J MATER SCI, V16, P1592
   DHERT WJA, 1991, J BIOMED MATER RES, V25, P1183, DOI 10.1002/jbm.820251002
   DOI Y, 1987, J JPN SOC DENTAL MAT, V6, P53
   DOLPHIN D, 1977, TABULATION INFRARED, P241
   DUCHEYNE P, 1993, J BIOMED MATER RES, V27, P25, DOI 10.1002/jbm.820270105
   Ducheyne P, 1992, Clin Orthop Relat Res, P102
   GATTI AM, 1990, BIOMATERIALS, V11, P513, DOI 10.1016/0142-9612(90)90068-2
   GILMORE RS, 1982, J MATER SCI, V17, P1131, DOI 10.1007/BF00543533
   GOTO T, 1993, JPN J DENT MAT, V12, P743
   Hulbert SF, 1993, INTRO BIOCERAMICS, P25
   Ito A, 1996, J CRYST GROWTH, V163, P311, DOI 10.1016/0022-0248(95)00955-8
   Ito A, 1997, J BIOMED MATER RES, V36, P522, DOI 10.1002/(SICI)1097-4636(19970915)36:4<522::AID-JBM10>3.0.CO;2-C
   ITO A, 1996, BIOCERAMICS, V9, P189
   JAHNKE RA, 1984, AM J SCI, V284, P58, DOI 10.2475/ajs.284.1.58
   JANSEN JA, 1991, J BIOMED MATER RES, V25, P973, DOI 10.1002/jbm.820250805
   JARCHO M, 1981, CLIN ORTHOP RELAT R, P259
   JARCHO M, 1976, J MATER SCI, V11, P2027, DOI 10.1007/BF02403350
   JURIAANSE AC, 1980, J COLLOID INTERF SCI, V76, P220, DOI 10.1016/0021-9797(80)90288-X
   KATZ JL, 1971, J BIOMECH, V4, P221, DOI 10.1016/0021-9290(71)90007-8
   LEGEROS RZ, 1967, SCIENCE, V155, P1409, DOI 10.1126/science.155.3768.1409
   SHIN Y, 1992, J MATER SCI-MATER M, V3, P219, DOI 10.1007/BF00713453
   Teraoka K, 1997, J BIOMED MATER RES, V34, P269, DOI 10.1002/(SICI)1097-4636(199702)34:2<269::AID-JBM16>3.0.CO;2-D
   THOMAS MB, 1980, J MATER SCI, V15, P891, DOI 10.1007/BF00552099
NR 27
TC 20
Z9 20
U1 0
U2 10
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022-0345
EI 1544-0591
J9 J DENT RES
JI J. Dent. Res.
PD JUL
PY 1998
VL 77
IS 7
BP 1560
EP 1568
DI 10.1177/00220345980770071201
PG 9
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA ZX850
UT WOS:000074561700012
PM 9663442
DA 2018-10-19
ER

PT J
AU Alimi, YS
   Chakfe, N
   Rivoal, E
   Slimane, KK
   Valerio, N
   Riepe, G
   Kretz, JG
   Juhan, C
AF Alimi, YS
   Chakfe, N
   Rivoal, E
   Slimane, KK
   Valerio, N
   Riepe, G
   Kretz, JG
   Juhan, C
TI Rupture of an abdominal aortic aneurysm after endovascular graft
   placement and aneurysm size reduction
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Article
ID ENDOLUMINAL REPAIR; LESIONS
AB Reduction in aneurysm size during the months after an endovascular graft placement generally is considered one of the criteria of success. We report the case of a patient with an abdominal aortic aneurysm rupture occurring 9 months after a bifurcated endovascular graft placement despite a greater than 45% reduction in size noted on contrast-enhanced computed tomography scan performed at 7 months. Biomaterial modifications of the stent and of the Dacron explanted stent-graft are analyzed.
C1 Hop Nord Marseille, Dept Vasc Surg, F-13915 Marseille 20, France.
   Hop Civil, Hop Univ Strasbourg, Dept Cardiovasc Surg, Biomat Lab, Strasbourg, France.
   Dept Gen Thorac & Vasc Surg, Hamburg, Germany.
RP Alimi, YS (reprint author), Hop Nord Marseille, Dept Vasc Surg, Chemin Bourrellys, F-13915 Marseille 20, France.
CR Kolvenbach R, 1997, J VASC SURG, V26, P351, DOI 10.1016/S0741-5214(97)70201-5
   LUMSDEN AB, 1995, AM J SURG, V170, P174, DOI 10.1016/S0002-9610(99)80280-3
   MARIN ML, 1995, ANN SURG, V222, P449
   Matsumura JS, 1997, J VASC SURG, V25, P113, DOI 10.1016/S0741-5214(97)70327-6
   MAY J, 1995, EUR J VASC ENDOVASC, V10, P51, DOI 10.1016/S1078-5884(05)80198-4
   May J, 1996, EUR J VASC ENDOVASC, V12, P11, DOI 10.1016/S1078-5884(96)80269-3
   MAY J, 1995, J ENDOVASC SURG, V2, P343, DOI 10.1583/1074-6218(1995)002<0343:APSOCI>2.0.CO;2
   Mialhe C, 1997, J VASC SURG, V26, P199, DOI 10.1016/S0741-5214(97)70180-0
   PARODI JC, 1995, J VASC SURG, V21, P549, DOI 10.1016/S0741-5214(95)70186-9
   PARODI JC, 1994, SURGICAL TECHNOLOGIC, P431
   RIEPE G, UNPUB EUR J VASC END
   VEITH FJ, 1995, J VASC SURG, V21, P670, DOI 10.1016/S0741-5214(95)70198-2
   White G H, 1994, J Endovasc Surg, V1, P16
   YUSUF SW, 1994, LANCET, V344, P650, DOI 10.1016/S0140-6736(94)92086-9
NR 14
TC 125
Z9 128
U1 0
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD JUL
PY 1998
VL 28
IS 1
BP 178
EP 183
DI 10.1016/S0741-5214(98)70213-7
PG 6
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 100RX
UT WOS:000074830100020
PM 9685144
OA Bronze
DA 2018-10-19
ER

PT J
AU Chang, YS
   Gu, HO
   Kobayashi, M
   Oka, M
AF Chang, YS
   Gu, HO
   Kobayashi, M
   Oka, M
TI Comparison of the bony ingrowth into an osteochondral defect and an
   artificial osteochondral composite device in load-bearing joints
SO KNEE
LA English
DT Article
DE bony ingrowth; loading condition; artificial articular cartilage;
   cancellous bone; shock-absorbing effect
ID CARTILAGE; IMPLANTS; TITANIUM
AB In order to preserve as much subchondral cancellous bone as possible in the repair of damaged joint surfaces, we have attempted to develop an artificial articular cartilage, using polyvinyl alcohol hydrogel, a rubber-like gel. In this study, osteochondral defects were made and an osteochondral composite device was implanted in the weight-bearing portions of medial and lateral femoral condyles of dogs. Cancellous bone ingrowth into the pores of titanium-fiber mesh and osteochondral defect and bone remodeling under loading conditions were observed histologically and roentgenologically for 24 weeks after implantation. Cancellous bone ingrowth into the titanium-fiber mesh could be observed as early as 4 weeks in the study. Bone ingrowth was abundant and increased with time after implantation. These findings were similar to the cancellous bone repair and remodeling observed in the osteochondral defects. Interstitial cancellous bone ingrowth resulted in the complete integration of this implant and the viable host bone. Moreover, both the polyvinyl alcohol hydrogel itself and the tibial joint surface that bore against the polyvinyl alcohol hydrogel surface of this implant remained intact, which suggests this composite is a very promising biomaterial for use in joint prostheses. Thus, we conclude that this artificial osteochondral composite device could reconstitute and achieve the shock-absorbing effect lost after total joint replacement or hemiarthroplasty. (C) 1998 Elsevier Science B.V. All rights reserved.
C1 Kyoto Univ, Biomed Engn Res Ctr, Sakyo Ku, Kyoto 606, Japan.
RP Chang, YS (reprint author), Kyoto Univ, Biomed Engn Res Ctr, Sakyo Ku, 53 Kawahara Cho, Kyoto 606, Japan.
EM changys@medeng.kyoto-u.ac.jp
CR AMSTUTZ HC, 1992, CLIN ORTHOP RELAT R, P7
   BOBYN JD, 1980, CLIN ORTHOP RELAT R, P263
   BOEREE NR, 1993, BIOMATERIALS, V14, P793, DOI 10.1016/0142-9612(93)90046-5
   BOURNE RB, 1994, CLIN ORTHOP RELAT R, P37
   Chang YS, 1996, J BIOMED MATER RES, V30, P117, DOI 10.1002/(SICI)1097-4636(199601)30:1<117::AID-JBM15>3.0.CO;2-L
   Chang YS, 1997, J BIOMED MATER RES, V37, P51, DOI 10.1002/(SICI)1097-4636(199710)37:1<51::AID-JBM7>3.3.CO;2-Y
   CLEMOW AJT, 1981, J BIOMED MATER RES, V15, P73, DOI 10.1002/jbm.820150111
   COOK SD, 1988, CLIN ORTHOP RELAT R, P90
   COOLIER JP, 1988, CLIN ORTHOP RELAT R, V235, P173
   DUCHEYNE P, 1977, J BIOMED MATER RES, V11, P811, DOI 10.1002/jbm.820110603
   GOODMAN SB, 1993, BIOMATERIALS, V14, P723, DOI 10.1016/0142-9612(93)90035-Z
   Gross U, 1988, Ann N Y Acad Sci, V523, P211, DOI 10.1111/j.1749-6632.1988.tb38514.x
   GROSS UM, 1988, ANN NY ACAD SCI, P211
   HAAS SB, 1995, J BONE JOINT SURG AM, V77A, P1700, DOI 10.2106/00004623-199511000-00009
   HARPER GD, 1995, J BONE JOINT SURG BR, V77B, P557
   Hill R A, 1992, J Arthroplasty, V7, P25, DOI 10.1016/0883-5403(92)90028-O
   INOUE K, 1992, BIOCERAMICS, V5, P125
   JANSEN JA, 1991, J BIOMED MATER RES, V25, P973, DOI 10.1002/jbm.820250805
   JASTY M, 1988, NONCEMENTED TOTAL HI, P175
   KALTSAS DS, 1986, INJURY, V17, P230, DOI 10.1016/0020-1383(86)90226-3
   KEMPSON GE, 1973, BIOCHIM BIOPHYS ACTA, V297, P456, DOI 10.1016/0304-4165(73)90093-7
   LEYSHON RL, 1984, J BONE JOINT SURG BR, V66, P172
   MARTELL JM, 1993, J BONE JOINT SURG AM, V75A, P554, DOI 10.2106/00004623-199304000-00010
   MCDONOUGH JM, 1967, J BONE JOINT SURG AM, VA 49, P625, DOI 10.2106/00004623-196749040-00003
   NOGUCHI T, 1991, J APPL BIOMATER, V2, P101, DOI 10.1002/jab.770020205
   OHGUSHI H, 1992, BIOCERAMICS, P119
   OKA M, 1990, Clinical Materials, V6, P361, DOI 10.1016/0267-6605(90)90053-X
   RADIN EL, 1971, ARTHRITIS RHEUM, V14, P356, DOI 10.1002/art.1780140306
   Roberts W E, 1988, J Dent Educ, V52, P804
   Rorabeck CH, 1996, CLIN ORTHOP RELAT R, P330
   SCHEIDLER PA, 1992, BIOMED SCI INSTRUM, V28, P183
   SCHMITZ JP, 1986, CLIN ORTHOP RELAT R, P299
   WALKER PS, 1988, CLIN ORTHOP RELAT R, P25
   WILLIAMS DF, 1974, J BIOMED MATER RES, V8, P1, DOI 10.1002/jbm.820080303
NR 34
TC 19
Z9 20
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0968-0160
J9 KNEE
JI Knee
PD JUL
PY 1998
VL 5
IS 3
BP 205
EP 213
DI 10.1016/S0968-0160(97)10001-1
PG 9
WC Orthopedics; Sport Sciences; Surgery
SC Orthopedics; Sport Sciences; Surgery
GA ZY079
UT WOS:000074584500010
DA 2018-10-19
ER

PT J
AU Fenice, M
   Di Giambattista, R
   Raetz, E
   Leuba, JL
   Federici, F
AF Fenice, M
   Di Giambattista, R
   Raetz, E
   Leuba, JL
   Federici, F
TI Repeated-batch and continuous production of chitinolytic enzymes by
   Penicillium janthinellum immobilised on chemically-modified macroporous
   cellulose
SO JOURNAL OF BIOTECHNOLOGY
LA English
DT Article
DE chitinolytic enzymes; immobilisation; repeated-batch processes;
   continuous culture; Penicillium janthinellum P9
ID TRICHODERMA-HARZIANUM; SUPPORT MATERIALS; ACID PRODUCTION; CELLS;
   IMMOBILIZATION; PURIFICATION; CARRIERS; FUNGI
AB Conidiospores of the fungus Penicillium janthinellum P9 were immobilised on polyurethane sponge and chemically-modified macroporous cellulose and cultivated for the production of chitinolytic enzymes in shaken culture, repeated-batch processes. The highest enzyme production (342 U l(-1))was obtained using the macroporous cellulose BR-L01T(70) (Biomaterial Co. Ltd., Japan); with this carrier cell leakage was negligible. The immobilised mycelium of P. janthinellum P9 was then used for repeated-batch and continuous production of chitinolytic enzymes and N-acetyl-beta-D-glucosamine in a fluidised-bed reactor (1.01 working volume). While the repeated-batch cultivation resulted in almost the same enzyme activity (338 U l(-1)) obtained in shaken culture, with the continuous operation a steady enzyme production of about 450 U l(-1) was reached and maintained for 168 h at a feed rate of 0.036 1 h(-1). At this feed rate, enzyme volumetric productivity and total N-acetyl-beta-D-glucosamine production were 14.76 U l(-1) h(-1) and 15.9 g, respectively. Carrier colonisation and hyphal growth were followed by observations under the scanning electron microscope. (C) 1998 Elsevier Science B.V. All rights reserved.
C1 Univ Tuscia, Dipartimento Agrobiol & Agrochim, I-01100 Viterbo, Italy.
   Nestec Ltd, Nestle Res Ctr, CH-1000 Lausanne 26, Switzerland.
RP Fenice, M (reprint author), Univ Tuscia, Dipartimento Agrobiol & Agrochim, I-01100 Viterbo, Italy.
OI Fenice, Massimiliano/0000-0001-8504-0885
CR Anderson JG, 1983, FILAMENTOUS FUNGI, P145
   CHEN JP, 1994, J CHEM TECHNOL BIOT, V60, P133, DOI 10.1002/jctb.280600204
   DEO YM, 1984, DEV IND MICROBIOL, V25, P491
   DIPIETRO A, 1993, PHYTOPATHOLOGY, V83, P308
   FEDERICI F, 1993, WORLD J MICROB BIOT, V9, P495, DOI 10.1007/BF00386282
   FEDERICI F, 1987, Annali di Microbiologia ed Enzimologia, V37, P243
   FEDERICI RG, 1990, BIOTECHNOL LETT, V12, P661, DOI 10.1007/BF01088190
   FUJII N, 1994, J FERMENT BIOENG, V78, P389, DOI 10.1016/0922-338X(94)90288-7
   GBEWONYO K, 1987, METHOD ENZYMOL, P318
   GYORGY P, 1955, P SOC EXP BIOL MED, V90, P219
   HANKIN L, 1975, MYCOLOGIA, V67, P597, DOI 10.2307/3758395
   JU N, 1986, APPL MICROBIOL BIOT, V23, P311
   KOGA K, 1991, AGR BIOL CHEM TOKYO, V55, P2817, DOI 10.1080/00021369.1991.10871049
   Leenen EJTM, 1996, PROGR BIOTECHNOL, V11, P205
   LINKO P, 1984, CRC CR REV BIOTECHN, V1, P289
   Linko S, 1996, PROGR BIOTECHNOL, V11, P592
   LORITO M, 1994, PHYTOPATHOLOGY, V84, P398, DOI 10.1094/Phyto-84-398
   LORITO M, 1996, CHITIN ENZIMOLOGY, P157
   MANOLOV RJ, 1993, WORLD J MICROB BIOT, V9, P29, DOI 10.1007/BF00656511
   MILLER GL, 1959, ANAL CHEM, V31, P426, DOI 10.1021/ac60147a030
   Muscat A, 1996, PROGR BIOTECHNOL, V11, P55
   PETRUCCIOLI M, 1994, BIOTECHNOL LETT, V16, P939, DOI 10.1007/BF00128629
   Petruccioli M, 1996, PROCESS BIOCHEM, V31, P463, DOI 10.1016/0032-9592(95)00089-5
   Portner R, 1996, PROGR BIOTECHNOL, V11, P424
   Quiros C, 1996, PROGR BIOTECHNOL, V11, P355
   Sakai K, 1990, DENPUN KAGAKU, V37, P79
   Simon JP, 1996, PROGR BIOTECHNOL, V11, P615
   VASSILEV N, 1992, MYCOL RES, V96, P63
   Vassilev N., 1990, PHYSL IMMOBILIZED CE, P331
   Webb C, 1996, STUDIES VIABLE CELL
   Wijffels RH, 1996, PROGR BIOTECHNOL, V11, P249
NR 31
TC 21
Z9 23
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-1656
J9 J BIOTECHNOL
JI J. Biotechnol.
PD JUN 30
PY 1998
VL 62
IS 2
BP 119
EP 131
DI 10.1016/S0168-1656(98)00051-0
PG 13
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 104CD
UT WOS:000074994000004
DA 2018-10-19
ER

PT J
AU Vinckier, A
   Semenza, G
AF Vinckier, A
   Semenza, G
TI Measuring elasticity of biological materials by atomic force microscopy
SO FEBS LETTERS
LA English
DT Article
DE atomic force microscopy; elasticity; biomaterial; young's modulus;
   resolution
ID VISCOELASTIC PROPERTIES; MECHANICAL-PROPERTIES; SURFACE; RESOLUTION;
   WATER; CELL
AB Atomic force microscopy (AFM) has proved its value not only for resolving the topographical structure of biological samples, but also for probing inherent properties of biological structures, like local interaction forces, mechanical properties or dynamics in a natural (physiological) environment. This minireview focuses on the acquisition of elasticity data of biomaterials by AFM. A possible theoretical model is presented, followed by a practical 'how to do it with AFM', and, finally, a brief overview of publications in this field is given, (C) 1998 Federation of European Biochemical Societies.
C1 Swiss Fed Inst Technol, ETH Zentrum, Dept Biochem, CH-8092 Zurich, Switzerland.
   Univ Zurich, Inst Anat, CH-8057 Zurich, Switzerland.
   Univ Milan, Dipartimento Chim & Biochem Med, I-20133 Milan, Italy.
RP Vinckier, A (reprint author), Swiss Fed Inst Technol, ETH Zentrum, Dept Biochem, Univ Str 16, CH-8092 Zurich, Switzerland.
EM vinckier@anatomie.unizh.ch
CR A-Hassan E, 1998, BIOPHYS J, V74, P1564, DOI 10.1016/S0006-3495(98)77868-3
   ALBRECHT TR, 1990, J VAC SCI TECHNOL A, V8, P3386, DOI 10.1116/1.576520
   Antonik MD, 1997, IEEE ENG MED BIOL, V16, P66, DOI 10.1109/51.582178
   ASHKIN A, 1989, P NATL ACAD SCI USA, V86, P7914, DOI 10.1073/pnas.86.20.7914
   BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930
   BURNHAM NA, 1989, J VAC SCI TECHNOL A, V7, P2906, DOI 10.1116/1.576168
   Cappella B, 1997, IEEE Eng Med Biol Mag, V16, P58, DOI 10.1109/51.582177
   CLEVELAND JP, 1993, REV SCI INSTRUM, V64, P403, DOI 10.1063/1.1144209
   DeRose JA, 1997, MICROSC MICROANAL, V3, P203
   Duquette JJ, 1996, J BIOMECH ENG-T ASME, V118, P557, DOI 10.1115/1.2796043
   ENGEL A, 1991, ANNU REV BIOPHYS BIO, V20, P79, DOI 10.1146/annurev.biophys.20.1.79
   EVANS E, 1995, BIOPHYS J, V68, P2215
   Fritzsche W, 1997, ULTRAMICROSCOPY, V69, P191, DOI 10.1016/S0304-3991(97)00043-0
   Goldmann WH, 1996, EXP CELL RES, V226, P234, DOI 10.1006/excr.1996.0223
   Goldmann WH, 1998, FEBS LETT, V424, P139, DOI 10.1016/S0014-5793(98)00155-0
   Grafstrom S., 1993, Nanotechnology, V4, P143, DOI 10.1088/0957-4484/4/3/003
   Grazi E, 1996, FEBS LETT, V387, P101, DOI 10.1016/0014-5793(96)00481-4
   Hansma HG, 1997, J STRUCT BIOL, V119, P99, DOI 10.1006/jsbi.1997.3855
   HANSMA HG, 1994, ANNU REV BIOPH BIOM, V23, P115, DOI 10.1146/annurev.bb.23.060194.000555
   HANSMA PK, 1988, SCIENCE, V242, P209, DOI 10.1126/science.3051380
   Hertz H., 1881, J REINE ANGEW MATH, V92, P156, DOI DOI 10.1515/CRIL.1882.92.156>
   Heuberger M, 1996, J VAC SCI TECHNOL B, V14, P1250, DOI 10.1116/1.588525
   Heuberger M., 1994, NANOTECHNOLOGY, V5, P12
   HILDEBRAND JA, 1984, J MICROSC-OXFORD, V134, P245, DOI 10.1111/j.1365-2818.1984.tb02518.x
   HOH JH, 1993, LANGMUIR, V9, P3310, DOI 10.1021/la00035a089
   ISRAELACHVILI JN, 1989, INTERMOLECULAR SURFA
   JANMEY PA, 1994, J BIOL CHEM, V269, P32503
   JOHNSON KL, 1971, PROC R SOC LON SER-A, V324, P301, DOI 10.1098/rspa.1971.0141
   LAL R, 1994, AM J PHYSIOL, V266, pC1
   LANDAU LD, 1986, STAT PHYSICS
   Laney DE, 1997, BIOPHYS J, V72, P806, DOI 10.1016/S0006-3495(97)78714-9
   LURE AI, 1964, 3 DIMENSIONAL PROBLE, P314
   Maivald P., 1991, Nanotechnology, V2, P103, DOI 10.1088/0957-4484/2/2/004
   Noy A, 1997, CHEM BIOL, V4, P519, DOI 10.1016/S1074-5521(97)90324-0
   Parpura V, 1996, BIOPHYS J, V71, P2356, DOI 10.1016/S0006-3495(96)79483-3
   PERSSON BNJ, 1987, CHEM PHYS LETT, V141, P366, DOI 10.1016/0009-2614(87)85040-6
   PETERSEN NO, 1982, P NATL ACAD SCI-BIOL, V79, P5327, DOI 10.1073/pnas.79.17.5327
   PETHICA JB, 1987, PHYS SCRIPTA, VT19A, P61, DOI 10.1088/0031-8949/1987/T19A/010
   RADMACHER M, 1994, LANGMUIR, V10, P3809, DOI 10.1021/la00022a068
   RADMACHER M, 1995, BIOPHYS J, V69, P264, DOI 10.1016/S0006-3495(95)79897-6
   Radmacher M, 1996, BIOPHYS J, V70, P556, DOI 10.1016/S0006-3495(96)79602-9
   Radmacher M, 1997, IEEE ENG MED BIOL, V16, P47, DOI 10.1109/51.582176
   Rho JY, 1997, BIOMATERIALS, V18, P1325, DOI 10.1016/S0142-9612(97)00073-2
   Rivetti C, 1996, J MOL BIOL, V264, P919, DOI 10.1006/jmbi.1996.0687
   SERWAY RA, 1982, PHYSICS, P298
   SHAO ZF, 1995, Q REV BIOPHYS, V28, P195, DOI 10.1017/S0033583500003061
   SHROFF SG, 1995, AM J PHYSIOL-CELL PH, V269, pC286
   Smith CW, 1996, J BIOMECH ENG-T ASME, V118, P56, DOI 10.1115/1.2795946
   Sneddon IN, 1965, INT J ENG SCI, V3, P47, DOI DOI 10.1016/0020-7225(65)90019-4
   STOKEY WF, 1996, SHOCK VIBRATION HDB, pCH7
   TAO NJ, 1992, BIOPHYS J, V63, P1165, DOI 10.1016/S0006-3495(92)81692-2
   TIMOSHENKO SP, 1970, THEORY ELASTICITY
   Vinckier A, 1996, J VAC SCI TECHNOL B, V14, P1427, DOI 10.1116/1.589113
   Vinckier A, 1998, BIOPHYS J, V74, P3256, DOI 10.1016/S0006-3495(98)78032-4
   WALCH M, 1998, IN PRESS
   WEAST RC, 1976, HDB CHEM PHYSICS, VF
   Weisenhorn A. L., 1993, Nanotechnology, V4, P106, DOI 10.1088/0957-4484/4/2/006
   WEISENHORN AL, 1989, APPL PHYS LETT, V54, P2651, DOI 10.1063/1.101024
   Xu W, 1996, J BACTERIOL, V178, P3106, DOI 10.1128/jb.178.11.3106-3112.1996
   Yang J, 1996, J MICROSC-OXFORD, V182, P106, DOI 10.1046/j.1365-2818.1996.140422.x
NR 60
TC 242
Z9 251
U1 2
U2 50
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-5793
J9 FEBS LETT
JI FEBS Lett.
PD JUN 23
PY 1998
VL 430
IS 1-2
SI SI
BP 12
EP 16
DI 10.1016/S0014-5793(98)00592-4
PG 5
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA ZZ833
UT WOS:000074771700003
PM 9678586
OA Bronze
DA 2018-10-19
ER

PT J
AU Combes, C
   Rey, C
   Freche, M
AF Combes, C
   Rey, C
   Freche, M
TI XPS and IR study of dicalcium phosphate dihydrate nucleation on titanium
   surfaces
SO COLLOIDS AND SURFACES B-BIOINTERFACES
LA English
DT Article
DE calcium phosphate; nucleation; phosphate uptake; surface
   characterization; titanium
ID CALCIUM PHOSPHATES; PRECIPITATION; DISSOLUTION; BIOMATERIAL; ADSORPTION;
   DIOXIDE; INVITRO
AB The nucleation and growth of dicalcium phosphate dihydrate (DCPD, CaHP4O.2H(2)O) on titanium powder at 37 degrees C and pH 5.5 has been investigated using the constant composition crystal growth method. The interaction between calcium phosphate nuclei and the oxidized titanium layer was characterized by XPS and IR analyses. At the earliest stage of contact with the supersaturated solution, the oxidized titanium surface exhibited an increase of the xylation rate associated with calcium and phosphate uptake. However, the calcium phosphate layer does not organize into DCPD nuclei at this stage, and exhibits the IR characteristics of amorphous calcium phosphate. The formation of DCPD crystals was observed at the end of the induction period: then, the crystals grow rapidly. Although phosphate uptake appeared to be the major reaction at the metal surface, the calcium concentration in solution determined the rate of nucleation. (C) 1998 Elsevier Science B.V. All rights reserved.
C1 ENSCT, Equipe Physicochim Solides, CNRS, UPRESA 5071, F-31400 Toulouse, France.
CR ALBREKTSSON T, 1983, ANN BIOMED ENG, V11, P1, DOI 10.1007/BF02363944
   AMRAHBOUALI S, 1994, BIOMATERIALS, V15, P269, DOI 10.1016/0142-9612(94)90050-7
   BOEHM HP, 1971, DISCUSS FARADAY SOC, P264
   BORGGREVEN JMPM, 1986, ARCH ORAL BIOL, V31, P139, DOI 10.1016/0003-9969(86)90118-4
   DAMEN JJM, 1991, J DENT RES, V70, P1346, DOI 10.1177/00220345910700100601
   FRANCIS MD, 1971, CALC TISS RES, V6, P335
   HANAWA T, 1992, APPL SURF SCI, V55, P269, DOI 10.1016/0169-4332(92)90178-Z
   HANAWA T, 1991, BIOMATERIALS, V12, P767, DOI 10.1016/0142-9612(91)90028-9
   HEALY KE, 1992, BIOMATERIALS, V13, P553, DOI 10.1016/0142-9612(92)90108-Z
   HEALY KE, 1992, J BIOMED MATER RES, V26, P319, DOI 10.1002/jbm.820260305
   HOLH H, 1982, J CRYST GROWTH, V57, P325
   JOLIVET JP, 1994, SOLUTION OXYDE, P264
   KASEMO B, 1988, J BIOMED MATER RES-A, V22, P145, DOI 10.1002/jbm.820221307
   KOUTSOUKOS PG, 1981, J CRYST GROWTH, V53, P10, DOI 10.1016/0022-0248(81)90051-8
   Lausmaa J, 1986, MATER RES SOC S P, V55, P351
   LAYROLLE P, 1994, CHEM MATER, V6, P1996, DOI 10.1021/cm00047a019
   LEBUGLE A, 1994, HYDROXYAPATITE AND RELATED MATERIALS, P319
   LEGEROS RZ, 1983, SCAN ELECTRON MICROS, P407
   LI P, 1993, J BIOMED MATER RES, V27, P129
   MIYAJI F, 1995, BIOCERAMICS, V8, P323
   MORTERRA C, 1979, GAZZ CHIM ITAL, V109, P683
   MORTERRA C, 1981, Z PHYS CHEM NEUE FOL, V124, P211, DOI 10.1524/zpch.1981.124.2.211
   ONG JL, 1995, J MATER SCI-MATER M, V6, P113, DOI 10.1007/BF00120418
   PASCAL P, 1963, NOUVEAU TRAITE CHIM, V9, P101
   PETROV I, 1967, SPECTROCHIM ACTA A-M, VA 23, P2637, DOI 10.1016/0584-8539(67)80155-7
   POURBAIX M, 1963, ATLAS EQUILIBRES ELE, P217
   SHAM TK, 1979, CHEM PHYS LETT, V68, P426, DOI 10.1016/0009-2614(79)87231-0
   SHIRKHANZADEH M, 1995, J MATER SCI-MATER M, V6, P206, DOI 10.1007/BF00146857
   TENGVALL P, 1992, Clinical Materials, V9, P115, DOI 10.1016/0267-6605(92)90056-Y
   TOMSON MB, 1978, SCIENCE, V200, P1059, DOI 10.1126/science.200.4345.1059
   Wagner C D, 1979, HDB XRAY PHOTOELECTR, P68
NR 31
TC 30
Z9 33
U1 0
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7765
EI 1873-4367
J9 COLLOID SURFACE B
JI Colloid Surf. B-Biointerfaces
PD JUN 15
PY 1998
VL 11
IS 1-2
BP 15
EP 27
DI 10.1016/S0927-7765(98)00014-9
PG 13
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
SC Biophysics; Chemistry; Materials Science
GA ZZ139
UT WOS:000074699600003
DA 2018-10-19
ER

PT J
AU Neff, JA
   Caldwell, KD
   Tresco, PA
AF Neff, JA
   Caldwell, KD
   Tresco, PA
TI A novel method for surface modification to promote cell attachment to
   hydrophobic substrates
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE PEO chemistry; cell adhesion; model surface; RGD peptide; surface
   modification
ID PROTEIN ADSORPTION; POLYETHYLENE OXIDE; EXTRACELLULAR-MATRIX;
   MONOCLONAL-ANTIBODIES; TRIBLOCK COPOLYMERS; ADHESION; PEPTIDE;
   FIBRONECTIN; RGD; DIFFERENTIATION
AB The ability to study and regulate cell behavior at a biomaterial interface requires strict control over material surface chemistry. Perhaps the greatest challenge to researchers working in this area is preventing the fouling of a given surface due to uncontrolled protein adsorption. This work describes a method for coupling peptides to hydrophobic materials for the purpose of simultaneously preventing nonspecific protein adsorption and controlling cell adhesion. A hexapeptide containing the ubiquitous RGD cell-adhesion motif was coupled to polystyrene (PS) via a polyethylene oxide (PEO) tether in the form of a modified PEO/PPO/PEO triblock copolymer. Triblocks were adsorbed onto PS at a density of 3.3 +/- (5.14 x 10(-4)) mg/m(2) (1.4 x 10(5) +/- 2.12 x 10(1) molecules/mu m(2)), which was determined by isotope I-125 labeling. The peptide, GRGDSY, was activated at the N terminus with N-Succinimidyl 3-(2-pyridyldithio) propionate and coupled to immobilized triblocks where the terminal hydroxyls had been converted to sulfhydryl groups. Surface peptide density was measured by amino acid analysis and found to be 1.4 x 10(4) +/- 0.47 x 10(4) molecules/mu m(2). PS modified with PEO/PPO/PEO copolymers alone was found to be inert to cell adhesion both in the presence of serum proteins and when exposed to activated RGD peptide. In contrast, PS conjugated with RGD via end-group-activated PEO/PPO/PEO copolymers supported cell adhesion and spreading. The surface coupling scheme reported here should prove valuable for studying cell-ligand interactions under simplified and highly controlled conditions. (C) 1998 John Wiley & Sons, Inc.
C1 Univ Utah, Dept Bioengn, Ctr Biopolymers Interfaces, Salt Lake City, UT 84112 USA.
RP Caldwell, KD (reprint author), Univ Utah, Dept Bioengn, Ctr Biopolymers Interfaces, 108 Biomed Polymers Res Bldg, Salt Lake City, UT 84112 USA.
CR ADAMS JC, 1993, DEVELOPMENT, V117, P1183
   AMIJI M, 1992, BIOMATERIALS, V13, P682, DOI 10.1016/0142-9612(92)90128-B
   Andrade J. D., 1996, INTERFACIAL PHENOMEN, P19
   ANDRADE JD, 1986, ADV POLYM SCI, V79, P1
   ATANKOV G, 1996, J BIOMED MATER RES, V30, P385
   BRANDLEY BK, 1988, ANAL BIOCHEM, V172, P270, DOI 10.1016/0003-2697(88)90442-3
   BRANDLEY BK, 1989, DEV BIOL, V135, P74, DOI 10.1016/0012-1606(89)90159-0
   CARLSSON J, 1978, BIOCHEM J, V173, P723, DOI 10.1042/bj1730723
   DESAI NP, 1991, J BIOMED MATER RES, V25, P829, DOI 10.1002/jbm.820250704
   DRUMHELLER PD, 1994, BIOTECHNOL BIOENG, V43, P772, DOI 10.1002/bit.260430812
   DRUMHELLER PD, 1994, T SOC BIOMATER, V17, P60
   DRUMHELLER PD, 1995, BIOMEDICAL ENG HDB, P1583
   DUNN SE, 1994, PHARMACEUT RES, V11, P1016, DOI 10.1023/A:1018939521589
   GLASS J, 1994, ANN NY ACAD SCI, V745, P177
   GOMBOTZ WR, 1991, J BIOMED MATER RES, V25, P1547, DOI 10.1002/jbm.820251211
   Huang SC, 1996, LANGMUIR, V12, P4292, DOI 10.1021/la951532+
   HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9
   JEON SI, 1991, J COLLOID INTERF SCI, V142, P149, DOI 10.1016/0021-9797(91)90043-8
   JULIANO DJ, 1993, J BIOMED MATER RES, V27, P1103
   Kamath KR, 1996, J BIOMAT SCI-POLYM E, V7, P977, DOI 10.1163/156856296X00381
   KESLER KA, 1986, J VASC SURG, V3, P58
   KOBAYASHI H, 1991, CURR EYE RES, V10, P899, DOI 10.3109/02713689109020325
   KONDOH A, 1993, J APPL POLYM SCI, V47, P1983, DOI 10.1002/app.1993.070471108
   LEE J, 1989, J COLLOID INTERF SCI, V131, P252, DOI 10.1016/0021-9797(89)90166-5
   LEE JH, 1990, BIOMATERIALS, V11, P455, DOI 10.1016/0142-9612(90)90058-X
   LEWANDOWSKA K, 1992, J BIOMED MATER RES, V26, P1343, DOI 10.1002/jbm.820261007
   Li JT, 1996, COLLOID SURFACE B, V7, P9, DOI 10.1016/0927-7765(96)01269-6
   Li JT, 1996, BIOCONJUGATE CHEM, V7, P592, DOI 10.1021/bc960048v
   Li JT, 1996, ADV CHEM SER, V248, P61
   LIN HB, 1994, J BIOMED MATER RES, V28, P329, DOI 10.1002/jbm.820280307
   MASSIA SP, 1991, J CELL BIOL, V114, P1089, DOI 10.1083/jcb.114.5.1089
   MASSIA SP, 1991, J BIOMED MATER RES, V25, P223, DOI 10.1002/jbm.820250209
   MATSUDA T, 1989, T AM SOC ART INT ORG, V35, P677
   McDonald JA, 1989, CURR OPIN CELL BIOL, V1, P995, DOI 10.1016/0955-0674(89)90071-9
   MOONEY DJ, 1995, J CELL SCI, V108, P2311
   NG CL, 1994, J CHROMATOGR A, V659, P427, DOI 10.1016/0021-9673(94)85085-2
   Olbrich KC, 1996, BIOMATERIALS, V17, P759, DOI 10.1016/0142-9612(96)81412-8
   OZEKI E, 1990, AM SOC ARTIF INTERN, V36, P7294
   PETTIT DK, 1994, J BIOMED MATER RES, V28, P685, DOI 10.1002/jbm.820280605
   PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0
   RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619
   RYDEN L, 1989, PROTEIN PURIFICATION, P252
   SUGAWARA T, 1995, J BIOMED MATER RES, V29, P1047, DOI 10.1002/jbm.820290904
   TASHIRO K, 1991, J CELL PHYSL, V146, P452
   TINOIS E, 1991, EXP CELL RES, V193, P310, DOI 10.1016/0014-4827(91)90102-Z
   UNDERWOOD PA, 1993, J CELL SCI, V104, P793
   YAMADA KM, 1991, J BIOL CHEM, V266, P12809
   YAN G, 1993, INVEST OPHTH VIS SCI, V34, P1803
NR 48
TC 136
Z9 140
U1 2
U2 26
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD JUN 15
PY 1998
VL 40
IS 4
BP 511
EP 519
DI 10.1002/(SICI)1097-4636(19980615)40:4<511::AID-JBM1>3.3.CO;2-M
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA ZL733
UT WOS:000073465000001
PM 9599026
DA 2018-10-19
ER

PT J
AU Stea, S
   Visentin, M
   Cervellati, M
   Verri, E
   Cenni, E
   Savarino, L
   Stea, S
   Pizzoferrato, A
AF Stea, S
   Visentin, M
   Cervellati, M
   Verri, E
   Cenni, E
   Savarino, L
   Stea, S
   Pizzoferrato, A
TI In vitro sister chromatid exchange induced by glass ionomer cements
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE glass ionomer cement; sister chromatid exchange; genotoxicity;
   biomaterial; biocompatibility
ID HUMAN-LYMPHOCYTES; INVITRO
AB The genotoxicity of three glass ionomer cements used in dentistry, manufactured by American (Vitrebond(TM)), Japanese (Fuji I(TM)), and European (Ketac Cem(TM)) companies were examined. The cement components were mixed according to the manufacturers' instructions and allowed to set for two defined times: 1 h or 1 week, before extracting them, as established by ISO standard 10993 part 12. To highlight sister chromatid exchange during mitosis, the extracts then were tested with human peripheral lymphocytes in the presence or absence of metabolic activation with S9 mix. The test performed was a genotoxicity test as provided for in standard EN 30993 part 3. Vitrebond(TM) resulted in direct genotoxicity and was strongly cytotoxic both in the extracts performed at 1 h and those at 1 week if they were allowed to set without photoactivation. Fuji I(TM) was noncytotoxic and showed only uncertain indirect genotoxicity in the extracts at 1 h; genotoxicity was not present in the extracts at 1 week. Ketac Cem(TM) cement was not genotoxic nor was it cytotoxic either at 1 h or 1 week. The authors concluded that of the three cements tested the European cement Ketac Cem(TM) passed one of the tests suggested by the EEC standard for assessing genotoxicy. (C) 1998 John Wiley & Sons, Inc.
C1 Ist Ortoped Rizzoli, Lab Biocompatibil Res Implant Mat, I-40136 Bologna, Italy.
   AUSL 29, Dept Maxillofacial Surg, Bologna, Italy.
RP Stea, S (reprint author), Ist Ortoped Rizzoli, Lab Biocompatibil Res Implant Mat, Via Barbiano 1-10, I-40136 Bologna, Italy.
EM ior.biocomp.@pt.tizeta.it
OI savarino, lucia/0000-0002-3177-3546
CR BEST RG, 1988, MUTAT RES, V206, P227, DOI 10.1016/0165-1218(88)90165-6
   CARRANO AV, 1980, ENVIRON MUTAGEN, V2, P325, DOI 10.1002/em.2860020303
   CHONG BS, 1994, ENDOD DENT TRAUMATOL, V10, P129
   Dahl B L, 1976, J Oral Rehabil, V3, P19, DOI 10.1111/j.1365-2842.1976.tb00926.x
   DEARCE MA, 1981, HUM GENET, V57, P83, DOI 10.1007/BF00271174
   DOERTHY PJ, 1991, CLIN MAT, V7, P335
   Heil J, 1996, MUTAT RES-GENET TOX, V368, P181, DOI 10.1016/S0165-1218(96)90060-9
   MCLEAN JW, 1978, JADA, V96, P785
   REIDY JA, 1988, ENVIRON MOL MUTAGEN, V12, P311, DOI 10.1002/em.2860120305
   TYAS MJ, 1983, J DENT RES, V62, P646
   WILSON A D, 1991, Clinical Materials, V7, P275, DOI 10.1016/0267-6605(91)90070-V
   WILSON AD, 1978, CHEM SOC REV, V7, P265, DOI 10.1039/cs9780700265
   WOLFF S, 1974, CHROMOSOMA, V48, P341, DOI 10.1007/BF00290991
NR 13
TC 17
Z9 17
U1 0
U2 1
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD JUN 15
PY 1998
VL 40
IS 4
BP 545
EP 550
DI 10.1002/(SICI)1097-4636(19980615)40:4<545::AID-JBM5>3.0.CO;2-F
PG 6
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA ZL733
UT WOS:000073465000005
PM 9599030
DA 2018-10-19
ER

PT J
AU Vyavahare, NR
   Hirsch, D
   Lerner, E
   Baskin, JZ
   Zand, R
   Schoen, FJ
   Levy, RJ
AF Vyavahare, NR
   Hirsch, D
   Lerner, E
   Baskin, JZ
   Zand, R
   Schoen, FJ
   Levy, RJ
TI Prevention of calcification of glutaraldehyde-crosslinked porcine aortic
   cusps by ethanol preincubation: Mechanistic studies of protein structure
   and water-biomaterial relationships
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE bioprostheses; type I collagen; infrared spectroscopy
ID BIOPROSTHETIC HEART-VALVES; LATTICE RELAXATION-TIME; CROSS-LINKING;
   COLLAGEN; PERICARDIUM; INVITRO; TISSUE; TEMPERATURE; SHRINKAGE; SYSTEMS
AB Clinical usage of bioprosthetic heart valves (BPHVs) fabricated from glutaraldehyde-pretreated porcine aortic valves is restricted due to calcification-related failure. We previously reported a highly efficacious ethanol pretreatment of BPHVs for the prevention of cuspal calcification. The aim of the present study is to extend our understanding of the material changes brought about by ethanol and the relationship of these material effects to the ethanol pretreatment anticalcification mechanism. Glutaraldehyde-crosslinked porcine aortic valve cusps (control and ethanol-pretreated) were studied for the effects of ethanol on tissue water content and for spin-lattice relaxation times (T1) using solid state proton NMR. Cusp samples were studied for protein conformational changes due to ethanol by ATR-FTIR spectroscopy. The changes in cuspal tissue-cholesterol (in vitro) interactions also were studied. Cusp material stability was assessed in terms of residual glutaraldehyde content and collagenase degradation. Water content of the cusp samples was decreased significantly due to ethanol pretreatment. The cuspal collagen conformational changes (per infrared spectroscopy) brought about by ethanol pretreatment were persistent even after rat subdermal implantation of cusp samples for 7 days. In vitro cholesterol uptake by cusps was greatly reduced as a result of ethanol pretreatment. Ethanol pretreatment of cusps also resulted in increased resistance to collagenase digestion. Cuspal glutaraldehyde content was not changed by ethanol pretreatment. We conclude that ethanol pretreatment of bioprosthetic heart valve cusps causes multi-component effects on the tissue/material and macromolecular characteristics, which partly may explain the ethanol-pretreatment anticalcification mechanism. (C) 1998 John Wiley & Sons, Inc.
C1 Univ Michigan, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA.
   Univ Michigan, Dept Biol Chem & Macromol Sci & Engn, Ann Arbor, MI 48109 USA.
   Univ Michigan, Div Biophys Res, Ann Arbor, MI 48109 USA.
   Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Boston, MA USA.
RP Levy, RJ (reprint author), Childrens Hosp Philadelphia, Abramson Pediat Res Ctr, Div Pediat Cardiol, Suite 1107,34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.
FU NHLBI NIH HHS [HL38118]
CR AKBER SF, 1992, MED HYPOTHESES, V37, P24, DOI 10.1016/0306-9877(92)90007-Y
   AKBER SF, 1993, NUKLEARMED, V32, P52
   Baker R., 1987, DIFFUSION CONTROLLED, P39
   Bartolini L, 1977, Boll Soc Ital Biol Sper, V53, P2294
   BOTTOMLEY PA, 1984, MED PHYS, V11, P425, DOI 10.1118/1.595535
   CHEN WL, 1994, CIRCULATION, V90, P323, DOI 10.1161/01.CIR.90.1.323
   DOYLE BB, 1975, BIOPOLYMERS, V14, P937, DOI 10.1002/bip.1975.360140505
   FINCH A, 1972, BIOCHIM BIOPHYS ACTA, V278, P433, DOI 10.1016/0005-2795(72)90003-7
   FRIDAY KE, 1991, METABOLISM, V40, P562, DOI 10.1016/0026-0495(91)90044-W
   GEORGE A, 1991, BIOCHEMISTRY-US, V30, P2372, DOI 10.1021/bi00223a011
   GLEASON MM, 1991, CIRC RES, V69, P216, DOI 10.1161/01.RES.69.1.216
   GOLOMB G, 1987, AM J PATHOL, V127, P122
   Imamura E, 1989, J Card Surg, V4, P50, DOI 10.1111/j.1540-8191.1989.tb00256.x
   JOHNSTON TP, 1990, INT J PHARM, V59, P95, DOI 10.1016/0378-5173(90)90083-G
   Jones M, 1989, J Card Surg, V4, P69, DOI 10.1111/j.1540-8191.1989.tb00258.x
   KAMMAN R L, 1985, Magnetic Resonance Imaging, V3, P245, DOI 10.1016/0730-725X(85)90353-4
   KASIM S, 1987, GERIATRICS, V42, P73
   LOKE WK, 1995, BIOMATERIALS, V16, P251, DOI 10.1016/0142-9612(95)92125-P
   MCCLAIN PE, 1972, J BIOL CHEM, V247, P692
   PELLETIER LC, 1989, ANN THORAC SURG, V47, P352, DOI 10.1016/0003-4975(89)90373-1
   PETITE H, 1990, J BIOMED MATER RES, V24, P179, DOI 10.1002/jbm.820240205
   POTKIN BN, 1988, AM J CARDIOL, V61, P947, DOI 10.1016/0002-9149(88)90388-8
   RAMP, 1984, AM J PHYSL, V246, pC30
   RENUGOPALAKRISHNAN V, 1989, MACROMOLECULES, V22, P4121, DOI 10.1021/ma00200a054
   ROKITA E, 1991, ATHEROSCLEROSIS, V87, P183, DOI 10.1016/0021-9150(91)90020-4
   RUBIN E, 1982, FED PROC, V41, P2465
   SCHOEN FJ, 1986, AM J PATHOL, V123, P134
   SCHOEN FJ, 1992, J THORAC CARDIOV SUR, V104, P1285
   SCHOEN FJ, 1992, EUR J CARDIO-THORAC, V6, pS91, DOI 10.1016/1010-7940(92)90030-2
   SCHOEN FJ, 1983, AM J CARDIOL, V51, P957, DOI 10.1016/S0002-9149(83)80173-8
   SCHOLZ TD, 1989, MAGNET RESON MED, V11, P367, DOI 10.1002/mrm.1910110310
   SIMIONESCU A, 1991, J BIOMED MATER RES, V25, P1495, DOI 10.1002/jbm.820251207
   SUSI H, 1971, BIOPOLYMERS, V10, P1597, DOI 10.1002/bip.360100913
   TANIMURA A, 1986, Journal of Experimental Pathology (New York), V2, P275
   TUNG MS, 1993, J MOL LIQ, V56, P237, DOI 10.1016/0167-7322(93)80030-Y
   Vyavahare N, 1997, CIRCULATION, V95, P479
   YOSHIOKA S, 1995, J PHARM SCI, V84, P1072, DOI 10.1002/jps.2600840908
NR 37
TC 51
Z9 51
U1 2
U2 15
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD JUN 15
PY 1998
VL 40
IS 4
BP 577
EP 585
DI 10.1002/(SICI)1097-4636(19980615)40:4<577::AID-JBM9>3.3.CO;2-B
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA ZL733
UT WOS:000073465000009
PM 9599034
DA 2018-10-19
ER

PT J
AU Basle, MF
   Grizon, F
   Pascaretti, C
   Lesourd, M
   Chappard, D
AF Basle, MF
   Grizon, F
   Pascaretti, C
   Lesourd, M
   Chappard, D
TI Shape and orientation of osteoblast-like cells (Saos-2) are influenced
   by collagen fibers in xenogenic bone biomaterial
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE osteoblast; collagen; xenogenic bone; integrins; bone substitute;
   biomaterials
ID EXTRACELLULAR-MATRIX; SURFACE-CHEMISTRY; IN-VITRO; ORGANIZATION;
   EXPRESSION; INTEGRINS; RECEPTORS; SUBSTRATA; ADHESION; INVITRO
AB The surface topography of a substratum has been shown to influence the growth and morphology of cells in culture. In this study, human osteoblast-like cells (Saos-2) were cultured on two types of xenogenic biomaterials obtained from bovine bone. Both biomaterials were similar in architectural organization and surface topography, but they differed in matrix components. The first one was characterized by preservation of the mineralized collagen matrix, and the second by complete deproteinization which only preserved the mineral phase. Cells cultured at the surface of both biomaterials were observed using scanning electron microscopy. The beta(1)-integrin subunit, known to bind cell and collagen, is the major integrin of the osteoblast. It was localized using immunogold in transmission electron microscopy. At the surface of the collagen-containing matrix, cells exhibited an elongated shape and oriented axis parallel to the underlying collagen bundles. The beta(1)-integrin subunit was localized at the outer surface of cells, in close association with collagen and at the contact points between cells and biomaterials. In contrast, at the surface of the single mineral matrix, cells were round shaped with random disposition. Gold particles were found around the cells with no specific relation to the biomaterial. These results strongly suggest that the chemical nature of the surface of a bone biomaterial directly influences adhesion process, shape, and spatial organization of cultured osteoblastic cells. (C) 1998 John Wiley & Sons, Inc.
C1 Fac Med, Lab Histol Embryol, F-49045 Angers, France.
   Univ Angers, Serv Commun Microscopie Elect, Angers, France.
   CHU Angers, F-49045 Angers, France.
RP Basle, MF (reprint author), Fac Med, Lab Histol Embryol, Rue Haute de Reculee, F-49045 Angers, France.
CR ARO HT, 1993, ANN MED, V25, P403, DOI 10.3109/07853899309147303
   Brunette D M, 1988, Int J Oral Maxillofac Implants, V3, P231
   BUCK BE, 1994, CLIN ORTHOP RELAT R, P8
   BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415
   Buttermann GR, 1996, CLIN ORTHOP RELAT R, P75
   CALLEN BW, 1993, J BIOMED MATER RES, V27, P851, DOI 10.1002/jbm.820270703
   CHAPPARD D, 1993, BIOMATERIALS, V14, P507, DOI 10.1016/0142-9612(93)90238-W
   Chappard Daniel, 1995, Biomedical Research (Aligarh), V6, P211
   CHIANG HS, 1995, BRIT J CANCER, V71, P265, DOI 10.1038/bjc.1995.54
   CLOVER J, 1992, J CELL SCI, V103, P267
   DAMIEN CJ, 1991, J APPL BIOMATER, V2, P187, DOI 10.1002/jab.770020307
   DAVIES JE, 1986, BIOMATERIALS, V7, P231
   DOMNINA LV, 1995, CELL BIOL INT, V19, P743, DOI 10.1006/cbir.1995.1125
   Gohel AR, 1995, J HISTOCHEM CYTOCHEM, V43, P1089
   GOMI K, 1993, J BIOMED MATER RES, V27, P429, DOI 10.1002/jbm.820270403
   GRONOWICZ GA, 1995, ENDOCRINOLOGY, V136, P598, DOI 10.1210/en.136.2.598
   GRZESIK WJ, 1994, J BONE MINER RES, V9, P487, DOI 10.1002/jbmr.5650090408
   HEALY KE, 1994, BIOTECHNOL BIOENG, V43, P792, DOI 10.1002/bit.260430814
   Healy KE, 1996, BIOMATERIALS, V17, P195, DOI 10.1016/0142-9612(96)85764-4
   Hemler ME, 1993, EXTRACELLULAR MATRIX, P143
   HOLDEN JL, 1995, J BONE MINER RES, V10, P1400
   HOLMES RE, 1987, J ORTHOPAED RES, V5, P114, DOI 10.1002/jor.1100050114
   HOROWITZ A, 1986, NATURE, V320, P531
   Hu R, 1995, Clin Orthop Relat Res, P252
   HUGHES DE, 1993, J BONE MINER RES, V8, P527
   Hure G, 1996, Int J Oral Maxillofac Implants, V11, P506
   HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9
   JARCHO M, 1981, CLIN ORTHOP RELAT R, P259
   JONES SJ, 1975, CELL TISSUE RES, V159, P73
   JONES SJ, 1985, SCANNING, V7, P5, DOI 10.1002/sca.4950070101
   KOMURO T, 1994, J ELECTRON MICROSC, V43, P72
   LEGEROS RZ, 1993, J BONE MINER RES, V8, pS583
   LEGEROS RZ, 1967, SCIENCE, V155, P1409, DOI 10.1126/science.155.3768.1409
   MEYLE J, 1995, J BIOMED MATER RES, V29, P81, DOI 10.1002/jbm.820290112
   OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721
   PROLO DJ, 1985, CLIN ORTHOP RELAT R, P322
   PULEO DA, 1991, BONE, V12, P271, DOI 10.1016/8756-3282(91)90075-T
   RODAN GA, 1984, BONE MINERAL RES ANN, V2, P244
   RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957
   SAITO T, 1994, J ORTHOP RES, V12, P384, DOI 10.1002/jor.1100120311
   SALAMA R, 1983, CLIN ORTHOP RELAT R, P113
   SHELTON RM, 1988, BIOMATERIALS, V9, P24, DOI 10.1016/0142-9612(88)90065-8
   ZAMBONINZALLONE A, 1989, EXP CELL RES, V182, P645, DOI 10.1016/0014-4827(89)90266-8
NR 43
TC 21
Z9 29
U1 0
U2 1
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD JUN 5
PY 1998
VL 40
IS 3
BP 350
EP 357
DI 10.1002/(SICI)1097-4636(19980605)40:3<350::AID-JBM2>3.0.CO;2-E
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA ZJ364
UT WOS:000073207100002
PM 9570064
DA 2018-10-19
ER

PT J
AU Drubaix, I
   Legeais, JM
   Mounier, F
   Briat, B
   Robert, L
   Renard, G
AF Drubaix, I
   Legeais, JM
   Mounier, F
   Briat, B
   Robert, L
   Renard, G
TI Quantification and localization of hyaluronan in a PTFE polymer
   implanted in the corneal stroma
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE artificial cornea; hyaluronan; ePTFE; cellular invasion; translucence;
   hydrophilicity
ID RABBIT CORNEA; EXTRACELLULAR-MATRIX; HUMAN-BRAIN; FLUOROCARBON; ACID;
   KERATOPROSTHESIS; TISSUE; TRANSPARENCY; ORGANIZATION; PROTEOGLYCAN
AB The amount and distribution of hyaluronan in a PTFE polymer used to support an artificial cornea implanted in the rabbit cornea were determined. The findings were used to describe the polymer-corneal stroma interface and the reason for the translucence and wettability of this originally opaque and hydrophobic biomaterial. PTFE disks (6 mm in diameter, 0.2 mm thick, 50 mu m in pore size) were implanted after a free-hand intralamellar dissection. The corneas were removed 15 days, 1 month, and 3 months after implantation. The hyaluronan content of pepsin-solubilized corneal stromal extracts and its distribution (7 mu m cryostat sections) were investigated using an alkaline phosphatase-linked hyaluronectin assay that specifically detects nanogram amounts of hyaluronan. A PTFE polymer implant caused large, transient increases in hyaluronan density in the implanted stroma. The presence of amphiphilic hyaluronan in the polymer 15 days post implantation probably produced translucence and wettability of this opaque, hydrophobic implant despite the absence of cells. The hyaluronan density in the PTFE polymer increased considerably during the first month and then decreased to stabilize at a moderate level by the third month. These changes in hyaluronan density parallel the invasion of the polymer by inflammatory cells during the first month and the subsequent replacement of these cells by fibroblasts. The PTFE polymer is a good interface that is compatible with the native corneal stroma, and our results indicate that hyaluronan, because of its amphiphilic character, plays a major role in the polymer wettability and translucence and in the production of typical corneal extracellular matrix within the pores of the polymer. (C) 1998 John Wiley & Sons, Inc.
C1 Hop Hotel Dieu, Dept Ophthalmol, Ctr Rech Univ Ophtalmol, F-75004 Paris, France.
   Univ Paris 07, Biol Cellulaire Lab, Paris, France.
RP Legeais, JM (reprint author), Hop Hotel Dieu, Dept Ophthalmol, Ctr Rech Univ Ophtalmol, 1 Pl Parvis Notre Dame, F-75004 Paris, France.
CR BORCHERDING MS, 1975, EXP EYE RES, V21, P59, DOI 10.1016/0014-4835(75)90057-3
   CHIRILA TV, 1994, J BIOMED MATER RES, V28, P745, DOI 10.1002/jbm.820280612
   DELPECH B, 1995, ANAL BIOCHEM, V229, P35, DOI 10.1006/abio.1995.1375
   DELPECH B, 1981, J NEUROCHEM, V36, P855, DOI 10.1111/j.1471-4159.1981.tb01672.x
   DELPECH B, 1991, INT J BIOCHEM, V23, P329, DOI 10.1016/0020-711X(91)90115-4
   DOANE KJ, 1992, EXP CELL RES, V202, P113, DOI 10.1016/0014-4827(92)90410-A
   DOANE KJ, 1991, EXP CELL RES, V195, P432, DOI 10.1016/0014-4827(91)90394-A
   Drubaix I, 1997, EXP EYE RES, V64, P301, DOI 10.1006/exer.1996.0212
   Drubaix I, 1996, EXP EYE RES, V62, P367, DOI 10.1006/exer.1996.0042
   EGGLI PS, 1993, EXP EYE RES, V56, P693, DOI 10.1006/exer.1993.1086
   EVERED D, 1989, CIBA FDN S, V143, P6
   FITZSIMMONS TD, 1994, INVEST OPHTH VIS SCI, V35, P2774
   FITZSIMMONS TD, 1992, INVEST OPHTH VIS SCI, V33, P3011
   GAILIT J, 1994, CURR OPIN CELL BIOL, V6, P717, DOI 10.1016/0955-0674(94)90099-X
   HASSELL JR, 1983, ARCH BIOCHEM BIOPHYS, V222, P362, DOI 10.1016/0003-9861(83)90532-5
   LEGEAIS JM, 1994, EXP EYE RES, V58, P41, DOI 10.1006/exer.1994.1193
   LEGEAIS JM, 1995, ARCH OPHTHALMOL-CHIC, V113, P757, DOI 10.1001/archopht.1995.01100060083038
   Legeais JM, 1997, J BIOMED MATER RES, V36, P49
   Legeais JM, 1997, J FR OPHTALMOL, V20, P42
   LEGEAIS JM, 1992, CORNEA, V11, P538, DOI 10.1097/00003226-199211000-00010
   LEIBOWITZ HM, 1994, PROG RETIN EYE RES, V13, P605, DOI 10.1016/1350-9462(94)90024-8
   LUTJENDRECOLL E, 1990, EXP EYE RES, V51, P55, DOI 10.1016/0014-4835(90)90170-Y
   MADSEN K, 1989, OPHTHALMIC PRACTICE, V7, P2
   MENASCHE M, 1988, PATHOL BIOL, V36, P781
   NISHIDA T, 1991, EXP EYE RES, V53, P753, DOI 10.1016/0014-4835(91)90110-Z
   Renard G, 1996, J BIOMED MATER RES, V31, P193
   RITTIG M, 1992, EXP EYE RES, V54, P455, DOI 10.1016/0014-4835(92)90057-Y
   SCOTT JE, 1991, BIOCHEM J, V274, P699, DOI 10.1042/bj2740699
   SCOTT JE, 1992, FASEB J, V6, P2639
   SHERMAN L, 1994, CURR OPIN CELL BIOL, V6, P726, DOI 10.1016/0955-0674(94)90100-7
   TOOLE BP, 1971, DEV BIOL, V26, P28, DOI 10.1016/0012-1606(71)90104-7
   TOOLE BP, 1991, CELL BIOL EXTRACELLU, P305
   TRINKAUSRANDALL V, 1988, INVEST OPHTH VIS SCI, V29, P393
   Wight Thomas N., 1992, Current Opinion in Cell Biology, V4, P793, DOI 10.1016/0955-0674(92)90102-I
NR 34
TC 2
Z9 2
U1 1
U2 7
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD JUN 5
PY 1998
VL 40
IS 3
BP 442
EP 448
DI 10.1002/(SICI)1097-4636(19980605)40:3<442::AID-JBM15>3.0.CO;2-L
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA ZJ364
UT WOS:000073207100015
PM 9570077
DA 2018-10-19
ER

PT J
AU Tagusari, O
   Yamazaki, K
   Litwak, P
   Kojima, A
   Klein, EC
   Antaki, JF
   Watach, M
   Gordon, LM
   Kono, K
   Mori, T
   Koyanagi, H
   Griffith, BP
   Kormos, RL
AF Tagusari, O
   Yamazaki, K
   Litwak, P
   Kojima, A
   Klein, EC
   Antaki, JF
   Watach, M
   Gordon, LM
   Kono, K
   Mori, T
   Koyanagi, H
   Griffith, BP
   Kormos, RL
TI Fine trabecularized carbon: Ideal material and texture for percutaneous
   device system of permanent left ventricular assist device
SO ARTIFICIAL ORGANS
LA English
DT Article; Proceedings Paper
CT 5th Congress of the International-Society-of-Rotary-Blood-Pumps
CY SEP 10-12, 1997
CL MARSEILLE, FRANCE
SP Int Soc Rotary Blood Pumps
DE percutaneous implant; percutaneous device system; biomaterial carbon;
   low temperature pyrolytic carbon; left ventricular assist device;
   epidermal downgrowth
ID FIBER-WEB MATERIALS; IMPLANTS
AB The development of a percutaneous artificial internal organ system requires a reliable biocompatible connection between the external environment and the inside of the human body. Such is necessary for the success of a permanent left ventricular assist device. However, the search for a satisfactory interface at the epidermal level has proven to be difficult. Carbon has been proposed for this application, but its texture does not typically promote ingrowth from surrounding tissue. We have therefore employed a new processing method to produce a fine trabecularized carbon implant. The method for preparing the implant involves infiltrating low temperature pyrolytic carbon into the surface of a carbon core which is wrapped with carbon fabric. This results in a tightly woven porous structure of carbon (carbon fiber diameter: 35-50 mu m, maximal pore size >200 mu m) with gradually increasing porosity from 15-75%. We implanted test samples percutaneously in a calf for in vivo histological evaluation. Thirty days after implantation epidermal downgrowth was minimal. Microscopic analysis revealed that a thin fibrous capsule surrounded the implant, and mature connective tissue with accompanying blood vessels filled the pores of the fine trabecularized carbon layer. From these results we suggest that fine trabecularized carbon is ideally suited for a percutaneous device system in a permanent left ventricular assist device.
C1 Univ Pittsburgh, Med Ctr, Artificial Heart & Lung Program, Div Cardiothorac Surg,Dept Surg, Pittsburgh, PA 15219 USA.
   Sun Med Technol Res Corp, Nagano, Japan.
   Gunma Tech Coll, Gunma, Japan.
   Tokyo Womens Med Coll, Tokyo 162, Japan.
RP Tagusari, O (reprint author), Univ Pittsburgh, Med Ctr, Artificial Heart & Lung Program, Div Cardiothorac Surg,Dept Surg, 300 Technol Dr, Pittsburgh, PA 15219 USA.
RI Antaki, James/S-3051-2016
OI Antaki, James/0000-0002-5430-7353
CR ALBREKTSSON T, 1987, PLAST RECONSTR SURG, V79, P721, DOI 10.1097/00006534-198705000-00007
   Bokros JC, 1973, CHEMISTRY PHYSICS CA, V9, P103
   BOKROS JC, 1977, CARBON, V15, P335
   Campbell C E, 1989, J Invest Surg, V2, P51, DOI 10.3109/08941938909016503
   Costantino P D, 1993, Facial Plast Surg, V9, P1, DOI 10.1055/s-2008-1064591
   GANGJEE T, 1985, ANN BIOMED ENG, V13, P451, DOI 10.1007/BF02407772
   GEOSSESIESTRUP C, 1984, J BIOMED MATER RES, V18, P357
   Jansen J A, 1994, J Biomater Appl, V9, P30, DOI 10.1177/088532829400900102
   JANSEN JA, 1992, BIOMATERIALS, V13, P959, DOI 10.1016/0142-9612(92)90121-4
   JANSEN JA, 1991, BIOMATERIALS, V12, P25, DOI 10.1016/0142-9612(91)90127-V
   KOJIMA A, 1984, CARBON, V22, P47, DOI 10.1016/0008-6223(84)90132-5
   McCarthy PM, 1996, ANN THORAC SURG, V61, P359, DOI 10.1016/0003-4975(95)00990-6
   ROBINSON WJ, 1980, SYNTHETIC BIOMEDICAL, P211
   SCHAKENRAAD JM, 1986, J BIOMED MATER RES, V20, P773, DOI 10.1002/jbm.820200609
   SCHREUDERS PD, 1988, J BIOMED MATER RES, V22, P121, DOI 10.1002/jbm.820220205
   SQUIER CA, 1981, J PERIODONTAL RES, V16, P434, DOI 10.1111/j.1600-0765.1981.tb00994.x
   TJELLSTROM A, 1990, CLIN PLAST SURG, V17, P355
   VONRECUM AF, 1984, J BIOMED MATER RES, V18, P323, DOI 10.1002/jbm.820180403
   VONRECUM AF, 1990, ADV BIOMAT, V9, P297
   VONRECUM AF, 1981, TXB CLIN REV BIOENGI, P37
   WINTER GD, 1974, J BIOMED MATER RES S, V5, P99
NR 21
TC 10
Z9 10
U1 0
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0160-564X
J9 ARTIF ORGANS
JI Artif. Organs
PD JUN
PY 1998
VL 22
IS 6
BP 481
EP 487
DI 10.1046/j.1525-1594.1998.06152.x
PG 7
WC Engineering, Biomedical; Transplantation
SC Engineering; Transplantation
GA ZT541
UT WOS:000074098200009
PM 9650669
DA 2018-10-19
ER

PT J
AU Frayssinet, P
   Gineste, L
   Conte, P
   Fages, J
   Rouquet, N
AF Frayssinet, P
   Gineste, L
   Conte, P
   Fages, J
   Rouquet, N
TI Short-term implantation effects of a DCPD-based calcium phosphate cement
SO BIOMATERIALS
LA English
DT Review
DE calcium phosphate cements; osseointegration; biomaterial; injectable
ID IN-VIVO; BONE
AB Calcium phosphate cements can be handled in paste form and set in a wet medium after precipitation of calcium phosphate crystals in the implantation site. Depending on the products entering into the chemical reaction leading to the precipitation of calcium phosphates, different phases can be obtained with different mechanical properties, setting times and injectability. We tested a cement composed of a powder, containing beta-tricalcium phosphate (beta-TCP) and sodium pyrophosphate mixed with a solution of phosphoric and sulphuric acids. The cement set under a dicalcium phosphate dihydrate (DCPD)-based matrix containing beta-TCP particles. This was injected with a syringe into a defect drilled in rabbit condyles, the control being an identical defect left empty in the opposite condyle. The condyles were analysed histologically 2, 6 and 18 weeks after implantation. After injection into the bone defect the cement set and formed a porous calcium phosphate structure. Two different calcium phosphate phases with different solubility rates could be identified by scanning electron microscopy (SEM) observation. The less-soluble fragments could be degraded by cell phagocytosis in cell compartments of low pH or integrated in the newly formed bone matrix. The degradation rate of the material was.relatively high but compatible with the ingrowth of bone trabeculae within the resorbing material. The ossification process was different from the creeping substitution occurring at the ceramic contact. Bone did not form directly at the cement surface following the differentiation of osteoblasts at the material surface. The trabeculae came to the material surface from the edges of the implantation site. Bone formation in the implantation site was significantly higher than in the control region during the first week of implantation.In conclusion, this material set in situ was well tolerated, inducing a mild foreign-body reaction, which did not impair its replacement by newly formed bone within a few weeks. (C) 1998 Published by Elsevier Science Ltd. All rights reserved.
C1 Univ Toulouse 3, Lab Tissu Osseux & Pathol Osteoarticulaires, F-31062 Toulouse, France.
   Univ Toulouse 3, Ecole Dent, F-31400 Toulouse, France.
   CHU Toulouse Purpan, Serv Chirurg Orthoped, Toulouse, France.
   Bioland, F-31100 Toulouse, France.
RP Frayssinet, P (reprint author), Univ Toulouse 3, Lab Tissu Osseux & Pathol Osteoarticulaires, F-31062 Toulouse, France.
RI FAGES, Jacques/E-8072-2011
OI FAGES, Jacques/0000-0001-9280-9007
CR BERMUDEZ O, 1994, J MATER SCI-MATER M, V5, P160, DOI 10.1007/BF00053337
   Brown WE, 1986, United States patent, Patent No. [4612053, EP 4612053]
   CONSTANTZ BR, 1995, SCIENCE, V267, P1796, DOI 10.1126/science.7892603
   Dreesmann H, 1892, BEITR KLIN CHIR, V9, P804
   DRIESSENS FCM, 1993, J MATER SCI-MATER M, V4, P503, DOI 10.1007/BF00120130
   DRIESSENS FCM, 1994, J MATER SCI-MATER M, V5, P164, DOI 10.1007/BF00053338
   FRAYSSINET P, 1993, BIOMATERIALS, V14, P423, DOI 10.1016/0142-9612(93)90144-Q
   IKSIHAWA K, 1996, J MAT SCI MAT MED, V17, P1429
   KURASHINA K, 1995, J MATER SCI-MATER M, V6, P343
   MIRTCHI AA, 1989, BIOMATERIALS, V10, P634, DOI 10.1016/0142-9612(89)90120-8
   MIYAMOTO Y, 1995, BIOMATERIALS, V16, P855, DOI 10.1016/0142-9612(95)94147-D
   Nancollas H., 1989, BIOMINERALIZATION CH, P157
   Ohura K, 1996, J BIOMED MATER RES, V30, P193, DOI 10.1002/(SICI)1097-4636(199602)30:2<193::AID-JBM9>3.0.CO;2-M
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
NR 14
TC 97
Z9 103
U1 2
U2 42
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD JUN
PY 1998
VL 19
IS 11-12
BP 971
EP 977
DI 10.1016/S0142-9612(97)00163-4
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA ZY578
UT WOS:000074637700001
PM 9692795
DA 2018-10-19
ER

PT J
AU Hubbell, JA
AF Hubbell, JA
TI Synthetic biodegradable polymers for tissue engineering and drug
   delivery
SO CURRENT OPINION IN SOLID STATE & MATERIALS SCIENCE
LA English
DT Review
ID TYROSINE-DERIVED POLYCARBONATES; POLY(ETHYLENE GLYCOL); BIOMATERIALS;
   FIBROBLAST; AGGREGATION; FIBRONECTIN; HYDROGELS; CONTACT; ACID); BONE
AB Advances in tissue engineering and drug delivery are often enabled by the development of new biomaterials, designed specifically for such purposes. Advances in synthetic degradable biomaterials that permit in situ transformations from liquid precursors to solid final forms that enable the biomaterial to be directly recognized by the biochemical features of the cells and that make use of novel approaches to material fabrication and self-assembly have been made.
C1 Swiss Fed Inst Technol, Dept Mat, CH-8044 Zurich, Switzerland.
   Swiss Fed Inst Technol, Inst Biomed Engn, CH-8044 Zurich, Switzerland.
   Univ Zurich, CH-8044 Zurich, Switzerland.
RP Hubbell, JA (reprint author), Swiss Fed Inst Technol, Dept Mat, Moussonstr 18, CH-8044 Zurich, Switzerland.
RI Hubbell, Jeffrey/A-9266-2008
OI Hubbell, Jeffrey/0000-0003-0276-5456
CR BELLAMKONDA R, 1995, J NEUROSCI RES, V41, P501, DOI 10.1002/jnr.490410409
   Bentz H, 1998, J BIOMED MATER RES, V39, P539, DOI 10.1002/(SICI)1097-4636(19980315)39:4<539::AID-JBM6>3.0.CO;2-K
   BREM H, 1995, LANCET, V345, P1008, DOI 10.1016/S0140-6736(95)90755-6
   Brocchini S, 1997, J AM CHEM SOC, V119, P4553, DOI 10.1021/ja970389z
   Cammas S, 1997, MAT SCI ENG C-BIOMIM, V4, P241, DOI 10.1016/S0928-4931(97)00007-6
   Choueka J, 1996, J BIOMED MATER RES, V31, P35, DOI 10.1002/(SICI)1097-4636(199605)31:1<35::AID-JBM5>3.0.CO;2-R
   CIMA LG, 1994, J CELL BIOCHEM, V56, P155, DOI 10.1002/jcb.240560206
   Cook AD, 1997, J BIOMED MATER RES, V35, P513
   Dai WG, 1996, BIOTECHNOL BIOENG, V50, P349, DOI 10.1002/(SICI)1097-0290(19960520)50:4<349::AID-BIT1>3.3.CO;2-D
   DAI WG, 1994, BIO-TECHNOL, V12, P797, DOI 10.1038/nbt0894-797
   DIMILLA PA, 1993, J CELL BIOL, V122, P729, DOI 10.1083/jcb.122.3.729
   Elbert DL, 1996, ANNU REV MATER SCI, V26, P365, DOI 10.1146/annurev.ms.26.080196.002053
   Elisseeff J, 1997, MACROMOLECULES, V30, P2182, DOI 10.1021/ma961411w
   ERTEL SI, 1994, J BIOMED MATER RES, V28, P919, DOI 10.1002/jbm.820280811
   GUTSCHE AT, 1994, BIOTECHNOL BIOENG, V43, P801, DOI 10.1002/bit.260430815
   Harada A, 1998, MACROMOLECULES, V31, P288, DOI 10.1021/ma971277v
   Hern DL, 1998, J BIOMED MATER RES, V39, P266, DOI 10.1002/(SICI)1097-4636(199802)39:2<266::AID-JBM14>3.0.CO;2-B
   Hrkach JS, 1997, BIOMATERIALS, V18, P27, DOI 10.1016/S0142-9612(96)00077-4
   HUBBELL JA, 1995, BIO-TECHNOL, V13, P565, DOI 10.1038/nbt0695-565
   Jeong B, 1997, NATURE, V388, P860, DOI 10.1038/42218
   Katayose S, 1998, J PHARM SCI, V87, P160, DOI 10.1021/js970304s
   Krejchi MT, 1997, MACROMOLECULES, V30, P5012, DOI 10.1021/ma9614050
   Kuhl PR, 1996, NAT MED, V2, P1022, DOI 10.1038/nm0996-1022
   LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529
   MASSIA SP, 1992, J BIOL CHEM, V267, P14019
   MASSIA SP, 1991, J CELL BIOL, V114, P1089, DOI 10.1083/jcb.114.5.1089
   MULLERMAI CM, 1995, J BIOMED MATER RES, V29, P9, DOI 10.1002/jbm.820290103
   Park A, 1998, J BIOMAT SCI-POLYM E, V9, P89, DOI 10.1163/156856298X00451
   PEPPAS NA, 1994, SCIENCE, V263, P1715, DOI 10.1126/science.8134835
   Peter SJ, 1997, J BIOMAT SCI-POLYM E, V8, P893, DOI 10.1163/156856297X00074
   PUTNAM D, 1995, BIOCONJUGATE CHEM, V6, P483, DOI 10.1021/bc00034a019
   Saad B, 1998, J BIOMED MATER RES, V39, P594, DOI 10.1002/(SICI)1097-4636(19980315)39:4<594::AID-JBM14>3.0.CO;2-7
   Saad B, 1997, J BIOMED MATER RES, V36, P65, DOI 10.1002/(SICI)1097-4636(199707)36:1<65::AID-JBM8>3.3.CO;2-#
   SAWHNEY AS, 1993, MACROMOLECULES, V26, P581, DOI 10.1021/ma00056a005
   SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0
   Sperinde JJ, 1997, MACROMOLECULES, V30, P5255, DOI 10.1021/ma970345a
   Stupp SI, 1997, SCIENCE, V276, P384, DOI 10.1126/science.276.5311.384
   Stupp SI, 1997, SCIENCE, V277, P1242, DOI 10.1126/science.277.5330.1242
   West JL, 1996, P NATL ACAD SCI USA, V93, P13188, DOI 10.1073/pnas.93.23.13188
   YEH PY, 1995, MACROMOL CHEM PHYS, V196, P2183, DOI 10.1002/macp.1995.021960709
   ZHAO X, 1997, J AM CHEM SOC S SER, V680, P458
NR 41
TC 69
Z9 70
U1 0
U2 27
PU CURRENT CHEMISTRY LTD
PI LONDON
PA 34-42 CLEVELAND STREET, LONDON W1P 6LE, ENGLAND
SN 1359-0286
J9 CURR OPIN SOLID ST M
JI Curr. Opin. Solid State Mat. Sci.
PD JUN
PY 1998
VL 3
IS 3
BP 246
EP 251
DI 10.1016/S1359-0286(98)80098-3
PG 6
WC Materials Science, Multidisciplinary; Physics, Applied; Physics,
   Condensed Matter
SC Materials Science; Physics
GA 100AA
UT WOS:000074790700006
DA 2018-10-19
ER

PT J
AU Dillow, AK
   Tirrell, M
AF Dillow, AK
   Tirrell, M
TI Targeted cellular adhesion at biomaterial interfaces
SO CURRENT OPINION IN SOLID STATE & MATERIALS SCIENCE
LA English
DT Review
ID SURFACES; BINDING
AB The interface of biomaterials must be carefully designed to elicit and eliminate specific responses when placed in contact with the body. The interaction of cells with the surfaces of biomaterials is a complex phenomenon that depends on a large number of variables,To design novel biomaterials that possess the desired characteristics, materials scientists and engineers rely heavily upon information provided by molecular biologists, information regarding cell receptor-ligand interactions is used to understand the role of cellular adhesion in the natural environment so that synthetic biomaterials may be developed successfully. The production of new synthetic materials, understanding how native proteins mediate cellular adhesion with these materials, molecularly engineering surfaces with controlled spatial patterns for optimal responses, evaluation of mechanical properties, and analyzing bioadhesion and surface properties of these materials are topics that must be addressed when discussing targeted cellular adhesion at biomaterial surfaces.
C1 Univ Minnesota, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA.
RP Tirrell, M (reprint author), Univ Minnesota, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA.
CR Altankov G, 1997, J BIOMAT SCI-POLYM E, V8, P721, DOI 10.1163/156856297X00524
   Amiji MM, 1996, J BIOMAT SCI-POLYM E, V8, P281, DOI 10.1163/156856296X00309
   Baumgartner JN, 1997, BIOMATERIALS, V18, P831, DOI 10.1016/S0142-9612(96)00197-4
   Bendas G, 1997, BBA-BIOMEMBRANES, V1325, P297, DOI 10.1016/S0005-2736(96)00268-4
   BERNDT P, 1995, J AM CHEM SOC, V117, P9515, DOI 10.1021/ja00142a019
   Brunk DK, 1997, BIOPHYS J, V72, P2820, DOI 10.1016/S0006-3495(97)78924-0
   CHAN CS, 1997, SCIENCE, V276, P1425
   Charych D, 1996, CHEM BIOL, V3, P113, DOI 10.1016/S1074-5521(96)90287-2
   CIMA LG, 1994, J CELL BIOCHEM, V56, P155, DOI 10.1002/jcb.240560206
   Cook AD, 1997, J BIOMED MATER RES, V35, P513
   DAMMER U, 1995, SCIENCE, V267, P1173, DOI 10.1126/science.7855599
   DERUELLE M, 1995, MACROMOLECULES, V28, P7419, DOI 10.1021/ma00126a021
   Dickinson RB, 1997, J BIOMED MATER RES, V36, P152, DOI 10.1002/(SICI)1097-4636(199708)36:2<152::AID-JBM3>3.0.CO;2-J
   DILLOW A, 1997, P TOP C BIOM CARR DR, P157
   DORI Y, 1997, S SURF BIOM, P144
   Elbert DL, 1996, ANNU REV MATER SCI, V26, P365, DOI 10.1146/annurev.ms.26.080196.002053
   Garcia AJ, 1997, BIOMATERIALS, V18, P1091, DOI 10.1016/S0142-9612(97)00042-2
   Gorman SP, 1997, J MATER SCI-MATER M, V8, P631, DOI 10.1023/A:1018571403609
   Hammer DA, 1996, ANNU REV MATER SCI, V26, P651
   Han DK, 1997, MACROMOLECULES, V30, P6077, DOI 10.1021/ma970302u
   HAVERSTICK K, 1997, PMSE, V77, P584
   Hern DL, 1998, J BIOMED MATER RES, V39, P266, DOI 10.1002/(SICI)1097-4636(199802)39:2<266::AID-JBM14>3.0.CO;2-B
   HORWITZ AF, 1997, SCI AM           MAY, P68
   Ishihara K, 1998, J BIOMED MATER RES, V39, P323, DOI 10.1002/(SICI)1097-4636(199802)39:2<323::AID-JBM21>3.0.CO;2-C
   Iwasaki Y, 1997, J BIOMED MATER RES, V36, P508, DOI 10.1002/(SICI)1097-4636(19970915)36:4<508::AID-JBM8>3.0.CO;2-I
   JOHNSON KL, 1971, PROC R SOC LON SER-A, V324, P301, DOI 10.1098/rspa.1971.0141
   Kohler AS, 1996, J BIOMED MATER RES, V32, P237, DOI 10.1002/(SICI)1097-4636(199610)32:2<237::AID-JBM13>3.0.CO;2-G
   Laemmel E, 1998, J BIOMED MATER RES, V39, P446, DOI 10.1002/(SICI)1097-4636(19980305)39:3<446::AID-JBM14>3.0.CO;2-8
   Lanza R. P., 1997, PRINCIPLES TISSUE EN
   Lauffenburger DA, 1996, NATURE, V383, P390, DOI 10.1038/383390a0
   Losche M, 1997, CURR OPIN SOLID ST M, V2, P546, DOI 10.1016/S1359-0286(97)80043-5
   Marra KG, 1997, MACROMOLECULES, V30, P6483, DOI 10.1021/ma970481f
   Mathur AB, 1997, J BIOMED MATER RES, V36, P246, DOI 10.1002/(SICI)1097-4636(199708)36:2<246::AID-JBM14>3.3.CO;2-9
   Mrksich M, 1996, P NATL ACAD SCI USA, V93, P10775, DOI 10.1073/pnas.93.20.10775
   Mrksich M, 1997, EXP CELL RES, V235, P305, DOI 10.1006/excr.1997.3668
   Mrksich M, 1997, CURR OPIN COLLOID IN, V2, P83, DOI 10.1016/S1359-0294(97)80012-X
   Nomura S, 1997, J BIOMED MATER RES, V38, P35
   NopplSimson DA, 1996, BIOPHYS J, V70, P1391, DOI 10.1016/S0006-3495(96)79697-2
   OKUMURA M, 1997, J BIOMED MATER RES, V37, P22
   Peckham SM, 1997, J BIOMAT SCI-POLYM E, V8, P847, DOI 10.1163/156856297X00047
   Peppas NA, 1996, BIOMATERIALS, V17, P1553, DOI 10.1016/0142-9612(95)00307-X
   Rezania A, 1997, J BIOMED MATER RES, V37, P9, DOI 10.1002/(SICI)1097-4636(199710)37:1<9::AID-JBM2>3.0.CO;2-W
   Saad B, 1996, J BIOMED MATER RES, V32, P355
   Saad B, 1997, J BIOMED MATER RES, V36, P65, DOI 10.1002/(SICI)1097-4636(199707)36:1<65::AID-JBM8>3.3.CO;2-#
   Saad B, 1997, J MATER SCI-MATER M, V8, P497, DOI 10.1023/A:1018582311361
   Seigel RR, 1997, ANAL CHEM, V69, P3321, DOI 10.1021/ac970047b
   Sheth SR, 1997, P NATL ACAD SCI USA, V94, P8399, DOI 10.1073/pnas.94.16.8399
   Slepian MJ, 1997, ADV DRUG DELIVER REV, V24, P11, DOI 10.1016/S0169-409X(96)00479-6
   Smetana K, 1997, BIOMATERIALS, V18, P1009, DOI 10.1016/S0142-9612(97)00037-9
   Spevak W, 1996, J MED CHEM, V39, P1018, DOI 10.1021/jm950914+
   Thomas CH, 1997, J BIOMED MATER RES, V37, P81, DOI 10.1002/(SICI)1097-4636(199710)37:1<81::AID-JBM10>3.0.CO;2-T
   Winger TM, 1996, BIOMATERIALS, V17, P437, DOI 10.1016/0142-9612(96)89661-X
   Wong JY, 1997, SCIENCE, V275, P820, DOI 10.1126/science.275.5301.820
   Yamamoto M, 1997, J BIOMED MATER RES, V37, P29, DOI 10.1002/(SICI)1097-4636(199710)37:1<29::AID-JBM4>3.0.CO;2-L
   Yu YC, 1997, METHOD ENZYMOL, V289, P571
   Yu YC, 1996, J AM CHEM SOC, V118, P12515, DOI 10.1021/ja9627656
   ZASADZINSKI JA, 1994, SCIENCE, V263, P1726, DOI 10.1126/science.8134836
   ZHANG YY, 1997, THESIS U MINNESOTA
NR 58
TC 35
Z9 37
U1 1
U2 9
PU CURRENT CHEMISTRY LTD
PI LONDON
PA 34-42 CLEVELAND STREET, LONDON W1P 6LE, ENGLAND
SN 1359-0286
J9 CURR OPIN SOLID ST M
JI Curr. Opin. Solid State Mat. Sci.
PD JUN
PY 1998
VL 3
IS 3
BP 252
EP 259
DI 10.1016/S1359-0286(98)80099-5
PG 8
WC Materials Science, Multidisciplinary; Physics, Applied; Physics,
   Condensed Matter
SC Materials Science; Physics
GA 100AA
UT WOS:000074790700007
DA 2018-10-19
ER

PT J
AU Buczkowski, S
   Hildgen, P
   Cartilier, L
AF Buczkowski, S
   Hildgen, P
   Cartilier, L
TI Comparison of three models of polymer erosion - In vivo, in vitro and
   computer simulation - Using fractal analysis
SO FRACTALS-AN INTERDISCIPLINARY JOURNAL ON THE COMPLEX GEOMETRY OF NATURE
LA English
DT Article
ID POLYURETHANE FOAM; BIODEGRADATION
AB Polyurethane foam has been examined extensively because of its use in many implantable devices. The influence of different environments on polymer structure has been investigated via a number of clinical studies, animal models, in vitro experiments and mathematical models to predict biomaterial behavior. In this work, we employed image analysis and fractal geometry in three models of polymer degradation. In the in vivo and in vitro degradation models, we observed structural collapse and thinning of the polymer backbone, which resulted in a decrease of fractal dimension. Also, an original graphic model was developed. This computer-simulated erosion model was generated by pixel withdrawal from images. A relative degree of erosion is attributed each time an erosion process is applied. Thus, these degrees of erosion can be associated with a general time-related operation. With the computer-simulated erosion model, an unambiguous relationship was demonstrated between the estimation of fractal dimension and the relative degree of erosion. Since such models are based on a loss of mass, the results of fractal dimension were plotted against image surface, allowing us to compare the three different sets of experiments. In all three models, a proportional relationship was found between fractal dimension and image surface. Indeed, the erosion process was well-characterized by decreased fractal dimension since it is a mass dimension. Finally, we showed that the combination of a graphic computer model and a box-counting algorithm is reliable for the quantification of surface erosion.
C1 Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada.
RP Buczkowski, S (reprint author), Univ Montreal, Fac Pharm, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.
CR Barnsley M., 1988, FRACTALS EVERYWHERE, P1
   BARNSLEY MF, 1987, ANN NY ACAD SCI, V504, P179, DOI 10.1111/j.1749-6632.1987.tb48732.x
   Buczkowski S, 1998, PATTERN RECOGN, V31, P411, DOI 10.1016/S0031-3203(97)00054-X
   BUCZKOWSKI S, IN PRESS PHYSICA A
   Falconer K., 1990, FRACTAL GEOMETRY MAT, P38
   GOPFERICH A, 1993, MACROMOLECULES, V26, P4105, DOI 10.1021/ma00068a006
   HUANG Q, 1994, PATTERN RECOGN, V27, P339, DOI 10.1016/0031-3203(94)90112-0
   Kaye B. K., 1989, RANDOM WALK FRACTAL
   Kyriacos S, 1994, FRACTALS, V2, P321, DOI 10.1142/S0218348X94000417
   Mandelbrot BB, 1983, FRACTAL GEOMETRY NAT, P34
   Marois Y, 1996, BIOMATERIALS, V17, P1289, DOI 10.1016/0142-9612(96)88674-1
   PENTLAND AP, 1984, IEEE T PATTERN ANAL, V6, P661, DOI 10.1109/TPAMI.1984.4767591
   SATO M, 1995, J BIOMED MATER RES, V29, P1201, DOI 10.1002/jbm.820291007
   SINCLAIR TM, 1993, PLAST RECONSTR SURG, V92, P1003, DOI 10.1097/00006534-199311000-00001
   SINCLAIR TM, 1995, PLAST RECONSTR SURG, V96, P1326, DOI 10.1097/00006534-199511000-00014
   STANLEY EH, 1985, SCALING PHENOMENA DI, P49
   Szycher M, 1991, J Biomater Appl, V5, P282, DOI 10.1177/088532829100500403
   Voss R. F., 1985, SCALING PHENOMENA DI, P1, DOI DOI 10.1007/978-1-4757-1402-9_1
   Zhang Z, 1997, BIOMATERIALS, V18, P113, DOI 10.1016/S0142-9612(96)00054-3
NR 19
TC 3
Z9 3
U1 1
U2 5
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA JOURNAL DEPT PO BOX 128 FARRER ROAD, SINGAPORE 9128, SINGAPORE
SN 0218-348X
J9 FRACTALS
JI Fractals-Interdiscip. J. Complex Geom. Nat.
PD JUN
PY 1998
VL 6
IS 2
BP 171
EP 179
DI 10.1142/S0218348X98000213
PG 9
WC Mathematics, Interdisciplinary Applications; Multidisciplinary Sciences
SC Mathematics; Science & Technology - Other Topics
GA 100GU
UT WOS:000074808700011
DA 2018-10-19
ER

PT J
AU Epple, M
   Herzberg, O
AF Epple, M
   Herzberg, O
TI Porous polyglycolide
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE polyglycolide; biodegradability; implant; microstructure; porosity
ID BIODEGRADABLE POLYMERS; IMPLANTS; BONE; DEGRADATION; FIBERS; ACID
AB The solid-state polymerization of halogenoacetates leads quantitatively to polyglycolide (polyglycolic acid) and an eliminated metal halide, Washing out this salt leaves highly porous polyglycolide (total pore volume about 50%) with pore sizes in the submicron range, Thorough examination of the product with different methods (DSC, IR, and X-ray diffraction) gave no indication of any remaining halogenoacetate. This distinct micromorphology should be advantageous for its application as a biomaterial. Special features of porous polyglycolide are an inherent surface roughness, a high specific surface, a higher gas permeability, and a lower density compared to conventionally prepared polyglycolide, The control over these properties should allow a fine-tuning of the biocompatibility of polyglycolide. (C) 1998 John Wiley & Sons, Inc.
C1 Univ Hamburg, Inst Inorgan & Appl Chem, D-20146 Hamburg, Germany.
RP Epple, M (reprint author), Univ Hamburg, Inst Inorgan & Appl Chem, Martin Luther King Pl 6, D-20146 Hamburg, Germany.
EM epple@xray.chemic.uni-hamburg.de
CR Ashammakhi N, 1997, BIOMATERIALS, V18, P3, DOI 10.1016/S0142-9612(96)00107-X
   Ashammakhi NA, 1996, J BIOMED MATER RES, V33, P297, DOI 10.1002/(SICI)1097-4636(199624)33:4<297::AID-JBM10>3.0.CO;2-C
   Bostman OM, 1996, CLIN ORTHOP RELAT R, P233
   Breuer CK, 1996, BIOTECHNOL BIOENG, V50, P562, DOI 10.1002/(SICI)1097-0290(19960605)50:5<562::AID-BIT11>3.0.CO;2-L
   Chiellini E, 1996, ADV MATER, V8, P305, DOI 10.1002/adma.19960080406
   Dee KC, 1996, BIOTECHNOL BIOENG, V50, P438, DOI 10.1002/(SICI)1097-0290(19960520)50:4<438::AID-BIT11>3.0.CO;2-F
   Epple M, 1996, CHEM COMMUN, P1755, DOI 10.1039/cc9960001755
   Epple M, 1997, J MATER CHEM, V7, P1037, DOI 10.1039/a700275k
   Epple M, 1996, J THERM ANAL CALORIM, V47, P331, DOI 10.1007/BF01983973
   Epple M, 1996, CHEM BER, V129, P1123, DOI 10.1002/cber.19961290923
   Epple M, 1996, J CHEM SOC DALTON, P11, DOI 10.1039/dt9960000011
   GILDING DK, 1979, POLYMER, V20, P1459, DOI 10.1016/0032-3861(79)90009-0
   GINDE RM, 1987, J APPL POLYM SCI, V33, P2411, DOI 10.1002/app.1987.070330712
   HARIHARAN R, 1993, POLYM BULL, V30, P91, DOI 10.1007/BF00296239
   HOFFMANN R, 1857, LIEBIGS ANN CHEM, V102, P1
   HOFMANN GO, 1995, ARCH ORTHOP TRAUM SU, V114, P123, DOI 10.1007/BF00443385
   ISHAUG SL, 1994, J BIOMED MATER RES, V28, P1445, DOI 10.1002/jbm.820281210
   Kapur R, 1996, J BIOMED MATER RES, V33, P205, DOI 10.1002/(SICI)1097-4636(199624)33:4<205::AID-JBM1>3.0.CO;2-T
   KEKULE A, 1858, LIEBIGS ANN CHEM, V105, P288
   Kiefer J, 1996, MACROMOLECULES, V29, P8546, DOI 10.1021/ma960960z
   Kiefer J, 1996, MACROMOLECULES, V29, P4158, DOI 10.1021/ma951674a
   KRICHELDORF HR, 1992, BOOK HDB POLYM SYNTH
   KUMTA SM, 1992, J BONE JOINT SURG BR, V74, P563
   MILLER RA, 1977, J BIOMED MATER RES, V11, P711, DOI 10.1002/jbm.820110507
   NAKAMURA T, 1989, J BIOMED MATER RES, V23, P1115, DOI 10.1002/jbm.820231003
   OSTHER PJ, 1995, BRIT J SURG, V82, P1080, DOI 10.1002/bjs.1800820824
   TORMALA P, 1988, Patent No. 4743257
   VACANTI CA, 1994, OTOLARYNG CLIN N AM, V27, P263
   WOOD JS, 1993, AM SURGEON, V59, P642
   YLINEN P, 1994, J MATER SCI-MATER M, V5, P522, DOI 10.1007/BF00124884
NR 30
TC 25
Z9 26
U1 5
U2 9
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD SUM
PY 1998
VL 43
IS 2
BP 83
EP 88
PG 6
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA ZR307
UT WOS:000073961000001
PM 9619425
DA 2018-10-19
ER

PT J
AU Begin-Colin, S
   Mocellin, A
   Von Stebut, J
   Bordji, K
   Mainard, D
AF Begin-Colin, S
   Mocellin, A
   Von Stebut, J
   Bordji, K
   Mainard, D
TI Al2O3 and Al2O3-TiN wear resistance in a simulated biological
   environment
SO JOURNAL OF MATERIALS SCIENCE
LA English
DT Article
ID WET EROSIVE WEAR; POLYCRYSTALLINE ALUMINA; SILICON-NITRIDE; GRAIN-SIZE;
   FRICTION; HUMIDITY; TRIBOLOGY; ALLOY
AB Alumina is widely used as a biomaterial because of its high biocompatibility and its good mechanical properties except toughness. In this study, a composite material Al2O3-TiN is considered as an alternative, the addition of TIN improving the mechanical properties of alumina. The wear behaviour of Al2O3 and Al2O3-TiN in aqueous solutions simulating living environments has been thus compared using a pin on disc wear-testing machine. The results show that the mechanisms of material removal during wear are different. For alumina, a mechanical wear mechanism is observed, reduced by the lubricating action of the wet media, and alumina-TiN is worn by a combination of tribochemical and abrasive effects. (C) 1998 Kluwer Academic Publishers.
C1 Ecole Mines, INPL, URA CNRS 159, Sci & Genie Mat Met Lab, F-54042 Nancy, France.
   Ecole Mines, INPL, URA CNRS 1402, Lab Sci & Genie Surfaces, F-54042 Nancy, France.
   CHU Brabois, IRC, IEBM, Fac Med,URA CNRS 1288, F-54511 Vandoeuvre Nancy, France.
RP Begin-Colin, S (reprint author), Ecole Mines, INPL, URA CNRS 159, Sci & Genie Mat Met Lab, F-54042 Nancy, France.
EM begin@mines.u-nancy.fr
CR BLOMBERG A, 1994, WEAR, V171, P77, DOI 10.1016/0043-1648(94)90350-6
   BORDJI K, UNPUB
   BOUTIN P, 1988, J BIOMED MATER RES, V22, P1203, DOI 10.1002/jbm.820221210
   CHRISTEL P, 1988, BIOCERAMICS MATERIAL, V523, P234
   CHRISTEL PS, 1992, CLIN ORTHOP RELAT R, P10
   Davidge RW, 1996, J EUR CERAM SOC, V16, P799, DOI 10.1016/0955-2219(95)00198-0
   FISCHER TE, 1985, WEAR, V105, P29, DOI 10.1016/0043-1648(85)90004-3
   FISCHER TE, 1992, J PHYS CHEM-US, V96, P5690, DOI 10.1021/j100193a008
   GEE MG, 1993, WEAR, V162, P234, DOI 10.1016/0043-1648(93)90506-H
   Jisheng E, 1996, J EUR CERAM SOC, V16, P25, DOI 10.1016/0955-2219(95)00109-3
   KATO K, 1990, WEAR, V136, P117, DOI 10.1016/0043-1648(90)90075-L
   Krell A, 1996, J AM CERAM SOC, V79, P1139, DOI 10.1111/j.1151-2916.1996.tb08565.x
   MARTINELLA R, 1985, MATER SCI ENG, V69, P247, DOI 10.1016/0025-5416(85)90399-4
   MIRANDAMARTINEZ M, 1994, WEAR, V172, P41, DOI 10.1016/0043-1648(94)90297-6
   MOCELLIN A, 1985, J MATER SCI, V20, P3697, DOI 10.1007/BF01113778
   PEREZUNZUETA AJ, 1991, WEAR, V146, P179, DOI 10.1016/0043-1648(91)90233-K
   RIEGER W, 1989, MED APPL CERAMIC HIG, P191
   SEDEL L, 1990, J BONE JOINT SURG BR, V72, P658
   SPERISEN T, 1990, THESIS EPFL
   VILLK YN, 1981, TRANSL POROSLIK META, V7, P492
   WALTER A, 1984, BIOMATERIALS BIOMECH, P55
   Yen BK, 1997, J MATER SCI, V32, P821, DOI 10.1023/A:1018581028433
NR 22
TC 6
Z9 6
U1 0
U2 1
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0022-2461
J9 J MATER SCI
JI J. Mater. Sci.
PD JUN 1
PY 1998
VL 33
IS 11
BP 2837
EP 2843
DI 10.1023/A:1017537903887
PG 7
WC Materials Science, Multidisciplinary
SC Materials Science
GA 149DU
UT WOS:000077590500013
DA 2018-10-19
ER

PT J
AU Pasquier, G
   Flautre, B
   Leclet, H
   Hardouin, P
AF Pasquier, G
   Flautre, B
   Leclet, H
   Hardouin, P
TI Experimental evaluation of a percutaneous injectable biomaterial used in
   radio-interventional bone-filling procedures
SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE
LA English
DT Article
ID VENOUS MALFORMATIONS; ETHIBLOC; INJECTION
AB Interventional radiology is beginning to be used in bone pathology. An injectable biomaterial Ethibloc*, composed of alcohol and a vegetal protein (zein), has been successfully used for percutaneous treatment of benign bone lesions. The reasons for this success remained unknown and needed to be understood. In this study, using a rabbit model, an evaluation was made of bone formation and tissue reaction during the first weeks after the injection of this biomaterial. Ethibloc* was injected percutaneously into bone defects in rabbit distal femurs. Three time intervals were studied: 2, 4 and 8 wks. The three control groups constituted unfilled, polymethylmethacrylate (PMMA), and alcohol. Undecalcified bone technique was used for a qualitative analysis and histomorphometric evaluation. A low bone formation was found which was less than in the control groups (PMMA and unfilled). The "Ethibloc group" was characterized by an early inflammatory reaction. Good clinical results obtained with Ethibloc* probably arose, after an initial vascular thrombosis, from a secondary bone reaction and spontaneous osteogenesis obtained after the disappearance of vascular or hyperpression reaction.
C1 Inst Calot, Inst Rech Malad Squelette, F-62608 Berck Sur Mer, France.
   Ctr Hosp Victor Provo, F-59100 Roubaix, France.
RP Pasquier, G (reprint author), Inst Calot, Inst Rech Malad Squelette, F-62608 Berck Sur Mer, France.
EM irms@wanadoo.fr
CR ADAMSBAUM C, 1993, SKELETAL RADIOL, V22, P317
   DERAMOND H, 1989, RACHIS, V1, P143
   DUBOIS JM, 1991, RADIOLOGY, V180, P195, DOI 10.1148/radiology.180.1.2052693
   HEISS JD, 1994, NEW ENGL J MED, V331, P508, DOI 10.1056/NEJM199408253310804
   KATTHAGEN BD, 1987, BONE REGENERATION BO
   KHUNE D, 1982, NEURORADIOLOGY, V23, P253
   LECLET H, 1993, REV RHUM, V60, P261
   Pasquier G, 1996, J MATER SCI-MATER M, V7, P683, DOI 10.1007/BF00123407
   RICHE MC, 1983, PLAST RECONSTR SURG, V71, P607, DOI 10.1097/00006534-198305000-00003
   RICHTER G, 1984, INVEST RADIOL, V19, P36, DOI 10.1097/00004424-198401000-00009
   Schultheis K H, 1981, Unfallchirurgie, V7, P324, DOI 10.1007/BF02592973
NR 11
TC 4
Z9 4
U1 0
U2 1
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0957-4530
J9 J MATER SCI-MATER M
JI J. Mater. Sci.-Mater. Med.
PD JUN
PY 1998
VL 9
IS 6
BP 333
EP 336
DI 10.1023/A:1008802913838
PG 4
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 102HH
UT WOS:000074918000005
PM 15348876
DA 2018-10-19
ER

PT J
AU Sugiyama, K
   Kato, K
   Kido, M
   Shiraishi, K
   Ohga, K
   Okada, K
   Matsuo, O
AF Sugiyama, K
   Kato, K
   Kido, M
   Shiraishi, K
   Ohga, K
   Okada, K
   Matsuo, O
TI Grafting of vinyl monomers on the surface of a poly(ethylene
   terephthalate) film using Ar plasma post polymerization technique to
   increase biocompatibility
SO MACROMOLECULAR CHEMISTRY AND PHYSICS
LA English
DT Article
ID GLOW-DISCHARGE; POLYETHYLENE SURFACE; BLOOD COMPATIBILITY; BIOMATERIAL;
   COPOLYMERIZATION; POLYAMIDES; POLYMERS; ION
AB Surface modified poly(ethylene terephthalate) (PET) films with 2-(methacryloyloxy)ethylphosphorylcholine (MPC) and 2-(glucosyloxy)ethyl methacrylate (GEMA) moieties, PMPC-g-PET and PGEMA-g-PET, were prepared by graft copolymerization using an Ar plasma-post polymerization technique. The degrees of polymerization of the grafts PMPC and PGEMA were (P) over bar(n) approximate to 30 and (P) over bar(n) approximate to 40, respectively. The contact angle of the modified PET film decreased from theta = 68 degrees (the original PET film) to theta = 26 degrees for PMPC-g-PET and to theta = 43 degrees for PGEMA-g-PET. The modified PET films adsorb less serum proteins than the original PET film. Egg yolk lecithin did not adsorb on PGEMA-g-PET but adsorbed on PMPC-g-PET. PMPC-g-PET showed activity for the inhibition of fibrin formation and no adhesion of mouse fibroblasts (L-929).
C1 Kinki Univ, Fac Engn, Dept Ind Chem, Hiroshima 7392116, Japan.
   Kinki Univ, Grad Sch Ind Technol, Hiroshima 7392116, Japan.
   Kinki Univ, Sch Med, Dept Physiol, Osaka 5890014, Japan.
RP Sugiyama, K (reprint author), Kinki Univ, Fac Engn, Dept Ind Chem, Hiroshima 7392116, Japan.
CR ALLMER K, 1990, J POLYM SCI POL CHEM, V28, P173, DOI 10.1002/pola.1990.080280112
   BORN GVR, 1962, J PHYSL, V166, P29
   ESQUIVEL CO, 1984, SURGERY, V95, P102
   FENG XD, 1985, MACROMOLECULES, V18, P2105, DOI 10.1021/ma00153a004
   GERENSER LJ, 1985, POLYMER, V26, P1162, DOI 10.1016/0032-3861(85)90245-9
   GRIESSER HJ, 1992, POLYM INT, V27, P109, DOI 10.1002/pi.4990270204
   HOLLAHAN JR, 1969, J APPL POLYM SCI, V13, P807, DOI 10.1002/app.1969.070130419
   HSIUE GH, 1988, J BIOMED MATER RES, V22, P405, DOI 10.1002/jbm.820220504
   ISHIHARA K, 1995, J BIOMED MATER RES, V29, P181, DOI 10.1002/jbm.820290207
   ISHIHARA K, 1982, J APPL POLYM SCI, V27, P1897, DOI 10.1002/app.1982.070270604
   IWATA H, 1988, J POLYM SCI POL CHEM, V26, P3309, DOI 10.1002/pola.1988.080261216
   LIU S Q, 1989, Journal of Biomaterials Science Polymer Edition, V1, P111
   LOPEZ GP, 1992, J BIOMED MATER RES, V26, P415, DOI 10.1002/jbm.820260402
   Mitzner E, 1996, J BIOMAT SCI-POLYM E, V7, P1105, DOI 10.1163/156856296X00598
   MUZYKEWICZ KJ, 1975, J BIOMED MATER RES, V9, P487, DOI 10.1002/jbm.820090511
   Ratner BD, 1979, J POLYM SCI POLYM S, V66, P363
   SHEU MS, 1993, CLIN MATER, V13, P41, DOI 10.1016/0267-6605(93)90088-O
   SHEU MS, 1994, APPL POLYM SYMP SER, V54, P29
   SUGIYAMA K, 1995, POLYM J, V27, P179, DOI 10.1295/polymj.27.179
   SUGIYAMA K, 1991, POLYM J, V23, P1287, DOI 10.1295/polymj.23.1287
   SUZUKI M, 1986, MACROMOLECULES, V19, P1804, DOI 10.1021/ma00161a005
   TAKAHARA A, 1993, J BIOMAT SCI-POLYM E, V5, P183
   TAMADA Y, 1986, POLYM MED, V2, P101
   UEDA T, 1992, POLYM J, V24, P1259, DOI 10.1295/polymj.24.1259
   WERTHEIMER MR, 1981, J APPL POLYM SCI, V26, P2087, DOI 10.1002/app.1981.070260630
   YUI N, 1986, J BIOMED MATER RES, V20, P929, DOI 10.1002/jbm.820200708
NR 26
TC 45
Z9 46
U1 1
U2 10
PU WILEY-V C H VERLAG GMBH
PI BERLIN
PA MUHLENSTRASSE 33-34, D-13187 BERLIN, GERMANY
SN 1022-1352
J9 MACROMOL CHEM PHYSIC
JI Macromol. Chem. Phys.
PD JUN
PY 1998
VL 199
IS 6
BP 1201
EP 1208
DI 10.1002/(SICI)1521-3935(19980601)199:6<1201::AID-MACP1201>3.3.CO;2-Y
PG 8
WC Polymer Science
SC Polymer Science
GA ZV418
UT WOS:000074302600036
DA 2018-10-19
ER

PT J
AU Levi, ADO
   Choi, WG
   Keller, PJ
   Heiserman, JE
   Sonntag, VKH
   Dickman, CA
AF Levi, ADO
   Choi, WG
   Keller, PJ
   Heiserman, JE
   Sonntag, VKH
   Dickman, CA
TI The radiographic and imaging characteristics of porous tantalum implants
   within the human cervical spine
SO SPINE
LA English
DT Article
DE cervical spine; computed tomography; magnetic resonance imaging;
   tantalum; titanium
ID RESONANCE; ARTIFACTS; CLIPS
AB Study Design. Seven cadaveric cervical spines were implanted with a porous tantalum spacer and a titanium alloy spacer, and their radiographic and imaging characteristics were evaluated.
   Objective. To determine the radiographic characteristics of porous tantalum and titanium implants used as spacers in the cervical spine.
   Summary of Background Data. Anterior decompressive surgery of the disc space or the vertebral body creates a defect that frequently is repaired with autologous bone grafts to promote spinal fusion. Donor site morbidity, insufficient donor material, and additional surgical time have spurred the development of biomaterials to replace or supplement existing spinal reconstruction techniques. Although the promotion of a solid bony fusion is critical, the implanted biomaterial should be compatible with modern imaging techniques, should allow visualization of the spinal canal and neural foramina, and should permit radiographic assessment of bony ingrowth.
   Methods. Cadaveric spines containing the implants were imaged with plain radiography, computerized tomography, and magnetic resonance imaging. The image distortion produced by the implants was determined qualitatively and quantitatively.
   Results. The tantalum and titanium spacers were opaque on plain radiographic films. On computed tomographic scans, more streak artifact was associated with the tantalum implants than with the titanium. On magnetic resonance imaging, the porous tantalum implant demonstrated less artifact than did the titanium spacer on T1- and T2-weighted spin echo and on T2*-weighted gradient-echo magnetic resonance images. Overall; the tantalum im pla nt produced less artifact on magnetic resonance imaging than did the titanium spacer and therefore allowed for better visualization of the surrounding bony and neural structures.
   Conclusion. The material properties of titanium and porous tantalum cervical interbody implants contribute to their differential appearance in different imaging methods. The titanium implant appears to image best with computed tomography, whereas the porous tantalum implant produces less artifact than does the titanium implant on several magnetic resonance imaging sequences.
C1 Mercy Healthcare Arizona, Barrow Neurol Inst, Div Neurol Surg, Phoenix, AZ 85013 USA.
   Univ Miami, Dept Neurosurg, Coral Gables, FL 33124 USA.
   Wallace Mem Baptist Hosp, Dept Neurosurg, Pusan, South Korea.
   Mercy Healthcare Arizona, Barrow Neurol Inst, Div Neuroradiol, Phoenix, AZ 85013 USA.
RP Dickman, CA (reprint author), Mercy Healthcare Arizona, Barrow Neurol Inst, Div Neurol Surg, 350 W Thomas Rd, Phoenix, AZ 85013 USA.
CR Black Jonathan, 1994, Clinical Materials, V16, P167, DOI 10.1016/0267-6605(94)90113-9
   BROWN MA, 1987, MAGN RESON IMAGING, V5, P443, DOI 10.1016/0730-725X(87)90378-X
   DAVIDSON TM, 1990, HEAD NECK-J SCI SPEC, V12, P500, DOI 10.1002/hed.2880120609
   GARDNER W J, 1946, Cleve Clin Q, V13, P72
   GOLD JP, 1989, ANN THORAC SURG, V48, P643, DOI 10.1016/0003-4975(89)90780-7
   GRAF CJ, 1945, AM J ROENTGENOL, V53, P157
   LAAKMAN RW, 1985, RADIOLOGY, V157, P711, DOI 10.1148/radiology.157.3.4059558
   LANE S, 1947, J NEUROSURG, V4, P526, DOI 10.3171/jns.1947.4.6.0526
   Lowery GL, 1996, MANUAL INTERNAL FIXA, P127
   MATHEWS JR, 1980, ANGLE ORTHOD, V50, P218
   NEW PFJ, 1983, RADIOLOGY, V147, P139, DOI 10.1148/radiology.147.1.6828719
   Ortiz O, 1996, NEUROSURGERY, V38, P741, DOI 10.1227/00006123-199604000-00022
   SCUDERI GJ, 1993, SPINE, V18, P1991, DOI 10.1097/00007632-199310001-00011
   STACKPOOL GJ, 1996, P 42 ANN M ORTH RES
   STITIK FP, 1975, ANN OTO RHINOL LARYN, V84, P589, DOI 10.1177/000348947508400505
   TARTAGLINO LM, 1994, RADIOLOGY, V190, P565, DOI 10.1148/radiology.190.2.8284417
NR 16
TC 29
Z9 29
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA
SN 0362-2436
J9 SPINE
JI SPINE
PD JUN 1
PY 1998
VL 23
IS 11
BP 1245
EP 1250
DI 10.1097/00007632-199806010-00014
PG 6
WC Clinical Neurology; Orthopedics
SC Neurosciences & Neurology; Orthopedics
GA ZU113
UT WOS:000074163600014
PM 9636978
DA 2018-10-19
ER

PT J
AU Peel, SAF
   Chen, H
   Renlund, R
   Badylak, SF
   Kandel, RA
AF Peel, SAF
   Chen, H
   Renlund, R
   Badylak, SF
   Kandel, RA
TI Formation of a SIS-cartilage composite graft in vitro and its use in the
   repair of articular cartilage defects
SO TISSUE ENGINEERING
LA English
DT Article; Proceedings Paper
CT SIS Symposium
CY DEC 11-12, 1996
CL ORLANDO, FLORIDA
ID SMALL-INTESTINAL SUBMUCOSA; RABBIT COSTAL CHONDROCYTES; ALLOGRAFT
   CHONDROCYTES; PROTEOGLYCAN SYNTHESIS; IN-VITRO; JOINT; TRANSPLANTATION;
   SURFACES; SCAFFOLDS; MATRICES
AB Porcine small intestinal submucosa (SIS) is a resorbable biomaterial that upon implantation induces tissue remodelling and so may be a suitable substratum for the formation of cartilage in vitro, which could then be used to resurface damaged joints. Chondrocytes were isolated from the deep portion of articular cartilage and seeded onto SIS. They formed cartilaginous tissue that contained large proteoglycans and type II collagen. The glycosaminoglycan content of 8 week SIS-cartilaginous tissue composites was 78.9 +/- 0.1% that of deep articular cartilage. The SIS-cartilaginous tissue composites were implanted into full-thickness articular cartilage defects. After 4 weeks, the composites had survived and retained their hyaline-like appearance, although fibrovascular and fibrocartilaginous tissue was also present. Defects receiving SIS alone contained predominantly fibrovascular tissue, whereas ungrafted defects were filled with fibrocartilage. SIS-cartilaginous tissue-resurfaced defects scored significantly better than SIS-filled defects, but were no different from the unfilled defects. However, the repair tissue in the composite-filled defects scored significantly higher than that in the unfilled defects. This pilot study suggests that SIS-cartilaginous tissue grafts may be useful for joint resurfacing. Further studies are required to optimize graft fixation and determine the long-term survival of the SIS-cartilaginous tissue grafts.
C1 Mt Sinai Hosp, Connect Tissue Res Grp, Toronto, ON M5G 1X5, Canada.
   Univ Toronto, Dept Comparat Med, Toronto, ON M5G 1X5, Canada.
   Purdue Univ, Hillenbrand Biomed Engn Ctr, W Lafayette, IN 47907 USA.
RI Peel, Sean/D-6112-2011
OI Peel, Sean/0000-0002-5245-1685; Badylak, Stephen/0000-0003-3555-0689
CR AMIEL D, 1985, J BONE JOINT SURG AM, V67A, P911, DOI 10.2106/00004623-198567060-00013
   ASTON JE, 1986, J BONE JOINT SURG BR, V68, P29
   BADYLAK SF, 1995, J BIOMED MATER RES, V29, P977, DOI 10.1002/jbm.820290809
   BADYLAK SF, 1989, J SURG RES, V47, P74, DOI 10.1016/0022-4804(89)90050-4
   Ben-Yishay A, 1995, Tissue Eng, V1, P119, DOI 10.1089/ten.1995.1.119
   BENTLEY G, 1971, NATURE, V230, P385, DOI 10.1038/230385a0
   BENTLEY G, 1992, ANN RHEUM DIS, V51, P292, DOI 10.1136/ard.51.3.292
   BOYLE J, 1995, OSTEOARTHR CARTILAGE, V3, P117, DOI 10.1016/S1063-4584(05)80044-5
   Brittberg M, 1996, CLIN ORTHOP RELAT R, P270
   BRITTBERG M, 1994, NEW ENGL J MED, V331, P889, DOI 10.1056/NEJM199410063311401
   BUCKWALTER J, 1987, INJURY REPAIR MUSCUL, P465
   CHU CR, 1995, J BIOMED MATER RES, V29, P1147, DOI 10.1002/jbm.820290915
   COUTTS RD, 1992, CLIN ORTHOP RELAT R, P263
   COUTTS RD, 1984, EUR SURG RES, V16, P322, DOI 10.1159/000128426
   ELVES MW, 1976, CLIN ORTHOP RELAT R, P232
   FREED LE, 1994, BIOTECHNOL BIOENG, V43, P605, DOI 10.1002/bit.260430710
   FREED LE, 1993, J BIOMED MATER RES, V27, P11, DOI 10.1002/jbm.820270104
   FREED LE, 1994, J BIOMED MATER RES, V28, P891, DOI 10.1002/jbm.820280808
   FURUKAWA T, 1980, J BONE JOINT SURG AM, V62, P79, DOI 10.2106/00004623-198062010-00012
   GADHER SJ, 1990, MATRIX, V10, P154, DOI 10.1016/S0934-8832(11)80164-2
   GOLDBERG RL, 1990, CONNECT TISSUE RES, V24, P265, DOI 10.3109/03008209009152154
   GRANDE DA, 1989, J ORTHOP RES, V7, P208, DOI 10.1002/jor.1100070208
   Hodde J P, 1996, Tissue Eng, V2, P209, DOI 10.1089/ten.1996.2.209
   ITAY S, 1987, CLIN ORTHOP RELAT R, P284
   Kandel R A, 1997, In Vitro Cell Dev Biol Anim, V33, P174
   KANDEL RA, 1995, ARTIF CELL BLOOD SUB, V23, P565, DOI 10.3109/10731199509117971
   KATO Y, 1985, J CELL BIOL, V100, P486, DOI 10.1083/jcb.100.2.486
   KATO Y, 1985, J CELL BIOL, V100, P477, DOI 10.1083/jcb.100.2.477
   KIM YJ, 1988, ANAL BIOCHEM, V174, P168, DOI 10.1016/0003-2697(88)90532-5
   KON M, 1981, EUR SURG RES, V13, P387, DOI 10.1159/000128206
   Kropp B P, 1995, Urology, V46, P396, DOI 10.1016/S0090-4295(99)80227-1
   MANKIN HJ, 1982, J BONE JOINT SURG AM, V64, P460, DOI 10.2106/00004623-198264030-00022
   MITCHELL N, 1976, J BONE JOINT SURG AM, V58, P230, DOI 10.2106/00004623-197658020-00012
   MORALES TI, 1991, ARCH BIOCHEM BIOPHYS, V286, P99, DOI 10.1016/0003-9861(91)90013-9
   NEVO Z, 1991, BONE, V5, P123
   NOGUCHI T, 1994, CLIN ORTHOP RELAT R, P251
   ODRISCOLL SW, 1988, J BONE JOINT SURG AM, V70A, P595, DOI 10.2106/00004623-198870040-00017
   PREVEL CD, 1995, ANN PLAS SURG, V35, P381, DOI 10.1097/00000637-199510000-00009
   SAMS AE, 1995, OSTEOARTHR CARTILAGE, V3, P47, DOI 10.1016/S1063-4584(05)80037-8
   SHAPIRO F, 1993, J BONE JOINT SURG AM, V75A, P532, DOI 10.2106/00004623-199304000-00009
   VACANTI CA, 1994, CLIN PLAST SURG, V21, P445
   VANKAMPEN GPJ, 1982, EXP CELL RES, V140, P440, DOI 10.1016/0014-4827(82)90136-7
   VoytikHarbin SL, 1997, J CELL BIOCHEM, V67, P478, DOI 10.1002/(SICI)1097-4644(19971215)67:4<478::AID-JCB6>3.0.CO;2-P
   WAKITANI S, 1989, J BONE JOINT SURG BR, V71, P74
   WAKITANI S, 1994, J BONE JOINT SURG AM, V76A, P579, DOI 10.2106/00004623-199404000-00013
NR 45
TC 25
Z9 30
U1 0
U2 2
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA
SN 1076-3279
J9 TISSUE ENG
JI Tissue Eng.
PD SUM
PY 1998
VL 4
IS 2
BP 143
EP 155
DI 10.1089/ten.1998.4.143
PG 13
WC Cell & Tissue Engineering
SC Cell Biology
GA ZY304
UT WOS:000074606700003
DA 2018-10-19
ER

PT J
AU Lin, S
   Rayson, GD
AF Lin, S
   Rayson, GD
TI Impact of surface modification on binding affinity distributions of
   Datura innoxia biomass to metal ions
SO ENVIRONMENTAL SCIENCE & TECHNOLOGY
LA English
DT Article
ID HUMIC SUBSTANCES; CHEMICAL MODIFICATION; COMPETITIVE-BINDING; ADSORPTION
   MODELS; CELL-WALLS; BIOMATERIAL; PROTONS; HETEROGENEITY; LUMINESCENCE;
   COMPLEXATION
AB Datura innoxia biomass has previously been targeted as a promising sorbent for heavy metal reclamation and remediation. Although the metal sequestering capabilities of biomaterials have been known, a general inability to accurately predict their binding characteristics has been a barrier to their implementation in remediation schemes. Of interest in our laboratory are the binding mechanisms as well as basic chemistry involved in the metal uptake of the material derived from fragments of cell walls from cultured cells from the plant D. innoxia. Previous studies have suggested the dependency of lead-ion affinity distributions of the biomaterial upon solution variables (i.e., ionic strength, pH) to be the result of two classes of binding sites: low-affinity sites involving sulfonates and carboxylates in an ion-exchange process and high-affinity sites resulting from the coordination of carboxylates to the metal. This hypothesis has been further investigated by the removal of the dominant functionality on the biomaterial (carboxylates) by carboxyl esterification by mildly acidic methanol. The resulting modified biomaterial was then studied in terms of affinity distributions toward proton and lead ions. The content of sulfonates on the biomaterial was found to be 43 mu mol/g. A total amount of carboxylates involved in Pb2+ binding was found to be 560 mu mol/g with 147 mu mol/g involved in an ion-exchange mechanism and coordination sites including 212 mu mol/g biomaterial.
C1 New Mexico State Univ, Dept Biochem & Chem, Las Cruces, NM 88003 USA.
RP Rayson, GD (reprint author), New Mexico State Univ, Dept Biochem & Chem, Box 30001 MSC 3C, Las Cruces, NM 88003 USA.
CR ATLAS RM, 1995, CHEM ENG NEWS, V73, P32, DOI 10.1021/cen-v073n014.p032
   BECKMANN N, 1995, CARBON 13 NMR SPECTR, P120
   Brown SL, 1996, ENVIRON SCI TECHNOL, V30, P3508, DOI 10.1021/es9601797
   BUFFLE J, 1990, GEOCHIM COSMOCHIM AC, V54, P1535, DOI 10.1016/0016-7037(90)90389-3
   CANTOR, BIOPHYSICAL CHEM 1, P49
   CERNIK M, 1995, ENVIRON SCI TECHNOL, V29, P413, DOI 10.1021/es00002a018
   CONLEY RT, 1972, INFRARED SPECTROSCOP, P700
   CRIST RH, 1994, ENVIRON SCI TECHNOL, V28, P1859, DOI 10.1021/es00060a016
   CRIST RH, 1981, ENVIRON SCI TECHNOL, V15, P1212, DOI 10.1021/es00092a010
   DARNALL DW, 1989, TRACE METAL REMOVAL, P1
   DEWIT JCM, 1993, ENVIRON SCI TECHNOL, V27, P2015, DOI 10.1021/es00047a005
   DOBBS JC, 1989, ANAL CHEM, V61, P1519, DOI 10.1021/ac00189a012
   Drake LR, 1996, ENVIRON SCI TECHNOL, V30, P110, DOI 10.1021/es950131d
   Drake LR, 1997, APPL SPECTROSC, V51, P1476, DOI 10.1366/0003702971939253
   DZOMBAK DA, 1986, ENVIRON SCI TECHNOL, V20, P669, DOI 10.1021/es00149a004
   EPHRAIM J, 1986, ENVIRON SCI TECHNOL, V20, P367, DOI 10.1021/es00146a008
   Fourest E, 1996, ENVIRON SCI TECHNOL, V30, P277, DOI 10.1021/es950315s
   GARDEATORRESDEY JL, 1990, ENVIRON SCI TECHNOL, V24, P1372, DOI 10.1021/es00079a011
   Huang JWW, 1997, ENVIRON SCI TECHNOL, V31, P800, DOI 10.1021/es9604828
   HUBER VJ, 1995, THESIS NEW MEXICO ST
   Hughes DL, 1996, J ORG CHEM, V61, P2967, DOI 10.1021/jo952180e
   KE HY, 1992, APPL SPECTROSC, V47, P44
   KE HYD, 1993, ENVIRON SCI TECHNOL, V27, P2466, DOI 10.1021/es00048a024
   KE HYD, 1994, ENVIRON SCI TECHNOL, V28, P586, DOI 10.1021/es00053a009
   KE HYD, 1992, ENVIRON SCI TECHNOL, V26, P1202, DOI 10.1021/es50002a609
   Kiefer E, 1997, ENVIRON SCI TECHNOL, V31, P759, DOI 10.1021/es960415d
   Lin S, 1996, ANAL CHEM, V68, P4087, DOI 10.1021/ac960569b
   LIN S.Z., UNPUB
   MANTSCH HH, 1996, INFRARED SPECTROSCOP, P165
   Martell A.E, 1977, CRITICAL STABILITY C, V3
   MOFFAT AS, 1995, SCIENCE, V269, P302, DOI 10.1126/science.269.5222.302
   MONCRIEF RM, 1995, SEPAR SCI TECHNOL, V30, P2421, DOI 10.1080/01496399508013120
   NAKAJIMA A, 1990, BIOMASS, V21, P55, DOI 10.1016/0144-4565(90)90047-N
   NEDERLOF MM, 1993, ENVIRON SCI TECHNOL, V27, P846, DOI 10.1021/es00042a006
   Plette ACC, 1996, ENVIRON SCI TECHNOL, V30, P1902, DOI 10.1021/es950568l
   SCHIEWER S, 1995, ENVIRON SCI TECHNOL, V29, P3049, DOI 10.1021/es00012a024
   STREITWIESER A, 1981, INTRO ORGANIC CHEM, P238
   TERNAY AL, 1979, CONT ORGANIC CHEM, P783
   Watanabe ME, 1997, ENVIRON SCI TECHNOL, V31, pA182, DOI 10.1021/es972219s
NR 39
TC 46
Z9 52
U1 1
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0013-936X
J9 ENVIRON SCI TECHNOL
JI Environ. Sci. Technol.
PD MAY 15
PY 1998
VL 32
IS 10
BP 1488
EP 1493
DI 10.1021/es970843z
PG 6
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA ZN466
UT WOS:000073648700019
DA 2018-10-19
ER

PT J
AU Gu, YJ
   Boonstra, PW
   Rijnsburger, AA
   Haan, J
   van Oeveren, W
AF Gu, YJ
   Boonstra, PW
   Rijnsburger, AA
   Haan, J
   van Oeveren, W
TI Cardiopulmonary bypass circuit treated with surface-modifying additives:
   A clinical evaluation of blood compatibility
SO ANNALS OF THORACIC SURGERY
LA English
DT Article
ID EXTRACORPOREAL CIRCUIT; INFLAMMATORY RESPONSE; FIBRINOGEN RECEPTORS;
   ACTIVATION; COMPLEMENT; HEPARIN; HEMOSTASIS
AB Background. The cardiopulmonary bypass (CPB) circuit induces blood activation and a systemic inflammatory response in cardiac surgical patients. The CPB circuit treated with surface-modifying additive (SMA) has been found to reduce blood activation by in vitro and ex vivo experiments. This study evaluates the surface thrombogenicity and complement activation of SMA circuits during clinical CPB.
   Methods. Twenty patients undergoing corollary artery bypass grafting were randomly divided into two groups. In the SMA group (n = 10), all blood-contacting surfaces in the CPB circuit were treated or coated with SMA, whereas in the control group (n = 10) patients were perfused with an identical circuit without treatment.
   Results. During CPB, platelet count and beta-thromboglobulin were found similar in both the SMA and the control groups. Prothrombin activation indicated by fragment F1+2 was found less in the SMA group (p < 0.05). After CPB, platelet deposition on the CPB circuit was significantly less (p < 0.05) in the SMA group than in the control group as assessed by the labeled monoclonal antibody against platelet glycoprotein IIIa. Complement activation identified by C3a and terminal complex C5b-9 did not differ between the two groups, but C4a generation was less in the SMA group (p < 0.05). Leukocyte activation identified by elastase and cytokine release indicated by interleukin-8 were found uniformly in both groups. Postoperatively, chest tube drainage, blood transfusion, duration of ventilatory support, as well as the intensive care unit and hospital stay were not significantly different between the two groups.
   Conclusions. These preliminary clinical results suggest that SMA inhibits platelet interaction with the biomaterial surface of the CPB circuit. Complement activation assessed by the terminal complement complex is not influenced by SMA. The clinical benefit of this surface-modifying technique has yet to be assessed in a larger population of patients undergoing cardiac operations. (C) 1998 by The Society of Thoracic Surgeons.
C1 Univ Groningen Hosp, Dept Cardiothorac Surg, Ctr Thorax, NL-9700 RB Groningen, Netherlands.
RP van Oeveren, W (reprint author), Univ Groningen Hosp, Dept Cardiothorac Surg, Ctr Thorax, Hanzeplein 1, NL-9700 RB Groningen, Netherlands.
CR ALLEN RDM, 1996, AUST NZ J SURG, V66, P742
   BOONSTRA PW, 1994, J THORAC CARDIOV SUR, V107, P289
   BUTLER J, 1993, ANN THORAC SURG, V55, P552, DOI 10.1016/0003-4975(93)91048-R
   COLLETT B, 1984, BRIT MED J, V289, P1251, DOI 10.1136/bmj.289.6454.1251
   DEHAAN J, 1995, ANN THORAC SURG, V59, P901, DOI 10.1016/0003-4975(95)00012-A
   EBERHART R, 1995, ARTIF ORGANS, V19, P1047
   EDMUNDS LH, 1993, J CARDIAC SURG, V8, P404, DOI 10.1111/j.1540-8191.1993.tb00384.x
   Farrar DJ, 1997, J THORAC CARDIOV SUR, V113, P202, DOI 10.1016/S0022-5223(97)70416-1
   GLUSZKO P, 1987, AM J PHYSIOL, V252, pH615
   GU YJ, 1993, ANN THORAC SURG, V55, P917, DOI 10.1016/0003-4975(93)90117-Z
   KIRKLIN JK, 1986, ANN THORAC SURG, V41, P193, DOI 10.1016/S0003-4975(10)62668-9
   KIRKLIN JK, 1991, ANN THORAC SURG, V51, P529, DOI 10.1016/0003-4975(91)90302-7
   MOLLNES TE, 1991, ANN THORAC SURG, V52, P92, DOI 10.1016/0003-4975(91)91426-V
   NACHMAN RL, 1982, J CLIN INVEST, V69, P263, DOI 10.1172/JCI110448
   OVRUM E, 1995, J THORAC CARDIOV SUR, V110, P1623, DOI 10.1016/S0022-5223(95)70023-4
   SALAMA A, 1988, NEW ENGL J MED, V318, P408, DOI 10.1056/NEJM198802183180704
   SPIJKER HT, IN PRESS CELLS MAT
   TAGGART DP, 1993, ANN THORAC SURG, V56, P1123, DOI 10.1016/0003-4975(95)90029-2
   TAMIYA T, 1992, J THORAC CARDIOV SUR, V103, P78
   Tsai C C, 1994, ASAIO J, V40, pM619, DOI 10.1097/00002480-199407000-00073
   VANOEVEREN W, 1994, CELL MATER, V4, P187
   VANOEVEREN W, 1985, J THORAC CARDIOV SUR, V89, P888
   VIDEM V, 1992, J THORAC CARDIOV SUR, V103, P806
   WENGER RK, 1989, J THORAC CARDIOV SUR, V97, P235
NR 24
TC 29
Z9 31
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA
SN 0003-4975
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD MAY
PY 1998
VL 65
IS 5
BP 1342
EP 1347
DI 10.1016/S0003-4975(98)00223-9
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA ZM201
UT WOS:000073514800030
PM 9594864
DA 2018-10-19
ER

PT J
AU Goodwin, CJ
   Braden, M
   Downes, S
   Marshall, NJ
AF Goodwin, CJ
   Braden, M
   Downes, S
   Marshall, NJ
TI Release of bioactive human growth hormone from a biodegradable material:
   Poly(epsilon-caprolactone)
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE growth hormone delivery; bioactivity; poly(epsilon-caprolactone);
   solvent casting; particulate leaching
ID DRUG DELIVERY SYSTEMS; IN-VITRO; ORTHOPEDIC-SURGERY; IMPLANTS; CELLS;
   REGENERATION; POLYMERS; BIOASSAY; MICROSPHERES; STIMULATION
AB We have characterized the biodegradable material poly(epsilon-caprolactone) (PCL) as a delivery system for recombinant human growth hormone (hGH). Two contrasting methods for the manufacture of the biomaterial were investigated: namely, solvent casting and solvent casting particulate leaching; the latter yielded porous PCL discs. The degree of porosity, which was assessed by scanning electron microscopy, could be controlled by incorporating selected concentrations of particulate sodium chloride during the manufacturing process. Bioactive hGH released from the PCL preparations was quantified with a highly sensitive and precise bioassay which was based upon hGH activation of rat lymphoma Nb2 cells. Eluates obtained from control discs of PCL which had not been loaded with hGH proved to be nontoxic when tested on these cells. The release of bioactive hGH from hormone-loaded nonporous discs of PCL was found to be a direct function of the initial hormone loading dose. Increased porosity of the discs manufactured by solvent casting particulate leaching increased the delivery of hGH from discs which had been immersion loaded. However, hGH release after surface loading was independent of porosity. Hormone concentrations were also assessed by immunoassay so that the ratios of bio-to immunoactivity (B:I ratio) of the hormone release could be determined. We found that the B:I ratio of the hormone after release from unstored discs was identical to that of the hormone prior to its incorporation into the PCL, demonstrating that the mild incorporation procedures utilized had not adversely affected the structural integrity of the hormone. However, if the hormone-loaded discs were stored at 37 degrees C prior to elution, the B:I ratios of the hGH released decreased indicating that this compromised the bioactive site. (C) 1998 John Wiley & Sons, Inc.
C1 UCL, Dept Mol Pathol, London W1P 6OB, England.
   Univ London, IRC Biomed Mat, London, England.
   Queens Med Ctr, Sch Med, Dept Human Morphol, Nottingham NG7 2UH, England.
RP Marshall, NJ (reprint author), UCL, Dept Mol Pathol, 46 Cleveland St, London W1P 6OB, England.
CR AGRAWAL CM, 1995, BIOMATERIALS, V16, P1255, DOI 10.1016/0142-9612(95)98133-Y
   BOS RR, 1989, J ORAL MAXIL SURG, V18, P203
   COOMBES AGA, 1994, CLIN MATER, V17, P35, DOI DOI 10.1016/0267-6605(94)90046-9
   Crank J, 1975, MATH DIFFUSION
   EALEY PA, 1988, J MOL ENDOCRINOL, V1, pR1, DOI 10.1677/jme.0.001R001
   EALEY PA, 1995, GROWTH REGULAT, V5, P36
   FREED LE, 1993, J BIOMED MATER RES, V27, P11, DOI 10.1002/jbm.820270104
   FUKUZAKI H, 1991, J BIOMED MATER RES, V25, P315, DOI 10.1002/jbm.820250304
   GOGOLEWSKI S, 1983, COLLOID POLYM SCI, V261, P477, DOI 10.1007/BF01419831
   GOMBOTZ WR, 1993, J BIOMAT SCI-POLYM E, V5, P49
   GOMBOTZ WR, 1994, J APPL BIOMATER, V5, P141, DOI 10.1002/jab.770050207
   Goodwin CJ, 1996, J BIOMED MATER RES, V32, P635, DOI 10.1002/(SICI)1097-4636(199612)32:4<635::AID-JBM17>3.0.CO;2-C
   GOODWIN CJ, 1995, J IMMUNOL METHODS, V179, P95, DOI 10.1016/0022-1759(94)00277-4
   GOODWIN CJ, 1995, J MATER SCI-MATER M, V6, P590, DOI 10.1007/BF00121283
   Goodwin CJ, 1997, J BIOMED MATER RES, V34, P47
   GURAV N, 1994, J MATER SCI-MATER M, V5, P784, DOI 10.1007/BF00213135
   Heling I, 1981, J Oral Implantol, V9, P548
   HOFMANN G O, 1992, Clinical Materials, V10, P75, DOI 10.1016/0267-6605(92)90088-B
   Hofmann G. O., 1993, Clinical Materials, V14, P207, DOI 10.1016/0267-6605(93)90004-Q
   HOLLAND S J, 1986, Journal of Controlled Release, V4, P155, DOI 10.1016/0168-3659(86)90001-5
   HORA MS, 1990, BIO-TECHNOL, V8, P755, DOI 10.1038/nbt0890-755
   HUATAN H, 1995, BIOMATERIALS, V16, P1297, DOI 10.1016/0142-9612(95)91044-Y
   KASSEM M, 1994, EUR J ENDOCRINOL, V130, P381, DOI 10.1530/eje.0.1300381
   KENLEY R, 1994, J BIOMED MATER RES, V28, P1139, DOI 10.1002/jbm.820281004
   KITCHELL JP, 1985, DRUG ENZYME TARGETIN, P436
   LAUFER D, 1988, J CRANIO MAXILL SURG, V16, P40, DOI 10.1016/S1010-5182(88)80013-1
   LEKOVIC V, 1993, J PERIODONTOL, V64, P1154, DOI 10.1902/jop.1993.64.11s.1154
   MARCH KL, 1994, CIRCULATION, V89, P1929, DOI 10.1161/01.CIR.89.5.1929
   MEIKLE MC, 1993, BIOMATERIALS, V14, P177, DOI 10.1016/0142-9612(93)90020-3
   MIKOS AG, 1993, BIOMATERIALS, V14, P323, DOI 10.1016/0142-9612(93)90049-8
   Nicoll SB, 1995, CELL MATER, V5, P231
   PITT CG, 1979, J BIOMED MATER RES, V13, P497, DOI 10.1002/jbm.820130313
   PITT CG, 1979, J PHARM SCI, V68, P1534, DOI 10.1002/jps.2600681219
   PRINGLE PJ, 1992, CLIN CHEM, V38, P553
   TANAKA T, 1980, J CLIN ENDOCR METAB, V51, P1058, DOI 10.1210/jcem-51-5-1058
   TENCER AF, 1989, J BIOMED MATER RES, V23, P571, DOI 10.1002/jbm.820230604
NR 36
TC 30
Z9 32
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD MAY
PY 1998
VL 40
IS 2
BP 204
EP 213
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA ZD360
UT WOS:000072677400005
PM 9549615
DA 2018-10-19
ER

PT J
AU Wilke, A
   Orth, J
   Lomb, M
   Fuhrmann, R
   Kienapfel, H
   Griss, P
   Franke, RP
AF Wilke, A
   Orth, J
   Lomb, M
   Fuhrmann, R
   Kienapfel, H
   Griss, P
   Franke, RP
TI Biocompatibility analysis of different biomaterials in human bone marrow
   cell cultures
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE biocompatibility; biomaterials; human bone marrow cell culture
ID POLYETHYLENE; CERAMICS; BEHAVIOR; IMPLANTS; GROWTH; DNA
AB A cell culture system for biocompatibility testing of hip implant materials is described. Human bone marrow cells have been chosen because these cells are in direct contact with the biomaterial after implantation in situ. The sensitivity of this method is evaluated for materials which are already being used as implants in humans and animal, e.g., hydroxyapatite (HA) ceramic, pure titanium, and ultra-high-molecular-weight polyethylene (UHMWPE). As indicative parameters of biocompatibility primary cell adherence, cell number, cell proliferation, production of extracellular matrix, cell vitality, and cell differentiation are described. After 2 weeks in culture, obvious differences between the biomaterials with respect to the indicative parameters could be observed. Cell numbers were greatest on the HA specimens. Ln the case of titanium alloys, we observed a decreased number of cells. The production of extracellular matrix was high for the HA ceramics but reduced for titanium specimens. The polymers allowed only a few adherent cells and showed no signs of extracellular matrix production. The results can be correlated astonishingly well to animal experiments and clinical experiences. Therefore, we suggest that this cell culture system seems to be a useful tool for biocompatibility testing of bone implantation materials. It also helps reduce animal experiments. With the help of flow cytophotometry, we analyzed the influence of biomaterials on large numbers of cells with respect to differentiation. There were similar populations of T cells and monocytes on all specimens tested. Extended B-cell and granulocyte populations, however, were observed with titanium and UHMWPE. Most osteocalcin-containing cells adhered to the HA ceramics. (C) 1998 John Wiley & Sons, Inc.
C1 Univ Marburg, Dept Orthoped Surg, D-35043 Marburg, Germany.
   Univ Ulm, ZBMT, Dept Biomat, D-89081 Ulm, Germany.
RP Wilke, A (reprint author), Univ Marburg, Dept Orthoped Surg, Baldinger Str, D-35043 Marburg, Germany.
CR ANDREW TA, 1986, CLIN ORTHOP RELAT R, P127
   BAGAMBISA FB, 1990, BIOMATERIALS, V11, P50, DOI 10.1016/0142-9612(90)90052-R
   BAYER JA, 1990, J IMMUNOL METHODS, V132, P13, DOI 10.1016/0022-1759(90)90393-A
   BOBYN JD, 1987, CLIN ORTHOP RELAT R, P303
   COOK SD, 1988, CLIN ORTHOP RELAT R, P303
   DEXTER TM, 1984, LONG TERM BONE MARRO, P57
   FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0
   GEESINK RGT, 1988, J BONE JOINT SURG BR, V70, P17
   GOSHIMA J, 1991, CLIN ORTHOP RELAT R, P298
   GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245
   GRISS P, 1993, Z ORTHOP GRENZGEB, V131, P488, DOI 10.1055/s-2008-1040059
   HARDY DCR, 1991, J BONE JOINT SURG BR, V73, P732
   HENCH LL, 1975, ADV BIOMED ENG, V5, P35
   KALLA P, 1990, BEHRING I MITT, V90, P93
   MAROUDAS NG, 1973, CELL RES, V16, P104
   MATHIESEN EB, 1987, J BIOMED MATER RES, V21, P459, DOI 10.1002/jbm.820210406
   ORTH J, 1990, ADV BIOMAT, V9, P283
   OSBORNE JF, 1985, IMPLANTATWERKSTOFF H
   ROSENBERG A, 1989, ORTHOPEDICS, V12, P1223
   ROSSO R, 1988, ARCH ORTHOP TRAUM SU, V107, P86, DOI 10.1007/BF00454491
   SCHACHTSCHABEL DO, 1976, EUR SURG RES, V8, P71, DOI 10.1159/000127849
   Stutzmann JJ, 1982, FACTORS MECHANISMS I, P29
   UCHIDA A, 1987, J BIOMED MATER RES, V21, P1, DOI 10.1002/jbm.820210106
   WEISS RE, 1981, J CELL BIOL, V88, P630, DOI 10.1083/jcb.88.3.630
   WILKE A, 1993, BIOMED TECH, V38, P126, DOI 10.1515/bmte.1993.38.6.126
   WILKE A, 1993, J MATER SCI-MATER M, V4, P260, DOI 10.1007/BF00122278
   Wilke A, 1995, Eur J Orthop Surg Traumatol, V5, P59, DOI 10.1007/BF02716218
   WILKE A, 1995, Z ORTHOP GRENZGEB, V133, P159, DOI 10.1055/s-2008-1039431
   WILKE A, 1995, ADV SCI TECHNOLOGY, V12, P343
   Wilsnack R E, 1973, Biomater Med Devices Artif Organs, V1, P543
NR 30
TC 61
Z9 67
U1 1
U2 9
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD MAY
PY 1998
VL 40
IS 2
BP 301
EP 306
DI 10.1002/(SICI)1097-4636(199805)40:2<301::AID-JBM15>3.0.CO;2-O
PG 6
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA ZD360
UT WOS:000072677400015
PM 9549625
DA 2018-10-19
ER

PT J
AU Kent, DG
   Peng, Q
   Isaacs, RT
   Whiteside, SB
   Barker, DL
   Apple, DJ
AF Kent, DG
   Peng, Q
   Isaacs, RT
   Whiteside, SB
   Barker, DL
   Apple, DJ
TI Mini-haptics to improve capsular fixation of plate-haptic silicone
   intraocular lenses
SO JOURNAL OF CATARACT AND REFRACTIVE SURGERY
LA English
DT Article; Proceedings Paper
CT Symposium on Cataract, IOL and Refractive Surgery
CY JUN 01-05, 1996
CL SEATTLE, WASHINGTON
ID EYES OBTAINED POSTMORTEM
AB Purpose: To evaluate the effects of a new mini-hepatic design on the strength and stability of capsular bag fixation of plate-hepatic silicone intraocular lenses (IOLs) and determine whether this design encourages the growth of regenerating lens material or fibrous tissue around the hepatic biomaterial and thus improves lens fixation in the capsular bag.
   Setting: Center for Research on Ocular Therapeutics and Biodevices, Storm Eye Institute, Medical University of South Carolina, Department of Ophthalmology, Charleston, South Carolina, USA.
   Methods: Six rabbits had bilateral continous curvilinear capsulorhexis, phacoemulsification, and plate-hepatic silicone IOL implantation. Each rabbit had a small-hole plate IOL (Chiron C10UB) implanted in the right eye and a mini-hepatic plate IOL (Chiron C40UB) in the left eye. All rabbits were killed at 2 months. The force required the extract one haptic from the capsular bag was measured with a digital force gauge. Histopathologic analysis was performed on all specimens.
   Results: The mini-hepatic style IOLs required significantly more extraction force than the small-hole design (P = .011). Histopathologically, proliferating lens epithelial cells were observed growing circumferentially around the mini-haptics, causing a 360 degree synechia formation. This formation did not occur with the conventional small-hole plate IOLs used as the control.
   Conclusions: Lens epithelial cell proliferation around the mini-haptics significantly improved capsular bag fixation of the plate-haptic silicone IOL. This should decrease the incidence of clinical decentration and dislocation.
C1 Med Univ S Carolina, Storm Eye Inst, Dept Ophthalmol, Ctr Res Ocular Therapeut & Biodevices, Charleston, SC 29425 USA.
RP Apple, DJ (reprint author), Med Univ S Carolina, Storm Eye Inst, Dept Ophthalmol, Ctr Res Ocular Therapeut & Biodevices, 171 Ashley Ave, Charleston, SC 29425 USA.
CR APPLE DJ, 1990, OPHTHALMOLOGY, V97, P810
   APPLE DJ, 1996, 10 K DGII BERL HEID, P159
   Auffarth GU, 1996, J CATARACT REFR SURG, V22, P1281, DOI 10.1016/S0886-3350(96)80085-X
   AUFFARTH GU, 1995, OPHTHALMOLOGY, V102, P1144, DOI 10.1016/S0161-6420(95)30898-6
   BLOTNICK CA, 1995, J CATARACT REFR SURG, V21, P447, DOI 10.1016/S0886-3350(13)80538-X
   Colin J, 1996, J CATARACT REFR SURG, V22, P1286, DOI 10.1016/S0886-3350(96)80086-1
   CUMMING JS, 1993, J CATARACT REFR SURG, V19, P263, DOI 10.1016/S0886-3350(13)80954-6
   Mackool RJ, 1996, J CATARACT REFR SURG, V22, P396, DOI 10.1016/S0886-3350(96)80030-7
   MASKET S, 1996, J CATARACT REFR SURG, V22, P159
NR 9
TC 8
Z9 9
U1 0
U2 0
PU AMER SOC CATARACT REFRACTIVE SURGERY
PI FAIRFAX
PA 4000 LEGATO RD, SUITE 850, FAIRFAX, VA 22030 USA
SN 0886-3350
J9 J CATARACT REFR SURG
JI J. Cataract. Refract. Surg.
PD MAY
PY 1998
VL 24
IS 5
BP 666
EP 671
DI 10.1016/S0886-3350(98)80263-0
PG 6
WC Ophthalmology; Surgery
SC Ophthalmology; Surgery
GA ZP955
UT WOS:000073805500023
PM 9610451
DA 2018-10-19
ER

PT J
AU Amrani, DL
   Lee, C
   Earles, K
   DiOrio, J
   Murphy, M
   Yang, J
   Rubalcaba, S
   LiVecchi, A
AF Amrani, DL
   Lee, C
   Earles, K
   DiOrio, J
   Murphy, M
   Yang, J
   Rubalcaba, S
   LiVecchi, A
TI An in vitro bovine pericardial hemocompatibility testing system
SO JOURNAL OF HEART VALVE DISEASE
LA English
DT Article
ID HEART-VALVES; GLUTARALDEHYDE; CALCIFICATION
AB Background and aims of the study: Bovine pericardium has been used as a biomaterial for heart valves since the late 1960s. Cross-linking agents have been applied routinely to reduce host-tissue response, including antigenicity, and to improve tissue leaflet durability. Evaluation of improvements in bovine pericardial valve leaflet calcification and flexibility require that in vitro systems be developed to correlate data with results from in vivo studies. This study describes an in vitro test system used to evaluate the effects of two surface-modifying treatments on pericardial tissue hemocompatibility.
   Methods: Non-fixed and glutaraldehyde fixation-processed (GA) bovine pericardial tissues were exposed to anticoagulated whole blood for 60 min. Blood was then removed, and platelet-poor plasma prepared and frozen at -70 degrees C until analyzed for kallikrein activation and release of platelet factor 4 (PF4). Blood-exposed tissue samples were analyzed for fibrin(ogen) binding with an anti-fibrinogen antibody and for tissue cellular responsiveness (blood cell adherence and aggregation) by scanning electron microscopy.
   Results: Conditions were determined for minimum extent of pumping action by the minicam system required to allow for solution movement while not tearing or wearing the tissue. A blood-tissue exposure time of 60 min provided sufficient first-pass exposure to evaluate the acute blood-tissue response. The relative degree of both kallikrein activation and PF4 release was greater in the non-fixed tissue but a greater number of fibrin(ogen) molecules per cm(2) was found on GA-treated tissue. Scanning electron microscopy showed a differential cell response of non-fixed tissue compared with GA-treated tissue.
   Conclusion: This non-static test system demonstrated great promise for use in routine in vitro hemocompatibility testing of blood-contacting biological biomaterials.
C1 Baxter Int, CRTS, Round Lake, IL 60073 USA.
   Baxter Healthcare Corp, Edwards CVS Div, Irvine, CA USA.
RP Amrani, DL (reprint author), Baxter Int, CRTS, RLT-12,Route 120 & Wilson Rd, Round Lake, IL 60073 USA.
CR Abolhoda A, 1996, ANN THORAC SURG, V62, P169, DOI 10.1016/0003-4975(96)00277-9
   Bernacca G M, 1992, J Heart Valve Dis, V1, P115
   CARPENTIER A, 1969, J THORAC CARDIOV SUR, V58, P467
   GENDLER E, 1984, J BIOMED MATER RES, V18, P727, DOI 10.1002/jbm.820180703
   GIRARDOT JM, 1995, ENCY HDB BIOMATERI B, V2, P1189
   Girardot JMD, 1996, J HEART VALVE DIS, V5, P518
   Grabenwoger M, 1996, ANN THORAC SURG, V62, P772
   LEVY RJ, 1983, AM J PATHOL, V113, P143
   NIMNI ME, 1987, J BIOMED MATER RES, V21, P741, DOI 10.1002/jbm.820210606
   NIMNI ME, 1968, J BIOL CHEM, V243, P1457
   NISTAL F, 1988, J THORAC CARDIOV SUR, V96, P642
   PETITE H, 1995, BIOMATERIALS, V16, P1003, DOI 10.1016/0142-9612(95)94908-4
   Schoen F J, 1984, Cardiol Clin, V2, P717
   SCHOEN FJ, 1986, AM J PATHOL, V123, P134
   WOODROOF EA, 1978, J BIOENG, V2, P1
NR 15
TC 1
Z9 2
U1 0
U2 1
PU I C R PUBLISHERS
PI NORTHWOOD
PA CRISPIN HOUSE, 12/A SOUTH APPROACH, MOOR PARK, NORTHWOOD, ENGLAND HA6
   2ET
SN 0966-8519
J9 J HEART VALVE DIS
JI J. Heart Valve Dis.
PD MAY
PY 1998
VL 7
IS 3
BP 268
EP 272
PG 5
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA ZP945
UT WOS:000073804400006
PM 9651838
DA 2018-10-19
ER

PT J
AU Chan, RW
   Titze, IR
AF Chan, RW
   Titze, IR
TI Viscosities of implantable biomaterials in vocal fold augmentation
   surgery
SO LARYNGOSCOPE
LA English
DT Article; Proceedings Paper
CT 1st International Conference on Voice Physiology and Biomechanics
CY MAY   31, 1997
CL EVANSTON, ILLINOIS
ID PHONATION THRESHOLD PRESSURE; INJECTABLE COLLAGEN; CORD PARALYSIS;
   INJECTION; FAT; REHABILITATION; HYDRATION; TEFLON
AB Vocal fold vibration depends critically on the viscoelasticity of vocal fold tissues. For instance, phonation threshold pressure, a measure of the "ease" of phonation, has been shown to be directly related to the viscosity of the vibrating mucosa. Various implantable biomaterials have been used in vocal fold augmentation surgery, with implantation sites sometimes close to or inside the mucosa. Yet their viscosities or other mechanical properties are seldom known. This study attempts to provide data on viscosities of commonly used phonosurgical biomaterials. Using a parallel-plate rotational rheometer, oscillatory shear experiments were performed on implantable polytetrafluoroethylene (Teflon or Polytef; Mentor Inc., Hingham, MA), collagen (Zyderm; Collagen Corp., Pale Alto, CA), glutaraldehyde crosslinked (GAX) collagen (Phonagel or Zyplast; Collagen Corp.), absorbable gelatin (Gelfoam; Upjohn Co., Kalamazoo, MI), and human abdominal subcutaneous fat. Samples of human vocal fold mucosal tissues were also tested, Under sinusoidal oscillatory shear at 10 Hz and at 37 degrees C, the dynamic viscosity was 116 Pascal-seconds (Pa-s) for polytetrafluoroethylene, 21 Pa-s for gelatin, 8-13 Pa-s for the two types of collagen, 3 Pa-s for fat, and 1 to 3 Pa-s for vocal fold mucosa. Results extrapolated to 100 Hz also show similar differences among the biomaterials, but all values are an order of magnitude lower because of the typical inverse frequency relation (shear thinning effect) for polymeric and biologic materials. The data suggest that the use of fat for vocal fold augmentation may be more conducive to the "ease" of phonation because of its relatively low viscosity, which is closest to physiologic levels. This implication is probably the most relevant in predicting initial outcome of the postoperative voice before there is any significant assimilation (e.g., resorption and fibrosis) of the implanted biomaterial.
C1 Univ Iowa, Dept Speech Pathol & Audiol, Natl Ctr Voice & Speech, Iowa City, IA 52242 USA.
RP Chan, RW (reprint author), Univ Iowa, Dept Speech Pathol & Audiol, Natl Ctr Voice & Speech, 330 WJSHC, Iowa City, IA 52242 USA.
FU NIDCD NIH HHS [P60 DC00976]
CR Balazs E. A., 1970, CHEMISTRY MOLECULAR, P1241
   BARNES HA, 1989, INTRO RHEOLOGY, P97
   Benninger MS, 1996, OTOLARYNG HEAD NECK, V115, P474, DOI 10.1016/S0194-5998(96)70087-6
   Bothner H, 1987, Acta Otolaryngol Suppl, V442, P25
   BRANDENBURG JH, 1992, LARYNGOSCOPE, V102, P495, DOI 10.1288/00005537-199205000-00005
   FERRY JD, 1970, VISCOELASTIC PROPERT, P1
   Finkelhor B. K., 1988, J VOICE, V1, P320, DOI DOI 10.1016/S0892-1997(88)80005-5
   Ford C. N., 1987, J VOICE, V1, P116
   FORD CN, 1984, LARYNGOSCOPE, V94, P513, DOI 10.1288/00005537-198404000-00016
   FORD CN, 1992, ANN OTO RHINOL LARYN, V101, P237, DOI 10.1177/000348949210100307
   FORD CN, 1995, LARYNGOSCOPE, V105, P944, DOI 10.1288/00005537-199509000-00014
   Gray SD, 1993, VOCAL FOLD PHYSL FRO, P1
   Hammond TH, 1997, J VOICE, V11, P59, DOI 10.1016/S0892-1997(97)80024-0
   HIRANO M, 1981, P C ASSESSMENT VOCAL, P11
   HOFFMAN H T, 1991, Ear Nose and Throat Journal, V70, P385
   HORN KL, 1980, LARYNGOSCOPE, V90, P281
   JIANG JJ, 1994, ANN OTO RHINOL LARYN, V103, P145, DOI 10.1177/000348949410300211
   Johnson D, 1996, PLAST RECONSTR SURG, V97, P387, DOI 10.1097/00006534-199602000-00017
   KAKITA Y, 1981, VOCAL FOLD PHYSL, P377
   Lehninger A.L., 1993, PRINCIPLES BIOCH, P298
   MATSUO K, 1984, Practica Otologica Kyoto, V77, P817
   MIKAELIAN DO, 1991, LARYNGOSCOPE, V101, P465
   Pawlak AS, 1996, ANN OTO RHINOL LARYN, V105, P6, DOI 10.1177/000348949610500102
   REMACLE M, 1995, ANN OTO RHINOL LARYN, V104, P437, DOI 10.1177/000348949510400604
   RUBIN HJ, 1975, ARCH OTOLARYNGOL, V101, P114
   Sataloff RT, 1997, J VOICE, V11, P238
   SCHRAMM VL, 1978, LARYNGOSCOPE, V88, P1268
   Shaw GY, 1997, LARYNGOSCOPE, V107, P177, DOI 10.1097/00005537-199702000-00008
   TITZE IR, 1995, J ACOUST SOC AM, V97, P3080, DOI 10.1121/1.411870
   TITZE IR, 1992, J ACOUST SOC AM, V91, P2926, DOI 10.1121/1.402928
   TITZE IR, 1988, J ACOUST SOC AM, V83, P1536, DOI 10.1121/1.395910
   VERDOLINI K, 1994, J SPEECH HEAR RES, V37, P1001, DOI 10.1044/jshr.3705.1001
   VERDOLINIMARSTON K, 1990, J VOICE, V4, P142, DOI 10.1016/S0892-1997(05)80139-0
   WARD AG, 1977, SCI TECHNOLOGY GELAT, P137
   WEXLER DB, 1989, ANN OTO RHINOL LARYN, V98, P668, DOI 10.1177/000348948909800902
   WHORLOW RW, 1980, RHEOLOGICAL TECHNIQU, P243
   Zhu WB, 1996, J BIOMECH, V29, P773, DOI 10.1016/0021-9290(95)00136-0
   ZHU WB, 1990, BIOMECHANICS DIARTHR, P313
NR 38
TC 108
Z9 112
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA
SN 0023-852X
J9 LARYNGOSCOPE
JI Laryngoscope
PD MAY
PY 1998
VL 108
IS 5
BP 725
EP 731
DI 10.1097/00005537-199805000-00019
PG 7
WC Medicine, Research & Experimental; Otorhinolaryngology
SC Research & Experimental Medicine; Otorhinolaryngology
GA ZM323
UT WOS:000073527000019
PM 9591554
DA 2018-10-19
ER

PT J
AU Reid, G
AF Reid, G
TI Bacterial colonization of prosthetic devices and measures to prevent
   infection
SO NEW HORIZONS-THE SCIENCE AND PRACTICE OF ACUTE MEDICINE
LA English
DT Article
DE medical devices; biofilms; infection; treatment
ID PSEUDOMONAS-AERUGINOSA CELLS; VASCULAR GRAFT MATERIAL; MICROBIAL
   ADHESION; URETERAL STENTS; URINARY-TRACT; IN-VIVO;
   STAPHYLOCOCCUS-EPIDERMIDIS; VOICE PROSTHESES; CATHETERS; BIOFILMS
AB Prosthetic devices are used extensively in surgical practice. This includes devices used on a temporary, intermittent, and long-term basis. In addition to problems with biocompatibility, the main health care issue concerning prostheses is the elevated risk of infection and the current inability to effectively prevent and treat such infections. An appreciation of microbial biofilm development has drawn attention to flaws in diagnosis and led to new methods to attack the problem. Future remedies will likely involve utilization of new biomaterial designs and application of either highly potent antimicrobials or agents used in combination that penetrate biofilms and eradicate the organisms.
C1 Lawson Res Inst, London, ON N6A 4V2, Canada.
RP Reid, G (reprint author), Lawson Res Inst, H414,268 Grosvenor St, London, ON N6A 4V2, Canada.
CR Aguiar E T, 1993, Rev Hosp Clin Fac Med Sao Paulo, V48, P76
   ALSAFFAR N, 1994, BRIT J RHEUMATOL, V33, P309
   ANGLEN JO, 1994, J ORTHOP TRAUMA, V8, P390, DOI 10.1097/00005131-199410000-00004
   Antunes M J, 1992, J Heart Valve Dis, V1, P15
   ASHBY MJ, 1994, J ANTIMICROB CHEMOTH, V33, P443, DOI 10.1093/jac/33.3.443
   BABYCOS CR, 1993, JPEN-PARENTER ENTER, V17, P61, DOI 10.1177/014860719301700161
   BLASER J, 1995, ANTIMICROB AGENTS CH, V39, P1134, DOI 10.1128/AAC.39.5.1134
   Bunt T J, 1993, Cardiovasc Surg, V1, P489
   CANUSA Peritoneal Dialysis Study Group, 1992, ADV PERIT DIAL, V8, P88
   Characklis W., 1990, BIOFILMS, P3
   CHRISTENSEN GD, 1989, INFECT ASS INDWELLIN, P27
   COSTERTON JW, 1993, INT J ARTIF ORGANS, V16, P765
   DAROUICHE RO, 1994, J INFECT DIS, V170, P72
   DELAHAYE F, 1995, EUR HEART J, V16, P394, DOI 10.1093/oxfordjournals.eurheartj.a060923
   FANG GD, 1993, ANN INTERN MED, V119, P560, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00003
   GREITEMANN B, 1992, ARCH ORTHOP TRAUM SU, V111, P138, DOI 10.1007/BF00388087
   GRISTINA AG, 1993, INT J ARTIF ORGANS, V16, P755
   GRISTINA AG, 1987, SCIENCE, V237, P1588, DOI 10.1126/science.3629258
   GRISTINA AG, 1994, CLIN ORTHOP RELAT R, P106
   Guo W, 1994, J Invest Surg, V7, P175, DOI 10.3109/08941939409018284
   HERSCHORN S, 1995, J UROLOGY, V154, P80, DOI 10.1016/S0022-5347(01)67233-1
   JEAN G, 1994, NEPHROLOGIE, V15, P81
   JOHNSON JR, 1990, J INFECT DIS, V162, P1145, DOI 10.1093/infdis/162.5.1145
   KESWICK BH, 1987, J CLIN MICROBIOL, V25, P216
   KUNIN CM, 1987, DETECTION PREVENTION, P57
   LALOR PA, 1991, J BONE JOINT SURG BR, V73, P25
   LIGHT JK, 1995, J UROLOGY, V153, P331, DOI 10.1097/00005392-199502000-00009
   LUNDEBERG T, 1986, LANCET, V2, P1031
   Maki DG, 1989, INFECT ASS INDWELLIN, P161
   MCMURDO MET, 1992, J EPIDEMIOL COMMUN H, V46, P222, DOI 10.1136/jech.46.3.222
   MERTENS RA, 1995, J VASC SURG, V21, P782, DOI 10.1016/S0741-5214(05)80009-6
   MICHIGAN S, 1976, J UROLOGY, V116, P390, DOI 10.1016/S0022-5347(17)58830-8
   MILLER JH, 1993, J VASC SURG, V17, P546
   NEU TR, 1992, CELL MATER, V2, P261
   NEU TR, 1993, BIOMATERIALS, V14, P459, DOI 10.1016/0142-9612(93)90149-V
   NICHOLOV R, 1993, CELL MATER, V3, P321
   NICKEL JC, 1985, ANTIMICROB AGENTS CH, V27, P619, DOI 10.1128/AAC.27.4.619
   NOSE Y, 1992, ARTIF ORGANS, V16, P19
   OZAKI CK, 1993, J SURG RES, V55, P543, DOI 10.1006/jsre.1993.1181
   PORTOLES M, 1993, J CATARACT REFR SURG, V19, P755, DOI 10.1016/S0886-3350(13)80345-8
   REID G, 1994, ANTIMICROB AGENTS CH, V38, P1490, DOI 10.1128/AAC.38.7.1490
   REID G, 1992, J UROLOGY, V148, P1592, DOI 10.1016/S0022-5347(17)36976-8
   REID G, 1994, PARAPLEGIA, V32, P468, DOI 10.1038/sc.1994.74
   REID G, 1993, COLLOID SURFACE B, V1, P9, DOI 10.1016/0927-7765(93)80012-N
   REID G, 1993, J MATER SCI-MATER M, V4, P17, DOI 10.1007/BF00122972
   REID G, 1994, SURF INTERFACE ANAL, V21, P581, DOI 10.1002/sia.740210812
   REID G, 1995, COLLOID SURFACE B, V5, P171, DOI 10.1016/0927-7765(95)01208-Z
   REID G, 1994, COLLOID SURFACE B, V2, P377
   Reid KA, 1995, ENVIRON CHEM, V1, P269
   ROBERTS JA, 1990, J UROLOGY, V144, P264, DOI 10.1016/S0022-5347(17)39428-4
   SHARP WJ, 1994, J VASC SURG, V19, P844, DOI 10.1016/S0741-5214(94)70009-5
   TEICHMAN JMH, 1994, J UROLOGY, V152, P213, DOI 10.1016/S0022-5347(17)32864-1
   THOMAS P, 1994, CLIN NUCL MED, V19, P1075, DOI 10.1097/00003072-199419120-00008
   TIERNO PM, 1989, REV INFECT DIS, V11, pS182, DOI 10.1093/clinids/11.Supplement_1.S182
   VANDERMEER JTM, 1992, ARCH INTERN MED, V152, P1863, DOI 10.1001/archinte.152.9.1863
   VITALE N, 1995, EUR J CARDIO-THORAC, V9, P181, DOI 10.1016/S1010-7940(05)80142-3
   WILSON SK, 1995, J UROLOGY, V153, P659, DOI 10.1016/S0022-5347(01)67678-X
   YASUDA H, 1994, ANTIMICROB AGENTS CH, V38, P138, DOI 10.1128/AAC.38.1.138
NR 58
TC 2
Z9 2
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA
SN 1063-7389
J9 NEW HORIZ-SCI PRACT
JI New Horiz.-Sci. Pract. Acute Med.
PD MAY
PY 1998
VL 6
IS 2
SU S
BP S58
EP S63
PG 6
WC Emergency Medicine
SC Emergency Medicine
GA 122NT
UT WOS:000076078900008
PM 9654313
DA 2018-10-19
ER

PT J
AU Kim, DD
   Takeno, MM
   Ratner, BD
   Horbett, TA
AF Kim, DD
   Takeno, MM
   Ratner, BD
   Horbett, TA
TI Glow discharge plasma deposition (GDPD) technique for the local
   controlled delivery of hirudin from biomaterials
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE local drug delivery; hirudin; glow discharge plasma deposition (GDPD);
   biomaterial; electron spectroscopy for chemical analysis (ESCA)
ID SYSTEMS; RELEASE
AB Purpose, Biomaterials which release locally high concentrations of antithrombotic agents should lessen the thrombogenicity of the materials. To evaluate this approach, we prepared novel polyurethane matrices loaded with hirudin and coated them with 2-hydroxyethyl methacrylate (HEMA) by glow discharge plasma deposition (GDPD) to reduce the release rate.
   Methods. Polyurethane (BioSpan(R)) matrices containing hirudin and pore former (d-mannitol or BSA) were prepared by the solvent casting method. HEMA plasma deposition was then applied using GDPD technique to create a diffusional barrier film on the surface of the matrices. The effect of pore former and HEMA plasma coating on the release of hirudin was systematically investigated. Surface properties of matrices was also studied using Scanning Electron Microscopy (SEM) and Electron Spectroscopy for Chemical Analysis (ESCA).
   Results, The release of hirudin from BioSpan(R) matrix could be controlled by changing the weight fraction and particle size of pore former HEMA plasma treatment of matrices produced a thin, highly crosslinked film on the surface. The initial burst and subsequent release of hirudin was significantly reduced after HEMA plasma coating, which suggested that the plasma disposition acted as a diffusional barrier and limited the release of hirudin incorporated in the polyurethane matrix.
   Conclusions, The plasma coating served as a diffusional barrier, and could work to control the release kinetics of hirudin by changing the various plasma coating conditions. Local delivery of hirudin using these biomaterials at the site of cardiovascular diseases can have the advantage of regional high levels of hirudin, as well as lowering systemic hirudin exposure, thereby minimizing the possibility of side effects.
C1 Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
   Univ Washington, Dept Chem Engn, Seattle, WA 98195 USA.
   Pusan Natl Univ, Coll Pharm, Pusan 609735, South Korea.
RP Horbett, TA (reprint author), Univ Washington, Dept Bioengn, Box 351750, Seattle, WA 98195 USA.
RI Kim, Dae Duk/D-8864-2013
FU NHLBI NIH HHS [HL 51260]
CR ALI MN, 1995, CHEST, V108, P1409, DOI 10.1378/chest.108.5.1409
   FAREED J, 1991, SEMIN THROMB HEMOST, V17, P137, DOI 10.1055/s-2007-1002602
   HAQUE Y, 1986, J APPL POLYM SCI, V32, P4369, DOI 10.1002/app.1986.070320407
   Kim DD, 1996, CARDIOVASC PATHOL, V5, P337, DOI 10.1016/S1054-8807(96)00045-2
   LEVY RJ, 1995, J CONTROL RELEASE, V36, P137, DOI 10.1016/0168-3659(95)00045-A
   LEVY RJ, 1992, TXB INTERVENTIONAL C, P776
   LOPEZ GP, 1992, J BIOMED MATER RES, V26, P415, DOI 10.1002/jbm.820260402
   MARKWARDT F, 1991, HAEMOSTASIS, V21, P11
   Ratner BD, 1990, PLASMA DEPOSITION TR, P463
   RHINE WD, 1980, J PHARM SCI, V69, P265, DOI 10.1002/jps.2600690305
   RIESSEN R, 1994, J AM COLL CARDIOL, V23, P1234, DOI 10.1016/0735-1097(94)90616-5
   SPANNAGL M, 1991, HAEMOSTASIS, V21, P36
   TAKENO MM, 1995, P INT S CONTR REL BI, V22, P147
NR 13
TC 11
Z9 11
U1 0
U2 7
PU PLENUM PUBL CORP
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
J9 PHARMACEUT RES
JI Pharm. Res.
PD MAY
PY 1998
VL 15
IS 5
BP 783
EP 786
PG 4
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA ZN313
UT WOS:000073633400019
PM 9619790
DA 2018-10-19
ER

PT J
AU Lemons, JE
AF Lemons, JE
TI Surface modifications of surgical implants
SO SURFACE & COATINGS TECHNOLOGY
LA English
DT Article; Proceedings Paper
CT 10th International Conference on Surface Modification of Metals by Ion
   Beams (SMMIB 97)
CY SEP 21-26, 1997
CL GATLINBURG, TENNESSEE
SP Oak Ridge Natl Lab, Danfysik, Implant Sci Corp, Spire Corp
DE biomaterials; implants; orthopaedic and dental; surface modification
AB A wide range of metallic alloys has been evaluated for musculoskeletal surgical implant devices. Significant issues relating to the biocompatibility and longevity of synthetic materials include: mechanical strength, surface stability along tissue interfaces and as articulating bearings for joint replacements, and relative cost. Metallic biomaterials have been the materials of choice for most orthopaedic and dental devices in which functional loads are transferred to bone. Multiple techniques have been utilized to alter surface properties to obtain more optimal integration with bone (osteointegration), bonding with polymeric lute fillers for rapid stabilization and functional loading (within hours), and resistance to fretting and wear during articulation. Experience over 25 years of biomaterial and device research and development is considered from a prospective of what has been attempted, what has shown advantages and where we should be heading in the future. (C) 1998 Elsevier Science S.A.
C1 Univ Alabama, Birmingham, AL 35294 USA.
RP Lemons, JE (reprint author), Univ Alabama, 1919 7th Ave S,POB 29,SDB 616, Birmingham, AL 35294 USA.
CR *ASTM, 1997, ASTM PUBL
   CALLAGHAN JJ, 1998, ADULT HIP
   HOCKMAN R, 1988, ION IMPLANTATION PLA
   LEMONS J, 1988, STP ASTM, V953
   Lemons J. E., 1991, JOINT REPLACEMENT AR, P13
   LEMONS JE, 1983, BIOMATERIALS RECONST
   LUDWIGSON DC, 1964, J MET, V16, P1
   MCKINNEY RV, 1991, ENDOSTEAL DENTAL IMP
   MISCH CE, 1991, CONT IMPLANT DENTIST
   Morrey B. F, 1991, JOINT REPLACEMENT AR
   Petty W., 1991, TOTAL JOINT REPLACEM
   Ratner B. D., 1996, BIOMATERIALS SCI INT
   VONRECUUM A, 1986, HDB BIOMATERIALS EVA
   WILLIAMS DF, 1991, CONCISE ENCY MED DEN
   WILLIAMS DF, 1973, IMPLANTS SURG
NR 15
TC 18
Z9 18
U1 0
U2 2
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0257-8972
J9 SURF COAT TECH
JI Surf. Coat. Technol.
PD MAY
PY 1998
VL 104
BP 135
EP 137
PG 3
WC Materials Science, Coatings & Films; Physics, Applied
SC Materials Science; Physics
GA ZZ476
UT WOS:000074733200026
DA 2018-10-19
ER

PT J
AU Zhang, F
   Liu, XH
   Mao, YJ
   Huang, N
   Chen, Y
   Zheng, ZH
   Zhou, ZY
   Chen, AQ
   Jiang, ZB
AF Zhang, F
   Liu, XH
   Mao, YJ
   Huang, N
   Chen, Y
   Zheng, ZH
   Zhou, ZY
   Chen, AQ
   Jiang, ZB
TI Artificial heart valves: improved hemocompatibility by titanium oxide
   coatings prepared by ion beam assisted deposition
SO SURFACE & COATINGS TECHNOLOGY
LA English
DT Article; Proceedings Paper
CT 10th International Conference on Surface Modification of Metals by Ion
   Beams (SMMIB 97)
CY SEP 21-26, 1997
CL GATLINBURG, TENNESSEE
SP Oak Ridge Natl Lab, Danfysik, Implant Sci Corp, Spire Corp
DE biomaterial; titanium oxide; hemocompatibility; in vivo investigation
ID PLATELET-ADHESION; SURFACES
AB Titanium oxide films were prepared by ion beam assisted deposition on an Eaten Z-200 system, in which the deposition of titanium evaporated from an electron beam evaporator and the bombardment with xenon ions at an energy of 40 keV extracted from an are discharge-type ion source proceeded simultaneously in an O-2 environment. X-ray photoelectron spectroscopy (XPS), Rutherford backscattering spectroscopy (RBS) and X-ray diffraction (XRD) were used to characterize the deposited films. It was found that the atomic ratio of O/Ti is about 1.85:1. XPS analysis shows that Ti2+, Ti3+ and Ti4+ chemical states exist on the titanium oxide films. The films deposited are in principle crystalline TiO2 with a rutile structure. The films exhibit a highly (100) orientation and increase the degree of (100) orientation with ion beam current density decreasing. The blood compatibility of titanium oxide films was studied by in vitro and in vivo investigation. In vitro investigation includes clotting time measurement and platelet adhesion. Clotting time measurements show that the clotting time of titanium oxide films is longer than that of low temperature isotropic pyrolytic carbon (LTI-carbon), which is widely used as artificial heart valves in clinics. There are also fewer platelets adhered to and deformed on the titanium oxide films compared to the LTI-carbon. In vivo investigation, implanting LTI-carbon and titanium oxide coated LTI-carbon into the ventral aorta of a dog for two weeks, shows that the amount of thrombus on titanium oxide coated LTI-carbon is only about 1/8 compared to that of LTI-carbon. The relationship between chemical states and blood compatibility was discussed. We think that the existence of Ti2+ and Ti3+ is beneficial for blood compatibility. (C) 1998 Elsevier Science S.A.
C1 Acad Sinica, Shanghai Inst Met, Ion Beam Lab, Shanghai 200050, Peoples R China.
   Zhongshan Hosp, Shanghai Cardiovasc Inst, Shanghai 200032, Peoples R China.
RP Zhang, F (reprint author), Acad Sinica, Shanghai Inst Met, Ion Beam Lab, Shanghai 200050, Peoples R China.
EM xhliu@fudan.ac.cn
CR AMIJI M, 1992, BIOMATERIALS, V13, P682, DOI 10.1016/0142-9612(92)90128-B
   Bauer E., 1964, SINGLE CRYSTAL FILMS, P43
   BAURSCHMIDT P, 1980, MED BIOL ENG COMPUT, V18, P496, DOI 10.1007/BF02443327
   BAURSCHMIDT P, 1977, J BIOENG, V1, P261
   BOLZ A, 1990, ARTIF ORGANS, V14, P260, DOI 10.1111/j.1525-1594.1990.tb02967.x
   BOLZ A, 1990, ARTIF ORGANS, V144, P160
   Dion I., 1993, Bio-Medical Materials and Engineering, V3, P51
   EBERT R, 1982, P WORLD C MED PHYS B
   FRIEDMAN LI, 1970, T AM SOC ART INT ORG, V16, P63
   IMAI Y, 1972, J BIOMED MATER RES, V6, P165, DOI 10.1002/jbm.820060305
   LI JG, 1993, BIOMATERIALS, V14, P229, DOI 10.1016/0142-9612(93)90028-Z
   LYMAN DJ, 1968, T AM SOC ART INT ORG, V14, P250
   Mitamura Y, 1989, J Biomater Appl, V4, P33, DOI 10.1177/088532828900400103
   NYILAS E, 1978, ARTIF ORGANS S, V2, P56
   SIPEHIA R, 1982, BIOMATER ARTIF CELL, V10, P229, DOI 10.3109/10731198209118783
   SLACK S M, 1991, Journal of Biomaterials Science Polymer Edition, V2, P227
   WILLIAMS DF, 1987, BLOOD COMPATIBILITY, V1, P5
   Zhang F, 1997, THIN SOLID FILMS, V310, P29, DOI 10.1016/S0040-6090(97)00338-6
   Zhang F, 1997, J VAC SCI TECHNOL A, V15, P1824, DOI 10.1116/1.580798
NR 19
TC 40
Z9 47
U1 0
U2 1
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0257-8972
J9 SURF COAT TECH
JI Surf. Coat. Technol.
PD MAY
PY 1998
VL 104
BP 146
EP 150
DI 10.1016/S0257-8972(98)00434-4
PG 5
WC Materials Science, Coatings & Films; Physics, Applied
SC Materials Science; Physics
GA ZZ476
UT WOS:000074733200028
DA 2018-10-19
ER

PT J
AU Yu, JL
   Andersson, R
   Ljungh, A
AF Yu, JL
   Andersson, R
   Ljungh, A
TI Binding of immobilized fibronectin by biliary drain isolates
SO ZENTRALBLATT FUR BAKTERIOLOGIE-INTERNATIONAL JOURNAL OF MEDICAL
   MICROBIOLOGY VIROLOGY PARASITOLOGY AND INFECTIOUS DISEASES
LA English
DT Article
ID ESCHERICHIA-COLI; BACTERIAL ADHERENCE; EXTRACELLULAR-MATRIX; COLLAGEN
   BINDING; PROTEINS; ATTACHMENT; RECEPTOR; FIMBRIAE; ENDOPROSTHESES;
   ADHESION
AB Occlusion of biliary stents, as the result of bacterial adhesion and colonization onto biliary stents, still remains a major problem. Biliary proteins, such as fibronectin (Fn) and vitronectin (Vn), have been presumed to be involved in the process of bacterial adhesion to biliary biomaterial. In the present study, Fn binding by 5 strains of E. coli isolated from biliary drains or from bile was studied. All strains did not bind detectable amounts of soluble Fn but bound to immobilized plasma Fn. Adhesion of four strains of E. coli to ovalbumin was reduced by periodate treatment of ovalbumin, but adhesion to Fn was unaffected. Adhesion was inhibited by mannose-containing saccharides, trypsin treatment of the protein, and protease treatment of the bacterial cells. Autoradiography showed that components of cell extracts from three E. coli strains bind I-125-Fn but not a 150kD Fn fragment. The findings indicate that the adhesion of these bacteria to Fn is a protein-protein interaction, inhibited by D-mannose, and possibly mediated by fimbrial components.
C1 Univ Lund, Dept Med Microbiol, S-22362 Lund, Sweden.
   Univ Lund Hosp, Dept Surg, S-22362 Lund, Sweden.
RP Ljungh, A (reprint author), Univ Lund, Dept Med Microbiol, Solvegatan 23, S-22362 Lund, Sweden.
CR AKIYAMA SK, 1987, ADV ENZYMOL RAMB, V59, P1
   Balows A., 1991, MANUAL CLIN MICROBIO
   BEACHEY EH, 1981, J INFECT DIS, V143, P325, DOI 10.1093/infdis/143.3.325
   BRINTON CC, 1965, T NEW YORK ACAD SCI, V27, P1003, DOI 10.1111/j.2164-0947.1965.tb02342.x
   DICKINSON GM, 1989, ANTIMICROB AGENTS CH, V33, P597, DOI 10.1128/AAC.33.5.597
   DOWIDAR N, 1991, SCAND J GASTROENTERO, V26, P1137, DOI 10.3109/00365529108998605
   DOWIDAR N, 1991, SCAND J GASTROENTERO, V26, P1132, DOI 10.3109/00365529108998604
   GIBBONS RJ, 1988, INFECT IMMUN, V56, P439
   HULTGREN SJ, 1991, ANNU REV MICROBIOL, V45, P383, DOI 10.1146/annurev.micro.45.1.383
   JANSEN B, 1993, GASTROINTEST ENDOSC, V39, P670, DOI 10.1016/S0016-5107(93)70220-5
   KALLENIUS G, 1980, FEMS MICROBIOL LETT, V7, P297, DOI 10.1111/j.1574-6941.1980.tb01608.x
   KORHONEN TK, 1984, J BACTERIOL, V159, P762
   KUUSELA P, 1985, INFECT IMMUN, V50, P77
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LATERRA J, 1982, J BIOL CHEM, V257, P719
   LJUNGH A, 1995, METHOD ENZYMOL, V253, P501
   LJUNGH A, 1990, ZBL BAKT-INT J MED M, V274, P126, DOI 10.1016/S0934-8840(11)80982-5
   LOWRANCE JH, 1988, INFECT IMMUN, V56, P2279
   MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2
   MOSHER DF, 1981, J INVEST DERMATOL, V77, P175, DOI 10.1111/1523-1747.ep12479791
   NARASIMHAN C, 1988, BIOCHEMISTRY-US, V27, P4970, DOI 10.1021/bi00414a003
   SALONEN EM, 1985, J BIOL CHEM, V260, P2302
   SALONEN EM, 1989, EMBO J, V8, P4035, DOI 10.1002/j.1460-2075.1989.tb08586.x
   SAVAGE DC, 1985, BACTERIAL ADHESION, P437
   SMIT H, 1984, INFECT IMMUN, V46, P578
   SOKURENKO EV, 1992, INFECT IMMUN, V60, P4709
   SPEER AG, 1988, ANN INTERN MED, V108, P546, DOI 10.7326/0003-4819-108-4-546
   STEWART L, 1986, Surgical Forum (Chicago), V37, P157
   VALKONEN KH, 1993, FEMS IMMUNOL MED MIC, V7, P29, DOI 10.1016/0928-8244(93)90040-B
   WADSTROM T, 1990, PATHOGENESIS WOUND B
   WESTERLUND B, 1993, MOL MICROBIOL, V9, P687, DOI 10.1111/j.1365-2958.1993.tb01729.x
   WESTERLUND B, 1991, MOL MICROBIOL, V5, P2965, DOI 10.1111/j.1365-2958.1991.tb01856.x
   WIERSMA EJ, 1987, FEMS MICROBIOL LETT, V44, P365, DOI 10.1016/0378-1097(87)90349-1
   WILLIAMS EC, 1982, J BIOL CHEM, V257, P4973
   Yamada KM, 1989, FIBRONECTIN, P47
   YU JL, 1995, J SURG RES, V59, P596, DOI 10.1006/jsre.1995.1210
   YU JL, 1994, J MED MICROBIOL, V41, P133, DOI 10.1099/00222615-41-2-133
   Yu JL, 1996, J SURG RES, V62, P69, DOI 10.1006/jsre.1996.0175
   ZARDI L, 1980, J IMMUNOL METHODS, V34, P155, DOI 10.1016/0022-1759(80)90169-6
NR 39
TC 0
Z9 0
U1 0
U2 0
PU GUSTAV FISCHER VERLAG
PI JENA
PA VILLENGANG 2, D-07745 JENA, GERMANY
SN 0934-8840
J9 ZBL BAKT-INT J MED M
JI Zent.bl. Bakteriol.-Int. J. Med. Microbiol. Virol. Parasitol. Infect.
   Dis.
PD MAY
PY 1998
VL 287
IS 4
BP 461
EP 473
PG 13
WC Microbiology; Virology
SC Microbiology; Virology
GA ZQ654
UT WOS:000073889700015
PM 9638875
DA 2018-10-19
ER

PT J
AU Prestwich, GD
   Marecak, DM
   Marecek, JF
   Vercruysse, KP
   Ziebell, MR
AF Prestwich, GD
   Marecak, DM
   Marecek, JF
   Vercruysse, KP
   Ziebell, MR
TI Controlled chemical modification of hyaluronic acid: synthesis,
   applications, and biodegradation of hydrazide derivatives
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article; Proceedings Paper
CT 8th International Symposium on Recent Advances in Drug Delivery Systems
CY FEB 24-27, 1997
CL SALT LAKE CITY, UTAH
SP Univ Utah, Ctr Controlled Chem Delivery, Alza Corp, Becton Dickinson & Co, Chugai Pharm Co Ltd, Emisphere Technol Inc, Labopharm Inc, MacroMed Inc, Meiji Milk Prod Co Ltd, Pacific Corp, Pharmacia Upjohn Inc, Sam Yang Corp, Shiseido, Theratech Inc, 3M Co, Baxter Healthcare Corp, Boston Sci, Cygnus Therapeut Syst, Focal Inc, Genentech Inc, Hisamitsu Pharm Co Inc, Hoffman La Roche Inc, Novartis, Pfizer Inc, Sankyo Co Ltd, Schering Plough Res Inst, Teikoku Seiyaku Co Ltd, DuPont Merck Pharm Co, VivoRx Inc
DE biocompatible hydrogel; biomaterial; polyfunctional crosslinker;
   hyaluronidase; hydrocortisone
ID DRUG-DELIVERY; BIOMATERIALS
AB Controlled modification of the carboxylic acid moieties of hyaluronic acid with mono-and polyfunctional hydrazides leads to biochemical probes, biopolymers with altered physical and chemical properties, tethered drugs for controlled release, and crosslinked hydrogels as biocompatible scaffoldings for tissue engineering. Methods for polyhydrazide synthesis, for prodrug preparation, for hydrogel crosslinking, and for monitoring biodegradation are described. (C) 1998 Elsevier Science B.V.
C1 Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA.
   SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA.
RP Prestwich, GD (reprint author), Univ Utah, Dept Med Chem, 308 Skaggs Hall, Salt Lake City, UT 84112 USA.
CR DROBNIK J, 1991, ADV DRUG DELIVER REV, V7, P295, DOI 10.1016/0169-409X(91)90008-Z
   Entwistle J, 1996, J CELL BIOCHEM, V61, P569, DOI 10.1002/(SICI)1097-4644(19960616)61:4<569::AID-JCB10>3.0.CO;2-B
   FREED LE, 1994, BIO-TECHNOL, V12, P689, DOI 10.1038/nbt0794-689
   Larsen NE, 1995, MATER RES SOC SYMP P, V394, P149, DOI 10.1557/PROC-394-149
   LARSEN NE, 1991, ADV DRUG DELIVER REV, V7, P279, DOI 10.1016/0169-409X(91)90007-Y
   LAURENT TC, 1995, ANN RHEUM DIS, V54, P429, DOI 10.1136/ard.54.5.429
   Moore AR, 1995, INT J TISSUE REACT, V17, P153
   Park K., 1993, BIODEGRADABLE HYDROG, P252
   PEPPAS NA, 1994, SCIENCE, V263, P1715, DOI 10.1126/science.8134835
   POUYANI T, 1994, BIOCONJUGATE CHEM, V5, P339, DOI 10.1021/bc00028a010
   POUYANI T, 1994, J AM CHEM SOC, V116, P7515, DOI 10.1021/ja00096a007
   POUYANI T, 1994, BIOCONJUGATE CHEM, V5, P370, DOI 10.1021/bc00028a015
   POUYANI T, 1997, Patent No. 5616568
   PRESTWICH GD, 1997, CHEM BIOL MED APPL H
   RAJEWSKI LG, 1992, INT J PHARM, V82, P205, DOI 10.1016/0378-5173(92)90176-3
   Scott J. W., 1989, Circular - Agricultural Experiment Station, University of Florida
   Vercruysse KP, 1997, BIOCONJUGATE CHEM, V8, P686, DOI 10.1021/bc9701095
NR 17
TC 257
Z9 266
U1 3
U2 79
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
J9 J CONTROL RELEASE
JI J. Control. Release
PD APR 30
PY 1998
VL 53
IS 1-3
BP 93
EP 103
DI 10.1016/S0168-3659(97)00242-3
PG 11
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA ZM279
UT WOS:000073522600011
PM 9741917
DA 2018-10-19
ER

PT J
AU Cetta, F
   Oggiani, M
   Rappuoli, R
   Montalto, G
   Zuckermann, M
   Magnani, A
   Gori, M
   Baldi, C
   Valensin, PE
   Barbucci, R
AF Cetta, F
   Oggiani, M
   Rappuoli, R
   Montalto, G
   Zuckermann, M
   Magnani, A
   Gori, M
   Baldi, C
   Valensin, PE
   Barbucci, R
TI A new biomaterial more resistent to infection to be used to manufacture
   biliary endoprostheses.
SO GASTROENTEROLOGY
LA English
DT Meeting Abstract
C1 Univ Siena, Inst Surg Clin, I-53100 Siena, Italy.
   Univ Genoa, Inst Surg Anat, Genoa, Italy.
RI Magnani, Agnese/E-7999-2017
CR Cetta F, 1997, AM J GASTROENTEROL, V92, P542
   CETTA FM, 1986, HEPATOLOGY, V6, P482, DOI 10.1002/hep.1840060327
NR 2
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD APR 15
PY 1998
VL 114
IS 4
SU S
MA G2106
BP A517
EP A517
PN 2
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA ZH263
UT WOS:000073089602095
DA 2018-10-19
ER

PT J
AU Yamamoto, A
   Mishima, S
   Maruyama, N
   Sumita, M
AF Yamamoto, A
   Mishima, S
   Maruyama, N
   Sumita, M
TI A new technique for direct measurement of the shear force necessary to
   detach a cell from a material
SO BIOMATERIALS
LA English
DT Article
DE biomaterial; cell adhesion; detachment shear strength; murine
   fibroblast; microcantilever
ID ADHESION
AB Affinity for cells is one of the important properties for biomaterials, because they are always used adjacent to living tissue. For the development of new biomaterials with superior biocompatibility, quantitative evaluation of the materials' affinity for cells is necessary. One of the methods to evaluate the materials' affinity for cells quantitatively is to measure the detachment force of an adherent cell on a material.
   In this study, a new system was developed to measure directly the shear force necessary to detach a cell from a material. Using a microcantilever, the detachment force was measured in the cell culture medium by applying a lateral load to the cell which adhered to the material. During the measurement, the cell was observed using an optical microscope and the image of the cell was recorded on a video tape through a CCD camera. The cell adhesive area before detaching the cell was measured by analyzing the obtained video image of the cell.
   Reproducibility of the measurement was demonstrated by repeating the measurement of the shear forces to detach murine fibroblasts 1,929 incubated for 24 h on glass. The average shear strength, which is a detachment force per unit cell adhesive area, is 530-750 Pa, varying with the day of cell preparation. However, the shear strengths of the cells seeded at the same time into separate dishes are corresponding well to each other. This fact suggests that it is possible to compare the materials' affinity for cells using this system if the cells were seeded at the same time onto different materials. (C) 1998 Published by Elsevier Science Ltd. All rights reserved.
C1 Natl Res Inst Met Sci & Technol Agcy, Ibaraki, Osaka 3050047, Japan.
   Olympus Opt Co, Tokyo 1920047, Japan.
RP Yamamoto, A (reprint author), Natl Res Inst Met Sci & Technol Agcy, 1-2-1 Sengen, Ibaraki, Osaka 3050047, Japan.
CR ENDO K, 1995, MAT JAPAN, V34, P1166
   FRANCIS GW, 1987, J CELL SCI, V87, P519
   Garcia AJ, 1997, BIOMATERIALS, V18, P1091, DOI 10.1016/S0142-9612(97)00042-2
   HORBETT TA, 1988, J BIOMED MATER RES, V22, P383, DOI 10.1002/jbm.820220503
   II I, 1985, BIOINDUSTRY, V2, P981
   IKADA Y, 1994, BIOMATERIALS, V15, P725, DOI 10.1016/0142-9612(94)90025-6
   KATAOKA N, 1996, P 74 JSME FALL ANN M, P117
   KOKITA K, 1993, J JPN SOC DENTAL MAT, V12, P242
   LOTZ MM, 1989, J CELL BIOL, V109, P1795, DOI 10.1083/jcb.109.4.1795
   Otto M, 1997, J MATER SCI-MATER M, V8, P119, DOI 10.1023/A:1018515001850
   OWENS NF, 1987, J CELL SCI, V87, P667
   REUTELINGSPERGER CPM, 1994, J MATER SCI-MATER M, V5, P361, DOI 10.1007/BF00058964
   Rezania A, 1997, J BIOMED MATER RES, V37, P9, DOI 10.1002/(SICI)1097-4636(199710)37:1<9::AID-JBM2>3.0.CO;2-W
   Skarja GA, 1997, J BIOMED MATER RES, V34, P427, DOI 10.1002/(SICI)1097-4636(19970315)34:4<427::AID-JBM4>3.3.CO;2-R
   USHIDA T, 1990, CLIN IMPLANT MAT, V9, P231
   VOGLER EA, 1987, J BIOMED MATER RES, V21, P1197, DOI 10.1002/jbm.820211004
   WEISS L, 1961, EXP CELL RES, V25, P504, DOI 10.1016/0014-4827(61)90186-0
   YOKOYAMA M, 1988, J JPN SOC BIOMATER, V6, P29
NR 18
TC 73
Z9 73
U1 1
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD APR-MAY
PY 1998
VL 19
IS 7-9
BP 871
EP 879
DI 10.1016/S0142-9612(97)00248-2
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA ZT484
UT WOS:000074092500033
PM 9663764
DA 2018-10-19
ER

PT J
AU Seah, KHW
   Thampuran, R
   Teoh, SH
AF Seah, KHW
   Thampuran, R
   Teoh, SH
TI The influence of pore morphology on corrosion
SO CORROSION SCIENCE
LA English
DT Article
DE titanium; cyclic polarisation; porous implants; passivation
ID OXIDE-FILMS; TITANIUM; BEHAVIOR
AB Porous titanium parts fabricated powder-metallurgically are known to have pore morphologies that range from large, open, interconnected pores to small, isolated pores. Although the latter geometry is synonymous with highly dense and mechanically strong materials, it conceivably encourages stagnation of electrolyte and prevents its free flow crucial to the ion incorporation/titanium release process of passivation. In this case, the depletion of oxygen leads to crevice corrosion which further increases the corrosion rate of these large-surface-area systems. To investigate the localised corrosion resistance of porous titanium (porosity 10-30%, pore size 50-100 mu m), cyclic polarisation tests were performed in saline solution at 37 degrees C, on porous purl titanium compacts with varying porosities and pore sizes, solid titanium and 316L stainless steel. As expected, 316L stainless steel exhibited poor corrosion resistance compared to titanium. A distinct hysteresis was observed in the reverse scan of the former which indicates the weak resistance to crevice and pitting corrosion of this well-established metallic biomaterial. The main reason for the excellent corrosion resistance of the solid and porous titanium compacts is the strong affinity of the metal to even a slight trace of oxygen in an aqueous environment, resulting in a highly resistant and self-regenerating passive film. However, the cyclic polarisation studies also showed that the final E-corr value reduces with decreasing porosity. This is due to the small, isolated pore morphology that traps ionic species and exhausts the supply of oxygen. In highly porous compacts with an open, interconnected pore morphology, the free flow of species resulted in a material with much higher resistance to pitting. (C) 1998 Published by Elsevier Science Ltd. All rights reserved.
C1 Natl Univ Singapore, Dept Mech & Prod Engn, Inst Mat Res & Engn, Singapore 119260, Singapore.
RP Seah, KHW (reprint author), Natl Univ Singapore, Dept Mech & Prod Engn, Inst Mat Res & Engn, 10 Kent Ridge Crescent, Singapore 119260, Singapore.
CR BARBOIAN R, 1981, ASTM STP, V727, P274
   DUCHEYNE P, 1991, BONE-BIOMATERIAL INTERFACE, P62
   DUCHEYNE P, 1981, ASTM STP, V796, P7
   EDWARDS BJ, 1987, STP, V953, P115
   EKTESSABI AM, 1994, SURF COAT TECH, V68, P208, DOI 10.1016/0257-8972(94)90162-7
   GERMAN RM, POWDER METALLURGICAL
   Haddow DB, 1996, BIOMATERIALS, V17, P501, DOI 10.1016/0142-9612(96)82724-4
   HEALY KE, 1992, J BIOMED MATER RES, V26, P319, DOI 10.1002/jbm.820260305
   HOAR TP, 1966, PROC R SOC LON SER-A, V294, P486, DOI 10.1098/rspa.1966.0220
   ISHIZAWA H, 1995, J BIOMED MATER RES, V29, P967
   LAING PATRICK G., 1967, J BIOMED MAT RES, V1, P135, DOI 10.1002/jbm.820010113
   LAUSMAA J, 1990, APPL SURF SCI, V45, P189, DOI 10.1016/0169-4332(90)90002-H
   LI P, 1992, J BIOMED MATER RES, V27, P1495
   Mausli P., 1988, IMPLANT MAT BIOFUNCT
   MEACHIM G, 1973, J BIOMED MATER RES, V7, P555, DOI 10.1002/jbm.820070607
   OSBORN JF, 1990, ADV BIOMAT, V9, P75
   Pan J., 1996, THESIS ROYAL I TECHN
   SEAH KHW, 1995, CORROS SCI, V37, P1333, DOI 10.1016/0010-938X(95)00033-G
   SLOTER LE, 1979, ASTM STP, V684, P258
   Solar RJ, 1979, ASTM STP, P259
   STEINEMANN SG, 1984, COROSION TITANIUM TI, V2, P1373
   TEOH SH, 1992, BIOMATERIALS, V14, P407
   THAMPURAN R, 1996, THESIS NATL U SINGAP
   WILLIAMS DF, 1974, J BIOMED MATER RES, V8, P1, DOI 10.1002/jbm.820080303
   ZITTER H, 1987, J BIOMED MATER RES, V21, P881, DOI 10.1002/jbm.820210705
NR 25
TC 100
Z9 102
U1 1
U2 28
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0010-938X
J9 CORROS SCI
JI Corrosion Sci.
PD APR-MAY
PY 1998
VL 40
IS 4-5
BP 547
EP 556
DI 10.1016/S0010-938X(97)00152-2
PG 10
WC Materials Science, Multidisciplinary; Metallurgy & Metallurgical
   Engineering
SC Materials Science; Metallurgy & Metallurgical Engineering
GA ZX304
UT WOS:000074502000002
DA 2018-10-19
ER

PT J
AU Omura, S
   Mizuki, N
   Kawabe, R
   Ota, S
   Kobayashi, S
   Fujita, K
AF Omura, S
   Mizuki, N
   Kawabe, R
   Ota, S
   Kobayashi, S
   Fujita, K
TI A carrier for clinical use of recombinant human BMP-2: dehydrothermally
   cross-linked composite of fibrillar and denatured atelocollagen sponge
SO INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
LA English
DT Article
DE bone morphogenetic protein; carrier; atelocollagen; intramembranous
   ossification; endochondral ossification
ID FIBROUS COLLAGEN; BONE-FORMATION; LOCALIZATION; BIOMATERIAL
AB The clinical applicability of a dehydrothermally cross-linked composite of fibrillar and denatured atelocollagen sponge (DCFD-AS), as a carrier of recombinant human bone morphogenetic protein-2 (rhBMP-2) was evaluated in the rat subcutaneous pouch. After four weeks, DCFD-AS with rhBMP-2 formed compact bone, without undergoing significant changes in shape and size, by means of intramembranous ossification. The ultimate size, shape and location of induced new bone was accurately controlled by the carrier. Low antigenicity of soluble atelocollagen, cross-linking without chemicals, the combination of gelatin with fibrillar collagen, and the spongy structure probably all contributed to new bone formation through intramembranous ossification without inducing an inflammatory response. Atelocollagen sponge is easily sterilized, can be stored at room temperature, and can act as a rhBMP-2 carrier without the need for complex procedures.
C1 Yokohama City Univ, Sch Med, Dept Oral & Maxillofacial Surg, Knazawa Ku, Yokohama, Kanagawa 236, Japan.
RP Omura, S (reprint author), Yokohama City Univ, Sch Med, Dept Oral & Maxillofacial Surg, Knazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 236, Japan.
EM sos3728@med.yokohama-cu.ac.jp
CR GAO TJ, 1993, ANN CHIR GYNAECOL, V82, P77
   GERHART TN, 1993, CLIN ORTHOP RELAT R, P317
   HAHN GV, 1992, GENOMICS, V14, P759, DOI 10.1016/S0888-7543(05)80181-8
   HEY KB, 1990, BIOTECHNOL APPL BIOC, V12, P85
   JOHNSON EE, 1988, CLIN ORTHOP RELAT R, P257
   JOHNSON EE, 1990, CLIN ORTHOP RELAT R, P234
   KOIDE M, 1993, J BIOMED MATER RES, V27, P79, DOI 10.1002/jbm.820270111
   Lindholm T S, 1993, Ann Chir Gynaecol Suppl, V207, P3
   MIYATA T, 1992, Clinical Materials, V9, P139, DOI 10.1016/0267-6605(92)90093-9
   MOORE JC, 1990, INT J ORAL MAX SURG, V19, P172, DOI 10.1016/S0901-5027(05)80139-0
   NISHIKAWA A, 1987, EXP CELL RES, V171, P164, DOI 10.1016/0014-4827(87)90259-X
   Omura S, 1997, BRIT J ORAL MAX SURG, V35, P85, DOI 10.1016/S0266-4356(97)90681-1
   SAILER HF, 1994, J CRANIO MAXILL SURG, V22, P2, DOI 10.1016/S1010-5182(05)80289-6
   SHIGENOBU K, 1993, ANN CHIR GYNAECOL, V82, P85
   TORIUMI DM, 1991, ARCH OTOLARYNGOL, V117, P1101
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   WANG EA, 1988, P NATL ACAD SCI USA, V85, P9484, DOI 10.1073/pnas.85.24.9484
   WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   YASKO AW, 1992, J BONE JOINT SURG AM, V74A, P659, DOI 10.2106/00004623-199274050-00005
NR 20
TC 27
Z9 35
U1 0
U2 0
PU MUNKSGAARD INT PUBL LTD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 0901-5027
J9 INT J ORAL MAX SURG
JI Int. J. Oral Maxillofac. Surg.
PD APR
PY 1998
VL 27
IS 2
BP 129
EP 134
DI 10.1016/S0901-5027(98)80312-3
PG 6
WC Dentistry, Oral Surgery & Medicine; Surgery
SC Dentistry, Oral Surgery & Medicine; Surgery
GA ZE193
UT WOS:000072767400012
PM 9565272
DA 2018-10-19
ER

PT J
AU Rad, AY
   Ayhan, H
   Piskin, E
AF Rad, AY
   Ayhan, H
   Piskin, E
TI Adhesion of different bacterial strains to low-temperature plasma
   treated biomedical silicon catheter surfaces
SO JOURNAL OF BIOACTIVE AND COMPATIBLE POLYMERS
LA English
DT Article
ID COAGULASE-NEGATIVE STAPHYLOCOCCI; INTRAVASCULAR CATHETERS; ADHERENCE;
   HYDROPHOBICITY; INVITRO; EPIDERMIDIS; BIOMATERIAL; PREVENTION; INFECTION
AB In this study, two different strains of five different bacteria were isolated and characterized. Contact angles were measured by a captive-bubble technique. Surface free energies were calculated from the contact angles and hydrophobicities were evaluated by p-xylene adhesion. The zeta potentials and surface charges of the bacteria were measured. The contact angles of the gram positive bacteria and gram negative bacteria were in the range of 48-69 degrees and 43.5-55 degrees, respectively. While corresponding surface free energies were in the limits of 45.4-51.6 erg . cm(-2) and 51.7-61.8 erg . cm(-2), respectively. The p-xylene adhesions were parallel to hydrophobicity defined by contact angles, and 32.2-80.3% and 2.3-36.6% for the gram positive bacteria and gram negative bacteria, respectively. The zeta potentials for these bacteria were from -650.2 to +17.5 mV and from -159.6 to -6.0 mV; respectively. Most of the bacteria were negatively charged, except the CNS-2 and CPS-1 strains. In the second part of the study, the attachment of these bacteria to Si(R) catheters and to DMAEMA and AAc plasma treated Si(R) catheters were investigated. The hydrophobic bacteria attached best to the hydrophobic Si(R) catheter. Both plasma treatments caused significant drops in bacterial attachment in most cases. The effects of AAc plasma treatment were more pronounced.
C1 Hacettepe Univ, Dept Chem Engn, Div Bioengn, TR-06532 Ankara, Turkey.
   Tubitak Ctr Excellence, Polymer Biomat, Ankara, Turkey.
   Bayindir Hosp, Med Ctr, Ankara, Turkey.
RP Piskin, E (reprint author), Hacettepe Univ, Dept Chem Engn, Div Bioengn, PK 716, TR-06532 Ankara, Turkey.
CR ABSOLOM DR, 1983, APPL ENVIRON MICROB, V46, P90
   ANDRADE JD, 1979, J POLYM SCI POL SYM, P313
   ASHKENAZI S, 1984, PEDIATR RES, V18, P1361, DOI 10.1203/00006450-198412000-00029
   BAILEY J, 1990, DIAGNOSTIC MICROBIOL, pA37
   CHU CC, 1984, AM J SURG, V147, P197, DOI 10.1016/0002-9610(84)90088-6
   FATTOM A, 1984, APPL ENVIRON MICROB, V47, P135
   FRANSON TR, 1986, J CLIN MICROBIOL, V24, P559
   GOLOMB G, 1991, J BIOMED MATER RES, V25, P937, DOI 10.1002/jbm.820250803
   GORDON AS, 1984, APPL ENVIRON MICROB, V47, P495
   HARKES G, 1991, BIOMATERIALS, V12, P853, DOI 10.1016/0142-9612(91)90074-K
   HOGT AH, 1986, J BIOMED MATER RES, V20, P533, DOI 10.1002/jbm.820200409
   HOGT AH, 1985, J GEN MICROBIOL, V131, P2485
   HOGT H, 1986, INFECT IMMUN, P294
   JAMES AM, 1979, SURF COLLOID SCI, V11, P174
   JANSEN B, 1990, ADV BIOMAT, V9, P117
   JOHNSON JR, 1990, J INFECT DIS, V162, P1145, DOI 10.1093/infdis/162.5.1145
   LOPEZLOPEZ G, 1991, J MED MICROBIOL, V34, P349, DOI 10.1099/00222615-34-6-349
   MINAGI S, 1985, INFECT IMMUN, V47, P11
   MINAGI S, 1986, J GEN MICROBIOL, V132, P1111
   MOZES N, 1987, J MICROBIOL METH, V6, P99, DOI 10.1016/0167-7012(87)90058-3
   NEUMANN AQ, 1904, J COLLOID INTERF SCI, V49, P291
   PASCUAL A, 1986, EUR J CLIN MICROBIOL, V5, P518, DOI 10.1007/BF02017694
   Perry R.H., 1985, PERRYS CHEM ENG HDB, P3
   RAD AY, 1997, THESIS U HACETTEPE A
   ROSENBERG M, 1980, FEMS MICROBIOL LETT, V9, P29, DOI 10.1111/j.1574-6968.1980.tb05599.x
   SAMUEL RF, 1990, CAN J MICROBIOL, V37, P445
   SENNETT P, 1965, Patent No. 3208919
   SHETH NK, 1983, J SURG RES, V34, P213, DOI 10.1016/0022-4804(83)90062-8
   SINGHAL JP, 1991, BIOMAT ARTIF CELL IM, V19, P631, DOI 10.3109/10731199109117841
   STENSTROM TA, 1989, APPL ENVIRON MICROB, V55, P142
   SUGARMAN B, 1982, UROL RES, V10, P37
   VANDERMEI HC, 1987, J MICROBIOL METH, V6, P277, DOI 10.1016/0167-7012(87)90065-0
   VANDERMEI HC, 1988, J BACTERIOL, V170, P246
   VANETTA LL, 1982, J INFECT DIS, V146, P423, DOI 10.1093/infdis/146.3.423
   VANLOOSDERCHT MCM, 1987, APPL ENVIRON MICROB, V55, P1898
   VANLOOSDRECHT MCM, 1987, APPL ENVIRON MICROB, V53, P1898
   Veenstra GJC, 1996, J BACTERIOL, V178, P537, DOI 10.1128/jb.178.2.537-541.1996
   WADSTROM T, 1987, ZBL BAKT-INT J MED M, V266, P191
   WEERKAMP AH, 1988, J DENT RES, V67, P1483, DOI 10.1177/00220345880670120801
NR 39
TC 4
Z9 4
U1 0
U2 4
PU TECHNOMIC PUBL CO INC
PI LANCASTER
PA 851 NEW HOLLAND AVE, BOX 3535, LANCASTER, PA 17604 USA
SN 0883-9115
J9 J BIOACT COMPAT POL
JI J. Bioact. Compat. Polym.
PD APR
PY 1998
VL 13
IS 2
BP 81
EP 101
DI 10.1177/088391159801300201
PG 21
WC Biotechnology & Applied Microbiology; Materials Science, Biomaterials;
   Polymer Science
SC Biotechnology & Applied Microbiology; Materials Science; Polymer Science
GA ZM474
UT WOS:000073543800001
DA 2018-10-19
ER

PT J
AU Pereira, MC
   Pereira, ML
   Sousa, JP
AF Pereira, MC
   Pereira, ML
   Sousa, JP
TI Evaluation of nickel toxicity on liver, spleen, and kidney of mice after
   administration of high-dose metal ion
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE nickel; biomaterial; mice; microelectrodes; histology
ID STEEL CORROSION PRODUCTS; ACCUMULATION; ALLOYS
AB The toxic effects caused by nickel (Ni) per si were explored by performing in vivo studies on mice following subcutaneous administration of a metallic solution of nickel at 1, 2, 3, and 4 weeks to evaluate the side effects of this metal ion when released from stainless steel implants. Other groups were similarly injected with HBSS and used as controls. Accumulation of Ni ions on liver, spleen, and kidney was assessed by an electrochemical method, adsorptive stripping voltammetry (AdSV) using microelectrodes, and atomic absorption spectrometry (AAS). Alterations of those organs induced by Ni ions were studied, showing that several histological changes had been induced. Chemical analysis and histological features indicate that Ni is partially accumulated in the study organs. (C) 1998 John Wiley & Sons, Inc.
C1 Univ Porto, Fac Engn, INEB Inst Engn, P-4050 Porto, Portugal.
   FEUP, Dept Engn Quim, P-4099 Porto, Portugal.
   Univ Aveiro, Dept Biol, P-3810 Aveiro, Portugal.
RP Sousa, JP (reprint author), Univ Porto, Fac Engn, INEB Inst Engn, Praca Coronel Pacheco 1, P-4050 Porto, Portugal.
RI Pereira, Maria/S-6624-2016
OI Pereira, Maria/0000-0001-8505-3432; Pereira, Maria de
   Lourdes/0000-0001-6703-7869; Sousa, Joao/0000-0002-8269-9390
CR Abreu A. M., 1995, Biomedical Letters, V52, P133
   Black J, 1988, ORTHOPEDIC BIOMATERI
   Black J, 1981, BIOMEDICAL ENG INSTR, P180
   BUMGARDNER JD, 1993, DENT MATER, V9, P252, DOI 10.1016/0109-5641(93)90070-7
   BUMGARDNER JD, 1994, COMPATIBILITY BIOMED, P241
   CIGADA A, 1994, COMPATIBILITY BIOMED, P185
   *EPA, 1986, EPA600883012FF
   JACKS JJ, 1991, J BONE JOINT SURG AM, V73, P1475
   MULLER AWJ, 1990, DENT MATER, V6, P63, DOI 10.1016/0109-5641(90)90048-J
   NIEBOER E, 1980, NICKEL TOXICOLOGY, P359
   PANIGUTTI MA, 1992, T SOC BIOMATERIALS, V15, P7
   Pereira M. L., 1995, Biomedical Letters, V52, P235
   PEREIRA MC, 1996, ELECTROANAL, V9, P1
   POHLER OEM, 1983, BIOMATERIALS RECONST, P197
   Ross M, 1989, HISTOLOGY TEXT ATLAS
   STULBERG BN, 1994, J APPL BIOMATER, V5, P9, DOI 10.1002/jab.770050103
   TRACANA RB, 1994, J MATER SCI-MATER M, V5, P596, DOI 10.1007/BF00120337
   TRACANA RB, 1995, J MATER SCI-MATER M, V6, P56, DOI 10.1007/BF00121249
   WILLIAMS D, 1990, ENCY MED DENT MAT
   WILLIAMS DF, 1981, SYSTEMIC ASPECTS BIO, V2
   WILLIAMS DF, 1981, SYSTEMIC ASPECTS BIO, V1
NR 21
TC 40
Z9 40
U1 2
U2 8
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD APR
PY 1998
VL 40
IS 1
BP 40
EP 47
DI 10.1002/(SICI)1097-4636(199804)40:1<40::AID-JBM5>3.0.CO;2-R
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA YY687
UT WOS:000072173600005
PM 9511097
DA 2018-10-19
ER

PT J
AU Guicheux, J
   Kimakhe, S
   Heymann, D
   Pilet, P
   Daculsi, G
AF Guicheux, J
   Kimakhe, S
   Heymann, D
   Pilet, P
   Daculsi, G
TI Growth hormone stimulates the degradation of calcium phosphate
   biomaterial by human monocytes macrophages in vitro
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE growth hormone; biphasic calcium phosphate; monocyte;
   lipopolysaccharides; cell degradation
ID DELIVERY SYSTEM; IMMUNE-RESPONSE; SOMATOMEDIN-C; CELLS; RECEPTORS;
   LIPOPOLYSACCHARIDES; DIFFERENTIATION; BIODEGRADATION; MODULATION;
   INFECTION
AB This study investigated the effects of human growth hormone (hGH) on the monocyte/macrophage lineage, the first cell population involved in degradation of calcium phosphate ceramic after in vivo implantation. Monocytes isolated from human blood were cultured on biphasic calcium pellets (200 mg) for 8 days in the presence of lipopolysaccharides (LPS, 0.5 mu g/mL), hGH (10 and 50 ng/mL), or an association of LPS with hGH (10 and 50 ng/mL). Unlike LPS, hGH significantly decreased (about 25%) the total number of lacunae formed by monocytes. However, hGH induced the formation of lacunae with a greater surface area (about a 90% increase) as compared to the control. Finally, intense upmodulation (about a 250% increase) of lacuna surface area was observed in the presence of both soluble factors, suggesting that hGH and LPS act synergistically. In view of the development of a drug delivery system for hGH bone release, this study shows that hGH not only stimulates bone cells implicated in the synthesis of the extracellular matrix but also those involved in the early degradation of calcium phosphate biomaterial. (C) 1998 John Wiley & Sons, Inc.
C1 Fac Chirurg Dent, UPRES EA 2159, Lab Rech Mat Interet Biol, F-44042 Nantes 01, France.
RP Guicheux, J (reprint author), Fac Chirurg Dent, UPRES EA 2159, Lab Rech Mat Interet Biol, 1 Pl Alexis Ricordeau,BP 84215, F-44042 Nantes 01, France.
RI Daculsi, Guy/P-1320-2014; Paul, Pilet/A-3755-2015; guicheux,
   Jerome/F-7767-2013
OI Daculsi, Guy/0000-0003-1030-3446; guicheux, Jerome/0000-0003-2754-3024
CR AGARWAL S, 1995, J PERIODONTAL RES, V30, P382, DOI 10.1111/j.1600-0765.1995.tb01291.x
   BAJPAI PK, 1988, J BIOMED MATER RES, V22, P1245, DOI 10.1002/jbm.820221212
   BARNARD R, 1991, ENDOCRINOLOGY, V128, P1459, DOI 10.1210/endo-128-3-1459
   Benahmed M, 1996, BIOMATERIALS, V17, P2173, DOI 10.1016/0142-9612(96)00046-4
   Benahmed M, 1997, J BIOMED MATER RES, V34, P115, DOI 10.1002/(SICI)1097-4636(199701)34:1<115::AID-JBM15>3.0.CO;2-J
   BENAHMED M, 1994, BIOMATERIALS, V15, P25, DOI 10.1016/0142-9612(94)90191-0
   Benahmed MD, 1996, J HISTOCHEM CYTOCHEM, V44, P1131, DOI 10.1177/44.10.8813078
   BLOTTIERE HM, 1995, BIOMATERIALS, V16, P497, DOI 10.1016/0142-9612(95)98824-X
   DACULSI G, 1990, J BIOMED MATER RES, V24, P379, DOI 10.1002/jbm.820240309
   Daculsi G., 1992, BIOMATER TISSUE INT, V10, P296
   de Groot K, 1983, BIOCERAMICS CALCIUM
   DENISSEN H, 1994, BONE MINER, V25, P123, DOI 10.1016/S0169-6009(08)80254-1
   DOWNES S, 1991, J MATER SCI-MATER M, V2, P176, DOI 10.1007/BF00692977
   DOWNES S, 1992, BONE BONDING, P101
   EDWARDS CK, 1992, INFECT IMMUN, V60, P2514
   EDWARDS CK, 1988, SCIENCE, V239, P769, DOI 10.1126/science.2829357
   GALA RR, 1991, P SOC EXP BIOL MED, V198, P513
   Guicheux J, 1997, J BIOMED MATER RES, V34, P165, DOI 10.1002/(SICI)1097-4636(199702)34:2<165::AID-JBM4>3.0.CO;2-O
   Guicheux J, 1997, J BIOMED MATER RES, V36, P258, DOI 10.1002/(SICI)1097-4636(199708)36:2<258::AID-JBM15>3.0.CO;2-C
   INOUE T, 1994, CLIN NUTR S, V12, pS16
   ISAKSSON OGP, 1982, SCIENCE, V216, P1237, DOI 10.1126/science.7079756
   JAFARI P, 1990, IMMUNOL LETT, V24, P199, DOI 10.1016/0165-2478(90)90048-U
   JARCHO M, 1981, CLIN ORTHOP RELAT R, P259
   KASSEM M, 1993, CALCIFIED TISSUE INT, V52, P222, DOI 10.1007/BF00298723
   KELLEY KW, 1990, ANN NY ACAD SCI, V594, P95
   KIESS W, 1985, J CLIN ENDOCR METAB, V60, P740, DOI 10.1210/jcem-60-4-740
   Legeros Racquel Z., 1993, Clinical Materials, V14, P65, DOI 10.1016/0267-6605(93)90049-D
   LINDEMANN RA, 1989, ARCH ORAL BIOL, V34, P459, DOI 10.1016/0003-9969(89)90125-8
   LINDEMANN RA, 1988, J DENT RES, V67, P1131, DOI 10.1177/00220345880670081401
   MERCHAV S, 1988, J CLIN INVEST, V81, P791, DOI 10.1172/JCI113385
   NGUYEN TH, 1994, P INT S CONTR REL BI, V21, P122
   Nishiyama K, 1996, ENDOCRINOLOGY, V137, P35, DOI 10.1210/en.137.1.35
   OTSUKA M, 1994, J PHARM SCI, V83, P611, DOI 10.1002/jps.2600830502
   PASSUTI N, 1989, CLIN ORTHOP RELAT R, V248, P12
   RUSSELL SM, 1985, ENDOCRINOLOGY, V116, P2563, DOI 10.1210/endo-116-6-2563
   Saito H, 1996, HORM RES, V45, P50, DOI 10.1159/000184759
   SHINTO Y, 1992, J BONE JOINT SURG BR, V74, P600
   WARWICKDAVIES J, 1995, J IMMUNOL, V154, P1909
   WEI GX, 1991, J BONE JOINT SURG BR, V73, P246
NR 39
TC 9
Z9 9
U1 0
U2 1
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD APR
PY 1998
VL 40
IS 1
BP 79
EP 85
DI 10.1002/(SICI)1097-4636(199804)40:1<79::AID-JBM9>3.0.CO;2-O
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA YY687
UT WOS:000072173600009
PM 9511101
DA 2018-10-19
ER

PT J
AU Guicheux, J
   Gauthier, O
   Aguado, E
   Pilet, P
   Couillaud, S
   Jegou, D
   Daculsi, G
   Heymann, D
AF Guicheux, J
   Gauthier, O
   Aguado, E
   Pilet, P
   Couillaud, S
   Jegou, D
   Daculsi, G
   Heymann, D
TI Human growth hormone locally released in bone sites by calcium-phosphate
   biomaterial stimulates ceramic bone substitution without systemic
   effects: A rabbit study
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
ID HUMAN MONOCYTES; FACTOR-I; HYDROXYAPATITE; SOMATOMEDIN; INSULIN; CELLS;
   DIFFERENTIATION; MACROPHAGES; ACTIVATION; RECEPTORS
AB Calcium-phosphate bone replacement biomaterial has been used as a drug carrier for therapeutic agents, This study investigated the efficacy of local administration of human growth hormone (hGH) by macroporous biphasic calcium phosphate (MBCP) implants in improving the bone substitution qualities of ceramics. hGH release from MBCP implants loaded with 1 mu g of hGH was rapid during the first 48 h and then sustained for a total of 9 days, Immunolocalization of hGH in vitro and in vivo by transmission electron microscopy showed its presence inside the material, indicating that it was able to penetrate within the porosity of the ceramic during the adsorption process. MBCP cylinders (6 x 6 mm) were loaded with 0.1, 1, and 10 mu g of hGH and implanted into rabbit femurs (n = 40). The effects of locally released hGH on bone ingrowth and ceramic resorption were evaluated by scanning electron microscopy and image analysis, The results indicated that hGH increased bone ingrowth (+65%) and ceramic resorption (+140%) significantly in comparison with control implants and that the increase was dose dependent, Biochemical parameters monitored in rabbit plasma and urine, as well as the absence of any significant difference between contralateral implants and the control, indicated that hGH did not produce detectable systemic effects, Thus, the use of MBCP appears to be effective for local delivery of hGH, resulting in improved bone substitution.
C1 Fac Chirurg Dent, UPRES 2159, Lab Rech Mat Interet Biol, F-44042 Nantes 01, France.
   Ecole Natl Vet, Nantes, France.
RP Guicheux, J (reprint author), Fac Chirurg Dent, UPRES 2159, Lab Rech Mat Interet Biol, 1 Pl Alexis Ricordeau,BP 84215, F-44042 Nantes 01, France.
RI Paul, Pilet/A-3755-2015; BATTAGLIA, Severine/K-8715-2015; Gauthier,
   Olivier/A-4639-2015; Daculsi, Guy/P-1320-2014; guicheux,
   Jerome/F-7767-2013
OI Daculsi, Guy/0000-0003-1030-3446; guicheux, Jerome/0000-0003-2754-3024
CR Arm DM, 1996, BIOMATERIALS, V17, P703, DOI 10.1016/0142-9612(96)86740-8
   Auernhammer CJ, 1995, EUR J ENDOCRINOL, V133, P635, DOI 10.1530/eje.0.1330635
   BAJPAI PK, 1988, J BIOMED MATER RES, V22, P1245, DOI 10.1002/jbm.820221212
   BARNARD R, 1991, ENDOCRINOLOGY, V128, P1459, DOI 10.1210/endo-128-3-1459
   BRIXEN K, 1995, J BONE MINER RES, V10, P1865
   DACULSI G, 1990, BIOMATERIALS, V11, P86
   DACULSI G, 1988, J SUBMICR CYTOL PATH, V20, P379
   DACULSI G, 1990, J BIOMED MATER RES, V24, P379, DOI 10.1002/jbm.820240309
   Denissen H, 1997, J BONE MINER RES, V12, P290, DOI 10.1359/jbmr.1997.12.2.290
   DENISSEN H, 1994, BONE MINER, V25, P123, DOI 10.1016/S0169-6009(08)80254-1
   DOWNES S, 1991, J MATER SCI-MATER M, V2, P176, DOI 10.1007/BF00692977
   DOWNES S, 1995, J BIOMED MATER RES, V29, P1053, DOI 10.1002/jbm.820290905
   EDWARDS CK, 1988, SCIENCE, V239, P769, DOI 10.1126/science.2829357
   Gouin F, 1996, J BONE JOINT SURG BR, V78B, P38
   GREEN H, 1985, DIFFERENTIATION, V29, P195, DOI 10.1111/j.1432-0436.1985.tb00316.x
   Guicheux J, 1997, J BIOMED MATER RES, V34, P165, DOI 10.1002/(SICI)1097-4636(199702)34:2<165::AID-JBM4>3.0.CO;2-O
   Guicheux J, 1997, J BIOMED MATER RES, V36, P258, DOI 10.1002/(SICI)1097-4636(199708)36:2<258::AID-JBM15>3.0.CO;2-C
   Guicheux J, 1998, BONE, V22, P25, DOI 10.1016/S8756-3282(97)00224-X
   GUICHEUX J, 1998, IN PRESS J BIOMED MA
   HEDNER E, 1997, J BONE MINER RES, V12, P1952
   HIGUCHI T, 1963, J PHARM SCI, V52, P1145, DOI 10.1002/jps.2600521210
   Hollinger J O, 1990, J Craniofac Surg, V1, P60, DOI 10.1097/00001665-199001000-00011
   Hollinger JO, 1996, CLIN ORTHOP RELAT R, P55
   Hou P, 1997, J BONE MINER RES, V12, P534, DOI 10.1359/jbmr.1997.12.4.534
   ISAKSSON OGP, 1982, SCIENCE, V216, P1237, DOI 10.1126/science.7079756
   ISAKSSON OGP, 1987, ENDOCR REV, V8, P426, DOI 10.1210/edrv-8-4-426
   JARCHO M, 1981, CLIN ORTHOP RELAT R, P259
   KASSEM M, 1994, J BONE MINER RES, V9, P1365
   KASSEM M, 1993, CALCIFIED TISSUE INT, V52, P222, DOI 10.1007/BF00298723
   Kelley KW, 1996, HORM RES, V45, P38, DOI 10.1159/000184757
   KELLEY KW, 1989, BIOCHEM PHARMACOL, V38, P705, DOI 10.1016/0006-2952(89)90222-0
   KELLEY KW, 1990, ANN NY ACAD SCI, V594, P95
   KENLEY RA, 1993, PHARMACEUT RES, V10, P1393, DOI 10.1023/A:1018902720816
   KIESS W, 1985, J CLIN ENDOCR METAB, V60, P740, DOI 10.1210/jcem-60-4-740
   KORKUSUZ F, 1993, J BONE JOINT SURG BR, V75, P111
   KUHNE JH, 1994, ACTA ORTHOP SCAND, V65, P246, DOI 10.3109/17453679408995448
   LeGeros R Z, 1988, Ann N Y Acad Sci, V523, P268, DOI 10.1111/j.1749-6632.1988.tb38519.x
   Legeros Racquel Z., 1993, Clinical Materials, V14, P65, DOI 10.1016/0267-6605(93)90049-D
   Lind M, 1996, J ORTHOPAED RES, V14, P343, DOI 10.1002/jor.1100140303
   MOCHIZUKI H, 1992, ENDOCRINOLOGY, V131, P1075, DOI 10.1210/en.131.3.1075
   Nishiyama K, 1996, ENDOCRINOLOGY, V137, P35, DOI 10.1210/en.137.1.35
   OTSUKA M, 1994, J PHARM SCI, V83, P255, DOI 10.1002/jps.2600830229
   PASSUTI N, 1989, CLIN ORTHOP RELAT R, P169
   Russell RGG, 1997, HORM METAB RES, V29, P138, DOI 10.1055/s-2007-979007
   RUSSELL SM, 1985, ENDOCRINOLOGY, V116, P2563, DOI 10.1210/endo-116-6-2563
   Saggese G, 1995, HORM RES, V44, P55, DOI 10.1159/000184675
   SALOMON F, 1989, NEW ENGL J MED, V321, P1797, DOI 10.1056/NEJM198912283212605
   SCHLECHTER NL, 1986, P NATL ACAD SCI USA, V83, P7932, DOI 10.1073/pnas.83.20.7932
   SLOOTWEG MC, 1993, HORM METAB RES, V25, P335, DOI 10.1055/s-2007-1002115
   STRACKE H, 1984, ACTA ENDOCRINOL-COP, V107, P16, DOI 10.1530/acta.0.1070016
   UCHIDA A, 1990, J BONE JOINT SURG BR, V72, P298
   UCHIDA A, 1992, J ORTHOPAED RES, V10, P440, DOI 10.1002/jor.1100100317
   URIST MR, 1984, CLIN ORTHOP RELAT R, P277
   URIST MR, 1987, CLIN ORTHOP RELAT R, P295
   WARWICKDAVIES J, 1995, J IMMUNOL, V154, P1909
   WARWICKDAVIES J, 1995, INFECT IMMUN, V63, P4312
   Yamada S, 1997, BIOMATERIALS, V18, P1037, DOI 10.1016/S0142-9612(97)00036-7
   YAMAMURA K, 1992, J BIOMED MATER RES, V26, P1053, DOI 10.1002/jbm.820260807
NR 58
TC 45
Z9 47
U1 0
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0884-0431
EI 1523-4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD APR
PY 1998
VL 13
IS 4
BP 739
EP 748
DI 10.1359/jbmr.1998.13.4.739
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA ZE554
UT WOS:000072805200022
PM 9556073
OA Bronze
DA 2018-10-19
ER

PT J
AU Bouwmeester, SJM
   Kuijer, R
   Sollie-Drees, MMWE
   Van der Linden, AJ
   Bulstra, SK
AF Bouwmeester, SJM
   Kuijer, R
   Sollie-Drees, MMWE
   Van der Linden, AJ
   Bulstra, SK
TI Quantitative histological analysis of bony ingrowth within the
   biomaterial Polyactive (TM) implanted in different bone locations: an
   experimental study in rabbits
SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE
LA English
DT Article
ID POROUS HYDROXYAPATITE; GRAFT SUBSTITUTES
AB The quantity of bone formed in cylinders of a newly developed erodible copolymer, Polyactive(TM) (PA60/40) was examined. PA60/40 was implanted in three different bone locations in the rabbit: in the cortex, in bone marrow and in trabecular subchondral bone. Bony ingrowth was assessed after 4, 8, 26 and 52 w after the operation and investigated by histology and image analysis. The ingrowth of bone was observed in PA60/40 placed in the cortex from 4 w onwards. After 8 w, more than 90% of the pores of the biomaterial were filled with dense bone. In bone marrow, initially some bone formation was seen. After 26 w, all newly formed bone was resorbed. Subchondral bone formation was less than in the cortex of the femur, but somewhat comparable to the amount of bone found in healthy trabecular bone. Bone formation appeared not to be affected by the degradation of the biomaterial. It was concluded that Polyactive(TM) is a suitable bone graft substitute. Bone formation within PA60/40 is site-dependent and this follows Wolff's law. (C) 1998 Chapman & Hall.
C1 Univ Hosp Maastricht, Maastricht Ctr Biomat Res, Dept Orthopaed Surg, NL-6202 AZ Maastricht, Netherlands.
RP Bouwmeester, SJM (reprint author), Univ Hosp Maastricht, Maastricht Ctr Biomat Res, Dept Orthopaed Surg, POB 5800, NL-6202 AZ Maastricht, Netherlands.
RI Kuijer, Roel/A-6690-2015
OI Kuijer, Roel/0000-0002-7637-4944
CR BAKKER D, 1990, ADV BIOMAT, V9, P99
   BAKKER D, 1993, SEN I GAKKAI S PREPR, pA33
   BUCHOLZ RW, 1987, ORTHOP CLIN N AM, V18, P323
   Ducheyne P., 1992, BONE BONDING BIOMATE, P13
   DUPOIRIEUX L, 1994, INT J ORAL MAX SURG, V23, P395, DOI 10.1016/S0901-5027(05)80028-1
   FRIEDLAENDER GE, 1987, CLIN ORTHOP RELAT R, P17
   FROST HM, 1983, CLIN ORTHOP RELAT R, P286
   GEESINK RGT, 1992, BONE BONDING BIOMATE, P121
   GOLDBERG VM, 1987, CLIN ORTHOP RELAT R, V225, P7
   GRUNDEL RE, 1991, CLIN ORTHOP RELAT R, V266, P244
   HOLMES RE, 1987, J ORTHOPAED RES, V5, P114, DOI 10.1002/jor.1100050114
   HUISKES R, 1987, J BIOMECH, V20, P1135, DOI 10.1016/0021-9290(87)90030-3
   HUISKES R, 1984, CALCIFIED TISSUE INT, V36, pS110, DOI 10.1007/BF02406143
   MARTIN RB, 1993, BIOMATERIALS, V14, P341, DOI 10.1016/0142-9612(93)90052-4
   MULLENDER MG, 1995, J ORTHOPAED RES, V13, P503, DOI 10.1002/jor.1100130405
   MULLERMAI C, 1991, BIOMATERIALS, V12, P865, DOI 10.1016/0142-9612(91)90076-M
   OKUMURA M, 1992, BONE BONDING BIOMATE, P189
   PREDECKI P, 1972, J BIOMED MATER RES, V6, P375, DOI 10.1002/jbm.820060506
   RADDER AM, 1994, THESIS LEIDEN
   RUBIN CT, 1984, J BONE JOINT SURG AM, V66A, P397, DOI 10.2106/00004623-198466030-00012
   SAUREN YMH, 1991, THESIS LEIDEN
   VANBERKEL WJH, 1991, CHEM BIOCH FLAVOENZY, V2, P1
   VANBLITTERSWIJK CA, 1991, BONE-BIOMATERIAL INTERFACE, P295
   VANBLITTERSWIJK CA, 1993, CELL MATER, V3, P23
   VANBLITTERSWIJK CA, 1985, BIOMATERIALS, V6, P243, DOI 10.1016/0142-9612(85)90020-1
   VANBLITTERSWIJK CA, 1986, BIOMATERIALS, V7, P137, DOI 10.1016/0142-9612(86)90071-2
   Wolff J., 1892, GESETZ TRANSFORMATIO
   Yamamuro T, 1994, Nihon Seikeigeka Gakkai Zasshi, V68, P505
   ZDEBLICK TA, 1994, SPINE, V19, P2348, DOI 10.1097/00007632-199410150-00017
NR 29
TC 7
Z9 7
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957-4530
EI 1573-4838
J9 J MATER SCI-MATER M
JI J. Mater. Sci.-Mater. Med.
PD APR
PY 1998
VL 9
IS 4
BP 181
EP 185
DI 10.1023/A:1008875821298
PG 5
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA ZA652
UT WOS:000072387500001
PM 15348889
DA 2018-10-19
ER

PT J
AU Nonami, T
   Kamiya, A
   Naganuma, K
   Kameyama, T
AF Nonami, T
   Kamiya, A
   Naganuma, K
   Kameyama, T
TI Separation of hydroxyapatite-granule-implanted superplastic
   titanium-alloy
SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE
LA English
DT Article
AB In order to obtain a biomaterial that has both biological affinity and high mechanical strength, hydroxyapatite (HAp) granules were implanted into the surface of superplastic titanium-alloy. HAp granules (32-38 mu m diameter) were spread over a superplastic titanium-alloy substrate and pressed to implant the granules into the substrate. This was achieved at 17 MPa, 750 degrees C for 10 min. Only the tops of the granules, which were surrounded by the alloy, remained exposed and they were firmly stuck in the substrate. The granules were enclosed in titanium-alloy and a reaction layer was formed at their interface. The HAp-implanted titanium-alloy composites are expected to be useful as biomaterials, such as artificial bones and dental roots. (C) 1998 Chapman & Hall.
C1 Natl Ind Res Inst Nagoya, Kita Ku, Nagoya, Aichi 462, Japan.
RP Nonami, T (reprint author), Natl Ind Res Inst Nagoya, Kita Ku, Hirate Cho 1-1, Nagoya, Aichi 462, Japan.
CR HANAWA T, 1993, J ELECTRON SPECTROSC, V63, P347, DOI 10.1016/0368-2048(93)80032-H
   KAMIYA A, 1996, REP NIRIN, V45, P251
   KATO K, 1980, B CERAM SOC JPN, V15, P418
   MARUNO S, 1992, NIPPON SERAM KYO GAK, V100, P362
   OHGAKI M, 1993, CHEM IND, V44, P693
   OUCHI C, 1992, NKK GIHOU, V138, P17
   TORIYAMA M, 1991, NIPPON SERAM KYO GAK, V99, P1268
NR 7
TC 14
Z9 15
U1 0
U2 3
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0957-4530
J9 J MATER SCI-MATER M
JI J. Mater. Sci.-Mater. Med.
PD APR
PY 1998
VL 9
IS 4
BP 203
EP 206
DI 10.1023/A:1008884023115
PG 4
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA ZA652
UT WOS:000072387500005
PM 15348893
DA 2018-10-19
ER

PT J
AU Maas, CS
   Eriksson, T
   McCalmont, T
   Mabry, M
   Cooke, D
   Schindler, R
AF Maas, CS
   Eriksson, T
   McCalmont, T
   Mabry, M
   Cooke, D
   Schindler, R
TI Evaluation of expanded polytetrafluoroethylene as a soft-tissue filling
   substance: An analysis of design-related implant behavior using the
   porcine skin model
SO PLASTIC AND RECONSTRUCTIVE SURGERY
LA English
DT Article
ID ABDOMINAL-WALL DEFECTS; GORE-TEX IMPLANTS; PERMANENT FILLER;
   AUGMENTATION; PTFE; EXPERIENCE; WRINKLES; ENHANCER; REPAIR
AB Soft-tissue augmentation using the synthetic nonfluid biomaterial expanded polytetrafluoroethylene (ePTFE) has been supported by number of recent reports citing the favorable characteristics of biocompatibility, soft and natural feel, ease of use, and permanent augmentation. Concern has been expressed about this application for ePTFE material because of the proximity of the implants to the skin surface and potential problems with infection and extrusion. We evaluated the behavior of a series of specific ePTFE implant designs using a long-term subcutaneous augmentation model. By using a porcine model, 466 implants of ePTFE in the form of strips, rolls, or tubes were placed using a percutaneous insertion device subcutaneously over the dorsum and face. Thp animals were divided into three study groups by length of implantation (3 weeks, control; 6 months, intermediate term; and 12 months, long-term) and en-bloc tissue specimens, including skin, implants, and underlying soft tissue, were harvested for gross and histologic examination. Implants were removed at the earliest sign of infection, exposure, or extrusion and the difficulty of removal was ascertained and recorded.
   These data reveal that ePTFE material elicits acceptable levels of tissue activity with low extrusion rates over the short and long term supporting its use for soft-tissue augmentation. The data show a clear difference, however: in the lost response and behavior of the implants fbr this application based on shape or-design. A statistically significant difference in the low, but measurable, extrusion rates was observed amongst these implant designs. ePTFE tubes showed greater stability and predictable augmentation over other implant designs for soft-tissue augmentation and seem to represent a substantial improvement for this application.
C1 Univ Calif San Francisco, Div Facial Plast Surg, Dept Otolaryngol, San Francisco, CA 94143 USA.
RP Maas, CS (reprint author), Univ Calif San Francisco, Div Facial Plast Surg, Dept Otolaryngol, 400 Parnassus Ave,Suite A717, San Francisco, CA 94143 USA.
CR ARTZ JS, 1994, ANN PLAS SURG, V32, P457, DOI 10.1097/00000637-199405000-00003
   BAUER JJ, 1987, ANN SURG, V206, P765, DOI 10.1097/00000658-198712000-00013
   CISNEROS JL, 1993, J DERMATOL SURG ONC, V19, P539, DOI 10.1111/j.1524-4725.1993.tb00387.x
   CONRAD K, 1992, J OTOLARYNGOL, V21, P218
   DANIEL RK, 1995, PLAST RECONSTR SURG, V95, P1336, DOI 10.1097/00006534-199506000-00046
   DANIEL RK, 1994, PLAST RECONSTR SURG, V94, P228
   ELLIS DAF, 1995, LARYNGOSCOPE, V105, P207, DOI 10.1288/00005537-199502000-00019
   FLORIAN A, 1976, ARCH SURG-CHICAGO, V111, P267
   JENKINS SD, 1983, SURGERY, V94, P392
   Lassus C, 1996, PLAST RECONSTR SURG, V97, P491, DOI 10.1097/00006534-199602000-00049
   LASSUS C, 1991, AESTHET PLAST SURG, V15, P167, DOI 10.1007/BF02273851
   LAVKER RM, 1991, AM J PATHOL, V138, P687
   MAAS CS, 1993, ARCH OTOLARYNGOL, V119, P1008
   MCAULEY CE, 1984, ANN SURG, V199, P57, DOI 10.1097/00000658-198401000-00010
   MOLE B, 1992, PLAST RECONSTR SURG, V90, P200, DOI 10.1097/00006534-199290020-00007
   NEEL HB, 1983, ARCH OTOLARYNGOL, V109, P427
   OWSLEY TG, 1994, PLAST RECONSTR SURG, V94, P241, DOI 10.1097/00006534-199408000-00003
   PANEPINTO LM, 1986, LAB ANIM SCI, V36, P344
   ROTHSTEIN S G, 1989, Ear Nose and Throat Journal, V68, P40
   Schoenrock LD, 1994, FACIAL PLAST SURG CL, V2, P373
   SOYER T, 1972, SURGERY, V72, P864
   Swindle M M, 1988, J Invest Surg, V1, P65, DOI 10.3109/08941938809141077
   TUMBLESON M, 1986, SWINE BIOMEDICAL RES
   VECCHIONE TR, 1994, ANN PLAS SURG, V33, P460, DOI 10.1097/00000637-199410000-00019
   WALDMAN SR, 1991, ANN PLAS SURG, V26, P520, DOI 10.1097/00000637-199106000-00005
   WOLF DL, 1995, PLAST RECONSTR SURG, V95, P1334, DOI 10.1097/00006534-199506000-00043
NR 26
TC 33
Z9 33
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA
SN 0032-1052
J9 PLAST RECONSTR SURG
JI Plast. Reconstr. Surg.
PD APR
PY 1998
VL 101
IS 5
BP 1307
EP 1314
DI 10.1097/00006534-199804050-00023
PG 8
WC Surgery
SC Surgery
GA ZD643
UT WOS:000072707500023
PM 9529217
DA 2018-10-19
ER

PT J
AU He, JA
   Samuelson, L
   Li, L
   Kumar, J
   Tripathy, SK
AF He, JA
   Samuelson, L
   Li, L
   Kumar, J
   Tripathy, SK
TI Oriented bacteriorhodopsin/polycation multilayers by electrostatic
   layer-by-layer assembly
SO LANGMUIR
LA English
DT Article
ID LANGMUIR-BLODGETT-FILMS; PURPLE MEMBRANE; ARTIFICIAL PHOTORECEPTOR;
   SUCCESSIVE DEPOSITION; ULTRATHIN MULTILAYER; ALTERNATE LAYERS; PROTEIN;
   ADSORPTION; ORIENTATION; POLYELECTROLYTES
AB The purple membrane (PM) containing bacteriorhodopsin (BR) is a promising biomaterial for many potential optical and optoelectronic device applications. Organized, heterogeneous assemblies using polycationic poly(dimethyldiallylammonium chloride) (PDAC) and PM fragments have been successfully constructed by the spontaneous alternating adsorption of PDAC and PM. The fabrication process of the multilayers was followed by UV-vis absorption spectroscopy and ellipsometry. The results indicate that the deposition process is linear and highly reproducible from layer to layer and that a monomolecular film of PM may be obtained in each PDAC/PM bilayer by controlling the adsorption time. Second harmonic generation measurements from the composite films gave a second-order susceptibility chi((2)) of 8.1 X 10(-9) esu and confirm that the PM fragments are arrayed with a high degree of orientation and acentric polar order in the films. Atomic force microscopy images provided the surface morphology of sequential layers of PDAC and PM fragments. Relative PDAC/PM bilayer thicknesses of 55 Angstrom were observed, and the homogeneity of the layers was found to improve as the number of layers increased.
C1 Univ Lowell, Dept Chem, Ctr Adv Mat, Lowell, MA 01854 USA.
   Univ Lowell, Dept Phys, Ctr Adv Mat, Lowell, MA 01854 USA.
   USA, Natick Res Dev & Engn Ctr, Sci & Technol Directorate, Natick, MA 01760 USA.
   Mol Technol Inc, Westford, MA 01886 USA.
RP Tripathy, SK (reprint author), Univ Lowell, Dept Chem, Ctr Adv Mat, Lowell, MA 01854 USA.
CR Ariga K, 1997, J AM CHEM SOC, V119, P2224, DOI 10.1021/ja963442c
   BALASUBRAMANIAN S, UNPUB CHEM MAT
   Baty AM, 1996, J COLLOID INTERF SCI, V177, P307, DOI 10.1006/jcis.1996.0036
   BIRGE RR, 1990, ANNU REV PHYS CHEM, V41, P683, DOI 10.1146/annurev.pc.41.100190.003343
   BIRGE RR, 1994, AM SCI, V82, P348
   BOUEVITCH O, 1995, OPT COMMUN, V116, P170, DOI 10.1016/0030-4018(95)00030-C
   BRIZZOLARA RA, 1995, BIOSYSTEMS, V35, P137, DOI 10.1016/0303-2647(94)01501-W
   Caruso F, 1997, LANGMUIR, V13, P3427, DOI 10.1021/la9608223
   Chen X, 1997, LANGMUIR, V13, P4106, DOI 10.1021/la970172i
   CHEN ZP, 1993, TRENDS BIOTECHNOL, V11, P292, DOI 10.1016/0167-7799(93)90017-4
   DECHER G, 1992, THIN SOLID FILMS, V210, P831, DOI 10.1016/0040-6090(92)90417-A
   Decher G, 1997, SCIENCE, V277, P1232, DOI 10.1126/science.277.5330.1232
   FERREIRA M, 1994, THIN SOLID FILMS, V244, P806, DOI 10.1016/0040-6090(94)90575-4
   FISHER KA, 1978, J CELL BIOL, V77, P611, DOI 10.1083/jcb.77.2.611
   HILDEBRANDT P, 1984, BIOCHEMISTRY-US, V23, P5539, DOI 10.1021/bi00318a025
   HUANG JY, 1989, BIOPHYS J, V55, P835, DOI 10.1016/S0006-3495(89)82883-8
   HUANG JY, 1989, J PHYS CHEM-US, V93, P3314, DOI 10.1021/j100345a086
   HWANG SB, 1978, BIOCHIM BIOPHYS ACTA, V509, P300, DOI 10.1016/0005-2736(78)90049-4
   HWANG SB, 1977, J MEMBRANE BIOL, V36, P115, DOI 10.1007/BF01868147
   IKONEN M, 1992, THIN SOLID FILMS, V213, P277, DOI 10.1016/0040-6090(92)90294-L
   KESZTHELYI L, 1980, BIOCHIM BIOPHYS ACTA, V598, P429, DOI 10.1016/0005-2736(80)90023-1
   KORENBROT JI, 1982, METHOD ENZYMOL, V88, P45
   KOYAMA K, 1994, SCIENCE, V265, P762, DOI 10.1126/science.265.5173.762
   KOYAMA K, 1995, ADV MATER, V7, P590, DOI 10.1002/adma.19950070620
   LI DQ, 1990, J AM CHEM SOC, V112, P7389, DOI 10.1021/ja00176a045
   LVOV Y, 1993, MACROMOLECULES, V26, P5396, DOI 10.1021/ma00072a016
   LVOV Y, 1995, J AM CHEM SOC, V117, P6117, DOI 10.1021/ja00127a026
   Lvov Y, 1996, LANGMUIR, V12, P3038, DOI 10.1021/la951002d
   LVOV Y, 1994, LANGMUIR, V10, P4232, DOI 10.1021/la00023a052
   Lvov Y, 1996, THIN SOLID FILMS, V284, P797, DOI 10.1016/S0040-6090(95)08449-5
   MIYASAKA T, 1992, SCIENCE, V255, P342, DOI 10.1126/science.255.5042.342
   MIYASAKA T, 1992, THIN SOLID FILMS, V210, P146, DOI 10.1016/0040-6090(92)90193-F
   MIYASAKA T, 1993, APPL OPTICS, V32, P6371, DOI 10.1364/AO.32.006371
   Muthukumar M, 1997, SCIENCE, V277, P1225, DOI 10.1126/science.277.5330.1225
   NIEMI HEM, 1993, LANGMUIR, V9, P2436, DOI 10.1021/la00033a029
   OESTERHELT D, 1971, NATURE-NEW BIOL, V233, P149, DOI 10.1038/newbio233149a0
   Oesterhelt D, 1974, Methods Enzymol, V31, P667
   OESTERHELT D, 1989, NATURE, V338, P16
   Onda M, 1996, BIOTECHNOL BIOENG, V51, P163, DOI 10.1002/(SICI)1097-0290(19960720)51:2<163::AID-BIT5>3.0.CO;2-H
   SHEN Y, 1993, NATURE, V366, P48, DOI 10.1038/366048a0
   Sun YP, 1997, LANGMUIR, V13, P5168, DOI 10.1021/la9703510
   TAKEI H, 1991, APPL OPTICS, V30, P500, DOI 10.1364/AO.30.000500
   TRIPATHY SK, IN RPESS JPN J APPL
   Wang XG, 1997, MACROMOL RAPID COMM, V18, P451, DOI 10.1002/marc.1997.030180601
   WOLPERDINGER M, 1995, BIOPHYS CHEM, V56, P189, DOI 10.1016/0301-4622(95)00032-S
NR 45
TC 130
Z9 132
U1 1
U2 16
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD MAR 31
PY 1998
VL 14
IS 7
BP 1674
EP 1679
DI 10.1021/la971336y
PG 6
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
SC Chemistry; Materials Science
GA ZF614
UT WOS:000072914700027
DA 2018-10-19
ER

PT J
AU Pishko, M
   Amirpour, M
AF Pishko, M
   Amirpour, M
TI Influence of biomaterial topography on neo-vascularization of
   surrounding tissue
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 Texas A&M Univ, Dept Chem Engn, College Stn, TX 77843 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD MAR 20
PY 1998
VL 12
IS 5
SU S
MA 4250
BP A733
EP A733
PN 2
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 121HD
UT WOS:000076006500636
DA 2018-10-19
ER

PT J
AU San Martin, AC
   Paez, JMG
   Sestafe, JVG
   Herrero, EJ
   Salvador, J
   Cordon, A
   Castillo-Olivares, JL
AF San Martin, AC
   Paez, JMG
   Sestafe, JVG
   Herrero, EJ
   Salvador, J
   Cordon, A
   Castillo-Olivares, JL
TI Selection and interaction of biomaterials used in the construction of
   cardiac bioprostheses
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE biomaterials; bioprostheses; suture; pericardium; heart valves
ID HEART-VALVE BIOPROSTHESES; BOVINE PERICARDIUM; BEHAVIOR; FAILURE; TISSUE
AB The mechanical behavior of calf pericardium employed in the manufacture of cardiac bioprostheses was assessed according to the region from which it was selected. For this purpose, selected samples of the tissue were sewn with different types of commercially available sutures and subjected to tensile testing, the results of which were compared with the findings in selected, but not sutured, tissue used as a control. The results confirm a loss of resistance-that is, a reduction of the capacity of sutured samples of the biomaterial to withstand and breakage stress compared with control samples. Taking into account the marked resistance to breakage of the suture thread, this phenomenon can only be explained as a consequence of the deleterious mechanical interaction between the suture and chemically treated pericardium. This interaction is illustrated by the shearing force which is responsible for the loss of resistance in the tested samples. These trials demonstrate that the results can be improved and the deleterious interaction diminished, although not eliminated, when the pericardium is selected from a given region. (C) 1998 John Wiley & Sons, Inc.
C1 Clin Puerta Hierro, Serv Cirugia Expt, Madrid 28035, Spain.
   Inst Nacl Estad, Madrid, Spain.
   Escuela Super Tecn Ingn Ind, Dept Mecan Estruct, Madrid, Spain.
RP Paez, JMG (reprint author), Clin Puerta Hierro, Serv Cirugia Expt, San Martin Porres 4, Madrid 28035, Spain.
CR BORTOLOTTI U, 1987, J THORAC CARDIOV SUR, V94, P200
   CLARK R E, 1971, Surgical Forum (Chicago), V22, P134
   DHATT GS, 1970, AIAA J, V2, P2100
   GABBAY S, 1988, J THORAC CARDIOV SUR, V95, P208
   GONZALEZ CLL, 1983, REV ESP CARDIOL, V36, P309
   Gould P. L., 1973, Computers and Structures, V3, P377, DOI 10.1016/0045-7949(73)90024-2
   HILBERT SL, 1992, AM J PATHOL, V140, P1195
   JORGEHERRERO E, 1991, BIOMATERIALS, V12, P249, DOI 10.1016/0142-9612(91)90208-R
   PAEZ JMG, 1990, J THORAC CARDIOV SUR, V100, P580
   Paez JMG, 1996, J BIOMED MATER RES, V30, P47
   PAEZ JMG, 1994, BIOMATERIALS, V15, P170
   PURINYA B, 1994, J BIOMECH, V27, P1, DOI 10.1016/0021-9290(94)90027-2
   SANMARTIN AC, 1993, BIOMATERIALS, V14, P76
   SCHOEN FJ, 1987, CIRCULATION, V76, P618, DOI 10.1161/01.CIR.76.3.618
   TIMOSSHENKO S, 1970, RESISTENCIA MAT, P55
   TROWBRIDGE EA, 1988, J THORAC CARDIOV SUR, V95, P577
   WALLEY VM, 1987, J THORAC CARDIOV SUR, V93, P925
   ZIOUPOS P, 1994, BIOMATERIALS, V15, P366, DOI 10.1016/0142-9612(94)90249-6
NR 18
TC 3
Z9 3
U1 0
U2 3
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD MAR 15
PY 1998
VL 39
IS 4
BP 568
EP 574
DI 10.1002/(SICI)1097-4636(19980315)39:4<568::AID-JBM10>3.0.CO;2-3
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA YV340
UT WOS:000071813400010
DA 2018-10-19
ER

PT J
AU Saad, B
   Ciardelli, G
   Matter, S
   Welti, M
   Uhlschmid, GK
   Neuenschwander, P
   Suter, UW
AF Saad, B
   Ciardelli, G
   Matter, S
   Welti, M
   Uhlschmid, GK
   Neuenschwander, P
   Suter, UW
TI Degradable and highly porous polyesterurethane foam as biomaterial:
   Effects and phagocytosis of degradation products in osteoblasts
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE polyesterurethane; degradation; phagocytosis; osteoblasts
ID CHAIN POLY<(R)-3-HYDROXYBUTYRIC ACID>; CULTURED MACROPHAGES; POLYMER
   SURFACES; CELL RESPONSE; FIBROBLASTS; PARTICLES; BONE; HEPATOCYTES; LINE
AB Recently, a new class of biodegradable PHB-based polyesterurethane (DegraPol/btc(R)) has been prepared and found to exhibit favorable cell and tissue compatibility. The present study has been designed to evaluate the response of primary isolated rat tibia osteoblasts to small crystalline particles of short-chain poly[(R)-3-hydroxybutyric acid] (PHB-P diameter: 2-20 mu m), of fluorescent-labeled analogs (DPHP-P), and of lysine methyl ester as possible degradation products of DegraPol/btc(R). Observations made using confocal microscopy clearly indicate that osteoblasts have the capability of taking up PHB-P particles. Although in single-cell analysis the number of DPHB-P positive osteoblasts gradually increased up to 16 days, the fluorescence intensity per osteoblast increased only during the first 4 h after DPHB-P incubation, and then it retained the 4 h level up to 16 days. No significant change in the production levels of collagen type I and osteocalcin was detectable after treatment with low concentrations of PHB-P for up to 32 days. In contrast, a time- and dose-dependent alteration of the alkaline phosphatase (ALP) activity was found. Maximal activity was measured after 4 days of treatment with 2 mu g of PHB-P/mL (170% of control cells). Rat peritoneal macrophages co-cultured with osteoblasts in a transwell culture system mimicked the observed PHB-P induced ALP elevation. Therefore, the PHB-P-induced ALP increase could be the result of direct or indirect stimulation of osteoblasts, possibly via soluble factors produced by contaminating osteoclasts. Taken collectively, the data demonstrate that osteoblasts are capable of phagocytosing PHB-P and that this process is accompanied at low PHB-P concentrations by dose- and time-dependent alteration of alkaline phosphatase activity but not of collagen type I or osteocalcin. (C) 1998 John Wiley & Sons, Inc.
C1 ETH Zentrum CNB E 93, Inst Polymers, Dept Mat, CH-8092 Zurich, Switzerland.
   Univ Zurich Hosp, Dept Surg, Div Res, CH-8091 Zurich, Switzerland.
RP Suter, UW (reprint author), ETH Zentrum CNB E 93, Inst Polymers, Dept Mat, Univ Str6, CH-8092 Zurich, Switzerland.
RI Suter, Ulrich/H-8900-2013
OI Suter, Ulrich/0000-0001-7467-7346; Ciardelli,
   Gianluca/0000-0003-0199-1427; Saad, Bashar/0000-0003-4052-2279
CR BOWERS VM, 1989, J BIOMED MATER RES, V23, P1453, DOI 10.1002/jbm.820231208
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Ciardelli G, 1995, J MATER SCI-MATER M, V6, P725, DOI 10.1007/BF00134308
   ESPEVIK T, 1986, J IMMUNOL METHODS, V95, P99, DOI 10.1016/0022-1759(86)90322-4
   Hirt TD, 1996, MACROMOL CHEM PHYS, V197, P4253, DOI 10.1002/macp.1996.021971221
   LIU SQ, 1992, J BIOMED MATER RES, V26, P1489, DOI 10.1002/jbm.820261108
   LOWRY OH, 1954, J BIOL CHEM, V207, P19
   LYDON MJ, 1985, BIOMATERIALS, V6, P396, DOI 10.1016/0142-9612(85)90100-0
   MANKIN HJ, 1987, ORTHOP CLIN N AM, V18, P275
   MARINKOVICH MP, 1986, J CELL PHYSIOL, V128, P61, DOI 10.1002/jcp.1041280111
   OLMO N, 1988, J BIOMED MATER RES, V22, P257, DOI 10.1002/jbm.820220402
   PARRISH FF, 1972, CLIN ORTHOP RELAT R, P36
   REICH S, 1984, EXP CELL RES, V153, P556, DOI 10.1016/0014-4827(84)90625-6
   Saad B, 1996, J BIOMED MATER RES, V32, P355
   SAAD B, 1993, EUR J BIOCHEM, V213, P805, DOI 10.1111/j.1432-1033.1993.tb17823.x
   Saad B, 1997, J BIOMED MATER RES, V36, P65, DOI 10.1002/(SICI)1097-4636(199707)36:1<65::AID-JBM8>3.3.CO;2-#
   Saad B, 1996, J MATER SCI-MATER M, V7, P56, DOI 10.1007/BF00121191
   Saad B, 1996, J BIOMED MATER RES, V30, P429, DOI 10.1002/(SICI)1097-4636(199604)30:4<429::AID-JBM1>3.3.CO;2-D
   SAAD B, 1995, LANGENBECKS ARCH CHI, P65
   STRINGA E, 1995, BONE, V16, P663, DOI 10.1016/8756-3282(95)00100-R
   VANDERVALK P, 1983, J BIOMED MATER RES, V17, P807, DOI 10.1002/jbm.820170508
   VOGLER EA, 1987, J BIOMED MATER RES, V21, P1197, DOI 10.1002/jbm.820211004
   WHANG K, 1995, POLYMER, V36, P837, DOI 10.1016/0032-3861(95)93115-3
   Yaszemski MJ, 1996, BIOMATERIALS, V17, P175, DOI 10.1016/0142-9612(96)85762-0
NR 24
TC 37
Z9 39
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD MAR 15
PY 1998
VL 39
IS 4
BP 594
EP 602
DI 10.1002/(SICI)1097-4636(19980315)39:4<594::AID-JBM14>3.0.CO;2-7
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA YV340
UT WOS:000071813400014
PM 9492221
DA 2018-10-19
ER

PT J
AU Gorman, SP
   Tunney, MM
   Keane, PF
   Van Bladel, K
   Bley, B
AF Gorman, SP
   Tunney, MM
   Keane, PF
   Van Bladel, K
   Bley, B
TI Characterization and assessment of a novel poly(ethylene
   oxide)/polyurethane composite hydrogel (Aquavene (R)) as a ureteral
   stent biomaterial
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE ureteral stent; encrustation; hydrogel; Aquavene (R); silicone;
   polyurethane
ID ENCRUSTATION; ADHERENCE; SILICONE
AB The effective long-term use of indwelling ureteral stents is often hindered by the formation of encrusting deposits which may cause obstruction and blockage of the stent. Development of improved ureteral stent biomaterials capable of preventing or reducing encrustation is therefore particularly desirable. In this study, the suitability as a ureteral stent biomaterial of Aquavene(R), a novel poly(ethylene oxide)/polyurethane composite hydrogel was compared with that of silicone and polyurethane, two materials widely employed in ureteral stent manufacture. Examination of Aquavene(R) in dry and hydrated states by confocal laser scanning microscopy, scanning electron microscopy, and atomic force microscopy showed the presence of numerous channels within a cellular matrix structure. The channel size increased considerably to as much as 10 mu m in diameter in the hydrated state. Aquavene(R) provided superior resistance to encrustation and intraluminal blockage over a 24-week period in a simulated urine flow model. Unobstructed urine flow continued with Aquavene(R) at 24 weeks, whereas silicone and polyurethane stents became blocked with encrustation at 8 and 10 weeks, respectively. Weight loss within Aquavene(R) on the order of 9% (w/w) over the 24-week flow period indicates that extraction of the noncrosslinked poly(ethylene oxide) hydrogel may be responsible for the prevention of encrustation blockage of this biomaterial. In the dry state, Aquavene(R) was significantly harder than either silicone or polyurethane, as shown by Young's modulus, and rapidly became soft on hydration. These additional properties of Aquavene(R) would facilitate ease of stent insertion in the dry state past obstructions in the ureter and provide improved patient comfort on subsequent biomaterial hydration in situ. Aquavene(R) is a promising candidate for use in the urinary tract, as it is probable that effective longterm urine drainage would be maintained in vivo. Further evaluation of this novel biomaterial is therefore warranted. (C) 1995 John Wiley & Sons, Inc.
C1 Menlo Care Inc, Menlo Park, CA 94025 USA.
   Queens Univ Belfast, Ctr Med Biol, Sch Pharm, Med Devices Grp, Belfast BT9 7BL, Antrim, North Ireland.
RP Gorman, SP (reprint author), Menlo Care Inc, Menlo Park, CA 94025 USA.
CR AXELSSON H, 1977, SCAND J UROL NEPHROL, V11, P283, DOI 10.3109/00365597709179966
   BLOCK NL, 1977, T AM SOC ART INT ORG, V23, P367
   CIFKOVA I, 1990, BIOMATERIALS, V11, P393, DOI 10.1016/0142-9612(90)90093-6
   CORMIO L, 1995, J UROLOGY, V153, P494, DOI 10.1097/00005392-199502000-00069
   Cormio L, 1995, Scand J Urol Nephrol Suppl, V171, P1
   COX AJ, 1988, BRIT J UROL, V61, P156, DOI 10.1111/j.1464-410X.1988.tb05067.x
   DENYER SP, 1990, J CLIN MICROBIOL, V28, P1813
   Desgrandchamps Francois, 1995, Journal of Urology, V153, p250A
   ECKSTEIN EC, 1984, POLYM BIOMATERIALS, P323
   ELFAQIH SR, 1991, J UROLOGY, V146, P1487, DOI 10.1016/S0022-5347(17)38146-6
   GORMAN SP, 1991, P 10 PHARM TECH C, V2, P649
   HOLMANG S, 1991, J UROLOGY, V145, P176, DOI 10.1016/S0022-5347(17)38285-X
   HUBNER WA, 1992, J UROLOGY, V148, P278
   KEANE PF, 1994, BRIT J UROL, V73, P687, DOI 10.1111/j.1464-410X.1994.tb07557.x
   MARDIS HK, 1987, SEMIN INTERVENT RAD, V4, P36, DOI 10.1055/s-2008-1075982
   RAMSAY JWA, 1986, BRIT J UROL, V58, P70, DOI 10.1111/j.1464-410X.1986.tb05431.x
   Ratner B.D., 1976, HYDROGELS MED RELATE, p[1, 1]
   THOMAS R, 1993, J ENDOUROL, V7, P137, DOI 10.1089/end.1993.7.137
   Tunney MM, 1996, BIOMATERIALS, V17, P1541, DOI 10.1016/0142-9612(96)89780-8
   Tunney MM, 1996, BIOMATERIALS, V17, P1025, DOI 10.1016/0142-9612(96)84679-5
NR 20
TC 36
Z9 36
U1 0
U2 11
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD MAR 15
PY 1998
VL 39
IS 4
BP 642
EP 649
DI 10.1002/(SICI)1097-4636(19980315)39:4<642::AID-JBM20>3.0.CO;2-7
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA YV340
UT WOS:000071813400020
PM 9492227
DA 2018-10-19
ER

PT J
AU Grimandi, G
   Weiss, P
   Millot, F
   Daculsi, G
AF Grimandi, G
   Weiss, P
   Millot, F
   Daculsi, G
TI In vitro evaluation of a new injectable calcium phosphate material
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE injectable bone substitute; biphasic calcium phosphate; cellulose
   derivatives
ID FIBROBLASTS IN-VITRO; CELL-CULTURE; RABBIT BONE; TEST SYSTEM;
   BIOCOMPATIBILITY; CERAMICS; INVITRO; BIOMATERIALS; GROWTH
AB The purpose of this study was to develop an injectable bone substitute (IBS) for percutaneous orthopedic surgery. The multiphasic material used was composed of a 2% aqueous solution of methylhydroxypropylcellulose (MHPC) and biphasic calcium phosphate (BCP, 60% hydroxyapatite and 40% beta-tricalcium phosphate) in which MHPC served as the carrier for 80-200 mu m of BCP granules. The best BCP/polymer ratio was determined by the rheological properties and higher BCP content of the material. Steam sterilization was more effective than gamma irradiation in maintaining the stability of the mixture and conserving its physiochemical and mechanical properties. The in vitro biocompatibility of the composite was checked by direct-contact cytotoxicity and cell-proliferation assays. A preliminary in vivo test was performed in the rabbit using intraosseous implantations in the femoral epiphysis. Histological analysis was done after 1, 2, 4, and 10 weeks. Bone ingrowth into the IBS, in close association with BCP granules, was observed after 1 week and increased regularly from the surface inward at 2, 4, and 10 weeks. At the same time, smaller BCP granules (less than 80 microns in diameter) were degraded and resorbed. This injectable biomaterial proved suitable for cavity filling. The water solubility and viscosity of the polymer allow cells to recolonize, with in situ bonding of the mineral phase. (C) 1998 John Wiley & Sons, Inc.
C1 Univ Nantes, Ctr Interdisciplinaire Tissus CAlcifies Biomat, F-44042 Nantes, France.
RP Grimandi, G (reprint author), Univ Nantes, Ctr Interdisciplinaire Tissus CAlcifies Biomat, Pl A Ricordeau, F-44042 Nantes, France.
RI Daculsi, Guy/P-1320-2014; Weiss, Pierre/P-1372-2014
OI Daculsi, Guy/0000-0003-1030-3446; Weiss, Pierre/0000-0002-6159-8590
CR BASLE MF, 1993, J MATER SCI-MATER M, V4, P273, DOI 10.1007/BF00122280
   BASLE MF, 1993, CALCIFIED TISSUE INT, V53, P348, DOI 10.1007/BF01351842
   CERVINKA M, 1990, TOXICOL IN VITRO, V4, P711, DOI 10.1016/0887-2333(90)90149-N
   CINGI MR, 1991, TOXICOL IN VITRO, V5, P119, DOI 10.1016/0887-2333(91)90031-8
   CONSTANTZ BR, 1995, SCIENCE, V267, P1796, DOI 10.1126/science.7892603
   DACULSI G, 1989, J BIOMED MATER RES, V23, P883, DOI 10.1002/jbm.820230806
   DACULSI G, 1990, J BIOMED MATER RES, V24, P379, DOI 10.1002/jbm.820240309
   DACULSI G, 1989, CLIN ORTHOP RELAT R, V248, P169
   Dempsey D J, 1989, J Biomater Appl, V3, P454
   Dumitriu Severian, 1994, P3
   GUILLEMIN G, 1993, J MATER SCI-MATER M, V4, P575, DOI 10.1007/BF00125596
   HARMAND MF, 1992, BIOMATERIALS, P163
   HYAKUNA K, 1989, J BIOMED MATER RES, V23, P1049, DOI 10.1002/jbm.820230906
   JACOBS GP, 1991, STERILE PHARM MANUFA, V1, P57
   JARCHO M, 1981, CLIN ORTHOP RELAT R, P259
   JOHNSON HJ, 1983, J BIOMED MATER RES, V17, P571, DOI 10.1002/jbm.820170403
   JUST EK, 1985, ENCY POLYM SCI ENG, P226
   KIRKPATRICK CJ, 1990, J MATER SCI-MATER M, V1, P9, DOI 10.1007/BF00705347
   KOHRI M, 1993, BIOMATERIALS, V14, P299, DOI 10.1016/0142-9612(93)90122-I
   LeGeros R Z, 1988, Adv Dent Res, V2, P164
   LENGHEDEN A, 1994, SCAND J DENT RES, V102, P130
   Li J., 1993, Clinical Materials, V12, P197, DOI 10.1016/0267-6605(93)90073-G
   MIYAMOTO T, 1989, J BIOMED MATER RES, V23, P125, DOI 10.1002/jbm.820230110
   MUZARELLI RAA, 1994, BIOMATERIALS, V15, P1075
   MUZARELLI RAA, 1993, BIOMATERIALS, V14, P925
   Pizzoferrato Arturo, 1994, Clinical Materials, V15, P173, DOI 10.1016/0267-6605(94)90081-7
   ROVIRA A, 1993, J MATER SCI-MATER M, V4, P372, DOI 10.1007/BF00122195
   VANLUYN MJA, 1991, J MATER SCI-MATER M, V2, P142, DOI 10.1007/BF00692972
   VERHEYEN CCPM, 1993, J MATER SCI-MATER M, V4, P58, DOI 10.1007/BF00122979
   WILLIAMS DF, 1982, BIOCOMPATIBILITY ORT
NR 30
TC 77
Z9 77
U1 2
U2 13
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD MAR 15
PY 1998
VL 39
IS 4
BP 660
EP 666
DI 10.1002/(SICI)1097-4636(19980315)39:4<660::AID-JBM22>3.0.CO;2-9
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA YV340
UT WOS:000071813400022
PM 9492229
OA Green Published
DA 2018-10-19
ER

PT J
AU Botha, SJ
AF Botha, SJ
TI Surface properties and bio-acceptability of Ti2O3 surfaces
SO MATERIALS SCIENCE AND ENGINEERING A-STRUCTURAL MATERIALS PROPERTIES
   MICROSTRUCTURE AND PROCESSING
LA English
DT Article; Proceedings Paper
CT Conference on Thermomechanical Processing and Metallurgy of Titanium
   Alloys
CY JUL 07-11, 1997
CL UNIV WOLLONGONG, WOLLONGONG, AUSTRALIA
SP Asian Off Aerosp Res & Dev, USAF, Off Sci Res
HO UNIV WOLLONGONG
DE Ti2O3 surfaces; bio-acceptibility; surface properties
ID HUMAN GINGIVAL FIBROBLASTS; TITANIUM IMPLANTS; CELL ATTACHMENT;
   IN-VITRO; STERILIZATION; INVITRO; BONE; BIOCOMPATIBILITY; BIOMATERIAL;
   INTERFACE
AB TiO2 has been identified as a major and probably most desired surface for high bio-acceptability. South African manufactured implant surfaces revealed that Ti2O3 is the predominant surface layer. Chemical surface characteristics after evaluation of Ti2O3 surfaces using X-ray photoelectron spectroscopy (XPS) and Auger electron spectroscopy (AES) showed surfaces to be relatively free from contamination by unwanted chemical elements. Surface layers of different Ti-core metals consisted mainly of Ti. O and C. XPS analysis of surface oxide layers on all Ti-surfaces showed mainly Ti2O3 and TiO in smaller quantities. When evaluating in vitro bio-acceptability, percentage attachment efficiency and proliferation (%-AEP) of human fetal fibroblasts (HFF) and human gingival fibroblast (HGF) on Ti-surfaces showed that the Ti2O3-surface oxide furnished a highly bio-acceptable surface. Evaluation of attached HGF on Ti-surfaces using scanning electron microscopy (SEM) showed fibroblasts attached and spread on Ti-surfaces by formation of numerous filopodia. Metal leaching as determined using inductively coupled plasma emission spectroscopy (ICP) were practically absent for all Ti2O3-surfaces. Absence of toxic metals (V, Pd) on surfaces prepared from Ti-6Al-4V-alloy and Ti with Pd impurity, and practical absence of metal leaching, indicated that these metals did not compete for oxidation of the surface and indicated a possible masking effect of the metal surface by the Ti2O3-surface oxide layer. Implants with Ti2O3-surfaces are widely used in South Africa and have proved to be very successful. (C) 1998 Elsevier Science S.A. All rights reserved.
C1 Univ Pretoria, Fac Dent, Ctr Stomatol Res, ZA-0001 Pretoria, Gauteng, South Africa.
RP Botha, SJ (reprint author), Univ Pretoria, Fac Dent, Ctr Stomatol Res, POB 1266, ZA-0001 Pretoria, Gauteng, South Africa.
CR Abdulla M., 1993, ESSENTIAL TRACE ELEM, V380, P311
   ALBREKTSSON T, 1983, ANN BIOMED ENG, V11, P1, DOI 10.1007/BF02363944
   ALBREKTSSON T, 1989, T ACAD DENT MAT, V2, P143
   BAIER RE, 1982, BIOMATERIALS, V3, P241, DOI 10.1016/0142-9612(82)90027-8
   BERSTEIN A, 1992, BIOMATERIALS, V13, P98, DOI 10.1016/0142-9612(92)90002-6
   Binon P P, 1992, Int J Oral Maxillofac Implants, V7, P168
   BLUMENTHAL NC, 1989, J BIOMED MATER RES-A, V23, P13, DOI 10.1002/jbm.820231305
   BRUNEEL N, 1988, J BIOMED MATER RES, V22, P203, DOI 10.1002/jbm.820220305
   BUDD T W, 1991, International Journal of Oral and Maxillofacial Implants, V6, P253
   Burchard W B, 1991, Int J Oral Maxillofac Implants, V6, P418
   DIPPENAAR A P, 1991, Journal of Dental Research, V70, P383
   DMYTRYK JJ, 1990, J PERIODONTOL, V61, P491, DOI 10.1902/jop.1990.61.8.491
   DOUNDOULAKIS JH, 1987, J PROSTHET DENT, V58, P471, DOI 10.1016/0022-3913(87)90279-4
   DUCHEYNE P, 1988, Journal of Oral Implantology, V14, P325
   EFFAH EAB, 1995, J BIOMED MATER RES, V29, P73, DOI 10.1002/jbm.820290111
   GUY SC, 1993, J PERIODONTOL, V64, P542, DOI 10.1902/jop.1993.64.6.542
   Hartman L C, 1989, Int J Oral Maxillofac Implants, V4, P11
   HOFMANN S, 1990, PRACTICAL SURFACE AN, V1
   KASEMO B, 1991, BONE-BIOMATERIAL INTERFACE, P19
   Kasemo B, 1988, Int J Oral Maxillofac Implants, V3, P247
   KASEMO B, 1983, J PROSTHET DENT, V49, P832, DOI 10.1016/0022-3913(83)90359-1
   KASEMO B, 1988, J BIOMED MATER RES-A, V22, P145, DOI 10.1002/jbm.820221307
   Kasemo B, 1985, TISSUE INTEGRATED PR, P99
   Kawahara D, 1996, Int J Oral Maxillofac Implants, V11, P435
   KAWAHARA H, 1983, INT DENT J, V33, P350
   KELLER J C, 1990, International Journal of Oral and Maxillofacial Implants, V5, P360
   Klauber C, 1990, Int J Oral Maxillofac Implants, V5, P264
   KONONEN M, 1992, J BIOMED MATER RES, V26, P1325
   Kuliralo M, 1991, J Biol Buccale, V19, P247
   LOUW CW, 1991, SURF COAT TECH, V49, P348, DOI 10.1016/0257-8972(91)90081-7
   LOWENBERG BF, 1988, BIOMATERIALS, V9, P302, DOI 10.1016/0142-9612(88)90023-3
   MICHAELS C M, 1991, Journal of Oral Implantology, V17, P132
   MORRISON DF, 1982, MULTIVARIATE STAT ME, P205
   Niznick G A, 1988, J Prosthet Dent, V59, P120, DOI 10.1016/0022-3913(88)90126-6
   OBATAKE RM, 1991, J PROSTHET DENT, V66, P553, DOI 10.1016/0022-3913(91)90522-X
   ONG JL, 1995, J BIOMED MATER RES, V29, P165, DOI 10.1002/jbm.820290205
   PILLIAR RM, 1991, BIOMATERIALS, V12, P95, DOI 10.1016/0142-9612(91)90185-D
   SCHROEDER A, 1981, J MAXILLOFAC SURG, V9, P15, DOI 10.1016/S0301-0503(81)80007-0
   SENDAX V I, 1992, Dental Clinics of North America, V36, P221
   Singh S, 1989, Int J Oral Maxillofac Implants, V4, P139
   Smith D C, 1988, J Dent Educ, V52, P815
   Smith D C, 1993, Int J Prosthodont, V6, P106
   SMITH DC, 1991, BONE-BIOMATERIAL INTERFACE, P3
   STANFORD CM, 1994, J DENT RES, V73, P1061, DOI 10.1177/00220345940730050801
   Vargas E, 1992, Int J Oral Maxillofac Implants, V7, P338
   Vezeau PJ, 1996, J ORAL MAXIL SURG, V54, P738, DOI 10.1016/S0278-2391(96)90694-1
   VINTSENZOS SJ, 1988, J PROSTHET DENT, V59, P587
   Williams D.F, 1981, BIOCOMPATIBILITY CLI, V1, P9
NR 48
TC 15
Z9 16
U1 0
U2 17
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0921-5093
J9 MAT SCI ENG A-STRUCT
JI Mater. Sci. Eng. A-Struct. Mater. Prop. Microstruct. Process.
PD MAR 15
PY 1998
VL 243
IS 1-2
BP 221
EP 230
DI 10.1016/S0921-5093(97)00805-8
PG 10
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Metallurgy & Metallurgical Engineering
SC Science & Technology - Other Topics; Materials Science; Metallurgy &
   Metallurgical Engineering
GA ZH762
UT WOS:000073145100030
DA 2018-10-19
ER

PT J
AU van Luyn, MJA
   Khouw, IMSL
   van Wachem, PB
   Blaauw, EH
   Werkmeister, JA
AF van Luyn, MJA
   Khouw, IMSL
   van Wachem, PB
   Blaauw, EH
   Werkmeister, JA
TI Modulation of the tissue reaction to biomaterials. II. The function of T
   cells in the inflammatory reaction to crosslinked collagen implanted in
   T-cell-deficient rats
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE T cells; phagocytosis; collagens; biocompatibility; biomaterials
ID DERMAL SHEEP COLLAGEN; TUMOR-PROMOTING ACTIVITY; METABOLIC COOPERATION;
   MONOCLONAL-ANTIBODIES; CROSS-LINKING; BIOCOMPATIBILITY; EXPRESSION;
   CYTOTOXICITY; INHIBITION; MONOCYTES
AB Unwanted tissue reactions are often observed resulting in events such as early resorption of the biomaterial, loosening of the implant, or a chronic (immunologic) response. From immunologic studies it is known that inflammatory reactions can be modulated by use of (anti)-growth factors or anti-inflammatory drugs. Before this can be employed with respect to biomaterials, the role of individual factors (humoral and cellular) has to be studied. In this part of the investigation, the role of T cells was studied by use of T-cell-deficient (nude) rats and control (AO) rats. Hexamethylenediisocyanate-crosslinked dermal sheep collagen (HDSC) was selected as the test material. The results showed that T cells or T cell-related factors played a prominent role in the attraction of macrophages and the formation of giant-cells, their antigen presentation, and their phagocytotic capacity. As a consequence, degradation of HDSC was strongly delayed. This study also showed that infiltration of fibroblasts and creation of stromal areas in HDSC was restricted to areas subjected to degradation. However, in time, absence of T cells resulted in increased formation and maturation of autologous rat collagen. Results obtained suggest that the inflammatory reaction to biomaterials might be modulated by controlling T-cell activation. (C) 1998 John Wiley & Sons, Inc.
C1 Univ Groningen, Fac Med Sci, Lab Cell Biol & Electron Microscopy, NL-9713 EZ Groningen, Netherlands.
   CSIRO, Div Biomol Engn, Parkville, Vic 3052, Australia.
RP van Luyn, MJA (reprint author), Univ Groningen, Fac Med Sci, Lab Cell Biol & Electron Microscopy, Oostersingel 69-2, NL-9713 EZ Groningen, Netherlands.
CR ALBELDA SM, 1990, FASEB J, V4, P2868
   BANCROFT GJ, 1986, J IMMUNOL, V137, P4
   CARDONA MA, 1992, J BIOMED MATER RES, V26, P851, DOI 10.1002/jbm.820260703
   COOK JL, 1995, J IMMUNOL, V155, P5512
   DAMAS J, 1990, EUR J PHARMACOL, V175, P341, DOI 10.1016/0014-2999(90)90573-O
   DAMINK LHHO, 1995, J MATER SCI-MATER M, V6, P429
   DEFIFE KM, 1995, J BIOMED MATER RES, V29, P431, DOI 10.1002/jbm.820290403
   DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589
   GARSIDE P, 1995, IMMUNOL TODAY, V16, P220, DOI 10.1016/0167-5699(95)80162-6
   GOODMAN SB, 1994, ACTA ORTHOP SCAND, V65, P1
   JIRANEK W, 1995, J BONE JOINT SURG AM, V77A, P1650, DOI 10.2106/00004623-199511000-00003
   LAM KH, 1995, J BIOMED MATER RES, V29, P929, DOI 10.1002/jbm.820290804
   PAINEAU J, 1991, J HEART LUNG TRANSPL, V10, P424
   PETILLO O, 1994, J BIOMED MATER RES, V28, P635, DOI 10.1002/jbm.820280514
   REMES A, 1992, BIOMATERIALS, V13, P731, DOI 10.1016/0142-9612(92)90010-L
   ROZEMA FR, 1992, ADV BIOMAT, V10, P349
   SANTAVIRTA S, 1991, ARCH ORTHOP TRAUM SU, V110, P288, DOI 10.1007/BF00443460
   TANG LP, 1995, AM J CLIN PATHOL, V103, P466
   THOMPSON RC, 1992, INT J IMMUNOPHARMACO, V14, P475, DOI 10.1016/0192-0561(92)90178-N
   TORGERSEN S, 1995, EUR J ORAL SCI, V103, P46, DOI 10.1111/j.1600-0722.1995.tb00010.x
   TSUCHIYA T, 1995, J BIOMED MATER RES, V29, P121, DOI 10.1002/jbm.820290117
   TSUCHIYA T, 1995, J BIOMED MATER RES, V29, P113, DOI 10.1002/jbm.820290116
   VANGULIK TM, 1987, NETH J SURG, V39, P90
   VANLUYN MJA, 1992, J BIOMED MATER RES, V26, P1091, DOI 10.1002/jbm.820260810
   VANLUYN MJA, 1995, J MATER SCI-MATER M, V6, P288, DOI 10.1007/BF00120273
   VANLUYN MJA, 1994, J MATER SCI-MATER M, V5, P671, DOI 10.1007/BF00120354
   VANLUYN MJA, 1993, STP PHARMA SCI, V3, P35
   VANOTTERLOO JCAD, 1992, J VASC SURG, V16, P774
   VANWACHEM PB, 1991, CELL MATER, V1, P251
   VANWACHEM PB, 1994, J BIOMED MATER RES, V28, P353, DOI 10.1002/jbm.820280310
   WERKMEISTER JA, 1989, J BIOMED MATER RES-A, V23, P273, DOI 10.1002/jbm.820231403
   WOLFF SM, 1991, J HEART LUNG TRANSPL, V10, P424
   ZAOUI P, 1991, KIDNEY INT, V39, P1020, DOI 10.1038/ki.1991.129
NR 33
TC 32
Z9 32
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD MAR 5
PY 1998
VL 39
IS 3
BP 398
EP 406
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA YR639
UT WOS:000071515400008
PM 9468048
DA 2018-10-19
ER

PT J
AU Chou, LS
   Firth, JD
   Uitto, VJ
   Brunette, DM
AF Chou, LS
   Firth, JD
   Uitto, VJ
   Brunette, DM
TI Effects of titanium substratum and grooved surface topography on
   metalloproteinase-2 expression in human fibroblasts
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE titanium; surface topography; MMP-2; molecular biocompatibility
ID GROWTH FACTOR-BETA; MATRIX METALLOPROTEINASES; IV COLLAGENASE;
   EXTRACELLULAR-MATRIX; EPITHELIAL-CELLS; GENE-EXPRESSION;
   POSTTRANSCRIPTIONAL REGULATION; SIGNAL TRANSDUCTION; 72-KDA GELATINASE;
   TISSUE INHIBITOR
AB The chemical and topographic effects of commercially pure titanium on cell morphology and the regulation of matrix metalloproteinase-2 (MMP-2) gene expression, synthesis, and activity were investigated in early passage human gingival fibroblasts. Scanning electron microscopy showed that on smooth titanium (Ti), fibroblasts remained well spread and randomly oriented throughout the culture period. In contrast, cells on V-shaped grooved titanium (VTi) were oriented along the grooves by 16 h and proliferated in this organization throughout the culture period. The effects of substratum surface chemistry on MMP-2 expression were found to be distinct from those of topography. Northern hybridization analysis of fibroblasts cultured on Ti revealed an MMP-2 mRNA time-course expression pattern parallel to that observed on the tissue culture plastic (TCP) dishes, but at significantly lower levels at each time-point. The Ti mRNA levels were decreased by 34% at 16 h, 55% at 40 h, and 45% at 90 h relative to TCP. Ln contrast, MMP-2 mRNA expression on VTi showed both an altered time-course expression pattern and altered levels compared to Ti and TCP. Relative to TCP, VTi MMP-2 mRNA levels were similar to 80% less at 16 h and similar to 50% less at 40 h, but not significantly different at 90 h. Relative to Ti, VTi MMP-2 mRNA levels were similar to 75% less at 16 h, but similar to 40% greater at 40 h and similar to 70% greater at 90 h. These differences may be explained in part by the observed changes in MMP-2 mRNA half-life which decreased by similar to 40% on Ti but increased by over fourfold on VTi relative to TCP. The smooth Ti also showed an approximate twofold increase of MMP-2 secretion in the late cultures over TCP controls. These results indicate that substratum surface chemistry and topography-induced changes in cell shape can alter MMP-2 expression in normal fibroblasts. The molecular approach to investigating the major molecules involved in tissue degradation may provide sensitive indicators of tissue remodeling at the tissue-biomaterial interface. (C) 1998 John Wiley & Sons, Inc.
C1 Boston Univ, Goldman Sch Dent Med, Dept Biomat, Boston, MA 02118 USA.
   Univ British Columbia, Dept Oral Biol, Vancouver, BC V6T 1Z3, Canada.
RP Chou, LS (reprint author), Boston Univ, Goldman Sch Dent Med, Dept Biomat, 100 E Newton St, Boston, MA 02118 USA.
CR BAIER R E, 1988, Journal of Oral Implantology, V13, P594
   BENYA PD, 1982, CELL, V30, P215, DOI 10.1016/0092-8674(82)90027-7
   BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401
   BIRKEDALHANSEN H, 1993, J PERIODONTOL, V64, P474, DOI 10.1902/jop.1993.64.5s.474
   BRUNETTE DM, 1986, EXP CELL RES, V164, P11, DOI 10.1016/0014-4827(86)90450-7
   BRUNETTE DM, 1986, EXP CELL RES, V167, P203, DOI 10.1016/0014-4827(86)90217-X
   BRUNETTE DM, 1983, J DENT RES, V62, P1045, DOI 10.1177/00220345830620100701
   BRUNETTE DM, 1976, ARCH ORAL BIOL, V21, P393, DOI 10.1016/0003-9969(76)90001-7
   BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415
   CAMPORESE DS, 1981, ELECTRON DEVIC LETT, V2, P61, DOI 10.1109/EDL.1981.25341
   CHEHROUDI B, 1989, J BIOMED MATER RES, V23, P1067, DOI 10.1002/jbm.820230907
   CHEHROUDI B, 1991, J BIOMED MATER RES, V25, P387, DOI 10.1002/jbm.820250310
   Chou LS, 1996, J BIOMED MATER RES, V31, P209
   CHOU LS, 1995, J CELL SCI, V108, P1563
   COLLIER IE, 1988, J BIOL CHEM, V263, P6579
   CURTIS ASG, 1990, CRIT REV BIOCOMPAT, V5, P343
   DUNN GA, 1986, J CELL SCI, V83, P313
   DUNN GA, 1976, EXP CELL RES, V101, P1, DOI 10.1016/0014-4827(76)90405-5
   FRENKEL L, 1986, DNA-J MOLEC CELL BIO, V5, P539, DOI 10.1089/dna.1.1986.5.539
   GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025
   HEALY KE, 1992, BIOMATERIALS, V13, P553, DOI 10.1016/0142-9612(92)90108-Z
   HONG HL, 1987, J CELL SCI, V87, P259
   HORWITZ AF, 1994, CURR OPIN CELL BIOL, V6, P645, DOI 10.1016/0955-0674(94)90089-2
   HUHTALA P, 1990, GENOMICS, V6, P554, DOI 10.1016/0888-7543(90)90486-E
   HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S
   Ishiguro N, 1996, J BIOMED MATER RES, V32, P611, DOI 10.1002/(SICI)1097-4636(199612)32:4<611::AID-JBM14>3.3.CO;2-4
   JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577
   KIRCOS LT, 1989, ORAL SURG ORAL MED O, V68, P787, DOI 10.1016/0030-4220(89)90174-6
   MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705
   MURPHY G, 1989, BIOCHEM J, V258, P463, DOI 10.1042/bj2580463
   OAKLEY C, 1993, J CELL SCI, V106, P343
   OGRADY RL, 1984, ANAL BIOCHEM, V140, P490, DOI 10.1016/0003-2697(84)90199-4
   OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x
   OVERALL CM, 1989, CONNECT TISSUE RES, V20, P289, DOI 10.3109/03008208909023899
   OVERALL CM, 1989, J BIOL CHEM, V264, P1860
   OVERALL CM, 1991, J BIOL CHEM, V266, P14064
   OVERALL CM, 1990, J BIOL CHEM, V265, P21141
   SELTZER JL, 1989, J BIOL CHEM, V264, P3822
   SENIOR RM, 1991, J BIOL CHEM, V266, P7870
   SINGHVI R, 1994, BIOTECHNOL BIOENG, V43, P764, DOI 10.1002/bit.260430811
   TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485
   UITTO VJ, 1994, ANN NY ACAD SCI, V732, P140, DOI 10.1111/j.1749-6632.1994.tb24731.x
   ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648
   UNEMORI EN, 1986, J CELL BIOL, V103, P1021, DOI 10.1083/jcb.103.3.1021
   von der Mark K, 1980, Curr Top Dev Biol, V14, P199
   WEISS L, 1978, INT DENT J, V28, P7
   WELGUS HG, 1990, J BIOL CHEM, V265, P13521
   WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877
   WEST CM, 1979, CELL, V17, P491
   WOESSNER JF, 1991, FASEB J, V5, P2145
NR 50
TC 56
Z9 58
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD MAR 5
PY 1998
VL 39
IS 3
BP 437
EP 445
DI 10.1002/(SICI)1097-4636(19980305)39:3<437::AID-JBM13>3.0.CO;2-7
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA YR639
UT WOS:000071515400013
PM 9468053
DA 2018-10-19
ER

PT J
AU Cobos, JA
   Yang, JP
   Zhang, RW
   Krukowski, M
   Simmons, DJ
AF Cobos, JA
   Yang, JP
   Zhang, RW
   Krukowski, M
   Simmons, DJ
TI Positively charged dextran resin inhibits trabecular bone repair in the
   rabbit tibial physis
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE bone repair; biomaterial; positively charged resin; physeal injury
AB Because exposure to positively charged dextran resin (PCDR) inhibits the growth of cultured rat and human bone cells, we tested the hypothesis that PCDR might inhibit bone repair in vivo. Central physeal defects were created by drilling 3.0-mm holes from the proximal tibial plateau into the metaphysis. The defects in left tibiae were packed with neutral resin (control); those in right tibiae were filled with PCDR. At the end of the 1st, 2nd, 3rd, and 10th postoperative weeks, the outcomes were quantitated by documenting the percent trabecular bone volume within the defect. The PCDR-filled defects showed a significant decrease in trabecular bone formation as early as the 2nd week. By the 10th postoperative week, formation of trabeculae had been reduced by nearly 40%. The inhibition conferred by PCDR suggests that the resin could be used as a suppressive interpositional material. (C) 1998 John Wiley & Sons, Inc.
C1 Univ Texas, Med Branch, Dept Orthopaed & Rehabil, Galveston, TX 77555 USA.
   Washington Univ, Dept Biol, St Louis, MO 63130 USA.
RP Simmons, DJ (reprint author), Univ Texas, Med Branch, Dept Orthopaed & Rehabil, Galveston, TX 77555 USA.
CR BURWELL RG, 1964, J BONE JOINT SURG BR, V46, P110
   CAMPBELL CJ, 1959, J BONE JOINT SURG AM, V41, P1221, DOI 10.2106/00004623-195941070-00006
   COBOS J, 1993, J BONE MINER RES, V8, pS281
   FORD LT, 1956, J BONE JOINT SURG AM, V38, P84, DOI 10.2106/00004623-195638010-00008
   HAMAMOTO N, 1995, ARCH ORAL BIOL, V40, P97, DOI 10.1016/0003-9969(94)00153-3
   KRUKOWSKI M, 1994, CLIN ORTHOP RELAT R, P266
   KRUKOWSKI M, 1991, BONE-BIOMATERIAL INTERFACE, P275
   KRUKOWSKI M, 1990, J ORAL MAXIL SURG, V48, P468, DOI 10.1016/0278-2391(90)90233-R
   Lyle W. Glenn, 1996, Wound Repair and Regeneration, V4, P368, DOI 10.1046/j.1524-475X.1996.40314.x
   Martiana K, 1996, CLIN ORTHOP RELAT R, P218
   MASOUD I, 1986, J ORTHOPAED RES, V4, P331
   Nunnemacher RF, 1939, AM J ANAT, V65, P253, DOI 10.1002/aja.1000650205
   PETERSON HA, 1990, LOVELL WINTERS PEDIA, V2, P1071
   SALTER RB, 1963, J BONE JOINT SURG AM, V45, P587, DOI 10.2106/00004623-196345030-00019
   SIMMONS DJ, 1981, CLIN ORTHOP RELAT R, P315
   Simmons DJ, 1997, J BIOMED MATER RES, V34, P393, DOI 10.1002/(SICI)1097-4636(19970305)34:3<393::AID-JBM14>3.0.CO;2-H
   Simmons DJ, 1996, CALCIFIED TISSUE INT, V58, P129, DOI 10.1007/BF02526876
   SIMMONS DJ, 1996, J BONE MINER RES  S1, V11, pS263
   SIMMONS DJ, 1994, J BONE MINER RES  S1, V9, pS302
   SOKAL RR, 1969, BIOMETRY PRINCIPLES
NR 20
TC 6
Z9 6
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD MAR 5
PY 1998
VL 39
IS 3
BP 458
EP 461
DI 10.1002/(SICI)1097-4636(19980305)39:3<458::AID-JBM16>3.3.CO;2-Q
PG 4
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA YR639
UT WOS:000071515400016
PM 9468056
DA 2018-10-19
ER

PT J
AU Vasin, SL
   Rosanova, IB
   Sevastianov, VI
AF Vasin, SL
   Rosanova, IB
   Sevastianov, VI
TI The role of proteins in the nucleation and formation of
   calcium-containing deposits on biomaterial surfaces
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE biomaterial; mechanism of calcification; diffusion chamber;
   calcium-containing deposits; protein sorption; SEM-XRMA
ID INITIAL-STAGES; CALCIFICATION; HEART; MINERALIZATION; INHIBITORS;
   PREVENTION; MECHANISM; VALVES
AB In experiments in vivo using diffusion chambers, the morphology and composition of calcium-containing deposits on natural and artificial biomaterials that had no direct contact with cells were studied using scanning electron microscopy with energy dispersion X-ray microanalysis. It was revealed that the formation of a protein layer containing protein-calcium complexes is the key event in biomaterial calcification. A mechanism of formation of a calcium-containing protein matrix that creates the conditions for supersaturation of the crystal-forming medium over critical value has been proposed. The formation of nuclei of insoluble calcium phosphate starts predominantly deep in an adsorbed protein layer enriched by calcium ions. (C) 1998 John Wiley & Sons, Inc.
C1 Moscow Transplantol & Artificial Organ Res Inst, Ctr Blood Compatible Biomat, Moscow 123182, Russia.
RP Sevastianov, VI (reprint author), Moscow Transplantol & Artificial Organ Res Inst, Ctr Blood Compatible Biomat, Shukinskaya Str 1, Moscow 123182, Russia.
RI Sevastianov, Victor/B-6674-2017
OI Sevastianov, Victor/0000-0003-1995-3373
CR BARBARACH LS, 1991, THORAC CARDIOVASC SU, V7, P21
   Berezov T., 1983, BIOL CHEM, P596
   BISHOP MA, 1982, ANAT RECORD, V202, P177, DOI 10.1002/ar.1092020202
   BONNUCI E, 1969, CALCIF TISSUE RES, V3, P38
   BONUCCI E, 1967, J ULTRA MOL STRUCT R, V20, P33, DOI 10.1016/S0022-5320(67)80034-0
   BORTOLOTTI U, 1991, J CARDIAC SURG, V6, P638
   CAMPBELL AA, 1989, CALCIFIED TISSUE INT, V45, P122, DOI 10.1007/BF02561411
   CARPENTIER S, 1994, 6 INT S CARD BIOPR B, P126
   Cumming R., 1987, AM SOC ARTIF INTERN, V16, P28
   CUMMING RD, 1983, DEVICES TECHNOL BRAN, P136
   DZEMESHKEVICH SL, 1994, BIOMATER LIVING SYST, V2, P149
   GIRARDOT MN, 1995, J BIOMED MATER RES, V29, P793, DOI 10.1002/jbm.820290703
   Kim KM, 1995, SCANNING MICROSCOPY, V9, P1137
   LEVY RJ, 1995, J BIOMED MATER RES, V29, P217, DOI 10.1002/jbm.820290212
   LEVY RJ, 1986, CRIT REV BIOCOMPAT, V2, P147
   MARTIN GR, 1963, J CELL BIOL, V16, P243, DOI 10.1083/jcb.16.2.243
   NOSE Y, 1981, T AM SOC ART INT ORG, V27, P714
   OWEN DR, 1981, BIOMATERIALS INTERFA, P395
   PIEZ KA, 1960, NATURE, V188, P59, DOI 10.1038/188059a0
   ROSANOVA I, 1991, J BIOMED MATER RES, V25, P459, DOI 10.1002/jbm.820250404
   Rosanova I., 1993, BIOMATER LIVING SYST, V1, P11
   ROSANOVA IB, 1991, J BIOMED MATER RES, V25, P277, DOI 10.1002/jbm.820250213
   ROSANOVA IB, 1994, BIOMATER LIVING SYST, V2, P161
   ROSANOVA IB, 1994, BIOMATER LIVING SYST, V2, P177
   SCHOEN FJ, 1988, J BIOMED MATER RES-A, V22, P11
   SHAPIRO IM, 1970, CALC TISS RES, V5, P21, DOI 10.1007/BF02017530
   SHUMAKOV VI, 1991, T AM SOC ART INT ORG, V36, pM181
   VASKU J, 1995, ARTIF ORGANS, V19, P344, DOI 10.1111/j.1525-1594.1995.tb02339.x
   VOROBIEV YK, 1990, NATURAL DEV GROWTH E
   WUTHIER RE, 1968, J LIPID RES, V9, P68
NR 30
TC 24
Z9 26
U1 0
U2 12
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD MAR 5
PY 1998
VL 39
IS 3
BP 491
EP 497
DI 10.1002/(SICI)1097-4636(19980305)39:3<491::AID-JBM21>3.3.CO;2-Z
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA YR639
UT WOS:000071515400021
PM 9468061
DA 2018-10-19
ER

PT J
AU Chittur, KK
AF Chittur, KK
TI Surface techniques to examine the biomaterial-host interface: an
   introduction to the papers
SO BIOMATERIALS
LA English
DT Editorial Material
ID PROTEIN ADSORPTION; WETTABILITY GRADIENT; MANIPULATION; FIBRINOGEN;
   ADHESION; PLASMA; TIRF; SALT
C1 Univ Alabama, Dept Chem & Mat Engn, Huntsville, AL 35899 USA.
RP Chittur, KK (reprint author), Univ Alabama, Dept Chem & Mat Engn, Huntsville, AL 35899 USA.
CR ANDRADE J D, 1992, Clinical Materials, V11, P67, DOI 10.1016/0267-6605(92)90031-N
   Blomberg E, 1998, BIOMATERIALS, V19, P371, DOI 10.1016/S0142-9612(97)00114-2
   Burmeister JS, 1998, BIOMATERIALS, V19, P307, DOI 10.1016/S0142-9612(97)00109-9
   Burns NL, 1998, BIOMATERIALS, V19, P423, DOI 10.1016/S0142-9612(97)00225-1
   CHILKOTI A, 1993, SURFACE CHARACTERIZA
   Chittur KK, 1998, BIOMATERIALS, V19, P357, DOI 10.1016/S0142-9612(97)00223-8
   ELWING H, 1987, J COLLOID INTERF SCI, V119, P203, DOI 10.1016/0021-9797(87)90260-8
   Elwing H, 1998, BIOMATERIALS, V19, P397, DOI 10.1016/S0142-9612(97)00112-9
   GRAINGER DW, 1989, J COLLOID INTERF SCI, V132, P161, DOI 10.1016/0021-9797(89)90226-9
   GRISTINA AG, 1987, SCIENCE, V237, P1588, DOI 10.1126/science.3629258
   Johnston EE, 1996, J ELECTRON SPECTROSC, V81, P303, DOI 10.1016/0368-2048(95)02666-5
   LEE JH, 1993, J BIOMAT SCI-POLYM E, V4, P467
   LEE SH, 1988, J COLLOID INTERF SCI, V125, P365, DOI 10.1016/0021-9797(88)90001-X
   LU DR, 1991, J COLLOID INTERF SCI, V144, P271, DOI 10.1016/0021-9797(91)90258-A
   NORDE W, 1994, PURE APPL CHEM, V66, P491, DOI 10.1351/pac199466030491
   NYLANDER T, 1994, J COLLOID INTERF SCI, V164, P136, DOI 10.1006/jcis.1994.1152
   Ong JL, 1998, BIOMATERIALS, V19, P455, DOI 10.1016/S0142-9612(97)00224-X
   Park K, 1998, BIOMATERIALS, V19, P387, DOI 10.1016/S0142-9612(97)00111-7
   PEREZLUNA VH, 1994, J BIOMED MATER RES, V28, P1111, DOI 10.1002/jbm.820281002
   Plowman TE, 1998, BIOMATERIALS, V19, P341, DOI 10.1016/S0142-9612(97)00113-0
   RATNER B D, 1992, Clinical Materials, V11, P25, DOI 10.1016/0267-6605(92)90027-Q
   RATNER BD, 1995, SURF INTERFACE ANAL, V23, P521, DOI 10.1002/sia.740230712
   RATNER BD, 1994, COLLOID SURFACE B, V2, P333, DOI 10.1016/0927-7765(94)80048-0
   RATNER BD, 1997, SURFACE ANAL TECHNIQ
   SHIBATA CT, 1992, J COLLOID INTERF SCI, V148, P469, DOI 10.1016/0021-9797(92)90184-N
   SHIBATA CT, 1992, J COLLOID INTERF SCI, V148, P485, DOI 10.1016/0021-9797(92)90185-O
   Siedlecki CA, 1998, BIOMATERIALS, V19, P441, DOI 10.1016/S0142-9612(97)00222-6
   Suci PA, 1998, BIOMATERIALS, V19, P327, DOI 10.1016/S0142-9612(97)00108-7
   Tengvall P, 1998, BIOMATERIALS, V19, P407, DOI 10.1016/S0142-9612(97)00110-5
   TILTON RD, 1991, LANGMUIR, V7, P2710, DOI 10.1021/la00059a051
NR 30
TC 22
Z9 22
U1 1
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD MAR
PY 1998
VL 19
IS 4-5
BP 301
EP 305
DI 10.1016/S0142-9612(97)00107-5
PG 5
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA ZP913
UT WOS:000073794900001
PM 9677146
DA 2018-10-19
ER

PT J
AU Burmeister, JS
   Olivier, LA
   Reichert, WM
   Truskey, GA
AF Burmeister, JS
   Olivier, LA
   Reichert, WM
   Truskey, GA
TI Application of total internal reflection fluorescence microscopy to
   study cell adhesion to biomaterials
SO BIOMATERIALS
LA English
DT Article
DE total internal reflection fluorescence; microscopy; cell adhesion;
   cell-substrate separation
ID ENDOTHELIAL-CELLS; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX;
   SUBSTRATE ATTACHMENT; EVANESCENT DETECTION; CONTACT FORMATION; FOCAL
   ADHESIONS; PLASMA-MEMBRANE; CULTURED-CELLS; STRENGTH
AB Cell adhesion and function depend upon the formation of adhesive contacts between the cell and substrate. Determination of the cell-substrate contact area is necessary in order to understand how biomaterial properties influence cell adhesion. In this review we describe the development and application of total internal reflection fluorescence microscopy (TIRFM) to quantify the separation distance of cells from a biomaterial surface. An approximate theory is presented for the straightforward calculation of separation distances when a fluor is placed in the cell membrane. The validity of this approach is discussed. TIRFM is compared to interference reflection microscopy and related techniques that measure cell/substrate separation distances. This approach is then applied to a number of important problems in cell substrate interactions, including changes in contact area and adhesion strength on biomaterial surfaces, analysis of bond strength, and real-time measurement of cell/substrate separation distances following exposure to flow. (C) 1998 Elsevier Science Ltd. All rights reserved.
C1 Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA.
RP Truskey, GA (reprint author), Duke Univ, Dept Biomed Engn, Box 90281,136 Hudson Hall, Durham, NC 27708 USA.
RI Truskey, George/B-2215-2012
OI Truskey, George/0000-0002-6885-4489
FU NHLBI NIH HHS [HL-44972]
CR AITCHISON J, 1957, LOGNORMAL DISTRIBUTI, P9
   AKIYAMA SK, 1985, J BIOL CHEM, V260, P4492
   AXELROD D, 1981, J CELL BIOL, V89, P141, DOI 10.1083/jcb.89.1.141
   AXELROD D, 1979, BIOPHYS J, V26, P557, DOI 10.1016/S0006-3495(79)85271-6
   Axelrod D., 1990, NONINVASIVE TECHNIQU, P93
   BAILEY J, 1988, J CELL SCI, V90, P215
   BATCHELOR G. K., 1967, INTRO FLUID DYNAMICS
   BATES DM, 1988, NONLINEAR REGRESSION, P67
   BEREITERHAHN J, 1979, J CELL BIOL, V82, P767, DOI 10.1083/jcb.82.3.767
   BICKNESE S, 1993, BIOPHYS J, V65, P1272, DOI 10.1016/S0006-3495(93)81179-2
   BIRD RB, 1960, TRANSPORT PHENOMENA
   BLOCH RJ, 1989, EXP CELL RES, V182, P583, DOI 10.1016/0014-4827(89)90261-9
   Born M., 1986, PRINCIPLES OPTICS
   Burmeister JS, 1996, J BIOMED MATER RES, V30, P13, DOI 10.1002/(SICI)1097-4636(199601)30:1<13::AID-JBM3>3.0.CO;2-U
   BURMEISTER JS, 1994, BIOTECHNOL PROGR, V10, P26, DOI 10.1021/bp00025a003
   BURMEISTER JS, 1994, J MICROSC-OXFORD, V173, P39, DOI 10.1111/j.1365-2818.1994.tb03426.x
   BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893
   BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415
   CHEN QM, 1994, J BIOL CHEM, V269, P26602
   CHEN WT, 1982, J CELL BIOL, V95, P205, DOI 10.1083/jcb.95.1.205
   CHRZANOWSKAWODNICKA M, 1994, J CELL SCI, V107, P3643
   DAVIES PF, 1993, J CLIN INVEST, V91, P2640, DOI 10.1172/JCI116503
   DAVIES PF, 1994, J CLIN INVEST, V93, P2031, DOI 10.1172/JCI117197
   DEMBO M, 1988, PROC R SOC SER B-BIO, V234, P55, DOI 10.1098/rspb.1988.0038
   DENN MM, 1980, PROCESS FLUID MECH, P265
   EVANS E, 1995, BIOPHYS J, V68, P2580, DOI 10.1016/S0006-3495(95)80441-8
   EVANS E, 1991, BIOPHYS J, V59, P838, DOI 10.1016/S0006-3495(91)82296-2
   FARINAS J, 1995, BIOPHYS J, V68, P1613, DOI 10.1016/S0006-3495(95)80335-8
   FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628
   GINGELL D, 1985, J CELL BIOL, V100, P1334, DOI 10.1083/jcb.100.4.1334
   GINGELL D, 1987, J CELL SCI, V87, P677
   HANSEN WN, 1968, J OPT SOC AM, V58, P380, DOI 10.1364/JOSA.58.000380
   HEAVENS OS, 1990, J CELL SCI, V95, P175
   HSIEH HV, 1994, BIOPHYS J, V66, P898, DOI 10.1016/S0006-3495(94)80866-5
   HUBBELL JA, 1995, BIO-TECHNOL, V13, P565, DOI 10.1038/nbt0695-565
   IULIANO DJ, 1993, J BIOMED MATER RES, V27, P1103, DOI 10.1002/jbm.820270816
   JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0
   KLAUSNER RD, 1980, BIOCHEMISTRY-US, V19, P6199, DOI 10.1021/bi00567a039
   LANNI F, 1985, J CELL BIOL, V100, P1091, DOI 10.1083/jcb.100.4.1091
   LEE J, 1994, J CELL BIOL, V127, P1957, DOI 10.1083/jcb.127.6.1957
   MASSIA SP, 1991, J CELL BIOL, V114, P1089, DOI 10.1083/jcb.114.5.1089
   MELLOR JS, 1988, J MOD OPTIC, V35, P623, DOI 10.1080/09500348814550641
   NAKACHE M, 1986, P NATL ACAD SCI USA, V83, P2874, DOI 10.1073/pnas.83.9.2874
   OLIVIER LA, 1993, BIOTECHNOL BIOENG, V42, P963, DOI 10.1002/bit.260420807
   PADDOCK SW, 1989, J CELL SCI, V93, P143
   Park K, 1989, Scanning Microsc Suppl, V3, P137
   PHIMPHIVONG S, 1995, ANAL CHIM ACTA, V307, P403, DOI 10.1016/0003-2670(95)00005-K
   PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294
   PULEO DA, 1992, J BIOMED MATER RES, V26, P291, DOI 10.1002/jbm.820260303
   REICHERT WM, 1987, APPL SPECTROSC, V41, P503, DOI 10.1366/0003702874448913
   REICHERT WM, 1990, J CELL SCI, V96, P219
   REICHERT WM, 1989, CRIT REV BIOCOMPAT, V5, P173
   RINNERTHALER G, 1988, J CELL BIOL, V106, P747, DOI 10.1083/jcb.106.3.747
   ROMER LH, 1994, MOL BIOL CELL, V5, P349
   Satcher RL, 1996, BIOPHYS J, V71, P109, DOI 10.1016/S0006-3495(96)79206-8
   SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3
   Schlichting H, 1979, BOUNDARY LAYER THEOR, p[185, 241]
   SIMON KO, 1991, CURR TOP MEMBR, V38, P57
   STEELE JG, 1994, J BIOMAT SCI-POLYM E, V6, P511, DOI 10.1163/156856294X00473
   SUCI PA, 1988, LANGMUIR, V4, P1131, DOI 10.1021/la00083a013
   TAWIL N, 1993, J CELL BIOL, V120, P261, DOI 10.1083/jcb.120.1.261
   TODD I, 1988, J CELL SCI, V89, P107
   TRUSKEY GA, 1992, J CELL SCI, V103, P491
   TRUSKEY GA, 1990, J BIOMED MATER RES, V24, P1333, DOI 10.1002/jbm.820241006
   TRUSKEY GA, 1993, BIOMATERIALS, V14, P243, DOI 10.1016/0142-9612(93)90114-H
   VERSCHUEREN H, 1985, J CELL SCI, V75, P279
   WANG M, 1989, DEV DYNAMICS, V201, P29
   WARD MD, 1993, BIOPHYS J, V64, P936, DOI 10.1016/S0006-3495(93)81456-5
   WATTS TH, 1986, NATURE, V320, P179, DOI 10.1038/320179a0
   WEIS RM, 1982, J BIOL CHEM, V257, P6440
   WILLIAMS S, 1994, CELL TRANSPLANT, V4, P401
   WILLIAMS SK, 1994, J BIOMED MATER RES, V28, P203, DOI 10.1002/jbm.820280210
   Xiao Y, 1996, BIOPHYS J, V71, P2869, DOI 10.1016/S0006-3495(96)79484-5
   ZAND MS, 1989, CELL MOTIL CYTOSKEL, V13, P195, DOI 10.1002/cm.970130307
   ZAND MS, 1989, CELL MOTIL CYTOSKEL, V13, P94, DOI 10.1002/cm.970130204
NR 75
TC 82
Z9 83
U1 0
U2 14
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD MAR
PY 1998
VL 19
IS 4-5
BP 307
EP 325
DI 10.1016/S0142-9612(97)00109-9
PG 19
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA ZP913
UT WOS:000073794900002
PM 9677147
DA 2018-10-19
ER

PT J
AU Suci, PA
   Vrany, JD
   Mittelman, MW
AF Suci, PA
   Vrany, JD
   Mittelman, MW
TI Investigation of interactions between antimicrobial agents and bacterial
   biofilms using attenuated total reflection Fourier transform infrared
   spectroscopy
SO BIOMATERIALS
LA English
DT Article
DE antimicrobial agents; bacterial biofilms; ATR/FTIR
ID COAGULASE-NEGATIVE STAPHYLOCOCCI; PSEUDOMONAS-AERUGINOSA BIOFILM;
   SELF-ASSEMBLED MONOLAYERS; MUSSEL ADHESIVE PROTEIN; GROWTH-RATE;
   ESCHERICHIA-COLI; SLIME PRODUCTION; CAPSULAR POLYSACCHARIDE; BIOMATERIAL
   SURFACES; MICROBIAL ADHESION
AB Biomaterial-centred infections are often difficult to treat. An impaired immune response, acute inflammatory reactions and the presence of recalcitrant attached microorganisms are ail contributing factors. A brief review of the role of attached bacteria in biomaterial-centred infections is presented. Two major hypotheses which. may explain the recalcitrance of biofilms to antimicrobial agents are discussed. The analytical capabilities of attenuated total reflection Fourier transform infrared (ATR/FTIR) spectroscopy for providing information on both transport of an antimicrobial agent to bacteria embedded in the biofilm and interactions between an antimicrobial agent and biofilm components are described. (C) 1998 Elsevier Science Ltd. All rights reserved.
C1 Montana State Univ, Ctr Biofilm Engn, Bozeman, MT 59717 USA.
   Univ Toronto, Ctr Infect & Biomat Res, Dept Surg, Toronto, ON M5G 2C4, Canada.
RP Suci, PA (reprint author), Montana State Univ, Ctr Biofilm Engn, Bozeman, MT 59717 USA.
CR ALLISON DG, 1990, FEMS MICROBIOL LETT, V71, P101, DOI 10.1016/0378-1097(90)90039-S
   ANDERSON JM, 1984, BIOMATERIALS, V5, P5, DOI 10.1016/0142-9612(84)90060-7
   ANDERSON JM, 1988, T AM SOC ART INT ORG, V34, P101
   Andrade JD, 1985, SURFACE INTERFACIAL, V2, P1
   ANNISON G, 1987, AUST J BIOL SCI, V40, P435, DOI 10.1071/BI9870435
   ANWAR H, 1990, ANTIMICROB AGENTS CH, V34, P1666, DOI 10.1128/AAC.34.9.1666
   ANWAR H, 1992, ANTIMICROB AGENTS CH, V36, P890, DOI 10.1128/AAC.36.4.890
   ARIZONO T, 1992, ACTA ORTHOP SCAND, V63, P661
   Bach A, 1993, Anasthesiol Intensivmed Notfallmed Schmerzther, V28, P404, DOI 10.1055/s-2007-998954
   BAE IT, 1995, ANAL CHEM, V67, P4508, DOI 10.1021/ac00120a013
   Baty AM, 1996, J COLLOID INTERF SCI, V177, P307, DOI 10.1006/jcis.1996.0036
   BREMER PJ, 1991, APPL ENVIRON MICROB, V57, P1956
   BROWN MRW, 1990, ANTIMICROB AGENTS CH, V34, P1623, DOI 10.1128/AAC.34.9.1623
   BROZEL VS, 1993, WATER SA, V19, P259
   BURET A, 1991, J BIOMED MATER RES, V25, P865, DOI 10.1002/jbm.820250706
   CHENG SS, 1992, J AM CHEM SOC, V114, P5436, DOI 10.1021/ja00039a071
   CHENG SS, 1994, J COLLOID INTERF SCI, V162, P135, DOI 10.1006/jcis.1994.1018
   CHIANG CH, 1980, J COLLOID INTERF SCI, V74, P396, DOI 10.1016/0021-9797(80)90209-X
   CHITTUR KK, 1968, PROTEINS INTERFACES
   CHRISTENSEN GD, 1989, INFECT ASS INDWELLIN, P59
   COLEMAN DL, 1974, J BIOMED MATER RES, V8, P199, DOI 10.1002/jbm.820080503
   Costerton J. W., 1985, BACTERIAL ADHESION M, P3
   COSTERTON JW, 1995, ANNU REV MICROBIOL, V49, P711, DOI 10.1146/annurev.mi.49.100195.003431
   COSTERTON JW, 1981, ANNU REV MICROBIOL, V35, P299, DOI 10.1146/annurev.mi.35.100181.001503
   CRANK J, 1956, MATH DIFFUSION, P1
   DANKERT J, 1986, CRIT REV BIOCOMPAT, V2, P219
   DEBEER D, 1994, BIOTECHNOL BIOENG, V43, P1131, DOI 10.1002/bit.260431118
   DEIGHTON M, 1993, INFECT IMMUN, V61, P4473
   DELAROSA EJ, 1982, FEMS MICROBIOL LETT, V14, P91, DOI 10.1016/0378-1097(82)90020-9
   DERETIC V, 1994, J BACTERIOL, V176, P2773
   DICKINSON GM, 1989, ANTIMICROB AGENTS CH, V33, P602, DOI 10.1128/AAC.33.5.602
   DUNNE WM, 1993, ANTIMICROB AGENTS CH, V37, P2522, DOI 10.1128/AAC.37.12.2522
   EVANS DJ, 1991, J ANTIMICROB CHEMOTH, V27, P177, DOI 10.1093/jac/27.2.177
   EVANS DJ, 1990, J ANTIMICROB CHEMOTH, V25, P585, DOI 10.1093/jac/25.4.585
   EVANS E, 1994, MICROBIOL-UK, V140, P153, DOI 10.1099/13500872-140-1-153
   Finch J E, 1975, J Antimicrob Chemother, V1, P379, DOI 10.1093/jac/1.4.379
   FRANKLIN MJ, 1993, J BACTERIOL, V175, P5057
   GELLMAN AJ, 1990, J ADHES SCI TECHNOL, V4, P597, DOI 10.1163/156856190X00531
   GILBERT P, 1978, J BACTERIOL, V133, P1066
   GILBERT P, 1989, APPL ENVIRON MICROB, V55, P1038
   GIWERCMAN B, 1991, ANTIMICROB AGENTS CH, V35, P1008, DOI 10.1128/AAC.35.5.1008
   GORDON CA, 1991, ANTIMICROB AGENTS CH, V35, P1258, DOI 10.1128/AAC.35.6.1258
   GORDON CA, 1988, J ANTIMICROB CHEMOTH, V22, P667, DOI 10.1093/jac/22.5.667
   GORMAN SP, 1994, EPIDEMIOL INFECT, V112, P551, DOI 10.1017/S0950268800051256
   GRISTINA AG, 1987, SCIENCE, V237, P1588, DOI 10.1126/science.3629258
   GROVER FL, 1994, J THORAC CARDIOV SUR, V108, P207
   HOYLE BD, 1990, J ANTIMICROB CHEMOTH, V26, P1, DOI 10.1093/jac/26.1.1
   HOYLE BD, 1992, ANTIMICROB AGENTS CH, V36, P2054, DOI 10.1128/AAC.36.9.2054
   JEON JS, 1992, APPL SPECTROSC, V46, P1644, DOI 10.1366/0003702924926826
   JONES CJ, 1991, ADV MICROB PHYSIOL, V32, P109, DOI 10.1016/S0065-2911(08)60007-7
   JONES JW, 1992, J HOSP INFECT, V22, P217, DOI 10.1016/0195-6701(92)90046-O
   KNUTZEN K, 1985, SURFACE INTERFACIAL, V1
   KORBER DR, 1994, APPL ENVIRON MICROB, V60, P1663
   KOTILAINEN P, 1990, J CLIN MICROBIOL, V28, P2779
   LIN WS, 1994, J BACTERIOL, V176, P7005
   LOEWEN PC, 1994, ANNU REV MICROBIOL, V48, P53, DOI 10.1146/annurev.mi.48.100194.000413
   LOPEZ GP, 1992, J BIOMED MATER RES, V26, P415, DOI 10.1002/jbm.820260402
   MALINOWSKI ER, 1991, FACTOR ANAL CHEM, P1
   MATTHEWS KR, 1991, J APPL BACTERIOL, V70, P227, DOI 10.1111/j.1365-2672.1991.tb02929.x
   MOAT AG, 1995, MICROBIAL PHYSL, P146
   MORITA RY, 1982, ADV MICROB ECOL, V6, P171
   MULLER E, 1993, J INFECT DIS, V168, P1211, DOI 10.1093/infdis/168.5.1211
   NAUMANN D, 1991, NATURE, V351, P81, DOI 10.1038/351081a0
   Neidhardt F. C., 1990, PHYSL BACTERIAL CELL, P4
   NICHOLS WW, 1988, ANTIMICROB AGENTS CH, V32, P518, DOI 10.1128/AAC.32.4.518
   NICHOLS WW, 1989, J GEN MICROBIOL, V135, P1291
   NIVENS DE, 1993, J MICROBIOL METH, V17, P199, DOI 10.1016/0167-7012(93)90047-L
   NYSTROM T, 1992, APPL ENVIRON MICROB, V58, P55
   ONG JL, 1994, J BIOMED MATER RES, V28, P1337, DOI 10.1002/jbm.820281112
   PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T
   PELLETIER C, 1995, ANTIMICROB AGENTS CH, V39, P707, DOI 10.1128/AAC.39.3.707
   Pitt W.G., 1987, PROTEINS INTERFACES, P324
   PRIME KL, 1991, SCIENCE, V252, P1164, DOI 10.1126/science.252.5009.1164
   READ RR, 1987, CAN J MICROBIOL, V33, P1080, DOI 10.1139/m87-189
   REICHERT P, 1994, WATER SCI TECHNOL, V30, P21
   RUCKENSTEIN E, 1983, J COLLOID INTERF SCI, V96, P245, DOI 10.1016/0021-9797(83)90026-7
   SKJAKBRAEK G, 1986, CARBOHYD RES, V154, P239
   STICKLER DJ, 1993, J INFECTION, V27, P133, DOI 10.1016/0163-4453(93)94620-Q
   STIVER HG, 1988, CLIN INVEST MED, V11, P247
   SUCI PA, 1995, J COLLOID INTERF SCI, V172, P347, DOI 10.1006/jcis.1995.1263
   SUCI PA, 1994, ANTIMICROB AGENTS CH, V38, P2125, DOI 10.1128/AAC.38.9.2125
   SUTHERLAND IW, 1982, ADV MICROB PHYSIOL, V23, P79, DOI 10.1016/S0065-2911(08)60336-7
   TANNENBAUM CS, 1984, ANTIMICROB AGENTS CH, V25, P673, DOI 10.1128/AAC.25.6.673
   TIDSWELL IM, 1991, J CHEM PHYS, V95, P2854, DOI 10.1063/1.460886
   TILLMAN N, 1988, J AM CHEM SOC, V110, P6136, DOI 10.1021/ja00226a031
   TUOMANEN E, 1986, J GEN MICROBIOL, V132, P1297
   WENZL P, 1994, LANGMUIR, V10, P4253, DOI 10.1021/la00023a056
   WHITFIELD C, 1988, CAN J MICROBIOL, V34, P415, DOI 10.1139/m88-073
   WOLFAARDT GM, 1994, APPL ENVIRON MICROB, V60, P434
   WU Q, 1995, J BACTERIOL, V177, P1399, DOI 10.1128/jb.177.5.1399-1401.1995
   ZIATS NP, 1988, BIOMATERIALS, V9, P5, DOI 10.1016/0142-9612(88)90063-4
NR 91
TC 61
Z9 61
U1 1
U2 20
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD MAR
PY 1998
VL 19
IS 4-5
BP 327
EP 339
DI 10.1016/S0142-9612(97)00108-7
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA ZP913
UT WOS:000073794900003
PM 9677148
DA 2018-10-19
ER

PT J
AU Chittur, KK
AF Chittur, KK
TI FTIR/ATR for protein adsorption to biomaterial surfaces
SO BIOMATERIALS
LA English
DT Article
ID TRANSFORM-INFRARED-SPECTROSCOPY; ATTENUATED TOTAL-REFLECTION;
   LEAST-SQUARES METHODS; SCANNING TUNNELING MICROSCOPY; FOURIER
   SELF-DECONVOLUTION; BOVINE SERUM-ALBUMIN; FT-IR SPECTRA; SECONDARY
   STRUCTURE; AQUEOUS-SOLUTIONS; ATR SPECTROSCOPY
AB It is now well accepted that the initial rapid adsorption of blood proteins to biomaterial surfaces is important in the long-term performance of the implant. Cells that interact with the implant will be reacting to a layer (single or multiple) of adsorbed protein. The parameters of importance in a study of protein adsorption to surfaces of biomaterial interest include total amounts of different adsorbed proteins and the conformation and orientation of these adsorbed proteins. Researchers have developed a number of techniques with which we can now address all these questions. In this paper, we have discussed how Fourier transform infrared (FTIR) attenuated total internal reflection (ATR) techniques can be used for the study of biomaterial surfaces and events at biomaterial surfaces such as protein adsorption. FTIR spectroscopy offers higher signal-to-noise and speeds than spectrometers that use gratings and hence offers the capability of observing the critical early events when proteins interact with surfaces. Perhaps the biggest advantage of the FTIR technique over dispersive spectrometers is wavelength precision. This allows the subtraction of water, a strong infrared absorber, from the spectra of proteins in aqueous solutions. This review starts with an introduction of how ATR can be used to provide information about proteins on surfaces. Equations to calculate the amount of proteins adsorbed to surfaces from analysis of ATR spectra are presented. A discussion of the kinds of surfaces that can be analyzed by FTIR/ATR and difficulties with the subtraction of H2O is given. The rest of the review deals with how information of interest to biomaterials researchers such as kinetics of protein adsorption, changes in protein secondary structure and orientation upon adsorption to surfaces can be obtained by FTIR/ATR. (C) 1998 Published by Elsevier Science Ltd. All rights reserved.
C1 Univ Alabama, Dept Chem & Mat Engn, Huntsville, AL 35899 USA.
RP Chittur, KK (reprint author), Univ Alabama, Dept Chem & Mat Engn, Huntsville, AL 35899 USA.
EM chit-turk@uah.edu
FU NHLBI NIH HHS [HL-38936]
CR AHN DJ, 1992, J PHYS CHEM-US, V96, P9952, DOI 10.1021/j100203a068
   AXELSEN PH, 1995, APPL SPECTROSC, V49, P526, DOI 10.1366/0003702953964273
   Axelsen PH, 1995, BIOPHYS J, V69, P2770, DOI 10.1016/S0006-3495(95)80150-5
   BALE MD, 1988, J COLLOID INTERF SCI, V125, P516, DOI 10.1016/0021-9797(88)90017-3
   BOSSHARD HR, 1969, EUR J BIOCHEM, V9, P353, DOI 10.1111/j.1432-1033.1969.tb00616.x
   Buijs J, 1996, LANGMUIR, V12, P1605, DOI 10.1021/la950665s
   BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307
   CAMERON DG, 1984, J TEST EVAL, V12, P78
   CHENG SS, 1994, J COLLOID INTERF SCI, V162, P135, DOI 10.1006/jcis.1994.1018
   CHITTUR KK, 1986, J COLLOID INTERF SCI, V111, P419, DOI 10.1016/0021-9797(86)90045-7
   CORNELIUS RM, 1992, J COLLOID INTERF SCI, V150, P121, DOI 10.1016/0021-9797(92)90273-O
   CORNELL DG, 1989, BIOCHEMISTRY-US, V28, P2789, DOI 10.1021/bi00433a008
   DOUSSEAU F, 1989, APPL SPECTROSC, V43, P538, DOI 10.1366/0003702894202814
   DOUSSEAU F, 1990, BIOCHEMISTRY-US, V29, P8771, DOI 10.1021/bi00489a038
   EPPELL SJ, 1995, BIOPHYS J, V68, P671, DOI 10.1016/S0006-3495(95)80228-6
   FENG L, 1993, J BIOMED MATER RES, V27, P177, DOI 10.1002/jbm.820270206
   FINK DJ, 1987, ANAL BIOCHEM, V165, P147, DOI 10.1016/0003-2697(87)90213-2
   FREY S, 1991, BIOPHYS J, V60, P922, DOI 10.1016/S0006-3495(91)82126-9
   GRIFFITHS PR, 1986, FOURIER TRANSFORM IN
   HAALAND DM, 1988, ANAL CHEM, V60, P1193, DOI 10.1021/ac00162a020
   HAALAND DM, 1988, ANAL CHEM, V60, P1202, DOI 10.1021/ac00162a021
   HAALAND DM, 1991, SPIE, V1575, P87
   HADDEN JM, 1995, BBA-PROTEIN STRUCT M, V1248, P115, DOI 10.1016/0167-4838(95)00010-R
   HAGGERTY L, 1991, J VAC SCI TECHNOL B, V9, P1219, DOI 10.1116/1.585208
   HARIS PI, 1989, BIOCHEM SOC T, V17, P161, DOI 10.1042/bst0170161
   Harrick N. J, 1967, INTERNAL REFLECTION
   HOLLOWAY PW, 1989, BIOCHEMISTRY-US, V28, P931, DOI 10.1021/bi00429a002
   ISHIDA KP, 1994, ANAL CHEM, V66, P522, DOI 10.1021/ac00076a017
   ISHIGURO R, 1993, BIOCHEMISTRY-US, V32, P9792, DOI 10.1021/bi00088a034
   JACKSON M, 1991, BIOCHEMISTRY-US, V30, P9681, DOI 10.1021/bi00104a016
   JACKSON M, 1992, APPL SPECTROSC, V46, P699, DOI 10.1366/0003702924124862
   JACKSON RS, 1991, ANAL CHEM, V63, P2557, DOI 10.1021/ac00022a005
   JAKOBSEN RJ, 1986, BIOPOLYMERS, V25, P639, DOI 10.1002/bip.360250409
   JEON JS, 1992, APPL SPECTROSC, V46, P1644, DOI 10.1366/0003702924926826
   KATO K, 1987, APPL SPECTROSC, V41, P861, DOI 10.1366/0003702874448049
   KAUPPINEN JK, 1981, APPL SPECTROSC, V35, P271, DOI 10.1366/0003702814732634
   LEE DC, 1990, BIOCHEMISTRY-US, V29, P9185, DOI 10.1021/bi00491a012
   LENK TJ, 1991, LANGMUIR, V7, P1755, DOI 10.1021/la00056a030
   LENK TJ, 1989, J BIOMED MATER RES, V23, P549, DOI 10.1002/jbm.820230603
   LENK TJ, 1994, THESIS U WASHINGTON
   MARK H, 1987, ANAL CHEM, V59, P790, DOI 10.1021/ac00132a024
   MARK H, 1986, ANAL CHEM, V58, P379, DOI 10.1021/ac00293a026
   MARK HL, 1985, ANAL CHEM, V57, P1449, DOI DOI 10.1021/AC00284A061
   MEANS GE, 1971, CHEM MODIFICATION PR, P114
   NABEDRYK E, 1982, BIOPHYS J, V38, P243, DOI 10.1016/S0006-3495(82)84555-4
   NYDEN M, 1988, APPL SPECTROSC, V43, P123
   NYDEN MR, 1988, APPL SPECTROSC, V42, P588, DOI 10.1366/0003702884429436
   OHTA K, 1985, ANAL CHEM, V57, P2491, DOI 10.1021/ac00290a015
   OHTA K, 1985, APPL SPECTROSC, V39, P418, DOI 10.1366/0003702854248719
   ONG JL, 1994, J BIOMED MATER RES, V28, P1337, DOI 10.1002/jbm.820281112
   PITT WG, 1988, J BIOMED MATER RES, V22, P359, DOI 10.1002/jbm.820220502
   PITT WG, 1987, PROTEINS INTERFACES, V343
   POWELL JR, 1986, APPL SPECTROSC, V40, P339, DOI 10.1366/0003702864509330
   REICHERT WM, 1989, CRIT REV BIOCOMPAT, V5, P173
   ROTHSCHILD KJ, 1979, BIOPHYS J, V25, P473, DOI 10.1016/S0006-3495(79)85317-5
   SIEDLECKI CA, 1994, J BIOMED MATER RES, V28, P971, DOI 10.1002/jbm.820280902
   SLACK SM, 1989, J COLLOID INTERF SCI, V133, P148, DOI 10.1016/0021-9797(89)90288-9
   SLACK SM, 1988, J COLLOID INTERF SCI, V124, P533
   Smith B.C., 1996, FUNDAMENTALS FOURIER
   SPERLINE RP, 1987, LANGMUIR, V3, P198, DOI 10.1021/la00074a009
   SPERLINE RP, 1991, APPL SPECTROSC, V45, P677, DOI 10.1366/0003702914336840
   STUART JJ, 1994, THESIS U WASHINGTON
   SUSI H, 1988, APPL SPECTROSC, V42, P819, DOI 10.1366/0003702884428905
   TAMM LK, 1993, BIOCHEMISTRY-US, V32, P7720, DOI 10.1021/bi00081a017
   THOMAS EV, 1994, ANAL CHEM, V66, pA795, DOI 10.1021/ac00087a002
   TOMPKINS HG, 1974, APPL SPECTROSC, V28, P335, DOI 10.1366/000370274774332380
   WASACZ FM, 1987, BIOCHEMISTRY-US, V26, P1464, DOI 10.1021/bi00379a038
   WOJCIECHOWSKI P, 1986, J COLLOID INTERF SCI, V111, P455, DOI 10.1016/0021-9797(86)90048-2
   YANG WH, 1993, LANGMUIR, V9, P3159
   YANG WJ, 1985, APPL SPECTROSC, V39, P282, DOI 10.1366/0003702854248917
   1996, PLSPLUS IRQ USERS GU, P114
NR 71
TC 286
Z9 291
U1 9
U2 145
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD MAR
PY 1998
VL 19
IS 4-5
BP 357
EP 369
DI 10.1016/S0142-9612(97)00223-8
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA ZP913
UT WOS:000073794900005
PM 9677150
DA 2018-10-19
ER

PT J
AU Elwing, H
AF Elwing, H
TI Protein absorption and ellipsometry in biomaterial research
SO BIOMATERIALS
LA English
DT Review
DE ellipsometry; protein adsorption; biocompatibility
ID WETTABILITY GRADIENT-METHOD; SOLID-LIQUID INTERFACES; LENS-ON-SURFACE;
   COMPLEMENT ACTIVATION; PLASMA-PROTEIN; GOLD SURFACES; SILICON SURFACES;
   L-CYSTEINE; ADSORPTION; FIBRINOGEN
AB Ellipsometry is an optical surface-sensitive method for the investigation of various aspects of protein adsorption mainly at reflecting metal surfaces and ceramic surfaces. One interesting feature of the method is the possibility of detailed and accurate determination of real-time adsorption kinetics of proteins without labelling of the protein. It is else possible to detect protein adsorption with the use of antibodies that adsorb onto the antigen-coated surfaces and to detect antibodies by their adsorption behaviour with regard to antigen-coated surfaces. Compared to other solid phase methods such as enzyme linked immunosorbent assay (ELISA), immunofluorescence and radioimmunoassay, ellipsometry has the advantage of not involving any labelling of the reactant and it is a relatively inexpensive method to maintain. This review is a current report of 15 years of contributions in biomaterials and biochemical research. Special consideration has been given to biologically related surface phenomena such as protein conformation changes, protein displacement effects, early events in blood clotting and complement activation. Among the technical achievements given prominence are the wettability gradient method and the rational use of silicon as an experimental surface. It is clear that ellipsometry and related methods such as reflectometry and surface plasmon resonance (Biacore) are now being increasingly used in biomaterial research as well as in other areas of research. (C) 1998 Published by Elsevier Science Ltd. All rights reserved.
C1 Gothenburg Univ, Dept Gen & Marine Microbiol, Biointerface & Biofouling Lab, S-41390 Gothenburg, Sweden.
RP Elwing, H (reprint author), Univ Goteborg, Dept Cell & Mol Biol Microbiol, Box 462, SE-40530 Gothenburg, Sweden.
CR Alaeddine S, 1995, ACS SYM SER, V602, P41
   ALBREKTSSON T, 1983, ANN BIOMED ENG, V11, P1, DOI 10.1007/BF02363944
   ANDERSON JM, 1990, INT J ARTIF ORGANS, V13, P375
   ANDREE HAM, 1990, J BIOL CHEM, V265, P4923
   ARNEBRANT T, 1988, J COLLOID INTERF SCI, V122, P557, DOI 10.1016/0021-9797(88)90392-X
   ARWIN H, 1985, ANAL BIOCHEM, V145, P106, DOI 10.1016/0003-2697(85)90334-3
   ARWIN H, 1993, J COLLOID INTERF SCI, V156, P377, DOI 10.1006/jcis.1993.1125
   AZZAM RMA, 1991, SPIE MILESTONE SER, V27
   BAIER RE, 1982, J BIOMECH ENG-T ASME, V104, P257, DOI 10.1115/1.3138358
   BOUSSE L, 1991, J COLLOID INTERF SCI, V147, P22, DOI 10.1016/0021-9797(91)90130-Z
   BRASH JL, 1987, S SER AM CHEM SOC, V343
   BRASH JL, 1995, S SER AM CHEM SOC, V602
   BRECEVIC L, 1987, COLLOID SURFACE, V28, P301, DOI 10.1016/0166-6622(87)80191-9
   CHENOWETH DE, 1987, ARTIF ORGANS, V11, P155, DOI 10.1111/j.1525-1594.1987.tb02649.x
   CUYPERS PA, 1983, J BIOL CHEM, V258, P2426
   DEFEIJTER JA, 1978, BIOPOLYMERS, V17, P1759, DOI 10.1002/bip.1978.360170711
   DESGRANGES P, 1992, INT J ARTIF ORGANS, V15, P722
   DIJT JC, 1994, ADV COLLOID INTERFAC, V50, P79, DOI 10.1016/0001-8686(94)80026-X
   Drude P., 1889, ANN PHYS CHEM, V36, P532
   ELWING H, 1981, J IMMUNOL METHODS, V44, P343, DOI 10.1016/0022-1759(81)90052-1
   ELWING H, 1988, J COLLOID INTERF SCI, V123, P306, DOI 10.1016/0021-9797(88)90249-4
   ELWING H, 1988, J COLLOID INTERF SCI, V125, P139, DOI 10.1016/0021-9797(88)90062-8
   ELWING H, 1987, J BIOMED MATER RES, V21, P263, DOI 10.1002/jbm.820210209
   ELWING H, 1987, J COLLOID INTERF SCI, V119, P203, DOI 10.1016/0021-9797(87)90260-8
   ELWING H, 1991, J BIOMAT SCI-POLYM E, V3, P7
   ELWING H, 1990, ADV COLLOID INTERFAC, V32, P317, DOI 10.1016/0001-8686(90)80022-R
   ELWING H, 1986, EUR J BIOCHEM, V156, P359, DOI 10.1111/j.1432-1033.1986.tb09591.x
   ELWING H, 1987, ACS SYM SER, V343, P468
   ELWING H, 1990, PATHOGENESIS WOUND B
   ELWING H, J BIOMED MAT RES, V21, P1023
   Elwing HB, 1995, ACS SYM SER, V602, P138
   GIESEN PLA, 1991, J BIOL CHEM, V266, P18720
   GOLANDER CG, 1988, J COLLOID INTERF SCI, V121, P240, DOI 10.1016/0021-9797(88)90428-6
   GOLANDER CG, 1990, COLLOID SURFACE, V49, P289, DOI 10.1016/0166-6622(90)80111-G
   GRISTINA AG, 1993, J EXP MED, V178, P2147
   Ho CH, 1995, ACS SYM SER, V602, P371
   Horbett TA, 1995, ACS SYM SER, V602, P1
   HUSMARK U, COMMUNICATION
   HYGREN H, 1994, BIOPHYS BIOCH, V52, P45
   IVARSSON B, 1986, CRIT REV BIOCOMPAT, V2, P1
   Jahns Gerlinde, 1993, Clinical Materials, V14, P303, DOI 10.1016/0267-6605(93)90017-2
   JANATOVA J, 1991, COMPLEMENT INFLAMMAT, V8, P61, DOI 10.1159/000463181
   JANATOVA J, 1988, METHOD ENZYMOL, V162, P579
   JONSSON U, 1985, J COLLOID INTERF SCI, V103, P360, DOI 10.1016/0021-9797(85)90115-8
   JONSSON U, 1992, ADV BIOSENSORS, V2, P291
   KERN W, 1970, RCA REV, V31, P187
   Kiaei D, 1995, ACS SYM SER, V602, P450
   KOP JMM, 1984, J BIOL CHEM, V259, P3993
   KOZIN F, 1988, INFLAMMATION BASIC P, P101
   Langmuir I, 1937, J AM CHEM SOC, V59, P1406, DOI 10.1021/ja01286a510
   LASSEN B, 1995, THESIS GOTEBORG U SW
   LESTELIUS M, 1994, J BIOMED MATER RES, V28, P871, DOI 10.1002/jbm.820280806
   LI L, 1996, J BIOMED MATER RES, V30, P535
   LIEDBERG B, 1995, LANGMUIR, V11, P3821, DOI 10.1021/la00010a037
   LIU L, 1994, J BIOMED MATER RES, V28, P767, DOI 10.1002/jbm.820280703
   LUNDSTROM I, 1984, J THEOR BIOL, V110, P195, DOI 10.1016/S0022-5193(84)80052-1
   Malmsten M, 1995, ACS SYM SER, V602, P228
   McCrackin F. L., 1969, 479 NBS
   McGuire J, 1995, ACS SYM SER, V602, P52
   MCNALLY AK, 1994, P NATL ACAD SCI USA, V91, P10119, DOI 10.1073/pnas.91.21.10119
   Nadarajah A, 1995, ACS SYM SER, V602, P181
   NILSSON P, 1991, J COLLOID INTERF SCI, V144, P145, DOI 10.1016/0021-9797(91)90244-3
   NILSSON UR, 1982, J IMMUNOL, V129, P2594
   NILSSON UR, 1993, MOL IMMUNOL, V30, P211, DOI 10.1016/0161-5890(93)90050-L
   Norde W, 1995, ACS SYM SER, V602, P26
   NUZZO RG, 1983, J AM CHEM SOC, V105, P4481, DOI 10.1021/ja00351a063
   NYGREN H, 1988, J BIOMED MATER RES, V22, P1, DOI 10.1002/jbm.820220103
   NYGREN H, 1986, J IMMUNOL METHODS, V92, P219, DOI 10.1016/0022-1759(86)90169-9
   NYGREN H, J BIOMED MAT RES, V26, P77
   Painelli A, 2005, CHEM-EUR J, V11, P6053, DOI 10.1002/chem.200401081
   PANKOWSKY DA, 1990, J VASC SURG, V11, P599, DOI 10.1067/mva.1990.18272
   PITT WG, 1989, J COLLOID INTERF SCI, V133, P223, DOI 10.1016/0021-9797(89)90295-6
   PRIME KL, 1991, SCIENCE, V252, P1164, DOI 10.1126/science.252.5009.1164
   ROTHEN A, 1945, REV SCI INSTRUM, V16, P26, DOI 10.1063/1.1770315
   Sato H, 1995, ACS SYM SER, V602, P478
   SEVASTIANOV VI, 1988, CRIT REV BIOCOMPAT, V4, P109
   SLACK SM, 1995, S SER AM CHEM SOC, V602, pCH8
   Steele JG, 1995, ACS SYM SER, V602, P436
   Stenberg M, 1983, J PHYS C S12, VC10, P83
   TANG LP, 1993, J EXP MED, V178, P2147, DOI 10.1084/jem.178.6.2147
   TENGVALL P, 1992, LANGMUIR, V8, P1236, DOI 10.1021/la00041a001
   Tengvall P, 1996, BIOMATERIALS, V17, P1001, DOI 10.1016/0142-9612(96)84675-8
   TENGVALL P, 1992, BIOMATERIALS TISSUE, V10, P511
   UEDAYUKOSKI T, COMMUNICATION
   VANDERKAMP KW, 1993, INT J ARTIF ORGANS, V16, P755
   Vogler E., 1993, WETTABILITY, V49, P184
   VROMAN L, 1969, SURF SCI, V16, P438, DOI 10.1016/0039-6028(69)90037-5
   VROMAN L, 1980, BLOOD, V55, P156
   VROMAN L, 1964, NBS MISCELLANEOUS PU, V256, P335
   WAHLGREN M, 1990, J COLLOID INTERF SCI, V136, P259, DOI 10.1016/0021-9797(90)90096-7
   WAHLGREN M, 1991, TRENDS BIOTECHNOL, V9, P201, DOI 10.1016/0167-7799(91)90064-O
   Walivaara B, 1996, J BIOMAT SCI-POLYM E, V8, P49, DOI 10.1163/156856297X00579
   Walivaara B, 1996, J BIOMAT SCI-POLYM E, V8, P41, DOI 10.1163/156856297X00560
   WALIVAARA B, 1996, THESIS LINKOPING U S
   Warkentin PH, 1995, ACS SYM SER, V602, P163
   WELIN S, 1992, THESIS LINKOPING U S
   WELINKLINTSTROM S, 1993, J COLLOID INTERF SCI, V157, P498, DOI 10.1006/jcis.1993.1213
   WERTHEN M, 1988, J IMMUNOL METHODS, V115, P71, DOI 10.1016/0022-1759(88)90311-0
   Yan GY, 1995, ACS SYM SER, V602, P256
NR 99
TC 209
Z9 214
U1 2
U2 111
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD MAR
PY 1998
VL 19
IS 4-5
BP 397
EP 406
DI 10.1016/S0142-9612(97)00112-9
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA ZP913
UT WOS:000073794900008
PM 9677153
DA 2018-10-19
ER

PT J
AU Siedlecki, CA
   Marchant, RE
AF Siedlecki, CA
   Marchant, RE
TI Atomic force microscopy for characterization of the biomaterial
   interface
SO BIOMATERIALS
LA English
DT Article
ID SCANNING-PROBE-MICROSCOPY; VON-WILLEBRAND-FACTOR; ZNO WHISKER TIP;
   BIOLOGICAL APPLICATIONS; ELECTROLYTE-SOLUTIONS; AQUEOUS-SOLUTIONS; AFM
   TIPS; SURFACE; IMAGES; RESOLUTION
AB The molecular processes that occur at the interface of an implanted biomaterial determines the host response, including phenomena such as protein adsorption, conformational changes and subsequent interactions with cellular components. Until recently, such processes could not be observed directly. Over the past decade, atomic force microscopy (AFM) has provided mechanistic insights into the molecular level interactions that occur at the biomaterial interface. Several unique operational modes have been developed which utilize intermittent contact with the sample and decrease applied shear forces. These dynamic modes also can be used to study the role of different structural components on biomaterial micromechanical properties. Force detection techniques allow molecular level studies of individual receptor-ligand binding events, and force mapping for determining structure/function relationships. Advancements in tip manufacturing, image processing techniques, the use of model surfaces and labeling all have contributed to the advancement of the AFM as a state-of-the-art research instrument. In this report, we examine the applicability of the AFM to the study of biomaterials and cell/molecular interactions. (C) 1998 Published by Elsevier Science Ltd. All rights reserved.
C1 Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA.
   Case Western Reserve Univ, Dept Macromol Sci, Cleveland, OH 44106 USA.
RP Marchant, RE (reprint author), Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA.
EM rxm4@po.cwru.edu
FU NHLBI NIH HHS [HL-4007]
CR ALBRECHT TR, 1990, J VAC SCI TECHNOL A, V8, P3386, DOI 10.1116/1.576520
   ALBRECHT TR, 1988, J VAC SCI TECHNOL A, V6, P271, DOI 10.1116/1.575441
   ANSELMETTI D, 1994, J VAC SCI TECHNOL B, V12, P1500, DOI 10.1116/1.587272
   BALACHANDER N, 1988, TETRAHEDRON LETT, V29, P5593, DOI 10.1016/S0040-4039(00)80820-5
   BASELT DR, 1994, J APPL PHYS, V76, P33, DOI 10.1063/1.357150
   BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930
   BOLAND T, 1995, P NATL ACAD SCI USA, V92, P5297, DOI 10.1073/pnas.92.12.5297
   Bottomley LA, 1996, ANAL CHEM, V68, pR185, DOI 10.1021/a1960008+
   BRAUNSTEIN D, 1995, J VAC SCI TECHNOL A, V13, P1733, DOI 10.1116/1.579760
   BUTT HJ, 1992, BIOPHYS J, V63, P578, DOI 10.1016/S0006-3495(92)81601-6
   BUTT HJ, 1991, BIOPHYS J, V60, P1438, DOI 10.1016/S0006-3495(91)82180-4
   CLEVELAND JP, 1993, REV SCI INSTRUM, V64, P403, DOI 10.1063/1.1144209
   DAMMER U, 1995, SCIENCE, V267, P1173, DOI 10.1126/science.7855599
   DREIER M, 1994, J APPL PHYS, V76, P5095, DOI 10.1063/1.357221
   DUCKER WA, 1991, NATURE, V353, P239, DOI 10.1038/353239a0
   DUCKER WA, 1992, LANGMUIR, V8, P1831, DOI 10.1021/la00043a024
   ENGEL A, 1991, ANNU REV BIOPHYS BIO, V20, P79, DOI 10.1146/annurev.biophys.20.1.79
   EPPELL SJ, 1993, LANGMUIR, V9, P2281, DOI 10.1021/la00033a007
   EPPELL SJ, 1995, BIOPHYS J, V68, P671, DOI 10.1016/S0006-3495(95)80228-6
   FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628
   FRISBIE CD, 1994, SCIENCE, V265, P2071, DOI 10.1126/science.265.5181.2071
   FRITZ M, 1994, J VAC SCI TECHNOL B, V12, P1526, DOI 10.1116/1.587278
   FRITZ M, 1994, BIOPHYS J, V66, P1328, DOI 10.1016/S0006-3495(94)80963-4
   GOULD SAC, 1990, J VAC SCI TECHNOL A, V8, P369, DOI 10.1116/1.576398
   GRAFSTROM S, 1994, J VAC SCI TECHNOL B, V12, P1559, DOI 10.1116/1.587286
   HANSMA HG, 1993, NUCLEIC ACIDS RES, V21, P505, DOI 10.1093/nar/21.3.505
   HANSMA PK, 1988, SCIENCE, V242, P209, DOI 10.1126/science.3051380
   HANSMA PK, 1994, APPL PHYS LETT, V64, P1738, DOI 10.1063/1.111795
   HEGNER M, 1993, FEBS LETT, V336, P452, DOI 10.1016/0014-5793(93)80854-N
   HEINZELMANN H, 1988, J VAC SCI TECHNOL A, V6, P275, DOI 10.1116/1.575424
   HOLLAND NB, 1996, THESIS CASE W RESERV
   ILL CR, 1993, BIOPHYS J, V64, P919, DOI 10.1016/S0006-3495(93)81452-8
   ISHINO T, 1994, JPN J APPL PHYS 1, V33, P4718, DOI 10.1143/JJAP.33.4718
   ITOH T, 1994, J VAC SCI TECHNOL B, V12, P1581, DOI 10.1116/1.587291
   ITOH T, 1994, JPN J APPL PHYS 1, V33, P334, DOI 10.1143/JJAP.33.334
   KADO H, 1994, J VAC SCI TECHNOL B, V12, P1923, DOI 10.1116/1.587671
   KADO H, 1992, REV SCI INSTRUM, V63, P3330, DOI 10.1063/1.1142548
   KAJIYAMA T, 1994, MACROMOLECULES, V27, P7932, DOI 10.1021/ma00104a061
   KARRASCH S, 1994, P NATL ACAD SCI USA, V91, P836, DOI 10.1073/pnas.91.3.836
   KARRASCH S, 1993, BIOPHYS J, V65, P2437, DOI 10.1016/S0006-3495(93)81327-4
   KAWAI A, 1992, JPN J APPL PHYS 2, V31, pL977, DOI 10.1143/JJAP.31.L977
   KELLER D, 1991, SURF SCI, V253, P353, DOI 10.1016/0039-6028(91)90606-S
   KELLER DJ, 1992, SURF SCI, V268, P333, DOI 10.1016/0039-6028(92)90973-A
   KIKUKAWA A, 1994, JPN J APPL PHYS 2, V33, pL1286, DOI 10.1143/JJAP.33.L1286
   LAL R, 1994, AM J PHYSIOL, V266, pC1
   LANTZ MA, 1994, APPL PHYS LETT, V65, P409, DOI 10.1063/1.112317
   LEA AS, 1992, LANGMUIR, V8, P68, DOI 10.1021/la00037a015
   LEE GU, 1994, LANGMUIR, V10, P354, DOI 10.1021/la00014a003
   LEUNG OM, 1992, SCIENCE, V255, P64, DOI 10.1126/science.255.5040.64
   LI YQ, 1993, LANGMUIR, V9, P637, DOI 10.1021/la00027a003
   LUDWIG M, 1994, MICROSC MICROANAL M, V5, P321, DOI 10.1051/mmm:0199400504-6032100
   Magonov S. N., 1996, SURFACE ANAL STM AFM
   MARCHANT RE, 1992, J COLLOID INTERF SCI, V148, P261, DOI 10.1016/0021-9797(92)90135-9
   Marchant RE, 1997, THROMB HAEMOSTASIS, V77, P1048
   MARKIEWICZ P, 1994, LANGMUIR, V10, P5, DOI 10.1021/la00013a002
   MARTIN Y, 1987, J APPL PHYS, V61, P4723, DOI 10.1063/1.338807
   MCGHIE AJ, 1995, CHEMTECH         AUG, P20
   MELMED AJ, 1991, J VAC SCI TECHNOL B, V9, P601, DOI 10.1116/1.585467
   MEYER G, 1990, APPL PHYS LETT, V57, P2089, DOI 10.1063/1.103950
   MONTELIUS L, 1994, J VAC SCI TECHNOL B, V12, P2222, DOI 10.1116/1.587746
   MOY VT, 1994, COLLOID SURFACE A, V93, P343, DOI 10.1016/0927-7757(94)02933-4
   Mueller CD, 1997, POLYM ENG SCI, V37, P355, DOI 10.1002/pen.11678
   MULLER DJ, 1995, BIOPHYS J, V68, P1681
   NAKAGAWA T, 1994, J VAC SCI TECHNOL B, V12, P2215, DOI 10.1116/1.587744
   NAKAGAWA T, 1994, LANGMUIR, V10, P525, DOI 10.1021/la00014a031
   PARRAT D, 1994, ANALUSIS, V22, pM35
   PINGALI GS, 1994, J VAC SCI TECHNOL B, V12, P2184, DOI 10.1116/1.587737
   PUTNAM CAJ, 1994, BIOPHYS J, V67, P1749
   PUTNAM CAJ, 1995, APPL PHYS LETT, V64, P2454
   QUATE CF, 1994, SURF SCI, V299, P980, DOI 10.1016/0039-6028(94)90711-0
   RABINOVICH YI, 1994, LANGMUIR, V10, P1903, DOI 10.1021/la00018a048
   RADMACHER M, 1992, SCIENCE, V257, P1900, DOI 10.1126/science.1411505
   RADMACHER M, 1993, BIOPHYS J, V64, P735, DOI 10.1016/S0006-3495(93)81433-4
   RADMACHER M, 1994, BIOPHYS J, V66, P2159, DOI 10.1016/S0006-3495(94)81011-2
   Sarid D., 1991, SCANNING FORCE MICRO
   SAVI TS, 1991, J VAC SCI TECHNOL B, V8, P2733
   SENDEN TJ, 1994, LANGMUIR, V10, P1003, DOI 10.1021/la00016a600
   SHAIU WL, 1993, NUCLEIC ACIDS RES, V21, P99, DOI 10.1093/nar/21.1.99
   SHAOHUA X, 1995, P NATL ACAD SCI USA, V92, P10384
   SIEDLECKI CA, 1994, J BIOMED MATER RES, V28, P971, DOI 10.1002/jbm.820280902
   Siedlecki CA, 1996, BLOOD, V88, P2939
   TANSOCK J, 1992, ULTRAMICROSCOPY, V42, P1464, DOI 10.1016/0304-3991(92)90467-X
   Ulman A., 1991, INTRO ULTRATHIN ORGA
   VINCKIER A, 1995, ULTRAMICROSCOPY, V57, P337, DOI 10.1016/0304-3991(94)00194-R
   WAGNER P, 1994, FEBS LETT, V356, P267, DOI 10.1016/0014-5793(94)01296-2
   WARMACK RJ, 1994, REV SCI INSTRUM, V65, P394, DOI 10.1063/1.1145144
   WEISENDANGER R, 1994, SCANNING PROBE MICRO
   WEISMAN AD, 1992, J APPL PHYS, V71, P1565, DOI 10.1063/1.351233
   Wilson DL, 1996, J VAC SCI TECHNOL B, V14, P2407, DOI 10.1116/1.588870
   WILSON DL, 1995, LANGMUIR, V11, P265, DOI 10.1021/la00001a045
   WONG TMH, 1995, J MICROSC-OXFORD, V178, P7, DOI 10.1111/j.1365-2818.1995.tb03574.x
   XIMEN HY, 1992, ULTRAMICROSCOPY, V42, P1526, DOI 10.1016/0304-3991(92)90477-2
   YANG J, 1994, BBA-GEN SUBJECTS, V1199, P105, DOI 10.1016/0304-4165(94)90104-X
   YANG J, 1993, J MICROSC-OXFORD, V171, P183, DOI 10.1111/j.1365-2818.1993.tb03375.x
NR 94
TC 86
Z9 89
U1 1
U2 29
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD MAR
PY 1998
VL 19
IS 4-5
BP 441
EP 454
DI 10.1016/S0142-9612(97)00222-6
PG 14
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA ZP913
UT WOS:000073794900011
PM 9677156
DA 2018-10-19
ER

PT J
AU Ong, JL
   Lucas, LC
AF Ong, JL
   Lucas, LC
TI Auger electron spectroscopy and its use for the characterization of
   titanium and hydroxyapatite surfaces
SO BIOMATERIALS
LA English
DT Article
DE auger electron spectroscopy; titanium; hydroxyapatite; depth profiling;
   surface composition
ID CALCIUM-PHOSPHATE COATINGS; SENSITIVITY FACTORS; AES; ALLOYS;
   RESOLUTION; INTERFACE; ADHESION; IMPLANTS; PROFILES; SPECTRA
AB This review paper provides the basic background and underlying theory behind Auger electron spectroscopy (AES). Among the many surface analytical tools, AES has been shown to be very effective for surface composition analysis. These analyses are critically needed to better understand the interactions between the host and implant. The use of AES for titanium (Ti) and hydroxyapatite (HA) biomaterials characterization is demonstrated in this paper. The relative peak heights of TiL2,3M2,3V can be used as 'fingerprints' for TiO2 surfaces which have undergone different degrees of reduction. Similarly, for HA coatings, a shift in the phosphorus Auger peaks to a higher kinetic energy indicates the presence of a phosphate group, with strong P-O bonds.
   Depth compositional profiling and thin-film analysis can be performed using AES. In our studies, oxide thicknesses on Ti surfaces range from 36.8 +/- 7.4 Angstrom to 436 +/- 49 Angstrom depending on the surface treatment. Depth profiling can also be used to determine the subsurface composition of biomaterials. For HA coatings, a phosphorus concentration at the oxide/metal interface has been observed to be higher than at the outermost oxide surface. The HA coatings have also been observed to coexist within the titanium oxide, suggesting the occurrence of chemical bonding between the coatings and the metallic substrates.
   However, like other analytical tools, AES has its limitations. The electron beam damage can severely limit useful analysis of organic and biological materials and occasionally ceramic materials. Carbide buildup during long beam exposure times has been shown to affect the relative peak-to-peak intensities of the oxygen and metal Auger signals. The determination of film thickness requires a standard of known thickness and depth profiling of overlapping peaks can be very problematic. Even with these limitation, AES can be a powerful analytical tool for the characterization of biomaterial surfaces. (C) 1998 Published by Elsevier Science Ltd. All rights reserved.
C1 Univ Texas, Hlth Sci Ctr, Dept Restorat Dent, Div Biomat, San Antonio, TX 78284 USA.
   Univ Alabama Birmingham, Dept Biomed Engn, Birmingham, AL 35294 USA.
RP Ong, JL (reprint author), Univ Texas, Hlth Sci Ctr, Dept Restorat Dent, Div Biomat, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.
CR ALBREKTSSON T, 1981, ACTA ORTHOP SCAND, V52, P155, DOI 10.3109/17453678108991776
   BAIER RE, 1991, SURF BIOM S MINN
   BARTELS T, 1979, CARIES RES, V13, P218, DOI 10.1159/000260403
   Bassett P. J., 1973, Journal of Electron Spectroscopy and Related Phenomena, V2, P101, DOI 10.1016/0368-2048(73)80052-0
   BERNETT MK, 1977, J ELECTRON SPECTROSC, V12, P375, DOI 10.1016/0368-2048(77)85089-5
   BUMGARDNER JD, 1993, DENT MATER, V9, P252, DOI 10.1016/0109-5641(93)90070-7
   CHANG CC, 1974, J APPL PHYS, V45, P252, DOI 10.1063/1.1662969
   COBURN JW, 1976, J VAC SCI TECHNOL, V13, P1037, DOI 10.1116/1.569056
   DAVIS GD, 1983, APPL SURF SCI, V15, P321, DOI 10.1016/0378-5963(83)90026-0
   DAVIS LE, HDB AUGER ELECT SPEC
   DOUNDOULAKIS JH, 1987, J PROSTHET DENT, V58, P471, DOI 10.1016/0022-3913(87)90279-4
   DRIESSENS FCM, 1987, CALCIF TISS RES, V26, P127
   FERRON J, 1984, SURF SCI, V145, pL501, DOI 10.1016/0167-2584(84)90125-7
   FINE J, 1988, SURF INTERFACE ANAL, V11, P542, DOI 10.1002/sia.740111010
   GRANT JT, 1974, SURF SCI, V42, P1, DOI 10.1016/0039-6028(74)90002-8
   GRANT JT, 1974, J VAC SCI TECHNOL, V11, P227, DOI 10.1116/1.1318575
   GRANT JT, 1973, PHYS LETT A, VA 45, P309, DOI 10.1016/0375-9601(73)90092-3
   HAAS TW, 1972, ADSORPTION DESORPTIO, P359
   HALL PM, 1979, SURF SCI, V83, P391, DOI 10.1016/0039-6028(79)90052-9
   HANAWA T, 1991, BIOMATERIALS, V12, P767, DOI 10.1016/0142-9612(91)90028-9
   HANEIN D, 1993, J CELL SCI, V104, P275
   HARRIS LA, 1968, J APPL PHYS, V39, P1428, DOI 10.1063/1.1656375
   HARRIS LA, 1968, J APPL PHYS, V39, P1419, DOI 10.1063/1.1656374
   HENCH LL, 1974, J BIOMED MATER RES, V8, P49, DOI 10.1002/jbm.820080307
   HERCULES DM, 1992, CRIT REV SURF CHEM, V1, P243
   HOFFMAN S, 1990, PRACTICAL SURFACE AN, V1, P143
   HOLLOWAY PH, 1977, SURF SCI, V66, P635, DOI 10.1016/0039-6028(77)90043-7
   HORBETT TA, 1982, ADV CHEM SER, P233
   JARCHO M, 1977, J BIOENG, V1, P79
   JUNG A, 1973, CALC TISS RES, V11, P269, DOI 10.1007/BF02547227
   KASEMO B, 1986, CRIT REV BIOCOMPAT, V2, P335
   Kawahara D, 1996, Int J Oral Maxillofac Implants, V11, P435
   KELLER J C, 1990, International Journal of Oral and Maxillofacial Implants, V5, P360
   KELLER JC, 1989, J ADHESION, V28, P115, DOI 10.1080/00218468908030878
   KOOPMAN MC, 1990, MICROBEAM ANAL, V25, P263
   LANDER JJ, 1953, PHYS REV, V91, P1382, DOI 10.1103/PhysRev.91.1382
   LAUSMAA J, 1990, APPL SURF SCI, V44, P133, DOI 10.1016/0169-4332(90)90100-E
   LEGEROS RZ, 1991, CALCIUM PHOSPHATES O, P46
   LUCAS LC, 1993, COLLOID SURFACE A, V77, P141, DOI 10.1016/0927-7757(93)80110-Z
   MATHIEU HJ, 1977, J VAC SCI TECHNOL, V14, P1023, DOI 10.1116/1.569313
   MATTOX DM, 1982, DEPOSITION TECHNOLOG, P63
   MICHAELS C M, 1991, Journal of Oral Implantology, V17, P132
   MILLER RG, 1993, DENT MATER, V9, P280, DOI 10.1016/0109-5641(93)90075-2
   MITCHELL DF, 1981, J VAC SCI TECHNOL, V18, P690, DOI 10.1116/1.570928
   MROCZKOWSKI S, 1983, SURF SCI, V127, P119, DOI 10.1016/0039-6028(83)90403-X
   MROCZKOWSKI S, 1985, SURF SCI, V154, pL221, DOI 10.1016/0039-6028(85)90030-5
   MROCZKOWSKI S, 1985, J VAC SCI TECHNOL A, V3, P1860, DOI 10.1116/1.572933
   NORDBERG R, 1968, ARK KEMI, V28, P257
   NORDLING C, 1966, REV ROUM PHYS, V11, P797
   OECHSNER H, 1975, APPL PHYS, V8, P185, DOI 10.1007/BF00896610
   OKAZAKI M, 1983, CALCIFIED TISSUE INT, V35, P78, DOI 10.1007/BF02405010
   OLSSON J, 1991, COLLOID POLYM SCI, V269, P1295, DOI 10.1007/BF00652539
   OLSSON J, 1990, J DENT RES, V69, P1586, DOI 10.1177/00220345900690091001
   ONG JL, 1993, APPL SURF SCI, V72, P7, DOI 10.1016/0169-4332(93)90036-B
   ONG JL, 1992, BIOMATERIALS, V13, P249, DOI 10.1016/0142-9612(92)90192-Q
   ONG JL, 1994, BIOMATERIALS, V15, P337, DOI 10.1016/0142-9612(94)90245-3
   ONG JL, 1995, J MATER SCI-MATER M, V6, P113, DOI 10.1007/BF00120418
   ONG JL, 1994, COLLOID SURFACE A, V87, P151, DOI 10.1016/0927-7757(94)02774-9
   ONG JL, 1991, J AM CERAM SOC, V74, P2301, DOI 10.1111/j.1151-2916.1991.tb08301.x
   ONG JL, 1994, J BIOMED MATER RES, V28, P1337, DOI 10.1002/jbm.820281112
   PALMBERG PW, 1969, APPL PHYS LETT, V15, P254, DOI 10.1063/1.1652989
   PANTEL R, 1988, J VAC SCI TECHNOL A, V6, P2953, DOI 10.1116/1.575458
   PAYLING R, 1985, J ELECTRON SPECTROSC, V36, P99, DOI 10.1016/0368-2048(85)80010-4
   PAYLING R, 1985, J ELECTRON SPECTROSC, V37, P225, DOI 10.1016/0368-2048(85)80070-0
   PAYLING R, 1987, J ELECTRON SPECTROSC, V43, P37, DOI 10.1016/0368-2048(87)80017-8
   RAEMDONCK WV, 1984, J AM CERAM SOC, V67, P381
   RICCI JL, 1991, BONE BIOMATERIALS IN, P205
   RIVIERE JC, 1990, PRACTICAL SURFACE AN, V1, P19
   SATO T, 1989, SURF INTERFACE ANAL, V14, P787, DOI 10.1002/sia.740141116
   SEAH MP, 1984, VACUUM, V34, P463, DOI 10.1016/0042-207X(84)90084-8
   SEAH MP, 1988, NUCL INSTRUM METH B, V30, P128, DOI 10.1016/0168-583X(88)90109-7
   SEAH MP, 1981, THIN SOLID FILMS, V81, P279, DOI 10.1016/0040-6090(81)90490-9
   SEAH MP, 1981, THIN SOLID FILMS, V81, P239, DOI 10.1016/0040-6090(81)90486-7
   SEAH MP, 1981, THIN SOLID FILMS, V81, P257, DOI 10.1016/0040-6090(81)90488-0
   SICKAFUS EN, 1975, SURF SCI, V51, P131, DOI 10.1016/0039-6028(75)90238-1
   SOLOMON JS, 1975, SURF SCI, V51, P228, DOI 10.1016/0039-6028(75)90245-9
   TARNG ML, 1971, J APPL PHYS, V42, P2449, DOI 10.1063/1.1660561
   TENGVALL P, 1992, CLIN MAT, V11, P115
   THOMAS S, 1976, SURF SCI, V55, P754, DOI 10.1016/0039-6028(76)90279-X
   WAGNER CD, 1980, ANAL CHEM, V52, P1445, DOI 10.1021/ac50059a017
NR 80
TC 36
Z9 37
U1 1
U2 16
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD MAR
PY 1998
VL 19
IS 4-5
BP 455
EP 464
DI 10.1016/S0142-9612(97)00224-X
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA ZP913
UT WOS:000073794900012
PM 9677157
DA 2018-10-19
ER

PT J
AU Friess, W
AF Friess, W
TI Collagen - biomaterial for drug delivery
SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
LA English
DT Review
DE biomaterials; collagen; crosslinking; devices; growth factors;
   injectables; ophthalmology; sponges
ID DERMAL SHEEP COLLAGEN; CROSS-LINKED COLLAGEN; FIBROBLAST GROWTH-FACTOR;
   IN-VITRO DEGRADATION; BONE MORPHOGENETIC PROTEIN-2; CHEMICALLY MODIFIED
   COLLAGEN; ARTIFICIAL SKIN; MECHANICAL-PROPERTIES; EXTRACELLULAR-MATRIX;
   INJECTABLE COLLAGEN
AB The use of collagen as a biomaterial is currently undergoing a renaissance in the tissue engineering field. The biotechnological applications focus on the aspects of cellular growth or delivery of proteins capable of stimulating cellular response. However, basic knowledge about collagen biochemistry and the processing technology in combination with understanding of the physico-chemical properties is necessary for an adequate application of collagen for carrier systems. The purpose of this review article is to summarize information available on collagen dosage forms for drug delivery as well as to impart an overview of the chemical structures and the galenical properties including detailed description of the processing steps - extraction, purification, chemical crosslinking and sterilization. The most successful and stimulating applications are shields in ophthalmology, injectable dispersions for local tumor treatment, sponges carrying antibiotics and minipellets loaded with protein drugs. However, the scientific information about manipulating release properties or mechanistic studies is not as abundant as for some synthetic polymers. (C) 1998 Elsevier Science B.V.
C1 Univ Erlangen Nurnberg, Dept Pharmaceut Technol, D-91058 Erlangen, Germany.
EM wfriess@pharmtech.uni-erlangen.de
CR ALTANKOV G, 1991, Journal of Biomaterials Science Polymer Edition, V2, P81, DOI 10.1163/156856291X00089
   ANSELME K, 1992, MATRIX, V12, P264, DOI 10.1016/S0934-8832(11)80078-8
   ANSELME K, 1990, J BIOMED MATER RES, V24, P689, DOI 10.1002/jbm.820240605
   AQUAVELLA JV, 1988, J CATARACT REFR SURG, V14, P492, DOI 10.1016/S0886-3350(88)80004-X
   ASSIL KK, 1992, AM J OPHTHALMOL, V113, P418, DOI 10.1016/S0002-9394(14)76165-3
   Bajpai PK, 1985, BIOCOMPATIBILITY TIS, P5
   Baldwin SP, 1996, INT J DEV NEUROSCI, V14, P351, DOI 10.1016/0736-5748(96)00018-4
   Barnes MJ, 1982, COLLAGEN HLTH DISEAS, P179
   BAZIN S, 1976, METHODOLOGY CONNECTI, P13
   BAZIUK N, 1992, INT OPHTHALMOL, V16, P101, DOI 10.1007/BF00918940
   BECKER PL, 1994, J ORTHOPAED RES, V12, P737, DOI 10.1002/jor.1100120517
   BELL E, 1981, SCIENCE, V211, P1052, DOI 10.1126/science.7008197
   BENICEWICZ BC, 1990, J BIOACT COMPAT POL, V5, P453, DOI 10.1177/088391159000500407
   BERG RA, 1989, Patent No. 4837285
   BERG RA, 1994, Patent No. 16570
   BERTHIAUME F, 1995, BIOMEDICAL ENG HDB, P1556
   Berthold A, 1998, EUR J PHARM BIOPHARM, V45, P23, DOI 10.1016/S0939-6411(97)00119-7
   Bhatnagar R., 1991, HIGH PERFORMANCE BIO, P179
   BLOOMFIELD SE, 1978, ARCH OPHTHALMOL-CHIC, V96, P885
   Boden SD, 1996, SPINE, V21, P2689, DOI 10.1097/00007632-199611150-00020
   BOON ME, 1995, BIOMATERIALS, V16, P1089, DOI 10.1016/0142-9612(95)98905-T
   BOYCE ST, 1992, J BIOMED MATER RES, V26, P547, DOI 10.1002/jbm.820260410
   BOYCE ST, 1988, J BIOMED MATER RES, V22, P939, DOI 10.1002/jbm.820221008
   BRADLEY WG, 1977, BIOMATER ARTIF CELL, V5, P159, DOI 10.3109/10731197709118671
   *BRIT PHARM, 1993, MON ABS GEL SPONG, P1280
   BRODSKY B, 1988, COLLAGEN, V1, P95
   *BUND BUND, 1994, BEK SICH ARZN KORP R, P46
   BURKE JF, 1981, ANN SURG, V194, P413, DOI 10.1097/00000658-198110000-00005
   CALHOUN JH, 1989, AM J SURG, V157, P443, DOI 10.1016/0002-9610(89)90597-7
   CASCONE MG, 1995, BIOMATERIALS, V16, P569, DOI 10.1016/0142-9612(95)91131-H
   CAWSTON TE, 1981, METHOD ENZYMOL, V80, P711
   CENDRON M, 1995, J UROLOGY, V154, P808, DOI 10.1016/S0022-5347(01)67170-2
   CHEN CS, 1995, BIOMATERIALS, V16, P777, DOI 10.1016/0142-9612(95)99640-8
   CHEUNG DT, 1990, J BIOMED MATER RES, V24, P581, DOI 10.1002/jbm.820240505
   CHVAPIL M, 1993, J BIOMED MATER RES, V27, P313, DOI 10.1002/jbm.820270305
   CHVAPIL M, 1977, J BIOMED MATER RES, V11, P721, DOI 10.1002/jbm.820110508
   CHVAPIL M, 1982, J BIOMED MATER RES, V16, P245, DOI 10.1002/jbm.820160306
   CHVAPIL M, 1986, J SURG RES, V41, P410, DOI 10.1016/0022-4804(86)90055-7
   CHVAPIL M, 1973, INT REV CONNECTIVE T, P1
   CIOCA G, 1981, Patent No. 4279812
   *COMM EUR COMM, 1992, III329891EN EC
   COOK SD, 1995, J BONE JOINT SURG AM, V77A, P734, DOI 10.2106/00004623-199505000-00010
   COOK SD, 1994, J BONE JOINT SURG AM, V76A, P827, DOI 10.2106/00004623-199406000-00006
   COOPERMAN L, 1984, J AM ACAD DERMATOL, V10, P647, DOI 10.1016/S0190-9622(84)80272-8
   COOPERMAN L, 1984, J AM ACAD DERMATOL, V10, P638, DOI 10.1016/S0190-9622(84)80271-6
   DAGALAKIS N, 1980, J BIOMED MATER RES, V14, P511, DOI 10.1002/jbm.820140417
   DAMINCK LHH, 1992, THESIS U TWENTE NETH
   DAMINK LHH, 1992, J MATER SCI-MATER M, V2, P142
   Damink LHHO, 1996, BIOMATERIALS, V17, P679, DOI 10.1016/0142-9612(96)86737-8
   DAMINK LHHO, 1995, J BIOMED MATER RES, V29, P139, DOI 10.1002/jbm.820290202
   DAMINK LHHO, 1995, J BIOMED MATER RES, V29, P149, DOI 10.1002/jbm.820290203
   DAVIDSON BS, 1995, J SURG RES, V58, P618, DOI 10.1006/jsre.1995.1097
   DEATHERAGE JR, 1987, COLLAGEN REL RES, V7, P225
   DELUSTRO F, 1986, J BIOMED MATER RES, V20, P109, DOI 10.1002/jbm.820200110
   DeVore D. P., 1996, PRINCIPLES PRACTICE, P670
   Devore Dale P., 1995, P1233
   Deyl ZAM, 1976, METHODOLOGY CONNECTI, P1
   DIAMOND AM, 1991, MATRIX, V11, P321, DOI 10.1016/S0934-8832(11)80203-9
   DOCHERTY R, 1989, J CELL SCI, V92, P263
   DOILLON CJ, 1986, BIOMATERIALS, V7, P3, DOI 10.1016/0142-9612(86)90080-3
   DOILLON CJ, 1986, J BIOMED MATER RES, V20, P1219, DOI 10.1002/jbm.820200811
   DORIGO MT, 1995, CHEMOTHERAPY, V41, P1, DOI 10.1159/000239317
   DORR RT, 1982, J BIOMED MATER RES, V16, P839, DOI 10.1002/jbm.820160609
   DUNG SZ, 1994, ARCH ORAL BIOL, V39, P901, DOI 10.1016/0003-9969(94)90022-1
   ELLINGSWORTH LR, 1986, J IMMUNOL, V136, P877
   Ellis DL, 1996, BIOMATERIALS, V17, P291, DOI 10.1016/0142-9612(96)85567-0
   ETHERINGTON DJ, 1981, ACTA BIOL MED GER, V40, P1625
   ETHERINGTON DJ, CYSTEIN PROTEINASES, P269
   EYBL E, 1989, J BIOMED MATER RES, V23, P1355, DOI 10.1002/jbm.820231111
   *FDC, 1997, GEL BSE COUNTR MAY B, P5
   FIELDING AM, 1976, METHODOLOGY CONNECTI, P9
   FINKELSTEIN I, 1990, CURR EYE RES, V9, P653, DOI 10.3109/02713689008999580
   FIRSOV AA, 1987, DRUG DEV IND PHARM, V13, P1651, DOI 10.3109/03639048709068686
   Fleckenstein P.D.C.D., 1986, DE Patent, Patent No. [3429038 A1, 3429038]
   FRIEDBERG ML, 1991, OPHTHALMOLOGY, V98, P725
   Friess W, 1996, BIOMATERIALS, V17, P2289, DOI 10.1016/0142-9612(96)00047-6
   Friess W, 1996, Pharm Dev Technol, V1, P185, DOI 10.3109/10837459609029893
   Friess W, 1996, PHARM SCI, V2, P1
   Friess Wolfgang, 1997, Pharmaceutical Research (New York), V14, pS155
   Friess Wolfgang, 1997, Pharmaceutical Research (New York), V14, pS154
   FU CCR, 1990, Patent No. 901196261
   FUJIMURA K, 1995, BIOCHEM BIOPH RES CO, V208, P316, DOI 10.1006/bbrc.1995.1340
   FUJIOKA K, 1995, J CONTROL RELEASE, V33, P307, DOI 10.1016/0168-3659(94)00107-6
   FUJIOKA Y, 1991, PHARM TECH JAPAN, V7, P402
   Fujisato T, 1996, BIOMATERIALS, V17, P155, DOI 10.1016/0142-9612(96)85760-7
   Gao TJ, 1996, J BIOMED MATER RES, V32, P505, DOI 10.1002/(SICI)1097-4636(199612)32:4<505::AID-JBM2>3.0.CO;2-V
   GAO TJ, 1996, BONE MORPHOGENETIC P, P121
   GEBHARDT BM, 1995, J OCUL PHARMACOL TH, V11, P319, DOI 10.1089/jop.1995.11.319
   GEBHARDT BM, 1995, J OCUL PHARMACOL TH, V11, P509, DOI 10.1089/jop.1995.11.509
   Geesin JC, 1996, J BIOMED MATER RES, V33, P1
   GERHART TN, 1988, J ORTHOPAED RES, V6, P585, DOI 10.1002/jor.1100060417
   GERICKE R, 1990, Patent No. 4938257
   GERVAISLUGAN M, 1991, J BIOMED MATER RES, V25, P1339, DOI 10.1002/jbm.820251103
   GILBERT D, 1988, THESIS U UTACH UT
   Golker CF, 1996, BIOLOGICALS, V24, P103
   GOLOMB G, 1987, AM J PATHOL, V127, P122
   Gorham S. D., 1991, BIOMATERIALS, P55
   GORHAM SD, 1992, INT J BIOL MACROMOL, V14, P129, DOI 10.1016/S0141-8130(05)80002-9
   GORHAM SD, 1990, BIOMATERIALS, V11, P113, DOI 10.1016/0142-9612(90)90125-A
   GRABAREK Z, 1990, ANAL BIOCHEM, V185, P131, DOI 10.1016/0003-2697(90)90267-D
   GRAHAM L, 1994, ANAL BIOCHEM, V217, P298, DOI 10.1006/abio.1994.1122
   Grammer JB, 1996, CURR EYE RES, V15, P815, DOI 10.3109/02713689609017622
   Gratzer PF, 1996, J BIOMED MATER RES, V31, P533, DOI 10.1002/(SICI)1097-4636(199608)31:4<533::AID-JBM14>3.0.CO;2-H
   GREENWALD RA, 1987, J RHEUMATOL, V14, P28
   GUNKEL C, 1994, THESIS U MARBURG GER
   GUYURON B, 1992, PLAST RECONSTR SURG, V89, P234, DOI 10.1097/00006534-199202000-00005
   HANCOCK K, 1989, BRIT MED J, V299, P1179, DOI 10.1136/bmj.299.6709.1179
   Hanson DA, 1996, J BIOL CHEM, V271, P26508, DOI 10.1074/jbc.271.43.26508
   HASSELL J, 1974, J HISTOCHEM CYTOCHEM, V22, P223, DOI 10.1177/22.4.223
   HASTY B, 1990, AM J OPHTHALMOL, V109, P721, DOI 10.1016/S0002-9394(14)72443-2
   Heidemann E., 1988, COLLAGEN, VIII, P39
   HOBDEN JA, 1988, ARCH OPHTHALMOL-CHIC, V106, P1605, DOI 10.1001/archopht.1988.01060140773053
   HOCKEMANN PF, 1992, CHIRURG NAHT, P59
   Horakova Z, 1967, Therapie, V22, P1455
   HORISAKA Y, 1994, J BIOMED MATER RES, V28, P97, DOI 10.1002/jbm.820280113
   HUANGLEE LLH, 1990, J BIOMED MATER RES, V24, P1185, DOI 10.1002/jbm.820240905
   HUBBELL JA, 1995, BIO-TECHNOL, V13, P565, DOI 10.1038/nbt0695-565
   HUNT JA, 1993, BIOMATERIALS, V14, P378, DOI 10.1016/0142-9612(93)90058-A
   HWANG DG, 1989, ARCH OPHTHALMOL-CHIC, V107, P1375, DOI 10.1001/archopht.1989.01070020445052
   Jayakrishnan A, 1996, BIOMATERIALS, V17, P471, DOI 10.1016/0142-9612(96)82721-9
   JEFFERIES SR, 1977, BIOMATER ARTIF CELL, V5, P337, DOI 10.3109/10731197709118683
   JOOSTEN EAJ, 1995, J NEUROSCI RES, V41, P481, DOI 10.1002/jnr.490410407
   Jorgensen L G, 1991, Eur J Vasc Surg, V5, P87, DOI 10.1016/S0950-821X(05)80933-8
   JORTIKKA L, 1996, BONE MORPHOGENETIC P, P65
   Kanekal S., 1995, Pharmaceutical Research (New York), V12, pS228
   Kaufman H.E., 1989, US Patent, Patent No. [4865846 A, 4865846]
   KAUFMAN HE, 1988, J CATARACT REFR SURG, V14, P487, DOI 10.1016/S0886-3350(88)80002-6
   KENLEY RA, 1993, PHARMACEUT RES, V10, P1393, DOI 10.1023/A:1018902720816
   Khor E, 1997, BIOMATERIALS, V18, P95, DOI 10.1016/S0142-9612(96)00106-8
   KIMURA S, 1981, J BIOL CHEM, V256, P3230
   KINCL FA, 1980, ENDOCRINOL EXP, V14, P27
   KNAPP TR, 1977, J SURG RES, V23, P96, DOI 10.1016/0022-4804(77)90196-2
   KOIDE M, 1993, J BIOMED MATER RES, V27, P79, DOI 10.1002/jbm.820270111
   KREUTER J, 1990, Patent No. 4038887
   KSANDER GA, 1990, ANN SURG, V211, P288
   Kucharz EJ, 1992, COLLAGENS BIOCH PATH, P7
   KUCHARZ EJ, 1992, COLLAGENS BIOCH PATH, P55
   KUCHARZ EJ, 1992, COLLAGENS BIOCH PATH, P34
   LABOW TA, 1985, CUTIS, V35, P154
   Lee H. B., 1995, BIOMEDICAL ENG HDB, P581
   LEE JM, 1994, J BIOMED MATER RES, V28, P981, DOI 10.1002/jbm.820280903
   LEE SL, 1983, COLLAGEN REL RES, V3, P305
   LEFEBVRE F, 1992, BIOMATERIALS, V13, P28, DOI 10.1016/0142-9612(92)90091-2
   Lefebvre F, 1996, BIOMATERIALS, V17, P1813, DOI 10.1016/0142-9612(95)00346-0
   LEPISTO J, 1994, EUR SURG RES, V26, P267, DOI 10.1159/000129345
   LI ST, 1995, BIOMEDICAL ENG HDB, P627
   LINSENMAYER TF, 1982, COLLAGEN HLTH DISEAS, P244
   LU MYF, 1991, POLYM CONTROLLED DRU, P149
   MAFFIA GJ, 1994, MATER RES SOC SYMP P, V331, P53
   MARCHAND R, 1993, BRAIN RES BULL, V30, P415, DOI 10.1016/0361-9230(93)90273-E
   MARKS MG, 1991, J BIOMED MATER RES, V25, P683, DOI 10.1002/jbm.820250510
   MARMER RH, 1988, J CATARACT REFR SURG, V14, P496, DOI 10.1016/S0886-3350(88)80005-1
   MATSUDA K, 1991, BRIT J PLAST SURG, V44, P142, DOI 10.1016/0007-1226(91)90049-P
   MATSUDA K, 1992, BIOMATERIALS, V13, P119, DOI 10.1016/0142-9612(92)90007-B
   Matsuoka J, 1988, T AM SOC ART INT ORG, V34, P729
   MCNAMARA TF, 1990, Patent No. 4935412
   MCPHERSON IM, 1986, J BIOMED MATER RES, V20, P93
   MCPHERSON JM, 1986, J BIOMED MATER RES, V20, P79, DOI 10.1002/jbm.820200108
   MEADE KR, 1990, BIOMATERIALS, V11, P176, DOI 10.1016/0142-9612(90)90151-F
   MEGERMAN J, 1991, J BIOMED MATER RES, V25, P295, DOI 10.1002/jbm.820250303
   Mendicute Javier, 1995, CLAO Journal, V21, P252
   MILANI JK, 1993, AM J OPHTHALMOL, V116, P622, DOI 10.1016/S0002-9394(14)73206-4
   Miller E. J., 1984, EXTRACELLULAR MATRIX, P41
   MILLER EJ, 1988, COLLAGEN, V1, P139
   MINABE M, 1989, J PERIODONTOL, V60, P113, DOI 10.1902/jop.1989.60.2.113
   MINABE M, 1989, J PERIODONTOL, V60, P552, DOI 10.1902/jop.1989.60.10.552
   MIYATA T, 1971, BIOCHIM BIOPHYS ACTA, V229, P672, DOI 10.1016/0005-2795(71)90283-2
   NAIMARK WA, 1995, J MATER SCI-MATER M, V6, P235, DOI 10.1007/BF00146862
   NAKASHIMA M, 1994, ARCH ORAL BIOL, V39, P1085, DOI 10.1016/0003-9969(94)90062-0
   NAKASHIMA M, 1994, J DENT RES, V73, P1515, DOI 10.1177/00220345940730090601
   NASTRUZZI C, 1994, J MICROENCAPSUL, V11, P249, DOI 10.3109/02652049409040454
   NIMNI ME, 1987, J BIOMED MATER RES, V21, P741, DOI 10.1002/jbm.820210606
   NIMNI ME, 1988, COLLAGEN, V1, P1
   Nimni ME, 1988, COLLAGEN, VIII, P1
   Ning S, 1996, RADIOTHER ONCOL, V39, P179, DOI 10.1016/0167-8140(96)01718-5
   NISHI C, 1995, J BIOMED MATER RES, V29, P829, DOI 10.1002/jbm.820290707
   OBRIEN TP, 1988, J CATARACT REFR SURG, V14, P505, DOI 10.1016/S0886-3350(88)80007-5
   OKADA T, 1992, BIOMATERIALS, V13, P448, DOI 10.1016/0142-9612(92)90165-K
   OLIVER RF, 1982, BIOMATERIALS, V3, P38, DOI 10.1016/0142-9612(82)90059-X
   OLIVER RF, 1976, CLIN ORTHOP RELAT R, P291
   OLIVER RF, 1980, BRIT J EXP PATHOL, V61, P544
   Olmo N, 1996, J BIOMED MATER RES, V30, P77
   ONER L, 1993, PHARMACEUT RES, V10, P621, DOI 10.1023/A:1018974708637
   Othman MO, 1996, MED ENG PHYS, V18, P584, DOI 10.1016/1350-4533(95)00083-6
   Pachence JM, 1996, J BIOMED MATER RES, V33, P35, DOI 10.1002/(SICI)1097-4636(199621)33:1<35::AID-JBM6>3.0.CO;2-N
   Pachence JM, 1987, MED DEVICE DIAGN IND, V9, P49
   PAINO CL, 1994, J NEUROCYTOL, V23, P433, DOI 10.1007/BF01207115
   PAJEAN M, 1993, INT J PHARM, V91, P209, DOI 10.1016/0378-5173(93)90340-L
   PALEFSKY H, 1992, Patent No. 5428022
   PALMER RM, 1995, J CATARACT REFR SURG, V21, P125, DOI 10.1016/S0886-3350(13)80497-X
   PALOKANGAS H, 1992, MATRIX, V12, P291, DOI 10.1016/S0934-8832(11)80081-8
   PARKHURST MR, 1994, CELL IMMUNOL, V156, P77, DOI 10.1006/cimm.1994.1154
   PARKHURST MR, 1992, BIOPHYS J, V61, P306, DOI 10.1016/S0006-3495(92)81838-6
   PENG YM, 1986, INVEST NEW DRUG, V4, P245
   PETITE H, 1995, BIOMATERIALS, V16, P1003, DOI 10.1016/0142-9612(95)94908-4
   PETITE H, 1990, J BIOMED MATER RES, V24, P179, DOI 10.1002/jbm.820240205
   PHINNEY RB, 1988, ARCH OPHTHALMOL-CHIC, V106, P1599, DOI 10.1001/archopht.1988.01060140767052
   Piez K. A., 1985, ENCY POLYM SCI ENG, P699
   PIEZ KA, 1984, EXTRACELLULAR MATRIX, P1
   PLEYER U, 1994, CURR EYE RES, V13, P177, DOI 10.3109/02713689408995775
   POLAND DE, 1988, J CATARACT REFR SURG, V14, P489, DOI 10.1016/S0886-3350(88)80003-8
   PRATT DA, 1992, ANAL BIOCHEM, V207, P168, DOI 10.1016/0003-2697(92)90519-D
   PUNCH PI, 1987, J VET PHARMACOL THER, V10, P37, DOI 10.1111/j.1365-2885.1987.tb00074.x
   QUIJANO RC, 1994, J BIOMED MATER RES, V28, P677
   RAGHUNATH K, 1985, J MACROMOL SCI CHEM, VA22, P1735, DOI 10.1080/00222338508063368
   RAMESH DV, 1989, INDIAN J BIOCHEM BIO, V26, P196
   Rao KP, 1995, J BIOMAT SCI-POLYM E, V7, P623
   RASMUSSEN KE, 1974, HISTOCHEMISTRY, V38, P19, DOI 10.1007/BF00490216
   RATCLIFFE JH, 1984, J PHARM PHARMACOL, V36, P431, DOI 10.1111/j.2042-7158.1984.tb04419.x
   REICH RR, 1992, ENCY PHARM TECHNOLOG, V5, P315
   REISER K, 1992, FASEB J, V6, P2439
   REMACLE M, 1995, ANN OTO RHINOL LARYN, V104, P437, DOI 10.1177/000348949510400604
   Ripamonti U, 1996, GROWTH FACTORS, V13, P273, DOI 10.3109/08977199609003228
   RIPAMONTI U, 1996, BONE MORPHOGENETIC P, P131
   ROBIN JB, 1990, INVEST OPHTH VIS SCI, V31, P1294
   ROMANOS GE, 1995, J BIOMED MATER RES, V29, P1121, DOI 10.1002/jbm.820290912
   ROREGER M, 1995, Patent No. 28964
   ROS RE, 1991, CLAO J, V17, P187
   ROSENBLATT J, 1994, BIOMATERIALS, V15, P985, DOI 10.1016/0142-9612(94)90079-5
   ROSENBLATT J, 1989, J CONTROL RELEASE, V9, P195, DOI 10.1016/0168-3659(89)90088-6
   ROSENBLATT JS, 1995, Patent No. 951015890
   ROSSLER B, 1995, J MICROENCAPSUL, V12, P49, DOI 10.3109/02652049509051126
   ROSSLER B, 1994, PHARMAZIE, V49, P175
   ROSSLER B, 1993, THESIS U FRANKFURT G
   ROYCE PM, 1995, J DERMATOL SCI, V10, P42, DOI 10.1016/0923-1811(95)93713-B
   RUBIN AL, 1973, J CLIN PHARMACOL, V13, P309, DOI 10.1002/j.1552-4604.1973.tb00217.x
   RUDERMAN RJ, 1973, J BIOMED MATER RES, V7, P263, DOI 10.1002/jbm.820070213
   RUIJGROK JM, 1993, SCANNING, V15, P110, DOI 10.1002/sca.4950150207
   RUIJGROK JM, 1994, J MATER SCI-MATER M, V5, P80, DOI 10.1007/BF00121695
   Rushton N, 1997, EUR J SURG, V163, P27
   Sabolinski ML, 1996, BIOMATERIALS, V17, P311, DOI 10.1016/0142-9612(96)85569-4
   Sahai A., 1995, Pharmaceutical Research (New York), V12, pS227
   SALTZMAN WM, 1992, ANN NY ACAD SCI, V665, P259, DOI 10.1111/j.1749-6632.1992.tb42590.x
   SAWUSCH MR, 1988, AM J OPHTHALMOL, V106, P279, DOI 10.1016/0002-9394(88)90361-3
   SAWUSCH MR, 1988, J CATARACT REFR SURG, V14, P625
   Scaglione F, 1997, EUR J SURG, V163, P11
   SCHIMANDLE JH, 1995, SPINE, V20, P1326, DOI 10.1097/00007632-199506000-00002
   SCHWARTZ SD, 1990, AM J OPHTHALMOL, V109, P701, DOI 10.1016/S0002-9394(14)72439-0
   SHAKER GJ, 1989, INVEST OPHTH VIS SCI, V30, P1565
   SHORTLIFFE LMD, 1989, J UROLOGY, V141, P538
   SILVER FH, 1979, J BIOMED MATER RES, V13, P701, DOI 10.1002/jbm.820130504
   SIMIONESCU A, 1991, J BIOMED MATER RES, V25, P1495, DOI 10.1002/jbm.820251207
   SINGH M, 1993, P INT S CONTR REL BI, V20, P107
   SINGH M, 1994, P INT S CONTR REL BI, V21, P300
   SINGH MA, 1994, THESIS U MARYLAND BA
   SINGH MP, 1995, PHARMACEUT RES, V12, P1205, DOI 10.1023/A:1016272212833
   Sintzel MB, 1996, EUR J PHARM BIOPHARM, V42, P358
   SLAVIN J, 1992, BRIT J SURG, V79, P69, DOI 10.1002/bjs.1800790124
   SONG SZ, 1993, Patent No. 21908
   SONG SZ, 1992, Patent No. 923054673
   SPIRA M, 1994, J BIOMED MATER RES, V28, P91, DOI 10.1002/jbm.820280112
   SRIVASTAVA S, 1990, BIOMATERIALS, V11, P162, DOI 10.1016/0142-9612(90)90149-K
   SRIVASTAVA S, 1990, BIOMATERIALS, V11, P155, DOI 10.1016/0142-9612(90)90148-J
   STEFFAN W, 1985, Patent No. 821053410
   STEFFEN C, 1968, IMMUNOLOGY, V15, P135
   Stemberger A, 1997, EUR J SURG, V163, P17
   Stemberger A., 1990, COSMETIC PHARM APPL, P263
   STOMPRO BE, 1989, J SURG RES, V46, P413, DOI 10.1016/0022-4804(89)90153-4
   STRICKLIN GP, 1988, COLLAGEN, V1, P187
   Sung HW, 1996, J BIOMED MATER RES, V31, P511, DOI 10.1002/(SICI)1097-4636(199608)31:4<511::AID-JBM11>3.0.CO;2-J
   Sung HW, 1996, J BIOMED MATER RES, V30, P361, DOI 10.1002/(SICI)1097-4636(199603)30:3<361::AID-JBM10>3.0.CO;2-N
   SUTTON R, 1990, SELECT CANCER THER, V6, P35, DOI 10.1089/sct.1990.6.35
   TABATA Y, 1989, PHARMACEUT RES, V6, P422, DOI 10.1023/A:1015991617704
   TAKEDA U, 1982, Journal of Toxicological Sciences, V7, P63
   TAKENAKA H, 1986, PHARM TECH JAPAN, V2, P1083
   TAKEUCHI K, 1992, NIHON SHISHUBYO GAKK, V34, P741
   Tang Z, 1995, ASAIO J, V41, P72, DOI 10.1097/00002480-199501000-00012
   Taylor EW, 1997, EUR J SURG, V163, P5
   Timpl R, 1984, EXTRACELLULAR MATRIX, P159
   Toolan BC, 1996, J BIOMED MATER RES, V31, P273, DOI 10.1002/(SICI)1097-4636(199606)31:2<273::AID-JBM15>3.0.CO;2-M
   TRELSTAD RL, 1982, IMMUNOCHEMISTRY EXTR, V1, P32
   TU R, 1993, J BIOMED MATER RES, V27, P3, DOI 10.1002/jbm.820270103
   TU R, 1993, INT J ARTIF ORGANS, V16, P537
   TWEDEN KS, 1989, J PERIODONTOL, V60, P460, DOI 10.1902/jop.1989.60.8.460
   ULUDAG H, 1996, P 1996 M CONTR REL S, P51
   UNTERMAN SR, 1988, J CATARACT REFR SURG, V14, P500, DOI 10.1016/S0886-3350(88)80006-3
   URIST MR, 1996, BONE MORPHOGENETIC P, P7
   *US DEP HHS, 1997, GUID IND SOURC PROC
   *US PHARM, 1995, STER ION RAD, P1978
   VANLUYN MJA, 1992, J BIOMED MATER RES, V26, P1091, DOI 10.1002/jbm.820260810
   VANLUYN MJA, 1992, BIOMATERIALS, V13, P1017, DOI 10.1016/0142-9612(92)90153-F
   vanWachem PB, 1996, J BIOMED MATER RES, V30, P353, DOI 10.1002/(SICI)1097-4636(199603)30:3<353::AID-JBM9>3.0.CO;2-P
   VANWACHEM PB, 1994, INT J ARTIF ORGANS, V17, P230
   VANWACHEM PB, 1991, BIOMATERIALS, V12, P215, DOI 10.1016/0142-9612(91)90203-M
   VARDAXIS NJ, 1994, J BIOMED MATER RES, V28, P1013, DOI 10.1002/jbm.820280906
   VASANTHA R, 1988, INT J PHARM, V47, P95
   VINK P, 1986, BIOMATERIALS, V7, P225, DOI 10.1016/0142-9612(86)90108-0
   VISSER CE, 1992, BIOMATERIALS, V13, P34, DOI 10.1016/0142-9612(92)90092-3
   VONHASSELBACH C, 1988, 26 WORLD C INT C SUR
   VONHASSELBACH C, 1989, INFKETIONEN UNFALLCH, V29, P459
   WacholDrewek Z, 1996, BIOMATERIALS, V17, P1733, DOI 10.1016/0142-9612(96)87654-X
   WAHLIG H, 1980, ACTA ORTHOP SCAND, V51, P49, DOI 10.3109/17453678008990768
   WAHLIG H, 1986, P EUR C BIOM BOL IT, P196
   Wallace D. G., 1988, COLLAGEN, V3, P117
   WALLACE DG, 1987, J BIOMED MATER RES, V21, P861, DOI 10.1002/jbm.820210704
   WALLACE DG, 1989, J BIOMED MATER RES, V23, P931, DOI 10.1002/jbm.820230809
   WALLACE DG, 1988, Patent No. 873056519
   WANG CL, 1978, BIOCHIM BIOPHYS ACTA, V544, P555, DOI 10.1016/0304-4165(78)90330-6
   WANG E, 1993, INT J ARTIF ORGANS, V16, P530
   WANG MC, 1994, BIOMATERIALS, V15, P507
   WEADOCK K, 1983, BIOMATER ARTIF CELL, V11, P293, DOI 10.3109/10731198309118815
   WEADOCK KS, 1995, J BIOMED MATER RES, V29, P1373, DOI 10.1002/jbm.820291108
   Weadock KS, 1996, J BIOMED MATER RES, V32, P221, DOI 10.1002/(SICI)1097-4636(199610)32:2<221::AID-JBM11>3.0.CO;2-M
   WEINER AL, 1985, J PHARM SCI, V74, P922, DOI 10.1002/jps.2600740903
   WEISSMAN BA, 1988, ARCH OPHTHALMOL-CHIC, V106, P1706, DOI 10.1001/archopht.1988.01060140878032
   WELGUS HG, 1980, J BIOL CHEM, V255, P6806
   WIEBE D, 1988, SURGERY, V104, P26
   WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0
   WOODROOF EA, 1978, J BIOENG, V2, P1
   Woolley D. E., 1984, EXTRACELLULAR MATRIX, P119
   XI TF, 1992, J BIOMED MATER RES, V26, P1241
   YAMAHIRA Y, 1985, Patent No. 841123102
   YAMAHIRA Y, 1991, Patent No. 841123136
   Yamauchi M., 1988, COLLAGEN, P157
   YANNAS AV, 1967, NATURE, V215, P509
   YANNAS IV, 1990, ANGEW CHEM INT EDIT, V29, P20, DOI 10.1002/anie.199000201
   YANNAS IV, 1980, J BIOMED MATER RES, V14, P65, DOI 10.1002/jbm.820140108
   YANNAS IV, 1980, J BIOMED MATER RES, V14, P107, DOI 10.1002/jbm.820140203
   YANNAS IV, 1975, J BIOMED MATER RES, V9, P623, DOI 10.1002/jbm.820090608
   YU NY, 1995, CANCER CHEMOTH PHARM, V36, P27
NR 320
TC 696
Z9 729
U1 5
U2 199
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0939-6411
EI 1873-3441
J9 EUR J PHARM BIOPHARM
JI Eur. J. Pharm. Biopharm.
PD MAR
PY 1998
VL 45
IS 2
BP 113
EP 136
DI 10.1016/S0939-6411(98)00017-4
PG 24
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 133KP
UT WOS:000076686000002
PM 9704909
DA 2018-10-19
ER

PT J
AU Cunanan, CM
   Ghazizadeh, M
   Buchen, SY
   Knight, PM
AF Cunanan, CM
   Ghazizadeh, M
   Buchen, SY
   Knight, PM
TI Contact-angle analysis of intraocular lenses
SO JOURNAL OF CATARACT AND REFRACTIVE SURGERY
LA English
DT Article
ID SURFACE-PROPERTIES; SOLID-SURFACES; CELL ADHESION
AB Purpose: To present contact-angle measurements of commercially available intraocular lenses (IOLs) in air and in water to facilitate the understanding of how various IOLs might interact in different environments.
   Setting: Laboratory.
   Methods: Five commercially available IOLs were studied. AMO(R) DuraLens(R) PS-59NB(TM), AMO PhacoFlex(R) SI-26NB(TM), AMO PhacoFlex II(R) SI-30NB(R), Chiron(R) ChiroFlex(R) C10UB, and Alcon(R) AcrySof(R) MA60BM. The AMO soft acrylic model AR40(TM), currently under clinical study, was also evaluated. Contact-angle measurements were made in air and in water using sessile drop and captive bubble methods.
   Results: The sessile drop method indicated that all materials were hydrophobic in air. The captive bubble method differentiated materials based on their polar and dispersive forces.
   Conclusion: Contact-angle measurements differed depending on the test conditions. Proper choice of contact-angle measurement method can generate useful information about a material surface and its potential biomaterial interactions.
C1 Allergan Pharmaceut Inc, Irvine, CA USA.
RP Cunanan, CM (reprint author), 2525 Dupont Dr,POB 19534, Irvine, CA 92623 USA.
CR Andrade J D, 1973, Med Instrum, V7, P110
   ANDRADE JD, 1979, J POLYM SCI POL SYM, P313
   ANDRADE JD, 1986, ADV POLYM SCI, V79, P1
   BAIER RE, 1970, ADHESION BIOLOGICAL, pCH2
   CHANDY T, 1991, J BIOMED MATER RES, V25, P1085, DOI 10.1002/jbm.820250904
   CHRIST FR, 1992, J BIOMED MATER RES, V26, P607
   CUNANAN CM, 1991, J CATARACT REFR SURG, V17, P767
   EISENBERGER P, 1996, J BIOMED MATER RES, V32, P143
   HAMILTON WC, 1972, J COLLOID INTERF SCI, V40, P219, DOI 10.1016/0021-9797(72)90011-2
   HORBETT TA, 1985, J COLLOID INTERF SCI, V104, P28, DOI 10.1016/0021-9797(85)90006-2
   JANSEN JA, 1983, ADV BIOMATER, P259
   KAELBLE DH, 1977, POLYMER, V18, P475, DOI 10.1016/0032-3861(77)90164-1
   KINLOCH AJ, 1980, J MATER SCI, V15, P2141, DOI 10.1007/BF00552302
   LYDON MJ, 1985, BIOMATERIALS, V6, P396, DOI 10.1016/0142-9612(85)90100-0
   MATEO NB, 1989, INVEST OPHTH VIS SCI, V30, P853
   NAVASCUES G, 1981, CHEM PHYS LETT, V82, P586, DOI 10.1016/0009-2614(81)85446-2
   RUCKENSTEIN E, 1987, J COLLOID INTERF SCI, V120, P153, DOI 10.1016/0021-9797(87)90334-1
   SCHURCH S, 1981, BIOCHIM BIOPHYS ACTA, V640, P557, DOI 10.1016/0005-2736(81)90480-6
   TABOR D, 1977, J COLLOID INTERF SCI, V58, P2, DOI 10.1016/0021-9797(77)90366-6
   WEAST RC, 1984, CRC HDB CHEM PHYSICS, pF33
   WISE DL, 1995, ENCY HDB BIOMATERI A, V1
   Wu S., 1971, J POLYM SCI C, V34, P19, DOI DOI 10.1002/POLC.5070340105
   Young T, 1805, PHILOS T R SOC LONDO, V95, P65, DOI DOI 10.1098/RSTL.1805.0005
   Zisman WA, 1972, J PAINT TECH, V44, P42
NR 24
TC 39
Z9 42
U1 0
U2 4
PU AMER SOC CATARACT REFRACTIVE SURGERY
PI FAIRFAX
PA 4000 LEGATO RD, SUITE 850, FAIRFAX, VA 22030 USA
SN 0886-3350
J9 J CATARACT REFR SURG
JI J. Cataract. Refract. Surg.
PD MAR
PY 1998
VL 24
IS 3
BP 341
EP 351
DI 10.1016/S0886-3350(98)80322-2
PG 11
WC Ophthalmology; Surgery
SC Ophthalmology; Surgery
GA ZD939
UT WOS:000072740900018
PM 9559470
DA 2018-10-19
ER

PT J
AU Dahm, M
   Dohmen, G
   Prufer, D
   Krummenauer, F
   Hafner, G
   Oelert, H
AF Dahm, M
   Dohmen, G
   Prufer, D
   Krummenauer, F
   Hafner, G
   Oelert, H
TI Determinants of calcium uptake of bovine pericardium for heart valve
   replacement: Results of in vitro studies
SO JOURNAL OF HEART VALVE DISEASE
LA English
DT Article; Proceedings Paper
CT Symposium on Use of Pericardium in Cardiac Surgery
CY OCT 02-04, 1997
CL LONDON, ENGLAND
ID BIOPROSTHETIC VALVE; CALCIFICATION; GLUTARALDEHYDE; EXPERIENCE
AB Background and aims of the study: Reduction of biomaterial calcification is an important aim in the basic research of biological heart valves. An in vitro model was used to investigate the influence of serum calcium concentration and surface coverage with cells car basal proteins on calcium uptake of bovine pericardium.
   Methods: Samples of glutaraldehyde-tanned bovine pericardium, stored in formaldehyde and detoxified with borohydride were incubated for two weeks with cell culture medium containing low (1.0 mmol/l) or physiologic (2.3 mmol. Ca/l) calcium concentration. Specimens were either unseeded, completely surface-covered with rat fibrocytes (rf) ar fibrin (fi), or incompletely seeded with rabbit cells (re). Quality of surface coverage was assessed by surface scanning electron microscopy and calcium content by atomic absorption spectroscopy.
   Results: Serum calcium had a significant influence on calcium uptake (low versus physiological (1.58 +/- 2.45 mg/g versus 8.10 +/- 1.73 mg/g wet wt, p<0.001). This may explain early calcification of bioimplants in children, and patients on dialysis. Surface coverage significantly reduces calcium uptake (ft 1.20 +/- 0.41 mg/g, rf, 4.20 +/- 1.70 mg/g, p<0.001) but complete coverage is necessary (re, 6.98 +/- 1.64 mg/g, NS).
   Conclusions: In vitro testing of calcium uptake has proven to be a valuable tool for evaluation of biomaterial calcification.
C1 Univ Hosp Mainz, Dept Cardiothorac & Vasc Surg, D-55131 Mainz, Germany.
   Univ Hosp Mainz, Dept Med Stat, D-55131 Mainz, Germany.
   Univ Hosp Mainz, Dept Biochem, D-55131 Mainz, Germany.
RP Dahm, M (reprint author), Univ Hosp Mainz, Dept Cardiothorac & Vasc Surg, Langenbeckstr 1, D-55131 Mainz, Germany.
CR Abolhoda A, 1996, ANN THORAC SURG, V62, P169, DOI 10.1016/0003-4975(96)00277-9
   ANTUNES MJ, 1984, EUR HEART J, V5, P913, DOI 10.1093/oxfordjournals.eurheartj.a061591
   CARPENTIER A, 1969, J THORAC CARDIOV SUR, V58, P467
   CHEN WL, 1994, CIRCULATION, V90, P323, DOI 10.1161/01.CIR.90.1.323
   Dahm M, 1996, J HEART VALVE DIS, V5, P148
   DAHM M, 1990, Z HERZ THORAX GEFASS, V4, P38
   Fann JI, 1996, ANN THORAC SURG, V62, P1301, DOI 10.1016/0003-4975(96)00629-7
   FERRANS VJ, 1978, AM J CARDIOL, V41, P1159, DOI 10.1016/0002-9149(78)90873-1
   FOSTER AH, 1987, ANN THORAC SURG, V44, P568, DOI 10.1016/S0003-4975(10)62137-6
   GONZALEZLAVIN L, 1991, J THORAC CARDIOV SUR, V101, P75
   GOTT JP, 1992, ANN THORAC SURG, V53, P207, DOI 10.1016/0003-4975(92)91321-Y
   LENTZ DJ, 1982, Patent No. 4323358
   LEVY RJ, 1985, SCIENCE, V228, P190, DOI 10.1126/science.3919445
   MENASCHE P, 1986, BIOL BIOPROSTHETIC V, P478
   OYER PE, 1980, J THORAC CARDIOV SUR, V80, P824
   TOMAZIC BB, 1994, J BIOMED MATER RES, V28, P35, DOI 10.1002/jbm.820280106
NR 16
TC 2
Z9 2
U1 0
U2 0
PU I C R PUBLISHERS
PI NORTHWOOD
PA CRISPIN HOUSE, 12/A SOUTH APPROACH, MOOR PARK, NORTHWOOD, ENGLAND HA6
   2ET
SN 0966-8519
J9 J HEART VALVE DIS
JI J. Heart Valve Dis.
PD MAR
PY 1998
VL 7
IS 2
BP 170
EP 173
PG 4
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA ZD080
UT WOS:000072649400008
PM 9587857
DA 2018-10-19
ER

PT J
AU Schoen, FJ
AF Schoen, FJ
TI Pathologic findings in explanted clinical bioprosthetic valves
   fabricated form photooxidized bovine pericardium
SO JOURNAL OF HEART VALVE DISEASE
LA English
DT Article; Proceedings Paper
CT Symposium on Use of Pericardium in Cardiac Surgery
CY OCT 02-04, 1997
CL LONDON, ENGLAND
ID HEART-VALVES; CALCIFICATION; TISSUE; GLUTARALDEHYDE; FAILURE;
   STABILIZATION
AB Background and aims of the study: The study afm was to assess tissue quality and host-biomaterial interactions in clinical bioprostheses fabricated front bovine pericardium preserved by dye-mediated photooxidation, but not glutaraldehyde-pretreated.
   Methods: Ten ace-tie valves explanted for regurgitation after 8-23 months' function from 10 patients aged 67-83 years were analyzed by gross and dissecting microscope examination, radiography and light microscopy.
   Results: Each valve had one to several commissural-basal tears (5 am) to complete leaflet detachment (four valves). The path-ein of tearing was consistent among valves and suggested that a mechanism of design-related proximal inflow surface cuspal abrasion against Dacron cloth was contributory, Mild cuspal sagging/stretching was noted in five valves, pannus overgrowth was mild, and there was no evidence of infection or macroscopic thrombus. Microscopically, tissue distant from tears in all valves had an essentially intact;but acellular collagenous matric, was devoid of residual connective tissue cells and host inflammatory cells, with mild fragmentation of the inflow collagen bundles, and showed no evidence of endothelialization, Despite radiographs uniformly negative for mineralization, focal intrinsic cuspal microcalcification was noted histologically in four valves.
   Conclusions: Design-related and largely abrasion-induced tearing caused failures of:his cohort of photooxidized pericardial valves. Nevertheless, this non-glutaraldehyde-preserved photofixed pericardial tissue from valves suffering design-related cuspal tears to two years postoperatively remained without significant degradation, inflammation, infection,thrombus, pannus or calcification.
C1 Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Boston, MA USA.
RP Schoen, FJ (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.
CR Aupart MR, 1996, ANN THORAC SURG, V61, P615, DOI 10.1016/0003-4975(95)00953-1
   BENGTSSON LA, 1995, ANN THORAC SURG, V60, pS365, DOI 10.1016/0003-4975(95)00316-D
   Bianco RW, 1996, J HEART VALVE DIS, V5, P317
   Cosgrove D M, 1996, Semin Thorac Cardiovasc Surg, V8, P269
   Fisher J, 1987, Eur J Cardiothorac Surg, V1, P71, DOI 10.1016/1010-7940(87)90015-7
   Fisher J, 1987, Eng Med, V16, P105
   GIRARDOT MN, 1995, J BIOMED MATER RES, V29, P793, DOI 10.1002/jbm.820290703
   GOLOMB G, 1987, AM J PATHOL, V127, P122
   Grabenwoger M, 1996, ANN THORAC SURG, V62, P772
   HILBERT SL, 1992, AM J PATHOL, V140, P1195
   LEVY RJ, 1983, AM J PATHOL, V113, P143
   MCGONAGLEWOLFF K, 1992, AM J CARDIOL, V70, P263, DOI 10.1016/0002-9149(92)91286-D
   Moore MA, 1997, ASAIO J, V43, P23, DOI 10.1097/00002480-199701000-00006
   MOORE MA, 1994, J BIOMED MATER RES, V28, P611, DOI 10.1002/jbm.820280511
   Moore MA, 1996, J BIOMED MATER RES, V32, P209, DOI 10.1002/(SICI)1097-4636(199610)32:2<209::AID-JBM9>3.0.CO;2-X
   Moore MA, 1997, J HEART VALVE DIS, V6, P307
   Schoen F J, 1992, Cardiovasc Pathol, V1, P29, DOI 10.1016/1054-8807(92)90006-A
   SCHOEN FJ, 1986, AM J PATHOL, V123, P134
   SCHOEN FJ, 1995, CARDIOVASC PATHOL, V4, P241, DOI 10.1016/1054-8807(95)00051-6
   SCHOEN FJ, 1987, CIRCULATION, V76, P618, DOI 10.1161/01.CIR.76.3.618
   THIENE G, 1989, AM J CARDIOL, V63, P129, DOI 10.1016/0002-9149(89)91099-0
   Thoma R J, 1995, J Heart Valve Dis, V4, P214
   TURINA J, 1993, CIRCULATION, V88, P775, DOI 10.1161/01.CIR.88.2.775
   Vyavahare NR, 1997, CARDIOVASC PATHOL, V6, P219, DOI 10.1016/S1054-8807(97)00017-3
   WALLEY VM, 1987, J THORAC CARDIOV SUR, V93, P925
   WHEATLEY DJ, 1987, J THORAC CARDIOV SUR, V94, P367
NR 26
TC 45
Z9 47
U1 0
U2 6
PU I C R PUBLISHERS
PI NORTHWOOD
PA CRISPIN HOUSE, 12/A SOUTH APPROACH, MOOR PARK, NORTHWOOD, ENGLAND HA6
   2ET
SN 0966-8519
J9 J HEART VALVE DIS
JI J. Heart Valve Dis.
PD MAR
PY 1998
VL 7
IS 2
BP 174
EP 179
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA ZD080
UT WOS:000072649400009
PM 9587858
DA 2018-10-19
ER

PT J
AU An, YHH
   Friedman, RJ
AF An, YHH
   Friedman, RJ
TI Animal models of orthopedic implant infection
SO JOURNAL OF INVESTIGATIVE SURGERY
LA English
DT Article
DE animal models; bacterial adhesion; biomaterials; prosthetic infection;
   Staphylococcus epidermidis
ID FOREIGN-BODY INFECTION; STAPHYLOCOCCUS-EPIDERMIDIS; TOTAL HIP; BACTERIAL
   ADHERENCE; JOINT; OSTEOMYELITIS; ARTHROPLASTY; SEPSIS; AUREUS;
   REPLACEMENT
AB Prosthetic infection following total joint replacement can have catastrophic results both physically and psychologically for patients, leading to complete failure of the arthroplasty, possible amputation, prolonged hospitalization, and even death. Although with the use of prophylactic antibiotics and greatly improved operating room techniques the infection rate has decreased markedly during the years, challenges still remain for better preventive and therapeutic measures. In this review the in vivo experimental methods for studies of prosthetic infection are discussed, concentrating on (1) the animal models that have been established and the use of these animal models for studies of pathogenesis of bacteria, behavior of biofilm, effect of biomaterials on prosthetic infection rate, and the effect of infection on biomaterial surfaces, and (2) how to design and conduct an animal model of orthopedic prosthetic infection including animal selection, implant fabrication, bacterial inoculation, surgical technique, and the methods for evaluating the results.
C1 Med Univ S Carolina, Dept Orthoped Surg, Orthoped Res Lab, Charleston, SC 29425 USA.
RP An, YHH (reprint author), Med Univ S Carolina, Dept Orthoped Surg, Orthoped Res Lab, 171 Ashley AVe, Charleston, SC 29425 USA.
EM anh@musc.edu
CR An YH, 1996, J HOSP INFECT, V33, P93, DOI 10.1016/S0195-6701(96)90094-8
   An YH, 1997, J BONE JOINT SURG BR, V79B, P816, DOI 10.1302/0301-620X.79B5.7228
   An YH, 1996, J ORTHOPAED RES, V14, P846, DOI 10.1002/jor.1100140526
   ANDREWS HJ, 1981, J BONE JOINT SURG BR, V63, P53
   Arens S, 1996, J BONE JOINT SURG BR, V78B, P647
   Belmatoug N, 1996, J INFECT DIS, V174, P414, DOI 10.1093/infdis/174.2.414
   BLOMGREN G, 1981, ACTA ORTHOP SCAND, V52, P7
   BURET A, 1991, J BIOMED MATER RES, V25, P865, DOI 10.1002/jbm.820250706
   CHANG CC, 1994, J ORTHOPAED RES, V12, P526, DOI 10.1002/jor.1100120409
   CHEATLE MD, 1991, ORTHOP CLIN N AM, V22, P539
   CHRISTENSEN GD, 1983, INFECT IMMUN, V40, P407
   EFTEKHAR NS, 1976, ARCH SURG-CHICAGO, V111, P150
   ESPERSEN F, 1993, J ANTIMICROB CHEMOTH, V31, P103, DOI 10.1093/jac/31.suppl_D.103
   FITZGERALD RH, 1977, J BONE JOINT SURG AM, V59, P847, DOI 10.2106/00004623-197759070-00001
   GALLIMORE B, 1991, J INFECT DIS, V164, P1220, DOI 10.1093/infdis/164.6.1220
   ISIKLAR ZU, 1993, T ORTHOP RES SOC, V18, P458
   JOSEFSSON G, 1993, CLIN ORTHOP RELAT R, P210
   KIESWETTER K, 1992, T SOC BIOMATER, V16, P220
   LIDWELL OM, 1982, BRIT MED J, V285, P10, DOI 10.1136/bmj.285.6334.10
   MAYBERRYCARSON KJ, 1988, MICROBIOS, V54, P45
   MAYBERRYCARSON KJ, 1984, INFECT IMMUN, V43, P825
   MAYBERRYCARSON KJ, 1992, CLIN ORTHOP RELAT R, P289
   MELCHER GA, 1994, J BONE JOINT SURG BR, V76B, P955
   MERRITT K, 1979, J BIOMED MATER RES, V13, P101, DOI 10.1002/jbm.820130111
   MERRITT K, 1991, T SOC BIOMATER, V14, P106
   NAKAMOTO DA, 1995, INVEST RADIOL, V30, P341, DOI 10.1097/00004424-199506000-00003
   NELSON JP, 1980, CLIN ORTHOP RELAT R, P167
   NORDEN CW, 1988, REV INFECT DIS, V10, P103
   NORDEN CW, 1980, BRIT J EXP PATHOL, V61, P451
   PETTY W, 1985, J BONE JOINT SURG AM, V67A, P1236, DOI 10.2106/00004623-198567080-00015
   PETTY W, 1988, J BONE JOINT SURG AM, V70A, P536, DOI 10.2106/00004623-198870040-00009
   Rissing J P, 1990, Infect Dis Clin North Am, V4, P377
   SMITH MM, 1989, J AM VET MED ASSOC, V195, P765
   SOUTHWOOD RT, 1985, J BONE JOINT SURG BR, V67, P229
   VARMA S, 1974, J SURG RES, V17, P165, DOI 10.1016/0022-4804(74)90103-6
   VERHEYEN CCPM, 1993, J BIOMED MATER RES, V27, P775, DOI 10.1002/jbm.820270610
   ZIMMERLI W, 1982, J INFECT DIS, V146, P487, DOI 10.1093/infdis/146.4.487
   ZIMMERLI W, 1993, J ANTIMICROB CHEMOTH, V31, P97, DOI 10.1093/jac/31.suppl_D.97
NR 38
TC 58
Z9 60
U1 0
U2 20
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 0894-1939
J9 J INVEST SURG
JI J. Invest. Surg.
PD MAR-APR
PY 1998
VL 11
IS 2
BP 139
EP 146
DI 10.3109/08941939809032193
PG 8
WC Surgery
SC Surgery
GA 105CA
UT WOS:000075053700009
PM 9700622
DA 2018-10-19
ER

PT J
AU Everaert, EPJM
   Van de Belt-Gritter, B
   Van der Mei, HC
   Busscher, HJ
   Verkerke, GJ
   Dijk, F
   Mahieu, HF
   Reitsma, A
AF Everaert, EPJM
   Van de Belt-Gritter, B
   Van der Mei, HC
   Busscher, HJ
   Verkerke, GJ
   Dijk, F
   Mahieu, HF
   Reitsma, A
TI In vitro and in vivo microbial adhesion and growth on argon
   plasma-treated silicone rubber voice prostheses
SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE
LA English
DT Article
ID TOTAL LARYNGECTOMY; CANDIDA-ALBICANS; LOW-RESISTANCE; VOCAL
   REHABILITATION; HYDROPHOBIC RECOVERY; BACTERIA; AIR; COAGGREGATION;
   STREPTOCOCCI; PROVOX(TM)
AB Patients who undergo a total laryngectomy usually receive a silicone rubber voice prosthesis for voice rehabilitation. Unfortunately, biofilm formation on the esophageal side of voice prostheses limits their lifetime to 3-4 mon on average. The effects of repeated argon plasma treatment of medical grade, hydrophobic silicone rubber on in vitro adhesion and growth of bacteria and yeasts isolated from voice prostheses, as well as in vivo biofilm formation are presented here. In vitro experiments demonstrated that initial microbial adhesion over a 4 h time span to plasma-treated, hydrophilized, silicone rubber was generally less than on original, hydrophobic silicone rubber, both in the absence and presence of a salivary conditioning film on the biomaterial. Growth studies over a time period of 14 d at 37 degrees C in a modified Robbins device, showed that fewer Candida cells adhered on plasma-treated, hydrophilized silicone rubber as compared to on original, hydrophobic silicone rubber. For the in vivo evaluation of biofilm formation on plasma-treated silicone rubber voice prostheses, seven laryngectomized patients received a partly hydrophilized "Groningen Button" voice prosthesis for a planned evaluation period of 4 wk. After removal of the voice prostheses, the border between the hydrophilized and the original, hydrophobic side of the prostheses was clearly visible. However, biofilm formation was, unexpectedly, less on the original, hydrophobic sides, although the microbial compositions of the biofilms on both sides were not significantly different. Summarizing, this study demonstrates that in vitro microbial adhesion and growth on silicone rubber can be reduced by plasma treatment, but in vivo biofilm formation on silicone rubber voice prostheses is oppositely enhanced by hydrophilizing the silicone rubber surface. Nevertheless, from the results of this study the important conclusion can be drawn that in vivo biofilm formation on voice prostheses is controlled by the hydrophobicity of the biomaterials surface used. (C) 1998 Chapman & Hall.
C1 Univ Groningen, Dept Cell Biol & Electron Microscopy, Ctr Biomed Technol, Lab Mat Tecn, NL-9712 KZ Groningen, Netherlands.
   Vrije Univ Amsterdam, Univ Hosp, Ear Nose Throat Head & Neck Surg Dept, Amsterdam, Netherlands.
RP Busscher, HJ (reprint author), Univ Groningen, Dept Cell Biol & Electron Microscopy, Ctr Biomed Technol, Lab Mat Tecn, Bloemsingel 10, NL-9712 KZ Groningen, Netherlands.
CR Algaba J, 1987, Rev Laryngol Otol Rhinol (Bord), V108, P139
   BUSSCHER HJ, 1994, INT BIODETER BIODEGR, V33, P383, DOI 10.1016/0964-8305(94)90015-9
   BUSSCHER HJ, 1995, METHOD ENZYMOL, V253, P455
   BUSSCHER HJ, 1995, FEMS MICROBIOL LETT, V128, P229, DOI 10.1016/0378-1097(95)00103-C
   COOPER JD, 1989, ANN THORAC SURG, V47, P371, DOI 10.1016/0003-4975(89)90375-5
   COSTERTON JW, 1986, BACTERIA NATURE, V2, P49
   Everaert EP, 1996, J ADHES SCI TECHNOL, V10, P351, DOI 10.1163/156856196X00751
   EVERAERT EP, 1995, J ADHES SCI TECHNOL, V9, P1263, DOI 10.1163/156856195X01030
   Everaert EPJM, 1997, EUR ARCH OTO-RHINO-L, V254, P261, DOI 10.1007/BF02905983
   GRISTINA AG, 1987, SCIENCE, V237, P1588, DOI 10.1126/science.3629258
   HERRMANN IF, 1981, ARCH OTORHINOLARYNGO, V231, P647
   HILGERS FJM, 1993, CLIN OTOLARYNGOL, V18, P517, DOI 10.1111/j.1365-2273.1993.tb00627.x
   HILGERS JM, 1990, LARYNGOSCOPE, V100, P1202
   HOLMES AR, 1995, J IND MICROBIOL, V15, P208, DOI 10.1007/BF01569827
   IZDEBSKI K, 1987, LARYNGOSCOPE, V97, P594
   JENKINSON HF, 1990, INFECT IMMUN, V58, P1429
   KOLENBRANDER PE, 1988, ANNU REV MICROBIOL, V42, P627, DOI 10.1146/annurev.mi.42.100188.003211
   MAHIEU HF, 1986, ARCH OTOLARYNGOL, V112, P1090
   MAHIEU HF, 1986, ARCH OTOLARYNGOL, V112, P321
   MAHIEU HF, 1987, LARYNGOSCOPE, V97, P451
   MOZES N, 1988, BIOCHIM BIOPHYS ACTA, V945, P324, DOI 10.1016/0005-2736(88)90495-6
   NEU TR, 1993, BIOMATERIALS, V14, P459, DOI 10.1016/0142-9612(93)90149-V
   NEU TR, 1994, J APPL BACTERIOL, V76, P521, DOI 10.1111/j.1365-2672.1994.tb01111.x
   NEU TR, 1994, MICROB ECOL HEALTH D, V7, P27, DOI 10.3109/08910609409141571
   NIJDAM HF, 1982, ARCH OTO-RHINO-LARYN, V237, P27, DOI 10.1007/BF00453713
   PITT WG, 1993, BIOMATERIALS, V14, P605, DOI 10.1016/0142-9612(93)90179-6
   PRATTTERPSTRA IH, 1989, J DENT RES, V68, P463, DOI 10.1177/00220345890680030501
   QUIRYNEN M, 1988, J DENT RES, V67, P796
   QUIRYNEN M, 1991, BIOFOULING, V4, P187
   SINGER MI, 1981, ARCH OTOLARYNGOL, V107, P670
   STAFFIERI M, 1988, LARYNGOSCOPE, V98, P1027
   Traissac L, 1987, Rev Laryngol Otol Rhinol (Bord), V108, P157
   VandenHoogen FJA, 1996, ACTA OTO-LARYNGOL, V116, P119, DOI 10.3109/00016489609137724
   VERRAN J, 1987, J DENT, V15, P73, DOI 10.1016/0300-5712(87)90003-0
   ZIJLSTRA RJ, 1991, ARCH OTOLARYNGOL, V117, P657
NR 35
TC 38
Z9 38
U1 0
U2 9
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0957-4530
J9 J MATER SCI-MATER M
JI J. Mater. Sci.-Mater. Med.
PD MAR
PY 1998
VL 9
IS 3
BP 147
EP 157
DI 10.1023/A:1008867619481
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA YX865
UT WOS:000072087400005
PM 15348904
DA 2018-10-19
ER

PT J
AU Cotten, A
   Boutry, N
   Cortet, B
   Assaker, R
   Demondion, X
   Leblond, D
   Chastanet, P
   Duquesnoy, B
   Deramond, H
AF Cotten, A
   Boutry, N
   Cortet, B
   Assaker, R
   Demondion, X
   Leblond, D
   Chastanet, P
   Duquesnoy, B
   Deramond, H
TI Percutaneous vertebroplasty: State of the art
SO RADIOGRAPHICS
LA English
DT Article; Proceedings Paper
CT 82nd Annual Meeting of the Radiological-Society-of-North-America
CY DEC 01-06, 1996
CL CHICAGO, ILLINOIS
SP Radiol Soc N Amer
DE spine, diseases; spine, interventional procedure; spine, primary
   neoplasms; spine, secondary neoplasms
ID VERTEBRAL HEMANGIOMA; METHYL-METHACRYLATE; ABSOLUTE ETHANOL; ACRYLIC
   CEMENT; INJECTION; METASTASES; RELIEF; CT
AB Vertebroplasty is an effective new radiologic procedure consisting of the percutaneous injection of a biomaterial, usually methyl methacrylate, into a lesion of a vertebral body, This technique allows marked or complete pain relief and bone strengthening in most cases, The principal indications for vertebroplasty are osteolytic metastasis and myeloma, painful or aggressive hemangioma, and osteoporotic vertebral collapse with debilitating pain that persists despite correct medical treatment, Radiography and computed tomography must be performed in the days preceding vertebroplasty to assess the extent of vertebral collapse, the location and extent of the lytic process, the visibility and degree of involvement of the pedicles, the presence of cortical destruction or fracture, and the presence of epidural or foraminal stenosis caused by tumor extension or bone fragment retropulsion. Leakage of methyl methacrylate during vertebroplasty may cause compression of adjacent structures and necessitate emergency decompressive surgery; thus, the procedure should be performed only in a surgical center. The decision to perform vertebroplasty should be made by a multidisciplinary team because the choice between vertebroplasty, surgery, radiation therapy, medical treatment, or a combination thereof depends on a number of factors, Radiologists need to be aware of the various indications for vertebroplasty and of potential future developments and applications of the procedure.
C1 Ctr Hosp Reg & Univ Lille, Hop Roger Salengro, Dept Skeletal Radiol, F-59037 Lille, France.
   Ctr Hosp Reg & Univ Lille, Hop Roger Salengro, Dept Rheumatol, F-59037 Lille, France.
   Ctr Hosp Reg & Univ Lille, Hop Roger Salengro, Dept Neurosurg, F-59037 Lille, France.
   Ctr Oscar Lambret, Dept Radiol, F-59020 Lille, France.
   Hop Nord, Dept Neuroradiol, Amiens, France.
RP Cotten, A (reprint author), Ctr Hosp Reg & Univ Lille, Hop Roger Salengro, Dept Skeletal Radiol, Blvd Pr J Leclercq, F-59037 Lille, France.
OI Assaker, Richard/0000-0003-1763-2445
CR ADAMSBAUM C, 1993, SKELETAL RADIOL, V22, P317
   CARDON T, 1994, CLIN RHEUMATOL, V13, P518, DOI 10.1007/BF02242955
   CHIRAS J, 1993, AM J NEURORADIOL, V14, P1113
   Chiras J, 1995, ECHECS COMPLICATIONS, P149
   Cotten A, 1996, AM J NEURORADIOL, V17, P137
   COTTEN A, 1995, RADIOLOGY, V197, P307, DOI 10.1148/radiology.197.1.7568843
   Cotten A, 1996, RADIOLOGY, V200, P525, DOI 10.1148/radiology.200.2.8685351
   DERAMOND H, 1993, B CANCER, V80, P36
   DERAMOND H, 1990, Feuillets de Radiologie, V30, P262
   Deramond H, 1996, Bull Cancer Radiother, V83, P277
   DERAMOND H, 1989, RACHIS, V1, P143
   Deramond H, 1991, NEURORADIOLOGY S, V33, P177
   Galibert P, 1990, Chirurgie, V116, P326
   GALIBERT P, 1987, NEUROCHIRURGIE, V33, P166
   Gangi A, 1996, RADIOGRAPHICS, V16, P1289, DOI 10.1148/radiographics.16.6.8946536
   GANGI A, 1994, AM J NEURORADIOL, V15, P83
   GILBERT HA, 1977, AM J ROENTGENOL, V129, P1095, DOI 10.2214/ajr.129.6.1095
   HEISS JD, 1994, NEW ENGL J MED, V331, P508, DOI 10.1056/NEJM199408253310804
   Heiss JD, 1996, NEW ENGL J MED, V334, P1340, DOI 10.1056/NEJM199605163342017
   KAEMMERLEN P, 1989, NEW ENGL J MED, V321, P121
   LAPRAS C, 1989, ANN CHIR, V43, P371
   LAREDO JD, 1993, ACTUALITE RHUMATOLOG, V30, P332
   MURRAY JA, 1974, J BONE JOINT SURG AM, VA 56, P311, DOI 10.2106/00004623-197456020-00009
   SHEPHERD S, 1988, CLIN RADIOL, V39, P547, DOI 10.1016/S0009-9260(88)80234-4
   Weill A, 1996, RADIOLOGY, V199, P241, DOI 10.1148/radiology.199.1.8633152
NR 25
TC 347
Z9 408
U1 0
U2 11
PU RADIOLOGICAL SOC NORTH AMER
PI EASTON
PA 20TH AND NORTHAMPTON STS, EASTON, PA 18042 USA
SN 0271-5333
J9 RADIOGRAPHICS
JI Radiographics
PD MAR-APR
PY 1998
VL 18
IS 2
BP 311
EP 320
DI 10.1148/radiographics.18.2.9536480
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA ZB643
UT WOS:000072493100006
PM 9536480
OA Bronze
DA 2018-10-19
ER

PT J
AU Brugnoni, C
   Lanza, F
   Macchi, G
   Muller, R
   Parnisari, E
   Stroosnijder, MF
   Vinhas, J
AF Brugnoni, C
   Lanza, F
   Macchi, G
   Muller, R
   Parnisari, E
   Stroosnijder, MF
   Vinhas, J
TI Evaluation of the wear resistance of ZrN coatings using thin layer
   activation
SO SURFACE & COATINGS TECHNOLOGY
LA English
DT Article; Proceedings Paper
CT Symposium K on Coatings and Surface Modifications for Surface Protection
   and Tribological Applications, at ICAM 97
CY JUN 16-20, 1997
CL STRASBOURG, FRANCE
DE thin layer activation; wear; biomaterial; zirconium nitride
AB Zirconium has an excellent biocompatibility and thus could be used for biomedical applications. However, its tribological properties are rather poor. In order to overcome this drawback, a ZrN coating was prepared by thermal nitridation of Zircalloy-2. Wear tests using a pin-on-disk tribometer combined with gravimetry indicated a very good wear resistance. To obtain reliable numerical data and avoid very long tests, the potential use of thin layer activation (TLA) in combination with a pin-on-disk tribometer was explored. The results indicate that TLA, in particular due to its high sensitivity, can provide important information regarding the surface degradation of these very wear-resistant coatings. (C) 1998 Elsevier Science S.A.
C1 Commiss European Communities, Joint Res Ctr, Inst Adv Mat, I-21020 Ispra, VA, Italy.
RP Stroosnijder, MF (reprint author), Commiss European Communities, Joint Res Ctr, Inst Adv Mat, I-21020 Ispra, VA, Italy.
CR CONLON TW, 1985, CONTEMP PHYS, V26, P521, DOI 10.1080/00107518508210990
   DAVIDSON JA, 1994, BIO-MED MATER ENG, V4, P231
   NEUMANN W, 1990, NUCL INSTRUM METH B, V50, P57, DOI 10.1016/0168-583X(90)90330-W
   Okazaki Y, 1996, MAT SCI ENG A-STRUCT, V213, P138, DOI 10.1016/0921-5093(96)10247-1
   Stroosnijder MF, 1995, NATO ADV SCI INST SE, V283, P399
NR 5
TC 23
Z9 25
U1 0
U2 2
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0257-8972
J9 SURF COAT TECH
JI Surf. Coat. Technol.
PD MAR
PY 1998
VL 100
IS 1-3
BP 23
EP 26
DI 10.1016/S0257-8972(97)00582-3
PG 4
WC Materials Science, Coatings & Films; Physics, Applied
SC Materials Science; Physics
GA ZN366
UT WOS:000073638700006
DA 2018-10-19
ER

PT J
AU McPherson, TB
   Badylak, SF
AF McPherson, TB
   Badylak, SF
TI Characterization of fibronectin derived from porcine small intestinal
   submucosa
SO TISSUE ENGINEERING
LA English
DT Article; Proceedings Paper
CT Inaugural Meeting of the Tissue-Engineering-Society
CY DEC 13-15, 1996
CL ORLANDO, FLORIDA
SP Tissue Engn Soc
ID TISSUE FIBRONECTIN; HUMAN-PLASMA; GRAFT; DOG; QUANTITATION; IMMUNOASSAY;
   REPAIR; ELISA
AB Small intestinal submucosa (SIS) is an acellular biomaterial derived from porcine jejunum. When used as a soft tissue graft material, SIS induces site-specific remodeling of the organ or tissue in which it is placed, The mechanism by which SIS induces tissue remodeling is only partially understood. Fibronectin (Fn) is a dimeric glycoprotein present in plasma and extracellular matrix. Fn exhibits chemotactic and adhesive properties for many cells, including fibroblasts and endothelial cells. Thus, Fn may play a key role in the tissue-remodeling activity of SIS. The goals of this study were to localize and quantify the Fn in SIS, and characterize the structure of SIS-derived Fn. Immunohistochemical staining confirmed the transmural presence of Fn in SIS. The Fn content of SIS was 0.08 +/- 0.05% dry weight, similar to the Fn content of other similar tissues, as determined with a competitive ELISA. SDS-PAGE and Western blots of purified protein showed SIS-derived Fn to migrate similar to human and porcine plasma fibronectins, Fn derived from SIS did not contain domains associated with embryonic or transitional extracellular matrix. Fn is transmurally distributed throughout the thickness of SIS and its content and structure are consistent with stable, mature tissue.
C1 Purdue Univ, Hillenbrand Biomed Engn Ctr, W Lafayette, IN 47907 USA.
OI Badylak, Stephen/0000-0003-3555-0689
CR BADYLAK SF, 1995, J BIOMED MATER RES, V29, P977, DOI 10.1002/jbm.820290809
   BADYLAK SF, 1989, J SURG RES, V47, P74, DOI 10.1016/0022-4804(89)90050-4
   BRAY BA, 1981, SCIENCE, V214, P793, DOI 10.1126/science.7292011
   BRAY BA, 1985, BIOCHEM J, V226, P811, DOI 10.1042/bj2260811
   BREES DK, 1995, RENAL PHYSIOL BIOCH, V18, P1
   BRIGMAN BE, 1994, J ORTHOPAED RES, V12, P253, DOI 10.1002/jor.1100120215
   Clark R., 1996, Mezhdunarodnyi Sel'skokhozyaistvennyi Zhurnal, P3
   Clarke KM, 1996, J SURG RES, V60, P107, DOI 10.1006/jsre.1996.0018
   Cobb MA, 1996, SURG NEUROL, V46, P389, DOI 10.1016/S0090-3019(96)00202-9
   HILES MC, 1995, J BIOMED MATER RES, V29, P883, DOI 10.1002/jbm.820290714
   Hodde J P, 1996, Tissue Eng, V2, P209, DOI 10.1089/ten.1996.2.209
   Hynes RO, 1990, FIBRONECTINS
   KNAPP PM, 1994, J ENDOUROL, V8, P125, DOI 10.1089/end.1994.8.125
   Kropp B P, 1995, Urology, V46, P396, DOI 10.1016/S0090-4295(99)80227-1
   MANABE N, 1995, NEPHRON, V71, P79, DOI 10.1159/000188678
   MOSER TL, 1993, J BIOL CHEM, V268, P18917
   PETERS JH, 1995, CELL ADH COMMUN, V3
   PREVEL CD, 1995, ANN PLAS SURG, V35, P381, DOI 10.1097/00000637-199510000-00009
   RENNARD SI, 1980, ANAL BIOCHEM, V104, P205, DOI 10.1016/0003-2697(80)90300-0
   SANDUSKY GE, 1992, AM J PATHOL, V140, P317
   VoytikHarbin SL, 1997, J CELL BIOCHEM, V67, P478, DOI 10.1002/(SICI)1097-4644(19971215)67:4<478::AID-JCB6>3.0.CO;2-P
   VUENTO M, 1981, J IMMUNOL METHODS, V40, P101, DOI 10.1016/0022-1759(81)90085-5
   VUENTO M, 1979, BIOCHEM J, V183, P331, DOI 10.1042/bj1830331
   Yamada K.M., 1996, MOL CELLULAR BIOL WO, P51
NR 24
TC 105
Z9 118
U1 0
U2 8
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA
SN 1076-3279
J9 TISSUE ENG
JI Tissue Eng.
PD SPR
PY 1998
VL 4
IS 1
BP 75
EP 83
DI 10.1089/ten.1998.4.75
PG 9
WC Cell & Tissue Engineering
SC Cell Biology
GA ZF720
UT WOS:000072925300009
DA 2018-10-19
ER

PT J
AU Gutensohn, K
   Kuehnl, P
AF Gutensohn, K
   Kuehnl, P
TI The role of flow cytometry in improving biocompatibility in transfusion
   medicine
SO TRANSFUSION SCIENCE
LA English
DT Article; Proceedings Paper
CT International Symposium on Transfusion Medicine
CY JUN   29, 1996
CL BERN, SWITZERLAND
ID PLATELET MEMBRANE-GLYCOPROTEINS; ACTIVATED PLATELETS; CARDIOPULMONARY
   BYPASS; BLOOD COMPATIBILITY; MONOCLONAL-ANTIBODY; UNITED-STATES; DONORS;
   APHERESIS; STORAGE; BIOMATERIALS
AB In transfusion medicine, blood and blood components, donors and patients are increasingly confronted with biomaterials. The need to understand the response of human blood to contact with these artificial surfaces has led to multiple studies on the biocompatibilty of biomaterials. Up to this time, these investigations have predominantly been performed using physical, immunological and biochemical methods. Many of these approaches are useful in investigating the multiple factors involved in blood-biomaterial interactions. However, they always reflect the overall behaviour of whole cellular populations in local or systemic reactions. The application of multiparameter flow cytometry, on the other hand, provides insight into antigenic expression and changes at the single-cell level. Therefore, the technique of flow cytometry represents a new and powerful way of analysing and improving the biocompatibility of these materials in blood-contacting applications in this field. (C) 1998 Elsevier Science Ltd. All rights reserved.
C1 Univ Hamburg, Hosp Eppendorf, Dept Transfus Med Transplantat Immunol, D-20246 Hamburg, Germany.
RP Gutensohn, K (reprint author), Univ Hamburg, Hosp Eppendorf, Dept Transfus Med Transplantat Immunol, Martinistr 52, D-20246 Hamburg, Germany.
CR AULT KA, 1994, METHOD CELL BIOL, V42, P275
   BERTOLINI F, 1990, VOX SANG, V59, P201, DOI 10.1111/j.1423-0410.1990.tb00236.x
   COURTNEY JM, 1994, BIOMATERIALS, V15, P737, DOI 10.1016/0142-9612(94)90026-4
   COURTNEY JM, 1993, INT J ARTIF ORGANS, V16, P164
   COURTNEY JM, 1993, MANAGEMENT BLEEDING, P236
   FORBES CD, 1994, HAEMOSTASIS THROMBOS, P1301
   FREEDMAN J, 1995, TRANSFUS MED REV, V9, P87, DOI 10.1016/S0887-7963(05)80049-5
   GARRATTY G, 1995, TRANSFUSION, V35, P157, DOI 10.1046/j.1537-2995.1995.35295125739.x
   GAWAZ M, 1994, CLIN INVESTIGATOR, V72, P424
   GEORGE JN, 1992, BLOOD CELLS, V18, P501
   GIVAN AL, 1994, FLOW CYTOMETRY 1 PRI
   Gutensohn K, 1997, THROMB RES, V86, P49, DOI 10.1016/S0049-3848(97)00044-3
   Gutensohn K, 1997, J HEMATOTHER, V6, P315, DOI 10.1089/scd.1.1997.6.315
   Gutensohn K, 1997, TRANSFUSION, V37, P809, DOI 10.1046/j.1537-2995.1997.37897424403.x
   Gutensohn K., 1996, Transfusion (Bethesda), V36, p15S
   GUTENSOHN K, 1995, 25 HAM S HAMB 1994, P451
   GUTENSOHN K, 1994, INFUSIONSTHER TRANSF, V21, P9
   GUTENSOHN K, 1994, INFUSIONSTHER TRANSF, V21, P67
   HAMBURGER SA, 1990, BLOOD, V75, P550
   HAYCOX CL, 1993, J BIOMED MATER RES, V27, P1181, DOI 10.1002/jbm.820270909
   HEAL JM, 1983, VOX SANG, V45, P14, DOI 10.1111/j.1423-0410.1983.tb04118.x
   HORAN PK, 1989, NATURE, V340, P167, DOI 10.1038/340167a0
   KLINEFELTER H F, 1984, P1
   Klinkmann H., 1987, UREMIA THERAPY, P125
   Kondo C, 1993, ASAIO, V39, P550
   LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4
   LINDSAY RM, 1980, T AM SOC ART INT ORG, V26, P603
   MAMMEN EF, 1985, SEMIN THROMB HEMOST, V11, P281, DOI 10.1055/s-2007-1004382
   Mandy FF, 1995, TRANSFUS SCI, V16, P303, DOI 10.1016/0955-3886(95)90002-0
   MATSUI Y, 1986, TRANSFUSION, V26, P446, DOI 10.1046/j.1537-2995.1986.26587020123.x
   MCEVER RP, 1984, J BIOL CHEM, V259, P9799
   MURPHY S, 1995, BLOOD, V86, P3951
   NIEUWENHUIS HK, 1987, BLOOD, V70, P838
   POLESKY HF, 1985, TRANSFUSION, V25, P304, DOI 10.1046/j.1537-2995.1985.25485273805.x
   Prior C R, 1991, J Clin Apher, V6, P69, DOI 10.1002/jca.2920060202
   RATNER BD, 1993, J BIOMED MATER RES, V27, P283, DOI 10.1002/jbm.820270302
   RINDER CS, 1991, ANESTHESIOLOGY, V75, P563, DOI 10.1097/00000542-199110000-00004
   RINDER HM, 1991, TRANSFUSION, V31, P409, DOI 10.1046/j.1537-2995.1991.31591263195.x
   SHAPIRO HM, 1994, PRACTICAL FLOW CYTOM
   SHATTIL SJ, 1987, BLOOD, V70, P307
   SILVA VA, 1994, TRANSFUS SCI, V15, P67, DOI 10.1016/0955-3886(94)90058-2
   SLEZAK SE, 1989, BLOOD, V74, P2172
   SLICHTER SJ, 1990, HEMATOL ONCOL CLIN N, V4, P291
   SREEDHARA R, 1995, AM J KIDNEY DIS, V25, P555, DOI 10.1016/0272-6386(95)90123-X
   STRAUSS RG, 1994, J CLIN APHERESIS, V9, P130, DOI 10.1002/jca.2920090208
   SURGENOR DM, 1990, NEW ENGL J MED, V322, P1646, DOI 10.1056/NEJM199006073222306
   TRIULZI DJ, 1992, TRANSFUSION, V32, P529, DOI 10.1046/j.1537-2995.1992.32692367196.x
   URDAHL SG, 1989, INFUSIONSTHERAPIE, V16, P30
   WUN T, 1994, J CLIN APHERESIS, V9, P10, DOI 10.1002/jca.2920090104
   1992, GEBRAUCHSANWEISUNG B
NR 50
TC 9
Z9 9
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0955-3886
J9 TRANSFUS SCI
JI Transfus. Sci.
PD MAR
PY 1998
VL 19
IS 1
BP 17
EP 25
DI 10.1016/S0955-3886(98)00005-8
PG 9
WC Hematology
SC Hematology
GA ZV874
UT WOS:000074350400004
PM 10182178
DA 2018-10-19
ER

PT J
AU Vogler, EA
AF Vogler, EA
TI Structure and reactivity of water at biomaterial surfaces
SO ADVANCES IN COLLOID AND INTERFACE SCIENCE
LA English
DT Review
DE water structure; biomaterials; biological response; surface energy;
   hydrophobic; hydrophilic; surface forces
ID BOVINE PANCREAS RIBONUCLEASE; HUMAN-PLASMA ALBUMIN; CHARGED POLYSTYRENE
   SURFACES; SOFT CONTACT-LENSES; PERFORMANCE LIQUID-CHROMATOGRAPHY;
   MACROSCOPIC HYDROPHOBIC SURFACES; AQUEOUS-ELECTROLYTE SOLUTIONS; DIRECT
   FORCE MEASUREMENTS; ACID-BASE PROPERTIES; HUMAN-SERUM-ALBUMIN
AB Molecular self association in liquids is a physical process that can dominate cohesion (interfacial tension) and miscibility. In water, self association is a powerful organizational force leading to a three-dimensional hydrogen-bonded network (water structure). Localized perturbations in the chemical potential of water as by, for example, contact with a solid surface, induces compensating changes in water structure that can be sensed tens of nanometers from the point of origin using the surface force apparatus (SFA) and ancillary techniques. These instruments reveal attractive or repulsive forces between opposing surfaces immersed in water, over and above that anticipated by continuum theory (DLVO), that are attributed to a variable density (partial molar volume) of a more-or-less ordered water structure, depending on the water wettability (surface energy) of the water-contacting surfaces. Water structure at surfaces is thus found to be a manifestation of hydrophobicity and, while mechanistic/theoretical interpretation of experimental results remain the subject of some debate in the literature, convergence of experimental observations permit, for the first time, quantitative definition of the relative terms 'hydrophobic' and 'hydrophilic'. In particular, long-range attractive forces are detected only between surfaces exhibiting a water contact angle theta > 65 degrees (herein defined as hydrophobic surfaces with pure water adhesion tension tau degrees = gamma degrees cos theta < 30 dyn/cm where gamma degrees is water interfacial tension = 72.8 dyn/cm). Repulsive forces are detected between surfaces exhibiting theta < 65 degrees (hydrophilic surfaces, tau degrees > 30 dyn/cm). These findings suggest at least two distinct kinds of water structure and reactivity: a relatively less-dense water region against hydrophobic surfaces with an open hydrogen-bonded network and a relatively more-dense water region against hydrophilic surfaces with a collapsed hydrogen-bonded network. Importantly, membrane and SFA studies reveal a discrimination between biologically-important ions that preferentially solubilizes divalent ions in more-dense water regions relative to less-dense water regions in which monovalent ions are enriched. Thus, the compelling conclusion to be drawn from the collective scientific evidence gleaned from over a century of experimental and theoretical investigation is that solvent properties of water within the interphase separating a solid surface from bulk water solution vary with contacting surface chemistry. This interphase can extend tens of nanometers from a water-contacting surface due to a propagation of differences in self association between vicinal water and bulk-phase water. Physicochemical properties of interfacial water profoundly influence the biological response to materials in a surprisingly straightforward manner when key measures of biological activity sensitive to interfacial phenomena are scaled against water adhesion tension tau degrees of contacting surfaces. As examples, hydrophobic surfaces ( tau degrees < 30 dyn/cm) support adsorption of various surfactants and proteins from water because expulsion of solute from solution into the interphase between bulk solid and solution phases is energetically favorable. Adsorption to hydrophobic surfaces is driven by the reduction of interfacial energetics concomitant with replacement of water molecules at the surface by adsorbed solute (surface dehydration). Hydrophilic surfaces ( tau degrees > 30 dyn/cm) do not support adsorption because this mechanism is energetically unfavorable.
   Protein-adsorbing hydrophobic surfaces an inefficient contact activators of the blood coagulation cascade whereas protein-repellent hydrophilic surfaces are efficient activators of blood coagulation. Mammalian cell attachment is a process distinct from protein adsorption that occurs efficiently to hydrophilic surfaces but inefficiently to hydrophobic surfaces. Thus, the hydrophobic/hydrophilic contrast in the biological response to materials, often disputed in biomaterials science, is very clear when viewed from the perspective of water structure and reactivity at surfaces, The key measure of water structure and activity important to biomaterial scientists is tau degrees rather than parameters such as Zisman's critical surface tension gamma(c) or 'surface free energy' gamma(s) that are shown not to correlate sensibly with either tau degrees or results from the surface force apparatus. (C) 1998 Elsevier Science B.V.
C1 Becton Dickinson Res Ctr, Res Triangle Pk, NC 27709 USA.
RP Vogler, EA (reprint author), Becton Dickinson Res Ctr, 21 Davis Dr, Res Triangle Pk, NC 27709 USA.
EM vogler@bdrc.bd.com
CR ANDRADE JD, 1990, CROAT CHEM ACTA, V63, P527
   Andrade JD, 1986, ADV POLYM SCI, V79, P3
   ANISIMOVA VI, 1967, RUSS J PHYS CHEM+, V41, P1282
   ANTONCHENKO VY, 1984, MOL PHYS, V52, P345, DOI 10.1080/00268978400101261
   Baier R E, 1969, J Biomed Mater Res, V3, P191, DOI 10.1002/jbm.820030115
   Baier R. E., 1970, ADHESION BIOL SYSTEM, P15
   BAIER RE, 1978, ARTIF ORGANS, V2, P422
   BAIER RE, 1982, J BIOMED MATER RES, V16, P173, DOI 10.1002/jbm.820160210
   BAIER RE, 1972, B NEW YORK ACAD MED, V48, P257
   BAIER RE, 1981, PHYSICOCHEMICAL ASPE, V2, P805
   BAIER RE, 1976, 8 SCI C GES DTSCH NA, V13, P159
   BAIER RE, 1971, YB MED PUBLISHERS, P147
   BAIER RE, 1969, P AM CHEM SOC S SURF, P235
   Basiuk VA, 1996, COLLOID SURFACE A, V118, P127, DOI 10.1016/0927-7757(96)03734-X
   BERG JC, 1993, SURFACTANT SCI SERIE, V49, P76
   BERG JM, 1994, LANGMUIR, V10, P1225, DOI 10.1021/la00016a041
   Brown B., 1980, HEMATOLOGY PRINCIPLE
   CADENA RAD, 1992, PROTEIN SCI, V1, P151
   CARTER DC, 1994, ADV PROTEIN CHEM, V45, P153
   CARTER DC, 1990, SCIENCE, V249, P302, DOI 10.1126/science.2374930
   CASTILLO EJ, 1985, BIOMATERIALS, V6, P338, DOI 10.1016/0142-9612(85)90089-4
   CASTILLO EJ, 1984, BIOMATERIALS, V5, P186, DOI 10.1016/0142-9612(84)90014-0
   CASTILLO EJ, 1986, BIOMATERIALS, V7, P9, DOI 10.1016/0142-9612(86)90081-5
   CASTILLO EJ, 1986, BIOMATERIALS, V7, P89, DOI 10.1016/0142-9612(86)90062-1
   CASTILLO EJ, 1984, BIOMATERIALS, V5, P319, DOI 10.1016/0142-9612(84)90029-2
   Chadwell HM, 1927, CHEM REV, V4, P375
   CHRISTENSON HK, 1989, J PHYS CHEM-US, V93, P1472, DOI 10.1021/j100341a057
   CHRISTENSON HK, 1990, J PHYS CHEM-US, V94, P8004, DOI 10.1021/j100384a002
   CHRISTENSON HK, 1987, P INDIAN AS-CHEM SCI, V98, P379
   CHRISTENSON HK, 1988, SCIENCE, V239, P390, DOI 10.1126/science.239.4838.390
   CHURAEV NV, 1995, ADV COLLOID INTERFAC, V58, P87, DOI 10.1016/0001-8686(95)00245-L
   CLAESSON PM, 1988, J PHYS CHEM-US, V92, P1650, DOI 10.1021/j100317a052
   CLAESSON PM, 1986, J COLLOID INTERF SCI, V114, P234, DOI 10.1016/0021-9797(86)90257-2
   CLAESSON PM, 1987, J COLLOID INTERF SCI, V118, P68, DOI 10.1016/0021-9797(87)90435-8
   CLIFFORD J, 1975, WATER COMPREHENSIVE, V5, P75
   COCHRANE CG, 1979, AM J MED, V67, P657, DOI 10.1016/0002-9343(79)90253-5
   Colic M, 1997, LANGMUIR, V13, P3129, DOI 10.1021/la960965p
   CRAWFORD R, 1987, COLLOID SURFACE, V27, P57, DOI 10.1016/0166-6622(87)80328-1
   CRYSTALL B, 1993, J COLLOID INTERF SCI, V155, P247, DOI 10.1006/jcis.1993.1030
   CUYPERS PA, 1977, ANN NY ACAD SCI, V283, P77, DOI 10.1111/j.1749-6632.1977.tb41754.x
   Derjaguin B, 1939, ACTA PHYSICOCHIM URS, V10, P25
   Derjaguin B, 1944, ACTA PHYSICOCHIM URS, V19, P0541
   DERJAGUIN B, 1978, J COLLOID INTERF SCI, V66, P573, DOI 10.1016/0021-9797(78)90076-0
   DERJAGUIN B, 1964, T FARADAY SOC, V60, P449, DOI 10.1039/tf9646000449
   DERJAGUIN BV, 1992, PROG SURF SCI, V40, P272, DOI 10.1016/0079-6816(92)90054-L
   DERJAGUIN BV, 1974, J COLLOID INTERF SCI, V49, P249, DOI 10.1016/0021-9797(74)90358-0
   DERJAGUIN BV, 1987, LANGMUIR, V3, P601
   DERJAGUIN BV, 1965, DISCUSS FARADAY SOC, P246, DOI 10.1039/df9654000246
   DERJAGUIN BV, 1976, CHEM SCRIPTA, V9, P97
   DERJAGUIN BV, 1978, NATURE, V272, P313, DOI 10.1038/272313a0
   DERJAGUIN BV, 1978, J COLLOID INTERF SCI, V66, P329
   DICKINSON E, 1993, LANGMUIR, V9, P242, DOI 10.1021/la00025a046
   DILLMAN WJ, 1973, J COLLOID INTERF SCI, V44, P221, DOI 10.1016/0021-9797(73)90215-4
   Dolezalek F, 1908, Z PHYS CHEM-STOCH VE, V64, P727
   Douillard JM, 1997, J COLLOID INTERF SCI, V188, P511, DOI 10.1006/jcis.1997.4768
   DROSTHANSEN W, 1969, IND ENG CHEM, V61, P10, DOI 10.1021/ie50719a005
   DU Q, 1994, SCIENCE, V264, P826, DOI 10.1126/science.264.5160.826
   DU Q, 1994, PHYS REV LETT, V72, P238, DOI 10.1103/PhysRevLett.72.238
   DU Q, 1993, PHYS REV LETT, V70, P2313, DOI 10.1103/PhysRevLett.70.2313
   DULM PV, 1981, J COLLOID INTERF SCI, V82, P77
   ELWING H, 1987, J COLLOID INTERF SCI, V119, P203, DOI 10.1016/0021-9797(87)90260-8
   FISHER LR, 1981, NATURE, V290, P575, DOI 10.1038/290575a0
   FITZPATRICK H, 1992, J COLLOID INTERF SCI, V149, P1, DOI 10.1016/0021-9797(92)90384-X
   FLETCHER M, 1985, J COLLOID INTERF SCI, V104, P5, DOI 10.1016/0021-9797(85)90004-9
   FOWKES FM, 1962, J PHYS CHEM-US, V66, P382, DOI 10.1021/j100808a524
   FOWKES FM, 1991, LANGMUIR, V7, P2464, DOI 10.1021/la00059a012
   FOWKES FM, 1990, COLLOID SURFACE, V43, P367, DOI 10.1016/0166-6622(90)80298-I
   FOWKES FM, 1990, J ADHES SCI TECHNOL, V4, P669, DOI 10.1163/156856190X00595
   FRAGNETO G, 1995, SCIENCE, V267, P657, DOI 10.1126/science.7839141
   Franks F, 1979, WATER COMPREHENSIVE
   FRANKS F, 1972, WATER COMPREHENSIVE, V1, P1
   GAUTHIERMANUEL G, 1995, J COLLOID INTERF SCI, V175, P478
   GEE ML, 1990, J CHEM SOC FARADAY T, V86, P4049, DOI 10.1039/ft9908604049
   GEKCLER KE, 1997, ADV MATER, V9, P513
   GOMPPER G, 1994, J CHEM PHYS, V101, P3378, DOI 10.1063/1.468413
   Gragson DE, 1997, LANGMUIR, V13, P4804, DOI 10.1021/la970497z
   GRAHAM DE, 1979, J COLLOID INTERF SCI, V70, P415, DOI 10.1016/0021-9797(79)90049-3
   GREEN R, 1995, POLYM PREPR, V36, P63
   Gregory JK, 1997, SCIENCE, V275, P814, DOI 10.1126/science.275.5301.814
   Guggenheim E.A., 1967, THERMODYNAMICS ADV T
   HANEIN D, 1993, LANGMUIR, V9, P1058, DOI 10.1021/la00028a030
   HARTLEY P, 1994, 2 DAY S RUGB UK, P262
   Hato M, 1996, J PHYS CHEM-US, V100, P18530, DOI 10.1021/jp961927h
   HAYNES CA, 1994, COLLOID SURFACE B, V2, P517
   Heinrich L, 1996, LANGMUIR, V12, P4857, DOI 10.1021/la9602630
   Heinrich L, 1997, LANGMUIR, V13, P3177, DOI 10.1021/la9610314
   HENNIKER JC, 1949, REV MOD PHYS, V21, P322, DOI 10.1103/RevModPhys.21.322
   HILDEBRAND JH, 1979, P NATL ACAD SCI USA, V76, P194, DOI 10.1073/pnas.76.1.194
   Hofmeister F., 1888, N-S ARCH EXP PATH PH, V24, P247
   HORBETT T, 1982, ADV CHEM SER, V199, P234
   HORN RG, 1981, J CHEM PHYS, V75, P1400, DOI 10.1063/1.442146
   HSIEH YL, 1988, J COLLOID INTERF SCI, V123, P275, DOI 10.1016/0021-9797(88)90244-5
   Hunter R. J., 1989, FDN COLLOID SCI
   HUNTSBERGER JR, 1976, J ADHESION, V7, P289, DOI 10.1080/00218467608075060
   Israelachvili J, 1996, NATURE, V379, P219, DOI 10.1038/379219a0
   ISRAELACHVILI J, 1987, P NATL ACAD SCI USA, V84, P4722, DOI 10.1073/pnas.84.14.4722
   ISRAELACHVILI J, 1982, NATURE, V300, P341, DOI 10.1038/300341a0
   ISRAELACHVILI J, 1987, ACCOUNTS CHEM RES, V20, P415, DOI 10.1021/ar00143a005
   Israelachvili J. N., 1976, Nature, V262, P774, DOI 10.1038/262774a0
   ISRAELACHVILI JN, 1983, NATURE, V306, P249, DOI 10.1038/306249a0
   ISRAELACHVILI JN, 1978, J CHEM SOC FARAD T 1, V74, P975, DOI 10.1039/f19787400975
   ISRAELACHVILI JN, 1992, SURF SCI REP, V14, P109, DOI 10.1016/0167-5729(92)90015-4
   ISRAELACHVILI JN, 1990, LANGMUIR, V6, P873, DOI 10.1021/la00094a028
   ISRAELACHVILI JN, 1992, J PHYS CHEM-US, V96, P520, DOI 10.1021/j100181a007
   ISRAELACHVILI JN, 1982, BIOPHYSICS WATER, P183
   IVARSSON BA, 1985, COLLOID SURFACE, V13, P169
   Janczuk B, 1996, J COLLOID INTERF SCI, V181, P108, DOI 10.1006/jcis.1996.0361
   JEON JS, 1992, APPL SPECTROSC, V46, P1644, DOI 10.1366/0003702924926826
   JOHNSON D, 1993, PSYCHOL SCI, V4, P1, DOI 10.1111/j.1467-9280.1993.tb00547.x
   Johnson R.E., 1969, SURF COLLOID SCI, V2, P85
   JOHNSON RE, 1989, LANGMUIR, V5, P293, DOI 10.1021/la00085a061
   Koehler JA, 1997, LANGMUIR, V13, P4162, DOI 10.1021/la970010m
   KURIHARA K, 1992, J AM CHEM SOC, V114, P10927, DOI 10.1021/ja00053a033
   Latimer WM, 1920, J AM CHEM SOC, V42, P1419, DOI 10.1021/ja01452a015
   LAW BM, 1990, J COLLOID INTERF SCI, V134, P1, DOI 10.1016/0021-9797(90)90247-L
   LECKBAND D, 1993, ENZYME MICROB TECH, V15, P450, DOI 10.1016/0141-0229(93)90077-F
   LEE CY, 1984, J CHEM PHYS, V80, P4448, DOI 10.1063/1.447226
   Lee JH, 1997, J BIOMED MATER RES, V34, P105, DOI 10.1002/(SICI)1097-4636(199701)34:1<105::AID-JBM14>3.0.CO;2-J
   LEE SH, 1988, J COLLOID INTERF SCI, V125, P365, DOI 10.1016/0021-9797(88)90001-X
   LENEVEU DM, 1976, NATURE, V259, P601, DOI 10.1038/259601a0
   LENEVEU DM, 1977, BIOPHYS J, V18, P209, DOI 10.1016/S0006-3495(77)85608-7
   LENSEN HGW, 1984, J COLLOID INTERF SCI, V99, P1, DOI 10.1016/0021-9797(84)90079-1
   LIEBMANN A, 1995, SURF BIOM S MINN MN, P1
   LiebmannVinson A, 1996, LANGMUIR, V12, P2256, DOI 10.1021/la950642d
   Lin JC, 1996, J COLLOID INTERF SCI, V182, P315, DOI 10.1006/jcis.1996.0470
   LIS LJ, 1982, BIOPHYS J, V37, P657
   Loosdrecht M, 1990, AQUAT SCI, V52, P103
   Lyklema J, 1991, FUNDAMENTALS INTERFA
   MACRITCHIE F, 1972, J COLLOID INTERF SCI, V38, P484, DOI 10.1016/0021-9797(72)90264-0
   MALMSTEN M, 1994, J COLLOID INTERF SCI, V166, P333, DOI 10.1006/jcis.1994.1303
   MANDENIUS CF, 1991, BIOMATERIALS, V12, P369, DOI 10.1016/0142-9612(91)90004-T
   MANUEL BG, 1997, LANGMUIR, V13, P2541
   MARGEL S, 1993, J BIOMED MATER RES, V27, P1463, DOI 10.1002/jbm.820271202
   McHaffie IR, 1925, J CHEM SOC, V127, P1559, DOI 10.1039/ct9252701559
   MEAGHER L, 1992, J COLLOID INTERF SCI, V152, P293, DOI 10.1016/0021-9797(92)90030-P
   MEYER AE, 1990, THESIS LUND U MALMO
   MIZUTANI T, 1981, J COLLOID INTERF SCI, V82, P162, DOI 10.1016/0021-9797(81)90135-1
   Morra M, 1996, J COLLOID INTERF SCI, V182, P312, DOI 10.1006/jcis.1996.0469
   MORRISON ID, 1989, LANGMUIR, V5, P540, DOI 10.1021/la00086a045
   NEMETHY G, 1962, J CHEM PHYS, V36, P3382, DOI 10.1063/1.1732472
   NEUMANN AW, 1980, SEPAR PURIF METHOD, V9, P69, DOI 10.1080/03602548008057240
   NEUMANN AW, 1974, J COLLOID INTERF SCI, V49, P291, DOI 10.1016/0021-9797(74)90365-8
   NINHAM BW, 1980, J PHYS CHEM-US, V84, P1423, DOI 10.1021/j100449a001
   NINHAM BW, 1985, CHEM SCRIPTA, V25, P3
   Ninham BW, 1997, LANGMUIR, V13, P2097, DOI 10.1021/la960974y
   Ninham BW, 1997, COLLOID SURFACE A, V123, P7, DOI 10.1016/S0927-7757(96)03794-6
   NORDE W, 1979, J COLLOID INTERF SCI, V71, P350, DOI 10.1016/0021-9797(79)90245-5
   NORDE W, 1978, J COLLOID INTERF SCI, V66, P285, DOI 10.1016/0021-9797(78)90306-5
   NORDE W, 1978, J COLLOID INTERF SCI, V66, P266, DOI 10.1016/0021-9797(78)90304-1
   NORDE W, 1978, J COLLOID INTERF SCI, V66, P257, DOI 10.1016/0021-9797(78)90303-X
   NORDE W, 1986, ADV COLLOID INTERFAC, V25, P267, DOI 10.1016/0001-8686(86)80012-4
   NORDE W, 1978, J COLLOID INTERF SCI, V66, P295, DOI 10.1016/0021-9797(78)90307-7
   NORDE W, 1978, J COLLOID INTERF SCI, V66, P277, DOI 10.1016/0021-9797(78)90305-3
   OCONNOR CJ, 1988, BIOCATALYSIS, V1, P249
   OWENS DK, 1969, J APPL POLYM SCI, V13, P1741, DOI 10.1002/app.1969.070130815
   PARKER JL, 1994, LANGMUIR, V10, P635, DOI 10.1021/la00015a008
   PARKER JL, 1989, J PHYS CHEM-US, V93, P6121, DOI 10.1021/j100353a034
   PARKER JL, 1994, J PHYS CHEM-US, V98, P8468, DOI 10.1021/j100085a029
   PARSEGIAN VA, 1991, LANGMUIR, V7, P1299, DOI 10.1021/la00054a047
   PARSEGIAN VA, 1982, ADV COLLOID INTERFAC, V16, P49
   PASHLEY RM, 1979, J COLLOID INTERF SCI, V71, P491, DOI 10.1016/0021-9797(79)90323-0
   PASHLEY RM, 1981, J COLLOID INTERF SCI, V83, P531, DOI 10.1016/0021-9797(81)90348-9
   PASHLEY RM, 1981, J COLLOID INTERF SCI, V80, P153, DOI 10.1016/0021-9797(81)90171-5
   PASHLEY RM, 1981, COLLOID SURFACE, V2, P169, DOI 10.1016/0166-6622(81)80006-6
   PASHLEY RM, 1985, SCIENCE, V229, P1088, DOI 10.1126/science.4035349
   PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0
   Petrash S, 1997, LANGMUIR, V13, P1881, DOI 10.1021/la9610821
   RABINOVICH YI, 1994, LANGMUIR, V10, P1903, DOI 10.1021/la00018a048
   RABINOVICH YI, 1988, COLLOID SURFACE, V30, P273
   RAND RP, 1989, BIOCHIM BIOPHYS ACTA, V988, P351, DOI 10.1016/0304-4157(89)90010-5
   RAU DC, 1990, SCIENCE, V249, P1278, DOI 10.1126/science.2144663
   RAU DC, 1984, P NATL ACAD SCI-BIOL, V81, P2621, DOI 10.1073/pnas.81.9.2621
   RIDDLE FL, 1990, J AM CHEM SOC, V112, P3259, DOI 10.1021/ja00165a001
   ROYXHET PG, 1990, WATER SCI TECHNOL, V72, P1
   Ruckenstein E, 1997, J COLLOID INTERF SCI, V188, P218, DOI 10.1006/jcis.1997.4770
   SCHAKENRAAD JM, 1986, J BIOMED MATER RES, V20, P773, DOI 10.1002/jbm.820200609
   SCHAKENRAAD JM, 1987, THESIS U GRONINGEN G
   Schneider RP, 1997, COLLOID SURFACE A, V126, P1, DOI 10.1016/S0927-7757(96)03885-X
   Schrader ME, 1996, LANGMUIR, V12, P3728, DOI 10.1021/la940962h
   Serro APV, 1997, COLLOID SURFACE A, V125, P209, DOI 10.1016/S0927-7757(97)00017-4
   SHIRAHAMA H, 1990, J COLLOID INTERF SCI, V139, P177, DOI 10.1016/0021-9797(90)90455-W
   SIEWIERSKI L, 1995, SPIE P, V2, P2441
   SPELT JK, 1986, LANGMUIR, V2, P620, DOI 10.1021/la00071a017
   SPELT JK, 1988, J COLLOID INTERF SCI, V122, P294, DOI 10.1016/0021-9797(88)90315-3
   Suresh SJ, 1996, LANGMUIR, V12, P6151, DOI 10.1021/la960153t
   SUTTIPRASIT P, 1992, J COLLOID INTERF SCI, V154, P316, DOI 10.1016/0021-9797(92)90146-D
   SUZAWA T, 1982, J COLLOID INTERF SCI, V86, P144, DOI 10.1016/0021-9797(82)90049-2
   SYMONS MCR, 1981, ACCOUNTS CHEM RES, V14, P179, DOI 10.1021/ar00066a003
   TANFORD C, 1978, SCIENCE, V200, P1012, DOI 10.1126/science.653353
   Tanford C, 1973, HYDROPHOBIC EFFECT F
   TELETZKE GF, 1987, CHEM ENG COMMUN, V55, P41, DOI 10.1080/00986448708911919
   VERWEY EJW, 1948, THEORY STABILITY LYO
   VIGIL G, 1994, J COLLOID INTERF SCI, V165, P367, DOI 10.1006/jcis.1994.1242
   VOGLER EA, 1995, J BIOMED MATER RES, V29, P1005, DOI 10.1002/jbm.820290813
   VOGLER EA, 1989, J COLLOID INTERF SCI, V133, P228, DOI 10.1016/0021-9797(89)90296-8
   Vogler EA, 1996, J ELECTRON SPECTROSC, V81, P237, DOI 10.1016/0368-2048(96)02526-1
   Vogler EA, 1998, J BIOMED MATER RES, V40, P92, DOI 10.1002/(SICI)1097-4636(199804)40:1<92::AID-JBM11>3.3.CO;2-W
   VOGLER EA, 1987, J BIOMED MATER RES, V21, P1197, DOI 10.1002/jbm.820211004
   VOGLER EA, 1993, LANGMUIR, V9, P497, DOI 10.1021/la00026a023
   VOGLER EA, 1995, J BIOMED MATER RES, V29, P1017, DOI 10.1002/jbm.820290814
   VOGLER EA, 1992, LANGMUIR, V8, P2005, DOI 10.1021/la00044a022
   VOGLER EA, 1992, LANGMUIR, V8, P2013, DOI 10.1021/la00044a023
   VOGLER EA, 1993, SURFACTANT SCI SERIE, V49, P184
   VOGLER EA, UNPUB
   VONGIESSEN AE, 1997, J COLLOID INTERF SCI, V192, P257
   VONOSS CJ, 1980, COLLOID POLYM SCI, V258, P424
   VONOSS CJ, 1988, LANGMUIR, V4, P884
   VONWACHEM PB, 1985, BIOMATERIALS, V6, P403
   VROMAN L, 1972, B NEW YORK ACAD MED, V48, P302
   WALTON AG, 1979, J COLLOID INTERF SCI, V72, P265, DOI 10.1016/0021-9797(79)90108-5
   Wannerberger K, 1997, LANGMUIR, V13, P784, DOI 10.1021/la9605652
   WIGGINS PM, 1990, MICROBIOL REV, V54, P432
   WIGGINS PM, 1971, J THEOR BIOL, V32, P131, DOI 10.1016/0022-5193(71)90141-X
   WIGGINS PM, 1986, J MACROMOL SCI CHEM, VA23, P875, DOI 10.1080/00222338608069479
   WIGGINS PM, 1990, BIOPHYS J, V58, P585, DOI 10.1016/S0006-3495(90)82402-4
   WIGGINS PM, 1988, PROG POLYM SCI, V13, P1, DOI 10.1016/0079-6700(88)90009-3
   Williams DF, 1986, P CONS C EUR SOC BIO
   WOJCIECHOWSKI P, 1986, J COLLOID INTERF SCI, V111, P455, DOI 10.1016/0021-9797(86)90048-2
   WOJCIECHOWSKI P, 1991, Journal of Biomaterials Science Polymer Edition, V2, P203
   YAMINSKY VV, 1993, LANGMUIR, V9, P3618, DOI 10.1021/la00036a043
   Yaminsky VV, 1997, LANGMUIR, V13, P2, DOI 10.1021/la960773u
   Yaminsky VV, 1996, LANGMUIR, V12, P1936, DOI 10.1021/la950740z
   Yoon RH, 1997, J COLLOID INTERF SCI, V185, P363, DOI 10.1006/jcis.1996.4583
   Zisman W. A., 1964, ADV CHEM SER, V43, P1
   ZISMAN WA, 1964, ADV CHEM SER, V25, P1
   1910, T FARADAY SOC, V6, P71
NR 226
TC 777
Z9 796
U1 46
U2 536
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-8686
EI 1873-3727
J9 ADV COLLOID INTERFAC
JI Adv. Colloid Interface Sci.
PD FEB
PY 1998
VL 74
BP 69
EP 117
DI 10.1016/S0001-8686(97)00040-7
PG 49
WC Chemistry, Physical
SC Chemistry
GA ZG001
UT WOS:000072954700003
PM 9561719
DA 2018-10-19
ER

PT J
AU Sabokbar, A
   Pandey, R
   Quinn, JMW
   Athanasou, NA
AF Sabokbar, A
   Pandey, R
   Quinn, JMW
   Athanasou, NA
TI Osteoclastic differentiation by mononuclear phagocytes containing
   biomaterial particles
SO ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY
LA English
DT Article
ID BONE-RESORBING CELLS; MACROPHAGES; RESORPTION
AB Aseptic loosening of implant components is a common and important complication of both cemented and uncemented prosthetic joint replacements. Wear particles derived from organic polymer and metal implant biomaterials are commonly found within macrophages and macrophage polykaryons in the fibrous membrane between loose implant components and the host bone undergoing resorption. In order to deter-mine whether biomaterial particle-containing, foreign-body macrophages may contribute to periprosthetio bone resorption. we cultured murine monocytes that had phagocytosed particles of biomaterials commonly employed in bone implant surgery [polymethylmethacrylate (PMMA), ultra-high molecular weight polyethylene (PE), titanium and chromium-cobalt] on bone slices and glass coverslips with UMR 106 osteoblast-like stromal cells in the presence of 1.25-dihydroxy-vitamin D-3. Under these conditions, all biomaterial particle-containing. foreign-body macrophages differentiated into osteoclastic cells, i.e. tartrate-resistant acid, phosphatase (TRAP)-positive multinucleated cells capable of extensive lacunar bone resorption. This study shows that particle phagocytosis by macrophages does not abrogate the ability of these cells to undergo osteoclast differentiation. These findings emphasise the importance of the foreign-body macrophage response to biomaterial wear particles in the pathogenesis of aseptic loosening.
C1 Univ Oxford, Nuffield Orthopaed Ctr, Nuffield Dept Pathol, Oxford OX3 7LD, England.
   Univ Oxford, Nuffield Orthopaed Ctr, Nuffield Dept Orthopaed Surg, Oxford OX3 7LD, England.
RP Athanasou, NA (reprint author), Univ Oxford, Nuffield Orthopaed Ctr, Nuffield Dept Pathol, Oxford OX3 7LD, England.
FU Wellcome Trust
CR AMSTUTZ HC, 1992, CLIN ORTHOP RELAT R, P7
   ATHANASOU NA, 1992, BRIT J CANCER, V65, P523, DOI 10.1038/bjc.1992.108
   AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013
   CHAMBERS TJ, 1984, CALCIFIED TISSUE INT, V36, P556, DOI 10.1007/BF02405365
   CHAMBERS TJ, 1984, J CELL SCI, V66, P383
   CHAMBERS TJ, 1982, J PATHOL, V136, P27, DOI 10.1002/path.1711360104
   Fujikawa Y, 1996, ENDOCRINOLOGY, V137, P4058, DOI 10.1210/en.137.9.4058
   GLANT TT, 1993, J BONE MINER RES, V8, P1071
   JOHANSON NA, 1987, CLIN ORTHOP RELAT R, P123
   JONES LC, 1987, CLIN ORTHOP RELAT R, P192
   LENNOX DW, 1987, CLIN ORTHOP RELAT R, P171
   MALCOLM AJ, 1988, J BONE JOINT SURG BR, V70, P153
   MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252
   MURRAY DW, 1990, J BONE JOINT SURG BR, V72, P988
   Pandey R, 1996, ANN RHEUM DIS, V55, P388, DOI 10.1136/ard.55.6.388
   PARTRIDGE NC, 1981, ENDOCRINOLOGY, V108, P213, DOI 10.1210/endo-108-1-213
   QUINN J, 1992, J BONE JOINT SURG BR, V74, P652
   QUINN JMW, 1994, ENDOCRINOLOGY, V134, P2416, DOI 10.1210/en.134.6.2416
   SANTAVIRTA S, 1990, J BONE JOINT SURG AM, V72A, P252, DOI 10.2106/00004623-199072020-00014
   TAKAHASHI N, 1994, DEV BIOL, V163, P212, DOI 10.1006/dbio.1994.1137
NR 20
TC 44
Z9 44
U1 0
U2 5
PU SPRINGER VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010 USA
SN 0936-8051
J9 ARCH ORTHOP TRAUM SU
JI Arch. Orthop. Trauma Surg.
PD FEB
PY 1998
VL 117
IS 3
BP 136
EP 140
DI 10.1007/s004020050213
PG 5
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA YY369
UT WOS:000072140200004
PM 9521517
DA 2018-10-19
ER

PT J
AU De Iaco, PA
   Stefanetti, M
   Pressato, D
   Piana, S
   Dona, M
   Pavesio, A
   Bovicelli, L
AF De Iaco, PA
   Stefanetti, M
   Pressato, D
   Piana, S
   Dona, M
   Pavesio, A
   Bovicelli, L
TI A novel hyaluronan-based gel in laparoscopic adhesion prevention:
   preclinical evaluation in an animal model
SO FERTILITY AND STERILITY
LA English
DT Article
DE adhesion prevention; animal model; cross-linked hyaluronan; laparoscopic
   surgery
ID OXIDIZED REGENERATED CELLULOSE; TEX SURGICAL MEMBRANE; UTERINE HORN
   MODEL; POSTOPERATIVE ADHESIONS; ACID; INTERCEED; BARRIER
AB Objective: To evaluate the effectiveness of a crosslinked hyaluronan solution (ACP gel) in the prevention of postsurgical adhesions in laparoscopic surgery.
   Design: A randomized blinded study using a rabbit model in laparoscopic surgery.
   Setting: A standardized surgical trauma in the rabbit uterine horn to induce adhesion formation.
   Animals: Sixty-four sexually matured female New Zealand white rabbits weighing 2.5 to 3.0 kg and aged 3-4 months.
   Intervention(s): After trauma, group 1 (n = 22) received no treatment, group 2 animals (n = 20) received oxidized-regenerated cellulose (Interceed [TC7]), in group 3 (n = 22) 5 mL of ACP gel were applied on the lesion.
   Main Outcome Measure(s): Six weeks after laparoscopy, a laparotomy was performed and the adhesions were scored according to Blauer's scoring system.
   Result(s): 66% of the untreated animals and 85% of the animals treated with Interceed presented with severe adhesions, whereas only 35% of the ACP gel treatment group had significant adhesions. The mean (+/- SEM) increased adhesion score was 2.24 +/- 0.26 in the untreated group, 2.45 +/- 0.22 in the Interceed group, and was 1.25 +/- 0.28 in the ACP gel group.
   Conclusion(s): This study revealed that ACP gel holds promise as a novel resorbable biomaterial for the reduction of postoperative adhesions after laparoscopic surgery. (C) 1998 by American Society for Reproductive Medicine.
C1 Univ Bologna, Osped S Orsola, Clin Ostetr & Ginecol, Dept Obstet & Gynecol, I-40138 Bologna, Italy.
   Fidia Adv Biopolymers Srl, Abano Terme, Italy.
   Univ Bologna, S Orsola Hosp, Dept Pathol, Bologna, Italy.
RP De Iaco, PA (reprint author), Univ Bologna, Osped S Orsola, Clin Ostetr & Ginecol, Dept Obstet & Gynecol, Via Massarenti 13, I-40138 Bologna, Italy.
CR BALAZS EA, 1991, BLOOD COAGUL FIBRIN, V2, P173, DOI 10.1097/00001721-199102000-00026
   BALAZS EA, 1989, P NISSH INT C CELL U, P233
   BENEDETTI L, 1994, NOVEL BIOMATERIALS B, P20
   BEST CL, 1991, OBSTET GYNECOL, V78, P858
   BLAUER KL, 1988, FERTIL STERIL, V49, P144
   BOULDORIS O, 1992, J CHIR, V129, P160
   Burns JM, 1995, J SURG RES, V59, P644, DOI 10.1006/jsre.1995.1218
   Burns JW, 1996, FERTIL STERIL, V66, P814, DOI 10.1016/S0015-0282(16)58642-7
   DEIACO P, 1994, FERTIL STERIL, V62, P400
   DIAMOND MP, 1988, INT J FERTIL, V33, P372
   DIAMOND MP, 1990, TREATMENT POSTSURGIC, P27
   FRASER JRE, 1984, CLIN EXP PHARMACOL P, V11, P17, DOI 10.1111/j.1440-1681.1984.tb00235.x
   GRAINGER DA, 1991, J GYNECOL SURG, V7, P97, DOI 10.1089/gyn.1991.7.97
   HAGBERG L, 1992, J HAND SURG-AM, V17A, P935, DOI 10.1016/0363-5023(92)90474-4
   HANEY AF, 1995, FERTIL STERIL, V63, P1021, DOI 10.1016/S0015-0282(16)57541-4
   HILLWEST JL, 1994, FERTIL STERIL, V62, P630
   KING SR, 1991, SURGERY, V109, P76
   LI TC, 1994, BRIT J OBSTET GYNAEC, V101, P335, DOI 10.1111/j.1471-0528.1994.tb13621.x
   Mensitieri M, 1996, J MATER SCI-MATER M, V7, P695, DOI 10.1007/BF00123409
   PAGIDAS K, 1992, FERTIL STERIL, V57, P199
   Saravelos H, 1996, HUM REPROD, V11, P992
   Saravelos HG, 1996, J REPROD MED, V41, P42
   SAWHNEY AS, 1994, J BIOMED MATER RES, V28, P831, DOI 10.1002/jbm.820280710
   URMAN B, 1991, FERTIL STERIL, V56, P563
NR 24
TC 55
Z9 56
U1 0
U2 6
PU AMER SOC REPRODUCTIVE MEDICINE
PI BIRMINGHAM
PA 1209 MONTGOMERY HIGHWAY, BIRMINGHAM, AL 35216-2809 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD FEB
PY 1998
VL 69
IS 2
BP 318
EP 323
PG 6
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA YY935
UT WOS:000072202700024
PM 9496348
DA 2018-10-19
ER

PT J
AU Rupp, ME
   Hamer, KE
AF Rupp, ME
   Hamer, KE
TI Effect of subinhibitory concentrations of vancomycin, cefazolin,
   ofloxacin, L-ofloxacin and D-ofloxacin on adherence to intravascular
   catheters and biofilm formation by Staphylococcus epidermidis
SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
LA English
DT Article
ID COAGULASE-NEGATIVE STAPHYLOCOCCI; CAPSULAR POLYSACCHARIDE ADHESIN;
   TRANSPOSON MUTANTS; SILICONE-RUBBER; ANTIBIOTICS; SLIME; MODEL;
   IDENTIFICATION; DEFICIENT; INVITRO
AB Staphylococcus epidermidis is the preeminent cause of nosocomial bacteraemia and infection of prosthetic medical devices. Bacterial adherence to biomaterial is a crucial early event in the pathogenesis of these infections. Antibiotics affect bacterial adherence to eukaryotic cells, capsule formation and biofilm production. However, results from studies involving coagulase-negative staphylococci are equivocal. In this study, the in-vitro adherence of radiolabelled bacteria was assayed to determine the effect of sublethal concentrations of a number of antibiotics on the attachment of four strains of S. epidermidis, with well-characterized adherence profiles, to intravascular catheters. The effect of antibiotics on biofilm production by S. epidermidis was assayed using a quantitative spectrophotometric assay. Although there was some strain-to-strain variability, none of the tested antibiotics affected bacterial attachment. However, treatment with cefazolin or vancomycin resulted in a significant decrease in biofilm elaboration. These data suggest that bacterial attachment by S. epidermidis, the initiating event associated with prosthetic device infection, cannot be prevented by subtherapeutic levels of fluoroquinolone, glycopeptide or beta-lactam antibiotics. However, later aggregative stages of adherence, associated with biofilm production, may be influenced by cell wall-active agents such as cefazolin and vancomycin.
C1 Univ Nebraska, Med Ctr, Dept Internal Med, Omaha, NE 68198 USA.
RP Rupp, ME (reprint author), Univ Nebraska, Med Ctr, Dept Internal Med, 600 S 42nd St, Omaha, NE 68198 USA.
EM merupp@unmc.edu
CR AHMED K, 1990, TOHOKU J EXP MED, V161, P1, DOI 10.1620/tjem.161.1
   Baldassarri L, 1996, INFECT IMMUN, V64, P3410
   BANERJEE SN, 1991, AM J MED S3B, V91, P86
   BROWN E, 1989, J INFECT DIS, V160, P644, DOI 10.1093/infdis/160.4.644
   CHRISTENSEN GD, 1985, J CLIN MICROBIOL, V22, P996
   CHRISTENSEN GD, 1990, INFECT IMMUN, V58, P2906
   Christensen Gordon D., 1994, P45
   CHUGH TD, 1989, CHEMOTHERAPY, V35, P113, DOI 10.1159/000238656
   FINCH RG, 1989, PERITON DIALYSIS INT, V9, P103
   GILSDORF JR, 1986, ANTIMICROB AGENTS CH, V30, P370, DOI 10.1128/AAC.30.3.370
   GOLDMANN DA, 1993, CLIN MICROBIOL REV, V6, P176
   GRISTINA AG, 1987, SCIENCE, V237, P1588, DOI 10.1126/science.3629258
   HELD TK, 1995, ANTIMICROB AGENTS CH, V39, P1093, DOI 10.1128/AAC.39.5.1093
   KARCHMER AW, 1991, INFECT DIS, P1374
   KHARDORI N, 1991, J INFECT DIS, V164, P108, DOI 10.1093/infdis/164.1.108
   LIMOGES J, 1995, 95 GEN M AM SOC MICR, P241
   LORIAN V, 1993, J ANTIMICROB CHEMOTH, V31, P137, DOI 10.1093/jac/31.suppl_D.137
   MACK D, 1994, INFECT IMMUN, V62, P3244
   MACK D, 1992, INFECT IMMUN, V60, P2048
   Mayhall C G, 1992, Curr Clin Top Infect Dis, V12, P83
   MIYAKE Y, 1990, FEMS MICROBIOL LETT, V69, P211
   MULLER E, 1993, INFECT IMMUN, V61, P551
   MULLER E, 1993, J INFECT DIS, V168, P1211, DOI 10.1093/infdis/168.5.1211
   MULLER E, 1991, INFECT IMMUN, V59, P3323
   *NAT COMM CLIN LAB, 1991, METH DIL ANT SUSC TE
   PASCUAL A, 1986, EUR J CLIN MICROBIOL, V5, P518, DOI 10.1007/BF02017694
   PETERS G, 1982, J INFECT DIS, V146, P479, DOI 10.1093/infdis/146.4.479
   RUPP ME, 1994, CLIN INFECT DIS, V19, P231, DOI 10.1093/clinids/19.2.231
   RUPP ME, 1995, J INFECT DIS, V172, P1509, DOI 10.1093/infdis/172.6.1509
   RUPP ME, 1992, INFECT IMMUN, V60, P4322
   RUPP ME, 1997, STAPHYLOCOCCI HUMAN, P379
   SCHADOW KH, 1988, J INFECT DIS, V157, P71, DOI 10.1093/infdis/157.1.71
   SCHMITT DD, 1990, J SURG RES, V48, P373, DOI 10.1016/0022-4804(90)90078-G
   SHIRO H, 1994, J INFECT DIS, V169, P1042, DOI 10.1093/infdis/169.5.1042
   SOBOH F, 1995, ANTIMICROB AGENTS CH, V39, P1281, DOI 10.1128/AAC.39.6.1281
   SONSTEIN SA, 1993, DIAGN MICR INFEC DIS, V16, P277, DOI 10.1016/0732-8893(93)90078-L
   TOJO M, 1988, J INFECT DIS, V157, P713, DOI 10.1093/infdis/157.4.713
   Tullio V, 1992, Microbios, V69, P67
   WILCOX MH, 1991, J ANTIMICROB CHEMOTH, V27, P577, DOI 10.1093/jac/27.5.577
NR 39
TC 41
Z9 43
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-7453
J9 J ANTIMICROB CHEMOTH
JI J. Antimicrob. Chemother.
PD FEB
PY 1998
VL 41
IS 2
BP 155
EP 161
DI 10.1093/jac/41.2.155
PG 7
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA ZB581
UT WOS:000072486900003
PM 9533456
OA Bronze
DA 2018-10-19
ER

PT J
AU Hiester, ED
   Sacks, MS
AF Hiester, ED
   Sacks, MS
TI Optimal bovine pericardial tissue selection sites. I. Fiber architecture
   and tissue thickness measurements
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE bovine pericardium; heart valves; bioprostheses; light scattering;
   collagen fibers; tissue thickness
ID HEART-VALVES; BIOPROSTHESES; STRENGTH; PORCINE
AB Use of bovine pericardium as an engineered biomaterial in the fabrication of bioprosthetic heart valves is Limited, in part, by substantial intra-and intersac variations in its fibrous structure. To quantitatively assess this variability, we determined the fiber architecture of 20 whole BP sacs. Each sac was mounted on a prolate spheroidal mold, cleared and preserved in 100% glycerol, then sectioned into four equisized quadrants. This preparation method allowed for accurate intersac comparisons and minimized tissue distortions. The fiber architecture was evaluated by small-angle Light scattering (SALS) using a 2.54-mm rectilinear grid resulting in similar to 1200 SALS measurements per quadrant, along with tissue thickness measured at 55 locations per quadrant. The fiber architecture was described in terms of fiber preferred directions, degree of orientation, and asymmetry of the fiber angular distribution. The BP sac fiber architecture demonstrated substantial intra-and intersac variability, with local fiber preferred directions changing by as much as 90 degrees within similar to 5 mm. Overall, most sacs revealed potential selection areas in the apex region characterized by a high degree of orientation, high uniformity in fiber Preferred directions, and uniform tissue thickness. However, the size, location, and fiber orientation of these potential selection areas varied sufficiently from sac-to-sac to question whether anatomic location alone is sufficient for consistent localization of regions of high structural uniformity suitable for improved BHV design. (C) 1998 John Wiley & Sons, Inc.
C1 Univ Miami, Dept Biomed Engn, Tissue Mech Lab, Miami, FL 33152 USA.
RP Sacks, MS (reprint author), Univ Miami, Dept Biomed Engn, Tissue Mech Lab, Miami, FL 33152 USA.
EM msacks@coeds.eng.miami.edu
CR Barbenel J. C., 1987, BIOMATERIALS CLIN AP, P421
   BELENKIE I, 1992, AM HEART J, V123, P733, DOI 10.1016/0002-8703(92)90514-V
   BLACK MM, 1986, BIOL BIOPROSTHETIC V, P709
   BORCH J, 1971, J POLYM SCI A2, V9, P313, DOI 10.1002/pol.1971.160090207
   CHIEN JCW, 1972, MACROMOLECULES, V5, P610, DOI 10.1021/ma60029a016
   CHUOUNG CJ, 1990, J BIOMECH, V24, P563
   Cooley DA, 1986, BIOL BIOPROSTHETIC V, P177
   CROFTS CE, 1989, BIOMATERIALS, V10, P230, DOI 10.1016/0142-9612(89)90098-7
   FENTIE IH, 1986, J SUBMICR CYTOL PATH, V18, P53
   GABBAY S, 1984, J THORAC CARDIOV SUR, V88, P758
   GONZALEZLEVIN L, 1983, ANN THORAC SURG, V26, P270
   GRANT DA, 1992, CIRCULATION, V86, P1615, DOI 10.1161/01.CIR.86.5.1615
   GRANT DA, 1994, AM J PHYSIOL, V266, pH2327
   HIESTER E, 1996, THESIS U MIAMI MIAMI, P106
   Hiester ED, 1998, J BIOMED MATER RES, V39, P215, DOI 10.1002/(SICI)1097-4636(199802)39:2<215::AID-JBM7>3.0.CO;2-S
   HOLT JP, 1970, AM J CARDIOL, V26, P455, DOI 10.1016/0002-9149(70)90702-2
   IONESCU MI, 1982, CARDIAC BIOPROSTHESE, P709
   Lee JM, 1996, J BIOMECH, V29, P829, DOI 10.1016/0021-9290(95)00121-2
   LEE JM, 1997, 23 ANN M SOC BIOM NE, P177
   LEE JM, 1985, CIRC RES, V55, P475
   LEE MC, 1987, AM J PHYSIOL, V253, pH75
   Moore MA, 1996, J BIOMED MATER RES, V32, P209, DOI 10.1002/(SICI)1097-4636(199610)32:2<209::AID-JBM9>3.0.CO;2-X
   MORITANI M, 1971, POLYM J, V2, P74, DOI 10.1295/polymj.2.74
   MUGGLI R, 1971, J POLYM SCI, V36, P121
   PELLETIER LC, 1989, ANN THORAC SURG, V47, P352, DOI 10.1016/0003-4975(89)90373-1
   RAMAN CV, 1954, P INDIAN ACAD SCI A, V40, P109
   Sacks M S, 1994, ASAIO J, V40, pM632, DOI 10.1097/00002480-199407000-00075
   Sacks MS, 1997, ANN BIOMED ENG, V25, P678, DOI 10.1007/BF02684845
   SHABETAI R, 1981, PERICARDIUM
   SIMIONESCU D, 1993, J BIOMED MATER RES, V27, P697, DOI 10.1002/jbm.820270602
   SMISETH O, 1994, CIRCULATION, V75, P1229
   Stein R S, 1966, J POLYM SCI C, V13, P1
   STEIN RS, 1962, J APPL PHYS, V33, P1914, DOI 10.1063/1.1728869
   SUZIGAN S, 1994, J CARDIOVASC SURG, V35, P139
   TROWBRIDGE EA, 1989, CRIT REV BIOCOMPAT, V5, P105
   TROWBRIDGE EA, 1989, J BIOMED ENG, V11, P311, DOI 10.1016/0141-5425(89)90065-4
   WALKER DK, 1983, MED BIOL ENG COMPUT, V21, P31, DOI 10.1007/BF02446403
NR 37
TC 47
Z9 47
U1 0
U2 9
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD FEB
PY 1998
VL 39
IS 2
BP 207
EP 214
DI 10.1002/(SICI)1097-4636(199802)39:2<207::AID-JBM6>3.0.CO;2-T
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA YR131
UT WOS:000071461400006
PM 9457549
DA 2018-10-19
ER

PT J
AU Phipatanakul, WP
   Johnson, SA
   Good, V
   Clarke, IC
AF Phipatanakul, WP
   Johnson, SA
   Good, V
   Clarke, IC
TI The fallacy of evaluating biomaterial wear-rates with water as
   lubricant: A hip simulator study of alumina-PTFE and CoCr-PTFE
   combinations
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE hip-joint; simulator; wear; PTFE; lubricants
ID POLYETHYLENE ACETABULAR CUP; CERAMIC HEADS; FEMORAL HEADS; UHMWPE;
   JOINTS; SERUM; METAL
AB Controversy surrounds wear data from hip-simulator studies, whether from the choice of lubricants or other parameters such as the particular biomaterial combinations used, and whether any such interactions could bias the resulting wear predictions. To investigate these phenomena, we studied the wear performance of CoCr and alumina femoral heads, in water and serum-based lubricants, using as our standard the polytetrafluoroethylene wear data derived clinically by Charnley. To model Chamley's clinical experience, PTFE acetabular cups were used in sets of three each with each size of femoral head for 22.25, 28, and 42-mm diameters in a nine-channel hip simulator. From the serum-based tests, the CoCr-PTFE wear data were consistently linear with duration of test, exhibited very large wear rates of 3,000-8,400 mm(3)/10(6), cycles had a precision within +/- 4% for each set of three cups, and copious amounts of small particulate were clearly seen circulating. The wear data clearly demonstrated Charnley's thesis that volume of wear increased with regard to size of femoral head. From the waterbased tests, the CoCr-PTFE wear data were nonlinear with duration of test, had much reduced wear rates compared to the serum tests, lost the clinical relationship with ball size, and precision deteriorated to +/- 27% for each set. The wear debris appeared as 1-2 cm long ribbons which floated to the surface. For the alumina-PTFE combination in serum, the wear data appeared identical in performance to the CoCr-PTFE data in serum. Thus, the PTFE wear rates were not sensitive to the choice of femoral-head material. The most surprising outcome in this study was the zero-wear performance of the ceramic-PTFE combination in water. This contrasted remarkably with the large wear rates established for the same combinations run in serum. The zero-wear performance of the ceramic-PTFE combination in water was unexpected, but a similar phenomenon was noted in published simulator tests of ceramic-UHMWPE run in water. It now seems Likely that such data may reflect the capricious behavior of water lubrication rather than any other variables under evaluation. The water-based experiments clearly favored the ceramic's superior tribological performance and placed metal bearings at a decided disadvantage. Therefore, for an in vitro simulation of materials wear-ranking of clinical relevance, it may be advisable to use a serum-based lubricant. (C) 1998 John Wiley & Sons, Inc.
C1 Loma Linda Univ, Med Ctr, Dept Orthopaed, Howard & Irene Paterson Tribol Lab, Loma Linda, CA 92354 USA.
RP Clarke, IC (reprint author), Loma Linda Univ, Med Ctr, Dept Orthopaed, Howard & Irene Paterson Tribol Lab, Loma Linda, CA 92354 USA.
CR CAMPBELL P, 1995, J BIOMED MATER RES, V29, P127, DOI 10.1002/jbm.820290118
   CHARNLEY J, 1969, MED BIOL ENG, V7, P31, DOI 10.1007/BF02474667
   CHARNLEY J, 1975, PLASTICS MED SURG
   Clarke IC, 1996, ACTA ORTHOP SCAND, V67, P128, DOI 10.3109/17453679608994656
   CLARKE IC, 1996, UNPUB 6 BIOM S IMPL
   CLARKE IC, 1995, T 2 COMB ORTH RES SO, P204
   DERBYSHIRE B, 1994, MED ENG PHYS, V16, P229, DOI 10.1016/1350-4533(94)90042-6
   Good VD, 1996, J BIOMED MATER RES, V33, P275, DOI 10.1002/(SICI)1097-4636(199624)33:4<275::AID-JBM7>3.0.CO;2-M
   MCKELLOP H, 1981, J BIOMED MATER RES, V15, P619, DOI 10.1002/jbm.820150503
   MCKELLOP H, 1978, J BIOMED MATER RES, V12, P895, DOI 10.1002/jbm.820120611
   McKellop H.A., 1985, CORROSION DEGRADATIO, P351
   SAIKKO VO, 1993, ACTA ORTHOP SCAND, V64, P391, DOI 10.3109/17453679308993653
   SAIKKO VO, 1993, ACTA ORTHOP SCAND, V64, P507, DOI 10.3109/17453679308993680
   Saikko VO, 1995, ACTA ORTHOP SCAND, V66, P501, DOI 10.3109/17453679509002302
   SEMLITSCH M, 1977, J BIOMED MATER RES, V11, P537, DOI 10.1002/jbm.820110409
   SHROEDER DW, 1995, T 2 COMB ORTH RES SO, P178
   UNSWORTH A, 1995, ORTHOPEDIC PRODU MAR, P485
   Wang A, 1996, BIOMATERIALS, V17, P865, DOI 10.1016/0142-9612(96)83281-9
   WRIGHT KWJ, 1980, EVALUATION BIOMATERI, P135
NR 19
TC 24
Z9 24
U1 0
U2 4
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD FEB
PY 1998
VL 39
IS 2
BP 229
EP 233
DI 10.1002/(SICI)1097-4636(199802)39:2<229::AID-JBM9>3.0.CO;2-R
PG 5
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA YR131
UT WOS:000071461400009
PM 9457552
DA 2018-10-19
ER

PT J
AU San Martin, AC
   Paez, JMG
   Sestafe, JVG
   Herrero, EJ
   Navidad, R
   Cordon, A
   Castillo-Olivares, JL
AF San Martin, AC
   Paez, JMG
   Sestafe, JVG
   Herrero, EJ
   Navidad, R
   Cordon, A
   Castillo-Olivares, JL
TI Analysis of shearing stress in the limited durability of bovine
   pericardium used as a biomaterial
SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE
LA English
DT Article
ID BIOPROSTHETIC HEART-VALVE; SUTURE MATERIALS; CALCIFICATION; TISSUE;
   PREVENTION; PROSTHESES
AB The objective of the study was to determine the shearing stress exerted by the suture th read under conditions of normal working stress. Thirty-six samples of calf pericardium, similar to that employed in the manufacture of bioprosthetic cardiac valve leaflets, were subjected to tensile testing. Prior to the trial, a continuous suture was sewn in the central zone of each sample, at a 45 degrees angle to the longest axis of the sample, using commercially-available threads (silk, Gore-Tex, Surgilene and nylon). Application of the Mohr circle for combined wear revealed that the shearing stress ranged between 2.68-fold greater (for samples sewn with silk) and 5.48-fold greater (for samples sewn with nylon) than the working tensile stress in the region of the suture. It is concluded that the shearing stress is responsible for the limited durability of sutured samples of calf pericardium prepared to simulate bioprosthetic cardiac valve leaflets. (C) 1998 Chapman & Hall.
C1 Clin Puerta Hierro, Serv Cirugia Expt, Madrid, Spain.
   Escuela Tecn Super Ingn Ind, Dept Mecan Estruct, Madrid, Spain.
   Inst Nacl Estadist, Madrid, Spain.
RP Paez, JMG (reprint author), Clin Puerta Hierro, Serv Cirugia Expt, C San Martin Porres 4, Madrid, Spain.
CR Bernacca G M, 1994, J Heart Valve Dis, V3, P205
   CLARK R E, 1971, Surgical Forum (Chicago), V22, P134
   GABBAY S, 1988, J THORAC CARDIOV SUR, V95, P208
   Gould P. L., 1973, Computers and Structures, V3, P377, DOI 10.1016/0045-7949(73)90024-2
   Herrmann J B, 1971, Am Surg, V37, P209
   HILBERT SL, 1992, AM J PATHOL, V140, P1195
   HIRSCH D, 1993, J BIOMED MATER RES, V27, P1477, DOI 10.1002/jbm.820271203
   HOOKE R, 1678, POTENCIA RESTITUTIVA
   JAMIESON WRE, 1993, J CARDIAC SURG, V8, P89, DOI 10.1111/j.1540-8191.1993.tb00580.x
   JORGEHERRERO E, 1991, BIOMATERIALS, V12, P683, DOI 10.1016/0142-9612(91)90117-S
   JORGEHERRERO E, 1991, BIOMATERIALS, V12, P249, DOI 10.1016/0142-9612(91)90208-R
   LEVY RJ, 1986, CRIT REV BIOCOMPAT, V2, P147
   PAEZ JMG, 1990, J THORAC CARDIOV SUR, V100, P580
   Paez JMG, 1996, J BIOMED MATER RES, V30, P47
   PAEZ JMG, 1994, BIOMATERIALS, V15, P172, DOI 10.1016/0142-9612(94)90063-9
   PURINYA B, 1994, J BIOMECH, V27, P1, DOI 10.1016/0021-9290(94)90027-2
   SANMARTIN AC, 1993, BIOMATERIALS, V14, P76
   TIMOSSHENKO S, 1970, RESISTENCIA MAT, V1, P55
   TROWBRIDGE EA, 1989, CRIT REV BIOCOMPAT, V5, P105
   TROWBRIDGE EA, 1985, J MATER SCI, V20, P114, DOI 10.1007/BF00555905
   Valente M, 1992, J Heart Valve Dis, V1, P216
   VONFRAUNHOFER JA, 1988, BIOMATERIALS, V9, P324, DOI 10.1016/0142-9612(88)90027-0
   VONFRAUNHOFER JA, 1985, J BIOMED MATER RES, V19, P595, DOI 10.1002/jbm.820190511
   WALLEY VM, 1987, J THORAC CARDIOV SUR, V93, P925
   WIKA KE, 1993, J BIOMED MATER RES, V27, P1293, DOI 10.1002/jbm.820271009
   XI TF, 1992, J BIOMED MATER RES, V26, P1241
NR 26
TC 14
Z9 14
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957-4530
EI 1573-4838
J9 J MATER SCI-MATER M
JI J. Mater. Sci.-Mater. Med.
PD FEB
PY 1998
VL 9
IS 2
BP 77
EP 81
PG 5
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA YV418
UT WOS:000071821000004
PM 15348911
DA 2018-10-19
ER

PT J
AU Ragaller, M
   Werner, C
   Bleyl, J
   Adam, S
   Jacobasch, HJ
   Albrecht, DM
AF Ragaller, M
   Werner, C
   Bleyl, J
   Adam, S
   Jacobasch, HJ
   Albrecht, DM
TI Blood compatible polymers in intensive care units: State of the art and
   current aspects of biomaterials research
SO KIDNEY INTERNATIONAL
LA English
DT Article; Proceedings Paper
CT 1st International Course on Critical Care Nephrology
CY MAY 02-03, 1997
CL DRESDEN, GERMANY
SP JANSSEN CILAG
DE artificial organs; biocompatibility; systemic inflammatory response
   syndrome; extracorporeal bypass; polymers; biomaterials research
ID HEPARIN-COATED CIRCUITS; EXTRACORPOREAL MEMBRANE-OXYGENATION;
   ACUTE-RENAL-FAILURE; CARDIOPULMONARY BYPASS; COMPLEMENT ACTIVATION;
   PLATELET ACTIVATION; CLINICAL-TRIAL; BIOCOMPATIBILITY; HEMODIALYSIS;
   CIRCULATION
AB The use of artificial organs in cases of acute renal failure, acute respiratory distress syndrome (ARDS) and multiorgan dysfunction syndrome (MODS) has lead to a significant reduction of mortality. However, the interaction between body and biomaterials results in the activation of the coagulation system and in the induction of systemic inflammatory response syndrome. The necessary anticoagulation may be contraindicated and may even further increase the risk for the patient. This article evaluates the currently applied polymeric materials used in intensive care units (ICU) and gives a possible outlook into future developments. It is emphasized that systematic interdisciplinary research of physicans and biomaterial scientists is essential for the successful development of new polymers with improved biocompatibility. For this purpose a brief overview of analytical techniques for surface characterization is given, and future developments to a fully biocompatible polymer are described.
C1 Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Klin Anasthesie & Intens Therapie, Dept Anaesthesiol & Intens Care Med, D-01307 Dresden, Germany.
   Inst Polymer Res Dresden, Dresden, Germany.
RP Ragaller, M (reprint author), Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Klin Anasthesie & Intens Therapie, Dept Anaesthesiol & Intens Care Med, Fetscherstasse 74, D-01307 Dresden, Germany.
RI Umlauf, Ursula/D-3356-2014; Werner, Carsten/F-8127-2010
OI Werner, Carsten/0000-0003-0189-3448
CR ALVAREZ V, 1991, KIDNEY INT, V40, P899, DOI 10.1038/ki.1991.291
   Barstad RM, 1996, BRIT J HAEMATOL, V94, P517, DOI 10.1111/j.1365-2141.1996.tb08989.x
   BLASS C, 1997, MED DES MAT C C P, P21
   Bone RC, 1996, CRIT CARE MED, V24, P1125, DOI 10.1097/00003246-199607000-00010
   BOZADAYI M, 1996, ARTIF ORGANS, V20, P1008
   BRASH JL, 1977, ANN NY ACAD SCI, V283, P356, DOI 10.1111/j.1749-6632.1977.tb41781.x
   BRASH JL, 1996, INTERFACIAL PHENOMEN
   CANAUD B, 1988, NEPHRON, V48, P206, DOI 10.1159/000184913
   CHENOWETH DE, 1987, ARTIF ORGANS, V11, P155, DOI 10.1111/j.1525-1594.1987.tb02649.x
   CLAESSON PM, 1994, STUDYING CELL ADHESI, P15
   ERDTMANN M, 1994, BIOMATERIALS, V15, P1043, DOI 10.1016/0142-9612(94)90089-2
   FJALLDAL O, 1993, ACTA ANAESTH SCAND, V37, P115, DOI 10.1111/j.1399-6576.1993.tb03611.x
   FORSTER RI, 1988, AM J SURG, V156, P1256
   FRIEDLANDER MA, 1993, AM J KIDNEY DIS, V22, P11, DOI 10.1016/S0272-6386(12)70161-0
   Fukutomi M, 1996, ARTIF ORGANS, V20, P767, DOI 10.1111/j.1525-1594.1996.tb04538.x
   GOLDBERG EP, 1980, POLYM MAT PHARM BIOM
   GORMAN C, 1996, J THORAC CARDIOVASC, V111, P1
   GRETZ N, 1995, CONTRIB NEPHROL, V116, P130
   GU YJ, 1993, ANN THORAC SURG, V55, P917, DOI 10.1016/0003-4975(93)90117-Z
   GURLAND HJ, 1994, NEPHROL DIAL TRANSPL, V9, P4
   HAKIM RM, 1994, NEW ENGL J MED, V331, P1338, DOI 10.1056/NEJM199411173312003
   HAKIM RM, 1993, KIDNEY INT, V44, P484, DOI 10.1038/ki.1993.272
   Heering P, 1997, INTENS CARE MED, V23, P288, DOI 10.1007/s001340050330
   HIMMELFARB J, 1992, KIDNEY INT, V41, P388, DOI 10.1038/ki.1992.54
   HOFFMANN JN, 1995, KIDNEY INT, V48, P1563, DOI 10.1038/ki.1995.448
   HORL WH, 1985, KIDNEY INT, V28, P791, DOI 10.1038/ki.1985.199
   JACOBS HA, 1989, J BIOMED MATER RES, V23, P611, DOI 10.1002/jbm.820230606
   Jansen PGM, 1996, ANN THORAC SURG, V61, P1363, DOI 10.1016/0003-4975(96)00056-2
   Janvier G, 1996, ANN THORAC SURG, V62, P1926, DOI 10.1016/S0003-4975(96)00942-3
   KIM SW, 1974, T AM SOC ART INT ORG, VB 20, P449
   KISHIDA A, 1994, BIOMATERIALS, V15, P848, DOI 10.1016/0142-9612(94)90041-8
   KLINKMANN H, 1994, NEPHROL DIAL TRANSPL, V9, P1
   KNOCH M, 1992, INT J ARTIF ORGANS, V15, P103
   Kolb G., 1996, Wiener Klinische Wochenschrift, V108, P15
   Korn RL, 1996, J THORAC CARDIOV SUR, V111, P1073, DOI 10.1016/S0022-5223(96)70384-7
   LEE JH, 1989, J BIOMED MATER RES, V23, P351, DOI 10.1002/jbm.820230306
   LEMKE H-D, 1992, Journal of the American Society of Nephrology, V3, P376
   LEVY M, 1996, INT J CARDIOL S, V53, P81
   LYSAGHT MJ, 1995, CONTRIB NEPHROL, V113, P1
   Manert W, 1996, ANAESTHESIST, V45, P437
   MELLGREN K, 1995, INT J ARTIF ORGANS, V18, P315
   METHA RL, 1990, KIDNEY INT, V38, P976
   MOAT NE, 1993, ANN THORAC SURG, V56, P1509, DOI 10.1016/0003-4975(93)90742-Z
   Moen O, 1997, ANN THORAC SURG, V63, P105
   MOTTAGHY K, 1991, INT J ARTIF ORGANS, V14, P721
   Muehrcke DD, 1996, J THORAC CARDIOV SUR, V112, P472, DOI 10.1016/S0022-5223(96)70275-1
   NOJIRI C, 1995, ASAIO J, V41, pM561, DOI 10.1097/00002480-199507000-00074
   Nowak G., 1996, Wiener Klinische Wochenschrift, V108, P9
   Ovrum E, 1996, EUR J CARDIO-THORAC, V10, P54, DOI 10.1016/S1010-7940(96)80266-1
   PARK KD, 1992, J BIOMED MATER RES, V26, P739, DOI 10.1002/jbm.820260605
   Phaneuf MD, 1997, BIOMATERIALS, V18, P755, DOI 10.1016/S0142-9612(96)00193-7
   REINHARDT B, 1997, BLUTREINIGUNGSVERFAH, V5, P20
   RINDER CS, 1995, J CLIN INVEST, V96, P1564, DOI 10.1172/JCI118195
   ROGIERS P, 1997, YB INTENSIVE CARE EM, P868
   ROSENKRANZ AR, 1994, CLIN EXP IMMUNOL, V98, P300
   ROSSAINT R, 1992, INT J ARTIF ORGANS, V15, P29
   Salmon J, 1997, INTENS CARE MED, V23, P38, DOI 10.1007/s001340050288
   SCHIFFL H, 1994, LANCET, V344, P570, DOI 10.1016/S0140-6736(94)91964-X
   Schiffl H., 1996, Wiener Klinische Wochenschrift, V108, P4
   SCHRADER J, 1985, KIDNEY INT, V28, P823, DOI 10.1038/ki.1985.204
   Takano H, 1992, ASAIO J, V38, pM390, DOI 10.1097/00002480-199207000-00062
   Te Velthuis Henk, 1996, Annals of Thoracic Surgery, V61, P1153
   VANDEUREN M, 1997, YB INTENSIVE CARE EM, P140
   VASILETS V, IN PRESS BIOMATERIAL
   VICKERMANN JC, 1990, SURFACE ANAL TECHNIQ
   VIDEM V, 1991, J THORAC CARDIOV SUR, V101, P654
   WAN S, 1997, YB INTENSIVE CARE EM, P868
   Weiss BM, 1996, J CARDIOTHOR VASC AN, V10, P464, DOI 10.1016/S1053-0770(05)80005-9
   Yamada H, 1996, ACTA ANAESTH SCAND, V40, P311, DOI 10.1111/j.1399-6576.1996.tb04438.x
NR 69
TC 0
Z9 0
U1 0
U2 6
PU BLACKWELL SCIENCE INC
PI MALDEN
PA 350 MAIN ST, MALDEN, MA 02148 USA
SN 0085-2538
J9 KIDNEY INT
JI Kidney Int.
PD FEB
PY 1998
SU 64
BP S84
EP S90
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA YV782
UT WOS:000071862800020
DA 2018-10-19
ER

PT J
AU Koole, LH
   Kruft, MAB
   Aldenhoff, YBJ
   van't Oost, NE
   van Kroonenburgh, MJPG
   van der Veen, FH
AF Koole, LH
   Kruft, MAB
   Aldenhoff, YBJ
   van't Oost, NE
   van Kroonenburgh, MJPG
   van der Veen, FH
TI Sustained local drug delivery from a radiopaque implanted reservoir
SO NATURE BIOTECHNOLOGY
LA English
DT Article
ID POLYMERIC BIOMATERIALS; SOLID TUMORS; CHEMOTHERAPY; ACCESS
AB A new polymeric biomaterial that contains covalently bound iodine, and is therefore radiopaque, was used to construct a sustained local drug-delivery device. A polymeric wall was designed to be porous (i.e., passage of low-molecular-weight molecules across the wall is possible), self-healing, and biocompatible. Once implanted, the sphere cavity can be filled and refilled with a concentrated solution of a (cytostatic) drug, which is subsequently released by slow diffusion into the tissue region surrounding the sphere, This principle of sustained local drug delivery is shown by a series of in vitro experiments on the release of 5-fluorouracil, and in vivo animal experiments, using x-ray fluoroscopic and scintigraphic techniques.
C1 Univ Limburg, Ctr Biomat Res, NL-6200 MD Maastricht, Netherlands.
   Acad Hosp Maastricht, Dept Nucl Med, NL-6202 AZ Maastricht, Netherlands.
   Acad Hosp Maastricht, Dept Cardiol, NL-6202 AZ Maastricht, Netherlands.
RP Koole, LH (reprint author), Univ Limburg, Ctr Biomat Res, POB 616, NL-6200 MD Maastricht, Netherlands.
CR Benzina A, 1996, J BIOMED MATER RES, V32, P459, DOI 10.1002/(SICI)1097-4636(199611)32:3<459::AID-JBM20>3.0.CO;2-A
   BREM H, 1995, LANCET, V345, P1008, DOI 10.1016/S0140-6736(95)90755-6
   BREM H, 1996, SCI MED, V12, P52
   Chasin Mark, 1995, P1
   CHIRILA TV, 1993, BIOMATERIALS, V14, P26, DOI 10.1016/0142-9612(93)90072-A
   Davy KWM, 1997, POLYM INT, V43, P143, DOI 10.1002/(SICI)1097-0126(199706)43:2<143::AID-PI717>3.0.CO;2-M
   Dionne KE, 1996, BIOMATERIALS, V17, P257, DOI 10.1016/0142-9612(96)85563-3
   DRENTH W, 1982, KINETICS APPL ORGANI
   EATCOCK MM, 1996, CANC CHEMOTHER PHARM, V38, P110
   Giovanini MA, 1996, NEUROSURGERY, V39, P404, DOI 10.1097/00006123-199608000-00039
   Haaz MC, 1996, CANCER CHEMOTH PHARM, V38, P52, DOI 10.1007/s002800050447
   Jain RK, 1996, ANN BIOMED ENG, V24, P457, DOI 10.1007/BF02648108
   JAIN RK, 1994, SCI AM, V271, P58, DOI 10.1038/scientificamerican0794-58
   Jain RK, 1996, SCIENCE, V271, P1079, DOI 10.1126/science.271.5252.1079
   Kruft MAB, 1997, BIOMATERIALS, V18, P31, DOI 10.1016/S0142-9612(96)00085-3
   Kruft MAB, 1996, BIOMATERIALS, V17, P1803, DOI 10.1016/0142-9612(95)00339-8
   Kruft MAB, 1996, MACROMOLECULES, V29, P5513, DOI 10.1021/ma951399s
   KRUFT MAB, 1994, J BIOMED MATER RES, V28, P1259, DOI 10.1002/jbm.820281103
   Laurencin Cato T., 1995, P59
   LEROUX JC, 1996, MICROENCAPSULATION M, P535
   MOSZNER N, 1995, ANGEW MAKROMOL CHEM, V224, P115, DOI 10.1002/apmc.1995.052240112
   OMMAYA AK, 1984, CANC DRUG DEL, V1, P169, DOI 10.1089/cdd.1984.1.169
   TAMADA J, 1992, J BIOM SCI PE, V3, P305
   TOGUCHI H, 1992, CLIN THER, V14, P121
   WALTER KA, 1995, NEUROSURGERY, V37, P1129, DOI 10.1227/00006123-199512000-00013
NR 25
TC 10
Z9 10
U1 0
U2 5
PU NATURE AMERICA INC
PI NEW YORK
PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA
SN 1087-0156
J9 NAT BIOTECHNOL
JI Nat. Biotechnol.
PD FEB
PY 1998
VL 16
IS 2
BP 172
EP 176
DI 10.1038/nbt0298-172
PG 5
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA YV500
UT WOS:000071831300031
PM 9487525
DA 2018-10-19
ER

PT J
AU Vansteenkiste, SO
   Davies, MC
   Roberts, CJ
   Tendler, SJB
AF Vansteenkiste, SO
   Davies, MC
   Roberts, CJ
   Tendler, SJB
TI Scanning probe microscopy of biomedical interfaces
SO PROGRESS IN SURFACE SCIENCE
LA English
DT Review
ID ATOMIC-FORCE MICROSCOPY; LANGMUIR-BLODGETT-FILMS; SELF-ASSEMBLED
   MONOLAYERS; TUNNELING-MICROSCOPY; POLYMER SURFACES; POLY(ETHYLENE
   OXIDE); AQUEOUS-SOLUTIONS; HIGH-RESOLUTION; DNA-MOLECULES; INSITU
   HYBRIDIZATION
AB The development of the scanning probe microscopes over the past decade has provided a number of exciting new surface analytical techniques making a significant progress in the characterisation of biomedical interfaces. In this review, several examples are presented to illustrate that SPM is a powerful and promising tool for surface investigations including biomolecules, cell membranes, polymers and even living cells. The ability of the SPM instrument to monitor adhesion phenomena and provide quantitative information about intermolecular interactions is also described. Moreover, the huge potential of the scanning probe microscopes to study dynamic processes at interfaces under nearly physiological conditions is highlighted. Novel applications in the field of biochemistry, microbiology, biomaterial engineering, drug delivery and even medicine are discussed.
C1 Univ Nottingham, Dept Pharmaceut Sci, Lab Biophys & Surface Anal, Nottingham NG7 2RD, England.
RP Vansteenkiste, SO (reprint author), Univ Nottingham, Dept Pharmaceut Sci, Lab Biophys & Surface Anal, Univ Pk, Nottingham NG7 2RD, England.
RI Roberts, Clive/C-6970-2009
OI Roberts, Clive/0000-0001-9443-3445; Davies, Martyn/0000-0001-7695-0596
CR ABSOLOM DR, 1984, BIOMATER ARTIF CELL, V12, P235, DOI 10.3109/10731198409118834
   AKAMA Y, 1990, J VAC SCI TECHNOL A, V8, P429, DOI 10.1116/1.576413
   AKAMINE S, 1990, APPL PHYS LETT, V57, P316, DOI 10.1063/1.103677
   AKAMINE S, 1992, J VAC SCI TECHNOL B, V10, P2307, DOI 10.1116/1.586059
   ALBRECHT TR, 1990, J VAC SCI TECHNOL A, V8, P3386, DOI 10.1116/1.576520
   ALLEN MJ, 1993, BIOCHEMISTRY-US, V32, P8390, DOI 10.1021/bi00084a002
   Allen S, 1996, FEBS LETT, V390, P161, DOI 10.1016/0014-5793(96)00651-5
   Allen S, 1997, BIOCHEMISTRY-US, V36, P7457, DOI 10.1021/bi962531z
   Allen S, 1997, TRENDS BIOTECHNOL, V15, P101, DOI 10.1016/S0167-7799(97)01015-9
   ALLEN S, 1997, UNPUB BIOCHEM
   Allison DP, 1997, GENOMICS, V41, P379, DOI 10.1006/geno.1997.4686
   Andrade J.D., 1985, SURFACE INTERFACIAL, V1, P1985
   ANDRADE JD, 1985, SURFACE INTERFACIAL
   ARCA M, 1994, ANALYST, V119, P719, DOI 10.1039/an9941900719
   Arnsdorf MF, 1996, J CARDIOVASC ELECTR, V7, P639, DOI 10.1111/j.1540-8167.1996.tb00572.x
   Aspinall G. O., 1983, POLYSACCHARIDES
   Atsushi Ikai, 1996, SURF SCI REP, V26, P261
   BABCOCK K, 1995, MATER RES SOC SYMP P, V355, P311
   BAGUET J, 1995, BIOMATERIALS, V16, P3, DOI 10.1016/0142-9612(95)91089-H
   BAGUET J, 1993, BIOMATERIALS, V14, P279, DOI 10.1016/0142-9612(93)90118-L
   Bard A.J., 1994, ELECTROANALYTICAL CH, V18, P243
   Baselt DR, 1996, J VAC SCI TECHNOL B, V14, P789, DOI 10.1116/1.588714
   BINNIG G, 1986, PHYS REV LETT, V56, P55
   BINNING G, 1982, PHYS REV LETT, V49, P57, DOI 10.1103/PhysRevLett.49.57
   BIRDI KS, 1994, SURF COAT TECH, V67, P183, DOI 10.1016/0257-8972(94)90118-X
   BODO P, 1993, SYNTHETIC MET, V55, P329, DOI 10.1016/0379-6779(93)90953-T
   Bottomley LA, 1996, ANAL CHEM, V68, pR185, DOI 10.1021/a1960008+
   BURNHAM NA, 1990, PHYS REV LETT, V64, P1931, DOI 10.1103/PhysRevLett.64.1931
   BURNHAM NA, 1993, SCANNING TUNNELING M, P191
   BUSTAMANTE C, 1992, BIOCHEMISTRY-US, V31, P22, DOI 10.1021/bi00116a005
   BUSTAMANTE C, 1994, CURR OPIN STRUC BIOL, V4, P750, DOI 10.1016/S0959-440X(94)90175-9
   BUSTAMANTE C, 1995, PHYS TODAY, V48, P32, DOI 10.1063/1.881478
   Chen X, 1997, LANGMUIR, V13, P4106, DOI 10.1021/la970172i
   CHEN X, 1997, UNPUB MACROMOL
   Chen XY, 1996, ANAL CHEM, V68, P1451, DOI 10.1021/ac950844e
   CHERNOFF DA, 1996, NANOVATIONS, V3, P6
   CHI LF, 1993, SCIENCE, V259, P213, DOI 10.1126/science.259.5092.213
   CHOMAKOVAHAEFKE M, 1994, APPL PHYS A-MATER, V59, P151, DOI 10.1007/BF00332208
   CLEMMER CR, 1991, SCIENCE, V251, P640, DOI 10.1126/science.1992517
   Coen MC, 1996, APPL SURF SCI, V103, P27, DOI 10.1016/0169-4332(96)00461-8
   CULLEN DC, 1994, J COLLOID INTERF SCI, V166, P102, DOI 10.1006/jcis.1994.1276
   DAMMER U, 1995, SCIENCE, V267, P1173, DOI 10.1126/science.7855599
   DAVIES J, 1994, LANGMUIR, V10, P2654, DOI 10.1021/la00020a026
   Davies MC, 1996, MACROMOLECULES, V29, P2205, DOI 10.1021/ma950889h
   DAVIES MC, 1990, CRIT REV BIOCOMPAT, V5, P297
   DAVIES MC, 1997, BIOCOMPATIBILITY ASS, P65
   DAVIS SS, 1993, J CONTROL RELEASE, V24, P157, DOI 10.1016/0168-3659(93)90175-5
   DELAMARCHE E, 1996, LANGMUIR, V12, P1977
   Denuault G, 1995, NATO ADV SCI INST SE, V288, P69
   DRAKE B, 1989, SCIENCE, V243, P1586, DOI 10.1126/science.2928794
   DREYER M, 1995, APPL PHYS A-MATER, V61, P357
   EDINGER K, 1993, LANGMUIR, V9, P4, DOI 10.1021/la00025a002
   Engel A, 1997, CURR OPIN STRUC BIOL, V7, P279, DOI 10.1016/S0959-440X(97)80037-1
   ERIE DA, 1994, SCIENCE, V266, P1562, DOI 10.1126/science.7985026
   FARE TL, 1992, LANGMUIR, V8, P3116, DOI 10.1021/la00048a043
   FILLARD JP, 1994, I PHYS C SER, V135, P247
   FIOL C, 1992, THIN SOLID FILMS, V215, P88, DOI 10.1016/0040-6090(92)90706-H
   Firtel M, 1995, MICRON, V26, P347, DOI 10.1016/0968-4328(95)00012-7
   FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628
   Frazier RA, 1997, LANGMUIR, V13, P4795, DOI 10.1021/la970288e
   Frazier RA, 1996, THESIS U NOTTINGHAM
   FRISBIE CD, 1994, SCIENCE, V265, P2071, DOI 10.1126/science.265.5181.2071
   FRITZ M, 1994, BIOPHYS J, V66, P1328, DOI 10.1016/S0006-3495(94)80963-4
   FRITZ M, 1993, EXP CELL RES, V205, P187, DOI 10.1006/excr.1993.1074
   FROMMER J, 1992, ANGEW CHEM INT EDIT, V31, P1298, DOI 10.1002/anie.199212981
   Frommer JE, 1996, THIN SOLID FILMS, V273, P112, DOI 10.1016/0040-6090(95)06997-6
   FUJIHIRA M, 1995, J JPN SOC TRIBOLOGIS, V40, P470
   FUJIWARA I, 1992, LANGMUIR, V8, P2219, DOI 10.1021/la00045a025
   GAROFF S, 1989, J CHEM PHYS, V90, P7505, DOI 10.1063/1.456184
   GIESSIBL FJ, 1994, REV SCI INSTRUM, V65, P1923, DOI 10.1063/1.1145232
   GOETTGENS BM, 1992, LANGMUIR, V8, P1768, DOI 10.1021/la00043a014
   GOUDONNET JP, 1994, J I PHYS C SER, V135, P229
   Green RJ, 1997, BIOMATERIALS, V18, P405, DOI 10.1016/S0142-9612(96)00141-X
   GREENWOOD OD, 1995, J ADHES SCI TECHNOL, V9, P311, DOI 10.1163/156856195X00527
   GREF R, 1994, SCIENCE, V263, P1600, DOI 10.1126/science.8128245
   GUTHOLD M, 1994, P NATL ACAD SCI USA, V91, P12927, DOI 10.1073/pnas.91.26.12927
   HAGGERTY L, 1993, BIOTECHNOL PROGR, V9, P1, DOI 10.1021/bp00019a001
   HAMERS RJ, 1986, PHYS REV LETT, V56, P1972, DOI 10.1103/PhysRevLett.56.1972
   Han WH, 1997, NATURE, V386, P563, DOI 10.1038/386563a0
   HAN WH, 1995, BIOCHEMISTRY-US, V34, P8215, DOI 10.1021/bi00026a001
   HANSMA HG, 1993, NUCLEIC ACIDS RES, V21, P505, DOI 10.1093/nar/21.3.505
   HANSMA HG, 1992, NUCLEIC ACIDS RES, V20, P3585, DOI 10.1093/nar/20.14.3585
   HANSMA HG, 1992, SCIENCE, V256, P1180, DOI 10.1126/science.256.5060.1180
   HANSMA HG, 1995, BIOPHYS J, V68, P1672, DOI 10.1016/S0006-3495(95)80343-7
   HANSMA HG, 1994, BIOCHEMISTRY-US, V33, P8436, DOI 10.1021/bi00194a007
   HANSMA HG, 1995, BIOPHYS J, V68, P3, DOI 10.1016/S0006-3495(95)80155-4
   HANSMA HG, 1998, IN PRESS
   HANSMA PK, 1994, APPL PHYS LETT, V64, P1738, DOI 10.1063/1.111795
   HARPER GR, 1995, BIOMATERIALS, V16, P427, DOI 10.1016/0142-9612(95)98815-V
   Hartmann U, 1996, J MAGN MAGN MATER, V157, P545, DOI 10.1016/0304-8853(95)01264-8
   Haugstad G, 1995, MAT SCI ENG C-BIOMIM, V3, P85, DOI 10.1016/0928-4931(95)00096-8
   HAUGSTAD G, 1995, LANGMUIR, V11, P3473, DOI 10.1021/la00009a033
   HAUGSTAD G, 1994, ULTRAMICROSCOPY, V54, P31, DOI 10.1016/0304-3991(94)90090-6
   HAUGSTAD G, 1995, TRENDS POLYM SCI, V3, P353
   HAYASHI T, 1992, POLYMER, V33, P3751, DOI 10.1016/0032-3861(92)90668-M
   HECKL WM, 1992, ULTRAMICROSCOPY, V42, P1073, DOI 10.1016/0304-3991(92)90404-8
   HEINZELMANN H, 1994, APPL PHYS A-MATER, V59, P89, DOI 10.1007/BF00332200
   HENDERSON E, 1994, PROG SURF SCI, V46, P39, DOI 10.1016/0079-6816(94)90006-X
   HENDERSON E, 1992, SCIENCE, V257, P1944, DOI 10.1126/science.1411511
   Heuberger M., 1994, NANOTECHNOLOGY, V5, P12
   HOH J H, 1992, Trends in Cell Biology, V2, P208, DOI 10.1016/0962-8924(92)90248-L
   HOH JH, 1993, BIOPHYS J, V65, P149, DOI 10.1016/S0006-3495(93)81074-9
   HOH JH, 1992, J AM CHEM SOC, V114, P4917, DOI 10.1021/ja00038a075
   HOPKINS J, 1994, MACROMOLECULES, V27, P5498, DOI 10.1021/ma00097a033
   HORBER JKH, 1992, SCANNING MICROSCOPY, V6, P919
   HORBETT TA, 1995, ACS S SER, V602
   HUNTERDORFER P, 1996, P NATL ACAD SCI USA, V93, P3477
   IKADA Y, 1994, BIOMATERIALS, V15, P725, DOI 10.1016/0142-9612(94)90025-6
   ILL CR, 1993, BIOPHYS J, V64, P919, DOI 10.1016/S0006-3495(93)81452-8
   ILLUM L, 1987, LIFE SCI, V40, P1553, DOI 10.1016/0024-3205(87)90120-2
   JEFFREY AM, 1993, NUCLEIC ACIDS RES, V21, P5896, DOI 10.1093/nar/21.25.5896
   JOSEFOWICZ JY, 1993, SCIENCE, V260, P323, DOI 10.1126/science.260.5106.323
   Kajiyama T, 1996, PROG SURF SCI, V52, P1, DOI 10.1016/0079-6816(96)00006-8
   KARIN A, 1994, AM PHYS SOC ANN M PI
   KARTHAUS O, 1992, LANGMUIR, V8, P2279, DOI 10.1021/la00045a034
   Kasas S, 1997, INT J IMAG SYST TECH, V8, P151, DOI 10.1002/(SICI)1098-1098(1997)8:2<151::AID-IMA2>3.0.CO;2-9
   Kasas S, 1997, BIOCHEMISTRY-US, V36, P461, DOI 10.1021/bi9624402
   Kaupp G., 1995, ADV PHOTOCHEM, V19, P119
   KELLER D, 1992, ULTRAMICROSCOPY, V42, P1481, DOI 10.1016/0304-3991(92)90470-5
   KELLER DJ, 1993, SURF SCI, V294, P409, DOI 10.1016/0039-6028(93)90126-5
   KIM Y, 1992, LANGMUIR, V8, P1097
   Kirby A. R., 1995, BIOPHYS J, V68, P359
   Kirby AR, 1996, BIOPOLYMERS, V38, P355, DOI 10.1002/(SICI)1097-0282(199603)38:3<355::AID-BIP8>3.0.CO;2-T
   KIRBY AR, 1995, POLYM B, V34, P615
   KNUTSON K, 1985, SURFACE INTERFACIAL, P197
   KOPELMAN R, 1993, PRACT SPECTROSC, V16, P227
   KUUTTI L, 1995, J MICROSC-OXFORD, V178, P1, DOI 10.1111/j.1365-2818.1995.tb03573.x
   LAL R, 1994, AM J PHYSIOL, V266, pC1
   LAL R, 1993, P NATL ACAD SCI USA, V90, P7280, DOI 10.1073/pnas.90.15.7280
   LAL R, 1995, AM J PHYSL C, V968, P268
   LAL R, 1993, AM J PHYSIOL, V265, P851
   LEA AS, 1994, COLLOID SURFACE A, V93, P349, DOI 10.1016/0927-7757(94)02878-8
   LECKBAND D, 1995, BIOPHYS J, V69, P1162, DOI 10.1016/S0006-3495(95)79990-8
   LEE GU, 1994, LANGMUIR, V10, P354, DOI 10.1021/la00014a003
   LEE GU, 1994, SCIENCE, V266, P771, DOI 10.1126/science.7973628
   Leggett GJ, 1996, J ELECTRON SPECTROSC, V81, P249, DOI 10.1016/0368-2048(95)02527-8
   LEUNG OM, 1992, SCIENCE, V255, P64, DOI 10.1126/science.255.5040.64
   LI SFY, 1994, BIOPHYS J, V66, P1209, DOI 10.1016/S0006-3495(94)80903-8
   LIEBER CM, 1994, CHEM ENG NEWS   0418, P28
   LINDSAY SM, 1993, J VAC SCI TECHNOL A, V11, P808, DOI 10.1116/1.578309
   LINDSAY SM, 1989, J BIOMOL STRUCT DYN, V7, P279, DOI 10.1080/07391102.1989.10507771
   LINDSAY SM, 1993, SCANNING TUNNELING M, P335
   LOUDER DR, 1995, ANAL CHEM, V67, pA297, DOI 10.1021/ac00105a001
   LYUBCHENKO Y, 1993, P NATL ACAD SCI USA, V90, P2137, DOI 10.1073/pnas.90.6.2137
   LYUBCHENKO YL, 1993, NUCLEIC ACIDS RES, V21, P1117, DOI 10.1093/nar/21.5.1117
   LYUBCHENKO YL, 1992, NUCLEIC ACIDS RES, V20, P3983, DOI 10.1093/nar/20.15.3983
   Magonov SN, 1996, AM LAB, V28, P59
   MARCH TC, 1995, NUCLEIC ACIDS RES, V23, P696
   MARTIN Y, 1987, J APPL PHYS, V61, P4723, DOI 10.1063/1.338807
   MEYER E, 1992, PHYS REV LETT, V69, P1777, DOI 10.1103/PhysRevLett.69.1777
   MEYER G, 1988, APPL PHYS LETT, V53, P2400, DOI 10.1063/1.100425
   MISSIRLIS Y, 1991, MODERN ASPECTS PROTE
   MOTOMATSU M, 1994, JPN J APPL PHYS 1, V33, P3775, DOI 10.1143/JJAP.33.3775
   MOU JX, 1995, J MOL BIOL, V248, P507, DOI 10.1006/jmbi.1995.0238
   MOU JX, 1995, FEBS LETT, V371, P279, DOI 10.1016/0014-5793(95)00906-P
   MOYER P, 1995, TOPOMETRIX APPL NEWS, V95, P1
   Muller DJ, 1996, J BACTERIOL, V178, P3025
   MULLER DJ, 1995, BIOPHYS J, V68, P1681
   Muller DJ, 1997, J STRUCT BIOL, V119, P149, DOI 10.1006/jsbi.1997.3878
   NOY A, 1995, J AM CHEM SOC, V117, P7943, DOI 10.1021/ja00135a012
   NYFFENEGGER R, 1995, ELECTROCHIM ACTA, V40, P1411, DOI 10.1016/0013-4686(95)00041-C
   OBERLEITHNER H, 1995, KIDNEY INT, V48, P923, DOI 10.1038/ki.1995.373
   OVERNEY RM, 1993, LANGMUIR, V9, P341, DOI 10.1021/la00025a063
   OVERNEY RM, 1992, NATURE, V359, P133, DOI 10.1038/359133a0
   OVERNEY RM, 1993, MRS BULL, V28, P26
   PATEL N, 1998, IN PRESS LANGMUIR
   PECHMANN R, 1994, REV SCI INSTRUM, V65, P3702, DOI 10.1063/1.1144495
   Pierres A, 1996, J IMMUNOL METHODS, V196, P105, DOI 10.1016/0022-1759(96)00103-2
   Pingali G. S., 1992, Proceedings. IEEE Workshop on Applications of Computer Vision (Cat. No.92TH0446-5), P282, DOI 10.1109/ACV.1992.240301
   POLLOCK HM, 1995, TOPOMETRIX APPL NEWL, V95, P8
   PRATER CB, 1991, J VAC SCI TECHNOL B, V9, P989, DOI 10.1116/1.585442
   PUTMAN CAJ, 1993, CYTOMETRY, V14, P356, DOI 10.1002/cyto.990140403
   PUTMAN CAJ, 1992, LANGMUIR, V8, P3014, DOI 10.1021/la00048a027
   QUIST AP, 1995, SCANNING MICROSCOPY, V9, P395
   RADMACHER M, 1994, SCIENCE, V265, P1577, DOI 10.1126/science.8079171
   RADMACHER M, 1995, BIOPHYS J, V69, P264, DOI 10.1016/S0006-3495(95)79897-6
   RASCH P, 1993, P NATL ACAD SCI USA, V90, P2509, DOI 10.1073/pnas.90.6.2509
   RATNER BD, 1990, J VAC SCI TECHNOL A, V8, P2306, DOI 10.1116/1.576755
   REES WA, 1993, SCIENCE, V260, P1646, DOI 10.1126/science.8503010
   REICHE J, 1992, THIN SOLID FILMS, V226, P265
   RENEKER DH, 1993, NATO ADV SCI INST SE, V405, P357
   REVENKO I, 1994, BIOL CELL, V80, P67, DOI 10.1016/0248-4900(94)90019-1
   ROBERTS CJ, 1995, LANGMUIR, V11, P1822, DOI 10.1021/la00005a063
   ROBERTS CJ, 1994, TRENDS BIOTECHNOL, V12, P127, DOI 10.1016/0167-7799(94)90090-6
   RYAN ME, 1995, MACROMOLECULES, V28, P1377, DOI 10.1021/ma00109a008
   SAFAROV VI, 1995, ULTRAMICROSCOPY, V57, P270, DOI 10.1016/0304-3991(94)00151-C
   SAKAI H, 1994, KOKAGAKU, V18, P39
   SALMERON M, 1990, J VAC SCI TECHNOL A, V8, P635, DOI 10.1116/1.576361
   SAMORI B, 1993, ANGEW CHEM INT EDIT, V32, P1461, DOI 10.1002/anie.199314611
   SCHABERT FA, 1995, SCIENCE, V268, P92, DOI 10.1126/science.7701347
   SCHAKENRA JM, 1984, J BIOMED MATER RES, V20, P773
   Schiffmann K. I., 1993, Nanotechnology, V4, P163, DOI 10.1088/0957-4484/4/3/006
   SCHWARTZ DK, 1993, LANGMUIR, V9, P1384, DOI 10.1021/la00029a036
   SCHWARTZ DK, 1992, PHYS REV LETT, V69, P3354, DOI 10.1103/PhysRevLett.69.3354
   SHAKESHEFF KM, 1995, LANGMUIR, V11, P2547, DOI 10.1021/la00007a038
   Shakesheff KM, 1996, CRIT REV THER DRUG, V13, P225, DOI 10.1615/CritRevTherDrugCarrierSyst.v13.i3-4.20
   SHAKESHEFF KM, 1995, MACROMOLECULES, V28, P1108, DOI 10.1021/ma00108a044
   SHAKESHEFF KM, 1994, LANGMUIR, V10, P4417, DOI 10.1021/la00024a005
   SHAKESHEFF KM, 1994, NANOBIOLOGY, V3, P41
   SHAO ZF, 1995, Q REV BIOPHYS, V28, P195, DOI 10.1017/S0033583500003061
   Shao ZF, 1995, ANNU REV CELL DEV BI, V11, P241, DOI 10.1146/annurev.cb.11.110195.001325
   Shao ZF, 1996, ADV PHYS, V45, P1, DOI 10.1080/00018739600101467
   SIDLES JA, 1995, REV MOD PHYS, V67, P249, DOI 10.1103/RevModPhys.67.249
   SIDLES JA, 1994, MATER RES SOC SYMP P, V332, P25, DOI 10.1557/PROC-332-25
   SNETIVY D, 1992, POLYMER, V33, P432, DOI 10.1016/0032-3861(92)91006-N
   Stine WB, 1996, J PROTEIN CHEM, V15, P193, DOI 10.1007/BF01887400
   STOCKER W, 1993, MACROMOLECULES, V26, P5915, DOI 10.1021/ma00074a013
   STRAUSSER YE, 1994, AM LAB, V26, P20
   SYKES KE, 1995, J MATER SCI, V30, P623, DOI 10.1007/BF00356320
   Tang SL, 1996, LANGMUIR, V12, P1088, DOI 10.1021/la950646i
   THUNDAT T, 1992, J VAC SCI TECHNOL A, V10, P630, DOI 10.1116/1.577700
   TIDSWELL IM, 1991, PHYS REV B, V44, P10869, DOI 10.1103/PhysRevB.44.10869
   TOMANEK D, 1993, SPRINGER SERIES SURF, V29, P269
   TSUKRUK VV, 1995, POLYMER, V36, P1791, DOI 10.1016/0032-3861(95)90925-R
   TSUKRUK VV, 1993, LANGMUIR, V9, P614, DOI 10.1021/la00026a042
   TSUKRUK VV, 1994, MACROMOLECULES, V27, P1274, DOI 10.1021/ma00083a030
   TSUKRUK VV, 1993, LANGMUIR, V9, P3538, DOI 10.1021/la00036a032
   Ulman A., 1991, INTRO ULTRATHIN ORGA
   Ushiki T, 1996, ARCH HISTOL CYTOL, V59, P421
   VANDEVYVER M, 1993, LANGMUIR, V9, P1565
   VESENKA J, 1995, BIOTECHNIQUES, V19, P240
   VESENKA J, 1992, ULTRAMICROSCOPY, V42, P1243, DOI 10.1016/0304-3991(92)90430-R
   Villarrubia JS, 1996, J VAC SCI TECHNOL B, V14, P1518, DOI 10.1116/1.589130
   VILLARRUBIA JS, 1994, SURF SCI, V321, P287, DOI 10.1016/0039-6028(94)90194-5
   Vogler EA, 1996, J ELECTRON SPECTROSC, V81, P237, DOI 10.1016/0368-2048(96)02526-1
   WALTERS DA, 1994, APPL PHYS LETT, V65, P787, DOI 10.1063/1.112231
   WALZL T, 1997, IN PRESS J MOL BIOL
   Wang T, 1996, MATER RES BULL, V31, P1361, DOI 10.1016/0025-5408(96)00127-4
   WARKENTIN P, 1994, BIOMATERIALS, V15, P786, DOI 10.1016/0142-9612(94)90033-7
   WEISENHORN AL, 1991, LANGMUIR, V7, P10
   WELLSTOOD FC, 1994, P SPIE INT SOC OPT E, V118, P2160
   WILCOX MH, 1993, MICROBIAL BIOFILMS F
   Williams PM, 1997, ANALYST, V122, P1001, DOI 10.1039/a703049e
   Williams PM, 1996, LANGMUIR, V12, P3468, DOI 10.1021/la940915p
   WILLIAMS PM, 1996, J VAC SCI TECHNOL B, V14, P1157
   YANG J, 1994, BBA-GEN SUBJECTS, V1199, P105, DOI 10.1016/0304-4165(94)90104-X
   YANG J, 1992, FEBS LETT, V301, P173, DOI 10.1016/0014-5793(92)81241-D
   YANG J, 1993, ULTRAMICROSCOPY, V50, P157, DOI 10.1016/0304-3991(93)90006-J
   YANG J, 1991, FEBS LETT, V2, P295
   Zasadzinski JA, 1996, CURR OPIN COLLOID IN, V1, P264, DOI 10.1016/S1359-0294(96)80014-8
   Zastawny Tomasz H., 1993, Acta Biochimica Polonica, V40, P555
NR 241
TC 30
Z9 31
U1 0
U2 23
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0079-6816
J9 PROG SURF SCI
JI Prog. Surf. Sci.
PD FEB
PY 1998
VL 57
IS 2
BP 95
EP 136
DI 10.1016/S0079-6816(98)00014-8
PG 42
WC Chemistry, Physical; Physics, Condensed Matter
SC Chemistry; Physics
GA 102NF
UT WOS:000074929900001
DA 2018-10-19
ER

PT J
AU Yoo, JJ
   Meng, J
   Oberpenning, F
   Atala, A
AF Yoo, JJ
   Meng, J
   Oberpenning, F
   Atala, A
TI Bladder augmentation using allogenic bladder submucosa seeded with cells
SO UROLOGY
LA English
DT Article
ID SMALL-INTESTINAL SUBMUCOSA; WALL SUBSTITUTE; UROTHELIUM; MODEL
AB Objectives. The search for a suitable material to reconstruct the genitourinary tract has been a challenging task. Bower has been widely used for urinary tract reconstruction, despite its subsequent complications. We investigated the possibility of using allogenic bladder submucosa, a tissue consisting of nonimmunogenic acellular collagen, either with or without cells, as a material for bladder augmentation.
   Methods. Partial cystectomies were performed in 10 beagle dogs. Both urothelial and smooth muscle cells were harvested and expanded separately in 5 animals. The allogenic bladder submucosa obtained from sacrificed dogs was seeded with muscle cells on one side and urothelial cells on the opposite side. All beagles underwent cruciate cystotomies on the bladder dome. Augmentation cystoplasty was performed with the allogenic bladder submucosa seeded with cells in 5 animals and with the allogenic bladder submucosa without cells in 5. The augmented bladders were retrieved 2 and 3 months after augmentation.
   Results. Bladders augmented with the allogenic bladder submucosa seeded with cells showed a 99% increase in capacity compared with bladders augmented with the cell-free allogenic bladder submucosa, which showed only a 30% increase in capacity. All dogs showed a normal bladder compliance, as evidenced by urodynamic studies. Histologically, all retrieved bladders contained a normal cellular organization consisting of a urothelial lined lumen surrounded by submucosal tissue and smooth muscle. Immunocytochemical analyses confirmed the urothelial and muscle cell phenotype and showed the presence of nerve fibers.
   Conclusions. These results show that allogenic bladder submucosa seeded with cells appears to be an excellent option as a biomaterial for bladder augmentation. (C) 1998, Elsevier Science Inc. All rights reserved.
C1 Childrens Hosp, Dept Urol, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Boston, MA USA.
RP Atala, A (reprint author), Childrens Hosp, Dept Urol, 300 Longwood Ave, Boston, MA 02115 USA.
RI Sano, Michael/E-1715-2011
OI Atala, Anthony/0000-0001-8186-2160
CR ASHKAR L, 1967, J UROLOGY, V98, P679, DOI 10.1016/S0022-5347(17)62956-2
   ATALA A, 1992, J UROLOGY, V148, P658, DOI 10.1016/S0022-5347(17)36685-5
   ATALA A, 1993, J UROLOGY, V150, P608, DOI 10.1016/S0022-5347(17)35561-1
   Atala A, 1996, J UROLOGY, V156, P338, DOI 10.1016/S0022-5347(01)65845-2
   ATALA A, 1995, DIAL PEDIAT UROL, V18, P6
   ATALA A, 1994, CLIN UROLOGY, P507
   Atala Anthony, 1997, P149
   BADYLAK SF, 1995, J BIOMED MATER RES, V29, P977, DOI 10.1002/jbm.820290809
   CILENTO BG, 1994, J UROLOGY, V152, P665, DOI 10.1016/S0022-5347(17)32676-9
   Freeman MR, 1997, J CLIN INVEST, V99, P1028, DOI 10.1172/JCI119230
   GARIBAY JT, 1995, J UROLOGY, V154, P903, DOI 10.1016/S0022-5347(01)67199-4
   GONZALEZ R, 1995, UROLOGY, V45, P124, DOI 10.1016/S0090-4295(95)97364-8
   HILES MC, 1993, J BIOMED MATER RES, V27, P139, DOI 10.1002/jbm.820270202
   KELAMI A, 1971, J UROLOGY, V105, P518, DOI 10.1016/S0022-5347(17)61563-5
   KELAMI A, 1970, J UROLOGY, V104, P693, DOI 10.1016/S0022-5347(17)61813-5
   Kropp BP, 1996, J UROLOGY, V155, P2098, DOI 10.1016/S0022-5347(01)66117-2
   KUDISH HG, 1957, J UROLOGY, V78, P232, DOI 10.1016/S0022-5347(17)66428-0
   Probst M, 1997, BRIT J UROL, V79, P505, DOI 10.1046/j.1464-410X.1997.00103.x
   Satar Nihat, 1996, Journal of Urology, V155, p336A
   Tobin Matthew S., 1994, Surgical Forum, V45, P786
   TSUJI I, 1967, J UROLOGY, V98, P91, DOI 10.1016/S0022-5347(17)62828-3
   TSUJI I, 1961, J UROLOGY, V85, P42, DOI 10.1016/S0022-5347(17)65279-0
   Yoo JJ, 1997, J UROLOGY, V158, P1066, DOI 10.1016/S0022-5347(01)64390-8
NR 23
TC 289
Z9 316
U1 0
U2 17
PU CAHNERS PUBL CO
PI NEW YORK
PA 249 WEST 17 STREET, NEW YORK, NY 10011 USA
SN 0090-4295
J9 UROLOGY
JI UROLOGY
PD FEB
PY 1998
VL 51
IS 2
BP 221
EP 225
DI 10.1016/S0090-4295(97)00644-4
PG 5
WC Urology & Nephrology
SC Urology & Nephrology
GA YX582
UT WOS:000072055000008
PM 9495701
DA 2018-10-19
ER

PT J
AU Teoh, SH
   Thampuran, R
   Seah, WKH
AF Teoh, SH
   Thampuran, R
   Seah, WKH
TI Coefficient of friction under dry and lubricated conditions of a
   fracture and wear resistant P/M titanium-graphite composite for
   biomedical applications
SO WEAR
LA English
DT Article
DE sintered titanium; titanium graphite composite; titanium carbide;
   pin-on-disc; coefficient of friction; wear debris; fracture; wear
   resistant biomaterials
ID BONE
AB Recent studies have shown that aseptic loosening of orthopaedic implants is a biomechanical phenomenon initiated mechanically and propelled by biological responses to the presence of wear debris released from the biomaterial. A triphasic composite, fabricated by the heterogeneous sintering of titanium and graphite powders was developed to address the fracture and wear performance of titanium. The composite is designed to smear graphite on both articulating surfaces and hence reduced wear and maintained a low friction tribosystem with fracture properties better than conventional bioceramics. The composite is made up of ductile titanium and a colony of hard, wear resistant titanium carbide produced by the controlled sintering of titanium and graphite particles. Free graphite is present in varying quantities depending upon compaction pressure and initial graphite composition. Initial graphite content composites of 4% and 8% were made with different compaction pressure to give a range of porosities from 10% to 45%. The coefficient of frictional was measured on a pin-on-disc (hardened steel) configuration. Under dry state, the coefficient of friction was observed to reduce with increasing porosity. Graphite smearing and the entrapment of debris by the pores contributed to the reduction of the wear components which in rum reduced the coefficient of friction. Under lubricated conditions, the sintered titanium and its composites were observed to be independent of porosity and pore size. The frictional behaviour of the titanium-8% graphite composites showed first, a titanium carbide dominated-wear stage and the second, a free graphite smearing stage. The results proved the concept that the coefficient of friction of titanium-graphite composites approaches that between graphite-graphite surfaces after the running-in period. This proof of concept is the first realisation of a biomaterial that could reduce the coefficient of friction on both articulating surfaces, a step closer to the development of fracture and wear resistant biomaterials that also protects the other counter surface. (C) 1998 Elsevier Science S.A.
C1 Natl Univ Singapore, Inst Mat Res & Engn, Singapore 119260, Singapore.
   Natl Univ Singapore, Ctr Biomed Mat Applicat & Technol, BIOMAT, Dept Mech & Prod Engn, Singapore 119260, Singapore.
RP Teoh, SH (reprint author), Natl Univ Singapore, Inst Mat Res & Engn, 10 Kent Ridge Crescent, Singapore 119260, Singapore.
CR AGINS HJ, 1988, J BONE JOINT SURG AM, V70A, P347, DOI 10.2106/00004623-198870030-00005
   Axen N, 1996, TRIBOL INT, V29, P467, DOI 10.1016/0301-679X(95)00104-C
   BANNISTER G, 1988, ORTHOP CLIN N AM, V19, P567
   BLACK AJ, 1993, P I MECH ENG C-J MEC, V207, P335, DOI 10.1243/PIME_PROC_1993_207_138_02
   Black AJ, 1996, WEAR, V200, P30, DOI 10.1016/S0043-1648(96)07281-X
   CAMPBELL P, 1989, J BONE JT SURG B, V71, P571
   CLARKE IC, 1992, AM SOC TEST MATER, V1144, P7, DOI 10.1520/STP14848S
   EYRE TS, 1976, POWDER METALL, V19, P22, DOI 10.1179/pom.1976.19.1.22
   FREEMAN MAR, 1982, J BONE JOINT SURG BR, V64, P489
   GOWEN M, 1983, NATURE, V306, P378, DOI 10.1038/306378a0
   HEALY KE, 1992, J BIOMED MATER RES, V26, P316
   Kapoor A, 1996, WEAR, V200, P38
   LEHEUP ER, 1994, WEAR, V176, P111, DOI 10.1016/0043-1648(94)90204-6
   Li J., 1993, Clinical Materials, V12, P197, DOI 10.1016/0267-6605(93)90073-G
   LIM SC, 1981, WEAR, V69, P355
   PAN J, THESIS ROYAL I TECHN
   PIMBERTMICHAUX S, 1989, MAT SCI ENG A-STRUCT, V115, P209, DOI 10.1016/0921-5093(89)90681-3
   SAKA N, 1989, TRIBOL T, V32, P389, DOI 10.1080/10402008908981904
   SALVATI EA, 1989, ARTHROPLASTY, P55
   SPECTOR M, 1990, CLIN ORTHOP RELAT R, P140
   STRAFFELINI G, 1992, WEAR, V159, P127, DOI 10.1016/0043-1648(92)90294-I
   SUH NP, 1994, WEAR, V175, P151, DOI 10.1016/0043-1648(94)90178-3
   SUH NP, 1986, TRIBOPHYSICS, pCH3
   TALLROTH K, 1989, J BONE JOINT SURG BR, V71, P571
   TENGVALL P, 1992, Clinical Materials, V9, P115, DOI 10.1016/0267-6605(92)90056-Y
   Teoh SH, 1997, J MATER SCI LETT, V16, P639, DOI 10.1023/A:1018567216717
NR 26
TC 22
Z9 24
U1 0
U2 7
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0043-1648
J9 WEAR
JI Wear
PD FEB
PY 1998
VL 214
IS 2
BP 237
EP 244
DI 10.1016/S0043-1648(97)00231-7
PG 8
WC Engineering, Mechanical; Materials Science, Multidisciplinary
SC Engineering; Materials Science
GA YZ626
UT WOS:000072272900013
DA 2018-10-19
ER

PT J
AU Yang, JM
   Wang, MC
   Hsu, YG
   Chang, CH
   Lo, SK
AF Yang, JM
   Wang, MC
   Hsu, YG
   Chang, CH
   Lo, SK
TI Preparation of heparin containing SBS-g-VP copolymer membrane for
   biomaterial usage
SO JOURNAL OF MEMBRANE SCIENCE
LA English
DT Article
DE styrene-butadiene-styrene triblock copolymer; vinyl pyridine; graft
   copolymer; heparin; biomaterial
ID STYRENE BLOCK COPOLYMER; INDUCED GRAFT-POLYMERIZATION; OXYGEN
   PERMEATION; IMMOBILIZED HEPARIN; PLASMA; ADSORPTION; THROMBIN; SURFACE;
   COMPLEXES; GLYCOL)
AB Vinyl pyridine (VP) was grafted onto styrene-butadiene-styrene (SBS) triblock copolymer membrane by W-radiation induced graft copolymerization without degassing to obtain the SBS-g-VP copolymer membrane. The substituted pyridine groups on the SBS-g-VP graft copolymer membrane were quaternized with iodomethane, and then the membrane was treated with heparin to prepare the heparin containing SBS-g-VP copolymer membrane (SBS-g-VP-HEP). The SBS-g-VP and SBS-g-VP-HEP were characterized by electron spectroscopy for chemical analysis (ESCA). The heparin content was determined by toluidine blue heparin assay. The contact angles of dry and wet SBS-g-VP and SBS-g-VP-HEP with different amount of grafting and heparin content were determined. By using Kaelble's equation, the surface energies of SBS-g-VP and SBS-g-VP-HEP were determined. It was found that the surface energy and water content of SBS-g-VP and SBS-g-VP-HEP membrane increased with increasing graft amount and the heparin content, whereas the contact angle decreased, Protein adsorption of fibrinogen and albumin onto the membranes was also performed to evaluate the effect of graft amount and heparin content on the biocompatibility of SBS-g-VP and SBS-g-VP-HEP membranes. The amount of the adsorption of albumin and fibrinogen decreased with increasing grafting amount and heparin content. (C) 1998 Elsevier Science B.V.
C1 Chang Gung Univ, Dept Chem Engn, Tao Yuan 333, Taiwan.
   Natl Taiwan Inst Technol, Grad Sch Text & Polymer Engn, Taipei 104, Taiwan.
   Chang Gung Mem Hosp, Div Thorac & Cardiovasc Surg, Tao Yuan 333, Taiwan.
   Deakin Univ, Fac Hlth & Behav Sci, Burwood, Vic 3125, Australia.
RP Yang, JM (reprint author), Chang Gung Univ, Dept Chem Engn, Tao Yuan 333, Taiwan.
CR EBERT CD, 1982, THROMB RES, V26, P43, DOI 10.1016/0049-3848(82)90149-9
   FUJIMOTO K, 1993, J BIOMED MATER RES, V27, P1559, DOI 10.1002/jbm.820271213
   FUJIMOTO K, 1993, J POLYM SCI POL CHEM, V31, P1035, DOI 10.1002/pola.1993.080310426
   FUJIMOTO K, 1993, BIOMATERIALS, V14, P441
   GOOSEN MFA, 1980, THROMB RES, V20, P543, DOI 10.1016/0049-3848(80)90142-5
   HATTON MWC, 1983, THROMB HAEMOSTASIS, V50, P873
   Holden G., 1969, J POLYM SCI        C, VC26, P37
   HSIUE GH, 1990, J POLYM SCI POL CHEM, V28, P3363, DOI 10.1002/pola.1990.080281215
   HSIUE GH, 1993, J POLYM SCI POL CHEM, V31, P1457, DOI 10.1002/pola.1993.080310614
   HSIUE GH, 1990, J POLYM SCI POL CHEM, V28, P3761, DOI 10.1002/pola.1990.080281319
   HSIUE GH, 1991, MAKROMOL CHEM, V192, P2687
   HSIUE GH, 1988, J BIOMED MATER RES, V22, P405, DOI 10.1002/jbm.820220504
   KAELBLE DH, 1977, POLYMER, V18, P475, DOI 10.1016/0032-3861(77)90164-1
   KIM S W, 1985, Critical Reviews in Biocompatibility, V1, P229
   KOCHWA S, 1977, ANN NY ACAD SCI, V283, P37, DOI 10.1111/j.1749-6632.1977.tb41751.x
   LAI JY, 1991, J APPL POLYM SCI, V43, P1431, DOI 10.1002/app.1991.070430804
   NOJIRI C, 1989, T ASAIO, V35, P357
   NOJIRI C, 1988, T ASAIO, V34, P386
   PARK KD, 1992, J BIOMED MATER RES, V26, P739, DOI 10.1002/jbm.820260605
   PARK KD, 1988, J BIOMED MATER RES, V22, P977, DOI 10.1002/jbm.820221103
   PLATE NA, 1986, ADV POLYM SCI, V79, P96
   ROLLASON G, 1989, Journal of Biomaterials Science Polymer Edition, V1, P31, DOI 10.1163/156856289X00046
   SMITH BAH, 1993, J BIOMED MATER RES, V27, P89, DOI 10.1002/jbm.820270112
   SMITH PK, 1980, ANAL BIOCHEM, V109, P466, DOI 10.1016/0003-2697(80)90679-X
   TSENG YC, 1992, J BIOMED MATER RES, V26, P373, DOI 10.1002/jbm.820260308
   YANG JM, 1991, MACROMOLECULES, V24, P4010, DOI 10.1021/ma00014a007
   YANG JM, 1990, ANGEW MAKROMOL CHEM, V179, P99, DOI 10.1002/apmc.1990.051790108
   Yang JM, 1996, J BIOMED MATER RES, V31, P281
   Yang JM, 1997, J BIOMED MATER RES, V35, P175, DOI 10.1002/(SICI)1097-4636(199705)35:2<175::AID-JBM5>3.0.CO;2-K
   Yang JM, 1997, J APPL POLYM SCI, V65, P109
   YANG JM, 1995, ANGEW MAKROMOL CHEM, V231, P1, DOI 10.1002/apmc.1995.052310101
   YANG JM, 1990, J APPL POLYM SCI, V39, P1475, DOI 10.1002/app.1990.070390706
   Yang JM, 1997, J MEMBRANE SCI, V128, P133, DOI 10.1016/S0376-7388(96)00312-2
   YANG JM, 1990, J APPL POLYM SCI, V41, P1141, DOI 10.1002/app.1990.070410523
   YANG JM, 1997, IN PRESS J BIOMED MA
   YANG JM, 1994, J MEMBRANE SCI, V87, P223
NR 36
TC 37
Z9 39
U1 1
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0376-7388
J9 J MEMBRANE SCI
JI J. Membr. Sci.
PD JAN 7
PY 1998
VL 138
IS 1
BP 19
EP 27
PG 9
WC Engineering, Chemical; Polymer Science
SC Engineering; Polymer Science
GA YR169
UT WOS:000071467200002
DA 2018-10-19
ER

PT B
AU Tsimoyiannis, EC
AF Tsimoyiannis, EC
BE Montori, A
   Lirici, MM
   Montori, J
TI Laparoscopic incisional hernia repair
SO 6TH WORLD CONGRESS OF ENDOSCOPIC SURGERY, PTS 1 AND 2
LA English
DT Proceedings Paper
CT 6th World Congress of Endoscopic Surgery
CY JUN 03-06, 1998
CL ROME, ITALY
SP European Assoc Endoscop Surg
AB Laparoscopic hernioplasty was used in patients with incisional abdominal hernias. All repairs were made using an intraperitoneal onlay patch of expanded polytetrafluoroethylene Gore-Tex DualMesh Biomaterial. The patch was secured by whole thickness sutures, that tied subcutaneously through stab holes, and staples between the sutures to cover the hernia defect without excision of the hernia sac. There were three postoperative complications, one seroma, one haematoma and one infection. These complications were successfully healed without reoperation. No recurrence was observed during a follow-up of 8-21 months (average 15 months). Laparoscopic incisional hernioplasty using the new material, Gore-Tex DualMesh Biomaterial, which is securely sutured and stapled on the abdominal wall, is a promising minimally invasive procedure. Continued follow-up is necessary to determine long-term results.
C1 G Hatzikosta Gen Hosp, Dept Surg, Ioannina, Greece.
RP Tsimoyiannis, EC (reprint author), G Hatzikosta Gen Hosp, Dept Surg, Ioannina, Greece.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MEDIMOND S R L
PI 40128 BOLOGNA
PA VIA MASERATI 5, 40128 BOLOGNA, 00000, ITALY
BN 88-323-0603-0
PY 1998
BP 709
EP 713
PG 5
WC Surgery
SC Surgery
GA BL71V
UT WOS:000076427100107
DA 2018-10-19
ER

PT J
AU Manato, JA
   Kiyoshima, T
   Kobayashi, I
   Shima, K
   Ohishi, M
   Sakai, H
AF Manato, JA
   Kiyoshima, T
   Kobayashi, I
   Shima, K
   Ohishi, M
   Sakai, H
TI The role of macrophages in the absorption process of suture materials: A
   histological and immunohistochemical study
SO ACTA HISTOCHEMICA ET CYTOCHEMICA
LA English
DT Article
DE suturing threads; macrophage; immunohistochemistry
ID ABSORBABLE SUTURES; BIOMATERIAL; VICRYL; MAXON; PDS
AB This study was performed to investigate the cellular interactions between three different suture materials including Poliglecaprone 25 (Monocryl, MM), Polyglycolic acid (Dexon, DX) and Blacksilk (BS), and living tissue regarding the absorption process and biocompatibility of the thread, and to determine the localization of macrophages using ED1 monoclonal antibody. These threads were applied in gluteal muscle closures of thirty-six male Wistar strain rats. Both histological and immunohistochemical observations were performed at the following intervals: 1, 3, 6, 9, 12, and 24 weeks, postoperatively. The absorption of DX occurred in the early experimental phase by the penetration of various amount of ED1-positive macrophages, The absorption of MN was delayed compared with that of the DX, while many ED1-positive macrophages penetrated inside the WIN in the mid-experimental phases. Both MN and DX were substantially absorbed at 24 weeks postoperatively with minimal scar tissue. Meanwhile, the BS still remained in the muscular tissue at 24 weeks postoperatively, with a remarkable proliferation of fibrous tissue around the thread. This study suggested that the ED1-positive macrophages played a central role of absorption of MN and DX, and that the MN could possess a superior healing response with a minimum of scar formation.
C1 Kyushu Univ 61, Fac Dent, Dept Oral Pathol, Higashi Ku, Fukuoka 8128582, Japan.
   Kyushu Univ 61, Fac Dent, Dept Oral & Maxillofacial Surg 1, Higashi Ku, Fukuoka 8128582, Japan.
RP Sakai, H (reprint author), Kyushu Univ 61, Fac Dent, Dept Oral Pathol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
CR ALISON MR, 1992, OXFORD TXB PATHOLOGY, P365
   BEELEN RHJ, 1987, TRANSPLANT P, V19, P3166
   BEZWADA RS, 1995, BIOMATERIALS, V16, P1141, DOI 10.1016/0142-9612(95)93577-Z
   BOURNE RB, 1988, CAN J SURG, V31, P43
   DAMOISEAUX JGMC, 1994, IMMUNOLOGY, V83, P140
   EDLICH RF, 1973, ANN SURG, V177, P679, DOI 10.1097/00000658-197306000-00006
   EILERT JB, 1971, AM J SURG, V121, P561, DOI 10.1016/0002-9610(71)90139-5
   Hunt JA, 1996, J BIOMED MATER RES, V31, P139, DOI 10.1002/(SICI)1097-4636(199605)31:1<139::AID-JBM15>3.0.CO;2-I
   LaBagnara J Jr, 1995, Ear Nose Throat J, V74, P409
   LAROCHE G, 1995, J BIOMED MATER RES, V29, P1525, DOI 10.1002/jbm.820291209
   POSTLETHWAIT RW, 1970, ANN SURG, V171, P892, DOI 10.1097/00000658-197006010-00010
   POSTLETHWAIT RW, 1974, AM J SURG, V127, P617, DOI 10.1016/0002-9610(74)90332-8
   SALTHOUSE TN, 1969, J SURG RES, V9, P481, DOI 10.1016/0022-4804(69)90122-X
   SANZ LE, 1988, OBSTET GYNECOL, V71, P418
   SCOTT ADN, 1993, BRIT J SURG, V80, P387, DOI 10.1002/bjs.1800800342
   THOMA KH, 1969, ORAL SURG, P95
   Turner N.C., 1992, OXFORD TXB PATHOLOGY, P351
   UFF CR, 1995, BIOMATERIALS, V16, P355, DOI 10.1016/0142-9612(95)93852-5
   VINCE DG, 1991, BIOMATERIALS, V12, P731, DOI 10.1016/0142-9612(91)90021-2
   WALLACE WR, 1970, J ORAL SURG, V28, P739
NR 20
TC 0
Z9 0
U1 0
U2 1
PU JAPAN SOC HISTOCHEMISTRY & CYTOCHEMISTRY
PI KYOTO
PA C/O NAKANISHI PRINTING CO LTD, SHIMODACHIURI-OGAWA, KAMIGYO-KU, KYOTO,
   602-8048, JAPAN
SN 0044-5991
EI 1347-5800
J9 ACTA HISTOCHEM CYTOC
JI Acta Histochem. Cytochem.
PY 1998
VL 31
IS 2
BP 113
EP 120
DI 10.1267/ahc.31.113
PG 8
WC Cell Biology
SC Cell Biology
GA ZH946
UT WOS:000073163800004
DA 2018-10-19
ER

PT J
AU Viala, S
   Freche, M
   Lacout, JL
AF Viala, S
   Freche, M
   Lacout, JL
TI Preparation of a new organic-mineral composite: Chitosan-hydroxyapatite
SO ANNALES DE CHIMIE-SCIENCE DES MATERIAUX
LA English
DT Article; Proceedings Paper
CT 7th Moroccan Meeting on Solid State Chemistry (REMCES VII)
CY OCT 30-NOV 01, 1996
CL MARRAKECH, MOROCCO
AB This study concerns the development of a new composite biomaterial containing calcium phosphate and chitosan, a natural polymer. In acidic medium, the precipitation of the dicalcium phosphate dihydrate (DCPD) in the presence of soluble chitosan, shows the close association between this polymer and the phosphate. In basic medium, the precipitation of chitosan with a previously prepared hydroxyapatite leads to the elaboration of a shapable composite. The precipitation conditions are studied.
C1 ENSCT, INPT, Lab Mat Physicochim Solides, UPRESA 5071, F-31400 Toulouse, France.
RP Freche, M (reprint author), ENSCT, INPT, Lab Mat Physicochim Solides, UPRESA 5071, 38 Rue 36 Ponts, F-31400 Toulouse, France.
CR DOMARD A, 1987, INT J BIOL MACROMOL, V9, P98, DOI 10.1016/0141-8130(87)90033-X
   DRAGET KI, 1992, BIOMATERIALS, V13, P635, DOI 10.1016/0142-9612(92)90032-J
   KATO K, 1979, BIOMATER ARTIF CELL, V7, P291, DOI 10.3109/10731197909117584
   LI Q, 1992, J BIOACT COMPAT POL, V7, P370, DOI 10.1177/088391159200700406
   MIYA M, 1980, INT J BIOL MACROMOL, V2, P323, DOI 10.1016/0141-8130(80)90056-2
   MUZZARELLI R, 1988, BIOMATERIALS, V9, P247, DOI 10.1016/0142-9612(88)90092-0
   MUZZARELLI RAA, 1994, BIOMATERIALS, V15, P1075, DOI 10.1016/0142-9612(94)90093-0
   MUZZARELLI RAA, 1993, CHITIN ENZYMOLOGY, P187
   TROMBE JC, 1972, THESIS U P SABATIER
   Viala S, 1996, CARBOHYD POLYM, V29, P197, DOI 10.1016/0144-8617(96)00023-9
NR 10
TC 26
Z9 31
U1 0
U2 10
PU EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS CEDEX 15
PA 23 RUE LINOIS, 75724 PARIS CEDEX 15, FRANCE
SN 0151-9107
J9 ANN CHIM-SCI MAT
JI Ann. Chim.-Sci. Mat.
PD JAN-FEB
PY 1998
VL 23
IS 1-2
BP 69
EP 72
DI 10.1016/S0151-9107(98)80025-1
PG 4
WC Chemistry, Multidisciplinary; Materials Science, Multidisciplinary
SC Chemistry; Materials Science
GA ZE735
UT WOS:000072825700015
DA 2018-10-19
ER

PT J
AU Francois, P
   Vaudaux, P
   Lew, PD
AF Francois, P
   Vaudaux, P
   Lew, PD
TI Role of plasma and extracellular matrix proteins in the physiopathology
   of foreign body infections
SO ANNALS OF VASCULAR SURGERY
LA English
DT Article
ID STAPHYLOCOCCUS-AUREUS; ADHERENCE; FIBRONECTIN; FIBRINOGEN; SURFACES;
   PATHOGENESIS; CATHETERS; MODEL
AB Foreign body implants are highly susceptible to microorganism infection. The infectious agents may be of low pathogenicity (such as S. epidermidis) or involve more virulent strains (such as S. aureus). The common denominator for the three main elements that play a role in the physiopathlology of such infections (bacteria, neutrophils, and different biomaterials) are host proteins deposited over the surface of the devices immediately after their implantation. These proteins modulate that host cells response but can also promote Staphylococcus adhesion to the biomaterial. Neutrophils and other cells such as fibroblasts adhere to several extracellular matrix proteins such as fibronectin, fibrinogen, collagen, vitronectin, via specific cell surface receptor. The evolution of the technology and the increasing numbers of long-term artificial implants require a better understanding of fundamental mechanisms of foreign body infections to reduce their incidence and optimize their treatment.
C1 Univ Hosp Geneva, Div Infect Dis, CH-1211 Geneva 4, Switzerland.
   Univ Geneva, Appl Phys Grp, Geneva, Switzerland.
RP Francois, P (reprint author), Univ Hosp Geneva, Div Infect Dis, CH-1211 Geneva 4, Switzerland.
CR Foster T. J., 1994, P31
   FRANCOIS P, 1995, IN PRESS BIOMATERIAL
   HERRMANN M, 1990, J CLIN INVEST, V86, P942
   HERRMANN M, 1991, INFECT IMMUN, V59, P279
   HERRMANN M, 1988, J INFECT DIS, V158, P693, DOI 10.1093/infdis/158.4.693
   LELAH MD, 1984, J BIOMED MATER RES, V18, P475, DOI 10.1002/jbm.820180503
   LEW PD, 1979, J CLIN INVEST, V63, P326, DOI 10.1172/JCI109306
   LUCET JC, 1990, ANTIMICROB AGENTS CH, V34, P2312, DOI 10.1128/AAC.34.12.2312
   MCDEVITT D, 1994, MOL MICROBIOL, V11, P237, DOI 10.1111/j.1365-2958.1994.tb00304.x
   MCDEVITT D, 1995, IN PRESS MOL MICROBI
   VAUDAUX P, 1984, J INFECT DIS, V150, P546, DOI 10.1093/infdis/150.4.546
   VAUDAUX P, 1993, J INFECT DIS, V167, P633, DOI 10.1093/infdis/167.3.633
   VAUDAUX P, 1989, J INFECT DIS, V160, P865, DOI 10.1093/infdis/160.5.865
   VAUDAUX P, 1992, J INFECT DIS, V166, P58, DOI 10.1093/infdis/166.1.58
   VAUDAUX PE, 1995, INFECT IMMUN, V63, P585
   Vaudaux Pierre E., 1994, P1
   ZIMMERLI W, 1984, J CLIN INVEST, V73, P1191, DOI 10.1172/JCI111305
   ZIMMERLI W, 1982, J INFECT DIS, V146, P487, DOI 10.1093/infdis/146.4.487
NR 18
TC 43
Z9 46
U1 0
U2 3
PU SPRINGER VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010 USA
SN 0890-5096
J9 ANN VASC SURG
JI Ann. Vasc. Surg.
PD JAN
PY 1998
VL 12
IS 1
BP 34
EP 40
DI 10.1007/s100169900112
PG 7
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA YP657
UT WOS:000071300900006
PM 9451994
DA 2018-10-19
ER

PT B
AU Gielen, DJ
   van Doorn, J
AF Gielen, DJ
   van Doorn, J
BE Kopetz, H
   Weber, T
   Palz, W
   Chartier, P
   Ferrero, GL
TI Optimisation of Western European bioenergy and biomaterial strategies
   for greenhouse gas emission reduction in the 21st century
SO BIOMASS FOR ENERGY AND INDUSTRY
LA English
DT Proceedings Paper
CT 10th European Conference and Technology Exhibition on Biomass for Energy
   and Industry
CY JUN 08-11, 1998
CL WURZBURG, GERMANY
AB Combined production of energy and materials fr urn biomass seems a more promising strategy than stand alone bioenergy production. The future of bioenergy will be significantly influenced by the development of biomaterials. A Western European MARKAL systems analysis model has been developed for the analysis of combined energy and materials strategies.
C1 Netherlands Energy Res Fdn, ECN, NL-1755 ZG Petten, Netherlands.
RP Gielen, DJ (reprint author), Netherlands Energy Res Fdn, ECN, POB 1, NL-1755 ZG Petten, Netherlands.
CR Gielen D., 1998, ECNC97103
   Gielen DJ, 1995, ENERG POLICY, V23, P1049, DOI 10.1016/0301-4215(95)00115-8
   GIELEN DJ, 1997, REGIONAL NATL MAT FL
   GOLDSTEIN G, 1995, MARKAL DOCUMENTATION, V1
   GOLDSTEIN G, 1995, MARKAL DOCUMENTATION, V2
   WATSON RT, 1996, IMPACTS ADAPTIONS MI
NR 6
TC 0
Z9 0
U1 0
U2 1
PU CENTRALES AGRAR ROHSTOFF MKT & ENTWICKLUNG NETZWERK
PI RIMPAR
PA TECHNOL PK 13, D-97222 RIMPAR, GERMANY
PY 1998
BP 330
EP 332
PG 3
WC Energy & Fuels
SC Energy & Fuels
GA BQ87V
UT WOS:000089906600077
DA 2018-10-19
ER

PT B
AU Hochheim, FW
   Noiriel, E
   Diss, JM
AF Hochheim, FW
   Noiriel, E
   Diss, JM
BE Kopetz, H
   Weber, T
   Palz, W
   Chartier, P
   Ferrero, GL
TI Selected aspects in accordance and analogy to the bit granulation
   technology
SO BIOMASS FOR ENERGY AND INDUSTRY
LA English
DT Proceedings Paper
CT 10th European Conference and Technology Exhibition on Biomass for Energy
   and Industry
CY JUN 08-11, 1998
CL WURZBURG, GERMANY
AB Unlike the situation in primary energies, some of the significant benefits of second energies (e.g. fuel pellets generated from biomass like ligneous materials) are relatively unknown and consequently little utilized. Biomass, specially wood-waste is eminently exploitable, the heating capacity expressed in energy flow can be quite remarkable with an energy efficiency of about 80% and a favourable cost regime; BIT fuel pellets are an actual and competive form of secondary energy. The costs of conversion loss will be estimated with 5% on average... expressed in energy value flow.
   It is, however, necessary to consider the supplying structure of the biomass wood-waste ("green circuit"), to locate the central granulation plant close to forestry resource and woodworking industries and to create "contracting" selling BIT fuel pellets to the users of these energies (e.g. users and operators of the fuel pellet fed and fired heating installations).
   Therefore the biomass wood-waste industry will be increasingly directed to refuse management. In accordance and analogy to the BIT granulation technology secondary energy form of fuel pellets, biomass-biomaterial-specific, in the Mediterranean regions could be generated and processed like olive-stones, crops and fruit stones as well.
C1 Biomat Int Technol SA, Head Off, L-4803 Rodange, Luxembourg.
RP Hochheim, FW (reprint author), Biomat Int Technol SA, Head Off, POB 27, L-4803 Rodange, Luxembourg.
CR DISS JM, 1980, ETUDE CONDITIONEMENT
   HOCHHEIM FW, 1989, 2 3 EUR S SOFT EN SO
   HOCHHEIM FW, 1989, INT C PYR GAS 23 25
   HOCHHEIM FW, 1994, INT C ADV THERM BIOM
   KARLSVIK E, 1993, 2 INT C COMB TECHN C
   KARLSVIK E, 1993, EMISSIONS WOOD STOVE
NR 6
TC 0
Z9 0
U1 0
U2 0
PU CENTRALES AGRAR ROHSTOFF MKT & ENTWICKLUNG NETZWERK
PI RIMPAR
PA TECHNOL PK 13, D-97222 RIMPAR, GERMANY
PY 1998
BP 791
EP 792
PG 2
WC Energy & Fuels
SC Energy & Fuels
GA BQ87V
UT WOS:000089906600209
DA 2018-10-19
ER

PT S
AU Rezania, A
   Healy, KE
AF Rezania, A
   Healy, KE
BE Thomson, RC
   Mooney, DJ
   Healy, KE
   Ikada, Y
   Mikos, AG
TI Biomolecular surface engineering of materials for controlling bone cell
   adhesion and spreading
SO BIOMATERIALS REGULATING CELL FUNCTION AND TISSUE DEVELOPMENT
SE MATERIALS RESEARCH SOCIETY SYMPOSIUM PROCEEDINGS
LA English
DT Proceedings Paper
CT Symposium on Biomaterials Regulating Cell Function and Tissue
   Development at MRS Spring Meeting
CY APR 13-14, 1998
CL SAN FRANCISCO, CA
SP Mat Res Soc
AB Model biomaterial surfaces were modified with a peptide that contained a -RGD- (Arg-Gly-Asp) sequence, unique to bone sialoprotein, to determine its effect on strength of adhesion, spreading, and focal contact formation of primary bone-derived cells. Peptide surfaces were fabricated by using a heterobifunctional crosslinker to graft the peptide to surfaces (quartz and silicon). Contact angle measurements, spectroscopic ellipsometry, and X-ray photoelectron spectroscopy were used to confirm the chemistry and thickness of the overlayers. Furthermore, spectroscopic ellipsometry was used to estimate the density of immobilized peptide on metal oxide surfaces. A radial flow apparatus was used to measure the strength of adhesion on peptide grafted surfaces. Following 20 min of cell incubation, the strength of cell adhesion was significantly (p<0.05 higher on the -RGD- compared to -RGE- (control) surfaces. The mean area of cells contacting the -RGD- surface was significantly (p<0.05) higher than -RGE- surfaces. Vinculin staining revealed formation of focal contact patches on the periphery of bone cells incubated for 4 hr on the -RGD- surfaces; however, cells seeded on the -RGE- grafted surfaces formed little or no focal contacts. The methods of peptide immobilization utilized in this study can be applied to medical devices, biosensors, and diagnostic assays that require specificity in cell adhesion.
C1 Northwestern Univ, Dept Biol Mat, Chicago, IL 60611 USA.
RP Rezania, A (reprint author), Northwestern Univ, Dept Biol Mat, 311 E Chicago Ave, Chicago, IL 60611 USA.
NR 0
TC 1
Z9 1
U1 0
U2 2
PU MATERIALS RESEARCH SOCIETY
PI WARRENDALE
PA 506 KEYSTONE DRIVE, WARRENDALE, PA 15088-7563 USA
SN 0272-9172
BN 1-55899-436-X
J9 MATER RES SOC SYMP P
PY 1998
VL 530
BP 99
EP 103
DI 10.1557/PROC-530-99
PG 5
WC Biotechnology & Applied Microbiology; Materials Science, Biomaterials
SC Biotechnology & Applied Microbiology; Materials Science
GA BL98P
UT WOS:000077368400015
DA 2018-10-19
ER

PT S
AU Schaefer, DJ
   Munder, B
   Voigt, M
   Stark, GB
AF Schaefer, DJ
   Munder, B
   Voigt, M
   Stark, GB
BE Thomson, RC
   Mooney, DJ
   Healy, KE
   Ikada, Y
   Mikos, AG
TI Proliferation of human osteoblastic cells and synthesis of extracellular
   bone matrix on biomaterials
SO BIOMATERIALS REGULATING CELL FUNCTION AND TISSUE DEVELOPMENT
SE MATERIALS RESEARCH SOCIETY SYMPOSIUM PROCEEDINGS
LA English
DT Proceedings Paper
CT Symposium on Biomaterials Regulating Cell Function and Tissue
   Development at MRS Spring Meeting
CY APR 13-14, 1998
CL SAN FRANCISCO, CA
SP Mat Res Soc
AB Primary human osteoblasts were cultered on biomaterials to develop living bone substitutes by Tissue Engineering. Monolayer cultures were established from iliac crest biopsies. Single cell suspensions were then seeded onto tricalciumphosphate (TCP) BIOBASE(R), hydroxyapatite-collagen(HAC), autoclaved cancellous bone (CB) and fibrin glue (FG) Tissucol(R). The constructs were analyzed by electronmicroscopy, Cell proliferation assay (XTT) and histology to assess adhesion, proliferation and extracellular matrix formation on the biomaterial. The osteoblastic cells survived in the fibrin glue and established a mesenchymal phenotype. They adhered to the MAC-sponges, TCP and CB. Prolifertion was seen on TCP and CB. HAC had a suppressive effect on the cells. An inmature matrix was found on TCP and a bone neomatrix on CB after 4 weeks in vitro.
C1 Univ Freiburg, Dept Plast & Handsurg, Valley Tissue Engn Ctr, D-79106 Freiburg, Germany.
RP Schaefer, DJ (reprint author), Univ Freiburg, Dept Plast & Handsurg, Valley Tissue Engn Ctr, Hugstetter Str 55, D-79106 Freiburg, Germany.
NR 0
TC 3
Z9 3
U1 0
U2 1
PU MATERIALS RESEARCH SOCIETY
PI WARRENDALE
PA 506 KEYSTONE DRIVE, WARRENDALE, PA 15088-7563 USA
SN 0272-9172
BN 1-55899-436-X
J9 MATER RES SOC SYMP P
PY 1998
VL 530
BP 105
EP 109
DI 10.1557/PROC-530-105
PG 5
WC Biotechnology & Applied Microbiology; Materials Science, Biomaterials
SC Biotechnology & Applied Microbiology; Materials Science
GA BL98P
UT WOS:000077368400016
DA 2018-10-19
ER

PT J
AU Fields, GB
   Lauer, JL
   Dori, Y
   Forns, P
   Yu, YC
   Tirrell, M
AF Fields, GB
   Lauer, JL
   Dori, Y
   Forns, P
   Yu, YC
   Tirrell, M
TI Proteinlike molecular architecture: Biomaterial applications for
   inducing cellular receptor binding and signal transduction
SO BIOPOLYMERS
LA English
DT Article
DE molecular architecture; biomaterials; tissue engineering; cellular
   receptor binding; signal transduction; endothelial cell attachment;
   thrombosis; self-assembly; peptide-amphiphile
ID PHASE PEPTIDE-SYNTHESIS; MEMBRANE COLLAGEN ALPHA-1(IV)531-543;
   POLYPEPTIDE MODEL COMPOUNDS; TRIPLE-HELICAL PEPTIDES; ATOMIC FORCE
   MICROSCOPY; ENDOTHELIAL-CELL; TYROSINE PHOSPHORYLATION; VASCULAR GRAFTS;
   SMALL-DIAMETER; AMINO-ACIDS
AB The development of biomaterials with desirable biocompatibility has presented a difficult challenge for tissue engineering researchers. First and foremost, materials themselves tend to be hydrophobic and/or thrombogenic in nature, and face compatibility problems upon implantation. To mediate this problem, researchers have attempted to graft proteins or protein fragments onto biomaterial surfaces to promote endothelial cell attachment and minimize thrombosis. We envisioned a novel approach, based on the capability of biomolecules to self-assemble into well-defined and intricate structures, for creating biomimetic biomaterials that promote cell adhesion and proliferation. One of the most intriguing self-assembly processes is the folding of peptide chains into native protein structures. We have developed a method for building proteinlike structural motifs that incorporate sequences of biological interest. A lipophilic moiety is attached onto an N-alpha-amino group of a peptide chain, resulting in a "peptide-amphiphile." The alignment of amphiphilic compounds at the lipid-solvent interface is used to facilitate peptide alignment and structure initiation and propagation, while the lipophilic region adsorbs to hydrophobic surfaces. Peptide-amphiphiles containing potentially triple-helical or alpha-helical structural motifs have been synthesized. The resultant head group structures have been characterized by CD spectroscopy and found to be thermally stable over physiological temperature ranges. Triple-helical peptide-amphiphiles have been applied to studies of surface modification and cell receptor binding. Cell adhesion and spreading was promoted by triple-helical peptide-amphiphiles. Cellular interaction with the type IV collagen sequence alpha 1(IV) 1263-1277 increased signal transduction, with both the time mid level of induction dependent upon triple-helical conformation. Collectively, these results suggest that peptide-amphiphiles may be used to form stable molecular structures on biomaterial surfaces that promote cellular activities and improve biocompatibility. (C) 1998 John Wiley & Sons, Inc.
C1 Florida Atlantic Univ, Dept Chem & Biochem, Boca Raton, FL 33431 USA.
   Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA.
   Univ Minnesota, Ctr Biomed Engn, Minneapolis, MN 55455 USA.
   Univ Minnesota, Dept Chem Engn, Minneapolis, MN 55455 USA.
RP Fields, GB (reprint author), Florida Atlantic Univ, Dept Chem & Biochem, 777 Glades Rd, Boca Raton, FL 33431 USA.
FU NIAMS NIH HHS [AR01929]; PHS HHS [KD44494]
CR ALLEN BT, 1984, J VASC SURG, V1, P224, DOI 10.1067/mva.1984.avs0010224
   BELLA J, 1995, STRUCTURE, V3, P893, DOI 10.1016/S0969-2126(01)00224-6
   BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699
   BERNDT P, 1995, J AM CHEM SOC, V117, P9515, DOI 10.1021/ja00142a019
   Brodsky B, 1995, FASEB J, V9, P1537
   CHAN HS, 1991, J CHEM PHYS, V94, P8542, DOI 10.1063/1.460088
   CHELBERG MK, 1990, J CELL BIOL, V111, P261, DOI 10.1083/jcb.111.1.261
   CLOWES AW, 1986, J VASC SURG, V3, P877, DOI 10.1067/mva.1986.avs0030877
   DEFILIPPI P, 1994, CELL ADHES COMMUN, V2, P75, DOI 10.3109/15419069409014203
   DEGRADO WF, 1985, J AM CHEM SOC, V107, P7684, DOI 10.1021/ja00311a076
   DELDEN T, 1982, T AM SOC ART INT ORG, V28, P173
   DICHEK DA, 1989, CIRCULATION, V80, P1347, DOI 10.1161/01.CIR.80.5.1347
   FIELDS CG, 1993, PEPTIDE RES, V6, P39
   FIELDS CG, 1993, J BIOL CHEM, V268, P14153
   FIELDS CG, 1993, TETRAHEDRON LETT, V34, P6661, DOI 10.1016/S0040-4039(00)61669-6
   FIELDS CG, 1993, BIOPOLYMERS, V33, P1695, DOI 10.1002/bip.360331107
   FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x
   HEIDEMANN E, 1982, ADV POLYM SCI, V43, P143
   Huebsch JB, 1996, J BIOMED MATER RES, V31, P555, DOI 10.1002/(SICI)1097-4636(199608)31:4<555::AID-JBM16>3.0.CO;2-F
   HUNT J, 1997, BLOOD COAGUL FIBRIN, V8, P223
   KAEHLER J, 1989, J VASC SURG, V9, P535, DOI 10.1067/mva.1989.vs0090535
   KESLER KA, 1986, J VASC SURG, V3, P58
   KING DS, 1990, INT J PEPT PROT RES, V36, P255
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lauer JL, 1997, J MED CHEM, V40, P3077, DOI 10.1021/jm970206j
   LAUER JL, 1998, IN PRESS BIOCHEMISTR, V37
   Lauer JL, 1995, LETT PEPT SCI, V1, P197
   Lee PC, 1996, J BIOMED MATER RES, V32, P645, DOI 10.1002/(SICI)1097-4636(199612)32:4<645::AID-JBM18>3.0.CO;2-C
   LIN HB, 1992, BIOMATERIALS, V13, P905, DOI 10.1016/0142-9612(92)90113-3
   MASSIA SP, 1990, ANAL BIOCHEM, V187, P292, DOI 10.1016/0003-2697(90)90459-M
   MAYO KH, 1991, BIOCHEMISTRY-US, V30, P8251, DOI 10.1021/bi00247a022
   MILES AJ, 1994, J BIOL CHEM, V269, P30939
   MILES AJ, 1995, J BIOL CHEM, V270, P29047, DOI 10.1074/jbc.270.49.29047
   MOORADIAN DL, 1992, INVEST OPHTH VIS SCI, V33, P3034
   OSAPAY G, 1990, J AM CHEM SOC, V112, P6046, DOI 10.1021/ja00172a021
   OSAPAY G, 1992, J AM CHEM SOC, V114, P6966, DOI 10.1021/ja00044a003
   PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349
   POLANOWSKAGRABOWSKA R, 1993, BIOCHEM J, V296, P543, DOI 10.1042/bj2960543
   PRASS W, 1987, BIOCHIM BIOPHYS ACTA, V900, P116, DOI 10.1016/0005-2736(87)90283-5
   RAMACHANDRAN GN, 1988, INT J PEPT PROT RES, V31, P1
   RATNER BD, 1993, J BIOMED MATER RES, V27, P283, DOI 10.1002/jbm.820270302
   ROECKEL D, 1994, EXP CELL RES, V211, P42, DOI 10.1006/excr.1994.1056
   SANK A, 1992, AM J SURG, V164, P199, DOI 10.1016/S0002-9610(05)81070-0
   SCHMIDT SP, 1984, J VASC SURG, V1, P434, DOI 10.1067/mva.1984.avs0010434
   SCHNEIDER A, 1992, J VASC SURG, V15, P649, DOI 10.1016/0741-5214(92)90010-6
   SCOTT NA, 1995, AM HEART J, V129, P860, DOI 10.1016/0002-8703(95)90104-3
   SEEGER JM, 1988, J VASC SURG, V8, P476
   SHINDO S, 1987, J VASC SURG, V6, P325, DOI 10.1067/mva.1987.avs0060325
   STANLEY JC, 1982, SURGERY, V92, P994
   SU JY, 1994, BIOCHEMISTRY-US, V33, P15501, DOI 10.1021/bi00255a032
   SZYCHER M, 1983, BIOCOMPATIBLE POLYM, P1
   VENUGOPAL MG, 1994, BIOCHEMISTRY-US, V33, P7948, DOI 10.1021/bi00191a023
   VISWANATHAN R, 1992, LANGMUIR, V8, P1603, DOI 10.1021/la00042a018
   WATTENBARGER MR, 1990, J CHEM PHYS, V93, P8343, DOI 10.1063/1.459317
   Winger TM, 1996, BIOMATERIALS, V17, P437, DOI 10.1016/0142-9612(96)89661-X
   Yu YC, 1997, METHOD ENZYMOL, V289, P571
   Yu YC, 1996, J AM CHEM SOC, V118, P12515, DOI 10.1021/ja9627656
   ZASADZINSKI JAN, 1991, BIOPHYS J, V59, P755, DOI 10.1016/S0006-3495(91)82288-3
NR 58
TC 132
Z9 139
U1 0
U2 25
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0006-3525
J9 BIOPOLYMERS
JI Biopolymers
PY 1998
VL 47
IS 2
BP 143
EP 151
DI 10.1002/(SICI)1097-0282(1998)47:2<143::AID-BIP3>3.3.CO;2-P
PG 9
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 106WG
UT WOS:000075173300003
PM 9703769
DA 2018-10-19
ER

PT J
AU Cordes, JA
   Chang, AT
   Charvet, JL
AF Cordes, JA
   Chang, AT
   Charvet, JL
TI Predicting fracture from the tensile properties of a composite
   biomaterial
SO COMPOSITES PART A-APPLIED SCIENCE AND MANUFACTURING
LA English
DT Article
DE fracture; finite element analysis (FEA); biomaterial; tensile tests
AB Fracture and tensile tests were conducted on a composite biomaterial consisting of polycarbonate matrix and calcium phosphate fibers. The fibers were short and randomly oriented. Test results were compared for composites with and without a surface treatment of the fibers.
   A nonlinear finite element method was used to predict the maximum loads on pre-cracked panels. The method used the unnotched stress-strain behavior to predict the failure process in notched panels. A cohesive stress zone near the crack tip was used to model damage, stable crack growth, and failure. As in the experiments, the predicted loads were lower for the composite with coated fibers. For both materials, the predicted maximum loads were within the 6% of the experimental loads. (C) 1998 Published by Elsevier Science Ltd. All rights reserved.
C1 Stevens Inst Technol, Dept Mech Engn, Hoboken, NJ 07030 USA.
RP Cordes, JA (reprint author), Stevens Inst Technol, Dept Mech Engn, Hoboken, NJ 07030 USA.
CR *ASTM, 1995, E399990 ASTM
   *ASTM, 1995, D38881 ASTM
   *ASTM, 1995, D303976 ASTM
   Chang AT, 1997, AM SOC TEST MATER, V1321, P562, DOI 10.1520/STP12330S
   CHANG AT, 1996, ASTM STP, V1292, P100
   CHOUEKA A, 1995, J BIOMED MATER RES, V29, P1309
   Choueka J, 1996, J BIOMED MATER RES, V31, P35, DOI 10.1002/(SICI)1097-4636(199605)31:1<35::AID-JBM5>3.0.CO;2-R
   CORDES J, 1995, ENG FRACT MECH, V51, P151, DOI 10.1016/0013-7944(94)00223-5
   CORDES JA, 1995, ASTM STP, V1256
   *HIBB KARLSS SOR I, 1992, ABAQUS VERS 5 2
   PEREZ BJ, 1996, T 5 WORLD BIOM C TOR
   RICE JR, 1969, J MECH PHYS SOLIDS, V17, P201, DOI 10.1016/0022-5096(69)90033-7
NR 12
TC 4
Z9 4
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-835X
J9 COMPOS PART A-APPL S
JI Compos. Pt. A-Appl. Sci. Manuf.
PY 1998
VL 29
IS 12
BP 1475
EP 1480
DI 10.1016/S1359-835X(98)00107-9
PG 6
WC Engineering, Manufacturing; Materials Science, Composites
SC Engineering; Materials Science
GA 133VY
UT WOS:000076708900002
DA 2018-10-19
ER

PT B
AU Lbath, F
   Rumelhart, C
AF Lbath, F
   Rumelhart, C
BE Middleton, J
   Jones, ML
   Pande, GN
TI 3D finite element modelling of a carpometacarpal implant coated with
   hydroxyapatite
SO COMPUTER METHODS IN BIOMECHANICS & BIOMEDICAL ENGINEERING - 2
LA English
DT Proceedings Paper
CT 3rd International Symposium on Computer Methods in Biomechanics and
   Biomedical Engineering
CY MAY, 1997
CL BARCELONA, SPAIN
SP 3M Unitek (Div 3M Hlth Care Ltd), Gordon & Breach Publishers, Welsh Dev Agcy, Wilde & Partners (FE Div)
DE finite element modelling; carpometacarpal implant; hydroxyapatite; non
   linear interface; medical imaging
ID THUMB
AB A three-dimensional finite element model of a total cementless carpometacarpal prosthesis coated with hydroxyapatite was developed in order to study the coating and the bone/implant interface in two clinical situations for key pinch. A semi-automatic mesh generator was developed. Finite element analysis was carried out using the commercial ABAQUS(R) package. Hydroxyapatite mechanical characteristics were determined, in order to take into account this biomaterial behaviour in the finite element model. The hydroxyapatite/trabecular bone interface was either perfectly bonded representing a long term situation where the implant is perfectly osteointegrated, or considered in contact with friction at bone/implant interface in the early post-operative situation. The finite element model predicted, immediately after surgery (non linear interface) and in the long term after bony ingrowth (fully bonded interface), large stresses in the hydroxyapatite coating.
C1 Inst Natl Sci Appl, LMSo, F-69621 Villeurbanne, France.
RP Lbath, F (reprint author), Inst Natl Sci Appl, LMSo, Bat 304,20 Av A Einstein, F-69621 Villeurbanne, France.
CR BROWN TD, 1988, J BIOMECH, V21, P115, DOI 10.1016/0021-9290(88)90005-X
   Cooney W P 3rd, 1977, J Bone Joint Surg Am, V59, P27
   DHERT W, 1993, THESIS U LEIDEN NETH
   GEESINK R, 1993, ACT C EFORT 1 C EUR
   GIURINTANO DJ, 1995, MED ENG PHYS, V17, P297, DOI 10.1016/1350-4533(95)90855-6
   HVID I, 1989, J BIOM, P837
   KEAVENY TM, 1994, J BIOMECH, V27, P1147, DOI 10.1016/0021-9290(94)90055-8
   LASSAYSLBATH F, 1996, THESIS I SCI APPL
   LBATH F, 1996, MAIN, V1, P13
   LBATHLASSAYS F, 1997, 3 DIMENSIONAL BIOMEC
   MUNTING E, 1993, P 10 EUR C BIOM DAV, P98
   NOURRISSAT C, 1993, ACT C EFORT 1 C EUR
   RUBIN PJ, 1993, J BIOMECH, V26, P725, DOI 10.1016/0021-9290(93)90035-D
   SOBALLE K, 1993, ACTA ORTHOP SCAND, V64, pR1
   TANNER KE, 1995, MED ENG PHYS, V17, P291, DOI 10.1016/1350-4533(95)90854-5
   VANRIETBERGEN B, 1993, J BIOM, P369
NR 16
TC 0
Z9 0
U1 0
U2 1
PU GORDON AND BREACH SCIENCE PUBL
PI 1062 EV AMSTERDAM
PA RIJSWIJKSTRAAT 175, 1062 EV AMSTERDAM, NETHERLANDS
BN 90-5699-206-6
PY 1998
BP 447
EP 454
PG 8
WC Computer Science, Interdisciplinary Applications; Dentistry, Oral
   Surgery & Medicine; Engineering, Biomedical; Orthopedics; Surgery
SC Computer Science; Dentistry, Oral Surgery & Medicine; Engineering;
   Orthopedics; Surgery
GA BM39Z
UT WOS:000078630800055
DA 2018-10-19
ER

PT J
AU Vercruysse, KP
   Prestwich, GD
AF Vercruysse, KP
   Prestwich, GD
TI Hyaluronate derivatives in drug delivery
SO CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS
LA English
DT Review
DE glycosaminoglycan; biomaterial; polysaccharide; chemical modification;
   drug targeting
ID HIGH-MOLECULAR-WEIGHT; ANGIOGENESIS IN-VITRO; ACID ESTER MEMBRANES;
   SOLID-STATE NMR; OPHTHALMIC VEHICLES; MURINE MACROPHAGES; RECEPTOR
   RHAMM; POSTSURGICAL ADHESIONS; RESPONSIVE DEGRADATION; HYDROCORTISONE
   ESTERS
AB Hyaluronan (HA), an abundant nonsulfated glycosaminoglycan component of synovial fluid and the extracellular matrix, is an attractive building block for new biocompatible and biodegradable polymers that have applications in drug delivery, tissue engineering, and visco-supplementation. This review consists of three subtopics: (i) chemical modification of HA; (ii) physicochemical and biochemical characterization of HA derivatives; and (iii) in vitro and in vivo bioevaluation studies. Important new products have already reached die marketplace, and the approval and introduction of a variety of new medical applications of HA-based biomaterials can be anticipated in the next decade.
C1 Univ Utah, Coll Pharm, Dept Med Chem, Salt Lake City, UT 84112 USA.
RP Prestwich, GD (reprint author), Univ Utah, Coll Pharm, Dept Med Chem, 30 S 2000 E,Room 201, Salt Lake City, UT 84112 USA.
EM gprestwich@deans.pharm.utah.edu
CR Abatangelo G, 1997, BIOMATERIALS, V18, P1411, DOI 10.1016/S0142-9612(97)00089-6
   Akima K, 1996, J DRUG TARGET, V4, P1, DOI 10.3109/10611869609046255
   AKIMA K, 1992, Patent No. 0506976
   ANDREASSI L, 1991, WOUNDS, V3, P116
   Assmann V, 1996, CLIN CANCER RES, V2, P1607
   BAKOS D, 1997, ADV MED PHYSICS BIOP
   BALAZS EA, 1995, ENCY HDB BIOMATERIAL, P2719
   BALAZS EA, 1989, CIBA F SYMP, V143, P265
   Baum HP, 1996, BRIT J DERMATOL, V134, P465, DOI 10.1046/j.1365-2133.1996.32793.x
   BENEDETTI L, 1993, BIOMATERIALS, V14, P1154, DOI 10.1016/0142-9612(93)90160-4
   BENEDETTI LM, 1990, J CONTROL RELEASE, V13, P33, DOI 10.1016/0168-3659(90)90072-2
   BENEDETTI LM, 1991, NEW POLYM MAT, V3, P41
   BONUCCI E, 1995, CALCIFIED TISSUE INT, V56, P274, DOI 10.1007/BF00318046
   Brown MB, 1995, INT J TISSUE REACT, V17, P133
   Burns JM, 1995, J SURG RES, V59, P644, DOI 10.1006/jsre.1995.1218
   Burns JW, 1996, FERTIL STERIL, V66, P814, DOI 10.1016/S0015-0282(16)58642-7
   BURNS JW, 1991, Patent No. 5017229
   Campoccia D, 1996, BIOMATERIALS, V17, P963, DOI 10.1016/0142-9612(96)84670-9
   CAMPOCCIA D, 1993, BIOMATERIALS, V14, P1135, DOI 10.1016/0142-9612(93)90156-V
   CASCONE MG, 1995, BIOMATERIALS, V16, P569, DOI 10.1016/0142-9612(95)91131-H
   Catterall JB, 1997, GLYCOCONJUGATE J, V14, P647, DOI 10.1023/A:1018500929514
   Catterall JB, 1995, CANCER J, V8, P320
   CERA C, 1988, INT J BIOL MACROMOL, V10, P66, DOI 10.1016/0141-8130(88)90013-X
   Chen GP, 1997, BIOCONJUGATE CHEM, V8, P730, DOI 10.1021/bc9700493
   Cooper Matthew L., 1996, Journal of Burn Care and Rehabilitation, V17, P108, DOI 10.1097/00004630-199603000-00004
   CORTIVO R, 1991, BIOMATERIALS, V12, P727, DOI 10.1016/0142-9612(91)90020-B
   Croft DR, 1997, EUR J IMMUNOL, V27, P1680, DOI 10.1002/eji.1830270713
   CULTY M, 1994, J CELL PHYSIOL, V160, P275, DOI 10.1002/jcp.1041600209
   DAVIDSON J M, 1991, Clinical Materials, V8, P171, DOI 10.1016/0267-6605(91)90027-D
   Deed R, 1997, INT J CANCER, V71, P251, DOI 10.1002/(SICI)1097-0215(19970410)71:2<251::AID-IJC21>3.0.CO;2-J
   Delpech B, 1997, J INTERN MED, V242, P41, DOI 10.1046/j.1365-2796.1997.00172.x
   DEMEESTER J, 1997, PHARM ENZYMES, P155
   DROBNIK J, 1991, ADV DRUG DELIVER REV, V7, P295, DOI 10.1016/0169-409X(91)90008-Z
   Entwistle J, 1996, J CELL BIOCHEM, V61, P569, DOI 10.1002/(SICI)1097-4644(19960616)61:4<569::AID-JCB10>3.0.CO;2-B
   Fraser JRE, 1997, J INTERN MED, V242, P27, DOI 10.1046/j.1365-2796.1997.00170.x
   GECIOVA R, 1995, MACROMOL CHEM PHYS, V196, P2891, DOI 10.1002/macp.1995.021960914
   Gerdin B, 1997, J INTERN MED, V242, P49, DOI 10.1046/j.1365-2796.1997.00173.x
   GHEZZO E, 1992, INT J PHARM, V87, P21, DOI 10.1016/0378-5173(92)90223-O
   Glass JR, 1996, BIOMATERIALS, V17, P1101, DOI 10.1016/0142-9612(96)85911-4
   GOEI L, 1990, 4 INT C POL MED BIOM
   GOEI L, 1989, PHARM RES, V6, pS94
   Gowland G, 1996, CLIN DRUG INVEST, V11, P245, DOI 10.2165/00044011-199611040-00008
   Griffioen AW, 1997, BLOOD, V90, P1150
   Gunning AP, 1996, CARBOHYD POLYM, V30, P1, DOI 10.1016/S0144-8617(96)00094-X
   Gustafson S, 1997, GLYCOCONJUGATE J, V14, P561, DOI 10.1023/A:1018528308132
   GUSTAFSON S, 1994, GLYCOCONJUGATE J, V11, P608, DOI 10.1007/BF00731313
   GUSTAFSON S, 1995, GLYCOCONJUGATE J, V12, P350, DOI 10.1007/BF00731337
   GUSTAFSON S, 1997, CHEM BIOL MED APPL H
   HALL CL, 1994, J CELL BIOL, V126, P575, DOI 10.1083/jcb.126.2.575
   HALL CL, 1995, CELL, V82, P19, DOI 10.1016/0092-8674(95)90048-9
   HUME LR, 1994, INT J PHARM, V111, P295, DOI 10.1016/0378-5173(94)90352-2
   HUME LR, 1990, PHARM RES, V7, pS174
   HUNT JA, 1990, J CONTROL RELEASE, V12, P159, DOI 10.1016/0168-3659(90)90092-8
   ILLUM L, 1994, J CONTROL RELEASE, V29, P133, DOI 10.1016/0168-3659(94)90129-5
   JOSHI HN, 1992, J CONTROL RELEASE, V20, P109, DOI 10.1016/0168-3659(92)90157-M
   Juhlin L, 1997, J INTERN MED, V242, P61, DOI 10.1046/j.1365-2796.1997.00175.x
   KAY JS, 1986, OPHTHALMIC SURG LAS, V17, P626
   KNUDSON CB, 1993, FASEB J, V7, P1233
   KOOCHEKPOUR S, 1995, INT J CANCER, V63, P450, DOI 10.1002/ijc.2910630325
   KORNOVSKI BS, 1994, FERTIL STERIL, V61, P935
   KUO JW, 1991, BIOCONJUGATE CHEM, V2, P232, DOI 10.1021/bc00010a007
   KUO JW, 1994, Patent No. 5356883
   KUO JW, 1996, Patent No. 5502081
   KYYRONEN K, 1992, INT J PHARM, V80, P161, DOI 10.1016/0378-5173(92)90274-6
   LAREN NE, 1994, BIOTECHNOLOGY BIOACT, P25
   Larsen NE, 1995, MATER RES SOC SYMP P, V394, P193, DOI 10.1557/PROC-394-193
   Larsen NE, 1995, MATER RES SOC SYMP P, V394, P149, DOI 10.1557/PROC-394-149
   LARSEN NE, 1991, COSMETIC AND PHARMACEUTICAL APPLICATIONS OF POLYMERS, P147
   LARSEN NE, 1991, ADV DRUG DELIVER REV, V7, P279, DOI 10.1016/0169-409X(91)90007-Y
   LAURENT TC, 1992, FASEB J, V6, P2397
   LAURENT TC, 1964, ACTA CHEM SCAND, V18, P274, DOI 10.3891/acta.chem.scand.18-0274
   Lesley J, 1997, GLYCOCONJUGATE J, V14, P611, DOI 10.1023/A:1018540610858
   LOWRY KM, 1994, J BIOMED MATER RES, V28, P861, DOI 10.1002/jbm.820280804
   Magnani A, 1996, THROMB RES, V81, P383, DOI 10.1016/0049-3848(96)00009-6
   McKee CM, 1997, J BIOL CHEM, V272, P8013, DOI 10.1074/jbc.272.12.8013
   McKee CM, 1996, J CLIN INVEST, V98, P2403, DOI 10.1172/JCI119054
   Miller JA, 1997, J BIOMED MATER RES, V38, P25, DOI 10.1002/(SICI)1097-4636(199721)38:1<25::AID-JBM4>3.0.CO;2-J
   Montesano R, 1996, LAB INVEST, V75, P249
   Moore AR, 1995, INT J TISSUE REACT, V17, P153
   MORIMOTO K, 1991, PHARMACEUT RES, V8, P471, DOI 10.1023/A:1015894910416
   MORRA M, 1997, P AM CHEM SOC DIV PO, P566
   Nakagawa T, 1996, ANTICANCER RES, V16, P2917
   NIGHTLINGER NS, 1995, P INT S CONTROL REL, V22, P738
   Noble PW, 1996, J EXP MED, V183, P2373, DOI 10.1084/jem.183.5.2373
   NOBLE PW, 1993, J CLIN INVEST, V91, P2368, DOI 10.1172/JCI116469
   NOMURA M, 1994, J PHARM PHARMACOL, V46, P768, DOI 10.1111/j.2042-7158.1994.tb03900.x
   PAPINI D, 1993, J CONTROL RELEASE, V27, P47, DOI 10.1016/0168-3659(93)90056-B
   PARK K, 1993, BIODEGRADABLE HYDROG
   PODDER SK, 1992, EXP EYE RES, V54, P747, DOI 10.1016/0014-4835(92)90030-V
   PONTA H, 1994, INVAS METAST, V14, P82
   POUYANI T, 1994, BIOCONJUGATE CHEM, V5, P339, DOI 10.1021/bc00028a010
   POUYANI T, 1992, J AM CHEM SOC, V114, P5972, DOI 10.1021/ja00041a010
   POUYANI T, 1994, J AM CHEM SOC, V116, P7515, DOI 10.1021/ja00096a007
   POUYANI T, 1994, BIOCONJUGATE CHEM, V5, P370, DOI 10.1021/bc00028a015
   POUYANI T, 1997, Patent No. 5652347
   POUYANI T, 1997, Patent No. 5616568
   PRESTWICH GD, 1997, CHEM BIOL MED APPL H
   PRESTWICH GD, 1998, J CONTROL RELEASE, V53, P99
   PRISELL PT, 1992, INT J PHARM, V85, P51, DOI 10.1016/0378-5173(92)90133-M
   Pritchard K, 1996, INT J PHARM, V129, P137, DOI 10.1016/0378-5173(95)04280-6
   RAJEWSKI LG, 1992, INT J PHARM, V82, P205, DOI 10.1016/0378-5173(92)90176-3
   Rehakova M, 1996, J BIOMED MATER RES, V30, P369, DOI 10.1002/(SICI)1097-4636(199603)30:3<369::AID-JBM11>3.0.CO;2-F
   RICHARDSON JL, 1995, INT J PHARM, V115, P9, DOI 10.1016/0378-5173(94)00226-U
   Rochira M, 1996, INT J PHARM, V144, P19, DOI 10.1016/S0378-5173(96)04686-8
   Rockey DC, 1998, HEPATOLOGY, V27, P86, DOI 10.1002/hep.510270115
   ROONEY P, 1995, INT J CANCER, V60, P632, DOI 10.1002/ijc.2910600511
   Ropponen K, 1998, CANCER RES, V58, P342
   SAETTONE MF, 1994, J OCUL PHARMACOL, V10, P83, DOI 10.1089/jop.1994.10.83
   SAETTONE MF, 1991, INT J PHARM, V72, P131, DOI 10.1016/0378-5173(91)90051-O
   SAETTONE MF, 1989, INT J PHARM, V51, P203, DOI 10.1016/0378-5173(89)90193-2
   SAETTONE MF, 1987, 3 EUR C BIOPH PHARM, V1
   Sakurai K, 1997, GLYCOCONJUGATE J, V14, P723, DOI 10.1023/A:1018521501289
   SAMUEL SK, 1993, J CELL BIOL, V123, P749, DOI 10.1083/jcb.123.3.749
   Samuelsson C, 1998, GLYCOCONJUGATE J, V15, P169, DOI 10.1023/A:1006920323095
   SANZGIRI YD, 1994, INT J PHARM, V107, P91, DOI 10.1016/0378-5173(94)90446-4
   SCOTT JE, 1989, CIBA F SYMP, V143, P6
   SHAH CB, 1992, ACS SYM SER, V480, P116
   SHERMAN L, 1994, CURR OPIN CELL BIOL, V6, P726, DOI 10.1016/0955-0674(94)90100-7
   Simon LD, 1997, J CONTROL RELEASE, V45, P273, DOI 10.1016/S0168-3659(96)01593-3
   SOLDAN M, 1997, ADV MED PHYSICS BIOP
   Sparer R.V., 1983, CONTROLLED RELEASE D, P107
   SUNG KC, 1995, J CONTROL RELEASE, V37, P95, DOI 10.1016/0168-3659(95)00068-J
   TANABE KK, 1994, CRIT REV ONCOGENESIS, V5, P201, DOI 10.1615/CritRevOncog.v5.i2-3.50
   Tomihata K, 1997, BIOMATERIALS, V18, P189, DOI 10.1016/S0142-9612(96)00116-0
   Tomihata K, 1997, J BIOMED MATER RES, V37, P243
   Toole BP, 1997, J INTERN MED, V242, P35, DOI 10.1046/j.1365-2796.1997.00171.x
   Trochon V, 1996, INT J CANCER, V66, P664, DOI 10.1002/(SICI)1097-0215(19960529)66:5<664::AID-IJC14>3.0.CO;2-4
   Vercruysse KP, 1997, BIOCONJUGATE CHEM, V8, P686, DOI 10.1021/bc9701095
   WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340
   WILLOUGHBY DA, 1995, 3 INT WORKSH HYAL DR
   WILLOUGHBY DA, 1992, 1 INT WORKSH HYAL DR
   WILLOUGHBY DA, 1994, 2 INT WORKSH HYAL DR
   WILLOUGHBY DA, 1996, 3 INT WORKSH HYAL DR
   WINNIK FM, 1996, 4 INT WORKSH HYAL DR
   YERUSHALMI N, 1994, ARCH BIOCHEM BIOPHYS, V313, P267, DOI 10.1006/abbi.1994.1387
   Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985
   YUI N, 1992, J CONTROL RELEASE, V22, P105
   YUI N, 1993, J CONTROL RELEASE, V25, P133
   YUI N, 1993, J CONTROL RELEASE, V26, P141, DOI 10.1016/0168-3659(93)90113-J
   ZHONG SP, 1994, BIOMATERIALS, V15, P359, DOI 10.1016/0142-9612(94)90248-8
NR 140
TC 153
Z9 155
U1 1
U2 30
PU BEGELL HOUSE INC
PI REDDING
PA 50 CROSS HIGHWAY, REDDING, CT 06896 USA
SN 0743-4863
J9 CRIT REV THER DRUG
JI Crit. Rev. Ther. Drug Carr. Syst.
PY 1998
VL 15
IS 5
BP 513
EP 555
PG 43
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 137CR
UT WOS:000076897600003
PM 9822869
DA 2018-10-19
ER

PT B
AU Villegas, R
   Lariot, C
   Gonzalez, R
AF Villegas, R
   Lariot, C
   Gonzalez, R
BE Benavides, HAC
   Yacaman, MJ
TI Morphological and structural study of some corals from the cuban
   platform. A biomaterial precursor
SO ELECTRON MICROSCOPY 1998, VOL 3: MATERIALS SCIENCE 2
LA English
DT Proceedings Paper
CT 14th International Congress on Electron Microscopy
CY AUG 31-SEP 04, 1998
CL CANCUN, MEXICO
SP Mexican Soc Microscopy, Consejo Nacl Ciencia & Tecnol, Inst Nacl Invest Nucl, Univ Autonoma Estado Mexico, Univ Veracruzana, Ctr Invest & Estudios Avanzados, Univ Nacl Autonoma Mexico, Ctr Invest Mat Avanzados, Inst Politecn Nacl, Univ Autonoma Nuevo Leon
C1 Natl Ctr Sci Res, Electron Microscopy Lab, C Habana, Cuba.
RP Villegas, R (reprint author), Natl Ctr Sci Res, Electron Microscopy Lab, POB 6990, C Habana, Cuba.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU IOP PUBLISHING LTD
PI BRISTOL
PA DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND
BN 0-7503-0566-5
PY 1998
BP 247
EP 248
PG 2
WC Chemistry, Physical; Materials Science, Multidisciplinary; Materials
   Science, Biomaterials; Microscopy
SC Chemistry; Materials Science; Microscopy
GA BL87J
UT WOS:000077020300119
DA 2018-10-19
ER

PT J
AU Remunan-Lopez, C
   Lorenzo-Lamosa, ML
   Vila-Jato, JL
   Alonso, MJ
AF Remunan-Lopez, C
   Lorenzo-Lamosa, ML
   Vila-Jato, JL
   Alonso, MJ
TI Development of new chitosan-cellulose multicore microparticles for
   controlled drug delivery
SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
LA English
DT Article
DE chitosan; microencapsulation; protein delivery; controlled release; oral
   administration; anti-inflammatory drugs; cellulose acetate butyrate;
   ethyl cellulose
ID SOLVENT EVAPORATION METHOD; MICROSPHERES; RELEASE; POLYMERS; FILMS;
   FORMULATIONS; ACID
AB Chitosan (CS) is a very interesting biomaterial for drug delivery; however its Use in oral administration is restricted by its fast dissolution in the stomach and limited capacity for controlling the release of drugs. To address this limitation, a new microparticulate CS controlled release system, consisting of hydrophilic CS microcores entrapped in a hydrophobic cellulosic polymer, such as cellulose acetate butyrate (CAB) or ethyl cellulose (EC) was proposed. These microparticles were obtained with different types of CS and various core/coat ratios, with the particle size in all cases being smaller that 70 mu m. Using sodium diclofenac (SD) and fluorescein isothiocyanate-labeled bovine serum albumin (FITC-BSA) as model compounds, the properties of these new microparticles for the entrapment and controlled release of drugs and proteins were investigated. Results showed that the entrapment efficiency of SD was very high irrespective of the processing conditions. Furthermore, for both model compounds (SD and FITC-BSA) it was possible to modulate the in vitro release of the encapsulated molecules by changing the core properties (CS salt, M-w, core/coat ratio) or the coating polymer. The microparticles were stable at low pH and thus, suitable for oral delivery without requiring any harmful cross-linkage treatment. (C) 1998 Elsevier Science B.V.
C1 Univ Santiago de Compostela, Santiago De Compostela, Spain.
RI Buchan, Shari/B-6924-2012
CR ADUSUMILLI PS, 1991, DRUG DEV IND PHARM, V17, P1931, DOI 10.3109/03639049109048059
   AKBUGA J, 1994, INT J PHARM, V111, P217, DOI 10.1016/0378-5173(94)90344-1
   ALEX R, 1990, J MICROENCAPSUL, V7, P347, DOI 10.3109/02652049009021845
   ALONSO MJ, 1993, PHARMACEUT RES, V10, P945, DOI 10.1023/A:1018942118148
   Berthold A, 1996, STP PHARMA SCI, V6, P358
   BODMEIER R, 1989, DRUG DEV IND PHARM, V15, P1475, DOI 10.3109/03639048909062758
   Borchard G, 1996, J CONTROL RELEASE, V39, P131, DOI 10.1016/0168-3659(95)00146-8
   Calvo P, 1997, J APPL POLYM SCI, V63, P125, DOI 10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4
   CHEN RH, 1994, CARBOHYD POLYM, V24, P41, DOI 10.1016/0144-8617(94)90115-5
   GENTA I, 1995, STP PHARMA SCI, V5, P202
   Herrmann J, 1995, INT J PHARM, V126, P129, DOI 10.1016/0378-5173(95)04106-0
   HILLYARD IW, 1964, P SOC EXP BIOL MED, V115, P1108
   HIRANO S, 1990, PROGRESS IN BIOMEDICAL POLYMERS, P283
   HOSOKAWA J, 1991, IND ENG CHEM RES, V30, P788, DOI 10.1021/ie00052a025
   HOU WM, 1985, CHEM PHARM BULL, V33, P3986
   ILLUM L, 1994, PHARMACEUT RES, V11, P1186, DOI 10.1023/A:1018901302450
   KARLSEN J, 1991, MANUFACTURING CH JUN, P18
   KIENZLESTERZER CA, 1982, MAKROMOL CHEM, V183, P1353
   KNAPCZYK J, 1989, CHITIN CHITOSAN SOUR, P657
   LEHR CM, 1992, INT J PHARM, V78, P43, DOI 10.1016/0378-5173(92)90353-4
   NIGALAYE AG, 1990, DRUG DEV IND PHARM, V16, P449, DOI 10.3109/03639049009114897
   REMUANLOPEZ C, 1995, P INT S CONTROL RELE, V22, P430
   RemunanLopez C, 1996, DRUG DEV IND PHARM, V22, P1201, DOI 10.3109/03639049609063238
   SAWAYANAGI Y, 1982, CHEM PHARM BULL, V30, P4464
   TOZAKI H, 1996, P INT S CONTROL RELE, V23, P551
NR 25
TC 56
Z9 58
U1 2
U2 27
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0939-6411
J9 EUR J PHARM BIOPHARM
JI Eur. J. Pharm. Biopharm.
PD JAN
PY 1998
VL 45
IS 1
BP 49
EP 56
DI 10.1016/S0939-6411(97)00122-7
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 133KK
UT WOS:000076685600007
PM 9689535
DA 2018-10-19
ER

PT J
AU Gil, FJ
   Planell, JA
AF Gil, FJ
   Planell, JA
TI In vitro thermomechanical ageing of Ni-Ti alloys
SO JOURNAL OF BIOMATERIALS APPLICATIONS
LA English
DT Article
AB NiTi alloy is used as a biomaterial due to its pseudoelastic behaviour. It exhibits a great potential in dental and orthopedic applications where constant correcting loads are required. In order to use such materials, it is necessary to investigate the effect of the cyclic straining upon the transformation stresses and temperatures of the material, the effect of thermal cycling and the ageing at different temperatures and times of heat treatment. The aim of this work is to study the load and thermal cycling and the ageing with the temperature of a superelastic NiTi shape memory alloy.
C1 Univ Politecn Cataluna, Dept Ciencia Mat & Ingn Met, ETSEIB, E-08028 Barcelona, Spain.
CR BUEHLER WJ, 1963, J APPL PHYS, V34, P1475, DOI 10.1063/1.1729603
   Duerig T.W., 1990, ENG ASPECTS SHAPE ME, P124
   DUERING TW, 1990, ENG ASPECTS SHAPE ME, P52
   GIL FJ, 1995, J MATER SCI, V30, P2526, DOI 10.1007/BF00362129
   Greninger AB, 1938, T AM I MIN MET ENG, V128, P337
   GUILEMANY JM, 1990, THERMOCHIM ACTA, V167, P136
   GUILEMANY JM, 1990, MAT RES B, V25, P1352
   GUILLEMANY JM, 1986, REV TECNICA METALURG, V5, P213
   IWASAKI K, 1982, MARTENSITIC TRANSFOR, P198
   KAUFMAN L, 1958, PROG MET PHYS, V7, P165, DOI 10.1016/0502-8205(58)90005-4
   KURDYUMOV GV, 1949, DOKL AKAD NAUK SSSR+, V66, P211
   LEE JH, 1988, J BIOMED MATER RES, V22, P573, DOI 10.1002/jbm.820220611
   MIYAZAKI D, 1986, METALLURGICAL T A, V4, P53
   MIYAZAKI D, 1982, J PHYSIQUE S12, V43, pC4
   ORTIN J, 1988, ACTA METALL MATER, V36, P1873, DOI 10.1016/0001-6160(88)90291-X
   PERKINS J, 1975, SHAPE MEMORY EFFECTS, P12
   Purdy G.R., 1981, T AIME, V6, P23
   Sabria J, 1996, BIO-MED MATER ENG, V6, P153
   SABURI T, 1982, J PHYSIQUE
   TOSHO S, 1984, SHAPE MEMORY ALLOYS, V1, P23
   WATANABE K, 1983, J JAPANESE SOC DENTA, V2, P594
NR 21
TC 4
Z9 5
U1 0
U2 1
PU TECHNOMIC PUBL CO INC
PI LANCASTER
PA 851 NEW HOLLAND AVE, BOX 3535, LANCASTER, PA 17604 USA
SN 0885-3282
J9 J BIOMATER APPL
JI J. Biomater. Appl.
PD JAN
PY 1998
VL 12
IS 3
BP 237
EP 248
DI 10.1177/088532829801200304
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA YW018
UT WOS:000071887400003
PM 9493070
DA 2018-10-19
ER

PT J
AU Han, DK
   Park, KD
   Kim, YH
AF Han, DK
   Park, KD
   Kim, YH
TI Sulfonated poly(ethylene oxide)-grafted polyurethane copolymer for
   biomedical applications
SO JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION
LA English
DT Article
DE biomaterial; polyurethane; sulfonated PEO; copolymer; bulk modification;
   biocompatibility
ID BLOOD COMPATIBILITY; ANTICOAGULANT ACTIVITY; SURFACE; PEO; ADHESION;
   ADSORPTION; POLYMERS
AB Sulfonated poly(ethylene oxide) (PEO-SO3)-grafted polyurethane (PU) copolymer (PU-PEO-SO3) was developed for utilization as a material for biomedical applications. Its bulk properties and biocompatibility were investigated and the results were compared to those of PU and PU-PEO (not sulfonated). PU-PEO-SO3 copolymer showed higher water uptake than PU and PU-PEO, indicative of increased hydrophilicity due to the grafting of PEO-SO3. Compared with PU, PU-PEO-SO3 displayed lower glass transition temperature (T-g) and melting endotherm from DSC analysis, suggesting the increase of microphase separation and the suppression of hard-segment packing. PU-PEO-SO3 had practically similar mechanical properties to PU, indicating that the chemical modification of PU was accomplished without reducing its bulk properties. From the results of biocompatibility tests, PU-PEO-SO3 copolymer showed significantly lower adhesion of platelets and S. epidermidis than PU control and PU-PEO. In addition, the platelet factor 4 (PF4) released from platelets was the lowest in PU-PEO-SO3 among the test materials. PU-PEO-SO3 copolymer, which has excellent mechanical properties and biocompatibility, is expected to be useful as coating, molding, and blending materials for artificial organs and medical devices.
C1 Korea Inst Sci & Technol, Biomat Res Ctr, Seoul 130650, South Korea.
RP Kim, YH (reprint author), Korea Inst Sci & Technol, Biomat Res Ctr, POB 131, Seoul 130650, South Korea.
EM yhakim@kistmail.kist.re.kr
OI Han, Dong Keun/0000-0003-4641-7883
CR Andrade J. D., 1987, ASAIO J, V33, P75
   BRUNSTEDT MR, 1995, J BIOMED MATER RES, V29, P455, DOI 10.1002/jbm.820290405
   CHEN WY, 1982, J POLYM SCI POL CHEM, V20, P547, DOI 10.1002/pol.1982.170200228
   DESAI NP, 1992, BIOMATERIALS, V13, P417, DOI 10.1016/0142-9612(92)90160-P
   HAN DK, 1995, BIOMATERIALS, V16, P467, DOI 10.1016/0142-9612(95)98819-Z
   HAN DK, 1993, J BIOMED MATER RES, V27, P1063, DOI 10.1002/jbm.820270812
   HAN DK, 1991, J BIOMED MATER RES, V25, P561, DOI 10.1002/jbm.820250502
   HAN DK, 1989, J BIOMED MATER RES-A, V23, P211
   Han DK, 1996, J BIOMED MATER RES, V30, P23, DOI 10.1002/(SICI)1097-4636(199601)30:1<23::AID-JBM4>3.0.CO;2-T
   HAN DK, 1993, J BIOMAT SCI-POLYM E, V4, P579
   HAN DK, 1993, ASAIO J, V39, P537
   HAN DK, 1993, THESIS SEOUL NATL U
   IKADA Y, 1984, ADV POLYM SCI, V57, P103
   ISHIHARA K, 1990, J BIOMED MATER RES, V24, P1069, DOI 10.1002/jbm.820240809
   ITO Y, 1989, CRIT REV BIOCOMPAT, V5, P45
   ITO Y, 1988, ARTIFICIAL HEART, V2, P35
   JOZEFONVICZ J, 1990, Journal of Biomaterials Science Polymer Edition, V1, P147
   KIM S W, 1985, Critical Reviews in Biocompatibility, V1, P229
   KIM YH, 1995, ENCY HDB BIOMATERI B, V2, P1071
   KIM YH, 1996, POLYM MAT ENCY, V1, P825
   Lelah M. D., 1986, POLYURETHANES MED
   LELAH MD, 1986, J BIOMED MATER RES, V20, P433, DOI 10.1002/jbm.820200403
   MILLER GW, 1970, J POLYM SCI A, V18, P1923
   Nagel JA, 1996, J BIOMAT SCI-POLYM E, V7, P769, DOI 10.1163/156856296X00110
   *NIH, 1985, NIH PUBL
   OKANO T, 1981, J BIOMED MATER RES, V15, P393, DOI 10.1002/jbm.820150310
   PARK KD, 1992, J BIOMED MATER RES, V26, P739, DOI 10.1002/jbm.820260605
   Ratner B. D., 1976, ACS SYM SER, V31, P1, DOI DOI 10.1021/SYMPOSIUM
   SALZMAN EW, 1977, ANN NY ACAD SCI, V283, P114, DOI 10.1111/j.1749-6632.1977.tb41760.x
   SEMOUR RW, 1973, MACROMOLECULES, V6, P48
   Szycher M., 1991, HIGH PERFORMANCE BIO
   Tsuruta T, 1996, ADV POLYM SCI, V126, P1
   YU J, 1994, BIOMATERIALS, V15, P805, DOI 10.1016/0142-9612(94)90035-3
NR 33
TC 43
Z9 46
U1 1
U2 16
PU VSP BV
PI ZEIST
PA PO BOX 346, 3700 AH ZEIST, NETHERLANDS
SN 0920-5063
J9 J BIOMAT SCI-POLYM E
JI J. Biomater. Sci.-Polym. Ed.
PY 1998
VL 9
IS 2
BP 163
EP 174
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials; Polymer
   Science
SC Engineering; Materials Science; Polymer Science
GA YX386
UT WOS:000072034800005
PM 9493843
DA 2018-10-19
ER

PT J
AU Yamauchi, K
   Maniwa, M
   Mori, T
AF Yamauchi, K
   Maniwa, M
   Mori, T
TI Cultivation of fibroblast cells on keratin-coated substrata
SO JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION
LA English
DT Article
DE keratin; fibroblast cell; cell-substratum; cell attachment; biomaterial
ID INTERMEDIATE FILAMENTS; ALPHA-KERATIN; ATTACHMENT; ADHESION; GROWTH;
   INTEGRINS; COLLAGEN
AB By means of a cell culture method, the attachment and growth of mouse L929 fibroblast cells were studied on matrices of the (-SDS)- and (+SDS)-keratins, which were extracted from wool in the absence and presence of sodium dodecyl sulfate, respectively. The (+SDS)-keratin showed some toxic effect on the cell growth, but upon washing with a pH7/phosphate buffer, the protein behaved similarly to a substratum of the (-SDS)-keratin. The comparative culture assay on the keratins, collagen (type I), and glass revealed that the keratins were more adhesive to the cells and more supportive for cell proliferation than the collagen and glass. The results were explained by an enhanced initial adsorption of mediator proteins from fetal bovine serum onto the keratin substrata.
C1 Osaka City Univ, Fac Engn, Dept Bioappl Chem, Sumiyoshi Ku, Osaka 558, Japan.
RP Yamauchi, K (reprint author), Osaka City Univ, Fac Engn, Dept Bioappl Chem, Sumiyoshi Ku, Osaka 558, Japan.
EM yamauchi@bioa.eng.osaka-cu.ac.jp
CR ALBELDA SM, 1990, FASEB J, V4, P2868
   CREWTHER WG, 1983, INT J BIOL MACROMOL, V5, P267, DOI 10.1016/0141-8130(83)90040-5
   DOWLING LM, 1986, BIOCHEM J, V236, P705, DOI 10.1042/bj2360705
   FEUGHELMAN M, 1985, ENCY POLYM SCI ENG, V8, P566
   GLOXHUBER C, 1974, ARCH TOXICOL, V32, P245, DOI 10.1007/BF00330108
   Grinnell F, 1978, Int Rev Cytol, V53, P65
   HEID HW, 1986, DIFFERENTIATION, V32, P101, DOI 10.1111/j.1432-0436.1986.tb00562.x
   HYNES RO, 1986, SCI AM, V254, P42, DOI 10.1038/scientificamerican0686-42
   KANG IK, 1989, J BIOMED MATER RES, V23, P223, DOI 10.1002/jbm.820230207
   MINOURA N, 1995, BIOCHEM BIOPH RES CO, V208, P511, DOI 10.1006/bbrc.1995.1368
   PIERSCHBACHER MD, 1984, P NATL ACAD SCI-BIOL, V81, P5985, DOI 10.1073/pnas.81.19.5985
   RUBIN K, 1977, EXP CELL RES, V109, P413, DOI 10.1016/0014-4827(77)90021-0
   RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619
   TAMADA Y, 1994, J BIOMED MATER RES, V28, P783, DOI 10.1002/jbm.820280705
   TAMADA Y, 1986, POLYM MED, V2, P101
   THOMAS H, 1986, INT J BIOL MACROMOL, V8, P258, DOI 10.1016/0141-8130(86)90038-3
   YAMADA Y, 1993, J COLLOID INTERF SCI, V155, P334
   Yamauchi K, 1996, J BIOMED MATER RES, V31, P439, DOI 10.1002/(SICI)1097-4636(199608)31:4<439::AID-JBM1>3.0.CO;2-M
NR 18
TC 104
Z9 104
U1 0
U2 10
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0920-5063
EI 1568-5624
J9 J BIOMAT SCI-POLYM E
JI J. Biomater. Sci.-Polym. Ed.
PY 1998
VL 9
IS 3
BP 259
EP 270
DI 10.1163/156856298X00640
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials; Polymer
   Science
SC Engineering; Materials Science; Polymer Science
GA ZF076
UT WOS:000072860200005
PM 9556761
DA 2018-10-19
ER

PT J
AU Leon, EJ
   Verma, N
   Zhang, SG
   Lauffenburger, DA
   Kamm, RD
AF Leon, EJ
   Verma, N
   Zhang, SG
   Lauffenburger, DA
   Kamm, RD
TI Mechanical properties of a self-assembling oligopeptide matrix
SO JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION
LA English
DT Article
DE biomaterial; self-assembling peptides; elastic modulus; model; tensile
   test; microstructure
ID COMPLEMENTARY OLIGOPEPTIDE; MEDICAL APPLICATIONS; POLYMERS
AB We have begun studies of a novel type of biomaterial derived from a recently-discovered class of ionic self-complementary oligopeptides. These short peptides (typically 8, 16, 24, or 32 amino acid residues with internally-repeating sequences) self-assemble in aqueous salt solution into three-dimensional matrices capable of favorable interactions with cells, and offer promise for useful bioengineering design based on rational changes in sequence. In this paper we present preliminary results on mechanical properties, combining experimental and theoretical approaches, of one particular example of these peptide materials, EFK8. The static elastic modulus was measured using an apparatus designed to allow sample fabrication and mechanical testing in the same system with the sample in aqueous solution. The material microstructure was examined by SEM and the measurements interpreted with the aid of a model for cellular solids. Values for the elastic modulus increased from 1.59 +/- 0.06 to 14.7 +/- 1.0 kPa for peptide concentrations increasing from 2.7 to 10 mg ml(-1) SEM photographs showed the microstructure to consist of a relatively homogeneous lattice with fiber thickness of 10-30 nm independent of peptide concentration, but with fiber density increasing with peptide concentration. This behavior is consistent with scaling predictions from the cellular solids model and yields an estimate for the individual fiber elastic modulus in the range of 1-20 MPa. We therefore have provided some initial physical principles for guiding improvement of the mechanical properties of these new materials.
C1 MIT, Ctr Biomed Engn, Cambridge, MA 02139 USA.
RP Kamm, RD (reprint author), MIT, Ctr Biomed Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
EM rdkamm@mit.edu
OI /0000-0002-7232-304X
CR BADER DL, 1983, BIOMATERIALS, V11, P721
   CHVAPIL M, 1977, J BIOMED MATER RES, V11, P721, DOI 10.1002/jbm.820110508
   CHVAPIL M, 1982, J BIOMED MATER RES, V16, P245, DOI 10.1002/jbm.820160306
   DOI M, 1961, THEORY POLYM DYNAMIC
   ENGELBERG I, 1991, BIOMATERIALS, V12, P292, DOI 10.1016/0142-9612(91)90037-B
   Evans DA, 1997, NATURE, V386, P262, DOI 10.1038/386262a0
   Gibson L. J., 1988, CELLULAR SOLIDS
   HOFFMAN AS, 1992, ARTIF ORGANS, V16, P43
   JAMES K, 1996, MRS B           1102
   LANGER R, 1995, ANN BIOMED ENG, V23, P101, DOI 10.1007/BF02368317
   LAWRENCEKATZ J, 1985, HDB BIOMEDICAL ENG, P460
   RATNER BD, 1993, J BIOMED MATER RES, V27, P837, DOI 10.1002/jbm.820270702
   Satcher RL, 1996, BIOPHYS J, V71, P109, DOI 10.1016/S0006-3495(96)79206-8
   TIMOSHENKO SP, 1970, THEORY ELASTICITY
   TIRRELL JG, 1994, CHEM ENG NEWS, V72, P40, DOI 10.1021/cen-v072n051.p040
   ZHANG S, 1993, P NATL ACAD SCI USA, V90, P3332
   ZHANG SG, 1994, BIOPOLYMERS, V34, P663, DOI 10.1002/bip.360340508
   ZHANG SG, 1995, BIOMATERIALS, V16, P1385, DOI 10.1016/0142-9612(95)96874-Y
NR 18
TC 72
Z9 74
U1 0
U2 12
PU VSP BV
PI ZEIST
PA PO BOX 346, 3700 AH ZEIST, NETHERLANDS
SN 0920-5063
J9 J BIOMAT SCI-POLYM E
JI J. Biomater. Sci.-Polym. Ed.
PY 1998
VL 9
IS 3
BP 297
EP 312
DI 10.1163/156856298X00668
PG 16
WC Engineering, Biomedical; Materials Science, Biomaterials; Polymer
   Science
SC Engineering; Materials Science; Polymer Science
GA ZF076
UT WOS:000072860200007
PM 9556763
DA 2018-10-19
ER

PT J
AU Dalton, BA
   McFarland, CD
   Gengenbach, TR
   Griesser, HJ
   Steele, JG
AF Dalton, BA
   McFarland, CD
   Gengenbach, TR
   Griesser, HJ
   Steele, JG
TI Polymer surface chemistry and bone cell migration
SO JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION
LA English
DT Article
DE bone cell; surface chemistry; cell migration; vitronectin; XPS; protein
   adsorption
ID TISSUE-CULTURE POLYSTYRENE; HUMAN OSTEOBLASTS; IN-VITRO; UNMODIFIED
   POLYSTYRENE; BIOMATERIAL SURFACES; CHEMOTACTIC RESPONSE; MORPHOLOGIC
   ASPECTS; PROTEIN ADSORPTION; ATTACHMENT; ADHESION
AB Implant devices for orthopaedic applications may be improved if the surface of the biomaterial provides for osteointegration. To understand the effect of hydrophilicity on colonisation by human bone derived (HBD) cells, we compared untreated polystyrene (PS) and a sulfuric acid-treated PS surface for mechanisms of cell migration. The chemical composition of the acid-treated PS surface was analysed by monochromatic X-ray photoelectron spectroscopy;nd found to contain various oxidatively produced groups and a minor amount of sulfonate groups. It was found that migration of HBD cells on both PS and acid-treated PS surfaces was dependent on the presence of vitronectin (Vn) and was higher on the hydrophilic acid-treated surface. Minimal migration of HBD cells occurred on either surface in the absence of Vn, even when fibronectin was present in the culture medium. Using radiolabelled protein, it was shown that Vn adsorption onto the acid-treated surface was two to three fold greater than that on the hydrophobic PS. When HBD cells were seeded onto a patterned surface in a medium containing Vn, the cells preferentially colonised the hydrophilic region and few, if any, cells traversed the haptotactic boundary from the hydrophilic to the hydrophobic side.
   Thus the enhanced HBD cell migration seen on the acid-treated PS compared viith the untreated PS surface and the haptotactic boundary phenomenon, relate to Vn adsorption.
C1 CSIRO, Mol Sci, Sydney Labs, N Ryde, NSW 2113, Australia.
   CSIRO, Mol Sci, Ian Wark Labs, Clayton, Vic 3169, Australia.
RP Steele, JG (reprint author), CSIRO, Mol Sci, Sydney Labs, POB 184, N Ryde, NSW 2113, Australia.
RI Griesser, Hans/E-5628-2011
OI Griesser, Hans/0000-0003-1072-7863
CR Beamson G., 1992, SCI ESCA300 DATABASE
   BELLAIRS R, 1982, CELL BEHAV, P109
   BRASH JL, 1995, PROTEINS INTERFACES, V2, P1
   BRIGHTON CT, 1992, J ORTHOPAED RES, V10, P766, DOI 10.1002/jor.1100100604
   CALLEN BW, 1993, J BIOMED MATER RES, V27, P851, DOI 10.1002/jbm.820270703
   CARTER SB, 1967, NATURE, V213, P256, DOI 10.1038/213256a0
   CHESMEL KD, 1995, J BIOMED MATER RES, V29, P1089, DOI 10.1002/jbm.820290909
   CHESMEL KD, 1995, J BIOMED MATER RES, V29, P1101, DOI 10.1002/jbm.820290910
   CURTIS ASG, 1983, J CELL BIOL, V97, P1500, DOI 10.1083/jcb.97.5.1500
   DAI L, 1997, IN PRESS SURF INTERF
   Dalton BA, 1996, BIOTECHNIQUES, V21, P298
   Davies JE, 1996, ANAT REC, V245, P426
   FISCHER EG, 1990, J IMMUNOL METHODS, V128, P235, DOI 10.1016/0022-1759(90)90215-H
   GRINNELL F, 1981, J BIOMED MATER RES, V15, P363, DOI 10.1002/jbm.820150308
   GRINNELL F, 1983, J CELL PHYSIOL, V116, P289, DOI 10.1002/jcp.1041160305
   GRZESIK WJ, 1994, J BONE MINER RES, V9, P487, DOI 10.1002/jbmr.5650090408
   HAVELIN, 1995, HIP AETHEOPLASTY NOR
   HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003
   Healy KE, 1996, BIOMATERIALS, V17, P195, DOI 10.1016/0142-9612(96)85764-4
   HORBETT TA, 1988, J BIOMED MATER RES, V22, P763, DOI 10.1002/jbm.820220903
   HOWLETT CR, 1994, J MATER SCI-MATER M, V5, P715, DOI 10.1007/BF00120363
   HOWLETT CR, 1994, BIOMATERIALS, V15, P213, DOI 10.1016/0142-9612(94)90070-1
   HUNTER A, 1995, BIOMATERIALS, V16, P287, DOI 10.1016/0142-9612(95)93256-D
   KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0
   LAZAR M, 1992, ADV POLYM SCI, V102, P189
   LIND M, 1995, APMIS, V103, P140, DOI 10.1111/j.1699-0463.1995.tb01089.x
   Lind M, 1996, BONE, V18, P53, DOI 10.1016/8756-3282(95)00423-8
   LIND M, 1995, CYTOKINE, V7, P78, DOI 10.1006/cyto.1995.1010
   Listgarten MA, 1996, ANAT RECORD, V245, P410
   LYDON MJ, 1985, CELL BIOL INT REP, V9, P911, DOI 10.1016/S0309-1651(85)90112-2
   MALIK MA, 1992, BIOMATERIALS, V13, P123, DOI 10.1016/0142-9612(92)90008-C
   MAROUDAS NG, 1975, J THEOR BIOL, V49, P417, DOI 10.1016/0022-5193(75)90182-4
   MCFARLAND CD, 1997, UNPUB
   PADLEY RA, 1991, J PERIODONTOL, V62, P15, DOI 10.1902/jop.1991.62.1.15
   PFEILSCHIFTER J, 1990, J BONE MINER RES, V5, P825
   PIZZOFERRATO A, 1991, Clinical Materials, V7, P51, DOI 10.1016/0267-6605(91)90057-M
   PULEO DA, 1992, J BIOMED MATER RES, V26, P291, DOI 10.1002/jbm.820260303
   PULEO DA, 1991, J BIOMED MATER RES, V25, P71
   REDEPENNING J, 1993, ANAL CHEM, V65, P3378, DOI 10.1021/ac00071a008
   ROBERTS RF, 1980, SURF INERF ANAL, V2
   SCHAFFER MC, 1984, J LAB CLIN MED, V103, P738
   SHELTON RM, 1988, BIOMATERIALS, V9, P24, DOI 10.1016/0142-9612(88)90065-8
   STAHLI C, 1983, METHOD ENZYMOL, V92, P242
   STEELE JG, 1993, J BIOMAT SCI-POLYM E, V5, P245
   STEELE JG, 1992, J BIOMED MATER RES, V26, P861, DOI 10.1002/jbm.820260704
   STEELE JG, 1993, J BIOMED MATER RES, V27, P927, DOI 10.1002/jbm.820270712
   STEELE JG, 1994, PROTEINS INTERFACES, V2, P602
   THOMAS CH, 1997, IN PRESS J BIOMED MA
   UNDERWOOD PA, 1991, J IMMUNOL METHODS, V142, P83, DOI 10.1016/0022-1759(91)90295-Q
   UNDERWOOD PA, 1989, J CELL SCI, V93, P641
   Zreiqat H., 1996, Cells and Materials, V6, P45
   ZUC A, 1986, ANAT REC, V214, P96
NR 52
TC 31
Z9 33
U1 0
U2 6
PU VSP BV
PI ZEIST
PA PO BOX 346, 3700 AH ZEIST, NETHERLANDS
SN 0920-5063
J9 J BIOMAT SCI-POLYM E
JI J. Biomater. Sci.-Polym. Ed.
PY 1998
VL 9
IS 8
BP 781
EP 799
DI 10.1163/156856298X00154
PG 19
WC Engineering, Biomedical; Materials Science, Biomaterials; Polymer
   Science
SC Engineering; Materials Science; Polymer Science
GA 111TG
UT WOS:000075453200002
PM 9724894
DA 2018-10-19
ER

PT J
AU Rad, AY
   Ayhan, H
   Kisa, U
   Piskin, E
AF Rad, AY
   Ayhan, H
   Kisa, U
   Piskin, E
TI Adhesion of different bacterial strains to low-temperature plasma
   treated biomedical PVC catheter surfaces
SO JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION
LA English
DT Article
DE contact angles; adherence to p-xylene; zeta potentials; surface charges
   of bacteria; PVC catheter; low temperature plasma treatment; bacterial
   attachment
ID COAGULASE-NEGATIVE STAPHYLOCOCCI; INTRAVASCULAR CATHETERS; ADHERENCE;
   HYDROPHOBICITY; INVITRO; EPIDERMIDIS; BIOMATERIAL; PREVENTION;
   INFECTION; ENERGY
AB In this study, firstly five different bacteria (i.e. Coagulas positive and negative staphylocaccus, Streptococcus pyogene, Escherichia coli, Pseudomonas aeruginosae) with their different strains were isolated and used. The contact angle, surface free energy, p-xylene adhesion, and zeta potential of these bacteria were in the range of 43-69 deg, 45.4-61.8 erg cm(-2), 2.3-80.3%, and from -650.2 to +17.5 mV, respectively. Most of the bacteria were negatively charged. Attachment of these bacteria to PVC catheter and its DMAEMA- and AAc-plasma treated forms were investigated. Bacterial attachment to the hydrophobic PVC catheter was high. Both plasma treatments caused significant drops in bacterial attachment in most of the cases. The effects of AAc-plasma treatment was more significant.
C1 Hacettepe Univ, Dept Chem Engn, Bioengn Div, TR-06532 Ankara, Turkey.
   TUBITAK, Ctr Excellence Polymer Biomat, Ankara, Turkey.
   Gulhane Mil Med Acad, GATA, Biochem & Clin Biochem Div, Ankara, Turkey.
RP Piskin, E (reprint author), Hacettepe Univ, Dept Chem Engn, Bioengn Div, TR-06532 Ankara, Turkey.
RI KISA, UCLER/V-5443-2017
OI KISA, UCLER/0000-0002-8131-6810
CR ABSOLOM DR, 1983, APPL ENVIRON MICROB, V46, P90
   ANDRADE JD, 1979, J POLYM SCI POL SYM, P313
   ASHKENAZI S, 1984, PEDIATR RES, V18, P1361, DOI 10.1203/00006450-198412000-00029
   BAILEY J, 1990, DIAGNOSTIC MICROBIOL, pA37
   CHU CC, 1984, AM J SURG, V147, P197, DOI 10.1016/0002-9610(84)90088-6
   FATTOM A, 1984, APPL ENVIRON MICROB, V47, P135
   FRANSON TR, 1986, J CLIN MICROBIOL, V24, P559
   GOLOMB G, 1991, J BIOMED MATER RES, V25, P937, DOI 10.1002/jbm.820250803
   GORDON AS, 1984, APPL ENVIRON MICROB, V47, P495
   HARKES G, 1991, BIOMATERIALS, V12, P853, DOI 10.1016/0142-9612(91)90074-K
   HOGT AH, 1986, J BIOMED MATER RES, V20, P533, DOI 10.1002/jbm.820200409
   HOGT AH, 1985, J GEN MICROBIOL, V131, P2485
   HOGT H, 1986, INFECT IMMUN, P294
   JAMES AM, 1979, SURF COLLOID SCI, V11, P174
   JANSEN B, 1990, ADV BIOMAT, V9, P117
   JOHNSON JR, 1990, J INFECT DIS, V162, P1145, DOI 10.1093/infdis/162.5.1145
   LOPEZLOPEZ G, 1991, J MED MICROBIOL, V34, P349, DOI 10.1099/00222615-34-6-349
   MINAGI S, 1985, INFECT IMMUN, V47, P11
   MINAGI S, 1986, J GEN MICROBIOL, V132, P1111
   MOZES N, 1987, J MICROBIOL METH, V6, P99, DOI 10.1016/0167-7012(87)90058-3
   NEUMANN AW, 1974, J COLLOID INTERF SCI, V49, P291, DOI 10.1016/0021-9797(74)90365-8
   PASCUAL A, 1986, EUR J CLIN MICROBIOL, V5, P518, DOI 10.1007/BF02017694
   Perry R. H., 1985, PERRYS CHEM ENG HDB
   RAD AY, 1997, THESIS U HACETTEPE A
   ROSENBERG M, 1980, FEMS MICROBIOL LETT, V9, P29, DOI 10.1111/j.1574-6968.1980.tb05599.x
   SAMUEL RF, 1990, CAN J MICROBIOL, V37, P445
   SENNETT P, 1965, Patent No. 3208919
   SHETH NK, 1983, J SURG RES, V34, P213, DOI 10.1016/0022-4804(83)90062-8
   SINGHAL JP, 1991, BIOMAT ARTIF CELL IM, V19, P631, DOI 10.3109/10731199109117841
   SUGARMAN B, 1982, UROL RES, V10, P37
   VANDERMEI HC, 1987, J MICROBIOL METH, V6, P277, DOI 10.1016/0167-7012(87)90065-0
   VANDERMEI HC, 1988, J BACTERIOL, V170, P246
   VANETTA LL, 1982, J INFECT DIS, V146, P423, DOI 10.1093/infdis/146.3.423
   VANLOOSDERCHT MCM, 1987, APPL ENVIRON MICROB, V55, P1898
   VANLOOSDRECHT MCM, 1987, APPL ENVIRON MICROB, V53, P1898
   Veenstra GJC, 1996, J BACTERIOL, V178, P537, DOI 10.1128/jb.178.2.537-541.1996
   WADSTROM T, 1987, ZBL BAKT-INT J MED M, V266, P191
   WEERKAMP AH, 1988, J DENT RES, V67, P1483, DOI 10.1177/00220345880670120801
NR 38
TC 17
Z9 17
U1 1
U2 11
PU VSP BV
PI ZEIST
PA PO BOX 346, 3700 AH ZEIST, NETHERLANDS
SN 0920-5063
J9 J BIOMAT SCI-POLYM E
JI J. Biomater. Sci.-Polym. Ed.
PY 1998
VL 9
IS 9
BP 915
EP 929
PG 15
WC Engineering, Biomedical; Materials Science, Biomaterials; Polymer
   Science
SC Engineering; Materials Science; Polymer Science
GA 114EA
UT WOS:000075595100003
DA 2018-10-19
ER

PT J
AU Culp, LA
   Sukenik, CN
AF Culp, LA
   Sukenik, CN
TI Cell type-specific modulation of fibronectin adhesion functions on
   chemically-derivatized self-assembled monolayers
SO JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION
LA English
DT Article
DE adhesion; chemical derivatization; differentiation; fibronectin
   self-assembled monolayer
ID BINDING DOMAIN; III REPEATS; INTEGRINS; MOLECULES; FIBROBLASTS;
   ADSORPTION; FRAGMENTS; SUBSTRATA; SEQUENCE; SURFACES
AB Cell type-specific responses (microfilament stress fibers for fibroblasts or neurites for neuroblastoma cells) were evaluated in culture on inert and chemically-derivatized silane substrata adsorbed with fibronectin (Fn). Substrata of self-assembled monolayers contain a 14-17 carbon aliphatic chain terminating with different chemical endgroups - [CH3], [C=C], [Br], [CN], [Diol], [COOH], [NH2], [SH], [SCOCH3], or [SO3H]. Fn adsorbed effectively to all derivatized surfaces. 3T3 fibroblasts or neuroblastoma cells attached equivalently to all surfaces preadsorbed with Fn, indicating availability of receptor binding sites on Fns. However, transmembrane signaling from Fn(adsorbed) : receptor(cell suface) complexes yielded a range of abilities for generating F-actin stress fibers in fibroblasts or neurites in neuroblastoma cells. Efficiency for stress fiber formation was very different from that of neurite extension. The same chemical endgroups on glass, titanium, or germanium yielded the same patterns of cellular physiological responses, indicating that inert substrata do not act at a distance and that only chemical endgroups regulate Fn signaling functions. When adhesion-inert albumin is co-adsorbed with Fn, efficiency of neurite extension is improved on some surfaces or diminished on others. These results indicate that the conformation of Fn(adsorbed) changes in specific ways on derivatized substrata. Change in Fn conformation was confirmed by FTIR/ATR spectroscopy experiments of Fn(adsorbed) Overall, these studies indicate changes in Fn conformations on chemically-derivatized self-assembled monolayers leading to up- or downregulation of cell type-specific physiological responses from receptors via their signaling pathways. They also offer predictability for regulating responses of specific cell types when these cells interact with biomaterial implants in vivo.
C1 Case Western Reserve Univ, Sch Med, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA.
   Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA.
RP Culp, LA (reprint author), Case Western Reserve Univ, Sch Med, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA.
FU NINDS NIH HHS [NS171139]; NCI NIH HHS [CA27755]
CR ALBELDA SM, 1993, LAB INVEST, V68, P4
   AOTA S, 1991, J BIOL CHEM, V266, P15938
   BALACHANDER N, 1990, LANGMUIR, V6, P1621, DOI 10.1021/la00101a001
   BALACHANDER N, 1988, TETRAHEDRON LETT, V29, P5593, DOI 10.1016/S0040-4039(00)80820-5
   BARKALOW FJB, 1991, J BIOL CHEM, V266, P7812
   BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143
   Chen WS, 1996, EXP CELL RES, V223, P9, DOI 10.1006/excr.1996.0053
   CHENG SS, 1994, J COLLOID INTERF SCI, V162, P135, DOI 10.1006/jcis.1994.1018
   CULP LA, 1991, ASPECTS BIOCH MOL BI, P99
   Culp Lloyd A., 1994, Journal of Tissue Culture Methods, V16, P161, DOI 10.1007/BF01540644
   FLICKINGER KS, 1994, EXP CELL RES, V213, P156, DOI 10.1006/excr.1994.1185
   GRINNELL F, 1981, J BIOMED MATER RES, V15, P363, DOI 10.1002/jbm.820150308
   GRINNELL F, 1987, ANN NY ACAD SCI, V516, P280, DOI 10.1111/j.1749-6632.1987.tb33048.x
   HALL MD, 1988, EXP CELL RES, V179, P115, DOI 10.1016/0014-4827(88)90353-9
   HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S
   Hynes RO, 1990, FIBRONECTINS
   JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577
   LARK MW, 1986, DIS CONNECTIVE TISSU, P185
   LEWANDOWSKA K, 1992, J BIOMED MATER RES, V26, P1343, DOI 10.1002/jbm.820261007
   LEWANDOWSKA K, 1989, J CELL PHYSIOL, V141, P334, DOI 10.1002/jcp.1041410215
   LITINOVICH SV, 1995, J MOL BIOL, V248, P611
   MCDONALD JA, 1988, ANNU REV CELL BIOL, V4, P183, DOI 10.1146/annurev.cellbio.4.1.183
   MOULD AP, 1991, EMBO J, V10, P4089, DOI 10.1002/j.1460-2075.1991.tb04985.x
   MUGNAI G, 1988, J CELL BIOL, V106, P931, DOI 10.1083/jcb.106.3.931
   OCONNOR KJ, UNPUB
   PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0
   Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cb.11.110195.003001
   SCHWARTZ MA, 1993, CANCER RES, V53, P1503
   SUKENIK CN, 1990, J BIOMED MATER RES, V24, P1307, DOI 10.1002/jbm.820241004
   XIA P, 1994, EXP CELL RES, V213, P253, DOI 10.1006/excr.1994.1197
   YAMADA KM, 1987, J CELL PHYSIOL, V130, P21, DOI 10.1002/jcp.1041300105
   ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P
NR 32
TC 29
Z9 29
U1 0
U2 5
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0920-5063
EI 1568-5624
J9 J BIOMAT SCI-POLYM E
JI J. Biomater. Sci.-Polym. Ed.
PY 1998
VL 9
IS 11
BP 1161
EP 1176
DI 10.1163/156856298X00703
PG 16
WC Engineering, Biomedical; Materials Science, Biomaterials; Polymer
   Science
SC Engineering; Materials Science; Polymer Science
GA 142LM
UT WOS:000077202000004
PM 9860178
DA 2018-10-19
ER

PT J
AU McFarland, CD
   Jenkins, M
   Griesser, HJ
   Chatelier, RC
   Steele, JG
   Underwood, PA
AF McFarland, CD
   Jenkins, M
   Griesser, HJ
   Chatelier, RC
   Steele, JG
   Underwood, PA
TI Albumin-binding surfaces: synthesis and characterization
SO JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION
LA English
DT Article
DE haemocompatibility; human serum albumin radiofrequency glow discharge;
   monoclonal antibody; protein adsorption; immobilization; covalent
   attachment
ID AVIDIN-BIOTIN TECHNOLOGY; DISCHARGE TREATED POLYMERS;
   MONOCLONAL-ANTIBODIES; ENDOTHELIAL-CELLS; GLOW-DISCHARGE; COVALENT
   IMMOBILIZATION; SECONDARY STRUCTURE; PROTEIN ADSORPTION;
   MEMBRANE-ANTIGENS; PLASMA POLYMERS
AB The nature of the proteinaceous film deposited on a biomaterial surface following implantation is a key determinant of the subsequent biological response. To achieve selectivity in the formation of this film, monoclonal antibodies have been coupled to a range of solid substrates using avidin-biotin technology. Antibody clones varied in their antigen-binding activity following insertion of biotin groups into lysine residues. Biotinylated antibodies coupled to solid substrates via an immobilized avidin bridge retained their biological activity. During immobilization of avidin a significant proportion of the protein molecules were passively adsorbed rather than covalently attached to the surface. This loosely bound material could be removed by stringent elution procedures which resulted in a surface density of 5.4 pmol avidin cm(-2). Although these conditions would be harsh enough to denature monoclonal antibodies, they did not destroy the biotin-binding activity of the residual surface-coupled avidin, enabling the subsequent immobilization of biotinylated antibodies. The two-step immobilization technique allowed the use of gentle protein modification procedures, reduced the risk of surface-induced denaturation and removed loosely bound material from the surface. The versatility of the technique encourages its application to a wide range of immobilization systems where retention of biological activity is a key requirement.
C1 CSIRO, Cooperat Res Ctr Cardiac Technol, Sydney Lab, N Ryde, NSW 2113, Australia.
   CSIRO, Cooperat Res Ctr Cardiac Technol, Clayton Lab, Clayton, Vic 3169, Australia.
RP McFarland, CD (reprint author), CSIRO, Cooperat Res Ctr Cardiac Technol, Sydney Lab, POB 184, N Ryde, NSW 2113, Australia.
RI Griesser, Hans/E-5628-2011
OI Griesser, Hans/0000-0003-1072-7863
CR ACHTNICH UR, 1992, BIOSENS BIOELECTRON, V7, P279, DOI 10.1016/0956-5663(92)87006-B
   ANDRADE JD, 1987, ANN NY ACAD SCI, V516, P158, DOI 10.1111/j.1749-6632.1987.tb33038.x
   Aronsson BO, 1997, J BIOMED MATER RES, V35, P49
   BATICH CD, 1988, APPL SURF SCI, V32, P57, DOI 10.1016/0169-4332(88)90073-6
   BAYER EA, 1990, METHOD ENZYMOL, V184, P138
   BAYER EA, 1990, J CHROMATOGR, V510, P3, DOI 10.1016/S0021-9673(01)93733-1
   CARTER DC, 1994, ADV PROTEIN CHEM, V45, P153
   Chatelier RC, 1995, J BIOMAT SCI-POLYM E, V7, P601, DOI 10.1163/156856295X00517
   COOK BC, 1992, J COLLOID INTERF SCI, V153, P1, DOI 10.1016/0021-9797(92)90292-T
   DEKKER A, 1991, THROMB HAEMOSTASIS, V66, P715
   DeQueiroz AAA, 1997, J BIOMAT SCI-POLYM E, V8, P667, DOI 10.1163/156856297X00489
   DIMITRIADIS GJ, 1979, ANAL BIOCHEM, V98, P445, DOI 10.1016/0003-2697(79)90165-9
   FISCHER EG, 1990, J IMMUNOL METHODS, V128, P235, DOI 10.1016/0022-1759(90)90215-H
   GENGENBACH TR, 1994, J POLYM SCI POL CHEM, V32, P1399, DOI 10.1002/pola.1994.080320801
   GOMBOTZ WR, 1987, CRIT REV BIOCOMPAT, V4, P1
   GOMBOTZ WR, 1991, J BIOMED MATER RES, V25, P1547, DOI 10.1002/jbm.820251211
   GREEN NM, 1990, METHOD ENZYMOL, V184, P51
   GRETCH DR, 1987, ANAL BIOCHEM, V163, P270, DOI 10.1016/0003-2697(87)90123-0
   GRIESSER HJ, 1994, J BIOMAT SCI-POLYM E, V5, P531, DOI 10.1163/156856294X00194
   GRIESSER HJ, 1989, VACUUM, V39, P485, DOI 10.1016/0042-207X(89)90272-8
   HASHIDA S, 1984, Journal of Applied Biochemistry, V6, P56
   HOFFMAN AS, 1987, ANN NY ACAD SCI, V516, P96, DOI 10.1111/j.1749-6632.1987.tb33033.x
   HONZATKO RB, 1982, BIOCHEMISTRY-US, V21, P6201, DOI 10.1021/bi00267a027
   Kang IK, 1996, BIOMATERIALS, V17, P841, DOI 10.1016/0142-9612(96)81422-0
   KIAEI D, 1992, J BIOMAT SCI-POLYM E, V4, P35
   LAWLER JW, 1978, J BIOL CHEM, V253, P8609
   LIU SQ, 1993, J BIOMED MATER RES, V27, P909, DOI 10.1002/jbm.820270710
   LOPEZ GP, 1990, J APPL POLYM SCI APP, V46, P493
   Mohri H, 1996, J INVEST MED, V44, P429
   MULLERLEIRHEIM WGK, 1989, Patent No. 4828563
   MUZYKANTOV VR, 1995, ANAL BIOCHEM, V226, P279, DOI 10.1006/abio.1995.1226
   Nakashima Y, 1997, J BIOMED MATER RES, V35, P287
   Norde W., 1995, PROTEINS INTERFACES, P26
   PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9
   PADLAN EA, 1995, FASEB J          JAN, V133
   PANCHALINGAM V, 1993, J BIOMAT SCI-POLYM E, V5, P131
   PLANT AL, 1991, APPL BIOCHEM BIOTECH, V30, P83
   PUGLIESE L, 1993, J MOL BIOL, V231, P698, DOI 10.1006/jmbi.1993.1321
   PULEO DA, 1995, J BIOMED MATER RES, V29, P951, DOI 10.1002/jbm.820290806
   SAFRANJ A, 1991, BIOTECHNOL PROGR, V7, P173, DOI 10.1021/bp00008a012
   SHARMA CP, 1987, J BIOMATER APPL, V1, P353
   STAHLI C, 1983, METHOD ENZYMOL, V92, P242
   STEELE JG, 1994, J BIOMAT SCI-POLYM E, V6, P511, DOI 10.1163/156856294X00473
   SUTER M, 1986, IMMUNOL LETT, V13, P313, DOI 10.1016/0165-2478(86)90064-7
   Swamy MJ, 1996, BIOPHYS J, V71, P840, DOI 10.1016/S0006-3495(96)79285-8
   Tang YW, 1997, BIOMATERIALS, V18, P37, DOI 10.1016/S0142-9612(96)00101-9
   TRESCA JP, 1995, ANN BIOL CLIN-PARIS, V53, P227
   UNDERWOOD PA, 1988, J IMMUNOL METHODS, V107, P119
   UNDERWOOD PA, 1983, J IMMUNOL METHODS, V60, P33, DOI 10.1016/0022-1759(83)90332-0
   UNDERWOOD PA, 1993, J IMMUNOL METHODS, V164, P119, DOI 10.1016/0022-1759(93)90282-C
   UNDERWOOD PA, 1985, J IMMUNOL METHODS, V85, P309, DOI 10.1016/0022-1759(85)90140-1
   UNDERWOOD PA, 1982, J GEN VIROL, V62, P153, DOI 10.1099/0022-1317-62-1-153
   UPDYKE TV, 1984, J IMMUNOL METHODS, V73, P83, DOI 10.1016/0022-1759(84)90034-6
   VARGO TG, 1995, J BIOMED MATER RES, V29, P767, DOI 10.1002/jbm.820290613
   Wagner W C, 1992, J Oral Implantol, V18, P231
   WILCHEK M, 1990, METHOD ENZYMOL, V184, P5
   WILCHEK M, 1990, METHOD ENZYMOL, V184, P14
   WILCHEK M, 1990, METHOD ENZYMOL, V184, P467
   WILCHEK M, 1987, METHOD ENZYMOL, V138, P429
   WILLIAMS RL, 1995, J BIOMED MATER RES, V29, P1545, DOI 10.1002/jbm.820291211
NR 60
TC 10
Z9 10
U1 0
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0920-5063
EI 1568-5624
J9 J BIOMAT SCI-POLYM E
JI J. Biomater. Sci.-Polym. Ed.
PY 1998
VL 9
IS 11
BP 1207
EP 1225
DI 10.1163/156856298X00730
PG 19
WC Engineering, Biomedical; Materials Science, Biomaterials; Polymer
   Science
SC Engineering; Materials Science; Polymer Science
GA 142LM
UT WOS:000077202000007
PM 9860181
DA 2018-10-19
ER

PT J
AU McFarland, CD
   De Filippis, C
   Jenkins, M
   Tunstell, A
   Rhodes, NP
   Williams, DF
   Steele, JG
AF McFarland, CD
   De Filippis, C
   Jenkins, M
   Tunstell, A
   Rhodes, NP
   Williams, DF
   Steele, JG
TI Albumin-binding surfaces: In vitro activity
SO JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION
LA English
DT Article
DE haemocompatibility; human serum albumin; platelets; fibrinogen;
   passivation; protein adsorption; monoclonal antibody; immobilization
ID PLATELET-ADHESION; MONOCLONAL-ANTIBODIES; SERUM-ALBUMIN; HUMAN-BLOOD;
   SHEAR RATE; PROTEIN ADSORPTION; CELL-ADHESION; FIBRINOGEN; BIOMATERIALS;
   SUBENDOTHELIUM
AB Immobilized monoclonal antibodies (Mabs) have been used to attract specific molecules to a solid surface from complex mixtures such as blood, plasma or serum, thereby directing the response to the modified substrate, a key goal in rational biomaterial design. The nature of the Mab dictated the nature of the response: anti-albumin antibodies were used to prevent cell and platelet adhesion in vitro, whilst anti-fibronectin Mabs promoted attachment. Patterned surfaces could be formed, bearing Mabs that generated adhesive and non-adhesive regions. Fibrinogen adsorption from plasma showed a Vroman peak on unmodified control polymer, which was reduced by 64% in the presence of surface-bound anti-albumin Mab. Immobilization of a control Mab reduced fibrinogen adsorption only slightly, implying an albumin-mediated effect. In static tests, platelet adhesion from human platelet rich plasma was significantly reduced by the immobilization of anti-HSA Mab when compared to the untreated FEP surface (p < 0.0001). This effect was also seen with citrated blood flowing through Mab-treated polyurethane tubing at a shear rate of 132 s(-1) (p = 0.034). Since platelets and proteins (as blood, plasma or serum) were introduced to the surface simultaneously, the generation of a defined protein film must have been sufficiently rapid as to shape the platelet or cell response.
C1 CSIRO, Cooperat Res Ctr Cardiac Technol, Sydney Lab, N Ryde, NSW 2113, Australia.
   Univ New S Wales, Grad Sch Biomed Engn, Cooperat Res Ctr Cardiac Technol, Sydney, NSW 2052, Australia.
   Univ Liverpool, Dept Clin Engn, Liverpool L69 3BX, Merseyside, England.
RP McFarland, CD (reprint author), CSIRO, Cooperat Res Ctr Cardiac Technol, Sydney Lab, POB 184, N Ryde, NSW 2113, Australia.
CR AMIJI M, 1993, J BIOMAT SCI-POLYM E, V4, P217, DOI 10.1163/156856293X00537
   ANDERSON J M, 1985, Critical Reviews in Biocompatibility, V1, P111
   ANDRADE JD, 1987, ANN NY ACAD SCI, V516, P158, DOI 10.1111/j.1749-6632.1987.tb33038.x
   BALE MD, 1989, BLOOD, V74, P2698
   Baumgartner JN, 1996, ASAIO J, V42, pM476, DOI 10.1097/00002480-199609000-00033
   BLOCKMANS D, 1995, BLOOD REV, V9, P143, DOI 10.1016/0268-960X(95)90020-9
   Blomback B, 1996, THROMB RES, V83, P1, DOI 10.1016/0049-3848(96)00111-9
   BRASH JL, 1984, THROMB HAEMOSTASIS, V51, P326
   BUTLER JE, 1992, J IMMUNOL METHODS, V150, P77, DOI 10.1016/0022-1759(92)90066-3
   CARTER DC, 1994, ADV PROTEIN CHEM, V45, P153
   CHINN JA, 1991, THROMB HAEMOSTASIS, V65, P608
   Compagnini A, 1996, J CHROMATOGR A, V736, P115, DOI 10.1016/0021-9673(95)01362-8
   COURTNEY JM, 1994, BIOMATERIALS, V15, P737, DOI 10.1016/0142-9612(94)90026-4
   EDWARDS PAW, 1981, BIOCHEM J, V200, P1
   ENGBERS GHM, 1987, J BIOMED MATER RES, V21, P613, DOI 10.1002/jbm.820210507
   FISCHER EG, 1990, J IMMUNOL METHODS, V128, P235, DOI 10.1016/0022-1759(90)90215-H
   GOODMAN SL, 1993, J BIOMED MATER RES, V27, P683, DOI 10.1002/jbm.820270516
   GROTH T, 1994, J BIOMAT SCI-POLYM E, V6, P497, DOI 10.1163/156856294X00464
   HOFFMAN AS, 1987, ANN NY ACAD SCI, V516, P96, DOI 10.1111/j.1749-6632.1987.tb33033.x
   HORBETT TA, 1994, COLLOID SURFACE B, V2, P225, DOI 10.1016/0927-7765(94)80037-5
   HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S
   KEOGH JR, 1994, J LAB CLIN MED, V124, P537
   KIAEI D, 1992, J BIOMAT SCI-POLYM E, V4, P35
   LANG E, 1994, J IMMUNOL METHODS, V170, P103, DOI 10.1016/0022-1759(94)90250-X
   LEONARD EF, 1991, J BIOMAT SCI-POLYM E, V3, P95, DOI 10.1163/156856292X00105
   LOFTUS JC, 1984, J CELL BIOL, V98, P2019, DOI 10.1083/jcb.98.6.2019
   McFarland CD, 1998, J BIOMAT SCI-POLYM E, V9, P1207, DOI 10.1163/156856298X00730
   Mohri H, 1996, J INVEST MED, V44, P429
   PACKHAM MA, 1994, CAN J PHYSIOL PHARM, V72, P278, DOI 10.1139/y94-043
   PADLAN EA, 1995, FASEB J, V9, P133
   POOT A, 1988, BIOMATERIALS, V9, P126, DOI 10.1016/0142-9612(88)90110-X
   RETZINGER GS, 1995, ARTERIOSCL THROM VAS, V15, P786, DOI 10.1161/01.ATV.15.6.786
   Rhodes NP, 1996, BIOMATERIALS, V17, P1995, DOI 10.1016/0142-9612(96)00018-X
   ROALD HE, 1994, BLOOD COAGUL FIBRIN, V5, P355
   SAKARIASSEN KS, 1979, NATURE, V279, P636, DOI 10.1038/279636a0
   SHEPPARD JI, 1994, J BIOMED MATER RES, V28, P1175, DOI 10.1002/jbm.820281008
   SLACK SM, 1995, PROTEINS INTERFACES, V2, P112
   STEELE JG, 1992, J BIOMED MATER RES, V26, P861, DOI 10.1002/jbm.820260704
   TABORELLI M, 1995, J BIOMED MATER RES, V29, P707, DOI 10.1002/jbm.820290606
   TANG LP, 1993, J EXP MED, V178, P2147, DOI 10.1084/jem.178.6.2147
   TURITTO VT, 1979, MICROVASC RES, V17, P38, DOI 10.1016/0026-2862(79)90006-2
   TURITTO VT, 1980, MICROVASC RES, V19, P352, DOI 10.1016/0026-2862(80)90054-0
   UNDERWOOD PA, 1989, J CELL SCI, V93, P641
   UNDERWOOD PA, 1990, J IMMUNOL METHODS, V127, P91, DOI 10.1016/0022-1759(90)90344-U
   WEBSTER DM, 1994, APPL BIOCHEM BIOTECH, V47, P119, DOI 10.1007/BF02787929
   WILLIAMS RL, 1995, J BIOMED MATER RES, V29, P1545, DOI 10.1002/jbm.820291211
   ZUCKER MB, 1989, METHOD ENZYMOL, P117
NR 47
TC 19
Z9 19
U1 0
U2 4
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0920-5063
EI 1568-5624
J9 J BIOMAT SCI-POLYM E
JI J. Biomater. Sci.-Polym. Ed.
PY 1998
VL 9
IS 11
BP 1227
EP 1239
DI 10.1163/156856298X00749
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials; Polymer
   Science
SC Engineering; Materials Science; Polymer Science
GA 142LM
UT WOS:000077202000008
PM 9860182
DA 2018-10-19
ER

PT J
AU Tang, LP
AF Tang, LP
TI Mechanisms of fibrinogen domains: biomaterial interactions
SO JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION
LA English
DT Article
DE fibrinogen; fibrinogen fragments; inflammation; polyethylene
   terephthalate; phagocytes
ID INFLAMMATORY RESPONSES; CONFORMATIONAL-CHANGES; TISSUE REACTION;
   IMPLANTS; POLYURETHANE; SILICONE; CELLS; ADHESION; POLYMERS; SURFACES
AB Spontaneous adsorption of fibrinogen is critical to the pathogenesis of biomaterial-mediated inflammatory responses. However, the mechanism by which adsorbed fibrinogen affects phagocyte responses is still not clear. To investigate the molecular interaction between fibrinogen and biomaterials, fibrinogen fragments (D100 and E50) were generated and used in the present study. The results indicate that biomaterial:D100 interaction is essential to fibrinogen-mediated inflammatory responses, because biomaterials precoated with D100, but not E50, prompt strong inflammatory responses. Furthermore, the results from in vitro studies show that whole molecule fibrinogen and D100 exhibit very similar protein:surface interactions. Specifically: (1) both D100 and fibrinogen have high affinity for biomaterial surfaces; and (2) the retention rates of adsorbed D100 in both in vivo and in vitro environments are as high as that for adsorbed fibrinogen. On the other hand, E50 does bind to biomaterials but with low affinity because, once bound, it is not tightly adherent to the biomaterial surfaces. Taken together, the results suggest that the mechanism of fibrinogen mediated inflammatory responses may involve the following three consecutive events: (1) after contact with blood or tissue fluid, the D domain tends to interact with biomaterial surfaces and is important in the tight binding of fibrinogen to implant surfaces; (2) the biomaterial surface then promotes conformational changes within the D domain, exposing P1 epitope (gamma 190-202, which interacts with phaocyte Mac-1 integrin); and (3) the engagement of Mac-1 integrin with P1 epitope then triggers subsequent phagocyte adherence and reactions.
C1 Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.
RP Tang, LP (reprint author), Baylor Coll Med, Dept Pediat, 1 Baylor Plaza, Houston, TX 77030 USA.
CR ANDERSON JM, 1990, INT J ARTIF ORGANS, V13, P375
   BEHLING CA, 1986, J BIOMED MATER RES, V20, P653, DOI 10.1002/jbm.820200509
   CHAN SC, 1991, CLIN CHEM, V37, P756
   CHRISTENSON L, 1989, J BIOMED MATER RES, V23, P705, DOI 10.1002/jbm.820230704
   CHRISTENSON L, 1991, J BIOMED MATER RES, V25, P1119, DOI 10.1002/jbm.820250906
   DESAI NP, 1992, BIOMATERIALS, V13, P505, DOI 10.1016/0142-9612(92)90101-S
   DOOLITTLE RF, 1967, ARCH BIOCHEM BIOPHYS, V118, P456, DOI 10.1016/0003-9861(67)90374-8
   GORDON M, 1982, J BONE JOINT SURG AM, V64, P574, DOI 10.2106/00004623-198264040-00013
   HENRY CH, 1993, J ORAL MAXIL SURG, V51, P352, DOI 10.1016/S0278-2391(10)80343-X
   HIMMELHOCH SR, 1969, BIOCHEMISTRY-US, V8, P914, DOI 10.1021/bi00831a022
   HUBBARD AL, 1972, J CELL BIOL, V55, P390, DOI 10.1083/jcb.55.2.390
   KOSSOVSKY N, 1991, J BIOMED MATER RES, V25, P1287, DOI 10.1002/jbm.820251009
   Kozinn S C, 1986, J Arthroplasty, V1, P249, DOI 10.1016/S0883-5403(86)80015-8
   LEININGER RI, 1987, ANN NY ACAD SCI, V516, P173, DOI 10.1111/j.1749-6632.1987.tb33039.x
   LENK TJ, 1991, LANGMUIR, V7, P1755, DOI 10.1021/la00056a030
   LINDSAY RM, 1980, T AM SOC ART INT ORG, V26, P603
   LU DR, 1991, J COLLOID INTERF SCI, V144, P271, DOI 10.1016/0021-9797(91)90258-A
   NELSON GD, 1981, PLAST RECONSTR SURG, V68, P969, DOI 10.1097/00006534-198112000-00027
   PICHA GJ, 1990, PLAST RECONSTR SURG, V85, P903, DOI 10.1097/00006534-199006000-00011
   Reiner E., 1989, ENZYMES HYDROLYSING
   Schlager S I, 1980, Methods Enzymol, V70, P252
   SLACK SM, 1989, J COLLOID INTERF SCI, V133, P148, DOI 10.1016/0021-9797(89)90288-9
   SUTHERLAND K, 1993, J CLIN INVEST, V92, P2360, DOI 10.1172/JCI116841
   TANG L, 1998, IN PRESS J BIOMED MA
   TANG LP, 1993, J LAB CLIN MED, V122, P292
   TANG LP, 1993, J EXP MED, V178, P2147, DOI 10.1084/jem.178.6.2147
   Tang LP, 1996, J CLIN INVEST, V97, P1329, DOI 10.1172/JCI118549
   TORRES JL, 1988, ARCH BIOCHEM BIOPHYS, V267, P271, DOI 10.1016/0003-9861(88)90032-X
   TRUMPY IG, 1993, J ORAL MAXIL SURG, V51, P624, DOI 10.1016/S0278-2391(10)80259-9
   UGAROVA TP, 1993, J BIOL CHEM, V268, P21080
   VISTNES LM, 1978, PLAST RECONSTR SURG, V62, P580, DOI 10.1097/00006534-197810000-00015
   VROMAN L, 1977, ANN NY ACAD SCI, V283, P65, DOI 10.1111/j.1749-6632.1977.tb41753.x
   ZHAO Q, 1990, J BIOMED MATER RES, V24, P621, DOI 10.1002/jbm.820240508
   ZHAO Q, 1991, J BIOMED MATER RES, V25, P177, DOI 10.1002/jbm.820250205
NR 34
TC 34
Z9 35
U1 1
U2 15
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0920-5063
EI 1568-5624
J9 J BIOMAT SCI-POLYM E
JI J. Biomater. Sci.-Polym. Ed.
PY 1998
VL 9
IS 12
BP 1257
EP 1266
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials; Polymer
   Science
SC Engineering; Materials Science; Polymer Science
GA 142LN
UT WOS:000077202100002
PM 9860168
DA 2018-10-19
ER

PT J
AU Balasubramanian, V
   Hall, CL
   Shivashankar, S
   Slack, SM
   Turitto, VT
AF Balasubramanian, V
   Hall, CL
   Shivashankar, S
   Slack, SM
   Turitto, VT
TI Vascular cell attachment and procoagulant activity on metal alloys
SO JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION
LA English
DT Article
DE biomaterials; smooth muscle cells; titanium; zirconium; stainless steel
ID TISSUE FACTOR ACTIVATION; SMOOTH-MUSCLE; EXPRESSION; ADHESION;
   PHOSPHATIDYLSERINE; FIBRONECTIN; ADSORPTION; RESTENOSIS; MECHANISM;
   VESICLES
AB The attachment and growth of vascular smooth muscle cells on biomaterials used as components of devices implanted in the vascular space may influence the biocompatibility of such materials. The nature of the materials may affect the attachment and/or the activation of these cells procoagulant responses. Therefore, the main objective of this study was to measure the strength of adhesion of these vascular cells to potential biomaterials (titanium, zirconium alloys, and stainless steel) by exposing them to a range of shear stresses (50-300 dyn cm(-2)) in a parallel plate flow chamber. The procoagulant responses of the cells a ere evaluated by measuring the tissue factor (TF) activity promoted by the different materials under flow conditions. The materials supported distinctly different levels of initial cell adhesion in static culture. However, the fraction of adherent cells did not decline significantly with incrementally increasing shear stress within the range tested. TF expression, as measured by factor Xa (FXa) production, was material-dependent. For example, cells cultured on Ti1313 exhibited more FXa production (13.2 nhl 10(-5) cells) than Ti1313(DH) (8.5 nM 10(-5) cells) or stainless steel (2 nM 10(-5) cells). Thus, our studies indicate that the level of adhesion, strength of attachment and the expression of procoagulant activity of adherent vascular cells depend strongly on the nature of the underlying biomaterial.
C1 Univ Memphis, Dept Biomed Engn, Memphis, TN 38152 USA.
RP Hall, CL (reprint author), Univ Memphis, Dept Biomed Engn, Campus Box 526582, Memphis, TN 38152 USA.
EM clhall@memphis.edu
FU NHLBI NIH HHS [P01 HL 29019]
CR BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005
   BACH R, 1990, P NATL ACAD SCI USA, V87, P6995, DOI 10.1073/pnas.87.18.6995
   Bach RR, 1997, BLOOD, V89, P3270
   Camerer E, 1996, HAEMOSTASIS, V26, P25
   CARSON SD, 1994, BLOOD, V84, P526
   CONNOR J, 1989, P NATL ACAD SCI USA, V86, P3184, DOI 10.1073/pnas.86.9.3184
   DAVID L, 1992, MODERN PATHOL, V5, P384
   Davidson D L, 1993, Seizure, V2, P1, DOI 10.1016/S1059-1311(05)80095-0
   EDWARDS RL, 1979, BLOOD, V54, P359
   GOODWIN TH, 1993, J BUS ECON STAT, V11, P331
   GRINNELL F, 1981, J BIOMED MATER RES, V15, P363, DOI 10.1002/jbm.820150308
   Grinnell F, 1983, BIOCOMPATIBLE POLYM, P674
   HALL CL, 1995, THESIS U MEMPHIS TN
   HORBETT TA, 1988, J BIOMED MATER RES, V22, P383, DOI 10.1002/jbm.820220503
   Kearney M, 1997, CIRCULATION, V95, P1998, DOI 10.1161/01.CIR.95.8.1998
   LE DT, 1994, THROMB HAEMOSTASIS, V72, P848
   MAJACK RA, 1987, VASCULAR SMOOTH MUSC, P117
   MARMUR JD, 1993, J CLIN INVEST, V91, P2253, DOI 10.1172/JCI116452
   Marmur JD, 1996, CIRCULATION, V94, P1226, DOI 10.1161/01.CIR.94.6.1226
   MATTSSON E, 1995, TRENDS CARDIOVAS MED, V5, P200, DOI 10.1016/1050-1738(95)00075-K
   MISHRA AK, 1994, SURFACE MODIFICATION, V7, P453
   Nordrehaug Jan Erik, 1994, P857
   Park J. B., 1995, BIOMEDICAL ENG HDB, P537
   Ratner B. D., 1996, BIOMATERIALS SCI INT
   ROSS R, 1990, ANN NY ACAD SCI, V598, P102, DOI 10.1111/j.1749-6632.1990.tb42282.x
   SUEISHI K, 1995, ANN NY ACAD SCI, V748, P185
   TAUBMAN MB, 1993, AM J CARDIOL, V72, pC55, DOI 10.1016/0002-9149(93)90256-C
   TAUBMAN MB, 1993, J CLIN INVEST, V91, P547, DOI 10.1172/JCI116234
   TRUSKEY GA, 1990, J BIOMED MATER RES, V24, P1333, DOI 10.1002/jbm.820241006
   TRUSKEY GA, 1993, BIOMATERIALS, V14, P243, DOI 10.1016/0142-9612(93)90114-H
   VANKOOTEN TG, 1992, BIOMATERIALS, V13, P897, DOI 10.1016/0142-9612(92)90112-2
   WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839
   Yun YH, 1996, J BIOMED MATER RES, V32, P77, DOI 10.1002/(SICI)1097-4636(199609)32:1<77::AID-JBM9>3.0.CO;2-M
   YUN YH, 1994, S COMPATIBILITY BIOM, P105
NR 34
TC 11
Z9 11
U1 0
U2 0
PU VSP BV
PI ZEIST
PA PO BOX 346, 3700 AH ZEIST, NETHERLANDS
SN 0920-5063
J9 J BIOMAT SCI-POLYM E
JI J. Biomater. Sci.-Polym. Ed.
PY 1998
VL 9
IS 12
BP 1349
EP 1359
DI 10.1163/156856298X00433
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials; Polymer
   Science
SC Engineering; Materials Science; Polymer Science
GA 142LN
UT WOS:000077202100008
PM 9860174
DA 2018-10-19
ER

PT J
AU Razatos, A
   Ong, YL
   Sharma, MM
   Georgiou, G
AF Razatos, A
   Ong, YL
   Sharma, MM
   Georgiou, G
TI Evaluating the interaction of bacteria with biomaterials using atomic
   force microscopy
SO JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION
LA English
DT Article
DE AFM; bacterial adhesion; E-coli; lipopolysaccharide; colanic acid;
   biomaterials
ID ESCHERICHIA-COLI; ADHESION; SURFACE; LIPOPOLYSACCHARIDES;
   HYDROPHOBICITY; MEMBRANE
AB Bacterial infection of biomaterials represents one of the most important reasons for the failure of transdermal or implanted medical devices. The first and least understood step in biomaterial-associated infections is the initial interaction between bacteria and a surface. This initial interaction can be either attractive or repulsive depending on the physiochemical nature of the biological and synthetic surfaces, as well as the properties of the interstitial fluid. We have shown that atomic force microscopy (AFM) can be employed as an exquisitely sensitive and versatile tool for quantifying the interaction between bacteria and surfaces in physiological solutions. The forces of interaction between an AFM cantilever tip and a uniform lawn of bacteria immobilized on glass were determined. By comparing the interactions of cantilever tips with lawns of isogenic E. coli strains carrying genetic lesions that alter their cell surface composition, it was possible to evaluate the effect of macromolecules such as lipopolysaccharide and capsular polysaccharide on the adhesion process. Mutations that result in the synthesis of truncated lipopolysaccharide or in the overproduction of the negatively charged capsular polysaccharide colanic acid render the interaction of the bacteria. with the AFM tip unfavorable due to increased electrostatic repulsion. Furthermore, AFM could be used to evaluate the adhesion of bacteria. onto commercially relevant biomaterials. In one approach, micron-size polystyrene beads were attached to AFM tips which Mere then used to measure forces. Unfortunately, this approach is limited by the meager number of materials manufactured as bead, of a size suitable for AFM measurements. As an alternative approach, AFM cantilever tips were coated with a confluent layer of bacteria and used to probe planar surfaces. In this configuration, AFM could be employed to measure the force of interaction between virtually any bacterium and surface of interest.
C1 Univ Texas, Dept Chem Engn, Austin, TX 78712 USA.
   Univ Texas, Dept Petr Engn, Austin, TX 78712 USA.
   Univ Texas, Inst Mol & Cell Biol, Austin, TX 78712 USA.
RP Georgiou, G (reprint author), Univ Texas, Dept Chem Engn, Austin, TX 78712 USA.
CR Basu S, 1996, J COLLOID INTERF SCI, V181, P443, DOI 10.1006/jcis.1996.0401
   BIGGS S, 1995, LANGMUIR, V11, P156, DOI 10.1021/la00001a028
   BOMAN HG, 1975, J BACTERIOL, V121, P455
   BRYERS JD, 1993, J APPL BACTERIOL, V74, pS98, DOI 10.1111/j.1365-2672.1993.tb04346.x
   BUSSCHER HJ, 1984, APPL ENVIRON MICROB, V48, P980
   BUTT HJ, 1995, BIOELECTROCH BIOENER, V38, P191, DOI 10.1016/0302-4598(95)01800-T
   CHRISTENSEN GD, 1995, METHOD ENZYMOL, V253, P477
   DUCKER WA, 1992, LANGMUIR, V8, P1831, DOI 10.1021/la00043a024
   ELGAVISH A, 1993, INFECT IMMUN, V61, P3304
   ERIKSSON.KG, 1971, J BACTERIOL, V108, P1210
   FLETCHER M, 1985, J COLLOID INTERF SCI, V140, P5
   Freeman A, 1996, BIOTECHNOL BIOENG, V52, P625, DOI 10.1002/(SICI)1097-0290(19961205)52:5<625::AID-BIT10>3.3.CO;2-O
   GOTTESMAN S, 1991, MOL MICROBIOL, V5, P1599, DOI 10.1111/j.1365-2958.1991.tb01906.x
   GOTTESMAN S, 1996, COMMUNICATION
   GRISTINA AG, 1987, SCIENCE, V237, P1588, DOI 10.1126/science.3629258
   HAVEKES L, 1977, J BACTERIOL, V129, P1
   Israelachvili J. N., 1991, INTERMOLECULAR SURFA
   Klein NJ, 1996, J INFECT DIS, V173, P172, DOI 10.1093/infdis/173.1.172
   Klotz SA, 1990, MICROBIAL CELL SURFA, P107
   LUGTENBERG B, 1983, BIOCHIM BIOPHYS ACTA, V737, P51, DOI 10.1016/0304-4157(83)90014-X
   MOZES N, 1987, BIOTECHNOL BIOENG, V30, P439, DOI 10.1002/bit.260300315
   NEIDHADT FC, 1996, ESCHERICHIA COLI SAL
   NIKAIDO H, 1987, ESCHERICHIA COLI SAL, P7
   OFEK I, 1994, BACTERIAL ADHESION C
   RADMACHER M, 1994, LANGMUIR, V10, P3809, DOI 10.1021/la00022a068
   Raetz C. R. H., 1987, ESCHERICHIA COLI SAL, P498
   RAZATOS A, 1998, IN PRESS P NATL ACAD
   ROONEY SA, 1972, J BACTERIOL, V111, P531
   SCHOENENBERGER CA, 1994, BIOPHYS J, V67, P929, DOI 10.1016/S0006-3495(94)80556-9
   SEEBERGH JE, 1995, COLLOID SURFACE A, V100, P139, DOI 10.1016/0927-7757(95)03155-7
   SENDEN TJ, 1995, COLLOID SURFACE A, V94, P29, DOI 10.1016/0927-7757(94)02954-Q
   STICKLER DJ, 1995, CELL MATER, V5, P167
   STOUT V, 1990, J BACTERIOL, V172, P659, DOI 10.1128/jb.172.2.659-669.1990
   VALKONEN KH, 1994, INFECT IMMUN, V62, P3640
   VANLOOSDRECHT MCM, 1987, APPL ENVIRON MICROB, V53, P1893
   VANLOOSDRECHT MCM, 1987, APPL ENVIRON MICROB, V53, P1898
   Yoon RH, 1997, J COLLOID INTERF SCI, V185, P363, DOI 10.1006/jcis.1996.4583
NR 37
TC 54
Z9 55
U1 1
U2 21
PU VSP BV
PI ZEIST
PA PO BOX 346, 3700 AH ZEIST, NETHERLANDS
SN 0920-5063
J9 J BIOMAT SCI-POLYM E
JI J. Biomater. Sci.-Polym. Ed.
PY 1998
VL 9
IS 12
BP 1361
EP 1373
DI 10.1163/156856298X00442
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials; Polymer
   Science
SC Engineering; Materials Science; Polymer Science
GA 142LN
UT WOS:000077202100009
PM 9860175
DA 2018-10-19
ER

PT J
AU Yang, JM
   Jong, YJ
   Hsu, KY
   Chang, CH
AF Yang, JM
   Jong, YJ
   Hsu, KY
   Chang, CH
TI Preparation and characterization of heparin-containing SBS-g-DMAEMA
   copolymer membrane
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE styrene-butadiene-styrene triblock copolymer; dimethyl amino ethyl
   methacrylate; graft copolymer; heparin; biomaterial
ID IMMOBILIZED HEPARIN; PLATELET-ADHESION; G-VP; BIOMATERIAL; SURFACES;
   PLASMA; ADSORPTION; THROMBIN; GLYCOL)
AB The grafting of dimethyl amino ethyl methacrylate (DMAEMA) onto styrene-butadiene-styrene triblock copolymer (SBS) membrane was subsequently conducted by UV-radiation induced graft copolymerization without degassing to obtain the SBS-g-DMAEMA copolymer membrane. The substituted amino groups on the SBS-g-DMAEMA graft copolymer membrane were quaternized with iodomethane, and then the membrane was treated with heparin to prepare the heparin-containing SBS-g-DMAEMA copolymer membrane (SBS-g-DMAEMA-HEP). The graft copolymer membrane (SBS-g-DMAEMA) and the heparin-containing SBS-g-DMAEMA copolymer membrane (SBS-g-DMAEMA-HEP) were characterized by FTIR spectroscopy. The heparin content was determined by toluidine blue heparin assay. Contact angle, water content, and protein adsorption of fibrinogen and albumin experiments were also performed to evaluate the effect of graft amount and heparin content on the biocompatibility of SBS-g-DMAEMA and SBS-g-DMAEMA-HEP graft copolymer membranes. By using Kaelble's equation, the surface tension of SBS-g-DMAEMA and SBS-g-DMAEMA-HEP were determined. It was found that with increasing grafting amount and the heparin content, the surface tension and water content of SBS-g-DMAEMA membrane increased, whereas the contact angle decreased. The amount of the adsorption of albumin and fibrinogen decreased with increasing graft amount and heparin content. However, there was a minimum for adsorption of proteins in the SBS-g-DMAEMA and SBS-g-DMAEMA-HEP membranes. (C) 1998 John Wiley & Sons, Inc.
C1 Chang Gung Coll Med & Technol, Dept Chem Engn, Tao Yuan 333, Taiwan.
   Chung Yuan Christian Univ, Dept Chem Engn, Chungli 32023, Taiwan.
   Chang Gung Mem Hosp, Div Thorac & Cardiovasc Surg, Tao Yuan 333, Taiwan.
RP Yang, JM (reprint author), Chang Gung Coll Med & Technol, Dept Chem Engn, Tao Yuan 333, Taiwan.
CR BIANCHI JJ, 1993, AM SOC ARTIF INTERN, pM143
   EBERT CD, 1982, THROMB RES, V26, P43, DOI 10.1016/0049-3848(82)90149-9
   FUJIMOTO K, 1993, J BIOMED MATER RES, V27, P1559, DOI 10.1002/jbm.820271213
   FUJIMOTO K, 1993, J POLYM SCI POL CHEM, V31, P1035, DOI 10.1002/pola.1993.080310426
   FUJIMOTO K, 1993, BIOMATERIALS, V14, P441
   GOOSEN MFA, 1980, THROMB RES, V20, P543, DOI 10.1016/0049-3848(80)90142-5
   Hari P R, 1993, J Biomater Appl, V8, P174, DOI 10.1177/088532829300800205
   Hari P R, 1991, J Biomater Appl, V6, P170, DOI 10.1177/088532829100600205
   HATTON MWC, 1983, THROMB HAEMOSTASIS, V50, P873
   Holden G., 1969, J POLYM SCI        C, VC26, P37
   HSIUE GH, 1988, J BIOMED MATER RES, V22, P405, DOI 10.1002/jbm.820220504
   KAELBLE DH, 1977, POLYMER, V18, P475, DOI 10.1016/0032-3861(77)90164-1
   KIM S W, 1985, Critical Reviews in Biocompatibility, V1, P229
   KOCHWA S, 1977, ANN NY ACAD SCI, V283, P37, DOI 10.1111/j.1749-6632.1977.tb41751.x
   LAI JY, 1991, J APPL POLYM SCI, V43, P1431, DOI 10.1002/app.1991.070430804
   NOJIRI C, 1989, T ASAIO, V35, P357
   NOJIRI C, 1988, T ASAIO, V34, P386
   PARK KD, 1992, J BIOMED MATER RES, V26, P739, DOI 10.1002/jbm.820260605
   PARK KD, 1988, J BIOMED MATER RES, V22, P977, DOI 10.1002/jbm.820221103
   PLATE NA, 1986, ADV POLYM SCI, V79, P96
   ROLLASON G, 1989, Journal of Biomaterials Science Polymer Edition, V1, P31, DOI 10.1163/156856289X00046
   SMITH BAH, 1993, J BIOMED MATER RES, V27, P89, DOI 10.1002/jbm.820270112
   SMITH PK, 1980, ANAL BIOCHEM, V109, P466, DOI 10.1016/0003-2697(80)90679-X
   TSENG YC, 1992, J BIOMED MATER RES, V26, P373, DOI 10.1002/jbm.820260308
   VONSEGESSER LK, 1992, J THORAC CARDIOV SUR, V103, P790
   Yang JM, 1996, J BIOMED MATER RES, V31, P281
   Yang JM, 1997, J BIOMED MATER RES, V35, P175, DOI 10.1002/(SICI)1097-4636(199705)35:2<175::AID-JBM5>3.0.CO;2-K
   Yang JM, 1997, J APPL POLYM SCI, V65, P109
   Yang JM, 1997, J MEMBRANE SCI, V128, P133, DOI 10.1016/S0376-7388(96)00312-2
   YANG JM, 1990, J APPL POLYM SCI, V41, P1141, DOI 10.1002/app.1990.070410523
NR 30
TC 40
Z9 41
U1 2
U2 13
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD JAN
PY 1998
VL 39
IS 1
BP 86
EP 91
DI 10.1002/(SICI)1097-4636(199801)39:1<86::AID-JBM11>3.0.CO;2-M
PG 6
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA YL812
UT WOS:000070995300011
PM 9429100
DA 2018-10-19
ER

PT J
AU Somers, A
   Schwartz, Z
   Carnes, DL
   Dean, DD
   Mellonig, JT
   Cochran, DL
   Boyan, BD
AF Somers, A
   Schwartz, Z
   Carnes, DL
   Dean, DD
   Mellonig, JT
   Cochran, DL
   Boyan, BD
TI Addition of BMP-2 to inactive DFDBA results in an osteoinductive
   composite biomaterial.
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Meeting Abstract
C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX USA.
   Hebrew Univ Jerusalem, IL-91905 Jerusalem, Israel.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022-0345
EI 1544-0591
J9 J DENT RES
JI J. Dent. Res.
PY 1998
VL 77
SI B
MA 1168
BP 777
EP 777
PG 1
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA ZK546
UT WOS:000073335401162
DA 2018-10-19
ER

PT J
AU Love, JW
AF Love, JW
TI Autologous pericardial reconstruction of semilunar valves
SO JOURNAL OF HEART VALVE DISEASE
LA English
DT Article; Proceedings Paper
CT Symposium on Use of Pericardium in Cardiac Surgery
CY OCT 02-04, 1997
CL LONDON, ENGLAND
ID BOVINE PERICARDIUM; REPLACEMENT
AB Background and aims of the study: Previous methods for reconstructing semilunar valves have been characterized by lack of precision and reproducibility and, with one exception, the use of unsuitable biomaterial. A new method combines precision with simplicity to reconstruct aortic and pulmonary valves with lightly tanned autologous tissue supported by the annulus of the native valve. Essential components include sizing based on distance between adjacent commissures, cutting a seamless, size-specific trefoil-shaped pattern of tissue with a tricuspid orifice, temporary mounting of the pattern on disposable formers, and suturing with continuous or interrupted monofilament suture to join the autologous tissue pattern with the valve annulus.
   Methods: The tissue pattern is cut and mounted on farming devices that enable the implanting surgeon to visualize the orientation clearly, and perform repair accurately and rapidly. One, two or three leaflets can be reconstructed. The forming and cutting devices are discarded when reconstruction is complete. Diseased valves can be reconstructed in no more time than is required for replacement with a prosthesis of any type. Advantages of the method include preservation of full effective orifice area, lack of need for any foreign body other than the sutures used for reconstruction and the use of non-immunogenic autologous tissue known to be durable and resistant to calcific degeneration. Contraindications include heavily calcified annulus that cannot be satisfactorily debrided, bicuspid anatomy, or a significantly asymmetric annulus.
   Results: Pulmonary valve reconstructions have been performed in four juvenile sheep by this method. Three animals survived five months; there was one operative death due to non-valve related causes.
   Conclusions: Semilunar valve reconstruction with autologous tissue can be simple, precise, and reproducible.
C1 CardioMend LLC, Santa Barbara, CA USA.
RP Love, JW (reprint author), 785 Carosam Rd, Santa Barbara, CA 93110 USA.
CR ALFAGIH MR, 1988, J THORAC CARDIOV SUR, V96, P760
   BATISTA RJV, 1987, J THORAC CARDIOV SUR, V93, P19
   CHAUVAUD S, 1991, J THORAC CARDIOV SUR, V102, P171
   DURAN C, 1991, ANN THORAC SURG, V52, P447, DOI 10.1016/0003-4975(91)90904-5
   DURAN CMG, 1995, J THORAC CARDIOV SUR, V110, P511, DOI 10.1016/S0022-5223(95)70248-2
   EDWARDS WS, 1969, J THORAC CARDIOV SUR, V58, P854
   IONESCU MI, 1969, LANCET, V2, P335
   LEE JM, 1989, J BIOMED MATER RES, V23, P457, DOI 10.1002/jbm.820230502
   LEE JM, 1985, CIRC RES, V55, P475
   LEE MC, 1987, AM J PHYSIOL, V253, pH75
   Love J W, 1992, J Heart Valve Dis, V1, P232
   LOVE JW, 1993, AUTOLOGOUS TISSUE HE, P1
   LOVE JW, 1993, AUTOLOGOUS TISSUE HE, P80
   Love JW, 1986, P 3 INT S CARD BIOPR, P691
   Moore MA, 1997, J HEART VALVE DIS, V6, P307
   Sands M P, 1969, Ann Thorac Surg, V8, P407
   SENNING A, 1967, J THORAC CARDIOV SUR, V54, P465
   SENNING A, 1984, P 2 INT S CARD BIOPR, P140
   THUBRIKAR M, 1990, AORTIC VALVE, P4
   TROWBRIDGE EA, 1989, CRIT REV BIOCOMPAT, V5, P105
   VANDECIC M, 1994, NEW HORIZONS FUTURE, P143
   Yacoub M, 1986, BIOL BIOPROSTHETIC V, P684
   ZIOUPOS P, 1994, J BIOMED MATER RES, V28, P49, DOI 10.1002/jbm.820280107
NR 23
TC 11
Z9 11
U1 0
U2 0
PU I C R PUBLISHERS
PI NORTHWOOD
PA CRISPIN HOUSE, 12/A SOUTH APPROACH, MOOR PARK, NORTHWOOD, ENGLAND HA6
   2ET
SN 0966-8519
J9 J HEART VALVE DIS
JI J. Heart Valve Dis.
PD JAN
PY 1998
VL 7
IS 1
BP 40
EP 47
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA YU967
UT WOS:000071774600008
PM 9502138
DA 2018-10-19
ER

PT J
AU Odum, BC
   Bussard, GM
   Lewis, RP
   Lara, WC
   Edlich, RF
   Gampper, TJ
AF Odum, BC
   Bussard, GM
   Lewis, RP
   Lara, WC
   Edlich, RF
   Gampper, TJ
TI High-density porous polyethylene for facial bone augmentation
SO JOURNAL OF LONG-TERM EFFECTS OF MEDICAL IMPLANTS
LA English
DT Article
DE porous polyethylene; preformed shapes; orbital floor; external ear;
   chin; mandible; nasal; malar
ID IMPLANTS
AB Medpor(R) is a porous polyethylene biomaterial used in plastic and reconstructive surgery in the craniofacial skeleton. Its porous nature allows for substantial vascular and soft-tissue ingrowth. Medpor is available in a variety of implants including block, sheet, and preformed shapes. In vitro and in vivo studies have demonstrated that Medpor has been successfully used in the reconstruction of the orbital floor and external ear, and in augmentation of the chin, mandibular, nasal, and malar regions.
C1 Univ Virginia, Sch Med, Dept Plast Surg, Charlottesville, VA 22908 USA.
RP Edlich, RF (reprint author), Univ Virginia, Sch Med, Dept Plast Surg, POB 332, Charlottesville, VA 22908 USA.
CR BERGHAUS A, 1984, ARCH OTO-RHINO-LARYN, V240, P115
   BIKHAZI HB, 1990, PLASTIC RECONSTRUCTI, P270
   CESTERO HJ, 1975, J BIOMED MATER RES, V6, P1
   EPKER BN, 1994, ESTHETIC MAXILLOFACI
   GOLSHANI S, 1994, AM J COSMET SURG, V11, P105
   HAUG RH, 1993, J ORAL MAXIL SURG, V51, P1217, DOI 10.1016/S0278-2391(10)80292-7
   KLAWITTER JJ, 1976, J BIOMED MATER RES, V10, P311, DOI 10.1002/jbm.820100212
   MILLARD DR, 1981, CLIN PLAST SURG, V8, P169
   Romano J J, 1993, J Craniofac Surg, V4, P142, DOI 10.1097/00001665-199307000-00007
   RUBIN PAD, 1994, OPHTHALMIC PLAST REC, V10, P96, DOI 10.1097/00002341-199406000-00005
   RUBIN PAD, 1994, OPTHALMOLOGY, V10, P1698
   SPECTOR M, 1976, J BIOMED MATER RES, V10, P595, DOI 10.1002/jbm.820100416
   WELLISZ T, 1993, J LONG-TERM EFF MED, V3, P223
   WELLISZ T, 1993, PLAST RECONSTR SURG, V91, P811, DOI 10.1097/00006534-199304001-00009
   WELLISZ T, 1995, PLAST RECONSTR SURG, V96, P957, DOI 10.1097/00006534-199509001-00029
   Wellisz T, 1992, J Craniofac Surg, V3, P101, DOI 10.1097/00001665-199209000-00009
NR 16
TC 5
Z9 5
U1 0
U2 0
PU BEGELL HOUSE INC
PI NEW YORK
PA 79 MADISON AVE, SUITE 1205, NEW YORK, NY 10016-7892 USA
SN 1050-6934
J9 J LONG-TERM EFF MED
JI J. Long-Term Eff. Med. Implants
PY 1998
VL 8
IS 1
BP 3
EP 17
PG 15
WC Engineering, Biomedical; Medicine, Research & Experimental; Orthopedics;
   Pathology
SC Engineering; Research & Experimental Medicine; Orthopedics; Pathology
GA ZA617
UT WOS:000072382600002
PM 10177457
DA 2018-10-19
ER

PT J
AU Ogiso, M
AF Ogiso, M
TI Bone formation on HA implants: A commentary
SO JOURNAL OF LONG-TERM EFFECTS OF MEDICAL IMPLANTS
LA English
DT Article
DE dense HA; chemical bone bonding; epitaxial crystal growth; HA-coated
   implant
ID PLASMA-SPRAYED COATINGS; HYDROXYAPATITE; TITANIUM; STABILITY; INTERFACE
AB The present paper reviews bone formation on dense hydroxyapatite (HA) implants. Calcification of bone matrix formed on HA is different in areas where collagen fibers are dense and scattered with matrix vesicles than in those interfacial layers containing few or no collagen fibers and matrix vesicles. Calcification of collagen-coated areas begins with crystallization within the matrix vesicles. In contrast, calcification of the interfacial layer is initiated by epitaxial crystal growth on the HA. Crystallization within the matrix vesicles near the HA and those on the HA start: simultaneously. Calcification of the interfacial layer is the most important feature of HA as a biomaterial. Such calcification is never observed on titanium implants. The recent postulation that the rate of bone formation on calcium-phosphate (CP) ceramics correlates with the solubility of CP ceramics is improbable, as in vitro immersion tests have been unable to establish correlation between osteoblast differentiation and the solubility of the CP ceramics. With regard to HA-plasma spray-coated implants, future research should focus on the purity of HA and the structure of the ceramics in order to increase the in vivo chemical and mechanical durability of HA coating.
C1 Tokyo Med & Dent Univ, Fac Dent, Dept Fixed Prosthodont, Bunkyo Ku, Tokyo 113, Japan.
RP Ogiso, M (reprint author), Tokyo Med & Dent Univ, Fac Dent, Dept Fixed Prosthodont, Bunkyo Ku, 1-5-45 Yushima, Tokyo 113, Japan.
CR ALBREKTSSON T, 1982, ADV BIOMATER, V4, P167
   ANDERSON HC, 1967, J CELL BIOL, V35, P81, DOI 10.1083/jcb.35.1.81
   AOKI H, 1975, 1975 S BIOM KYOT JAP, P197
   DEGROOT K, 1987, J BIOMED MATER RES, V21, P1375, DOI 10.1002/jbm.820211203
   DENISSEN H, 1979, DENTAL ROOT IMPLANTS, P65
   DUCHEYNE P, 1986, BIOMATERIALS, V7, P97, DOI 10.1016/0142-9612(86)90063-3
   HYAKUNA K, 1990, J BIOMED MATER RES, V24, P471, DOI 10.1002/jbm.820240406
   Johnson B W, 1992, J Calif Dent Assoc, V20, P33
   KARLIS AG, 1997, INT J ORAL MAXILLOF, V12, P589
   KAY J, 1987, J PROSTHET DENT, V38, P339
   KLEIN CPAT, 1994, J BIOMED MATER RES, V28, P909, DOI 10.1002/jbm.820280810
   KOCH B, 1990, J BIOMED MATER RES, V24, P655, DOI 10.1002/jbm.820240603
   LINDER L, 1983, ACTA ORTHOP SCAND, V54, P45, DOI 10.3109/17453678308992868
   Ogiso M, 1998, J BIOMED MATER RES, V39, P23, DOI 10.1002/(SICI)1097-4636(199801)39:1<23::AID-JBM4>3.3.CO;2-X
   OGISO M, 1992, J LONG-TERM EFF MED, V2, P235
   Ogiso M, 1995, Int J Oral Maxillofac Implants, V10, P415
   Ogiso M, 1998, J BIOMED MATER RES, V39, P364
   Ogiso M, 1998, J DENT RES, V77, P1426, DOI 10.1177/00220345980770060701
   OGISO M, 1992, J LONG-TERM EFF MED, V2, P137
   Ogiso M, 1998, J BIOMED MATER RES, V41, P296, DOI 10.1002/(SICI)1097-4636(199808)41:2<296::AID-JBM15>3.0.CO;2-J
   OGISO M, 1983, J STOMATOL SOC JAP, V50, P1
   OGISO M, 1993, J LONG TERM EFFECTS, V1, P57
   OGISO M, 1998, J BIOMED MATER RES, P43
   OGISO M, 1978, J STOMATOL SOC JPN, V45, P170
   OGISO M, 1994, J BIOMED MATER RES, V18, P805
   PILLIAR RM, 1991, J DENT RES, V70, P1338, DOI 10.1177/00220345910700100501
   RADIN SR, 1992, J MATER SCI-MATER M, V3, P33, DOI 10.1007/BF00702942
   SNNERBY L, 1993, J MAT SCI MED, V4, P494
   WATANABE I, 1985, Journal of the Stomatological Society Japan, V52, P397
NR 29
TC 15
Z9 15
U1 0
U2 1
PU BEGELL HOUSE INC
PI NEW YORK
PA 79 MADISON AVE, SUITE 1205, NEW YORK, NY 10016-7892 USA
SN 1050-6934
J9 J LONG-TERM EFF MED
JI J. Long-Term Eff. Med. Implants
PY 1998
VL 8
IS 3-4
BP 193
EP 200
PG 8
WC Engineering, Biomedical; Medicine, Research & Experimental; Orthopedics;
   Pathology
SC Engineering; Research & Experimental Medicine; Orthopedics; Pathology
GA 129ZY
UT WOS:000076495200002
PM 10186965
DA 2018-10-19
ER

PT J
AU Kong, JY
   Lee, HW
   Hong, JW
   Kang, YS
   Kim, JD
   Chang, MW
   Bae, SK
AF Kong, JY
   Lee, HW
   Hong, JW
   Kang, YS
   Kim, JD
   Chang, MW
   Bae, SK
TI Utilization of a cell-bound polysaccharide produced by the marine
   bacterium Zoogloea sp: New biomaterial for metal adsorption and enzyme
   immobilization
SO JOURNAL OF MARINE BIOTECHNOLOGY
LA English
DT Article
AB A cell-bound polysaccharide (CBP) produced by the marine bacterium Zoogloea sp. (KCCM 10036) was used as the adsorbent of metal ions and as a new support for enzyme immobilization, The CBP gel beads showed highly effective adsorbing in Cr, Pb, and Fe ion in solutions. The adsorption rates were above 95% at pH 5.0, 25 degrees C, in 10 mg/liter of each metal solution. The gel beads formed by the CBP were stable within the range of pH 4.0-7.0 and at a temperature of 40-55 degrees C, The optimum pH and temperature of the immobilized glucoamylase by the CBP gel beads (poly-G) were 5.0 and 45 degrees C, respectively. The immobilized glucoamylase produced 10.5 mg/liter of glucose from 10 mg/ml of soluble starch.
C1 Pukyong Natl Univ, Dept Biotechnol & Bioengn, Pusan 608737, South Korea.
   Univ Illinois, Dept Med Chem & Pharmacognosy, Chicago, IL 60612 USA.
   Yosu Natl Fisheries Univ, Dept Biol Engn, Yosu 550749, South Korea.
   Kosin Univ, Sch Med, Dept Microbiol, Pusan 606030, South Korea.
RP Kong, JY (reprint author), Pukyong Natl Univ, Dept Biotechnol & Bioengn, 599-1 Daeyeon Dong, Pusan 608737, South Korea.
CR BLUMENKRANZ B, 1993, ANAL BIOCHEM, V54, P484
   Bollag DM, 1991, PROTEIN METHODS, P50
   CHANG D, 1995, WATER ENVIRON RES, V67, P822, DOI 10.2175/106143095X131745
   CHANG MW, 1995, KOREAN J LIFE SCI, V5, P25
   CHANG MW, 1995, KOREAN J BIOTECHNOL, V10, P518
   CHAPLIN MF, 1986, CARBOHYDRATE ANAL PR, P2
   HALWACHS W, 1978, BIOTECHNOL BIOENG, V20, P281, DOI 10.1002/bit.260200210
   KNORR D, 1987, FOOD BIOTECHNOL, P63
   KWON KJ, 1994, BIOTECHNOL LETT, V16, P783, DOI 10.1007/BF00133954
   MCLEAN RJC, 1992, APPL ENVIRON MICROB, V58, P405
   MCMURRY J, 1988, ORGANIC CHEM, P102
   PERRIN DD, 1979, BUFFERS PH METAL ION, P53
   SANDERSON GR, 1983, FOOD TECHNOL, V37, P63
   SUH IS, 1992, BIOTECHNOL BIOENG, V39, P85, DOI 10.1002/bit.260390113
   ULBRICH R, 1986, BIOTECHNOL BIOENG, V28, P511, DOI 10.1002/bit.260280407
NR 15
TC 12
Z9 12
U1 0
U2 5
PU SPRINGER VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010 USA
SN 0941-2905
J9 J MAR BIOTECHNOL
JI J. Mar. Biotechnol.
PY 1998
VL 6
IS 2
BP 99
EP 103
PG 5
WC Biotechnology & Applied Microbiology; Marine & Freshwater Biology
SC Biotechnology & Applied Microbiology; Marine & Freshwater Biology
GA ZP973
UT WOS:000073807500009
DA 2018-10-19
ER

PT J
AU Frische, S
   Maunsbach, AB
   Vollrath, F
AF Frische, S
   Maunsbach, AB
   Vollrath, F
TI Elongate cavities and skin-core structure in Nephila spider silk
   observed by electron microscopy
SO JOURNAL OF MICROSCOPY-OXFORD
LA English
DT Article
DE biomaterial; biopolymer; fibrous protein; microstructure; Nephila
   madagascariensis
ID MAJOR AMPULLATE SILK; DRAGLINE SILK; CLAVIPES
AB Major ampullate silk fibres from the orb-weaving spider Nephila madagascariensis were analysed by transmission electron microscopy. The fibres have a thin outer layer surrounding a column of apparently homogeneous material which contains elongate cavities orientated parallel to the silk fibre axis. The cavities appear similar to 'elongate vacuolar droplets' observed in the silk of Antheraea silkmoth larvae. The overall skin-core structure is probably the result of a rheological pattern originating in the two secreting regions recognized in Nephila silk glands; the cavities indicate material inhomogeneities.
C1 Aarhus Univ, Inst Anat, Dept Cell Biol, DK-8000 Aarhus C, Denmark.
   Aarhus Univ, Inst Biol, Dept Zool, DK-8000 Aarhus, Denmark.
RP Vollrath, F (reprint author), Aarhus Univ, Inst Biol, Dept Zool, DK-8000 Aarhus C, Denmark.
RI Frische, Sebastian/B-2332-2009
OI Frische, Sebastian/0000-0002-0270-3602
CR AFZELIUS B, 1959, J BIOPHYS BIOCHEM CY, V5, P269, DOI 10.1083/jcb.5.2.269
   AKAI H, 1993, INT J INSECT MORPHOL, V22, P497, DOI 10.1016/0020-7322(93)90036-Z
   AKAI H, 1988, ANTHERAEA YAMAMAI AN, P9
   BECKER MA, 1994, ACS SYM SER, V544, P185
   BECKWITT R, 1994, J BIOL CHEM, V269, P6661
   DOBB MG, 1967, J CELL BIOL, V32, P289, DOI 10.1083/jcb.32.2.289
   FREYWYSSLING A, 1948, SUBMICROSCOPIC MORPH
   GOSLINE JM, 1986, ENDEAVOUR, V10, P37, DOI 10.1016/0160-9327(86)90049-9
   GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x
   HINMAN MB, 1992, J BIOL CHEM, V267, P19320
   KERKAM K, 1991, NATURE, V349, P596, DOI 10.1038/349596a0
   Kovoor J., 1987, P160
   KOVOOR J, 1972, Z ZELLFORSCH MIK ANA, V128, P188, DOI 10.1007/BF00306898
   KOVOOR J, 1986, Revue Arachnologique, V7, P15
   KRATKY O, 1964, MONATSH CHEM, V95, P359
   Kummerlen J, 1996, MACROMOLECULES, V29, P2920, DOI 10.1021/ma951098i
   LI SFY, 1994, BIOPHYS J, V66, P1209, DOI 10.1016/S0006-3495(94)80903-8
   Lucas F., 1968, Comprehensive Biochem, V26, P475
   MAHONEY DV, 1994, ACS SYM SER, V544, P196
   PETERS HM, 1989, ZOOL JAHRB ALLG ZOOL, V93, P125
   Putthanarat S, 1996, J MACROMOL SCI PURE, VA33, P899, DOI 10.1080/10601329608014640
   RUDALL KM, 1971, ANNU REV ENTOMOL, V16, P73, DOI 10.1146/annurev.en.16.010171.000445
   Simmons AH, 1996, SCIENCE, V271, P84, DOI 10.1126/science.271.5245.84
   STUBBS DG, 1992, NATURWISSENSCHAFTEN, V79, P231, DOI 10.1007/BF01227136
   TERMONIA Y, 1994, MACROMOLECULES, V27, P7378, DOI 10.1021/ma00103a018
   THIEL BL, 1994, BIOPOLYMERS, V34, P1089, DOI 10.1002/bip.360340812
   THIEL BL, 1995, MRS BULL, V20, P52
   TILLINGHAST EK, 1984, J INSECT PHYSIOL, V30, P591, DOI 10.1016/0022-1910(84)90088-X
   VOLLRATH F, 1992, SCI AM, V266, P70, DOI 10.1038/scientificamerican0392-70
   Vollrath F, 1996, P ROY SOC B-BIOL SCI, V263, P147, DOI 10.1098/rspb.1996.0023
   WARWICKER JO, 1960, J MOL BIOL, V2, P350, DOI 10.1016/S0022-2836(60)80046-0
   Willcox PJ, 1996, MACROMOLECULES, V29, P5106, DOI 10.1021/ma960588n
   WILSON RS, 1962, Q J MICROSC SCI, V103, P549
   WORK RW, 1984, T AM MICROSC SOC, V103, P113, DOI 10.2307/3226233
   XU M, 1990, P NATL ACAD SCI USA, V87, P7120, DOI 10.1073/pnas.87.18.7120
   Zahn H., 1952, MELLIAND TEXTILBER, V33, P1076
   Zar J. H., 1984, BIOSTATISTICAL ANAL
NR 37
TC 58
Z9 65
U1 0
U2 10
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 0022-2720
J9 J MICROSC-OXFORD
JI J. Microsc.-Oxf.
PD JAN
PY 1998
VL 189
BP 64
EP 70
PN 1
PG 7
WC Microscopy
SC Microscopy
GA YY304
UT WOS:000072133700009
DA 2018-10-19
ER

PT J
AU Glantz, PO
AF Glantz, PO
TI Biomaterial considerations for the optimized therapy for the edentulous
   predicament
SO JOURNAL OF PROSTHETIC DENTISTRY
LA English
DT Article; Proceedings Paper
CT Annual Meeting of the Academy-of-Prosthodontics
CY MAY-JUN -, 1997
CL HALIFAX, CANADA
SP Acad Prosthodont
ID IMPLANTS
AB A range of biomaterials are used in rendering prosthodontic treatment for the completely edentulous patient. This article reviews the biomaterials considerations in the use of metals and metal alloys, ceramics and carbons, and synthetic materials for implant therapy. It also discusses implant material selection, biomaterial aspects of bioadhesion, and osseointegration and hygiene-related biomaterial factors.
C1 Univ Lund, Fac Odontol, Dept Prosthet Dent, S-21421 Malmo, Sweden.
RP Glantz, PO (reprint author), Univ Lund, Fac Odontol, Dept Prosthet Dent, Carl Gustafs Vag 34, S-21421 Malmo, Sweden.
CR DUCHEYNE P, 1988, ANN NY ACAD SCI, P523
   Glantz P O, 1993, Clin Oral Implants Res, V4, P99, DOI 10.1034/j.1600-0501.1993.040206.x
   Gottlander M, 1992, Int J Oral Maxillofac Implants, V7, P485
   HANSSON S, 1997, THESIS CHALMERS U TE, P1
   KASEMO B, 1983, J PROSTHET DENT, V49, P832, DOI 10.1016/0022-3913(83)90359-1
   MEYER A, 1991, DENT IMPLANTS PRINCI, P31
   MUSTER D, 1995, ENCY HDB BIOMATERIAL, V1
   NIKI M, 1991, BONE-BIOMATERIAL INTERFACE, P350
   WENNERBERG A, 1996, THESIS GOTEBORG U GO, P7
   1994, DORLANDS ILLUSTRATED
NR 10
TC 2
Z9 2
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA
SN 0022-3913
J9 J PROSTHET DENT
JI J. Prosthet. Dent.
PD JAN
PY 1998
VL 79
IS 1
BP 90
EP 92
DI 10.1016/S0022-3913(98)70199-4
PG 3
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA YU334
UT WOS:000071706900017
PM 9474547
DA 2018-10-19
ER

PT J
AU Henke, PK
   Bergamini, TM
   Watson, AL
   Brittian, KR
   Powell, DW
   Peyton, JC
AF Henke, PK
   Bergamini, TM
   Watson, AL
   Brittian, KR
   Powell, DW
   Peyton, JC
TI Bacterial products primarily mediate fibroblast inhibition in
   biomaterial infection
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article; Proceedings Paper
CT Annual Symposium of the Association-of-Veterans-Administration-Surgeons
CY MAY 05-07, 1997
CL LOUISVILLE, KENTUCKY
SP Assoc Vet Adm Surgeons
ID TUMOR-NECROSIS-FACTOR; VASCULAR GRAFT INFECTION;
   STAPHYLOCOCCUS-EPIDERMIDIS SLIME; IN-SITU REPLACEMENT; FACTOR-ALPHA;
   COLLAGEN-SYNTHESIS; HUMAN MONOCYTES; PROSTHESES; PROLIFERATION;
   STIMULATION
AB Purpose. The stimulation of fibroblast growth is essential for the normal healing and tissue integration of biomaterials. The local elevation of proinflammatory mediators in infected perigraft fluid (PGF) may inhibit this growth. We sought to determine whether infected PGF inhibited fibroblast growth, and, if so, whether this was primarily dependent on the biomaterial, bacteria, or host.
   Methods. In vivo Dacron or expandable polytetrafluoroethylene (ePTFE) grafts, sterile or colonized with slime-producing (RP-62A, viable or formalin-killed) or nonslime-producing (RP-62NA) Staphylococcus epidermidis (1 x 10(7) CFU/cm(2)), were implanted in Swiss Webster mice, and the PGF was harvested at 7 and 28 days. Antibodies to tumor necrosis factor alpha, interleukin 1 alpha, interferon gamma (7 gamma g/day), and indomethacin (50 mu g/day) were administered by microinfusion pumps for 7 days and the PGF was harvested. Inhibition of the proinflammatory mediators was confirmed by enzyme-linked immunosorbant assay. The nontreated, heat-treated, or trypsin-digested in vivo PGF was incubated with an in vitro [H-3]thymidine murine fibroblast (ATCC CCL-12) proliferation assay.
   Results. Fibroblast inhibition was significant at 7 and 28 days with infected PGF incubation compared with sterile and was not dependent on bacterial slime production or viability. Dacron sterile PGF did not significantly inhibit fibroblasts compared with control, whereas sterile ePTFE stimulated (P < 0.05) fibroblasts, Treatment of the PGF with proinflammatory cytokines, heat, and trypsin failed to reverse fibroblast inhibition in the infected state.
   Conclusion. Biomaterial infection is associated with fibroblast inhibition that is dependent primarily on bacterial products and not the host or biomaterial, Conservative intervention strategies for graft infection need to address the problem of poor healing as well as bacterial clearance. (C) 1998 Academic Press.
C1 Univ Louisville, Dept Surg, Sch Med, Louisville, KY 40292 USA.
   Vet Affairs Med Ctr, Louisville, KY 40292 USA.
RP Bergamini, TM (reprint author), Univ Louisville, Dept Surg, Sch Med, Louisville, KY 40292 USA.
CR AHN SS, 1994, J VASC SURG, V20, P202, DOI 10.1016/0741-5214(94)90007-8
   Ahrendt GM, 1996, AM J SURG, V171, P102, DOI 10.1016/S0002-9610(99)80082-8
   BANDYK DF, 1991, J VASC SURG, V13, P575
   BARBUL A, 1990, CLIN PLAST SURG, V17, P433
   CALLIGARO KD, 1994, ANN SURG, V220, P461, DOI 10.1097/00000658-199410000-00005
   CHAUDHARY R, 1991, J VASC SURG, V13, P755
   Concannon M. J., 1993, Journal of Burn Care and Rehabilitation, V14, P141, DOI 10.1097/00004630-199303000-00003
   FREUNDLICH B, 1986, IMMUNOL TODAY, V7, P303, DOI 10.1016/0167-5699(86)90067-8
   GOEAUBRISSONNIERE O, 1994, J VASC SURG, V19, P739, DOI 10.1016/S0741-5214(94)70050-8
   GRISTINA AG, 1993, INT J ARTIF ORGANS, V16, P755
   HENKE PK, IN PRESS J SURG RES
   HEUMANN D, 1994, INFECT IMMUN, V62, P2715
   HORI T, 1991, BIOCHEM BIOPH RES CO, V174, P758, DOI 10.1016/0006-291X(91)91482-R
   JOHNSON GM, 1986, INFECT IMMUN, V54, P13
   KAEBNICK HW, 1987, SURGERY, V102, P756
   Kinnaert P, 1996, ANN SURG, V224, P749, DOI 10.1097/00000658-199612000-00010
   KORN JH, 1980, J CLIN INVEST, V65, P543, DOI 10.1172/JCI109698
   LORENTZEN JE, 1985, SURGERY, V98, P81
   Marois Y, 1996, BIOMATERIALS, V17, P1835, DOI 10.1016/0142-9612(95)00245-6
   MARTAKOS P, 1995, ASAIO J, V41, pM735, DOI 10.1097/00002480-199507000-00110
   MERTENS RA, 1995, J VASC SURG, V21, P782, DOI 10.1016/S0741-5214(05)80009-6
   MORRIS GE, 1994, J VASC SURG, V20, P88, DOI 10.1016/0741-5214(94)90179-1
   MORYKWAS MJ, 1992, INFLAMMATION, V16, P251, DOI 10.1007/BF00918814
   PADBERG FT, 1995, ARCH SURG-CHICAGO, V130, P183
   PATRICK CC, 1992, INFECT IMMUN, V60, P1363
   POSTLETHWAITE AE, 1984, J IMMUNOL, V132, P2470
   PRICOLO VE, 1990, J SURG RES, V48, P534, DOI 10.1016/0022-4804(90)90226-R
   STEENFOS HH, 1989, SURGERY, V106, P171
   STOUT RD, 1994, INFECT IMMUN, V62, P4160
   TIMMERMAN CP, 1993, INFECT IMMUN, V61, P4167
   TOWNE JB, 1994, J VASC SURG, V19, P226, DOI 10.1016/S0741-5214(94)70098-2
   TSUKAYAMA DT, 1991, ORTHOPEDICS, V14, P841
NR 32
TC 12
Z9 13
U1 0
U2 1
PU ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
J9 J SURG RES
JI J. Surg. Res.
PD JAN
PY 1998
VL 74
IS 1
BP 17
EP 22
DI 10.1006/jsre.1997.5210
PG 6
WC Surgery
SC Surgery
GA ZK885
UT WOS:000073373600005
PM 9536967
DA 2018-10-19
ER

PT S
AU Niino, H
   Kruger, J
   Kautek, W
AF Niino, H
   Kruger, J
   Kautek, W
BE Dubowski, JJ
   Dyer, PE
TI Photochemical surface modification of polyurethane films with
   biomaterial by excimer laser processing
SO LASER APPLICATIONS IN MICROELECTRONIC AND OPTOELECTRONIC MANUFACTURING
   III
SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
   (SPIE)
LA English
DT Proceedings Paper
CT Conference on Laser Applications in Microelectronic and Optoelectronic
   Manufacturing (LAMOM III) at LASE 98 at Photonics West
CY JAN 26-28, 1998
CL SAN JOSE, CA
SP Int Soc Optical Engn
DE laser irradiation surface effects; surface and interface chemistry of
   polymers; photochemical reactions of biomolecules; biochemical reaction
   mechanisms and kinetics
AB The surface chemical modification of polyurethane (PU) films was performed by a UV laser-induced chemical reaction in a polysaccharide solution. This was undertaken with the possible application of hydrophilic packaging of implantable medical devices and in-vivo sensors. When a PU film in an aqueous alginic acid (AAC) solution was irradiated with the XeCl laser, it turned hydrophilic. Contact angles of water on the film were changed from 110 degrees to 60 degrees. Since the absorption of AAC solution at 308 nm was negligibly small, the laser irradiation produced reactive sites solely on the PU surface, where AAC could be immobilized by chemical bonds. The mechanism for the modification was investigated by surface analyses with Fourier transform infrared spectroscopy and a photometric dye staining technique. This hydrophilic modification was interpreted as nanometer-scaled grafting of AAC induced by one-photon photochemical processes.
C1 Fed Inst Mat Res & Testing, Lab Thin Film Technol, D-12205 Berlin, Germany.
RP Kautek, W (reprint author), Fed Inst Mat Res & Testing, Lab Thin Film Technol, Unter Eichen 87, D-12205 Berlin, Germany.
RI Kruger, Jorg/C-2833-2009; Niino, Hiroyuki/L-9508-2018
OI Niino, Hiroyuki/0000-0003-2375-1256
NR 0
TC 1
Z9 1
U1 0
U2 2
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 0-8194-2713-6
J9 P SOC PHOTO-OPT INS
PY 1998
VL 3274
BP 128
EP 132
DI 10.1117/12.309503
PG 3
WC Engineering, Electrical & Electronic; Optics; Physics, Applied
SC Engineering; Optics; Physics
GA BL30Y
UT WOS:000075053800015
DA 2018-10-19
ER

PT S
AU Viator, JA
   Jacques, SL
   Prahl, SA
AF Viator, JA
   Jacques, SL
   Prahl, SA
BE Jacques, SL
   Katzir, A
TI Generating subsurface acoustic waves in indocyanine green stained
   elastin biomaterial using a Q-switched laser
SO LASER-TISSUE INTERACTION IX. PROCEEDINGS OF
SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
   (SPIE)
LA English
DT Proceedings Paper
CT Conference on Laser-Tissue Interaction IX
CY JAN 26-28, 1998
CL SAN JOSE, CA
SP USAF Off Sci Res, Int Biomed Opt Soc, Soc Photo Opt Instrumentat Engineers
DE photoacoustic imaging; photothermal imaging; depth profiling; absorption
   coefficient
AB A Q-switched frequency-doubled Nd-YAG laser coupled to an optical parametric oscillator generated 4.75 ns 800 nm laser pulses to create a subsurface acoustic wave in planar indocyanine green gel samples and flat segments of elastin biomaterial stained with indocyanine green. The acoustic waves traveled through the target and were detected by a piezoelectric transducer. The waveforms were converted to measurements of pressure (and temperature) as a function of depth in the material. An algorithm was developed and applied to the acoustic signals to extract information about the the absorption coefficient as a function of depth in the samples.
C1 Oregon Grad Inst, Portland, OR 97291 USA.
RP Viator, JA (reprint author), Oregon Grad Inst, Portland, OR 97291 USA.
NR 0
TC 4
Z9 4
U1 0
U2 0
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 0-8194-2693-8
J9 P SOC PHOTO-OPT INS
PY 1998
VL 3254
BP 104
EP 111
DI 10.1117/12.308154
PG 8
WC Engineering, Biomedical; Optics
SC Engineering; Optics
GA BL09D
UT WOS:000074238700014
DA 2018-10-19
ER

PT S
AU Shangguan, HQ
   Prahl, SA
   Jacques, SL
   Casperson, LW
   Gregory, KW
AF Shangguan, HQ
   Prahl, SA
   Jacques, SL
   Casperson, LW
   Gregory, KW
BE Jacques, SL
   Katzir, A
TI Pressure effects on soft tissues monitored by changes in tissue optical
   properties
SO LASER-TISSUE INTERACTION IX. PROCEEDINGS OF
SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
   (SPIE)
LA English
DT Proceedings Paper
CT Conference on Laser-Tissue Interaction IX
CY JAN 26-28, 1998
CL SAN JOSE, CA
SP USAF Off Sci Res, Int Biomed Opt Soc, Soc Photo Opt Instrumentat Engineers
DE hydration; transmittance; diffuse reflectance; adding-doubling
AB For pulsed laser tissue welding, an appropriate pressure needs to be applied to the tissues to achieve successful welds. In this study, we investigated the influences of pressure on in vitro optical properties of elastin biomaterial. The optical properties were measured as a function of pressure with a double integrating-sphere system. A He-Ne laser (633 nm) was used for all measurements. Each sample was sandwiched between microscope slides and then compressed with a spring-loaded apparatus. Transmittance and diffuse reflectance of each sample were measured under a pressure (0-1.5 kg/cm(2) and then released to 0). Absorption and reduced scattering coefficients were calculated using the inverse doubling method from the measured transmittance and reflectance values. Results from this study demonstrated: 1) The overall transmittance increased while the reflectance decreased as the tissue thicknesses were reduced up to 72% and the tissue weights were decreased about 40%, 2) The absorption and scattering coefficients increased with increasing the pressure, and 3) The pressure effects on the tissue optical properties were irreversible. Possible mechanisms responsible for the changes in the tissue optical properties were also investigated by changing tissue thicknesses or weights (through dehydration). This study implies that changes in tissue thickness and water content are important factors that affect tissue optical properties in different ways.
C1 Oregon Med Laser Ctr, Portland, OR 97225 USA.
RP Shangguan, HQ (reprint author), Oregon Med Laser Ctr, 9205 SW Barnes Rd, Portland, OR 97225 USA.
NR 0
TC 34
Z9 35
U1 0
U2 2
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 0-8194-2693-8
J9 P SOC PHOTO-OPT INS
PY 1998
VL 3254
BP 366
EP 371
DI 10.1117/12.308187
PG 6
WC Engineering, Biomedical; Optics
SC Engineering; Optics
GA BL09D
UT WOS:000074238700044
DA 2018-10-19
ER

PT J
AU Lauto, A
   Poppas, DP
   Murrell, GAC
AF Lauto, A
   Poppas, DP
   Murrell, GAC
TI Solubility study of albumin solders for laser tissue-welding
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Article
DE tensile strength; protein concentration; biomaterial; mechanical
   properties
ID PROTEIN SOLDER; NERVE; RECONSTRUCTION; PARAMETERS
AB Background/Objective: Current albumin solders for tissue-welding are soluble in physiological fluids, prior to laser irradiation. These solders are therefore subjected to mechanical alterations, which can weaken the solder-tissue repair. In this study, an albumin solder (laser activated) was developed with low solubility and with the ability to retain (partially) its mechanical characteristics in saline solution.
   Study Design/Materials and Methods: Gauged protein samples of solder were immersed into 0.5 mi saline solution for fixed intervals of time. The solder samples contained four Bovine Serum Albumin (BSA) concentrations: 56%, 66%, 70%, and 75% (by weight). A Bradford protein assay measured the BSA solubility of the solders. The 70% and 75% BSA solders were also used to weld in vitro Wistar rat intestine sections with a diode laser (lambda = 810 nm, power 270 mW).
   Results: The solubility of the 75% BSA solder was significantly decreased with respect to the other solders (Anova, P < 0.05). This solder also showed comparable weld strength (13 gm) to the 70% BSA solder.
   Conclusion: The 75% BSA solder strongly reduced the albumin solubility in saline solution, without affecting its tissue-welding properties. (C) 1998 Wiley-Liss, Inc.
C1 Cornell Univ, Med Ctr, New York Hosp, New York, NY 10021 USA.
   St George Hosp, Dept Orthoped Surg, Kogarah, NSW 2217, Australia.
   St George Hosp, Canc Care Ctr, Kogarah, NSW 2217, Australia.
RP Lauto, A (reprint author), Cornell Univ, Med Ctr, New York Hosp, 525 E 68th St, New York, NY 10021 USA.
CR BASS LS, 1992, LASER SURG MED, V12, P500, DOI 10.1002/lsm.1900120508
   KIM DH, 1990, NEUROSURGERY, V26, P211, DOI 10.1227/00006123-199002000-00005
   KIRSCH AJ, 1995, UROLOGY, V46, P261, DOI 10.1016/S0090-4295(99)80206-4
   Lauto A, 1997, LASER SURG MED, V21, P134, DOI 10.1002/(SICI)1096-9101(1997)21:2<134::AID-LSM4>3.0.CO;2-R
   Lauto A, 1998, LASER SURG MED, V22, P120, DOI 10.1002/(SICI)1096-9101(1998)22:2<120::AID-LSM8>3.0.CO;2-R
   MENOVSKY T, 1994, MICROSURG, V15, P44, DOI 10.1002/micr.1920150112
   Menovsky T, 1996, LASER SURG MED, V19, P152, DOI 10.1002/(SICI)1096-9101(1996)19:2<152::AID-LSM5>3.0.CO;2-R
   OZ MC, 1990, J VASC SURG, V11, P718, DOI 10.1067/mva.1990.18591
   Poppas DP, 1996, LASER SURG MED, V19, P360
   POPPAS DP, 1988, J UROLOGY, V139, P415, DOI 10.1016/S0022-5347(17)42446-3
   POPPAS DP, 1992, J UROLOGY, V148, P220, DOI 10.1016/S0022-5347(17)36557-6
   SCHOBER R, 1986, SCIENCE, V232, P1421, DOI 10.1126/science.3715454
NR 12
TC 8
Z9 8
U1 0
U2 1
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0196-8092
J9 LASER SURG MED
JI Lasers Surg. Med.
PY 1998
VL 23
IS 5
BP 258
EP 262
DI 10.1002/(SICI)1096-9101(1998)23:5<258::AID-LSM5>3.0.CO;2-K
PG 5
WC Dermatology; Surgery
SC Dermatology; Surgery
GA 154EF
UT WOS:000077875100005
PM 9888321
DA 2018-10-19
ER

PT S
AU Murakami, Y
   Yokoyama, K
   Tamiya, E
AF Murakami, Y
   Yokoyama, K
   Tamiya, E
BE Gourley, PL
   Katzir, A
TI Miniaturization of multifunctional biosensor with enzyme-immobilized
   beads
SO MICRO- AND NANOFABRICATED STRUCTURES AND DEVICES FOR BIOMEDICAL
   ENVIRONMENTAL APPLICATIONS
SE PROGRESS IN BIOMEDICAL OPTICS
LA English
DT Proceedings Paper
CT Conference on Microfabricated and Nanofabricated Structures and Devices
   for Biomedical Environmental Applications
CY JAN 26-27, 1998
CL SAN JOSE, CA
SP SPIE, Int Soc Opt Engn, Int Biomed Opt Soc
DE self-assembly; micromachining; heterogeneous integration; biosensor;
   photolithography
AB We propose a novel method for individual immobilization. Biomaterials were first immobilized on certain support material of which size is almost the same as the size of sensor element. The immobilization enlarges the size of biomaterials to the size of sensor element. Then the support is arranged on the sensor element by self-assembling. The element was microfabricated to have a microstructure for self-assembling, When both size of biomaterial and the element are the same, self-assemble is expected to give one-to-one correspondence, and then individual response. Mixed glass beads immobilized each of various enzyme were put near the pits fabricated one chip and the chip was slanted to roll the beads into the pits. When the beads immobilized only with peroxidase were arranged, the addition of luminol and hydrogen peroxide gave chemiluminescence at almost every site. Next, the beads immobilized only with glucose oxidase as dummy enzyme were mixed with HRP-beads and arranged to the sites. Addition of substrate gave limited number of luminescence-giving sites, though every site had an enzyme-immobilized bead. These results show that two kinds of enzymes were separately arranged in the site in one-to-one correspondence.
C1 Japan Adv Inst Sci & Technol, Tatsunokuchi, Ishikawa 9231292, Japan.
RP Murakami, Y (reprint author), Japan Adv Inst Sci & Technol, Hokuriku 1-1, Tatsunokuchi, Ishikawa 9231292, Japan.
RI Tamiya, Eiichi/M-6111-2018
OI Tamiya, Eiichi/0000-0002-7646-4827
NR 0
TC 3
Z9 3
U1 0
U2 1
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 1017-2661
BN 0-8194-2697-0
J9 PROG BIOM O
PY 1998
VL 3258
BP 11
EP 14
DI 10.1117/12.304381
PG 4
WC Engineering, Multidisciplinary; Engineering, Biomedical; Optics
SC Engineering; Optics
GA BK80K
UT WOS:000073452100002
DA 2018-10-19
ER

PT S
AU Kirkpatrick, CJ
   Wagner, M
   Hermanns, I
   Otto, M
   Bittinger, F
AF Kirkpatrick, CJ
   Wagner, M
   Hermanns, I
   Otto, M
   Bittinger, F
BE Haris, PI
   Chapman, D
TI Endothelial-biomaterial interactions: A central role in
   haemocompatibility
SO NEW BIOMEDICAL MATERIALS: BASIC AND APPLIED STUDIES
SE BIOMEDICAL AND HEALTH RESEARCH
LA English
DT Proceedings Paper
CT 1st International Conference on Biomedical Materials
CY MAY, 1997
CL ANCONA, ITALY
SP Biocompatibles Int, Dideco SPA, Johnson & Johnson Corp Biomat Ctr, Smith & Nephew Res Ltd, Univ London, Interdisciplinary Res Ctr Biomed Appl Sci
AB Up until now the topic of the endothelium and biomaterials has tended to centre on the study of how endothelial cells (EC) can colonize a biomaterial surface, such as in vascular prostheses. That EC might be very relevant to other aspects of haemocompatibility has not received much attention. The highly reactive nature of the endothelium, however, makes it an important candidate for a regulatory role in the reactions to intravascular implants, whether in the short-term (e.g. catheters, haemodialysis) or in the long-term, as in prosthetic heart valves or vascular stents. In the present paper the ability of biomaterials to alter the activation state of the endothelium, both in the vicinity of, as well as at a distance from a cardiovascular implant, will be discussed. Among the relevant activating signals affecting EC are metal ions, bacterial toxins and mediators from blood cells and plasma cascade systems, which can elicit EC production of inflammatory mediators and up-regulate cell adhesion molecules (CAM). This in turn can lead to an amplification of the inflammatory response. These complex reactions are intricately involved in the complications associated with such biomaterial applications. Nevertheless, knowledge of these pathomechanisms could offer the possibility of therapeutic control, in order to minimize the negative effects. Targeting signal transduction pathways within the endothelium represents one such approach and will be illustrated in the context of CAM expression. Finally, the problems of inadequate growth of EC on implants will be discussed and the importance of intensive research on biomaterial-induced angiogenesis emphasized. Examples from out own research activities will be presented to illustrate these principles.
C1 Univ Mainz, Inst Pathol, D-55101 Mainz, Germany.
RP Kirkpatrick, CJ (reprint author), Univ Mainz, Inst Pathol, D-55101 Mainz, Germany.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU I O S PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 0929-6743
BN 90-5199-365-X
J9 BIOM HLTH R
PY 1998
VL 16
BP 3
EP 11
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA BL79T
UT WOS:000076774700001
DA 2018-10-19
ER

PT S
AU Lundberg, F
   Tegenfeldt, JO
   Ljungh, A
AF Lundberg, F
   Tegenfeldt, JO
   Ljungh, A
BE Haris, PI
   Chapman, D
TI Immunimaging of proteins deposited on catheter exposed to body fluids
SO NEW BIOMEDICAL MATERIALS: BASIC AND APPLIED STUDIES
SE BIOMEDICAL AND HEALTH RESEARCH
LA English
DT Proceedings Paper
CT 1st International Conference on Biomedical Materials
CY MAY, 1997
CL ANCONA, ITALY
SP Biocompatibles Int, Dideco SPA, Johnson & Johnson Corp Biomat Ctr, Smith & Nephew Res Ltd, Univ London, Interdisciplinary Res Ctr Biomed Appl Sci
AB Studies of surface topography is an important tool in biomaterial research. Catheters from human cerebral ventricles were examined using Scanning force microscopy and field-emission scanning electron microscopy. The catheter pieces were preincubated with antibodies against human proteins deposited on the catheter surface. Gold-protein G-conjugates could be identified on catheters incubated with antibodies against the neoepitope of C9 (aE11) and against vitronectin.
C1 Univ Lund Hosp, Dept Med Microbiol, S-22185 Lund, Sweden.
RP Lundberg, F (reprint author), Univ Lund Hosp, Dept Med Microbiol, S-22185 Lund, Sweden.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU I O S PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 0929-6743
BN 90-5199-365-X
J9 BIOM HLTH R
PY 1998
VL 16
BP 53
EP 57
PG 5
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA BL79T
UT WOS:000076774700006
DA 2018-10-19
ER

PT S
AU Ljungh, A
   Lundberg, F
AF Ljungh, A
   Lundberg, F
BE Haris, PI
   Chapman, D
TI Bacterial adhesion to biomaterials
SO NEW BIOMEDICAL MATERIALS: BASIC AND APPLIED STUDIES
SE BIOMEDICAL AND HEALTH RESEARCH
LA English
DT Proceedings Paper
CT 1st International Conference on Biomedical Materials
CY MAY, 1997
CL ANCONA, ITALY
SP Biocompatibles Int, Dideco SPA, Johnson & Johnson Corp Biomat Ctr, Smith & Nephew Res Ltd, Univ London, Interdisciplinary Res Ctr Biomed Appl Sci
AB Microbial adhesion to a biomaterial surface is the initial event of a biomaterial infection which is a common and important complication to the frequent use of biomaterials in modern medicine. In this review we discuss current knowledge of microbial putative adhesive determinants and host proteins and other structures they may adhere to. Thorough knowledge in this area during in vivo-like conditions is mandatory for designation of biomaterials less prone to microbial colonization.
C1 Univ Lund, Dept Med Microbiol, Lund, Sweden.
RP Ljungh, A (reprint author), Univ Lund, Dept Med Microbiol, Solvegatan 23, Lund, Sweden.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU I O S PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 0929-6743
BN 90-5199-365-X
J9 BIOM HLTH R
PY 1998
VL 16
BP 105
EP 114
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA BL79T
UT WOS:000076774700014
DA 2018-10-19
ER

PT J
AU Kirkpatrick, CJ
   Bittinger, F
   Wagner, M
   Kohler, H
   van Kooten, TG
   Klein, CL
   Otto, M
AF Kirkpatrick, CJ
   Bittinger, F
   Wagner, M
   Kohler, H
   van Kooten, TG
   Klein, CL
   Otto, M
TI Current trends in biocompatibility testing
SO PROCEEDINGS OF THE INSTITUTION OF MECHANICAL ENGINEERS PART H-JOURNAL OF
   ENGINEERING IN MEDICINE
LA English
DT Review
DE biocompatibility; in vitro testing; human cells; cell biology; molecular
   biology; quantification
ID SCANNING ELECTRON-MICROSCOPY; ADHESIVE PROTEIN EXPRESSION; IN-VITRO;
   ENDOTHELIAL-CELLS; SHEAR-STRESS; POLYETHYLENE TEREPHTHALATE; TYROSINE
   PHOSPHORYLATION; VASCULAR PROSTHESES; SIGNAL-TRANSDUCTION; ANGIOGENESIS
AB Biocompatibility remains the central theme for biomaterials applications in medicine. It is generally accepted that this term means not only absence of a cytotoxic effect but also positive effects in the sense of biofunctionality, i.e. promotion of biological processes which further the intended aim of the application of a biomaterial. The national and international standards for testing regimes represent a lowest common denominator for such applications and do not necessarily ensure that optimal function will be achieved. The authors' thesis is that biocompatibility testing has scope for extensive development with respect to biofunctionality. The present paper reviews current trends in the in vitro aspects of biocompatibility testing. As well as a critical appraisal of the recent literature, future trends are also stressed, which the authors regard as essential for a meaningful integration of a modern biological approach into new developments in the material sciences. These include the application of modern techniques of cell and molecular biology, the concepts of tissue remodelling, hybrid organ development and encapsulated cell technology.
C1 Johannes Gutenberg Univ Mainz, Inst Pathol, Mainz, Germany.
RP Kirkpatrick, CJ (reprint author), Johannes Gutenberg Univ Mainz, Inst Pathol, Mainz, Germany.
CR ALBELDA SM, 1994, FASEB J, V8, P504
   Altankov G, 1996, J BIOMED MATER RES, V30, P385, DOI 10.1002/(SICI)1097-4636(199603)30:3<385::AID-JBM13>3.0.CO;2-J
   AMES BN, 1973, P NATL ACAD SCI USA, V70, P2281, DOI 10.1073/pnas.70.8.2281
   Bernatchez SF, 1996, BIOMATERIALS, V17, P2077, DOI 10.1016/0142-9612(96)00014-2
   BERTHOD F, 1993, BIOMATERIALS, V14, P749, DOI 10.1016/0142-9612(93)90039-5
   Bittinger F, 1996, J MATER SCI-MATER M, V7, P543, DOI 10.1007/BF00122177
   CARDONA MA, 1992, J BIOMED MATER RES, V26, P851, DOI 10.1002/jbm.820260703
   CARLOS TM, 1994, BLOOD, V84, P2068
   Cary LA, 1996, J CELL SCI, V109, P1787
   Cenni E, 1996, BIOMATERIALS, V17, P2071, DOI 10.1016/0142-9612(96)00037-3
   Cenni E, 1996, J BIOMED MATER RES, V31, P145, DOI 10.1002/(SICI)1097-4636(199605)31:1<145::AID-JBM16>3.0.CO;2-M
   CENNI E, 1995, BIOMATERIALS, V16, P1223, DOI 10.1016/0142-9612(95)98128-2
   CHANG PL, 1993, HUM GENE THER, V4, P433, DOI 10.1089/hum.1993.4.4-433
   CHARISSOUX JL, 1996, CLIN ORTHOP RELAT R, V326, P259
   ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403
   CLARK P, 1990, DEVELOPMENT, V108, P635
   Clifford CJ, 1996, J MATER SCI-MATER M, V7, P637, DOI 10.1007/BF00058204
   Cohen MC, 1996, AM J CLIN PATHOL, V105, P589
   DARQUY S, 1985, DIABETOLOGIA, V28, P776
   DEKKER A, 1994, CELL MATER, V4, P101
   denBraber ET, 1996, BIOMATERIALS, V17, P2037, DOI 10.1016/0142-9612(96)00032-4
   Dike LE, 1996, J CELL SCI, V109, P2855
   DIPIETRO LA, 1993, AM J PATHOL, V143, P678
   Doyle V, 1996, J MATER SCI-MATER M, V7, P381, DOI 10.1007/BF00154554
   DUVAL JL, 1992, CELL MATER, V2, P179
   EZEKOWITZ RAB, 1992, NEW ENGL J MED, V326, P1456, DOI 10.1056/NEJM199205283262203
   FOLKMAN J, 1992, J BIOL CHEM, V267, P10931
   Fukuchi N, 1995, BIO-MED MATER ENG, V5, P219
   Giancotti FG, 1996, J CELL SCI, V109, P1165
   Goodman SL, 1996, BIOMATERIALS, V17, P2087, DOI 10.1016/0142-9612(96)00016-6
   GRANCHI D, 1995, ORAL SURG ORAL MED O, V79, P359, DOI 10.1016/S1079-2104(05)80230-6
   GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245
   Groth T, 1996, BIOMATERIALS, V17, P1227, DOI 10.1016/0142-9612(96)84943-X
   HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092
   HEMBRY RM, 1995, HISTOPATHOLOGY, V27, P149, DOI 10.1111/j.1365-2559.1995.tb00023.x
   *ISO, 1992, ISO109934 4
   Isomaki P, 1996, ARTHRITIS RHEUM, V39, P386, DOI 10.1002/art.1780390306
   Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2
   Kanda K, 1993, ASAIO J, V39, pM561
   Kirkpatrick CJ, 1997, J MATER SCI-MATER M, V8, P131, DOI 10.1023/A:1018567018688
   KIRKPATRICK CJ, 1992, ADV BIOMAT, V10, P31
   KIRKPATRICK CJ, 1990, J MATER SCI-MATER M, V1, P9, DOI 10.1007/BF00705347
   KIRKPATRICK CJ, 1992, CELL MATER, V2, P169
   KIRKPATRICK CJ, 1994, COLLOID SURFACE B, V2, P251, DOI 10.1016/0927-7765(94)80039-1
   KIRKPATRICK CJ, 1991, CELL MATER, V1, P93
   KIRKPATRICK CJ, 1982, RES EXP MED, V181, P259, DOI 10.1007/BF01851199
   KIRKPATRICK CJ, 1992, REGULATORY AFFAIRS, V4, P13
   KLEIN CL, 1994, PATHOBIOLOGY, V62, P90, DOI 10.1159/000163883
   KLEIN CL, 1994, J MATER SCI-MATER M, V5, P798, DOI 10.1007/BF00213138
   KLEIN CL, 1994, COLLOID SURFACE B, V3, P229
   KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554
   KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392
   Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2
   LABAT B, 1995, J BIOMED MATER RES, V29, P1397, DOI 10.1002/jbm.820291111
   LANZA RP, 1995, TRANSPLANTATION, V59, P1485, DOI 10.1097/00007890-199505270-00023
   Lanza RP, 1996, NAT BIOTECHNOL, V14, P1107, DOI 10.1038/nbt0996-1107
   LANZA RP, 1993, TRANSPLANTATION, V56, P1067, DOI 10.1097/00007890-199311000-00003
   LILES WC, 1995, J INFECT DIS, V172, P1573, DOI 10.1093/infdis/172.6.1573
   Macnair R, 1997, J MATER SCI-MATER M, V8, P105, DOI 10.1023/A:1018510900941
   MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470
   Maki T, 1996, DIABETES, V45, P342, DOI 10.2337/diabetes.45.3.342
   Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9
   MEYLE J, 1994, J MATER SCI-MATER M, V5, P463, DOI 10.1007/BF00058984
   MILLER KM, 1988, J BIOMED MATER RES, V22, P713, DOI 10.1002/jbm.820220805
   MIOSSEC P, 1995, CLIN EXP RHEUMATOL, V13, P13
   MOLLNES TE, 1995, ARTIF ORGANS, V19, P909, DOI 10.1111/j.1525-1594.1995.tb02450.x
   Montesano R, 1996, LAB INVEST, V75, P249
   OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3
   Otto M, 1997, J MATER SCI-MATER M, V8, P119, DOI 10.1023/A:1018515001850
   Polverini PJ, 1996, AM J PATHOL, V148, P1023
   PURCHASE IFH, 1994, HUM EXP TOXICOL, V13, P17, DOI 10.1177/096032719401300104
   Richter E, 1996, J MATER SCI-MATER M, V7, P85, DOI 10.1007/BF00058719
   SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149
   SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5
   Smith ML, 1996, AM J PATHOL, V148, P1019
   SUTHERLAND DER, 1994, TRANSPLANT REV, V8, P185
   THOUMINE O, 1995, LAB INVEST, V73, P565
   Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4
   Tresco P A, 1992, ASAIO J, V38, P17, DOI 10.1097/00002480-199201000-00006
   VONSCHROEDER HP, 1991, J BIOMED MATER RES, V25, P329, DOI 10.1002/jbm.820250305
   Wan H, 1997, J MATER SCI-MATER M, V8, P45, DOI 10.1023/A:1018542313236
   WAROCQUIERCLEROUT R, 1995, CELL MATER, V5, P1
   Williams DF, 1987, PROGR BIOMEDICAL ENG, V4, P54
   YANG J, 1990, J MATER SCI-MATER M, V26, P1217
   YANG MB, 1994, CELL TRANSPLANT, V3, P373, DOI 10.1177/096368979400300504
   Yokohama Y, 1995, LAB INVEST, V73, P899
   Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X
NR 87
TC 89
Z9 114
U1 1
U2 25
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0954-4119
EI 2041-3033
J9 P I MECH ENG H
JI Proc. Inst. Mech. Eng. Part H-J. Eng. Med.
PY 1998
VL 212
IS H2
BP 75
EP 84
DI 10.1243/0954411981533845
PG 10
WC Engineering, Biomedical
SC Engineering
GA ZM809
UT WOS:000073578000002
PM 9611998
DA 2018-10-19
ER

PT J
AU Macnair, R
   Underwood, MJ
   Angelini, GD
AF Macnair, R
   Underwood, MJ
   Angelini, GD
TI Biomaterials and cardiovascular devices
SO PROCEEDINGS OF THE INSTITUTION OF MECHANICAL ENGINEERS PART H-JOURNAL OF
   ENGINEERING IN MEDICINE
LA English
DT Article
DE biomaterials; blood interaction; circulatory support devices; mechanical
   heart valves; vascular grafts
ID STAPHYLOCOCCUS-AUREUS; ENDOTHELIAL-CELLS; VASCULAR GRAFTS; IN-VITRO;
   SURFACE; PROSTHESIS; BINDING; BLOOD
AB In the field of cardiovascular surgery there is presently a lack of biomaterials possessing essential characteristics of the native tissue or organ which is to be replaced. This paper describes various biomaterials that have been introduced into the circulatory system and the complex reactions that subsequently occur. The risk of infection is also discussed as well as prevention and treatment regimes that can be used. Examples of future biomaterial development are outlined in an attempt to achieve biocompatibility.
C1 Bristol Royal Infirm, Bristol Heart Inst, Bristol, Avon, England.
RP Macnair, R (reprint author), Bristol Royal Infirm, Bristol Heart Inst, Bristol, Avon, England.
RI Underwood, Malcolm John/L-6823-2016
OI angelini, gianni/0000-0002-1753-3730
CR Brunette D M, 1988, Int J Oral Maxillofac Implants, V3, P231
   BURNS GL, 1993, INT J ARTIF ORGANS, V16, P771
   BUSER D, 1991, J BIOMED MATER RES, V25, P889, DOI 10.1002/jbm.820250708
   Carr HMH, 1996, ANN VASC SURG, V10, P469, DOI 10.1007/BF02000595
   CHHATWAL GS, 1987, INFECT IMMUN, V55, P1878
   DE BAKEY M E, 1958, Am Surg, V24, P862
   *DEP HLTH, 1995, UK HEART VAL REG
   DEWANJEE MK, 1983, T AM SOC ART INT ORG, V298, P188
   DEWEY CF, 1981, J BIOMECH ENG-T ASME, V103, P177, DOI 10.1115/1.3138276
   Didisheim P, 1994, ASAIO J, V40, P230, DOI 10.1097/00002480-199404000-00020
   Dunn PF, 1996, CIRCULATION, V93, P1439, DOI 10.1161/01.CIR.93.7.1439
   EDWARDS WS, 1978, ARCH SURG-CHICAGO, V113, P1225
   FRAZIER OH, 1994, ANN THORAC SURG, V57, P1416, DOI 10.1016/0003-4975(94)90094-9
   GIRIDHAR G, 1995, J BIOMED MATER RES, V29, P1179, DOI 10.1002/jbm.820291004
   Gordon S M, 1995, Semin Thorac Cardiovasc Surg, V7, P2
   GRAF T, 1991, INT J ARTIF ORGANS, V14, P221
   Greisler HP, 1996, J CONTROL RELEASE, V39, P267, DOI 10.1016/0168-3659(95)00159-X
   HAWIGER J, 1982, BIOCHEMISTRY-US, V21, P1407, DOI 10.1021/bi00535a047
   HOFFMAN AS, 1995, ARTIF ORGANS, V19, P458, DOI 10.1111/j.1525-1594.1995.tb02359.x
   KASEMO B, 1994, ENVIRON HEALTH PERSP, V102, P41, DOI 10.2307/3432057
   Kito H, 1996, J BIOMED MATER RES, V30, P321
   KUUSELA P, 1978, NATURE, V276, P718, DOI 10.1038/276718a0
   LARENBY D, 1991, INFECT MED, V8, P15
   LARENBY D, 1991, INFECT MED, V8, P42
   Mackay TG, 1996, BIOMATERIALS, V17, P1857, DOI 10.1016/0142-9612(95)00242-1
   Meyle J, 1993, J Biomater Appl, V7, P362, DOI 10.1177/088532829300700404
   NAWROTH PP, 1987, SEMIN THROMB HEMOST, V13, P391, DOI 10.1055/s-2007-1003516
   NOJIRI C, 1995, ARTIF ORGANS, V19, P32, DOI 10.1111/j.1525-1594.1995.tb02241.x
   OKANO T, 1986, J BIOMED MATER RES, V20, P1035, DOI 10.1002/jbm.820200716
   RATNR BD, 1987, J BIOMED MATER RES-A, V21, P59
   Sackman J E, 1996, Tissue Eng, V2, P223, DOI 10.1089/ten.1996.2.223
   SCHOEN FJ, 1991, REPLACEMENT CARDIAC, P357
   SCHWARTZ Z, 1994, J CELL BIOCHEM, V56, P340, DOI 10.1002/jcb.240560310
   SIROIS E, 1993, INT J ARTIF ORGANS, V16, P609
   SPEZIALE P, 1986, J BACTERIOL, V167, P77, DOI 10.1128/jb.167.1.77-81.1986
   STEIN PD, 1992, CHEST, V102, pS445, DOI 10.1378/chest.102.4_Supplement.445S
   Taggart DP, 1997, BRIT MED J, V314, P453, DOI 10.1136/bmj.314.7079.453
   TANZI M C, 1991, Clinical Materials, V8, P57, DOI 10.1016/0267-6605(91)90010-D
   Tayama E, 1996, ARTIF ORGANS, V20, P197, DOI 10.1111/j.1525-1594.1996.tb04427.x
   TUNNEY MM, 1996, REV MED MICROBIOL, V7, P195
   VOORHEES AB, 1952, ANN SURG, V135, P332, DOI 10.1097/00000658-195203000-00006
   Williams D, 1995, Med Device Technol, V6, P6
   YAMADA KM, 1978, NATURE, V275, P179, DOI 10.1038/275179a0
NR 43
TC 9
Z9 9
U1 1
U2 3
PU PROFESSIONAL ENGINEERING PUBLISHING LTD
PI BURY ST EDMUNDS
PA NORTHGATE AVENUE,, BURY ST EDMUNDS, SUFFOLK, ENGLAND IP32 6BW
SN 0954-4119
J9 P I MECH ENG H
JI Proc. Inst. Mech. Eng. Part H-J. Eng. Med.
PY 1998
VL 212
IS H6
BP 465
EP 471
DI 10.1243/0954411981534222
PG 7
WC Engineering, Biomedical
SC Engineering
GA 140LJ
UT WOS:000077088500007
PM 9852741
DA 2018-10-19
ER

PT B
AU Yang, XJ
   Kumar, RR
   Ban, S
   Maruno, S
AF Yang, XJ
   Kumar, RR
   Ban, S
   Maruno, S
BE Khor, KA
   Srivatsan, TS
   Moore, JJ
TI Characterization of ceramic glass in hydroxyapatite containing glass
   coated titanium composites
SO PROCESSING AND FABRICATION OF ADVANCED MATERIALS VI, VOLS 1 & 2
LA English
DT Proceedings Paper
CT International Symposium on Processing and Fabrication of Advanced
   Materials
CY NOV 24-26, 1997
CL SINGAPORE, SINGAPORE
SP Nanyang Technol Univ, Sch Mech & Prod Engn, Inst Mat, Minerals Met & Mat Soc, Adv Mat Res Ctr
DE hydroxyapatite (HA); biomaterial; composite; implant; functionally
   gradient material
ID FUNCTIONALLY GRADIENT COMPOSITE; PHOSPHATE; PRECIPITATION; BEHAVIOR;
   SURFACE; BONE
AB The hydroxyapatite (HA)-glass (G) ceramics were prepared using HA with different degrees of crystallinity and characteristics, wherein the HA was synthesized chemically and fired at various temperature (200-1200 degrees C) for 2h. The properties of these HA-G ceramics as well as the reaction of glass with HA, were investigated by XRD, DSC and FTIR. The results showed that HA slightly reacted with glass and formed a small amount of boron containing apatite. The pun-out strength study of the HA-G-Ti composite implants from the bone demonstrated that the composite using HA fired at 1200 degrees C showed 20.6 MPa pull-out strength value for one month implantation. The results of the strength test and SEM observation confirm that HA-G-Ti composite consisting of HA fired at 1200 degrees C is the best composite showing excellent biocompatability and mechanical strength.
C1 Nagoya Inst Technol, Showa Ku, Nagoya, Aichi 466, Japan.
RP Yang, XJ (reprint author), Nagoya Inst Technol, Showa Ku, Nagoya, Aichi 466, Japan.
CR BAN S, 1994, J BIOMED MATER RES, V28, P65, DOI 10.1002/jbm.820280109
   BAN SJ, 1995, BIOMATERIALS, V16, P977, DOI 10.1016/0142-9612(95)94904-Y
   BAN SJ, 1991, JPN J APPL PHYS 2, V30, pL1333, DOI 10.1143/JJAP.30.L1333
   DACULSI G, 1990, CALCIFIED TISSUE INT, V46, P20, DOI 10.1007/BF02555820
   FUJISHIRO Y, 1995, J MATER SCI-MATER M, V6, P172, DOI 10.1007/BF00120295
   Ishikawa Tomoji, 1993, Clinical Materials, V14, P277, DOI 10.1016/0267-6605(93)90014-X
   ITO A, 1995, PHOSPHORUS LETT, V24, P24
   ITO A, 1988, J CERAM SOC JPN, V96, P302
   JARCHO M, 1976, J MATER SCI, V11, P2027, DOI 10.1007/BF02403350
   KITSUGI T, 1987, J BIOMED MATER RES, V21, P1109, DOI 10.1002/jbm.820210905
   MARUNO S, 1991, BIOMATERIALS, V12, P225, DOI 10.1016/0142-9612(91)90204-N
   MARUNO S, 1992, NIPPON SERAM KYO GAK, V100, P362
   MARUNO S, 1993, P IMMM93, P305
   MARUNO S, 1992, BIOCERAMICS, V5, P165
   MARUNO S, 1996, INT M KOR SOC BIOM S, P27
   OGINO M, 1980, J NON-CRYST SOLIDS, V38-9, P673, DOI 10.1016/0022-3093(80)90514-1
   RADIN SR, 1993, J BIOMED MATER RES, V27, P35, DOI 10.1002/jbm.820270106
   WU JM, 1988, J MATER SCI, V23, P3771, DOI 10.1007/BF00540526
   YAMADA K, 1996, BIOCERAMICS, V9, P285
NR 19
TC 0
Z9 0
U1 0
U2 1
PU IOM COMMUNICATIONS LTD
PI LONDON
PA 1 CARLTON HOUSE TERRACE, LONDON SW1Y 5DB, ENGLAND
BN 1-86125-039-8
PY 1998
BP 1693
EP 1701
PG 9
WC Materials Science, Ceramics; Materials Science, Multidisciplinary;
   Metallurgy & Metallurgical Engineering; Materials Science, Composites
SC Materials Science; Metallurgy & Metallurgical Engineering
GA BP03C
UT WOS:000083931500155
DA 2018-10-19
ER

PT B
AU Cheang, P
   Khor, KA
AF Cheang, P
   Khor, KA
BE Khor, KA
   Srivatsan, TS
   Moore, JJ
TI Role of powder morphology in the mechanical properties of plasma sprayed
   HA coatings
SO PROCESSING AND FABRICATION OF ADVANCED MATERIALS VI, VOLS 1 & 2
LA English
DT Proceedings Paper
CT International Symposium on Processing and Fabrication of Advanced
   Materials
CY NOV 24-26, 1997
CL SINGAPORE, SINGAPORE
SP Nanyang Technol Univ, Sch Mech & Prod Engn, Inst Mat, Minerals Met & Mat Soc, Adv Mat Res Ctr
DE hydroxyapatite; spheroidised; plasma spraying; powder morphology and
   cohesive strength
ID HYDROXYAPATITE COATINGS; COATED IMPLANTS; INTERFACE; TITANIUM; APATITE;
   BONE; BIOCERAMICS
AB Hydroxyapatite is a biomaterial with unique bioactive properties that promote rapid bone growth without soft tissue interaction. This property has enabled artificial implants to establish strong intimate bio-chemical fixation that differs from other classes of bioinert or bioresorbable materials. Its chemical similarity to natural bone has created numerous implant possibilities involving bony-tissue interaction. Today, the material has been used successfully as coating and bulk composites in both dental and orthopeadic applications. A layer of HA coating can significantly enhance the biofunctionality and biocompatibility of clinically proven implants. HA coatings are generally deposited using plasma spraying. The spray technique has proven to be convenient, economical and effective. However, complexity in the spraying process, inconsistency in the feedstock material and physico-chemical changes have caused variations in phase composition, crystallinity and porosity. Previous studies have shown that the geometric and structural morphology of the starting HA powder has significant effect on the structural and chemical property of the coating. Our study has shown that using spheroidised HA powder improves structural integrity, while particle size affects phase composition and crystallinity. This study examines the effect of powder morphology on the fracture behaviour and coating bond strength of plasma sprayed HA coatings. Coatings generated from three different types of HA powders namely; calcined HA (CHA), spray dried HA (SDHA) and spheroidised HA (SHA) were evaluated using SEM, EDAX and tensile adhesion test (TAT). The TAT results showed that SHA coatings have higher cohesive bond strength over both CHA and SDHA coatings.
C1 Nanyang Technol Univ, Ctr Adv Mat Res, Singapore 639798, Singapore.
RP Cheang, P (reprint author), Nanyang Technol Univ, Ctr Adv Mat Res, Nanyang Ave, Singapore 639798, Singapore.
RI Khor, Khiam Aik (Michael)/B-6929-2009; Khor, Khiam Aik/G-2827-2010
CR AKAO M, 1981, J MATER SCI, V16, P809, DOI 10.1007/BF00552220
   Bailey D., 1988, MATER DESIGN, V9, P330
   Cheang P, 1996, BIOMATERIALS, V17, P537, DOI 10.1016/0142-9612(96)82729-3
   CHEANG P, 1995, J MATER PROCESS TECH, V48, P429, DOI 10.1016/0924-0136(94)01679-U
   CHEANG P, 1995, THERMAL SPRAYING CUR, V1, P181
   COURTENEYHARRIS RG, 1995, BIOMATERIALS, V16, P489, DOI 10.1016/0142-9612(95)98823-W
   DEGROOT K, 1983, BIOCERAMICS CALCIUM, P1
   DUCHEYNE P, 1980, J BIOMED MATER RES, V14, P225, DOI 10.1002/jbm.820140305
   GEESINK RGT, 1988, J BONE JOINT SURG BR, V70, P17
   GROSS KA, 1991, 2ND P PLASM TECHN S, V3, P159
   HENCH LL, 1991, J AM CERAM SOC, V74, P1487, DOI 10.1111/j.1151-2916.1991.tb07132.x
   Hulbert S. F., 1987, HIGH TECH CERAMICS, P189
   JARCHO M, 1981, CLIN ORTHOP RELAT R, P259
   JARCHO M, 1977, J BIOENG, V1, P79
   KAY J F, 1992, Dental Clinics of North America, V36, P1
   KHOR KA, 1994, J THERM SPRAY TECHN, V3, P45, DOI 10.1007/BF02648998
   KLEIN CPAT, 1991, J BIOMED MATER RES, V25, P53, DOI 10.1002/jbm.820250105
   MCPHERSON R, 1995, J MATER SCI-MATER M, V6, P327, DOI 10.1007/BF00120300
   MCPHERSON R, 1981, THIN SOLID FILMS, V83, P297, DOI 10.1016/0040-6090(81)90633-7
   NICHOLL AR, 1987, SURF COAT TECH, V30, P95
   ONG JL, 1995, J BIOMED MATER RES, V29, P165, DOI 10.1002/jbm.820290205
   PILLIAR RM, 1991, MRS BULL, V16, P55
   RADIN SR, 1992, J MATER SCI-MATER M, V3, P33, DOI 10.1007/BF00702942
   WOLKE JGC, 1992, J THERM SPRAY TECHN, V1, P75
   YANG CY, 1995, J MATER SCI-MATER M, V6, P249, DOI 10.1007/BF00120267
NR 25
TC 0
Z9 0
U1 0
U2 0
PU IOM COMMUNICATIONS LTD
PI LONDON
PA 1 CARLTON HOUSE TERRACE, LONDON SW1Y 5DB, ENGLAND
BN 1-86125-039-8
PY 1998
BP 1751
EP 1760
PG 10
WC Materials Science, Ceramics; Materials Science, Multidisciplinary;
   Metallurgy & Metallurgical Engineering; Materials Science, Composites
SC Materials Science; Metallurgy & Metallurgical Engineering
GA BP03C
UT WOS:000083931500160
DA 2018-10-19
ER

PT J
AU Favia, P
   d'Agostino, R
AF Favia, P
   d'Agostino, R
TI Plasma treatments and plasma deposition of polymers for biomedical
   applications
SO SURFACE & COATINGS TECHNOLOGY
LA English
DT Article; Proceedings Paper
CT 5th International Conference on Plasma Surface Engineering
CY SEP 09-13, 1996
CL GARMISCH PARTENKI, GERMANY
SP European Joint Comm Plasma & Ion Surf Engn
DE plasma processes; PE-CVD; plasma-treatments; biomaterials
ID RAY PHOTOELECTRON-SPECTROSCOPY; CHEMICAL VAPOR-DEPOSITION;
   GLOW-DISCHARGE; THIN-FILMS; FLUORINATED MONOMERS; GLUCOSE-OXIDASE;
   TETRAETHOXYSILANE; IMMOBILIZATION; DIAGNOSTICS; MECHANISMS
AB The aim of this review is to describe how biomaterial engineering processes, particularly in the field of polymer modifications for enhanced blood-compatibility, can take advantage of low-pressure plasma techniques. It will also be emphasized how a diagnostic approach on both plasma and surface reactions can lead to understand and control the chemistry of plasma processes. (C) 1998 Elsevier Science S.A.
C1 Univ Bari, CNR, Ctr Studio Chim Plasmi, Dept Chem, I-70126 Bari, Italy.
RP Favia, P (reprint author), Univ Bari, CNR, Ctr Studio Chim Plasmi, Dept Chem, Via Orabona 4, I-70126 Bari, Italy.
OI Favia, Pietro/0000-0002-5896-895X
CR Andrade J. D., 1987, ASAIO J, V33, P75
   AREFI F, 1992, METALLIZED PLASTICS, V3
   Bruno G., 1995, PLASMA DEPOSITION AM
   CASTNER DG, 1993, LANGMUIR, V9, P537, DOI 10.1021/la00026a029
   CASTNER DG, 1997, SURFACE MODIFICATION
   Chapman B., 1980, GLOW DISCHARGE PROCE
   COBURN JW, 1980, J APPL PHYS, V51, P3134, DOI 10.1063/1.328060
   d'Agostino R., 1990, PLASMA DEPOSITION TR
   DAGOSTINO R, 1981, J APPL PHYS, V52, P1259, DOI 10.1063/1.329748
   DAGOSTINO R, 1990, J POLYM SCI POL CHEM, V28, P3387, DOI 10.1002/pola.1990.080281217
   DAGOSTINO R, 1987, J APPL PHYS, V61, P2754, DOI 10.1063/1.337864
   DANILICH MJ, 1992, J BIOMAT SCI-POLYM E, V3, P195, DOI 10.1163/156856292X00123
   DANILICH MJ, 1993, ANN BIOMED ENG, V21, P655, DOI 10.1007/BF02368645
   ERTEL SI, 1991, J BIOMAT SCI-POLYM E, V3, P163, DOI 10.1163/156856291X00269
   FAVIA P, 1994, J POLYM SCI POL CHEM, V32, P121, DOI 10.1002/pola.1994.080320114
   FAVIA P, 1992, J BIOMAT SCI-POLYM E, V4, P61
   FAVIA P, 1994, PURE APPL CHEM, V66, P1373, DOI 10.1351/pac199466061373
   FAVIA P, 1997, SURFACE MODIFICATION
   Favia P, 1996, PLASMAS POLYM, V1, P297
   Favia P, 1996, PLASMAS POLYM, V1, P91, DOI DOI 10.1007/BF02532821
   FAVIA P, 1995, P 21 ANN M SOC BIOM
   Favia P, 1992, PLASMA SOURCES SCI T, V1, P59, DOI 10.1088/0963-0252/1/1/007
   FELTS JT, 1991, Patent No. 913071247
   Flamm DL, 1981, PLASMA CHEM PLASMA P, V1, P317
   FRACASSI F, 1992, J ELECTROCHEM SOC, V139, P2636, DOI 10.1149/1.2221277
   GARFINKLE AM, 1984, T AM SOC ART INT ORG, V30, P432
   GEGENBACH TR, 1994, J ADHES SCI TECHNOL, V8, P305
   GOMBOTZ WR, 1987, CRIT REV BIOCOMPAT, V4, P1
   GRIESLER HP, 1989, ARCH SURG-CHICAGO, V124, P967
   GRIESSER HJ, 1994, J BIOMAT SCI-POLYM E, V5, P531, DOI 10.1163/156856294X00194
   HASIRCI N, 1986, J BIOMED MATER RES, V20, P963, DOI 10.1002/jbm.820200711
   HU C, 1995, POLYM PREPR, V36, P111
   Kang IK, 1996, BIOMATERIALS, V17, P841, DOI 10.1016/0142-9612(96)81422-0
   KIAEI D, 1992, J BIOMAT SCI-POLYM E, V4, P35
   KIAEI D, 1988, J APPL POLYM SCI APP, V42, P269
   LAMENDOLA R, 1995, P 10 INT C PLASM PRO
   LOPEZ GP, 1992, J BIOMED MATER RES, V26, P415, DOI 10.1002/jbm.820260402
   Manos D. M., 1989, PLASMA ETCHING INTRO
   Merrill EW, 1983, AM SOC ARTIF INTERN, V6, P60
   NARAYANAN PV, 1994, J BIOMAT SCI-POLYM E, V6, P181, DOI 10.1163/156856294X00301
   PACCAGNELLA A, 1986, INT J ARTIF ORGANS, V9, P127
   PAI CS, 1990, J APPL PHYS, V68, P793, DOI 10.1063/1.346759
   Ratner BD, 1990, PLASMA DEPOSITION TR
   SAHLI S, 1994, THIN SOLID FILMS, V250, P206, DOI 10.1016/0040-6090(94)90187-2
   SELAMOGLU N, 1989, J VAC SCI TECHNOL B, V7, P1345, DOI 10.1116/1.584536
   SENATORE F, 1988, CRIT REV BIOCOMPAT, V4, P281
   SHEU MS, 1993, CLIN MATER, V13, P41, DOI 10.1016/0267-6605(93)90088-O
   TATOULIAN M, 1995, P 12 INT S PLASM CHE
   TERLINGEN JGA, 1993, J BIOMAT SCI-POLYM E, V4, P165, DOI 10.1163/156856293X00500
   Wrobel A M, 1990, PLASMA DEPOSITION TR
   Yasuda H., 1985, PLASMA POLYM
NR 51
TC 196
Z9 203
U1 2
U2 44
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0257-8972
J9 SURF COAT TECH
JI Surf. Coat. Technol.
PD JAN
PY 1998
VL 98
IS 1-3
BP 1102
EP 1106
DI 10.1016/S0257-8972(97)00285-5
PG 5
WC Materials Science, Coatings & Films; Physics, Applied
SC Materials Science; Physics
GA ZD063
UT WOS:000072647200050
DA 2018-10-19
ER

PT J
AU Fallgren, C
   Utt, M
   Petersson, AC
   Ljungh, A
   Wadstrom, T
AF Fallgren, C
   Utt, M
   Petersson, AC
   Ljungh, A
   Wadstrom, T
TI In vitro anti-staphylococcal activity of heparinized biomaterials bonded
   with combinations of rifampicin
SO ZENTRALBLATT FUR BAKTERIOLOGIE-INTERNATIONAL JOURNAL OF MEDICAL
   MICROBIOLOGY VIROLOGY PARASITOLOGY AND INFECTIOUS DISEASES
LA English
DT Article
ID ANTIMICROBIAL ACTIVITY; GRAFT INFECTION; RELEASE SYSTEM; PREVENTION;
   PROSTHESES; ANTIBIOTICS; SURFACES; POLYESTER; ADHERENCE; EFFICACY
AB Biomaterial implants in various human body tissues are highly susceptible to bacterial colonization. We report here on the coating of heparinized biomaterials with heparin binding extracellular matrix proteins giving special regard to the efficient adsorption and slow release of antibiotics. Heparin was partially degraded and the resulting fragments were covalently end-point attached to 0.5 cm long silicone biomaterial surface. Collagen type I was immobilized on the heparinized biomaterials and then cross-linked with acyl-azide or carbodiimide. Finally, the resulting biosurfaces were exposed to antibiotics, i.e. rifampicin in combination with cefuroxime, fusidic acid, ofloxacin or vancomycin, respectively. The antibiotic bonded biomaterials were evaluated for their anti-staphylococcal activity after elution in NaCl, serum or blood by measuring the zones of inhibition for S. epidermidis strain RP12. Furthermore, we examined the in-vitro colonization resistance to S. epidermidis RP12 for these combinations of rifampicin-bonded biomaterials by an ATP bioluminescence assay. The ATP measurements showed that initially adherent bacteria were eradicated from the polymer surface, for at least 24 or 48 h (fusidic acid > cefuroxime > vancomycin > ofloxacin). The anti-staphylococcal activity of rifampicin-fusidic acid bonded heparinized biomaterials seems of sufficient duration and efficacy to merit testing in an animal model.
C1 Univ Lund, Dept Med Microbiol, S-22362 Lund, Sweden.
RP Fallgren, C (reprint author), Univ Lund, Dept Med Microbiol, Solvegatan 23, S-22362 Lund, Sweden.
RI Utt, Meeme/G-3831-2016
CR APPELGREN P, 1996, CRIT CARE MED, V24, P1
   BONZON N, 1995, BIOMATERIALS, V16, P747, DOI 10.1016/0142-9612(95)99636-Z
   BROWN DFJ, 1991, J ANTIMICROB CHEMOTH, V27, P185, DOI 10.1093/jac/27.2.185
   BUTCHER WG, 1994, CHEMOTHERAPY, V40, P114, DOI 10.1159/000239182
   CHERVU A, 1991, J VASC SURG, V13, P897
   CHERVU A, 1991, J VASC SURG, V14, P521, DOI 10.1016/0741-5214(91)90246-Q
   CHVAPIL M, 1977, J BIOMED MATER RES, V11, P721, DOI 10.1002/jbm.820110508
   COSTERTON JW, 1995, ANNU REV MICROBIOL, V49, P711, DOI 10.1146/annurev.mi.49.100195.003431
   Eliopoulos GM, 1996, ANTIBIOTICS LAB MED, P330
   Goeau-Brissonniere O, 1991, Ann Vasc Surg, V5, P408, DOI 10.1007/BF02133043
   GRISTINA A, 1988, ANTIMICROB AGENTS CH, V33, P813
   HAMPL J, 1995, ACTA NEUROCHIR, V133, P147, DOI 10.1007/BF01420065
   HAVERICH A, 1992, J VASC SURG, V15, P187, DOI 10.1016/0741-5214(92)70027-I
   LARM O, 1983, BIOMATER ARTIF CELL, V11, P161, DOI 10.3109/10731198309118804
   MAROIS Y, 1995, BIOMATERIALS, V16, P1131, DOI 10.1016/0142-9612(95)93576-Y
   MERMEL LA, 1993, J INFECT DIS, V167, P920, DOI 10.1093/infdis/167.4.920
   MOLLNES TE, 1995, ARTIF ORGANS, V19, P909, DOI 10.1111/j.1525-1594.1995.tb02450.x
   MUEHRCKE DD, 1995, J THORAC CARDIOV SUR, V110, P843, DOI 10.1016/S0022-5223(95)70119-2
   PAULSSON M, 1994, J BIOMED MATER RES, V28, P311, DOI 10.1002/jbm.820280305
   PETITE H, 1994, J BIOMED MATER RES, V28, P159, DOI 10.1002/jbm.820280204
   Raad I, 1996, J INFECT DIS, V173, P418, DOI 10.1093/infdis/173.2.418
   RICHARDS GK, 1993, INT J ARTIF ORGANS, V16, P777
   SANTOSHAM M, 1977, J PEDIATR-US, V91, P719, DOI 10.1016/S0022-3476(77)81022-6
   Schierholz JM, 1996, ZBL BAKT-INT J MED M, V284, P390
   Strachan C J, 1991, Eur J Vasc Surg, V5, P627, DOI 10.1016/S0950-821X(05)80896-5
   STRACHAN CJL, 1995, J HOSP INFECT, V30, P54, DOI 10.1016/0195-6701(95)90006-3
   TUNNEY MM, 1996, REV MED MICROBIOL, V7, P195
   TYLEWSKA S, 1981, ANTIMICROB AGENTS CH, V20, P563, DOI 10.1128/AAC.20.5.563
   WADSTROM T, 1990, PATHOGENESIS WOUND B
   YANNAS I V, 1992, Clinical Materials, V9, P179, DOI 10.1016/0267-6605(92)90098-E
   YANNAS IV, 1994, J CELL BIOCHEM, V56, P188, DOI 10.1002/jcb.240560212
   YU JL, 1994, J MED MICROBIOL, V41, P133, DOI 10.1099/00222615-41-2-133
NR 32
TC 1
Z9 1
U1 0
U2 5
PU GUSTAV FISCHER VERLAG
PI JENA
PA VILLENGANG 2, D-07745 JENA, GERMANY
SN 0934-8840
J9 ZBL BAKT-INT J MED M
JI Zent.bl. Bakteriol.-Int. J. Med. Microbiol. Virol. Parasitol. Infect.
   Dis.
PD JAN
PY 1998
VL 287
IS 1-2
BP 19
EP 31
PG 13
WC Microbiology; Virology
SC Microbiology; Virology
GA YV547
UT WOS:000071836000003
PM 9532261
DA 2018-10-19
ER

PT J
AU VoytikHarbin, SL
   Brightman, AO
   Kraine, MR
   Waisner, B
   Badylak, SF
AF VoytikHarbin, SL
   Brightman, AO
   Kraine, MR
   Waisner, B
   Badylak, SF
TI Identification of extractable growth factors from small intestinal
   submucosa
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE growth factors; biomaterial; cell proliferation; extracellular matrix;
   tissue repair
ID BETA BINDING-PROTEIN; LATENT TGF-BETA; EXTRACELLULAR-MATRIX;
   GENE-EXPRESSION; HEPARIN; PROTEOGLYCAN; BIOMATERIALS; DECORIN; REPAIR;
   BONE
AB When implanted as a biomaterial for tissue replacement, selected submucosal layers of porcine small intestine induce site-specific tissue remodelling. Small intestinal submucosa (SIS), as isolated, is primarily an acellular extracellular matrix material. In an attempt to discover the components of small intestinal submucosa which are able to induce this tissue remodelling, the material was extracted and extracts were tested for the ability to stimulate Swiss 3T3 fibroblasts to synthesize DNA and proliferate. Each of the four different extracts of small intestinal submucosa had measurable cell-stimulating activity when analysed in both a whole cell proliferation assay (alamarBlue dye reduction) and a DNA synthesis assay ([H-3]-thymidine incorporation). Proteins extracted from SIS with 2 M urea induced activity profiles in the two assays which were very similar to the activity profiles of basic fibroblast growth factor (FGF-2) in the assays. As well, the changes in cell morphology in response to the extracted proteins mimicked the changes induced by FGF-2. Neutralization experiments with specific antibodies to this growth factor confirmed the presence of FGF-2 and indicated that it was responsible for 60% of the fibroblast-stimulating activity of the urea extract of small intestinal submucosa. Western blot analysis with a monoclonal antibody specific for FGF-2 detected a reactive doublet at approximately 19 kDa and further confirmed the presence of FGF-2. Cell stimulating activity of proteins extracted from SIS with 4 M guanidine was neutralized by an antibody specific for transforming growth factor beta (TGF beta). Changes in the morphology of the fibroblasts exposed to this extract were nearly identical to changes induced by TGF beta. Although no reactive protein band was detected at 25 kDa in nonreduced western blot analysis, several bands were reactive at higher molecular weight. The identity of this TGF beta-related component of small intestinal submucosa is unknown. Identification of FGF-2 and TGF beta-related activities in SIS, two growth factors known to significantly affect critical processes of tissue development and differentiation, provides the opportunity to further elucidate the mechanisms by which this extracellular matrix biomaterial modulates wound healing and tissue remodelling. J. Cell. Biochem. 67:478-491, 1997. (C) 1997 Wiley-Liss, Inc.
RP VoytikHarbin, SL (reprint author), PURDUE UNIV, HILLENBRAND BIOMED ENGN CTR, W LAFAYETTE, IN 47907 USA.
OI Badylak, Stephen/0000-0003-3555-0689
FU NICHD NIH HHS [HD 31425]
CR AIKEN SW, 1994, VET COMP ORTHOPAED, V7, P124
   AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0
   BADYLAK SF, 1995, J BIOMED MATER RES, V29, P977, DOI 10.1002/jbm.820290809
   BADYLAK SF, 1993, TISSUE ENGINEERING, P179
   BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047
   Bell E, 1995, Tissue Eng, V1, P163, DOI 10.1089/ten.1995.1.163
   BROWN KJ, 1995, J CELL BIOCHEM, V58, P6, DOI 10.1002/jcb.240580103
   CARTHIDGE SA, 1990, BRIT J CANCER, V60, P657
   DALLAS SL, 1995, J CELL BIOL, V131, P539, DOI 10.1083/jcb.131.2.539
   FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110
   GREENHALGH DG, 1990, AM J PATHOL, V136, P1235
   HELLMAN KB, 1994, J CELL BIOCHEM, V56, P210, DOI 10.1002/jcb.240560216
   Hodde J P, 1996, Tissue Eng, V2, P209, DOI 10.1089/ten.1996.2.209
   HOWELL JM, 1996, EMERG MED CLIN N AM, V10, P655
   HUBBELL JA, 1995, BIO-TECHNOL, V13, P565, DOI 10.1038/nbt0695-565
   KNAPP PM, 1994, J ENDOUROL, V8, P125, DOI 10.1089/end.1994.8.125
   Langer R, 1995, Tissue Eng, V1, P151, DOI 10.1089/ten.1995.1.151
   Lantz G C, 1993, J Invest Surg, V6, P297, DOI 10.3109/08941939309141619
   LYSIAK JJ, 1995, PLACENTA, V16, P221, DOI 10.1016/0143-4004(95)90110-8
   MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889
   MIAO HQ, 1995, J CELL BIOCHEM, V57, P173, DOI 10.1002/jcb.240570202
   MOSCATELLI D, 1987, P NATL ACAD SCI USA, V84, P5778, DOI 10.1073/pnas.84.16.5778
   NICE EC, 1991, J BIOL CHEM, V266, P14425
   OGAWA Y, 1992, J BIOL CHEM, V267, P2325
   OGAWA Y, 1991, METHOD ENZYMOL, V198, P317
   PIERCE GF, 1991, J CELL BIOCHEM, V45, P319, DOI 10.1002/jcb.240450403
   PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836
   PREVEL CD, 1995, ANN PLAS SURG, V35, P374, DOI 10.1097/00000637-199510000-00008
   QUAGLINO D, 1990, LAB INVEST, V63, P307
   RAPRAEGER AC, 1994, METHOD ENZYMOL, V245, P219
   REDDI AH, 1994, J CELL BIOCHEM, V56, P192, DOI 10.1002/jcb.240560213
   Roberts AB, 1996, MOL CELLULAR BIOL WO, P275
   ROSKELLEY CD, 1995, CURR OPIN CELL BIOL, V7, P736, DOI 10.1016/0955-0674(95)80117-0
   SCHULTZ G, 1991, J CELL BIOCHEM, V45, P346, DOI 10.1002/jcb.240450407
   TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171
   TAKEUCHI Y, 1994, J BIOL CHEM, V269, P32634
   TENDIJKE P, 1989, BIO-TECHNOL, V7, P793, DOI 10.1038/nbt0889-793
   VOYTIKHARBIN SL, IN VITRO CELL DEV BI
   WAHL SM, 1993, P NATL ACAD SCI USA, V90, P4577, DOI 10.1073/pnas.90.10.4577
   WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896
   YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0
   YANNAS IV, 1994, J CELL BIOCHEM, V56, P188, DOI 10.1002/jcb.240560212
NR 42
TC 425
Z9 468
U1 0
U2 26
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD DEC 15
PY 1997
VL 67
IS 4
BP 478
EP 491
DI 10.1002/(SICI)1097-4644(19971215)67:4<478::AID-JCB6>3.0.CO;2-P
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA YE699
UT WOS:A1997YE69900006
PM 9383707
DA 2018-10-19
ER

PT J
AU Vasku, J
   Urbanek, P
AF Vasku, J
   Urbanek, P
TI Etiopathogenesis of hemolytic reactions in total artificial heart
   recipients
SO ARTIFICIAL ORGANS
LA English
DT Article
DE total artificial heart hemolysis as multifactorial state; exogenous and
   endogenous hemolytic factors; role of red blood cell membrane resistance
AB Hemolysis in total artificial heart (TAH) recipients was analyzed, From a total of 66 long-term experiments lasting from 30-314 days per-Formed in the Bma Research Center, in 53 animals, tilt: total red blood cell (RBC) count, hematocrit, total hemoglobin, and free plasma hemoglobin were investigated, We could essentially divide the whole group of calves in 2 subgroups. The first subgroup was calves with hemolytic reactions, and the second subgroup tvas calves without any hemolytic reaction at all, In the first subgroup, hemolysis occurred in 47% of the overall number of animals during extracorporeal circulation (ECC), in 15% during ECC and later periodically during the experiment, in 8% during ECC and then continuously during the experiment, and finally in 10% not during ECC but repeatedly during the experiment, In 20% of the animals from the overall number, hemolysis did not occur at all (second subgroup), These results testify to the great individual differences within 1 breed (Bohemian with a substantial component of Holstein). These differences are further modified by exogenous and endogenous factors. First. the inborn resistance of the RBC membrane and also thrombi formation and the mineralization of the driving diaphragm are very important. The extreme situation of decreased RBC membrane resistance was proved using a calf from another breed, the slow growing Scottish Highland breed, which did not survive 22 days of pumping due to intractable lethal hemolysis. These factors are also indicated by the hemolytic action of some drugs (e.g., Dopegyt) used during the experiment for another reason. Also important are the mechanical forces of pumping, surface moieties of the biomaterial, mineralization of the driving diaphragms, thrombi formation, infection, etc. Essentially, the hemolytic reaction in the TAH recipient has a multifactorial character. Hemolysis is undoubtedly an important factor, which can have a profound impact on the length of survival. The experimental and clinical experiences must be continuously integrated, and conclusions valid for human TAW application must be considered as very important for further TAI-I experimental and clinical research.
C1 HP MEDIA GMBH, D-86150 AUGSBURG, GERMANY.
   VACORD BIOENGN RES CO, BRNO, CZECH REPUBLIC.
CR AKUTSU T, 1983, PROGR ARTIFICIAL ORG, V1, P162
   BRAIN MC, 1969, NEW ENGL J MED, V81, P833
   Fairley N H, 1940, Br Med J, V2, P213
   HJELM M, 1966, ACTA PHYSIOL SCAND, V67, P43, DOI 10.1111/j.1748-1716.1966.tb03285.x
   KOLFF WJ, 1983, PROGR ARTIFICIAL ORG, V1, P165
   Kramer C, 1971, Biomed Tech (Berl), V16, P164, DOI 10.1515/bmte.1971.16.5.164
   MASEK J, 1988, SCRIPTA MED FAC MED, V61, P199
   PETZ LD, 1985, NEW ENGL J MED, V31, P510
   REDDY SB, 1984, CAN MED ASSOC J, V131, P1469
   VANAKEN WG, 1989, DEV HEMATOL, V23, P13
   VASKU J, 1995, ARTIF ORGANS, V19, P535, DOI 10.1111/j.1525-1594.1995.tb02374.x
   VASKU J, 1995, ARTIF ORGANS, V19, P344, DOI 10.1111/j.1525-1594.1995.tb02339.x
   VASKU J, 1990, INT J ARTIF ORGANS, V13, P830
   Vasku J, 1987, Czech Med, V10, P16
   VASKU J, 1992, INT J ARTIF ORGANS, V15, P307
   VASKU J, 1996, HEART REPLACEMENT AR, P53
   VASKU J, 1989, ASSISTED CIRCULATION, P340
   VASKU J, 1993, HEART REPLACEMENT AR, P161
   VASKU J, 1982, ACTA FM U BRUNENSIS, P397
   VASKU J, 1984, ACTA FAC MED U BRUN, P622
   VELKER JA, 1977, T AM SOC ART INT ORG, V23, P732
   WAMPLER RK, 1988, T AM SOC ART INT ORG, V34, P450
   WELLHAUSEN SR, 1988, J CLIN IMMUNOL, V8, P307, DOI 10.1007/BF00916559
   WIEBALCK A, 1995, INT J ARTIF ORGANS, V18, P365
   Wurzinger L. J., 1986, ANGIOLOGIE, V38, P81
NR 25
TC 2
Z9 2
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0160-564X
J9 ARTIF ORGANS
JI Artif. Organs
PD DEC
PY 1997
VL 21
IS 12
BP 1268
EP 1276
PG 9
WC Engineering, Biomedical; Transplantation
SC Engineering; Transplantation
GA YK280
UT WOS:A1997YK28000006
PM 9423978
DA 2018-10-19
ER

PT J
AU Larsson, R
   Elgue, G
   Larsson, A
   Ekdahl, KN
   Nilsson, UR
   Nilsson, B
AF Larsson, R
   Elgue, G
   Larsson, A
   Ekdahl, KN
   Nilsson, UR
   Nilsson, B
TI Inhibition of complement activation by soluble recombinant CR1 under
   conditions resembling those in a cardiopulmonary circuit: reduced
   up-regulation of CD11b and complete abrogation of binding of PMNs to the
   biomaterial surface
SO IMMUNOPHARMACOLOGY
LA English
DT Article; Proceedings Paper
CT 6th European Meeting on Complement in Human Disease
CY MAR 12-15, 1997
CL INNSBRUCK, AUSTRIA
DE complement activation; C3a; sC5b-9; cardiopulmonary bypass; sCR1
ID C5 CONVERTASE; BYPASS; GENERATION; HEPARIN; NEUTROPHILS; ENDOTHELIUM;
   COMPONENTS; EXPRESSION; LEUKOCYTE; RECEPTOR
AB The influence of soluble recombinant CR1 (sCR1) on complement activation, and its indirect effects on the coagulation system and cellular responses were assessed in two models for the study of blood/surface and blood/air interactions, as are encountered in e.g. cardiopulmonary bypass circuits. The concentrations of C3a and sC5b-9 and the amount of bound C3/C3 fragments were analyzed as indicators of complement activation. Thrombin-antithrombin complexes, the platelet count, surface-ATP, beta-thromboglobulin, and the expression of CD11b on leukocytes were the parameters analyzed to reflect coagulation and cellular responses. In addition, immunochemical analyses of the phenotypes of surface-bound leukocytes and platelets were performed. Recombinant sCR1, at doses ranging between 0.1-0.25 mg/ml, was found to completely inhibit the generation of sC5b-9, and of C3a by two thirds; the binding of C3 and/or C3 fragments to the surface was almost entirely abolished. As a result of the inhibition of complement activation, the expression of CD11b on PMNs, and the binding of these cells to the biomaterial surface was almost completely lost. In contrast, the thrombin-antithrombin complexes, the platelet count, and the adherence of platelets to the surface, as reflected by the ATP binding and the release of beta-thromboglobulin, were not affected. These data show that complement activation, in association with extra-corporeal treatment, causes activation and binding of PMNs to the biomaterial and that these effects can be completely abolished by the addition of soluble recombinant sCR1. (C) 1997 Elsevier Science B.V.
C1 Univ Uppsala Hosp, Dept Clin Chem, S-75185 Uppsala, Sweden.
   Univ Uppsala Hosp, Dept Clin Immunol & Transfus Med, S-75185 Uppsala, Sweden.
RP Nilsson, B (reprint author), Univ Uppsala Hosp, Dept Clin Chem, S-75185 Uppsala, Sweden.
EM bo.nilsson@klinimm.uu.se
RI Nilsson Ekdahl, Kristina/B-5301-2012; Nilsson, Bo/B-3102-2012
OI Nilsson, Bo/0000-0003-0057-2730
CR ALTIERI DC, 1990, J BIOL CHEM, V265, P12119
   BECHERER JD, 1989, COMPLEMENT INFLAMMAT, V6, P142, DOI 10.1159/000463091
   BOKISCH VA, 1969, J EXP MED, V129, P1109, DOI 10.1084/jem.129.5.1109
   BROWN GE, 1991, J IMMUNOL, V147, P965
   EKDAHL KN, 1992, SCAND J IMMUNOL, V35, P85, DOI 10.1111/j.1365-3083.1992.tb02837.x
   GILLINOV AM, 1993, ANN THORAC SURG, V55, P619, DOI 10.1016/0003-4975(93)90264-I
   GONG J, 1996, J CLIN IMMUNOL, V16, P223
   GREELEY WJ, 1991, ANN THORAC SURG, V52, P417, DOI 10.1016/0003-4975(91)90900-B
   Johnson R J, 1990, Prog Clin Biol Res, V337, P507
   KIM YU, 1992, J BIOL CHEM, V267, P4171
   KINOSHITA T, 1988, J IMMUNOL, V141, P3895
   Kirklin JK, 1989, CARDIOPULMONARY BYPA, P131
   LARSSON R, 1977, THROMB RES, V11, P517, DOI 10.1016/0049-3848(77)90205-5
   LO SK, 1989, J EXP MED, V169, P1779, DOI 10.1084/jem.169.5.1779
   MAYER MM, 1961, EXPT IMMUNOCHEMISTRY, P133
   MELLBYE OJ, 1988, EUR SURG RES, V20, P101, DOI 10.1159/000128748
   MOLLNES T, 1985, SCAND J IMMUNOL, V22, P703
   MOLLNES TE, 1991, ANN THORAC SURG, V52, P92, DOI 10.1016/0003-4975(91)91426-V
   MULLIGAN MS, 1992, J IMMUNOL, V148, P1479
   NILSSON L, 1990, ARTIF ORGANS, V14, P46
   OEVEREN W, 1985, J THORAC CARDIOVASC, V89, P888
   PEKNA M, 1993, CLIN EXP IMMUNOL, V91, P404
   PEKNA M, 1993, BIOMATERIALS, V14, P189, DOI 10.1016/0142-9612(93)90022-T
   PEKNA M, 1994, ANN THORAC SURG, V58, P421, DOI 10.1016/0003-4975(94)92219-5
   RINDER CS, 1995, J CLIN INVEST, V96, P1564, DOI 10.1172/JCI118195
   ROSS GD, 1982, J EXP MED, V155, P96, DOI 10.1084/jem.155.1.96
   Sahu A, 1996, J IMMUNOL, V157, P884
   SIMS PJ, 1991, IMMUNOL TODAY, V12, P338, DOI 10.1016/0167-5699(91)90012-I
   VEDDER NB, 1988, J CLIN INVEST, V81, P676, DOI 10.1172/JCI113372
   VIDEM V, 1989, J THORAC CARDIOV SUR, V97, P764
   VIDEM V, 1992, J THORAC CARDIOV SUR, V103, P806
   WESTABY S, 1987, INTENS CARE MED, V13, P89
   WURZNER R, 1991, COMPLEMENT INFLAMMAT, V8, P328
NR 33
TC 34
Z9 34
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0162-3109
J9 IMMUNOPHARMACOLOGY
JI Immunopharmacology
PD DEC
PY 1997
VL 38
IS 1-2
BP 119
EP 127
DI 10.1016/S0162-3109(97)00064-7
PG 9
WC Immunology; Pharmacology & Pharmacy
SC Immunology; Pharmacology & Pharmacy
GA YT508
UT WOS:000071614100015
PM 9476123
DA 2018-10-19
ER

PT J
AU Filmon, R
   Chappard, D
   Basle, MF
AF Filmon, R
   Chappard, D
   Basle, MF
TI Scanning and transmission electron microscopy of poly 2-hydroxyethyl
   methacrylate-based biomaterials
SO JOURNAL OF HISTOTECHNOLOGY
LA English
DT Article
DE biomaterial; bone mineralization; HEMA; pHEMA; poly 2-hydroxyethyl
   methacrylate; scanning electron microscopy; transmission electron
   microscopy; 2-hydroxyethyl methacrylate
ID BONE; SPECIMENS
AB Hydrogels, especially poly 2-hydroxyethyl methacrylate, or pHEMA, have received increased attention for numerous biomedical applications. We have prepared several pHEMA-based biomaterials suitable as bone substitutes; alkaline phosphatase, for example, when immobilized in pHEMA in a copolymerization technique at 4 degrees C retains its biological activity. When pellets of the biomaterial were placed in synthetic body fluids or tissue culture medium containing organic phosphates, numerous calcified nodules formed spontaneously. Osteoblast-like cells harvested on pHEMA or pHEMA/alkaline phosphatase materials can spread and establish direct contacts. However, the hydrophilicity of pHEMA is a real handicap for preparing scanning and transmission electron microscopic analyses. We have found that 2-propanol was an excellent dehydrating preparing for scanning electron microscopy before critical point drying. HEMA itself was found to dehydrate the transmission electron microscopy blocks because it can copolymerize with the methacrylate-based embedding resin Lowicryl K4M. These 2 preparation techniques have allowed us to study calcium-phosphate crystal growth and cellular responses in vitro on these hydrogel biomaterials.
C1 FAC MED,LHEA,F-49045 ANGERS,FRANCE.
   SERV COMMUN MICROSCOPIE ELECTON,ANGERS,FRANCE.
   CGU,LAB HISTOL EMBRYOL,ANGERS,FRANCE.
CR ACETARIN JD, 1986, J MICROSC-OXFORD, V143, P81, DOI 10.1111/j.1365-2818.1986.tb02766.x
   ARMBRUSTER BL, 1982, J MICROSC-OXFORD, V126, P77, DOI 10.1111/j.1365-2818.1982.tb00358.x
   BECKSTEAD JH, 1981, BLOOD, V57, P1088
   BENNETT HS, 1976, STAIN TECHNOL, V51, P71, DOI 10.3109/10520297609116677
   BRADBEER JN, 1992, J BONE MINER RES, V7, P905
   CASWELL AM, 1991, CRIT REV CL LAB SCI, V28, P175, DOI 10.3109/10408369109106862
   CHAPPARD D, 1983, STAIN TECHNOL, V58, P299, DOI 10.3109/10520298309066802
   FILMON R, IN PRESS CELLS MAT
   GLAUERT AM, 1965, TECHNICS ELECT MICRO
   MONTHEARD JP, 1992, J MACROMOL SCI R M C, VC32, P1, DOI 10.1080/15321799208018377
   MONTHEARD JP, 1997, DESK REFERENCE FUNCT, P669
   PINCHUK L, 1984, J BIOMED MATER RES, V18, P671, DOI 10.1002/jbm.820180608
   SMETANA K, 1992, BIOMATERIALS, V13, P639, DOI 10.1016/0142-9612(92)90033-K
   WUTHIER RE, 1982, CLIN ORTHOP RELAT R, V169, P219
   YAMADA S, 1994, J BIOMED MATER RES, V28, P1357, DOI 10.1002/jbm.820281114
NR 15
TC 6
Z9 6
U1 0
U2 3
PU NATL SOC HISTOTECHNOLOGY
PI BOWIE
PA 4201 NORTHVIEW DR, STE 502, BOWIE, MD 20716-1073
SN 0147-8885
J9 J HISTOTECHNOL
JI J. Histotechnol.
PD DEC
PY 1997
VL 20
IS 4
BP 343
EP 346
PG 4
WC Cell Biology
SC Cell Biology
GA YJ241
UT WOS:A1997YJ24100008
DA 2018-10-19
ER

PT J
AU Bhardwaj, RS
   Henze, U
   Klein, B
   ZwadloKlarwasser, G
   Klinge, U
   Mittermayer, C
   Klosterhalfen, B
AF Bhardwaj, RS
   Henze, U
   Klein, B
   ZwadloKlarwasser, G
   Klinge, U
   Mittermayer, C
   Klosterhalfen, B
TI Monocyte-biomaterial interaction inducing phenotypic dynamics of
   monocytes: a possible role of monocyte subsets in biocompatibility
SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE
LA English
DT Article; Proceedings Paper
CT 13th European Conference on Biomaterials
CY 1997
CL GOTHENBURG, SWEDEN
ID CALCIUM-BINDING PROTEINS; SUPEROXIDE PRODUCTION; ENDOTHELIAL-CELLS;
   TNF-ALPHA; IN-VITRO; ADHERENCE; SURFACE; MACROPHAGES; FIBRONECTIN;
   INTEGRINS
AB For the in vitro study of cell-biomaterial surface interactions, the choice of cell type is crucial. in vivo data indicate that during the healing of the implant in the tissues, the pivotal cell types are the macrophages. These cells, upon interaction with any foreign material, might initiate a spectrum of responses, which could lead to acute and chronic inflammatory changes affecting the biocompatibility of the implant. Whether the mechanisms governing the type of evolving inflammatory reaction could be attributed to the macrophages functional differentiation mirrored by monocyte subsets during the polymer interaction, is poorly described. This in vitro study, therefore, attempted to investigate whether different biomaterials influence monocyte cellular activity, determined by the myeloperoxidase level and mitochondrial XTT cleavage, and phenotype dynamics characterized by the presence of CD14, RM 3/1 and 27E10 antigens. It is shown that different polymers exert differential potential to influence monocytes, both in their cellular activity and their phenotypic pattern. Thus, these findings demonstrating material-induced monocyte activation and monocyte phenotype modulation, are suggestive of the monocyte role as reporter cells in evaluating the biocompatibility of a synthetic medical device.
C1 RHEIN WESTFAL TH AACHEN,INST PHARMACOL & TOXICOL,D-52057 AACHEN,GERMANY.
   RHEIN WESTFAL TH AACHEN,SURG CLIN,D-52057 AACHEN,GERMANY.
   RHEIN WESTFAL TH AACHEN,INST PATHOL,D-52057 AACHEN,GERMANY.
RP Bhardwaj, RS (reprint author), RHEIN WESTFAL TH AACHEN,IZKF BIOMAT,PAUWELSSTR 30,D-52057 AACHEN,GERMANY.
CR ALI SAM, 1994, BIOMATERIALS, V15, P779, DOI 10.1016/0142-9612(94)90032-9
   ANDERSON JM, 1988, ASAIO, V11, P101
   ANDERSON JM, 1993, CARDIOVASC PATHOL, V2, pS35
   BEEKHUIZEN H, 1993, J IMMUNOL, V150, P950
   BHARDWAJ RS, 1992, EUR J IMMUNOL, V22, P1891, DOI 10.1002/eji.1830220732
   BOYUM A, 1983, SCAND J IMMUNOL, V17, P429, DOI 10.1111/j.1365-3083.1983.tb00809.x
   DEFIFE KM, 1995, J BIOMED MATER RES, V29, P431, DOI 10.1002/jbm.820290403
   EIERMAN DF, 1989, J IMMUNOL, V142, P1970
   ERIKSSON AS, 1994, J MATER SCI-MATER M, V5, P269, DOI 10.1007/BF00122396
   Gretzer C, 1996, BIOMATERIALS, V17, P851, DOI 10.1016/0142-9612(96)83279-0
   Hunt JA, 1996, J BIOMED MATER RES, V31, P139, DOI 10.1002/(SICI)1097-4636(199605)31:1<139::AID-JBM15>3.0.CO;2-I
   KAO WJ, 1994, J BIOMED MATER RES, V38, P73
   KAPLAN SS, 1992, J BIOMED MATER RES, V26, P1039, DOI 10.1002/jbm.820260806
   Kapur R, 1996, J BIOMED MATER RES, V32, P133
   Klosterhalfen B, 1997, LANGENBECK ARCH CHIR, V382, P87
   MAHNKE K, 1995, J LEUKOCYTE BIOL, V57, P63
   MERCHANT RE, 1984, J BIOMED MATER RES, V18, P1169
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Nordsletten L, 1996, BIOMATERIALS, V17, P1521, DOI 10.1016/0142-9612(96)89777-8
   ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0
   OWEN CA, 1992, J LEUKOCYTE BIOL, V51, P400
   OWEN CA, 1994, AM J PHYSIOL, V267, P267
   SALTHOUSE TN, 1984, J BIOMED MATER RES, V18, P395, DOI 10.1002/jbm.820180407
   SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410
   VERDEGAAL EME, 1992, MONONUCLEAR PHAGOCYTES, P123
   Wenzel I, 1996, EUR J IMMUNOL, V26, P2758, DOI 10.1002/eji.1830261131
   WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311
   YUROCHKO AD, 1992, P NATL ACAD SCI USA, V89, P9034, DOI 10.1073/pnas.89.19.9034
   Zenni G C, 1994, J Invest Surg, V7, P135, DOI 10.3109/08941939409015357
   ZHAO QH, 1992, J BIOMED MATER RES, V26, P1019, DOI 10.1002/jbm.820260805
   ZWADLO G, 1986, J IMMUNOL, V137, P512
NR 31
TC 14
Z9 14
U1 0
U2 1
PU CHAPMAN HALL LTD
PI LONDON
PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8HN
SN 0957-4530
J9 J MATER SCI-MATER M
JI J. Mater. Sci.-Mater. Med.
PD DEC
PY 1997
VL 8
IS 12
BP 737
EP 742
DI 10.1023/A:1018552326808
PG 6
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA YL604
UT WOS:A1997YL60400004
PM 15348782
DA 2018-10-19
ER

PT J
AU Ignatius, A
   Unterricker, K
   Wenger, K
   Richter, M
   Claes, L
   Lohse, P
   Hirst, H
AF Ignatius, A
   Unterricker, K
   Wenger, K
   Richter, M
   Claes, L
   Lohse, P
   Hirst, H
TI A new composite made of polyurethane and glass ceramic in a loaded
   implant model: a biomechanical and histological analysis
SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE
LA English
DT Article; Proceedings Paper
CT 13th European Conference on Biomaterials
CY 1997
CL GOTHENBURG, SWEDEN
ID INTERFACE
AB The biocompatibility and osseous integration of a new composite material made of polyurethane and a calcium silicophosphate ceramic was investigated in a loaded implant model in sheep and compared to that of commercially pure titanium. Six months after implantation, interfacial shear strength was higher between the titanium and bone than between the composite and bone. After 2 years, however, the shear strength was significantly higher in the composite group. Histologically, both implants were surrounded by bone and fibrous tissue and there were no signs of inflammation. Direct contact of bone on the composite surface increased significantly with time, whereas there was no time-dependent increase of bone contact on titanium. It can be concluded that the biocompatibility and osseous integration of the composite was very good in the loaded implant model used. It is therefore suggested that the new composite is a promising biomaterial for orthopaedic implants.
C1 BIOVIS GMBH,D-98693 ILMENAU,GERMANY.
RP Ignatius, A (reprint author), UNIV ULM,DEPT ORTHOPAED RES & BIOMECH,HELMHOLTZSTR 14,D-89081 ULM,GERMANY.
RI Ignatius, Anita/M-6012-2013; Claes, Lutz/O-4697-2014
OI Ignatius, Anita/0000-0002-4782-1979; 
CR BEHIRI JC, 1988, BIOMED TECH, V33, P109, DOI 10.1515/bmte.1988.33.5.109
   BONFIELD W, 1981, BIOMATERIALS, V2, P185, DOI 10.1016/0142-9612(81)90050-8
   Bonfield W., 1996, BIOCERAMICS, V9, P11
   CLAES L, 1996, INT SOC FRACT REP 5, P77
   Flahiff CM, 1996, J BIOMED MATER RES, V32, P419
   GROSS U, 1985, J BIOMED MATER RES, V19, P251, DOI 10.1002/jbm.820190308
   Hench LL, 1971, J BIOMED MATER RES S, V2, P117, DOI DOI 10.1002/JBM.820050611
   JARCHO M, 1981, CLIN ORTHOP RELAT R, V157, P259
   TRACY BM, 1984, J BIOMED MATER RES, V18, P719, DOI 10.1002/jbm.820180702
   Wang M., 1996, BIOCERAMICS, V9, P387
NR 10
TC 27
Z9 27
U1 0
U2 7
PU CHAPMAN HALL LTD
PI LONDON
PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8HN
SN 0957-4530
J9 J MATER SCI-MATER M
JI J. Mater. Sci.-Mater. Med.
PD DEC
PY 1997
VL 8
IS 12
BP 753
EP 756
DI 10.1023/A:1018508511787
PG 4
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA YL604
UT WOS:A1997YL60400007
PM 15348785
DA 2018-10-19
ER

PT J
AU Vasconcelos, M
   Afonso, A
   Branco, R
   Cavalheiro, J
AF Vasconcelos, M
   Afonso, A
   Branco, R
   Cavalheiro, J
TI Guided bone regeneration using osteopatite(R) granules and
   polytetrafluoroethylene membranes
SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE
LA English
DT Article; Proceedings Paper
CT 13th European Conference on Biomaterials
CY 1997
CL GOTHENBURG, SWEDEN
ID TISSUE REGENERATION
AB Granules of a modified hydroxyapatite, Osteopatite(R), were implanted in the right posterior tibiae of adult rabbits. We studied the extent of bone regeneration in bone holes. In the right tibiae, that were filled with granules of this biomaterial covered with a polytetrafluoroethylene (PTFE) membrane using, as a control, uncovered granules. In the left tibia, an empty hole was covered with PTFE membrane and a second hole was left empty to be used as a control. A histomorphometric study was carried out using light microscopy, four and eight weeks after the surgery. The covered granules presented a higher percentage of bone contact than the uncovered ones, and it was also possible to observe a better bone tissue organization, mainly produced by the immobilization action of the PTFE membrane. Empty bone defects covered with PTFE membranes, two months after implantation, presented large areas of Haversian bone and direct bone contact to the PTFE membrane.
C1 INST BIOMED ENGN, INEB, P-4000 OPORTO, PORTUGAL.
RP Vasconcelos, M (reprint author), UNIV PORTO, FAC MED DENT, RUA DR ROBERTO FRIAS, P-4200 OPORTO, PORTUGAL.
RI Vasconcelos, Mario/G-5472-2013
CR Afonso A, 1996, J MATER SCI-MATER M, V7, P507, DOI 10.1007/BF00705433
   AUGHTUN M, 1995, INT J ORAL MAXILLOF, V4, P421
   CAVALHEIRO J, 1994, STOMA, V30, P15
   CAVALHEIRO J, 1991, P 4 INT C BIOC LOND, P305
   Dahlin C, 1995, Int J Oral Maxillofac Implants, V10, P312
   GREVSTAD HJ, 1993, J CLIN PERIODONTOL, V20, P193, DOI 10.1111/j.1600-051X.1993.tb00343.x
   JOVANOVIC SA, 1995, INT J ORAL MAXILLOF, V1, P27
   Piattelli A, 1996, BIOMATERIALS, V17, P791, DOI 10.1016/0142-9612(96)81416-5
   SANDER L, 1995, J CLIN PERIODONTOL, V22, P295, DOI 10.1111/j.1600-051X.1995.tb00151.x
   SIMION M, 1995, INT J ORAL MAXILLOF, V3, P312
NR 10
TC 4
Z9 4
U1 0
U2 3
PU CHAPMAN HALL LTD
PI LONDON
PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8HN
SN 0957-4530
J9 J MATER SCI-MATER M
JI J. Mater. Sci.-Mater. Med.
PD DEC
PY 1997
VL 8
IS 12
BP 815
EP 818
DI 10.1023/A:1018533217238
PG 4
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA YL604
UT WOS:A1997YL60400019
PM 15348797
DA 2018-10-19
ER

PT J
AU VanKooten, TG
   Klein, CL
   Kohler, H
   Kirkpatrick, CJ
   Williams, DF
   Eloy, R
AF VanKooten, TG
   Klein, CL
   Kohler, H
   Kirkpatrick, CJ
   Williams, DF
   Eloy, R
TI From cytotoxicity to biocompatibility testing in vitro: cell adhesion
   molecule expression defines a new set of parameters
SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE
LA English
DT Article; Proceedings Paper
CT 13th European Conference on Biomaterials
CY 1997
CL GOTHENBURG, SWEDEN
ID HUMAN ENDOTHELIAL-CELLS; 96-WELL PLATES; IN-VITRO; SURFACES;
   QUANTIFICATION
AB Determination of potential cytotoxicity is a central issue in current biocompatibility testing standards such as ISO and ASTM. Most of these tests do not assess biocompatibility of a biomaterial with regard to cell function. This study was aimed at screening a number of potential parameters that could be included in assessment of cell functional aspects of biocompatibility. Human umbilical vein endothelial cells (HUVEC) were seeded directly on titanium, NiCr alloy, CoCr alloy, PMMA, PE, PU, PVC, and silicone, or were exposed to the material extracts. Cytotoxicity was assessed for these materials through MTT conversion, crystal violet protein determination and Ki67 expression. In addition, expression of the cell adhesion molecules E-selectin, cadherin-5 and PECAM, as well as of the adhesion associated proteins fibronectin and vinculin (focal adhesions), was determined by immunocytochemistry and western blotting. Cytotoxicity was not detected with the material extracts. Cells were able to adhere to bare metals, but not polymers. Fibronectin preadsorption resulted in adhesion and spreading also on the polymers. Cells were able to establish cell-cell contacts and focal adhesions. Western blotting, in combination with differential detergent extraction, indicated that linkage of cell-cell adhesion markers to the cytoskeleton may be used as an additional parameter relevant to cell function.
C1 UNIV LIVERPOOL,DEPT CLIN ENGN,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.
   BIOMATECH SA,F-38670 CHASSE SUR RHONE,FRANCE.
RP VanKooten, TG (reprint author), UNIV MAINZ,INST PATHOL,LANGENBECKSTR 1,D-55101 MAINZ,GERMANY.
CR Altankov G, 1996, J BIOMED MATER RES, V30, P385, DOI 10.1002/(SICI)1097-4636(199603)30:3<385::AID-JBM13>3.0.CO;2-J
   BATES RC, 1995, CANCER METAST REV, V14, P191, DOI 10.1007/BF00690291
   Davies JE, 1996, ANAT REC, V245, P426
   ERTEL SI, 1994, J BIOMED MATER RES, V28, P667, DOI 10.1002/jbm.820280603
   GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3
   GROTH T, 1995, J BIOMAT SCI-POLYM E, V7, P297
   JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470
   KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0
   RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537
   Scott G, 1997, J INVEST DERMATOL, V108, P147, DOI 10.1111/1523-1747.ep12332650
   SCRAGG MA, 1991, ANAL BIOCHEM, V198, P80, DOI 10.1016/0003-2697(91)90509-R
NR 11
TC 23
Z9 24
U1 1
U2 11
PU CHAPMAN HALL LTD
PI LONDON
PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8HN
SN 0957-4530
J9 J MATER SCI-MATER M
JI J. Mater. Sci.-Mater. Med.
PD DEC
PY 1997
VL 8
IS 12
BP 835
EP 841
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA YL604
UT WOS:A1997YL60400023
PM 15348801
DA 2018-10-19
ER

PT J
AU Remy, M
   Valli, N
   Villars, F
   Bordenave, L
   Gorodkov, A
AF Remy, M
   Valli, N
   Villars, F
   Bordenave, L
   Gorodkov, A
TI Up-regulation of thrombomodulin is inducible on an endothelialized
   polyester
SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE
LA English
DT Article; Proceedings Paper
CT 13th European Conference on Biomaterials
CY 1997
CL GOTHENBURG, SWEDEN
ID TISSUE FACTOR; CYCLIC-AMP; CELLS
AB The concept of endothelial cell seeding of vascular prostheses is designed as a method for improving long-term patency substitutes because endothelium is considered as the haemocompatible surface of reference. The assessment of the functionality of cells lining a biomaterial is thus of crucial importance. We have reported encouraging results concerning the ability of a polyester coated with albumin and chitosan (M 11) to be lined by a confluent monolayer of cu Itu red hu man endothelia I cells (EC). The a im of the present work was to study the expression of thrombomodulin (membrane glycoprotein responsible for anticoagulant activity) in EC lying on M.11 by anticoagulant activity and mRNA level with and without stimulation. Results obtained in basal conditions showed that EC on M.11 have a comparable expression of TM mRNA when compared to control (EC on tissue culture plates) despite a lower TM surface activity for EC on the biomaterial. In terms of ratio (stimulated cells to unstimulated ones) the response in activity for EC on M.11 is comparable to that of the control. These results indicate that cells lying on M.11 are able to respond to physiological-like stimuli, despite a tendency for these cells to express a procoagulant phenotype when compared with control EC.
C1 AN BAKULEV CARDIOVASC SURG INST,MOSCOW,RUSSIA.
RP Remy, M (reprint author), UNIV BORDEAUX 2,BIOPHYS LAB,INSERM,U443,F-33076 BORDEAUX,FRANCE.
CR ARCHIPOFF G, 1993, BRIT J PHARMACOL, V109, P18, DOI 10.1111/j.1476-5381.1993.tb13526.x
   BARTHA K, 1993, J BIOL CHEM, V268, P421
   ISHII H, 1990, THROMB RES, V59, P841, DOI 10.1016/0049-3848(90)90397-U
   REMY M, 1994, J MATER SCI-MATER M, V5, P808, DOI 10.1007/BF00213139
   ZILLA P, 1994, J VASC SURG, V19, P540, DOI 10.1016/S0741-5214(94)70083-4
NR 5
TC 0
Z9 0
U1 0
U2 0
PU CHAPMAN HALL LTD
PI LONDON
PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8HN
SN 0957-4530
J9 J MATER SCI-MATER M
JI J. Mater. Sci.-Mater. Med.
PD DEC
PY 1997
VL 8
IS 12
BP 877
EP 879
DI 10.1023/A:1018505905852
PG 3
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA YL604
UT WOS:A1997YL60400030
PM 15348808
DA 2018-10-19
ER

PT J
AU Noiset, O
   Schneider, YJ
   MarchandBrynaert, J
AF Noiset, O
   Schneider, YJ
   MarchandBrynaert, J
TI Surface modification of poly(aryl ether ether ketone) (PEEK) film by
   covalent coupling of amines and amino acids through a spacer arm
SO JOURNAL OF POLYMER SCIENCE PART A-POLYMER CHEMISTRY
LA English
DT Article
DE biomaterial; cell cultivation; PEEK amination; PEEK carboxylation; PEEK
   film; surface reactivity assay; surface wet-chemistry
ID POLY(ETHYLENE-TEREPHTHALATE) PET FILM; LABELED DERIVATIZATION REAGENTS;
   RAY PHOTOELECTRON-SPECTROSCOPY; HYDROXYL CHAIN-ENDS; POLYMER SURFACES;
   ENDOTHELIAL-CELLS; REACTIVITY ASSAYS; MEMBRANES; ADHESION; XPS
AB Using the wet-chemistry technique, we selectively reduced the surface of the PEEK film (PEEK-OH), and covalently fixed hexamethylene diisocyanate by addition onto the hydroxyl functions. The resulting PEEK-NCO film displayed free isocya nate termini, the basic hydrolysis of which gave the PEEK-NH2 film in 85% extent of derivatization. The PEEK-NCO film reacted with trifluoroethylamine in toluene, trifluoroethylamine in PBS buffer, GABA, and lysine in PBS buffer to furnish, respectively, the PEEK-CF3(A), PEEK-CF3(B), PEEK-CO2H, and PEEK(NH2)CO2H films in 80%, 45%, 30%, and 25% extents of derivatization, as determined from the F/C and N/C atomic ratios recorded in the corresponding XPS spectra. The surface reactivity of the PEEK-NH2 and PEEK-NCO films was assayed by coupling with appropriate H-3 labels followed by liquid scintillation counting of the sample-associated radioactivity. The PEEK-NH2, PEEK-CO2H, and PEEK-(NH2)CO2H films were used as substrates for the cultivation of CaCo2 epithelial cells; the presence of surface amine and carboxyl functions significantly improves the cellular adhesion and growth. (C) 1997 John Wiley & Sons, Inc.
C1 UNIV CATHOLIQUE LOUVAIN, DEPT CHIM, LAB CHIM ORGAN SYNTHESE, B-1348 LOUVAIN, BELGIUM.
   UNIV CATHOLIQUE LOUVAIN, BIOCHIM CELLULAIRE LAB, B-1348 LOUVAIN, BELGIUM.
CR Alexander MR, 1996, SURF INTERFACE ANAL, V24, P217
   AMEEN AP, 1993, POLYMER, V34, P1795, DOI 10.1016/0032-3861(93)90418-A
   AUDUS KL, 1990, PHARM RES-DORDR, V7, P435, DOI 10.1023/A:1015800312910
   BENNETT GS, 1991, POLYMER, V32, P1633, DOI 10.1016/0032-3861(91)90399-4
   Boxus T, 1996, POLYM ADVAN TECHNOL, V7, P589, DOI 10.1002/(SICI)1099-1581(199607)7:7<589::AID-PAT551>3.3.CO;2-2
   CHILKOTI A, 1991, CHEM MATER, V3, P51, DOI 10.1021/cm00013a016
   DELDIME M, 1995, APPL SURF SCI, V90, P1, DOI 10.1016/0169-4332(95)00077-1
   DEWEZ JL, 1991, INTERFACES NEW MAT, P84
   Feast W.J, 1987, POLYM SURFACES INTER
   FRANCHINA NL, 1992, CHEM MOD S, V4, P173
   GAN LS, 1994, DRUG DEV IND PHARM, V20, P615, DOI 10.3109/03639049409038322
   GRIESSER HJ, 1994, J BIOMAT SCI-POLYM E, V5, P531, DOI 10.1163/156856294X00194
   HALLEUX C, 1994, J CELL PHYSIOL, V158, P17, DOI 10.1002/jcp.1041580104
   HENNEUSE C, 1995, B SOC CHIM FR, V132, P333
   Henneuse C, 1996, SYNTHESIS-STUTTGART, P495
   HIRANO Y, 1991, POLYM BULL, V26, P363, DOI 10.1007/BF00302601
   HUBBELL JA, 1994, TRENDS POLYM SCI, V2, P20
   HUBBELL JA, 1993, PATHOL S, V2, pS121
   JAMA C, 1992, SURF INTERFACE ANAL, V18, P751, DOI 10.1002/sia.740181103
   JaumotteThelen S, 1996, J BIOMED MATER RES, V32, P569, DOI 10.1002/(SICI)1097-4636(199612)32:4<569::AID-JBM10>3.0.CO;2-9
   JAUMOTTETHELEN S, 1996, J MATER SCI-MATER M, V7, P162
   KOBAYASHI H, 1991, BIOMATERIALS, V12, P747, DOI 10.1016/0142-9612(91)90024-5
   KOCH T, 1995, MACROMOLECULES, V28, P4806, DOI 10.1021/ma00118a004
   KONDOH A, 1993, J APPL POLYM SCI, V47, P1983, DOI 10.1002/app.1993.070471108
   LEE JH, 1993, J BIOMAT SCI-POLYM E, V4, P467
   LEE JH, 1994, BIOMATERIALS, V15, P705, DOI 10.1016/0142-9612(94)90169-4
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MARCHANDBRYNAER.J, EPF 94 P 5 EUR POL F
   MARCHANDBRYNAER.J, 1997, ICPS 2 P
   MARCHANDBRYNAERT J, 1995, J COLLOID INTERF SCI, V173, P236, DOI 10.1006/jcis.1995.1319
   MarchandBrynaert J, 1997, POLYMER, V38, P1387, DOI 10.1016/S0032-3861(96)00661-1
   MORRISON C, 1995, BIOMATERIALS, V16, P987, DOI 10.1016/0142-9612(95)94906-2
   Mougenot P, 1996, MACROMOLECULES, V29, P3552, DOI 10.1021/ma9513224
   Mougenot P, 1996, J COLLOID INTERF SCI, V177, P162, DOI 10.1006/jcis.1996.0017
   Noiset O, 1997, MACROMOLECULES, V30, P540, DOI 10.1021/ma960368+
   PEPPAS NA, 1994, SCIENCE, V263, P1715, DOI 10.1126/science.8134835
   PETILLO O, 1994, J BIOMED MATER RES, V28, P635, DOI 10.1002/jbm.820280514
   RAMSEY WS, 1984, IN VITRO CELL DEV B, V20, P802
   SERGENTENGELEN T, 1993, BIOCHEM PHARMACOL, V46, P1393, DOI 10.1016/0006-2952(93)90104-5
   SHARD AG, 1992, MACROMOLECULES, V25, P2053, DOI 10.1021/ma00033a034
   Silver FH., 1994, BIOMATERIALS MED DEV
   TAMADA Y, 1993, J COLLOID INTERF SCI, V155, P334, DOI 10.1006/jcis.1993.1044
   TAMADA Y, 1993, POLYMER, V34, P2209
   TONDEUR JJ, 1992, CHIM NOUVELLE, V10, P1148
   VANWACHEM PB, 1987, BIOMATERIALS, V8, P323, DOI 10.1016/0142-9612(87)90001-9
   YKADA Y, 1994, BIOMATERIALS, V15, P725
NR 46
TC 34
Z9 35
U1 5
U2 41
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0887-624X
J9 J POLYM SCI POL CHEM
JI J. Polym. Sci. Pol. Chem.
PD DEC
PY 1997
VL 35
IS 17
BP 3779
EP 3790
DI 10.1002/(SICI)1099-0518(199712)35:17<3779::AID-POLA17>3.0.CO;2-A
PG 12
WC Polymer Science
SC Polymer Science
GA YF496
UT WOS:A1997YF49600017
DA 2018-10-19
ER

PT J
AU Iwasaki, K
AF Iwasaki, K
TI Production of a functionally graded artificial tooth root by unique
   sequence of processes
SO MATERIALS RESEARCH INNOVATIONS
LA English
DT Article
DE ultrafine particle; functionally graded material; artificial tooth root;
   biomaterial; radio-frequency plasma; dry-jet spraying;
   temperature-gradient sintering; plasma spraying; mechanical property;
   biocompatibility
ID ULTRAFINE PARTICLES; PLASMA
AB A unique sequence of processes is used to produce a prototype of a functionally graded artificial tooth root: (1) Dry-jet spraying of the mixture of Ti and Al2O3 ultrafine particles (UFPs) produced by radio-frequency plasma onto the surface of a cylindrical Ti rod, where the composition of the UFPs is changed gradually in the outward radial direction from Ti to Al2O3; (2) Temperature-gradient sintering of the deposited composite, where the Ti - and the Al2O3 - rich sides are heated simultaneously at about 1400 K and 1800 K, respectively; (3) Plasma spray coating of hydroxyapatite (HAP) onto the outermost Al2O3 surface of the sintered composite. The final product has compressive strength of more than 200 MPa and is durable against fatigue test of 10(7) stress cycles at 1000 N. The adhesion strength between the Ti substrate and the Ti-Al2O3 functionally graded layer exceeds 65 MPa. No contamination with heavy metals is detected throughout the processes and biological cell growth is confirmed to occur on the HAP surface. With these mechanical and biochemical properties the composite produced here is considered to be highly suitable for an artificial tooth root. A series of processes developed here are expected to be applied to the production of various kinds of fine-grained functionally graded materials with complicated forms.
C1 Nisshin Steel Co Ltd, Steel & Technol Dev Labs, Ichikawa, Chiba 272, Japan.
RP Iwasaki, K (reprint author), Nisshin Steel Co Ltd, Steel & Technol Dev Labs, 7-1 Koyashinmachi, Ichikawa, Chiba 272, Japan.
EM n04313@nisshin-steel.co.jp
CR AOKI A, 1989, B CERAM SOC JAPAN, V24, P614
   KAMEYAMA T, 1995, P 14 INT THERM PLASM, P187
   KASHU S, 1984, J APPL PHYS, V23, P1900
   Kawasaki A., 1990, Journal of the Japan Society of Powder and Powder Metallurgy, V37, P287
   Koura S, 1996, MAT SCI ENG A-STRUCT, V208, P69, DOI 10.1016/0921-5093(95)10057-1
   MEACHIM G, 1973, J BIOMED MATER RES, V7, P555, DOI 10.1002/jbm.820070607
   OHSAKI K, 1994, P 7 S PLASM SCI MAT, P83
   OTSUKA A, 1997, J JAPAN SOC POWDER P, V44, P334
   OTSUKA A, 1997, IN PRESS P 4 INT S F
   OTSUKA A, 1996, T MAT RES SOC JAPAN, V20, P25
   SHIGERU K, 1989, J CERAM SOC JPN, V100, P377
   SIEGEL RW, 1993, PHYS TODAY, V46, P64, DOI 10.1063/1.881365
   Tanizaki H, 1996, MAT SCI ENG A-STRUCT, V215, P157, DOI 10.1016/0921-5093(96)10385-3
   TANIZAKI H, 1996, T MAT RES SOC JAPAN, V20, P29
   TSUCHIYA T, 1993, J APPL BIOMATER, V4, P153, DOI 10.1002/jab.770040206
   VEAL CR, 1972, FINE PATICLES
   WADA N, 1984, B CERAM SOC JPN, V19, P464
   YUKI M, 1990, J JAPAN SOC POWDER P, V37, P929
NR 18
TC 6
Z9 6
U1 2
U2 5
PU SPRINGER VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010 USA
SN 1432-8917
J9 MATER RES INNOV
JI Mater. Res. Innov.
PD DEC
PY 1997
VL 1
IS 3
BP 180
EP 187
DI 10.1007/s100190050038
PG 8
WC Materials Science, Multidisciplinary
SC Materials Science
GA YX892
UT WOS:000072090800008
DA 2018-10-19
ER

PT J
AU Borowiec, JW
   Venge, P
   Henze, A
   Nilsson, B
   Stiernstrom, H
AF Borowiec, JW
   Venge, P
   Henze, A
   Nilsson, B
   Stiernstrom, H
TI Biomaterial-dependent blood activation during simulated extracorporeal
   circulation: a study of heparin-coated and uncoated circuits
SO THORACIC AND CARDIOVASCULAR SURGEON
LA English
DT Article
DE simulated extracorporeal circulation; blood activation; heparin coating;
   nitric oxide
ID CARDIOPULMONARY BYPASS CIRCUITS; NEUTROPHIL LIPOCALIN HNL; FREE-RADICAL
   ACTIVITY; NITRIC-OXIDE; SURGERY; COMPLEMENT; RELEASE; DYSFUNCTION;
   INHIBITION; CYTOKINES
AB Objective: Blood activation during extracorporeal circulation is associated with morbidity and mortality in cardiac surgery. This activation can be diminished by usage of heparin-coated circuits. Nitric oxide has also been reported to influence humoral and cellular components of blood. This study was performed to determine biomaterial-dependent part of blood activation. Design: Fresh, whole human blood mixed with Ringer's solution was circulated through a heart-lung machine for two and half hours. Five circuits were heparin-coated (group HC), whilst five other circuits were uncoated (group NC). During the last half hour NO was added to the oxygen/air mixture. Methods: Blood activation was estimated by measuring following parameters: interluekin 6, complement activation products C3a and terminal complement complex, and oxygen free radicals (OFR) production capacity, which was determined using chemiluminescence enhanced by serum opsonized zymosan (SOZ) and phorbol myristate acetate (PMA). Granulocyte activation was measured as release of myeloperoxidase (MPG) and human neutrophil lipocalin (HNL). Results: OFR in granulocyte suspension stimulated by SOZ and PMA were significantly lower in the NC group, mostly later during ECC. Similarly, lower neutrophil and monocyte counts were observed in this group. NO increased superoxide production in the whole blood in heparin-coated circuits, but did not change OFR in isolated granulocytes. MPO was also affected by heparin-coating. NO supply seemed to increase release of MPO and HNL. It is concluded that heparin-coating contributed to reduction of biomaterial-dependent blood activation. An addition of NO at late stage of ECC tended to influence this activation.
C1 Univ Uppsala Hosp, Dept Cardiothorac Surg, S-75185 Uppsala, Sweden.
   Univ Uppsala Hosp, Dept Clin Chem, S-75185 Uppsala, Sweden.
   Univ Uppsala Hosp, Dept Clin Immunol, S-75185 Uppsala, Sweden.
   Univ Uppsala Hosp, Dept Anesthesiol, S-75185 Uppsala, Sweden.
RP Borowiec, JW (reprint author), Univ Uppsala Hosp, Dept Cardiothorac Surg, S-75185 Uppsala, Sweden.
RI Nilsson, Bo/B-3102-2012
OI Nilsson, Bo/0000-0003-0057-2730
CR BOROWIEC J, 1992, J THORAC CARDIOV SUR, V104, P642
   Borowiec JW, 1995, SCAND J THORAC CARD, V29, P167, DOI 10.3109/14017439509107225
   Bozdayi M, 1996, ARTIF ORGANS, V20, P1008, DOI 10.1111/j.1525-1594.1996.tb04588.x
   DAVIES SW, 1993, J THORAC CARDIOV SUR, V105, P979
   ElHabbal MH, 1995, CARDIOVASC RES, V30, P676, DOI 10.1016/0008-6363(95)00069-0
   EPPINGER MJ, 1995, ANN THORAC SURG, V60, P1169, DOI 10.1016/0003-4975(95)00697-J
   FAYMONVILLE ME, 1991, J THORAC CARDIOV SUR, V102, P309
   Finn A, 1996, J THORAC CARDIOV SUR, V111, P451, DOI 10.1016/S0022-5223(96)70456-7
   FUKUHARA K, 1997, EUR J CARDIO-THORAC, V11, P343
   Fullerton DA, 1996, ANN THORAC SURG, V61, P1856, DOI 10.1016/0003-4975(96)00046-X
   HENNEIN HA, 1994, J THORAC CARDIOV SUR, V108, P626
   LARM O, 1983, BIOMATER ARTIF CELL, V11, P161, DOI 10.3109/10731198309118804
   MCBRIDE WT, 1995, BRIT J ANAESTH, V75, P724, DOI 10.1093/bja/75.6.724
   Mellgren K, 1996, ANN THORAC SURG, V61, P1194, DOI 10.1016/0003-4975(96)00017-3
   MENASCHE P, 1995, CURR OPIN CARDIOL, V10, P597, DOI 10.1097/00001573-199511000-00008
   MOAT NE, 1993, EUR J CARDIO-THORAC, V7, P563, DOI 10.1016/1010-7940(93)90241-3
   Moen O, 1997, ANN THORAC SURG, V63, P105
   OVRUM E, 1995, J THORAC CARDIOV SUR, V110, P1623, DOI 10.1016/S0022-5223(95)70023-4
   PEKNA M, 1994, SCAND J THORAC CARD, V28, P5, DOI 10.3109/14017439409098703
   PRASAD K, 1992, AM HEART J, V123, P37, DOI 10.1016/0002-8703(92)90744-G
   RUVOLO G, 1995, EUR J CARDIO-THORAC, V9, P651, DOI 10.1016/S1010-7940(05)80112-5
   STEINBERG JB, 1993, J THORAC CARDIOV SUR, V106, P1008
   VENGE P, 1993, TXB RHEUMATOLOGY, P269
   Worrall NK, 1996, ANN THORAC SURG, V62, P378, DOI 10.1016/0003-4975(96)00241-X
   XU SY, 1994, SCAND J CLIN LAB INV, V54, P365, DOI 10.3109/00365519409088436
   XU SY, 1994, J IMMUNOL METHODS, V171, P245, DOI 10.1016/0022-1759(94)90044-2
NR 26
TC 7
Z9 7
U1 0
U2 0
PU GEORG THIEME VERLAG
PI STUTTGART
PA P O BOX 30 11 20, D-70451 STUTTGART, GERMANY
SN 0171-6425
J9 THORAC CARDIOV SURG
JI Thorac. Cardiovasc. Surg.
PD DEC
PY 1997
VL 45
IS 6
BP 295
EP 301
DI 10.1055/s-2007-1013752
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA YP477
UT WOS:000071280700006
PM 9477462
DA 2018-10-19
ER

PT J
AU Wen, JM
   Somorjai, G
   Lim, F
   Ward, R
AF Wen, JM
   Somorjai, G
   Lim, F
   Ward, R
TI XPS study of surface composition of a segmented polyurethane block
   copolymer modified by PDMS end groups and its blends with phenoxy
SO MACROMOLECULES
LA English
DT Article
ID DIBLOCK COPOLYMERS; INTERFACIAL-TENSION; POLY(DIMETHYLSILOXANE)
AB Quantitative angle-resolved X-ray photoelectron spectroscopy (XPS) was used to investigate surface modification of a newly developed biomaterial, segmented polyurethane capped with poly-(dimethylsiloxane) (PDMS) end groups, and its blends with phenoxy. The composition of the freshly prepared films are not in equilibrium but they can be equilibrated both in air and in water. The surface segregation of PDMS is found both in nonequilibrium and in equilibrium states, XPS data also indicate that the PDMS is enriched in the film surfaces of both air/polymer and glass substrate/polymer interfaces for the pure segmented polyurethane and its blends. The surface composition is affected by annealing temperature and water. Below the polymer glass transition temperature, there is a small increase in PDMS surface concentration during annealing. Above Tg, PDMS surface concentration can increase by a factor of 2. The presence of water will decrease the PDMS surface segregation at temperatures both below and above Tg.
C1 UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DEPT CHEM,BERKELEY,CA 94720.
   UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DIV SCI MAT,BERKELEY,CA 94720.
   POLYMER TECHNOL GRP INC,EMERYVILLE,CA 94608.
CR ANDRADE JD, 1988, SURFACE INTERFACIALA
   CASTNER DG, 1988, J VAC SCI TECHNOL A, V6, P964, DOI 10.1116/1.575040
   CHEN X, 1994, MACROMOLECULES, V27, P2206, DOI 10.1021/ma00086a034
   COULON G, 1989, MACROMOLECULES, V22, P2581, DOI 10.1021/ma00196a006
   FLEISCHER CA, 1993, MACROMOLECULES, V26, P4172, DOI 10.1021/ma00068a016
   HEARN MJ, 1987, SURF INTERFACE ANAL, V10, P384, DOI 10.1002/sia.740100803
   HEARN MJ, 1988, MACROMOLECULES, V21, P2951
   HU WC, 1995, MACROMOLECULES, V28, P5209, DOI 10.1021/ma00119a007
   JALBERT CJ, 1994, MACROMOLECULES, V27, P2409, DOI 10.1021/ma00087a008
   Lelah M. D., 1986, POLYURETHANES MED
   Seah M. P., 1979, Surface and Interface Analysis, V1, P2, DOI 10.1002/sia.740010103
   SOMORJAI GA, 1994, INTRO SURFACE CHEM C, P286
   VAVASOUR JD, 1992, MACROMOLECULES, V25, P5477, DOI 10.1021/ma00046a055
   WARD RS, 1994, T 20 ANN M SOC BIOM
   WARD RS, 1996, 5 WORLD BIOM C TOR C
   WHITE KA, 1995, ACS POLYM DIV S POLY
   WIRPSZA A, 1993, POLYURETHANES CHEM T
   ZHANG DL, IN PRESS
NR 18
TC 44
Z9 45
U1 3
U2 18
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0024-9297
J9 MACROMOLECULES
JI Macromolecules
PD NOV 17
PY 1997
VL 30
IS 23
BP 7206
EP 7213
DI 10.1021/ma961442r
PG 8
WC Polymer Science
SC Polymer Science
GA YH247
UT WOS:A1997YH24700026
DA 2018-10-19
ER

PT J
AU Chehade, M
   Elder, MJ
AF Chehade, M
   Elder, MJ
TI Intraocular lens materials and styles: A review
SO AUSTRALIAN AND NEW ZEALAND JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE intraocular lens; polymethylmethacrylate; silicone
ID PLATE HAPTIC SILICONE; LASER POSTERIOR CAPSULOTOMY; CYSTOID MACULAR
   EDEMA; ENDOTHELIAL-CELL LOSS; POLY(METHYL METHACRYLATE); CAPSULAR BAG;
   RETINAL-DETACHMENT; CATARACT-SURGERY; INCISION SIZE; IMPLANTATION
AB Biomaterial science has lead to the development of a variety of foldable intraocular lens (IOL) biomaterials. This literature review examines these lenses from both a basic science and a clinical perspective. By most parameters, hydrogel, soft acrylic and silicone IOL are better than polymethylmethacrylate (PMMA) lenses.
   Plate haptic silicone IOL have the lowest incidence of cystoid macula oedema and posterior capsule opacification, but these lenses require an intact anterior capsularhexis and posterior capsule. Yttrium aluminium garnet (YAG) laser capsulotomy must be delayed at least 3 months to avoid posterior lens dislocation. Silicone has the lowest threshold for YAG laser damage of all IOL materials and also adheres irreversibly to silicone oil with subsequent optical impairment. Three piece silicone IOL with polypropylene haptics have a higher incidence of decentration, pigment adherence and capsule opacification compared with PMMA haptics. Hydrogel lenses are very biocompatible and resistant to YAG laser damage, but pigment adheres to the surface more readily than PMMA. Soft acrylic IOL unfold slowly, resulting in controlled insertion, but it is possible to crack the lens and some lenses develop glistenings due to water accumulation.
   There are significant socioeconomic implications to the large differences in posterior capsule opacification rates between the various biomaterials and the lens styles.
C1 CHRISTCHURCH HOSP,DEPT OPHTHALMOL,CHRISTCHURCH,NEW ZEALAND.
CR AMBER JS, 1988, AUST NZ J OPHTHALMOL, V16, P337
   AMBROSE VMG, 1991, J CATARACT REFR SURG, V17, P622
   AMON M, 1991, J CATARACT REFR SURG, V17, P774, DOI 10.1016/S0886-3350(13)80410-5
   AMON M, 1992, OPHTHALMOLOGICA, V204, P13, DOI 10.1159/000310260
   ANDERSON CJ, 1994, J CATARACT REFR SURG, V20, P295, DOI 10.1016/S0886-3350(13)80581-0
   Apple DJ, 1996, OPHTHALMOLOGY, V103, P1555, DOI 10.1016/S0161-6420(96)30463-6
   ARTARIA LG, 1994, KLIN MONATSBL AUGENH, V204, P268, DOI 10.1055/s-2008-1035532
   ASSIA EI, 1995, OPHTHALMOLOGY, V102, P1151, DOI 10.1016/S0161-6420(95)30897-4
   BARTZSCHMIDT KU, 1995, KLIN MONATSBL AUGENH, V207, P162, DOI 10.1055/s-2008-1035362
   BATH PE, 1986, INVEST OPHTH VIS SCI, V27, P795
   BATTERBURY M, 1994, EYE, V8, P547, DOI 10.1038/eye.1994.135
   BERKEL H, 1992, NEW ENGL J MED, V326, P1649, DOI 10.1056/NEJM199206183262501
   BLOMQUIST PH, 1990, OPHTHALMIC SURG LAS, V21, P223
   BLOTNICK CA, 1995, J CATARACT REFR SURG, V21, P447, DOI 10.1016/S0886-3350(13)80538-X
   BRADY DG, 1994, J CATARACT REFR SURG, V20, P310, DOI 10.1016/S0886-3350(13)80583-4
   BRINT SF, 1991, J CATARACT REFR SURG, V17, P32, DOI 10.1016/S0886-3350(13)80981-9
   BRINT SF, 1993, OPHTHALIC PRACT, V11, P14
   BUCHEN SY, 1986, J CATARACT REFR SURG, V12, P292
   CAPON MRC, 1990, J CATARACT REFR SURG, V16, P603, DOI 10.1016/S0886-3350(13)80778-X
   CHRIST FR, 1989, J CATARACT REFR SURG, V15, P176, DOI 10.1016/S0886-3350(89)80007-0
   CUMMING JS, 1993, J CATARACT REFR SURG, V19, P275, DOI 10.1016/S0886-3350(13)80955-8
   CUMMING JS, 1993, J CATARACT REFR SURG, V19, P263, DOI 10.1016/S0886-3350(13)80954-6
   CUMMING JS, 1994, EUR J IMPLANT REFRAC, V6, P200
   CUNANAN CM, 1991, J CATARACT REFR SURG, V17, P767
   Dhaliwal DK, 1996, J CATARACT REFR SURG, V22, P452, DOI 10.1016/S0886-3350(96)80041-1
   ELMAGHRABY A, 1993, J CATARACT REFR SURG, V19, P494, DOI 10.1016/S0886-3350(13)80613-X
   FRANCESE JE, 1992, J CATARACT REFR SURG, V18, P402, DOI 10.1016/S0886-3350(13)80080-6
   Fruscella S, 1994, Eur J Ophthalmol, V4, P111
   GALIN MA, 1977, AM J OPHTHALMOL, V84, P153, DOI 10.1016/0002-9394(77)90847-9
   GILGER BC, 1993, AM J VET RES, V54, P1183
   GOBEL RJ, 1987, BIOMATERIALS, V8, P285, DOI 10.1016/0142-9612(87)90116-5
   Gonzalez GA, 1996, ARCH OPHTHALMOL-CHIC, V114, P775, DOI 10.1001/archopht.1996.01100130767038
   HANSEN SO, 1988, J CATARACT REFR SURG, V14, P605, DOI 10.1016/S0886-3350(88)80027-0
   HE SZ, 1994, CHINESE J OPHTHALMOL, V30, P180
   HUMPHRY RC, 1991, EYE, V5, P66, DOI 10.1038/eye.1991.13
   JOO CK, 1992, J CATARACT REFR SURG, V18, P240, DOI 10.1016/S0886-3350(13)80900-5
   Kim M S, 1990, Korean J Ophthalmol, V4, P73
   KNORZ MC, 1993, J CATARACT REFR SURG, V19, P766, DOI 10.1016/S0886-3350(13)80347-1
   KOCHOUNIAN HH, 1991, J CATARACT REFR SURG, V17, P139, DOI 10.1016/S0886-3350(13)80243-X
   Kohnen T., 1995, Ophthalmologe, V92, P297
   KRAFF MC, 1985, OPHTHALMOLOGY, V92, P366
   Lee GA, 1997, AUST NZ J OPHTHALMOL, V25, P71, DOI 10.1111/j.1442-9071.1997.tb01279.x
   LEEN MM, 1993, OPHTHALMIC SURG LAS, V24, P586
   LEMMING DV, 1997, J CATARACT REFR SURG, V22, P931
   LEVY JH, 1988, J CATARACT REFR SURG, V14, P299, DOI 10.1016/S0886-3350(88)80120-2
   LEVY JH, 1994, J CATARACT REFR SURG, V20, P630, DOI 10.1016/S0886-3350(13)80652-9
   Mackool RJ, 1996, J CATARACT REFR SURG, V22, P721, DOI 10.1016/S0886-3350(96)80310-5
   MARTIN RG, 1993, J CATARACT REFR SURG, V19, P170, DOI 10.1016/S0886-3350(13)80402-6
   MARTIN RG, 1992, OPHTHALMIC SURG LAS, V23, P770
   MASKET S, 1986, J CATARACT REFR SURG, V12, P252, DOI 10.1016/S0886-3350(86)80003-7
   MCDONNELL PJ, 1986, OPHTHALMIC SURG LAS, V17, P655
   MILAUSKAS AT, 1991, ARCH OPHTHALMOL-CHIC, V109, P913, DOI 10.1001/archopht.1991.01080070023006
   MILAUSKAS AT, 1990, J CATARACT REFR SURG, V16, P583, DOI 10.1016/S0886-3350(13)80773-0
   MILAUSKAS AT, 1994, OPHTHAL PRACT, V12, P123
   NEWLAND TJ, 1994, J CATARACT REFR SURG, V20, P527, DOI 10.1016/S0886-3350(13)80233-7
   NOBLE BA, 1990, EYE, V4, P450, DOI 10.1038/eye.1990.57
   OSHIKA T, 1994, OPHTHALMOLOGY, V101, P1183
   Oshika T, 1996, J CATARACT REFR SURG, V22, P104, DOI 10.1016/S0886-3350(96)80278-1
   Pharmakakis N, 1989, Fortschr Ophthalmol, V86, P295
   RAVALICO G, 1993, OPHTHALMOLOGICA, V207, P202, DOI 10.1159/000310433
   RICHARDSON RR, 1993, BIOMATERIALS, V14, P627, DOI 10.1016/0142-9612(93)90183-3
   RICKMANBARGER L, 1989, AM J OPHTHALMOL, V107, P531, DOI 10.1016/0002-9394(89)90500-X
   ROG SJ, 1986, AM J OPTOM PHYS OPT, V63, P867
   SANCHEZGUERRERO J, 1995, NEW ENGL J MED, V332, P1666, DOI 10.1056/NEJM199506223322502
   SANTOS BA, 1986, J CATARACT REFR SURG, V12, P23, DOI 10.1016/S0886-3350(86)80050-5
   SHEPHERD JR, 1989, J CATARACT REFR SURG, V15, P448, DOI 10.1016/S0886-3350(89)80069-0
   SHIMIZU K, 1987, J CATARACT REFR SURG, V13, P151, DOI 10.1016/S0886-3350(87)80130-X
   SKORPIK C, 1989, GRAEF ARCH CLIN EXP, V227, P413, DOI 10.1007/BF02172890
   SORENSEN EJ, 1991, ACTA OPHTHALMOL, V69, P761
   SPEAKER MG, 1991, OPHTHALMOLOGY, V98, P1761
   STEINERT RF, 1991, AM J OPHTHALMOL, V112, P373, DOI 10.1016/S0002-9394(14)76242-7
   TINGEY DP, 1991, CAN J OPHTHALMOL, V26, P3
   VERSURA P, 1991, OPHTHALMIC RES, V23, P1, DOI 10.1159/000267079
   WEGHAUPT H, 1993, GRAEF ARCH CLIN EXP, V231, P449, DOI 10.1007/BF02044230
   Wenzel M, 1991, Fortschr Ophthalmol, V88, P132
   YGGE J, 1990, OPHTHALMOLOGY, V97, P1216
   ZEHETMAYER M, 1994, KLIN MONATSBL AUGENH, V204, P220, DOI 10.1055/s-2008-1035521
NR 77
TC 57
Z9 62
U1 1
U2 31
PU ROYAL AUSTRALIAN COLL OPHTHAL
PI SYDNEY
PA 27 COMMONWEALTH ST, SYDNEY NSW 2010, AUSTRALIA
SN 0814-9763
J9 AUST NZ J OPHTHALMOL
JI Aust. N. Z. J. Ophthalmol.
PD NOV
PY 1997
VL 25
IS 4
BP 255
EP 263
DI 10.1111/j.1442-9071.1997.tb01512.x
PG 9
WC Ophthalmology
SC Ophthalmology
GA YG672
UT WOS:A1997YG67200003
PM 9395827
DA 2018-10-19
ER

PT J
AU Hunt, JA
   McLaughlin, PJ
   Flanagan, BF
AF Hunt, JA
   McLaughlin, PJ
   Flanagan, BF
TI Techniques to investigate cellular and molecular interactions in the
   host response to implanted biomaterials
SO BIOMATERIALS
LA English
DT Review
DE molecular biology; antibodies; cellular; host response
ID IN-SITU HYBRIDIZATION; POLYMERASE CHAIN-REACTION; MESSENGER-RNA
   EXPRESSION; SOFT-TISSUE RESPONSE; THERAPEUTIC MONOCLONAL-ANTIBODIES;
   TNF-ALPHA PRODUCTION; METAL-IONS; ADHESION MOLECULES; GROWTH-FACTOR;
   QUANTITATIVE ASSESSMENT
AB Evaluation of the host response to implanted materials requires systematic, objective investigations of responses at both the cellular and molecular levels. This article explains the basis behind two technologies: antibody and molecular techniques, which will give valuable information when applied to investigations of cells and molecules involved in the host biomaterial interaction. Such investigations are well underway, and a number of groups are now studying well characterised cell markers or molecules to evaluate the host response to biomaterials. Here we outline current technologies for the development of antibodies as tools to study cell markers or molecules, including those for which reagents are not yet available and DNA based technologies, whose continued application should prove an invaluable adjunct to existing approaches. These technologies may be particularly valuable to investigations focusing on newly characterised cytokines, receptors or cell adhesion molecules and subsequently provide a way forward for the production of advanced biomaterials. (C) 1997 Elsevier Science Limited. All rights reserved.
C1 UNIV LIVERPOOL, ROYAL LIVERPOOL HOSP, DEPT IMMUNOL, LIVERPOOL L69 3GA, MERSEYSIDE, ENGLAND.
RP Hunt, JA (reprint author), UNIV LIVERPOOL, ROYAL LIVERPOOL HOSP, DEPT CLIN ENGN, DUNCAN BLDG, DAULBY ST, LIVERPOOL L69 3GA, MERSEYSIDE, ENGLAND.
RI Hunt, John/G-6366-2012
OI Hunt, John/0000-0002-5168-4778
CR Alves A, 1997, J HISTOTECHNOL, V20, P53
   Atamas SP, 1996, J IMMUNOL, V156, P435
   AZZAWI M, 1995, J HEART LUNG TRANSPL, V14, P519
   BACH JF, 1993, IMMUNOL TODAY, V14, P421, DOI 10.1016/0167-5699(93)90243-E
   Bartlett JMS, 1996, BRIT J CANCER, V73, P1538, DOI 10.1038/bjc.1996.290
   BONFIELD TL, 1992, J BIOMED MATER RES, V26, P837, DOI 10.1002/jbm.820260702
   BUKLEY A, 1989, J CELL PHYSL, V138, P70
   BURNETT KG, 1987, IMMUNOLOGY SERIES, V30, P253
   BURTHEM J, 1994, BLOOD, V83, P1381
   BURTHEM J, 1994, BLOOD, V84, P873
   BURTON DR, 1994, HOSP PRACT, V29, P111, DOI 10.1080/21548331.1994.11443111
   Campoccia D, 1996, BIOMATERIALS, V17, P963, DOI 10.1016/0142-9612(96)84670-9
   CAMPOCCIA D, 1993, BIOMATERIALS, V14, P1135, DOI 10.1016/0142-9612(93)90156-V
   CHADHA HS, 1995, INFLAMM RES, V44, P145, DOI 10.1007/BF01782811
   CHILKOTI A, 1995, ANAL CHEM, V67, P2883, DOI 10.1021/ac00113a024
   CHOU LS, 1995, J CELL SCI, V108, P1563
   CLARK P, 1990, DEVELOPMENT, V108, P635
   Cohen J, 1995, AM J MED, V99, pS45, DOI 10.1016/S0002-9343(99)80286-1
   CROIZE J, 1993, APMIS, V101, P487, DOI 10.1111/j.1699-0463.1993.tb00137.x
   deMoraesPinto MI, 1997, IMMUNOLOGY, V90, P87, DOI 10.1046/j.1365-2567.1997.00139.x
   Dike LE, 1996, J CELL SCI, V109, P2855
   DINARELLO CA, 1988, INFLAMMATION BASIC P, P195
   Eliaz R, 1996, CYTOKINE, V8, P482, DOI 10.1006/cyto.1996.0065
   ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9
   FINOTTO S, 1994, J IMMUNOL, V153, P2278
   Frautschi JR, 1996, J BIOMAT SCI-POLYM E, V7, P707, DOI 10.1163/156856296X00471
   Goodman SB, 1996, J BIOMED MATER RES, V31, P421, DOI 10.1002/(SICI)1097-4636(199607)31:3<421::AID-JBM17>3.0.CO;2-L
   GOSPODAROWICZ D, 1979, EXP EYE RES, V28, P501, DOI 10.1016/0014-4835(79)90038-1
   GRAY MR, 1995, GUT, V36, P522, DOI 10.1136/gut.36.4.522
   HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408
   HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053
   Herbert W. J., 1978, HDB EXPT IMMUNOLOGY, pA41
   HUNT JA, 1992, J MATER SCI-MATER M, V3, P160, DOI 10.1007/BF00713443
   HUNT JA, 1993, BIOMATERIALS, V14, P378, DOI 10.1016/0142-9612(93)90058-A
   HUNT JA, 1992, J MATER SCI-MATER M, V3, P192, DOI 10.1007/BF00713449
   Hunt JA, 1995, J MATER SCI-MATER M, V6, P839, DOI 10.1007/BF00134328
   HUNT JA, 1992, J BIOMED MATER RES, V26, P819, DOI 10.1002/jbm.820260610
   HUNT JA, 1994, J MATER SCI-MATER M, V5, P381, DOI 10.1007/BF00058968
   HUNT JA, 1995, BIOMATERIALS, V16, P167, DOI 10.1016/0142-9612(95)92113-K
   HUNT JA, 1994, ANAL CELL PATHOL, V7, P43
   HUNT JA, 1993, J BIOMED ENG, V15, P39, DOI 10.1016/0141-5425(93)90091-C
   Hunt JA, 1996, J BIOMED MATER RES, V31, P139, DOI 10.1002/(SICI)1097-4636(199605)31:1<139::AID-JBM15>3.0.CO;2-I
   HUNT JA, 1996, J CELL ENG, V1, P209
   HUNT JA, 1997, IN PRESS J BIOMED MA
   Jenkins ME, 1996, J INVEST SURG, V9, P1, DOI 10.3109/08941939609012455
   JIRANEK W, 1995, J BONE JOINT SURG AM, V77A, P1650, DOI 10.2106/00004623-199511000-00003
   JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3
   KARR LJ, 1995, J IMMUNOL METHODS, V182, P93, DOI 10.1016/0022-1759(95)00027-8
   KASEMO B, 1994, ENVIRON HEALTH PERSP, V102, P41, DOI 10.2307/3432057
   KENNEY JS, 1989, J IMMUNOL METHODS, V121, P157, DOI 10.1016/0022-1759(89)90156-7
   Kidd IM, 1996, J INFECT DIS, V174, P396
   Kishida A, 1996, BIOMATERIALS, V17, P1301, DOI 10.1016/0142-9612(96)88675-3
   KLEIN CL, 1994, J MATER SCI-MATER M, V5, P798, DOI 10.1007/BF00213138
   KLEIN CL, 1994, PATHOBIOLOGY, V62, P199, DOI 10.1159/000163911
   KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0
   KUUSREICHEL K, 1994, CLIN DIAGN LAB IMMUN, V1, P365
   LATTIME EC, 1995, CANCER IMMUNOL IMMUN, V41, P151, DOI 10.1007/BF01521340
   LEIBOVICH SJ, 1975, AM J PATHOL, V78, P71
   LEITCH AR, 1994, IN SITU HYBRIDISATIO
   LLEWELYN MB, 1992, BRIT MED J, V305, P1269, DOI 10.1136/bmj.305.6864.1269
   MARKS C, 1986, NEW ENGL J MED, V355, P730
   MATSUDA T, 1994, J BIOMED MATER RES, V28, P1387, DOI 10.1002/jbm.820281202
   MATSUDA T, 1995, ASAIO, V41, pM374
   MCPHERSON MJ, 1995, PCR PRACTICAL APPROA
   MOHANTY M, 1992, BIOMATERIALS, V13, P651, DOI 10.1016/0142-9612(92)90123-6
   MOQBEL R, 1995, J IMMUNOL, V155, P4939
   MORVAN PY, 1994, EUR CYTOKINE NETW, V5, P469
   Neo M, 1996, J BIOMED MATER RES, V30, P485, DOI 10.1002/(SICI)1097-4636(199604)30:4<485::AID-JBM6>3.0.CO;2-L
   OAKLEY C, 1993, J CELL SCI, V106, P343
   OJENIYI B, 1991, ANTIBIOT CHEMOTHER, V44, P13
   PARSSON H, 1995, J BIOMED MATER RES, V29, P519, DOI 10.1002/jbm.820290412
   RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594
   Reis SA, 1996, CLIN ORAL IMPLAN RES, V7, P253, DOI 10.1034/j.1600-0501.1996.070307.x
   REMES A, 1992, BIOMATERIALS, V13, P731, DOI 10.1016/0142-9612(92)90010-L
   REMES A, 1990, J MATER SCI-MATER M, V1, P26, DOI 10.1007/BF00705350
   RHODES NP, 1994, J MATER SCI-MATER M, V5, P666, DOI 10.1007/BF00120353
   RHODES NP, 1997, IN PRESS J BIOMED MA
   RICHARDSON JH, 1995, TRENDS BIOTECHNOL, V13, P306, DOI 10.1016/S0167-7799(00)88970-2
   Sambrook J., 1989, MOL CLONING LAB MANU
   SAMOILOVICH SR, 1987, J IMMUNOL METHODS, V101, P153, DOI 10.1016/0022-1759(87)90147-5
   SLAVIN J, 1992, BRIT J SURG, V79, P918, DOI 10.1002/bjs.1800790921
   SPARGO BJ, 1994, BIOMATERIALS, V15, P853, DOI 10.1016/0142-9612(94)90042-6
   STUDNICKA GM, 1994, PROTEIN ENG, V7, P805, DOI 10.1093/protein/7.6.805
   Thompson J, 1996, J MOL BIOL, V256, P77, DOI 10.1006/jmbi.1996.0069
   TOMCZOK J, 1994, MICRON, V25, P257, DOI 10.1016/0968-4328(94)90031-0
   UNGERSBOCK A, 1994, J MATER SCI-MATER M, V5, P702, DOI 10.1007/BF00120360
   VINCE DG, 1991, BIOMATERIALS, V12, P731, DOI 10.1016/0142-9612(91)90021-2
   Vincent R, 1996, J IMMUNOL, V156, P603
   VITOLO D, 1994, AM J PATHOL, V145, P322
   WAKSMAN BH, 1979, SPRINGER SEMIN IMMUN, V2, P5
   WATAHA JC, 1995, DENT MATER, V11, P239, DOI 10.1016/0109-5641(95)80056-5
   WESTERWOUDT RJ, 1986, METHOD ENZYMOL, V121, P3
   WILLIAMS RL, 1995, J BIOMED MATER RES, V29, P1545, DOI 10.1002/jbm.820291211
   Wooley PH, 1996, CLIN ORTHOP RELAT R, P63
   WRIGHT A, 1992, CRIT REV IMMUNOL, V12, P125
   XIA ZD, 1994, CHINESE MED J-PEKING, V107, P845
   YOSHINARI K, 1995, J IMMUNOL METHODS, V186, P17, DOI 10.1016/0022-1759(95)00125-T
   Yung LYL, 1996, IMMUNOPHARMACOLOGY, V32, P19, DOI 10.1016/0162-3109(96)00003-3
   Zreiqat H, 1996, J BIOMED MATER RES, V33, P217, DOI 10.1002/(SICI)1097-4636(199624)33:4<217::AID-JBM2>3.0.CO;2-S
NR 99
TC 39
Z9 43
U1 0
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD NOV
PY 1997
VL 18
IS 22
BP 1449
EP 1459
DI 10.1016/S0142-9612(97)00091-4
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA YG752
UT WOS:A1997YG75200001
PM 9426174
DA 2018-10-19
ER

PT J
AU Erfle, DJ
   Santerre, JP
   Labow, RS
AF Erfle, DJ
   Santerre, JP
   Labow, RS
TI Lysosomal enzyme release from human neutrophils adherent to foreign
   material surfaces: Enhanced release of elastase activity
SO CARDIOVASCULAR PATHOLOGY
LA English
DT Article
ID CELL ACTIVATION; DEGRADATION; OXIDANTS; PROTEINS
AB Neutrophils are the major phagocytic white blood cell present during the acute inflammatory response to cardiovascular medical devices and can become activated to release a wide variety of products that help mediate the overall host response. The purpose of this investigation was to develop an in vitro system to study the release of lysosomal enzymes from neutrophils adherent to biomaterial surfaces, Neutrophils isolated from peripheral human blood were allowed to adhere to different biomaterials and lysosomal enzyme release assessed by monitoring elastase-like activity in the supernatant. The number of adherent neutrophils with intact cytoplasmic membranes was estimated by extracting the cells and quantifying lactate dehydrogenase. Stimulated and non-stimulated neutrophils released significantly different amounts of elastase-like activity depending on the biomaterial surface to which they were adhered. The techniques developed in this study form the basis of an in vitro system for investigating the events associated with neutrophil/biomaterial interactions as well as a method for evaluating the white blood cell response td the materials used in circulatory support devices. (C) 1997 by Elsevier Science Inc.
C1 UNIV OTTAWA,INST HEART,CARDIOVASC DEVICES DIV,OTTAWA,ON K1Y 4E9,CANADA.
   UNIV OTTAWA,INST HEART,DEPT BIOCHEM,OTTAWA,ON K1Y 4E9,CANADA.
   UNIV TORONTO,FAC DENT,DEPT BIOMAT,TORONTO,ON,CANADA.
CR ANDERSON JM, 1993, CARDIOVASC PATHOL S, V4, P33
   BANGALORE N, 1994, BIOL CHEM H-S, V375, P659, DOI 10.1515/bchm3.1994.375.10.659
   BECKER EL, 1974, J IMMUNOL, V112, P2047
   Bergstrand H, 1990, Agents Actions Suppl, V30, P199
   BERTON G, 1992, J CELL BIOL, V116, P1007, DOI 10.1083/jcb.116.4.1007
   BONFIELD TL, 1992, J BIOMED MATER RES, V26, P1039
   BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77
   CABAUD PG, 1958, AM J CLIN PATHOL, V30, P234, DOI 10.1093/ajcp/30.3.234
   CERASOLI F, 1988, TISSUE CELL, V20, P505, DOI 10.1016/0040-8166(88)90053-5
   FALCK P, 1995, BIOMATERIALS, V16, P61, DOI 10.1016/0142-9612(95)91097-I
   HENSON PM, 1987, J CLIN INVEST, V79, P669, DOI 10.1172/JCI112869
   Kaplan S S, 1990, ASAIO Trans, V36, pM172
   KAPLAN SS, 1994, J BIOMED MATER RES, V28, P377, DOI 10.1002/jbm.820280313
   KAPLAN SS, 1992, J BIOMED MATER RES, V26, P1039, DOI 10.1002/jbm.820260806
   LABOW RS, 1995, BIOMATERIALS, V16, P51, DOI 10.1016/0142-9612(95)91096-H
   RIEU P, 1992, EUR J IMMUNOL, V22, P3021, DOI 10.1002/eji.1830221138
   RUOTSALAINEN M, 1995, TOXICOLOGY, V99, P67, DOI 10.1016/0300-483X(94)02996-8
   SANDBORG RR, 1988, LAB INVEST, V59, P300
   SANTERRE JP, 1994, J BIOMED MATER RES, V28, P1187, DOI 10.1002/jbm.820281009
   Shankar Ravi, 1994, P67
   SKARLATOS SI, 1992, J TISS CULT METH, V14, P113
   SUCHARD SJ, 1994, J IMMUNOL, V152, P290
   SUTHERLAND K, 1993, J CLIN INVEST, V92, P2360, DOI 10.1172/JCI116841
   UNDERWOOD PA, 1993, J CELL SCI, V104, P793
   WEISS SJ, 1989, NEW ENGL J MED, V320, P365
   WILLIAMS DF, 1979, SPECH TECH PUBL, V684, P61
   WYATT TA, 1993, AM J PHYSIOL, V265, pC201
   ZHOU WG, 1994, ARCH BIOCHEM BIOPHYS, V308, P439, DOI 10.1006/abbi.1994.1062
NR 28
TC 11
Z9 11
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010
SN 1054-8807
J9 CARDIOVASC PATHOL
JI Cardiovasc. Pathol.
PD NOV-DEC
PY 1997
VL 6
IS 6
BP 333
EP 340
DI 10.1016/S1054-8807(97)00031-8
PG 8
WC Cardiac & Cardiovascular Systems; Pathology
SC Cardiovascular System & Cardiology; Pathology
GA YG493
UT WOS:A1997YG49300004
PM 25989886
DA 2018-10-19
ER

PT J
AU Yu, JL
   Mansson, R
   Flock, JI
   Ljungh, A
AF Yu, JL
   Mansson, R
   Flock, JI
   Ljungh, A
TI Fibronectin binding by Propionibacterium acnes
SO FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY
LA English
DT Article
ID STAPHYLOCOCCUS-AUREUS; AFFINITY-CHROMATOGRAPHY; HIP-ARTHROPLASTY;
   COLLAGEN-BINDING; HUMAN-PLASMA; PURIFICATION; ADHERENCE; PROTEINS;
   OSTEOMYELITIS; RECEPTOR
AB Strains of Propionibacterium acnes, isolated from different kinds of orthopaedic and biomaterial-associated infections and from skin flora were shown to express binding of soluble as well as immobilized fibronectin. Among these 7 strains isolated from orthopaedic infections, 2 from breast prostheses, and 9 skin isolates, 2, 2, and 5 strains respectively bound immobilized fibronectin. The fibronectin binding was sensitive to protease and heat treatment, and was inhibited by a cell surface extract from one of the binding strains. In SDS-PAGE and autoradiography of cell surface extracts, a band corresponding to a MW of about 80 kD reacted with fibronectin and the 150 kD fragment of fibronectin. Binding to fibronectin and the 150 kD fragment of fibronectin could be inhibited with heparin. We thus present a first Fn binding protein of P. acnes, a surface exposed protein of 80 kD. None of the strains bound soluble collagen, and only one strain expressed weak binding of vitronectin and bone sialoprotein II.
C1 LUND UNIV,DEPT MED MICROBIOL,S-22362 LUND,SWEDEN.
   HUDDINGE HOSP,KAROLINSKA INST,DEPT IMMUNOL MICROBIOL PATHOL & INFECT DIS,S-14186 HUDDINGE,SWEDEN.
CR ALELJUNG P, 1994, CURR MICROBIOL, V28, P231, DOI 10.1007/BF01575966
   ANTTIPOIKA I, 1990, ACTA ORTHOP SCAND, V61, P163, DOI 10.3109/17453679009006513
   BAYSTON R, 1983, J ANTIMICROB CHEMOTH, V59, P735
   BOZZINI S, 1992, EUR J BIOCHEM, V207, P327, DOI 10.1111/j.1432-1033.1992.tb17054.x
   EDLUND E, 1988, ANN RHEUM DIS, V47, P809, DOI 10.1136/ard.47.10.809
   HERRMANN M, 1988, J INFECT DIS, V158, P693, DOI 10.1093/infdis/158.4.693
   KAMME C, 1974, SCAND J INFECT DIS, V6, P161, DOI 10.3109/inf.1974.6.issue-2.10
   KAMME C, 1981, CLIN ORTHOP RELAT R, V154, P201
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LIANG OD, 1992, INFECT IMMUN, V60, P899
   LJUNGH A, 1995, METHODS ENZYMOLOGY M, P501
   NOBLE RC, 1987, J CLIN MICROBIOL, V25, P251
   PAULSSON M, 1994, J BIOMED MATER RES, V28, P311, DOI 10.1002/jbm.820280305
   RYDEN C, 1989, EUR J BIOCHEM, V184, P331, DOI 10.1111/j.1432-1033.1989.tb15023.x
   RYDEN C, 1990, J INFECT DIS, V161, P814, DOI 10.1093/infdis/161.4.814
   SAKATA N, 1994, MICROBIOL IMMUNOL, V38, P359, DOI 10.1111/j.1348-0421.1994.tb01791.x
   SHEN W, 1993, CURR MICROBIOL, V27, P311, DOI 10.1007/BF01568953
   SWITALSKI LM, 1993, MOL MICROBIOL, V7, P99, DOI 10.1111/j.1365-2958.1993.tb01101.x
   VUENTO M, 1979, BIOCHEM J, V183, P331, DOI 10.1042/bj1830331
   WADSTROM T, 1988, BAYER S, V8, P193
   YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281
   YU JL, 1995, J SURG RES, V59, P596, DOI 10.1006/jsre.1995.1210
NR 22
TC 8
Z9 8
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928-8244
J9 FEMS IMMUNOL MED MIC
JI FEMS Immunol. Med. Microbiol.
PD NOV
PY 1997
VL 19
IS 3
BP 247
EP 253
DI 10.1016/S0928-8244(97)00092-8
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA YK218
UT WOS:A1997YK21800008
PM 9453395
OA Bronze
DA 2018-10-19
ER

PT J
AU Carr, AB
   Gerard, DA
   Larsen, PE
AF Carr, AB
   Gerard, DA
   Larsen, PE
TI Quantitative histomorphometric description of implant anchorage for
   three types of dental implants following 3 months of healing in baboons
SO INTERNATIONAL JOURNAL OF ORAL & MAXILLOFACIAL IMPLANTS
LA English
DT Article
DE percentage integration; percentage bone area; jaws; healed implants
AB Important to the understanding of the dynamics associated with dental implant anchorage over time is a knowledge of the supporting anatomy for common endosseous implants prior to being placed into function. This study followed 20 screw-shaped dental implants placed in edentulated (2 months' healing time) posterior jaws of five adult female baboons. Implants made of three biomaterials were placed and allowed to heal for 3 months prior to processing for evaluation. Percentage integration and bone area data from six horizontal sections along the entire length of each implant were collected and analyzed for differences between jaws, implant biomaterials, jaw/biomaterial, and sections of the implants (ANOVA, pairwise comparison using LSM with Bonferroni adjustment). The results indicated that overall mean percentage integration was 46.5 and mean percentage bone area was 39.9. Maxillary and mandibular differences for both parameters were statistically different (integration: maxillary = 38.1%, mandibular = 56.7%; bone area: maxillary = 35.8%, mandibular = 44.9%; both were significant at the P < .05 level). The biomaterial analyses revealed significant differences for percentage integration between the metal implants and the hydroxyapatite-coated implant (commercially pure titanium = 39.1%, titanium-aluminum-vanadium = 40.0%, hydroxyapatite-coated = 61.5%), but no such difference was noted for percentage bone area (commercially pure titanium = 38.8%, titanium-aluminum-vanadium = 38.9%, hydroxyapatite-coated = 42.3%). Discussion of the relative importance of the two parameters highlights the fact that resistance to functional loads requires establishing and then maintaining an adequate volume of bone, which may have a functionally specific structure based on the mechanical properties of the local jaw environment.
C1 UNIV TENNESSEE,MED CTR,KNOXVILLE,TN.
RP Carr, AB (reprint author), OHIO STATE UNIV,COLL DENT,305 W 12TH AVE,COLUMBUS,OH 43210, USA.
OI Carr, Alan/0000-0002-7944-4143
CR ADELL R, 1990, International Journal of Oral and Maxillofacial Implants, V5, P347
   Albrektsson T., 1993, Clinical Materials, V12, P1, DOI 10.1016/0267-6605(93)90021-X
   Brunski J B, 1988, J Dent Educ, V52, P775
   BRUNSKI JB, 1989, MATER RES SOC S P, V110, P505
   Carlsson L, 1988, Int J Oral Maxillofac Implants, V3, P21
   CARLSSON L V, 1989, International Journal of Oral and Maxillofacial Implants, V4, P199
   COOK SD, 1992, J BIOMED MATER RES, V26, P989, DOI 10.1002/jbm.820260803
   Dattilo D J, 1995, Int J Oral Maxillofac Implants, V10, P405
   Ettinger R L, 1993, Int J Oral Maxillofac Implants, V8, P420
   FROST HM, 1988, CALCIFIED TISSUE INT, V42, P145, DOI 10.1007/BF02556327
   GERNER BT, 1988, SCAND J DENT RES, V96, P143
   Gottlander M, 1992, Int J Oral Maxillofac Implants, V7, P485
   HALE TM, J ORAL IMPLANTOL, V17, P118
   Johansson C, 1987, Int J Oral Maxillofac Implants, V2, P69
   JOHANSSON C B, 1991, International Journal of Oral and Maxillofacial Implants, V6, P437
   Johansson CB, 1991, CLIN ORAL IMPLAN RES, V2, P24, DOI 10.1034/j.1600-0501.1991.020103.x
   KELLER JC, 1987, J BIOMED MATER RES, V21, P305, DOI 10.1002/jbm.820210304
   Lekholm U, 1985, TISSUE INTEGRATED PR, P199, DOI DOI 10.1111/J.1708-8208.2002.TB00174.X
   LUM LB, 1988, J PROSTHET DENT, V60, P700, DOI 10.1016/0022-3913(88)90403-9
   MARTIN RB, 1989, STRUCTURE FUNCTION A, P83
   MEENAGHAN MA, 1979, J BIOMED MATER RES, V13, P631, DOI 10.1002/jbm.820130409
   Rohrer M D, 1995, Int J Oral Maxillofac Implants, V10, P466
   RUBIN CT, 1985, CALCIFIED TISSUE INT, V37, P411, DOI 10.1007/BF02553711
   SENNERBY L, 1992, International Journal of Oral and Maxillofacial Implants, V7, P62
   SOBALLE K, 1990, ACTA ORTHOP SCAND, V61, P299, DOI 10.3109/17453679008993521
   STEFLIK DE, 1994, INT J ORAL MAXILLOF, V9, P501
   Weinlaender M, 1992, Int J Oral Maxillofac Implants, V7, P491
   YOUNG FA, 1979, J BIOMED MATER RES, V13, P843, DOI 10.1002/jbm.820130604
NR 28
TC 18
Z9 19
U1 0
U2 1
PU QUINTESSENCE PUBL CO INC
PI CAROL STREAM
PA 551 KIMBERLY DR, CAROL STREAM, IL 60188-1881
SN 0882-2786
J9 INT J ORAL MAX IMPL
JI Int. J. Oral Maxillofac. Implants
PD NOV-DEC
PY 1997
VL 12
IS 6
BP 777
EP 784
PG 8
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA YL456
UT WOS:A1997YL45600006
PM 9425758
DA 2018-10-19
ER

PT J
AU Zhang, M
   Powers, RM
   Wolfinbarger, L
AF Zhang, M
   Powers, RM
   Wolfinbarger, L
TI Effect(s) of the demineralization process on the osteoinductivity of
   demineralized bone matrix
SO JOURNAL OF PERIODONTOLOGY
LA English
DT Article
DE biological assay; bone regeneration; bone matrix; alkaline phosphatase;
   osteogenesis; periodontal diseases, physiopathology
ID FIBROBLASTS
AB THE RELATIONSHIPS BETWEEN RESIDUAL calcium levels and particle size of ground demineralized bone matrix and its osteoinductive potential were investigated using in vitro and in vivo assays. The effects of variable residual calcium levels, variable particle sizes, and donor age and gender were studied using a tissue culture-based bioassay (in vitro) as well as an athymic mouse (in vivo) bioassay. The osteoinductive potential of the bone-derived biomaterial was assessed by measuring the degree of new bone formation (change in percent calcium content after 4 weeks of implantation) in the in vivo assay and levels of alkaline phosphatase activity associated with cultures of human periosteal cells (HPO cells) in the in vitro assay, respectively. Slightly demineralized bone matrix and overly demineralized bone matrix possessed a degree of osteoinductive potential whereas bone demineralized to levels of approximately 2% residual calcium provided for maximum osteoinductive potential in both assay systems. The osteoinductive potential of ground demineralized bone varied relative to the particle size such that DBM particles ranging from 500 to 710 microns provided for the highest level of calcium deposition (increase of 8.1 weight percent calcium) after 4 weeks of implantation in muscle pouches of an athymic mouse, whereas explanted particles less than 250 microns showed the lowest level of calcium deposition (increase of only 2.8 weight percent calcium). In the donor age and gender study, DBM from different donors were divided into 5 age groups for both female and male donor derived bone: less than 20, 21 to 30, 31 to 40, 41 to 50, and 51 to 60 year old age groups. This study indicated that DBM from female donors in the 31 to 40 years old age group and male donors in the 41 to 50 year age group possess the highest osteoinductive potential, whereas DBM derived from donor bone from both female and male donors in the 51 to 60 year age group presented the lowest osteoinductive potential. DBM derived from male and female donors did not in general show significant differences in osteoinductive potential.
C1 LIFENET, VIRGINIA BEACH, VA 23455 USA.
   OLD DOMINION UNIV, CTR BIOTECHNOL, NORFOLK, VA USA.
CR ANASTASSIADES T, 1978, CALC TISS RES, V26, P173, DOI 10.1007/BF02013253
   Dubuc F L, 1967, Clin Orthop Relat Res, V55, P217
   HUGGINS C, 1970, J EXP MED, V132, P1250, DOI 10.1084/jem.132.6.1250
   LACROIX P, 1947, J BONE JOINT SURG, V29, P292
   Leriche R., 1928, NORMAL PATHOLOGICAL
   LEVANDER G, 1964, INDUCTION PHENOMENA
   SAMPATH TK, 1983, P NATL ACAD SCI-BIOL, V80, P6591, DOI 10.1073/pnas.80.21.6591
   Senn N, 1889, AM J MED SCI, V98, P219
   SYFTESTAD GT, 1982, CLIN ORTHOP RELAT R, V162, P288
   SYFTESTAD GT, 1979, CLIN ORTHOP RELAT R, V141, P281
   TAKAOKA K, 1980, CLIN ORTHOP RELAT R, V148, P274
   URIST MR, 1970, CLIN ORTHOP RELAT R, P271
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   URIST MR, 1983, P SOC EXP BIOL MED, V173, P194
   URIST MR, 1982, CLIN ORTHOP RELAT R, P219
   URIST MR, 1981, MECHANISMS GROWTH CO, P406
   URIST MR, 1992, BONE GRAFTS BONE SUB, P70
   VAIL TB, 1994, VET SURG, V23, P386, DOI 10.1111/j.1532-950X.1994.tb00499.x
   WEISS RE, 1981, J CELL BIOL, V88, P630, DOI 10.1083/jcb.88.3.630
   WOLFINBARGER L, 1993, IN VITRO CELL DEV-AN, V29A, P914
   ZHANG M, 1996, THESIS OLD DOMINION
NR 21
TC 85
Z9 93
U1 0
U2 7
PU AMER ACAD PERIODONTOLOGY
PI CHICAGO
PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611-2690 USA
SN 0022-3492
EI 1943-3670
J9 J PERIODONTOL
JI J. Periodont.
PD NOV
PY 1997
VL 68
IS 11
BP 1085
EP 1092
DI 10.1902/jop.1997.68.11.1085
PG 8
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA YK293
UT WOS:A1997YK29300008
PM 9407401
DA 2018-10-19
ER

PT J
AU Geiger, TL
   Perrotta, PL
   Davenport, R
   Baril, L
   Snyder, EL
AF Geiger, TL
   Perrotta, PL
   Davenport, R
   Baril, L
   Snyder, EL
TI Removal of anaphylatoxins C3a and C5a and chemokines interleukin 8 and
   RANTES by polyester white cell-reduction and plasma filters
SO TRANSFUSION
LA English
DT Article
ID COMPLEMENT ACTIVATION; CARDIOPULMONARY BYPASS; TRANSFUSION REACTIONS;
   CYTOKINE GENERATION; PLATELET ACTIVATION; LEUKOCYTE REDUCTION; BLOOD
   COMPONENTS; FILTRATION; BIOCOMPATIBILITY
AB BACKGROUND: A few bedside polyester white cell (WBC)-reduction filters have been shown to scavenge C3a anaphylatoxin from stored blood components. One has been shown to remove the chemokines interleukin (IL)-8 and RANTES, but not the proinflammatory cytokines IL-1, IL-6, and tumor necrosis factor alpha. Removal by any filter of the anaphylatoxin C5a or the soluble membrane attack complex (SC5b-9) has not been studied. Further, the ability of other filters to scavenge these biologic response modifiers (BRM) is not known. Four WBC-reduction filters and one plasma filter were studied for their ability to remove IL-8, RANTES, IL-1 beta, C3a, C5a, and SC5b-9.
   STUDY DESIGN AND METHODS: Plasma was obtained either as freshly thawed fresh-frozen plasma, fresh-frozen plasma thawed and stored for 5 days, or platelet-poor supernatant. Cell-poor plasma was obtained and samples were taken before and after filtration through the various filters. Levels of IL-1 beta, IL-8, RANTES, C3a, and SC5b9 were quantitated by enzyme immunoassay. To evaluate filter scavenging of C5a, an in vitro model was developed to generate high levels of C5a in plasma by activating plasma with zymosan.
   RESULTS: Levels of C3a, C5a, IL-8, and RANTES were reduced by filtration through two bedside platelet WBC-reduction filters, a plasma filter, and a prestorage red cell WBC-reduction filter, but not following filtration through a prestorage platelet WBC-reduction filter. For some BRMs and filters, however, evidence of filter saturation was seen. IL-1 beta was not removed by any of the filters tested.
   CONCLUSION: Some, but not all, bedside polyester filters and prestorage polyester filters can remove IL-8, RANTES, C3a, and C5a from units of plasma or platelets. Improved biomaterial engineering of these and other filters could maximize scavenging of BRMs and potentially diminish the adverse reactions associated with their infusion during transfusion.
C1 Yale Univ, Sch Med, Dept Lab Med, Blood Bank, New Haven, CT 06504 USA.
   Yale New Haven Hosp, Blood Bank CB 459, Transfus Serv, New Haven, CT 06504 USA.
   Univ Michigan, Dept Pathol, Blood Bank, Ann Arbor, MI 48109 USA.
RP Snyder, EL (reprint author), Yale Univ, Sch Med, Dept Lab Med, Blood Bank, 20 York St, New Haven, CT 06504 USA.
RI Geiger, Terrence/M-4516-2018
OI Geiger, Terrence/0000-0001-8290-5732
CR BENGTSON JP, 1990, ANESTHESIOLOGY, V73, P376, DOI 10.1097/00000542-199009000-00002
   BOWDEN RA, 1995, BLOOD, V86, P3598
   BUSUND R, 1995, ACTA ANAESTH SCAND, V39, P100, DOI 10.1111/j.1399-6576.1995.tb05600.x
   CHENOWETH DE, 1981, NEW ENGL J MED, V304, P497, DOI 10.1056/NEJM198102263040901
   CLEMENTS DH, 1992, J BONE JOINT SURG AM, V74A, P646, DOI 10.2106/00004623-199274050-00003
   DEMLING RH, 1995, ANNU REV MED, V46, P193
   DZIECZKOWSKI JS, 1995, TRANSFUSION, V35, P20, DOI 10.1046/j.1537-2995.1995.35195090654.x
   EBERT SJ, 1989, TRANSFUSION S, V29, pS10
   FINN A, 1993, J THORAC CARDIOV SUR, V105, P234
   Flegel WA, 1995, TRANSFUSION, V35, P917, DOI 10.1046/j.1537-2995.1995.351196110895.x
   GU YJ, 1993, ARTIF ORGANS, V17, P660
   GYONGYOSSYISSA MIC, 1994, J LAB CLIN MED, V123, P859
   HEDDLE NM, 1994, NEW ENGL J MED, V331, P625, DOI 10.1056/NEJM199409083311001
   HETLAND G, 1992, TRANSFUSION, V32, P557, DOI 10.1046/j.1537-2995.1992.32692367201.x
   HOLME S, 1989, VOX SANG, V57, P112, DOI 10.1111/j.1423-0410.1989.tb01146.x
   HUGLI TE, 1982, PROTEINS BIOL MED, P91
   Krailadsiri P, 1996, THROMB RES, V83, P469, DOI 10.1016/0049-3848(96)00156-9
   LANE TA, 1994, ARCH PATHOL LAB MED, V118, P392
   Marcus-Bagley D, 1992, MANUAL CLIN LAB IMMU, P124
   MUYLLE L, 1994, VOX SANG, V66, P14, DOI 10.1111/j.1423-0410.1994.tb00270.x
   MUYLLE L, 1993, TRANSFUSION, V33, P195, DOI 10.1046/j.1537-2995.1993.33393174443.x
   RINDER CS, 1991, ANESTHESIOLOGY, V75, P388, DOI 10.1097/00000542-199109000-00002
   RINDER CS, 1995, J CLIN INVEST, V96, P1564, DOI 10.1172/JCI118195
   SHIMIZU T, 1994, VOX SANG, V66, P161, DOI 10.1111/j.1423-0410.1994.tb00303.x
   Snyder EL, 1996, TRANSFUSION, V36, P707, DOI 10.1046/j.1537-2995.1996.36896374374.x
   SOUTHERN EP, 1995, CLIN ORTHOP RELAT R, P235
   STACK G, 1995, TRANSFUSION, V35, P199, DOI 10.1046/j.1537-2995.1995.35395184274.x
   STACK G, 1994, TRANSFUSION, V34, P20, DOI 10.1046/j.1537-2995.1994.34194098597.x
   STJOHN RC, 1993, CHEST, V103, P932, DOI 10.1378/chest.103.3.932
   Takahashi TA, 1995, TRANSFUSION, V35, P967, DOI 10.1046/j.1537-2995.1995.351196110903.x
   TAKAHASHI TA, 1994, TRANSFUS CLIN BIOL, V1, P481, DOI 10.1016/S1246-7820(06)80033-9
   VANOTTEREN GM, 1995, J IMMUNOL, V154, P1900
   VROMAN L, 1980, BLOOD, V55, P156
NR 33
TC 25
Z9 25
U1 1
U2 3
PU AMER ASSOC BLOOD BANKS
PI BETHESDA
PA 8101 GLENBROOK RD, BETHESDA, MD 20814-2749 USA
SN 0041-1132
J9 TRANSFUSION
JI Transfusion
PD NOV-DEC
PY 1997
VL 37
IS 11-12
BP 1156
EP 1162
DI 10.1046/j.1537-2995.1997.37111298088045.x
PG 7
WC Hematology
SC Hematology
GA YN427
UT WOS:000071167500010
PM 9426639
DA 2018-10-19
ER

PT J
AU Taniguchi, H
   Tanosaki, S
   Devaraj, B
   Inaba, H
AF Taniguchi, H
   Tanosaki, S
   Devaraj, B
   Inaba, H
TI Visible and near-infrared laser emission of pigment extracted from green
   algae in microdroplet mixed with highly scattering Intralipid-10%
SO ELECTRONICS LETTERS
LA English
DT Article
DE scattering; lasers
ID DYE-LASER
AB Pigment extracted directly from green algae contained in liquid microdroplets was found, for the first time to the authors' knowledge. to produce biomaterial laser action by substituting strongly scattering Intralipid-10%. No laser emission was observed using microdroplets without the addition of of this scattering medium. Spectral narrowing and increased emission intensity with a well-defined lasing threshold were confirmed at visible and near-infrared wavelengths, depending on the microdroplet size and mixture concentration.
C1 Iwate Univ, Dept Elect & Elect Engn, Morioka, Iwate 020, Japan.
   Biophoton Informat Labs, Yamagata 990, Japan.
   Tohoku Inst Technol, Dept Elect, Taihaku Ku, Sendai, Miyagi 982, Japan.
RP Taniguchi, H (reprint author), Iwate Univ, Dept Elect & Elect Engn, 4-3-5 Ueda, Morioka, Iwate 020, Japan.
CR BALACHANDRAN RM, 1995, OPT LETT, V20, P1271, DOI 10.1364/OL.20.001271
   Balachandran RM, 1997, OPT LETT, V22, P319, DOI 10.1364/OL.22.000319
   Chang N., 1985, Oyo Buturi, V54, P841
   LAWANDY NM, 1994, NATURE, V368, P436, DOI 10.1038/368436a0
   Taniguchi H, 1996, OPT LETT, V21, P263, DOI 10.1364/OL.21.000263
   Taniguchi H, 1996, IEEE J QUANTUM ELECT, V32, P1864, DOI 10.1109/3.541672
   Tanosaki S, 1996, APPL PHYS LETT, V69, P719, DOI 10.1063/1.117869
   Tanosaki S, 1996, ELECTRON LETT, V32, P1484, DOI 10.1049/el:19960963
NR 8
TC 4
Z9 4
U1 0
U2 1
PU IEE-INST ELEC ENG
PI HERTFORD
PA MICHAEL FARADAY HOUSE SIX HILLS WAY STEVENAGE, HERTFORD SG1 2AY, ENGLAND
SN 0013-5194
J9 ELECTRON LETT
JI Electron. Lett.
PD OCT 9
PY 1997
VL 33
IS 21
BP 1797
EP 1798
DI 10.1049/el:19971215
PG 2
WC Engineering, Electrical & Electronic
SC Engineering
GA YX452
UT WOS:000072041400036
DA 2018-10-19
ER

PT J
AU Pihlajamaki, H
   Kinnunen, J
   Bostman, O
AF Pihlajamaki, H
   Kinnunen, J
   Bostman, O
TI In vivo monitoring of the degradation process of bioresorbable polymeric
   implants using magnetic resonance imaging
SO BIOMATERIALS
LA English
DT Article
DE biodegradable implants; bone fixation; poly(L-lactide); magnetic
   resonance imaging; biodegradation
ID FIXATION; FRACTURES; BONE; POLYLACTIDE; SCREWS; PLUG
AB The degradation of a bioresorbable poly(L-lactide) osteosynthesis plug after fixation of a transferred coracoid bone block using the Bristow-Latarjet procedure was examined by means of magnetic resonance (MR) imaging. There were 15 patients with a mean follow-up time of 38 months (range 34-42 months). The gross geometry of the biomaterial plug remained unaltered on the MR images. The bone marrow signal reached the implant surfaces in all cases, and no signs of liquid phase around the implant could be discerned. The implants themselves were visible as homogeneous low signal intensity (SI) black linear structures when compared to the surrounding bone, which had a much higher SI. The mean implant SI was 18.2 (s.d. +/- 6.6), that of the scapular bone 48.9 (s.d. +/- 14.3) and that of the background 4.3 (s.d. +/- 1.5). The SI of a newly manufactured intact implant was 5.7. Serial plain radiographs showed no decreased bone density or focal osteolytic lesions around the poly(L-lactide) expansion plug. The implant channel was discernible on most of the radiographs and a sclerotic rim was detected to outline the implant profile in some of the projections of plain radiographs at each follow-up examination. Computer tomography scans on five patients 3 years postoperatively also revealed a discernible implant channel outlined with a sclerotic rim. The radiographic appearance of the radiolucent implant channel did not change over the follow-up period. Summarizing the present findings, MR imaging seems to be able to visualize poly(L-lactide) implants within the bone. Actually, at present it is the only method available to study the degradation process of implants made of this polymer in humans. No signs of degradation of or of an osteolytic foreign-body reaction to poly(L-lactide) at the host tissue-implant interface could be observed within the follow-up times of this study. (C) 1997 Elsevier Science Limited. All rights reserved.
C1 UNIV CENT HOSP,DEPT DIAGNOST RADIOL,FIN-00260 HELSINKI,FINLAND.
RP Pihlajamaki, H (reprint author), UNIV CENT HOSP,DEPT ORTHOPAED & TRAUMATOL,TOPELIUKSENK 5,FIN-00260 HELSINKI,FINLAND.
OI Pihlajamaki, Harri/0000-0002-2998-0773
CR Ashammakhi N, 1997, BIOMATERIALS, V18, P3, DOI 10.1016/S0142-9612(96)00107-X
   BERGSMA JE, 1995, BIOMATERIALS, V16, P25, DOI 10.1016/0142-9612(95)91092-D
   BOSTMAN O, 1992, J BONE JOINT SURG AM, V74A, P1021, DOI 10.2106/00004623-199274070-00008
   Bostman O M, 1995, Clin Orthop Relat Res, P101
   BOSTMAN OM, 1991, J BONE JOINT SURG BR, V73, P679
   BOSTMAN OM, 1991, J BONE JOINT SURG AM, V73A, P148
   BUCHOLZ RW, 1994, J BONE JOINT SURG AM, V76A, P319, DOI 10.2106/00004623-199403000-00001
   EITENMULLER J, 1990, 92 C FRANC CHIR PAR
   FRASER RK, 1992, J BONE JOINT SURG BR, V74, P929
   HOFMANN GO, 1995, ARCH ORTHOP TRAUM SU, V114, P123, DOI 10.1007/BF00443385
   HOLLINGER JO, 1986, CLIN ORTHOP RELAT R, V207, P290
   MATSUSUE Y, 1995, CLIN ORTHOPAEDICS, V317, P246
   MATSUSUE Y, 1996, CLIN ORTHOPAEDICS, V322, P166
   PAIVARINTA U, 1993, ARCH ORTHOP TRAUM SU, V112, P71, DOI 10.1007/BF00420258
   PIHLAJAMAKI H, 1994, INT ORTHOP, V18, P66, DOI 10.1007/BF02484413
   PIHLAJAMAKI H, 1992, J BONE JOINT SURG BR, V74, P853
   PIHLAJAMAKI H, 1994, ARCH ORTHOP TRAUM SU, V113, P101, DOI 10.1007/BF00572915
   ROKKANEN P, 1992, ORTHOP TRAUMATOL, V2, P107
   SVENSSON PJ, 1994, J PEDIATR ORTHOPED, V14, P220, DOI 10.1097/01241398-199403000-00017
   TORMALA P, 1992, Clinical Materials, V10, P29, DOI 10.1016/0267-6605(92)90081-4
   VERT M, 1986, POLYM MED, V2, P263
   WILLIAMS DF, 1982, J MATER SCI, V17, P1233, DOI 10.1007/BF00752233
   YAMAMURO T, 1994, INT ORTHOP, V18, P332
NR 23
TC 30
Z9 30
U1 1
U2 12
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD OCT
PY 1997
VL 18
IS 19
BP 1311
EP 1315
DI 10.1016/S0142-9612(97)00068-9
PG 5
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA XU957
UT WOS:A1997XU95700008
PM 9307221
DA 2018-10-19
ER

PT J
AU Knabe, C
   Gildenhaar, R
   Berger, G
   Ostapowicz, W
   Fitzner, R
   Radlanski, RJ
   Gross, U
AF Knabe, C
   Gildenhaar, R
   Berger, G
   Ostapowicz, W
   Fitzner, R
   Radlanski, RJ
   Gross, U
TI Morphological evaluation of osteoblasts cultured on different calcium
   phosphate ceramics
SO BIOMATERIALS
LA English
DT Article
DE calcium phosphates; osteoblasts; in vitro; cell-biomaterial
   interactions; bone substitutes; ion release
ID POROUS HYDROXYAPATITE; BONE-FORMATION; DEFECTS; INVITRO; IMPLANTATION;
   DISSOLUTION; ADHESION; LESIONS; GRAFT; CELLS
AB The objective of these investigations was to develop an in vitro test system for evaluating novel rapidly resorbable calcium phosphate ceramics of varying composition. Fat bone marrow cells were cultured on the disc-shaped test substrates for 14 days. Five calcium phosphates were examined: R1, CaNaPO4; R1/M2, composed of CaNaPO4 and MgNaPO4; R1/2 composed of CaNaPO4 and MS2SiO4; R1+9% SiO2 consisting of CaNaPO4 and 9% SiO2 (wt%) and R17, Ca2KNa(PO4)(2). Two studies were performed. In study I cultures were re-fed every two to three days. In study II the medium was changed daily, and calcium and phosphate concentrations of the medium were determined daily. Specimens were prepared for light microscopy and morphometric evaluation of the cell-covered substrate area, scanning electron microscopy and energy-dispersive X-ray analysis. With all materials tested except for R1/2, an increase of cellular growth was observed after changing the medium daily. Of the different calcium phosphate ceramics tested, R17 and R1/M2 facilitated osteoblast growth and elaboration of extracellular matrix to the highest degree. The inhibition of cell growth encountered with R1 in study I and R1/2 in both studies seemed to be related to a high phosphate-ion release from these materials. (C) 1997 Elsevier Science Limited. All rights reserved.
C1 FED INST MAT RES & TESTING,LAB BIOMAT,D-12200 BERLIN,GERMANY.
   FREE UNIV BERLIN,UNIV HOSP BENJAMIN FRANKLIN,INST CLIN CHEM & BIOCHEM,D-12200 BERLIN,GERMANY.
   FREE UNIV BERLIN,UNIV HOSP BENJAMIN FRANKLIN,DEPT ORAL BIOL,D-14197 BERLIN,GERMANY.
   FREE UNIV BERLIN,UNIV HOSP BENJAMIN FRANKLIN,INST PATHOL,D-12200 BERLIN,GERMANY.
RP Knabe, C (reprint author), FREE UNIV BERLIN,UNIV HOSP BENJAMIN FRANKLIN,DEPT RESTORAT DENT & PERIODONTOL,D-14197 BERLIN,GERMANY.
CR ANDERSSON OH, 1993, J BIOMED MATER RES, V27, P941, DOI 10.1002/jbm.820270713
   ANDERSSON OH, 1994, BIOCERAMICS, V7, P67
   BARNEY VC, 1986, J PERIODONTOL, V57, P764, DOI 10.1902/jop.1986.57.12.764
   BERGER G, 1995, BIOMATERIALS, V16, P1241, DOI 10.1016/0142-9612(95)98131-W
   BERGER G, 1995, BIOCERAMICS, V8, P453
   BOWERS GM, 1986, J PERIODONTOL, V57, P286, DOI 10.1902/jop.1986.57.5.286
   DACULSI G, 1989, CALCIFIED TISSUE INT, V45, P95, DOI 10.1007/BF02561408
   DAVIES JE, 1990, J BIOMED MATER RES, V24, P1289, DOI 10.1002/jbm.820241003
   EGGLI PS, 1988, CLIN ORTHOP RELAT R, V232, P127
   Fitton J. H., 1995, P 5 ANN C AUSTR SOC, P22
   FRANK RM, 1991, J CLIN PERIODONTOL, V18, P669, DOI 10.1111/j.1600-051X.1991.tb00108.x
   Fusenig NE, 1986, BIOL INTEGUMENT, V2, P409
   HOLMES RE, 1987, J ORTHOPAED RES, V5, P114, DOI 10.1002/jor.1100050114
   HOWLETT CR, 1994, J MATER SCI-MATER M, V5, P715, DOI 10.1007/BF00120363
   HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S
   KLAWITTER JJ, 1971, J BIOMED MATER RES S, V2, P161, DOI DOI 10.1002/JBM.820050613
   KOKUBO T, 1993, BIOCERAMICS, V6, P73
   LEGREOS RZ, 1994, HYDROXYAPATITE RELAT, P3
   LOWENBERG B, 1991, CELL MATER, V1, P177
   MANIATOPOULOS C, 1988, CELL TISSUE RES, V254, P317
   MEFFERT RM, 1985, J PERIODONTOL, V56, P63, DOI 10.1902/jop.1985.56.2.63
   MEI J, 1993, BIOCERAMICS, V6, P67
   METSGER DS, 1982, J AM DENT ASSOC, V105, P1035, DOI 10.14219/jada.archive.1982.0408
   RADIN S, 1993, BIOCERAMICS, V6, P59
   SAFFAR JL, 1990, J PERIODONTOL, V61, P209, DOI 10.1902/jop.1990.61.4.209
   SCHNEIDER M, 1994, CRYST RES TECHNOL, V29, P671, DOI 10.1002/crat.2170290516
   WACHTEL HC, 1989, DEUT ZAHNAERZTL Z, V44, P277
   Yaszemski MJ, 1996, BIOMATERIALS, V17, P175, DOI 10.1016/0142-9612(96)85762-0
NR 28
TC 39
Z9 42
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD OCT
PY 1997
VL 18
IS 20
BP 1339
EP 1347
DI 10.1016/S0142-9612(97)00078-1
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA YB250
UT WOS:A1997YB25000003
PM 9363333
DA 2018-10-19
ER

PT J
AU Phaneuf, MD
   Quist, WC
   LoGerfo, FW
   Szycher, M
   Dempsey, DJ
   Bide, MJ
AF Phaneuf, MD
   Quist, WC
   LoGerfo, FW
   Szycher, M
   Dempsey, DJ
   Bide, MJ
TI Chemical and physical characterization of a novel poly(carbonate urea)
   urethane surface with protein crosslinker sites
SO JOURNAL OF BIOMATERIALS APPLICATIONS
LA English
DT Article
DE polyurethane; biomaterial; tensile strength; crosslinking; albumin
ID ARTERIAL PROSTHESES; BIOSTABLE POLYURETHANE; HEPARIN IMMOBILIZATION;
   INVITRO; ALBUMIN; DACRON; INVIVO; ANTITHROMBIN; MECHANISMS; ACTIVATION
AB A major complication which occurs with implantable polyurethane biomaterials is bioincompatibility between blood and the biomaterial surface. Development of a novel biodurable polyurethane surface to which biological agents, such as growth factors or anticoagulants could be covalently bound, would be beneficial. The purpose of this study was to synthesize a novel poly(carbonate urea) urethane polymer with carboxylic acid groups which would serve as ''anchor'' sites for protein attachment. Physical characteristics such as tensile strength, initial modulus, ultimate elongation, tear strength, water/alcohol uptake and water vapor permeation were then evaluated and compared to other biomedical-grade polyurethanes. Covalent linkage of the blood protein albumin to this novel surface was then examined. A biodurable polycarbonate-based polyurethane containing carboxylic acid groups (cPU) was synthesized using a two step procedure incorporating the chain extender 2,2-bis (hydroxymethyl)-propionic acid (DHMPA). Tensile strength of this cPU film was 2.7 and 2.6 fold greater than both a polycarbonate-based polyurethane synthesized with a 1,4-butanediol chain extender (bdPU) and Mitrathane (Mit) controls, respectively. The cPU polymer also possessed 7.8 and 31 fold greater structural rigidity upon evaluation of initial modulus as compared to the bdPU and Mit, respectively. Ultimate elongation for the bdPU films was slightly higher than the cPU and Mit films, which had comparable elongation properties. The force required to tear the bdPU film was 1.9 and 32 fold greater than the cPU and Mit films, respectively. Alcohol solution uptake by all of the polyurethane segments increased with increasing alcohol concentrations, with the cPU having the greatest uptake. Water uptake was minimal for all the polyurethanes examined and was not affected by altering pH. Water vapor permeation was lowest for the cPU films as compared to both bdPU and Mit. Swelling the cPU in 50% ethanol prior to evaluation slightly increased water vapor permeation through the films. Covalent linkage of the radiolabelled blood protein albumin (I-125-BSA) to the cPU segments incubated with the heterobifunctional crosslinker 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) was greatest in the higher percent of ethanol as compared to controls. These results serve as foundation for developing a novel poly(carbonate urea) urethane with physical characteristics comparable to other medical-grade polyurethanes while having protein binding capabilities.
C1 HARVARD UNIV,SCH MED,BETH ISRAEL DEACONESS MED CTR,DEPT SURG,BOSTON,MA 02115.
   HARVARD UNIV,SCH MED,BETH ISRAEL DEACONESS MED CTR,DEPT PATHOL,BOSTON,MA 02115.
   CARDIOTECH INT INC,WOBURN,MA 01801.
   UNIV RHODE ISL,DEPT TEXT,KINGSTON,RI 02881.
   CHILDRENS HOSP,DEPT CARDIOVASC SURG,BOSTON,MA 02115.
FU NHLBI NIH HHS [1R43HL53856-01A1]
CR *ASTM, 1995, ANN BOOK ASTM STAND, P697
   BAKKER WW, 1991, BIOMATERIALS, V12, P603, DOI 10.1016/0142-9612(91)90059-J
   BARBUCCI R, 1994, BIOMATERIALS, V15, P955, DOI 10.1016/0142-9612(94)90075-2
   BASCOM J, 1961, SURGERY, V50, P947
   BORETOS JW, 1972, J BIOMED MATER RES, V6, P473, DOI 10.1002/jbm.820060513
   Carson RJ, 1996, J BIOMATER APPL, V11, P121, DOI 10.1177/088532829601100201
   Colman RW, 1987, HEMOSTASIS THROMBOSI
   COURY AJ, 1987, LIFE SUPPORT SYST, V5, P25
   COURY AJ, 1991, Patent No. 500121019
   DRURY J, 1987, ANN VASC SURG, P542
   ELGUE G, 1993, THROMB HAEMOSTASIS, V70, P289
   Freischlag J A, 1990, Ann Vasc Surg, V4, P449, DOI 10.1016/S0890-5096(07)60069-7
   GRAINGER DW, 1989, J COLLOID INTERF SCI, V132, P161, DOI 10.1016/0021-9797(89)90226-9
   GUIDOIN R, 1989, BIOMATERIALS, V10, P156, DOI 10.1016/0142-9612(89)90018-5
   Hardhammar PA, 1996, CIRCULATION, V93, P423, DOI 10.1161/01.CIR.93.3.423
   HENNINK WE, 1983, THROMB RES, V29, P1, DOI 10.1016/0049-3848(83)90120-2
   ITO RK, 1991, J VASC SURG, V13, P822
   ITO Y, 1988, BIOMATERIALS, V9, P235, DOI 10.1016/0142-9612(88)90090-7
   JACOBS H, 1986, J PHARM SCI, V75, P172, DOI 10.1002/jps.2600750215
   JONAS RA, 1988, J VASC SURG, V7, P414, DOI 10.1067/mva.1988.avs0070414
   KISHIDA A, 1994, BIOMATERIALS, V15, P848, DOI 10.1016/0142-9612(94)90041-8
   KOTTKEMARCHANT K, 1989, BIOMATERIALS, V10, P147, DOI 10.1016/0142-9612(89)90017-3
   KREITZ M, 1997, ARTIF ORGANS, V21, P493
   LIN SC, 1991, J BIOMED MATER RES, V25, P791, DOI 10.1002/jbm.820250608
   LINDON JN, 1985, J LAB CLIN MED, V105, P219
   LYMAN DJ, 1971, FED PROC, V30, P1658
   MA XH, 1991, J COLLOID INTERF SCI, V147, P251, DOI 10.1016/0021-9797(91)90152-X
   MAKSIMENKO AV, 1985, THROMB RES, V38, P277, DOI 10.1016/0049-3848(85)90156-2
   MERHI Y, 1989, BIOMATERIALS, V10, P56, DOI 10.1016/0142-9612(89)90010-0
   NARCHANT RE, 1987, POLYMER, V28, P2032
   NARCHANT RE, 1988, SURFACE CHARACTERIZA, P297
   NEMETS EA, 1991, ARTIF ORGANS, V15, P381
   Nojiri C, 1990, ASAIO Trans, V36, pM168
   PARINS DJ, 1981, IN VIVO DEGRADATION
   PARK KD, 1988, J BIOMED MATER RES, V22, P977, DOI 10.1002/jbm.820221103
   Phaneuf MD, 1997, BIOMATERIALS, V18, P755, DOI 10.1016/S0142-9612(96)00193-7
   PHANEUF MD, 1995, J APPL BIOMATER, V6, P289, DOI 10.1002/jab.770060410
   PHILLIPS R, 1986, PACE, V9, P1166, DOI 10.1111/j.1540-8159.1986.tb06688.x
   PHUA SK, 1987, J BIOMED MATER RES, V21, P231, DOI 10.1002/jbm.820210207
   QUINONESBALDRICH WJ, 1986, J VASC SURG, V3, P895, DOI 10.1067/mva.1986.avs0030895
   RAMBIC HE, 1986, C E NEWS        0414, P31
   Reed A M, 1991, J Biomater Appl, V6, P3, DOI 10.1177/088532829100600101
   RUMISEK JD, 1989, SURGERY, V105, P654
   SCHOEN FJ, 1988, J BIOMED MATER RES-A, V22, P11
   SHEPARD AD, 1984, J VASC SURG, V1, P829, DOI 10.1067/mva.1984.avs0010829
   SILVER JH, 1992, BIOMATERIALS, V13, P339, DOI 10.1016/0142-9612(92)90037-O
   SLIMANE S B, 1988, European Surgical Research, V20, P18
   SLIMANE S B, 1988, European Surgical Research, V20, P66
   STOKES K, 1990, Journal of Biomaterials Science Polymer Edition, V1, P207
   Stokes K, 1987, J Biomater Appl, V1, P411
   STOKES K, 1982, BIOMATERIALS, V3, P225, DOI 10.1016/0142-9612(82)90024-2
   STOKES K, 1958, J BIOMATER APPL, V3, P228
   STOKES K, 1983, BIOSTABILITY VARIOUS
   STOKES K, 1987, POLYURETHANES BIOMED, V2, P109
   Szycher M, 1991, J Biomater Appl, V6, P110, DOI 10.1177/088532829100600202
   Szycher M, 1992, Med Device Technol, V3, P42
   Szycher M, 1993, J Biomater Appl, V8, P31, DOI 10.1177/088532829300800103
   SZYCHER M, 1984, T SOC BIOMATER, V7, P24
   SZYCHER M, 1985, ASTM STP, V859, P308
   Szycher M, 1993, [1993, Biostable polyurethane products US Patent], Patent No. 5254662
   TAKAHARA A, 1991, J BIOMED MATER RES, V25, P341, DOI 10.1002/jbm.820250306
   TAY SW, 1989, BIOMATERIALS, V10, P11, DOI 10.1016/0142-9612(89)90003-3
   VANDERLEI B, 1985, T AM SOC ART INT ORG, V31, P107
   VULIC I, 1988, J POLYM SCI POL CHEM, V26, P381, DOI 10.1002/pola.1988.080260204
   WILSON JE, 1986, POLYM-PLAST TECHNOL, V25, P233, DOI 10.1080/03602558608070086
   ZHENG J, 1994, BIOMATERIALS, V15, P963, DOI 10.1016/0142-9612(94)90076-0
NR 66
TC 12
Z9 14
U1 0
U2 6
PU TECHNOMIC PUBL CO INC
PI LANCASTER
PA 851 NEW HOLLAND AVE, BOX 3535, LANCASTER, PA 17604
SN 0885-3282
J9 J BIOMATER APPL
JI J. Biomater. Appl.
PD OCT
PY 1997
VL 12
IS 2
BP 100
EP 120
DI 10.1177/088532829701200202
PG 21
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA YG954
UT WOS:A1997YG95400001
PM 9399137
DA 2018-10-19
ER

PT J
AU Thomas, CH
   McFarland, CD
   Jenkins, ML
   Rezania, A
   Steele, JG
   Healy, KE
AF Thomas, CH
   McFarland, CD
   Jenkins, ML
   Rezania, A
   Steele, JG
   Healy, KE
TI The role of vitronectin in the attachment and spatial distribution of
   bone-derived cells on materials with patterned surface chemistry
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE tissue engineering; vitronectin; protein adsorption; cell adhesion;
   surface modification
ID TISSUE-CULTURE POLYSTYRENE; CHEMICALLY DERIVATIZED SUBSTRATA;
   ARG-GLY-ASP; UNMODIFIED POLYSTYRENE; INITIAL ATTACHMENT; SERUM
   VITRONECTIN; ENDOTHELIAL-CELLS; MAMMALIAN-CELLS; FIBRONECTIN; ADHESION
AB In recent years a central objective of tissue engineering has been understanding the interaction of cells with biomaterial surfaces. In this study we examined the protein adsorption events necessary to control the attachment and the subsequent spatial distribution of bone-derived cells exposed to chemically modified surfaces. Silane chemistry and photolithography techniques were used to create substrates with alternating regions of an aminosilane, N-(2-aminoethyl)-3-aminopropyl-trimethoxysilane (EDS), along side an alkylsilane, dimethyldichlorosilane (DMS), on quartz surfaces. Sera depleted of fibronectin (Fn), vitronectin (Vn), or both were used to determine if these proteins were necessary for the initial attachment and spatial distribution of bone-derived cells exposed to modified surfaces in vitro. The kinetics and mechanisms of the spatial distribution of cells were examined using light microscopy and digital image acquisition and subsequently were analyzed. Compared to complete serum, the use of serum depleted of fibronectin with vitronectin included had minimal effect on the cell attachment, spreading and spatial distribution on the EDS regions of the surface. However, the use of serum depleted of vitronectin with or without fibronectin included resulted in greatly reduced cell attachment and spreading. Thus the presence of vitronectin was required for the attachment, spreading, and spatial distribution of bone-derived cells exposed to EDS/DMS-patterned surfaces. (C) 1997 John Wiley & Sons, Inc.
C1 NORTHWESTERN UNIV,SCH DENT,DIV BIOL MAT,CHICAGO,IL 60611.
   NORTHWESTERN UNIV,ROBERT R MCCORMICK SCH ENGN & APPL SCI,DEPT BIOMED ENGN,EVANSTON,IL 60201.
   CSIRO,DEPT BIOMOL ENGN,N RYDE,NSW 2113,AUSTRALIA.
FU NIDCR NIH HHS [R03 DE10264, T32 DE07042]; NIAMS NIH HHS [R01 AR43187]
CR BRITLAND S, 1992, EXP CELL RES, V198, P124, DOI 10.1016/0014-4827(92)90157-4
   CURTIS ASG, 1984, J CELL SCI, V71, P17
   ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102
   FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0
   GRINNELL F, 1986, J CELL BIOL, V103, P2697, DOI 10.1083/jcb.103.6.2697
   GRINNELL F, 1982, J BIOL CHEM, V257, P4888
   GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q
   HAYMAN EG, 1985, EXP CELL RES, V160, P245, DOI 10.1016/0014-4827(85)90173-9
   HEALY KE, 1994, BIOTECHNOL BIOENG, V43, P792, DOI 10.1002/bit.260430814
   HEALY KE, 1996, BIOMATERIALS, V17, P95
   HOWLETT CR, 1994, BIOMATERIALS, V15, P213, DOI 10.1016/0142-9612(94)90070-1
   KLEINFELD D, 1988, J NEUROSCI, V8, P4098
   LEWANDOWSKA K, 1992, J BIOMED MATER RES, V26, P1343, DOI 10.1002/jbm.820261007
   LEWANDOWSKA K, 1989, J CELL PHYSIOL, V141, P334, DOI 10.1002/jcp.1041410215
   LOM B, 1993, J NEUROSCI METH, V50, P385, DOI 10.1016/0165-0270(93)90044-R
   LOPEZ GP, 1993, J AM CHEM SOC, V115, P5877, DOI 10.1021/ja00066a087
   MCFARLAND CD, 1996, 5 WORLD BIOM C TOR C, P980
   OPAS M, 1994, INT REV CYTOL, V150, P119
   OPAS M, 1989, DEV BIOL, V131, P281, DOI 10.1016/S0012-1606(89)80001-6
   PRIME KL, 1991, SCIENCE, V252, P1164, DOI 10.1126/science.252.5009.1164
   PULEO DA, 1992, J BIOMED MATER RES, V26, P291, DOI 10.1002/jbm.820260303
   PULEO DA, 1991, J BIOMED MATER RES, V25, P711, DOI 10.1002/jbm.820250603
   RANIERI JP, 1993, J BIOMED MATER RES, V27, P917, DOI 10.1002/jbm.820270711
   RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X
   SHELTON RM, 1988, BIOMATERIALS, V9, P24, DOI 10.1016/0142-9612(88)90065-8
   SINGHVI R, 1994, SCIENCE, V264, P696, DOI 10.1126/science.8171320
   Soekarno A, 1993, Neuroimage, V1, P129, DOI 10.1006/nimg.1993.1006
   STEELE JG, 1993, J BIOMAT SCI-POLYM E, V5, P245
   STEELE JG, 1992, J BIOMED MATER RES, V26, P861, DOI 10.1002/jbm.820260704
   STEELE JG, 1993, J BIOMED MATER RES, V27, P927, DOI 10.1002/jbm.820270712
   STEELE JG, 1994, J BIOMAT SCI-POLYM E, V6, P511, DOI 10.1163/156856294X00473
   STEELE JG, 1991, BIOMATERIALS, V12, P531, DOI 10.1016/0142-9612(91)90046-D
   SUGAWARA T, 1995, J BIOMED MATER RES, V29, P1047, DOI 10.1002/jbm.820290904
   UNDERWOOD PA, 1989, J CELL SCI, V93, P641
   VUKICEVIC S, 1990, CELL, V63, P437, DOI 10.1016/0092-8674(90)90176-F
   WHITSON SW, 1992, J BONE MINER RES, V7, P727
NR 36
TC 134
Z9 137
U1 1
U2 6
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD OCT
PY 1997
VL 37
IS 1
BP 81
EP 93
DI 10.1002/(SICI)1097-4636(199710)37:1<81::AID-JBM10>3.0.CO;2-T
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA XZ371
UT WOS:A1997XZ37100010
PM 9335352
DA 2018-10-19
ER

PT J
AU Loty, C
   Forest, N
   Boulekbache, H
   Kokubo, T
   Sautier, JM
AF Loty, C
   Forest, N
   Boulekbache, H
   Kokubo, T
   Sautier, JM
TI Behavior of fetal rat chondrocytes cultured on a bioactive glass-ceramic
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE in vitro; chondrocytes; bioactive glass-ceramic; cell attachment; cell
   differentiation
ID IN-VITRO; BONE-FORMATION; SURFACE CHARACTERISTICS; EXTRACELLULAR-MATRIX;
   CELL-SHAPE; TITANIUM; OSTEOBLASTS; CARTILAGE; INVITRO; COLLAGEN
AB We examined the behavior of fetal rat chondrocytes cultured on a bioactive glass-ceramic containing apatite and wollastonite (A.W.G.C.). Biomaterial surface topography and profiles were evaluated by bidimensional profilometry and revealed a rough surface for the glass-ceramic compared to the plastic coverslips used as controls. Chondrocyte attachment was evaluated by measuring the number of attached cells after one day of culture and by morphological observations. Chondrocytes attached in great numbers to the material surface by means of focal contacts containing vinculin and beta 1-integrin. Fluorescent labeling of actin and vimentin revealed a poor spreading of chondrocytes on the bioactive glass-ceramic compared to the plastic coverslips, where the cells appeared to adhere intimately to the surface and exhibited polygonal arrays of stress fibers. During the following days of culture, chondrocytes proliferated, colonized the surface of the material, and, finally, on day 10, formed nodular structures composed of round cells separated by a dense extracellular matrix. Furthermore, these clusters of round cells were positive for type II collagen and chondroitin sulfate, both hard markers of the chondrocyte phenotype. In addition, protein synthesis, alkaline phosphatase activity, and proteoglycan production were found to increase gradually during the culture period with a pattern similar to that observed on control cultures. These results demonstrate that the bioactive glass-ceramic tested in this study appears to be a suitable substrate for in vitro chondrocyte attachment, differentiation, and matrix production. (C) 1997 John Wiley & Sons, Inc.
C1 UNIV PARIS 07,DEV BIOL LAB,F-75251 PARIS 05,FRANCE.
   KYOTO UNIV,FAC ENGN,SAKYO KU,KYOTO 60601,JAPAN.
RP Loty, C (reprint author), UNIV PARIS 07,INST BIOMED CORDELIERS,FAC CHIRURG DENTAIRE,LAB BIOL ODONTOL,15-21 RUE ECOLE MED,F-75270 PARIS 06,FRANCE.
CR ALTHOFF J, 1982, HISTOCHEMISTRY, V74, P541, DOI 10.1007/BF00496668
   BENYA PD, 1982, CELL, V30, P215, DOI 10.1016/0092-8674(82)90027-7
   BENYA PD, 1988, J CELL BIOL, V30, P215
   BERESFORD WA, 1969, EXPERIENTIA, V25, P383, DOI 10.1007/BF01899934
   BLOCK MS, 1987, J ORAL MAXIL SURG, V45, P601, DOI 10.1016/0278-2391(87)90270-9
   Bowers K T, 1992, Int J Oral Maxillofac Implants, V7, P302
   Boyan BD, 1995, CELL MATER, V5, P323
   BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415
   BUSER D, 1991, J BIOMED MATER RES, V25, P889, DOI 10.1002/jbm.820250708
   DAVIES JE, 1986, BIOMATERIALS, V7, P231
   DAVIES JE, 1990, HDB BIOACTIVE CERAMI, V1, P195
   DEBERNARD B, 1986, J CELL BIOL, V103, P1615, DOI 10.1083/jcb.103.4.1615
   DEBRUIJN JD, 1993, CELL MATER, V3, P115
   DURR J, 1993, EXP CELL RES, V207, P235, DOI 10.1006/excr.1993.1189
   ELGHANNAM A, 1995, J BIOMED MATER RES, V29, P359, DOI 10.1002/jbm.820290311
   GOMI K, 1993, J BIOMED MATER RES, V27, P429, DOI 10.1002/jbm.820270403
   GRANSTROM G, 1987, SCAND J PLAST RECONS, V21, P159, DOI 10.3109/02844318709078095
   GROESSNERSCHREIBER B, 1992, J CELL SCI, V101, P209
   GROSS UM, 1980, J BIOMED MATER RES, V14, P607, DOI 10.1002/jbm.820140507
   HALL BK, 1975, ANAT RECORD, V181, P55, DOI 10.1002/ar.1091810105
   HAMBLETON J, 1994, J ORTHOPAED RES, V12, P542, DOI 10.1002/jor.1100120411
   Hench LL, 1971, J BIOMED MATER RES S, V2, P117, DOI DOI 10.1002/JBM.820050611
   HOWLETT CR, 1994, BIOMATERIALS, V15, P213, DOI 10.1016/0142-9612(94)90070-1
   Hulth A, 1989, Clin Orthop Relat Res, P265
   IANNOTTI JP, 1990, ORTHOP CLIN N AM, V21, P1
   KOKUBO T, 1991, NIPPON SERAM KYO GAK, V99, P965
   KOKUBO T, 1991, BIOMATERIALS, V12, P155, DOI 10.1016/0142-9612(91)90194-F
   Kokubo T., 1982, Bulletin of the Institute for Chemical Research, Kyoto University, V60, P260
   KOKUBO T, 1990, J BIOMED MATER RES, V24, P331, DOI 10.1002/jbm.820240306
   KOMURO Y, 1994, PLAST RECONSTR SURG, V94, P152, DOI 10.1097/00006534-199407000-00017
   KONONEN M, 1992, J BIOMED MATER RES, V26, P1325
   LIVECCHI AB, 1994, J BIOMED MATER RES, V28, P839, DOI 10.1002/jbm.820280802
   LOTY S, 1995, BIOL CELL, V83, P149, DOI 10.1016/0248-4900(96)81303-7
   MARTIN JY, 1995, J BIOMED MATER RES, V29, P389, DOI 10.1002/jbm.820290314
   MASLOW DE, 1976, J CELL SCI, V21, P219
   MATSUDA T, 1987, BIOMATERIALS, V8, P275, DOI 10.1016/0142-9612(87)90115-3
   MICHAELS CM, 1989, J DENT RES, V68, P268
   NEO M, 1992, J BIOMED MATER RES, V26, P1419, DOI 10.1002/jbm.820261103
   NEO M, 1992, J BIOMED MATER RES, V26, P255, DOI 10.1002/jbm.820260210
   Osborn J. F., 1980, DENT IMPLANTS MAT SY, P111
   PULEO DA, 1992, J BIOMED MATER RES, V26, P291, DOI 10.1002/jbm.820260303
   RATNR BD, 1987, J BIOMED MATER RES-A, V21, P59
   REDDI AH, 1981, COLLAGEN REL RES, V1, P209
   ROSEN V, 1992, TRENDS GENET, V8, P97, DOI 10.1016/0168-9525(92)90197-C
   SAUTIER JM, 1994, CALCIFIED TISSUE INT, V55, P458, DOI 10.1007/BF00298560
   SAUTIER JM, 1993, BIOL CELL, V78, P181, DOI 10.1016/0248-4900(93)90128-2
   SAUTIER JM, 1991, CELL MATER, V1, P209
   SAUTIER JM, 1990, IN VITRO CELL DEV B, V26, P1079
   SAUTIER JM, 1992, BIOMATERIALS, V13, P400, DOI 10.1016/0142-9612(92)90046-Q
   SCHENK RK, 1980, TREATMENT FRACTURES, P3
   SCHROEDER A, 1981, J MAXILLOFAC SURG, V9, P15, DOI 10.1016/S0301-0503(81)80007-0
   SHAKIBAEI M, 1993, HISTOL HISTOPATHOL, V8, P715
   SIMMONS DJ, 1985, CLIN ORTHOP RELAT R, V200, P100
   SOLURSH M, 1975, CELL DIFFER DEV, V4, P131, DOI 10.1016/0045-6039(75)90034-2
   THOMAS KA, 1985, J BIOMED MATER RES, V19, P875, DOI 10.1002/jbm.820190802
   VONDERMARK K, 1977, NATURE, V267, P531, DOI 10.1038/267531a0
   VROUWENVELDER WCA, 1992, BIOMATERIALS, V13, P382, DOI 10.1016/0142-9612(92)90044-O
NR 57
TC 28
Z9 28
U1 0
U2 2
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD OCT
PY 1997
VL 37
IS 1
BP 137
EP 149
DI 10.1002/(SICI)1097-4636(199710)37:1<137::AID-JBM17>3.0.CO;2-D
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA XZ371
UT WOS:A1997XZ37100017
PM 9335359
DA 2018-10-19
ER

PT J
AU Korn, D
   Soyez, G
   Elssner, G
   Petzow, G
   Bres, EF
   dHoedt, B
   Schulte, W
AF Korn, D
   Soyez, G
   Elssner, G
   Petzow, G
   Bres, EF
   dHoedt, B
   Schulte, W
TI Study of interface phenomena between bone and titanium and alumina
   surfaces in the case of monolithic and composite dental implants
SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE
LA English
DT Article
ID RABBIT CORTICAL BONE; TRANSMISSION ELECTRON-MICROSCOPY; EARLY
   TISSUE-RESPONSE; BIOMATERIAL; LIGHT
AB The interface between mandibular bone and dental implants was examined with the in vivo dog model. Implant/bone interfaces were investigated for three types of materials: Ti-30 wt% Ta/Al2O3, titanium and Al2O3 using microscopy techniques covering a large magnification range: scanning electron microscopy, transmission electron microscopy, energy dispersive X-ray analysis and Auger spectroscopy. During the interaction of the Al2O3 ceramic with bone, an interfacial layer about 15 mu m thick is formed. The same phenomenon was observed at the titanium bone interface, where the thickness of the layer was about 10 mu m. In all cases, interface layers were sharp with well-defined borders between bone tissue and implant materials. No calcification took place inside the interface layer. A chemical analysis performed on this layer shows the presence of titanium, calcium and phosphorus in the case of titanium implants, and aluminium, calcium and phosphorus in the case of alumina implants. A rapid decrease in metal composition with increasing distances from the implant surface is correlated to a slow increase in calcium and phosphorus in the direction of the bone. Direct contact between implant and bone was observed. No biocorrosive effects were detected at the Ti-30 wt% Ta/Al2O3 metal-ceramic interface.
C1 UNIV LILLE 1,LSPES,URA 234,CNRS,MET PHYS LAB,F-59655 VILLENEUVE DASCQ,FRANCE.
   SONDERFORSCHUNGSBEREICH 175,D-72076 TUBINGEN,GERMANY.
RP Korn, D (reprint author), MAX PLANCK INST MET RES,SEESTR 92,D-70174 STUTTGART,GERMANY.
CR BIEHL V, 1994, HERBSTT EDO EMAS SAA, V27
   BRIGGS D, 1983, PRACTICAL SURFACE AN
   DHOEDT B, 1990, 13 WISS TAG ARB IMPL
   DHOEDT B, 1994, 17 WISS JAHR ARB IMP
   Donath K., 1988, PRAPARATOR, V34, P197
   DONATH K, 1991, Z ZAHNARZTL IMPLANTO, V7, P58
   Dorre E, 1980, Zahnarztl Prax, V31, P343
   FAWCETT PW, 1954, HISTOLOGY, P132
   FLECHSIG T, 1991, THESIS U GOTTINGEN
   FULLER RA, 1986, SPECTRUM WISSENSCHAF, V12, P86
   HEALY KE, 1992, J BIOMED MATER RES, V26, P319, DOI 10.1002/jbm.820260305
   HEALY KE, 1993, J MAT SCI MAT MED, V3, P117
   HENNING F, 1991, THESIS U HAMBURG
   Johansson C, 1987, Int J Oral Maxillofac Implants, V2, P69
   JOHANSSON CB, 1993, J MATER SCI-MATER M, V4, P132, DOI 10.1007/BF00120382
   KASEMO B, 1994, MAT SCI ENG C-BIOMIM, V1, P115, DOI 10.1016/0928-4931(94)90041-8
   KORN D, 1992, Z ZAHNARZTLICHE IMPL, V8, P136
   LI PJ, 1993, J BIOMED MATER RES, V27, P1495, DOI 10.1002/jbm.820271205
   LINDER L, 1989, ACTA ORTHOP SCAND, V60, P135, DOI 10.3109/17453678909149240
   MEYLE J, 1993, J BIOMED MATER RES, V27, P1553, DOI 10.1002/jbm.820271212
   POSNER AS, 1985, CLIN ORTHOP RELAT R, V200, P87
   SENNERBY L, 1993, J MATER SCI-MATER M, V4, P240, DOI 10.1007/BF00122275
   SENNERBY L, 1993, J MATER SCI-MATER M, V4, P494, DOI 10.1007/BF00120129
   SKERRY TM, 1988, J ORTHOPAED RES, V6, P547, DOI 10.1002/jor.1100060411
   SOYEZ G, 1997, P WERKST 96 STUTTG M, V4, P29
   SRECKER A, 1992, PRAKT METALLOGR, V30, P482
   STEFLIK DE, 1990, SCANNING MICROSCOPY, V4, P1021
   SUNDGREN JE, 1986, J COLLOID INTERF SCI, V110, P9, DOI 10.1016/0021-9797(86)90348-6
   Taylor M. G., 1989, BIOMINERALIZATION CH, P427
   TENGVALL P, 1992, Clinical Materials, V9, P115, DOI 10.1016/0267-6605(92)90056-Y
   TETSCH P, 1983, ENOSSALE IMPLANTATIO
   THOMSEN P, 1985, BIOMATERIALS, V6, P421, DOI 10.1016/0142-9612(85)90104-8
   VANTRAN P, 1982, CELL TISSUE RES, V225, P283
NR 33
TC 15
Z9 15
U1 0
U2 3
PU CHAPMAN HALL LTD
PI LONDON
PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8HN
SN 0957-4530
J9 J MATER SCI-MATER M
JI J. Mater. Sci.-Mater. Med.
PD OCT
PY 1997
VL 8
IS 10
BP 613
EP 620
DI 10.1023/A:1018567302700
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA YA172
UT WOS:A1997YA17200006
PM 15348830
DA 2018-10-19
ER

PT J
AU Weiss, P
   Lapkowski, M
   Legeros, RZ
   Bouler, JM
   Jean, A
   Daculsi, G
AF Weiss, P
   Lapkowski, M
   Legeros, RZ
   Bouler, JM
   Jean, A
   Daculsi, G
TI Fourier-transform infrared spectroscopy study of an organic-mineral
   composite for bone and dental substitute materials
SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE
LA English
DT Article
ID CELLULOSE; RATIOS; TCP
AB A new injectable biomaterial for bone and dental surgery is a composite consisting of a polymer as a matrix and bioactive calcium phosphate (CaP) ceramics as fillers. The stability of the polymer is essential in the production of a ready-to-use injectable sterilized biomaterial. The purpose of this study was to detect possible polymer degradation which may have been caused by the interaction with the fillers using Fourier transform infrared spectroscopy. Composites containing CaP fillers (biphasic calcium phosphate, hydroxyapatite and peroxidized hydroxyapatite) and polymer (hydroxypropyl methyl cellulose) were prepared. To investigate the properties of the polymer, the inorganic and organic phases of the composite were separated using several extraction methods. The difficulty in separating the organic (polymer) from the mineral (CaP fillers) phases in the composite investigated in this study suggested the presence of strong interactions between the two phases. Spectra of extracted polymers showed new absorption bands of low intensities and indications that some chemical modifications of the original polymers have occurred. Results also indicated that the filler composition has an effect on the integrity of the polymer.
C1 SILESIAN TECH UNIV,FAC CHEM,PL-44101 GLIWICE,POLAND.
   NYU,COLL DENT,CALCIUM PHOSPHATE RES LAB,DAVID B KRISER DENT CTR,NEW YORK,NY 10010.
RP Weiss, P (reprint author), CTR RECH INTERDISCIPLINAIRE TISSUS CALCIFIES & BI,FAC CHIRURG DENT,PL ALEXIS RICORDEAU,F-44042 NANTES,FRANCE.
RI Lapkowski, Mieczyslaw/D-5242-2014; Weiss, Pierre/P-1372-2014; Daculsi,
   Guy/P-1320-2014
OI Lapkowski, Mieczyslaw/0000-0001-7099-3982; Weiss,
   Pierre/0000-0002-6159-8590; Daculsi, Guy/0000-0003-1030-3446; BOULER,
   Jean-Michel/0000-0001-9784-5584
CR APFELBAUM F, 1992, J INORG BIOCHEM, V45, P227
   Colthup N. B., 1990, INTRO INFRARED RAMAN
   DACULSI G, 1995, Patent No. 21634
   de Groot K, 1983, BIOCERAMICS CALCIUM
   FENGEL D, 1991, PAPIER, V45, P45
   HATAKEYAMA H, 1976, CARBOHYD RES, V48, P149, DOI 10.1016/S0008-6215(00)83211-5
   JARCHO M, 1981, CLIN ORTHOP RELAT R, V157, P257
   JOHANSSON MH, 1975, J APPL POLYM SCI, V19, P3007, DOI 10.1002/app.1975.070191106
   Just E.K., 1989, ENCY POLYM SCI ENG, V3, P226
   LeGeros R. Z., 1970, DEV APPL SPEC      B, V7B, P3
   Legeros R.Z., 1991, MONOGRAPHS ORAL SCI, V15
   LEGEROS RZ, 1986, J DENT RES, V65, P292
   LeGeros RZ, 1990, HDB BIOACTIVE CERAMI, P17
   LEGEROS RZ, 1994, COMMUNICATION
   Machell G., 1960, J CHEM SOC, P1924
   NERY EB, 1992, J PERIODONTOL, V63, P729, DOI 10.1902/jop.1992.63.9.729
   NEVELL TP, 1985, CELLULOSE CHEM ITS A, P242
   Nevell TP, 1985, CELLULOSE CHEM ITS A, P223
   OCONNOR RT, 1957, ANAL CHEM, V29, P998, DOI 10.1021/ac60127a003
   PASSUTI N, 1995, INNOV TECH BIOL MED, V16, P20
   POUCHERT CJ, 1970, ALDRICH LIBR INFRARE
   REY C, 1995, J BONE MINER RES, V10, P1577
   RICHARDS GN, 1957, J CHEM SOC, P4492, DOI 10.1039/jr9570004492
NR 23
TC 42
Z9 42
U1 0
U2 6
PU CHAPMAN HALL LTD
PI LONDON
PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8HN
SN 0957-4530
J9 J MATER SCI-MATER M
JI J. Mater. Sci.-Mater. Med.
PD OCT
PY 1997
VL 8
IS 10
BP 621
EP 629
DI 10.1023/A:1018519419539
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA YA172
UT WOS:A1997YA17200007
PM 15348831
DA 2018-10-19
ER

PT J
AU Gorman, SP
   Jones, DS
   Mawhinney, WM
   McGovern, JG
   Adair, CG
AF Gorman, SP
   Jones, DS
   Mawhinney, WM
   McGovern, JG
   Adair, CG
TI Conditioning fluid influences on the surface properties of silicone and
   polyurethane peritoneal catheters: implications for infection
SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE
LA English
DT Article
ID COAGULASE-NEGATIVE STAPHYLOCOCCI; LASER-SCANNING MICROSCOPY;
   SOLID-SURFACES; EPIDERMIDIS; ADHERENCE; HYDROPHOBICITY; ELASTOMER;
   ADHESION; GROWTH
AB Catheter-related infection remains a considerable problem in continuous ambulatory peritoneal dialysis (CAPD). This study examined the adherence of clinical isolates of Staphylococcus epidermidis to commercially available polyurethane and silicone peritoneal catheters in the presence and absence of a proteinaceous conditioning film. In addition, the effects of the conditioning film on the surface properties (advancing and receding contact angles, and surface rugosity) of these biomaterials were investigated. Bacterial adherence to polyurethane and silicone catheters, pre-treated with phosphate-buffered saline (PBS) or artificial spent peritoneal dialysate (ASD) for 1 h at 37 degrees C, was examined using a radiometric (2-H-3-adenine) adherence assay. The advancing and receding contact angles and the surface rugosity of ASD- and PBS-treated biomaterials were examined using a dynamic contact angle analyser and an atomic force microscope, respectively. The bacterial isolates were selected to represent high and low cell surface hydrophobicity. The hydrophobic isolate exhibited both a significantly greater rate and a significantly greater extent of adherence than the hydrophilic isolate to both catheter materials, independent of pre-treatment. In general, pre-treatment of the catheter materials with ASD significantly decreased the subsequent adherence of both isolates owing to the deposition of a conditioning film on the surface of the biomaterial. ASD treatment also decreased both the advancing and receding contact angles and the surface rugosity of both catheter materials. This study highlights the influence of both bacterial cell surface hydrophobicity and biomaterial surface conditioning films on bacterial adherence to CAPD catheters. In addition, it is recommended that the effects of proteinaceous conditioning films on biomaterial surface properties should be considered when assessing materials for medical devices and products.
RP Gorman, SP (reprint author), QUEENS UNIV BELFAST,SCH PHARM,97 LISBURN RD,BELFAST BT9 7BL,ANTRIM,NORTH IRELAND.
CR ASHKENAZI S, 1986, J LAB CLIN MED, V107, P136
   BUSSCHER HJ, 1990, MICROBIAL CELL SURFA, P335
   CARBELLO J, 1991, MED MICROBIOL IMMUN, V180, P139
   DENYER SP, 1990, J CLIN MICROBIOL, V28, P1813
   DENYER SP, 1993, BLACKWELL PUBLICATIO, V30, P147
   EVANS RC, 1987, ANTIMICROB AGENTS CH, V31, P889, DOI 10.1128/AAC.31.6.889
   FLETCHER M, 1979, APPL ENVIRON MICROB, V37, P67
   GILBERT P, 1991, J APPL BACTERIOL, V71, P72
   GORMAN SP, 1994, EPIDEMIOL INFECT, V112, P551, DOI 10.1017/S0950268800051256
   GORMAN SP, 1993, J MED MICROBIOL, V38, P411, DOI 10.1099/00222615-38-6-411
   GORMAN SP, 1991, SOC APPLIED BACTERIO, V27, P271
   HARKES G, 1992, APPL ENVIRON MICROB, V58, P1500
   HOGT AH, 1985, J GEN MICROBIOL, V13, P2485
   HOLMES CJ, 1989, BIOMATERIALS, V10, P625, DOI 10.1016/0142-9612(89)90118-X
   Jones DS, 1996, INT J PHARM, V131, P83, DOI 10.1016/0378-5173(95)04368-3
   MARTINEZMARTINEZ L, 1991, J MED MICROBIOL, V34, P7, DOI 10.1099/00222615-34-1-7
   MAWHINNEY WM, 1992, INT J PHARM PRACT, V1, P136
   MAWHINNEY WM, 1991, INT J PHARM PRACT, V1, P1
   McGovern J. G., 1995, Journal of Pharmacy and Pharmacology, V47, P1063
   ONAOLAPO JA, 1987, J MED MICROBIOL, V24, P227, DOI 10.1099/00222615-24-3-227
   REED WP, 1986, FRONTIERS PERITONEAL, P176
   REID G, 1994, SURF INTERFACE ANAL, V21, P581, DOI 10.1002/sia.740210812
   STENSTROM TA, 1989, J APPL BACTERIOL, V67, P53, DOI 10.1111/j.1365-2672.1989.tb04954.x
   WILCOX MH, 1994, J HOSP INFECT, V26, P239, DOI 10.1016/0195-6701(94)90014-0
   WILKINS KM, 1989, INT J PHARM, V57, P1, DOI 10.1016/0378-5173(89)90256-1
NR 25
TC 13
Z9 14
U1 0
U2 2
PU CHAPMAN HALL LTD
PI LONDON
PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8HN
SN 0957-4530
J9 J MATER SCI-MATER M
JI J. Mater. Sci.-Mater. Med.
PD OCT
PY 1997
VL 8
IS 10
BP 631
EP 635
DI 10.1023/A:1018571403609
PG 5
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA YA172
UT WOS:A1997YA17200008
PM 15348832
DA 2018-10-19
ER

PT J
AU Fowers, KD
   Kopecek, J
AF Fowers, KD
   Kopecek, J
TI Development of a fibrinolytic surface: specific and non-specific binding
   of plasminogen
SO COLLOIDS AND SURFACES B-BIOINTERFACES
LA English
DT Article
DE fibrinolytic surfaces; plasminogen
ID EPSILON-AMINOCAPROIC ACID; OMEGA-AMINO ACIDS; LIGAND-BINDING;
   EXTRACELLULAR-MATRIX; POLYSTYRENE RESINS; LYSINE RESIDUES; HUMAN-PLASMA;
   2 ISOZYMES; ACTIVATION; ADSORPTION
AB Plasminogen is the primary zymogen in the fibrinolytic pathway, and its primary function involves degradation of fibrin. Biomaterials often show adsorption of fibrinogen and subsequent formation of fibrin. Plasminogen's function in vivo could be adapted to facilitate its activation and fibrinolytic function on a biomaterial surface. In order to elucidate plasminogen function adsorbed to a model fibrinolytic surface ligands known to affect plasminogen properties in solution were attached to model silica surfaces to study the effects of immobilized ligands as fibrinolytic activators. Model silica surfaces were synthesized which contained covalently attached lysine moieties (surface I), sulfonate moieties (surface II) or a combination of both (surface III). Lysine moieties on these model surfaces interact specifically with multiple lysine binding sites of plasminogen and induce a number of changes in conformation and function. Sulfonate moieties interact non-specifically with accessible lysine and arginine residues of plasminogen and also affect the function of plasminogen. Inherent physico-chemical properties monitored following plasminogen adsorption were activation to plasmin, enzymatic activity, fluorescent intensity, and fluorescent polarization, monitored br total internal reflection fluorescence, each of which are affected by plasminogen conformation.
   Correlations were as follows: increased fluorescent intensity and decreased fluorescent polarization were indicative of plasminogen conformational changes and are correlated to increased enzymatic activity of plasmin. Surfaces I and III showed a 20% increase in fluorescent intensity, and a 25% and 8% decrease in fluorescent polarization, respectively, in comparison to surface II. The specific activity for surfaces I and III was increased 11.3 and 1.8 fold above that found for surface II. Plasminogen incubated with sulfonate groups in solution resulted in no increase in fluorescent intensity and a slight decrease in fluorescent polarization as compared with plasminogen alone and reduced specific activity of plasmin in the presence of sulfonate as compared with plasmin alone. Lysine or E-aminocaproic acid (ACA) incubated with plasmin in solution showed a 30% and 10% increase in fluorescent intensity, a 24% and 5% decrease in fluorescent intensity, and maximum specific activity increased 3.6 and 2.5 fold, respectively, over plasminogen alone.
   Interactions of plasminogen with ligands for its lysine-binding sites produced dramatic effects both in solution and adsorbed to model fibrinolytic surfaces. The characterization of these interactions along with known fibrin interactions will allow selection of appropriate surface modifications to enhance the fibrinolysis of thrombus formed at a biomaterial interface. These modifications may lead to a native-like surface structure to protein and cellular components of blood and create a more biocompatible surface. (C) 1997 Elsevier Science B.V.
C1 UNIV UTAH,DEPT BIOENGN,SALT LAKE CITY,UT 84112.
CR ANONICK PK, 1992, ARTERIOSCLER THROMB, V12, P708, DOI 10.1161/01.ATV.12.6.708
   ASTRUP T, 1978, PROGR CHEM FIBRINOLY, V3, pCH1
   BOISSONVIDAL C, 1991, J BIOMED MATER RES, V25, P67, DOI 10.1002/jbm.820250106
   BROCKWAY WJ, 1971, P NATL ACAD SCI USA, V86, P2568
   BURGE SM, 1992, BRIT J DERMATOL, V126, P35, DOI 10.1111/j.1365-2133.1992.tb08400.x
   CASTELLINO FJ, 1981, J BIOL CHEM, V256, P4778
   CASTELLINO FJ, 1973, BIOCHEMISTRY-US, V12, P2787, DOI 10.1021/bi00739a002
   CHRISTENSEN U, 1985, FEBS LETT, V182, P43, DOI 10.1016/0014-5793(85)81150-9
   DEMARCO A, 1987, EUR BIOPHYS J BIOPHY, V14, P359, DOI 10.1007/BF00262321
   DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095
   DUDANI AK, 1991, MOL CELL BIOCHEM, V108, P133
   EDELBERG JM, 1991, BIOCHEMISTRY-US, V30, P10999, DOI 10.1021/bi00109a027
   FEARS R, 1989, BIOCHEM J, V261, P313, DOI 10.1042/bj2610313
   FLEURY V, 1991, BIOCHEMISTRY-US, V30, P7630, DOI 10.1021/bi00244a035
   FOSTER RI, 1988, AM J SURG, V156, P130
   GOLANDER CG, 1990, COLLOID SURFACE, V49, P289, DOI 10.1016/0166-6622(90)80111-G
   HIGAZI AA, 1992, BIOCHEM J, V282, P863, DOI 10.1042/bj2820863
   HLADY V, 1991, APPL SPECTROSC, V45, P246, DOI 10.1366/0003702914337533
   HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912
   KICHENINMARTIN V, 1988, THROMB RES, V52, P469, DOI 10.1016/0049-3848(88)90030-8
   KNUDSEN BS, 1986, J BIOL CHEM, V261, P765
   KUSSEROW BK, 1971, T AM SOC ART INT ORG, V17, P1
   LIJNEN HR, 1982, SEMIN THROMB HEMOST, V8, P2, DOI 10.1055/s-2007-1005038
   LIJNEN HR, 1993, METHODS ENZYMOLOGY, pCH1
   MANGEL WF, 1990, SCIENCE, V248, P69, DOI 10.1126/science.2108500
   MATSUKA YV, 1990, EUR J BIOCHEM, V190, P93, DOI 10.1111/j.1432-1033.1990.tb15550.x
   MENHART N, 1991, BIOCHEMISTRY-US, V30, P1948, DOI 10.1021/bi00221a031
   MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034
   MORRISON M, 1970, BIOCHEMISTRY-US, V9, P2995, DOI 10.1021/bi00817a010
   NOVOKHATNY VV, 1989, THROMB RES, V53, P243, DOI 10.1016/0049-3848(89)90099-6
   OSHIMA G, 1988, INT J BIOL MACROMOL, V10, P153, DOI 10.1016/0141-8130(88)90042-6
   PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411
   RADCLIFFE R, 1978, ARCH BIOCHEM BIOPHYS, V189, P185, DOI 10.1016/0003-9861(78)90131-5
   REICH E, 1975, PROTEASES BIOL CONTR, pCH4
   SANTERRE JP, 1992, J BIOMED MATER RES, V26, P39, DOI 10.1002/jbm.820260105
   SENATORE F, 1986, J BIOMED MATER RES, V20, P189, DOI 10.1002/jbm.820200208
   SENATORE F, 1986, J BIOMED MATER RES, V20, P177, DOI 10.1002/jbm.820200207
   SHANKAR H, 1987, J BIOMED MATER RES, V21, P897, DOI 10.1002/jbm.820210706
   SJOHOLM I, 1973, EUR J BIOCHEM, V29, P471
   SMITH AJ, 1991, FEBS LETT, V278, P17
   SOEDA S, 1989, BIOCHIM BIOPHYS ACTA, V999, P29, DOI 10.1016/0167-4838(89)90025-3
   STACK MS, 1994, ARCH BIOCHEM BIOPHYS, V309, P117, DOI 10.1006/abbi.1994.1093
   STACK MS, 1992, BIOCHEM J, V284, P103, DOI 10.1042/bj2840103
   STACK S, 1990, BIOCHEMISTRY-US, V29, P4966, DOI 10.1021/bi00472a029
   STRICKLAND S, 1978, REGULATORY PROTEOLYT, pCH13
   SUENSON E, 1984, EUR J BIOCHEM, V140, P513, DOI 10.1111/j.1432-1033.1984.tb08132.x
   SUENSON E, 1990, J BIOL CHEM, V265, P22228
   SUGAWARA Y, 1984, THROMB RES, V33, P269, DOI 10.1016/0049-3848(84)90162-2
   SUGIYAMA N, 1988, BIOCHIM BIOPHYS ACTA, V952, P1, DOI 10.1016/0167-4838(88)90094-5
   TAKADA A, 1982, THROMB RES, V27, P671, DOI 10.1016/0049-3848(82)90005-6
   TAKADA A, 1984, THROMB RES, V33, P461, DOI 10.1016/0049-3848(84)90011-2
   TEUTEN AJ, 1993, BIOCHEM J, V293, P567, DOI 10.1042/bj2930567
   THEWES T, 1990, J BIOL CHEM, V265, P3906
   URANO T, 1988, ARCH BIOCHEM BIOPHYS, V264, P222, DOI 10.1016/0003-9861(88)90588-7
   VIOLAND BN, 1978, J BIOL CHEM, V253, P5395
   WOODHOUSE KA, 1994, J BIOMED MATER RES, V28, P407, DOI 10.1002/jbm.820280402
   WOODHOUSE KA, 1992, BIOMATERIALS, V13, P1103, DOI 10.1016/0142-9612(92)90143-C
   WOODHOUSE KA, 1994, J COLLOID INTERF SCI, V164, P40, DOI 10.1006/jcis.1994.1141
   WOODHOUSE KA, 1991, SOC BIOMATER P, V17, P94
   WU HL, 1990, J BIOL CHEM, V265, P19658
   WU TP, 1991, BIOCHEMISTRY-US, V30, P10589, DOI 10.1021/bi00107a030
   YANG HC, 1990, THROMB RES, V59, P149, DOI 10.1016/0049-3848(90)90280-P
NR 62
TC 6
Z9 6
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7765
J9 COLLOID SURFACE B
JI Colloid Surf. B-Biointerfaces
PD SEP 30
PY 1997
VL 9
IS 6
BP 315
EP 330
DI 10.1016/S0927-7765(97)00034-9
PG 16
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
SC Biophysics; Chemistry; Materials Science
GA YJ384
UT WOS:A1997YJ38400004
DA 2018-10-19
ER

PT J
AU Davies, JE
   Baldan, N
AF Davies, JE
   Baldan, N
TI Scanning electron microscopy of the bone bioactive implant interface
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE bone; interface; cement line; bioactive glass; AW glass ceramic;
   hydroxyapatite
ID HYDROXYAPATITE INTERFACE; TITANIUM INTERFACE; TISSUE-RESPONSE; IN-VIVO;
   INVITRO; RAT; GLASS; OSTEOBLASTS; BIOGLASS; CERAMICS
AB Rods of three bioactive materials, apatite/wollastonite glass ceramic (AW-GC), bioactive glass (BG), and dense slip-cast hydroxyapatite (HA), were implanted in the femora of 23 Wistar rats for periods of 1-4 weeks. The samples were harvested following vascular perfusion fixation and the femora freeze-fractured for scanning electron microscopy to expose the bone/implant interface. The focus of our observations was when new bone was forming on the implant surfaces irrespective of the implantation period. Scanning microscopy of the hydroxyapatite rods demonstrated that in areas where bone bonding had occurred, the implant surface was composed of globular accretions which fused to form a cement-like matrix to which collagen fibers were attached. Dissolution of individual grains of the implant surface created a roughened surface topography. Such features were not found in the transcortical portions of these implants. Similar globular accretions were also found on the surfaces of bulk AW-GC, although bone apposition was not disrupted by the critical point-drying procedure, and thus the interface was more difficult to image. Nevertheless, the collagen of the bony compartment interdigitated with an interfacial layer which was morphologically similar to that found on HA. The most surface reactive material, BG, demonstrated an interfacial structure where the surface reactive calcium phosphate layer was clearly distinguished from the underlying bulk implant material. However, this layer was separated from the overlying collagen-containing bony compartment by a second, thinner, calcified layer which corresponded to the cement line matrix into which the collagen fibers were inserted. Our results show that the new bone interface formed with these three bioactive materials is morphologically comparable to that of cement lines found naturally in bone-remodeling sites, and that this interfacial layer is formed on the chemically active surface of the biomaterial. The degree to which the cement line matrix interdigitated with the implant was a product of the reactivity of the implant surface. (C) 1997 John Wiley & Sons, Inc.
RP Davies, JE (reprint author), UNIV TORONTO, CTR BIOMAT, 170 COLL ST, TORONTO, ON M5S 3E3, CANADA.
CR ALBREKTSSON T, 1983, ANN BIOMED ENG, V11, P1, DOI 10.1007/BF02363944
   Albrektsson T O, 1994, Periodontol 2000, V4, P58, DOI 10.1111/j.1600-0757.1994.tb00006.x
   BAGAMBISA F B, 1990, International Journal of Oral and Maxillofacial Implants, V5, P217
   DACULSI G, 1990, SCANNING MICROSCOPY, V4, P309
   DAVIES JE, 1991, CELL MATER, V1, P3
   DAVIES JE, 1991, BONE-BIOMATERIAL INTERFACE, P285
   DAVIES JE, 1991, BONE-BIOMATERIAL INTERFACE, P214
   DAVIES JE, 1991, BIOCERAMICS, V4, P199
   DAVIES JE, 1991, BONE BIOMATERIAL INT, P226
   DEBRUIJN JD, 1995, J BIOMED MATER RES, V29, P89, DOI 10.1002/jbm.820290113
   DEBRUIJN JD, 1992, J BIOMED MATER RES, V26, P1365, DOI 10.1002/jbm.820261008
   DEBRUIJN JD, 1993, THESIS U LEIDEN
   DENISSEN HW, 1980, J BIOMED MATER RES, V14, P713, DOI 10.1002/jbm.820140603
   GROSS UM, 1990, CRC HDB BIOACTIVE CE, V1, P25
   HENCH LL, 1974, J BIOMED MATER RES, V8, P49, DOI 10.1002/jbm.820080307
   HENCH LL, 1986, MATER RES SOC S P, V55, P65
   Hench LL, 1971, J BIOMED MATER RES S, V2, P117, DOI DOI 10.1002/JBM.820050611
   HOSSEINI MM, IN PRESS CELLS MAT
   ITOH S, 1994, T 20 ANN M SOC BIOM, P40
   JARCHO M, 1981, CLIN ORTHOP RELAT R, P259
   JARCHO M, 1978, 4TH T ANN M SOC BIOM, P112
   JIANGUO Z, 1994, J MATER SCI-MATER M, V5, P243
   JOHANSSON C, 1989, J BIOMED ENG, V11, P3, DOI 10.1016/0141-5425(89)90158-1
   KASEMO B, 1991, BONE-BIOMATERIAL INTERFACE, P19
   KAWAGUCHI H, 1993, CELL MATER, V3, P337
   KITSUGI T, 1987, J BIOMED MATER RES, V21, P1255, DOI 10.1002/jbm.820211008
   KOKUBO T, 1986, J MATER SCI, V21, P536, DOI 10.1007/BF01145520
   KOKUBO T, 1990, J BIOMED MATER RES, V24, P331, DOI 10.1002/jbm.820240306
   KRAJEWSKI A, 1988, BIOMATERIALS, V9, P449, DOI 10.1016/0142-9612(88)90011-7
   KUKUBO T, 1992, BONE BONDING, P31
   LINDER L, 1983, ACTA ORTHOP SCAND, V54, P45, DOI 10.3109/17453678308992868
   LINDER L, 1992, CLIN ORTHOP RELAT R, V276, P147
   LOWENBERG B, 1991, CELL MATER, V1, P177
   MATSUDA T, 1987, J BIOMED MATER RES, V21, P499, DOI 10.1002/jbm.820210409
   MATSUDA T, 1987, BIOMATERIALS, V8, P275, DOI 10.1016/0142-9612(87)90115-3
   MCKEE MD, 1993, CELL MATER, V3, P219
   NANCI A, 1994, CELL MATER, V4, P1
   NEO M, 1994, J BIOMED MATER RES, V28, P365, DOI 10.1002/jbm.820280311
   NEO M, 1993, J BIOMED MATER RES, V27, P999, DOI 10.1002/jbm.820270805
   NEO M, 1992, J BIOMED MATER RES, V26, P255, DOI 10.1002/jbm.820260210
   OGINO M, 1980, J BIOMED MATER RES, V14, P55, DOI 10.1002/jbm.820140107
   ORR RD, 1992, CELL MATER, V2, P241
   PEEL SA, 1994, T 20 ANN M SOC BIOM, P287
   PILLIAR RM, 1991, MRS BULL, V16, P55
   RAVAGLIOLI A, 1992, BIOMATERIALS, V13, P162, DOI 10.1016/0142-9612(92)90065-V
   SHEN X, 1993, CELL MATER, V3, P257
   STEIN GS, 1990, FASEB J, V4, P3111
   TAKAHASHI S, 1981, J JPN ORTHOP ASSOC, V55, P347
   VANBLITTERSWIJK CA, 1985, BIOMATERIALS, V6, P243, DOI 10.1016/0142-9612(85)90020-1
   von Ebner V, 1875, SHER AKAD WISS WIEN, V72, P49
NR 50
TC 86
Z9 87
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD SEP 15
PY 1997
VL 36
IS 4
BP 429
EP 440
DI 10.1002/(SICI)1097-4636(19970915)36:4<429::AID-JBM1>3.0.CO;2-G
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA XU176
UT WOS:A1997XU17600001
PM 9294759
DA 2018-10-19
ER

PT J
AU Wright, DD
   Lautenschlager, EP
   Gilbert, JL
AF Wright, DD
   Lautenschlager, EP
   Gilbert, JL
TI Bending and fracture toughness of woven self-reinforced composite
   poly(methyl methacrylate)
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE composite; bone cement; flexure; fracture toughness; gamma irradiation
ID ACRYLIC BONE-CEMENT; LINEAR POLYETHYLENE FIBERS; TOTAL HIP-REPLACEMENT;
   MECHANICAL-PROPERTIES; FATIGUE PROPERTIES; PMMA; INTERFACE;
   ARTHROPLASTY; DEFORMATION; FIXATION
AB Loosening remains an impediment to the long-term success of total hip replacements despite numerous improvements in the materials used. In cemented prostheses, fatigue and fracture of bone cement have been implicated in the failure of these devices. A new material, self-reinforced composite poly(methyl methacrylate) (SRC-PMMA), has been developed. SRC-PMMA is formed by a novel processing method that will be described. The composite consists of high strength, highly oriented PMMA fibers embedded in a matrix of PMMA. Using a woven form of SRC-PMMA, an in vitro physical and mechanical evaluation was performed to assess the feasibility of its use in an orthopedic prosthesis. Three different weaves of SRC-PMMA were evaluated in bending and fracture toughness in air, after immersion for 30 days in 37 degrees C saline, and after gamma irradiation followed by immersion. Bending modulus and strength were decreased by gamma irradiation followed by saline immersion. The effect of saline immersion alone on bending strength and modulus was negligible. Saline immersion and gamma irradiation followed by saline immersion was shown to have little or no effect on the fracture toughness of woven SRC-PMMA. Differences in the fracture processes of the different weaves were found and can be related to the differing orientation of fibers to the fracture toughness pre-crack. Optimally incorporated SRC-PMMA absorbs the same amount of water as bone cement. Comparison to previous and current work with bone cement controls shows that SRC-PMMA is a material equal to or better than bone cement in all tests performed. It deserves further consideration as a candidate biomaterial. (C) 1997 John Wiley & Sons, Inc.
C1 NORTHWESTERN UNIV,DIV BIOL MAT,CHICAGO,IL 60611.
   NORTHWESTERN UNIV,INST TECHNOL,DEPT BIOMED ENGN,EVANSTON,IL 60208.
CR AHMED A M, 1984, Journal of Orthopaedic Research, V2, P105, DOI 10.1002/jor.1100020201
   *ASTM, 1985, E39983 ASTM
   *ASTM, 1990, D790M86 ASTM
   BARRACK RL, 1992, J BONE JOINT SURG BR, V74, P385
   BROEK D, 1988, PRACTICAL USE FRACTU
   BROWN SA, 1984, J BIOMED MATER RES, V18, P523, DOI 10.1002/jbm.820180506
   BUCKLEY CA, 1992, J APPL POLYM SCI, V44, P1321, DOI 10.1002/app.1992.070440802
   CHARNLEY J, 1975, CLIN ORTHOP RELAT R, V111, P105
   CHOW TW, 1992, AUST DENT J, V37, P433, DOI 10.1111/j.1834-7819.1992.tb05897.x
   CHWIRUT DJ, 1984, J BIOMED MATER RES, V18, P25, DOI 10.1002/jbm.820180105
   DAVIES JP, 1989, J BONE JOINT SURG BR, V71, P39
   EKSTRAND K, 1987, J BIOMED MATER RES, V21, P1065, DOI 10.1002/jbm.820210902
   ESTOK DM, 1994, CLIN ORTHOP RELAT R, V299, P190
   FREITAG TA, 1976, J BIOMED MATER RES, V10, P805, DOI 10.1002/jbm.820100512
   GILBERT JL, 1995, BIOMATERIALS, V16, P1043, DOI 10.1016/0142-9612(95)98900-Y
   GILBERT JL, 1987, THESIS CARNEGIEMELLO
   GOLDRING SR, 1986, ARTHRITIS RHEUM-US, V29, P836, DOI 10.1002/art.1780290704
   GOODMAN SB, 1988, CLIN ORTHOP RELAT R, V232, P255
   HARRIS WH, 1982, J BONE JOINT SURG AM, V64, P1063, DOI 10.2106/00004623-198264070-00017
   HARRIS WH, 1986, J BONE JOINT SURG AM, V68A, P1064, DOI 10.2106/00004623-198668070-00014
   JOCKISCH KA, 1994, AM SOC TEST MATER, V1173, P212, DOI 10.1520/STP18106S
   JOCKISCH KA, 1991, 17 ANN M SOC BIOM SC
   Kavanagh B F, 1994, J Arthroplasty, V9, P229, DOI 10.1016/0883-5403(94)90076-0
   Knott J.F., 1973, FUNDAMENTALS FRACTUR
   KUSY RP, 1978, THERMOCHIM ACTA, V26, P415, DOI 10.1016/0040-6031(78)80084-7
   LADIZESKY NH, 1992, AUST DENT J, V37, P277, DOI 10.1111/j.1834-7819.1992.tb04744.x
   LADIZESKY NH, 1993, AUST DENT J, V38, P28, DOI 10.1111/j.1834-7819.1993.tb05448.x
   LAUTENSCHLAGER EP, 1984, FUNCTIONAL BEHAVIOR, V2, P87
   MALONEY WJ, 1989, CLIN ORTHOP RELAT R, V249, P129
   MANLEY MT, 1985, J BIOMED MATER RES, V19, P563, DOI 10.1002/jbm.820190508
   MANLEY TR, 1988, POLYM COMMUN, V29, P17
   MJOBERG B, 1994, ACTA ORTHOP SCAND, V65, P361, DOI 10.3109/17453679408995473
   MULROY RD, 1990, J BONE JOINT SURG BR, V72, P757
   MURRAY JA, 1974, J BONE JOINT SURG AM, VA 56, P311, DOI 10.2106/00004623-197456020-00009
   NORDIN M, 1989, BASIC BIOMECHANICS M
   PAL S, 1982, BIOMATERIALS, V3, P93
   PILLIAR RM, 1976, J BIOMED MATER RES, V10, P893, DOI 10.1002/jbm.820100608
   POURDEYHIMI B, 1989, J BIOMED MATER RES, V23, P63, DOI 10.1002/jbm.820230106
   POURDEYHIMI B, 1986, ANN BIOMED ENG, V14, P277, DOI 10.1007/BF02584275
   RAAB S, 1982, J BIOMED MATER RES, V16, P679, DOI 10.1002/jbm.820160515
   Roberts D W, 1986, J Arthroplasty, V1, P241, DOI 10.1016/S0883-5403(86)80014-6
   SAHA S, 1984, J BIOMECH, V17, P467, DOI 10.1016/0021-9290(84)90015-0
   SAHA S, 1984, J BIOMED MATER RES, V18, P435, DOI 10.1002/jbm.820180411
   SAHA S, 1986, J BIOMED MATER RES, V20, P817, DOI 10.1002/jbm.820200612
   SAHA S, 1983, J BIOMED MATER RES, V17, P1041, DOI 10.1002/jbm.820170613
   SCHULTE KR, 1993, J BONE JOINT SURG AM, V75A, P961, DOI 10.2106/00004623-199307000-00002
   SCHULTZ AR, 1956, J POLYM SCI, V22, P495
   SKIRVIN DR, 1982, MIL MED, V147, P1037
   TOPOLESKI LDT, 1992, J BIOMED MATER RES, V26, P1599, DOI 10.1002/jbm.820261206
   TOPOLESKI LDT, 1990, J BIOMED MATER RES, V24, P135, DOI 10.1002/jbm.820240202
   Wixson R L, 1987, J Arthroplasty, V2, P141, DOI 10.1016/S0883-5403(87)80021-9
NR 51
TC 41
Z9 42
U1 0
U2 10
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD SEP 15
PY 1997
VL 36
IS 4
BP 441
EP 453
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA XU176
UT WOS:A1997XU17600002
PM 9294760
DA 2018-10-19
ER

PT J
AU Salzmann, DL
   Yee, DC
   Roach, DJ
   Berman, SS
   Williams, SK
AF Salzmann, DL
   Yee, DC
   Roach, DJ
   Berman, SS
   Williams, SK
TI Effects of balloon dilatation on ePTFE structural characteristics
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE endovascular grafts; ePTFE; balloon angioplasty; stents; biomaterial
ID POLYTETRAFLUOROETHYLENE; GRAFTS; POROSITY; ANASTOMOSIS; STENT
AB The search for less invasive treatments for cardiovascular disease has lead to the development of endovascular stent grafts, metallic and alloy stents surrounded by prosthetic vascular graft material. Introduced intravascularly, the deployment of stent grafts requires balloon dilatation of the device which results in expansion of the stent along with the vascular graft material. We hypothesized that balloon dilatation of stent grafts would alter the physical structure of the prosthetic graft material. In this study, noncompliant angioplasty balloons were used to dilate expanded polytetrafluoroethylene (ePTFE), a material commonly used for endovascular stent-graft technology. The maximal outer diameter (inflated balloon within the lumen) and the recoiled outer diameter (balloon removed) of two types of ePTFE, 3-mm inside diameter (i.d.) thin wall (30-mu m internodal distance) and 4-mm i.d. standard wall (30-mu m internodal distance), were measured to compare material recoil. Following balloon dilatation, ePTFE samples were prepared for scanning electron microscopic examination and the following parameters were measured: wall thickness, internodal distance, nodal width, interfiber distance, and fiber width. Following primary dilatation, both types of ePTFE recoiled approximately 20% regardless of inflated balloon diameter. However, following eight repetitive balloon dilatations, recoil decreased to approximately 10%. Scanning electron microscopic analysis revealed variations in internodal distance and significant decreases in wall thickness, nodal thickness, and interfiber distance. Fiber width was significantly decreased following dilatation of 3 mm, but not 4 mm ePTFE. Our data support our initial hypothesis that balloon dilatation alters the structure of ePTFE. (C) 1997 John Wiley & Sons, Inc.
C1 UNIV ARIZONA, DEPT SURG, SECT SURG RES, TUCSON, AZ 85724 USA.
   UNIV ARIZONA, DEPT RADIOL, SECT VASC INTERVENT RADIOL, TUCSON, AZ 85724 USA.
CR CHALMERS RTA, 1994, BRIT J SURG, V81, P1443, DOI 10.1002/bjs.1800811012
   CHALMERS RTA, 1994, AM J SURG, V168, P85, DOI 10.1016/S0002-9610(94)80041-3
   CLOWES AW, 1986, AM J PATHOL, V123, P220
   GOLDEN MA, 1990, J VASC SURG, V11, P838, DOI 10.1067/mva.1990.18047
   HIRABAYASHI K, 1992, J BIOMED MATER RES, V26, P1433, DOI 10.1002/jbm.820261104
   KOHLER TR, 1992, SURGERY, V112, P901
   MARIN ML, 1995, J VASC SURG, V21, P595, DOI 10.1016/S0741-5214(95)70191-5
   MCCLURKEN ME, 1986, STP, V898, P82
   NAGAE T, 1995, J INVEST SURG, V8, P235, DOI 10.3109/08941939509031597
   Palmaz JC, 1995, J VASC INTERV RADIOL, V6, P879, DOI 10.1016/S1051-0443(95)71207-6
   Salzmann DL, 1997, J BIOMED MATER RES, V34, P463, DOI 10.1002/(SICI)1097-4636(19970315)34:4<463::AID-JBM7>3.0.CO;2-I
NR 11
TC 10
Z9 10
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD SEP 15
PY 1997
VL 36
IS 4
BP 498
EP 507
DI 10.1002/(SICI)1097-4636(19970915)36:4<498::AID-JBM7>3.0.CO;2-9
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA XU176
UT WOS:A1997XU17600007
PM 9294765
DA 2018-10-19
ER

PT J
AU Tanzi, MC
   Mantovani, D
   Petrini, P
   Guidoin, R
   Laroche, G
AF Tanzi, MC
   Mantovani, D
   Petrini, P
   Guidoin, R
   Laroche, G
TI Chemical stability of polyether urethanes versus polycarbonate urethanes
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE polyurethane; chemical stability; DSC; GPC; FTIR
ID SOFT SEGMENT CHEMISTRY; SUBCUTANEOUS IMPLANTATION; POLYURETHANE
   ELASTOMERS; OXIDATIVE-DEGRADATION; POLY(ETHER URETHANE); BIOMER LOTS;
   INVITRO; BIOSTABILITY; BIODEGRADATION; CRACKING
AB The relative chemical stability of two commercially available polyurethanes-Pellethane, currently used in biomedical devices, and Corethane, considered as a potential biomaterial-was investigated following aging protocols in hydrolytic and oxidative conditions (HOC, water, hydrogen peroxide, and nitric acid) and in physiological media (PHM, phosphate buffer, lipid dispersion, and bile from human donors). The chemical modifications induced on these polymers were characterized using differential scanning calorimetry (DSC), gel permeation chromatography (GPC), and Fourier transform infrared spectroscopy (FTIR). With the exception of nitric acid, all of the aging media promoted a mild hydrolytic reaction leading to a slight molecular weight loss in both polymers. When aged in water and hydrogen peroxide, Pellethane experienced structural modifications through microdomain phase separation along with an increase of the order within the soft-hard segment domains. The incubation of Pellethane in nitric acid also resulted in an important decrease of the melting temperature of its hard segments with chain scission mechanisms. Moreover, incubation in PHM led to an increase of the order within shorter hard-segment domains. FTIR data revealed the presence of aliphatic amide molecules used as additives on the Pellethane's surface. The incubation of Corethane under the same conditions promoted an almost uniform molecular reorganization through a phase separation between the hard and soft segments as well as an increase of the short-range order within the hard-segment domains. Incubation of this polymer in nitric acid also resulted in a chain scission process that was less pronounced than that measured for the Pellethane samples. Finally, lipid adsorption occurred on the Corethane sample incubated in bile for 120 days. Overall data indicate that polycarbonate urethane presents a greater chemical stability than does polyetherurethane. (C) 1997 John Wiley & Sons, Inc.
C1 UNIV LAVAL,DEPT CHIRURG,QUEBEC CITY,PQ G1L 3L5,CANADA.
   POLITECN MILAN,DIPARTIMENTO BIOINGN,I-20133 MILAN,ITALY.
   CTR HOSP UNIV QUEBEC,INST BIOMAT QUEBEC INC,QUEBEC CITY,PQ G1L 3L5,CANADA.
RI Tanzi, Maria Cristina/I-4620-2013; Petrini, Paola/A-3150-2013
OI Tanzi, Maria Cristina/0000-0002-4913-6633; Petrini,
   Paola/0000-0002-5081-5254; Mantovani, Diego/0000-0001-9672-895X
CR BOUVIER M, 1991, J BIOMED MATER RES, V25, P773, DOI 10.1002/jbm.820250607
   DILLION JG, 1989, INFRARED SPECTROSCOP
   GRIESSER HJ, 1991, POLYM DEGRAD STABIL, V33, P329, DOI 10.1016/0141-3910(91)90080-B
   Hasirci N, 1991, HIGH PERFORMANCE BIO, P71
   HAYASHI K, 1987, JSME INT J, V30, P1517, DOI 10.1299/jsme1987.30.1517
   HERGENROTHER RW, 1993, BIOMATERIALS, V14, P449, DOI 10.1016/0142-9612(93)90148-U
   HERGENROTHER RW, 1992, J APPL BIOMATER, V3, P17, DOI 10.1002/jab.770030104
   LELAH MD, 1986, POLYURETHANE MED
   MEIJS GF, 1993, J BIOMED MATER RES, V27, P345, DOI 10.1002/jbm.820270308
   NIELSEN L, 1994, MECHANICAL PROPERTIE
   PINCHUK L, 1994, J BIOMAT SCI-POLYM E, V6, P225, DOI 10.1163/156856294X00347
   PINCHUK L, 1994, T 19 ANN M SFB, V22
   RATNER BD, 1988, J BIOMED MATER RES, V22, P509, DOI 10.1002/jbm.820220607
   SANTERRE JP, 1994, J BIOMED MATER RES, V28, P1187, DOI 10.1002/jbm.820281009
   SANTERRE JP, 1993, J BIOMED MATER RES, V27, P97, DOI 10.1002/jbm.820270113
   SATO M, 1995, J BIOMED MATER RES, V29, P1201, DOI 10.1002/jbm.820291007
   SEYMOUR RW, 1973, MACROMOLECULES, V6, P48, DOI 10.1021/ma60031a008
   SMITH R, 1987, J BIOMED MATER RES, V21, P1149, DOI 10.1002/jbm.820210908
   STOKES K, 1990, Journal of Biomaterials Science Polymer Edition, V1, P207
   STOKES K, 1995, J BIOMATER APPL, V9, P321, DOI 10.1177/088532829500900402
   STOKES K, 1987, POLYURETHANES BIOMED, V2, P109
   Szycher M., 1991, BLOOD COMPATIBLE MAT, P33
   Szycher M., 1992, MED DEVICE TECHNOL, V11, P42
   Szycher Michael, 1994, P233
   TAKAHARA A, 1991, J BIOMED MATER RES, V25, P341, DOI 10.1002/jbm.820250306
   TAKAHARA A, 1992, J BIOMED MATER RES, V26, P801, DOI 10.1002/jbm.820260609
   TYLER BJ, 1993, J BIOMED MATER RES, V27, P327, DOI 10.1002/jbm.820270306
   TYLER BJ, 1992, J BIOMED MATER RES, V26, P273, DOI 10.1002/jbm.820260302
   XI TF, 1994, J BIOMED MATER RES, V28, P483, DOI 10.1002/jbm.820280411
   ZHANG Z, 1994, BIOMATERIALS, V15, P483
   ZHANG Z, 1994, BIOMATERIALS, V15, P1099, DOI 10.1016/0142-9612(94)90096-5
   ZHAO Q, 1990, J BIOMED MATER RES, V24, P621, DOI 10.1002/jbm.820240508
   ZHAO Q, 1987, POLYMER, V28, P2040, DOI 10.1016/0032-3861(87)90038-3
   ZHAO Q, 1991, J BIOMED MATER RES, V25, P177, DOI 10.1002/jbm.820250205
   ZHAO QH, 1995, J BIOMED MATER RES, V29, P467, DOI 10.1002/jbm.820290406
NR 35
TC 105
Z9 111
U1 3
U2 61
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD SEP 15
PY 1997
VL 36
IS 4
BP 550
EP 559
DI 10.1002/(SICI)1097-4636(19970915)36:4<550::AID-JBM14>3.0.CO;2-E
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA XU176
UT WOS:A1997XU17600014
PM 9294772
DA 2018-10-19
ER

PT J
AU Caldwell, KD
AF Caldwell, KD
TI Modulation of biomaterial interactions with proteins and cells.
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
C1 UNIV UTAH,CTR BIOPOLYMERS INTERFACES,SALT LAKE CITY,UT 84112.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD SEP 7
PY 1997
VL 214
BP 298
EP PMSE
PN 2
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA XQ859
UT WOS:A1997XQ85901560
DA 2018-10-19
ER

PT J
AU Cenni, E
   Granchi, D
   Verri, E
   Cavedagna, D
   Gamberini, S
   Falsone, G
   Pizzoferrato, A
AF Cenni, E
   Granchi, D
   Verri, E
   Cavedagna, D
   Gamberini, S
   Falsone, G
   Pizzoferrato, A
TI CD65 thromboxane B2, and beta-thromboglobulin: A comparison between
   different markers of platelet activation after contact with biomaterials
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE biomaterial; platelet; release reaction; GMP-140
ID MEMBRANE-GLYCOPROTEINS; BLOOD COMPATIBILITY; RELEASE REACTION;
   HEMODIALYSIS; INVITRO
AB The authors examined the modifications of some markers of platelet activation after contact with biomaterials. Glycoprotein GMP-140 (CD62) was evaluated by flow cytometry; beta-thromboglobulin (beta-TG) and thromboxane B-2 (TXB2) were determined by radioimmunoassay. Polyethylene terephthalate (PET) induced a remarkable platelet adhesion and a significant increase in beta-TG and TXB2, with no increase in CD62 on the nonadherent platelets. Pyrolytic carbon-coated PET (PC) did not induce platelet adhesion after 15 min of contact, but a significant increase in CD62 was detected. After 30 min a significant increase in platelet adhesion as well as the release of beta-TG and TXB2 were noted. The increase was lower than that observed for uncoated PET, and after 30 min of contact with PC the increase no longer was observed. (C) 1997 John Wiley & Sons, Inc.
C1 CTR REG SRVIZIO TRASFUS,USL 27,BOLOGNA,ITALY.
RP Cenni, E (reprint author), IST ORTOPEDICI RIZZOLI,LAB BIOCOMPATIBIL RES IMPLANT MAT,VIA BARBIANO 1-10,I-40136 BOLOGNA,ITALY.
RI Granchi, Donatella/J-3647-2016
OI Granchi, Donatella/0000-0001-7225-0023
CR BOWRY SK, 1984, BIOMATERIALS, V5, P289, DOI 10.1016/0142-9612(84)90075-9
   CAHILL MR, 1993, BRIT J HAEMATOL, V84, P527, DOI 10.1111/j.1365-2141.1993.tb03112.x
   CENNI E, 1993, BIOMATERIALS, V14, P588, DOI 10.1016/0142-9612(93)90176-3
   CENNI E, 1995, BIOMATERIALS, V16, P973, DOI 10.1016/0142-9612(95)94903-X
   CENNI E, 1991, POLYMERS AND BIOMATERIALS, P407
   GAWAZ M, 1994, CLIN INVESTIGATOR, V72, P424
   GAWAZ MP, 1994, KIDNEY INT, V46, P489, DOI 10.1038/ki.1994.299
   GEMMELL CH, 1993, 19 ANN M SOC BIOM BI, P137
   KANG IK, 1988, J BIOMED MATER RES, V22, P595, DOI 10.1002/jbm.820220702
   KOTTKEMARCHANT K, 1989, BIOMATERIALS, V10, P147, DOI 10.1016/0142-9612(89)90017-3
   LEAKE DL, 1989, BIOMATERIALS, V10, P441, DOI 10.1016/0142-9612(89)90083-5
   METZELAAR MJ, 1993, J LAB CLIN MED, V121, P579
   RHODES NP, 1994, J BIOMED MATER RES, V28, P435, DOI 10.1002/jbm.820280405
   SCHULTHEISS HP, 1994, EUR J CLIN INVEST, V24, P243, DOI 10.1111/j.1365-2362.1994.tb01081.x
   TSCHOEPE D, 1993, CIRCULATION, V88, P37, DOI 10.1161/01.CIR.88.1.37
   TSCHOEPE D, 1993, SEMIN THROMB HEMOST, V19, P122, DOI 10.1055/s-2007-994015
   UMEMURA Y, 1988, BIOMATERIALS, V9, P133, DOI 10.1016/0142-9612(88)90111-1
   WILHELM CR, 1995, 21 ANN M SOC BIOM SA, P11
NR 18
TC 14
Z9 17
U1 0
U2 3
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD SEP 5
PY 1997
VL 36
IS 3
BP 289
EP 294
DI 10.1002/(SICI)1097-4636(19970905)36:3<289::AID-JBM3>3.0.CO;2-A
PG 6
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA XP501
UT WOS:A1997XP50100003
PM 9260099
DA 2018-10-19
ER

PT J
AU denDunnen, WFA
   Robinson, PH
   vanWessel, R
   Pennings, AJ
   vanLeeuwen, MBM
   Schakenraad, JM
AF denDunnen, WFA
   Robinson, PH
   vanWessel, R
   Pennings, AJ
   vanLeeuwen, MBM
   Schakenraad, JM
TI Long-term evaluation of degradation and foreign-body reaction of
   subcutaneously implanted poly(DL-lactide-epsilon-caprolactone)
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE poly(DL-lactide-epsilon-caprolactone); degradation; foreign body
   reaction; subcutaneous implant
ID ALIPHATIC POLYESTERS; NERVE REGENERATION; POLY(EPSILON-CAPROLACTONE);
   INVIVO; GUIDE
AB The aim of this study was to evaluate the degradation and foreign-body reaction of poly(DL-lactide-epsilon-caprolactone) (PLA(85)CL(50)) bars. This specific biomaterial is used for the construction of nerve guides, which can be used in the reconstruction of short nerve gaps. Subcutaneously implanted PLA(85)CL(50) bars were harvested after implantation periods ranging from 3 to 12 months and evaluated for the rate of degradation and the degree of foreign-body reaction. It was observed that this copolymer degraded completely within 12 months and that no lactide or epsilon-caprolactone crystals were formed. Furthermore, we conclude that the foreign-body reaction of PLA(85)CL(50) is very mild. These properties make the amorphous copolymer of DL-lactide and epsilon-caprolactone (50:50) suitable for the construction of nerve guides. (C) 1997 John Wiley & Sons, Inc.
C1 UNIV GRONINGEN,BIOMAT RES CTR,NL-9712 KZ GRONINGEN,NETHERLANDS.
   UNIV GRONINGEN,DEPT PLAST & RECONSTRUCT SURG,NL-9713 EZ GRONINGEN,NETHERLANDS.
   UNIV GRONINGEN,DEPT POLYMER CHEM,NL-9747 AG GRONINGEN,NETHERLANDS.
RI den Dunnen, Wilfred/A-4034-2009
CR ALI SAM, 1993, J BIOMED MATER RES, V27, P1409, DOI 10.1002/jbm.820271108
   DENDUNNEN WFA, 1993, J MATER SCI-MATER M, V4, P521, DOI 10.1007/BF00120133
   DENDUNNEN WFA, 1993, MICROSURG, V14, P508, DOI 10.1002/micr.1920140808
   denDunnen WFA, 1996, J BIOMED MATER RES, V31, P105, DOI 10.1002/(SICI)1097-4636(199605)31:1<105::AID-JBM13>3.0.CO;2-M
   DENDUNNEN WFA, 1995, J BIOMED MATER RES, V29, P757, DOI 10.1002/jbm.820290612
   HOLLAND S J, 1986, Journal of Controlled Release, V4, P155, DOI 10.1016/0168-3659(86)90001-5
   LAM KH, 1992, BIOCOMPATIBILITY DEG
   MATLAGA BF, 1976, J BIOMED MATER RES, V10, P391, DOI 10.1002/jbm.820100308
   MERLE M, 1989, MICROSURG, V10, P130, DOI 10.1002/micr.1920100213
   PITT CG, 1981, BIOMATERIALS, V2, P215
   PITT CG, 1981, J APPL POLYM SCI, V26, P3779, DOI 10.1002/app.1981.070261124
   VERT M, 1992, J MATER SCI-MATER M, V3, P432, DOI 10.1007/BF00701240
NR 12
TC 67
Z9 68
U1 1
U2 8
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD SEP 5
PY 1997
VL 36
IS 3
BP 337
EP 346
DI 10.1002/(SICI)1097-4636(19970905)36:3<337::AID-JBM9>3.3.CO;2-8
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA XP501
UT WOS:A1997XP50100009
PM 9260105
DA 2018-10-19
ER

PT J
AU Ishikawa, K
   Miyamoto, Y
   Takechi, M
   Toh, T
   Kon, M
   Nagayama, M
   Asaoka, K
AF Ishikawa, K
   Miyamoto, Y
   Takechi, M
   Toh, T
   Kon, M
   Nagayama, M
   Asaoka, K
TI Non-decay type fast-setting calcium phosphate cement: Hydroxyapatite
   putty containing an increased amount of sodium alginate
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE calcium phosphate cement; non-decay type; putty; sodium alginate;
   hydroxyapatite
ID CLAY
AB A hydroxyapatite [(HAP) Ca-10(PO4)(6)(OH)(2)] putty that behaves like a putty or self-curing resin was made by increasing the amount of sodium alginate in non-decay type fast-setting calcium phosphate cement (nd-FSCPC). nd-FSCPC became viscous as the sodium alginate concentration was increased. The best handling properties were obtained when nd-FSCPC contained 8% sodium alginate in its liquid phase. When a 2-kg glass plate was placed on the paste, HAP putty spread to form an area three times that of FSCPC paste. Thus, HAP putty is expected to be easier to use than FSCPC in the filling of bone defects. HAP putty did not decay; in fact, it set within approximately 20 min when immersed in distilled water immediately after mixing. The wet diametral tensile strength value of HAP putty was approximately 12 MPa after 24 h, the same as that for nd-FSCPC containing 0.5% sodium alginate in its liquid phase, or FSCPC that is free from sodium alginate. The elements constituting set HAP putty were examined using powder X-ray diffraction and found to be predominantly apatitic minerals after 24 h. Since the handling properties of a putty or self-curing resinlike cement are very useful in certain surgical procedures, HAP putty made by increasing the sodium alginate concentration in nd-FSCPC is potentially a valuable new biomaterial for use in plastic and reconstructive surgery, as well as oral and maxillofacial surgery. (C) 1997 John Wiley & Sons, Inc.
C1 UNIV TOKUSHIMA,SCH DENT,DEPT ORAL & MAXILLOFACIAL SURG 1,TOKUSHIMA 770,JAPAN.
RP Ishikawa, K (reprint author), UNIV TOKUSHIMA,DEPT DENT ENGN,3-18-15 KURAMOTO CHO,TOKUSHIMA 770,JAPAN.
CR Brown WE, 1986, CEMENTS RES PROGR, P351
   CHOW LC, 1989, SPECIALTY CEMENTS AD, V179, P3
   DAIGO K, 1985, YAKUGAKU ZASSHI, V105, P171, DOI 10.1248/yakushi1947.105.2_171
   DAIGO K, 1982, YAKUGAKU ZASSHI, V102, P573, DOI 10.1248/yakushi1947.102.6_573
   ISHIKAWA K, 1995, J BIOMED MATER RES, V29, P1537, DOI 10.1002/jbm.820291210
   ISHIKAWA K, 1995, BIOMATERIALS, V16, P527, DOI 10.1016/0142-9612(95)91125-I
   ISHIKAWA K, 1994, DENT MATER, V10, P26, DOI 10.1016/0109-5641(94)90018-3
   Ishikawa K, 1990, Dent Mater J, V9, P58
   ISHIKAWA K, 1995, J MATER SCI-MATER M, V6, P528, DOI 10.1007/BF00151034
   ISHIKAWA K, 1993, JAP J DENT MAT, V12, P222
   MARUYAMA M, 1995, J BIOMED MATER RES, V29, P683, DOI 10.1002/jbm.820290602
   MARUYAMA M, 1995, J BIOMED MATER RES, V29, P329, DOI 10.1002/jbm.820290308
   MARUYAMA M, 1995, J BONE JOINT SURG BR, V77B, P213
   Miyamato Y, 1996, BIOMATERIALS, V17, P1429, DOI 10.1016/0142-9612(96)87286-3
   Takechi M, 1996, J MATER SCI-MATER M, V7, P317, DOI 10.1007/BF00154542
NR 15
TC 91
Z9 97
U1 4
U2 17
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD SEP 5
PY 1997
VL 36
IS 3
BP 393
EP 399
DI 10.1002/(SICI)1097-4636(19970905)36:3<393::AID-JBM14>3.0.CO;2-F
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA XP501
UT WOS:A1997XP50100014
PM 9260110
DA 2018-10-19
ER

PT J
AU Hemmerle, J
   Oncag, A
   Erturk, S
AF Hemmerle, J
   Oncag, A
   Erturk, S
TI Ultrastructural features of the bone response to a plasma-sprayed
   hydroxyapatite coating in sheep
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE hydroxyapatite; hydroxyapatite-coated implants; interface; bone;
   ultrastructure
ID CALCIUM-PHOSPHATE CERAMICS; X-RAY-DIFFRACTION; SYNTHETIC HYDROXYAPATITE;
   HISTOLOGICAL-EVALUATION; ELECTRON-MICROSCOPY; TITANIUM IMPLANTS;
   BIOACTIVE GLASS; METAL IMPLANTS; IN-VITRO; INTERFACE
AB The intentions of this study were to characterize the macrosopic, microscopic, and structural aspects of a plasma-sprayed implant and to thoroughly investigate bone tissue response after its implantation in sheep. Therefore, we used scanning electron microscopy, transmission electron microscopy (TEM), high-resolution TEM, X-ray diffraction, and energy-dispersive X-ray analyses. Assessment of the biomaterial prior to implantation showed a coating with irregular outlines and varying thickness, mainly consisting of hydroxyapatite (HA) covering a rough metallic implant core. Six months after insertion of the HA-coated Ti-6Al-4V implant, neither mechanical failure of the coating-substrate interface nor a significant loss of coating thickness was evident. However, an occasional lack of HA coating and phagocytosis of HA particles were noted. More generally, the implant was surrounded by well-mineralized bone investing the smallest cavities of the plasma-sprayed layer. Newly formed microcrystals with size, shape, and structure similar to those of bone apatite crystals were growing directly at the coating surface. These results suggest that the bone-bonding behavior of the considered grooved implant should provide satisfactory osseointegration and be suitable for fixed prostheses. (C) 1997 John Wiley & Sons, Inc.
C1 EGE UNIV,FAC DENT,DEPT ORAL & MAXILLOFACIAL SURG,IZMIR,TURKEY.
RP Hemmerle, J (reprint author), UNIV STRASBOURG 1,INSERM,U424,11 RUE HUMANN,F-67085 STRASBOURG,FRANCE.
CR Boyde A, 1996, MICROSC RES TECHNIQ, V33, P92
   COOK SD, 1991, CLIN ORTHOP RELAT R, V265, P280
   DACULSI G, 1990, CALCIFIED TISSUE INT, V46, P20, DOI 10.1007/BF02555820
   DACULSI G, 1989, J BIOMED MATER RES, V23, P883, DOI 10.1002/jbm.820230806
   DASARATHY H, 1993, J BIOMED MATER RES, V27, P477, DOI 10.1002/jbm.820270408
   DEBRUIJN JD, 1995, J BIOMED MATER RES, V29, P89, DOI 10.1002/jbm.820290113
   DELANGE GL, 1990, J BIOMED MATER RES, V24, P829, DOI 10.1002/jbm.820240704
   DENISSEN H W, 1991, International Journal of Prosthodontics, V4, P432
   DENISSEN H W, 1990, International Journal of Prosthodontics, V3, P53
   DUCHEYNE P, 1990, BIOMATERIALS, V11, P531
   Dunn M G, 1991, J Long Term Eff Med Implants, V1, P193
   ELLIES LG, 1992, BIOMATERIALS, V13, P313, DOI 10.1016/0142-9612(92)90055-S
   FRANK RM, 1991, J APPL BIOMATER, V2, P243, DOI 10.1002/jab.770020405
   GAO TJ, 1995, BIOMATERIALS, V16, P1175, DOI 10.1016/0142-9612(95)93583-Y
   GARCIA R, 1992, J MATER SCI-MATER M, V3, P154, DOI 10.1007/BF00705285
   GREGOIRE M, 1990, J BIOMED MATER RES, V24, P165, DOI 10.1002/jbm.820240204
   HAYASHI K, 1991, J BIOMED MATER RES, V25, P515, DOI 10.1002/jbm.820250408
   HAYASHI K, 1989, J BIOMED MATER RES, V23, P1247, DOI 10.1002/jbm.820231103
   INADOME T, 1995, J BIOMED MATER RES, V29, P19, DOI 10.1002/jbm.820290104
   JANSEN JA, 1993, J BIOMED MATER RES, V27, P603, DOI 10.1002/jbm.820270507
   JI HX, 1993, BIOMATERIALS, V14, P64, DOI 10.1016/0142-9612(93)90077-F
   KANDORI K, 1995, COLLOID SURFACE B, V5, P81, DOI 10.1016/0927-7765(95)98210-E
   KITSUGI T, 1995, BIOMATERIALS, V16, P1101, DOI 10.1016/0142-9612(95)98907-V
   KLEIN CPAT, 1994, J BIOMED MATER RES, V28, P909, DOI 10.1002/jbm.820280810
   KLEIN CPAT, 1994, J BIOMED MATER RES, V28, P961, DOI 10.1002/jbm.820280815
   KOCH B, 1990, J BIOMED MATER RES, V24, P655, DOI 10.1002/jbm.820240603
   LABAT B, 1995, J BIOMED MATER RES, V29, P1397, DOI 10.1002/jbm.820291111
   MAXIAN SH, 1993, J BIOMED MATER RES, V27, P717, DOI 10.1002/jbm.820270604
   OGILVIE A, 1987, J PERIODONTAL RES, V22, P270, DOI 10.1111/j.1600-0765.1987.tb01585.x
   OGUCHI H, 1995, BIOMATERIALS, V16, P33, DOI 10.1016/0142-9612(95)91093-E
   ONG JL, 1995, J BIOMED MATER RES, V29, P165, DOI 10.1002/jbm.820290205
   OONISHI H, 1991, BIOMATERIALS, V12, P171, DOI 10.1016/0142-9612(91)90196-H
   PIATTELLI A, 1994, J BIOMED MATER RES, V28, P529, DOI 10.1002/jbm.820280502
   Piattelli A, 1993, Int J Oral Maxillofac Implants, V8, P309
   Piattelli A., 1993, INT J ORAL MAXILLOF, V8, P69
   REHMAN I, 1995, J BIOMED MATER RES, V29, P1287, DOI 10.1002/jbm.820291016
   SAVARINO L, 1993, BIOMATERIALS, V14, P900, DOI 10.1016/0142-9612(93)90131-K
   Sousa SR, 1996, BIOMATERIALS, V17, P397, DOI 10.1016/0142-9612(96)89655-4
   TISDEL CL, 1994, J BONE JOINT SURG AM, V76A, P159, DOI 10.2106/00004623-199402000-00001
   TRAUB W, 1989, P NATL ACAD SCI USA, V86, P9822, DOI 10.1073/pnas.86.24.9822
   VROUWENVELDER WCA, 1993, J BIOMED MATER RES, V27, P465, DOI 10.1002/jbm.820270407
   WENG J, 1993, BIOMATERIALS, V14, P578, DOI 10.1016/0142-9612(93)90174-Z
   Yoshinari M, 1991, Bull Tokyo Dent Coll, V32, P147
   YOSHINARI M, 1994, BIOMATERIALS, V15, P529, DOI 10.1016/0142-9612(94)90019-1
NR 44
TC 17
Z9 17
U1 0
U2 1
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD SEP 5
PY 1997
VL 36
IS 3
BP 418
EP 425
DI 10.1002/(SICI)1097-4636(19970905)36:3<418::AID-JBM17>3.3.CO;2-N
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA XP501
UT WOS:A1997XP50100017
PM 9260113
DA 2018-10-19
ER

PT J
AU Vasudev, SC
   Chandy, T
   Sharma, CP
AF Vasudev, SC
   Chandy, T
   Sharma, CP
TI Glutaraldehyde treated bovine pericardium: Changes in calcification due
   to vitamins and platelet inhibitors
SO ARTIFICIAL ORGANS
LA English
DT Article
DE calcification; fibrinogen; vitamins; cellular involvement
ID ARTIFICIAL SURFACE; PROTEIN ADSORPTION; PHOSPHATE; BLOOD; POLYURETHANE;
   BIOMATERIAL; MECHANISMS; PREVENTION; MAGNESIUM; ADHESION
AB Cardiovascular calcification, the formation of calcium phosphate deposits in cardiovascular tissue, is a common endstage phenomenon affecting a wide variety of bioprostheses. The purpose of the present paper is to study the possibility that some antiplatelet drugs (aspirin and persantine) and certain vitamins (vitamin C, vitamin B-6, and vitamin E) and their combinations might prevent the mineralization of glutaraldehyde treated bovine pericardium (GABP) by modifying the pericardial surface. In this experimental protocol, we used Golomb and Wagner's (1991) in vitro model for studying GABP calcification and a diffusion cell with 2 compartments for evaluating the diffusion of calcium across the GAFF. The results showed that a combination of aspirin and vitamins (0.5 mg% aspirin, 1.5 mg% vitamin C, 4 mg% vitamin B-6, and 2 mg% vitamin E) in a metastable calcium phosphate solution not only reduced the transport of calcium ions through GABP, but along with the combinations of 0.5 mg% aspirin and 5 mg% persantine also produced significant reductions in GABP calcification. The exact mechanism of these changes in the calcification of GABP are still unknown. From these in vitro findings, it appears that a combined vitamin therapy with low doses of aspirin may be beneficial for platelet suppression and thereby prevent thrombosis. In addition, the vitamins may modify calcium transport and interfere with the adsorption at the surface, thus reducing GABP calcification. However, an important question that remains unanswered is whether this inhibitory effect would continue if the antiplatelet drugs and vitamins were discontinued. For the answer, more in vivo studies are needed to develop applications.
C1 SREE CHITRA TIRUNAL INST MED SCI & TECHNOL,DIV BIOSURFACE TECHNOL,TRIVANDRUM 695012,KERALA,INDIA.
RI Sharma, Chandra/A-4140-2009
OI Sharma, Chandra/0000-0002-6982-0926
CR Black M. M., 1991, REPLACEMENT CARDIAC, P1
   BUCHANAN M R, 1982, Thrombosis Research, V25, P363, DOI 10.1016/0049-3848(82)90127-X
   CHANDY T, 1994, J APPL BIOMATER, V5, P245, DOI 10.1002/jab.770050310
   CHANDY T, 1994, CLIN MATER, V17, P165, DOI 10.1016/0267-6605(94)90032-9
   Chandy T, 1996, BIOMATERIALS, V17, P577, DOI 10.1016/0142-9612(96)88708-4
   Chandy T, 1996, ARTIF ORGANS, V20, P752, DOI 10.1111/j.1525-1594.1996.tb04536.x
   CHANDY T, 1988, ARTIF ORGANS, V12, P143, DOI 10.1111/j.1525-1594.1988.tb02747.x
   CHANDY T, 1986, PROGR ARTIFICIAL ORG, P969
   CHEN W, 1994, CIRCULATION, V90, P233
   COURTMAN DW, 1994, J BIOMED MATER RES, V28, P655, DOI 10.1002/jbm.820280602
   Golomb G, 1987, J Biomater Appl, V2, P266, DOI 10.1177/088532828700200205
   GOLOMB G, 1991, BIOMATERIALS, V12, P397, DOI 10.1016/0142-9612(91)90008-X
   KIM SW, 1977, J BIOMED MATER RES, V11, P23, DOI 10.1002/jbm.820110104
   LEVY RJ, 1986, AM J PATHOL, V71, P122
   PACKHAM MA, 1984, BLOOD PLATELET FUNCT, P61
   PASQUINO E, 1992, J MATER SCI-MATER M, V3, P272
   PATHAK YV, 1990, BIOMATERIALS, V11, P718, DOI 10.1016/0142-9612(90)90034-N
   ROSANOVA IB, 1993, BIOMATER LIVING SYST, V1, P13
   SCHOEN FJ, 1988, J BIOMED MATER RES-A, V22, P11
   SCHOEN FJ, 1987, J BIOMED MATER RES-A, V21, P91
   SHARMA CP, 1991, ARTIF ORGANS, V15, P498
   SHARMA CP, 1989, ARTIF ORGANS, V13, P219, DOI 10.1111/j.1525-1594.1989.tb02867.x
   SHUTTIL SJ, 1980, J CLIN INVEST, V65, P329
   Thoma R J, 1987, J Biomater Appl, V1, P449
   TUNG MS, 1992, ARCH ORAL BIOL, V37, P585, DOI 10.1016/0003-9969(92)90142-U
   VROMAN L, 1977, ANN NY ACAD SCI, V283, P65, DOI 10.1111/j.1749-6632.1977.tb41753.x
   WEBB CL, 1991, AM J PATHOL, V138, P971
   WOUTERS LHG, 1986, P 2 INT C POL BIOM E
NR 28
TC 7
Z9 7
U1 0
U2 7
PU BLACKWELL SCIENCE INC
PI MALDEN
PA 350 MAIN ST, MALDEN, MA 02148
SN 0160-564X
J9 ARTIF ORGANS
JI Artif. Organs
PD SEP
PY 1997
VL 21
IS 9
BP 1007
EP 1013
PG 7
WC Engineering, Biomedical; Transplantation
SC Engineering; Transplantation
GA XR279
UT WOS:A1997XR27900009
PM 9288872
DA 2018-10-19
ER

PT J
AU Wika, KE
   Muramoto, K
   Harasaki, H
AF Wika, KE
   Muramoto, K
   Harasaki, H
TI Analysis of subcutaneous fluid in rats
SO ASAIO JOURNAL
LA English
DT Article
ID CALCIFICATION; MODEL
AB Subcutaneous implantation in rats is a commonly used model for biomaterial calcification studies. Although this model is frequently used, its components have not been characterized with respect to calcification. Exudate from the subcutaneous spaces of 18 young rats was collected using diffusion chambers. These chambers consisted of polymethyl methacrylate tubes with 0.22 mu m pore filters covering each end allowing fluid, but not cells, to enter the chambers. Glutaraldehyde treated bovine pericardial strips were implanted subcutaneously, inside the chambers and outside the chambers, to test the calcification inducing abilities of the various environments. The animals were killed on postoperative day 10, and the exudate and materials were collected. The exudate was analyzed for ionic calcium, total calcium, inorganic phosphorus, and albumin, and for cells by a differentiated cell smear. The materials were analyzed for calcification by radiography, histology, and atomic absorption. Calcification was present in the materials inside the chambers where no cells were present and in the materials that were not in chambers. The distinct features of the exudate were elevated ionic calcium, a high Ca x P product, and elevated phosphorus.
C1 KUMAMOTO REG MED CTR,KUMAMOTO,JAPAN.
RP Wika, KE (reprint author), CLEVELAND CLIN FDN,DEPT BIOMED ENGN,RES INST,9500 EUCLID AVE,WB3,CLEVELAND,OH 44195, USA.
CR BARNHART GR, 1982, J THORAC CARDIOV SUR, V83, P618
   Dewanjee M K, 1986, ASAIO Trans, V32, P24
   FELIX R, 1978, BIOCHEM J, V170, P681, DOI 10.1042/bj1700681
   FISHBEIN MC, 1982, J THORAC CARDIOV SUR, V83, P602
   Fiske CH, 1925, J BIOL CHEM, V66, P375
   Harasaki H, 1985, Trans Am Soc Artif Intern Organs, V31, P489
   HARASAKI H, 1980, J THORAC CARDIOV SUR, V79, P125
   Harkness J. E., 1983, BIOL MED RABBITS ROD
   LEVY RJ, 1983, AM J CARDIOL, V52, P629, DOI 10.1016/0002-9149(83)90040-1
   LEVY RJ, 1983, AM J PATHOL, V113, P143
   MARCHANT RE, 1984, J BIOMED MATER RES, V18, P1169, DOI 10.1002/jbm.820180917
   PETER T, 1982, SELECTED METHODS CLI, V9, P139
   SCHOEN FJ, 1985, LAB INVEST, V52, P523
   SIGGAARDANDERSE.O, 1981, RADIOMETER, P163
   Tietz N.W, 1986, TXB CLIN CHEM
NR 15
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 1058-2916
J9 ASAIO J
JI Asaio J.
PD SEP-OCT
PY 1997
VL 43
IS 5
BP M405
EP M408
PG 4
WC Engineering, Biomedical; Transplantation
SC Engineering; Transplantation
GA YD658
UT WOS:A1997YD65800009
PM 9360071
DA 2018-10-19
ER

PT J
AU Rudnicka, W
   Sadowska, B
   Ljungh, A
   Rozalska, B
AF Rudnicka, W
   Sadowska, B
   Ljungh, A
   Rozalska, B
TI Specific immune response to staphylococcal antigens during long-lasting
   biomaterial implantation
SO FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY
LA English
DT Article
DE biomaterial-associated infection; staphylococci; proliferative response;
   antibody
ID AUREUS; INFECTIONS; ANTIBODIES; CELL; PROTEIN; MODEL; MICE
AB Biomaterial-associated infections caused by staphylococci are one of the main therapeutic problems in modern medicine. There is no doubt that local disfunction of polymorphonuclear leukocytes and macrophages predisposes to such infections. However, it is not clear how implantation of a foreign body influences the antibacterial immune response. We analyzed some parameters of the specific immune response to staphylococcal antigens, in mice implanted for 3 months with heparinized polyethylene. Three weeks before the evaluation of the immune response, mice (implanted and non-implanted) were infected i.p. with 2x10(7) cells of Staphylococcus aureus Cowan 1. The proliferation of splenocytes was determined on the basis of [H-3]thymidine incorporation in cultures stimulated with staphylococcal lipoteichoic acid, protein A, alpha-toxin, or phytohemagglutinin. Moreover, the level of specific antibodies to staphylococcal antigens was determined in serum samples (ELISA with the antigens lipoteichoic acid, protein A, and alpha-toxin). The data obtained indicate that long-lasting implantation caused evident changes in proliferative activity of lymphocytes and in humoral response to staphylococcal antigens. It enhanced spontaneous and lipoteichoic acid- or alpha-toxin-stimulated proliferation of splenocytes, in vitro. In contrast, heparinized polyethylene-implanted animals showed a significant decrease in the production of anti-protein A IgG2b and anti-alpha-toxin IgG2a and IgG2b.
C1 LUND UNIV,DEPT MED MICROBIOL,S-22362 LUND,SWEDEN.
RP Rudnicka, W (reprint author), UNIV LODZ,INST MICROBIOL & IMMUNOL,DEPT INFECT BIOL,BANACHA 12,PL-90237 LODZ,POLAND.
CR Averbakh Michael M. Jr., 1995, Immunology and Infectious Diseases (Oxford), V5, P250
   BHAKDI S, 1989, INFECT IMMUN, V57, P3214
   BREDIUS RGM, 1992, INFECT IMMUN, V60, P4838
   BREWER JM, 1994, CLIN EXP IMMUNOL, V97, P164
   CONSTANT P, 1994, SCIENCE, V264, P267, DOI 10.1126/science.8146660
   GILBERT FB, 1994, VACCINE, V12, P369, DOI 10.1016/0264-410X(94)90103-1
   GREENBERG DP, 1990, J CLIN MICROBIOL, V28, P458
   GREENBERG DP, 1989, INFECT IMMUN, V57, P1113
   KAPLAN SS, 1990, ASAIO T, V36, pMI172
   LAMBERT PA, 1992, FEMS MICROBIOL LETT, V100, P67, DOI 10.1016/0378-1097(92)90189-U
   Lee JC, 1996, TRENDS MICROBIOL, V4, P162, DOI 10.1016/0966-842X(96)10021-4
   Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2
   PAULSSON M, 1993, BIOMATERIALS, V14, P845, DOI 10.1016/0142-9612(93)90006-N
   Rozalska B, 1996, IMMUNOL LETT, V49, P99, DOI 10.1016/0165-2478(95)02489-1
   Rozalska B, 1996, MICROBIOL IMMUNOL, V40, P931, DOI 10.1111/j.1348-0421.1996.tb01162.x
   ROZALSKA B, 1995, MICROBIOL IMMUNOL, V39, P443
   ROZALSKA B, 1995, FEMS IMMUNOL MED MIC, V11, P307, DOI 10.1111/j.1574-695X.1995.tb00161.x
   Rozalska Barbara, 1995, Acta Microbiologica Polonica, V44, P243
   RYDING U, 1992, FEMS MICROBIOL IMMUN, V89, P105, DOI 10.1111/j.1574-6968.1992.tb04976.x
   Shparago N, 1996, INT IMMUNOL, V8, P781, DOI 10.1093/intimm/8.5.781
   SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404
   SNAPPER CM, 1993, IMMUNOL TODAY, V14, P15, DOI 10.1016/0167-5699(93)90318-F
   Soderquist B, 1993, SERODIAGN IMMUNOTHER, V5, P139
   SUTRA L, 1994, J MED MICROBIOL, V40, P79, DOI 10.1099/00222615-40-2-79
   WADSTROM T, 1990, PATHOGENESIS WOUND B
NR 25
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928-8244
J9 FEMS IMMUNOL MED MIC
JI FEMS Immunol. Med. Microbiol.
PD SEP
PY 1997
VL 19
IS 1
BP 7
EP 14
DI 10.1016/S0928-8244(97)00045-X
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA XY265
UT WOS:A1997XY26500002
PM 9322064
OA Bronze
DA 2018-10-19
ER

PT J
AU Rosenzweig, M
   Pykett, M
   Marks, DF
   Johnson, RP
AF Rosenzweig, M
   Pykett, M
   Marks, DF
   Johnson, RP
TI Enhanced maintenance and retroviral transduction of primitive
   hematopoietic progenitor cells using a novel three-dimensional culture
   system
SO GENE THERAPY
LA English
DT Article
DE stem cell gene therapy; hematopoietic progenitor culture; retroviral
   transduction; three-dimensional culture device
ID LONG-TERM-CULTURE; VITRO T-LYMPHOPOIESIS; NYLON MESH TEMPLATES;
   IN-VITRO; NONHUMAN-PRIMATES; INITIATING CELLS; GROWTH-FACTORS; CD34(+)
   CELLS; SELF-RENEWAL; MARROW-CELLS
AB Current techniques for the in vitro maintenance of hematopoietic stem cells often lead to loss of pluripotency. Overcoming the technical difficulties that result in alterations in stem cells in vitro has important implications for areas of basic science and clinical medicine such as cell expansion, bone marrow transplantation and gene therapy. Recent insights into hematopoietic stem cell biology have demonstrated that the three-dimensional architecture of the culture environment may influence the maintenance of stem cell pluripotency in vitro. An intriguing hypothesis is that the utilization of three-dimensional culture systems may improve the maintenance and manipulation of these cells in vitro. We report that a novel, three-dimensional, tantalum-coated porous biomaterial (TCPB) may be employed effectively as a hematopoietic progenitor cell culture device that offers distinct advantages over conventional culture systems. Specifically, we demonstrate that the use of TCPB for culturing hematopoietic progenitor cells in the absence of exogenous cytokines results in enhanced hematopoietic progenitor cell survival, improved maintenance of the immature CD34(+)/38(-) phenotype, and improved retroviral transduction of CD34(+) cells and long-term culture initiating cells (LTCIC), without compromising multipotency, as compared with cultures in plastic dishes or bone marrow stroma. These findings suggest that this three-dimensional culture system may be useful in advancing the in vitro culture and transduction of hematopoietic stem and progenitor cells.
C1 CYTOMATRIX INC, CAMBRIDGE, MA USA.
   MASSACHUSETTS GEN HOSP, AIDS RES CTR, CHARLESTOWN, MA USA.
   MASSACHUSETTS GEN HOSP, INFECT DIS UNIT, CHARLESTOWN, MA USA.
RP Rosenzweig, M (reprint author), HARVARD UNIV, SCH MED, NEW ENGLAND REG PRIMATE RES CTR, DIV IMMUNOL, 1 PINE HILL DR, SOUTHBOROUGH, MA 01772 USA.
FU NCRR NIH HHS [RR00168]; NIAID NIH HHS [AI36550]
CR BACKX B, 1992, BLOOD, V80, P1213
   BAINES P, 1994, BRIT J HAEMATOL, V88, P472, DOI 10.1111/j.1365-2141.1994.tb05062.x
   Donahue RE, 1996, BLOOD, V87, P1644
   GORE SD, 1995, EXP HEMATOL, V23, P413
   Hanenberg H, 1996, NAT MED, V2, P876, DOI 10.1038/nm0896-876
   HIRAYAMA F, 1994, BLOOD CELLS, V20, P341
   JACOBSEN SEW, 1995, J EXP MED, V181, P1357, DOI 10.1084/jem.181.4.1357
   KAWAI T, 1994, TRANSPLANT P, V26, P1845
   LI CL, 1994, BLOOD, V84, P408
   MAYANI H, 1993, BLOOD, V82, P2664
   MIGLIACCIO AR, 1994, BLOOD CELLS, V20, P424
   MILLER AD, 1991, J VIROL, V65, P2220
   MOORE KA, 1992, BLOOD, V79, P1393
   MORITZ T, 1994, J CLIN INVEST, V93, P1451, DOI 10.1172/JCI117122
   NAUGHTON B, 1987, J MED, V18, P219
   NAUGHTON BA, 1990, PROG CLIN BIOL RES, V333, P435
   NAUGHTON BA, 1991, J BIOMECH ENG-T ASME, V113, P171, DOI 10.1115/1.2891230
   NAUGHTON BA, 1989, ANN NY ACAD SCI, V554, P125, DOI 10.1111/j.1749-6632.1989.tb22415.x
   NAUGHTON BA, 1992, SOMAT CELL MOLEC GEN, V18, P451, DOI 10.1007/BF01233085
   PETERS SO, 1995, EXP HEMATOL, V23, P461
   Peters SO, 1996, BLOOD, V87, P30
   Petzer AL, 1996, P NATL ACAD SCI USA, V93, P1470, DOI 10.1073/pnas.93.4.1470
   QUESENBERRY PJ, 1994, BLOOD CELLS, V20, P97
   Rosenzweig M, 1996, BLOOD, V87, P4040
   Rosenzweig M, 1997, J VIROL, V71, P2740
   Rosenzweig M, 1996, J MED PRIMATOL, V25, P192, DOI 10.1111/j.1600-0684.1996.tb00016.x
   ROSENZWEIG M, 1996, UNPUB CHARACTERIZATI
   Sutherland Heather J., 1994, P139
   Taichman RS, 1996, BLOOD, V87, P518
   Urashima Mitsuyoshi, 1995, Acta Paediatrica Japonica, V37, P160
   VANBEUSECHEM VW, 1995, GENE THER, V2, P245
   vanBeusechem VW, 1996, HUM GENE THER, V7, P1649, DOI 10.1089/hum.1996.7.14-1649
   VERFAILLIE CM, 1993, BLOOD, V82, P2045
   XU LC, 1995, P NATL ACAD SCI USA, V92, P4372, DOI 10.1073/pnas.92.10.4372
   Young JC, 1996, BLOOD, V87, P545
NR 35
TC 32
Z9 32
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969-7128
EI 1476-5462
J9 GENE THER
JI Gene Ther.
PD SEP
PY 1997
VL 4
IS 9
BP 928
EP 936
DI 10.1038/sj.gt.3300480
PG 9
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Medicine, Research & Experimental
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Research & Experimental Medicine
GA XW192
UT WOS:A1997XW19200007
PM 9349429
OA Bronze
DA 2018-10-19
ER

PT J
AU Carr, AB
   Beals, DW
   Larsen, PE
AF Carr, AB
   Beals, DW
   Larsen, PE
TI Reverse-torque failure of screw-shaped implants in baboons after 6
   months of healing
SO INTERNATIONAL JOURNAL OF ORAL & MAXILLOFACIAL IMPLANTS
LA English
DT Article
DE commercially pure titanium; dental implants; reverse-torque failure;
   titanium plasma-sprayed implants; titanium-6Al-4V
ID POROUS COATED IMPLANTS
AB Mechanical testing of the implant-tissue interface has been the focus of numerous investigations concerning the anchorage capacity of implants. The purpose of this study was to measure reverse-torque failure after 6 months of healing for three different biomaterials in the posterior jaws of four adult female baboons. The animals had all of their posterior teeth surgically extracted and, following 10 weeks of healing, 7 implants were placed in each quadrant. The biomaterials included titanium plasma-sprayed surfaces, titanium-aluminum-vanadium surfaces (both 3.8 mm x 10 mm), and a commercially pure titanium surface (3.75 mm x 10 mm). After 6 months, torque data were collected using a counterclockwise computerized torque driver and were analyzed by repeated measures analysis of variance for differences related to biomaterial, jaw and biomaterial/jaw. Post-hoc Tukey Kramer analysis was also performed for within-group differences (alpha = .05 level). The biomaterial comparison revealed a significant difference between the titanium plasma-sprayed and the combined commercially pure titanium/titanium-aluminum-vanadium groups (analysis of variance, Tukey Kramer, P < .05). The jaw comparison showed no significant difference, although the data suggest that higher forces may be required for mandibular torsional failure. The biomaterial/jaw comparison revealed that jaw differences for the mean values of commercially pure titanium and titanium-aluminum-vanadium implants were greater than jaw differences for mean values of titanium plasma-sprayed implants, although these differences were not statistically significant. Because of the lack of correlation between single-cycle biomechanical tests and clinical performance, it is necessary to be selective in assigning usefulness to data of this type.
C1 OHIO STATE UNIV,COLL DENT,SECT ORAL & MAXILLOFACIAL SURG,COLUMBUS,OH 43210.
   OHIO STATE UNIV,COLL DENT,SECT ORAL & MAXILLOFACIAL SURG,COLUMBUS,OH 43210.
RP Carr, AB (reprint author), OHIO STATE UNIV,COLL DENT,SECT RESTORAT DENT PROSTHODONT & ENDODONT DENT,305 W 12TH AVE,COLUMBUS,OH 43210, USA.
OI Carr, Alan/0000-0002-7944-4143
CR ADELL R, 1990, International Journal of Oral and Maxillofacial Implants, V5, P347
   Carlsson L, 1988, Int J Oral Maxillofac Implants, V3, P21
   CARLSSON LV, 1991, INT J ORAL MAXILLOF, V4, P199
   Carr A B, 1995, Int J Oral Maxillofac Implants, V10, P167
   Cook S D, 1987, Int J Oral Maxillofac Implants, V2, P15
   COOK SD, 1992, J BIOMED MATER RES, V26, P989, DOI 10.1002/jbm.820260803
   DUCHEYNE P, 1980, J BIOMED MATER RES, V14, P225, DOI 10.1002/jbm.820140305
   GERNER BT, 1988, SCAND J DENT RES, V96, P143
   HONG L, 1992, Journal of Biomedical Materials Research, V26, P7, DOI 10.1002/jbm.820260103
   Johansson C, 1987, Int J Oral Maxillofac Implants, V2, P69
   JOHANSSON C B, 1991, International Journal of Oral and Maxillofacial Implants, V6, P437
   Johansson CB, 1991, CLIN ORAL IMPLAN RES, V2, P24, DOI 10.1034/j.1600-0501.1991.020103.x
   KRAUT R A, 1991, International Journal of Oral and Maxillofacial Implants, V6, P187
   LeGeros R.Z., 1993, J BONE MINER RES, V8, P583
   MARTIN RB, 1989, STRUCTURE FUNCTION A, P75
   NIKI M, 1992, BONE BIOMATERIAL INT, P173
   SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, pCH4
   SENNERBY L, 1992, International Journal of Oral and Maxillofacial Implants, V7, P62
   SOBALLE K, 1990, ACTA ORTHOP SCAND, V61, P299, DOI 10.3109/17453679008993521
   Sullivan D Y, 1996, Int J Oral Maxillofac Implants, V11, P179
   TAYLOR JL, 1992, TISSUE INTEGRATION IN ORAL, ORTHOPEDIC, AND MAXILLOFACIAL RECONSTRUCTION, P125
   Tjellstrom A, 1988, Int J Oral Maxillofac Implants, V3, P287
   Ueda M, 1991, Int J Oral Maxillofac Implants, V6, P442
NR 23
TC 18
Z9 19
U1 1
U2 4
PU QUINTESSENCE PUBL CO INC
PI CAROL STREAM
PA 551 KIMBERLY DR, CAROL STREAM, IL 60188-1881
SN 0882-2786
J9 INT J ORAL MAX IMPL
JI Int. J. Oral Maxillofac. Implants
PD SEP-OCT
PY 1997
VL 12
IS 5
BP 598
EP 603
PG 6
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA YA923
UT WOS:A1997YA92300003
PM 9337019
DA 2018-10-19
ER

PT J
AU Wang, W
   Ferguson, DJP
   Quinn, JMW
   Simpson, AHRW
   Athanasou, NA
AF Wang, W
   Ferguson, DJP
   Quinn, JMW
   Simpson, AHRW
   Athanasou, NA
TI Biomaterial particle phagocytosis by bone-resorbing osteoclasts
SO JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME
LA English
DT Article
ID INFLAMMATORY RESPONSE; HIP-REPLACEMENT; GIANT-CELLS; RESORPTION; DEBRIS;
   ARTHROPLASTY; OSTEOLYSIS
AB Abundant implant-derived biomaterial wear particles are generated in aseptic loosening and are deposited in periprosthetic tissues in which they are phagocytosed by mononuclear and multinucleated macrophage-like cells. It has been stated that the multinucleated cells which contain wear particles are not bone-resorbing osteoclasts. To investigate the validity of this claim we isolated human osteoclasts from giant-cell tumours of bone and rat osteoclasts from long bones. These were cultured on glass coverslips and on cortical bone slices in the presence of particles of latex, PMMA and titanium. Osteoclast phagocytosis of these particle types was shown by light microscopy, energy-dispersive X-ray analysis and SEM. Giant cells containing phagocytosed particles were seen to be associated with the formation of resorption lacunae. Osteoclasts containing particles were also calcitonin-receptor-positive and showed an inhibitory response to calcitonin.
   Our findings demonstrate that osteoclasts are capable of phagocytosing particles of a wide range of size, including particles of polymeric and metallic biomaterials found in periprosthetic tissues, and that after particle phagocytosis, they remain fully functional, hormone-responsive, bone-resorbing cells.
C1 NUFFIELD ORTHOPAED CTR,OXFORD OX3 7LD,ENGLAND.
RI Simpson, Alasdair/F-1887-2013
OI Simpson, Alasdair/0000-0001-7793-642X; Ferguson,
   David/0000-0001-5045-819X
CR AMSTUTZ HC, 1992, CLIN ORTHOP RELAT R, V276, P7
   Athanasou NA, 1996, J BONE JOINT SURG AM, V78A, P1096, DOI 10.2106/00004623-199607000-00016
   BURGER EH, 1982, J EXP MED, V156, P1604, DOI 10.1084/jem.156.6.1604
   CHAMBERS TJ, 1978, J PATHOL, V126, P125, DOI 10.1002/path.1711260302
   CHAMBERS TJ, 1984, J CELL SCI, V66, P383
   CHAMBERS TJ, 1982, J PATHOL, V136, P27, DOI 10.1002/path.1711360104
   CHAMBERS TJ, 1977, J PATHOL, V122, P71, DOI 10.1002/path.1711220204
   CHAMBERS TJ, 1979, J PATHOL, V127, P55, DOI 10.1002/path.1711270202
   CHAMBERS TJ, 1985, J PATHOL, V145, P297, DOI 10.1002/path.1711450403
   CHAMBERS TJ, 1980, CLIN ORTHOP RELAT R, V151, P283
   FOREST M, 1991, PATHOL RES PRACT, V187, P963, DOI 10.1016/S0344-0338(11)81068-X
   GELB H, 1994, J ORTHOP RES, V12, P83, DOI 10.1002/jor.1100120111
   GOTHLIN G, 1976, CLIN ORTHOP RELAT R, V120, P201
   HARRIS WH, 1994, ACTA ORTHOP SCAND, V65, P113, DOI 10.3109/17453679408993734
   HARRIS WH, 1976, J BONE JOINT SURG AM, V58, P612, DOI 10.2106/00004623-197658050-00005
   KADOYA Y, 1994, BONE MINER, V27, P85, DOI 10.1016/S0169-6009(08)80211-5
   LAZARUS MD, 1994, J ORTHOPAED RES, V12, P532, DOI 10.1002/jor.1100120410
   LENNOX DW, 1987, CLIN ORTHOP RELAT R, V225, P171
   MALONEY WJ, 1995, J BONE JOINT SURG AM, V77, P1448, DOI 10.2106/00004623-199509000-00022
   MUNDY GR, 1978, NATURE, V275, P132, DOI 10.1038/275132a0
   NICHOLSON GC, 1986, J CLIN INVEST, V78, P355, DOI 10.1172/JCI112584
   *NIH, 1994, NIH CONSENSUS STATE, V12, P1
   Pandey R, 1996, ANN RHEUM DIS, V55, P388, DOI 10.1136/ard.55.6.388
   PAZZAGLIA UE, 1987, ARCH ORTHOP TRAUM SU, V106, P209, DOI 10.1007/BF00450457
   REVELL PA, 1982, BONE JOINT DISEASE, P73
   Sabokbar A, 1997, J BONE JOINT SURG BR, V79B, P129, DOI 10.1302/0301-620X.79B1.6966
   SANTAVIRTA S, 1990, J BONE JOINT SURG AM, V72A, P252, DOI 10.2106/00004623-199072020-00014
   SCHMALZRIED TP, 1992, J BONE JOINT SURG AM, V74A, P849, DOI 10.2106/00004623-199274060-00006
   STATHAM PJ, 1979, MIKROCHIM ACTA     S, V8, P229
   VANFURTH R, 1980, MONONUCLEAR PHAGOCYT, P1
   Willert HG, 1990, CLIN ORTHOPAEDICS, V258, P95
   WILLERT HG, 1990, CLIN ORTHOP RELAT R, V258, P108
   WRIGHT T, 1995, IMPLANT WEAR FUTURE
   Zambonin Zallone A, 1984, J Cell Sci, V66, P335
NR 34
TC 72
Z9 72
U1 0
U2 2
PU BRITISH EDITORIAL SOC BONE JOINT SURGERY
PI LONDON
PA 22 BUCKINGHAM STREET, LONDON, ENGLAND WC2N 6ET
SN 0301-620X
J9 J BONE JOINT SURG BR
JI J. Bone Joint Surg.-Br. Vol.
PD SEP
PY 1997
VL 79B
IS 5
BP 849
EP 856
DI 10.1302/0301-620X.79B5.7780
PG 8
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA XY444
UT WOS:A1997XY44400033
PM 9331049
DA 2018-10-19
ER

PT J
AU Zilla, P
   Zhang, YX
   Human, P
   Koen, W
   vonOppell, U
AF Zilla, P
   Zhang, YX
   Human, P
   Koen, W
   vonOppell, U
TI Improved ultrastructural preservation of bioprosthetic tissue
SO JOURNAL OF HEART VALVE DISEASE
LA English
DT Article; Proceedings Paper
CT VII International Symposium on Cardiac Bioprostheses
CY JUN 13-15, 1997
CL BARCELONA, SPAIN
ID BOVINE PERICARDIUM; CARDIAC VALVES; CALCIFICATION; GLUTARALDEHYDE;
   PROTEOGLYCANS; BIOMATERIAL; INHIBITION; INVITRO
AB Background and aims of the study: Poor ultrastructural tissue preservation of bioprosthetic heart valves is associated with a higher propensity for calcification, In spite of this realization, commercial valve fixation remains suboptimal.
   Methods: In an attempt to maintain tissue integrity through improved cross-linking procedures, transmission electron microscopy and a 21-point damage score were applied to assess the ultrastructural preservation of aortic wall tissue - the main component of contemporary aortic valve bioprostheses. An ideal glutaraldehyde (GA) concentration was assessed by immediate tissue fixation at 4 degrees C comparing 0.2%, 0.5%, 0.65%, 1.0%, 2.0%, 3.0% and 4.0% GA in phosphate-buffered saline (PBS). Subsequently, an optimal concentration of 3.0% GA was used to determine the effect of fixation temperature (4 degrees, 22 degrees and 37 degrees C). Finally, the superior glutaraldehyde concentration (3.0%) and cross-linking temperature (4 degrees C) were used to assess tolerance towards delayed fixation.
   Results: When different GA concentrations were used almost identical damage scores of 6.3 and 5.8 were found for 0.2% and 0.65% fixation. The first significant improvement was found at a concentration of 1.0% (score 3.3; p <0.01) followed by a further improvement at 3.0% (score 2.6; p = 0.05). The optimal fixation temperature was 4 degrees C (3.7) with the worst results obtained at room temperature (scope 9.2; p <0.03). When fixation was delayed, the mast significant damage occurred during the initial 30 minn after slaughter (from 2.3 to 7.4; p <0.02) followed by another significant deterioration between 4 and 16 h (from 5.6 to 9.7; p <0.02).
   Conclusions: In summary, the prerequisites for an ideal ultrastructural preservation of bioprosthetic aortic wall tissue are immediate fixation (within 30 min), high GA concentrations (>1.0%) and cold-temperature fixation (4 degrees C).
RP Zilla, P (reprint author), UNIV CAPE TOWN,SCH MED,DEPT CARDIOTHORAC SURG,CHRISTIAN BARNARD BLDG,ANZIO RD,OBSERVATORY,CAPE TOWN,SOUTH AFRICA.
CR ANDERSON PJ, 1967, J HISTOCHEM CYTOCHEM, V15, P652, DOI 10.1177/15.11.652
   BLUMENTHAL NC, 1979, CALCIFIED TISSUE INT, V27, P75, DOI 10.1007/BF02441164
   BONE Q, 1971, J CELL BIOL, V49, P571, DOI 10.1083/jcb.49.3.571
   BULL C, 1987, J THORAC CARDIOV SUR, V94, P12
   CAMILLERI JP, 1982, ARCH PATHOL LAB MED, V106, P490
   CHAMBERS RW, 1968, ARCH PATHOL, V85, P18
   CHEN WL, 1994, CIRCULATION, V90, P323, DOI 10.1161/01.CIR.90.1.323
   COURTMAN DW, 1994, J BIOMED MATER RES, V28, P655, DOI 10.1002/jbm.820280602
   DAHM M, 1990, J THORAC CARDIOV SUR, V99, P1082
   ELBERS PF, 1966, BIOCHIM BIOPHYS ACTA, V112, P318, DOI 10.1016/0926-6585(66)90330-X
   FERRANS VJ, 1978, AM J CARDIOL, V41, P1159, DOI 10.1016/0002-9149(78)90873-1
   GIRARDOT JM, 1990, Patent No. 4976733
   GRIMM M, 1991, J THORAC CARDIOV SUR, V102, P195
   GROSS C, 1995, ANN THORAC SURG, V60, P418
   HAYAT MA, 1981, FIXATION ELECT MICRO, P67
   Hughes H, 1994, J Heart Valve Dis, V3, P105
   Jayakrishnan A, 1996, BIOMATERIALS, V17, P471, DOI 10.1016/0142-9612(96)82721-9
   KETHARNATHAN V, 1980, ARCH SURG-CHICAGO, V115, P967
   LAWFORD PV, 1995, CARD SCI TECHN C AAM
   LEVY RJ, 1995, J BIOMED MATER RES, V29, P217, DOI 10.1002/jbm.820290212
   MARANTO AR, 1988, CIRC RES, V63, P844, DOI 10.1161/01.RES.63.4.844
   MARANTO AR, 1988, J BIOMED MATER RES, V22, P819, DOI 10.1002/jbm.820220905
   MITCHELL RN, 1995, ANN THORAC SURG, V60, pS108, DOI 10.1016/0003-4975(95)00258-M
   Nimni M E, 1988, J Card Surg, V3, P523, DOI 10.1111/j.1540-8191.1988.tb00446.x
   NIMNI ME, 1987, J BIOMED MATER RES, V21, P741, DOI 10.1002/jbm.820210606
   SCHOEN FJ, 1986, AM J PATHOL, V123, P134
   SCHOEN FJ, 1994, J THORAC CARDIOV SUR, V108, P880
   SEIFTER E, Patent No. 5476516
   Simionescu A, 1996, ASAIO J, V42, pM561, DOI 10.1097/00002480-199609000-00049
   Sung HW, 1993, ASAIO J, V39, P532
   VALENTE M, 1985, AM J PATHOL, V119, P12
   VALENTE M, 1983, CHEST, V83, P607, DOI 10.1378/chest.83.4.607
   WEBB CL, 1992, AM J PATHOL, V141, P487
   WEBB CL, 1988, ANN THORAC SURG, V46, P309, DOI 10.1016/S0003-4975(10)65932-2
   WIGHT TN, 1975, J CELL BIOL, V67, P660, DOI 10.1083/jcb.67.3.660
   Zilla P, 1997, J HEART VALVE DIS, V6, P510
   ZILLA P, 1997, IN PRESS ANN THORAC
NR 37
TC 12
Z9 12
U1 0
U2 1
PU I C R PUBLISHERS
PI NORTHWOOD
PA CRISPIN HOUSE, 12/A SOUTH APPROACH, MOOR PARK, NORTHWOOD, ENGLAND HA6
   2ET
SN 0966-8519
J9 J HEART VALVE DIS
JI J. Heart Valve Dis.
PD SEP
PY 1997
VL 6
IS 5
BP 492
EP 501
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA XW538
UT WOS:A1997XW53800008
PM 9330171
DA 2018-10-19
ER

PT J
AU Zilla, P
   Fullard, L
   Trescony, P
   Meinhart, J
   Bezuidenhout, D
   Gorlitzer, M
   Human, P
   vonOppell, U
AF Zilla, P
   Fullard, L
   Trescony, P
   Meinhart, J
   Bezuidenhout, D
   Gorlitzer, M
   Human, P
   vonOppell, U
TI Glutaraldehyde detoxification of aortic wall tissue: A promising
   perspective for emerging bioprosthetic valve concepts
SO JOURNAL OF HEART VALVE DISEASE
LA English
DT Article; Proceedings Paper
CT VII International Symposium on Cardiac Bioprostheses
CY JUN 13-15, 1997
CL BARCELONA, SPAIN
ID GLUTAMIC ACID TREATMENT; BOVINE PERICARDIUM; HEART-VALVES; CROSS-LINKS;
   CALCIFICATION; COLLAGEN; INVITRO; ENDOTHELIALIZATION; BIOCOMPATIBILITY;
   BIOMATERIAL
AB Background cmd aims of the study: Due to its superb crosslinking activity, glutaraldehyde (GA) is still the most widely used fixative for bioprosthetic heart valves. At the same time, however, GA is also believed to be partly responsible for tissue calcification and the lack of surface re-endothelialization, both of which may contribute to valve degeneration. Although excess GA has previously been extracted from thin leaflet tissue, this treatment proved insufficient for the detoxification of thick aortic wall tissue of stentless valves or root prostheses.
   Methods: In order to Establish a detoxification procedure which thoroughly extracts biologically active GA from aortic wall tissue, we used a highly sensitive bioassay where endothelial cells were seeded onto glutaraldehyde-fixed aortic wall discs following various detoxification procedures. Absolute cell numbers and morphologic shape were correlated with shrinkage temperature and shrinkage extent of the tissue to determine the potential of the treatments to reverse crosslinks. To optimize treatment conditions, pH (3.2 versus 4.5), temperature (22 degrees C versus 37 degrees C) and incubation time (48 h versus one week) were varied. In order to identify an optimal detoxification agent, 12 different amino-reagents from four chemical groups were compared: low pKa aromatic amines, amino acids, low pKa N-heterocyclic compounds and amino sugars.
   Results: Amines-reagent treatment required warm temperature (37 degrees C), prolonged reaction time (one week) and a pH of 4.5 to achieve long-term cell growth on glutaraldehyde-fixed aortic wall. All 12 amino-reagents were able to detoxify aortic tissue satisfactorily; and all mildly reversed crosslinks, although there were differences between candidates. When summarized data were ranked correlating cell growth and quality with shrinkage temperature and shrinkage extent, seven reagents had a rank sum above the overall mean value, and five below with statistically significant differences between candidates. The additional stabilization of the detoxification reaction through boronhydride-reduction had no further effect on tissue biocompatibility and crosslinks.
   Conclusions: Efficient detoxification of thick aortic wall tissue is possible if a one-week incubation in an acetic acid buffer-based amino-reagent is carried out at 37 degrees C.
C1 MEDTRONIC INC,MINNEAPOLIS,MN.
   CITY HOSP VIENNA LAINZ,DEPT SURG,VIENNA,AUSTRIA.
RP Zilla, P (reprint author), UNIV CAPE TOWN,SCH MED,DEPT CARDIOTHORAC SURG,ANZIO RD,ZA-7925 OBSERVATORY,CAPE TOWN,SOUTH AFRICA.
RI Bezuidenhout, Deon/B-8656-2009
OI Bezuidenhout, Deon/0000-0001-8052-7491
CR BENGTSSON L, 1993, EUR J CARDIO-THORAC, V7, P393, DOI 10.1016/1010-7940(93)90001-R
   BROOM ND, 1979, THORAX, V34, P166, DOI 10.1136/thx.34.2.166
   CHEN WL, 1994, CIRCULATION, V90, P323, DOI 10.1161/01.CIR.90.1.323
   COURTMAN DW, 1994, J BIOMED MATER RES, V28, P655, DOI 10.1002/jbm.820280602
   DAHM M, 1990, J THORAC CARDIOV SUR, V99, P1082
   DAVID TE, 1990, J THORAC CARDIOV SUR, V99, P113
   DEWANJEE MK, 1986, T AM SOC ART INT ORG, V32, P24
   GOLOMB G, 1987, AM J PATHOL, V127, P122
   GRABENWOGER M, 1992, J BIOMED MATER RES, V26, P1231, DOI 10.1002/jbm.820260912
   GRIMM M, 1991, J THORAC CARDIOV SUR, V102, P195
   GRIMM M, 1992, J CARDIAC SURG, V7, P58, DOI 10.1111/j.1540-8191.1992.tb00775.x
   HOFFMAN D, 1992, CIRCULATION, V86, P75
   HUANGLEE LLH, 1990, J BIOMED MATER RES, V24, P1185, DOI 10.1002/jbm.820240905
   Hughes H, 1994, J Heart Valve Dis, V3, P105
   Hughes Rod J., 1994, Journal of Sleep Research, V3, P111
   Jayakrishnan A, 1996, BIOMATERIALS, V17, P471, DOI 10.1016/0142-9612(96)82721-9
   KORN AH, 1972, J MOL BIOL, V65, P525, DOI 10.1016/0022-2836(72)90206-9
   Leukauf C, 1993, J Heart Valve Dis, V2, P230
   LEVY RJ, 1983, AM J PATHOL, V113, P143
   MONSAN P, 1975, BIOCHIMIE, V57, P1281
   Nimni M E, 1988, J Card Surg, V3, P523, DOI 10.1111/j.1540-8191.1988.tb00446.x
   NIMNI ME, 1987, J BIOMED MATER RES, V21, P741, DOI 10.1002/jbm.820210606
   SCHROETER D, 1984, J ELECTRON MICR TECH, V1, P219, DOI 10.1002/jemt.1060010302
   SHERMAN FS, 1984, T AM SOC ART INT ORG, V30, P577
   SPEER DP, 1980, J BIOMED MATER RES, V14, P753, DOI 10.1002/jbm.820140607
   TOMIMATSU U, 1971, J COLLOID INTERF SCI, V31, P51
   VINCENTELLI A, 1997, 7 INT S CARD BIOPR S, P121
   WADE LG, 1995, ORGANIC CHEM, P839
   WEBB CL, 1988, ANN THORAC SURG, V46, P309, DOI 10.1016/S0003-4975(10)65932-2
   WESTABY S, 1995, ANN THORAC SURG, V60, pS422, DOI 10.1016/0003-4975(95)00278-S
   WIEBE D, 1988, SURGERY, V104, P26
   Zilla P, 1997, J HEART VALVE DIS, V6, P502
   Zilla P, 1997, J HEART VALVE DIS, V6, P492
   ZILLA P, 1989, SURGERY, V105, P515
   ZILLA P, 1990, J VASC SURG, V12, P180, DOI 10.1067/mva.1990.20844
NR 35
TC 39
Z9 41
U1 1
U2 3
PU I C R PUBLISHERS
PI NORTHWOOD
PA CRISPIN HOUSE, 12/A SOUTH APPROACH, MOOR PARK, NORTHWOOD, ENGLAND HA6
   2ET
SN 0966-8519
J9 J HEART VALVE DIS
JI J. Heart Valve Dis.
PD SEP
PY 1997
VL 6
IS 5
BP 510
EP 520
PG 11
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA XW538
UT WOS:A1997XW53800010
PM 9330173
DA 2018-10-19
ER

PT J
AU Knabe, C
   GrosseSiestrup, C
   Hunder, A
   Ziemann, A
AF Knabe, C
   GrosseSiestrup, C
   Hunder, A
   Ziemann, A
TI A computer-assisted in-vitro biomaterial test for percutaneous devices
   using human keratinocyte cultures
SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE
LA English
DT Article
ID CELLS; LINE
AB The aim of this study was to assess the suitability of a computer-assisted in vitro test system to evaluate candidate biomaterials used for percutaneous devices. Silicone rubber (Silastic(TM)) and five different polymers from the Eurobiomat concerted action, polyetherurethane, polyvinylchloride with plasticizer, di-ethylhexylphthalate (PVC-DEHP), polyvinylchloride with plasticizer, tri-ethylhexyltrimellitate (PVC-TEHTM), polyethylene and polypropylene were examined with respect to their qualities to facilitate keratinocyte attachment. HaCaT-cells, a spontaneously transformed non-tumorigenic human keratinocyte cell line, were cultured on the different materials for 3 days. Cellular behaviour was examined morphologically by phase-contrast and scanning electron microscopy throughout the 72 h incubation period. For the computer-assisted measurement of the cell-covered substrate surface and subsequent statistical analysis the cells were fixed after 3 days of incubation, stained, photographed and the images then digitally transformed. Of the different polymers examined silicone rubber showed the most favourable results with respect to the quantitative analysis of the cell-covered substrate surface as well as concerning cytomorphological findings. The results of this study indicate that the in vitro test system described is a sensitive screening method for evaluating candidate biomaterials used for percutaneous devices in a fast and reproducible manner, thus reducing number of animal experiments.
C1 HUMBOLDT UNIV BERLIN,VIRCHOW CLIN,ANIM EXPT FACIL,BERLIN,GERMANY.
   TECH UNIV BERLIN,DEPT BIOENGN,D-1000 BERLIN,GERMANY.
   FREE UNIV BERLIN,UNIV HOSP BENJAMIN FRANKLIN,DEPT PROSTHET DENT 2,BERLIN,GERMANY.
CR BAUSER H, 1992, REFERENCE MATERIALS OF THE EUROPEAN COMMUNITIES, P17
   BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761
   BREITKREUTZ D, 1989, PHARM SKIN, P8
   Brunette D M, 1988, Int J Oral Maxillofac Implants, V3, P231
   CASTNER DG, 1992, REFERENCE MATERIALS OF THE EUROPEAN COMMUNITIES, P3
   COSTA MD, 1992, REFERENCE MATERIALS OF THE EUROPEAN COMMUNITIES, P37
   ELOY R, 1992, REFERENCE MATERIALS OF THE EUROPEAN COMMUNITIES, P237
   Fusenig NE, 1986, BIOL INTEGUMENT, V2, P409
   FUSENIG NE, 1992, CULTURE EPITHELIAL C, P25
   GRINNELL F, 1977, EXP CELL RES, V110, P175, DOI 10.1016/0014-4827(77)90284-1
   GROSSESIESTRUP C, 1984, J BIOMED MATER RES, V18, P357, DOI 10.1002/jbm.820180405
   Ireland G W, 1987, J Cell Sci Suppl, V8, P19
   JANSEN JA, 1989, BIOMATERIALS, V10, P604, DOI 10.1016/0142-9612(89)90114-2
   KNABE C, 1995, P 5 ANN C AUSTR SOC, pA14
   LEMM W, 1992, REFERENCE MAT EUROPE, pR11
   NOSER FK, 1987, IN VITRO CELL DEV B, V23, P541
   NUHLEN U, 1992, REFERENCE MATERIALS OF THE EUROPEAN COMMUNITIES, P217
   RYLE CM, 1989, DIFFERENTIATION, V40, P42, DOI 10.1111/j.1432-0436.1989.tb00812.x
   SCHURNERRITTER S, 1995, INT J ARTIF ORGANS, V18, P478
   SIEGEL R, 1993, Patent No. 42162711
   VONRECUM AF, 1984, J BIOMED MATER RES, V18, P323, DOI 10.1002/jbm.820180403
   VONRECUM AF, 1995, J BIOMAT SCI-POLYM E, V7, P181, DOI 10.1163/156856295X00698
   VONRECUM AF, 1981, CRC CR REV BIOM ENG, V5, P37
NR 23
TC 3
Z9 3
U1 0
U2 1
PU CHAPMAN HALL LTD
PI LONDON
PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8HN
SN 0957-4530
J9 J MATER SCI-MATER M
JI J. Mater. Sci.-Mater. Med.
PD SEP
PY 1997
VL 8
IS 9
BP 577
EP 582
DI 10.1023/A:1018555032743
PG 6
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA XV771
UT WOS:A1997XV77100008
PM 15348710
DA 2018-10-19
ER

PT J
AU Lewandrowski, KU
   Tomford, WW
   Schomacker, KT
   Deutsch, TF
   Mankin, HJ
AF Lewandrowski, KU
   Tomford, WW
   Schomacker, KT
   Deutsch, TF
   Mankin, HJ
TI Improved osteoinduction of cortical bone allografts: A study of the
   effects of laser perforation and partial demineralization
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
ID POWDER ALLOGRAFTS; MATRIX; BIOMATERIAL; INDUCTION; ABLATION; GEOMETRY
AB Massive cortical bone allografts have been found to incorporate slowly into host bone and thus are subject to complications such as nonunion, fatigue fracture, and infection. To better understand and improve the process of osteoinduction in these types of bone grafts, a new experimental model was developed with use of diaphyseal cortical bone grafts from rat tibiae that were prepared by partial demineralization and drilling of 0.33 mm diameter holes with a pulsed, 2.94 mu m wavelength, erbiumyttrium-aluminum-garnet laser. Six types of grafts were analyzed: untreated (Type I), demineralized 25 mu m deep (Type II), demineralized 150 mu m deep (Type III), laser perforated (Type V), laser perforated and then demineralized 25 mu m deep (Type V), and laser perforated and then demineralized 150 mu m deep (Type VI). The graft was orthotopically transplanted in the tibia of an adult Sprague-Dawley rat and followed for as long as 4 months. Histologic evaluation at 1 and 4 months postoperatively with use of hematoxylin and eosin staining confirmed that there was new bone growth in Types II, III, V, and VI grafts. The amount of growth was estimated by comparing bone miner-al density before implantation with values obtained after retrieval of the graft. These measurements were correlated to histomorphometric analysis of graft incorporation. The results show that the processes of partial demineralization (p < 0.000001) and laser perforation with partial demineralization (p < 0.000001) were both significant in enhancing bone growth in this model, New bane growth was significantly increased when the grafts were prepared with extensive demineralization (p < 0.015). This study demonstrates that osteogenesis in cortical bone grafts can be fostered through the process of partial demineralization and laser perforation, To the extent that minimal partial demineralization and laser perforation allow maintenance of structural integrity while altering the osteoinductive properties in such a way as to promote ingrowth of new bone, this experimental model represents an advance in understanding how osteogenesis in cortical bone grafts may be improved.
C1 Massachusetts Gen Hosp, Orthopaedic Serv, WACC 508, Orthopaed Res Labs, Boston, MA 02114 USA.
   Massachusetts Gen Hosp, Wellman Labs Photomed, Boston, MA 02114 USA.
RP Lewandrowski, KU (reprint author), Massachusetts Gen Hosp, Orthopaedic Serv, WACC 508, Orthopaed Res Labs, Boston, MA 02114 USA.
FU NIAMS NIH HHS [AR-21896]
CR ARO HT, 1993, ANN MED, V25, P403, DOI 10.3109/07853899309147303
   BERNICK S, 1989, J ORTHOPAED RES, V7, P1, DOI 10.1002/jor.1100070102
   BERREY BH, 1990, J BONE JOINT SURG AM, V72A, P825, DOI 10.2106/00004623-199072060-00005
   ENNEKING WF, 1991, J BONE JOINT SURG AM, V73A, P1123, DOI 10.2106/00004623-199173080-00002
   GENDLER E, 1986, J BIOMED MATER RES, V20, P687, DOI 10.1002/jbm.820200603
   GENDLER E, 1990, Patent No. 4932973
   GUO MZ, 1991, J BONE JOINT SURG BR, V73, P791
   Hollinger J O, 1990, J Craniofac Surg, V1, P60, DOI 10.1097/00001665-199001000-00011
   HOLMES RE, 1986, J BONE JOINT SURG AM, V68A, P904, DOI 10.2106/00004623-198668060-00013
   HOSNY M, 1985, J ORAL MAXIL SURG, V43, P837, DOI 10.1016/0278-2391(85)90219-8
   HOSNY M, 1985, J ORAL MAXIL SURG, V43, P925, DOI 10.1016/0278-2391(85)90004-7
   Huo M H, 1992, J Arthroplasty, V7, P109, DOI 10.1016/0883-5403(92)90003-9
   KABAN LB, 1982, J ORAL MAXIL SURG, V40, P623, DOI 10.1016/0278-2391(82)90109-4
   Lewandrowski KU, 1996, J BIOMED MATER RES, V31, P365
   LEWANDROWSKI KU, UNPUB MECH PROPERTIE
   LEWANDROWSKI KU, 1995, FLEXURAL RIGIDITY PA, V317, P254
   LORD CF, 1988, J BONE JOINT SURG AM, V70A, P369, DOI 10.2106/00004623-198870030-00008
   MANKIN HJ, 1992, ORTHOPEDICS, V15, P1147
   Mankin HJ, 1996, CLIN ORTHOP RELAT R, P86
   MULLIKEN JB, 1981, ANN SURG, V194, P366, DOI 10.1097/00000658-198109000-00015
   NARANG R, 1982, J ORAL MAXIL SURG, V40, P133, DOI 10.1016/0278-2391(82)90044-1
   NUSS RC, 1988, LASER SURG MED, V8, P381, DOI 10.1002/lsm.1900080408
   ODONNELL U, 1996, J ORTHOPAED RES, V14, P108
   PAK JH, 1993, CLIN ORTHOP RELAT R, P172
   POWER RA, 1991, J BONE JOINT SURG BR, V73, P595
   REDDI AH, 1973, P SOC EXP BIOL MED, V143, P634
   RIPAMONTI U, 1991, J BONE JOINT SURG AM, V73A, P692, DOI 10.2106/00004623-199173050-00007
   Salyer K E, 1992, J Craniofac Surg, V3, P55, DOI 10.1097/00001665-199209000-00002
   SAMPATH TK, 1984, J CELL BIOL, V98, P2192, DOI 10.1083/jcb.98.6.2192
   SCANLON CE, 1991, THESIS NW U CHICAGO
   SIRES BS, 1992, Patent No. 5112354
   Sonis S T, 1983, J Oral Med, V38, P117
   TOMFORD WW, 1981, J BONE JOINT SURG AM, V63, P244, DOI 10.2106/00004623-198163020-00010
   TOMFORD WW, 1990, J BONE JOINT SURG AM, V72A, P1137, DOI 10.2106/00004623-199072080-00003
   VANDERSTEENHOVEN JJ, 1983, J BIOMED MATER RES, V17, P1003, DOI 10.1002/jbm.820170610
   WALSH JT, 1989, LASER SURG MED, V9, P314, DOI 10.1002/lsm.1900090403
NR 36
TC 23
Z9 25
U1 0
U2 1
PU JOURNAL BONE JOINT SURGERY INC
PI NEEDHAM
PA 20 PICKERING ST, NEEDHAM, MA 02192 USA
SN 0736-0266
J9 J ORTHOPAED RES
JI J. Orthop. Res.
PD SEP
PY 1997
VL 15
IS 5
BP 748
EP 756
DI 10.1002/jor.1100150518
PG 9
WC Orthopedics
SC Orthopedics
GA YM802
UT WOS:000071102400017
PM 9420606
DA 2018-10-19
ER

PT J
AU Rubens, FD
   Labow, RS
   Meek, E
   Dudani, AK
   Ganz, PR
AF Rubens, FD
   Labow, RS
   Meek, E
   Dudani, AK
   Ganz, PR
TI Tissue factor expression by cells used for sodding of prosthetic
   vascular grafts
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
ID CULTURED ENDOTHELIAL-CELLS; FUNCTIONAL EXPRESSION; VONWILLEBRAND-FACTOR;
   FLOW CONDITIONS; FACTOR-X; BLOOD; COAGULATION; BIOLOGY; PATHWAY;
   HEMOSTASIS
AB Sodding of vascular grafts involves coating the biomaterial with cells prepared from collagenase-digested fat tissue after removal of the adipocytes by centrifugation. The goal of this study was to investigate the staining characteristics of the sodding cells as well as their ability to express the procoagulant protein tissue factor, and to compare these findings to those found with extensively purified microvascular endothelial cells (MEC) prepared from similar tissue. Sodding cells and MEC, isolated using immunomagnetic separation with anti-PECAM antibodies, were prepared from liposuction material and endothelial-specific staining was compared. The expression of tissue factor on these cells was examined using both an ELISA and a chromogenic assay to assess the rate of generation of factor Xa. Sodding cells expressed significantly more tissue factor than the unstimulated MEC in which the expression was undetectable (sodding cells 2466 +/- 830 pg/mL, P < 0.05). There was no further increase in tissue factor expression in the sodding cells with stimulation with lipopolysaccharide (LPS); however, purified MEC expressed significantly more tissue factor after exposure to LPS (1247 +/- 356 pg/mL, P < 0.05). These results were confirmed by the determination of procoagulant activity of the cells whereby the procoagulant activity on unstimulated MEC was significantly less than that found after stimulation of these cells, and it was also less than stimulated and unstimulated sodding cells (absorbance at 405 nm: 0.423 +/- 0.125, unstimulated MEC; 1.000 +/- 0.438, stimulated MEC; 1.129 +/- 0.396, unstimulated sodding cells; 1.171 +/- 0.254, stimulated sodding cells, P < 0.05). Staining of these two cell types also demonstrated significant uptake of acetylated LDL (Ac-LDL) in the purified MEC which was essentially absent in the sodding cells. Further, vWf staining was found to a greater degree in the purified MEC than in the sodding cells. These experiments demonstrated that the cells prepared for cell sodding express large amounts of tissue factor. The sodding cells do not stain for antigens known to be specific for endothelial cells, whereas MEC do and therefore the concentration of endothelial cells in the sodding cells is small. The significance of the tissue factor expression on the surface of sodded grafts is not yet known. (C) 1997 Academic Press.
C1 UNIV OTTAWA,FAC MED,DEPT BIOCHEM,OTTAWA,ON,CANADA.
RP Rubens, FD (reprint author), UNIV OTTAWA,INST HEART,DEPT SURG,1053 CARLING AVE,OTTAWA,ON K1Y 4E9,CANADA.
CR AHLSWEDE KM, 1994, ARTERIOSCLER THROMB, V14, P25, DOI 10.1161/01.ATV.14.1.25
   ALMUS FE, 1989, THROMB HAEMOSTASIS, V62, P1067
   ANDOH K, 1990, THROMB HAEMOSTASIS, V63, P298
   ARCHIPOFF G, 1991, BIOCHEM J, V273, P679, DOI 10.1042/bj2730679
   BAUER KA, 1990, BLOOD, V76, P731
   Carabasi R A, 1991, Ann Vasc Surg, V5, P477, DOI 10.1007/BF02133057
   DAVIES MG, 1993, ANN SURG, V218, P593, DOI 10.1097/00000658-199321850-00003
   FONG Y, 1994, CARE SURG PATIENT, V2, P1
   FURIE B, 1992, NEW ENGL J MED, V326, P800
   GOMEZ DE, 1993, IN VITRO CELL DEV-AN, V29A, P451, DOI 10.1007/BF02639378
   GRABOWSKI EF, 1993, BLOOD, V81, P3265
   HASHEMI S, 1990, BIOCHIM BIOPHYS ACTA, V1052, P63, DOI 10.1016/0167-4889(90)90058-L
   HASHEMI S, 1991, AM J HEMATOL, V38, P293, DOI 10.1002/ajh.2830380408
   HERBERT JM, 1992, FEBS LETT, V310, P31, DOI 10.1016/0014-5793(92)81139-D
   HEWETT PW, 1993, EUR J CELL BIOL, V62, P451
   HEWETT PW, 1993, IN VITRO CELL DEV-AN, V29A, P325
   KIRCHHOFER D, 1993, BLOOD, V81, P2050
   LENZI R, 1990, LIVER, V10, P372
   LINDHOUT T, 1992, BLOOD, V79, P2909
   MOSQUERA DA, 1991, BRIT J SURG, V78, P656, DOI 10.1002/bjs.1800780608
   NABEL EG, 1991, AM J CARDIOL, V68, pC6
   NEMERSON Y, 1988, BLOOD, V71, P1
   NOGUCHI M, 1989, THROMB RES, V55, P87, DOI 10.1016/0049-3848(89)90459-3
   RUBENS FD, IN PRESS J CARDIOVAS
   RYAN J, 1992, BLOOD, V80, P966
   SALATTI JA, 1993, BLOOD COAGUL FIBRIN, V4, P881, DOI 10.1097/00001721-199304060-00004
   SILVERBERG SA, 1977, J BIOL CHEM, V252, P8481
   STERN D, 1985, P NATL ACAD SCI USA, V82, P2523, DOI 10.1073/pnas.82.8.2523
   TRACY PB, 1988, SEMIN THROMB HEMOST, V14, P227, DOI 10.1055/s-2007-1002782
   VOYTA JC, 1984, J CELL BIOL, V99, pA81
   Welch M, 1992, Ann Vasc Surg, V6, P473, DOI 10.1007/BF02007007
   Williams S K, 1989, Ann Vasc Surg, V3, P146, DOI 10.1016/S0890-5096(06)62008-6
   Williams SK, 1996, NAT MED, V2, P32, DOI 10.1038/nm0196-32
   WILLIAMS SK, 1994, J VASC SURG, V19, P594, DOI 10.1016/S0741-5214(94)70031-1
   WILLIAMS SK, 1994, J BIOMED MATER RES, V28, P203, DOI 10.1002/jbm.820280210
   WILLIAMS SK, 1994, J VASC SURG, V19, P916, DOI 10.1016/S0741-5214(94)70019-2
   WILLIAMS SK, 1991, J ELECTRON MICR TECH, V19, P439, DOI 10.1002/jemt.1060190406
   WILLIAMS SK, 1992, J BIOMED MATER RES, V26, P103, DOI 10.1002/jbm.820260110
   WU KK, 1992, HOSP PRACT, V27, P145
NR 39
TC 9
Z9 9
U1 0
U2 1
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0022-4804
J9 J SURG RES
JI J. Surg. Res.
PD SEP
PY 1997
VL 72
IS 1
BP 22
EP 28
DI 10.1006/jsre.1997.5149
PG 7
WC Surgery
SC Surgery
GA YD827
UT WOS:A1997YD82700004
PM 9344710
DA 2018-10-19
ER

PT J
AU Hicks, CR
   Fitton, JH
   Chirila, TV
   Crawford, GJ
   Constable, IJ
AF Hicks, CR
   Fitton, JH
   Chirila, TV
   Crawford, GJ
   Constable, IJ
TI Keratoprostheses: Advancing toward a true artificial cornea
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE artificial cornea; core-and-skirt keratoprosthesis; epithelialization;
   hydrogel; keratoprosthesis
ID OSTEO-ODONTO-KERATOPROSTHESIS; MONOMER MIXTURE COMPOSITION; RABBIT
   CORNEA; EXPANDED POLYTETRAFLUOROETHYLENE; 2-HYDROXYETHYL METHACRYLATE;
   IMPLANT MATERIALS; EPITHELIAL-CELLS; POROUS POLYMER; GORE-TEX; SPONGES
AB Keratoprosthesis surgery is carried out in very few centers. Elaborate surgical techniques and high complication rates limit the application of currently available keratoprostheses (KPros). However, the clinical need for an alternative to donor tissue has sparked considerable research interest in the development of new KPros. This paper charts the evolution of KPros from the earliest devices to those currently used, describes their drawbacks and discusses the specifications of an ideal device. Recent research focuses upon the use of porous polymers as the skirt component of core-and-skirt KPros in order to obtain improved biological integration of the prosthetic material. Developments in biomaterial als technology make a KPro analogous to a donor corneal button an increasingly realistic goal. However, two particular problems still need to be addressed. First, it must be demonstrated that secure longterm fixation that is able to withstand trauma is achievable in a full-thickness artificial cornea. Second, an ideal artificial cornea for a wet eye requires an epithelialized surface, and this has yet to be achieved. (C) 1997 by Elsevier Science Inc. All rights reserved.
RP Hicks, CR (reprint author), LIONS EYE INST, 2ND FLOOR, 2 VERDUN ST, NEDLANDS, WA 6009, AUSTRALIA.
CR ALLANSMITH MR, 1988, INT OPHTHALMOL CLIN, V28, P309, DOI 10.1097/00004397-198802840-00010
   AQUAVELLA JV, 1982, OPHTHALMOLOGY, V89, P655
   BANWATT RS, 1991, INVEST OPHTH VIS SCI, V32, P1164
   BARBER JC, 1988, INT OPHTHALMOL CLIN, V28, P103, DOI 10.1097/00004397-198802820-00002
   BARBER JC, 1980, INVEST OPHTH VIS SCI, V19, P182
   Barber JC, 1993, REFRACT CORNEAL SURG, V9, P200
   BARNHAM JJ, 1983, BRIT J OPHTHALMOL, V67, P468, DOI 10.1136/bjo.67.7.468
   BARRON BA, 1987, AM J OPHTHALMOL, V103, P331
   BARRON BA, 1988, CORNEA, P787
   BARVIC M., 1967, J BIOMED MAT RES, V1, P313, DOI 10.1002/jbm.820010303
   BOCK RH, 1953, AMA ARCH OPHTHALMOL, V50, P282, DOI 10.1001/archopht.1953.00920030289003
   BROWN SI, 1965, ARCH OPHTHALMOL-CHIC, V73, P635
   BURNS FR, 1989, INVEST OPHTH VIS SCI, V30, P1569
   BUXTON JN, 1977, T AM ACAD OPHTHALMOL, V83, P268
   CAIAZZA S, 1990, CORNEA, V9, P23
   CALDWELL D, 1991, 4 INT CAT IMPL MICR, P53
   CAPECCHI J T, 1987, Investigative Ophthalmology and Visual Science, V28, P160
   Cardona H, 1991, Refract Corneal Surg, V7, P468
   CARDONA H, 1969, AM J OPHTHALMOL, V68, P604, DOI 10.1016/0002-9394(69)91239-2
   CARDONA H, 1977, T AM ACAD OPHTHALMOL, V83, P271
   CARDONA H, 1962, AM J OPHTHALMOL, V54, P284, DOI 10.1016/0002-9394(62)93291-9
   CARDONA H, 1982, CORNEA, V2, P179
   Casey T A, 1970, Proc R Soc Med, V63, P313
   CASEY TA, 1966, P ROY SOC MED, V59, P530
   CASTROVIEJO R, 1969, T AM OPHTHAL SOC, V67, P204
   CERNY E, 1970, SCRIPTA MED, V43, P63
   CHEN YC, 1993, MATER FORUM, V17, P57
   CHILARIS G, 1973, AM J OPHTHALMOL, V76, P35, DOI 10.1016/0002-9394(73)90006-8
   CHIRILA TV, 1993, POLYM INT, V32, P221, DOI 10.1002/pi.4990320303
   Chirila TV, 1996, GRAEF ARCH CLIN EXP, V234, P193, DOI 10.1007/BF00462032
   CHIRILA TV, 1993, BIOMATERIALS, V14, P26, DOI 10.1016/0142-9612(93)90072-A
   CHIRILA TV, 1994, J BIOMED MATER RES, V28, P745, DOI 10.1002/jbm.820280612
   CHIRILA TV, 1994, TRENDS POLYM SCI, V2, P296
   CHOYCE DP, 1973, OPHTHALMIC SURG LAS, V4, P23
   CIFKOVA I, 1987, BIOMATERIALS, V8, P30, DOI 10.1016/0142-9612(87)90024-X
   CLAYTON AB, IN PRESS POLYM INT
   CORKHILL PH, 1989, BIOMATERIALS, V10, P3, DOI 10.1016/0142-9612(89)90002-1
   Crawford GJ, 1996, J REFRACT SURG, V12, P525
   CRAWFORD GJ, 1993, CORNEA, V12, P348, DOI 10.1097/00003226-199307000-00012
   DAVISON PF, 1990, CONNECT TISSUE RES, V24, P129, DOI 10.3109/03008209009152429
   DEVORE DP, 1993, REFRACT CORNEAL SURG, V9, P208
   Doane MG, 1996, CORNEA, V15, P179, DOI 10.1097/00003226-199603000-00011
   DOHLMAN CH, 1974, AM J OPHTHALMOL, V77, P694, DOI 10.1016/0002-9394(74)90534-0
   DOHLMAN CH, 1994, CORNEA, V13, P214, DOI 10.1097/00003226-199405000-00004
   DOHLMAN CH, 1967, ARCH OPHTHALMOL-CHIC, V77, P252, DOI 10.1001/archopht.1967.00980020254021
   DOHLMAN CH, 1996, 4 WORLD C CORN CASTR, P36
   FALCINELLI GC, 1995, BRIT J OPHTHALMOL, V79, P129, DOI 10.1136/bjo.79.2.129
   FERRY AP, 1974, ARCH OPHTHALMOL-CHIC, V91, P281, DOI 10.1001/archopht.1974.03900060291009
   Fini ME, 1996, INVEST OPHTH VIS SCI, V37, P1000
   FITTON JH, 1996, 5 WORLD BIOM C TOR, P966
   Franceschetti A., 1949, T OPHTHAL SOC UK, V69, P17
   Girard L J, 1977, Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol, V83, P252
   GIRARD LJ, 1983, CORNEA, V2, P207
   Girard LJ, 1993, REFRACT CORNEAL SURG, V9, P194
   Guo A, 1996, CORNEA, V15, P210, DOI 10.1097/00003226-199603000-00016
   GYORFFY I, 1951, AM J OPHTHALMOL, V34, P757
   HEIMKE G, 1983, CORNEA, V2, P197
   Hicks CR, 1996, AUST NZ J OPHTHALMOL, V24, P297, DOI 10.1111/j.1442-9071.1996.tb01597.x
   Hicks CR, 1996, INVEST OPHTH VIS SCI, V37, P2524
   HICKS CR, IN PRESS AUST NZJ OP
   HIRSCHBERG J, 1984, HIST OPHTHALMOLOGY, V3, P327
   HWANG WJ, 1992, INVEST OPHTH VIS SCI, V33, P992
   INOUE M, 1993, INVEST OPHTH VIS SCI, V34, P2313
   JACOBLABARRE JT, 1990, PROGRESS IN BIOMEDICAL POLYMERS, P27
   Jester JV, 1996, INVEST OPHTH VIS SCI, V37, P998
   JEYANTHI R, 1990, BIOMATERIALS, V11, P238, DOI 10.1016/0142-9612(90)90004-A
   KAIN H L, 1988, Investigative Ophthalmology and Visual Science, V29, P452
   KAIN H L, 1987, Investigative Ophthalmology and Visual Science, V28, P231
   Kain HL, 1993, REFRACT CORNEAL SURG, V9, P209
   KNOWLES WF, 1961, AM J OPHTHALMOL, V51, P1146
   KOZARSKY AM, 1987, OPHTHALMOLOGY, V94, P904
   LAMBERTS DW, 1978, OPHTHALMIC SURG LAS, V9, P35
   LANE SS, 1991, INT OPHTHALMOL CLIN, V31, P37, DOI 10.1097/00004397-199103110-00007
   LEGEAIS JM, 1992, INVEST OPHTH VIS SCI, V33, P992
   LEGEAIS JM, 1994, EXP EYE RES, V58, P41, DOI 10.1006/exer.1994.1193
   LEGEAIS JM, 1995, ARCH OPHTHALMOL-CHIC, V113, P757, DOI 10.1001/archopht.1995.01100060083038
   LEGEAIS JM, 1991, INVEST OPHTH VIS SCI, V32, P778
   LEGEAIS JM, 1991, OPHTHALMIC SURG LAS, V22, P213
   LEGEAIS JM, 1992, CORNEA, V11, P538, DOI 10.1097/00003226-199211000-00010
   Legeais JM, 1996, INVEST OPHTH VIS SCI, V37, P1450
   LEGEAIS JM, 1991, Patent No. 2649605
   LEGEAIS JM, 1995, INVEST OPHTHALMOL  S, V36, P1466
   LEIBOWITZ H, 1988, Investigative Ophthalmology and Visual Science, V29, P452
   LEIBOWITZ HM, 1994, PROG RETIN EYE RES, V13, P605, DOI 10.1016/1350-9462(94)90024-8
   LEON GR, 1996, 4 WORLD C CORN CASTR
   LINDAHL KJ, 1992, CORNEA, V11, P183, DOI 10.1097/00003226-199203000-00015
   LIU C, 1996, 4 WORLD C CORN CASTR, P91
   MARCHI V, 1994, CORNEA, V13, P125, DOI 10.1097/00003226-199403000-00004
   Masur SK, 1996, INVEST OPHTH VIS SCI, V37, P999
   MCCAREY BE, 1991, INT OPHTHALMOL CLIN, V31, P87, DOI 10.1097/00004397-199103110-00012
   MESTER CL, 1978, CLAO J, V4, P88
   MINETT TW, 1984, CELL BIOL INT REP, V8, P151, DOI 10.1016/0309-1651(84)90082-1
   Murphy CJ, 1996, INVEST OPHTH VIS SCI, V37, P4647
   NAKADA S, 1993, INVEST OPHTH VIS SCI, V34, P1088
   NAKAO H, 1993, INVEST OPHTH VIS SCI, V34, P1088
   NEWSOME DA, 1977, INVEST OPHTH VIS SCI, V16, P21
   NISHIDA T, 1984, ARCH OPHTHALMOL-CHIC, V102, P455
   OLSON RJ, 1988, CORNEA, P743
   Perez E P, 1995, Tissue Eng, V1, P263, DOI 10.1089/ten.1995.1.263
   PINTUCCI S, 1995, BRIT J OPHTHALMOL, V79, P825, DOI 10.1136/bjo.79.9.825
   POLACK FM, 1980, OPHTHALMOLOGY, V87, P693
   POLACK FM, 1971, BRIT J OPHTHALMOL, V55, P838, DOI 10.1136/bjo.55.12.838
   Polack FM, 1983, CORNEA, V2, P185
   POLACK FM, 1980, BER DTSCH OPHTHALMOL, V77, P469
   PY DC, 1993, REFRACT CORNEAL SURG, V9, P206
   RALPH RA, 1993, DUANES CLIN OPHTHALM, V4, P1
   RAO GN, 1979, AM J OPHTHALMOL, V88, P190, DOI 10.1016/0002-9394(79)90465-3
   REFOJO MF, 1982, SURV OPHTHALMOL, V26, P257, DOI 10.1016/0039-6257(82)90161-8
   RICCI R, 1992, BRIT J OPHTHALMOL, V76, P232, DOI 10.1136/bjo.76.4.232
   SEEDOR JA, 1987, ARCH OPHTHALMOL-CHIC, V105, P268
   SHEA JJ, 1974, LARYNGOSCOPE, V84, P1835, DOI 10.1288/00005537-197410000-00014
   SIPEHIA R, 1990, BIOMATER ARTIF CELL, V18, P643, DOI 10.3109/10731199009117333
   SMAKEK J, 1971, ACTA CHIR PLAST, V13, P193
   SPRINCL L, 1981, J BIOMED MATER RES, V15, P437, DOI 10.1002/jbm.820150314
   SPRINCL L, 1973, CALC TISS RES, V13, P63, DOI 10.1007/BF02015397
   SPRINCL L, 1971, J BIOMED MATER RES, V5, P477
   SRINIVASAN BD, 1979, ARCH OPHTHALMOL-CHIC, V97, P892
   STONE W, 1953, AM J OPHTHALMOL, V36, P168, DOI 10.1016/0002-9394(53)90167-6
   STRAMPELLI B, 1963, Ann Ottalmol Clin Ocul, V89, P1039
   Swart J. G. N., 1976, ACS SYM SER, V31, P151
   TEMPRANO J, 1993, REFRACT CORNEAL SURG, V9, P192
   THOMAS J W T, 1955, Trans Ophthalmol Soc U K, V75, P473
   Thompson K P, 1991, Refract Corneal Surg, V7, P240
   TRINKAUSRANDALL V, 1991, INVEST OPHTH VIS SCI, V32, P1072
   TRINKAUSRANDALL V, 1988, INVEST OPHTH VIS SCI, V29, P393
   TRINKAUSRANDALL V, 1994, J BIOMED MATER RES, V28, P195, DOI 10.1002/jbm.820280209
   TRINKAUSRANDALL V, 1991, INVEST OPHTH VIS SCI, V32, P3245
   TRINKAUSRANDALL V, 1987, INVEST OPHTH VIS SCI, V28, P54
   TU EY, 1992, INVEST OPHTH VIS SCI, V33, P992
   VIJAYASCKARAN S, IN PRESS CORNEA
   WHITE JH, 1988, OPHTHALMIC SURG LAS, V19, P331
   WICHTERLE O, 1960, NATURE, V185, P117, DOI 10.1038/185117a0
   Wilson SE, 1996, INVEST OPHTH VIS SCI, V37, P1582
   WISNIEWSKI S, 1980, J MEMBRANE SCI, V6, P299, DOI 10.1016/S0376-7388(00)82171-7
   Wu XY, 1996, INVEST OPHTH VIS SCI, V37, P1451
   WU XY, 1995, INVEST OPHTHALMOL  S, V36, P1472
NR 136
TC 123
Z9 137
U1 1
U2 31
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD SEP-OCT
PY 1997
VL 42
IS 2
BP 175
EP 189
DI 10.1016/S0039-6257(97)00024-6
PG 15
WC Ophthalmology
SC Ophthalmology
GA YB161
UT WOS:A1997YB16100008
PM 9381372
DA 2018-10-19
ER

PT J
AU Hunkeler, D
AF Hunkeler, D
TI Polymers for bioartificial organs
SO TRENDS IN POLYMER SCIENCE
LA English
DT Article
ID ALGINATE BEADS; ISLETS; ENCAPSULATION; BIOCOMPATIBILITY; IMMOBILIZATION;
   MICROCAPSULES; LANGERHANS; PANCREAS
AB A review of polymers used for the formation of permselective capsular membranes is presented. In particular, the immunoisolation of pancreatic islets for the production of a bioartificial pancreas is evaluated. A screening of polyelectrolytes with respect to cell cytotoxicity is discussed, together with an evaluation of the polymer-structure-biomaterial-function relationship. A summary of the various polymer chemistries, mechanisms of membrane formation and microencapsulation technologies is presented and a categorization proposed. Four cases are compared in detail: Sun's alginate-calcium chloride-based precast beads, binary polyanion-polycation coacervation systems, multicomponent polyelectrolyte capsules with gel precasting and oligocation diffusion to control the cut-off, and Sefton's phase-inversion systems based on non-ionic, elastic, hydrophobic copolymers.
C1 SWISS FED INST LAUSANNE,DEPT CHEM,LAB POLYMERS & BIOMAT,CH-1015 LAUSANNE,SWITZERLAND.
CR Avramenko NV, 1996, J THERM ANAL, V46, P347, DOI 10.1007/BF02135012
   BALDWIN SP, 1996, TRENDS POLYM SCI, V6, P177
   Basta G, 1996, J SUBMICR CYTOL PATH, V28, P209
   Colton CK, 1996, TRENDS BIOTECHNOL, V14, P158, DOI 10.1016/0167-7799(96)10021-4
   Dautzenberg H, 1996, BER BUNSEN PHYS CHEM, V100, P1045, DOI 10.1002/bbpc.19961000657
   Dautzenberg H, 1996, PROG COLL POL SCI S, V101, P149
   DAUZENBERG H, 1984, Patent No. 2135954
   HUBBELL JA, 1994, TRENDS POLYM SCI, V2, P20
   Hwang JR, 1995, J MEMBRANE SCI, V108, P257, DOI 10.1016/0376-7388(95)00168-9
   Jen AC, 1996, BIOTECHNOL BIOENG, V50, P357, DOI 10.1002/(SICI)1097-0290(19960520)50:4<357::AID-BIT2>3.0.CO;2-K
   Jung B, 1996, MACROMOL THEOR SIMUL, V5, P829, DOI 10.1002/mats.1996.040050503
   LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529
   LIM F, 1980, SCIENCE, V210, P908, DOI 10.1126/science.6776628
   MARTINSEN A, 1989, BIOTECHNOL BIOENG, V33, P79, DOI 10.1002/bit.260330111
   Morris PJ, 1996, TRENDS BIOTECHNOL, V14, P163, DOI 10.1016/0167-7799(96)10020-2
   PONCELET D, 1992, APPL MICROBIOL BIOT, V38, P39
   PROKOP A, BIOARTIFICIAL ORGANS
   PROKOP A, IN PRESS ADV POLYM S
   Rajotte RV, 1995, TRANSPLANT P, V27, P3389
   SAWHNEY AS, 1992, BIOMATERIALS, V13, P863, DOI 10.1016/0142-9612(92)90180-V
   SEFTON MV, 1993, ADV POLYM SCI, V107, P143
   SEFTON MV, 1989, CAN J CHEM ENG, V67, P705, DOI 10.1002/cjce.5450670501
   SEFTON MV, 1994, PANCREATIC ISLET TRA, V3, P107
   STEVENSON WTK, 1993, FUNDAMENTALS ANIMAL, P144
   SUN AM, 1984, BIOCHIM BIOPHYS ACTA, V804, P133
   Sun YL, 1996, J CLIN INVEST, V98, P1417, DOI 10.1172/JCI118929
   Tai Isabella T. Vvan Vacek, 1995, Xenotransplantation, V2, P37, DOI 10.1111/j.1399-3089.1995.tb00064.x
   TERAYAMA H, 1952, J POLYM SCI, V8, P243, DOI 10.1002/pol.1952.120080209
   Thu B, 1996, BIOMATERIALS, V17, P1069, DOI 10.1016/0142-9612(96)85907-2
   ULUDAG H, 1994, BIOTECHNOL BIOENG, V44, P1199, DOI 10.1002/bit.260441007
   Wang T, 1997, NAT BIOTECHNOL, V15, P358, DOI 10.1038/nbt0497-358
   Willaert RG, 1996, REV CHEM ENG, V12, P5
   YAROSLAVOV AA, 1996, P INT BIOENC WORKSH, V5, pT18
   ZEKORN T, 1992, TRANSPLANT P, V24, P937
   Zekorn TDC, 1996, INT J ARTIF ORGANS, V19, P251
NR 35
TC 40
Z9 42
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0966-4793
J9 TRENDS POLYM SCI
JI Trends Polym. Sci.
PD SEP
PY 1997
VL 5
IS 9
BP 286
EP 293
PG 8
WC Polymer Science
SC Polymer Science
GA XX094
UT WOS:A1997XX09400004
DA 2018-10-19
ER

PT J
AU Zhou, YS
   Ohashi, M
   Ikeuchi, K
AF Zhou, YS
   Ohashi, M
   Ikeuchi, K
TI Start up and steady state friction of alumina against alumina
SO WEAR
LA English
DT Article
DE ceramic; friction; artificial joint; alumina; hip joint replacement;
   biomaterial
ID ARTIFICIAL HIP JOINTS; POLYETHYLENE
AB Using a pin-on-disc testing machine, the authors investigated the start up and steady state friction of highly polished alumina against itself and studied the factors affecting the friction. The lubricants used in this paper were 1 wt.% water solution of carboxymethyl cellulose sodium salt (CMC-Na 1 wt.% water solution) and distilled water. It is observed that many factors, such as lubricants, load, sliding velocity, resting time and start up acceleration etc., have an influence on the friction of alumina against alumina. The experimental results indicate that the coefficients of the start up and steady state friction when CMC-Na 1 wt.% water solution is the lubricant are much smaller than when distilled water is used, and it is possible that alumina-on-alumina hip joints may enjoy full fluid film lubrication with good machining, good fit and a proper lubricant. (C) 1997 Elsevier Science S.A.
C1 KYOTO UNIV,BIOMED ENGN RES CTR,SAKYO KU,KYOTO 60601,JAPAN.
CR Auger D D, 1993, Proc Inst Mech Eng H, V207, P25, DOI 10.1243/PIME_PROC_1993_207_265_02
   BOUTIN P, 1981, REV CHIR ORTHOP, V67, P279
   Boutin P.M., 1981, ORTHOPEDIC CERAMIC I, V1, P11
   COOPER JR, 1993, WEAR, V162, P378, DOI 10.1016/0043-1648(93)90521-M
   COOPER JR, 1991, J MED ENG TECHNOL, V15, P63, DOI 10.3109/03091909109009970
   DAWIHL W, 1965, BER DTSCH KERAMISCHE, V42, P243
   DORLOT JM, 1992, CLIN ORTHOP RELAT R, V282, P47
   DORRE E, 1984, MATERIALS RES ENG, P265
   GEDULDIG D, 1976, ADV ARTIFICIAL HIP K, P434
   GOHAR R, 1988, ELASTOHYDRODYNAMICS, P157
   HOWIE DW, 1988, J BONE JOINT SURG AM, V70, P256
   LIVERMORE J, 1990, J BONE JOINT SURG AM, V72A, P518, DOI 10.2106/00004623-199072040-00008
   MAHONEY OM, 1990, J BONE JOINT SURG AM, V72A, P663, DOI 10.2106/00004623-199072050-00004
   MITTELMEIER H, 1992, CLIN ORTHOP RELAT R, V282, P64
   MURRAY W, 1986, AAOS 53 ANN M NEW OR
   Nizard R. S., 1992, CLIN ORTHOP RELAT R, V282, P53
   SEDEL L, 1990, J BONE JOINT SURG BR, V72, P658
   SEIDELMANN U, 1982, J BIOMED MATER RES, V16, P705, DOI 10.1002/jbm.820160516
   SEMLITSCH M, 1977, J BIOMED MATER RES, V11, P537, DOI 10.1002/jbm.820110409
   SIEBER HP, 1983, CERAMICS SURGERY, P297
   TAKADOUM J, 1993, WEAR, V170, P285, DOI 10.1016/0043-1648(93)90249-L
   VAUGHN BK, 1990, COMMUNICATION
   WALTER IA, 1992, CLIN ORTHOP RELAT R, V282, P31
NR 23
TC 19
Z9 21
U1 0
U2 1
PU ELSEVIER SCIENCE SA LAUSANNE
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0043-1648
J9 WEAR
JI Wear
PD SEP
PY 1997
VL 210
IS 1-2
BP 112
EP 119
DI 10.1016/S0043-1648(97)00041-0
PG 8
WC Engineering, Mechanical; Materials Science, Multidisciplinary
SC Engineering; Materials Science
GA YC793
UT WOS:A1997YC79300015
DA 2018-10-19
ER

PT J
AU Goldstein, AS
   DiMilla, PA
AF Goldstein, AS
   DiMilla, PA
TI Application of fluid mechanic and kinetic models to characterize
   mammalian cell detachment in a radial-flow chamber
SO BIOTECHNOLOGY AND BIOENGINEERING
LA English
DT Article
DE cell adhesion; radial-flow chamber; hydrodynamic shear; detachment
   kinetics
ID SELF-ASSEMBLED MONOLAYERS; SHEAR-STRESS; ADHESION; SURFACES; GOLD;
   ATTACHMENT; ADSORPTION; FORCES; ASSAY; FIBRONECTIN
AB The strength of adhesion and dynamics of detachment of murine 3T3 fibroblasts from self-assembled monolayers were measured in a radial-flow chamber (RFC) by applying models for fluid mechanics, adhesion strength probability distributions, and detachment kinetics. Four models for predicting fluid mechanics in a RFC were compared to evaluate the accuracy of each model and the significance of inlet effects. Analysis of these models indicated an outer region at large radial positions consistent with creeping flow, an intermediate region influenced by inertial dampening, and an inner region dominated by entrance effects from the axially-oriented inlet. In accompanying experiments patterns of the fraction of cells resisting detachment were constructed for individual surfaces as a function of the applied shear stress and evaluated by comparison with integrals of both a normal and a log-normal distribution function. The two functions were equally appropriate, yielding similar estimates of the mean strength of adhesion. Further, varying the Reynolds number in the inlet, Re-d, between 630 and 1480 (corresponding to volumetric flow rates between 0.9 and 2.1 mL/s) did not affect the mean strength of adhesion. For these same experiments, analysis of the dynamics of detachment revealed three temporal phases: 1) rapid detachment of cells at the onset of flow, consistent with a first-order homogeneous kinetic model; 2) time-dependent rate of detachment during the first 30 sec. of exposure to hydrodynamic shear, consistent with the first-order heterogeneous kinetic model proposed by Dickinson and Cooper (1995); and 3) negligible detachment, indicative of pseudo-steady state after 60 sec. of flow. Our results provide rigorous guidelines for the measurement of adhesive interactions between mammalian cells and prospective biomaterial surfaces using a RFC. (C) 1997 John Wiley & Sons, Inc.
C1 CARNEGIE MELLON UNIV,CTR LIGHT MICROSCOPE IMAGING & BIOTECHNOL,PITTSBURGH,PA 15213.
CR BAIN CD, 1989, J AM CHEM SOC, V111, P7155, DOI 10.1021/ja00200a039
   BAIN CD, 1989, J PHYS CHEM-US, V93, P1670, DOI 10.1021/j100341a095
   BIRD RB, 1960, TRANSPORT PHENOMENA
   CHU L, 1994, AICHE J, V40, P692, DOI 10.1002/aic.690400412
   COZENSROBERTS C, 1990, BIOPHYS J, V58, P107, DOI 10.1016/S0006-3495(90)82357-2
   CROUCH CF, 1985, J CHEM TECHNOL BIOT, V35, P273, DOI 10.1002/jctb.280350408
   DICKINSON RB, 1995, AICHE J, V41, P2160, DOI 10.1002/aic.690410915
   DIMILLA PA, 1993, J CELL BIOL, V122, P729, DOI 10.1083/jcb.122.3.729
   DIMILLA PA, 1994, J AM CHEM SOC, V116, P2225, DOI 10.1021/ja00084a105
   EVANS E, 1991, BIOPHYS J, V59, P838, DOI 10.1016/S0006-3495(91)82296-2
   EVANS SD, 1995, LANGMUIR, V11, P3811, DOI 10.1021/la00010a035
   FARKAS DL, 1993, ANNU REV PHYSIOL, V55, P785, DOI 10.1146/annurev.physiol.55.1.785
   Finger EB, 1996, NATURE, V379, P266, DOI 10.1038/379266a0
   Forsythe G., 1977, COMPUTER METHODS MAT
   FOWLER HW, 1980, MICROBIAL ADHESION S, P143
   FRYER PJ, 1985, BIOTECHNOL BIOENG, V27, P434, DOI 10.1002/bit.260270407
   GOETZ DJ, 1994, BIOPHYS J, V66, P2202, DOI 10.1016/S0006-3495(94)81016-1
   GRABOWSKI EF, 1995, THROMB HAEMOSTASIS, V74, P123
   GROVES BJ, 1987, CYTOBIOS, V52, P49
   HANSEN LK, 1994, MOL BIOL CELL, V5, P967
   HUBBE MA, 1984, COLLOID SURFACE, V12, P151, DOI 10.1016/0166-6622(84)80096-7
   Jackson J. D., 1965, INT J MECH SCI, V7, P239
   LAW HS, 1984, IND ENG CHEM FUND, V23, P446, DOI 10.1021/i100016a012
   LIEBERT RB, 1995, BIOPHYS J, V69, P66, DOI 10.1016/S0006-3495(95)79876-9
   LOPEZ GP, 1993, J AM CHEM SOC, V115, P5877, DOI 10.1021/ja00066a087
   MCINTIRE L V, 1991, Annals of Biomedical Engineering, V19, P606
   MOLLER PS, 1963, AERONAUT QUART, V14, P163, DOI 10.1017/S0001925900002742
   MRKSICH M, 1995, J AM CHEM SOC, V117, P12009, DOI 10.1021/ja00153a029
   NGUYEN HV, 1987, J COLLOID INTERF SCI, V115, P410, DOI 10.1016/0021-9797(87)90057-9
   OLIVIER LA, 1993, BIOTECHNOL BIOENG, V42, P963, DOI 10.1002/bit.260420807
   PEPPAS NA, 1994, SCIENCE, V263, P1715, DOI 10.1126/science.8134835
   PRATT KJ, 1988, J VASC SURG, V7, P591, DOI 10.1067/mva.1988.avs0070591
   PRIME KL, 1991, SCIENCE, V252, P1164, DOI 10.1126/science.252.5009.1164
   REZANIA A, 1996, ANN BIOMED ENG, V25, P190
   SATERBAK A, 1993, BIOPHYS J, V65, P243, DOI 10.1016/S0006-3495(93)81077-4
   SCHMID C, 1994, COMPUT CHEM ENG, V18, P817, DOI 10.1016/0098-1354(94)E0001-4
   STONE JA, 1993, THESIS U PENNSYLVANI
   STUART JK, 1995, LANGMUIR, V11, P1369
   TRUSKEY GA, 1990, J BIOMED MATER RES, V24, P1333, DOI 10.1002/jbm.820241006
   TRUSKEY GA, 1993, BIOMATERIALS, V14, P243, DOI 10.1016/0142-9612(93)90114-H
   USAMI S, 1993, ANN BIOMED ENG, V21, P77, DOI 10.1007/BF02368167
   VANKOOTEN TG, 1992, J BIOMED MATER RES, V26, P723
   WHITESIDES GM, 1990, LANGMUIR, V6, P87, DOI 10.1021/la00091a013
   WILLIAMS SK, 1994, J BIOMED MATER RES, V28, P203, DOI 10.1002/jbm.820280210
   Xiao Y, 1996, BIOPHYS J, V71, P2869, DOI 10.1016/S0006-3495(96)79484-5
NR 45
TC 37
Z9 38
U1 0
U2 4
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0006-3592
J9 BIOTECHNOL BIOENG
JI Biotechnol. Bioeng.
PD AUG 20
PY 1997
VL 55
IS 4
BP 616
EP 629
DI 10.1002/(SICI)1097-0290(19970820)55:4<616::AID-BIT4>3.0.CO;2-K
PG 14
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA XM213
UT WOS:A1997XM21300004
PM 18636572
DA 2018-10-19
ER

PT J
AU Saito, T
   Takatsuka, T
   Kato, T
   Ishihara, K
   Okuda, K
AF Saito, T
   Takatsuka, T
   Kato, T
   Ishihara, K
   Okuda, K
TI Adherence of oral streptococci to an immobilized antimicrobial agent
SO ARCHIVES OF ORAL BIOLOGY
LA English
DT Article
DE immobilized antimicrobial agent; adherence; hydrophobicity; oral
   streptococci
ID COAGGREGATION PROPERTIES; SURFACE-PROTEINS; HYDROPHOBICITY; GINGIVALIS;
   BACTERIA
AB An antimicrobial agent, 3-(trimethoxysilyl)-propyldimethyloctadecyl ammonium chloride, was immobilized on silica. Interaction between the material (termed) OAIS) and various oral bacterial species were then studied. Seven species of Streptococcus and two Actinomyces were investigated for their ability to adhere to this biomaterial. Cell-surface hydrophobicity and zeta-potential were examined as well. Analysis of extracted hydrophobic proteins which adhered to OAIS revealed that the adherence of these micro-organisms was closely related to the hydrophobicity of their cell surfaces. The results of zeta-potential assays indicated that negative charge on the cell surface inhibited adherence to OAIS. Gel electrophoresis revealed that OAIS could absorb cell-surface hydrophobic proteins from all bacterial species tested. Preadsorption of hydrophobic components on the cell surface inhibited adherence of the St,ep. mutans strain to OAIS in a dose-dependent manner. The results indicate that OAIS adsorption of these oral bacteria was dependent on the degree of hydrophobicity of their surfaces. A major component of this adherence was hydrophobic cell-surface proteins. (C) 1997 Elsevier Science Ltd.
C1 TOKYO DENT COLL,DEPT MICROBIOL,MIHAMA,CHIBA 261,JAPAN.
RP Saito, T (reprint author), SUNSTAR INC,ORAL CARE BUSINESS HEADQUARTERS,DEPT RES & DEV,5-30-1 KAMIHAMURO,TAKATSUKI,OSAKA 569,JAPAN.
OI Ishihara, Kazuyuki/0000-0002-6567-807X
CR BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   CLARK WB, 1978, INFECT IMMUN, V19, P846
   DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017
   GIBBONS RJ, 1983, INFECT IMMUN, V41, P1190
   GIBBONS RJ, 1989, J DENT RES, V68, P750, DOI 10.1177/00220345890680050101
   GIBBONS RJ, 1976, INFECT IMMUN, V14, P1109
   ISQUITH AJ, 1972, APPL MICROBIOL, V24, P859
   JENKINSON HF, 1986, J GEN MICROBIOL, V132, P1575
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   MCNAB R, 1992, MOL MICROBIOL, V6, P2939, DOI 10.1111/j.1365-2958.1992.tb01753.x
   NAITO Y, 1988, J DENT RES, V67, P1075, DOI 10.1177/00220345880670080301
   NAITO Y, 1993, ORAL MICROBIOL IMMUN, V8, P195, DOI 10.1111/j.1399-302X.1993.tb00559.x
   OFEK I, 1994, BACTERIAL ADHESION C, P1
   OFEK I, 1994, BACTERIAL ADHESION C, P54
   ROSENBERG M, 1980, FEMS MICROBIOL LETT, V9, P29, DOI 10.1111/j.1574-6968.1980.tb05599.x
   SATOU N, 1988, J GEN MICROBIOL, V134, P1299
   SCHONFELD SE, 1991, CONT ORAL MICROBIO 4, P267
   TAKATSUKA T, 1994, J DENT RES, V73, P156
   WALTERS PA, 1973, APPL MICROBIOL, V25, P253
   WIBAWAN IWT, 1992, J GEN MICROBIOL, V138, P1237, DOI 10.1099/00221287-138-6-1237
NR 20
TC 22
Z9 23
U1 0
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0003-9969
J9 ARCH ORAL BIOL
JI Arch. Oral Biol.
PD AUG
PY 1997
VL 42
IS 8
BP 539
EP 545
DI 10.1016/S0003-9969(97)00054-X
PG 7
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA YB439
UT WOS:A1997YB43900002
PM 9347116
DA 2018-10-19
ER

PT J
AU TrecantViana, M
   LeNeel, T
   CantoNicolazo, C
   Champion, E
   Leroy, M
   Daculsi, G
AF TrecantViana, M
   LeNeel, T
   CantoNicolazo, C
   Champion, E
   Leroy, M
   Daculsi, G
TI Dynamic compaction of biomaterial powders
SO JOURNAL DE PHYSIQUE IV
LA English
DT Article; Proceedings Paper
CT 5th International Conference on Mechanical and Physical Behaviour of
   Materials under Dynamics Loading (EURODYMAT 97)
CY SEP 22-26, 1997
CL TOLEDO, SPAIN
SP Univ Carlos III Madrid, Assoc DYMAT
ID GENERATED SHOCK-WAVES; TITANIUM ALUMINIDES; STEEL
AB Dynamic compaction which requires no external heating for consolidation was used to compact hydroxyapatite. Static precompaction of 3 MPa and dynamic compaction using a projectile velocity of 50 m/s resulted in compacts having a compaction degree of 65% and a tensile strength of 12.4 +/- 2.7 MPa. This strength was very close to that obtained with sintered compacts one and seemed to indicate that some interparticle boundaries had been created during dynamic compaction.
C1 FAC CHIRURG DENT,CTR RECH TISSUS CALCIFIES & BIOMAT,F-44042 NANTES,FRANCE.
   IUT,LAB FORSEM COMPOSITES,F-44041 NANTES,FRANCE.
   FAC SCI,LAB RECH MAT CERAM & TRAITEMENTS SURFACE,F-87060 LIMOGES,FRANCE.
   FAC PHARM,PHARM GALEN LAB,F-44042 NANTES,FRANCE.
RI Daculsi, Guy/P-1320-2014
OI Daculsi, Guy/0000-0003-1030-3446
CR BEST S, 1989, P 1 INT BIOC S, P68
   BIGI A, 1980, BIOMATERIALS, V1, P140, DOI 10.1016/0142-9612(80)90036-8
   BOHNE W, 1993, CELLS MAT, V3, P419
   DACULSI G, 1989, J BIOMED MATER RES, V23, P883, DOI 10.1002/jbm.820230806
   DACULSI G, 1990, J BIOMED MATER RES, V24, P379, DOI 10.1002/jbm.820240309
   DEGROOT K, 1980, BIOMATERIALS, V1, P47, DOI 10.1016/0142-9612(80)90059-9
   ESSAHEB MH, 1992, J MATER SCI, V27, P4151, DOI 10.1007/BF01105119
   FERREIRA A, 1992, METALL TRANS A, V23, P3251, DOI 10.1007/BF02663434
   FERREIRA A, 1991, METALL TRANS A, V22, P685, DOI 10.1007/BF02670291
   GUICHEUX J, IN PRESS J BIOMED MA
   KRAJEWSKI A, 1981, BIOMATERIALS, V2, P105, DOI 10.1016/0142-9612(81)90007-7
   MEYERS MA, 1988, ACTA METALL MATER, V36, P925, DOI 10.1016/0001-6160(88)90147-2
   MORDFIN L, 1968, S MECH THERM PROP CE, P243
   MORIMOTO Y, 1984, I PHYS C SER, V70, P427
   MORRIS DG, 1981, MET SCI, V15, P116, DOI 10.1179/030634581790426606
   PAGE NW, 1989, MAT SCI ENG A-STRUCT, V118, P179, DOI 10.1016/0921-5093(89)90070-1
   RAYBOULD D, 1984, J MATER SCI, V19, P3498, DOI 10.1007/BF00552264
   RAYBOULD D, 1981, J MATER SCI, V16, P589, DOI 10.1007/BF02402774
   Trecant M, 1997, BIOMATERIALS, V18, P141, DOI 10.1016/S0142-9612(96)00108-1
   TRECANT M, 1995, J MATER SCI-MATER M, V6, P545, DOI 10.1007/BF00151037
   VANBLITTERSWIJK CA, 1986, BIOMATERIALS, V7, P137, DOI 10.1016/0142-9612(86)90071-2
NR 21
TC 1
Z9 1
U1 0
U2 0
PU EDITIONS PHYSIQUE
PI LES ULIS CEDEX
PA Z I DE COURTABOEUF AVE 7 AV DU HOGGAR, BP 112, 91944 LES ULIS CEDEX,
   FRANCE
SN 1155-4339
J9 J PHYS IV
JI J. Phys. IV
PD AUG
PY 1997
VL 7
IS C3
BP 3
EP 6
DI 10.1051/jp4:1997303
PG 4
WC Physics, Multidisciplinary
SC Physics
GA YA512
UT WOS:A1997YA51200004
DA 2018-10-19
ER

PT J
AU Wataha, JC
   Sun, ZL
   Hanks, CT
   Fang, DN
AF Wataha, JC
   Sun, ZL
   Hanks, CT
   Fang, DN
TI Effect of Ni ions on expression of intercellular adhesion molecule 1 by
   endothelial cells
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article; Proceedings Paper
CT 23rd Annual Meeting of the Society-for-Biomaterials
CY APR 30-MAY 04, 1997
CL NEW ORLEANS, LA
SP Soc Biomat
ID DENTAL CASTING ALLOYS; METAL RELEASE; NICKEL CARCINOGENESIS; ALVEOLAR
   MACROPHAGES; COBALT; INVITRO; CHROMIUM; CORROSION; INVIVO; BIOMATERIALS
AB Previous studies have shown that Ni-based alloys implanted into soft tissues cause an infiltration of inflammatory cells around the implant. This phenomenon is potentially important to dental alloys which are adjacent to oral tissues. To help define the mechanisms by which Ni causes an infiltration of inflammatory cells, we exposed endothelial cells in vitro to Ni ions and measured the expression of intercellular adhesion molecule 1 (ICAM-1). ICAM-1 is known to be involved in the recruitment of inflammatory cells from the bloodstream. We also exposed macrophages to Ni ions to test the hypothesis that Ni might alter cytokine secretion and subsequently cause expression of ICAM-1 on endothelial cells. The results showed that Ni ions could promote the expression of ICAM-1 on endothelial cells, but only at concentrations which were high enough (850 mu mol/L for 24 h) to suppress cell metabolic activity. Although we had previous evidence that Ni could cause macrophages to secrete cytokines such as interleukin 1 beta, Ni-exposed macrophage supernatants did not induce expression of ICAM-1 on endothelial cells at concentrations subtoxic to the macrophages (85 mu mol/L). At subtoxic concentrations, Ni ions were able to suppress ICAM-1 expression on endothelial cells which were stimulated with Lipopolysaccharide. Thus, Ni ions either promoted or suppressed the expression of ICAM-1 depending on their concentration. This dual action of Ni ions may be important in vivo where a gradient of concentrations of released ions is Likely to exist around the implanted biomaterial. Further studies are necessary to determine the effect of time of exposure and the molecular mechanisms of increased ICAM-1 expression. (C) 1997 John Wiley & Sons, Inc.
C1 UNIV MICHIGAN,SCH DENT,ANN ARBOR,MI 48109.
RP Wataha, JC (reprint author), MED COLL GEORGIA,SCH DENT,DEPT ORAL REHABIL,AUGUSTA,GA 30912, USA.
CR ALBELDA SM, 1994, FASEB J, V8, P504
   ANDERSON JM, 1984, BIOMATERIALS, V5, P5, DOI 10.1016/0142-9612(84)90060-7
   BERGMAN M, 1980, J ORAL REHABIL, V7, P325, DOI 10.1111/j.1365-2842.1980.tb00451.x
   BINGHAM E, 1972, ARCH ENVIRON HEALTH, V25, P406, DOI 10.1080/00039896.1972.10666195
   BLACK J, 1983, BIOMATERIALS, V4, P160, DOI 10.1016/0142-9612(83)90003-0
   BROWN SA, 1988, J BIOMED MATER RES, V22, P321, DOI 10.1002/jbm.820220406
   BRUNE D, 1986, BIOMATERIALS, V7, P163, DOI 10.1016/0142-9612(86)90097-9
   COOGAN TP, 1989, CRC CR REV TOXICOL, V19, P341, DOI 10.3109/10408448909029327
   COSTA M, 1989, ENVIRON HEALTH PERSP, V81, P73, DOI 10.2307/3430808
   COSTA M, 1991, ANNU REV PHARMACOL, V31, P321
   COSTA M, 1980, SCIENCE, V209, P515, DOI 10.1126/science.7394519
   COVINGTON JS, 1985, J PROSTHET DENT, V54, P127, DOI 10.1016/S0022-3913(85)80087-1
   DEMELO JF, 1983, ACTA ODONTOL SCAND, V41, P71, DOI 10.3109/00016358309162305
   DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321
   GERSTORFER J. G., 1991, INT J PROSTHODONT, V4, P152
   GJERDET NR, 1991, ACTA ODONTOL SCAND, V49, P73, DOI 10.3109/00016359109005889
   GOEBELER M, 1993, J INVEST DERMATOL, V100, P759, DOI 10.1111/1523-1747.ep12476328
   HAO S Q, 1989, Journal of Dental Research, V68, P322
   HILDEBRAND HF, 1989, BIOMATERIALS, V10, P545, DOI 10.1016/0142-9612(89)90060-4
   JOHANSSON BI, 1989, DENT MATER, V5, P324, DOI 10.1016/0109-5641(89)90124-3
   LUCAS LC, 1985, ASTM STP, V859, P208
   MAREK M, 1990, J DENT RES, V69, P1167, DOI 10.1177/00220345900690050901
   MCNAMARA A, 1982, BIOMATERIALS, V3, P160, DOI 10.1016/0142-9612(82)90006-0
   MERRITT K, 1995, J BIOMED MATER RES, V29, P1175, DOI 10.1002/jbm.820291003
   MERRITT K, 1992, J BIOMED MATER RES, V26, P1503, DOI 10.1002/jbm.820261109
   OKABE T, 1987, J DENT RES, V66, P33, DOI 10.1177/00220345870660010701
   RECHMANN P, 1992, Journal of Dental Research, V71, P599
   REULING N, 1990, J BIOMED MATER RES, V24, P979, DOI 10.1002/jbm.820240802
   SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0
   STENBERG T, 1982, SCAND J DENT RES, V90, P472
   SUNDERMAN FW, 1989, TOXICOL APPL PHARM, V100, P107, DOI 10.1016/0041-008X(89)90095-1
   TORGERSEN S, 1992, ACTA ODONTOL SCAND, V50, P83, DOI 10.3109/00016359209012750
   WATAHA JC, 1995, DENT MATER, V11, P239, DOI 10.1016/0109-5641(95)80056-5
   WATAHA JC, 1991, J BIOMED MATER RES, V25, P1133, DOI 10.1002/jbm.820250907
   WATAHA JC, 1991, J DENT RES, V70, P1014, DOI 10.1177/00220345910700060301
   WATAHA JC, 1994, DENT MATER, V10, P156, DOI 10.1016/0109-5641(94)90025-6
   WATAHA JC, IN PRESS DENT MAT
   Wildner O, 1992, Exp Dermatol, V1, P191, DOI 10.1111/j.1600-0625.1992.tb00188.x
   WILLIAMS DF, 1981, FUNDAMENTAL ASPECTS, V1, P127
   WOODMAN JL, 1983, J BIOMED MATER RES, V17, P655, DOI 10.1002/jbm.820170410
NR 40
TC 38
Z9 41
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD AUG
PY 1997
VL 36
IS 2
BP 145
EP 151
DI 10.1002/(SICI)1097-4636(199708)36:2<145::AID-JBM2>3.0.CO;2-K
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA XP499
UT WOS:A1997XP49900002
PM 9261675
DA 2018-10-19
ER

PT J
AU Dickinson, RB
   Nagel, JA
   Proctor, RA
   Cooper, SL
AF Dickinson, RB
   Nagel, JA
   Proctor, RA
   Cooper, SL
TI Quantitative comparison of shear-dependent Staphylococcus aureus
   adhesion to three polyurethane ionomer analogs with distinct surface
   properties
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article; Proceedings Paper
CT 23rd Annual Meeting of the Society-for-Biomaterials
CY APR 30-MAY 04, 1997
CL NEW ORLEANS, LA
SP Soc Biomat
ID SULFONATE-CONTAINING POLYURETHANES; BLOOD-CONTACTING PROPERTIES;
   CLUMPING FACTOR; ADSORPTION-ISOTHERMS; DETACHMENT KINETICS; BACTERIAL
   ADHESION; SIDE-CHAINS; POLYOL TYPE; FIBRINOGEN; FIBRONECTIN
AB Bacterial adhesion is a central step in infection on biomaterial surfaces; however, the relation between biomaterial surface properties and adhesion remains poorly understood. To quantitatively determine the relationship among polyurethane surface properties, protein coating, and adhesion, we have compared attachment and detachment kinetics of Staphylococcus aureus on three different novel polyurethanes with different protein coatings. Rate constants for attachment or detachment were measured as a function of shear rate in a well-defined laminar flow field. The tested polyurethanes included a relatively hydrophobic-base polyether urethane and hydrophilic anionomer and cationomer analogs of the base material. Materials were tested bare, or coated with human fibrinogen, plasma, or albumin. The results suggest that the presence of fibrinogen or plasma greatly enhance the attachment rate constants and decrease the detachment rate constants on all materials. The most extreme differences among the different materials were observed on the bare materials, with the base polyurethane being most resistant to both attachment and detachment. However, except for a reduced attachment rate constant on the plasma-coated sulfonated polyurethane, few differences in the rate constants were observed among protein-coated materials, suggesting the primary role of surface properties is masked by the presence of the adsorbed protein layer. (C) 1997 John Wiley & Sons, Inc.
C1 UNIV DELAWARE, DEPT CHEM ENGN, NEWARK, DE USA.
   UNIV WISCONSIN, SCH MED, DEPT MED, MADISON, WI USA.
   UNIV WISCONSIN, SCH MED, DEPT MED MICROBIOL & IMMUNOL, MADISON, WI USA.
RP Dickinson, RB (reprint author), UNIV FLORIDA, DEPT CHEM ENGN, POB 116005, 227 CHE BLDG, GAINESVILLE, FL 32611 USA.
RI Dickinson, Richard/A-4435-2012
OI Dickinson, Richard/0000-0002-7415-2889
CR Andrade J. D., 1985, SURFACE INTERFACIAL, P249
   Bates D. M., 1988, NONLINEAR REGRESSION
   CHEUNG AL, 1990, J INFECT DIS, V161, P1177, DOI 10.1093/infdis/161.6.1177
   COZENSROBERTS C, 1990, BIOPHYS J, V58, P841, DOI 10.1016/S0006-3495(90)82430-9
   DANKERT J, 1986, CRIT REV BIOCOMPAT, V2, P219
   DICKINSON RB, 1995, INFECT IMMUN, V63, P3143
   DICKINSON RB, 1995, AICHE J, V41, P2160, DOI 10.1002/aic.690410915
   DOUGHERTY SH, 1988, REV INFECT DIS, V10, P1102
   FOWLER HW, 1980, MICROBIAL ADHESION S, P143
   GODDARD RJ, 1994, J POLYM SCI POL PHYS, V32, P1557, DOI 10.1002/polb.1994.090320827
   GOLDSMITH HL, 1986, THROMB HAEMOSTASIS, V55, P415
   GRASEL TG, 1989, J BIOMED MATER RES, V23, P311, DOI 10.1002/jbm.820230304
   GRASEL TG, 1987, THESIS U WISCONSIN
   GREGONIS DE, 1982, MACROMOLECULAR SOLUT, P120
   Gristina A. G., 1987, ZENTRALBL BAKTERIO S, V16, P143
   GRISTINA AG, 1987, SCIENCE, V237, P1588, DOI 10.1126/science.3629258
   HERGENROTHER RW, 1991, THESIS U WISCONSIN
   HERRMANN M, 1993, J INFECT DIS, V167, P312, DOI 10.1093/infdis/167.2.312
   HERRMANN M, 1988, J INFECT DIS, V158, P693, DOI 10.1093/infdis/158.4.693
   HOGG RV, 1983, PROBABILITYS TAT INF
   ITO Y, 1986, J BIOMED MATER RES, V20, P1017, DOI 10.1002/jbm.820200715
   KAWABATA S, 1985, J BIOCHEM, V98, P1603, DOI 10.1093/oxfordjournals.jbchem.a135430
   KUUSELA P, 1984, INFECT IMMUN, V45, P433
   KUUSELA P, 1985, INFECT IMMUN, V50, P77
   Lelah M. D., 1986, POLYURETHANES MED
   LELAH MD, 1985, J COLLOID INTERF SCI, V104, P422, DOI 10.1016/0021-9797(85)90051-7
   LELAH MD, 1986, J BIOMED MATER RES, V20, P433, DOI 10.1002/jbm.820200403
   MCDEVITT D, 1992, INFECT IMMUN, V60, P1514
   MCDEVITT D, 1994, MOL MICROBIOL, V11, P237, DOI 10.1111/j.1365-2958.1994.tb00304.x
   MCGAVIN MH, 1993, INFECT IMMUN, V61, P2479
   MOHAMMAD SF, 1988, T AM SOC ART INT ORG, V34, P573
   MOLLER PS, 1963, AERONAUT QUART, V14, P163, DOI 10.1017/S0001925900002742
   *NASA, 1989, NUM SIM FLOW ART HEA
   OHTOMO T, 1988, ZBL BAKT-INT J MED M, V268, P325
   OKKEMA AZ, 1991, BIOMATERIALS, V12, P668, DOI 10.1016/0142-9612(91)90115-Q
   PROCTOR RA, 1982, J BIOL CHEM, V257, P4788
   SATERBAK A, 1993, BIOPHYS J, V65, P243, DOI 10.1016/S0006-3495(93)81077-4
   SCHMITT A, 1983, J COLLOID INTERF SCI, V92, P25, DOI 10.1016/0021-9797(83)90113-3
   SEBER GAF, 1989, NONLINAR REGRESSION
   SILVER JH, 1993, J BIOMED MATER RES, V27, P735, DOI 10.1002/jbm.820270606
   SILVER JH, 1993, J BIOMED MATER RES, V27, P1443, DOI 10.1002/jbm.820271111
   TAKAHARA A, 1991, J BIOMED MATER RES, V25, P1095, DOI 10.1002/jbm.820250905
   VAUDAUX P, 1984, J INFECT DIS, V150, P546, DOI 10.1093/infdis/150.4.546
   Vaudaux P, 1990, J Biomater Appl, V5, P134, DOI 10.1177/088532829000500204
   WABERS HD, 1992, J BIOMAT SCI-POLYM E, V4, P107
   YOUNG BR, 1988, J COLLOID INTERF SCI, V124, P28, DOI 10.1016/0021-9797(88)90321-9
NR 46
TC 37
Z9 39
U1 0
U2 11
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD AUG
PY 1997
VL 36
IS 2
BP 152
EP 162
DI 10.1002/(SICI)1097-4636(199708)36:2<152::AID-JBM3>3.0.CO;2-J
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA XP499
UT WOS:A1997XP49900003
PM 9261676
DA 2018-10-19
ER

PT J
AU An, YH
   Friedman, RJ
AF An, YH
   Friedman, RJ
TI Laboratory methods for studies of bacterial adhesion
SO JOURNAL OF MICROBIOLOGICAL METHODS
LA English
DT Review
DE bacterial adhesion; bacterial counting; biofilm formation; biomaterials;
   microscopy; Staphylococcus epidermidis
ID COAGULASE-NEGATIVE STAPHYLOCOCCI; ANALYZED EPIFLUORESCENCE MICROSCOPY;
   EXTRACELLULAR SLIME SUBSTANCE; SCANNING ELECTRON-MICROSCOPY;
   FOREIGN-BODY INFECTION; TISSUE-CULTURE PLATES; FLUORESCENT REDOX DYE;
   PSEUDOMONAS-FLUORESCENS; BIOFILM FORMATION; SOLID-SURFACES
AB Prosthetic infection following total joint replacement can have catastrophic results both physically and psychologically for the patients, leading to complete failure of the arthroplasty, possible amputation, prolonged hospitalization, and even death. Bacterial adherence to biomaterial surfaces is an important step in the pathogenesis of prosthetic infection. The exact mechanism of prosthetic infection remains unclear. It is thought that certain bacteria, particularly coagulase-negative staphylococci, after adhering to biomaterial surfaces, secrete a layer polysaccharide, an extracellular substance (slime) and then form a biofilm (a biomass of bacteria and slime). The biofilm makes the embedded bacteria less accessible to the human defense system and significantly decreases antibiotic susceptibility. Before effective preventive or therapeutic measures can be achieved, the process, characteristics, or mechanism of bacterial adhesion to biomaterials have to be studied. In this review, the in-vitro experimental methods for bacterial adhesion will be discussed, which concentrates on (1) how to design a new in-vitro model of bacterial adhesion or biofilm formation, including the selection of bacteria, sample surface preparation, conducting bacterial adhesion or biofilm formation experiments, and the sample preparation for evaluation; and (2) methods for examining adhered bacteria and biofilm, which include microscopy for counting and morphological observation of adhered bacteria, viable bacterial counting methods, other direct or indirect bacterial counting methods, and the methods for evaluating biofilm. (C) 1997 Elsevier Science B.V.
RP An, YH (reprint author), MED UNIV S CAROLINA, DEPT ORTHOPAED SURG, ORTHOPAED RES LAB, 171 ASHLEY AVE, CHARLESTON, SC 29425 USA.
CR ABBOTT A, 1983, J GEN MICROBIOL, V129, P439
   ALEXANDER MK, 1981, J CLIN PATHOL, V34, P194, DOI 10.1136/jcp.34.2.194
   ALLISON DG, 1984, J MICROBIOL METH, V2, P93, DOI 10.1016/0167-7012(84)90034-4
   An YH, 1996, J HOSP INFECT, V33, P93, DOI 10.1016/S0195-6701(96)90094-8
   An YH, 1995, J MICROBIOL METH, V24, P29, DOI 10.1016/0167-7012(95)00051-8
   An YH, 1996, J ORTHOPAED RES, V14, P846, DOI 10.1002/jor.1100140526
   *ASTM, 1985, ANN BOOK ASTM STAND, P15
   BAKKE R, 1986, J MICROBIOL METH, V5, P93, DOI 10.1016/0167-7012(86)90005-9
   BAYSTON R, 1990, J CLIN PATHOL, V43, P866, DOI 10.1136/jcp.43.10.866
   BERGAMINI TM, 1989, J VASC SURG, V9, P665, DOI 10.1067/mva.1989.vs0090665
   BLENKINSOPP SA, 1991, TRENDS BIOTECHNOL, V9, P138, DOI 10.1016/0167-7799(91)90045-J
   BRYERS J, 1981, WATER RES, V15, P483, DOI 10.1016/0043-1354(81)90059-2
   BURET A, 1991, J BIOMED MATER RES, V25, P865, DOI 10.1002/jbm.820250706
   BUSSCHER HJ, 1995, METHOD ENZYMOL, V253, P455
   CALDWELL DE, 1985, CAN J MICROBIOL, V31, P35, DOI 10.1139/m85-009
   CALDWELL DE, 1986, MICROBIAL ECOL, V12, P299, DOI 10.1007/BF02011173
   CAMPBELL L, 1983, APPL ENVIRON MICROB, V46, P553
   CARSENTIETESSE H, 1993, ANTIMICROB AGENTS CH, V37, P921, DOI 10.1128/AAC.37.4.921
   CHANG CC, 1992, J BIOMED MATER RES, V26, P197, DOI 10.1002/jbm.820260206
   CHEATLE MD, 1991, ORTHOP CLIN N AM, V22, P539
   CHRISTENSEN GD, 1995, METHOD ENZYMOL, V253, P477
   CHRISTENSEN GD, 1982, INFECT IMMUN, V37, P318
   CHRISTENSEN GD, 1985, J CLIN MICROBIOL, V22, P996
   Cormio L, 1996, SCAND J UROL NEPHROL, V30, P19, DOI 10.3109/00365599609182343
   DAHLE AB, 1982, APPL ENVIRON MICROB, V43, P169
   DANKERT J, 1986, CRIT REV BIOCOMPAT, V2, P219
   DAVENPORT DS, 1986, J INFECT DIS, V153, P332, DOI 10.1093/infdis/153.2.332
   DUDDRIDGE JE, 1982, BIOTECHNOL BIOENG, V24, P153, DOI 10.1002/bit.260240113
   DUNNE WM, 1991, APPL ENVIRON MICROB, V57, P863
   FALCIERI E, 1987, J INFECT DIS, V155, P524, DOI 10.1093/infdis/155.3.524
   Fitzgerald R H Jr, 1989, Infect Dis Clin North Am, V3, P329
   FLETCHER M, 1990, METHOD MICROBIOL, V22, P251
   FLETCHER M, 1988, J BACTERIOL, V170, P2027, DOI 10.1128/jb.170.5.2027-2030.1988
   FLETCHER M, 1976, J GEN MICROBIOL, V94, P400, DOI 10.1099/00221287-94-2-400
   FLETCHER M, 1979, APPL ENVIRON MICROB, V37, P67
   FOWLER HW, 1980, MICROBIAL ADHESION S
   FRASER TW, 1986, J APPL BACTERIOL, V60, P527, DOI 10.1111/j.1365-2672.1986.tb01092.x
   FRY JC, 1990, METHOD MICROBIOL, V22, P41
   Gabriel MM, 1996, CURR MICROBIOL, V33, P1, DOI 10.1007/s002849900064
   GALLIMORE B, 1991, J INFECT DIS, V164, P1220, DOI 10.1093/infdis/164.6.1220
   GANDERTON L, 1992, EUR J CLIN MICROBIOL, V11, P789, DOI 10.1007/BF01960877
   GRAY ED, 1984, LANCET, V1, P365
   GRISTINA AG, 1989, ANTIMICROB AGENTS CH, V33, P813, DOI 10.1128/AAC.33.6.813
   GRISTINA AG, 1985, J BONE JOINT SURG AM, V67A, P264, DOI 10.2106/00004623-198567020-00014
   GRISTINA AG, 1987, BIOMATERIALS, V8, P423, DOI 10.1016/0142-9612(87)90077-9
   GRISTINA AG, 1984, ORTHOP CLIN N AM, V15, P517
   HARBER MJ, 1983, J GEN MICROBIOL, V129, P621
   HERBERT RA, 1990, METHOD MICROBIOL, V22, P1
   HERRMANN M, 1993, J INFECT DIS, V167, P312, DOI 10.1093/infdis/167.2.312
   HOEHN RC, 1973, J WATER POLLUT CON F, V45, P2302
   HOFF KA, 1988, APPL ENVIRON MICROB, V54, P2949
   HOGT AH, 1983, J GEN MICROBIOL, V129, P2959
   HOGT AH, 1986, J BIOMED MATER RES, V20, P533, DOI 10.1002/jbm.820200409
   HOLMES CJ, 1989, BIOMATERIALS, V10, P625, DOI 10.1016/0142-9612(89)90118-X
   HOYLE BD, 1990, 90 ANN M AM SOC MICR
   HUSSAIN M, 1992, J MED MICROBIOL, V37, P62, DOI 10.1099/00222615-37-1-62
   HUSSAIN M, 1991, J INFECT DIS, V163, P534, DOI 10.1093/infdis/163.3.534
   ISIKLAR ZU, 1993, T ORTHOP RES SOC, V18, P458
   ISIKLAR ZU, 1993, T ORTHOP RES SOC, V18, P454
   IWAOKA T, 1986, APPL SPECTROSC, V40, P1062, DOI 10.1366/0003702864507972
   JOLLEY JG, 1989, APPL SPECTROSC, V43, P1062, DOI 10.1366/0003702894203921
   KEFFORD B, 1984, ARCH MICROBIOL, V138, P84, DOI 10.1007/BF00425413
   KOTILAINEN P, 1990, EUR J CLIN MICROBIOL, V9, P262, DOI 10.1007/BF01968057
   KUBITSCHEK HE, 1958, NATURE, V182, P234, DOI 10.1038/182234a0
   KUUSELA P, 1985, INFECT IMMUN, V50, P77
   LADD TI, 1990, METHOD MICROBIOL, V22, P285
   LADD TI, 1987, J UROLOGY, V138, P1451, DOI 10.1016/S0022-5347(17)43673-1
   LAWRENCE JR, 1991, J BACTERIOL, V173, P6558, DOI 10.1128/jb.173.20.6558-6567.1991
   LEAKE ES, 1982, J CLIN MICROBIOL, V15, P320
   LUDWICKA A, 1985, J MICROBIOL METH, V4, P169, DOI 10.1016/0167-7012(85)90033-8
   MACKOWIAK PA, 1984, J MICROBIOL METH, V2, P147, DOI 10.1016/0167-7012(84)90003-4
   MAXE I, 1986, INFECT IMMUN, V54, P695
   MAYBERRYCARSON KJ, 1984, INFECT IMMUN, V43, P825
   MAYBERRYCARSON KJ, 1992, CLIN ORTHOP RELAT R, P289
   MCCOY WF, 1981, CAN J MICROBIOL, V27, P910, DOI 10.1139/m81-143
   MCDANIEL JA, 1985, J MICROBIOL METH, V3, P291, DOI 10.1016/0167-7012(85)90011-9
   MCDOWELL SG, 1995, LETT APPL MICROBIOL, V21, P1, DOI 10.1111/j.1472-765X.1995.tb00992.x
   MEYERREIL LA, 1978, MAR BIOL, V48, P161, DOI 10.1007/BF00395016
   MOLIN G, 1985, APPL ENVIRON MICROB, V50, P946
   Naylor P T, 1990, Clin Orthop Relat Res, P126
   NICKEL JC, 1985, ANTIMICROB AGENTS CH, V27, P619, DOI 10.1128/AAC.27.4.619
   OLSON ME, 1988, J BIOMED MATER RES, V22, P485, DOI 10.1002/jbm.820220605
   OLSSON J, 1976, SCAND J DENT RES, V84, P20
   ORSTAVIK D, 1977, ACTA PATH MICRO IM B, V85, P38
   PASCUAL A, 1986, EUR J CLIN MICROBIOL, V5, P518, DOI 10.1007/BF02017694
   PATRICK CC, 1992, INFECT IMMUN, V60, P1363
   PAUL JH, 1983, APPL ENVIRON MICROB, V46, P338
   PETERS G, 1982, J INFECT DIS, V146, P479, DOI 10.1093/infdis/146.4.479
   PETT KV, 1990, J ORTHOP RES, V8, P321
   PETTIPHER GL, 1982, J APPL BACTERIOL, V53, P323, DOI 10.1111/j.1365-2672.1982.tb01278.x
   PFALLER M, 1988, EUR J CLIN MICROBIOL, V7, P30, DOI 10.1007/BF01962167
   PITT WG, 1993, BIOMATERIALS, V14, P605, DOI 10.1016/0142-9612(93)90179-6
   Potera C, 1996, SCIENCE, V273, P1795, DOI 10.1126/science.273.5283.1795
   PRATTTERPSTRA IH, 1987, J GEN MICROBIOL, V133, P3199
   PRINGLE JH, 1983, APPL ENVIRON MICROB, V45, P811
   PROSSER BL, 1987, ANTIMICROB AGENTS CH, V31, P1502, DOI 10.1128/AAC.31.10.1502
   Qian Z, 1996, BIOMATERIALS, V17, P1975, DOI 10.1016/0142-9612(96)00022-1
   Reid G, 1996, NEW ZEAL MED J, V109, P41
   REID G, 1992, J UROLOGY, V148, P1592, DOI 10.1016/S0022-5347(17)36976-8
   ROBRISH SA, 1978, APPL ENVIRON MICROB, V35, P743
   RODRIGUEZ GG, 1992, APPL ENVIRON MICROB, V58, P1801
   ROSENBERG M, 1981, APPL ENVIRON MICROB, V42, P375
   RUTTER P, 1980, J GEN MICROBIOL, V120, P301
   RUTTER PR, 1978, J GEN MICROBIOL, V105, P219, DOI 10.1099/00221287-105-2-219
   SATOU N, 1988, J GEN MICROBIOL, V134, P1299
   SHEA C, 1990, BIOTECHNIQUES, V8, P610
   SHETH NK, 1985, LANCET, V2, P1266
   SIERACKI ME, 1985, APPL ENVIRON MICROB, V49, P799
   SINGH A, 1990, APPL ENVIRON MICROB, V56, P389
   SMITHER R, 1977, J CLIN PATHOL, V30, P1158, DOI 10.1136/jcp.30.12.1158
   STELLMACH J, 1987, HISTOCHEM J, V19, P21, DOI 10.1007/BF01675289
   Sugarman B, 1989, Infect Dis Clin North Am, V3, P187
   SUGARMAN B, 1982, UROL RES, V10, P37
   TIMMERMAN CP, 1991, INFECT IMMUN, V59, P4187
   TOLLEFSON DF, 1987, ARCH SURG-CHICAGO, V122, P38
   TRULEAR MG, 1982, J WATER POLLUT CON F, V54, P1288
   TSAI CL, 1988, J ORTHOPAED RES, V6, P666, DOI 10.1002/jor.1100060507
   VANPELT AWJ, 1985, APPL ENVIRON MICROB, V49, P1270
   VAUDAUX P, 1989, J INFECT DIS, V160, P865, DOI 10.1093/infdis/160.5.865
   WATSON SW, 1977, APPL ENVIRON MICROB, V33, P940
   YU J, 1994, BIOMATERIALS, V15, P805, DOI 10.1016/0142-9612(94)90035-3
   Yu JL, 1996, J SURG RES, V62, P69, DOI 10.1006/jsre.1996.0175
   ZAMBON JJ, 1984, APPL ENVIRON MICROB, V48, P1214
NR 123
TC 112
Z9 112
U1 4
U2 42
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-7012
EI 1872-8359
J9 J MICROBIOL METH
JI J. Microbiol. Methods
PD AUG
PY 1997
VL 30
IS 2
BP 141
EP 152
DI 10.1016/S0167-7012(97)00058-4
PG 12
WC Biochemical Research Methods; Microbiology
SC Biochemistry & Molecular Biology; Microbiology
GA XX677
UT WOS:A1997XX67700006
DA 2018-10-19
ER

PT J
AU Owen, TJ
   Lantz, GC
   Hiles, MC
   VanVleet, J
   Martin, BR
   Geddes, LA
AF Owen, TJ
   Lantz, GC
   Hiles, MC
   VanVleet, J
   Martin, BR
   Geddes, LA
TI Calcification potential of small intestinal submucosa in a rat
   subcutaneous model
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
ID CARDIAC-VALVE BIOPROSTHESES; HEART-VALVE; CAROTID-ARTERY; DOG-MODEL;
   GLUTARALDEHYDE; TISSUE; GRAFT; MECHANISM; REPAIR; CROSSLINKING
AB Glutaraldehyde treatment of collagen biomaterials promotes calcification, poor host-tissue incorporation, and ultimately mechanical failure of bioprostheses. Porcine small-intestinal submucosa (SIS) is a biomaterial which has been investigated for several applications including arterial and venous grafts and repair of tendon, ligament, body wall, and urinary bladder defects. The calcification potential of peracetic acid (PAA)-sterilized SIS was studied. Four test samples, (1) native (cleaned, untreated) SIS, (2) SIS sterilized with 0.1% PAA, (3) SIS treated with 0.25% glutaraldehyde for 20 min, and (4) commercially available glutaraldehyde-preserved porcine bioprosthetic heart valve cusp segments (GPV), were each implanted subcutaneously in each of 24 weanling rats. Six rats were euthanatized at 1, 2, 4, and 8 weeks. Evaluation of calcium concentration by atomic absorption spectroscopy and extent of mineralization and fibrosis by light microscopy were performed. Atomic absorption revealed no calcification in native or peracetic acid-treated SIS at any time point compared with preimplant calcium concentration. Statistically significant (P<0.0001) calcification occurred in glutaraldehyde-treated materials (SIS and GPV) at each evaluation as compared to native and peracetic acid-treated samples. Histopathology indicated native and peracetic acid-treated SIS showed no implant mineralization (P<0.0001) and little peri-implant fibrosis (P<0.0001). Results suggested that native and peracetic acid-treated SIS have a low calcification potential and further study of this biomaterial is warranted. (C) 1997 Academic Press.
C1 PURDUE UNIV,SCH VET MED,DEPT VET PATHOBIOL,W LAFAYETTE,IN 47907.
   PURDUE UNIV,WILLIAM A HILLENBRAND BIOMED ENGN CTR,W LAFAYETTE,IN 47907.
   PURDUE UNIV,DEPT FOODS & NUTR,W LAFAYETTE,IN 47907.
RP Owen, TJ (reprint author), PURDUE UNIV,SCH VET MED,DEPT VET CLIN SCI,1248 LYNN HALL,W LAFAYETTE,IN 47907, USA.
OI Owen, Tina/0000-0002-6652-5315
CR AIKEN SW, 1994, VET COMP ORTHOPAED, V7, P124
   BADYLAK SF, 1995, J BIOMED MATER RES, V29, P977, DOI 10.1002/jbm.820290809
   BADYLAK SF, 1989, J SURG RES, V47, P74, DOI 10.1016/0022-4804(89)90050-4
   BADYLAK SF, 1994, J VASC SURG, V19, P465, DOI 10.1016/S0741-5214(94)70073-7
   BARNHART GR, 1982, AM J PATHOL, V106, P136
   CARPENTIER A, 1984, CIRCULATION, V70, P165
   CARPENTIER A, 1969, J THORAC CARDIOV SUR, V58, P467
   CHAUVAUD S, 1991, J THORAC CARDIOV SUR, V102, P171
   CHEN WL, 1994, CIRCULATION, V90, P323, DOI 10.1161/01.CIR.90.1.323
   CHEN WL, 1994, J BIOMED MATER RES, V28, P1485, DOI 10.1002/jbm.820281214
   CHEUNG DT, 1982, CONNECT TISSUE RES, V10, P187, DOI 10.3109/03008208209034418
   CHEUNG DT, 1982, CONNECT TISSUE RES, V10, P201, DOI 10.3109/03008208209034419
   CHEUNG DT, 1985, CONNECT TISSUE RES, V13, P109, DOI 10.3109/03008208509152389
   Clarke KM, 1996, J SURG RES, V60, P107, DOI 10.1006/jsre.1996.0018
   EVANS GH, 1990, J HYPERTENS, V8, P327, DOI 10.1097/00004872-199004000-00006
   FISHBEIN MC, 1982, J THORAC CARDIOV SUR, V83, P602
   GOLOMB G, 1992, BIOMAT ARTIF CELL IM, V20, P31, DOI 10.3109/10731199209117856
   GOLOMB G, 1987, AM J PATHOL, V127, P122
   HANCOCK WD, 1978, Patent No. 4090878
   HILES MC, 1995, J BIOMED MATER RES, V29, P883, DOI 10.1002/jbm.820290714
   JORGEHERRERO E, 1991, BIOMATERIALS, V12, P249, DOI 10.1016/0142-9612(91)90208-R
   JORGEHERRERO E, 1994, BIOMATERIALS, V15, P815, DOI 10.1016/0142-9612(94)90036-1
   KEMP PD, 1995, Patent No. 5460962
   KNAPP PM, 1994, J ENDOUROL, V8, P125, DOI 10.1089/end.1994.8.125
   Kropp B P, 1995, Urology, V46, P396, DOI 10.1016/S0090-4295(99)80227-1
   Lantz G C, 1990, J Invest Surg, V3, P217, DOI 10.3109/08941939009140351
   Lantz G C, 1993, J Invest Surg, V6, P297, DOI 10.3109/08941939309141619
   LANTZ GC, 1992, J SURG RES, V53, P175, DOI 10.1016/0022-4804(92)90031-T
   LEVY RJ, 1985, CIRCULATION, V71, P349, DOI 10.1161/01.CIR.71.2.349
   LEVY RJ, 1983, AM J PATHOL, V113, P143
   LEVY RJ, 1986, AM J PATHOL, V122, P71
   LEVY RJ, 1987, J THORAC CARDIOV SUR, V94, P551
   LOVE CS, 1991, J CARDIAC SURG, V6, P499, DOI 10.1111/j.1540-8191.1991.tb00351.x
   LOVE JW, 1986, 3RD P INT S CARD BIO, P691
   MILANO A, 1984, AM J CARDIOL, V53, P1066, DOI 10.1016/0002-9149(84)90638-6
   PREVEL CD, 1995, ANN PLAS SURG, V35, P374, DOI 10.1097/00000637-199510000-00008
   SANDERS SP, 1980, AM J CARDIOL, V46, P429, DOI 10.1016/0002-9149(80)90012-0
   SANDUSKY GE, 1995, J SURG RES, V58, P415, DOI 10.1006/jsre.1995.1064
   SANDUSKY GE, 1992, AM J PATHOL, V140, P317
   Schoen F J, 1984, Cardiol Clin, V2, P717
   SCHOEN FJ, 1986, AM J PATHOL, V123, P134
   SCHOEN FJ, 1985, LAB INVEST, V52, P523
   SCHOEN FJ, 1994, J THORAC CARDIOV SUR, V108, P880
   SCHOEN FJ, 1983, AM J CARDIOL, V51, P957, DOI 10.1016/S0002-9149(83)80173-8
   Vaught JD, 1996, J UROLOGY, V155, P374, DOI 10.1016/S0022-5347(01)66663-1
   VESELY I, 1988, ANN THORAC SURG, V46, P302, DOI 10.1016/S0003-4975(10)65930-9
   Wallace DG, 1988, COLLAGEN BIOTECHNOLO, P118
   WEAVER CM, 1981, CEREAL CHEM, V58, P120
   Webb C L, 1990, ASAIO Trans, V36, P56, DOI 10.1097/00002480-199004000-00003
   WEBB CL, 1988, T AM SOC ART INT ORG, V34, P855
NR 50
TC 8
Z9 11
U1 0
U2 3
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0022-4804
J9 J SURG RES
JI J. Surg. Res.
PD AUG
PY 1997
VL 71
IS 2
BP 179
EP 186
DI 10.1006/jsre.1997.5148
PG 8
WC Surgery
SC Surgery
GA XZ242
UT WOS:A1997XZ24200013
PM 9299288
DA 2018-10-19
ER

PT J
AU Gutensohn, K
   Bartsch, N
   Kuehnl, P
AF Gutensohn, K
   Bartsch, N
   Kuehnl, P
TI Flow cytometric analysis of platelet membrane antigens during and after
   continuous-flow plateletpheresis
SO TRANSFUSION
LA English
DT Article
ID CARDIOPULMONARY BYPASS-SURGERY; ACTIVATED PLATELETS;
   MONOCLONAL-ANTIBODIES; GLYCOPROTEIN-IIB; FIBRINOGEN RECEPTORS;
   TRANSFUSION THERAPY; UNITED-STATES; WHOLE-BLOOD; SURFACE; CIRCULATION
AB BACKGROUND: The influence, extent, and duration of changes in platelet antigen expression caused by blood-biomaterial interaction in plateletpheresis were assessed.
   STUDY DESIGN AND METHODS: Twenty-two apheresis donors were studied by using two automated continuous-flow apheresis devices. Blood samples were taken before, during, and for 4 days after extracorporeal circulation. The platelet surface expression of glycoproteins GD41a, CD42b, CD62p, and CD63 was analyzed by flow cytometry
   RESULTS: Over the course of plateletpheresis, there was a significant increase in mean channel fluorescence intensity (MCFI) of CD62p, from 25.1 +/- 7.9 (mean +/- SD) to 50.4 +/- 28.9, and of CD63, from 22.3 +/- 6.5 to 33.3 +/- 13.2. There was a significant decrease in CD41a expression as measured by the MCFI, from 1129.8 +/- 125.0 to 1066.6 +/- 102.2, and in CD42b MCFI, from 329.6 +/- 49.4 to 321.4 +/- 52.0. The two apheresis devices showed different platelet activation kinetics, but the overall MCFI of CD62p and GD63 did not significantly diverge after 60 minutes of apheresis. CD62p and CD63 expression as measured by the MCFI returned to preapheresis levels during the follow-up period in 25 and 25 of 44 procedures, respectively, within 24 hours; in 10 and 13 of 44 procedures after 48 hours; in 7 and 3 of 44 procedures after 72 hours; and in 2 and 3 of 44 procedures on Day 5.
   CONCLUSION: The varying kinetics of expression, as measured by the MCFI, of platelet antigens CD62p, CD63, CD41a, and CD42b during extracorporeal circulation may be useful for biocompatibility testing. Activated platelets continue to circulate in donors for several days after cytapheresis, which suggests that a sufficient interval between apheresis procedures is necessary to avoid the collection of activated platelets.
RP Gutensohn, K (reprint author), UNIV HAMBURG,HOSP EPPENDORF,DEPT TRANSFUS MED TRANSPLANTAT IMMUNOL,MARTINISTR 52,D-20246 HAMBURG,GERMANY.
CR ADDONIZIO VP, 1990, HEMATOL ONCOL CLIN N, V4, P145
   AULT KA, 1994, METHOD CELL BIOL, V42, P275
   BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542
   BRASS LF, 1994, J BIOL CHEM, V269, P2943
   CLEMETSON KJ, 1985, PLATELET MEMBRANE GL, P51
   COURTNEY JM, 1994, BIOMATERIALS, V15, P737, DOI 10.1016/0142-9612(94)90026-4
   DU XP, 1987, BLOOD, V69, P1524
   *FENW DIV, 1993, CS 3000 GEBR UNT
   *FRES AG, 1992, GEBR BLUTZ AS, V104
   GAWAZ M, 1994, CLIN INVESTIGATOR, V72, P424
   GAWAZ MP, 1991, KIDNEY INT, V40, P257, DOI 10.1038/ki.1991.208
   GEMMELL CH, 1995, J LAB CLIN MED, V125, P276
   GEORGE JN, 1992, BLOOD CELLS, V18, P501
   GEORGE JN, 1986, J CLIN INVEST, V78, P340, DOI 10.1172/JCI112582
   GINSBERG MH, 1988, THROMB HAEMOSTASIS, V59, P1
   HARKER LA, 1980, BLOOD, V56, P824
   HAYCOX CL, 1993, J BIOMED MATER RES, V27, P1181, DOI 10.1002/jbm.820270909
   HELLUMS JD, 1981, RHEOLOGY BLOOD BLOOD, P160
   HEYMAN MR, 1990, SEMIN ONCOL, V17, P198
   JENNINGS LK, 1982, J BIOL CHEM, V257, P458
   KLEIN HG, 1994, STANDARDS BLOOD BANK
   Kondo C, 1993, ASAIO J, V39, pM550
   LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4
   MAMMEN EF, 1985, SEMIN THROMB HEMOST, V11, P281, DOI 10.1055/s-2007-1004382
   MAZUROV AV, 1987, THROMB RES, V48, P505, DOI 10.1016/0049-3848(87)90407-5
   MCEVER RP, 1983, J BIOL CHEM, V258, P5269
   MCEVER RP, 1984, J BIOL CHEM, V259, P9799
   METZELAAR MJ, 1990, BLOOD CELLS, V16, P85
   MICHELSON AD, 1988, J CLIN INVEST, V81, P1734, DOI 10.1172/JCI113513
   MUSIAL J, 1985, J LAB CLIN MED, V105, P514
   NIEUWENHUIS HK, 1987, BLOOD, V70, P838
   NIIYA K, 1987, BLOOD, V70, P475
   PARETI FI, 1980, AM J MED, V69, P235, DOI 10.1016/0002-9343(80)90383-6
   PEERSCHKE EIB, 1992, AM J CLIN PATHOL, V98, P455
   POLESKY HF, 1985, TRANSFUSION, V25, P304, DOI 10.1046/j.1537-2995.1985.25485273805.x
   RIEGER H, 1980, THROMB HAEMOSTASIS, V44, P144
   RINDER CS, 1992, BLOOD, V79, P1201
   RINDER CS, 1991, ANESTHESIOLOGY, V75, P563, DOI 10.1097/00000542-199110000-00004
   RINDER HM, 1991, TRANSFUSION, V31, P409, DOI 10.1046/j.1537-2995.1991.31591263195.x
   RUF A, 1995, SEMIN THROMB HEMOST, V21, P146, DOI 10.1055/s-2007-1000389
   SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107
   SHATTIL SJ, 1987, BLOOD, V70, P307
   SLICHTER SJ, 1990, HEMATOL ONCOL CLIN N, V4, P291
   SREEDHARA R, 1995, AM J KIDNEY DIS, V25, P555, DOI 10.1016/0272-6386(95)90123-X
   SURGENOR DM, 1990, NEW ENGL J MED, V322, P1646, DOI 10.1056/NEJM199006073222306
   TRIULZI DJ, 1992, TRANSFUSION, V32, P529, DOI 10.1046/j.1537-2995.1992.32692367196.x
   URDAHL SG, 1989, INFUSIONSTHERAPIE, V16, P30
   WENGER RK, 1989, J THORAC CARDIOV SUR, V97, P235
   WOLFF R, 1986, J BIOL CHEM, V261, P6840
   WUN T, 1994, J CLIN APHERESIS, V9, P10, DOI 10.1002/jca.2920090104
   WUN T, 1992, TRANSFUSION, V32, P534, DOI 10.1046/j.1537-2995.1992.32692367197.x
NR 51
TC 32
Z9 32
U1 0
U2 0
PU AMER ASSOC BLOOD BANKS
PI BETHESDA
PA 8101 GLENBROOK RD, BETHESDA, MD 20814-2749
SN 0041-1132
J9 TRANSFUSION
JI Transfusion
PD AUG
PY 1997
VL 37
IS 8
BP 809
EP 815
DI 10.1046/j.1537-2995.1997.37897424403.x
PG 7
WC Hematology
SC Hematology
GA XT165
UT WOS:A1997XT16500007
PM 9280325
DA 2018-10-19
ER

PT J
AU Landau, EH
   Jayanthi, VR
   McLorie, GA
   Churchill, BM
   Khoury, AE
AF Landau, EH
   Jayanthi, VR
   McLorie, GA
   Churchill, BM
   Khoury, AE
TI Renal transplantation in children following augmentation
   ureterocystoplasty
SO UROLOGY
LA English
DT Article
ID BLADDER AUGMENTATION; RECONSTRUCTION; DISEASE
AB Objectives. To assess the impact of augmentation ureterocystoplasty on the success of cadaveric renal transplantation in children with dysfunctional bladders.
   Methods. Two patients with end-stage renal failure secondary to dysfunctional bladders (one myelodysplasia and one posterior urethral valves) underwent augmentation ureterocystoplasty prior to renal transplantation in order to increase bladder capacity and improve compliance.
   Results, Significant improvement of bladder storage function was achieved in both patients. By the use of megaureter for augmentation, untoward sequelae of enteric or gastric augmentation were obviated. Renal transplantation was successful in both patients. Both have normal renal function 4 and 3 years after transplantation.
   Conclusions. Renal transplantation into bladders previously augmented with megaureters is successful. The use of urothelial-lined biomaterial for augmentation avoids the potential complications of gastro- or enterocystoplasty, which are especially dangerous in transplant patients. (C) 1997, Elsevier Science Inc. All rights reserved.
C1 HOSP SICK CHILDREN,DEPT SURG,DIV UROL,TORONTO,ON M5G 1X8,CANADA.
CR BLYTH B, 1992, J UROLOGY, V148, P575, DOI 10.1016/S0022-5347(17)36657-0
   CHURCHILL BM, 1988, J UROLOGY, V140, P1129, DOI 10.1016/S0022-5347(17)41979-3
   CHURCHILL BM, 1993, J UROLOGY, V150, P716, DOI 10.1016/S0022-5347(17)35596-9
   CHURCHILL BM, 1992, CLIN PEDIAT UROLOGY, V2, P1234
   FILMER RB, 1990, J UROLOGY, V143, P671, DOI 10.1016/S0022-5347(17)40055-3
   HITCHCOCK RJI, 1994, BRIT J UROL, V73, P575, DOI 10.1111/j.1464-410X.1994.tb07647.x
   HOULE AM, 1993, J UROLOGY, V149, P561, DOI 10.1016/S0022-5347(17)36148-7
   KABLER RL, 1983, J UROLOGY, V129, P475, DOI 10.1016/S0022-5347(17)52188-6
   KOYLE MA, 1994, TRANSPLANT P, V26, P35
   LANDAU EH, 1994, J UROLOGY, V152, P716, DOI 10.1016/S0022-5347(17)32689-7
   MCDOUGAL WS, 1992, J UROLOGY, V147, P1199, DOI 10.1016/S0022-5347(17)37517-1
   MURRAY K, 1987, BRIT J UROL, V60, P532, DOI 10.1111/j.1464-410X.1987.tb05037.x
   NAJARIAN JS, 1986, ANN SURG, V204, P246, DOI 10.1097/00000658-198609000-00004
   NGUYEN DH, 1992, J UROLOGY, V150, P707
   REINBERG Y, 1992, J UROLOGY, V148, P369, DOI 10.1016/S0022-5347(17)36600-4
   REINBERG Y, 1988, J UROLOGY, V140, P1491, DOI 10.1016/S0022-5347(17)42082-9
   WARSHAW BL, 1980, J UROLOGY, V123, P737, DOI 10.1016/S0022-5347(17)56112-1
NR 17
TC 15
Z9 15
U1 0
U2 0
PU CAHNERS PUBL CO
PI NEW YORK
PA 249 WEST 17 STREET, NEW YORK, NY 10011
SN 0090-4295
J9 UROLOGY
JI UROLOGY
PD AUG
PY 1997
VL 50
IS 2
BP 260
EP 262
DI 10.1016/S0090-4295(97)00255-0
PG 3
WC Urology & Nephrology
SC Urology & Nephrology
GA XP368
UT WOS:A1997XP36800019
PM 9255299
DA 2018-10-19
ER

PT J
AU Suggs, LJ
   Payne, RG
   Yaszemski, MJ
   Alemany, LB
   Mikos, AG
AF Suggs, LJ
   Payne, RG
   Yaszemski, MJ
   Alemany, LB
   Mikos, AG
TI Synthesis and characterization of a block copolymer consisting of
   poly(propylene fumarate) and poly(ethylene glycol)
SO MACROMOLECULES
LA English
DT Article
ID POLYETHYLENE GLYCOLS; MOLECULAR-WEIGHT; POLYURETHANES
AB Poly(propylene fumarate-co-ethylene glycol) has been synthesized in an effort to develop a cross-linkable biomaterial for use as a vascular implant. This copolymer has been fabricated in a block configuration with two to three homopolymer units in series through a transesterification reaction between the linear polyester and the terminal hydroxyl functionalities of the poly(ethylene glycol)(PEG). A number of design parameters including the molecular weights of the two homopolymers, the copolymer reaction time, and the weight percent of PEG were varied in order to assess their effects on the properties of the resulting copolymer. This material has been characterized in terms of structure and composition as well as thermal properties and solubility behavior, All formulations of the copolymer exhibited a single glass transition temperature and a single melting temperature, with a degree of crystallinity which was dependent upon the relative amount of PEG. The copolymers were water soluble and demonstrated enhanced solubilities in organic solvents compared to the parent homopolymers.
C1 RICE UNIV,COX LAB BIOMED ENGN,INST BIOSCI & BIOENGN,HOUSTON,TX 77251.
   RICE UNIV,DEPT CHEM ENGN,HOUSTON,TX 77251.
   MAYO CLIN & MAYO FDN,DEPT ORTHOPAED SURG,ROCHESTER,MN 55905.
   RICE UNIV,DEPT CHEM,HOUSTON,TX 77251.
CR BAILEY FE, 1976, POLY ETHYLENE OXIDE
   BALKE ST, 1991, MODERN METHODS POLYM, P1
   BOX GEP, 1978, STATISTICS EXPT
   CHAIKOF EL, 1990, NEW POLYM MATER, V2, P125
   COHN D, 1988, J BIOMED MATER RES, V22, P993, DOI 10.1002/jbm.820221104
   Domb AJ, 1996, BIOMATERIALS, V17, P411, DOI 10.1016/0142-9612(96)89657-8
   GERHART TN, 1988, J ORTHOPAED RES, V6, P585, DOI 10.1002/jor.1100060417
   GILDING DK, 1979, POLYMER, V20, P1454, DOI 10.1016/0032-3861(79)90008-9
   HEROLD DA, 1989, BIOCHEM PHARMACOL, V38, P73, DOI 10.1016/0006-2952(89)90151-2
   HILLWEST JL, 1994, P NATL ACAD SCI USA, V91, P5967, DOI 10.1073/pnas.91.13.5967
   HORII F, 1975, J POLYM SCI POL CHEM, V13, P755, DOI 10.1002/pol.1975.170130319
   KOENIG JL, 1992, SPECTROSCOPY POLYM
   KRAUSE S, 1978, POLYM POLYM COMPATIB, V1
   MERRILL EW, 1982, T AM SOC ART INT ORG, V28, P482
   MERRILL EW, 1982, J AM SOC ARTIF INT O, V6, P60
   MODY PC, 1981, J APPL POLYM SCI, V26, P2853, DOI 10.1002/app.1981.070260904
   PETER SJ, IN PRESS J BIOMATER
   PETER SJ, IN PRESS HDB BIODEGR
   pitt C.G., 1990, BIODEGRADABLE POLYM
   Rashkov I, 1996, MACROMOLECULES, V29, P50, DOI 10.1021/ma950530t
   SAWHNEY AS, 1993, MACROMOLECULES, V26, P581, DOI 10.1021/ma00056a005
   SILVER JH, 1994, BIOMATERIALS, V15, P695, DOI 10.1016/0142-9612(94)90168-6
   SILVERSTEIN RM, 1991, SPECTROMETRIC IDENTI
   TAKAHARA A, 1991, J BIOMED MATER RES, V25, P1095, DOI 10.1002/jbm.820250905
   West JL, 1996, P NATL ACAD SCI USA, V93, P13188, DOI 10.1073/pnas.93.23.13188
   WITSCHGER PM, 1991, J ORTHOPAED RES, V9, P48, DOI 10.1002/jor.1100090107
   YAN DY, 1987, MAKROMOL CHEM-RAPID, V8, P83
   Yaszemski M J, 1995, Tissue Eng, V1, P41, DOI 10.1089/ten.1995.1.41
   Yaszemski MJ, 1996, BIOMATERIALS, V17, P2127, DOI 10.1016/0142-9612(96)00008-7
   ZHU KJ, 1986, J POLYM SCI POL LETT, V24, P331, DOI 10.1002/pol.1986.140240706
NR 30
TC 48
Z9 48
U1 1
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0024-9297
J9 MACROMOLECULES
JI Macromolecules
PD JUL 28
PY 1997
VL 30
IS 15
BP 4318
EP 4323
DI 10.1021/ma970312v
PG 6
WC Polymer Science
SC Polymer Science
GA XP202
UT WOS:A1997XP20200011
DA 2018-10-19
ER

PT J
AU Babu, PR
   Sastry, TP
   Rose, C
   Rao, NM
AF Babu, PR
   Sastry, TP
   Rose, C
   Rao, NM
TI Hydrogels based on gelatin poly(hydroxyethyl methacrylate) and
   poly(butyl acrylate) graft copolymer impregnated with fibrin
SO JOURNAL OF APPLIED POLYMER SCIENCE
LA English
DT Article
DE graft copolymerization; gelatin; fibrin; hydroxyethyl methacrylate;
   butyl acrylate
ID SKIN
AB Gelatin was graft copolymerized with poly(hydroxyethyl methacrylate and butyl acrylate) and subsequently crosslinked with glutaraldehyde. Fibrin of bovine origin was incorporated onto this graft copolymer and characterized for the percentage of grafting. The infrared spectroscopy, mechanical strength, and water absorption capacity of the composite were also studied. This biomaterial can be used as a hemostat in many phases of surgery and as a wound dressing material. (C) 1997 John Wiley & Sons, Inc.
C1 CENT LEATHER RES INST,BIOPROD LAB,MADRAS 600020,TAMIL NADU,INDIA.
CR Bergel S, 1909, DEUT MED WOCHENSCHR, V35, P663, DOI 10.1055/s-0029-1201395
   CHATTERJI PR, 1989, J APPL POLYM SCI, V37, P2203, DOI 10.1002/app.1989.070370812
   ERMAN S, 1989, Patent No. 4822867
   FISCHER H, 1980, Patent No. 48323
   GEORGE A, 1984, ANGEW MACROMAL CHEM, V173, P128
   JEYANTHI R, 1990, BIOMATERIALS, V11, P283
   KIM KY, 1988, POLLIMO, V12, P702
   Laki K., 1968, FIBRINOGEN
   MIN DS, 1984, POLLIMO, V8, P185
   ORARZALESI G, 1968, B CHIM FARM, V107, P822
   PIECHOTTA FU, 1983, AESTHET PLAST SURG, V17, P263
   PLENK A, 1940, ARCH KLIN CHIR, V198, P402
   Pulapura S, 1992, J Biomater Appl, V6, P216, DOI 10.1177/088532829200600303
   Rao K.P., 1969, LEATHER SCI, V16, P401
   ROBSON MC, 1973, ANN SURG, V177, P144, DOI 10.1097/00000658-197302000-00003
   Santin M, 1996, BIOMATERIALS, V17, P1459, DOI 10.1016/0142-9612(96)89769-9
   SASTRY TP, 1990, J BIOACT COMPAT POL, V5, P430, DOI 10.1177/088391159000500405
   SASTRY TP, 1991, HIGH PERFORMANCE BIO, pCH11
   SILVER FH, 1995, BIOMATERIALS, V16, P891, DOI 10.1016/0142-9612(95)93113-R
   TICE LF, 1940, AM PROFESSIONAL PHAR, V6, P289
   TICE LF, 1937, DRUG COSMET IND, V41, P191
   VOGEL HG, 1971, BIOCHIM BIOPHYS ACTA, V252, P580, DOI 10.1016/0304-4165(71)90162-0
   WARD AG, 1977, SCI TECHNOLOGY
   YANNAS IV, 1980, J BIOMED MATER RES, V14, P65, DOI 10.1002/jbm.820140108
NR 24
TC 12
Z9 12
U1 2
U2 6
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-8995
J9 J APPL POLYM SCI
JI J. Appl. Polym. Sci.
PD JUL 18
PY 1997
VL 65
IS 3
BP 555
EP 560
DI 10.1002/(SICI)1097-4628(19970718)65:3<555::AID-APP15>3.0.CO;2-W
PG 6
WC Polymer Science
SC Polymer Science
GA XG034
UT WOS:A1997XG03400015
DA 2018-10-19
ER

PT J
AU Yang, JM
   Wang, MC
   Hsu, YG
   Chang, CH
AF Yang, JM
   Wang, MC
   Hsu, YG
   Chang, CH
TI Preparation of SBS-g-VP copolymer membrane by UV radiation without
   degassing
SO JOURNAL OF APPLIED POLYMER SCIENCE
LA English
DT Article
DE styrene-butadiene-styrene block copolymer; vinyl pyridine; graft
   copolymer; biomaterial
ID GRAFT-POLYMERIZATION; PLATELET-ADHESION; SURFACE; IRRADIATION;
   POLY(ETHYLENE-TEREPHTHALATE); IMMOBILIZATION; ADSORPTION
AB The solvent-cast film of styrene-butadiene-styrene triblock copolymer (SBS) was prepared, and the grafting of 4-vinyl pyridine (VP) to the SBS membrane was induced by ultraviolet radiation without degassing to obtain the SBS-g-VP copolymer membrane. The chemical composition of the graft copolymer membrane was studied by infrared spectroscopy. In addition to those absorption peaks associated with pure SBS, the SBS-g-VP graft copolymer also showed a peak of absorption at 820 cm(-1) which appeared in the spectra of homopolyvinylpyridine. The degree of grafting and the mechanical properties of SBS and SBS-g-VP were measured. Contact angle, water content, and protein absorption of fibrinogen and albumin experiments were also performed to evaluate the blood biocompatibility of the SBS-g-VP membrane. It was found that the degree of grafting exhibited an approximate linear increase with VP concentration at O degrees C. The degree of grafting increased sharply with VP concentration above 30% v/v at 10 degrees C. The degree of grafting increased with VP concentration and then leveled off when the temperature was at 30 degrees C. The rate of grafting followed Arrhenius law. The activation energy obtained was 3.25 kcal/mol. PolyVP has a glass transition temperature (T-g) at about 240 degrees C, and hence, it performes as a hard rigid plastic at room temperature. Therefore, the SBS-g-VP graft copolymer showed the plastic performance with increasing degree of grafting. The surface tension of SBS-g-VP was determined by using Kaelble's equation and the contact angle data. It was found that the surface tension and water content of SBS-g-VP membrane increased, whereas the contact angle decreased with grafting degree. Albumin and fibrinogen adsorption increased with time and reached a steady-state level after 20 and 40 min, respectively. The maximum desorption appeared in 30 min for albumin, but it took more time to reach maximum desorption for fibrinogen. The amount of protein adsorption decreased with the increasing of grafting degree, and the amount of protein adsorption eventually leveled off. (C) 1997 John Wiley & Sons, Inc.
C1 NATL TAIWAN INST TECHNOL,GRAD SCH TEXT & POLYMER ENGN,TAIPEI 104,TAIWAN.
   CHANG GUNG MEM HOSP,DIV THORAC & CARDIOVASC SURG,TAYUAN 333,TAIWAN.
RP Yang, JM (reprint author), CHANG GUNG COLL MED & TECHNOL,DEPT CHEM ENGN,TAYUAN 333,TAIWAN.
CR FUJIMOTO K, 1993, J BIOMED MATER RES, V27, P1559, DOI 10.1002/jbm.820271213
   FUJIMOTO K, 1993, BIOMATERIALS, V14, P441
   Hari P R, 1993, J Biomater Appl, V8, P174, DOI 10.1177/088532829300800205
   Hari P R, 1991, J Biomater Appl, V6, P170, DOI 10.1177/088532829100600205
   Holden G., 1969, J POLYM SCI        C, VC26, P37
   HSIUE GH, 1988, J BIOMED MATER RES, V22, P405, DOI 10.1002/jbm.820220504
   IKADA Y, 1994, BIOMATERIALS, V15, P725, DOI 10.1016/0142-9612(94)90025-6
   KAELBLE DH, 1977, POLYMER, V18, P475, DOI 10.1016/0032-3861(77)90164-1
   KINOSHITA Y, 1993, BIOMATERIALS, V14, P546, DOI 10.1016/0142-9612(93)90244-V
   KOCHWA S, 1977, ANN NY ACAD SCI, V283, P37, DOI 10.1111/j.1749-6632.1977.tb41751.x
   KULIK EA, 1993, BIOMATERIALS, V14, P763, DOI 10.1016/0142-9612(93)90041-Y
   LAI JY, 1991, J APPL POLYM SCI, V43, P1431, DOI 10.1002/app.1991.070430804
   OKADA T, 1992, J BIOMED MATER RES, V26, P1569, DOI 10.1002/jbm.820261204
   TABATA Y, 1991, CRIT REV THER DRUG, V7, P121
   TOMITA N, 1994, J APPL BIOMATER, V5, P175, DOI 10.1002/jab.770050211
   UCHIDA E, 1990, J APPL POLYM SCI, V41, P677, DOI 10.1002/app.1990.070410317
   UCHIDA E, 1993, J APPL POLYM SCI, V47, P417, DOI 10.1002/app.1993.070470305
   UYAMA Y, 1990, J APPL POLYM SCI, V39, P489, DOI 10.1002/app.1990.070390301
   YANG J, IN PRESS J BIOMED MA
   YANG JM, 1990, ANGEW MAKROMOL CHEM, V179, P99, DOI 10.1002/apmc.1990.051790108
   Yang JM, 1996, J BIOMED MATER RES, V31, P281
   YANG JM, 1990, J APPL POLYM SCI, V39, P1475, DOI 10.1002/app.1990.070390706
   YANG JM, 1990, J APPL POLYM SCI, V41, P1141, DOI 10.1002/app.1990.070410523
NR 23
TC 21
Z9 21
U1 1
U2 3
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-8995
J9 J APPL POLYM SCI
JI J. Appl. Polym. Sci.
PD JUL 5
PY 1997
VL 65
IS 1
BP 109
EP 116
PG 8
WC Polymer Science
SC Polymer Science
GA XC343
UT WOS:A1997XC34300014
DA 2018-10-19
ER

PT J
AU Sabokbar, A
   Fujikawa, Y
   Neale, S
   Murray, DW
   Athanasou, NA
AF Sabokbar, A
   Fujikawa, Y
   Neale, S
   Murray, DW
   Athanasou, NA
TI Human arthroplasty derived macrophages differentiate into osteoclastic
   bone resorbing cells
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Article
ID COLONY-STIMULATING FACTOR; MONOCLONAL-ANTIBODIES; RESORPTION;
   REPLACEMENT; MOUSE
AB Objective-In aseptic loosening, a heavy macrophage response to biomaterial wear particles is commonly found in arthroplasty tissues. The aim of this study was to discover if these cells contribute to the bone resorption of aseptic loosening by differentiating into osteoclasts.
   Methods-Macrophages were isolated from the pseudocapsule and pseudomembrane of loose cemented and uncemented hip arthroplasties at the time of revision surgery and then co-cultured on glass coverslips and dentine slices with UMR 106 rat osteoblast-like cells, both in the presence and absence of 1,25 dihydroxyvitamin D-3 [1,25(OH)(2)D-3]. Macrophages isolated from the synovial membrane of patients with osteoarthritis (OA) undergoing hip replacements were similarly studied as a control group.
   Results-After 24 hours incubation, most cells isolated from the above periprosthetic tissues strongly expressed macrophage (CD11b, CD14) but not osteoclast markers. However, after 14 days incubation, numerous multinucleated cells showing the phenotypic features of osteoclasts (that is, positive for tartrate resistant acid phosphatase, the vitronectin receptor, and capable of extensive lacunar resorption) formed in co-cultures of arthroplasty derived macrophages and UMR 106 cells, in the presence of 1,25(OH)(2)D-3. The addition of an antibody to macrophage colony stimulating factor (M-CSF) considerably reduced macrophage-osteoclast differentiation and hence the lacunar resorption seen in these co-cultures. In contrast, OA synovial macrophage/UMR 106 co-cultures showed little or no evidence of macrophage-osteoclast differentiation and this was only seen when human M-CSF was added to the co-cultures.
   Conclusion-This is the first report showing that human macrophages isolated directly from periprosthetic tissues surrounding loosened implants differentiate into multinucleated showing all the functional and cytochemical characteristics of osteoclasts. In contrast with other macrophage populations, exogenous M-CSF is not required for this to occur. In the context of the heavy macrophage response to wear particles in periprosthetic tissues macrophage-osteoclast differentiation may represent an important cellular mechanism whereby osteolysis is effected in aseptic loosening.
C1 NUFFIELD ORTHOPAED CTR,DEPT PATHOL,OXFORD OX3 7LD,ENGLAND.
   NUFFIELD ORTHOPAED CTR,NUFFIELD DEPT ORTHOPAED SURG,OXFORD OX3 7LD,ENGLAND.
   UNIV ADELAIDE,DEPT ORTHOPAED & TRAUMA,ADELAIDE,SA 5005,AUSTRALIA.
RI Murray, David/D-7117-2011
FU Wellcome Trust
CR AMSTUTZ HC, 1992, CLIN ORTHOP RELAT R, V276, P7
   ATHANASOU NA, 1992, J BONE JOINT SURG BR, V74, P57
   ATHANASOU NA, 1990, J CLIN PATHOL, V43, P997, DOI 10.1136/jcp.43.12.997
   ATHANASOU NA, 1990, BONE MINER, V8, P7, DOI 10.1016/0169-6009(91)90136-N
   BOYDE A, 1984, BRIT DENT J, V156, P216, DOI 10.1038/sj.bdj.4805313
   BULLOUGH PG, 1988, ORTHOP CLIN N AM, V19, P611
   CHAMBERS TJ, 1984, CALCIFIED TISSUE INT, V36, P556, DOI 10.1007/BF02405365
   FELIX R, 1990, ENDOCRINOLOGY, V127, P2592, DOI 10.1210/endo-127-5-2592
   Fujikawa Y, 1996, ANN RHEUM DIS, V55, P816, DOI 10.1136/ard.55.11.816
   Fujikawa Y, 1996, ENDOCRINOLOGY, V137, P4058, DOI 10.1210/en.137.9.4058
   GOODMAN SB, 1989, CLIN ORTHOP RELAT R, V244, P182
   GOODMAN SB, 1990, CLIN ORTHOP RELAT R, V257, P305
   HARRIS WH, 1994, ACTA ORTHOP SCAND, V65, P113, DOI 10.3109/17453679408993734
   HARRIS WH, 1995, CLIN ORTHOPAEDICS, V311, P46
   HOROWITZ SM, 1995, CALCIFIED TISSUE INT, V57, P301, DOI 10.1007/BF00298886
   HORTON MA, 1985, CANCER RES, V45, P5663
   JIRANEK WA, 1993, J BONE JOINT SURG AM, V75A, P863, DOI 10.2106/00004623-199306000-00007
   KADOYA Y, 1994, BONE MINER, V27, P85, DOI 10.1016/S0169-6009(08)80211-5
   KIM KJ, 1993, CLIN ORTHOPAEDICS, V287, P142
   KREUTZ M, 1990, Blood, V76, P2457
   LENNOX DW, 1987, CLIN ORTHOP RELAT R, V225, P171
   MALCOLM AJ, 1988, J BONE JOINT SURG BR, V70, P153
   MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252
   MURRAY DW, 1990, J BONE JOINT SURG BR, V72, P988
   Pandey R, 1996, ANN RHEUM DIS, V55, P388, DOI 10.1136/ard.55.6.388
   PARTRIDGE N, 1981, ENDOCRINOLOGY, V116, P213
   QUINN J, 1992, J BONE JOINT SURG BR, V74, P652
   QUINN JMW, 1994, ENDOCRINOLOGY, V134, P2416, DOI 10.1210/en.134.6.2416
   Quinn JMW, 1996, J PATHOL, V179, P106
   REVELL PA, 1982, CURRENT TRENDS PATHO, P73
   RIGBY WFC, 1988, IMMUNOL TODAY, V9, P54
   Roth P, 1992, Curr Top Microbiol Immunol, V181, P141
   SANTAVIRTA S, 1990, J BONE JOINT SURG AM, V72A, P252, DOI 10.2106/00004623-199072020-00014
   SANTAVIRTA S, 1990, J BONE JOINT SURG BR, V72, P980
   SCHLOSSMAN SF, 1995, P 5 INT WORKSH C HEL, V1
   Suda T., 1986, BONE MINERAL RES, V4, P1
   TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo-122-4-1373
   TAKAHASHI N, 1994, DEV BIOL, V163, P212, DOI 10.1006/dbio.1994.1137
   TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0
NR 41
TC 112
Z9 113
U1 1
U2 5
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR
SN 0003-4967
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUL
PY 1997
VL 56
IS 7
BP 414
EP 420
DI 10.1136/ard.56.7.414
PG 7
WC Rheumatology
SC Rheumatology
GA XP597
UT WOS:A1997XP59700006
PM 9486003
OA Green Published, Bronze
DA 2018-10-19
ER

PT J
AU Monties, JR
   Dion, I
   Havlik, P
   Rouais, F
   Trinkl, J
   Baquey, C
AF Monties, JR
   Dion, I
   Havlik, P
   Rouais, F
   Trinkl, J
   Baquey, C
TI Cora rotary pump for implantable left ventricular assist device:
   Biomaterial aspects
SO ARTIFICIAL ORGANS
LA English
DT Article
DE biomaterials; artificial heart; biocompatibility; hemocompatibility
ID HEMOCOMPATIBILITY
AB Our group is developing a left ventricular assist device based on the principle of the Maillard-Wankel rotative compressor: it is a rotary, not centrifugal, pump that produces a pulsatile flow. Stringent requirements have been defined for construction materials. They must be light, yet sufficiently hard and rigid, and able to be machined with high precision. The friction coefficient must be low and the wear resistance high. The materials must be chemically inert and not deformable. Also, the materials must be biocompatible, and the blood contacting surface must be hemocompatible. We assessed the materials in terms of physiochemistry, mechanics, and tribology to select the best for hemocompatibility (determined by studies of protein adsorption; platelet, leukocyte, and red cell retention; and hemolysis, among other measurements) and biocompatibility (determined by measurement of complement activation and toxicity, among other criteria). Of the materials tested, for short- and middle-term assistance, we chose titanium alloy (Ti6Al4V) and alumina ceramic (Al2O3) and for long-term and permanent use, composite materials (TIN coating on graphite). We saw that the polishing process of the substrate must be improved. For the future, the best coating material would be diamond-like carbon (DLC) or crystalline diamond coating.
C1 MARSEILLES UNIV,FAC MED,SURG RES LAB,MARSEILLE,FRANCE.
   BORDEAUX UNIV,INSERM U443,BORDEAUX,FRANCE.
CR DION I, 1993, BIOMATERIALS, V14, P122, DOI 10.1016/0142-9612(93)90222-N
   DION I, 1993, INT J ARTIF ORGANS, V16, P623
   DION I, 1993, INT J ARTIF ORGANS, V16, P545
   DION I, 1993, BIOMATERIALS, V14, P169, DOI 10.1016/0142-9612(93)90019-X
   MCCARTHY PM, 1995, ANN THORAC SURG, V59, P946
   Monties JRE, 1996, ANN THORAC SURG, V61, P463, DOI 10.1016/0003-4975(95)01046-7
   PENNINGTON DG, 1994, J THORAC CARDIOV SUR, V108, P604
NR 7
TC 33
Z9 34
U1 0
U2 7
PU BLACKWELL SCIENCE INC
PI MALDEN
PA 350 MAIN ST, MALDEN, MA 02148
SN 0160-564X
J9 ARTIF ORGANS
JI Artif. Organs
PD JUL
PY 1997
VL 21
IS 7
BP 730
EP 734
DI 10.1111/j.1525-1594.1997.tb03731.x
PG 5
WC Engineering, Biomedical; Transplantation
SC Engineering; Transplantation
GA XG012
UT WOS:A1997XG01200029
PM 9212947
DA 2018-10-19
ER

PT J
AU Giardino, R
   Fini, M
   Aldini, NN
   Giavaresi, G
   Rocca, M
   Orienti, L
   DeLollis, A
   Fambri, L
AF Giardino, R
   Fini, M
   Aldini, NN
   Giavaresi, G
   Rocca, M
   Orienti, L
   DeLollis, A
   Fambri, L
TI Experimental evaluation of a resorbable intramedullary plug for cemented
   total hip replacement
SO BIOMATERIALS
LA English
DT Article
DE orthopaedics; intramedullary plug; hip replacement; biodegradation;
   poly(D,L-lactic acid); rabbit
ID CIRCULATORY REACTIONS; POLY(LACTIC ACID); FIXATION; DEGRADATION; BONE;
   PATHOGENESIS; SYNOVITIS; KNEE
AB In order to evaluate degradation kinetics and biocompatibility of a resorbable poly(D,L-lactic acid) (PDLLA) plug for total cemented hip prostheses, an experimental in vitro and in vivo study was carried out. Degradation rate studies were performed in Ringer solution and after in vivo plug implantation in the femoral medullar cavity of rabbits. In vitro biocompatibility was evaluated in murine fibroblast cell cultures. PDLLA plugs showed faster degradation kinetics in vivo than in vitro. Histological evaluations showed that PDLLA completely disappeared in vivo 26 weeks after implantation. Fibrous tissue in the medullar cavity was observed at 13 weeks, but no histological changes were observed after 26 weeks. Also, the in vitro tests showed good biocompatibility of the biomaterial. Our results show the possibility of considering this resorbable plug for clinical situations instead of the traditionally used plugs [polyethylene, poly(methyl methacrylate) or cancellous bone] due to its biocompatibility, degradation properties and simplicity of use. (C) 1997 Elsevier Science Limited.
C1 UNIV TRENT,DEPT MAT ENGN,I-38050 TRENT,ITALY.
   CREMASCOLI MILANO,I-20138 MILAN,ITALY.
RP Giardino, R (reprint author), UNIV BOLOGNA,RES INST CODIVILIA PUTTI,DEPT EXPT SURG,RIZZOLI ORTHOPAED INST,CHAIR PATHOPHYSIOL,I-40136 BOLOGNA,ITALY.
RI Fini, Milena/J-4808-2016
OI Fini, Milena/0000-0002-3732-3570; Fambri, Luca/0000-0002-8627-8833;
   Giavaresi, Gianluca/0000-0001-7843-5969
CR BAKKER D, 1996, 5 WORLD BIOM C 29 MA, V1, P35
   BALLARD WT, 1994, J BONE JOINT SURG AM, V76A, P959
   BARFOD G, 1992, ACTA ORTHOP SCAND, V63, P680
   Barrows TH, 1986, CLIN MATER, V1, P233
   DAVIS FM, 1989, J BONE JOINT SURG BR, V71, P181
   ENGELBERG I, 1991, BIOMATERIALS, V12, P292, DOI 10.1016/0142-9612(91)90037-B
   FAMBRI L, 1995, P 12 EUR C BIOM PORT, P38
   FRIDEN T, 1992, ACTA ORTHOP SCAND, V63, P94, DOI 10.3109/17453679209154859
   HOFFMANN AA, 1987, CLIN ORTHOP RELAT R, V218, P290
   HUTMACHER D, 1990, INT J ARTIF ORGANS, V13, P580
   KNIGHT WE, 1980, CLIN ORTHOP RELAT R, V163, P167
   KUMTA SM, 1992, J BONE JOINT SURG BR, V74, P563
   LEHNINGER AL, 1975, BIOCHEMISTRY-US, P400
   Lewis D. H., 1990, BIODEGRADABLE POLYM, P1
   LI SM, 1990, J MATER SCI-MATER M, V1, P123, DOI 10.1007/BF00700871
   MALLORY TH, 1981, CLIN ORTHOPAEDICS, V155, P37
   McLaughlin J R, 1994, Orthop Rev, V23, P344
   MICHEL R, 1980, ANAESTHESIA, V35, P858, DOI 10.1111/j.1365-2044.1980.tb03943.x
   MIGLIARESI C, 1994, J BIOMAT SCI-POLYM E, V5, P591, DOI 10.1163/156856294X00220
   OH I, 1978, J BONE JOINT SURG AM, V60, P608, DOI 10.2106/00004623-197860050-00004
   ORSINI EC, 1987, J BONE JOINT SURG AM, V69A, P822, DOI 10.2106/00004623-198769060-00005
   RAK J, 1985, PHARM ACTA HELV, V60, P162
   ROGERS LL, 1993, 19 ANN M SOC BIOM 28, P112
   RUDIGIER JFM, 1983, RES EXP MED, V183, P77, DOI 10.1007/BF01851774
   SAHA S, 1993, 19 ANN M SOC BIOM 28, P113
   SONG Y, 1994, CLIN ORTHOP RELAT R, V302, P297
   SUGANUMA J, 1993, J APPL BIOMATER, V4, P13, DOI 10.1002/jab.770040103
   VAIIONPAA S, 1989, PROG POLYM SCI, V14, P679
   WENDA K, 1988, ARCH ORTHOP TRAUM SU, V107, P316, DOI 10.1007/BF00451513
   WENDA K, 1993, ARCH ORTHOP TRAUM SU, V112, P260, DOI 10.1007/BF00452961
   WROBLEWSKI BM, 1984, J BONE JOINT SURG BR, V66, P639
   ZHANG XC, 1994, J BIOACT COMPAT POL, V9, P80
NR 32
TC 8
Z9 8
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD JUL
PY 1997
VL 18
IS 13
BP 907
EP 913
DI 10.1016/S0142-9612(97)00014-8
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA XD775
UT WOS:A1997XD77500003
PM 9199760
DA 2018-10-19
ER

PT J
AU Smetana, K
   Lukas, J
   Paleckova, V
   Bartunkova, J
   Liu, FT
   Vacik, J
   Gabius, HJ
AF Smetana, K
   Lukas, J
   Paleckova, V
   Bartunkova, J
   Liu, FT
   Vacik, J
   Gabius, HJ
TI Effect of chemical structure of hydrogels on the adhesion and phenotypic
   characteristics of human monocytes such as expression of galectins and
   other carbohydrate-binding sites
SO BIOMATERIALS
LA English
DT Article
DE macrophages; endogenous lectins; galectins; biocompatability
ID MIGRATION INHIBITORY FACTOR; FUNCTIONAL-GROUPS; HUMAN-PLACENTA;
   INFLAMMATORY RESPONSES; BIOMEDICAL POLYMERS; CELL-FORMATION; IN-VIVO;
   MACROPHAGE; LECTIN; BIOMATERIALS
AB The reactivity of diverse immune aspects to the presence of synthetic polymers represents one of the most important aspects of implantable device biocompatibility. In this report, we show the effect of the chemical structure of a synthetic polymer support on monocyte adhesion and selected phenotypic characteristics in vitro as a model for the initial steps of non-self-recognition of an implant. The extent of monocyte adhesion was significantly influenced by the support chemistry. The highest level of monocyte adhesion was observed on a surface copolymer of 2-hydroxyethyl methacrylate with dimethyl aminoethyl methacrylate relative to results of experiments in which poly(2-hydroxyethyl methacrylate) or the copolymer of 2-hydroxyethyl methacrylate with the sodium salt of methacrylic acid was used. Cell adhesion to the polymers tested and to glass was accompanied by enhanced expression of the carbohydrate-binding sites tested for asialoglycoprotein beta-galactosides such as galectins, beta-N-acetylgalactosamine, alpha-mannoside, specific lectin for heparin as well as the lymphokine-macrophage migration inhibitory factor in the monocytes tested. These results suggest the importance of monocyte adhesion to the biomaterial surface for their development into macrophages and further non-self-recognition of the implanted device. (C) 1997 Elsevier Science Limited. All rights reserved.
C1 ACAD SCI CZECH REPUBL, INST MACROMOL CHEM, CZ-16502 PRAGUE 6, CZECH REPUBLIC.
   CHARLES UNIV, FAC MED 2, DEPT IMMUNOL, CZ-15018 PRAGUE, CZECH REPUBLIC.
   Scripps Res Inst, DEPT MOL & EXPT MED, LA JOLLA, CA 92037 USA.
   UNIV MUNICH, FAC VET MED, INST PHYSIOL CHEM, D-80539 MUNICH, GERMANY.
RP Smetana, K (reprint author), CHARLES UNIV, FAC MED 1, INST ANAT, U NEMOCNICE 3, CR-12800 PRAGUE 2, CZECH REPUBLIC.
RI Smetana, Karel/D-7039-2017
OI Smetana, Karel/0000-0002-7878-8403
CR ALI SAM, 1994, BIOMATERIALS, V15, P779, DOI 10.1016/0142-9612(94)90032-9
   ANDERSON JM, 1995, J BIOMAT SCI-POLYM E, V7, P159, DOI 10.1163/156856295X00670
   Andrade J.D., 1985, SURFACE INTERFACIAL, V1, P1985
   BONFIELD TL, 1993, J BIOMED MATER RES, V27, P1195, DOI 10.1002/jbm.820270910
   BRUIL A, 1992, BIOMATERIALS, V13, P915, DOI 10.1016/0142-9612(92)90114-4
   CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895
   Gabius Hans-Joachim, 1992, European Archives of Biology, V103, P15
   GABIUS HJ, 1991, PROG HISTOCHEM CYTOC, V22, P1
   GABIUS HJ, 1991, J HISTOCHEM CYTOCHEM, V39, P1249, DOI 10.1177/39.9.1918943
   GABIUS HJ, 1993, HISTOL HISTOPATHOL, V8, P369
   KAO WYJ, 1995, J BIOMED MATER RES, V29, P1267, DOI 10.1002/jbm.820291014
   KATAOKA M, 1985, EXP HEMATOL, V13, P44
   KAYSER K, 1994, EUR J CANCER, V30A, P653, DOI 10.1016/0959-8049(94)90538-X
   KAYSER K, 1995, ROUX ARCH DEV BIOL, V204, P344, DOI 10.1007/BF02179503
   KOHNKEGODT B, 1989, BIOCHEMISTRY-US, V28, P6531, DOI 10.1021/bi00442a001
   LEE RT, 1993, LECTINS GLYCOBIOLOGY, P9
   LIU FT, 1995, AM J PATHOL, V147, P1016
   MCNALLY AK, 1995, AM J PATHOL, V147, P1487
   MCNALLY AK, 1994, P NATL ACAD SCI USA, V91, P10119, DOI 10.1073/pnas.91.21.10119
   PEREZ RL, 1995, J IMMUNOL, V154, P1879
   ROSALES C, 1995, J LEUKOCYTE BIOL, V57, P189
   ROULEUXBONNIN F, 1995, BIOCHEM BIOPH RES CO, V217, P106, DOI 10.1006/bbrc.1995.2751
   RUSSELL ME, 1994, J CLIN INVEST, V94, P722, DOI 10.1172/JCI117391
   SEYFERT S, 1995, BIOMATERIALS, V16, P201, DOI 10.1016/0142-9612(95)92118-P
   SMETANA K, 1993, BIOMATERIALS, V14, P1046, DOI 10.1016/0142-9612(93)90203-E
   SMETANA K, 1991, J BIOACT COMPAT POL, V6, P377
   SMETANA K, 1990, J BIOMED MATER RES, V24, P463, DOI 10.1002/jbm.820240405
   SMETANA K, 1993, J MATER SCI-MATER M, V4, P526, DOI 10.1007/BF00120134
   SMETANA K, 1987, EXP MOL PATHOL, V47, P271, DOI 10.1016/0014-4800(87)90080-3
   SMETANA K, 1993, CLIN MATER, V13, P47, DOI 10.1016/0267-6605(93)90089-P
   SORIMACHI K, 1995, CELL BIOL INT, V19, P547, DOI 10.1006/cbir.1995.1099
   TANG LP, 1993, J EXP MED, V178, P2147, DOI 10.1084/jem.178.6.2147
   TANG LP, 1995, AM J CLIN PATHOL, V103, P466
   TANG LP, 1994, CELL MATER, V4, P429
   VANFURTH R, 1985, J INVEST DERMATOL, V85, P398, DOI 10.1111/1523-1747.ep12277056
   YUN JK, 1995, J BIOMED MATER RES, V29, P257, DOI 10.1002/jbm.820290217
   ZENG FY, 1994, BIOCHEM BIOPH RES CO, V200, P89, DOI 10.1006/bbrc.1994.1418
   ZENG FY, 1993, ARCH BIOCHEM BIOPHYS, V303, P74, DOI 10.1006/abbi.1993.1257
NR 38
TC 27
Z9 27
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD JUL
PY 1997
VL 18
IS 14
BP 1009
EP 1014
DI 10.1016/S0142-9612(97)00037-9
PG 6
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA XG555
UT WOS:A1997XG55500008
PM 9212197
DA 2018-10-19
ER

PT J
AU Elves, AWS
   Feneley, RCL
AF Elves, AWS
   Feneley, RCL
TI Long-term urethral catheterization and the urine - Biomaterial interface
SO BRITISH JOURNAL OF UROLOGY
LA English
DT Review
ID TAMM-HORSFALL PROTEIN; INDWELLING CATHETERS; ESCHERICHIA-COLI;
   NURSING-HOMES; ENCRUSTATION; ADHERENCE; ADHESION; MANAGEMENT; BLADDER;
   SURFACE
C1 SOUTHMEAD GEN HOSP,DEPT UROL,BRISTOL,AVON,ENGLAND.
CR BAYSTON R, 1972, DEV MED CHILD NEUROL, V14, P25
   BLOCK NL, 1977, T AM SOC ART INT ORG, V23, P367
   BROCKLEHURST JC, 1978, BRIT J UROL, V50, P102, DOI 10.1111/j.1464-410X.1978.tb03035.x
   BRUCE AW, 1974, CAN MED ASSOC J, V111, P238
   CHEUNG AL, 1989, J CLIN INVEST, V83, P2041, DOI 10.1172/JCI114115
   CHOONG S, 1996, EUR UROL S2, V30, P34
   DUNCAN JL, 1988, J INFECT DIS, V158, P1379, DOI 10.1093/infdis/158.6.1379
   FUSE H, 1994, J UROLOGY, V151, P1703, DOI 10.1016/S0022-5347(17)35348-X
   GETLIFFE KA, 1991, BRIT J UROL, V67, P337, DOI 10.1111/j.1464-410X.1991.tb15157.x
   GLEESON MJ, 1989, T AM SOC ART INT ORG, V35, P495
   HAWTHORN L, 1990, J BIOMED MATER RES, V24, P1325, DOI 10.1002/jbm.820241005
   HUKINS DWL, 1983, BRIT J UROL, V55, P304, DOI 10.1111/j.1464-410X.1983.tb03304.x
   JOHNSON GM, 1986, INFECT IMMUN, V54, P13
   KEANE PF, 1994, BRIT J UROL, V73, P687, DOI 10.1111/j.1464-410X.1994.tb07557.x
   KohlerOckmore J, 1996, BRIT J UROL, V77, P347, DOI 10.1046/j.1464-410X.1996.09074.x
   KUNIN CM, 1992, AM J EPIDEMIOL, V135, P291
   LEIDBERG H, 1989, UROL RES, V17, P357
   LEW PD, 1978, J CLIN INVEST, V63, P326
   LUNDBERG T, 1989, UROL RES, V17, P359
   MOBELY HL, 1987, J CLIN MICROBIOL, V25, P2216
   NICKEL JC, 1989, UROLOGY, V34, P284
   NOBEL MA, 1986, DIAGN MICR INFEC DIS, V4, P335
   ORSKOV I, 1980, LANCET, V1, P887
   PARSONS CL, 1975, INVEST UROL, V13, P72
   PETERS G, 1987, PATHOGENICITY CLIN S, P15
   PLATT R, 1982, NEW ENGL J MED, V307, P637, DOI 10.1056/NEJM198209093071101
   REID G, 1988, MICROBIAL ECOL, V16, P241, DOI 10.1007/BF02011698
   REID G, 1994, J BIOMED MATER RES, V28, P731, DOI 10.1002/jbm.820280610
   REID G, 1994, COLLOID SURFACE B, V2, P377
   RUGGIERI MR, 1987, J UROLOGY, V138, P423, DOI 10.1016/S0022-5347(17)43177-6
   SARANGAPANI S, 1995, J BIOMED MATER RES, V29, P1185, DOI 10.1002/jbm.820291005
   Sassoon E, 1991, Health Trends, V23, P109
   STAMM WE, 1991, AM J MED S3B, V91, pS65
   STICKLER D, 1993, UROL RES, V21, P407, DOI 10.1007/BF00300077
   STICKLER DJ, 1994, J HOSP INFECT, V28, P177, DOI 10.1016/0195-6701(94)90101-5
   Tunney Michael, 1996, Journal of Urology, V155, p473A
   VONBRONSWIJK H, 1989, IMMUNOLOGY, V67, P816
   ZIMAKOFF J, 1993, J HOSP INFECT, V24, P183, DOI 10.1016/0195-6701(93)90048-5
   ZIMMERLI W, 1982, J INFECT DIS, V146, P487, DOI 10.1093/infdis/146.4.487
NR 39
TC 19
Z9 20
U1 0
U2 2
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0NE
SN 0007-1331
J9 BRIT J UROL
JI Br. J. Urol.
PD JUL
PY 1997
VL 80
IS 1
BP 1
EP 5
DI 10.1046/j.1464-410X.1997.00208.x
PG 5
WC Urology & Nephrology
SC Urology & Nephrology
GA XL503
UT WOS:A1997XL50300002
PM 9240171
OA Bronze
DA 2018-10-19
ER

PT J
AU McDevitt, D
   Nanavaty, T
   HousePompeo, K
   Bell, E
   Turner, N
   McIntire, L
   Foster, T
   Hook, M
AF McDevitt, D
   Nanavaty, T
   HousePompeo, K
   Bell, E
   Turner, N
   McIntire, L
   Foster, T
   Hook, M
TI Characterization of the interaction between the Staphylococcus aureus
   clumping factor (ClfA) and fibrinogen
SO EUROPEAN JOURNAL OF BIOCHEMISTRY
LA English
DT Article
DE clumping factor; Staphylococcus aureus; fibrinogen; microbial surface
   components recognizing adhesive matrix molecules; platelet integrin
ID BINDING PROTEIN; NUCLEOTIDE-SEQUENCE; PLATELET-AGGREGATION; ALPHA-CHAIN;
   GAMMA-CHAIN; ADHERENCE; FIBRONECTIN; RECEPTOR; GENE; IDENTIFICATION
AB The ability of Staphylococcus aureus to adhere to adsorbed fibrinogen and fibrin is believed to be an important step in the initiation of biomaterial and wound-associated infections. In this study, we show that the binding site in fibrinogen for the recently identified S. aureus fibrinogen-binding protein clumping factor (ClfA) is within the C-terminus of the fibrinogen gamma chain. S. aureus Newman cells expressing ClfA adhered to microtitre wells coated with recombinant fibrinogen purified from BHK cells, but did not adhere to wells coated with a purified recombinant fibrinogen variant where the 4 C-terminal residues of the gamma chain were replaced by 20 unrelated residues. In addition, a synthetic peptide corresponding to the 17 C-terminal amino acids of the fibrinogen gamma chain effectively inhibited adherence of ClfA-expressing cells to fibrinogen. In western ligand blots, a recombinant truncated ClfA protein called Clf33 (residues 221-550) recognized intact recombinant fibrinogen gamma chains, but failed to recognize recombinant fibrinogen gamma chains when the 4 C-terminal amino acids were altered by deletion or substitution. Previous studies have shown that the C-terminal domain of fibrinogen gamma chains contains a binding site for the integrin alpha(IIb)beta(3) (glycoprotein gpIIb/IIIa) receptor on platelets [Kloczewiak, M., Timmons, S., Bednarek, M. A., Sakon, M. & Mawiger. J. (1989) Biochemistry 28, 2915-1919; Farrell, D. H., Thiagarajan, P., Chung, D. W. & Davie, E. W. (1992) Proc. Natl Acad Sci. USA 89, 10729-10732; Hettasch, J. M., Bolyard, M. G. & Lord, S. T. (1992) Thromb. Haemostasis 68, 701-706]. We now show that Clf33 inhibits ADP-induced, fibrinogen-dependent platelet aggregation in a concentration-dependent manner and inhibits adhesion of platelets to immobilized fibrinogen under fluid shear stress, indicating that the binding sites for the platelet integrin and the staphylococcal adhesin overlap. The interaction between Clf33 and fibrinogen was further characterized using the BIAcore biosensor. When soluble Clf33 was allowed to bind to immobilized fibrinogen, a K-d of 0.51+/-0.19 mu M was experimentally determined using equilibrium binding data. It was also shown that the synthetic C-terminal gamma-chain peptide effectively inhibited this interaction.
C1 TEXAS A&M UNIV,INST BIOSCI & TECHNOL,CTR EXTRACELLULAR MATRIX BIOL,HOUSTON,TX 77030.
   TEXAS A&M UNIV,INST BIOSCI & TECHNOL,DEPT BIOSCI & BIOTECHNOL,HOUSTON,TX 77030.
   RICE UNIV,COX LAB BIOMED ENGN,HOUSTON,TX 77251.
   TRINITY COLL DUBLIN,MOYNE INST,DEPT MICROBIOL,DUBLIN,IRELAND.
FU NHLBI NIH HHS [HO/18672]; NIAID NIH HHS [AI20624]; NINDS NIH HHS
   [NS/23327]; Wellcome Trust
CR BAIER RE, 1977, ANN NY ACAD SCI, V283, P17, DOI 10.1111/j.1749-6632.1977.tb41750.x
   BODEN MK, 1994, MOL MICROBIOL, V12, P599, DOI 10.1111/j.1365-2958.1994.tb01046.x
   BODEN MK, 1989, INFECT IMMUN, V57, P2358
   BORN GVR, 1963, J PHYSIOL-LONDON, V168, P178, DOI 10.1113/jphysiol.1963.sp007185
   CHEUNG AI, 1995, INFECT IMMUN, V63, P1914
   CHEUNG AL, 1990, J INFECT DIS, V161, P1177, DOI 10.1093/infdis/161.6.1177
   CHEUNG AL, 1991, J CLIN INVEST, V87, P2236, DOI 10.1172/JCI115259
   COTTONARO CN, 1981, ASAIO T, V27, P391
   CROWE JS, 1991, NUCLEIC ACIDS RES, V19, P184, DOI 10.1093/nar/19.1.184
   DISE CA, 1982, J BIOL CHEM, V257, P4701
   DUTHIE ES, 1952, J GEN MICROBIOL, V6, P95, DOI 10.1099/00221287-6-1-2-95
   FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729
   HAWIGER J, 1982, BIOCHEMISTRY-US, V21, P1407, DOI 10.1021/bi00535a047
   HAWIGER J, 1989, BIOCHEMISTRY-US, V28, P2909, DOI 10.1021/bi00433a024
   HERRMANN M, 1993, J INFECT DIS, V167, P312, DOI 10.1093/infdis/167.2.312
   HETTASCH JM, 1992, THROMB HAEMOSTASIS, V68, P701
   House-Pompeo Karen, 1994, Methods (Orlando), V6, P134, DOI 10.1006/meth.1994.1016
   HUBBELL JA, 1986, REV SCI INSTRUM, V57, P892, DOI 10.1063/1.1138830
   HUNTER WM, 1978, HDB EXPT IMMUNOLOGY
   JOH HJ, 1994, BIOCHEMISTRY-US, V33, P6086, DOI 10.1021/bi00186a007
   JONSSON K, 1991, EUR J BIOCHEM, V202, P1041, DOI 10.1111/j.1432-1033.1991.tb16468.x
   JONSSON K, 1995, J BIOL CHEM, V270, P21457, DOI 10.1074/jbc.270.37.21457
   KLOCZEWIAK M, 1989, BIOCHEMISTRY-US, V28, P2915, DOI 10.1021/bi00433a025
   KRISTINSSON KG, 1989, J MED MICROBIOL, V28, P249, DOI 10.1099/00222615-28-4-249
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LEONARD EF, 1977, ANN NY ACAD SCI, V201, P329
   MAKI DG, 1982, CURRENT CLIN TOPICS, V3, P309
   MCDEVITT D, 1992, INFECT IMMUN, V60, P1514
   MCDEVITT D, 1995, MOL MICROBIOL, V16, P895, DOI 10.1111/j.1365-2958.1995.tb02316.x
   MCDEVITT D, 1994, MOL MICROBIOL, V11, P237, DOI 10.1111/j.1365-2958.1994.tb00304.x
   MCGAVIN MH, 1993, INFECT IMMUN, V61, P2479
   PATTI JM, 1994, CURR OPIN CELL BIOL, V6, P752, DOI 10.1016/0955-0674(94)90104-X
   PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101
   PATTI JM, 1993, BIOCHEMISTRY-US, V32, P11428, DOI 10.1021/bi00093a021
   PATTI JM, 1995, J BIOL CHEM, V270, P12005, DOI 10.1074/jbc.270.20.12005
   RUSS JC, 1990, COMPUTER ASS MICROSC
   SIGNAS C, 1989, P NATL ACAD SCI USA, V86, P699, DOI 10.1073/pnas.86.2.699
   STRONG DD, 1982, BIOCHEMISTRY-US, V21, P1414, DOI 10.1021/bi00535a048
   TURITTO VT, 1982, PROG HEMOST THROMB, V6, P139
   VAUDAUX P, 1989, J INFECT DIS, V160, P865, DOI 10.1093/infdis/160.5.865
NR 40
TC 141
Z9 148
U1 1
U2 12
PU SPRINGER VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010
SN 0014-2956
J9 EUR J BIOCHEM
JI Eur. J. Biochem.
PD JUL 1
PY 1997
VL 247
IS 1
BP 416
EP 424
DI 10.1111/j.1432-1033.1997.00416.x
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA XJ247
UT WOS:A1997XJ24700054
PM 9249055
OA Bronze
DA 2018-10-19
ER

PT J
AU Bujan, J
   Contreras, LA
   CarreraSanMartin, A
   Bellon, JM
AF Bujan, J
   Contreras, LA
   CarreraSanMartin, A
   Bellon, JM
TI The behavior of different types of polytetrafluoroethylene (PTFE)
   prostheses in the reparative scarring process of abdominal wall defects
SO HISTOLOGY AND HISTOPATHOLOGY
LA English
DT Article
DE polytetrafluoroethylene; PTFE prostheses; abdominal wall; macrophages;
   rabbits
ID EXPANDED POLYTETRAFLUOROETHYLENE; MACROPHAGE RESPONSE; POLYPROPYLENE
   MESH; REPAIR; PATCH; RAT
AB Currently one of the most widely used prosthetic materials in the repair of abdominal wall defects, is expanded polytetrafluoroethylene (ePTFE). It has been suggested that its behavior with respect to the reparative process may depend on its structure. The aim of the present study was to evaluate the effect of the structure of 3 ePTFE prostheses on the scarring process in an abdominal-wall-defect experimental model. The prostheses employed were the Soft Tissue Patch (STP) which is laminar in structure, Mycro Mesh (MM) which is multilaminar with perforations, and the Dual Mesh (DM) prosthesis which has one non-porous surface. Abdominal wall defects (7x5 cm) were created in 36 New Zealand rabbits and repaired using fragments of STP, MM and DM. Follow-up periods were 14, 30, 60 and 90 days post-implant. At these times prostheses were macroscopically examined for the presence of infection and/or rejection and the formation of adhesions to abdominal viscera. Specimens were also taken for microscopic analysis (optical and scanning electron) and for immunohistochemical analysis using the rabbit macrophage-specific monoclonal antibody RAM-11. Labelled macrophage counts were performed at each follow-up session. No cases of infection or rejection were found. Loose adhesions between prosthesis and underlying viscera were observed in 2 of the STP, 4 of the MM and 2 of the DM implants. STP and DM implants were progressively encapsulated by organized connective tissue on both peritoneal and subcutaneous surfaces. Cellular colonization was observed on both STP surfaces and on the porous surface of the DM although no more than a third of the biomaterial was penetrated by cells in either case. Colonization was very slight at prosthesis anchorage points. MM implants differed only in the formation of connective tissue bridges in perforated areas, and cellular infiltration in interlaminar spaces. Macrophage response was similar in the 3 prostheses with a reduction in RAM-11 labelled cells (p<0.05) between 14 and 90 days post-implant. We conclude: a) the 3 types of PTFE prosthesis induced low incidence of adhesion formation between biomaterial and viscera; b) integration mechanisms of the 3 prostheses were similar and culminated with the encapsulation of the PTFE by the neoformed tissue; c) the macrophage response induced by the 3 prostheses was similar to that of any reparative process in the absence of biomaterial.
RP Bujan, J (reprint author), UNIV ALCALA DE HENARES, FAC MED, DEPT MORPHOL SCI & SURG, CRTA MADRID BARCELONA, KM 33-600, ALCALA DE HENARES 28871, MADRID, SPAIN.
OI bujan, Julia/0000-0003-2419-2476
CR AMID PK, 1994, J BIOMED MATER RES, V28, P373, DOI 10.1002/jbm.820280312
   Bellon JM, 1996, J AM COLL SURGEONS, V183, P11
   BELLON JM, 1995, BIOMATERIALS, V16, P381, DOI 10.1016/0142-9612(95)98855-8
   BELLON JM, 1994, EUR SURG RES, V26, P46, DOI 10.1159/000129317
   Bellon JM, 1996, J MATER SCI-MATER M, V7, P331, DOI 10.1007/BF00154544
   BERLINER SD, 1993, SURG GYNECOL OBSTET, V176, P323
   BJURSTEN LM, 1991, 9 EUR C BIOM CHEST U, P39
   BLACK J, 1992, BIOL PERFORMANCE MAT, P125
   DABROWIECKI S, 1991, EUR SURG RES, V23, P240, DOI 10.1159/000129159
   JENKINS SD, 1983, SURGERY, V94, P392
   LAW NW, 1991, SURGERY, V109, P652
   LAW NW, 1990, ACTA CHIR SCAND, V156, P759
   LEIBOVICH SJ, 1975, AM J PATHOL, V78, P71
   LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0
   MURPHY JL, 1989, CAN J SURG, V32, P244
   PANS A, 1992, EUR SURG RES, V24, P54, DOI 10.1159/000129188
   SIMMERMACHER RKJ, 1991, BIOMATERIALS, V12, P22, DOI 10.1016/0142-9612(91)90126-U
   TYRELL J, 1989, SURG GYNECOL OBSTET, V168, P227
   WALKER AP, 1993, J SURG RES, V55, P32, DOI 10.1006/jsre.1993.1104
NR 19
TC 16
Z9 16
U1 0
U2 2
PU F HERNANDEZ
PI MURCIA
PA PLAZA FUENSANTA 2-7 C, 30008 MURCIA, SPAIN
SN 0213-3911
EI 1699-5848
J9 HISTOL HISTOPATHOL
JI Histol. Histopath.
PD JUL
PY 1997
VL 12
IS 3
BP 683
EP 690
PG 8
WC Cell Biology; Pathology
SC Cell Biology; Pathology
GA XJ586
UT WOS:A1997XJ58600013
PM 9225151
DA 2018-10-19
ER

PT J
AU Lampin, M
   WarocquierClerout, R
   Legris, C
   Degrange, M
   SigotLuizard, MF
AF Lampin, M
   WarocquierClerout, R
   Legris, C
   Degrange, M
   SigotLuizard, MF
TI Correlation between substratum roughness and wettability, cell adhesion,
   and cell migration
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE biomaterial roughness; surface free-energy; cell adhesion; organotypic
   culture
ID SURFACE-PROPERTIES; POLYMER SURFACES; CONTACT-ANGLE; PROLIFERATION;
   FIBROBLASTS; ADSORPTION; CYTOCOMPATIBILITY; TITANIUM; ENERGY
AB Cell adhesion and spreading of chick embryo vascular and corneal explants grown on rough and smooth poly (methyl methacrylate) (PMMA) were analyzed to test the cell response specificity to substratum surface properties. Different degrees of roughness were obtained by sandblasting PMMA with alumina grains. Hydrophilic and hydrophobic components of the surface free energy (SFE) were calculated according to Good-van Oss's model. Contact angles were determined using a computerized angle meter. The apolar component of the SFE, gamma s(LW), increased with a slight roughness whereas the basic component, gamma s(-), decreased. The acido-basic properties disappeared as roughness increased. incubation of PMMA in culture medium, performed to test the influence of the biological environment, allowed surface adsorption of medium proteins which annihilated roughness effect and restored hydrophilic properties. An organotypic culture assay was carried out in an attempt to relate the biocompatibility to substratum surface state. Cell migration was calculated from the area of cell layer. Cellular adhesion was determined by measuring the kinetic of release of enzymatically dissociated cells. A slight roughness raised the migration area to an upper extent no matter which cell type. Enhancement of the cell adhesion potential was related to the degree of roughness and the hydrophobicity. (C) 1997 John Wiley & Sons, Inc.
C1 UNIV PARIS 05, FAC CHIRURG DENT, GRP RECH BIOMAT, PARIS, FRANCE.
RP Lampin, M (reprint author), UNIV TECHNOL COMPIEGNE, LAB BIOL CELLULAIRE EXPT, BP 529, F-60206 COMPIEGNE, FRANCE.
CR ABSOLOM DR, 1987, J BIOMED MATER RES, V21, P161, DOI 10.1002/jbm.820210202
   ALTANKOV G, 1994, J MATER SCI-MATER M, V5, P732, DOI 10.1007/BF00120366
   Brunette D M, 1988, Int J Oral Maxillofac Implants, V3, P231
   BUSSCHER HJ, 1984, COLLOID SURFACE, V9, P319, DOI 10.1016/0166-6622(84)80175-4
   BUSSCHER HJ, 1991, CELL MATER, V1, P243
   CHARRIER JL, 1993, J BIOMAT DENT, V8, P111
   COGNARD J, 1987, J CHIM PHYS PCB, V84, P357, DOI 10.1051/jcp/1987840357
   Dupre A., 1869, THEORIE MECANIQUE CH, P369
   DUVAL JL, 1988, BIOMATERIALS, V9, P155, DOI 10.1016/0142-9612(88)90115-9
   FOWKES FM, 1990, J ADHES SCI TECHNOL, V4, P669, DOI 10.1163/156856190X00595
   GOOD RJ, 1992, J ADHES SCI TECHNOL, V6, P1269, DOI 10.1163/156856192X00629
   GROTH T, 1995, J BIOMAT SCI-POLYM E, V7, P297
   HACHOM GC, 1994, 11 EUR C BIOM PIS IT, P353
   HATTORI S, 1985, J COLLOID INTERF SCI, V104, P72, DOI 10.1016/0021-9797(85)90010-4
   KEISLER C, 1995, J ADHES SCI TECHNOL, V9, P395, DOI 10.1163/156856195X00347
   KONONEN M, 1992, J BIOMED MATER RES, V26, P1325
   Kothari S, 1995, J MATER SCI-MATER M, V6, P695, DOI 10.1007/BF00134303
   LAMPIN M, 1995, J BIOMATERIAUX DENTA, V10, P67
   MARTIN JY, 1995, J BIOMED MATER RES, V29, P389, DOI 10.1002/jbm.820290314
   NAJI A, 1990, J BIOMED MATER RES, V24, P861, DOI 10.1002/jbm.820240706
   PEREZLUNA VH, 1994, J BIOMED MATER RES, V28, P1111, DOI 10.1002/jbm.820281002
   QUIRYNEN M, 1990, J CLIN PERIODONTOL, V17, P138, DOI 10.1111/j.1600-051X.1990.tb01077.x
   ROUX H, 1992, ADV BIOMAT, V10, P81
   RUARDY TG, 1995, J BIOMED MATER RES, V29, P1415, DOI 10.1002/jbm.820291113
   SCHULZE RD, 1989, J ADHES SCI TECHNOL, V3, P39, DOI 10.1163/156856189X00038
   Sigot-Luizard M F, 1993, J Invest Surg, V6, P251, DOI 10.3109/08941939309141616
   SIGOTLUIZARD MF, 1986, IN VITRO CELL DEV B, V22, P234
   UEDA T, 1995, J BIOMED MATER RES, V29, P381, DOI 10.1002/jbm.820290313
   VANOSS CJ, 1986, J COLLOID INTERF SCI, V111, P378, DOI 10.1016/0021-9797(86)90041-X
   VANWACHEM PB, 1987, BIOMATERIALS, V8, P323, DOI 10.1016/0142-9612(87)90001-9
   YASUDA H, 1978, J BIOMED MATER RES, V12, P701, DOI 10.1002/jbm.820120510
   Young T, 1805, PHILOS T R SOC LONDO, V95, P65, DOI DOI 10.1098/RSTL.1805.0005
NR 32
TC 524
Z9 532
U1 11
U2 220
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD JUL
PY 1997
VL 36
IS 1
BP 99
EP 108
DI 10.1002/(SICI)1097-4636(199707)36:1<99::AID-JBM12>3.0.CO;2-E
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA XG354
UT WOS:A1997XG35400012
PM 9212394
DA 2018-10-19
ER

PT J
AU Hanawa, T
   Kamiura, Y
   Yamamoto, S
   Kohgo, T
   Amemiya, A
   Ukai, H
   Murakami, K
   Asaoka, K
AF Hanawa, T
   Kamiura, Y
   Yamamoto, S
   Kohgo, T
   Amemiya, A
   Ukai, H
   Murakami, K
   Asaoka, K
TI Early bone formation around calcium-ion-implanted titanium inserted into
   rat tibia
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE titanium; calcium ion implantation; rat tibia; fluorescence microscope;
   bone formation
ID PHOSPHATE PRECIPITATION; ELECTROLYTE
AB Rat tibia tissue into which calcium ion (Ca2+)-implanted titanium was surgically placed was histologically analyzed to investigate the performance of the Ca2+-implanted titanium as a biomaterial. Calcium ions were implanted into only one side of titanium plates at 10(17) ions/cm(2) and the Ca2+-treated titanium was surgically implanted into rat tibia for 2, 8, and 18 days. Tetracycline and calcein were used as hard-tissue labels. After excision of the tibia, the tissues were fixed, stained, embedded in polymethyl methacrylate, and sliced. The specimens were observed using a fluorescence microscope. A larger amount of new bone was formed on the Ca2+-treated side than on the untreated side, even at 2 days after surgery. In addition, part of the bone made contact with the Ca2+-treated surface. On the other hand, bone formation on the untreated side was delayed and the bone did not make contact with the surface. Mature bone with bone marrow formed in 8 days. Neither macrophage nor inflammatory cell infiltration was observed. The results indicated that Ca2+-implanted titanium is superior to titanium alone for bone conduction. (C) 1997 John Wiley & Sons.
C1 HOKKAIDO UNIV,SCH DENT,DEPT PROSTHET DENT 1,SAPPORO,HOKKAIDO,JAPAN.
   HOKKAIDO UNIV,SCH DENT,DEPT ORAL PATHOL,SAPPORO,HOKKAIDO,JAPAN.
   ISHIKAWAJIMA HARIMA HEAVY IND CO LTD,RES INST,TOKYO 135,JAPAN.
RP Hanawa, T (reprint author), UNIV TOKUSHIMA,SCH DENT,DEPT DENT ENGN,3 KURAMOTO CHO,TOKUSHIMA 770,JAPAN.
CR DAMEN JJM, 1991, J DENT RES, V70, P1346, DOI 10.1177/00220345910700100601
   HANAWA T, 1991, BONE-BIOMATERIAL INTERFACE, P49
   HANAWA T, 1992, APPL SURF SCI, V55, P269, DOI 10.1016/0169-4332(92)90178-Z
   HANAWA T, 1991, BIOMATERIALS, V12, P767, DOI 10.1016/0142-9612(91)90028-9
   HANAWA T, 1995, MATER T JIM, V36, P438, DOI 10.2320/matertrans1989.36.438
   HANAWA T, 1994, AM SOC TEST MATER, V1196, P170, DOI 10.1520/STP25192S
   HANAWA T, 1993, J ELECTRON SPECTROSC, V63, P347, DOI 10.1016/0368-2048(93)80032-H
   HANAWA T, 1996, T 5 WORLD BIOM C SOC, P224
   HANAWA T, 1994, J JPN SOC BIOMATER, V12, P209
   KOHAVI D, 1992, BIOMATERIALS, V13, P255, DOI 10.1016/0142-9612(92)90193-R
   MIZUTA S, 1986, CERAMIC MAT, P109
   SCHWARTZ Z, 1991, CALCIFIED TISSUE INT, V49, P359, DOI 10.1007/BF02556260
   SPECTOR M, 1994, P 20 ANN M SOC BIOM, P330
   SUNDGREN JE, 1986, J COLLOID INTERF SCI, V113, P530, DOI 10.1016/S0021-9797(86)90446-7
NR 14
TC 184
Z9 185
U1 2
U2 20
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD JUL
PY 1997
VL 36
IS 1
BP 131
EP 136
DI 10.1002/(SICI)1097-4636(199707)36:1<131::AID-JBM16>3.0.CO;2-L
PG 6
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA XG354
UT WOS:A1997XG35400016
PM 9212398
DA 2018-10-19
ER

PT J
AU Li, SH
   Liu, Q
   deWijn, J
   Zhou, BL
   deGroot, K
AF Li, SH
   Liu, Q
   deWijn, J
   Zhou, BL
   deGroot, K
TI Calcium phosphate formation induced on silica in bamboo
SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE
LA English
DT Article
AB The effect of in vitro induction of calcium phosphate on bamboo surfaces is reported for the first time. Bamboo is studied for biomaterial application due to its elasticity modulus being closer to human bone than other biomaterials. Following an earlier study of cytotoxicity and precipitation of apatite on ground tissue and vascular bundles of bamboo, the composition a nd function of the minerals in bamboo, especially silica, a reconsidered in the present work. It is found that in both outer and inner surfaces of bamboo culm, there exists-some silica. Bamboo elicits an inert response when soaked directly in calcification solution. After the rind of bamboo is treated with sodium hydroxide solution, the silica underneath can induce precipitation of calcium phosphate in an ambient environment. Furthermore, by subsequent grafting with polyethylene glycol (PEG 1000), calcium phosphate induction of bamboo rind can be improved,depending on the concentration of NaOH solution and treatment time. Heat treatment of bamboo can remove the organic materials around the minerals in bamboo, allowing the calcification behaviour of the silica-containing inorganic phase of bamboo in aqueous solution to be studied.
C1 ACAD SINICA,INST MET RES,SHENYANG 110015,PEOPLES R CHINA.
RP Li, SH (reprint author), LEIDEN UNIV,BIOMAT RES GRP,PROF BRONKHORSTLAAN 10,NL-3723 MB BILTHOVEN,NETHERLANDS.
CR ABE Y, 1990, J MATER SCI-MATER M, V1, P233, DOI 10.1007/BF00701082
   FRENSDORFF HK, 1971, J AM CHEM SOC, V93, P4684, DOI 10.1021/ja00748a006
   HENCH LL, 1993, INTRO BIOCERAMICS, P48
   HOSSAINY SFA, 1994, BIOMATERIALS, V15, P921, DOI 10.1016/0142-9612(94)90118-X
   KOKUBO T, 1991, P 4 INT S CER MED LO, P113
   KOKUBO T, 1992, BONE BONDING BIOMATE, P38
   LI PJ, 1992, J AM CERAM SOC, V75, P2094, DOI 10.1111/j.1151-2916.1992.tb04470.x
   LI SH, 1996, IN PRESS BIOMATERIAL
   LIESE W, 1985, BAMBOOS BIOL SILVICS, P73
NR 9
TC 9
Z9 9
U1 1
U2 4
PU CHAPMAN HALL LTD
PI LONDON
PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8HN
SN 0957-4530
J9 J MATER SCI-MATER M
JI J. Mater. Sci.-Mater. Med.
PD JUL
PY 1997
VL 8
IS 7
BP 427
EP 433
DI 10.1023/A:1018557605910
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA XJ842
UT WOS:A1997XJ84200006
PM 15348726
DA 2018-10-19
ER

PT J
AU Sapatnekar, S
   Kao, WJ
   Anderson, JM
AF Sapatnekar, S
   Kao, WJ
   Anderson, JM
TI Leukocyte-biomaterial interactions in the presence of Staphylococcus
   epidermidis: Flow cytometric evaluation of leukocyte activation
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE leukocyte activation; S-epidermidis; shear stress; adhesion
ID COMPLEMENT ACTIVATION; GRAFT INFECTION; POLYMORPHONUCLEAR LEUKOCYTES;
   CARDIOPULMONARY BYPASS; ADHESION; HEMODIALYSIS; AUREUS; MAC-1;
   NEUTROPHILS; INDUCTION
AB The adhesion of bacteria on a biomaterial surface is believed to be the first step in the development of biomaterial-related infection. The goal of this study was to investigate the mechanisms that permit adherent bacteria to persist on the surface of an implanted cardiovascular biomaterial. We hypothesized that circulating leukocytes are unable to adhere to the biomaterial surface under physiologic shear stress conditions, and this prevents them from interacting with adherent bacteria. To address this hypothesis, we investigated the adhesion profiles of Staphylococcus epidermidis and polymorphonuclear leukocytes (PMN), incubated under controlled shear stress conditions with the test biomaterial. We found that bacteria could adhere on the biomaterial surface, even when their concentration in the test medium was as low as 10(3) cfu/mL. At this concentration, the bacteria did not induce significant complement activation. PMN adhesion on the biomaterial surface was sensitive to shear stress and minimal at shear stress >10 dynes/cm(2). Low concentrations of bacteria could induce a significant increase in the expression of PMN adhesion molecules CD11b and CD11c. We conclude that the presence of bacteria induces PMN activation but does not increase PMN adhesion on biomaterial surfaces under physiologic shear stress conditions. This could be a major mechanism that protects adherent bacteria from PMN antibacterial activity. (C) 1997 John Wiley & Sons, Inc.
C1 CASE WESTERN RESERVE UNIV,INST PATHOL,CLEVELAND,OH 44106.
   CASE WESTERN RESERVE UNIV,DEPT MACROMOL SCI,CLEVELAND,OH 44106.
FU NHLBI NIH HHS [HL-47300, HL-25239, HL-33849]
CR ARNOUT MA, 1985, NEW ENGL J MED, V312, P457
   BANDYK DF, 1984, ARCH SURG-CHICAGO, V119, P102
   BANDYK DF, 1994, SURG CLIN N AM, V74, P571
   BRUNSTEDT MR, 1994, J BIOMED MATER RES, V29, P455
   CHEUNG AK, 1994, NEPHROL DIAL TRANSPL, V9, P96
   COSTERTON JW, 1995, ANNU REV MICROBIOL, V49, P711, DOI 10.1146/annurev.mi.49.100195.003431
   CRAMER EB, 1992, INFLAMMATION BASIC P, P341
   DEPPISCH R, 1990, KIDNEY INT, V37, P696, DOI 10.1038/ki.1990.36
   DESCAMPSLATSCHA B, 1991, NEPHRON, V59, P279, DOI 10.1159/000186565
   DICKINSON GM, 1989, ANTIMICROB AGENTS CH, V33, P597, DOI 10.1128/AAC.33.5.597
   DREYER WJ, 1991, J THORAC CARDIOV SUR, V102, P318
   GABOURY JP, 1994, BLOOD, V83, P345
   GRISTINA AG, 1993, INT J ARTIF ORGANS, V16, P755
   GRISTINA AG, 1987, SCIENCE, V237, P1588, DOI 10.1126/science.3629258
   HENSON PM, 1992, INFLAMMATION BASIC P, P511
   HERRMANN M, 1993, J INFECT DIS, V167, P312, DOI 10.1093/infdis/167.2.312
   HIMMELFARB J, 1992, KIDNEY INT, V41, P388, DOI 10.1038/ki.1992.54
   HIMMELFARB J, 1991, AM J KIDNEY DIS, V17, P271, DOI 10.1016/S0272-6386(12)80473-2
   JACOBS AA, 1989, NEPHRON, V52, P119
   Kao WJ, 1996, J BIOMED MATER RES, V32, P99, DOI 10.1002/(SICI)1097-4636(199609)32:1<99::AID-JBM12>3.3.CO;2-E
   KAPPELMAYER J, 1993, J LAB CLIN MED, V121, P118
   KEARNEY RA, 1994, ANN INTERN MED, V121, P219, DOI 10.7326/0003-4819-121-3-199408010-00010
   LAWRENCE MB, 1990, BLOOD, V75, P227
   LAWRENCE MB, 1987, BLOOD, V70, P1284
   LEWIS SL, 1991, ADV EXP MED BIOL, V297, P167
   NATION JL, 1983, STAIN TECHNOL, V58, P347, DOI 10.3109/10520298309066811
   OBRIEN T, 1992, BRIT J SURG, V79, P1262, DOI 10.1002/bjs.1800791205
   OFEK I, 1994, BACTERIAL ADHESION C, P136
   RIBER U, 1995, APMIS, V103, P439, DOI 10.1111/j.1699-0463.1995.tb01130.x
   RIBER U, 1993, APMIS, V101, P55, DOI 10.1111/j.1699-0463.1993.tb00081.x
   RINDER CS, 1992, BLOOD, V79, P1201
   SLACK SM, 1993, CARDIOVASC PATHOL, V2, pS11
   STOSSEL TP, 1971, J CLIN INVEST, V50, P1745, DOI 10.1172/JCI106664
   THYLEN P, 1992, AM J NEPHROL, V12, P393, DOI 10.1159/000168488
   VAUDAUX PE, 1985, INFECT IMMUN, V50, P472
   WANG IW, 1993, J INFECT DIS, V167, P329, DOI 10.1093/infdis/167.2.329
NR 36
TC 8
Z9 8
U1 0
U2 1
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD JUN 15
PY 1997
VL 35
IS 4
BP 409
EP 420
DI 10.1002/(SICI)1097-4636(19970615)35:4<409::AID-JBM1>3.0.CO;2-L
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA XD086
UT WOS:A1997XD08600001
PM 9189819
DA 2018-10-19
ER

PT J
AU Ryhanen, J
   Niemi, E
   Serlo, W
   Niemela, E
   Sandvik, P
   Pernu, H
   Salo, T
AF Ryhanen, J
   Niemi, E
   Serlo, W
   Niemela, E
   Sandvik, P
   Pernu, H
   Salo, T
TI Biocompatibility of nickel-titanium shape memory metal and its corrosion
   behavior in human cell cultures
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE biocompatibility; nitinol; shape memory alloy; corrosion; human cell
   cultures
ID ESOPHAGEAL STRICTURES; GINGIVAL FIBROBLASTS; ORTHOPEDIC IMPLANTS;
   NITINOL STENT; OSTEOBLASTS; SENSITIVITY; ALLOYS; BONE
AB Nickel-titanium alloy (Nitinol) is a metallic biomaterial. that has a unique thermal shape memory, superelasticity, and high damping properties. Nitinol is potentially very useful in orthopedic surgery, for example. At present, there are not enough confirmative biocompatibility data available on Nitinol. The aim of our study was to clarify the primary cytotoxicity and corrosion rate of Nitinol in human cell cultures. Comparisons were made with stainless steel (Stst), titanium (Ti), composite material (C), and control cultures with no test discs. Human osteoblasts (OB) and fibroblasts (FB) were incubated for 10 days with test discs of equal size, 6 x 7 mm. The cultures were photographed and the cells counted. Samples from culture media were collected on days 2, 4, 6, and 8, and the analysis of metals in the media was done using flameless atomic absorption spectrophotometry. The proliferation of FB was 108% (Nitinol), 134% (Ti) (p < 0.02), 107% (Stst), and 48% (C)(p < 0.0001) compared to the control cultures. The proliferation of OB was 101% (Nitinol), 100% (Ti), 105% (Stst), and 54% (C) (p < 0.025) compared to the controls. Initially, Nitinol released more nickel (129-87 mu g/L) into the cell culture media than Stst (7 mu g/L), but after 2 days the concentrations were about equal (23-5 mu g/L versus 11-1 mu g/L). The titanium concentrations from both Nitinol and Ti samples were all <20 mu g/L. We conclude that Nitinol has good in vitro biocompatibility with human osteoblasts and fibroblasts. Despite the higher initial nickel dissolution, Nitinol induced no toxic effects, decrease in cell proliferation, or inhibition on the growth of cells in contact with the metal surface. (C) 1997 John Wiley & Sons, Inc.
C1 UNIV OULU,INST DENT,DEPT ORAL & MAXILLOFACIAL SURG,FIN-90220 OULU,FINLAND.
   UNIV OULU,DEPT PEDIAT & SURG,FIN-90220 OULU,FINLAND.
   RAAHE HOSP,DEPT SURG,FIN-92100 RAAHE,FINLAND.
   RAUTARUUKKI OY,RES CTR,FIN-92101 RAAHE,FINLAND.
RP Ryhanen, J (reprint author), UNIV OULU,DEPT SURG,KAJAANINTIE 52 A,FIN-90220 OULU,FINLAND.
CR ALBREKTSSON T, 1983, ANN BIOMED ENG, V11, P1, DOI 10.1007/BF02363944
   Andreasen G. F., 1987, ENCY MED DEVICES INS, V2, P15
   BARNETSON R, 1993, IMMUNOLOGY
   Baumgart F., 1980, CURRENT CONCEPTS INT, P122
   BEZZI M, 1994, J VASC INTERV RADIOL, V5, P287, DOI 10.1016/S1051-0443(94)71485-8
   Bhattacharyya K. C., 1994, MECH PHASE TRANSFORM, P1
   BJURHOLM A, 1990, ACTA ORTHOP SCAND, V61, P248, DOI 10.3109/17453679008993510
   BROWN SA, 1987, ENCY MED DEVICES INS, V2, P351
   Buehler WJ, 1968, OCEAN ENGNG, V1, P105
   CASTLEMAN LS, 1976, J BIOMED MATER RES, V10, P695, DOI 10.1002/jbm.820100505
   CRAGG AH, 1993, RADIOLOGY, V189, P775, DOI 10.1148/radiology.189.3.8234703
   CWIKIEL W, 1993, RADIOLOGY, V187, P667, DOI 10.1148/radiology.187.3.8497612
   CWIKIEL W, 1993, RADIOLOGY, V187, P661, DOI 10.1148/radiology.187.3.7684528
   EDIE JW, 1981, ANGLE ORTHOD, V51, P319
   Endo K, 1994, Dent Mater J, V13, P228
   FERGUSON AB, 1960, J BONE JOINT SURG AM, V42, P77, DOI 10.2106/00004623-196042010-00007
   GAWKRODGER DJ, 1993, CONTACT DERMATITIS, V28, P257, DOI 10.1111/j.1600-0536.1993.tb03427.x
   Gerber H, 1980, EVALUATION BIOMATERI, P307
   GRIMSDOTTIR M R, 1992, European Journal of Orthodontics, V14, P47
   Hornbogen E, 1992, PROGR SHAPE MEMORY A, P3
   Ishii Norihisa, 1993, Journal of Dermatological Science, V6, P159, DOI 10.1016/0923-1811(93)90007-C
   KONONEN M, 1992, J BIOMED MATER RES, V26, P1325
   KRUGER J, 1983, BIOMATERIALS RECONST, P145
   KUO PPF, 1989, ORTHOPEDICS, V12, P68
   MALONEY WJ, 1993, J BONE JOINT SURG AM, V75A, P835, DOI 10.2106/00004623-199306000-00005
   MEACHIM G, 1973, J BIOMED MATER RES, V7, P555, DOI 10.1002/jbm.820070607
   MORRISON C, 1995, BIOMATERIALS, V16, P987, DOI 10.1016/0142-9612(95)94906-2
   NAKAMURA T, 1991, ASAIO T, V37, P319
   OSHIDA Y, 1992, Bio-Medical Materials and Engineering, V2, P51
   PELTOLA M, 1992, ENDOD DENT TRAUMATOL, V8, P120
   PELTONEN L, 1979, CONTACT DERMATITIS, V5, P27, DOI 10.1111/j.1600-0536.1979.tb05531.x
   PUTTERS JLM, 1992, EUR SURG RES, V24, P378, DOI 10.1159/000129231
   RAE T, 1986, TECHNIQUES BIOCOMPAT, V2, P81
   RANDIN JP, 1988, J BIOMED MATER RES, V22, P649, DOI 10.1002/jbm.820220706
   RIFAS L, 1989, J CLIN INVEST, V84, P686, DOI 10.1172/JCI114216
   SANDERS JO, 1993, SPINE, V18, P1640, DOI 10.1097/00007632-199309000-00012
   SERRE CM, 1994, ACTA ORTHOP SCAND, V65, P323, DOI 10.3109/17453679408995462
   SHANBHAG AS, 1994, J BIOMED MATER RES, V28, P81, DOI 10.1002/jbm.820280111
   SIMON M, 1989, RADIOLOGY, V172, P99, DOI 10.1148/radiology.172.1.2662259
   SIMSKE SJ, 1995, J BIOMED MATER RES, V29, P527, DOI 10.1002/jbm.820290413
   VANHOOGSTRATEN IMW, 1992, J INVEST DERMATOL, V99, P608, DOI 10.1111/1523-1747.ep12668010
NR 41
TC 235
Z9 248
U1 3
U2 50
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD JUN 15
PY 1997
VL 35
IS 4
BP 451
EP 457
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA XD086
UT WOS:A1997XD08600005
PM 9189823
DA 2018-10-19
ER

PT J
AU Cook, AD
   Hrkach, JS
   Gao, NN
   Johnson, IM
   Pajvani, UB
   Cannizzaro, SM
   Langer, R
AF Cook, AD
   Hrkach, JS
   Gao, NN
   Johnson, IM
   Pajvani, UB
   Cannizzaro, SM
   Langer, R
TI Characterization and development of RGD-peptide-modified poly(lactic
   acid-co-lysine) as an interactive, resorbable biomaterial
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
ID FUNCTIONAL-GROUPS; SURFACE; COPOLYMERS; POLYMERS; BEHAVIOR; ADHESION;
   GROWTH
AB The design of biomaterials containing specific ligands on the surface offers the possibility of creating materials that can interact with and potentially control mammalian cell behavior. Biodegradable materials further provide the significant advantage that the polymer will disappear in vivo, obviating long-term negative tissue responses as well as the need for retrieval. In earlier studies we synthesized and characterized arginine-glycine-aspartic acid (RGD) peptide-modified poly(lactic acid-co-lysine) (PLAL). In this study, both bulk properties and surface features have been characterized, with a focus on surface analysis as a means of interpreting observed changes in cell behavior. Bulk peptide attachments were performed using 1,1'-carbonyldiimidazole (CDI). Amino groups were measured using colorimetric assays and X-ray photoelectron spectroscopy (XPS). Peptides were measured by incorporating iodine into the peptide as a distinct elemental marker for use with XPS. Typical samples contained 13 +/- 4 pmol/cm(2) of amino groups and 4 +/- 0.2 pmol/ cm(2) of peptides, as calculated from XPS measurements of nitrogen and iodine. The wettability and crystallinity of the samples were determined by contact angles and differential scanning calorimetry, respectively Wettability and crystallinity were not altered by the incorporation of lysine or peptides. After incubating bovine aortic endothelial (BAE) cells for 4 h on surfaces with RGD-containing peptides, the mean spread cell area increased from 77 +/- 2 mu m(2) to 405 +/- 29 mu m(2) compared to 116 +/- 11 mu m(2) an poly(lactic acid), 87 +/- 4 mu m(2) on PLAL, and 105 +/- 4 mu m(2) on surfaces with RDG-containing (control) peptides. The significance of this work is that the first synthetic interactive, resorbable biomaterial has been developed, and use of this material to control cell behavior has been demonstrated. (C) 1997 John Wiley & Sons, Inc.
C1 MIT,DEPT CHEM ENGN,CAMBRIDGE,MA 02139.
FU NIGMS NIH HHS [GM08334-06]
CR ANDERSON J M, 1987, P687
   BARRERA DA, 1993, J AM CHEM SOC, V115, P11010, DOI 10.1021/ja00076a077
   BARRERA DA, 1995, MACROMOLECULES, V28, P425, DOI 10.1021/ma00106a004
   BARRERA DA, 1993, THESIS MIT CAMBRIDGE
   BRANDLEY BK, 1988, ANAL BIOCHEM, V172, P270, DOI 10.1016/0003-2697(88)90442-3
   CIMA LG, 1991, J BIOMECH ENG-T ASME, V113, P143, DOI 10.1115/1.2891228
   COOK AD, 1996, THESIS MIT CAMBRIDGE, P168
   Desai N. P., 1990, POLYM MAT SCI ENG, V62, P731
   ERTEL SI, 1990, J BIOMED MATER RES, V24, P1637, DOI 10.1002/jbm.820241207
   FALB RD, 1971, FED PROC, V30, P1688
   FISCHER EW, 1973, KOLLOID Z Z POLYM, V251, P980, DOI 10.1007/BF01498927
   HRKACH JS, 1995, MACROMOLECULES, V28, P4736, DOI 10.1021/ma00117a055
   IKADA Y, 1994, BIOMATERIALS, V15, P725, DOI 10.1016/0142-9612(94)90025-6
   KALB B, 1980, POLYMER, V21, P607, DOI 10.1016/0032-3861(80)90315-8
   KOBAYASHI K, 1988, J MACROMOL SCI CHEM, VA25, P655, DOI 10.1080/00222338808053391
   LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529
   LEE JH, 1994, BIOMATERIALS, V15, P705, DOI 10.1016/0142-9612(94)90169-4
   LIN HB, 1991, J BIOMAT SCI-POLYM E, V3, P217
   MASSIA SP, 1990, ANAL BIOCHEM, V187, P292, DOI 10.1016/0003-2697(90)90459-M
   MASSIA SP, 1991, J CELL BIOL, V114, P1089, DOI 10.1083/jcb.114.5.1089
   MAZZUCOTELLI JP, 1993, ARTIF ORGANS, V17, P787
   OLIVIER LA, 1993, BIOTECHNOL BIOENG, V42, P963, DOI 10.1002/bit.260420807
   PEPPAS NA, 1994, SCIENCE, V263, P1715, DOI 10.1126/science.8134835
   RASMUSSEN JR, 1977, J AM CHEM SOC, V99, P4736, DOI 10.1021/ja00456a035
   VACANTI CA, 1991, PLAST RECONSTR SURG, V88, P753, DOI 10.1097/00006534-199111000-00001
   VACANTI JP, 1988, J PEDIATR SURG, V23, P3, DOI 10.1016/S0022-3468(88)80529-3
   VACANTI JP, 1988, ARCH SURG-CHICAGO, V123, P545
   WEIGEL PH, 1979, J BIOL CHEM, V254, P830
NR 28
TC 255
Z9 285
U1 3
U2 57
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD JUN 15
PY 1997
VL 35
IS 4
BP 513
EP 523
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA XD086
UT WOS:A1997XD08600011
PM 9189829
DA 2018-10-19
ER

PT J
AU Pan, J
   Leygraf, C
   Thierry, D
   Ektessabi, AM
AF Pan, J
   Leygraf, C
   Thierry, D
   Ektessabi, AM
TI Corrosion resistance for biomaterial applications of TiO2 films
   deposited on titanium and stainless steel by ion-beam-assisted
   sputtering
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
ID MOTT-SCHOTTKY PLOTS; PASSIVE FILMS; OXIDE-FILMS; IMPLANT MATERIALS;
   HYDROGEN; ELECTRODES; INTERFACE; ALLOYS; GROWTH
AB The high corrosion resistance and good biocompatibility of titanium and its alloys are due to a thin passive film that consists essentially of titanium dioxide. There is increasing evidence, however, that under certain conditions extensive titanium release may occur in vivo. An ion-beam-assisted sputtering deposition technique has been used to deposit thick and dense TiO2 films on titanium and stainless steel surfaces. In this study, using the following measurements these TiO2 films have been investigated in a phosphate-buffered saline solution: (1) open-circuit potential versus time of exposure, (2) electrochemical impedance spectroscopy, (3) potentiodynamic polarization, and (4) Mott-Schottky plot. A higher electrical film resistance, lower passive current density, and lower donor density (in the order of 10(15) cm(-3)) have been measured for the sputter-deposited oxide film on titanium in contrast to the naturally formed passive oxide film on titanium (donor density in the order of 10(20) cm(-3)). The improved corrosion protection of the sputter-deposited oxide film can be explained by a low defect concentration and, consequently, by a slow mass transport process across the film. As opposed to TiO2 on titanium, a deviation from normal n-type semiconducting Mott-Schottky behavior was observed for TiO2 on stainless steel. (C) 1997 John Wiley & Sons, Inc.
C1 SWEDISH CORROS INST,S-10405 STOCKHOLM,SWEDEN.
   KYOTO UNIV,FAC ENGN,SAKYO KU,KYOTO 60601,JAPAN.
RP Pan, J (reprint author), ROYAL INST TECHNOL,DEPT MAT SCI & ENGN,DR KRISTINAS VAG 51,S-10044 STOCKHOLM,SWEDEN.
CR ALBREKTSSON T, 1983, ANN BIOMED ENG, V11, P1, DOI 10.1007/BF02363944
   Albrektsson T., 1984, CRIT REV BIOCOMPAT, V1, P53
   BLACK J, 1994, COMPATIBILITY BIOMED, P35
   BLACKWOOD DJ, 1989, ELECTROCHIM ACTA, V34, P1505, DOI 10.1016/0013-4686(89)87033-1
   BONHAM DB, 1992, J ELECTROCHEM SOC, V139, P127, DOI 10.1149/1.2069156
   Brett C. M. A., 1993, ELECTROCHEMISTRY PRI
   CHOI YK, 1992, J ELECTROCHEM SOC, V139, P1803, DOI 10.1149/1.2069501
   CLAYTON CR, 1995, CORROSION MECH THEOR, P175
   COOPER G, 1982, J ELECTROCHEM SOC, V129, P1973, DOI 10.1149/1.2124334
   DAWSON JL, 1993, AM SOC TEST MATER, V1188, P255, DOI 10.1520/STP18074S
   DEAN MH, 1989, CORROS SCI, V29, P199, DOI 10.1016/0010-938X(89)90030-9
   EKTESSABI AM, 1994, SURF COAT TECH, V68, P208, DOI 10.1016/0257-8972(94)90162-7
   Ektessabi AM, 1995, THIN SOLID FILMS, V270, P335, DOI 10.1016/0040-6090(95)06714-0
   EKTESSABI AM, 1995, NUCL INSTRUM METH B, V99, P610, DOI 10.1016/0168-583X(94)00568-0
   EKTESSABI AM, UNPUB
   EKTESSABI AM, 1994, INT J PIXE, V4, P81
   ELBASIOUNY MS, 1982, CORROSION, V38, P237, DOI 10.5006/1.3577344
   Fraker A. C., 1987, METALS HDB, V13, P1324
   Fraker AC., 1973, TITANIUM SCI TECHNOL, V4, P2447, DOI 10.1007/BF03354319
   HAKIKI N, 1994, COMPATIBILITY BIOMED, P217
   HAKIKI NE, 1995, CORROS SCI, V37, P1809, DOI 10.1016/0010-938X(95)00084-W
   HANAWA T, 1991, BIOMATERIALS, V12, P767, DOI 10.1016/0142-9612(91)90028-9
   HURLEN T, 1991, ELECTROCHIM ACTA, V36, P189, DOI 10.1016/0013-4686(91)85200-Q
   JULIAO JF, 1980, J ELECTROCHEM SOC, V127, P2246
   KOVACS P, 1992, CORR 92 NACE
   LAUSMAA J, 1990, APPL SURF SCI, V44, P133, DOI 10.1016/0169-4332(90)90100-E
   LEE FJ, 1992, J APPL ELECTROCHEM, V22, P156
   Mansfeld F., 1993, 26 SOL SCHLUMB
   McQueen D, 1982, CLIN APPL BIOMATERIA, P179
   MEACHIM G, 1973, J BIOMED MATER RES, V7, P555, DOI 10.1002/jbm.820070607
   MERRITT K, 1994, COMPATIBILITY BIOMED, P14
   Nielsen K., 1987, British Corrosion Journal, V22, P272
   OHRING M, 1992, MAT SCI THIN FILMS, pCH5
   Pan J, 1996, ELECTROCHIM ACTA, V41, P1143, DOI 10.1016/0013-4686(95)00465-3
   PAN J, 1994, J BIOMED MATER RES, V28, P113, DOI 10.1002/jbm.820280115
   SCHUTZ RW, 1987, METALS HDB, V13, P669
   Silva R., 1990, British Corrosion Journal, V25, P136
   Solar R. J., 1979, ASTM STP, V684, P161
   SOLAR RJ, 1979, J BIOMED MATER RES, V13, P217, DOI 10.1002/jbm.820130206
   Solar RJ, 1979, ASTM STP, P259
   Steinemann S. C., 1994, CHALLENGE        NOV, P1
   SUNDGREN JE, 1986, J COLLOID INTERF SCI, V110, P9, DOI 10.1016/0021-9797(86)90348-6
   TOMASHOV ND, 1974, ELECTROCHIM ACTA, V19, P159, DOI 10.1016/0013-4686(74)85012-7
   TORRESI RM, 1987, ELECTROCHIM ACTA, V32, P1291, DOI 10.1016/0013-4686(87)85058-2
   WEBER MF, 1982, J ELECTROCHEM SOC, V129, P2022, DOI 10.1149/1.2124343
   WILLIAMS DF, 1976, ANNU REV MATER SCI, V6, P237, DOI 10.1146/annurev.ms.06.080176.001321
   WILLIAMS DF, 1981, BIOCOMPATIBILITY CLI, pCH2
   WOODMAN J L, 1984, Journal of Orthopaedic Research, V1, P421
   ZITTER H, 1987, J BIOMED MATER RES, V21, P881, DOI 10.1002/jbm.820210705
NR 49
TC 114
Z9 122
U1 5
U2 42
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD JUN 5
PY 1997
VL 35
IS 3
BP 309
EP 318
DI 10.1002/(SICI)1097-4636(19970605)35:3<309::AID-JBM5>3.3.CO;2-N
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA WW450
UT WOS:A1997WW45000005
PM 9138065
DA 2018-10-19
ER

PT J
AU Santin, M
   Wassall, MA
   Peluso, G
   Denyer, SP
AF Santin, M
   Wassall, MA
   Peluso, G
   Denyer, SP
TI Adsorption of alpha-1-microglobulin from biological fluids onto polymer
   surfaces
SO BIOMATERIALS
LA English
DT Article
DE protein adsorption; biocompatibility; alpha-1-microglobulin
ID COMPLEX-FORMING GLYCOPROTEIN; PLASMA-PROTEINS; STAPHYLOCOCCUS-AUREUS;
   FIBRONECTIN; ADHESION; CHARGE; URINE
AB A recent study in our laboratory has identified the potential role of urine-derived alpha-1-microglobulin (alpha-1-m) in mediating Pseudomonas aeruginosa adhesion to polystyrene, while other workers have suggested a possible role of the protein in the immunological response. Due to the ubiquitous presence of alpha-1-m in body fluids, the adsorption of the protein from serum, cerebrospinal fluid, urine and used continuous ambulatory peritoneal dialysis fluid onto polystyrene was investigated. The treated surfaces were sequentially immersed in water and increasingly concentrated isopropanol-water solutions in order to selectively desorb bound proteins on the basis of their binding strength. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis of the wash supernatants showed different protein desorption profiles for each biological fluid, despite the qualitative similarity between the protein composition of the fluids, and highlighted the uptake of alpha-1-m from each fluid to the surface. In the case of urine, the analysis was extended to commercial polyurethane and silicone stents. The ease of desorption of urine-derived alpha-1-m could be correlated with surface hydrophobicity of the stent biomaterial. (C) 1997 Published by Elsevier Science Limited.
C1 UNIV BRIGHTON,DEPT PHARM,BRIGHTON BN2 4GJ,E SUSSEX,ENGLAND.
   CNR,INST PROT BIOCHEM & ENZYMOL,I-80072 ARCO,ITALY.
CR AKERSTROM B, 1992, FOLIA HISTOCHEM CYTO, V30, P183
   AVRAMEAS S, 1971, IMMUNOCHEMISTRY, V8, P1175, DOI 10.1016/0019-2791(71)90395-8
   BARBUCCI R, 1994, BIOMATERIALS, V15, P955, DOI 10.1016/0142-9612(94)90075-2
   BEGGARD B, 1980, SCAND J CLIN LAB INV, V40, P63
   BRUNETTE WN, 1981, ANAL BIOCHEM, V112, P195
   BUELER MR, 1995, ELECTROPHORESIS, V16, P124, DOI 10.1002/elps.1150160122
   CHEUNG AK, 1990, KIDNEY INT, V37, P1055, DOI 10.1038/ki.1990.85
   DRUMHELLER PD, 1994, BIOTECHNOL BIOENG, V43, P772, DOI 10.1002/bit.260430812
   DUSSOL B, 1995, UROL RES, V23, P45, DOI 10.1007/BF00298850
   FALKENBERG C, 1994, BIOCHEM J, V301, P745, DOI 10.1042/bj3010745
   FLOWER DR, 1994, FEBS LETT, V354, P7, DOI 10.1016/0014-5793(94)01078-1
   GILDING DK, 1980, BIOMATERIALS, V1, P163, DOI 10.1016/0142-9612(80)90040-X
   GOTTLIEB M, 1987, ANAL BIOCHEM, V165, P33, DOI 10.1016/0003-2697(87)90197-7
   GRUBB AO, 1983, J BIOL CHEM, V258, P4698
   HAWTHORN L, 1990, J BIOMED MATER RES, V24, P1325, DOI 10.1002/jbm.820241005
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LOGDBERG L, 1981, SCAND J IMMUNOL, V13, P383, DOI 10.1111/j.1365-3083.1981.tb00148.x
   NILSSON UR, 1993, MOL IMMUNOL, V30, P211, DOI 10.1016/0161-5890(93)90050-L
   NORDE W, 1986, ADV COLLOID INTERFAC, V25, P267, DOI 10.1016/0001-8686(86)80012-4
   NORMAN ME, 1993, BIOMATERIALS, V14, P193, DOI 10.1016/0142-9612(93)90023-U
   SEEGER JM, 1988, J VASC SURG, V8, P476
   TAKAGI K, 1980, J CLIN PATHOL, V33, P786, DOI 10.1136/jcp.33.8.786
   TEJLER L, 1976, BIOCHIM BIOPHYS ACTA, V439, P82, DOI 10.1016/0005-2795(76)90164-1
   VAUDAUX PE, 1984, INFECT IMMUN, V45, P768
   VAUDAUX PE, 1995, INFECT IMMUN, V63, P585
   WAHLGREN M, 1991, TRENDS BIOTECHNOL, V9, P201, DOI 10.1016/0167-7799(91)90064-O
   Wassall M. A., 1995, Journal of Pharmacy and Pharmacology, V47, P1064
   Wassall M. A., 1994, Journal of Pharmacy and Pharmacology, V46, P1044
   WILCOX MH, 1990, J CLIN MICROBIOL, V28, P2183
NR 29
TC 11
Z9 11
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD JUN
PY 1997
VL 18
IS 11
BP 823
EP 827
DI 10.1016/S0142-9612(97)00004-5
PG 5
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA XA275
UT WOS:A1997XA27500009
PM 9177862
DA 2018-10-19
ER

PT J
AU Okazaki, SY
   Kamiya, N
   Goto, M
   Nakashio, F
AF Okazaki, SY
   Kamiya, N
   Goto, M
   Nakashio, F
TI Enantioselective esterification of glycidol by surfactant-lipase
   complexes in organic media
SO BIOTECHNOLOGY LETTERS
LA English
DT Article
ID CATALYZED ESTERIFICATION; SOLVENTS
AB Enantioselective esterification of glycidol has been performed with lauric acid in organic media dosed with surfactant-lipase complexes as catalysts. Lipase derived from various biomaterial sources was complexed with nonionic surfactant, dioleyl-N-D-glucono-L-glutamate, prior to use, Surfactant-lipase D (from Rhizopus delemar) complex had a higher enantioselectivity (v(R)/v(S) = 7.6) than the other lipases and the corresponding initial reaction rate was averaging 100-fold better than that of native powder lipase D in cyclohexane at 35 degrees C.
C1 KYUSHU UNIV,FAC ENGN,DEPT CHEM SCI & TECHNOL,FUKUOKA 81281,JAPAN.
CR DORDICK JS, 1989, ENZYME MICROB TECH, V11, P194, DOI 10.1016/0141-0229(89)90094-X
   GEERLOF A, 1994, ENZYME MICROB TECH, V16, P1059, DOI 10.1016/0141-0229(94)90143-0
   GOTO M, 1987, J CHEM ENG JPN, V20, P157, DOI 10.1252/jcej.20.157
   MARTINS JF, 1993, BIOTECHNOL BIOENG, V42, P465, DOI 10.1002/bit.260420409
   MARTINS JF, 1994, BIOTECHNOL BIOENG, V44, P119, DOI 10.1002/bit.260440117
   OKAZAKI S, 1997, IN PRESS BIOTECHNOL
   ZAKS A, 1985, P NATL ACAD SCI USA, V82, P3192, DOI 10.1073/pnas.82.10.3192
NR 7
TC 13
Z9 13
U1 0
U2 4
PU CHAPMAN HALL LTD
PI LONDON
PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8HN
SN 0141-5492
J9 BIOTECHNOL LETT
JI Biotechnol. Lett.
PD JUN
PY 1997
VL 19
IS 6
BP 541
EP 543
DI 10.1023/A:1018337320213
PG 3
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA XE214
UT WOS:A1997XE21400012
DA 2018-10-19
ER

PT J
AU Taborelli, M
   Jobin, M
   Francois, P
   Vaudaux, P
   Tonetti, M
   SzmuklerMoncler, S
   Simpson, JP
   Descouts, P
AF Taborelli, M
   Jobin, M
   Francois, P
   Vaudaux, P
   Tonetti, M
   SzmuklerMoncler, S
   Simpson, JP
   Descouts, P
TI Influence of surface treatments developed for oral implants on the
   physical and biological properties of titanium .1. Surface
   characterization
SO CLINICAL ORAL IMPLANTS RESEARCH
LA English
DT Article
DE titanium; surface treatments; characterization; dental implants
ID OXIDE-FILMS; THIN-FILMS; PROLIFERATION; BIOMATERIAL; INTERFACE; BONE
AB We present an investigation of the physico-chemical surface properties of commercially pure titanium coverslips which were submitted to various treatments designed to optimize their topography in view of application in oral implantology. The surface microroughness, chemical composition and water wettability were analyzed on titanium coverslips prepared by mechanical polishing, acid attack in HCl/H2SO4, after mechanical polishing or sandblasting, and titanium plasma-spray. The chemical composition has been measured by Auger electron spectroscopy. The treatments have no major influence on the surface chemical composition and all the samples display a composition approaching that of TiO, with minor amounts of carbon, sulfur, silicon and calcium as impurities. The roughness has been measured by scanning force microscopy on an area of 20 mu m x 20 mu m on each sample. Polished titanium is smooth (peak-to-valley roughness 81 nm), whereas the acid-attacked surfaces exhibit a micro-roughness in the pm range (2100 nm for polished and acid attacked; 3600 nm for sandblasted and acid attacked) which is quite reproducible over large areas of the sample. The acid attacked samples present a subsurface layer which contains hydrogen below the native passivating oxide layer. Water wettability measurement shows that all surfaces are hydrophobic with a slightly higher contact angle for the acid attacked surfaces. The different treatments analyzed in this study essentially influence the surface roughness by preserving the chemical composition and the wettability properties of titanium native oxide surface layer.
RP Taborelli, M (reprint author), UNIV GENEVA,GAP BIOMED,20 RUE ECOLE MED,CH-1211 GENEVA 4,SWITZERLAND.
CR ALBREKTSSON T, 1983, ANN BIOMED ENG, V11, P1, DOI 10.1007/BF02363944
   Baier R E, 1988, Int J Oral Maxillofac Implants, V3, P9
   Bowers K T, 1992, Int J Oral Maxillofac Implants, V7, P302
   BUSER D, 1991, J BIOMED MATER RES, V25, P889, DOI 10.1002/jbm.820250708
   CHATBI H, 1994, APPL PHYS LETT, V64, P1210, DOI 10.1063/1.111950
   CHEROUDI B, 1991, J BIOMEDICAL MAT RES, V25, P386
   Cochran David, 1994, Int J Oral Maxillofac Implants, V9, P289
   COCHRAN DL, 1996, UNPUB J BIOMED MAT R
   COCHRAN DL, 1995, ITI WORLD S 28 29 AP
   DAVIS D, 1976, HDB AUGER ELECT SPEC
   Francois P, 1997, CLIN ORAL IMPLAN RES, V8, P217, DOI 10.1034/j.1600-0501.1997.080308.x
   HANAWA T, 1992, APPL SURF SCI, V55, P269, DOI 10.1016/0169-4332(92)90178-Z
   HEALY KE, 1992, J COLLOID INTERF SCI, V150, P404, DOI 10.1016/0021-9797(92)90210-D
   JOBIN M, 1993, APPL SURF SCI, V72, P363, DOI 10.1016/0169-4332(93)90374-K
   KASEMO B, 1988, J BIOMED MATER RES-A, V22, P145, DOI 10.1002/jbm.820221307
   KASEMO B, 1988, PROGR BIOMEDICAL ENG, V6, P1
   KASEMO B, 1985, OSSEOINTEBRATION CLI, P99
   KONONEN M, 1992, J BIOMED MATER RES, V26, P1325
   LAUSMAA J, 1990, APPL SURF SCI, V45, P189, DOI 10.1016/0169-4332(90)90002-H
   LAUSMAA J, 1990, APPL SURF SCI, V44, P133, DOI 10.1016/0169-4332(90)90100-E
   MARTIN JY, 1995, J BIOMED MATER RES, V29, P389, DOI 10.1002/jbm.820290314
   MATHIEU HJ, 1977, J VAC SCI TECHNOL, V14, P1023, DOI 10.1116/1.569313
   MCQEEN D, 1982, ADV BIOMATER, V4, P179
   SCHLAPBACH L, 1983, APPL PHYS A-MATER, V32, P169, DOI 10.1007/BF00820257
   STANFORD CM, 1993, J DENT RES, V73, P1061
   STEINEMANN SG, 1985, TITANIUM SCI TECHNOL, V1
   SUNDGREN JE, 1986, J COLLOID INTERF SCI, V110, P9, DOI 10.1016/0021-9797(86)90348-6
   TENGVALL P, 1992, Clinical Materials, V9, P115, DOI 10.1016/0267-6605(92)90056-Y
   WEAST RC, 1976, HDB CHEM PHYSICS
   WEERKAMP AH, 1985, J DENT RES, V64, P1204, DOI 10.1177/00220345850640100501
   WILKE HJ, 1990, ADV BIOMAT, V9, P309
NR 31
TC 88
Z9 93
U1 0
U2 12
PU MUNKSGAARD INT PUBL LTD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 0905-7161
J9 CLIN ORAL IMPLAN RES
JI Clin. Oral Implant. Res.
PD JUN
PY 1997
VL 8
IS 3
BP 208
EP 216
DI 10.1034/j.1600-0501.1997.080307.x
PG 9
WC Dentistry, Oral Surgery & Medicine; Engineering, Biomedical
SC Dentistry, Oral Surgery & Medicine; Engineering
GA XE160
UT WOS:A1997XE16000007
PM 9586465
DA 2018-10-19
ER

PT J
AU Yourtee, DM
   Tong, PY
   Eick, JD
   Zhuang, WC
   Cobb, C
   Bean, TA
   Kostoryz, EL
AF Yourtee, DM
   Tong, PY
   Eick, JD
   Zhuang, WC
   Cobb, C
   Bean, TA
   Kostoryz, EL
TI In situ hybridization test for TNF-alpha: A simplified approach to
   confirming induction of the cytokine by biomaterials
SO IN VITRO TOXICOLOGY
LA English
DT Article
ID INSITU HYBRIDIZATION; PULMONARY SARCOIDOSIS; ALVEOLAR MACROPHAGES;
   GENE-EXPRESSION; CELLS; ESTERASE; INVITRO; RELEASE
AB When testing biocompatibility of biomaterials it is necessary to understand their ability to stimulate cytokines. Because traces of leachates may be the intoxicant, methods of confirmation are needed to improve confidence in results, Thus, we previously demonstrated that dental materials can induce the release of cytokine tumor necrosis factor-alpha (TNF-alpha) from mouse macrophage cells, This was measured by L929 cytotoxicity and anti-TNF-alpha antibody, The inducing source was methacrylic acid (MAA), the hydrolysis product of many methacrylate biomaterial monomers, In order to verify the finding we developed, and report here, a simplified in situ hybridization-mRNA probe method, The method was used to measure the effects of hydroxyethyl methacrylate (HEMA) monomer, its hydrolysis product MAA and the results were compared to the anti-TNF-alpha data. The mRNA probe was labeled by digoxigenin; the antisense was used for detection, and the sense was used as control. Macrophage cells were incubated with MAA and HEMA for 72 hours in a 96-well microplate, The negative control was macrophage cells without test materials and the positive control was lipopolysaccharide (LPS), After cell fixation and RNA denaturation, the cells were prehybridized with tRNA followed by the addition of the mRNA probe. After post-hybridization washes, antidigoxigenin antibody, and biotin-avidin-alkaline phosphatase were used for microscopic visualization of a purple precipitate that is confirmatory of TNF-alpha mRNA production, Using this test system, MAA and HEMA were both positive for TNF-alpha mRNA production, This result agreed with earlier tests demonstrating potential utility of the probe method for biomaterial cytokine induction studies.
CR BEAN TA, 1995, J DENT RES, V74, P186
   BEAN TA, 1994, J DENT RES, V73, P356
   BEAN TA, 1996, J DENT RES, V75, P381
   BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0
   BONFIELD TL, 1992, J BIOMED MATER RES, V26, P837, DOI 10.1002/jbm.820260702
   BRAHIC M, 1978, P NATL ACAD SCI USA, V75, P6125, DOI 10.1073/pnas.75.12.6125
   CHEN HL, 1993, BIOL REPROD, V48, P707, DOI 10.1095/biolreprod48.4.707
   CHILOSI M, 1988, AM J PATHOL, V131, P191
   HAFEN E, 1983, EMBO J, V2, P617, DOI 10.1002/j.1460-2075.1983.tb01472.x
   Hanks C. T., 1993, Journal of Dental Research, V72, P210
   HUNNINGHAKE GW, 1984, AM REV RESPIR DIS, V129, P569
   Munksgaard E C, 1992, Adv Dent Res, V6, P17
   ROBINSON BWS, 1985, J CLIN INVEST, V75, P1488, DOI 10.1172/JCI111852
   SHIKAMA Y, 1989, AM J PATHOL, V134, P1189
   SINGER RH, 1982, P NATL ACAD SCI-BIOL, V79, P7331, DOI 10.1073/pnas.79.23.7331
   ZHUANG WC, 1994, J DENT RES, V73, P250
NR 16
TC 7
Z9 7
U1 0
U2 1
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538
SN 0888-319X
J9 IN VITRO TOXICOL
JI In Vitro Toxicol.
PD SUM
PY 1997
VL 10
IS 2
BP 245
EP 251
PG 7
WC Toxicology
SC Toxicology
GA XT134
UT WOS:A1997XT13400009
DA 2018-10-19
ER

PT J
AU Stidham, DB
   Stager, DR
   Kamm, KE
   Grange, RW
AF Stidham, DB
   Stager, DR
   Kamm, KE
   Grange, RW
TI Stiffness of the inferior oblique neurofibrovascular bundle
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE connective tissue; extraocular muscle; orbit; stiffness; strabismus
ID BILATERAL ANTERIOR TRANSPOSITION; HUMAN-EYE; MUSCLE; SURGERY; MONKEYS;
   TENDONS; LENGTH
AB Purpose. To assess the mechanical ability of the inferior oblique neurofibrovascular bundle (NFVB) to act as an ancillary origin for the inferior oblique muscle after anterior transposition.
   Methods. Stress-strain relations and Young's modulus of elasticity, a measure of tissue stiffness, were determined for the NFVB in vitro, in situ, and in vivo in dynamic and static conditions. For comparison, similar studies were performed in vitro on the superior oblique tendon (SOT).
   Results. Young's moduli for NFVB in situ (6.3 MPa [megapascals]) and in vivo (11.8 MPa) were approximately 2 and 4 times greater (P < 0.05), respectively, than those of isolated NFVB in vitro at 5% to 10%, dynamic strain (3 MPa). In dynamic conditions, Young's moduli in vitro for the NFVB and the SOT were similar.
   Conclusions. The NFVB is a biomaterial that has stiffness properties similar to the SOT. Within the range of forces typical of normal eye movements (79 to 393 mN), the NFVB alone can tolerate forces of 98 mN at 0% to 10% strain and 393 mN at 15% to 20% strain based on dynamic in vitro analysis. The greater measured stiffness in situ and in vivo suggest that the NFVB in the intact orbit potentially has a resting strain of 15% to 20%, and additional tissues in parallel with the NFVB also contribute to total stiffness. These data support the hypothesis that the NFVB, acting alone or in concert with adjacent orbital tissues, may form an ancillary origin for the inferior oblique muscle after anterior transposition.
C1 UNIV TEXAS, SW MED CTR, DEPT OPHTHALMOL, DALLAS, TX USA.
   UNIV TEXAS, SW MED CTR, DEPT PHYSIOL, DALLAS, TX USA.
CR BENNETT MB, 1986, J ZOOL, V209, P537, DOI 10.1111/j.1469-7998.1986.tb03609.x
   BREMER DL, 1986, ARCH OPHTHALMOL-CHIC, V104, P229
   BURKE JP, 1993, OPHTHALMOLOGY, V100, P245
   BUTLER DL, 1984, J BIOMECH, V17, P579, DOI 10.1016/0021-9290(84)90090-3
   BUTLER DL, 1979, EXERCISE SPORT SCI R, V6, P125
   COLLINS CC, 1991, IEEE T BIO-MED ENG, V38, P230, DOI 10.1109/10.133203
   COLLINS CC, 1975, J PHYSIOL-LONDON, V245, P351, DOI 10.1113/jphysiol.1975.sp010850
   DEMER JL, 1995, INVEST OPHTH VIS SCI, V36, P1125
   ELLIOTT RL, 1981, J PEDIAT OPHTH STRAB, V18, P35
   GOLDSTEIN HP, 1983, BIOMEDICAL FDN OPHTH, P56
   GONZALEZ G, 1995, J PEDIATR OPHTHALMOL, V32, P107
   HERRICK WC, 1978, J BIOMED MATER RES, V12, P877, DOI 10.1002/jbm.820120610
   KAMM KE, 1985, AM J PHYSIOL, V249, pC238
   KOORNEEF L, 1979, OPHTHALMOLOGY, V86, P876
   Kratz R E, 1989, J Pediatr Ophthalmol Strabismus, V26, P212
   MAY MA, 1988, GRAEF ARCH CLIN EXP, V226, P407, DOI 10.1007/BF02169997
   MENDEZ J, 1960, METABOLISM, V9, P184
   MILLER JM, 1993, OPHTHALMOLOGY, V100, P475
   MIMS JL, 1989, ARCH OPHTHALMOL-CHIC, V107, P41, DOI 10.1001/archopht.1989.01070010043024
   MIMS JL, 1986, ARCH OPHTHALMOL-CHIC, V104, P800
   NOYES FR, 1976, J BONE JOINT SURG AM, V58, P1074, DOI 10.2106/00004623-197658080-00006
   OESTREICHER JH, 1995, OPHTHALMIC PLAST REC, V11, P113, DOI 10.1097/00002341-199506000-00007
   Parks M M, 1976, Int Ophthalmol Clin, V16, P17
   PARKS MM, 1985, INT OPHTHALMOL CLIN, V25, P107, DOI 10.1097/00004397-198502540-00010
   SIMONSZ HJ, 1986, ARCH OPHTHALMOL-CHIC, V104, P1495, DOI 10.1001/archopht.1986.01050220089034
   SIMONSZ HJ, 1984, VISION RES, V24, P961, DOI 10.1016/0042-6989(84)90071-3
   Stager D R, 1996, Trans Am Ophthalmol Soc, V94, P1073
   STAGER DR, 1992, ARCH OPHTHALMOL-CHIC, V110, P360, DOI 10.1001/archopht.1992.01080150058028
   VONNOORDEN GK, 1996, BINOCULAR VISION OCU, P44
   WEAKLEY DR, 1992, OPHTHALMOL CLIN N AM, V5, P57
   ZIFFER AJ, 1993, AM J OPHTHALMOL, V116, P224, DOI 10.1016/S0002-9394(14)71290-5
NR 31
TC 7
Z9 8
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 1997
VL 38
IS 7
BP 1314
EP 1320
PG 7
WC Ophthalmology
SC Ophthalmology
GA XE101
UT WOS:A1997XE10100008
PM 9191594
DA 2018-10-19
ER

PT J
AU Tunney, MM
   Keane, PF
   Gorman, SP
AF Tunney, MM
   Keane, PF
   Gorman, SP
TI Assessment of urinary tract biomaterial encrustation using a modified
   robbins device continuous flow model
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE ureteral stents; encrustation; modified Robbins device; silicone;
   polyurethane
ID URETERAL STENTS; CATHETER MATERIALS; BIOFILM; INVITRO
AB Encrustation of biomaterials employed in the urinary tract remains a major problem resulting in obstruction or blockage of catheters and stents. Therefore, resistance to encrustation is a desirable feature of biomaterials employed in such devices, The novel assessment of biomaterial encrustation employing a continuous flow model based on a modified Robbins device is described, Artificial urine was used in conjunction with 5% CO2 to simulate the physiological environment within the upper urinary tract, The widely used urinary device biomaterials, silicone and polyurethane, were investigated in the model for hydroxyapatite and struvite encrustation, Scanning electron microscopy, energy dispersive X-ray analysis, and atomic absorption spectroscopy all showed that silicone was less prone to encrustation than polyurethane and that hydroxyapatite deposition was predominant on both surfaces, The model has the advantage that a large number of biomaterials may be investigated simultaneously because several Robbins devices may be placed in parallel, The model is recommended for comparative evaluation of biomaterial candidates for use in urinary tract devices. (C) 1997 John Wiley & Sons, Inc.
C1 QUEENS UNIV BELFAST,SCH PHARM,PHARMACEUT DEVICES GRP,BELFAST BT9 7BL,ANTRIM,NORTH IRELAND.
   BELFAST CITY HOSP,DEPT UROL,BELFAST BT9 7BL,ANTRIM,NORTH IRELAND.
CR BASSETT J, 1978, VOGELS TXB QUANTITAT, P837
   BRUCE AW, 1974, CAN MED ASSOC J, V3, P238
   Cox A J, 1987, Eng Med, V16, P37
   DENYER SP, 1990, J CLIN MICROBIOL, V28, P1813
   ELFAQIH SR, 1991, J UROLOGY, V146, P1487, DOI 10.1016/S0022-5347(17)38146-6
   GETLIFFE KA, 1994, BRIT J UROL, V73, P696, DOI 10.1111/j.1464-410X.1994.tb07559.x
   GLEESON MJ, 1989, T AM SOC ART INT ORG, V35, P495
   GORMAN SP, 1991, P 10 PHARM TECH C, V2, P649
   GRIFFITH DP, 1976, INVEST UROL, V13, P346
   HOFMANN R, 1989, WORLD J UROL, V7, P154, DOI 10.1007/BF01637374
   HOLMES SAV, 1992, BRIT J UROL, V69, P651, DOI 10.1111/j.1464-410X.1992.tb15640.x
   KEANE PF, 1994, BRIT J UROL, V73, P687, DOI 10.1111/j.1464-410X.1994.tb07557.x
   KUMON H, 1995, ANTIMICROB AGENTS CH, V39, P1038, DOI 10.1128/AAC.39.5.1038
   KUNIN CM, 1987, J UROLOGY, V138, P899, DOI 10.1016/S0022-5347(17)43412-4
   MCCOY WF, 1981, CAN J MICROBIOL, V27, P910, DOI 10.1139/m81-143
   NICKEL JC, 1985, EUR J CLIN MICROBIOL, V4, P213, DOI 10.1007/BF02013600
   SARANGAPANI S, 1995, J BIOMED MATER RES, V29, P1185, DOI 10.1002/jbm.820291005
   SCHMITZ W, 1993, CELL MATER, V3, P1
   SRINIVASAN V, 1972, J UROLOGY, V108, P473, DOI 10.1016/S0022-5347(17)60777-8
   Tunney MM, 1996, BIOMATERIALS, V17, P1541, DOI 10.1016/0142-9612(96)89780-8
   Tunney MM, 1996, BIOMATERIALS, V17, P1025, DOI 10.1016/0142-9612(96)84679-5
NR 21
TC 19
Z9 19
U1 2
U2 7
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD SUM
PY 1997
VL 38
IS 2
BP 87
EP 93
DI 10.1002/(SICI)1097-4636(199722)38:2<87::AID-JBM2>3.0.CO;2-C
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA XC070
UT WOS:A1997XC07000002
PM 9178735
DA 2018-10-19
ER

PT J
AU Seki, H
   Suzuki, A
AF Seki, H
   Suzuki, A
TI A new method for the removal of toxic metal ions from acid-sensitive
   biomaterial
SO JOURNAL OF COLLOID AND INTERFACE SCIENCE
LA English
DT Article
DE competitive adsorption; toxic metal ions; cadmium; biomaterial
ID CADMIUM-BINDING-PROTEINS; CRAB CANCER-PAGURUS; MYTILUS-EDULIS;
   METALLOTHIONEIN; HEPATOPANCREAS; COPPER; ACCUMULATION; PURIFICATION;
   MUSSEL; LIVER
AB A new method (competitive adsorption method) for the removal of toxic heavy metals from acid-sensitive biomaterials was proposed and it was applied to the removal of cadmium from the mid-gut gland (MG) of scallop, Patinopecten yessoensis. Insolubilized humic acid, which has been developed in our laboratory, was used as a competitive adsorbent. A metal-complexation model was used to determine the adsorption characteristics of cadmium onto MG. Furthermore, the model was applied to the competitive adsorption system. The results showed that the competitive adsorption method enabled the simultaneous removal of toxic cadmium from both liquid and RIG phase under mild acidic condition (pH 5). (C) 1997 Academic Press.
RP Seki, H (reprint author), HOKKAIDO UNIV,FAC FISHERIES,DEPT MARINE BIORESOURCES CHEM,MINATO CHO 3-1-1,HAKODATE,HOKKAIDO 041,JAPAN.
CR CASTILLO L V, 1991, Bulletin of the Faculty of Fisheries Hokkaido University, V42, P26
   DALLINGER R, 1989, ARCH ENVIRON CON TOX, V18, P554, DOI 10.1007/BF01055022
   DOHI Y, 1983, BIOCHIM BIOPHYS ACTA, V745, P50, DOI 10.1016/0167-4838(83)90169-3
   FRANKENNE F, 1980, COMP BIOCHEM PHYS C, V66, P179, DOI 10.1016/0306-4492(80)90122-7
   FRAZIER JM, 1985, COMP BIOCHEM PHYS C, V80, P257, DOI 10.1016/0742-8413(85)90052-0
   HAYASHI K, 1989, NIPPON SUISAN GAKK, V55, P1383
   HAYASHI K, 1986, B JPN SOC SCI FISH, V52, P1559
   HAYASHI K, 1988, NIPPON SUISAN GAKK, V54, P1449, DOI 10.2331/suisan.54.1449
   LANGSTON WJ, 1986, MAR BIOL, V92, P505, DOI 10.1007/BF00392510
   LERCH K, 1982, J BIOL CHEM, V257, P2420
   MARGOSHES M, 1957, J AM CHEM SOC, V79, P4813, DOI 10.1021/ja01574a064
   NOELLAMBOT F, 1976, EXPERIENTIA, V32, P324
   OVERNELL J, 1984, COMP BIOCHEM PHYS C, V77, P245, DOI 10.1016/0742-8413(84)90008-2
   OVERNELL J, 1979, COMP BIOCHEM PHYS C, V64, P69, DOI 10.1016/0306-4492(79)90030-3
   OVERNELL J, 1984, COMP BIOCHEM PHYS C, V77, P237, DOI 10.1016/0742-8413(84)90007-0
   SEKI H, 1995, J COLLOID INTERF SCI, V171, P490, DOI 10.1006/jcis.1995.1207
   Seki Hideshi, 1992, Bulletin of the Faculty of Fisheries Hokkaido University, V43, P185
   STONE HC, 1986, COMP BIOCHEM PHYS C, V85, P259, DOI 10.1016/0742-8413(86)90192-1
   TANAKA T, 1983, EXPERIENTIA, V39, P746, DOI 10.1007/BF01990305
   VIARENGO A, 1987, MAR BIOL, V94, P251, DOI 10.1007/BF00392937
NR 20
TC 13
Z9 15
U1 1
U2 9
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0021-9797
J9 J COLLOID INTERF SCI
JI J. Colloid Interface Sci.
PD JUN 1
PY 1997
VL 190
IS 1
BP 206
EP 211
DI 10.1006/jcis.1997.4833
PG 6
WC Chemistry, Physical
SC Chemistry
GA XF572
UT WOS:A1997XF57200022
DA 2018-10-19
ER

PT J
AU Epple, M
   Herzberg, O
AF Epple, M
   Herzberg, O
TI Polyglycolide with controlled porosity: An improved biomaterial
SO JOURNAL OF MATERIALS CHEMISTRY
LA English
DT Article
ID SCANNING CALORIMETERS; TEMPERATURE CALIBRATION
AB A method to prepare polyglycolide, the simplest polyester, with defined microstructure by solid-state polymerization of halogenoacetates is presented. By choosing the appropriate halogenoacetate it is possible to obtain polyglycolide with variable porosity. The pore size distribution can be varied by choice of the precursor and an appropriate mechanical pretreatment (average pore diameters between 0.3 and 1.5 mu m). Porous polyglycolide should degrade faster in the environment or in the body than compact polyglycolide. Alternatively, microcrystals of the elmininated salts can be obtained by extracting the polyglycolide. Thermodynamic data for halogenoacetates are given.
RP Epple, M (reprint author), UNIV HAMBURG,INST INORGAN & APPL CHEM,MARTIN LUTHER KING PL 6,D-20146 HAMBURG,GERMANY.
CR BROWN WE, 1980, REACTIONS SOLID STAT
   CAMMENGA HK, 1993, THERMOCHIM ACTA, V219, P333, DOI 10.1016/0040-6031(93)80510-H
   CHU CC, 1991, ACS S SER, V457
   ELIZABE L, UNPUB
   Epple M, 1996, CHEM COMMUN, P1755, DOI 10.1039/cc9960001755
   Epple M, 1997, CHEM BER-RECL, V130, P291, DOI 10.1002/cber.19971300224
   Epple M, 1997, LIEBIGS ANN-RECL, P81
   Epple M, 1996, J THERM ANAL CALORIM, V47, P331, DOI 10.1007/BF01983973
   Epple M, 1996, CHEM BER, V129, P1123, DOI 10.1002/cber.19961290923
   Epple M, 1996, J CHEM SOC FARADAY T, V92, P5035, DOI 10.1039/ft9969205035
   Epple M, 1996, J CHEM SOC DALTON, P11, DOI 10.1039/dt9960000011
   GINDE RM, 1987, J APPL POLYM SCI, V33, P2411, DOI 10.1002/app.1987.070330712
   HOFMANN GO, 1995, ARCH ORTHOP TRAUM SU, V114, P123, DOI 10.1007/BF00443385
   HOHNE GWH, 1990, THERMOCHIM ACTA, V160, P1, DOI 10.1016/0040-6031(90)80235-Q
   Kricheldorf H. R., 1992, HDB POLYM SYNTHESIS
   POKORNY J, 1972, SB VYS SK CHEM TEC B, V14, P153
   POKORNY J, 1972, SB VYS SK CHEM TEC B, V14, P127
   RIES R, 1994, EUR J PHARM BIOPHARM, V40, P14
   SARGE SM, 1994, THERMOCHIM ACTA, V247, P129, DOI 10.1016/0040-6031(94)80118-5
   Schmalzried H., 1995, CHEM KINETICS SOLIDS
   VASENIUS J, 1994, CLIN MATER, V17, P119, DOI 10.1016/0267-6605(94)90134-1
NR 21
TC 37
Z9 37
U1 1
U2 2
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON ROAD, CAMBRIDGE, CAMBS,
   ENGLAND CB4 4WF
SN 0959-9428
J9 J MATER CHEM
JI J. Mater. Chem.
PD JUN
PY 1997
VL 7
IS 6
BP 1037
EP 1042
DI 10.1039/a700275k
PG 6
WC Chemistry, Physical; Materials Science, Multidisciplinary
SC Chemistry; Materials Science
GA XE227
UT WOS:A1997XE22700033
DA 2018-10-19
ER

PT J
AU White, EW
AF White, EW
TI Biomaterials innovation: it's a long road to the operating room
SO MATERIALS RESEARCH INNOVATIONS
LA English
DT Article
DE porous-bioceramic; hydroxyapatite; bone repair innovation-steps;
   time-involved; Replamineform; bone graft substitute; coral; (Interpore
   International)
ID REPLAMINEFORM; PROSTHESIS
AB An innovative process for forming a wide variety of porous biomaterials was conceived of and developed over several years at a University and later by a company that licensed the early patents. The family of patents formed the basis for several promising innovative biomaterials devices. However, only one commercial product has been realized. That product is the very successfull coralline hydroxyapatite (HA) now widely used in orthopaedic surgery, oral and maxillofacial bone repair and plastic surgery. This paper challenges the equation of discovery with a genuine innovation which reaches the marketplace. The paper reviews several aspects of the innovation and development history with an emphasis on the challenges of bringing any new biomaterial through all the conceptual, developmental, business and regulatory hurdles. New class three medical devices require huge investments of time and money typically requiring a minimum of eight years and 15-20 million dollars per new device to take it from concept to an approved product. These hurdles are so high that most research innovations in biomaterials never get put into the developmental pipeline. This paper is presented from an anecdotal perspective of an innovator who has had a continuous research and development involvement in the technology but has no significant management involvement beyond the early startup activities. It differs from predecessors is that it deals not only with the initial step of discovery but in the very difficult steps that follow on the road to a real innovation. Several strategies that may help other R&D groups outside the biomedical industry shorten the development cycle and increase the probability that a given biomaterials innovation can be seen through to approved product are discussed. Guidelines are suggested for culling out ideas that are technically sound but that likely won't lead to successful products.
RP White, EW (reprint author), RD 1 Box 182, Rossiter, PA 15772 USA.
CR KLAWITTER JJ, 1971, J BIOMED MATER RES S, V2, P161, DOI DOI 10.1002/JBM.820050613
   NELSON RJ, 1983, J THORAC CARDIOV SUR, V86, P800
   NEWNHAM RE, 1978, MATER RES BULL, V13, P525, DOI 10.1016/0025-5408(78)90161-7
   ROY DM, 1974, NATURE, V247, P220, DOI 10.1038/247220a0
   ROY DM, 1975, Patent No. 3929971
   SHORS EC, 1989, MATER RES SOC S P, V110, P211
   SKINNER DP, 1978, MATER RES BULL, V13, P599, DOI 10.1016/0025-5408(78)90185-X
   TARHAY L, 1985, THESIS PSU
   White E. W., 1989, Us Patent, Patent No. 4861733
   WHITE EW, 1988, Patent No. 4722870
   WHITE EW, 1990, Patent No. 4976736
   WHITE EW, 1975, Patent No. 3180107
   WHITE RA, 1976, SURGERY, V79, P229
   WHITE RA, 1972, SCIENCE, V176, P922, DOI 10.1126/science.176.4037.922
   WHITE RA, 1987, J CARDIOVASC SURG, V28, P485
   WHITE RA, 1982, BIOMATERIALS, V3, P145, DOI 10.1016/0142-9612(82)90003-5
   White RA, 1988, ASIAO, V11, P95
   WHITTINGHAM S, 1975, TISSUE ANTIGENS, V6, P23
   YUKNA RA, 1994, J PERIODONTOL, V65, P177, DOI 10.1902/jop.1994.65.2.177
NR 19
TC 6
Z9 6
U1 1
U2 7
PU SPRINGER VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010 USA
SN 1432-8917
J9 MATER RES INNOV
JI Mater. Res. Innov.
PD JUN
PY 1997
VL 1
IS 1
BP 57
EP 63
DI 10.1007/s100190050019
PG 7
WC Materials Science, Multidisciplinary
SC Materials Science
GA YX890
UT WOS:000072090600010
DA 2018-10-19
ER

PT J
AU Agboh, OC
   Qin, Y
AF Agboh, OC
   Qin, Y
TI Chitin and chitosan fibers
SO POLYMERS FOR ADVANCED TECHNOLOGIES
LA English
DT Article
DE chitin; chitosan; fibers; extrusion; rheology
ID ULTRAVIOLET SPECTROPHOTOMETRY; SPECTROSCOPIC DETERMINATION;
   N-ACETYLATION; GEL; CHROMATOGRAPHY
AB Chitin and chitosan are natural polymers extracted from various plants and animals. In recent years, these two polymers have attracted much interest because of their biodegradability, biocompatibility, wound-healing acceleration and many other unique properties. As a natural renewable resource, they offer many potential applications in a number of diversified fields. Chitin and chitosan fibers have been found useful as biomaterial for potential applications such as sutures and wound dressings. This article presents a brief introduction to the properties of chitin and chitosan, and reviews the various attempts for the production of fibers from the two polymers. (C) 1997 by John Wiley & Sons, Ltd.
RP Agboh, OC (reprint author), INNOVAT TECHNOL LTD,MED FIBRES LAB,RD 3,WINSFORD IND ESTATE,WINSFORD CW7 3PD,CHESHIRE,ENGLAND.
CR AGBOH OC, 1986, THESIS U LEEDS
   AIBA S, 1986, INT J BIOL MACROMOL, V8, P173, DOI 10.1016/0141-8130(86)90022-X
   ALONSO IG, 1983, J THERM ANAL, V28, P189
   Austin P. R, 1975, US patent, Patent No. [3879377, 3,879,377]
   AUSTIN PR, 1986, CHITIN NATURE TECHNO
   AUSTIN PR, 1977, Patent No. 4029727
   Austin PR, 1975, US patent, Patent No. [3892731, 3,892,731]
   AVERBACH BL, MITSG7517
   Balassa LL, 1978, P 1 INT C CHIT CHIT
   Blackwell J., 1978, P 1 INT C CHIT CHIT
   Broussignac P., 1968, CHIM IND GEN CHIM, V99, P1241
   Capozza R. C., 1976, US Patent, Patent No. 3988411
   CARLSTROM D, 1957, J BIOPHYS BIOCHEM CY, V3, P669, DOI 10.1083/jcb.3.5.669
   Clark GL, 1936, J PHYS CHEM-US, V40, P863, DOI 10.1021/j150376a001
   DOMARD A, 1987, INT J BIOL MACROMOL, V9, P333, DOI 10.1016/0141-8130(87)90004-3
   DOMSZY JG, 1985, MAKROMOL CHEM, V186, P1671
   DWELTZ NE, 1960, BIOCHIM BIOPHYS ACTA, V44, P416, DOI 10.1016/0006-3002(60)91597-3
   EAST GC, 1993, J APPL POLYM SCI, V50, P1773, DOI 10.1002/app.1993.070501013
   FALK M, 1966, CAN J CHEMISTRY, V44, P2269, DOI 10.1139/v66-342
   Gonell H. W., 1926, Zs phys Chem Berlin, V152, P18
   HACKMAN RH, 1974, CARBOHYD RES, V38, P35, DOI 10.1016/S0008-6215(00)82336-8
   HIRANO S, 1976, BIOPOLYMERS, V15, P1685, DOI 10.1002/bip.1976.360150906
   HIRANO S, 1977, AGR BIOL CHEM TOKYO, V41, P1547, DOI 10.1080/00021369.1977.10862716
   HIRANO S, 1981, AGR BIOL CHEM TOKYO, V45, P1335, DOI 10.1080/00021369.1981.10864712
   HYES ER, 1978, P 1 INT C CHIT CHIT
   KAWANO K, 1986, 53 GOV IND RES I
   Knecht E, 1926, J SOC DYERS COLOUR, V42, P343
   Koshijima T, 1973, CELL CHEM TECHNOL, V7, P197
   KUNIKE G, 1926, J SOC DYERS COLOUR, V42, P318
   LAL GS, 1984, J ANAL APPL PYROL, V6, P183, DOI 10.1016/0165-2370(84)80012-1
   LANDEL RF, 1957, J COLLOID SCI, V12, P400
   LOTMAR W, 1950, EXPERIENTIA, V6, P58, DOI 10.1007/BF02174818
   Meyer KH, 1935, HELV CHIM ACTA, V18, P589, DOI 10.1002/hlca.19350180177
   MIYA M, 1980, INT J BIOL MACROMOL, V2, P323, DOI 10.1016/0141-8130(80)90056-2
   MOORE GK, 1980, INT J BIOL MACROMOL, V2, P73, DOI 10.1016/0141-8130(80)90031-8
   MOORE GK, 1980, INT J BIOL MACROMOL, V2, P78, DOI 10.1016/0141-8130(80)90032-X
   MOORE GK, 1980, INT J BIOL MACROMOL, V2, P115, DOI 10.1016/0141-8130(80)90040-9
   MOORE GK, 1978, THESIS TRENT POLYTEC
   Muzzarelli R.A.A., 1973, NATURAL CHELATING PO
   MUZZARELLI RAA, 1985, CARBOHYD POLYM, V5, P461, DOI 10.1016/0144-8617(85)90005-0
   MUZZARELLI RAA, 1986, SPECIAL PUBL R SOC C, V61, P44
   MUZZARELLI RAA, 1977, CHITIN
   Nakajima M., 1984, CHITIN CHITOSAN RELA
   NOGUCHI J, 1978, P 1 INT C CHIT CHIT
   NUDGA LA, 1973, ZH OBSHCH KHIM+, V43, P2752
   QIN Y, 1993, J APPL POLYM SCI, V49, P727, DOI 10.1002/app.1993.070490418
   QIN Y, 1990, THESIS U LEEDS
   Roberts G, 1992, CHITIN CHEM
   RUTHERFORD FA, 1978, P 1 INT C CHIT CHIT
   SANNAN T, 1978, POLYMER, V19, P458, DOI 10.1016/0032-3861(78)90256-2
   THOR CJB, 1939, Patent No. 2168374
   THOR CJB, 1940, AM DYESTUFF REPTR, V29, P461
   THOR CJB, 1940, AM DYEST REP, V29, P489
   THOR CJB, 1939, Patent No. 2168375
   TOKURA S, 1979, POLYM J, V11, P781, DOI 10.1295/polymj.11.781
   TOKURA S, 1987, SEN-I GAKKAISHI, V43, P288
   YOSHINARI T, 1976, METAL TRANSFER ECOLO
   1959, Patent No. 116418
   1981, Patent No. 106901
   1960, Patent No. 59123
   1981, Patent No. 112937
NR 61
TC 103
Z9 105
U1 4
U2 36
PU JOHN WILEY & SONS LTD
PI W SUSSEX
PA BAFFINS LANE CHICHESTER, W SUSSEX, ENGLAND PO19 1UD
SN 1042-7147
J9 POLYM ADVAN TECHNOL
JI Polym. Adv. Technol.
PD JUN
PY 1997
VL 8
IS 6
BP 355
EP 365
DI 10.1002/(SICI)1099-1581(199706)8:6<355::AID-PAT651>3.0.CO;2-T
PG 11
WC Polymer Science
SC Polymer Science
GA XJ785
UT WOS:A1997XJ78500006
DA 2018-10-19
ER

PT J
AU Bonner, MC
   Tunney, MM
   Jones, DS
   Gorman, SP
AF Bonner, MC
   Tunney, MM
   Jones, DS
   Gorman, SP
TI Factors affecting in vitro adherence of ureteral stent biofilm isolates
   to polyurethane
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE bacterial adherence; hydrophobicity; zeta potential; ureteral stent;
   human urine; polyurethane
ID COAGULASE-NEGATIVE STAPHYLOCOCCI; SURFACE HYDROPHOBICITY; CARBON-DIOXIDE
AB Adherence of bacteria to biomaterials is the first stage in the development of a device-related infection. The adherence of bacterial cells to biomaterials may be influenced by surface characteristics of the cell, its growth conditions and the biomaterial surface chemistry. Following growth in human urine, the cell surface,hydrophobicity and zeta potential of two ureteral stent biofilm isolates, Enterococcus faecalis and Escherichia coli, were significantly altered. In addition, the adherence of human urine-grown Enterococcus faecalis and Escherichia coli to polyurethane was significantly increased by up to 52.1% and 58.6%, respectively. Treatment of the polyurethane with human urine rendered the polymer surface more hydrophilic (mean advancing water contact angle reduced from 97.59 degrees to 26.37 degrees). However, organisms grown in human urine showed less adherence (up to 90.4%) to the treated polymer than those grown in Mueller-Hinton broth. The results presented in this study indicate that in vivo conditions should be simulated as far as possible when carrying out in vitro bacterial adherence assays, especially if assessing novel methods for reduction of adherence. (C) 1997 Elsevier Science B.V.
C1 QUEENS UNIV BELFAST,SCH PHARM,PHARMACEUT DEVICES GRP,BELFAST BT9 7BL,ANTRIM,NORTH IRELAND.
CR Bonner M. C., 1995, Journal of Pharmacy and Pharmacology, V47, P1095
   CARBALLO J, 1991, MED MICROBIOL IMMUN, V180, P149
   DENYER SP, 1990, J CLIN MICROBIOL, V28, P1813
   Derjaguin B, 1941, ACTA PHYSICOCHIM URS, V14, P633, DOI DOI 10.1016/0079-6816(93)90013-L
   GORMAN SP, 1993, J MED MICROBIOL, V38, P411, DOI 10.1099/00222615-38-6-411
   HJERTEN S, 1974, J CHROMATOGR, V101, P281, DOI 10.1016/S0021-9673(00)82845-9
   JONES DS, 1991, J APPL BACTERIOL, V71, P218, DOI 10.1111/j.1365-2672.1991.tb04451.x
   KEANE PF, 1994, BRIT J UROL, V73, P687, DOI 10.1111/j.1464-410X.1994.tb07557.x
   LINDAHL M, 1981, BIOCHIM BIOPHYS ACTA, V677, P471, DOI 10.1016/0304-4165(81)90261-0
   REID G, 1992, CELL MATER, V2, P253
   REID G, 1991, BIOFOULING, V4, P171, DOI DOI 10.1080/08927019109378207
   ROSENBERG M, 1980, FEMS MICROBIOL LETT, V9, P29, DOI 10.1111/j.1574-6968.1980.tb05599.x
   TUNNEY MM, 1996, REV MED MICROBIOL, V7, P195
   VERWEY EJW, 1948, THEORY STABILITY LYO
   Wassall M. A., 1994, Journal of Pharmacy and Pharmacology, V46, P1044
   WEERKAMP AH, 1988, J DENT RES, V67, P1483, DOI 10.1177/00220345880670120801
   WILCOX MH, 1991, J ANTIMICROB CHEMOTH, V27, P577, DOI 10.1093/jac/27.5.577
NR 17
TC 12
Z9 12
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
J9 INT J PHARM
JI Int. J. Pharm.
PD MAY 26
PY 1997
VL 151
IS 2
BP 201
EP 207
DI 10.1016/S0378-5173(97)04903-X
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA XD236
UT WOS:A1997XD23600008
DA 2018-10-19
ER

PT J
AU Tunney, MM
   Jones, DS
   Gorman, SP
AF Tunney, MM
   Jones, DS
   Gorman, SP
TI Methacrylate polymers and copolymers as urinary tract biomaterials:
   Resistance to encrustation and microbial adhesion
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE bacterial adhesion; encrustation; poly(methylmethacrylate);
   poly(hydroxyethylmethacrylate); hydrophobicity
ID COAGULASE-NEGATIVE STAPHYLOCOCCI; BACTERIAL; ADHERENCE; SURFACES;
   ATTACHMENT; STENTS
AB The ability of bacteria to adhere to medical device biomaterials within the urinary tract is recognised as an essential mechanism in the pathogenesis of device-related infection. Colonisation of a biomaterial surface with urea-splitting bacteria also causes alkalinisation of the urine with subsequent formation of encrusting deposits of struvite and hydroxyapatite. This study examined the role of both bacterial cell surface hydrophobicity and biomaterial hydrophobicity in urinary device infection and encrustation. The polymers formed and investigated were poly(methyl methacrylate) (PMMA), poly(hydroxyethyl methacrylate) (PHEMA) and copolymers of PMMA with PHEMA (75:25, 50:50 and 25:75 w/w, respectively). Polymer surfaces were characterised by dynamic contact angle measurement in water. Polymer encrustation and adhesion of a hydrophilic Escherichia coli urinary isolate and a hydrophobic Enterococcus faecalis urinary isolate were also determined. The hydrophobic PMMA polymer was more effective in resisting encrustation than all of the more hydrophilic PMMA/PHEMA copolymer series. Adhesion of the hydrophilic Escherichia coli isolate to the copolymers increased with decreasing copolymer hydrophobicity. A relationship was not apparent between copolymer hydrophobicity and adherence of the hydrophobic Enterococcus faecalis isolate. (C) 1997 Elsevier Science B.V.
C1 QUEENS UNIV BELFAST, SCH PHARM, PHARMACEUT DEVICES GRP, BELFAST BT9 7BL, ANTRIM, NORTH IRELAND.
CR BASSETT J, 1978, VOGELS TXB QUANTITAT, P837
   Bonner M. C., 1995, Journal of Pharmacy and Pharmacology, V47, P1095
   BOULANGEPETERMANN L, 1993, J ADHES SCI TECHNOL, V7, P221, DOI 10.1163/156856193X00673
   Cormio L, 1995, Scand J Urol Nephrol Suppl, V171, P1
   DENYER SP, 1990, J CLIN MICROBIOL, V28, P1813
   FLETCHER M, 1979, APPL ENVIRON MICROB, V37, P67
   GORDON NSI, 1989, BRIT J UROL, V64, P195, DOI 10.1111/j.1464-410X.1989.tb05987.x
   GORMAN SP, 1995, J PHARM PHARMACOL, V47, P1060
   GORMAN SP, 1993, PHARMACOTHERAPY, V13, P281
   HARKES G, 1991, BIOMATERIALS, V12, P853, DOI 10.1016/0142-9612(91)90074-K
   HAWTHORN LA, 1990, J BIOMED MATER RES, V24, P39, DOI 10.1002/jbm.820240105
   HOGT AH, 1986, J BIOMED MATER RES, V20, P533, DOI 10.1002/jbm.820200409
   HOLMES SAV, 1992, BRIT J UROL, V69, P651, DOI 10.1111/j.1464-410X.1992.tb15640.x
   KEANE PF, 1994, BRIT J UROL, V73, P687, DOI 10.1111/j.1464-410X.1994.tb07557.x
   MINAGI S, 1985, INFECT IMMUN, V47, P11
   OGA M, 1988, BIOMATERIALS, V9, P285, DOI 10.1016/0142-9612(88)90100-7
   OHKAWA M, 1990, J UROLOGY, V143, P717, DOI 10.1016/S0022-5347(17)40071-1
   PRINGLE JH, 1983, J GEN MICROBIOL, V129, P2557
   STICKLER DJ, 1993, CELL MATER, V3, P315
   Tunney Michael, 1996, Journal of Urology, V155, p473A
   Tunney MM, 1996, BIOMATERIALS, V17, P1541, DOI 10.1016/0142-9612(96)89780-8
   Tunney MM, 1996, BIOMATERIALS, V17, P1025, DOI 10.1016/0142-9612(96)84679-5
   TUNNEY MM, 1996, REV MED MICROBIOL, V7, P195
   VANPELT AWJ, 1985, APPL ENVIRON MICROB, V49, P1270
NR 24
TC 21
Z9 23
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD MAY 12
PY 1997
VL 151
IS 1
BP 121
EP 126
DI 10.1016/S0378-5173(97)04902-8
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA XD088
UT WOS:A1997XD08800014
DA 2018-10-19
ER

PT J
AU Marcus, VA
   Roy, I
   Sullivan, JD
   Sutton, JR
AF Marcus, VA
   Roy, I
   Sullivan, JD
   Sutton, JR
TI Necrobiotic palisading suture granulomas involving bone and joint:
   Report of two cases
SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY
LA English
DT Article
DE suture granuloma; necrobiotic granuloma; palisading granuloma; bone
AB Biomaterial used in surgery is relatively inert and non-toxic; however, adverse reactions may follow implantation of such foreign material. We describe the first two cases of bone and joint destruction by necrobiotic palisading suture granulomas. The hypersensitivity reaction occurred years after shoulder repair using silk sutures. One patient received chemotherapy for a mistaken diagnosis of tuberculous arthritis. Although very rare, foreign material should be included in the differential diagnosis of necrotizing granulomas. A history of surgery and microscopic examination with polarized light should allow recognition of this entity.
C1 MCGILL UNIV,ST MARYS HOSP,DEPT PATHOL,MONTREAL,PQ H3T 1M5,CANADA.
   MCGILL UNIV,ST MARYS HOSP,DEPT ORTHOPED,MONTREAL,PQ H3T 1M5,CANADA.
CR ALGUACILGARCIA A, 1993, AM J SURG PATHOL, V17, P920, DOI 10.1097/00000478-199309000-00008
   BALOGH K, 1986, ARCH PATHOL LAB MED, V110, P1168
   BARR RJ, 1982, J AM ACAD DERMATOL, V6, P867, DOI 10.1016/S0190-9622(82)80123-0
   Boros D L, 1978, Prog Allergy, V24, P183, DOI 10.1159/000314417
   GERBERT J, 1981, J AM POD ASSOC, V71, P450, DOI 10.7547/87507315-71-8-450
   GOLDSTEIN SA, 1986, J HAND SURG-AM, V11A, P899, DOI 10.1016/S0363-5023(86)80247-7
   LYNCH TH, 1992, J UROLOGY, V147, P460, DOI 10.1016/S0022-5347(17)37273-7
   MORALESPIGA A, 1986, ARTHRITIS RHEUM, V29, P1278, DOI 10.1002/art.1780291015
   MORGAN AM, 1995, J CUTAN PATHOL, V22, P193, DOI 10.1111/j.1600-0560.1995.tb00740.x
   NISSIM F, 1981, ARCH PATHOL LAB MED, V105, P86
   TANG LP, 1995, AM J CLIN PATHOL, V103, P466
NR 11
TC 10
Z9 10
U1 0
U2 1
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 0147-5185
J9 AM J SURG PATHOL
JI Am. J. Surg. Pathol.
PD MAY
PY 1997
VL 21
IS 5
BP 563
EP 565
DI 10.1097/00000478-199705000-00009
PG 3
WC Pathology; Surgery
SC Pathology; Surgery
GA WZ255
UT WOS:A1997WZ25500009
PM 9158681
DA 2018-10-19
ER

PT J
AU Frey, A
   Neutra, MR
   Robey, FA
AF Frey, A
   Neutra, MR
   Robey, FA
TI Peptomer aluminum oxide nanoparticle conjugates as systemic and mucosal
   vaccine candidates: Synthesis and characterization of a conjugate
   derived from the C4 domain of HIV-1(MN) gp120
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; MONOCLONAL-ANTIBODIES;
   AFFINITY-CHROMATOGRAPHY; CONTAINING PEPTIDES; CYCLIC-PEPTIDES;
   AMINO-ACID; IDENTIFICATION; GLYCOPROTEIN; RECEPTOR; ADJUVANT
AB Peptomers are polymers composed of peptides that are specifically cross-linked in a head-to-tail fashion. Recently, a peptomer composed of an amphipathic peptide from the C4 domain of HIV-1(MN) gp120 was shown to display a prominent alpha-helical conformation that, as an immunogen, elicited rabbit antibodies recognizing native and recombinant gp120 [Robey et al. (1995) J. Biol. Chem. 270, 23918-23921]. For the present study, we synthesized a conjugate composed of the C4 peptomer covalently linked to calcinated aluminum oxide nanoparticles. The nanoparticles were first reacted with (3-aminopropyl)-triethoxysilane to provide an amine load of 15.9 mmol of R-NH2/g of solid. The amine-modified aluminum oxide nanoparticles then were reacted with N-acetylhomocysteine thiolactone at pH 10 to place a reactive thiol on the nanoparticles. A bromoacetylated C4 peptomer, modified at the E-amines of lysine residues, then was reacted with the thiolated nanoparticles to give the peptomer covalently linked to aluminum oxide via a thioether bond. The peptomer load was determined to be 16 mg of peptomer/g of particles, a 55% theoretical yield. Particle shape and size of the peptomer-conjugated alumina were analyzed by electron microscopy and displayed a mean maximum diameter of 355 nm and a mean minimum diameter of 113 nm, well within the desired size range of 300 nm believed to be optimal for mucosal immunization purposes. Experimentally determined values of mean particle diameters, specific surface area, and specific peptomer load provided the information necessary to calculate the mean antigen load, which was determined to be 53 000 +/- 42 000 peptomer epitopes per particle. Peptomer-alumina conjugates, such as that described here, could form the basis of a new class of biomaterial that combines a chemically defined organic immunogen with a nontoxic chemically defined inorganic adjuvant.
C1 NIDR,ORAL & PHARYNGEAL CANC BRANCH,NIH,BETHESDA,MD 20892.
   HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115.
   CHILDRENS HOSP,GI CELL BIOL RES LAB,BOSTON,MA 02115.
FU NICHD NIH HHS [HD17557]; NIAID NIH HHS [AI34757]; NIDDK NIH HHS
   [DK-34854]
CR AMERONGEN HM, 1991, J ACQ IMMUN DEF SYND, V4, P760
   ANSPACH B, 1988, J CHROMATOGR, V457, P195, DOI 10.1016/S0021-9673(01)82067-7
   BERNATOWICZ MS, 1986, ANAL BIOCHEM, V155, P107
   BJORK RL, 1991, IMMUNOL LETT, V28, P91, DOI 10.1016/0165-2478(91)90104-I
   BLAND PW, 1986, IMMUNOLOGY, V58, P9
   BORRASCUESTA F, 1988, EUR J IMMUNOL, V18, P199, DOI 10.1002/eji.1830180203
   Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023
   CHRISTEL PS, 1992, CLIN ORTHOPAEDICS, V282, P10
   CORDONNIER A, 1989, NATURE, V340, P571, DOI 10.1038/340571a0
   DELGIUDICE G, 1986, J IMMUNOL, V137, P2952
   DESCHRYVER A, 1990, B WORLD HEALTH ORGAN, V68, P639
   EARL PL, 1990, P NATL ACAD SCI USA, V87, P648, DOI 10.1073/pnas.87.2.648
   ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6
   Fairhurst C W, 1992, Adv Dent Res, V6, P78
   FORREST BD, 1992, VACCINE RES, V1, P137
   FRANCIS MJ, 1991, IMMUNOLOGY, V73, P249
   Frey A, 1996, J EXP MED, V184, P1045, DOI 10.1084/jem.184.3.1045
   GOLDING H, 1988, J EXP MED, V167, P914, DOI 10.1084/jem.167.3.914
   Gupta R K, 1995, Pharm Biotechnol, V6, P229
   GURGO C, 1988, VIROLOGY, V164, P531, DOI 10.1016/0042-6822(88)90568-5
   Hem S L, 1995, Pharm Biotechnol, V6, P249
   HILLMAN K, 1991, CELL IMMUNOL, V134, P1, DOI 10.1016/0008-8749(91)90326-7
   HUISDEN RE, 1990, J CHROMATOGR, V508, P289, DOI 10.1016/S0021-9673(00)91271-8
   IVANOV B, 1995, BIOCONJUGATE CHEM, V6, P269, DOI 10.1021/bc00033a006
   JAKOBY WB, 1984, REV BIOCHEM TOXICOL, V6, P97
   KOSSOVSKY N, 1995, BIOCONJUGATE CHEM, V6, P507, DOI 10.1021/bc00035a001
   LARSSON PO, 1983, ADV CHROMATOGR, V21, P41
   LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1
   LINDENSCHMIDT RC, 1990, TOXICOL APPL PHARM, V102, P268, DOI 10.1016/0041-008X(90)90026-Q
   LYNN M, 1975, IMMOBILIZED ENZYMES
   MARX PA, 1993, SCIENCE, V260, P1323, DOI 10.1126/science.8493576
   MASSIA SP, 1990, ANAL BIOCHEM, V187, P292, DOI 10.1016/0003-2697(90)90459-M
   MOORE JP, 1994, J VIROL, V68, P469
   NAKAMURA GR, 1993, J VIROL, V67, P6179
   Neutra Marian R., 1994, P685
   Neutra MR, 1996, CELL, V86, P345, DOI 10.1016/S0092-8674(00)80106-3
   Neutra MR, 1996, ANNU REV IMMUNOL, V14, P275, DOI 10.1146/annurev.immunol.14.1.275
   OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4
   Robey F A, 1994, Methods Mol Biol, V35, P73
   ROBEY FA, 1989, ANAL BIOCHEM, V177, P373, DOI 10.1016/0003-2697(89)90068-7
   Robey FA, 1996, J BIOL CHEM, V271, P17990, DOI 10.1074/jbc.271.30.17990
   ROBEY FA, 1995, J BIOL CHEM, V270, P23918, DOI 10.1074/jbc.270.41.23918
   SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1
   SASTRY KJ, 1991, AIDS, V5, P699, DOI 10.1097/00002030-199106000-00009
   SCIBIENS.RJ, 1973, J IMMUNOL, V111, P114
   SKEA DL, 1993, VACCINE, V11, P1018, DOI 10.1016/0264-410X(93)90127-J
   SPORTSMAN JR, 1980, ANAL CHEM, V52, P2013, DOI 10.1021/ac50063a006
   STARCICH BR, 1986, CELL, V45, P637, DOI 10.1016/0092-8674(86)90778-6
   SUN NC, 1989, J VIROL, V63, P3579
   TAKEDA A, 1988, SCIENCE, V242, P580, DOI 10.1126/science.2972065
   TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409
   Washburn EW, 1921, P NATL ACAD SCI USA, V7, P115, DOI 10.1073/pnas.7.4.115
   Weetall H H, 1976, Methods Enzymol, V44, P134
   YOKEL RA, 1994, J TOXICOL ENV HEALTH, V41, P131, DOI 10.1080/15287399409531834
NR 54
TC 38
Z9 38
U1 1
U2 13
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 1043-1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD MAY-JUN
PY 1997
VL 8
IS 3
BP 424
EP 433
DI 10.1021/bc970036p
PG 10
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA XB627
UT WOS:A1997XB62700022
PM 9177850
DA 2018-10-19
ER

PT J
AU Phaneuf, MD
   Berceli, SA
   Bide, MJ
   Quist, WC
   LoGerfo, FW
AF Phaneuf, MD
   Berceli, SA
   Bide, MJ
   Quist, WC
   LoGerfo, FW
TI Covalent linkage of recombinant hirudin to poly(ethylene terephthalate)
   (Dacron): Creation of a novel antithrombin surface
SO BIOMATERIALS
LA English
DT Article
DE poly(ethylene terephthalate); immobilization; albumin; recombinant
   hirudin; antithrombin
ID HEPARIN IMMOBILIZATION; CONCENTRATION PROFILES; THROMBIN; ALBUMIN;
   PLATELETS; INVITRO; BINDING; INACTIVATION; AGGREGATION; COAGULATION
AB Thrombus formation and intimal hyperplasia on the surface of implantable biomaterials such as poly(ethylene terepthalate) (Dacron) vascular grafts are major concerns when utilizing these materials in the clinical setting. Thrombin, a pivotal enzyme in the blood coagulation cascade primarily responsible for thrombus formation and smooth muscle cell activation, has been the target of numerous strategies to prevent this phenomenon from occurring. The purpose of this study was to covalently immobilize the potent, specific antithrombin agent recombinant hirudin (rHir) to a modified Dacron surface and characterize the in vitro efficacy of thrombin inhibition by this novel biomaterial surface. Bovine serum albumin (BSA), which was selected as the 'basecoat' protein, was reacted with various molar ratios of the cross-linker sulphosuccinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (sulpho-SMCC; 1:5-1:50). These BSA-SMCC complexes were then covalently linked to sodium hydroxide-hydrolysed Dacron (HD) segments via the cross-linker 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC). Covalent linkage of these complexes to HD (HD-BSA-SMCC) was not affected by any of the sulpho-SMCC cross-linker ratios assayed. rHir, which was initially reacted with 2-iminothiolane hydrochloride (Traut's reagent) in order to create sulphydryl groups, was then covalently bound to these HD-BSA-SMCC surfaces (HD-BSA-SMCC-S-rHir). The 1:50 (BSA: sulpho-SMCC) HD-BSA-SMCC-S-rHir segments bound 22-fold more rHir (111 ng per mg Dacron) compared to control segments and also possessed the greatest thrombin inhibition of the segments evaluated using a chromogenic substrate assay for thrombin. Further characterization of the HD-BSA-SMCC-S-rHir segments demonstrated that maximum thrombin inhibition was 20.43 NIHU, 14.6-fold greater inhibition than control segments (1.4 NIHU). Thrombin inhibition results were confirmed by I-125-thrombin binding experiments, which demonstrated that the 1:50 HD-BSA-SMCC-S-rHir segments had significantly greater specific thrombin adhesion compared to control segments. Non-specific I-125-thrombin binding to and release from the 1:50 HD-BSA-SMCC-S-rHir segments was also significantly less than the control segments. Thus, these results demonstrate that rHir can be covalently bound to a clinically utilized biomaterial (Dacron) while still maintaining its ability to bind and inhibit thrombin. (C) 1997 Elsevier Science Limited.
C1 UNIV RHODE ISL, DEPT TEXT, KINGSTON, RI 02881 USA.
RP Phaneuf, MD (reprint author), HARVARD UNIV, NEW ENGLAND DEACONESS HOSP, SCH MED, 12 BLACKFAN ST, BOSTON, MA 02215 USA.
OI Berceli, Scott/0000-0003-2257-0111
FU NHLBI NIH HHS [1R43HL53856-01A1]
CR BAKKER WW, 1991, BIOMATERIALS, V12, P603, DOI 10.1016/0142-9612(91)90059-J
   BALDWIN SA, 1994, ANN BIOMED ENG, V22, P357, DOI 10.1007/BF02368242
   BARBUCCI R, 1994, BIOMATERIALS, V15, P955, DOI 10.1016/0142-9612(94)90075-2
   BARSHAVIT R, 1983, SCIENCE, V220, P728, DOI 10.1126/science.6836310
   BIZIOS R, 1986, J CELL PHYSIOL, V128, P485, DOI 10.1002/jcp.1041280318
   CATCHMARCHANT K, 1989, BIOMATERIALS, V10, P147
   CHROMOGENIX AB, 1995, CHROMOGENIC SUBSTRAT
   ELGUE G, 1993, THROMB HAEMOSTASIS, V70, P289
   FENTON JW, 1988, SEMIN THROMB HEMOST, V14, P234, DOI 10.1055/s-2007-1002783
   FENTON JW, 1986, SEMIN THROMB HEMOST, V12, P200, DOI 10.1055/s-2007-1003551
   FOLIE BJ, 1989, BIOPHYS J, V56, P1121, DOI 10.1016/S0006-3495(89)82760-2
   GRAINGER DW, 1989, J COLLOID INTERF SCI, V132, P161, DOI 10.1016/0021-9797(89)90226-9
   Hardhammar PA, 1996, CIRCULATION, V93, P423, DOI 10.1161/01.CIR.93.3.423
   HENNINK WE, 1983, THROMB RES, V29, P1, DOI 10.1016/0049-3848(83)90120-2
   HOGG PJ, 1989, P NATL ACAD SCI USA, V86, P3619, DOI 10.1073/pnas.86.10.3619
   HUBBELL JA, 1986, BIOPHYS J, V50, P937, DOI 10.1016/S0006-3495(86)83535-4
   ITO Y, 1988, BIOMATERIALS, V9, P235, DOI 10.1016/0142-9612(88)90090-7
   JACOBS H, 1986, J PHARM SCI, V75, P172, DOI 10.1002/jps.2600750215
   KAPLAN JE, 1989, AM J PHYSIOL, V257, pH423
   KISHIDA A, 1994, BIOMATERIALS, V15, P848, DOI 10.1016/0142-9612(94)90041-8
   LIN SC, 1991, J BIOMED MATER RES, V25, P791, DOI 10.1002/jbm.820250608
   LINDON JN, 1985, J LAB CLIN MED, V105, P219
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   LYMAN DJ, 1971, FED PROC, V30, P1658
   MA XH, 1991, J COLLOID INTERF SCI, V147, P251, DOI 10.1016/0021-9797(91)90152-X
   MAKSIMENKO AV, 1985, THROMB RES, V38, P277, DOI 10.1016/0049-3848(85)90156-2
   MARKWARDT F, 1985, BIOMED BIOCHIM ACTA, V44, P1007
   MERHI Y, 1989, BIOMATERIALS, V10, P56, DOI 10.1016/0142-9612(89)90010-0
   NEMETS EA, 1991, ARTIF ORGANS, V15, P381
   NOJIRI C, 1990, T AM SOC ART INT ORG, V36, pM168
   OBBERGHENSCHILL.EV, 1982, BIOCHEM BIOPH RES CO, V106, P79
   OOSTA GM, 1982, J BIOL CHEM, V257, P1249
   PARK KD, 1988, J BIOMED MATER RES, V22, P977, DOI 10.1002/jbm.820221103
   PHANEUF MD, 1994, THROMB HAEMOSTASIS, V71, P481
   PHANEUF MD, 1994, BLOOD COAGUL FIBRIN, V5, P641
   PHANEUF MD, 1995, J APPL BIOMATER, V6, P289, DOI 10.1002/jab.770060410
   RUMISEK JD, 1989, SURGERY, V105, P654
   RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926
   SALZMAN EW, 1980, J CLIN INVEST, V65, P64, DOI 10.1172/JCI109661
   SILVER JH, 1992, BIOMATERIALS, V13, P339, DOI 10.1016/0142-9612(92)90037-O
   SLIMANE S B, 1988, European Surgical Research, V20, P18
   SLIMANE S B, 1988, European Surgical Research, V20, P66
   TAY SW, 1989, BIOMATERIALS, V10, P11, DOI 10.1016/0142-9612(89)90003-3
   TOLLEFSEN DM, 1974, J BIOL CHEM, V249, P2646
   VANDERLEI B, 1985, T AM SOC ART INT ORG, V31, P107
   VULIC I, 1988, J POLYM SCI POL CHEM, V26, P381, DOI 10.1002/pola.1988.080260204
   WALZ DA, 1986, ANN NY ACAD SCI, V485, P323, DOI 10.1111/j.1749-6632.1986.tb34594.x
   WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723
   WILSON JE, 1986, POLYM-PLAST TECHNOL, V25, P233, DOI 10.1080/03602558608070086
   ZHENG J, 1994, BIOMATERIALS, V15, P963, DOI 10.1016/0142-9612(94)90076-0
NR 50
TC 64
Z9 65
U1 4
U2 15
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD MAY
PY 1997
VL 18
IS 10
BP 755
EP 765
DI 10.1016/S0142-9612(96)00193-7
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA WY326
UT WOS:A1997WY32600008
PM 9158859
DA 2018-10-19
ER

PT J
AU Fini, M
   Aldini, NN
   Gandolfi, MG
   Belmonte, MM
   Giavaresi, G
   Zucchini, C
   DeBenedittis, A
   Amati, S
   Ravaglioli, A
   Krayewski, A
   Rocca, M
   Guzzardella, GA
   Biagini, G
   Giardino, R
AF Fini, M
   Aldini, NN
   Gandolfi, MG
   Belmonte, MM
   Giavaresi, G
   Zucchini, C
   DeBenedittis, A
   Amati, S
   Ravaglioli, A
   Krayewski, A
   Rocca, M
   Guzzardella, GA
   Biagini, G
   Giardino, R
TI Biomaterials for orthopedic surgery in osteoporotic bone: A comparative
   study in osteopenic rats
SO INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS
LA English
DT Article
DE osteoporosis; renal failure; pathological fractures; biomaterials;
   osteointegration; hydroxyapatite (HA)
ID HEMODIALYSIS-PATIENTS; DISEASE; HYDROXYAPATITE; RECIPIENTS; FRACTURES;
   TITANIUM
AB To evaluate orthopedic devices in pathological bone, an experimental study was performed by implanting Titanium (Ti) and Hydroxyapatite (HA) rods in normal and osteopenic bone. Twenty-four rats were used: 12 were left intact (Control: C) while the other 12 were ovariectomized (OVX). After 4 months all the animals were submitted to the implant of Ti or HA in the left femoral condyle (Ti-C, HA-C Ti-OVX, HA-OVX). Two months later the animals were sacrificed for histomorphometric, ultrastructural and microanalytic studies. Our results show a significant difference between the Affinity Index (A.I.) of HA-C and Ti-C (77.0 +/- 7.4 vs 61.2 +/- 9.7) (p < 0.05). No significant differences were observed between the osteointegration of Ti-C and Ti-OVX (61.2 +/- 9.7 vs 48.2 +/- 6.7). Significant differences also exist between the osteointegration of HA-C and HA-OVX (77.0 7.4 vs 57.6 +/- 11.5) (p < 0.01). Microanalysis shows some modifications in Sulphur (S) concentration at the bone/biomaterial interface of the Ti-OVX group. Therefore our results confirmed the importance of biomaterials characteristics and of bone quality in osteointegration processes.
C1 UNIV BOLOGNA,CHAIR SURG PATHOPHYSIOL,I-40126 BOLOGNA,ITALY.
   UNIV BOLOGNA,INST HISTOL & GEN EMBRIOL,I-40126 BOLOGNA,ITALY.
   UNIV ANCONA,DEPT MAT SCI,ANCONA,ITALY.
   UNIV ANCONA,INST NORMAL HUMAN MORPHOL,ANCONA,ITALY.
   CNR,INST TECHNOL RES CERAM,FAENZA,ITALY.
   IST RIC CODIVILLA PUTTI IOR,SERV CHIRURG SPERIMENTALE,I-40136 BOLOGNA,ITALY.
RI Fini, Milena/J-4808-2016; Mattioli-Belmonte, Monica/J-5861-2012
OI Fini, Milena/0000-0002-3732-3570; Giavaresi,
   Gianluca/0000-0001-7843-5969; Gandolfi, Maria
   Giovanna/0000-0001-7793-6227
CR BEDANI PL, 1993, INT J ARTIF ORGANS, V16, P704
   BOCCALATTE M, 1994, INT J ARTIF ORGANS, V17, P203
   Carlsson L, 1988, Int J Oral Maxillofac Implants, V3, P21
   COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184
   Epstein Sol, 1995, Current Opinion in Rheumatology, V7, P255, DOI 10.1097/00002281-199505000-00018
   FINI M, 1994, INT J ARTIF ORGANS, V17, P431
   GALLAGHERALLRED CR, 1994, PRIMARY CARE, V21, P175
   Gnudi S., 1993, Bollettino Societa Italiana Biologia Sperimentale, V69, P461
   GONZALES EA, 1995, NEPHROL DIAL TRANSPL, V10, pS15
   GROTZ WH, 1995, TRANSPLANTATION, V59, P982, DOI 10.1097/00007890-199504150-00010
   GROTZ WH, 1994, TRANSPLANTATION, V58, P912, DOI 10.1097/00007890-199410270-00009
   GRYNPAS M, 1993, CALCIFIED TISSUE INT, V53, pS57, DOI 10.1007/BF01673403
   GUZZARDELLA GA, 1996, ACTA BIOMED ATENEO P, V67, P56
   HARDY P, 1994, REV CHIR ORTHOP, V80, P702
   HAYASHI K, 1994, BIOMATERIALS, V15, P11, DOI 10.1016/0142-9612(94)90189-9
   HAYASHI K, 1989, J ARTHROPLASTY, V4, P256
   JABLONSKI G, 1995, CALCIFIED TISSUE INT, V57, P385, DOI 10.1007/BF00302075
   JOHNELL O, 1992, OSTEOPOROSIS INT, V2, P298, DOI 10.1007/BF01623186
   KHOSLA S, 1995, OSTEOPOROSIS ETIOLOG, V183, P204
   Kohn D H, 1992, J Oral Implantol, V18, P204
   Kraut J A, 1995, Adv Ren Replace Ther, V2, P40
   LEGEROS RZ, 1993, J BONE MINER RES, V8, pS583
   LYHNE N, 1995, NEPHROL DIAL TRANSPL, V10, P395
   MORONI A, 1996, J ORTHOP TRAUMA, V4, P236
   NAVEHMANY T, 1995, J CLIN INVEST, V96, P1786, DOI 10.1172/JCI118224
   NEWMAN E, 1995, BONE, V16, pS277, DOI 10.1016/8756-3282(95)00026-A
   ONEILL TW, 1994, J BONE MINER RES, V9, P1895
   Salusky IB, 1995, PEDIATR CLIN N AM, V42, P1531
   SENNERBY L, 1993, BIOMATERIALS, V14, P413, DOI 10.1016/0142-9612(93)90143-P
   SMITH DC, 1991, BONE BIOMATERIAL INT
   THOMPSON DD, 1995, BONE, V17, pS125, DOI 10.1016/8756-3282(95)00285-L
   TORIYAMA M, 1995, J MATER SCI, V30, P3216, DOI 10.1007/BF01209240
   Toriyama M, 1996, J EUR CERAM SOC, V16, P429, DOI 10.1016/0955-2219(95)00123-9
   TURNER AS, 1996, 42 ANN M ORTH RES SO
   ZWICKER HU, 1976, ARTIFICIAL HIP KNEE, P258
   1994, GUIDELINES PRECLINIC
   1994, BIOL EVALUATION MED
NR 37
TC 56
Z9 57
U1 0
U2 5
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 0391-3988
J9 INT J ARTIF ORGANS
JI Int. J. Artif. Organs
PD MAY
PY 1997
VL 20
IS 5
BP 291
EP 297
PG 7
WC Engineering, Biomedical; Transplantation
SC Engineering; Transplantation
GA XG839
UT WOS:A1997XG83900010
PM 9209931
DA 2018-10-19
ER

PT J
AU Berthaud, N
   Desnottes, JF
AF Berthaud, N
   Desnottes, JF
TI In-vitro bactericidal activity of quinupristin/dalfopristin against
   adherent Staphylococcus aureus
SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
LA English
DT Article; Proceedings Paper
CT 35th Interscience Conference on Antimicrobial Agents and Chemotherapy
   (ICAAC)
CY SEP 17-22, 1995
CL SAN FRANCISCO, CA
SP Amer Soc Microbiol
ID SUBINHIBITORY CONCENTRATIONS; RP 59500; INVITRO ACTIVITY; STREPTOGRAMIN;
   COLONIZATION; ANTIBIOTICS
AB A simple in-vitro assay was developed to test antibiotics for bactericidal activity against Staphylococcus aureus adhering to an artificial biomaterial. The activity of the semisynthetic injectable streptogramin quinupristin/dalfopristin combination was evaluated with this assay and compared with that of vancomycin. Fibronectin-coated nylon membranes were used to mimic implanted biomaterial. To obtain adherent bacteria, 400 mu L of a suspension of S. aureus strain Wood (5 x 10(6) cfu/ml) were placed for 1.5 h at 37 degrees C in contact with the membranes. After elimination of non-adherent bacteria by successive rinses, membranes were exposed to antibacterial agents at concentrations of 5, 10 and 50 x MIG. Drug-free controls were also prepared. After various incubation times, bacteria on both treated and control membranes were removed by sonication and subcultured on to agar medium. After incubation, the number of cfu on treated membranes was compared with that on t(0) control membranes. The criterion for bactericidal activity was a 99.9% reduction of the t(0) control inoculum. Under these experimental conditions, both quinupristin/dalfopristin and vancomycin, at concentrations achievable in blood (6.25 and 20 mg/L, respectively), demonstrated a potent bactericidal activity against S. aureus adhering to a support. The bactericidal effect of quinupristin/dalfopristin was more rapid than that of vancomycin. Quinupristin/dalfopristin may therefore be a useful alternative to vancomycin in the treatment of implant-associated S. aureus infections.
RP Berthaud, N (reprint author), RHONE POULENC RORER SA,CTR RECH,SERV BIOL ANTIBACTERIENS,13 QUAI J GUESDE,F-94403 VITRY SUR SEINE,FRANCE.
CR AHLBERG A, 1978, CLIN ORTHOP RELAT R, V137, P69
   BARRIERE JC, 1994, EXPERT OPIN INV DRUG, V3, P115
   BERTHAUD N, 1993, 33 INT C ANT AG CHEM, P311
   BROWN MRW, 1993, J APPL BACTERIOL, V74, pS87, DOI 10.1111/j.1365-2672.1993.tb04345.x
   CARSENTIETESSE H, 1993, ANTIMICROB AGENTS CH, V37, P921, DOI 10.1128/AAC.37.4.921
   Charnley J, 1972, Clin Orthop Relat Res, V87, P167, DOI 10.1097/00003086-197209000-00020
   DANKERT J, 1986, CRIT REV BIOCOMPAT, V2, P219
   DRUGEON HB, 1991, 31 INT C ANT AG CHEM, P248
   FASS RJ, 1991, ANTIMICROB AGENTS CH, V35, P553, DOI 10.1128/AAC.35.3.553
   FLANDROIS JP, 1988, ANTIMICROBIAL AGENTS, V32, P4554
   HamiltonMiller JMT, 1997, J ANTIMICROB CHEMOTH, V39, P103, DOI 10.1093/jac/39.suppl_1.103
   HOBAN DJ, 1992, J ANTIMICROB CHEMOTH, V30, P59, DOI 10.1093/jac/30.suppl_A.59
   KAISER AB, 1989, INFECT ASS INDWELLIN, P227
   KHARDORI N, 1991, J INFECT DIS, V164, P108, DOI 10.1093/infdis/164.1.108
   LECLERCQ R, 1992, J ANTIMICROB CHEMOTH, V30, P67, DOI 10.1093/jac/30.suppl_A.67
   MIYAKE Y, 1989, J ANTIMICROB CHEMOTH, V23, P79, DOI 10.1093/jac/23.1.79
   *NAT COMM CLIN LAB, 1992, M7A2 NCCLS
   NEU HC, 1992, J ANTIMICROB CHEMOTH, V30, P83, DOI 10.1093/jac/30.suppl_A.83
   PROCTOR RA, 1983, J ANTIMICROB CHEMOTH, V12, P85, DOI 10.1093/jac/12.suppl_C.85
   PROCTOR RA, 1987, REV INFECT DIS, V9, pS335
   VANDAUX P, 1984, J INFECT DIS, V150, P546
NR 21
TC 11
Z9 12
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD, ENGLAND OX2 6DP
SN 0305-7453
J9 J ANTIMICROB CHEMOTH
JI J. Antimicrob. Chemother.
PD MAY
PY 1997
VL 39
SU A
BP 99
EP 102
DI 10.1093/jac/39.suppl_1.99
PG 4
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA XP036
UT WOS:A1997XP03600019
PM 9511072
OA Bronze
DA 2018-10-19
ER

PT J
AU Sung, HW
   Hsu, CS
   Wang, SP
   Hsu, HL
AF Sung, HW
   Hsu, CS
   Wang, SP
   Hsu, HL
TI Degradation potential of biological tissues fixed with various
   fixatives: An in vitro study
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE biological tissue; epoxy compound; bacterial collagenase; pronase; in
   vitro degradation
ID DERMAL SHEEP COLLAGEN; MECHANICAL-PROPERTIES; EPOXY COMPOUNDS; VALVED
   CONDUIT; HEART-VALVE; BIOMATERIAL; CALCIFICATION; PREVENTION; INVITRO;
   INVIVO
AB The purpose of this study was to investigate the in vitro degradation potential of porcine pericardia fixed with various aldehyde or epoxy compound (EC) fixatives, using bacterial collagenase and pronase. The fixatives investigated were formaldehyde (FA), glutaraldehyde (GA), monofunctional EC (EX-131), and multifunctional ECs (EX-810, EX-313, and EX-512). Fresh porcine pericardium was used as a control. The test samples were well immersed in a 20-U/mt collagenase solution or a 10-U/mL pronase solution and incubated at 37 degrees C at PH 7.5 for 24 h. The extent of degradation of each test sample was determined by measuring its increment in free amino group content and changes in collagen structure, denaturation temperature, and tensile stress after degradation. In gereral, the extent of tissue degradation with pronase was more notable than with collagenase. As observed with fresh tissue, the EX-131 EC fixed tissue radically disintegrated after either collagenase or pronase degradation, whereas the other test samples remained intact. The reason for this may reside in the more random molecular packing of the EX-131 EC-fixed tissue, which led to some loss in its helical integrity. This made penetration of enzymes into biological tissue easier. Of the multifunctional EC test groups, tissues fixed with tetrafunctional EC (EX-521) or trifunctional EC (EX-313) had relatively better resistance to degradation than those fixed with bifunctional EC (EX-810). The extent of degradation for the EX-313 or EX-512 EC fixed tissues was similar to that observed for the FA- or GA-fixed tissues. The results of this study indicated that the biological tissue fixed with monofunctional EC (EX-131) cannot resist bacterial collagenase or pronase degradation. However, resistance to deg radation of the multifunctional EC (EX-313 or EX-152)-fixed tissues was comparable to that of the aldehyde (FA or GA)fixed tissues. Therefore, of various EC fixatives, the EC with a greater number of functional groups should be chosen for tissue fixation to increase its resistance to enzymatic degradation. (C) 1997 John Wiley & Sons, Inc.
RP Sung, HW (reprint author), NATL CENT UNIV,DEPT CHEM ENGN,CHUNGLI 32054,TAIWAN.
CR CHUENG DT, 1985, CONNECT TISSUE RES, V13, P109
   DAMINK LHHO, 1995, J BIOMED MATER RES, V29, P139, DOI 10.1002/jbm.820290202
   DAMINK LHHO, 1995, J BIOMED MATER RES, V29, P149, DOI 10.1002/jbm.820290203
   DIAMOND AM, 1991, MATRIX, V11, P321, DOI 10.1016/S0934-8832(11)80203-9
   GORHAM SD, 1990, BIOMATERIALS, V11, P113, DOI 10.1016/0142-9612(90)90125-A
   HARPER E, 1972, BIOPOLYMERS, V11, P1607, DOI 10.1002/bip.1972.360110807
   HATA C, 1992, ARTIF ORGANS, V16, P263, DOI 10.1111/j.1525-1594.1992.tb00307.x
   Imamura E, 1989, J Card Surg, V4, P50, DOI 10.1111/j.1540-8191.1989.tb00256.x
   LEE JM, 1995, MED ENG PHYS, V17, P115, DOI 10.1016/1350-4533(95)91882-H
   Lohre J M, 1993, ASAIO J, V39, P106, DOI 10.1097/00002480-199304000-00007
   LOHRE JM, 1992, ARTIF ORGANS, V16, P630
   MCCLAIN PE, 1972, J BIOL CHEM, V247, P692
   NAIMARK WA, 1992, AM J PHYSIOL, V263, pH1095
   Nimni ME, 1988, COLLAGEN, VIII, P1
   NISHI C, 1995, J BIOMED MATER RES, V29, P829, DOI 10.1002/jbm.820290707
   NOISHIKI Y, 1993, INT J ARTIF ORGANS, V16, P192
   NOISHIKI Y, 1986, T AM SOC ART INT ORG, V32, P114
   Noishiki Y., 1989, U. S. Patent, Patent No. [4,806,599, 4806599]
   SCHOEN FJ, 1988, J BIOMED MATER RES-A, V22, P11
   SCOTT R, 1986, BRIT J UROL, V58, P203, DOI 10.1111/j.1464-410X.1986.tb09027.x
   SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7
   SPERLING LH, 1993, INTRO PHYSICAL POLYM, P363
   STENZEL KH, 1974, ANNU REV BIOPHYS BIO, V3, P231, DOI 10.1146/annurev.bb.03.060174.001311
   Stryer L., 1988, BIOCHEMISTRY-US
   Sung H W, 1994, ASAIO J, V40, P192, DOI 10.1097/00002480-199404000-00013
   Sung H. W., 1993, ASIAN CARDIOVASC THO, V1, P104
   Sung HW, 1996, BIOMATERIALS, V17, P1693, DOI 10.1016/0142-9612(96)87649-6
   Sung HW, 1996, J BIOMED MATER RES, V31, P511, DOI 10.1002/(SICI)1097-4636(199608)31:4<511::AID-JBM11>3.0.CO;2-J
   Sung HW, 1996, J BIOMED MATER RES, V30, P361, DOI 10.1002/(SICI)1097-4636(199603)30:3<361::AID-JBM10>3.0.CO;2-N
   SUNG HW, 1993, INT J ARTIF ORGANS, V16, P199
   TU R, 1994, J BIOMED MATER RES, V28, P677, DOI 10.1002/jbm.820280604
   White M J, 1973, Biomater Med Devices Artif Organs, V1, P703
   Xi T, 1992, J Biomater Appl, V7, P61
   XI TF, 1992, J BIOMED MATER RES, V26, P1241
   YANNAS IV, 1975, J BIOMED MATER RES, V9, P623, DOI 10.1002/jbm.820090608
NR 35
TC 26
Z9 28
U1 1
U2 9
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD MAY
PY 1997
VL 35
IS 2
BP 147
EP 155
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA WW449
UT WOS:A1997WW44900002
PM 9135163
DA 2018-10-19
ER

PT J
AU Santini, MT
   Cametti, C
   Indovina, PL
   Morelli, G
   Donelli, G
AF Santini, MT
   Cametti, C
   Indovina, PL
   Morelli, G
   Donelli, G
TI Polylysine induces changes in membrane electrical properties of K562
   cells
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
ID EMBRYO MYOBLAST MEMBRANES; CESIUM-INDUCED DELAY; ASCITES TUMOR-CELLS;
   PROTEIN KINASE-C; MAGNETIC-FIELD; DIELECTRIC-PROPERTIES;
   HUMAN-ERYTHROCYTES; NEURITE OUTGROWTH; SURFACE-CHARGE; LIPID BILAYER
AB The ionic environment of the cell membrane is of extreme importance in maintaining cell integrity and the numerous functions necessary for cell growth, differentiation, etc., as well as in cell-biomaterial interactions. In this study, the effects of polylysine (a basic poly-amino acid with a net positive charge which is often used to coat biomaterials surfaces) on the erythroleukemic K562 cell membrane were investigated. In particular, the effects of this polycation were evaluated using dielectric relaxation studies in the radiofrequency range with which it is possible to measure both active ionic transport across the cell membrane (membrane conductivity) and the static charge distribution present on the cell surface due to the structural components of the cell membrane (membrane permittivity). The conductivity of the cytosol can also be determined. The results demonstrate that while the conductivity of the cytosol is not significantly altered, both the conductivity and permittivity of the K562 cell membrane are varied by exposure of these cells to polylysine. These observations indicate that both active ionic transport and the type, quantity, or distribution of membrane components such as lipids, proteins, and polysaccharides may also be altered. Although the precise mechanisms by which these variations in K562 cells occur are unknown, it can be hypothesized that changes in the growth characteristics of these cells may be in part responsible. In particular, as demonstrated by light microscopic examination of K562 cells directly in the culture flasks, the cells in polylysine-coated flasks do not grow in suspension as do the controls, but rather show anchorage-dependent-like behavior. It is this important change from suspension to monolayer growth induced by polylysine that may be responsible for the changes in membrane electrical parameters. (C) 1997 John Wiley & Sons, Inc.
C1 UNIV ROMA LA SAPIENZA,DIPARTIMENTO FIS,I-00185 ROME,ITALY.
   UNIV NAPLES FEDERICO II,DIPARTIMENTO SCI FIS,I-80125 NAPLES,ITALY.
RP Santini, MT (reprint author), IST SUPER SANITA,ULTRASTRUTTURE LAB,VIALE REGINA ELENA 299,I-00161 ROME,ITALY.
OI Cametti, Cesare/0000-0003-2077-3660
CR APELL HJ, 1979, BIOCHIM BIOPHYS ACTA, V552, P369, DOI 10.1016/0005-2736(79)90181-0
   ASAMI K, 1980, BIOPHYS J, V31, P215, DOI 10.1016/S0006-3495(80)85052-1
   BALLARIO C, 1984, Z NATURFORSCH C, V39, P1163
   BELL JD, 1989, J BIOL CHEM, V264, P12194
   BENZ R, 1976, BIOCHIM BIOPHYS ACTA, V455, P721, DOI 10.1016/0005-2736(76)90043-2
   BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345
   BOTTOMLEY PA, 1978, J PHYS E SCI INSTRUM, V11, P413, DOI 10.1088/0022-3735/11/5/012
   Bruggeman DAG, 1935, ANN PHYS-BERLIN, V24, P636
   CERBON J, 1990, BIOCHIM BIOPHYS ACTA, V1028, P261, DOI 10.1016/0005-2736(90)90175-N
   CIANI S, 1980, BIOPHYS J, V30, P199, DOI 10.1016/S0006-3495(80)85089-2
   CLARKE GA, 1994, J CELL SCI, V107, P3393
   ELHAYEK R, 1995, J BIOL CHEM, V270, P15634, DOI 10.1074/jbc.270.26.15634
   GRANDOLFO M, 1991, INT J RADIAT BIOL, V60, P877, DOI 10.1080/09553009114552681
   GURMAN SJ, 1992, J NON-CRYST SOLIDS, V143, P207, DOI 10.1016/S0022-3093(05)80569-1
   HANAI T, 1986, B INT CHEM RES KYOTO, V58, P533
   HARTMANN W, 1977, FEBS LETT, V78, P169, DOI 10.1016/0014-5793(77)80298-6
   HEIMBURG T, 1991, BIOCHEMISTRY-US, V30, P9084, DOI 10.1021/bi00101a025
   JAIN MK, 1989, BIOCHIM BIOPHYS ACTA, V1002, P127, DOI 10.1016/0005-2760(89)90281-6
   KELLER RCA, 1992, BIOCHEMISTRY-US, V31, P1672, DOI 10.1021/bi00121a014
   LOOYENGA H, 1965, PHYSICA, V31, P401, DOI 10.1016/0031-8914(65)90045-5
   MAKOHLISO SA, 1993, J BIOMED MATER RES, V27, P1075, DOI 10.1002/jbm.820270813
   MOCZYDLOWSKI E, 1985, J MEMBRANE BIOL, V83, P273, DOI 10.1007/BF01868701
   NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0
   NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651
   PETHIG R, 1987, PHYS MED BIOL, V32, P933, DOI 10.1088/0031-9155/32/8/001
   RINK T, 1994, EUR BIOPHYS J BIOPHY, V23, P155, DOI 10.1007/BF01007607
   SACKMANN E, 1983, BIOPHYSICS-USSR, P81
   SANTINI MT, 1988, BIOCHIM BIOPHYS ACTA, V945, P56, DOI 10.1016/0005-2736(88)90362-8
   SANTINI MT, 1990, BIOCHIM BIOPHYS ACTA, V1023, P298, DOI 10.1016/0005-2736(90)90426-O
   SANTINI MT, 1994, INT J RADIAT BIOL, V65, P277, DOI 10.1080/09553009414550311
   SANTINI MT, 1991, BIOCHIM BIOPHYS ACTA, V1070, P27, DOI 10.1016/0005-2736(91)90142-U
   SANTINI MT, 1994, EXP HEMATOL, V22, P40
   SANTINI MT, 1991, FEBS LETT, V291, P169, DOI 10.1016/0014-5793(91)81275-D
   SANTINI MT, 1990, INT J RADIAT BIOL, V58, P463, DOI 10.1080/09553009014551811
   SANTINI MT, 1995, BIOELECTROCH BIOENER, V36, P39, DOI 10.1016/0302-4598(94)01750-U
   SANTINI MT, 1995, ANTICANCER RES, V15, P29
   SANTINI MT, 1992, J MEMBRANE SCI, V65, P7, DOI 10.1016/0376-7388(92)87047-2
   SAWHNEY AS, 1992, BIOMATERIALS, V13, P863, DOI 10.1016/0142-9612(92)90180-V
   Schwan H. P., 1963, PHYSICAL TECHNIQUE B, V6, P323, DOI DOI 10.1002/JCP.1030660505
   SITTINGER M, 1994, BIOMATERIALS, V15, P451, DOI 10.1016/0142-9612(94)90224-0
   YAVIN E, 1974, J CELL BIOL, V62, P540, DOI 10.1083/jcb.62.2.540
NR 41
TC 25
Z9 32
U1 1
U2 4
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD MAY
PY 1997
VL 35
IS 2
BP 165
EP 174
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA WW449
UT WOS:A1997WW44900004
PM 9135165
DA 2018-10-19
ER

PT J
AU Yang, JM
   Jong, YJ
   Hsu, KY
AF Yang, JM
   Jong, YJ
   Hsu, KY
TI Preparation and properties of SBS-g-DMAEMA copolymer membrane by
   ultraviolet radiation
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE styrene-butadiene-styrene triblock copolymer; dimethyl amino ethyl
   methacrylate; graft copolymer; biomaterial
ID INDUCED GRAFT-POLYMERIZATION; PLATELET-ADHESION; SURFACE MODIFICATION;
   PROTEIN ADSORPTION; UV-IRRADIATION; POLY(ETHYLENE-TEREPHTHALATE);
   GLYCOL)
AB A styrene-butadiene-styrene triblock copolymer (SBS) membrane was prepared by solvent casting. Grafting of dimethyl amino ethyl methacrylate (DMAEMA) to this SBS membrane was subsequently conducted by ultraviolet radiation-induced graft copolymerization without degassing to obtain a SBS-g-DMAEMA copolymer membrane. The graft copolymer was characterized by infrared spectroscopy and scanning electron microscopy. The degree of grafting and the mechanical properties of SBS and SBS-g-DMAEMA were measured. Contact angle, water content, and protein absorption of fibrinogen and albumin experiments were also performed to evaluate the biocompatibility of SBS-g-DMAEMA graft copolymer membranes. It was found that the degree of grafting was related to the irradiation time, DMAEMA concentration, and temperature. The tensile strength of the degree of grafting. By using Kaelble's equation and the contact angle data, the surface tension of SBS-g-DMAEMA was determined. It was found that with an increase in the degree of grafting, the surface tension and water content of SBS-g-DMAEMA membrane increased, whereas the contact angle decreased. The amount of absorption of albumin and fibrinogen decreased with an increase In amount of grafting. Howevfr, there was a minimum for t:he adsorption of proteins in the SBS-gDMAEMA membrane. (C) 1997 lohn Wiley & Sons, Inc.
C1 CHUNG YUAN CHRISTIAN UNIV,DEPT CHEM ENGN,CHUNGLI 32023,TAIWAN.
RP Yang, JM (reprint author), CHANG GUNG COLL MED & TECHNOL,DEPT CHEM ENGN,TAYUAN 333,TAIWAN.
CR FUJIMOTO K, 1993, BIOMATERIALS, V14, P442, DOI 10.1016/0142-9612(93)90147-T
   FUJIMOTO K, 1993, J BIOMED MATER RES, V27, P1559, DOI 10.1002/jbm.820271213
   FUJIMOTO K, 1993, J POLYM SCI POL CHEM, V31, P1035, DOI 10.1002/pola.1993.080310426
   Hari P R, 1993, J Biomater Appl, V8, P174, DOI 10.1177/088532829300800205
   Hari P R, 1991, J Biomater Appl, V6, P170, DOI 10.1177/088532829100600205
   Holden G., 1969, J POLYM SCI        C, VC26, P37
   HSIUE GH, 1988, J BIOMED MATER RES, V22, P405, DOI 10.1002/jbm.820220504
   IKADA Y, 1994, BIOMATERIALS, V15, P725, DOI 10.1016/0142-9612(94)90025-6
   KAELBLE DH, 1977, POLYMER, V18, P475, DOI 10.1016/0032-3861(77)90164-1
   KOCHWA S, 1977, ANN NY ACAD SCI, V283, P37, DOI 10.1111/j.1749-6632.1977.tb41751.x
   LAI JY, 1991, J APPL POLYM SCI, V43, P1431, DOI 10.1002/app.1991.070430804
   TOMITA N, 1994, J APPL BIOMATER, V5, P175, DOI 10.1002/jab.770050211
   TSENG YC, 1992, J BIOMED MATER RES, V26, P373, DOI 10.1002/jbm.820260308
   UCHIDA E, 1990, J APPL POLYM SCI, V41, P677, DOI 10.1002/app.1990.070410317
   UCHIDA E, 1993, J APPL POLYM SCI, V47, P417, DOI 10.1002/app.1993.070470305
   UYAMA Y, 1990, J APPL POLYM SCI, V39, P489, DOI 10.1002/app.1990.070390301
   YANG JM, 1990, ANGEW MAKROMOL CHEM, V179, P99, DOI 10.1002/apmc.1990.051790108
   Yang JM, 1996, J BIOMED MATER RES, V31, P281
   YANG JM, 1990, J APPL POLYM SCI, V39, P1475, DOI 10.1002/app.1990.070390706
   YANG JM, 1990, J APPL POLYM SCI, V41, P1141, DOI 10.1002/app.1990.070410523
NR 20
TC 35
Z9 38
U1 1
U2 7
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD MAY
PY 1997
VL 35
IS 2
BP 175
EP 180
DI 10.1002/(SICI)1097-4636(199705)35:2<175::AID-JBM5>3.0.CO;2-K
PG 6
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA WW449
UT WOS:A1997WW44900005
PM 9135166
DA 2018-10-19
ER

PT J
AU Apple, DJ
   Isaacs, RT
   Kent, DG
   Martinez, LM
   Kim, S
   Thomas, SG
   Basti, S
   Barker, D
   Peng, Q
AF Apple, DJ
   Isaacs, RT
   Kent, DG
   Martinez, LM
   Kim, S
   Thomas, SG
   Basti, S
   Barker, D
   Peng, Q
TI Silicone oil adhesion to intraocular lenses: An experimental study
   comparing various biomaterials
SO JOURNAL OF CATARACT AND REFRACTIVE SURGERY
LA English
DT Article; Proceedings Paper
CT Symposium on Cataract, IOL and Refractive Surgery
CY JUN 01-05, 1996
CL SEATTLE, WA
ID VITREORETINAL SURGERY; SURFACE-PROPERTIES; CELL ADHESION; COMPLICATIONS
AB Purpose: To perform an in vitro experimental study comparing the degree of adherence of silicone oil to various rigid and foldable intraocular lens (IOL) designs and to the human lens capsule.
   Setting: Center for Research on Ocular Therapeutics and Biodevices, Department of Ophthalmology, Storm Eye Institute, Medical University of South Carolina, Charleston, South Carolina, USA.
   Methods: Seven IOL styles comprising various biomaterials were studied: fluorine-treated (Fluorlens(TM)), heparin-surface-modified (HSM(TM)), hydrogel, Memory-Lens(TM), poly(methyl methacrylate) (PMMA), soft acrylic, and silicone lenses; the human crystalline lens was also studied. Each lens was immersed in silicone oil for 12 hours, then photographed, studied by scanning electron microscopy (except the crystalline lens), and subjected to computer-generated image analysis to determine the silicone oil coverage.
   Results: Silicone oil coverage of dry silicone lenses was 100% and of lenses immersed in normal saline, 82.5%. The least coverage was on the heparin-surface-modified lens (mean score 9.4%). Coverage of the other four lenses ranged from approximately 15.1% to 33.7%. Mean coverage of the human lens capsule was 10.9%.
   Conclusion: Although a silicone IOL shows maximal adherence to silicone oil, other lens biomaterials are not immune to this complication. Silicone oil coverage was related to the dispersive energy component of the surface charge of the IOL biomaterial. Low dispersive energy materials had less silicone oil coverage, while those with higher dispersive energy had more oil coverage.
RP Apple, DJ (reprint author), MED UNIV S CAROLINA,DEPT OPHTHALMOL,STORM EYE INST,CTR RES OCULAR THERAPEUT & BIODEVICES,CHARLESTON,SC 29425, USA.
CR Andrade J D, 1973, Med Instrum, V7, P110
   Apple DJ, 1996, OPHTHALMOLOGY, V103, P1555, DOI 10.1016/S0161-6420(96)30463-6
   Baier R. E., 1970, ADHESION BIOL SYSTEM, P15
   BATTERBURY M, 1994, EYE, V8, P547, DOI 10.1038/eye.1994.135
   CUNANAN CM, 1991, J CATARACT REFR SURG, V17, P767
   FEDERMAN JL, 1988, OPHTHALMOLOGY, V95, P870
   FISK MJ, 1995, AUST NZ J OPHTHALMOL, V23, P25, DOI 10.1111/j.1442-9071.1995.tb01641.x
   FRANKS W A, 1991, Eye (London), V5, P333
   Hainsworth DP, 1996, OPHTHALMOLOGY, V103, P1410, DOI 10.1016/S0161-6420(96)30490-9
   HUTTON WL, 1994, ARCH OPHTHALMOL-CHIC, V112, P778, DOI 10.1001/archopht.1994.01090180076038
   Kusaka S, 1996, AM J OPHTHALMOL, V121, P574, DOI 10.1016/S0002-9394(14)75436-4
   LYDON MJ, 1985, BIOMATERIALS, V6, P396, DOI 10.1016/0142-9612(85)90100-0
   MABERLEY AL, 1989, CAN J OPHTHALMOL, V24, P265
   MATEO NB, 1989, INVEST OPHTH VIS SCI, V30, P853
   MCCUEN BW, 1985, RETINA-J RET VIT DIS, V5, P198, DOI 10.1097/00006982-198500540-00002
   PUNNONEN E, 1989, ACTA OPHTHALMOL, V67, P30
   RIEDEL KG, 1990, GRAEF ARCH CLIN EXP, V228, P19, DOI 10.1007/BF02764284
   Stolba U, 1996, GRAEF ARCH CLIN EXP, V234, P55, DOI 10.1007/BF00186519
   YEO JH, 1987, OPHTHALMOLOGY, V94, P1109
NR 19
TC 59
Z9 64
U1 3
U2 8
PU AMER SOC CATARACT REFRACTIVE SURGERY
PI FAIRFAX
PA 4000 LEGATO RD, SUITE 850, FAIRFAX, VA 22030
SN 0886-3350
J9 J CATARACT REFR SURG
JI J. Cataract. Refract. Surg.
PD MAY
PY 1997
VL 23
IS 4
BP 536
EP 544
DI 10.1016/S0886-3350(97)80210-6
PG 9
WC Ophthalmology; Surgery
SC Ophthalmology; Surgery
GA XE939
UT WOS:A1997XE93900015
PM 9209988
DA 2018-10-19
ER

PT J
AU Gordon, DD
   Cope, GH
   Brook, JM
   Hatton, PV
AF Gordon, DD
   Cope, GH
   Brook, JM
   Hatton, PV
TI Scanning electron microscopical evaluation of the bone-biomaterial
   interface.
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Meeting Abstract
C1 UNIV SHEFFIELD,SCH CLIN DENT,SHEFFIELD,S YORKSHIRE,ENGLAND.
   UNIV SHEFFIELD,DEPT BIOMED SCI,SHEFFIELD,S YORKSHIRE,ENGLAND.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC DENTAL RESEARCH
PI ALEXANDRIA
PA 1619 DUKE ST, ALEXANDRIA, VA 22314
SN 0022-0345
J9 J DENT RES
JI J. Dent. Res.
PD MAY
PY 1997
VL 76
IS 5
BP 1080
EP 1080
PG 1
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA WW075
UT WOS:A1997WW07501062
DA 2018-10-19
ER

PT J
AU Bonte, E
   Lasfargues, JJ
   Goldberg, M
AF Bonte, E
   Lasfargues, JJ
   Goldberg, M
TI The rat's upper first molars as an in vivo model for biomaterial testing
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Meeting Abstract
C1 UNIV PARIS 05,FAC CHIRURG DENT,LAB BIOL BIOMAT MILIEU BUCCAL & OSSEUX,F-75270 PARIS 06,FRANCE.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC DENTAL RESEARCH
PI ALEXANDRIA
PA 1619 DUKE ST, ALEXANDRIA, VA 22314
SN 0022-0345
J9 J DENT RES
JI J. Dent. Res.
PD MAY
PY 1997
VL 76
IS 5
BP 1098
EP 1098
PG 1
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA WW075
UT WOS:A1997WW07501154
DA 2018-10-19
ER

PT J
AU Wang, W
   Ferguson, DJP
   Quinn, JMW
   Simpson, AHRW
   Athanasou, NA
AF Wang, W
   Ferguson, DJP
   Quinn, JMW
   Simpson, AHRW
   Athanasou, NA
TI Osteoclasts are capable of particle phagocytosis and bone resorption
SO JOURNAL OF PATHOLOGY
LA English
DT Article
DE osteoclast; macrophage; bone resorption; foreign body; phagocytosis
ID TOTAL HIP-REPLACEMENT; MACROPHAGES; INVITRO; CELLS; OSTEOLYSIS;
   INTERFACE; CULTURES; CEMENT
AB Osteoclasts are multinucleated cells specialized for the function of lacunar bone resorption. Although they are known to be capable of phagocytosis of inert particles, it is not known whether this abolishes their ability to respond to hormones or to form resorption lacunae, Human and rat osteoclasts were isolated from giant cell tumours of bone and rat long bones, respectively, and cultured on coverslips and cortical bone slices, both in the presence and in the absence of particles of lates (1 mu m diameter) and polymethylmethacrylate (PMMA) (<50 mu m). By light microscopy, it was evident that osteoclasts which had phagocytosed both latex and PMMA particles remained responsive to calcitonin. Osteoclast phagocytosis of particles was also evident on scanning electron microscopy, where it could also be seen that these cells were associated with the formation of resorption lacunae, These findings underline the fact that the osteoclast is a true member of the mononuclear phagocyte system and that phagocytosis does not abrogate either its hormonal response to calcitonin or its highly specialized function of bone resorption, That osteoclasts which have phagocytosed biomaterial particles such as PMMA are still able to carry out lacunar bone resorption is of interest in clinical conditions such as aseptic loosening, where a heavy foreign body particle load is often associated with extensive bone resorption. (C) 1997 by John Wiley & Sons, Ltd.
C1 JOHN RADCLIFFE HOSP, NUFFIELD DEPT PATHOL & BACTERIOL, OXFORD OX3 9DU, ENGLAND.
   UNIV OXFORD, NUFFIELD DEPT ORTHOPAED SURG, OXFORD, ENGLAND.
   UNIV OXFORD, NUFFIELD ORTHOPAED CTR, DEPT PATHOL, OXFORD OX3 7LD, ENGLAND.
RI Simpson, Alasdair/F-1887-2013
OI Simpson, Alasdair/0000-0001-7793-642X; Ferguson,
   David/0000-0001-5045-819X
CR ALI NN, 1984, ANAT EMBRYOL, V170, P51, DOI 10.1007/BF00319457
   AMSTUTZ HC, 1992, CLIN ORTHOP RELAT R, P7
   ATHANASOU NA, 1990, J CLIN PATHOL, V43, P997, DOI 10.1136/jcp.43.12.997
   BURGER EH, 1982, J EXP MED, V156, P1604, DOI 10.1084/jem.156.6.1604
   CHAMBERS TJ, 1978, J PATHOL, V126, P125, DOI 10.1002/path.1711260302
   CHAMBERS TJ, 1984, J CELL SCI, V66, P383
   CHAMBERS TJ, 1981, J PATHOL, V135, P1, DOI 10.1002/path.1711350102
   CHAMBERS TJ, 1982, J PATHOL, V136, P27, DOI 10.1002/path.1711360104
   CHAMBERS TJ, 1979, J PATHOL, V127, P55, DOI 10.1002/path.1711270202
   CHAMBERS TJ, 1985, J PATHOL, V145, P297, DOI 10.1002/path.1711450403
   CHAMBERS TJ, 1985, J CLIN PATHOL, V38, P241, DOI 10.1136/jcp.38.3.241
   CHAMBERS TJ, 1976, J PATHOL, V122, P71
   CHAMBERS TJ, 1980, CLIN ORTHOP RELAT R, V151, P284
   FOREST M, 1991, PATHOL RES PRACT, V187, P963, DOI 10.1016/S0344-0338(11)81068-X
   FREEMAN MAR, 1982, J BONE JOINT SURG BR, V64, P489
   Fujikawa Y, 1996, ENDOCRINOLOGY, V137, P4058, DOI 10.1210/en.137.9.4058
   GOTHLIN G, 1976, CLIN ORTHOP RELAT R, P201
   HARRIS WH, 1994, ACTA ORTHOP SCAND, V65, P113, DOI 10.3109/17453679408993734
   HARRIS WH, 1976, J BONE JOINT SURG AM, V58, P612, DOI 10.2106/00004623-197658050-00005
   KURIHARA N, 1990, ENDOCRINOLOGY, V126, P2733, DOI 10.1210/endo-126-5-2733
   LENNOX DW, 1987, CLIN ORTHOP RELAT R, P171
   MALONEY WJ, 1995, J BONE JOINT SURG AM, V77, P1448, DOI 10.2106/00004623-199509000-00022
   NICHOLSON GC, 1986, J CLIN INVEST, V78, P355, DOI 10.1172/JCI112584
   Pandey R, 1996, ANN RHEUM DIS, V55, P388, DOI 10.1136/ard.55.6.388
   PAZZAGLIA UE, 1990, ARCH ORTHOP TRAUM SU, V109, P83, DOI 10.1007/BF00439384
   QUINN J, 1992, J BONE JOINT SURG BR, V74, P652
   Quinn JMW, 1996, J PATHOL, V179, P106
   REVELL PA, 1982, CURRENT TRENDS PATHO, P73
   SANTAVIRTA S, 1990, J BONE JOINT SURG AM, V72A, P252, DOI 10.2106/00004623-199072020-00014
   SCHNEIDER GB, 1988, BONE, V9, P303, DOI 10.1016/8756-3282(88)90014-2
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   VANFURTH R, 1980, MONONUCLEAR PHAGOCYT, P1
   WILLERT HG, 1990, CLIN ORTHOP RELAT R, P95
   WILLERT HG, 1990, CLIN ORTHOP RELAT R, P108
   Zambonin Zallone A, 1984, J Cell Sci, V66, P335
   1994, NIH CONSENSUS STATE, V12, P1
NR 36
TC 42
Z9 42
U1 0
U2 4
PU JOHN WILEY & SONS LTD
PI W SUSSEX
PA BAFFINS LANE CHICHESTER, W SUSSEX, ENGLAND PO19 1UD
SN 0022-3417
J9 J PATHOL
JI J. Pathol.
PD MAY
PY 1997
VL 182
IS 1
BP 92
EP 98
PG 7
WC Oncology; Pathology
SC Oncology; Pathology
GA XC280
UT WOS:A1997XC28000014
PM 9227347
DA 2018-10-19
ER

PT J
AU Henke, PK
   Bergamini, TM
   Brittian, KR
   Polk, HC
AF Henke, PK
   Bergamini, TM
   Brittian, KR
   Polk, HC
TI Prostaglandin E-2 modulates monocyte MHC-II (Ia) suppression in
   biomaterial infection
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article; Proceedings Paper
CT 30th Annual Meeting of the Association-for-Academic-Surgery
CY NOV 13-16, 1996
CL CHICAGO, IL
SP Assoc Acad Surg
ID TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; ANTIGEN EXPRESSION; INTERLEUKIN-1
   PRODUCTION; GRAFT INFECTIONS; CELL; MACROPHAGES; INDUCTION;
   SUBPOPULATIONS; PATHOGENESIS
AB Staphylococcus epidermidis biomaterial infection is associated with local cellular immune suppression measured by a depressed monocyte (M phi) Ia expression. The purpose of this study was to define the effect of proinflammatory mediators on Ia expression and bacterial clearance in experimental biomaterial infection. A l-cm-long Dacron tube graft, sterile or colonized with Staphylococcus epidermidis (1 x 10(7) cfu/ ml(2)), was implanted in Swiss-Webster mice. Perigraft fluid was collected at 7, 10, 14, and 28 days and assayed by enzyme-linked immunoassays for tumor necrosis factor alpha (TNF alpha), interleukin (IL)-1 alpha, IL-4, IL-10, and prostaglandin E-2 (PGE(2)). Grafts were sonicated and plated for quantitative growth. In vivo effector inhibition was accomplished with anti-TNF alpha, anti-IL-1 alpha antibodies (7 mu g/24 hr), or indomethacin (50 mu g/24 hr) via an Alzet 7-day microinfusion pump. M phi Ia expression was determined by how cytometry. A significant elevation of TNF alpha, IL-1 alpha, and PGE(2) was found during the first 10 days in the infected compared with sterile (P less than or equal to 0.05) grafts and correlated with maximal Ia suppression. Neither IL-4 nor IL-10 was significantly different in the sterile or infected perigraft fluid. Indomethacin completely prevented M phi Ia suppression, while anti-IL-1 alpha only partially (94%) prevented M phi Is suppression with a corresponding decrease in PGE(2) production in infected grafts. Anti-TNF alpha increased PGE(2) production by 189% and was associated with depressed M phi Is expression. Indomethacin treatment improved mean graft-adherent bacterial clearance by 54% at 7 days and 75% at 28 days compared with control (not significant). Interleukin-1 alpha but not TNF alpha increases PGE(2) production which modulates M phi Is suppression. To improve treatment of biomaterial infections, local immunomodulation of PGE(2) and IL-1 alpha is promising. (C) 1997 Academic Press.
C1 UNIV LOUISVILLE,SCH MED,DEPT SURG,LOUISVILLE,KY 40292.
   VET AFFAIRS MED CTR,LOUISVILLE,KY 40292.
CR ALLEVA DG, 1993, J LEUKOCYTE BIOL, V55, P550
   AYALA A, 1990, IMMUNOLOGY, V70, P33
   Ayala A, 1996, SHOCK, V5, P79, DOI 10.1097/00024382-199602000-00001
   BACHWICH PR, 1986, BIOCHEM BIOPH RES CO, V136, P94, DOI 10.1016/0006-291X(86)90881-8
   BANDYK DF, 1991, J VASC SURG, V13, P575
   BARBUL A, 1990, CLIN PLAST SURG, V17, P433
   CHAUDHARY R, 1991, J VASC SURG, V13, P755
   CHRISTOU NV, 1987, ARCH SURG-CHICAGO, V122, P239
   DINARELLO CA, 1993, NEW ENGL J MED, V328, P106
   EDWARDS MJ, 1988, AM J SURG, V155, P327, DOI 10.1016/S0002-9610(88)80725-6
   ERTEL W, 1991, IMMUNOLOGY, V74, P290
   ESSER P, 1993, BRIT J OPHTHALMOL, V77, P731, DOI 10.1136/bjo.77.11.731
   FIORENTINO DF, 1991, J IMMUNOL, V146, P3444
   Galandiuk S, 1996, AM J SURG, V171, P335, DOI 10.1016/S0002-9610(97)89637-7
   GRISTINA AG, 1993, INT J ARTIF ORGANS, V16, P755
   HENKE PK, IN PRESS ARCH SURG
   HULTH A, 1988, CLIN ORTHOP RELAT R, V234, P235
   JANEWAY CA, 1984, IMMUNOL TODAY, V5, P99, DOI 10.1016/0167-5699(84)90043-4
   JOHNSON GM, 1986, INFECT IMMUN, V54, P13
   KNIGHTON DR, 1989, PERSPECT SHOCK RES, V21, P217
   KUNKEL SL, 1986, J IMMUNOL, V136, P186
   LASTBARNEY K, 1988, J IMMUNOL, V141, P527
   LORENTZEN JE, 1985, SURGERY, V98, P81
   NUSING R, 1992, EUR J BIOCHEM, V206, P131, DOI 10.1111/j.1432-1033.1992.tb16910.x
   PAUL WE, 1991, BLOOD, V77, P1859
   PHILLIPS C, 1991, CELL IMMUNOL, V136, P173, DOI 10.1016/0008-8749(91)90392-O
   PHIPPS RP, 1991, IMMUNOL TODAY, V12, P349, DOI 10.1016/0167-5699(91)90064-Z
   RENZ H, 1988, J IMMUNOL, V141, P2388
   RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769
   RUTHERFORD MS, 1993, J LEUKOCYTE BIOL, V53, P602
   SCALES WE, 1989, J LEUKOCYTE BIOL, V45, P416
   SNYDER DS, 1982, NATURE, V299, P163, DOI 10.1038/299163a0
   STEENFOS HH, 1989, SURGERY, V106, P171
   STEPHAN RN, 1988, J SURG RES, V44, P733, DOI 10.1016/0022-4804(88)90108-4
   STOUT RD, 1992, INFECT IMMUN, V60, P922
   STOUT RD, 1994, INFECT IMMUN, V62, P4160
   TIMMERMAN CP, 1993, INFECT IMMUN, V61, P4167
   WYNN TA, 1992, CELL IMMUNOL, V140, P184, DOI 10.1016/0008-8749(92)90186-S
   ZIEGLERHEITBROCK HWL, 1992, BLOOD, V79, P503
   ZIMMERLI W, 1984, J CLIN INVEST, V73, P1191, DOI 10.1172/JCI111305
   ZURIER RB, 1990, ADV PROSTAGLANDIN TH, V21, P947
NR 41
TC 14
Z9 15
U1 0
U2 3
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0022-4804
J9 J SURG RES
JI J. Surg. Res.
PD MAY
PY 1997
VL 69
IS 2
BP 372
EP 378
DI 10.1006/jsre.1997.5088
PG 7
WC Surgery
SC Surgery
GA XL453
UT WOS:A1997XL45300023
PM 9224410
DA 2018-10-19
ER

PT J
AU Bellon, JM
   Contreras, LA
   Sabater, C
   Bujan, J
AF Bellon, JM
   Contreras, LA
   Sabater, C
   Bujan, J
TI Pathologic and clinical aspects of repair of large incisional hernias
   after implant of a polytetrafluoroethylene prosthesis
SO WORLD JOURNAL OF SURGERY
LA English
DT Article
ID ABDOMINAL-WALL DEFECTS; EXPANDED POLYTETRAFLUOROETHYLENE; MACROPHAGE
   RESPONSE; PATCH; RAT
AB One of the alternatives for the repair of large incisional hernias is the use of a prosthetic material. The present retrospective study relates the experience acquired for treatment of large incisional hernias (hernial orifice > 10 cm) with ePTFE prostheses. Thirty-eight massive incisional hernias were repaired using ePTFE 1 mm thick Soft Tissue Patches. Twenty-four patients received a prosthetic patch of 10 x 15 cm, 13 a patch of 15 x 20 cm, and 1 a patch of 20 x 30 cm. In 30 cases the ePTFE was sutured to the recipient tissues with a double row of polypropylene stitches. For the first eight interventions the ePTFE was secured using a single row of polypropylene sutures. Pathologic studies of biopsies from patients who bad undergone surgical reintervention at 40 days, 12 months, and 48 months, respectively, were done using light microscopy, scanning electron microscopy, and immunohistochemistry with human antimacrophage antibodies KP-1. The follow-up period for all patients was between 18 and 72 months. There was no perioperative mortality. No infection or rejection of prostheses was recorded. Seroma was present in four patients. Computed tomography was performed for evaluation purposes on 10 randomly selected patients (mean postoperative delay 1-4 years) and showed the ePTFE encapsulated by newly formed tissue. One of the patients suffered from mechanical intestinal obstruction 40 days after implant and suffered a recurrence a year later. Three recurrences at the patch-recipient tissue interface where the ePTFE had been secured with a single row of polypropylene stitches were recorded after 8, 12, and 28 months. At 40 days good integration of the biomaterial was observed in the newly formed tissue. On both sides of the implant an accumulation of four to six strata of cells was appreciable. Some of them were labeled with KP-1. Cell infiltration of the prosthesis was restricted to the most exterior third of the patch. There was no colonization at the patch-recipient tissue interface. At 12 and 28 months the cell barrier had almost disappeared. KP-1-labeled macrophages were scarce. Scanning electron microscopy revealed a well defined peritoneum. It may be concluded that: (1) a double suture row is recommended to secure the prosthesis; (2) ePTFE provides an adequate substrate for the formation of scar tissue; and (3) the macrophage response induced by the ePTFE decreases with time.
RP Bellon, JM (reprint author), UNIV ALCALA DE HENARES,FAC MED,DEPT MORPHOL SCI & SURG,CRTA MADRID BARCELONA KM 33,600,E-28871 ALCALA DE HENARES,SPAIN.
OI BELLON, JUAN M./0000-0002-6071-5011; bujan, Julia/0000-0003-2419-2476
CR AMID PK, 1994, J BIOMED MATER RES, V28, P373, DOI 10.1002/jbm.820280312
   BAUER JJ, 1987, ANN SURG, V206, P765, DOI 10.1097/00000658-198712000-00013
   Bellon JM, 1996, J BIOMED MATER RES, V31, P1, DOI 10.1002/(SICI)1097-4636(199605)31:1<1::AID-JBM1>3.0.CO;2-S
   BELLON JM, 1995, BIOMATERIALS, V16, P381, DOI 10.1016/0142-9612(95)98855-8
   BELLON JM, 1994, EUR SURG RES, V26, P46, DOI 10.1159/000129317
   Bellon JM, 1996, J MATER SCI-MATER M, V7, P331, DOI 10.1007/BF00154544
   BELLON JM, 1994, SOC ITALIANO FISIOPA, P85
   BENDAVID R, 1990, SURGERY, V108, P898
   BERLINER SD, 1993, SURG GYNECOL OBSTET, V176, P323
   BROWN GL, 1985, ANN SURG, V201, P705, DOI 10.1097/00000658-198506000-00006
   CHEVREL JP, 1979, NOUV PRESSE MED, V8, P695
   CHEVREL JP, 1990, MONOGRAPHIES ASS FRA, P1
   CHEVREL JP, 1990, 92 C FRANC CHIR 1990
   DEBORD JR, 1992, POSTGRAD GEN SURG, V4, P156
   DEYSINE M, 1992, AM J SURG, V163, P422, DOI 10.1016/0002-9610(92)90045-S
   FLAMENT JB, 1994, PROSTHESES MAJOR INC
   Flament JB, 1995, PROBL GEN SURG, V12, P151
   Hamer-Hodges D W, 1985, J R Coll Surg Edinb, V30, P65
   KAUFMAN Z, 1981, DIS COLON RECTUM, V24, P543, DOI 10.1007/BF02604320
   KENNEDY GM, 1994, AM J SURG, V168, P304, DOI 10.1016/S0002-9610(05)80153-9
   KUPCZYKJOERIS D, 1990, ZBL CHIR, V115, P1161
   Law NW, 1988, CLIN MATER, V3, P95
   LEBLANC KA, 1994, INGUINAL HERNIA ADV, P501
   MURPHY JL, 1989, CAN J SURG, V32, P244
   PANS A, 1992, EUR SURG RES, V24, P54, DOI 10.1159/000129188
   PIRE JC, 1977, NOUV PRESSE MED, V6, P3641
   Rives J, 1973, Chirurgie, V99, P547
   RIVES J, 1985, CHIRURGIE, V3, P215
   RIVES J, 1987, SURG ABDOMINAL WALL
   RIVES J, 1977, ENCY MED CHIR
   SEID AS, 1994, INGUINAL HERNIA ADV, P505
   SIMMERMACHER RKJ, 1991, BIOMATERIALS, V12, P22, DOI 10.1016/0142-9612(91)90126-U
   STOPPA R, 1979, CHIRURGIE, V105, P276
   VANDERLEI B, 1989, BRIT J SURG, V76, P803, DOI 10.1002/bjs.1800760813
   WOOL NL, 1985, P I MED CHICAGO, V38, P33
NR 35
TC 34
Z9 39
U1 0
U2 2
PU SPRINGER VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010
SN 0364-2313
J9 WORLD J SURG
JI World J.Surg.
PD MAY
PY 1997
VL 21
IS 4
BP 402
EP 407
DI 10.1007/PL00012261
PG 6
WC Surgery
SC Surgery
GA WU555
UT WOS:A1997WU55500011
PM 9143572
DA 2018-10-19
ER

PT J
AU McGovern, JG
   Garvin, CP
   Jones, DS
   Woolfson, AD
   Gorman, SP
AF McGovern, JG
   Garvin, CP
   Jones, DS
   Woolfson, AD
   Gorman, SP
TI Modification of biomaterial surface characteristics by body fluids in
   vitro
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE contact angle; polyurethane; polyvinyl chloride; saliva; surface
   roughness; urine
ID ENDOTRACHEAL-TUBES; BIOFILM
AB In practice, polyvinyl chloride endotracheal tubes and polyurethane urinary catheters are located in areas where they are exposed to the conditioning fluids saliva and urine, respectively. Samples of both biomaterials were incubated in these conditioning fluids and, following treatment, dynamic contact angle measurement and surface roughness assessment by atomic force microscopy were used to analyse surface characteristics. Over a 24 h period of contact with the conditioning fluids, the surface of both materials became significantly more hydrophilic (p < 0.05) and non-uniform changes in surface roughness were observed. This study has shown that in vitro treatment of polyvinyl chloride and polyurethane with conditioning body fluids alters the surface characteristics of the biomaterials and this effect is progressive with time as determined by surface advancing contact angle measurement. (C) 1997 Elsevier Science B.V.
C1 QUEENS UNIV BELFAST,CTR MED BIOL,SCH PHARM,PHARMACEUT DEVICES GRP,BELFAST BT9 7BL,ANTRIM,NORTH IRELAND.
CR CARBALLO J, 1991, MED MICROBIOL IMMUN, V180, P149
   GORMAN S, 1993, EUR J CLIN MICROBIOL, V12, P9, DOI 10.1007/BF01997050
   GORMAN SP, 1993, J MED MICROBIOL, V38, P411, DOI 10.1099/00222615-38-6-411
   JONES DS, 1997, IN PRESS BIOMATERIAL
   KEANE PF, 1994, BRIT J UROL, V73, P687, DOI 10.1111/j.1464-410X.1994.tb07557.x
   POISSON DM, 1991, RES MICROBIOL, V142, P1019, DOI 10.1016/0923-2508(91)90013-Z
   Tunney MM, 1996, BIOMATERIALS, V17, P1025, DOI 10.1016/0142-9612(96)84679-5
   ZAMPATTI O, 1994, CARIES RES, V28, P35, DOI 10.1159/000261618
NR 8
TC 6
Z9 7
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
J9 INT J PHARM
JI Int. J. Pharm.
PD APR 28
PY 1997
VL 149
IS 2
BP 251
EP 254
DI 10.1016/S0378-5173(97)04883-7
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA WY950
UT WOS:A1997WY95000012
DA 2018-10-19
ER

PT J
AU Tenan, MA
   Mesquita, MV
   Mosna, RA
AF Tenan, MA
   Mesquita, MV
   Mosna, RA
TI The transient regime in Frohlich's condensation phenomenon in biosystems
SO INTERNATIONAL JOURNAL OF QUANTUM CHEMISTRY
LA English
DT Article
DE bioenergetics; organized collective behavior; nonlinear kinetic
   equations; nonequilibrium thermodynamics; informational statistical
   thermodynamics
ID BIOLOGICAL-SYSTEMS; MODEL; EXCITATIONS
AB We consider the emergence of the so-called Frohlich's effect in a biosystem, a phenomenon consisting of the condensation of excitations in the polar vibrational modes lying at the bottom of these modes' frequency spectrum. This complex behavior of the system, which seems to have relevance in bioenergetics, may arise in open biomaterial, which is governed by nonlinear kinetic equations, and when under the action of a pumping source of metabolic energy. We analyze here in detail the dynamics of (i) the transient stage before the establishment of a steady state and (ii) the relaxation to the original thermodynamic equilibrium state after the pumping source is turned off. (C) 1997 John Wiley & Sons, Inc.
RP Tenan, MA (reprint author), UNIV ESTADUAL CAMPINAS,INST FIS GLEB WATAGHIN,UNICAMP,BR-13083970 CAMPINAS,SP,BRAZIL.
RI Mosna, Ricardo/A-6736-2013; Inst. of Physics, Gleb Wataghin/A-9780-2017
CR BRESLER SE, 1971, INTRO MOL BIOL, P188
   DAVYDOV AS, 1986, SOLITONS
   DAVYDOV AS, 1982, BIOL QUANTUM MECH, P111
   DAVYDOV AS, 1982, BIOL QUANTUM MECH, P44
   DAVYDOV AS, 1982, BIOL QUANTUM MECH, P190
   EICHWALD CF, 1995, PHYS LETT A, V207, P194, DOI 10.1016/0375-9601(95)00697-2
   FROHLICH H, 1970, NATURE, V228, P1093, DOI 10.1038/2281093a0
   Frohlich H., 1968, INT J QUANTUM CHEM, V2, P641, DOI DOI 10.1002/QUA.560020505
   FROHLICH H, 1969, THEORETICAL PHYSICS
   Frohlich H., 1980, ADV ELECTRON EL PHYS, V53, P85
   HIRSCH J, 1987, PHYS LETT A, V121, P447, DOI 10.1016/0375-9601(87)90496-8
   LIDE DR, 1991, CRC HDB CHEM PHYSICS, P14
   MESQUITA MV, 1993, PHYS REV E, V48, P4049, DOI 10.1103/PhysRevE.48.4049
   Mesquita MV, 1996, INT J QUANTUM CHEM, V60, P689, DOI 10.1002/(SICI)1097-461X(1996)60:2<689::AID-QUA7>3.0.CO;2-T
   MESQUITA MV, 1995, NUOVO CIMENTO, V17, P569
   MILLS RE, 1983, PHYS REV A, V28, P379, DOI 10.1103/PhysRevA.28.379
   MILLS RE, 1991, PHYS REV A, V43, P3176, DOI 10.1103/PhysRevA.43.3176
   MISHRA RK, 1979, INT J QUANTUM CHEM, V26, P691
   MOSKALENKO SA, 1979, INT J QUANTUM CHEM, V26, P745
   PAUL R, 1984, PHYS REV A, V30, P2676, DOI 10.1103/PhysRevA.30.2676
   SCOTT A, 1992, PHYS REP, V217, P1, DOI 10.1016/0370-1573(92)90093-F
   SERRA R, 1986, INTRO PHYSICS COMPLE, pCH5
   TUSZYNSKI JA, 1991, PHYS REV A, V43, P3179, DOI 10.1103/PhysRevA.43.3179
   WEBB SJ, 1980, PHYS REP, V60, P201, DOI 10.1016/0370-1573(80)90149-0
   WU TM, 1978, J THEOR BIOL, V71, P209, DOI 10.1016/0022-5193(78)90267-9
NR 25
TC 2
Z9 2
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0020-7608
J9 INT J QUANTUM CHEM
JI Int. J. Quantum Chem.
PD APR 15
PY 1997
VL 62
IS 4
BP 363
EP 372
DI 10.1002/(SICI)1097-461X(1997)62:4<363::AID-QUA4>3.0.CO;2-U
PG 10
WC Chemistry, Physical; Mathematics, Interdisciplinary Applications;
   Physics, Atomic, Molecular & Chemical
SC Chemistry; Mathematics; Physics
GA WN996
UT WOS:A1997WN99600004
DA 2018-10-19
ER

PT J
AU Werthen, M
   Hauch, KD
   Shen, MC
   Horbett, TA
AF Werthen, M
   Hauch, KD
   Shen, MC
   Horbett, TA
TI Calcium mobilization in monocytes/macrophages as a marker for activation
   during adhesion to biomaterial surfaces.
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
C1 UNIV WASHINGTON,DEPT CHEM ENGN,SEATTLE,WA 98195.
   UNIV WASHINGTON,CTR BIOENGN,SEATTLE,WA 98195.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD APR 13
PY 1997
VL 213
BP 301
EP COLL
PN 1
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA WP185
UT WOS:A1997WP18502542
DA 2018-10-19
ER

PT J
AU Omura, S
   Mizuki, N
   Horimoto, S
   Kawabe, R
   Fujita, K
AF Omura, S
   Mizuki, N
   Horimoto, S
   Kawabe, R
   Fujita, K
TI A newly developed collagen/silicone bilayer membrane as a mucosal
   substitute: A preliminary report
SO BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY
LA English
DT Article
ID ARTIFICIAL SKIN; COLLAGEN; INVITRO; BIOMATERIAL; FIBROBLASTS; DESIGN
AB A new bilayer membrane proved effective as a mucosal substitute. The membrane is composed of an outer layer of silicone and an inner layer of dehydrothermally cross linked composites of fibrillar and denatured collagen sponge. The membrane was placed on oral mucosal defects of five patients after operations for cancer. Ten to 14 days after application the outer silicone sheet was removed, leaving only the inner collagen sponge layer into which cellular tufts of fibroblasts and capillaries had infiltrated. The infiltrated collagen matrix became a new connective tissue that epithelialised rapidly by migration of peripheral epithelium 4-5 weeks after application. In all cases the postoperative course was unremarkable and the repair was effective.
RP Omura, S (reprint author), YOKOHAMA CITY UNIV,SCH MED,DEPT ORAL & MAXILLOFACIAL SURG,KNAZAWA KU,3-9 FUKUURA,YOKOHAMA,KANAGAWA 236,JAPAN.
CR BERTOLAMI CN, 1988, J ORAL MAXIL SURG, V46, P971, DOI 10.1016/0278-2391(88)90334-5
   BURKE JF, 1981, ANN SURG, V194, P413, DOI 10.1097/00000658-198110000-00005
   CUKIER J, 1993, ANN INTERN MED, V118, P920, DOI 10.7326/0003-4819-118-12-199306150-00002
   FEINBERG SE, 1989, J ORAL MAXIL SURG, V47, P712, DOI 10.1016/S0278-2391(89)80011-4
   HANSBROUGH JF, 1989, JAMA-J AM MED ASSOC, V262, P2125, DOI 10.1001/jama.262.15.2125
   HEY KB, 1990, BIOTECHNOL APPL BIOC, V12, P85
   KOIDE M, 1993, J BIOMED MATER RES, V27, P79, DOI 10.1002/jbm.820270111
   MATSUDA K, 1990, BIOMATERIALS, V11, P351, DOI 10.1016/0142-9612(90)90113-5
   MICHAELI D, 1990, Journal of Burn Care and Rehabilitation, V11, P21, DOI 10.1097/00004630-199001000-00005
   MIYATA T, 1992, Clinical Materials, V9, P139, DOI 10.1016/0267-6605(92)90093-9
   NISHIKAWA A, 1987, EXP CELL RES, V171, P164, DOI 10.1016/0014-4827(87)90259-X
   STERN R, 1990, Journal of Burn Care and Rehabilitation, V11, P7, DOI 10.1097/00004630-199001000-00003
   UEDA M, 1991, ANN PLAS SURG, V27, P540, DOI 10.1097/00000637-199112000-00005
   YANNAS IV, 1980, J BIOMED MATER RES, V14, P65, DOI 10.1002/jbm.820140108
   YANNAS IV, 1980, J BIOMED MATER RES, V14, P107, DOI 10.1002/jbm.820140203
NR 15
TC 27
Z9 27
U1 1
U2 1
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0266-4356
J9 BRIT J ORAL MAX SURG
JI Br. J. Oral Maxillofac. Surg.
PD APR
PY 1997
VL 35
IS 2
BP 85
EP 91
DI 10.1016/S0266-4356(97)90681-1
PG 7
WC Dentistry, Oral Surgery & Medicine; Surgery
SC Dentistry, Oral Surgery & Medicine; Surgery
GA WV145
UT WOS:A1997WV14500003
PM 9146864
DA 2018-10-19
ER

PT J
AU Probst, M
   Dahiya, R
   Carrier, S
   Tanagho, EA
AF Probst, M
   Dahiya, R
   Carrier, S
   Tanagho, EA
TI Reproduction of functional smooth muscle tissue and partial bladder
   replacement
SO BRITISH JOURNAL OF UROLOGY
LA English
DT Article
DE urinary incontinence; homograft; acellular matrix graft; rat model
ID SMALL-INTESTINAL SUBMUCOSA; URINARY-DIVERSION; AUGMENTATION; RATS;
   ENTEROCYSTOPLASTY; SUBSTITUTION; GRAFT
AB Objective To find a means of bladder augmentation that would avoid the complications encountered with the use of bowel segments, using a newly developed acellular biomaterial, the bladder acellular matrix graft (BAMG), as a homologous graft.
   Materials and methods Thirty-four rats underwent a partial cystectomy (40-50%) and grafting with a BAMG of equal size. Eleven rats died within the first 72 h, probably from urinary leakage caused by obstruction of the bladder neck with stones or coagula; the surviving 23 were killed at varying intervals after cystectomy and examined.
   Results After providing initial bladder enlargement, the graft was progressively infiltrated by the vessels and smooth muscle cells of the host; furthermore, the mucosal lining was complete within 10 days. After 4 weeks, all bladder wall components were evident histologically in the graft. The ingrowth was complete after 8 weeks, except for neural regeneration, which was only partial. At 12 weeks, the bladder wall muscle structure in the graft was so well developed that it was difficult to delineate the junction between host bladder and BAMG. Neural regeneration continued to improve. Normal bladder capacities were maintained throughout the study.
   Conclusion The BAMG appears to serve, without rejection, as a framework of collagen and elastin for the ingrowth of all bladder wall components. The reason for the better acceptance of the BAMG than of other bladder augmentation grafts requires further investigation.
C1 UNIV CALIF SAN FRANCISCO,DEPT UROL,U755,SCH MED,SAN FRANCISCO,CA 94143.
RI Sano, Michael/E-1715-2011
FU NINDS NIH HHS [R01 NS18029]
CR BADYLAK SF, 1989, J SURG RES, V47, P74, DOI 10.1016/0022-4804(89)90050-4
   DEBADIOLA F, 1991, J UROLOGY, V146, P559, DOI 10.1016/S0022-5347(17)37854-0
   DEERBERG F, 1985, J NATL CANCER I, V75, P1113
   DRAPER JW, 1956, SURGERY, V39, P434
   DUNN M, 1979, BRIT J UROL, V51, P458, DOI 10.1111/j.1464-410X.1979.tb03578.x
   FISHMAN IJ, 1987, J UROLOGY, V138, P1291, DOI 10.1016/S0022-5347(17)43586-5
   GOLDSTEIN MB, 1967, J UROLOGY, V97, P664, DOI 10.1016/S0022-5347(17)63095-7
   GOLDWASSER B, 1986, J UROLOGY, V135, P215, DOI 10.1016/S0022-5347(17)45589-3
   GOLDWASSER B, 1987, J UROLOGY, V138, P1007
   GRENABO L, 1988, J UROLOGY, V140, P428, DOI 10.1016/S0022-5347(17)41650-8
   HASELHUHN GD, 1994, J UROLOGY, V152, P2267, DOI 10.1016/S0022-5347(17)31655-5
   JELLY O, 1970, UROL INT, V25, P236, DOI 10.1159/000279676
   KAMBIC H, 1992, J UROLOGY, V148, P539, DOI 10.1016/S0022-5347(17)36649-1
   KELAMI A, 1971, J UROLOGY, V105, P518, DOI 10.1016/S0022-5347(17)61563-5
   KNAPP PM, 1994, J ENDOUROL, V8, P125, DOI 10.1089/end.1994.8.125
   KOCH MO, 1992, J UROLOGY, V147, P1343, DOI 10.1016/S0022-5347(17)37560-2
   KUUSANMAKI P, 1994, TRANSPLANTATION, V58, P757, DOI 10.1097/00007890-199410150-00001
   LUNDBORG G, 1982, EXP NEUROL, V76, P361, DOI 10.1016/0014-4886(82)90215-1
   MCDOUGAL WS, 1992, J UROLOGY, V147, P1199, DOI 10.1016/S0022-5347(17)37517-1
   NEHLS V, 1992, CELL TISSUE RES, V270, P469, DOI 10.1007/BF00645048
   Neuhoff H, 1917, SURG GYNECOL OBSTET, V14, P383
   NORRIS MA, 1982, UROLOGY, V19, P631, DOI 10.1016/0090-4295(82)90017-6
   NOVICK AC, 1978, J BIOMED MATER RES, V12, P125, DOI 10.1002/jbm.820120202
   OSANAI T, 1994, J UROLOGY, V152, P1002, DOI 10.1016/S0022-5347(17)32642-3
   PUST R, 1979, FORTSCHR MED, V97, P561
   SPENCER JR, 1993, J UROLOGY, V150, P1321, DOI 10.1016/S0022-5347(17)35769-5
   TSUJI I, 1961, J UROLOGY, V85, P42, DOI 10.1016/S0022-5347(17)65279-0
   UVELIUS B, 1991, UROL INT, V47, P245, DOI 10.1159/000282230
NR 28
TC 147
Z9 161
U1 0
U2 8
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0NE
SN 0007-1331
J9 BRIT J UROL
JI Br. J. Urol.
PD APR
PY 1997
VL 79
IS 4
BP 505
EP 515
DI 10.1046/j.1464-410X.1997.00103.x
PG 11
WC Urology & Nephrology
SC Urology & Nephrology
GA WT824
UT WOS:A1997WT82400005
PM 9126077
OA Bronze
DA 2018-10-19
ER

PT J
AU Turunen, T
   Peltola, J
   Helenius, H
   YliUrpo, A
   Happonen, RP
AF Turunen, T
   Peltola, J
   Helenius, H
   YliUrpo, A
   Happonen, RP
TI Bioactive glass and calcium carbonate granules as filler material around
   titanium and bioactive glass implants in the medullar space of the
   rabbit tibia
SO CLINICAL ORAL IMPLANTS RESEARCH
LA English
DT Article
DE bioactive glass; calcium carbonate; bone repair; implant
ID BONE-FORMATION; INTERFACE; DEFECTS; CORAL; GRAFT
AB The effect of bioactive glass (BG) and calcium carbonate (CC),granules on bone formation around titanium and BG implants projecting into the medullary space of rabbit tibia was studied. The bone marrow tissue was removed and the medullary space was filled either with BG or CC (Biocoral(R)) granules (Phi 630-800 mu m). Conical titanium and BG implants were inserted into the holes drilled in compact bone using the press fit-technique. Histomorphometry was used to measure the bone-biomaterial area in a 1.0 mm wide zone around the head of the implant and the contact between formed bone and implant. Significantly larger bone-biomaterial area was obtained around titanium implants using BG than CC,granules while no difference was found in connection of BG implants. Better bone-implant contact was achieved with BG implants than with titanium implants regardless of the type of granules used. The results indicate that BG may prove to be useful as filler and coating material in connection of implants, projecting into bone cavities.
RP Turunen, T (reprint author), UNIV TURKU,INST DENT,DEPT ORAL & MAXILLOFACIAL SURG,LEMMINKAISENKATU 2,FIN-20520 TURKU,FINLAND.
CR Andersson O. H., 1992, NEW TRENDS BONE GRAF, P127
   ANDERSSON OH, 1992, J MATER SCI-MATER M, V3, P145, DOI 10.1007/BF00705283
   ANDERSSON OH, 1990, J MATER SCI-MATER M, V1, P219, DOI 10.1007/BF00701080
   Branemark PI, 1985, TISSUE INTEGRATED PR, p[11, 253]
   DONATH K, 1982, J ORAL PATHOL MED, V11, P318, DOI 10.1111/j.1600-0714.1982.tb00172.x
   GROSS U, 1985, J BIOMED MATER RES, V19, P251, DOI 10.1002/jbm.820190308
   GUILLEMIN G, 1987, J BIOMED MATER RES, V21, P557, DOI 10.1002/jbm.820210503
   HEIKKILA JT, 1993, ACTA ORTHOP SCAND, V64, P678, DOI 10.3109/17453679308994597
   HEIKKILA JT, 1995, ACTA ORTHOP SCAND, V66, P463, DOI 10.3109/17453679508995588
   HENCH LL, 1991, MRS BULL, V16, P62
   HENCH LL, 1984, SCIENCE, V226, P303
   HENCH LL, 1973, J BIOMEDICAL MAT RES, V4, P24
   Hench LL, 1971, J BIOMED MATER RES S, V2, P117, DOI DOI 10.1002/JBM.820050611
   ITO G, 1987, J BIOMED MATER RES, V21, P485, DOI 10.1002/jbm.820210408
   Jennings D E, 1989, J Prosthet Dent, V61, P575, DOI 10.1016/0022-3913(89)90279-5
   JOHANSSON C B, 1991, International Journal of Oral and Maxillofacial Implants, V6, P437
   OHGUSHI H, 1992, J BIOMED MATER RES, V26, P885, DOI 10.1002/jbm.820260705
   OHGUSHI H, 1991, BIOCERAMICS, V4, P213
   PAJAMAKI KJJ, 1994, ARCH ORTHOP TRAUM SU, V113, P210, DOI 10.1007/BF00441834
   PAPACHARALAMBOUS SK, 1993, INT J ORAL MAX SURG, V22, P260, DOI 10.1016/S0901-5027(05)80511-9
   *SAS I INC, 1992, SAS STAT US GUID VER, V2
   *SAS I INC, 1990, SAS STAT US GUID VER, V1
   SHORS EC, 1989, MATER RES SOC S P, V110, P211
   Small S A, 1993, Int J Oral Maxillofac Implants, V8, P523
   SMILER D G, 1992, Dental Clinics of North America, V36, P151
   TURUNEN T, 1995, J MATER SCI-MATER M, V6, P639, DOI 10.1007/BF00123444
   WILSON J, 1981, J BIOMED MATER RES, V15, P805, DOI 10.1002/jbm.820150605
NR 27
TC 22
Z9 25
U1 0
U2 3
PU MUNKSGAARD INT PUBL LTD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 0905-7161
J9 CLIN ORAL IMPLAN RES
JI Clin. Oral Implant. Res.
PD APR
PY 1997
VL 8
IS 2
BP 96
EP 102
DI 10.1034/j.1600-0501.1997.080204.x
PG 7
WC Dentistry, Oral Surgery & Medicine; Engineering, Biomedical
SC Dentistry, Oral Surgery & Medicine; Engineering
GA WU168
UT WOS:A1997WU16800004
PM 9758960
DA 2018-10-19
ER

PT J
AU Kawakami, T
   Kawai, T
   Takei, N
   Kise, T
   Eda, S
   Urist, MR
AF Kawakami, T
   Kawai, T
   Takei, N
   Kise, T
   Eda, S
   Urist, MR
TI Evaluation of heterotopic bone formation induced by squalane and bone
   morphogenetic protein composite
SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
LA English
DT Article
ID CARRIER
AB Bone morphogenetic protein is an important molecule whose bioactivity depends on the carrier, Squalane is used in the formulation of various kinds of cosmetics because it is easily emulsified and has the property of spreading well. Thus, squalane might be effective as a bone morphogenetic protein delivery system, As a test for this possibility, gelatin capsules containing squalane and bone morphogenetic protein (bovine derived partially purified) composite were implanted under the hindquarter perimuscular membrane of ddY mice, Control capsules containing only bone morphogenetic protein were used for controls, The implants were radiographically and histologically examined at 1 to 4 weeks after the operation, According to the radiographic analysis, squalane and bone morphogenetic protein composite and bone morphogenetic protein only control specimens formed widespread heterotopic bone tissues. The amount of heterotopic bone formation in the composite experimental specimens was approximately 40% greater than that in the controls. Histologic examination of experimental and control specimens revealed varying amounts of perichondral ossification by 2 weeks, By 3 and 4 weeks, the bone deposits were colonized by hematopoietic bone marrow, Squalane was effective for the slow local release of bone morphogenetic protein, Furthermore, the squalane and bone morphogenetic protein composite was a reliable osteoinductive biomaterial.
C1 AICHI GAKUIN UNIV,SCH DENT,DEPT DENT MAT SCI,NAGOYA,AICHI 464,JAPAN.
   NEO DENT CHEM PROD CO,SHIOJIRI,JAPAN.
   UNIV CALIF LOS ANGELES,SCH MED,BONE RES LAB,LOS ANGELES,CA 90024.
RP Kawakami, T (reprint author), MATSUMOTO DENT COLL,DEPT ORAL PATHOL,1780 GOBARA,NAGANO 39907,JAPAN.
CR COOK SD, 1994, CLIN ORTHOPAEDICS, V301, P302
   GAO TJ, 1993, ANN CHIR GYNAECOL, V82, P77
   Kato N, 1995, J HARD TISSUE BIOL, V4, P15
   KATOH T, 1993, CLIN ORTHOP RELAT R, V287, P266
   Kawai T, 1988, Clin Orthop Relat Res, P262
   KAWAI T, 1993, CLIN ORTHOP RELAT R, V290, P296
   KAWAKAMI T, 1995, MED SCI RES, V23, P521
   KAWAKAMI T, 1993, BIOMATERIALS, V14, P575, DOI 10.1016/0142-9612(93)90173-Y
   LINDHOLM TS, 1993, ANN CHIR GYNAECOL FE, V82, P3
   Luyten F P, 1992, Acta Orthop Belg, V58 Suppl 1, P263
   MIYAMOTO S, 1993, ANN CHIR GYNAECOL FE, V82, P69
   MIYAMOTO S, 1992, CLIN ORTHOP RELAT R, V278, P274
   Miyazawa K, 1993, J HARD TISSUE BIOL, V2, P48
   SHIGENOBU K, 1993, ANN CHIR GYNAECOL, V82, P85
   UJI H, 1992, MATSUMOTO SHIGAKU, V18, P244
   UJI H, 1994, J JPN STOMATOL SOC, V43, P960
   URIST MR, 1984, P NATL ACAD SCI-BIOL, V81, P371, DOI 10.1073/pnas.81.2.371
   URIST MR, 1987, METHOD ENZYMOL, V146, P294
   URIST MR, 1982, CLIN ORTHOPAEDICS, V162, P219
NR 19
TC 8
Z9 10
U1 0
U2 1
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 0009-921X
J9 CLIN ORTHOP RELAT R
JI Clin. Orthop. Rel. Res.
PD APR
PY 1997
IS 337
BP 261
EP 266
PG 6
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA WT707
UT WOS:A1997WT70700029
PM 9137198
DA 2018-10-19
ER

PT J
AU Mutter, D
   Aprahamian, M
   Tiollier, J
   Sonzini, P
   Marescaux, J
AF Mutter, D
   Aprahamian, M
   Tiollier, J
   Sonzini, P
   Marescaux, J
TI Evaluation of human collagen biomaterials in the healing of colonic
   anastomoses in dogs
SO EUROPEAN JOURNAL OF SURGERY
LA English
DT Article
DE colonic anastomoses; collagen; biomaterial
ID CONNECTIVE-TISSUE; FIBRIN SEALANT; LEAKAGE; RAT
AB Objective: To investigate the ability of human collagen biomaterials to secure colonic anastomoses in dogs and to evaluate the biocompatibility of anastomotic protection patches (APP).
   Design: Experimental open study.
   Setting: Experimental research centre, France.
   Material: 21 mongrel dogs randomised into three groups of 7 each.
   Intervention: Standard transverse colonic end-to-end anastomoses were secured with two-layer oxidised collagen I + III sponge covered with thin crosslinked collagen IV film (APP 1) glued around the suture (n = 7); two-layer oxidised collagen I + III sponge covered with thin non-crosslinked collagen I + III film patch (APP 2) (n = 7); or sealed by fibrin sealant (n = 7), which acted as a controls.
   Main outcome measures: Gross examination, radiological control (barium enemas), and microscopic examination on day 35 postoperatively.
   Results: Gross clinical and radiological examinations on day 35 showed normal wound healing in all but one dog in which the anastomoses had occluded by day 16. There was significantly less stricturing with the APP 2 patch (p < 0.05 compared with the controls). Microscopic examination showed complete absorption of the APP 2 patches as well as quicker mucosal and extracellular matrix repair than controls. The APP 1 patch gave the best healing of the muscular layer but did not reduce anastomosis stricturing, and was not totally absorbed.
   Conclusions: Collagen supporting devices do not alter healing of the large bowel. Encircling patches do not increase the number of adhesions or the rate of anastomotic stricturing and a thin fibrillar collagen I + III dense layer may even improve it. The speed of absorption of the patch depends on the type of dense collagen film. These results argue for a prospective clinical evaluation in humans.
C1 IRCAD,EUROPEAN INST TELESURG,STRASBOURG,FRANCE.
   HOP CIVIL,CHIRURG CLIN A,F-67091 STRASBOURG,FRANCE.
   IMEDEX SA,SADUC BIOMAT,CHAPONOST,FRANCE.
CR ALDERI G, 1984, COLONIC ANASTOMOSIS, P134
   ALLARDYCE DB, 1983, AM J SURG, V145, P593, DOI 10.1016/0002-9610(83)90099-5
   APRAHAMIAN M, 1987, J BIOMED MATER RES, V21, P965, DOI 10.1002/jbm.820210803
   APRAHAMIAN M, 1993, BIOMATERIALS, V14, P556, DOI 10.1016/0142-9612(93)90246-X
   APRAHAMIAN M, 1992, BIOMATERIALS, V13, P697, DOI 10.1016/0142-9612(92)90130-G
   BLACKETT RL, 1978, BRIT J SURG, V65, P775, DOI 10.1002/bjs.1800651105
   BREW EC, 1995, J AM COLL SURGEONS, V180, P499
   BRUHN HD, 1980, 23 TAG DTSCH ARB BLU, P217
   CANALIS F, 1968, SURG GYNECOL OBSTETR, V126, P109
   CHAMPAULT G, 1982, 84 C FRANC CHIR PAR
   FEKETE F, 1981, ANN CHIR, V35, P697
   GRINNELL F, 1984, J CELL BIOCHEM, V26, P107, DOI 10.1002/jcb.240260206
   HAUKIPURO K, 1995, J SURG RES, V58, P443, DOI 10.1006/jsre.1995.1070
   HJORTRUP A, 1986, BRIT J SURG, V73, P760, DOI 10.1002/bjs.1800730928
   HUNT T, 1990, J TRAUMA, V30, pS123
   IRVIN TT, 1973, BRIT J SURG, V60, P461, DOI 10.1002/bjs.1800600612
   LEVARD H, 1982, MED CHIR DIG, V11, P567
   MAILLET P, 1975, 77 C FRANC CHIR PAR
   MARESCAUX JF, 1991, BRIT J SURG, V78, P440, DOI 10.1002/bjs.1800780417
   MURRAY JC, 1979, J CELL BIOL, V80, P197, DOI 10.1083/jcb.80.1.197
   Mutter D, 1996, EUR SURG RES, V28, P32, DOI 10.1159/000129437
   MUTTER D, IN PRESS BIOMATERIAL
   OKA H, 1982, AM J SURG, V143, P561, DOI 10.1016/0002-9610(82)90162-3
   PETRELLI NJ, 1983, J SURG ONCOL, V19, P59
   RABAUD M, 1986, THROMB RES, V43, P205, DOI 10.1016/0049-3848(86)90061-7
   SCHER KS, 1982, SURG GYNECOL OBSTET, V154, P548
   SHOSHAN S, 1974, ISRAEL J MED SCI, V10, P537
   TARDY M, 1990, Patent No. 4931546
   VACHON F, 1986, J CHIR-PARIS, V123, P197
   VANDERHAM AC, 1993, J SURG RES, V55, P256, DOI 10.1006/jsre.1993.1137
   VANDERHAM AC, 1991, BRIT J SURG, V78, P49, DOI 10.1002/bjs.1800780117
   WACLAWICZEK HW, 1990, LYON CHIR, V86, P142
   1993, Patent No. 5201745
   1836, Patent No. 545146
   7638022
NR 35
TC 10
Z9 10
U1 0
U2 0
PU SCANDINAVIAN UNIVERSITY PRESS
PI OSLO
PA PO BOX 2959 TOYEN, JOURNAL DIVISION CUSTOMER SERVICE, N-0608 OSLO,
   NORWAY
SN 1102-4151
J9 EUR J SURG
JI Eur. J. Surg.
PD APR
PY 1997
VL 163
IS 4
BP 287
EP 295
PG 9
WC Surgery
SC Surgery
GA WV888
UT WOS:A1997WV88800008
PM 9161827
DA 2018-10-19
ER

PT J
AU Sariri, R
AF Sariri, R
TI Protein interaction with novel hydrogel biomaterials
SO IRANIAN POLYMER JOURNAL
LA English
DT Article
DE biomaterials; hydrogels; poly(HEMA); polyethylene oxide; spoliation
AB To develop a biomaterial with high biocompatibility, one must take into consideration both bulk and surface properties of the material which is to be synthesized. In an attempt to produce a deposit resistant material, a group of copolymeric hydrogels, especially those of interest in contact lens industry, are synthesized and their resistance to protein spoliation is measured. Poly(2-hydroxyethylmethacrylate) known as poly(HEMA) has a number of limitations as a biomaterial, which is illustrated in its use as soft contact lenses where, even though it is found to be mechanically adequate, ocular incompatibility is observed leading ultimately to the formation of ''white spot deposits'' on the lens surface. Hydrogels synthesized during this study are polyethylene oxide modified poly(HEMA) based gels. The amount of protein adsorbed on these hydrogels is calculated by measuring the UV absorbance against a blank of the same hydrogel. The cell culture studies are also examined by other members in the group and the amount of protein absorbed on each hydrogel is calculated.
C1 GILAN UNIV,DEPT CHEM,RASHT,IRAN.
CR Andrade J D, 1973, Med Instrum, V7, P110
   ANDRADE JD, 1985, ADV POLYM SCI, V79, P3
   BAIER RE, 1970, ADV EXP MED BIOL, V7, P235
   CORKHILL PH, 1990, CRIT REV BIOCOMPAT, V5, P363
   FITTON JH, 1993, THESIS U ASTON BIRMI
   HIATT CW, 1971, J CHROMATOGR, V56, P362, DOI 10.1016/S0021-9673(00)97825-7
   SMITH MBE, 1994, THESIS ASTRON U
   TIGHE BJ, 1994, 11 EUR C BIOM PIS IT
NR 8
TC 5
Z9 6
U1 0
U2 2
PU POLYMER RESEARCH CENTER IRAN
PI TEHRAN
PA PO BOX 14185-515, TEHRAN, IRAN
SN 1026-1265
J9 IRAN POLYM J
JI Iran. Polym. J.
PD APR
PY 1997
VL 6
IS 2
BP 135
EP 143
PG 9
WC Polymer Science
SC Polymer Science
GA XN619
UT WOS:A1997XN61900008
DA 2018-10-19
ER

PT J
AU Litauszki, L
   Howard, L
   Salvati, L
   Tarcha, PJ
AF Litauszki, L
   Howard, L
   Salvati, L
   Tarcha, PJ
TI Surfaces modified with PEO by the Williamson reaction and their affinity
   for proteins
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
ID POLYETHYLENE OXIDE; BIOMATERIAL SURFACES; RADIATION; POLYURETHANES;
   SURFACTANTS; COPOLYMERS; ESCA
AB Poly(ethylene oxide) (PEO) was immobilized by the Williamson ether synthesis onto halogenated surfaces such as poly(vinylidene chloride), surface-brominated polypropylene, and surface-brominated poly(ethylene terephthalate). PEO (M(w) 20,000) was converted to its sodium salt and reacted for various times with the halogen-containing surfaces at 95 degrees C in the melt, or as a solution in 2-methoxyethyl ether. X-ray photon spectroscopy and water contact-angle measurements confirmed the surface-immobilization of PEO. The adsorption from phosphate buffer of human serum albumin, immunoglobulin G (IgG) and fibrinogen, and murine IgG was reduced after modification of the surfaces. In addition, IgG adsorption from pooled human sera was diminished. The difference in protein adsorption between test samples and controls exhibited a strong dependence on input protein concentration. (C) 1997 John Wiley & Sons, Inc.
C1 ABBOTT LABS,DIV DIAGNOST,DEPT MAT CHEM D97D,N CHICAGO,IL 60064.
FU NCRR NIH HHS [RR01296]
CR ABRIBAT B, 1994, SYNTHETIC COMMUN, V24, P1773, DOI 10.1080/00397919408010184
   AMIJI M, 1993, J COLLOID INTERF SCI, V155, P251, DOI 10.1006/jcis.1993.1031
   HAN DK, 1989, J BIOMED MATER RES-A, V23, P87, DOI 10.1002/jbm.820231309
   HAN DK, 1991, J BIOMED MATER RES, V25, P561, DOI 10.1002/jbm.820250502
   JEON SI, 1991, J COLLOID INTERF SCI, V142, P149, DOI 10.1016/0021-9797(91)90043-8
   KISHIDA A, 1992, BIOMATERIALS, V13, P113, DOI 10.1016/0142-9612(92)90006-A
   LEE JH, 1989, J BIOMED MATER RES, V23, P351, DOI 10.1002/jbm.820230306
   LEE JH, 1990, BIOMATERIALS, V11, P455, DOI 10.1016/0142-9612(90)90058-X
   LEWIS KB, 1993, J COLLOID INTERF SCI, V159, P77, DOI 10.1006/jcis.1993.1299
   LOPEZ GP, 1992, J BIOMED MATER RES, V26, P415, DOI 10.1002/jbm.820260402
   POOT A, 1990, J BIOMED MATER RES, V24, P1021, DOI 10.1002/jbm.820240805
   RATNER BD, 1978, J APPL POLYM SCI, V22, P643, DOI 10.1002/app.1978.070220306
   SHEU MS, 1993, CLIN MATER, V13, P41, DOI 10.1016/0267-6605(93)90088-O
   SHEU MS, 1993, J ADHES SCI TECHNOL, V7, P1065, DOI 10.1163/156856193X00583
   SLOOP SE, 1994, J APPL POLYM SCI, V53, P1563, DOI 10.1002/app.1994.070531202
   TSENG YC, 1992, J BIOMED MATER RES, V26, P373, DOI 10.1002/jbm.820260308
NR 16
TC 14
Z9 14
U1 0
U2 7
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD APR
PY 1997
VL 35
IS 1
BP 1
EP 8
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA WQ683
UT WOS:A1997WQ68300001
PM 9104693
DA 2018-10-19
ER

PT J
AU Aronsson, BO
   Lausmaa, J
   Kasemo, B
AF Aronsson, BO
   Lausmaa, J
   Kasemo, B
TI Glow discharge plasma treatment for surface cleaning and modification of
   metallic biomaterials
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
ID SCANNING TUNNELING MICROSCOPY; HOLLOW-CATHODE DISCHARGE; DENTAL IMPLANT
   MATERIALS; TITANIUM SURFACES; SPECTROSCOPIC CHARACTERIZATION;
   PREPARATIVE PROCEDURES; OXIDIZED TITANIUM; SCIENCE ASPECTS; OXIDE-FILMS;
   AUGER
AB Glow discharge plasma treatment is a frequently used method for cleaning, preparation, and modification of biomaterial and implant surfaces. The merits of such treatments are, however, strongly dependent on the process parameters. In the present work the possibilities, limitations, and risks of plasma treatment for surface preparation of metallic materials are investigated experimentally using titanium as a model system, and also discussed in more general terms. Samples were treated by different low-pressure direct current plasmas and analyzed using Auger electron spectroscopy (AES), x-ray photoelectron spectroscopy (XPS), atomic force microscopy, scanning electron microscopy, and light microscopy. The plasma system is a home-built, ultra-high vacuum-compatible system that allows sample introduction via a load-lock, and precise control of pressure, gas composition and flow rate, etc. This system allows uniform treatment of cylindrical and screw-shaped samples. With appropriate plasma parameters, argon plasma remove all chemical traces from former treatments (adsorbed contaminants and other impurities, and native oxide layers), in effect producing cleaner and more well-controlled surfaces than with conventional preparation methods. Removal (sputtering) rates up to 30 nm/min are possible. However, when inappropriate plasma parameters are used, the result may be increased contamination and formation of unintentional or undesired surface layers (e.g., carbides and nitrides). Plasma-cleaned surfaces provide a clean and reproducible starting condition for further plasma treatments to form well-controlled surface layers. Oxidation in pure O-2 (thermally or in oxygen plasmas) results in uniform and stoichiometric TiO2 surface oxide layers of reproducible composition and thicknesses in the range 0.5-150 nm, as revealed by AES and XPS analyses. Titanium nitride layers were prepared by using N-2 plasmas. While mild plasma treatments leave the surface microstructure unaffected, heavy plasma treatment can give rise to dramatic morphologic changes. Comparison of these results with corresponding analyses of commercial implants and electropolished and/or anodically oxidized samples shows that the plasma treatment offers superior control of the surface status. However, it is also shown that improper control of the plasma process can produce unwanted and irreproducible results. (C) 1997 John Wiley & Sons, Inc.
C1 GOTHENBURG UNIV,S-41296 GOTHENBURG,SWEDEN.
RP Aronsson, BO (reprint author), CHALMERS UNIV TECHNOL,DEPT APPL PHYS,S-41296 GOTHENBURG,SWEDEN.
CR AMEMIYA H, 1993, J PHYS D APPL PHYS, V26, P2174, DOI 10.1088/0022-3727/26/12/014
   ARMSTRONG NR, 1977, SURF SCI, V67, P451, DOI 10.1016/0039-6028(77)90007-3
   ARONSSON BO, UNPUB APPL SURFACE S
   ARONSSON BO, UNPUB SURFACE SCI SP
   ASK M, 1989, APPL SURF SCI, V35, P283, DOI 10.1016/0169-4332(89)90013-5
   AUCIELLO O, 1984, ION BOMBARDMENT MODI, P1
   Baier R E, 1988, Int J Oral Maxillofac Implants, V3, P9
   BAIER RE, 1982, BIOMATERIALS, V3, P241, DOI 10.1016/0142-9612(82)90027-8
   BAIER RE, 1970, 176 CALSP CORP ADV T
   BAIER RE, 1983, PHYSICOCHEMICAL ASPE, V2, P895
   BARO AM, 1986, BIOMATERIALS, V7, P463, DOI 10.1016/0142-9612(86)90036-0
   Beamson G., 1992, HIGH RESOLUTION XPS
   BECK RB, 1987, APPL SURF SCI, V30, P32, DOI 10.1016/0169-4332(87)90070-5
   BRANEMARK PI, 1985, TISSUE INTEGRATED PR
   CARLSSON L V, 1989, International Journal of Oral and Maxillofacial Implants, V4, P199
   Chapman B., 1980, GLOW DISCHARGE PROCE
   DAVIES JA, 1992, MRS BULL, P26
   DAVIS GD, 1983, APPL SURF SCI, V15, P321, DOI 10.1016/0378-5963(83)90026-0
   Davis L. E., 1978, HDB AUGER ELECT SPEC
   DAWSON PT, 1985, SURF SCI, V149, P105, DOI 10.1016/S0039-6028(85)80016-9
   DILKS A, 1981, ELECTRON SPECTROSCOP, V4, pCH5
   DOUNDOULAKIS JH, 1987, J PROSTHET DENT, V58, P471, DOI 10.1016/0022-3913(87)90279-4
   Fromhold Jr A.T., 1976, THEORY METAL OXIDATI, V1, P3
   GARDELLA JA, 1988, SURFACE CHARACTERIZA, P145
   GOMBOTZ WR, 1987, CRIT REV BIOCOMPAT, V4, P1
   GOPEL W, 1984, SURF SCI, V139, P333, DOI 10.1016/0039-6028(84)90054-2
   GRILL A., 1994, COLD PLASMA MAT FABR
   HAZAN R, 1993, BIOMATERIALS, V14, P570, DOI 10.1016/0142-9612(93)90172-X
   HOUSTON JE, 1973, J APPL PHYS, V44, P2504, DOI 10.1063/1.1662604
   HUTCHINGS R, 1983, WEAR, V92, P143, DOI 10.1016/0043-1648(83)90014-5
   IGNATOV DV, 1957, J CHIM PHYS PCB, V54, P96
   JOBIN M, 1991, J VAC SCI TECHNOL B, V9, P1263, DOI 10.1116/1.585217
   JOBIN M, 1994, THESIS U GENEVA SWIT
   JOHANSON A, 1990, NEUROBIOL AGING, V11, P276
   JOHANSSON C, 1991, THESIS U GOTHENBURG
   KASEMO B, 1986, CRIT REV BIOCOMPAT, V2, P335
   KASEMO B, 1991, BONE-BIOMATERIAL INTERFACE, P19
   KASEMO B, 1983, J PROSTHET DENT, V49, P832, DOI 10.1016/0022-3913(83)90359-1
   KASEMO B, 1988, J BIOMED MATER RES-A, V22, P145, DOI 10.1002/jbm.820221307
   KASEMO B, 1986, TISSUE INTEGRATION O, P41
   KAWASAKI H, 1991, MAT SCI ENG A-STRUCT, V140, P682, DOI 10.1016/0921-5093(91)90496-A
   KELLER J C, 1990, International Journal of Oral and Maxillofacial Implants, V5, P360
   KORZEC D, 1994, J VAC SCI TECHNOL A, V12, P369, DOI 10.1116/1.579249
   KUMMER FJ, 1992, J APPL BIOMATER, V3, P39, DOI 10.1002/jab.770030107
   Larsson C, 1996, BIOMATERIALS, V17, P605, DOI 10.1016/0142-9612(96)88711-4
   LARSSON C, 1994, BIOMATERIALS, V15, P1062, DOI 10.1016/0142-9612(94)90092-2
   LARSSON C, UNPUB
   LAUSMAA J, 1990, SURF INTERFACE ANAL, V15, P328, DOI 10.1002/sia.740150506
   LAUSMAA J, 1990, APPL SURF SCI, V45, P189, DOI 10.1016/0169-4332(90)90002-H
   LAUSMAA J, 1990, APPL SURF SCI, V44, P133, DOI 10.1016/0169-4332(90)90100-E
   LAUSMAA J, 1989, MATER RES SOC S P, V110, P647
   Lausmaa J., 1991, THESIS U GOTHENBURG
   LAUSMAA J, 1995, RECONSTRUCTIVE PREPR, P181
   LAUSMAA J, 1988, THESIS U GOTHENBURG
   LAUSMAA J, 1997, RECONSTRUCTIVE PREPR, V81, P343
   LAUSMAA J, 1988, SURFACE CHARACTERIZA, P161
   LAUSMAA J, 1986, BIOMEDICAL MAT, V55, P3551
   LESLIE JD, 1978, J ELECTROCHEM SOC, V125, P44, DOI 10.1149/1.2131395
   MATHIEU JB, 1978, J ELECTROCHEM SOC, V125, P1039, DOI 10.1149/1.2131617
   MATTOX DM, 1978, THIN SOLID FILMS, V53, P81, DOI 10.1016/0040-6090(78)90376-0
   MATTOX DM, 1973, J VAC SCI TECHNOL, V10, P47, DOI 10.1116/1.1318041
   MATTSSON H, 1990, ESCA CALIBRATION STU
   MAUSLI PA, 1988, 6TH P WORLD C TIT, P1759
   Mittal K. L., 1979, SURFACE CONTAMINATIO, V1, P3
   MONTERO I, 1991, SURF SCI, V251, P1038, DOI 10.1016/0039-6028(91)91147-P
   Moulder J. F., 1992, HDB XRAY PHOTOELECTR
   OHANLON JF, 1977, OXIDES OXIDE FILMS, P105
   OLIN H, 1992, ULTRAMICROSCOPY, V42, P567, DOI 10.1016/0304-3991(92)90325-E
   ONG JL, 1995, J BIOMED MATER RES, V29, P165, DOI 10.1002/jbm.820290205
   PALMER W, 1988, SURF INTERFACE ANAL, V13, P55
   PLATAU A, 1977, SURF SCI, V63, P153, DOI 10.1016/0039-6028(77)90334-X
   RADEGRAN G, 1991, J ELECTRON MICR TECH, V19, P99, DOI 10.1002/jemt.1060190110
   RATNER RD, 1988, SURFACE CHARACTERIZA
   ROBERTS RW, 1963, BRIT J APPL PHYS, V14, P537, DOI 10.1088/0508-3443/14/9/301
   Rogers Jr. J.W., 1989, APPL SURF SCI, V35, P137
   ROWLAND TW, 1995, PEDIATR EXERC SCI, V7, P1
   SCHARFE M, 1966, THESIS U MINNESOTA
   SENNERBY L, 1990, P ANN M BIOM SOC BIO, P82
   SMITH DC, 1991, J BIOMED MATER RES, V25, P1045, DOI 10.1002/jbm.820250902
   SMITH DC, 1991, J BIOMED MATER RES, V25, P1069, DOI 10.1002/jbm.820250903
   SODHI RNS, 1991, J VAC SCI TECHNOL A, V9, P1329, DOI 10.1116/1.577621
   SORIANO L, 1993, J VAC SCI TECHNOL A, V11, P47, DOI 10.1116/1.578718
   STANFORD CM, 1994, J DENT RES, V73, P1061, DOI 10.1177/00220345940730050801
   STEINEMANN SG, 1994, ANN M EL SOC S COMP, P1
   Swart K M, 1992, J Oral Implantol, V18, P130
   TENGVALL P, 1992, CLIN MAT, V9, P114
   WILLIAMS DF, 1981, BIOCOMPATIBILITY CLI, V2
   WILLIAMS DF, 1981, FUNDAMENTAL ASPECTS, V1
NR 88
TC 148
Z9 150
U1 2
U2 47
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD APR
PY 1997
VL 35
IS 1
BP 49
EP 73
PG 25
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA WQ683
UT WOS:A1997WQ68300006
PM 9104698
DA 2018-10-19
ER

PT J
AU Lundberg, F
   Schliamser, S
   Ljungh, A
AF Lundberg, F
   Schliamser, S
   Ljungh, A
TI Vitronectin may mediate staphylococcal adhesion to polymer surfaces in
   perfusing human cerebrospinal fluid
SO JOURNAL OF MEDICAL MICROBIOLOGY
LA English
DT Article
ID COAGULASE-NEGATIVE STAPHYLOCOCCI; HUMAN-PLASMA; AFFINITY-CHROMATOGRAPHY;
   PROTEIN ADSORPTION; SHUNT INFECTIONS; FIBRONECTIN; HEPARIN; FIBRINOGEN;
   ADHERENCE; AUREUS
AB Prosthetic devices are frequently used for temporary or permanent drainage of cerebrospinal fluid (CSF), i.e., ventricular catheters with or without external monitoring devices and shunts, Infections constitute a serious complication in the use of biomaterials in contact with CSF; coagulase-negative staphylococci (CNS) are the most common aetiological agents, In the present study, polyvinylchloride (PVC) and PVC with endpoint-attached heparin were exposed to human CSF under perfusion to mimic conditions in vivo, Adhesion of strains of CNS isolated from patients with or without biomaterial-associated infection was determined: (i) after pre-incubation with fibronectin (Fn) or vitronectin (Vn) to block bacterial surface binding structures; and (ii) after preincubation of biomaterials with antibodies to Fn or Vn to block exposure of bacteria-binding domains on these host proteins, Pre-incubation of bacterial cells with Vn significantly reduced subsequent adhesion to polystyrene precoated with Vn 0.5 mu g/ well, When PVC pre-exposed to CSF was incubated with antibodies to Vn, subsequent bacterial adhesion of a Vn-binding strain, S. epidermidis 5703, was significantly reduced, The study shows that Vn may mediate adhesion of CNS in the presence of CSF, However, strains retrieved from biomaterials did not express binding of Vn or Fn to a higher extent than non-biomaterial-associated strains. Expression of heparin binding under static conditions did not correlate with staphylococcal adhesion to heparinised polymers under perfusion with CSF. The extent of adhesion of staphylococci to heparinised PVC was either reduced or the same as to unheparinised PVC.
C1 LUND UNIV,DEPT MED MICROBIOL,LUND,SWEDEN.
   LUND UNIV,DEPT INFECT DIS,LUND,SWEDEN.
CR AMMIRATI M, 1987, CHILD NERV SYST, V3, P106, DOI 10.1007/BF00271135
   ANDERSON JM, 1990, INT J ARTIF ORGANS, V13, P375
   APPELGREN P, 1995, LANCET, V345, P130, DOI 10.1016/S0140-6736(95)90097-7
   BALE MD, 1989, BLOOD, V74, P2698
   BARBUCCI R, 1994, BIOMATERIALS, V15, P955, DOI 10.1016/0142-9612(94)90075-2
   BERNE RM, 1988, PHYSIOLOGY, P472
   BROOKS DE, 1983, J GEN MICROBIOL, V129, P3661
   CALLAGHAN R, 1961, BRIT MED J, V1, P860, DOI 10.1136/bmj.1.5229.860
   CHRISTENSEN GD, 1982, INFECT IMMUN, V37, P318
   DICKINSON RB, 1995, INFECT IMMUN, V63, P3143
   FABRIZIUSHOMAN DJ, 1991, J BIOMED MATER RES, V25, P953, DOI 10.1002/jbm.820250804
   Gardner P, 1988, Curr Clin Top Infect Dis, V9, P185
   GEORGE R, 1979, J NEUROSURG, V51, P804, DOI 10.3171/jns.1979.51.6.0804
   GOOSEN MFA, 1983, J BIOMED MATER RES, V17, P359, DOI 10.1002/jbm.820170212
   GRINNELL F, 1982, J BIOL CHEM, V257, P4888
   GRISTINA AG, 1987, SCIENCE, V237, P1588, DOI 10.1126/science.3629258
   HERRMANN M, 1991, INFECT IMMUN, V59, P279
   HJERTEN S, 1990, PATHOGENESIS OF WOUND AND BIOMATERIAL-ASSOCIATED INFECTIONS, P245
   KINNEY EV, 1991, J SURG RES, V50, P430, DOI 10.1016/0022-4804(91)90020-M
   LANGLEY JM, 1993, CLIN INFECT DIS, V17, P98, DOI 10.1093/clinids/17.1.98
   LARM O, 1987, THROMB HAEMOSTASIS, V58, P84
   LIANG OD, 1992, INFECT IMMUN, V60, P899
   LJUNGH A, 1995, METHODS ENZYMOLOGY M, P501
   MA XH, 1993, J BIOMED MATER RES, V27, P357, DOI 10.1002/jbm.820270309
   MAKI DG, 1977, NEW ENGL J MED, V296, P1305, DOI 10.1056/NEJM197706092962301
   NILSSON UR, 1993, SCAND J IMMUNOL, V37, P349, DOI 10.1111/j.1365-3083.1993.tb02564.x
   PAULSSON M, 1994, J BIOMED MATER RES, V28, P311, DOI 10.1002/jbm.820280305
   PAULSSON M, 1993, J MED MICROBIOL, V38, P96, DOI 10.1099/00222615-38-2-96
   PAULSSON M, 1993, BIOMATERIALS, V14, P845, DOI 10.1016/0142-9612(93)90006-N
   PITT WG, 1993, BIOMATERIALS, V14, P605, DOI 10.1016/0142-9612(93)90179-6
   PITT WG, 1986, J COLLOID INTERF SCI, V111, P343, DOI 10.1016/0021-9797(86)90039-1
   RAPOZA RJ, 1990, J BIOMED MATER RES, V24, P1263, DOI 10.1002/jbm.820241002
   RENIER D, 1984, J NEUROSURG, V61, P1072, DOI 10.3171/jns.1984.61.6.1072
   RYDEN C, 1983, J BIOL CHEM, V258, P3396
   SCHIERHOLZ J, 1994, BIOMATERIALS, V15, P996, DOI 10.1016/0142-9612(94)90080-9
   SIMBERKOFF MS, 1980, J LAB CLIN MED, V95, P362
   SPANGBERG M, 1990, J CATARACT REFR SURG, V16, P170, DOI 10.1016/S0886-3350(13)80726-2
   Strachan C J, 1991, Eur J Vasc Surg, V5, P627, DOI 10.1016/S0950-821X(05)80896-5
   VAUDAUX P, 1993, J INFECT DIS, V167, P633, DOI 10.1093/infdis/167.3.633
   VOHRA R, 1992, SURGERY, V111, P210
   VUENTO M, 1979, BIOCHEM J, V183, P331, DOI 10.1042/bj1830331
   VULIC I, 1993, J MATER SCI-MATER M, V4, P353, DOI 10.1007/BF00122193
   YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281
   YU J, 1994, BIOMATERIALS, V15, P805, DOI 10.1016/0142-9612(94)90035-3
   YU JL, 1995, J SURG RES, V59, P596, DOI 10.1006/jsre.1995.1210
   ZWAHLEN A, 1982, J INFECT DIS, V145, P635, DOI 10.1093/infdis/145.2.635
NR 46
TC 22
Z9 22
U1 0
U2 0
PU CHAPMAN HALL LTD
PI LONDON
PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8HN
SN 0022-2615
J9 J MED MICROBIOL
JI J. Med. Microbiol.
PD APR
PY 1997
VL 46
IS 4
BP 285
EP 296
DI 10.1099/00222615-46-4-285
PG 12
WC Microbiology
SC Microbiology
GA WQ729
UT WOS:A1997WQ72900004
PM 9128192
OA Bronze
DA 2018-10-19
ER

PT J
AU Guillard, O
   Pineau, A
   Fauconneau, B
   Chobaut, JC
   Desaulty, A
   Angot, A
   LeBorgne, E
   Furon, O
AF Guillard, O
   Pineau, A
   Fauconneau, B
   Chobaut, JC
   Desaulty, A
   Angot, A
   LeBorgne, E
   Furon, O
TI Biological levels of aluminium alter use of aluminium-containing bone
   cement in post-otoneurosurgery
SO JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY
LA English
DT Article
DE aluminium; otoneurosurgery; bone cement; electrothermal atomic
   absorption spectrometry
ID INDUCED NEUROFIBRILLARY DEGENERATION; ALZHEIMERS-DISEASE;
   TRACE-ELEMENTS; ENCEPHALOPATHY; PROTEIN; NEUROPATHOLOGY; ABSORPTION;
   NEURONS; FLUIDS; SERUM
AB Use aluminium-containing biomaterials in otoneurosurgery for reconstitution of bone in contact with cerebrospinal fluid (CSF) also led to cases of encephalopathy and death. We report aluminium (Al) concentrations in the biological fluids of six French patients following use of Al-containing bone cement in otoneurosurgery. In five patients, the mean plasma Al levels (mu g/L) were : 1.20 +/- 0.05 (case 2), 9.20 +/- 0.10 (case 3), 1.00 +/- 0.05 (case 4), 2.80 +/- 0.05 (case 5) and 2.00 +/- 0.05 (case 6). In case 1, Al concentrations were 176 mu g/L in the postauricular CSF accumulation, 34 mu g/L in the pontocerebellar angle and 4 and 6 mu g/L in the lumbar shunt. As a precautionary measure, in the first three cases the biomaterial was removed soon after the intervention, and no increase in plasma or CSF Al was observed. In the other cases, absence of neurobiological symptoms and normal concentrations of Al in plasma led neurosurgeons not to extract this biomaterial. Al assay thus may be considered to be a complementary and at times a decision-generating factor. Care is needed at all stages from sampling through analysis because Al is ubiquitous and factually high results may be clinically misleading. Herein, such considerations are discussed in conjunction with the neurotoxicity of this metal in man. In addition, the authors call for in-depth preliminary trials of these biomaterials in animals prior to introduction on the market.
C1 FAC PHARM NANTES,TOXICOL LAB,F-44000 NANTES,FRANCE.
   JEAN MINJOZ HOSP,DEPT NEUROSURG,F-25030 BESANCON,FRANCE.
   CALMETTE HOSP,DEPT NEUROL,F-59037 LILLE,FRANCE.
   FRENCH MINIST HLTH,F-75350 PARIS 07,FRANCE.
RP Guillard, O (reprint author), JEAN BERNARD HOSP,TOXICOL & BIOCHEM LAB,F-86021 POITIERS,FRANCE.
CR ALFREY AC, 1993, THER DRUG MONIT, V15, P593, DOI 10.1097/00007691-199312000-00025
   ALFREY AC, 1983, ADV CLIN CHEM, V23, P69, DOI 10.1016/S0065-2423(08)60398-4
   ALFREY AC, 1976, NEW ENGL J MED, V294, P184, DOI 10.1056/NEJM197601222940402
   BURGESS E, 1992, AM J MED, V92, P471, DOI 10.1016/0002-9343(92)90742-T
   CANDY JM, 1986, LANCET, V1, P354
   CRAPPER DR, 1973, SCIENCE, V180, P511, DOI 10.1126/science.180.4085.511
   CRAPPER DR, 1973, PHYSIOL BEHAV, V10, P925, DOI 10.1016/0031-9384(73)90063-2
   DEBONI U, 1976, ACTA NEUROPATHOL, V35, P285
   DEBROE ME, 1993, NEPHROL DIAL TRANS S, V1, P1
   DELONCLE R, 1990, NEUROCHEM RES, V15, P1239, DOI 10.1007/BF01208586
   DEVOTO E, 1994, ENVIRON HEALTH PERSP, V102, P940, DOI 10.2307/3431916
   EXLEY C, 1993, FEBS LETT, V324, P293, DOI 10.1016/0014-5793(93)80137-J
   FONCIN JF, 1986, CURRENT PROBLEMS SEN, P202
   *FRENCH MIN HLTH, 1994, 47 FRENCH MIN HLTH
   GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0
   GUILLARD O, 1988, CLIN CHEM, V34, P1603
   GUILLARD O, 1984, ANAL LETT PT B, V17, P1593, DOI 10.1080/00032718408065333
   HANTSON P, 1994, LANCET, V344, P1647, DOI 10.1016/S0140-6736(94)90446-4
   KATSETOS CD, 1990, NEUROPATH APPL NEURO, V16, P511, DOI 10.1111/j.1365-2990.1990.tb01290.x
   KAWAHARA M, 1994, BIOCHEM BIOPH RES CO, V198, P531, DOI 10.1006/bbrc.1994.1078
   KLATZO I, 1965, J NEUROPATH EXP NEUR, V24, P187, DOI 10.1097/00005072-196504000-00002
   KOWALL NW, 1989, NEUROSCIENCE, V29, P329, DOI 10.1016/0306-4522(89)90060-2
   MCCARTHY JT, 1986, AM J CLIN PATHOL, V86, P629
   PERL DP, 1980, SCIENCE, V208, P297, DOI 10.1126/science.7367858
   PINEAU A, 1993, CRIT REV CL LAB SCI, V30, P203, DOI 10.3109/10408369309084668
   RENARD JL, 1994, LANCET, V344, P63, DOI 10.1016/S0140-6736(94)91089-8
   REUSCHE E, 1995, LANCET, V345, P1633, DOI 10.1016/S0140-6736(95)90138-8
   ROUSH W, 1995, SCIENCE, V267, P793, DOI 10.1126/science.7846523
   TAYLOR A, 1986, J ANAL ATOM SPECTROM, V1, P391, DOI 10.1039/ja9860100391
   WEBER JP, 1988, SCI TOTAL ENVIRON, V71, P111, DOI 10.1016/0048-9697(88)90305-1
   WISNIEWSKI HM, 1990, ENVIRON GEOCHEM HLTH, V12, P115, DOI 10.1007/BF01734060
NR 31
TC 2
Z9 2
U1 0
U2 0
PU GUSTAV FISCHER VERLAG
PI JENA
PA VILLENGANG 2, D-07745 JENA, GERMANY
SN 0946-672X
J9 J TRACE ELEM MED BIO
JI J. Trace Elem. Med. Biol.
PD APR
PY 1997
VL 11
IS 1
BP 53
EP 56
DI 10.1016/S0946-672X(97)80011-9
PG 4
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA XA121
UT WOS:A1997XA12100011
PM 9176873
DA 2018-10-19
ER

PT J
AU Buriak, JM
   Ghadiri, MR
AF Buriak, JM
   Ghadiri, MR
TI Self-assembly of peptide based nanotubes
SO MATERIALS SCIENCE & ENGINEERING C-BIOMIMETIC MATERIALS SENSORS AND
   SYSTEMS
LA English
DT Article; Proceedings Paper
CT Bionic Design Workshop
CY MAR 18-19, 1996
CL TSUKUBA, JAPAN
DE cyclic peptide; self-assembly; nanotube; ion channel; covalent capture
ID NANOSCALE TUBULAR ENSEMBLES; CHANNELS; DESIGN
AB The recent advances towards the development of self-assembling peptide based nanotubes are reviewed. The design of this new class of biomaterial is based on the self-assembly of small cyclic peptide subunits. The facile construction of open-ended, hollow nanotubular structures with modifiable external surface characteristics and a hydrophilic interior is made possible with this design. The pore diameter of the nanotubes can be easily modified by simply changing the number of amino acid residues within the cyclic structure. The utility of the nanotubes has been demonstrated with applications such as ion and glucose transport through transmembrane ion channels, and a covalent capture to stabilize kinetically labile cylindrical structures. (C) 1997 Elsevier Science S.A.
C1 Scripps Res Inst, DEPT CHEM & MOL BIOL, LA JOLLA, CA 92037 USA.
   Scripps Res Inst, SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA.
OI Buriak, Jillian/0000-0002-9567-4328
CR ABRAHAMS BF, 1994, NATURE, V369, P727, DOI 10.1038/369727a0
   CHOPRA NG, 1995, SCIENCE, V269, P966, DOI 10.1126/science.269.5226.966
   CLARK TD, 1995, J AM CHEM SOC, V117, P12364, DOI 10.1021/ja00154a051
   CRAM DJ, 1992, NATURE, V356, P29, DOI 10.1038/356029a0
   DESANTIS P, 1974, MACROMOLECULES, V7, P52, DOI 10.1021/ma60037a011
   FREEDMAN DH, 1991, SCIENCE, V254, P1308, DOI 10.1126/science.1962190
   GHADIRI MR, 1993, NATURE, V366, P324, DOI 10.1038/366324a0
   GHADIRI MR, 1995, ADV MATER, V7, P675, DOI 10.1002/adma.19950070718
   GHADIRI MR, 1995, ANGEW CHEM INT EDIT, V34, P93, DOI 10.1002/anie.199500931
   GHADIRI MR, 1994, NATURE, V369, P301, DOI 10.1038/369301a0
   GRANJA JR, 1994, J AM CHEM SOC, V116, P10785, DOI 10.1021/ja00102a054
   HARADA A, 1993, NATURE, V364, P516, DOI 10.1038/364516a0
   Hartgerink JD, 1996, J AM CHEM SOC, V118, P43, DOI 10.1021/ja953070s
   IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0
   KHAZANOVICH N, 1994, J AM CHEM SOC, V116, P6011, DOI 10.1021/ja00092a079
   KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0
   Lehn J.-M., 1995, SUPRAMOLECULAR CHEM
   MAEDA K, 1995, ANGEW CHEM INT EDIT, V34, P1199, DOI 10.1002/anie.199511991
   OZIN GA, 1992, ADV MATER, V4, P612, DOI 10.1002/adma.19920041003
   Stryer L., 1988, BIOCHEMISTRY
   TURTON R, 1995, QUANTUM DOT, P71
   VANNOSTRUM CF, 1994, ANGEW CHEM INT EDIT, V33, P2173, DOI 10.1002/anie.199421731
   WU CG, 1994, SCIENCE, V264, P1757, DOI 10.1126/science.264.5166.1757
   WYLER R, 1993, ANGEW CHEM INT EDIT, V32, P1699, DOI 10.1002/anie.199316991
   YAGHI OM, 1995, ANGEW CHEM INT EDIT, V34, P207, DOI 10.1002/anie.199502071
NR 25
TC 18
Z9 20
U1 2
U2 12
PU ELSEVIER SCIENCE SA LAUSANNE
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0928-4931
J9 MAT SCI ENG C-BIOMIM
JI Mater. Sci. Eng. C-Biomimetic Mater. Sens. Syst.
PD APR
PY 1997
VL 4
IS 4
SI SI
BP 207
EP 212
DI 10.1016/S0928-4931(97)00002-7
PG 6
WC Materials Science, Multidisciplinary
SC Materials Science
GA YD687
UT WOS:A1997YD68700002
DA 2018-10-19
ER

PT J
AU Terada, N
   Bjursten, LM
   Papaloizos, M
   Lundborg, G
AF Terada, N
   Bjursten, LM
   Papaloizos, M
   Lundborg, G
TI Resorbable filament structures as a scaffold for matrix formation and
   axonal growth in bioartificial nerve grafts: Long term observations
SO RESTORATIVE NEUROLOGY AND NEUROSCIENCE
LA English
DT Article
DE nerve regeneration; axonal growth; nerve graft; silicone chamber;
   resorbable filament; biomaterial; axon counting
ID LAMININ-CONTAINING GEL; RAT SCIATIC-NERVE; REGENERATION INVIVO; SILICONE
   CHAMBERS; REPAIR; GUIDES; TUBES
AB Gaps, 10 mm wide, in rat sciatic nerves were bridged by bioartificial nerve grafts consisting of a silicone tube containing seven longitudinally placed synthetic filaments, which were expected to serve as a scaffold for axonal growth. The filaments were made of non-resorbable material (polyamide [Ethilon (R)]) or resorbable material (polydioxanon [PDS (R)], polyglactin [Vicryl (R)] or catgut). The purpose was to study the influence of resorbable materials on axonal regeneration and to choose, in the long term, the best filament material among the four. After 3 and 6 months, histological techniques were used to study the regenerated nerve structure. The total axon number in the nerve segment distal to the silicone chamber was counted in all specimens at 6 months. The histological findings were different depending on the filament materials; all the three resorbable materials showing significantly larger numbers of axons than polyamide (non-resorbable). All materials were covered with several layers of more or less flattened cells. These results indicate that resorbable filaments are superior to non-resorbabIe filaments when used as a scaffold inside a silicone tube, and polyglactin seems ideal for this purpose. (C) 1997 Elsevier Science Ireland Ltd.
C1 MALMO UNIV HOSP, DEPT HAND SURG, S-20502 MALMO, SWEDEN.
   KEIO UNIV, SCH MED, DEPT ORTHOPAED SURG, SHINJUKU KU, TOKYO 160, JAPAN.
   MALMO UNIV HOSP, DEPT EXPT RES, S-20502 MALMO, SWEDEN.
   UNIV ZURICH HOSP, DEPT SURG, DIV HAND PLAST & RECONSTRUCT SURG, CH-8091 ZURICH, SWITZERLAND.
CR DAHLIN LB, 1995, BRAIN RES, V679, P274, DOI 10.1016/0006-8993(95)00249-P
   DAHLIN LB, 1992, SCAND J PLAST RECONS, V26, P121, DOI 10.3109/02844319209016001
   Danielsen N, 1990, Restor Neurol Neurosci, V1, P253, DOI 10.3233/RNN-1990-13412
   DASILVA CF, 1990, BRAZ J MED BIOL RES, V23, P981
   KANJE M, 1988, BRAIN RES, V439, P116, DOI 10.1016/0006-8993(88)91467-9
   LANGONE F, 1995, BIOMATERIALS, V16, P347, DOI 10.1016/0142-9612(95)93851-4
   LINDHOLM D, 1987, NATURE, V330, P658, DOI 10.1038/330658a0
   Longo F M, 1982, Brain Res, V255, P277
   LUNDBORG G, 1991, SCAND J PLAST RECONS, V25, P79, DOI 10.3109/02844319109034927
   LUNDBORG G, 1982, EXP NEUROL, V76, P361, DOI 10.1016/0014-4886(82)90215-1
   LUNDBORG G, 1980, J HAND SURG-AM, V5, P451, DOI 10.1016/S0363-5023(80)80075-X
   Lundborg G, 1996, SCAND J PLAST RECONS, V30, P105, DOI 10.3109/02844319609056391
   LUNDBORG G, 1994, J HAND SURG-BRIT EUR, V19B, P273, DOI 10.1016/0266-7681(94)90068-X
   MACKINNON SE, 1990, PLAST RECONSTR SURG, V85, P419, DOI 10.1097/00006534-199003000-00015
   MADISON R, 1985, EXP NEUROL, V88, P767, DOI 10.1016/0014-4886(85)90087-1
   MADISON RD, 1987, EXP NEUROL, V95, P378, DOI 10.1016/0014-4886(87)90146-4
   TERADA N, IN PRESS J MAT SCI M
   TERADA N, IN PRESS SCAND J PLA
   Wiig M, 1996, J HAND SURG-AM, V21A, P599, DOI 10.1016/S0363-5023(96)80010-4
   WILLIAMS LR, 1985, J COMP NEUROL, V231, P209, DOI 10.1002/cne.902310208
   ZHAO Q, 1993, RESTOR NEUROL NEUROS, V5, P197, DOI 10.3233/RNN-1993-5304
NR 21
TC 20
Z9 20
U1 0
U2 1
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 0922-6028
EI 1878-3627
J9 RESTOR NEUROL NEUROS
JI Restor. Neurol. Neurosci.
PD APR
PY 1997
VL 11
IS 1-2
BP 65
EP 69
PG 5
WC Neurosciences
SC Neurosciences & Neurology
GA XB752
UT WOS:A1997XB75200007
PM 21551529
DA 2018-10-19
ER

PT J
AU LopezLopez, G
   Pascual, A
   Perea, EJ
AF LopezLopez, G
   Pascual, A
   Perea, EJ
TI Production of slime by Staphylococcus epidermidis and adherence to
   biomaterials
SO REVISTA DE MICROBIOLOGIA
LA English
DT Article
DE nosocomial infection; slime; catheter; bacterial adherence; biomaterial
ID COAGULASE-NEGATIVE STAPHYLOCOCCI; INTRAVENOUS CATHETERS; BACTERIAL
   ADHERENCE; INTRAVASCULAR CATHETERS; URINARY CATHETER; MEDICAL DEVICES;
   INVITRO; BIOFILM; SURFACES; RESISTANCE
AB The authors analysed the influence of the production of slime by S. epidermidis on the adherence to the biomaterials polivinylchloride (PVC), siliconised lates (LTX), teflon(R) (TFN), poliurethane (PUT) and vialon(R) (VLN). Sir; strains of S. epidermidis were compared, three slime producing and three not. With respect to PVC, LTX, PUT and VLN no significant difference between the two types of strains was noted. Teflon(R) on the other hand permitted atl even greater amount of adherence of slime producing strains. All biomaterials and especially teflon(R), which generally presents low ratios of adherence for S. epidermidis, demonstrated higher levels of adherence of slime producing strains and have a greater potential for pathogenicity. The influence of production of slime by S. epidermidis on their adherence to plastic biomaterials, in vivo, should be better studied. The clinical and laboratorial evidences suggest that S. epidermidis isolated from patients using medical devices should be tested for their capacity to produce slime since this information can help in establishing the virulence of the organism and thus orient therapeutic measures.
RP LopezLopez, G (reprint author), FAC MED PETROPOLIS, DEPT MED, RUA MACHADO FAGUNDES 326, BR-25716000 PETROPOLIS, RJ, BRAZIL.
OI Pascual Hernandez, Alvaro/0000-0002-8672-5891
CR ARIZONO T, 1992, ACTA ORTHOP SCAND, V63, P661
   ASHKENAZI S, 1984, PEDIATR RES, V18, P1361, DOI 10.1203/00006450-198412000-00029
   BAYSTON R, 1983, J CLIN PATHOL, V36, P987, DOI 10.1136/jcp.36.9.987
   BENNETT JV, 1979, HOSP INFECT
   CHRISTENSEN GD, 1982, INFECT IMMUN, V37, P318
   CHRISTENSEN GD, 1985, J CLIN MICROBIOL, V22, P996
   DUNNE WM, 1986, CLIN MICROBIOL NEWS, V8, P37
   EVANS RC, 1987, ANTIMICROB AGENTS CH, V31, P889, DOI 10.1128/AAC.31.6.889
   FLEER A, 1986, AM J MED, V80, P161, DOI 10.1016/0002-9343(86)90495-X
   Fleer A, 1990, J Biomater Appl, V5, P154, DOI 10.1177/088532829000500205
   GOLDMAN DA, 1993, CLIN MICROBIOL REV, P176
   GOLDMANN DA, 1990, AM J INFECT CONTROL, V18, P211, DOI 10.1016/0196-6553(90)90187-W
   HOLMES CJ, 1986, PERITON DIALYSIS INT, V6, P168
   ISHAK MA, 1985, J CLIN MICROBIOL, V22, P1025
   KARCHMER AW, 1983, ANN INTERN MED, V98, P447, DOI 10.7326/0003-4819-98-4-447
   Koike N, 1990, Kansenshogaku Zasshi, V64, P1542
   LOPEZLOPEZ G, 1990, EUR J CLIN MICROBIOL, V9, P324
   LOPEZLOPEZ G, 1991, DIAGN MICR INFEC DIS, V14, P1, DOI 10.1016/0732-8893(91)90078-T
   LOPEZLOPEZ G, 1991, J MED MICROBIOL, V34, P349, DOI 10.1099/00222615-34-6-349
   LOPEZLOPEZ G, 1989, THESIS UFRJ
   MAKI DG, 1981, AM J MED, V70, P719, DOI 10.1016/0002-9343(81)90603-3
   MAKI DG, 1981, HDB HOSPITAL ACQUIRE, P371
   MARRIE TJ, 1983, ARCH INTERN MED, V143, P1135, DOI 10.1001/archinte.143.6.1135
   NICKEL JC, 1985, ANTIMICROB AGENTS CH, V27, P619, DOI 10.1128/AAC.27.4.619
   PASCUAL A, 1986, EUR J CLIN MICROBIOL, V5, P518, DOI 10.1007/BF02017694
   PETERS G, 1982, J INFECT DIS, V146, P479, DOI 10.1093/infdis/146.4.479
   PROSSER BL, 1987, ANTIMICROB AGENTS CH, V31, P1502, DOI 10.1128/AAC.31.10.1502
   RAMOS ERA, 1992, THESIS FACULTAD MED
   SANDERS RA, 1976, AM J SURG, V132, P214, DOI 10.1016/0002-9610(76)90050-7
   SHETH NK, 1985, LANCET, V2, P1266
   SHETH NK, 1983, J SURG RES, V34, P213, DOI 10.1016/0022-4804(83)90062-8
   SOTTILE FD, 1986, CRIT CARE MED, V14, P265, DOI 10.1097/00003246-198604000-00001
   STAMM WE, 1978, ANN INTERN MED, V89, P764, DOI 10.7326/0003-4819-89-5-764
   TENNEY JH, 1986, ARCH INTERN MED, V146, P1949, DOI 10.1001/archinte.146.10.1949
NR 34
TC 0
Z9 0
U1 0
U2 1
PU SOC BRASILEIRA MICROBIOLOGIA
PI SAO PAULO
PA AV PROF LINEU PRESTES,1374, 05508 SAO PAULO, BRAZIL
SN 0001-3714
J9 REV MICROBIOL
JI Rev. Microbiol.
PD APR-JUN
PY 1997
VL 28
IS 2
BP 76
EP 81
PG 6
WC Microbiology
SC Microbiology
GA XU759
UT WOS:A1997XU75900002
DA 2018-10-19
ER

PT J
AU Green, SM
   Grant, DM
   Wood, JV
AF Green, SM
   Grant, DM
   Wood, JV
TI XPS characterisation of surface modified Ni-Ti shape memory alloy
SO MATERIALS SCIENCE AND ENGINEERING A-STRUCTURAL MATERIALS PROPERTIES
   MICROSTRUCTURE AND PROCESSING
LA English
DT Article
DE shape memory alloys; x-ray photoelectron spectroscopy; amorphisation
ID CRYSTAL; OXYGEN
AB Ni-Ti shape memory alloy has been surface amorphised by N+ ion implantation and by controlled shot peening in order to improve surface mechanical properties. X-ray photoelectron spectroscopy (XPS) and surface wetting measurements have been used to characterise the surface modified Ni-Ti to provide a fuller understanding of the biomaterial potential of such a material. The results of this study show that both the modified and unmodified Ni-Ti surfaces were predominantly covered with TiO2 and the under-lying substrate crystallography determined both the affinity for surface OH-/chemisorbed water and ultimately the wetting behaviour of distilled water. Additionally, N+ ion implanted Ni-Ti contained a TIN phase within the surface which reduced wetting, demonstrating a reduced interfacial energy. The surface concentrations of Ni were unaffected by the surface modifications, with all samples containing less than 3 at.% Ni. This study has shown that the surface TiO2 oxide layer was maintained despite the surface amorphisation treatments. It can be assumed that the TiO2 layer is almost identical in unimplanted and implanted surfaces and they will display the same biocompatibility. (C) 1997 Elsevier Science S.A.
RP Green, SM (reprint author), UNIV NOTTINGHAM,DEPT MAT ENGN & MAT DESIGN,UNIV PK,NOTTINGHAM NG7 2RD,ENGLAND.
OI Grant, David/0000-0002-6786-7720; green, sarah/0000-0002-8392-8159
CR ABIKO Y, 1994, P 1 INT C SHAP MEM S
   BRIGGS D, PRACTICAL SURFACE AN
   CUSCHIERI A, 1991, SURG ENDOSC-ULTRAS, V5, P179, DOI 10.1007/BF02653258
   ENDO K, 1994, P 1 INT C SHAP MEM S, P197
   GRANT DM, 1994, ACTA METALL, V43, P1045
   GREEN SM, 1993, J MATER SCI LETT, V12, P618, DOI 10.1007/BF00465570
   GREEN SM, 1995, THESIS U NOTTINGHAM
   JOHNSON WL, 1986, PROG MATER SCI, V30, P81, DOI 10.1016/0079-6425(86)90005-8
   MCBREEN PH, 1987, SURF SCI, V179, P483, DOI 10.1016/0039-6028(87)90071-9
   MENG LJ, 1994, THIN SOLID FILMS, V239, P117, DOI 10.1016/0040-6090(94)90117-1
   OSHIDA Y, 1993, J MATER SCI-MATER M, V4, P443, DOI 10.1007/BF00120123
   OTSUKA K, 1971, PHYS STATUS SOLIDI A, V5, P457, DOI 10.1002/pssa.2210050220
   PAN JM, 1992, J VAC SCI TECHNOL A, V10, P2470, DOI 10.1116/1.577986
   PELTON AR, 1994, P 1 INT C SHAP MEM S
   POPOOLA O, 1987, ACTA METALL, V37, P867
   ROBERTS MW, 1978, CHEM METAL GAS INTER, P26
   Shabalovskaya S., 1994, P 1 INT C SHAP MEM S, P209
   SHIRKHANZADEH M, 1995, J MATER SCI-MATER M, V6, P206, DOI 10.1007/BF00146857
   TIETZE H, 1984, J PHYS D APPL PHYS, V17, P1391, DOI 10.1088/0022-3727/17/7/013
   TRAPNELL BMW, 1953, PROC R SOC LON SER-A, V218, P566, DOI 10.1098/rspa.1953.0125
   WEAST RC, 1982, CRC HDB CHEM PHYS, P36
NR 21
TC 67
Z9 70
U1 0
U2 16
PU ELSEVIER SCIENCE SA LAUSANNE
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0921-5093
J9 MAT SCI ENG A-STRUCT
JI Mater. Sci. Eng. A-Struct. Mater. Prop. Microstruct. Process.
PD MAR 31
PY 1997
VL 224
IS 1-2
BP 21
EP 26
DI 10.1016/S0921-5093(96)10563-3
PG 6
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Metallurgy & Metallurgical Engineering
SC Science & Technology - Other Topics; Materials Science; Metallurgy &
   Metallurgical Engineering
GA XB337
UT WOS:A1997XB33700003
DA 2018-10-19
ER

PT J
AU Skarja, GA
   KinloughRathbone, RL
   Perry, DW
   Rubens, FD
   Brash, JL
AF Skarja, GA
   KinloughRathbone, RL
   Perry, DW
   Rubens, FD
   Brash, JL
TI Cone-and-plate device for the investigation of platelet biomaterial
   interactions
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
ID LAMINAR SHEAR-FLOW; ARTIFICIAL SURFACE; FOREIGN SURFACE; WHOLE-BLOOD;
   AGGREGATION; ADHESION; THROMBOSIS; COLLAGEN; STRESS; SUBCOMMITTEE
AB A device based on the cone-and-plate flow geometry commonly employed for viscometry was developed for the investigation of cell-surface interactions. The cone-and-plate geometry is capable of generating uniform, constant shear-rate flow fields, and control of cone rotational speed allows for easy variation of fluid shear rate. The current design is adapted for use with any material that is available in the form of a flat plate (film or coating). It also allows for replicate samples (the same or different surfaces) to be evaluated simultaneously The device was tested under varying flow conditions for its ability to measure platelet adhesion from suspensions of washed platelets containing red cells. Collagen- and albumin-coated polymer materials were used as ''standard'' surfaces of known platelet reactivity (high and low, respectively). Adhesion to the collagen-coated surface was measured over a range of shear rate from 0 to 300 s(-1) and times up to 15 min. Platelet adhesion was observed to increase with increasing shear rate and time. Adhesion was significantly higher in the presence of red cells as has been observed by others. Effective platelet diffusion coefficients, calculated from the data on adhesion to the collagen surface, increased with increasing shear rate. Very little platelet adhesion to the albumin-coated surface, known to be unreactive to platelets, was observed when measured over a 15 min time period at 300 s(-1) shear rate, indicating that the device itself does not stimulate the platelets in the flow field. The data generated provide validation for this device as a simple means of measuring cell adhesion under controlled flow conditions to any smooth surface available in flat plate form. (C) 1997 John Wiley & Sons, Inc.
C1 MCMASTER UNIV, DEPT CHEM ENGN, HAMILTON, ON L8S 4L7, CANADA.
   MCMASTER UNIV, DEPT PATHOL, HAMILTON, ON L8S 4L7, CANADA.
CR ALKHAMIS TM, 1994, J BIOMAT SCI-POLYM E, V6, P343
   ALKHAMIS TM, 1993, BIOMATERIALS, V14, P865, DOI 10.1016/0142-9612(93)90009-Q
   ALKHAMIS TM, 1990, BLOOD, V75, P1568
   AMIJI M, 1992, J BIOMAT SCI-POLYM E, V3, P375, DOI 10.1163/156856292X00196
   BARNHART MI, 1972, ANN NY ACAD SCI, V201, P360, DOI 10.1111/j.1749-6632.1972.tb16311.x
   BELVAL T, 1984, MICROVASC RES, V28, P279, DOI 10.1016/0026-2862(84)90001-3
   CAZENAVE JP, 1979, J LAB CLIN MED, V93, P60
   CAZENAVE JP, 1973, J LAB CLIN MED, V82, P978
   DEWEY CF, 1981, J BIOMECH ENG-T ASME, V103, P177, DOI 10.1115/1.3138276
   DOSNE AM, 1976, MICROVASC RES, V11, P111, DOI 10.1016/0026-2862(76)90082-0
   FEUERSTEIN IA, 1975, T AM SOC ART INT ORG, V21, P427
   Fewell M. E., 1977, Transactions of the Society of Rheology, V21, P535
   FUJIMURA A, 1992, LIFE SCI, V50, P1043, DOI 10.1016/0024-3205(92)90099-B
   FUKUYAMA M, 1989, THROMB RES, V54, P253, DOI 10.1016/0049-3848(89)90233-8
   GOLDSMITH HL, 1986, THROMB HAEMOSTASIS, V55, P415
   GRABOWSKI EF, 1972, IND ENG CHEM FUND, V11, P224, DOI 10.1021/i160042a013
   HANSON SR, 1980, J LAB CLIN MED, V95, P289
   HEUSER G, 1979, RHEOL ACTA, V18, P553, DOI 10.1007/BF01520351
   HOPPMANN WH, 1963, T SOC RHEOL, V7, P181, DOI 10.1122/1.548953
   HOU TH, 1981, RHEOL ACTA, V20, P14, DOI 10.1007/BF01517468
   IP WF, 1991, J BIOMED MATER RES, V25, P875, DOI 10.1002/jbm.820250707
   KING MJ, 1970, RHEOL ACTA, V9, P164
   KINLOUGHRATHBONE RL, 1977, THROMB HAEMOSTASIS, V37, P291
   MOLNAR J, 1961, ARCH BIOCHEM BIOPHYS, V93, P353, DOI 10.1016/0003-9861(61)90278-8
   MULVIHILL JN, 1990, J BIOMED MATER RES, V24, P155, DOI 10.1002/jbm.820240203
   MUSTARD JF, 1972, BRIT J HAEMATOL, V22, P193, DOI 10.1111/j.1365-2141.1972.tb08800.x
   NIEVELSTEIN PFEM, 1988, ARTERIOSCLEROSIS, V8, P200, DOI 10.1161/01.ATV.8.2.200
   OKKEMA AZ, 1991, BIOMATERIALS, V12, P668, DOI 10.1016/0142-9612(91)90115-Q
   PACKHAM MA, 1969, J LAB CLIN MED, V73, P686
   PARK K, 1990, BIOMATERIALS, V11, P24, DOI 10.1016/0142-9612(90)90047-T
   SAKARIASSEN KS, 1989, METHOD ENZYMOL, V169, P37
   SAKARIASSEN KS, 1990, ARTERIOSCLEROSIS, V10, P276, DOI 10.1161/01.ATV.10.2.276
   SCHMIDSCHONBEIN H, 1969, J APPL PHYSIOL, V26, P674
   SLACK SM, 1994, THROMB HAEMOSTASIS, V72, P777
   TAKAHARA A, 1991, J BIOMED MATER RES, V25, P1095, DOI 10.1002/jbm.820250905
   THAKUR ML, 1976, THROMB RES, V9, P345, DOI 10.1016/0049-3848(76)90135-3
   TURIAN RM, 1972, IND ENG CHEM FUND, V11, P361, DOI 10.1021/i160043a014
   TURITTO VT, 1979, MICROVASC RES, V17, P38, DOI 10.1016/0026-2862(79)90006-2
   WALTERS K, 1975, RHEOMETRY
   WHICHER SJ, 1980, T AM SOC ART INT ORG, V26, P268
   YUNG W, 1982, THROMB RES, V28, P361, DOI 10.1016/0049-3848(82)90118-9
   ZIJENAH LS, 1990, BIOCHEM J, V268, P481, DOI 10.1042/bj2680481
NR 42
TC 52
Z9 52
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD MAR 15
PY 1997
VL 34
IS 4
BP 427
EP 438
DI 10.1002/(SICI)1097-4636(19970315)34:4<427::AID-JBM4>3.3.CO;2-R
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA WL332
UT WOS:A1997WL33200004
PM 9054527
DA 2018-10-19
ER

PT J
AU Salzmann, DL
   Kleinert, LB
   Berman, SS
   Williams, SK
AF Salzmann, DL
   Kleinert, LB
   Berman, SS
   Williams, SK
TI The effects of porosity on endothelialization of ePTFE implanted in
   subcutaneous and adipose tissue
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
ID POLYTETRAFLUOROETHYLENE ARTERIAL GRAFTS; PTFE PROSTHESES; MECHANISMS;
   CELLS; PROLIFERATION; ENDOTHELIUM; MUSCLE
AB Healing of biomaterial implants varies depending on the type and structure of material and the tissue surrounding the implant. In this study we examined structural differences of 30 mu m, 60 mu m and 100 mu m expanded polytetra-fluoroethylene (ePTFE) using scanning electron microscopy, and we also investigated differences in healing for these three different porosity ePTFE grafts implanted within subcutaneous tissue and adipose tissue. Scanning electron microscopic examination of 30 mu m, 60 mu m, and 100 mu m ePTFE revealed structural differences and differences in fiber density within the internodal space. Circular patches (6 mm in diameter) of 30 mu m ePTFE were implanted within subcutaneous tissue and epididymal fat pads of male Sprague-Dawley rats. After 5 weeks, the implants were removed and analyzed for fibrous capsule formation, endothelialization, and for activated monocytes and macrophages in association with the material. Histological evaluation revealed dense fibrous capsule formation surrounding only the 30 mu m ePTFE subcutaneous implants. From immunohistochemistry data obtained, we generated an Endothelialization Index (measure of neovascularization) and a Monocyte/Macrophage Index (measure of inflammatory response) for each sample. Consistently, 69 mu m ePTFE had the greatest Endothelialization Index at both implant sites while 100 mu m ePTFE generally had the largest values for the Monocyte/Macrophage Index. These data indicate that both the structure of the material and the site of implant influence the healing characteristics of ePTFE and suggest that activated monocytes and/or macrophages associated with the implant may inhibit endothelialization of ePTFE. (C) 1997 John Wiley & Sons, Inc.
C1 UNIV ARIZONA, ARIZONA HLTH SCI CTR, DEPT SURG, SECT SURG RES, TUCSON, AZ 85724 USA.
CR BOSARI S, 1992, HUM PATHOL, V23, P755, DOI 10.1016/0046-8177(92)90344-3
   CLOWES AW, 1987, AM J SURG, V153, P501, DOI 10.1016/0002-9610(87)90802-6
   CLOWES AW, 1985, AM J PATHOL, V118, P43
   CLOWES AW, 1986, AM J PATHOL, V123, P220
   DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589
   GOLDEN MA, 1990, J VASC SURG, V11, P838, DOI 10.1067/mva.1990.18047
   HANSENSMITH F, 1992, MICROVASC RES, V44, P112, DOI 10.1016/0026-2862(92)90105-X
   HANSENSMITH FM, 1995, AM J PHYSIOL, V257, pH344
   HERRING M, 1978, SURGERY, V84, P498
   HIRABAYASHI K, 1992, J BIOMED MATER RES, V26, P1433, DOI 10.1002/jbm.820261104
   KOBAYASHI S, 1994, IMMUNOPHARMACOLOGY, V27, P23, DOI 10.1016/0162-3109(94)90004-3
   KOHLER TR, 1992, SURGERY, V112, P901
   Lansdown A B, 1995, ASAIO J, V41, P202
   LI VW, 1994, LANCET, V344, P82, DOI 10.1016/S0140-6736(94)91280-7
   MATHISEN SR, 1986, ANN SURG, V203, P382, DOI 10.1097/00000658-198604000-00008
   POLVERINI PJ, 1977, NATURE, V269, P804, DOI 10.1038/269804a0
   RUPNICK MA, 1989, J VASC SURG, V9, P788, DOI 10.1067/mva.1989.vs0090788
   SCHREUDERS PD, 1988, J BIOMED MATER RES, V22, P121, DOI 10.1002/jbm.820220205
   STERPETTI AV, 1992, SURGERY, V111, P677
   Williams S K, 1989, Ann Vasc Surg, V3, P146, DOI 10.1016/S0890-5096(06)62008-6
   ZACHARIAS RK, 1987, J VASC SURG, V6, P429, DOI 10.1067/mva.1987.avs0060429
   ZIATS NP, 1988, BIOMATERIALS, V9, P5, DOI 10.1016/0142-9612(88)90063-4
NR 22
TC 47
Z9 47
U1 3
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD MAR 15
PY 1997
VL 34
IS 4
BP 463
EP 476
DI 10.1002/(SICI)1097-4636(19970315)34:4<463::AID-JBM7>3.0.CO;2-I
PG 14
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA WL332
UT WOS:A1997WL33200007
PM 9054530
DA 2018-10-19
ER

PT J
AU Dunn, MG
   Bellincampi, LD
   Tria, AJ
   Zawadsky, JP
AF Dunn, MG
   Bellincampi, LD
   Tria, AJ
   Zawadsky, JP
TI Preliminary development of a collagen-PLA composite for ACL
   reconstruction
SO JOURNAL OF APPLIED POLYMER SCIENCE
LA English
DT Article
DE anterior cruciate ligament; collagen fibers; poly(lactic acid); tissue
   engineering; biomaterial; composite; scaffolds
ID LIGAMENT RECONSTRUCTION; FIBERS; PROSTHESIS
AB Our laboratory is developing resorbable composite implants for reconstruction of the anterior cruciate ligament (ACL) of the knee. Composites were fabricated by embedding parallel collagen fibers within a poly(lactic acid) (PLA) or collagen matrix. The mechanical properties, resorption rates, and subcutaneous tissue reactions were determined for both types of composites. The tensile strength and modulus of collagen-PLA composites were twice that of collagen-collagen composites. Subcutaneous fibrous tissue ingrowth was improved and implant resorption was slightly delayed in the collagen-PLA composites. ACL reconstruction surgeries were performed in rabbits using collagen-PLA composite implants. After 4 weeks, neoligament tissue was observed in seven of eight implants; however, four neoligaments had ruptured either in the midsubstance (n = 2) or at the bone tunnel interface (n = 2). These results and our previous work suggest that resorbable polymeric composite scaffolds are potentially useful for ACL reconstruction if the implants can be protected from excessive mechanical loading during formation of host neoligament tissue. (C) 1997 John Wiley & Sons, Inc.
C1 UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,ORTHOPAED RES LAB,DIV ORTHOPAED SURG,NEW BRUNSWICK,NJ 08903.
CR CABAUD HE, 1982, AM J SPORT MED, V10, P259, DOI 10.1177/036354658201000501
   DUNN MG, 1995, J BIOMED MATER RES, V29, P1363, DOI 10.1002/jbm.820291107
   DUNN MG, 1992, AM J SPORT MED, V20, P507, DOI 10.1177/036354659202000504
   DUNN MG, 1994, J ORTHOPAED RES, V12, P128, DOI 10.1002/jor.1100120116
   DUNN MG, 1993, J BIOMED MATER RES, V27, P1545, DOI 10.1002/jbm.820271211
   DUNN MG, 1995, LIGAMENTS KNEE, pCH13
   DUNN MG, 1994, IMPLANTATION BIOL HO, pCH13
   *DUP CO, 1989, MED BIOR POLYM PROP
   HEFTI FL, 1991, J BONE JOINT SURG AM, V73A, P373, DOI 10.2106/00004623-199173030-00008
   KATO YP, 1991, J BONE JOINT SURG AM, V73A, P561, DOI 10.2106/00004623-199173040-00013
   LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529
   National Institute of Health, 1985, NIH PUBLICATION, V85-23
   NOYES FR, 1984, J BONE JOINT SURG AM, V66A, P344, DOI 10.2106/00004623-198466030-00005
   SHIEH SJ, 1990, J BIOMED MATER RES, V24, P789, DOI 10.1002/jbm.820240702
   SUGANUMA J, 1993, J APPL BIOMATER, V4, P13, DOI 10.1002/jab.770040103
   VERT M, 1992, J MATER SCI-MATER M, V3, P432, DOI 10.1007/BF00701240
   WASSERMAN AJ, 1989, SCANNING MICROSCOPY, V3, P1183
   WEADOCK K, 1983, BIOMATER ARTIF CELL, V11, P293, DOI 10.3109/10731198309118815
   WEADOCK KS, 1995, J BIOMED MATER RES, V29, P1373, DOI 10.1002/jbm.820291108
   Weadock KS, 1996, J BIOMED MATER RES, V32, P221, DOI 10.1002/(SICI)1097-4636(199610)32:2<221::AID-JBM11>3.0.CO;2-M
NR 20
TC 59
Z9 60
U1 2
U2 15
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-8995
J9 J APPL POLYM SCI
JI J. Appl. Polym. Sci.
PD MAR 14
PY 1997
VL 63
IS 11
BP 1423
EP 1428
DI 10.1002/(SICI)1097-4628(19970314)63:11<1423::AID-APP4>3.0.CO;2-O
PG 6
WC Polymer Science
SC Polymer Science
GA WH586
UT WOS:A1997WH58600005
DA 2018-10-19
ER

PT J
AU Tangpasuthadol, V
   Shefer, A
   Yu, C
   Zhou, J
   Kohn, J
AF Tangpasuthadol, V
   Shefer, A
   Yu, C
   Zhou, J
   Kohn, J
TI Thermal properties and enthalpy relaxation of tyrosine-derived
   polyarylates
SO JOURNAL OF APPLIED POLYMER SCIENCE
LA English
DT Article
DE physical aging; enthalpy relaxation; glass transition temperature;
   differential scanning calorimetry; tyrosine; biomaterial; biopolymer;
   structure-property correlation
ID GLASS-TRANSITION TEMPERATURE; POLYVINYL METHYL-ETHER); AGING
   TEMPERATURE; DESIGN
AB Sixteen degradable, tyrosine-derived polyarylates with well-defined chemical structures were used to study the effect of polymer structure on the glass transition temperature and enthalpy relaxation kinetics (physical aging). These polyarylates compose a model system where the number of methylene groups present in either the pendent chain or the polymer backbone can be altered independently and in a systematic fashion. Quantitative differential scanning calorimetry was employed to measure the glass transition temperature and the enthalpy relaxation kinetics. Correlations between these material properties and the polymer structure were established. The glass transition temperature of this family of polymers ranged from 13 to 78 degrees C. The addition of methylene groups to either the pendent chain or the polymer backbone made a fairly constant contribution to lowering the glass transition temperature. The rate of enthalpy relaxation increased with an increasing number of methylene groups in the polymer backbone, but was independent of the number of methylene groups in the pendent chain. This observation indicated that the rate of enthalpy relaxation in these polymers was limited by the mobility of the polymer backbone. The enthalpy relaxation data was fitted to the Cowie-Ferguson model and the relaxation times obtained ranged from 44 min to about 100 min. Although these structure-property correlations facilitate the design of new materials with predictable thermal properties, they are rarely investigated for biomedical polymers. (C) 1997 John Wiley & Sons, Inc.
C1 RUTGERS STATE UNIV,DEPT CHEM,NEW BRUNSWICK,NJ 08903.
RI Tangpasuthadol, Varawut/F-9260-2010
CR BAUWENSCROWET C, 1986, POLYMER, V27, P709, DOI 10.1016/0032-3861(86)90128-X
   BROCCHINI S, 1996, POLYM MAT ENCY
   BRON S, 1993, POLYM MAT SCI ENG, V69, P37
   CAI H, 1995, POLYM PREPR, V36, P422
   CELLI A, 1992, POLYMER, V33, P2699, DOI 10.1016/0032-3861(92)90440-8
   CHENG SZD, 1991, POLYMER, V32, P2053, DOI 10.1016/0032-3861(91)90172-F
   CLARSON SJ, 1985, POLYMER, V26, P930, DOI 10.1016/0032-3861(85)90140-5
   COWIE JMG, 1986, POLYM COMMUN, V27, P258
   COWIE JMG, 1989, MACROMOLECULES, V22, P2312, DOI 10.1021/ma00195a054
   COWIE JMG, 1989, MACROMOLECULES, V22, P2307, DOI 10.1021/ma00195a053
   DIX LR, 1993, TRENDS POLYM SCI, V1, P25
   FIORDELISO J, 1994, J BIOMAT SCI-POLYM E, V5, P497
   FIORDELISO J, 1993, THESIS RUTGERS U
   JAMES K, 1996, CONTROLLED DRUG DELI
   KOHN J, 1994, 20 ANN M SOC BIOM BO, P67
   KOHN J, 1993, TRENDS POLYM SCI, V1, P206
   KOHN JB, 1993, Patent No. 5216115
   MONTSERRAT S, 1994, J POLYM SCI POL PHYS, V32, P509, DOI 10.1002/polb.1994.090320312
   PETHRICK RA, 1993, TRENDS POLYM SCI, V1, P226
   SCHERER GW, 1986, RELAXATION GLASS COM, P51
   SHEFER A, 1992, MACROMOLECULES, V25, P4036, DOI 10.1021/ma00041a028
   STRUIK LCE, 1978, PHYSICAL AGING AMORP
   TANGPASUTHADOL V, 1996, BIOMATERIALS, V17, P465
   YOSHIDA H, 1982, J MACROMOL SCI PHYS, VB21, P565, DOI 10.1080/00222348208215191
   ZHOU J, 1994, 20 ANN M SOC BIOM BO, P371
NR 25
TC 11
Z9 11
U1 0
U2 1
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-8995
J9 J APPL POLYM SCI
JI J. Appl. Polym. Sci.
PD MAR 14
PY 1997
VL 63
IS 11
BP 1441
EP 1448
PG 8
WC Polymer Science
SC Polymer Science
GA WH586
UT WOS:A1997WH58600007
DA 2018-10-19
ER

PT J
AU Suarez, N
   Laredo, E
   Bello, A
   Kohn, J
AF Suarez, N
   Laredo, E
   Bello, A
   Kohn, J
TI Molecular relaxation mechanisms of tyrosine-derived polycarbonates by
   thermally stimulated depolarization currents
SO JOURNAL OF APPLIED POLYMER SCIENCE
LA English
DT Article
DE polycarbonates; tyrosine; dielectric relaxations; TSDC; glass
   transition; biomaterial
ID PSEUDO-POLY(AMINO ACIDS); POLYMERS
AB A series of tyrosine-derived polycarbonates with different lengths (2 less than or equal to n less than or equal to 8) for the alkyl ester pendent chain were studied by measuring thermally stimulated depolarization currents (TSDC). The observed spectra could be separated into three regions: the low-temperature zone with a broad, complex beta band (80-240 K), the intermediate zone (250-300 K), and the high-temperature zone (300-400 K) with a sharp a peak. The application of direct signal analysis (DSA) to decompose the complex peaks into elementary processes led to the determination of the relaxation time distribution and temperature dependence of each process. The variation of the relaxation parameters as a function of the pendent chain length facilitated the tentative identification of the relaxation mechanisms responsible for the observed current peaks. It is proposed that as the temperature increases one observes, first, the individual motion of each polar group, then the concerted motion of the entire pendent chain, and, last, the movement of the polymer backbone. (C) 1997 John Wiley & Sons, Inc.
C1 RUTGERS STATE UNIV,DEPT CHEM,NEW BRUNSWICK,NJ 08903.
   UNIV SIMON BOLIVAR,DEPT PHYS,CARACAS,VENEZUELA.
RI Laredo, Estrella/A-1776-2008
CR ADAM G, 1965, J CHEM PHYS, V43, P139, DOI 10.1063/1.1696442
   ALDANA M, 1994, J POLYM SCI POL PHYS, V32, P2197, DOI 10.1002/polb.1994.090321307
   AOKI Y, 1976, J APPL POLYM SCI, V20, P2879, DOI 10.1002/app.1976.070201022
   Choueka J, 1996, J BIOMED MATER RES, V31, P35, DOI 10.1002/(SICI)1097-4636(199605)31:1<35::AID-JBM5>3.0.CO;2-R
   COFFEY D, 1992, S POLYM DEL SYST
   DONG Z, 1993, THESIS RUTGERS U
   ERTEL SI, 1994, J BIOMED MATER RES, V28, P919, DOI 10.1002/jbm.820280811
   ERTEL SI, 1995, J BIOMED MATER RES, V29, P1337, DOI 10.1002/jbm.820291105
   KOHN J, 1993, TRENDS POLYM SCI, V1, P206
   Laredo E, 1996, J POLYM SCI POL PHYS, V34, P641, DOI 10.1002/(SICI)1099-0488(199603)34:4<641::AID-POLB4>3.0.CO;2-T
   LAREDO E, 1995, ANN REPORT IEEE C EL, P432
   LAREDO E, 1993, MATER ENG, V4, P237
   MATSUOKA S, 1966, J POLYM SCI C, V14, P247
   PULAPURA S, 1992, BIOPOLYMERS, V32, P411, DOI 10.1002/bip.360320418
   SAUER BB, 1992, POLYMER, V33, P5128, DOI 10.1016/0032-3861(92)90793-V
   TANABE Y, 1970, POLYM J, V1, P107
   TANGPASUTHADOL V, 1996, BIOMATERIALS, V17, P465
NR 17
TC 11
Z9 11
U1 1
U2 1
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-8995
J9 J APPL POLYM SCI
JI J. Appl. Polym. Sci.
PD MAR 14
PY 1997
VL 63
IS 11
BP 1457
EP 1466
DI 10.1002/(SICI)1097-4628(19970314)63:11<1457::AID-APP8>3.0.CO;2-L
PG 10
WC Polymer Science
SC Polymer Science
GA WH586
UT WOS:A1997WH58600009
DA 2018-10-19
ER

PT J
AU Bellincampi, LD
   Dunn, MG
AF Bellincampi, LD
   Dunn, MG
TI Effect of crosslinking method on collagen fiber-fibroblast interactions
SO JOURNAL OF APPLIED POLYMER SCIENCE
LA English
DT Article
DE collagen fiber; crosslinking; fibroblast; biocompatibility; tissue
   engineering
ID PERFORMANCE LIQUID-CHROMATOGRAPHY; RECONSTRUCTION; DEGRADATION; CULTURE;
   ACL
AB Collagen, the major structural protein of the extracellular matrix in animals, is a versatile biomaterial used in various tissue engineering applications. Crosslinking influences the mechanical properties, resorption kinetics, and biocompatibility of collagen-based biomaterials. In this study, we evaluated the effects of crosslinking on collagen fiber-fibroblast interactions in vitro. Collagen fibers were left untreated or crosslinked by ultraviolet (UV) irradiation, dehydrothermal (DHT) treatment (3 or 5 days), or hexamethylenediisocyanate (HMDIC) exposure. The initial attachment, proliferation (through 8 days), and morphology of human dermal fibroblasts were evaluated on control and crosslinked bundles of 200 collagen fibers in vitro. Initial attachment (number of fibroblasts at day 0) was increased on UV and DHT5-treated collagen fiber bundles. Fibroblast proliferation was similar for control, UV crosslinked, and DHT crosslinked fibers. In contrast, fibroblast attachment was significantly decreased and proliferation was delayed on HMDIC crosslinked fibers. These results, coupled with our previous studies, suggest that UV crosslinking of collagen fibers provides a combination of biocompatibility, mechanical properties, and strength retention suitable for various tissue engineering applications. (C) 1997 John Wiley & Sons, Inc.
C1 UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,ORTHOPAED RES LAB,DIV ORTHOPAED,NEW BRUNSWICK,NJ 08903.
CR CHEN TR, 1977, EXP CELL RES, V104, P255, DOI 10.1016/0014-4827(77)90089-1
   CHVAPIL M, 1993, J BIOMED MATER RES, V27, P313, DOI 10.1002/jbm.820270305
   DAMINK LHHO, 1995, J BIOMED MATER RES, V29, P139, DOI 10.1002/jbm.820290202
   DUNN MG, 1995, J BIOMED MATER RES, V29, P1363, DOI 10.1002/jbm.820291107
   Dunn MG, 1997, J APPL POLYM SCI, V63, P1423, DOI 10.1002/(SICI)1097-4628(19970314)63:11<1423::AID-APP4>3.0.CO;2-O
   DUNN MG, 1992, AM J SPORT MED, V20, P507, DOI 10.1177/036354659202000504
   DUNN MG, 1995, LIGAMENTS KNEE
   FIELDS CG, 1993, J BIOL CHEM, V268, P14153
   HUANGLEE LLH, 1990, J BIOMED MATER RES, V24, P1185, DOI 10.1002/jbm.820240905
   LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529
   MILLER EJ, 1991, ANAL BIOCHEM, V196, P54, DOI 10.1016/0003-2697(91)90116-B
   MILLER EJ, 1990, ANAL BIOCHEM, V190, P92, DOI 10.1016/0003-2697(90)90139-Z
   MIYATA T, 1992, Clinical Materials, V9, P139, DOI 10.1016/0267-6605(92)90093-9
   MORYKWAS MJ, 1990, J BIOMED MATER RES, V24, P1105, DOI 10.1002/jbm.820240812
   NORTON L, 1981, J TRAUMA, V21, P463
   RIVARD CH, 1995, J APPL BIOMATER, V6, P65, DOI 10.1002/jab.770060109
   ROVENSKY YA, 1994, J CELL SCI, V107, P1255
   VANLUYN MJA, 1991, J MATER SCI-MATER M, V2, P142, DOI 10.1007/BF00692972
   WEADOCK KS, 1995, J BIOMED MATER RES, V29, P1373, DOI 10.1002/jbm.820291108
   Weadock KS, 1996, J BIOMED MATER RES, V32, P221, DOI 10.1002/(SICI)1097-4636(199610)32:2<221::AID-JBM11>3.0.CO;2-M
NR 20
TC 23
Z9 24
U1 0
U2 7
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-8995
J9 J APPL POLYM SCI
JI J. Appl. Polym. Sci.
PD MAR 14
PY 1997
VL 63
IS 11
BP 1493
EP 1498
DI 10.1002/(SICI)1097-4628(19970314)63:11<1493::AID-APP11>3.0.CO;2-3
PG 6
WC Polymer Science
SC Polymer Science
GA WH586
UT WOS:A1997WH58600012
DA 2018-10-19
ER

PT J
AU Tanahashi, M
   Matsuda, T
AF Tanahashi, M
   Matsuda, T
TI Surface functional group dependence on apatite formation on
   self-assembled monolayers in a simulated body fluid
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
ID BIOMIMETIC PROCESS; ORGANIC POLYMERS; MINERALIZED TISSUES; GOLD;
   CALCIFICATION; HYDROXYAPATITE; MULTILAYERS; IMPROVEMENT; MECHANISMS;
   SUBSTRATE
AB Self-assembled monolayers (SAMs) of alkanethiols having CH3, PO4H2, COOH, CONH2, OH, and NH2 terminal groups formed on a gold surface via sulfur attachment were soaked in a simulated body fluid (SBF), whose ion concentrations were nearly equal to those of human blood plasma, at 37 degrees C for up to 40 days. The effect of their terminal functional groups on apatite formation was assessed using X-ray photoelectron spectroscopic (XPS) measurement and a quartz crystal microbalance (QCM) technique. The Ca and P atoms were detected, of which element intensities increased with time, on SAMs except for the alkanethiol having the methyl terminal group. The Ca/P atomic ratios of the apatites formed on the SAMs ranged from around 1.0 to around 1.3. The most potent inducer for apatite formation, judged from the growth rate (micrometers per day) calculated from the weight change during QCM measurement, was the SAM of the alkanethiol with the PO4H2 group, followed by that of the alkanethiol with the COOH group. The SAMs of the alkanethiols with the CONH2, OH, and NH2 groups possessed much weaker inducing powers than the former two SAMs. Little weight change was observed for the methyl-group-terminated alkanethiol SAM. The growth rates increased with time, irrespective of the terminal group species among apatite formation-inducing groups. During the experimental observation period, the following relationship held. The growth rate decreased in the order PO4H2 > COOH much greater than CONH2 similar or equal to OH > NH2 much greater than CH3 similar or equal to 0. Since negatively charged groups strongly induced apatite formation but the positively charged group did not, it can be said that the apatite formation initiated via calcium ion-adsorption upon complexation with a negative surface-charged group may be dominant in biomaterial calcification where ionic species directly contact the biomaterial surface in body fluids. (C) 1997 John Wiley & Sons, Inc.
C1 NATL CARDIOVASC CTR,RES INST,DEPT BIOENGN,SUITA,OSAKA 565,JAPAN.
RI Hashimoto, Masami/J-7205-2013; Xu, Qingguo/C-1962-2014
OI Xu, Qingguo/0000-0003-3191-0771
CR BAIN CD, 1989, J AM CHEM SOC, V111, P7155, DOI 10.1021/ja00200a039
   BAIN CD, 1989, J AM CHEM SOC, V111, P321, DOI 10.1021/ja00183a049
   BOSKEY AL, 1977, CALC TISS RES, V23, P251, DOI 10.1007/BF02012794
   BUNKER BC, 1994, SCIENCE, V264, P48, DOI 10.1126/science.264.5155.48
   DALAS E, 1991, LANGMUIR, V7, P1822, DOI 10.1021/la00056a040
   Derek E.G., 1993, SCIENCE, V259, P1439
   FREY BL, 1993, LANGMUIR, V9, P1815, DOI 10.1021/la00031a032
   HAUTMAN J, 1989, J CHEM PHYS, V91, P4994, DOI 10.1063/1.457621
   KISHIMOTO K, 1995, 17 ANN M JAP SOC BIO, P57
   LEE S, 1982, INT J PEPT PROT RES, V16, P231
   LEVY RJ, 1985, SCIENCE, V228, P190, DOI 10.1126/science.3919445
   LINDE A, 1989, CALCIFIED TISSUE INT, V44, P286, DOI 10.1007/BF02553763
   NANCOLLAS GH, 1989, IN VITRO STUDIES CAL, pCH6
   OHTSUKI C, 1992, J NON-CRYST SOLIDS, V143, P84, DOI 10.1016/S0022-3093(05)80556-3
   OKAHATA Y, 1987, J CHEM SOC CHEM COMM, P1363, DOI 10.1039/c39870001363
   PORTER MD, 1987, J AM CHEM SOC, V109, P3559, DOI 10.1021/ja00246a011
   PUTVINSKI TM, 1990, LANGMUIR, V6, P1567, DOI 10.1021/la00100a007
   ROSANOVA IB, 1991, J BIOMED MATER RES, V25, P277, DOI 10.1002/jbm.820250213
   SAITO N, IN PRESS LANGMUIR
   SAUERBREY G, 1959, Z PHYS, V155, P206, DOI 10.1007/BF01337937
   SCHOEN FJ, 1986, AM J PATHOL, V123, P134
   SCHOEN FJ, 1988, J BIOMED MATER RES-A, V22, P11
   SHEEHAN JC, 1950, J AM CHEM SOC, V72, P2786, DOI 10.1021/ja01162a527
   Shumakov V I, 1990, ASAIO Trans, V36, pM181
   SPRINCL L, 1973, CALC TISS RES, V13, P63, DOI 10.1007/BF02015397
   SUH S, 1994, THESIS SEOUL NATL U
   SUZUKI K, 1993, BIOCERAMICS, V6, P245
   TAKEHARA K, 1994, ELECTROCHIM ACTA, V39, P817, DOI 10.1016/0013-4686(93)E0018-H
   TANAHASHI M, 1994, J AM CERAM SOC, V77, P2805, DOI 10.1111/j.1151-2916.1994.tb04508.x
   TANAHASHI M, 1994, J APPL BIOMATER, V5, P339, DOI 10.1002/jab.770050409
   Tanahashi M, 1996, J BIOMED MATER RES, V31, P243, DOI 10.1002/(SICI)1097-4636(199606)31:2<243::AID-JBM11>3.0.CO;2-M
   TANAHASHI M, 1995, J BIOMED MATER RES, V29, P349, DOI 10.1002/jbm.820290310
   TARLOV MJ, 1993, J AM CHEM SOC, V115, P5305, DOI 10.1021/ja00065a056
   TROUGHTON EB, 1988, LANGMUIR, V4, P365, DOI 10.1021/la00080a021
   WEINER S, 1986, CRC CR REV BIOCH MOL, V20, P365, DOI 10.3109/10409238609081998
   WEINER S, 1982, J CHROMATOGR, V245, P148, DOI 10.1016/S0021-9673(00)82489-9
NR 36
TC 495
Z9 511
U1 7
U2 124
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD MAR 5
PY 1997
VL 34
IS 3
BP 305
EP 315
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA WL071
UT WOS:A1997WL07100005
PM 9086400
DA 2018-10-19
ER

PT J
AU Schwartz, LB
   Moawad, J
AF Schwartz, LB
   Moawad, J
TI Gene therapy for vascular disease
SO ANNALS OF VASCULAR SURGERY
LA English
DT Article
ID MUSCLE CELL-PROLIFERATION; MODIFIED ENDOTHELIAL-CELLS; RAT
   CAROTID-ARTERY; IN-VIVO; ADENOVIRAL VECTOR; RECOMBINANT ADENOVIRUS;
   INTIMAL HYPERPLASIA; VEIN GRAFTS; ATHEROSCLEROTIC ARTERIES;
   CARDIOVASCULAR-DISEASE
AB Atherosclerosis is a degenerative process characterized by endothelial cell dysfunction, inflammatory cell adhesion and infiltration, and the accumulation of cellular and matrix elements leading to the formation of fibrocellular plaques. In the end stages, advanced occlusive plaques limit blood flow and oxygen delivery resulting in the well-known ischemic syndromes of the coronary, skeletal muscle, mesenteric, and cerebrovascular circulation. Moreover, sudden critical ischemic events may be precipitated by plaque disturbance, rupture, hemorrhage, and/or thrombosis. Traditional pharmacologic approaches have been effective in reducing serum cholesterol and controlling thrombosis but, in the main, have had little impact on the treatment of advanced lesions. The purpose of this review is to examine the current status of gene therapy for vascular proliferation, aberrant endothelial function, thrombosis, peripheral ischemia, and modification of the blood/biomaterial interface.
RP Schwartz, LB (reprint author), UNIV CHICAGO,DEPT SURG,VASC SURG SECT,MC 5028,5841 S MARYLAND AVE,CHICAGO,IL 60637, USA.
CR ASAHARA T, 1995, CIRCULATION, V91, P2793, DOI 10.1161/01.CIR.91.11.2793
   Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137
   BENNETT MR, 1995, CIRCULATION, V92, P1981, DOI 10.1161/01.CIR.92.7.1981
   BILLIAR TR, 1995, ANN SURG, V221, P339, DOI 10.1097/00000658-199504000-00003
   BILLIAR TR, 1996, J VASC SURG, V24, P159
   BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475
   CALIFF RM, 1991, J AM COLL CARDIOL, V17, pB2
   CALLOW AD, 1990, J VASC SURG, V11, P793, DOI 10.1067/mva.1990.20384
   CHANG MW, 1995, MOL MED, V1, P172, DOI 10.1007/BF03401565
   CHANG MW, 1995, J CLIN INVEST, V96, P2260, DOI 10.1172/JCI118281
   CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950
   CHAPMAN GD, 1992, CIRC RES, V71, P27, DOI 10.1161/01.RES.71.1.27
   CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5
   CHEN SJ, 1994, CIRCULATION, V89, P1922, DOI 10.1161/01.CIR.89.5.1922
   CHIEN KR, 1989, CIRCULATION, V80, P219, DOI 10.1161/01.CIR.80.2.219
   CLOWES AW, 1983, LAB INVEST, V49, P327
   Clowes AW, 1996, CIRCULATION, V93, P1319, DOI 10.1161/01.CIR.93.7.1319
   CLOWES AW, 1993, CARDIOVASC PATHOL, V2, pS179
   CLOWES AW, 1996, J VASC SURG, V24, P158
   COX JL, 1991, PROG CARDIOVASC DIS, V34, P45, DOI 10.1016/0033-0620(91)90019-I
   DEFRANG RD, 1994, BASIC DATA UNDERLYIN, P153
   DICHEK D, 1996, J VASC SURG, V24, P163
   DICHEK DA, 1989, CIRCULATION, V80, P1347, DOI 10.1161/01.CIR.80.5.1347
   DICHEK DA, 1991, BLOOD, V77, P533
   DICKEK DA, 1996, CIRCULATION, V93, P301
   Dunn PF, 1996, CIRCULATION, V93, P1439, DOI 10.1161/01.CIR.93.7.1439
   EBERHART R, 1996, J VASC SURG, V24, P173
   EKHTERAE D, 1995, J VASC SURG, V21, P953, DOI 10.1016/S0741-5214(95)70223-7
   Erickson CA, 1996, J VASC SURG, V23, P18, DOI 10.1016/S0741-5214(05)80031-X
   FINKEL T, 1995, FASEB J, V9, P843
   FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802
   FRENCH BA, 1994, CIRCULATION, V90, P2402, DOI 10.1161/01.CIR.90.5.2402
   GEARY RL, 1994, HUM GENE THER, V5, P1211, DOI 10.1089/hum.1994.5.10-1211
   Gibbons GH, 1996, SCIENCE, V272, P689, DOI 10.1126/science.272.5262.689
   GOLDEN MA, 1996, J VASC SURG, V24, P161
   GOZMAN RJ, 1994, P ANTL ACAD SCI US, V91, P10732
   GRAY BH, 1996, SOC VAS SURG, P66
   Guzman Raul J., 1993, Circulation, V88, P2838
   HERRING M, 1994, J VASC SURG, V20, P650, DOI 10.1016/0741-5214(94)90291-7
   Hollingsworth R E Jr, 1993, Curr Opin Genet Dev, V3, P55, DOI 10.1016/S0959-437X(05)80341-7
   HONGZHI B, 1995, CIRCULATION S1, V92, P642
   Huber TS, 1995, J VASC SURG, V22, P795, DOI 10.1016/S0741-5214(95)70071-4
   INDOLFI C, 1995, NAT MED, V1, P541, DOI 10.1038/nm0695-541
   Isner J M, 1996, Vasc Med, V1, P79
   Isner JM, 1996, HUM GENE THER, V7, P989, DOI 10.1089/hum.1996.7.8-989
   ISNER JM, 1995, CIRCULATION, V91, P2687, DOI 10.1161/01.CIR.91.11.2687
   JACKSON DA, 1972, P NATL ACAD SCI USA, V69, P2904, DOI 10.1073/pnas.69.10.2904
   KAY M, 1996, J VASC SURG, V24, P160
   Kozarsky K F, 1993, Curr Opin Genet Dev, V3, P499, DOI 10.1016/0959-437X(93)90126-A
   KUPFER JM, 1994, HUM GENE THER, V5, P1437, DOI 10.1089/hum.1994.5.12-1437
   LECLERC G, 1992, J CLIN INVEST, V90, P936, DOI 10.1172/JCI115970
   LEE SW, 1993, CIRC RES, V73, P797, DOI 10.1161/01.RES.73.5.797
   LEMARCHAND P, 1993, CIRC RES, V72, P1132, DOI 10.1161/01.RES.72.5.1132
   LIBBY P, 1992, CIRCULATION, V86, P47
   LIEDEN JM, 1996, J VASC SURG, V24, P163
   LIM CS, 1991, CIRCULATION, V83, P2007, DOI 10.1161/01.CIR.83.6.2007
   LIU MW, 1989, CIRCULATION, V79, P1374, DOI 10.1161/01.CIR.79.6.1374
   LUDWIG S, 1995, NAT MED, P513
   LYERLY HK, 1993, ARCH SURG-CHICAGO, V128, P1197
   MANN MJ, 1995, P NATL ACAD SCI USA, V92, P4502, DOI 10.1073/pnas.92.10.4502
   MARSHALL E, 1995, SCIENCE, V269, P1050, DOI 10.1126/science.7652552
   Mendel G., 1866, VERHANDLUNGEN NATURF, V4, P3, DOI DOI 10.5962/BHL.TITLE.61004
   MESSINA L, 1996, J VASC SURG, V24, P156
   MESSINA LM, 1992, P NATL ACAD SCI USA, V89, P12018, DOI 10.1073/pnas.89.24.12018
   MILLER AD, 1989, BIOTECHNIQUES, V7, P980
   Mintz GS, 1996, CIRCULATION, V94, P35, DOI 10.1161/01.CIR.94.1.35
   MORISHITA R, 1993, P NATL ACAD SCI USA, V90, P8474, DOI 10.1073/pnas.90.18.8474
   NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055
   NABEL EG, 1989, SCIENCE, V244, P1342, DOI 10.1126/science.2499928
   NABEL EG, 1995, CIRCULATION, V91, P541, DOI 10.1161/01.CIR.91.2.541
   NABEL EG, 1994, CARDIOVASC RES, V28, P445, DOI 10.1093/cvr/28.4.445
   Newman KD, 1995, J CLIN INVEST, V96, P2955, DOI 10.1172/JCI118367
   NEWMAN KD, 1991, J VASC SURG, V14, P140
   NICOLAU C, 1983, P NATL ACAD SCI-BIOL, V80, P1068, DOI 10.1073/pnas.80.4.1068
   OHNO T, 1994, SCIENCE, V265, P781, DOI 10.1126/science.8047883
   PLAUTZ G, 1991, CIRCULATION, V83, P578, DOI 10.1161/01.CIR.83.2.578
   PODRAZIK RM, 1992, ANN SURG, V216, P446, DOI 10.1097/00000658-199210000-00008
   RADE JJ, 1995, CIRCULATION S1, V92, P1501
   RIESSEN R, 1993, HUM GENE THER, V4, P479
   ROME JJ, 1994, HUM GENE THER, V5, P1249, DOI 10.1089/hum.1994.5.10-1249
   ROME JJ, 1994, ARTERIOSCLER THROMB, V14, P148, DOI 10.1161/01.ATV.14.1.148
   SCHULICK AH, 1995, CIRC RES, V77, P475, DOI 10.1161/01.RES.77.3.475
   SCHWARTZ LB, 1991, SURG FORUM, V27, P363
   SCHWARTZ RS, 1992, J AM COLL CARDIOL, V20, P1284, DOI 10.1016/0735-1097(92)90389-5
   SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445
   STANLEY JC, 1991, J VASC SURG, V13, P736
   STEG PG, 1994, CIRCULATION, V90, P1648, DOI 10.1161/01.CIR.90.4.1648
   SWAIN JL, 1989, CIRCULATION, V80, P1495, DOI 10.1161/01.CIR.80.5.1495
   TAKESHITA S, 1994, J CLIN INVEST, V93, P652, DOI 10.1172/JCI117017
   UMANS JG, 1995, ANNU REV PHYSIOL, V57, P771, DOI 10.1146/annurev.ph.57.030195.004011
   VEITH FJ, 1986, J VASC SURG, V3, P104
   VONDERLEYEN HE, 1995, P NATL ACAD SCI USA, V92, P1137, DOI 10.1073/pnas.92.4.1137
   WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578
   WATSON JD, 1953, NATURE, V171, P964, DOI 10.1038/171964b0
   WHITEHILL TA, 1992, SURG FORUM, V42, P337
   WILLARD JE, 1994, CIRCULATION, V89, P2190, DOI 10.1161/01.CIR.89.5.2190
   WILSON JM, 1989, SCIENCE, V244, P1344, DOI 10.1126/science.2734614
   WOLFF JA, 1994, HUM GENE THER, V5, P469, DOI 10.1089/hum.1994.5.4-469
   ZILLA P, 1994, J VASC SURG, V19, P540, DOI 10.1016/S0741-5214(94)70083-4
   Zoldhelyi P, 1996, CIRCULATION, V93, P10, DOI 10.1161/01.CIR.93.1.10
NR 100
TC 5
Z9 5
U1 0
U2 0
PU SPRINGER VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010
SN 0890-5096
J9 ANN VASC SURG
JI Ann. Vasc. Surg.
PD MAR
PY 1997
VL 11
IS 2
BP 189
EP 199
DI 10.1007/s100169900034
PG 11
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA WP859
UT WOS:A1997WP85900016
PM 9181778
DA 2018-10-19
ER

PT J
AU Patel, AM
   Spector, M
AF Patel, AM
   Spector, M
TI Tribological evaluation of oxidized zirconium using an articular
   cartilage counterface: A novel material for potential use in
   hemiarthroplasty
SO BIOMATERIALS
LA English
DT Article
DE hemiarthroplasty; wear; articular cartilage; oxidized zirconium
ID ACETABULAR EROSION; WEAR; HIP; PROSTHESIS; ARTHRITIS; NECK
AB Problems with total joint replacement that have surfaced in recent years have made reconsideration of more conservative hip reconstructive procedures compelling. Moreover, procedures such as hemiarthroplasty might benefit from newly developed materials that could provide more favourable tribological performance when employed as a counterface for articulation with articular cartilage. The objective of this study was to evaluate the tribology of a new biomaterial, oxidized zirconium, with articular cartilage in a laboratory test apparatus. Oxidized zirconium components are produced by oxidizing the zirconium alloy to form a relatively thick (7 mu m), adherent, abrasion-resistant ceramic surface. We found that the coefficient of friction of bovine articular cartilage rubbed against oxidized zirconium was lower than with cobalt-chromium alloy control surfaces, and that there was a trend toward less wear with oxidized zirconium. A defined layer of degraded tissue was found on the surface of the articular cartilage specimens, providing some indication of the mechanism of wear. Results of this study warrant further investigation of oxidized zirconium as the bearing surface for hemiarthroplasty. (C) 1997 Elsevier Science Limited. All rights reserved.
C1 HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT ORTHOPED SURG,BOSTON,MA 02115.
   BROCKTON W ROXBURY VET AFFAIRS MED CTR,REHABIL ENGN R&D LAB,W ROXBURY,MA.
OI Spector, Myron/0000-0003-3328-4858
CR AMSTUTZ HC, 1994, J BONE JOINT SURG BR, V76B, P423
   COOK SD, 1989, J BONE JOINT SURG BR, V71, P189
   Cox B., 1976, ADV CORROSION SCI TE, V5, P173
   CRUESS RL, 1984, J BONE JOINT SURG BR, V66, P592
   DALLDORF PG, 1995, J BONE JOINT SURG AM, V77A, P877, DOI 10.2106/00004623-199506000-00008
   DARCY J, 1976, J BONE JOINT SURG BR, V58, P279
   Davidson J. A., 1992, BIOCERAMICS, V5, P389
   DEE R, 1978, JOINTS SYNOVIAL FLUI, P177
   DEVAS M, 1983, J BONE JOINT SURG BR, V65, P548
   EISKJAER S, 1993, CLIN ORTHOPAEDICS, V286, P206
   GARZAROLLI F, 1991, AM SOC TEST MATER, V1132, P395, DOI 10.1520/STP25519S
   GODLEWSKI J, 1991, AM SOC TEST MATER, V1132, P416, DOI 10.1520/STP25520S
   LABERGE M, 1992, J BIOMED MATER RES, V26, P239, DOI 10.1002/jbm.820260209
   LADE R, 1983, CERAMICS SURG, P277
   LESTRANGE NR, 1990, CLIN ORTHOPAEDICS, V251, P7
   LEVINE JD, 1984, SCIENCE, V226, P547, DOI 10.1126/science.6208609
   LEYSHON RL, 1984, J BONE JOINT SURG BR, V66, P172
   LIPSHITZ H, 1979, WEAR, V52, P297, DOI 10.1016/0043-1648(79)90070-X
   LOTZ M, 1987, SCIENCE, V235, P893, DOI 10.1126/science.2433770
   LOTZ M, 1988, SCIENCE, V241, P1216
   MACIROWSKI T, 1994, J BIOMECH ENG-T ASME, V116, P10, DOI 10.1115/1.2895693
   MCKELLOP H, 1992, 4TH WORLD BIOM C BER, P118
   MENDES DG, 1975, CLIN ORTHOP RELAT R, V111, P274
   MOW VC, 1992, BIOMATERIALS, V13, P67, DOI 10.1016/0142-9612(92)90001-5
   NEWCOMB SB, 1988, I PHYS C SER, V93, P43
   NISHII T, 1995, CLIN ORTHOPAEDICS, V316, P112
   Patel A.M., 1995, BIOCERAMICS, P169
   WADMAN B, 1994, AM SOC TEST MATER, V1245, P579, DOI 10.1520/STP15210S
   WARR BD, 1989, P IAEA TECHN COMM M, P124
   WROBLEWSKI BM, 1979, J BONE JOINT SURG BR, V61, P498
NR 30
TC 65
Z9 68
U1 0
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD MAR
PY 1997
VL 18
IS 5
BP 441
EP 447
DI 10.1016/S0142-9612(96)00152-4
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA WK062
UT WOS:A1997WK06200010
PM 9061186
DA 2018-10-19
ER

PT J
AU Jones, DS
   McGovern, JG
   Woolfson, AD
   Gorman, SP
AF Jones, DS
   McGovern, JG
   Woolfson, AD
   Gorman, SP
TI Role of physiological conditions in the oropharynx on the adherence of
   respiratory bacterial isolates to endotracheal tube poly(vinyl chloride)
SO BIOMATERIALS
LA English
DT Article
DE PVC; contact angle; microrugosity; hydrophobicity; bacterial adhesion
ID COAGULASE-NEGATIVE STAPHYLOCOCCI; CARBON-DIOXIDE; SALIVA; ADHESION;
   STREPTOCOCCI; ANTIBIOTICS; RESISTANCE; PNEUMONIA; SURFACES; BIOFILMS
AB Pneumonia is a major problem in intensive care patients and can be induced by pathogenic bacteria adhering to poly(vinyl chloride) (PVC) endotracheal (ET) tubes. This study examines the influence of surface properties on the adherence of the respiratory isolates Staphylococcus aureus and Pseudomonas aeruginosa to PVC. In particular, the influence of respiratory tract physiological conditions, 5% CO2 and saliva, on adherence was investigated. In general, decreased adherence to PVC was observed when bacteria were grown in CO2. When these CO2-grown bacteria were treated with saliva their adherence to PVC significantly increased; however, their adherence was significantly reduced to saliva-treated PVC. Treatment of both bacterial isolates with saliva decreased their negative zeta potential, a factor which may directly contribute to the observed increased microbial (saliva pretreated) adherence to PVC. Cell surface hydrophobicity (CSH) was evaluated by measuring the initial rates of microbial removal from a buffered aqueous phase, to ensure the absence of electrostatic interactions, to an organic phase (xylene). Under physiological conditions, CSH did not appear to be a dominant factor in biomaterial adherence as the CSH of S. aureus was decreased by saliva treatment but was unchanged for Ps. aeruginosa. Additionally, CSH also differed for the two isolates when grown in CO2, significantly decreasing with S. aureus but remaining unaltered with Ps. aeruginosa. Saliva treatment of PVC also decreased the advancing and receding contact angles of the biomaterial and its surface roughness, which may be a factor in the decreased adherence of saliva-treated bacteria to this surface. Alternative biomaterials or surface modifications appear necessary for the desired improvements in ET tube effectiveness. This study highlights the influence of physiological conditions on biomaterial and bacterial surface characteristics and subsequent interactions. It is imperative that the physiological conditions predominating in the clinical area of biomaterial use be considered when investigating device biocompatibility. (C) 1997 Published by Elsevier Science Limited.
RP Jones, DS (reprint author), QUEENS UNIV BELFAST,CTR MED BIOL,SCH PHARM,PHARMACEUT DEVICES RES GRP,97 LISBURN RD,BELFAST BT9 7BL,ANTRIM,NORTH IRELAND.
CR ADAIR CG, 1993, J ANTIMICROB CHEMOTH, V31, P689, DOI 10.1093/jac/31.5.689
   ADAIR CG, 1993, PHARMACOTHERAPY, V13, P297
   Bonner M. C., 1995, Journal of Pharmacy and Pharmacology, V47, P1095
   BOWMAN WC, 1980, TXB PHARM, P1
   BROWN MRW, 1988, J ANTIMICROB CHEMOTH, V22, P777, DOI 10.1093/jac/22.6.777
   BUSSCHER HJ, 1995, COLLOID SURFACE B, V5, P111, DOI 10.1016/0927-7765(95)01224-7
   BUSSCHER HJ, 1990, MICROBIAL CELL SURFA, P335
   CANNON RD, 1995, MICROBIOL-SGM, V141, P213, DOI 10.1099/00221287-141-1-213
   Craven D E, 1990, Semin Respir Infect, V5, P157
   DENYER SP, 1990, J CLIN MICROBIOL, V28, P1813
   DOYLE RJ, 1990, MICROBIAL CELL SURFA, P387
   EMILSON CG, 1989, ARCH ORAL BIOL, V34, P335, DOI 10.1016/0003-9969(89)90106-4
   FLETCHER M, 1979, APPL ENVIRON MICROB, V37, P67
   GORMAN SP, 1993, J MED MICROBIOL, V38, P411, DOI 10.1099/00222615-38-6-411
   GORMAN SP, 1991, SOC APPLIED BACTERIO, V27, P271
   GORMAN SP, 1992, EUR J CLIN MICROBIOL, V12, P9
   GORMAN SP, 1993, PHARMACOTHERAPY, V13, P282
   GORMAN SP, 1993, P 12 PHARM TECH C, V2, P465
   HOYLE BD, 1990, J ANTIMICROB CHEMOTH, V26, P1, DOI 10.1093/jac/26.1.1
   LEEDOM JM, 1992, DIAGN MICR INFEC DIS, V15, P57, DOI 10.1016/0732-8893(92)90057-Z
   LIGTENBERG AJM, 1993, ANTON LEEUW INT J G, V64, P39, DOI 10.1007/BF00870920
   McGovern J. G., 1995, Journal of Pharmacy and Pharmacology, V47, P1063
   Miles AA, 1938, J HYG-CAMBRIDGE, V38, P732, DOI 10.1017/S002217240001158X
   ONAOLAPO JA, 1987, J MED MICROBIOL, V24, P227, DOI 10.1099/00222615-24-3-227
   REID G, 1992, J UROLOGY, V148, P1592, DOI 10.1016/S0022-5347(17)36976-8
   SATOU J, 1991, J ORAL REHABIL, V18, P421
   SCANNAPIECO FA, 1994, CRIT REV ORAL BIOL M, V5, P203, DOI 10.1177/10454411940050030201
   van Loosdrecht M C, 1990, J Biomater Appl, V5, P91, DOI 10.1177/088532829000500202
   VANDERMEI HC, 1995, COLLOID SURFACE B, V5, P117, DOI 10.1016/0927-7765(95)01225-8
   VANLOOSDRECHT MCM, 1987, APPL ENVIRON MICROB, V53, P1893
   WEERKAMP AH, 1985, J DENT RES, V64, P1204, DOI 10.1177/00220345850640100501
   WEERKAMP AH, 1988, J DENT RES, V67, P1483, DOI 10.1177/00220345880670120801
   WENZEL RP, 1989, EUR J CLIN MICROBIOL, V8, P56, DOI 10.1007/BF01964121
   WILCOX MH, 1990, J CLIN MICROBIOL, V28, P2183
   WILCOX MH, 1991, J ANTIMICROB CHEMOTH, V27, P577, DOI 10.1093/jac/27.5.577
   WILKINS KM, 1989, INT J PHARM, V57, P1, DOI 10.1016/0378-5173(89)90256-1
NR 36
TC 33
Z9 34
U1 1
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD MAR
PY 1997
VL 18
IS 6
BP 503
EP 510
DI 10.1016/S0142-9612(96)00170-6
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA WM670
UT WOS:A1997WM67000009
PM 9111955
DA 2018-10-19
ER

PT J
AU Yoshinaga, K
   Kondo, K
   Kondo, A
AF Yoshinaga, K
   Kondo, K
   Kondo, A
TI Capabilities of polymer-modified monodisperse colloidal silica particles
   as biomaterial carrier
SO COLLOID AND POLYMER SCIENCE
LA English
DT Article
DE biomaterial carrier; immunolatex; protein; immobilization; monodisperse
   colloidal silica; polymer modification
ID GRAFT-POLYMERIZATION; ADSORPTION; SURFACE
AB Polymer modification of monodispersed colloidal silica (0.5 mu m) with poly(maleic anhydride-co-styrene) (P(MA-ST)) and poly (maleic anhydride-co-methyl methacrylate) (P(MA-MMA)) and application of the composite particles to biomaterial carriers were investigated. The reaction of bovine serum albumin(BSA)-immobilized P(MA-MMA)/SiO2 with the anti-BSA antibody showed higher sensitivity in immunological agglutination test than BSA-P(MA-ST)/SiO2, though immobilization efficiency of BSA on P(MA-MMA)/SiO2 was lower than that on P(MA-ST)/SiO2. Alkaline phosphatase and glucose oxidase immobilized on the composite particles exhibited extremely low activities, but alpha-chymotrypsin immobilized on P(MA-MMA)/SiO2 and its derivative particles showed the relative activity of 12.5% and 16.1% to the native enzyme, respectively. Grafting of a hydrophilic polymer of poly(acrylic acid) to P(MA-ST)/SiO2 let to an increase of the immobilized alpha-chymotrypsin activity to give the maximum relative activity of 55.5%.
C1 KOBE UNIV,DEPT SCI & CHEM ENGN,KOBE,HYOGO 675,JAPAN.
RP Yoshinaga, K (reprint author), KYUSHU INST TECHNOL,DEPT APPL CHEM,KITAKYUSHU,FUKUOKA 804,JAPAN.
RI Kobe Univ, Engineering/D-2028-2017; Kondo, Akihiko/A-2130-2015
CR AUSES JP, 1975, ANAL CHEM, V47, P244, DOI 10.1021/ac60352a008
   BLOW DM, 1969, NATURE, V221, P337, DOI 10.1038/221337a0
   INADA Y, 1987, BIOCHEM BIOPH RES CO, V48, P392
   Kondo A, 1996, COLLOID SURFACE A, V109, P129, DOI 10.1016/0927-7757(95)03480-3
   LASKOWSKI M, 1955, METHOD ENZYMOL, V2, P8, DOI 10.1016/S0076-6879(55)02166-6
   MOLDAY RS, 1984, CELL SEPARATION METH, V3, P237
   NORDE W, 1978, J COLLOID INTERF SCI, V66, P257, DOI 10.1016/0021-9797(78)90303-X
   NORDE W, 1986, ADV COLLOID INTERFAC, V25, P267, DOI 10.1016/0001-8686(86)80012-4
   OKUBO M, 1987, KOBUNSHI RONBUNSHU, V44, P123, DOI 10.1295/koron.44.123
   SADA E, 1988, BIOTECHNOL BIOENG, V31, P635, DOI 10.1002/bit.260310702
   SINGER JM, 1987, FUTURE DIRECTIONS PO, P371
   SOWADSKI JM, 1985, J MOL BIOL, V186, P417, DOI 10.1016/0022-2836(85)90115-9
   SWOBODA BEP, 1965, J BIOL CHEM, V240, P2209
   TORIANI A, 1966, PROCEDURES NUCL ACID, P224
   TSUBOKAWA N, 1989, POLYM J, V21, P475, DOI 10.1295/polymj.21.475
   YOSHINAGA K, 1993, COLLOID SURFACE A, V77, P101, DOI 10.1016/0927-7757(93)80106-O
   Yoshinaga K, 1996, B CHEM SOC JPN, V69, P2667, DOI 10.1246/bcsj.69.2667
   YOSHINAGA K, 1994, POLYM J, V26, P1070, DOI 10.1295/polymj.26.1070
   Yoshinaga K, 1996, POLYM ADVAN TECHNOL, V7, P53, DOI 10.1002/(SICI)1099-1581(199601)7:1<53::AID-PAT482>3.0.CO;2-7
   YOSHINAGA K, 1994, COMPOSITE INTERFACES, V2, P95
NR 20
TC 17
Z9 17
U1 0
U2 2
PU DR DIETRICH STEINKOPFF VERLAG
PI DARMSTADT
PA PLATZ DER DEUTSCHEN EINHEIT 25, D-64293 DARMSTADT, GERMANY
SN 0303-402X
J9 COLLOID POLYM SCI
JI Colloid Polym. Sci.
PD MAR
PY 1997
VL 275
IS 3
BP 220
EP 226
DI 10.1007/s003960050075
PG 7
WC Chemistry, Physical; Polymer Science
SC Chemistry; Polymer Science
GA WT952
UT WOS:A1997WT95200003
DA 2018-10-19
ER

PT J
AU Atlan, G
   Balmain, N
   Berland, S
   Vidal, B
   Lopez, E
AF Atlan, G
   Balmain, N
   Berland, S
   Vidal, B
   Lopez, E
TI Reconstruction of human maxillary defects with nacre powder:
   histological evidence for bone regeneration
SO COMPTES RENDUS DE L ACADEMIE DES SCIENCES SERIE III-SCIENCES DE LA
   VIE-LIFE SCIENCES
LA English
DT Article
DE alveolar bone; bone defect; nacre; osteogenesis; biomaterial
ID OSTEOBLASTS MAINTAINED INVITRO
AB The defective areas in the premolar-molar region of maxillary alveolar bone of eight patients were reconstructed using powdered nacre from the giant oyster Pinctada maxima. Histological, microradiographic and polarized light studies of drill biopsies taken 6 months postoperatively showed that nacre was tightly bound to newly-formed bone. The nacre was gradually and centripetally biodissolved and replaced with immature and then mature lamellar bone. These results are in agreement with our previous experimental in vitro data indicating that nacre has good osteogenic properties.
C1 MUSEUM NATL HIST NAT, CNRS, URA 90, F-75231 PARIS 05, FRANCE.
   MUSEUM NATL HIST NAT, LAB PHYSIOL GEN & COMPAREE, F-75231 PARIS 05, FRANCE.
   CHU LAPEYRONIE, SERV CHIRURG MAXILLOFACIALE, F-34095 MONTPELLIER 5, FRANCE.
CR BANG G, 1967, ARCH SURG-CHICAGO, V94, P781
   BURCHARDT H, 1983, CLIN ORTHOP RELAT R, V174, P28
   Buring K, 1967, Clin Orthop Relat Res, V55, P225
   CLOCKIE CML, 1995, INT J ORAL MAXILLOF, V10, P155
   DELACURE MD, 1994, OTOLARYNG CLIN N AM, V27, P859
   DUBUC FL, 1967, CLIN ORTHOP RELAT R, V55, P225
   Glowacki J, 1996, CLIN ORTHOP RELAT R, P47
   GOLSTEIN JA, 1995, ANN PLAST SURG, V34, P162
   GUILLEMIN G, 1989, J BIOMED MATER RES, V23, P765, DOI 10.1002/jbm.820230708
   HOLLINGER J, 1992, CELL MATER, V2, P143
   Jee WSS, 1983, HISTOLOGY CELL TISSU
   Kale A A, 1995, Am J Orthop (Belle Mead NJ), V24, P752
   Le Faou A, 1995, CALCIFIED TISSUE INT, V56, pA156
   LEFAOU, 1996, THESIS MNHN PARIS
   LEFAOU A, 1996, ANN ENDOC, V57, pA75
   LI YB, 1994, BIOMATERIALS, V15, P835
   LOPEZ E, 1992, TISSUE CELL, V24, P667, DOI 10.1016/0040-8166(92)90037-8
   LOPEZ E, 1994, RECHERCHE, V25, P208
   LPEZ E, 1994, B I OCEANOGR MONACO, V14, P49
   Martin RB, 1989, STRUCTURE FUNCTION A
   MULLERMAI CM, 1995, J BIOMED MATER RES, V29, P9, DOI 10.1002/jbm.820290103
   MUSTER D, 1987, ENCYCL MED CHIRUR PA
   NEO M, 1992, J BIOMED MATER RES, V26, P1419, DOI 10.1002/jbm.820261103
   NIMB L, 1995, J BIOMED MATER RES, V29, P1477, DOI 10.1002/jbm.820291203
   REDDI AH, 1994, J CELL BIOCHEM, V56, P192, DOI 10.1002/jcb.240560213
   SILVE C, 1992, CALCIFIED TISSUE INT, V51, P363, DOI 10.1007/BF00316881
   SIMKISS K, 1988, CELL BIOL MINERAL DE
   STANLEY HR, 1987, J PROSTHET DENT, V58, P607, DOI 10.1016/0022-3913(87)90393-3
   WEINTRAUB PV, 1988, CALCIFIED TISSUE INT, V42, P255
NR 29
TC 94
Z9 100
U1 1
U2 16
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0764-4469
J9 CR ACAD SCI III-VIE
JI Comptes Rendus Acad. Sci. Ser. III-Sci. Vie-Life Sci.
PD MAR
PY 1997
VL 320
IS 3
BP 253
EP 258
DI 10.1016/S0764-4469(97)86933-8
PG 6
WC Biology; Multidisciplinary Sciences
SC Life Sciences & Biomedicine - Other Topics; Science & Technology - Other
   Topics
GA YC235
UT WOS:A1997YC23500007
PM 9183443
DA 2018-10-19
ER

PT J
AU Lundberg, F
   Lea, T
   Ljungh, A
AF Lundberg, F
   Lea, T
   Ljungh, A
TI Vitronectin-binding staphylococci enhance surface-associated complement
   activation
SO INFECTION AND IMMUNITY
LA English
DT Article
ID SERUM SPREADING FACTOR; COAGULASE-NEGATIVE STAPHYLOCOCCI; MEMBRANE
   ATTACK COMPLEX; POLYMER SURFACES; S-PROTEIN; PLASMA-PROTEINS;
   CELL-SURFACE; HEPARIN; ATTACHMENT; BIOCOMPATIBILITY
AB Coagulase-negative staphylococci are well recognized in medical device-associated infections, Complement activation is known to occur at the biomaterial surface, resulting in unspecific inflammation around the biomaterial, The human serum protein vitronectin (Vn), a potent inhibitor of complement activation by formation of an inactive terminal complement complex, adsorbs to biomaterial surfaces in contact with blood, In this report, we discuss the possibility that surface-immobilized Vn inhibits complement activation and the effect of Vn-binding staphylococci on complement activation on surfaces precoated with Vn, The extent of complement activation was measured with a rabbit anti-human C3c antibody and a mouse anti-human C9 antibody, raised against the neoepitope of C9, Our data show that Vn immobilized on a biomaterial surface retains its ability to inhibit complement activation, The additive complement activation-inhibitory effect of Vn on a heparinized surface is very small, In the presence of Vn-binding strain, Staphylococcus hemolyticus SM131, complement activation on a surface precoated with Vn occurred as it did in the absence of Vn precoating, For S. epidermidis 3380, which does not express binding of Vn, complement activation on a Vn-precoated surface was significantly decreased, The results could be repeated on heparinized surfaces. These data suggest that Vn adsorbed to a biomaterial surface may serve to protect against surface-associated complement activation, Furthermore, Vn-binding staphylococcal cells may enhance surface-associated complement activation by blocking the inhibitory effect of preadsorbed Vn.
C1 LUND UNIV,DEPT MED MICROBIOL,S-22362 LUND,SWEDEN.
   UNIV OSLO,INST IMMUNOL & RHEUMATOL,OSLO,NORWAY.
CR BALDASSARI L, COMMUNICATION
   BARBUCCI R, 1994, BIOMATERIALS, V15, P955, DOI 10.1016/0142-9612(94)90075-2
   BARNES DW, 1985, J BIOL CHEM, V260, P9117
   BECHERER JD, 1989, COMPLEMENT INFLAMMAT, V6, P142, DOI 10.1159/000463091
   BERGER M, 1994, J MATER SCI-MATER M, V5, P622, DOI 10.1007/BF00120343
   CLARKE DE, 1990, CHEST, V97, P966, DOI 10.1378/chest.97.4.966
   Dierich M.P., 1988, COMPLEMENT SYSTEM, P262
   EDENS RE, 1994, IMMUNOPHARMACOLOGY, V27, P145, DOI 10.1016/0162-3109(94)90049-3
   FEARON DT, 1983, ANNU REV IMMUNOL, V1, P243, DOI 10.1146/annurev.iy.01.040183.001331
   GEBB C, 1986, J BIOL CHEM, V261, P6698
   GIESE MJ, 1994, INVEST OPHTH VIS SCI, V35, P1026
   HAYASHI M, 1985, J BIOCHEM-TOKYO, V98, P1135, DOI 10.1093/oxfordjournals.jbchem.a135363
   HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003
   JPAULSSON M, 1990, J CLIN MICROBIOL, V30, P2006
   Kanse SM, 1996, EXP CELL RES, V224, P344, DOI 10.1006/excr.1996.0144
   LABARRE DJ, 1990, BIOMATERIALS, V9, P30
   LARM O, 1987, THROMB HAEMOSTASIS, V58, P84
   LAW SKA, 1988, COMPLEMENT COORDINAT
   LUDWICKA A, 1985, J MICROBIOL METH, V4, P169, DOI 10.1016/0167-7012(85)90033-8
   LUNDBERG F, IN PRESS J MED MICRO
   LUNDBERG F, UNPUB
   MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982
   MOLLNES TE, 1995, ARTIF ORGANS, V19, P909, DOI 10.1111/j.1525-1594.1995.tb02450.x
   MOLLNES TE, 1991, CLIN EXP IMMUNOL, V1, P21
   MONDINO BJ, 1985, INVEST OPHTH VIS SCI, V26, P905
   NICULESCU F, 1989, ATHEROSCLEROSIS, V78, P197, DOI 10.1016/0021-9150(89)90223-2
   NILSSON UR, 1993, MOL IMMUNOL, V30, P211, DOI 10.1016/0161-5890(93)90050-L
   NILSSONEKDAHL K, 1992, SCAND J IMMUNOL, V35, P85
   NYDEGGER UE, 1990, TRANSFUS SCI, V11, P43, DOI 10.1016/0955-3886(90)90006-5
   PAULSSON M, 1994, J BIOMED MATER RES, V28, P311, DOI 10.1002/jbm.820280305
   PAULSSON M, 1992, J CLIN MICROBIOL, V30, P2006
   PAULSSON M, 1992, ZBL BAKT-INT J MED M, V277, P54
   PEKNA M, 1993, CLIN EXP IMMUNOL, V91, P404
   PEKNA M, 1993, BIOMATERIALS, V14, P189, DOI 10.1016/0142-9612(93)90022-T
   PODACK ER, 1984, ACTA PATH MICRO IM C, V92, P89
   PODACK ER, 1979, J BIOL CHEM, V254, P9908
   PREISSNER KT, 1985, J IMMUNOL, V135, P445
   PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cb.07.110191.001423
   PREISSNER KT, 1985, EUR J BIOCHEM, V156, P645
   RAPOZA R, 1990, J BIOMED MATER RES, P1263
   ROZALSKA B, 1995, FEMS IMMUNOL MED MIC, V11, P307, DOI 10.1111/j.1574-695X.1995.tb00161.x
   SALAMA A, 1988, NEW ENGL J MED, V318, P408, DOI 10.1056/NEJM198802183180704
   TSCHOPP J, 1988, BIOCHEMISTRY-US, V31, P4103
   VANWAMEL WJB, 1995, J CLIN MICROBIOL, V33, P1769
   YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281
   YU J, 1994, BIOMATERIALS, V15, P805, DOI 10.1016/0142-9612(94)90035-3
   Zhuang P, 1996, J BIOL CHEM, V271, P14333, DOI 10.1074/jbc.271.24.14333
NR 47
TC 13
Z9 13
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD MAR
PY 1997
VL 65
IS 3
BP 897
EP 902
PG 6
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA WK953
UT WOS:A1997WK95300008
PM 9038294
DA 2018-10-19
ER

PT J
AU Wang, XD
   Agrawal, CM
AF Wang, XD
   Agrawal, CM
TI Interfacial fracture toughness of tissue-biomaterial systems
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE fracture toughness; interface; orthopedic biomaterials; sandwich
   specimen; finite element analysis
ID BONE-BONDING BEHAVIOR; PUSH-OUT TEST; FAILURE MECHANISMS;
   FINITE-ELEMENT; GLASS; SPECIMENS; STRENGTH; APATITE
AB Tissue-biomaterial interfacial bonding strength plays a significant role in the success of the biomaterials used for load-bearing orthopedic prostheses. To assess the interfacial bonding strength, this study examined a fracture mechanics approach using a bilayer compact sandwich (BCS) specimen, in which a bilayer coupon comprising the interface between tissue and biomaterial was sandwiched between two holders. First, the theoretical basis for measuring interfacial fracture toughness using the BCS specimen was developed. Next, the effect of finite interlayer thickness on the measurements was addressed and a correction factor was determined using finite element analysis techniques. Accordingly, the theoretical solution was modified to account for the effect of the interlayer thickness. Finally, using a bone to bone-cement interface the BCS technique was empirically verified in terms of overall size, material combination, and interlayer thickness. It is expected that the BCS technique will provide an effective means for researchers to study and analyze tissue-biomaterial interfaces. (C) 1997 John Wiley & Sons, Inc.
RP Wang, XD (reprint author), UNIV TEXAS,HLTH SCI CTR,DEPT ORTHOPAED,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA.
CR ANDERSSON OH, 1992, J MATER SCI-MATER M, V3, P145, DOI 10.1007/BF00705283
   *ASTM, 1993, 1993 ANN BOOK ASTM S
   BLACK J, 1989, J BIOMED MATER RES, V23, P1243, DOI 10.1002/jbm.820231102
   CANNON RM, 1991, ACTA METALL MATER, V39, P2145, DOI 10.1016/0956-7151(91)90184-3
   CURREY JD, 1970, CLIN ORTHOP RELAT R, V73, P210
   de Groot K, 1989, J Biomed Mater Res, V23, P1367, DOI 10.1002/jbm.820231112
   DHERT WJA, 1992, J BIOMED MATER RES, V26, P119, DOI 10.1002/jbm.820260111
   DUNDURS J, 1969, J APPL MECH, V36, P650, DOI 10.1115/1.3564739
   ENGLAND AH, 1965, J APPL MECH, V32, P400, DOI 10.1115/1.3625813
   ERDOGAN F, 1965, J APPL MECH, V32, P403, DOI 10.1115/1.3625814
   FONDRK M, 1988, J BIOMECH, V21, P623, DOI 10.1016/0021-9290(88)90200-X
   FUJIU T, 1984, J BIOMED MATER RES, V18, P845, DOI 10.1002/jbm.820180714
   HARRIGAN TP, 1990, J ORTHOPAED RES, V8, P678, DOI 10.1002/jor.1100080509
   KITSUGI T, 1986, J BIOMED MATER RES, V20, P1295, DOI 10.1002/jbm.820200906
   LIECHTI KM, 1992, INT J FRACTURE, V55, P95, DOI 10.1007/BF00017271
   LIN CP, 1994, J BIOMECH, V27, P1037, DOI 10.1016/0021-9290(94)90220-8
   LIN H, 1992, J BIOMED MATER RES, V26, P7
   NAKAMURA T, 1985, J BIOMED MATER RES, V19, P685, DOI 10.1002/jbm.820190608
   Park JB, 1984, BIOMATERIALS SCI ENG
   PILLIAR RM, 1991, MRS BULL, V16, P55
   RICE JR, 1965, J APPL MECH, V32, P418, DOI 10.1115/1.3625816
   RICE JR, 1988, J APPL MECH-T ASME, V55, P98, DOI 10.1115/1.3173668
   Spector M, 1987, J Arthroplasty, V2, P163, DOI 10.1016/S0883-5403(87)80024-4
   SUO ZG, 1989, MAT SCI ENG A-STRUCT, V107, P135, DOI 10.1016/0921-5093(89)90382-1
   TAKATSUKA K, 1995, J BIOMED MATER RES, V29, P157, DOI 10.1002/jbm.820290204
   TAM LE, 1994, J DENT RES, V73, P1530, DOI 10.1177/00220345940730090801
   WANG JS, 1990, ACTA METALL MATER, V38, P1279, DOI 10.1016/0956-7151(90)90200-Z
   WANG X, 1994, T 4 ANN C AUST SOC B, pA18
   WANG X, 1996, J APPL BIOMATER, V7, P13
   WANG X, 1996, 5 42 ANN M ORTH RES
   WANG XD, 1994, J APPL BIOMATER, V5, P315, DOI 10.1002/jab.770050406
   Wang XD, 1996, J BIOMED MATER RES, V33, P133, DOI 10.1002/(SICI)1097-4636(199623)33:3<133::AID-JBM2>3.3.CO;2-P
NR 32
TC 24
Z9 24
U1 0
U2 5
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD SPR
PY 1997
VL 38
IS 1
BP 1
EP 10
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA WM768
UT WOS:A1997WM76800001
PM 9086411
DA 2018-10-19
ER

PT J
AU Nomura, S
   Lundberg, F
   Stollenwerk, M
   Nakamura, K
   Ljungh, A
AF Nomura, S
   Lundberg, F
   Stollenwerk, M
   Nakamura, K
   Ljungh, A
TI Adhesion of staphylococci to polymers with and without immobilized
   heparin in cerebrospinal fluid
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
DE shunt infection; cerebrospinal fluid; surface heparinization; perfusion
   model; hydrophobic interaction
ID COAGULASE-NEGATIVE STAPHYLOCOCCI; SHUNT INFECTIONS; HYDROCEPHALUS;
   FIBRONECTIN; BINDING; ATTACHMENT; ADHERENCE; SURFACES; PLASMA; AUREUS
AB Infections of cerebrospinal fluid (CSF) shunts constitute a serious clinical problem. The role of adhesion by coagulase negative staphylococci, the most common etiological agent, was examined in vitro to polyvinyl chloride (PVC), silicone, and to PVC and silicone with end-point attached (EPA) heparin. These are flexible materials commonly used in neurosurgical implants. Bacterial adhesion was quantitated by bioluminescence. The bacterial adhesion to biomaterial surfaces increased with increasing concentrations of bacterial cells. Scatchard plot analysis showed continuous negative (concave) slopes, indicating multiple interactions between biomaterial and bacteria. The thermodynamic studies showed a positive value of the standard entropy change at 37 degrees C, which indicates that hydrophobic interactions are important in bacterial adhesion to polymers. Incubation with CSF for 1 h decreased bacterial adhesion in 75% of the samples compared to incubation in buffer. Thus, the contribution of CSF proteins, like fibronectin, for the initial bacterial adhesion might be small. Heparinization of silicone and PVC decreased the numbers of adhered bacteria by 23 to 54% and 0 to 43% compared to unheparinized surfaces. Among putative inhibitors tested, suramin, chondroitin sulfate, and fucoidan inhibited adhesion to 81 +/- 19, 78 +/- 22, and 64 +/- 7%, respectively. These findings indicate that hydrophobic interactions play an important role, and heparinization rendering the biomaterial surface hydrophilic is therefore effective to reduce bacterial adhesion. Heparinized polymers incubated with putative inhibitors may be the optimal way to prevent shunt infections. (C) 1997 John Wiley & Sons, Inc.
C1 LUND UNIV, DEPT MED MICROBIOL, LUND, SWEDEN.
   YAMAGUCHI UNIV, SCH MED, DEPT BIOCHEM 1, UBE, YAMAGUCHI 755, JAPAN.
CR AMMIRATI M, 1987, CHILD NERV SYST, V3, P106, DOI 10.1007/BF00271135
   ANDREW JH, 1986, J ANTIMICROB CHEMOTH, V18, P145, DOI 10.1093/jac/18.1.145
   APPELGREN P, 1995, LANCET, V345, P130, DOI 10.1016/S0140-6736(95)90097-7
   CHOUDHURY AR, 1990, CHILD NERV SYST, V6, P346
   CHOUX M, 1992, J NEUROSURG, V77, P875, DOI 10.3171/jns.1992.77.6.0875
   COFFEY RJ, 1987, J CELL PHYSIOL, V132, P143, DOI 10.1002/jcp.1041320120
   Dahlquist F W, 1978, Methods Enzymol, V48, P270
   ESPERSEN F, 1994, J MED MICROBIOL, V40, P37, DOI 10.1099/00222615-40-1-37
   FRAME PT, 1984, J NEUROSURG, V60, P354, DOI 10.3171/jns.1984.60.2.0354
   GOLDMANN DA, 1993, CLIN MICROBIOL REV, V6, P176
   GRISTINA AG, 1990, PATHOGENESIS OF WOUND AND BIOMATERIAL-ASSOCIATED INFECTIONS, P193
   GYRING J, 1989, ALFRED BENZON SYMP S, V27, P80
   HERRMANN M, 1991, INFECT IMMUN, V59, P279
   HIRMO S, 1995, FEMS IMMUNOL MED MIC, V10, P301, DOI 10.1111/j.1574-695X.1995.tb00048.x
   HJERTEN S, 1990, PATHOGENESIS OF WOUND AND BIOMATERIAL-ASSOCIATED INFECTIONS, P245
   HOGT AH, 1983, J GEN MICROBIOL, V129, P2959
   ITOH H, 1993, ANTICANCER RES, V13, P2045
   JIMENEZ DF, 1994, CHILD NERV SYST, V10, P59, DOI 10.1007/BF00313586
   KNUDSEN JD, 1993, COAGULASE NEGATIVE S, P97
   LARM O, 1983, BIOMATER ARTIF CELL, V11, P161, DOI 10.3109/10731198309118804
   LUNDBERG F, IN PRESS J MED MICRO, P2996
   MAXE I, 1986, INFECT IMMUN, V54, P695
   NAKAMURA K, 1992, J CHROMATOGR, V597, P351, DOI 10.1016/0021-9673(92)80131-D
   NILSSON UR, 1993, SCAND J IMMUNOL, V37, P349, DOI 10.1111/j.1365-3083.1993.tb02564.x
   Pascu C, 1995, MED MICROBIOL LETT, V4, P397
   PAULSSON M, 1994, J BIOMED MATER RES, V28, P311, DOI 10.1002/jbm.820280305
   PAULSSON M, 1993, BIOMATERIALS, V14, P845, DOI 10.1016/0142-9612(93)90006-N
   PUDENZ RH, 1981, SURG NEUROL, V15, P15, DOI 10.1016/S0090-3019(81)80084-5
   ROSS PD, 1981, BIOCHEMISTRY-US, V20, P3096, DOI 10.1021/bi00514a017
   RUGE JR, 1993, BRAIN SURGERY COMPLI, P1463
   SCHERHOLZ J, 1994, BIOMATERIALS, V15, P996
   SPANU G, 1986, ACTA NEUROCHIR, V80, P79, DOI 10.1007/BF01812278
   VAUDAUX P, 1993, J INFECT DIS, V167, P633, DOI 10.1093/infdis/167.3.633
   VROMAN L, 1986, J COLLOID INTERF SCI, V111, P391, DOI 10.1016/0021-9797(86)90042-1
   WOODS JJ, 1983, NEUROBIOLOGY CEREBRO, V2
   YU J, 1994, BIOMATERIALS, V15, P805, DOI 10.1016/0142-9612(94)90035-3
NR 36
TC 39
Z9 39
U1 1
U2 2
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD SPR
PY 1997
VL 38
IS 1
BP 35
EP 42
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA WM768
UT WOS:A1997WM76800005
PM 9086415
DA 2018-10-19
ER

PT J
AU Otto, M
   Klein, CL
   Kohler, H
   Wagner, M
   Rohrig, O
   Kirkpatrick, CJ
AF Otto, M
   Klein, CL
   Kohler, H
   Wagner, M
   Rohrig, O
   Kirkpatrick, CJ
TI Dynamic blood cell contact with biomaterials: Validation of a flow
   chamber system according to international standards
SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE
LA English
DT Article; Proceedings Paper
CT 1995 Conference of the European-Society-of-Biomaterials
CY SEP 10-13, 1995
CL OPORTO, PORTUGAL
SP Eur Soc Biomat
ID ENDOTHELIAL-CELLS; SHEAR-STRESS; P-SELECTIN; IN-VITRO; ADHESION;
   ACTIVATION; PLATELETS; GRANULOCYTES; SUBCOMMITTEE; THROMBOSIS
AB The increasing number of patients requiring prosthetic substitution of segments of the vascular system strongly supports the need to optimize a relevant, standardized testing panel for new materials designed for synthetic vascular prostheses. The ISO gives the standard requirements for testing biomaterials provided for implantation. Our primary interest was the establishment of a reliable in vitro panel as a useful and relevant screening system for vascular implant devices to evaluate blood/device interactions under flow conditions. The aim of the present study was to evaluate influences of different flow conditions on blood cell-biomaterial interactions with special emphasis on the interactions of human granulocytes (PMN) and polymeric surfaces. PMN were isolated and vital cells were quantified by flow cytometrical analysis directly before, as well as immediately after the experiments. The viscosity of the final cellular suspension was analysed by using a computerized cone-plate rheometer. As reference materials we used FEP-teflon, PVC-DEHD, PU, PP and PE. Dacron and ePTFE synthetic vascular protheses were tested in a comparative way to those references. The adhesion processes were observed over a period of 40 minutes under arterial (shear stress 0.74 Pa) and venous (shear stress 0.16 Pa) flow conditions in a parallel plate flow chamber system under highly standardized conditions and laminar flow. The cells were observed with the help of inverse light microscopy. Cell behaviour was recorded and analysed in both analogue (video) and digital (imaging system) modes. Samples of the cell suspensions were obtained at regular time intervals and analysed by enzyme linked immune sorbent assay (ELISA) to quantify LTB(4) release. Irrespective of the material, approximately 3 to 4 times more PMN adhered to the biomaterial surfaces under venous flow conditions compared to the arterial. Shear intensity did not influence the running order of biomaterials with respect to cell numbers. This response in descending order at the end of the experiments was as follows: PU, PVC-DEHD, PP, PE and ePTFE. The biochemical analyses indicate that in the system used only a weak effect on LTB(4) release induced by the different materials could be determined. A significant effect caused by flow conditions was not observed. Further experiments, both static as well as dynamic, must be performed for multiple, relevant parameters of haemocompatibility, for potential biomaterials as well as those currently in use in vascular prostheses.
RP Otto, M (reprint author), UNIV MAINZ,INST PATHOL,D-55101 MAINZ,GERMANY.
CR ABBASSI O, 1993, J CLIN INVEST, V92, P2719, DOI 10.1172/JCI116889
   [Anonymous], 1991, ANN BOOK ASTM STAND
   Bailey N. T. J., 1981, STATISTICAL METHODS
   BROWN RA, 1988, J CLIN PATHOL, V41, P1256, DOI 10.1136/jcp.41.12.1256
   CERLETTI C, 1993, ROLE PLATELETS BLOOD
   CURTIS ASG, 1986, J CELL SCI, V86, P9
   DAVID HA, 1954, BIOMETRIKA, V41, P482, DOI 10.1093/biomet/41.3-4.482
   DOOLEY DC, 1982, EXP HEMATOL, V10, P591
   GOLDSMITH HL, 1986, THROMB HAEMOSTASIS, V55, P415
   HIRAFUJI M, 1991, BRIT J PHARMACOL, V103, P1333, DOI 10.1111/j.1476-5381.1991.tb09789.x
   HORSTMANNJUNGEM.K, 1991, THESIS AACHEN
   HOWARD DW, 1991, FOOD TECHNOL-CHICAGO, V45, P82
   *ISO, 1992, 1099345 ISO
   KAPLAN SS, 1992, J BIOMED MATER RES, V26, P1039, DOI 10.1002/jbm.820260806
   KIRKPATRICK CJ, 1990, J MATER SCI-MATER M, V1, P9, DOI 10.1007/BF00705347
   KLEIN CL, 1995, INFUSIONSTHERAPIE, V22, P155
   KLEIN CL, 1994, PATHOBIOLOGY, V62, P90, DOI 10.1159/000163883
   KLEIN CL, 1994, SPEZIELLE METHODEN B
   KLEIN CL, 1994, COLLOID SURFACE B, V3, P229
   Lemm W., 1992, REFERENCE MAT EUROPE
   Lindblad B, 1990, Eur J Vasc Surg, V4, P341, DOI 10.1016/S0950-821X(05)80863-1
   LUNDELL A, 1993, EUR J VASCULAR SURG, V7, P698, DOI 10.1016/S0950-821X(05)80719-4
   MAUGERI N, 1994, THROMB HAEMOSTASIS, V72, P450
   MULLER KM, 1994, PATHOLOGY DEVICES
   Ormerod MG, 1990, FLOW CYTOMETRY PRACT
   RENESTO P, 1993, BLOOD, V82, P139
   RINDER HM, 1991, BLOOD, V78, P1730
   SLACK SM, 1994, THROMB HAEMOSTASIS, V72, P777
   Stehbens WE, 1995, VASCULAR PATHOLOGY
   TOMCZOK J, IN PRESS BIOMATERIAL
   TRUSKEY GA, 1990, J BIOMED MATER RES, V24, P1333, DOI 10.1002/jbm.820241006
   VANKOOTEN TG, 1992, J BIOMED MATER RES, V26, P725, DOI 10.1002/jbm.820260604
   WELCH BL, 1947, BIOMETRIKA, V34, P28, DOI 10.2307/2332510
   WILLIAMS DF, 1993, PROGR BIOMEDICAL ENG, V4
   YEO EL, 1994, BLOOD, V83, P2498
NR 35
TC 22
Z9 22
U1 0
U2 5
PU CHAPMAN HALL LTD
PI LONDON
PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8HN
SN 0957-4530
J9 J MATER SCI-MATER M
JI J. Mater. Sci.-Mater. Med.
PD MAR
PY 1997
VL 8
IS 3
BP 119
EP 129
DI 10.1023/A:1018515001850
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA WL651
UT WOS:A1997WL65100001
PM 15348765
DA 2018-10-19
ER

PT J
AU Kirkpatrick, CJ
   Wagner, M
   Kohler, H
   Bittinger, F
   Otto, M
   Klein, CL
AF Kirkpatrick, CJ
   Wagner, M
   Kohler, H
   Bittinger, F
   Otto, M
   Klein, CL
TI The cell and molecular biological approach to biomaterial research: A
   perspective
SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE
LA English
DT Article; Proceedings Paper
CT 11th European Conference on Biomaterials
CY SEP 10-14, 1994
CL PISA, ITALY
ID HUMAN ENDOTHELIAL-CELLS; EXPANDED POLYTETRAFLUOROETHYLENE GRAFTS;
   CALIBER VASCULAR GRAFTS; ADHESION MOLECULES; EXTRACELLULAR-MATRIX;
   SURFACE MODIFICATION; SIGNAL-TRANSDUCTION; ENHANCED ADHERENCE; TITANIUM
   IMPLANTS; GENE-EXPRESSION
AB The past two decades have witnessed a revolution in our understanding of chemical processes in living organisms. This is mainly a result of the massive advances in the fields of cell and molecular biology. These techniques are highly relevant to the biomaterials sector, as they offer the scientist the possibility to better understand the mechanisms involved in the interactions between cells and a material surface-a prerequisite for the rational development of medical devices with optimal biocompatibility. The purpose of the present article is to explain the rationale of the cell and molecular biological approach to biomaterial research and to present typical examples from the authors' laboratory, as well as from the literature, to illustrate its application. Important aspects of interfacial biology, including the underlying biological mechanisms and methodology, are presented. Of the latter the combination of morphological techniques with methods of cell and molecular biology as well as molecular genetics (so-called ''combinative techniques'') are particularly useful. The applicability of this approach is illustrated from a study on the pathomechanisms of metal ion-induced inflammation. In addition, the approach is essential to the development of targeted intervention strategies, as for example in the luminal surface modification of vascular prostheses to permit endothelial cell seeding.
RP Kirkpatrick, CJ (reprint author), UNIV MAINZ,INST PATHOL,D-6500 MAINZ,GERMANY.
CR AHLSWEDE KM, 1994, ARTERIOSCLER THROMB, V14, P25, DOI 10.1161/01.ATV.14.1.25
   AKIYAMA SK, 1990, BIOCHIM BIOPHYS ACTA, V1031, P91, DOI 10.1016/0304-4157(90)90004-V
   ALBELDA SM, 1994, FASEB J, V8, P504
   ALBELDA SM, 1990, FASEB J, V4, P2868
   ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8
   ANDERSON JS, 1987, SURGERY, V101, P577
   AUMAILLEY M, 1991, FEBS LETT, V291, P50, DOI 10.1016/0014-5793(91)81101-D
   AYALON O, 1994, J CELL BIOL, V126, P247, DOI 10.1083/jcb.126.1.247
   BERRIDGE MJ, 1988, P ROY SOC LOND B BIO, V234, P378
   BEVILACQUA MP, 1993, THROMB HAEMOSTASIS, V70, P152
   BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238
   BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210
   BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D
   BJURSTEN LM, 1990, BIOMATERIALS, V11, P596, DOI 10.1016/0142-9612(90)90085-5
   BORDENAVE L, 1992, BIOMATERIALS, V13, P439, DOI 10.1016/0142-9612(92)90164-J
   BOS JL, 1989, CANCER RES, V49, P4682
   BOYD JA, 1990, PHARMACOL THERAPEUT, V46, P469, DOI 10.1016/0163-7258(90)90028-Z
   BREUERS W, 1991, J MATER SCI-MATER M, V2, P106, DOI 10.1007/BF00703468
   CLARKE PR, 1994, CURR BIOL, V4, P647, DOI 10.1016/S0960-9822(00)00144-5
   COURTNEY JM, 1993, INT J ARTIF ORGANS, V16, P164
   CURTIS ASG, 1986, J CELL SCI, V86, P9
   DAVIES JE, 1990, J BIOMED MATER RES, V24, P1289, DOI 10.1002/jbm.820241003
   DAVIS RJ, 1993, J BIOL CHEM, V268, P14553
   DEDHAR S, 1990, BIOESSAYS, V12, P583, DOI 10.1002/bies.950121205
   DEKKER A, 1991, J MATER SCI-MATER M, V2, P227, DOI 10.1007/BF00703376
   DEKKER A, 1991, BIOMATERIALS, V12, P130, DOI 10.1016/0142-9612(91)90191-C
   DICHEK DA, 1989, CIRCULATION, V80, P1347, DOI 10.1161/01.CIR.80.5.1347
   Didisheim P, 1994, ASAIO J, V40, P230, DOI 10.1097/00002480-199404000-00020
   DONATH K, 1982, J ORAL PATHOL MED, V11, P318, DOI 10.1111/j.1600-0714.1982.tb00172.x
   DOYLE C, 1991, BIOMATERIALS, V12, P841, DOI 10.1016/0142-9612(91)90072-I
   DUSTIN ML, 1986, J IMMUNOL, V137, P245
   ERTEL SI, 1991, J BIOMAT SCI-POLYM E, V3, P163, DOI 10.1163/156856291X00269
   ESQUIVEL CO, 1986, J SURG RES, V41, P1, DOI 10.1016/0022-4804(86)90002-8
   FABRIZIUSHOMAN DJ, 1991, J BIOMED MATER RES, V25, P953, DOI 10.1002/jbm.820250804
   FASOL R, 1989, J VASC SURG, V9, P432, DOI 10.1067/mva.1989.vs0090432
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   FLUGELMAN MY, 1992, CIRC RES, V70, P348, DOI 10.1161/01.RES.70.2.348
   GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515
   GREISLER HP, 1992, SURGERY, V112, P244
   HANNUN YA, 1994, J BIOL CHEM, V269, P3125
   HORBETT TA, 1988, J BIOMED MATER RES, V22, P763, DOI 10.1002/jbm.820220903
   HUBBELL JA, 1991, BIO-TECHNOL, V9, P568, DOI 10.1038/nbt0691-568
   HUNT JA, 1992, J MATER SCI-MATER M, V3, P192, DOI 10.1007/BF00713449
   HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S
   ITOH H, 1992, BIOCHEM BIOPH RES CO, V188, P1205, DOI 10.1016/0006-291X(92)91359-X
   IULIANO DJ, 1993, J BIOMED MATER RES, V27, P1103, DOI 10.1002/jbm.820270816
   JARRELL BE, 1987, B NEW YORK ACAD MED, V63, P156
   KAEHLER J, 1989, J VASC SURG, V9, P535, DOI 10.1067/mva.1989.vs0090535
   KIRKPATRICK CJ, 1984, J PATHOL, V144, P201, DOI 10.1002/path.1711440307
   KIRKPATRICK CJ, 1990, J MATER SCI-MATER M, V1, P9, DOI 10.1007/BF00705347
   KIRKPATRICK CJ, 1991, CELL MATER, V1, P93
   KIRKPATRICK CJ, 1984, EXP CELL BIOL, V50, P108
   KLEIN CL, 1994, J MATER SCI-MATER M, V5, P798, DOI 10.1007/BF00213138
   KLEIN CL, 1994, COLLOID SURFACE B, V3, P229
   LEWANDOWSKA K, 1992, J BIOMED MATER RES, V26, P1343, DOI 10.1002/jbm.820261007
   LIN HB, 1992, BIOMATERIALS, V13, P905, DOI 10.1016/0142-9612(92)90113-3
   LINDHOUT T, 1994, NEPHROL DIAL TRANSPL, V9, P83
   LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1
   LUSCINSKAS FW, 1994, FASEB J, V8, P929
   MAGOMETSCHNIGG H, 1992, J VASC SURG, V15, P527, DOI 10.1016/0741-5214(92)90192-B
   MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8
   MASSIA SP, 1990, ANAL BIOCHEM, V187, P292, DOI 10.1016/0003-2697(90)90459-M
   MAZZUCOTELLI JP, 1991, INT J ARTIF ORGANS, V14, P482
   MCEVER RP, 1991, THROMB HAEMOSTASIS, V66, P80
   MCGREGOR PE, 1994, BIOCHEM BIOPH RES CO, V198, P359, DOI 10.1006/bbrc.1994.1050
   MIWA H, 1994, J VASC SURG, V19, P658, DOI 10.1016/S0741-5214(94)70039-7
   Miwa H, 1993, ASAIO J, V39, pM501
   MOORADIAN DL, 1992, J SURG RES, V53, P74, DOI 10.1016/0022-4804(92)90016-S
   MORLEY DJ, 1989, THROMB HAEMOSTASIS, V62, P1023
   PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0
   PITOT HC, 1993, CANCER-AM CANCER SOC, V72, P962, DOI 10.1002/1097-0142(19930801)72:3+<962::AID-CNCR2820721303>3.0.CO;2-H
   PRATT KJ, 1989, J BIOMED MATER RES, V23, P1131, DOI 10.1002/jbm.820231004
   PULEO DA, 1993, BIOMATERIALS, V14, P111, DOI 10.1016/0142-9612(93)90220-V
   PURCHASE IFH, 1994, HUM EXP TOXICOL, V13, P17, DOI 10.1177/096032719401300104
   RADDER AM, 1994, J MATER SCI-MATER M, V5, P582, DOI 10.1007/BF00120334
   RAGHOW R, 1994, FASEB J, V8, P823
   RIXEN H, 1989, EXP CELL BIOL, V57, P315
   RUOSLAHTI E, 1985, ARTERIOSCLEROSIS, V5, P581, DOI 10.1161/01.ATV.5.6.581
   SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055
   SANTERRE JP, 1993, J BIOMED MATER RES, V27, P97, DOI 10.1002/jbm.820270113
   SBARBATI R, 1991, INT J ARTIF ORGANS, V14, P491
   SCHAKENRAAD JM, 1991, CELL MATER, V1, P35
   SCHWARTZ Z, 1991, CALCIFIED TISSUE INT, V49, P359, DOI 10.1007/BF02556260
   SEEGER JM, 1985, J SURG RES, V38, P641, DOI 10.1016/0022-4804(85)90087-3
   SENTISSI JM, 1986, SURGERY, V99, P337
   SHANBHAG A, 1992, J BIOMED MATER RES, V26, P185, DOI 10.1002/jbm.820260205
   SINGER SJ, 1992, SCIENCE, V255, P1671, DOI 10.1126/science.1313187
   SMITH R, 1987, J BIOMED MATER RES, V21, P1149, DOI 10.1002/jbm.820210908
   STEINBERG J, 1989, J BIOMED MATER RES, V23, P591, DOI 10.1002/jbm.820230605
   TENGVALL P, 1989, BIOMATERIALS, V10, P166, DOI 10.1016/0142-9612(89)90019-7
   THERIN M, 1991, J MATER SCI-MATER M, V2, P1, DOI 10.1007/BF00701681
   TOMCZOK J, 1994, MICRON, V25, P257, DOI 10.1016/0968-4328(94)90031-0
   VANWACHEM PB, 1989, BIOMATERIALS, V10, P532, DOI 10.1016/0142-9612(89)90058-6
   VOGLER EA, 1987, J BIOMED MATER RES, V21, P1197, DOI 10.1002/jbm.820211004
   VROMAN L, 1986, J COLLOID INTERF SCI, V111, P391, DOI 10.1016/0021-9797(86)90042-1
   WARKENTIN PH, 1993, J MATER SCI-MATER M, V4, P318, DOI 10.1007/BF00122288
   WILLIAMS DF, 1987, J MATER SCI, V22, P3421, DOI 10.1007/BF01161439
   WILLIAMS DF, 1986, BIOL BIOMECHANICAL P, P239
   ZAMBETTI GP, 1993, FASEB J, V7, P855
   ZIATS NP, 1988, BIOMATERIALS, V9, P5, DOI 10.1016/0142-9612(88)90063-4
   ZILLA P, 1987, ENDOTHELIALIZATION V, P195
NR 101
TC 55
Z9 55
U1 0
U2 4
PU CHAPMAN HALL LTD
PI LONDON
PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8HN
SN 0957-4530
J9 J MATER SCI-MATER M
JI J. Mater. Sci.-Mater. Med.
PD MAR
PY 1997
VL 8
IS 3
BP 131
EP 141
DI 10.1023/A:1018567018688
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA WL651
UT WOS:A1997WL65100002
PM 15348766
DA 2018-10-19
ER

PT J
AU LaJoie, EN
   Barofsky, AD
   Gregory, KW
   Prahl, SA
AF LaJoie, EN
   Barofsky, AD
   Gregory, KW
   Prahl, SA
TI Patch welding with a pulsed diode laser and indocyanine green
SO LASERS IN MEDICAL SCIENCE
LA English
DT Article
ID DYE
AB Laser tissue welding is a sutureless method of wound closure that has been used successfully in nerve, skin and arterial anastomoses. An elastin-based biomaterial patch was welded to the intimal surface of porcine aorta in the present study. The aorta was stained with indocyanine green dye to efficiently absorb the 808 nm diode laser light. Laser welding with a pulsed diode laser thermally confines heating to the stained portion of tissue, minimizing adjacent tissue damage. Laser welds of stained aorta to biomaterial were attempted by sandwiching the samples between glass slides and applying pressures ranging from 4 to 20 N cm(-2) for 5 ms pulse durations and 83 mJ mm(-2) radiant exposure. Bleaching of the indocyanine green by as much as 85% was observed after exposure laser irradiation. Finally, successful welds required 5 N cm(-2) of pressure between the elastin biomaterial and aorta.
C1 OREGON MED LASER CTR, PORTLAND, OR 97225 USA.
   OREGON GRAD INST, PORTLAND, OR 97291 USA.
CR Anderson R R, 1981, Lasers Surg Med, V1, P263
   Bass LS, 1995, LASER SURG MED, V17, P315, DOI 10.1002/lsm.1900170402
   BASS LS, 1993, Patent No. 5209776
   CHUCK RS, 1989, LASER SURG MED, V9, P471, DOI 10.1002/lsm.1900090508
   DIMITROV D, 1995, P SOC PHOTO-OPT INS, V2395, P486, DOI 10.1117/12.209135
   GATHJE J, 1970, J APPL PHYSIOL, V29, P181
   GREGORY KW, 1994, CIRCULATION, V90, P596
   LANDSMAN MLJ, 1976, J APPL PHYSIOL, V40, P575
   MURRAY LW, 1989, LASER SURG MED, V9, P490, DOI 10.1002/lsm.1900090512
   OZ MC, 1990, J VASC SURG, V11, P718, DOI 10.1067/mva.1990.18591
   PRAHL SA, 1988, SPIE, V908, P29
   Rabaud M, 1992, J Biomater Appl, V7, P20, DOI 10.1177/088532829200700102
   ZHOU JF, 1994, P SOC PHOTO-OPT INS, V2128, P495, DOI 10.1117/12.184936
NR 13
TC 5
Z9 5
U1 0
U2 1
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0268-8921
EI 1435-604X
J9 LASER MED SCI
JI Lasers Med. Sci.
PD SPR
PY 1997
VL 12
IS 1
BP 49
EP 54
DI 10.1007/BF02763921
PG 6
WC Engineering, Biomedical; Surgery
SC Engineering; Surgery
GA WP575
UT WOS:A1997WP57500006
DA 2018-10-19
ER

PT J
AU Terada, N
   Bjursten, LM
   Dohi, DS
   Lundborg, G
AF Terada, N
   Bjursten, LM
   Dohi, DS
   Lundborg, G
TI Bioartificial nerve grafts based on absorbable guiding filament
   structures - Early observations
SO SCANDINAVIAN JOURNAL OF PLASTIC AND RECONSTRUCTIVE SURGERY AND HAND
   SURGERY
LA English
DT Article
DE nerve regeneration; axonal growth; nerve graft; silicone chamber;
   resorbable filament; biomaterial
ID LAMININ-CONTAINING GEL; MATRIX FORMATION; REPAIR; REGENERATION; GUIDES;
   TUBES
AB Gaps 10 mm wide in the sciatic nerves of 64 rats were bridged by bioartificial nerve grafts consisting of a silicone tube containing seven longitudinally placed filaments made of non-absorbable, (polyamide [Ethilon(R)]) or absorbable, material (polydioxanone [PDS(R)], polyglactin [Vicryl(R)], and catgut). The purpose was to study the organisation of axonal growth inside the tube along such filaments. After two and four weeks histological techniques were used to study the contents of the tube and at four weeks immunohistological techniques were used to confirm the presence of axons distal to the tube. in all experimental groups axons had traversed the tube and reached the distal segment after four weeks. inside the tube axons were organised in multiple minifascicles in all groups, but there were no axons growing in direct contact with the filaments. We conclude that resorbable filaments placed inside a silicone tube do not disturb axonal growth across the tube.
C1 UNIV LUND,MALMO UNIV HOSP,DEPT HAND SURG,S-20502 MALMO,SWEDEN.
   KEIO UNIV,SCH MED,DEPT ORTHOPAED SURG,TOKYO,JAPAN.
   LUND UNIV,MALMO UNIV HOSP,DEPT EXPT RES,MALMO,SWEDEN.
   HIROSHIMA UNIV,SCH MED,DEPT ORTHOPAED SURG,HIROSHIMA,JAPAN.
CR Danielsen N, 1990, Restor Neurol Neurosci, V1, P253, DOI 10.3233/RNN-1990-13412
   LANGONE F, 1995, BIOMATERIALS, V16, P347, DOI 10.1016/0142-9612(95)93851-4
   Longo F M, 1982, Brain Res, V255, P277
   LUNDBORG G, 1991, SCAND J PLAST RECONS, V25, P79, DOI 10.3109/02844319109034927
   Lundborg G, 1996, SCAND J PLAST RECONS, V30, P105, DOI 10.3109/02844319609056391
   LUNDBORG G, 1994, J HAND SURG-BRIT EUR, V19B, P273, DOI 10.1016/0266-7681(94)90068-X
   LUNDBORG G, 1980, J HAND SURG, V5, P35
   LUNDBORG G, 1996, J HAND SURG B, V21, P5
   MACKINNON SE, 1990, PLAST RECONSTR SURG, V85, P419, DOI 10.1097/00006534-199003000-00015
   MADISON R, 1985, EXP NEUROL, V88, P767, DOI 10.1016/0014-4886(85)90087-1
   MADISON RD, 1987, EXP NEUROL, V95, P378, DOI 10.1016/0014-4886(87)90146-4
   WILLIAMS LR, 1985, J COMP NEUROL, V231, P209, DOI 10.1002/cne.902310208
   ZHAO Q, 1993, RESTOR NEUROL NEUROS, V5, P197, DOI 10.3233/RNN-1993-5304
NR 13
TC 18
Z9 19
U1 0
U2 1
PU SCANDINAVIAN UNIVERSITY PRESS
PI OSLO
PA PO BOX 2959 TOYEN, JOURNAL DIVISION CUSTOMER SERVICE, N-0608 OSLO,
   NORWAY
SN 0284-4311
J9 SCAND J PLAST RECONS
JI Scand. J. Plast. Reconstr. Surg. Hand Surg.
PD MAR
PY 1997
VL 31
IS 1
BP 1
EP 6
PG 6
WC Surgery
SC Surgery
GA WL561
UT WOS:A1997WL56100001
PM 9075281
DA 2018-10-19
ER

PT J
AU Hodde, JP
   Badylak, SF
   Shelbourne, KD
AF Hodde, JP
   Badylak, SF
   Shelbourne, KD
TI The effect of range of motion on remodeling of small intestinal
   submucosa (SIS) when used as an Achilles tendon repair material in the
   rabbit
SO TISSUE ENGINEERING
LA English
DT Article
ID CAROTID-ARTERY; GRAFT; DOG; IMMOBILIZATION; MUSCLE
AB Small intestinal submucosa (SIS) is a biomaterial that has proven successful as a xenogeneic tissue graft in a variety of vascular, urological, dermatological, and orthopaedic applications. The effect of a single variable, the applied range of motion, on SIS graft remodeling was examined in a rabbit model of Achilles tendon replacement in the present study. A 1.5-cm long segment of the Achilles tendon was replaced by a porcine origin, braided SIS material in 36 New Zealand White rabbits. Following 2 weeks of complete immobilization in a long leg cast, rabbits were placed in ankle braces for an additional 4 weeks. These braces were especially designed to allow either no motion or full range of motion or to limit the range of motion to between 60 degrees and 90 degrees hock flexion. Histopathological examination of the remodeled tendons showed that immobilization slowed the wound healing response. The SIS material in rabbits with no motion was associated with an increased presence of fibroblasts, extracellular matrix, mononuclear cells, and blood vessels in the remodeling Achilles tendons compared with native tendons. However, either partial or full motion was associated with greater cellular infiltrate and more organized connective tissue matrix than was no motion. We conclude that early postsurgical motion in the presence of SIS facilitates new tissue deposition along the lines of stress in this rabbit model. Total immobilization slows the inflammatory phase of healing, including extracellular matrix deposition, to the midsubstance of the tendon. Unrestricted motion and weightbearing during the early remodeling phase clearly result in changes consistent with accelerated tissue remodeling compared with totally immobilized tendons following placement of tendon grafts in this animal model.
C1 PURDUE UNIV,HILLENBRAND BIOMED ENGN CTR,W LAFAYETTE,IN 47907.
   THOMAS A BRADY CLIN,METHODIST SPORTS MED CTR,INDIANAPOLIS,IN 46202.
OI Badylak, Stephen/0000-0003-3555-0689
CR BADYLAK SF, 1995, J BIOMED MATER RES, V29, P977, DOI 10.1002/jbm.820290809
   BADYLAK SF, 1993, TISSUE ENGINEERING, P179
   BADYLAK SF, 1989, J SURG RES, V47, P74, DOI 10.1016/0022-4804(89)90050-4
   BOOTH FW, 1982, J APPL PHYSIOL, V52, P1113
   DELEE JC, 1990, SPORTS-INDUCED INFLAMMATION : CLINICAL AND BASIC SCIENCE CONCEPTS, P547
   HERBERT RD, 1993, J ORTHOPAED RES, V11, P358, DOI 10.1002/jor.1100110307
   Kessler I, 1973, Hand, V5, P253, DOI 10.1016/0072-968X(73)90038-7
   KNAPP PM, 1994, J ENDOUROL, V8, P125, DOI 10.1089/end.1994.8.125
   LANDVATER SJ, 1992, CLIN SPORT MED, V11, P741
   Lantz G C, 1990, J Invest Surg, V3, P217, DOI 10.3109/08941939009140351
   LANTZ GC, 1992, J SURG RES, V53, P175, DOI 10.1016/0022-4804(92)90031-T
   SANDUSKY GE, 1995, J SURG RES, V58, P415, DOI 10.1006/jsre.1995.1064
   SANDUSKY GE, 1992, AM J PATHOL, V140, P317
   WOO SLY, 1987, J BONE JOINT SURG AM, V69A, P1200, DOI 10.2106/00004623-198769080-00014
NR 14
TC 58
Z9 59
U1 1
U2 6
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538
SN 1076-3279
J9 TISSUE ENG
JI Tissue Eng.
PD SPR
PY 1997
VL 3
IS 1
BP 27
EP 37
DI 10.1089/ten.1997.3.27
PG 11
WC Cell & Tissue Engineering
SC Cell Biology
GA XN989
UT WOS:A1997XN98900003
DA 2018-10-19
ER

PT J
AU Chen, GP
   Ito, Y
   Imanishi, Y
AF Chen, GP
   Ito, Y
   Imanishi, Y
TI Regulation of growth and adhesion of cultured cells by insulin
   conjugated with thermoresponsive polymers
SO BIOTECHNOLOGY AND BIOENGINEERING
LA English
DT Article
DE cell culture; tissue engineering; thermoresponsive polymer; cell
   adhesion; insulin conjugate
ID POLY(METHYL METHACRYLATE) MEMBRANE; FIBROBLAST CELLS; SURFACES;
   POLY(N-ISOPROPYLACRYLAMIDE); DETACHMENT; OLIGOMERS; ENZYME
AB We developed a new biomaterial for use in cell culture. The biomaterial enabled protein-free cell culture and the recovery of viable cells by lowering the temperature without the aid of supplements. insulin was immobilized and a thermoresponsive polymer was grafted onto a substrate. We investigated the effect of insulin coupling on the lower critical solution temperature (LCST) of the thermoresponsive polymer, poly(N-isopropylacrylamide-co-acrylic acid), using polymers that were ungrafted, or coupled with insulin. The insulin conjugates were precipitated from an aqueous solution at high temperatures, but they were soluble at low temperatures. The LCST was not significantly affected by the insulin coupling. The thermoresponsive polymer was grafted to glow-discharged polystyrene film and covalently conjugated with insulin. The surface wettability of the conjugate film was high at low temperatures and low at high temperatures. The amounts of immobilized insulin required to stimulate cell growth were 1-10% of the amount of free insulin required to produce the same effect. The maximal mitogenic effect of immobilized insulin was greater than that of free insulin. About half of the viable cells was detached from the film only by lowering the temperature. The recovered cells proliferated normally on new culture dishes. (C) 1997 John Wiley & Sons, Inc.
C1 KYOTO UNIV,FAC ENGN,DEPT CHEM MAT,KYOTO 60601,JAPAN.
RI Ito, Yoshihiro/F-4370-2012
CR CHEN GH, 1994, J BIOMAT SCI-POLYM E, V5, P371
   CHEN GH, 1995, NATURE, V373, P49, DOI 10.1038/373049a0
   CLAESSON PM, 1989, J COLLOID INTERF SCI, V130, P457, DOI 10.1016/0021-9797(89)90123-9
   FUJISHIGE S, 1989, J PHYS CHEM-US, V93, P3311, DOI 10.1021/j100345a085
   ITO Y, 1992, BIOMATERIALS, V13, P789, DOI 10.1016/0142-9612(92)90019-K
   Ito Y, 1996, P NATL ACAD SCI USA, V93, P3598, DOI 10.1073/pnas.93.8.3598
   ITO Y, 1992, BIOTECHNOL BIOENG, V40, P1271, DOI 10.1002/bit.260401017
   ITO Y, 1991, BIOMATERIALS, V12, P449, DOI 10.1016/0142-9612(91)90141-V
   LIU SQ, 1993, J BIOMED MATER RES, V27, P909, DOI 10.1002/jbm.820270710
   LIU SQ, 1992, J BIOCHEM BIOPH METH, V25, P139
   LIU SQ, 1992, BIOMATERIALS, V13, P50, DOI 10.1016/0142-9612(92)90095-6
   MATSUKATA M, 1994, J BIOCHEM-TOKYO, V116, P682, DOI 10.1093/oxfordjournals.jbchem.a124580
   OKANO T, 1995, BIOMATERIALS, V16, P297, DOI 10.1016/0142-9612(95)93257-E
   OKANO T, 1993, J BIOMED MATER RES, V27, P1243, DOI 10.1002/jbm.820271005
   PARK TG, 1993, J BIOMAT SCI-POLYM E, V4, P493
   SCHUTTLER A, 1982, H-S Z PHYSIOL CHEM, V363, P317, DOI 10.1515/bchm2.1982.363.1.317
   STAYTON PS, 1995, NATURE, V378, P472, DOI 10.1038/378472a0
   TAKEI YG, 1993, BIOCONJUGATE CHEM, V4, P42, DOI 10.1021/bc00019a006
   TAKEZAWA T, 1990, BIO-TECHNOL, V8, P854, DOI 10.1038/nbt0990-854
   TAKEZAWA T, 1993, POLYM PREPR JPN, V42, P3247
   VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156
   YAMADA N, 1990, MAKROMOL CHEM-RAPID, V11, P571
   ZHENG J, 1995, J BIOMAT SCI-POLYM E, V7, P515
   ZHENG J, 1994, BIOMATERIALS, V15, P963, DOI 10.1016/0142-9612(94)90076-0
NR 24
TC 52
Z9 61
U1 0
U2 13
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0006-3592
J9 BIOTECHNOL BIOENG
JI Biotechnol. Bioeng.
PD FEB 5
PY 1997
VL 53
IS 3
BP 339
EP 344
PG 6
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA WG069
UT WOS:A1997WG06900013
PM 18633989
DA 2018-10-19
ER

PT J
AU Tsuang, YH
   Lin, FH
   Sun, JS
   Hang, YS
   Liu, HC
AF Tsuang, YH
   Lin, FH
   Sun, JS
   Hang, YS
   Liu, HC
TI In vitro cell behavior of osteoblasts on pyrost bone substitute
SO ANATOMICAL RECORD
LA English
DT Article
DE pyrost bone; osteoblasts; adhesion; spreading
ID CULTURE; DIFFERENTIATION; HYDROXYAPATITE; FIBRONECTIN; ALLOGRAFTS;
   CARTILAGE; INVITRO
AB Background: Pyrost bone substitute has been shown to be a promising orthopedic biomaterial, However, little is known about mechanisms that are responsible for the genesis and development of the bond between bone and the Pyrost bone substitute, The purpose of this study is to elucidate the in vitro cell behavior of osteoblasts on Pyrost bone substitute.
   Methods: By using primary culture of rat osteoblasts, the changes in cell morphology during adhesion and flattening onto the surface of Pyrost bone substitute were studied in vitro, At 1 hour, at 3 hours, and at days 1, 3, and 7 after layering, the cell behavior was observed with scanning electron microscope.
   Results: The processes of trypsinized osteoblast adhesion and spreading on Pyrost bone substitute consisted of 1) contact of rounded osteoblasts with the Pyrost substrate; 2) attachment of osteoblasts at point of contact; 3) centrifugal growth of filopodia; 4) flattening and spreading of the osteoblasts on the Pyrost substrate; 5) division and growth of osteoblasts; and 6) suspension of the osteoblasts across the pores by their processes.
   Conclusions: These results demonstrated that Pyrost can form a physicochemical bond with osteoblasts, The Pyrost bone substitute not only supports osteoblasts attachment but also allows proliferation of the osteoblasts. (C) 1997 Wiley-Liss, Inc.
C1 NATL TAIWAN UNIV HOSP, COLL MED, DEPT ORTHOPED SURG, TAIPEI, TAIWAN.
   NATL TAIWAN UNIV, COLL MED, CTR BIOMED ENGN, TAIPEI 10764, TAIWAN.
   TAIWAN PROV TAO YUAN GEN HOSP, DEPT ORTHOPED SURG, TAYUAN, TAIWAN.
OI SUN, JUI-SHENG/0000-0001-5142-8777
CR BAGAMBISA FB, 1990, BIOMATERIALS, V11, P50, DOI 10.1016/0142-9612(90)90052-R
   BEGLEY CT, 1993, BONE, V14, P661, DOI 10.1016/8756-3282(93)90089-S
   BONFIGLIO M, 1972, CLIN ORTHOP RELAT R, P19
   BOONEKAMP PM, 1984, P K NED AKAD B PHYS, V87, P371
   BOS GD, 1983, J BONE JOINT SURG AM, V65, P239, DOI 10.2106/00004623-198365020-00015
   CARNESALE PL, 1959, J BONE JOINT SURG AM, V41, P887, DOI 10.2106/00004623-195941050-00008
   Doty S B, 1976, Prog Histochem Cytochem, V8, P1
   FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0
   Grinnell F, 1978, Int Rev Cytol, V53, P65
   JARCHO M, 1977, J BIOENG, V1, P79
   KATTHAGEN BD, 1986, BONE REGENERATION BO, P29
   MALIK MA, 1992, BIOMATERIALS, V13, P123, DOI 10.1016/0142-9612(92)90008-C
   MANKIN HJ, 1987, ORTHOP CLIN N AM, V18, P275
   PARRISH FF, 1972, CLIN ORTHOP RELAT R, P36
   RAJARAMAN R, 1974, EXP CELL RES, V88, P327, DOI 10.1016/0014-4827(74)90248-1
   REVEL JP, 1973, EXP CELL RES, V78, P1, DOI 10.1016/0014-4827(73)90031-1
   URIST MR, 1994, BONE GRAFTS DERIVATI, P220
   WEISS RE, 1980, P NATL ACAD SCI-BIOL, V77, P2074, DOI 10.1073/pnas.77.4.2074
   WEISS RE, 1981, J CELL BIOL, V88, P630, DOI 10.1083/jcb.88.3.630
NR 19
TC 4
Z9 8
U1 0
U2 0
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0003-276X
J9 ANAT RECORD
JI Anat. Rec.
PD FEB
PY 1997
VL 247
IS 2
BP 164
EP 169
PG 6
WC Anatomy & Morphology
SC Anatomy & Morphology
GA WF445
UT WOS:A1997WF44500002
PM 9025995
DA 2018-10-19
ER

PT J
AU Villermaux, F
   Tabrizian, M
   Yahia, LH
   Meunier, M
   Piron, DL
AF Villermaux, F
   Tabrizian, M
   Yahia, LH
   Meunier, M
   Piron, DL
TI Excimer laser treatment of NiTi shape memory alloy biomaterials
SO APPLIED SURFACE SCIENCE
LA English
DT Article; Proceedings Paper
CT Proceedings of Symposium H on Laser Processing of Surfaces and Thin
   Films of the 1996 E-MRS Spring Conference
CY JUN 04-07, 1996
CL STRASBOURG, FRANCE
SP European Mat Res Soc
DE NiTi shape memory alloy; laser surface treatment; corrosion resistance;
   biomaterials
ID CORROSION-RESISTANCE; STAINLESS-STEEL; BEHAVIOR; BIOCOMPATIBILITY
AB NiTi Shape Memory Alloys (SMA) are potential biomaterial candidates. However, due to its possible corrosion in physiological solution, dissolution of toxic Ni might be happening, rendering this material nonbiocompatible. We have used excimer laser surface treatment to improve corrosion resistance of NiTi SMA plates. Potentiodynamic tests in physiological Hank's solution show that the laser treatment performed in air improved all corrosion parameters. The surface is homogenized and a Scanning Electron Microscopy (SEM) observation indicates a decrease of corrosion pit size and numbers. Laser treatment improvement resistance is explained by a combination of the homogenization of the surface by melting, the hardening due to N incorporation and the thickening of the oxide layer.
C1 ECOLE POLYTECH, COUCHES MINCES GRP, DEPT ENGN PHYS, MONTREAL, PQ H3C 3A7, CANADA.
   ECOLE POLYTECH, DEPT MET, MONTREAL, PQ H3C 3A7, CANADA.
RP Villermaux, F (reprint author), INST BIOMED ENGN, BIOMECH BIOMAT RES GRP, MONTREAL, PQ H3C 3A7, CANADA.
RI Meunier, Michel/A-6127-2013
CR ABIKIDO Y, 1994, P 1 INT C SHAP MEM S
   BERGERON A, 1994, TRAITEMENT SURFACES
   BERGMANN HW, 1989, THIN SOLID FILMS, V174, P33, DOI 10.1016/0040-6090(89)90865-1
   CASTLEMAN LS, 1981, BIOCOMPATIBILITY CLI, P129
   DUTTA RS, 1993, BRIT CORROS J, V28, P217
   EDIE JW, 1981, ANGLE ORTHOD, V51, P319
   GREEN SM, 1993, J MATER SCI LETT, V12, P618, DOI 10.1007/BF00465570
   KIMURA H, 1987, DENT MAT APPARATUS, V6, P73
   LOMBARDI S, 1994, P 1 INT C SHAP MEM S
   NAKAYAMA Y, 1989, BIOMATERIALS, V10, P420, DOI 10.1016/0142-9612(89)90134-8
   PARVATHAVARTHINI N, 1992, MATER SCI TECH SER, V8, P1070, DOI 10.1179/mst.1992.8.12.1070
   REITZ W, 1992, J MATER SCI, V27, P2437, DOI 10.1007/BF01105055
   RONDELLI G, 1990, CORROS SCI, V30, P805, DOI 10.1016/0010-938X(90)90004-O
   SARKAR NK, 1983, J ORAL REHABIL, V10, P121, DOI 10.1111/j.1365-2842.1983.tb00106.x
   Shabalovskaya S., 1994, P 1 INT C SHAP MEM S
   SPECK KM, 1980, J DENT RES, V30, P805
   TANG RG, 1994, P 1 INT C SHAP MEM S
   TUCKER TR, 1982, MICROSTRUCT SCI, V10, P347
   ZITTER H, 1987, J BIOMED MATER RES, V21, P881, DOI 10.1002/jbm.820210705
NR 19
TC 70
Z9 76
U1 1
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-4332
J9 APPL SURF SCI
JI Appl. Surf. Sci.
PD FEB
PY 1997
VL 109
BP 62
EP 66
DI 10.1016/S0169-4332(96)00619-8
PG 5
WC Chemistry, Physical; Materials Science, Coatings & Films; Physics,
   Applied; Physics, Condensed Matter
SC Chemistry; Materials Science; Physics
GA WK227
UT WOS:A1997WK22700013
DA 2018-10-19
ER

PT J
AU Grande, DA
   Halberstadt, C
   Naughton, G
   Schwartz, R
   Manji, R
AF Grande, DA
   Halberstadt, C
   Naughton, G
   Schwartz, R
   Manji, R
TI Evaluation of matrix scaffolds for tissue engineering of articular
   cartilage grafts
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
ID ALLOGRAFT CHONDROCYTES; REPAIR; REPLACEMENT; DEFECTS
AB Injury to articular cartilage predisposes that joint to further degeneration and eventually osteoarthritis. Recent studies have demonstrated the feasibility of using chondrocytes together with different biomaterial carriers as grafts for the repair of cartilage defects. The following study was undertaken to determine the effect of a variety of these materials on chondrocyte growth and extracellular matrix synthesis. We cultured chondrocytes on several commonly used materials and compared their rates of synthesis of proteoglycan and collagen. Additionally, we evaluated them in a closed culture recirculating system on these materials and compared them with standard culture techniques. This was done to see whether such a bioreactor-type system can be used to enhance the quality of in vitro reconstructed tissues. Our results demonstrated marked variability with respect to how chondrocytes responded to culture on the various materials. Bioabsorbable polymers such as polyglycolic acid (PGA)-enhanced proteoglycan synthesis, whereas collagen matrices stimulated synthesis of collagen. The use of the closed culture system, in general, improved the rates of synthesis of collagen and proteoglycan on the different material scaffolds. Exceptions were collagen synthesis on collagen matrices: use of the closed culture system did not enhance the rate of synthesis. Rates of proteoglycan synthesis on PGA scaffold initially was higher in the closed culture system but did not sustain a difference over the entire course of the 3-week culture period. This study demonstrates the importance of carrier material for the purpose of cartilage tissue reconstruction in vitro. (C) 1997 John Wiley & Sons, Inc.
C1 ADV TISSUE SCI INC,LA JOLLA,CA.
RP Grande, DA (reprint author), N SHORE UNIV HOSP,CORNELL UNIV MED COLL,ORTHOPAED RES LAB,DEPT SURG,300 COMMUNITY DR,MANHASSET,NY 11030, USA.
FU NIAMS NIH HHS [R29 AR40959]
CR BENTLEY G, 1989, CRIT REV BIOCOMPAT, V5, P245
   BENYISHAY A, 1992, T ORTHOP RES SOC, V17, P174
   BRITTBERG M, 1994, NEW ENGL J MED, V331, P889, DOI 10.1056/NEJM199410063311401
   FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269
   FREED LE, 1994, BIO-TECHNOL, V12, P689, DOI 10.1038/nbt0794-689
   FREED LE, 1994, J BIOMED MATER RES, V28, P891, DOI 10.1002/jbm.820280808
   FREED LE, 1995, BIOMEDICAL ENG HDB, P1788
   GRANDE DA, 1989, J ORTHOP RES, V7, P208, DOI 10.1002/jor.1100070208
   GRANDE DA, 1993, T ORTHOP RES SOC, V18, P731
   GRAY ML, 1988, J ORTHOPAED RES, V6, P777, DOI 10.1002/jor.1100060602
   HARDINGHAM TE, 1972, BIOCHEM J, V129, P101, DOI 10.1042/bj1290101
   ITAY S, 1987, CLIN ORTHOP RELAT R, V220, P284
   KIM YJ, 1988, ANAL BIOCHEM, V173, P1
   MANKIN HJ, 1974, NEW ENGL J MED, V291, P1285, DOI 10.1056/NEJM197412122912406
   MAROUDAS A, 1986, ARTICULAR CARTILAGE, P311
   SOKOLOFF L, 1974, J RHEUMATOL, V1, P1
   SOLURSH M, 1991, J CELL BIOCHEM, V45, P258, DOI 10.1002/jcb.240450306
   Speer DP, 1979, CLIN ORTHOP RELAT R, V144, P326
   VACANTI CA, 1991, PLAST RECONSTR SURG, V88, P753, DOI 10.1097/00006534-199111000-00001
   VONSCHROEDER HP, 1991, J BIOMED MATER RES, V25, P329, DOI 10.1002/jbm.820250305
   WAKITANI S, 1989, J BONE JOINT SURG BR, V71, P74
NR 21
TC 328
Z9 361
U1 3
U2 35
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD FEB
PY 1997
VL 34
IS 2
BP 211
EP 220
DI 10.1002/(SICI)1097-4636(199702)34:2<211::AID-JBM10>3.0.CO;2-L
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA WF102
UT WOS:A1997WF10200010
PM 9029301
DA 2018-10-19
ER

PT J
AU Hemmerle, J
   Cuisinier, FJG
   Schultz, P
   Voegel, JC
AF Hemmerle, J
   Cuisinier, FJG
   Schultz, P
   Voegel, JC
TI HRTEM study of biological crystal growth mechanisms in the vicinity of
   implanted synthetic hydroxyapatite crystals
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE hydroxyapatite; bone-grafting; high-resolution TEM; hydroxyapatite/bone
   interface; crystal growth
ID PHOSPHATE CERAMIC COMPOSITION; ELECTRON-MICROSCOPY; INVITRO BEHAVIOR;
   DENTAL IMPLANT; METAL IMPLANTS; BONE; INTERFACE; PRECIPITATION; DEFECTS;
   INVIVO
AB Calcium phosphates are widely used as biomaterials. Ultrastructural assessments are of the utmost importance in our understanding of interfacial phenomena. The aim of this study was to learn more about the newly formed crystal growth mechanisms. The interfaces between implanted synthetic hydroxyapatite crystals (HAS) and newly formed crystallites were thoroughly examined on a molecular level. The bone-grafting material (HAS) was implanted into two adult patients, and small biopsies were recovered 6 months after implantation. The raw biomaterial was analyzed by x-ray diffraction and high-resolution transmission electron microscopy (HRTEM). Six months after their implantation, the HAS aggregates were surrounded by a mineralized bone matrix. Tiny crystallites also filled the spaces between the HAS crystals within the aggregates. These newly formed crystallites growing at the surfaces of the implanted HAS crystals appeared to be apatitic. The crystallographic investigations of the nucleation and growing mechanisms of the newly formed crystallites were performed by HRTEM in association with computer simulation and mathematical processing of digitized images. A relationship was noted between the orientation axes of crystallites growing nearby and the zone axes of the implanted HAS, thus strongly suggesting a guiding or substratum role of the HAS particles.
C1 INST GENET & BIOL MOL & CELLULAIRE, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE.
RP Hemmerle, J (reprint author), INSERM, U424, FEDERAT RECH ODONTOL, 11 RUE HUMANN, F-67085 STRASBOURG, FRANCE.
CR BAGAMBISA FB, 1993, J BIOMED MATER RES, V27, P1047, DOI 10.1002/jbm.820270810
   BAY BK, 1993, BONE, V14, P225, DOI 10.1016/8756-3282(93)90145-Z
   DACULSI G, 1989, J BIOMED MATER RES, V23, P883, DOI 10.1002/jbm.820230806
   DAMEN JJM, 1991, J DENT RES, V70, P1346, DOI 10.1177/00220345910700100601
   DEBRUIJN JD, 1995, J BIOMED MATER RES, V29, P89, DOI 10.1002/jbm.820290113
   DELANGE GL, 1990, J BIOMED MATER RES, V24, P829, DOI 10.1002/jbm.820240704
   DUCHEYNE P, 1993, J BIOMED MATER RES, V27, P25, DOI 10.1002/jbm.820270105
   FRANK RM, 1991, J CLIN PERIODONTOL, V18, P669, DOI 10.1111/j.1600-051X.1991.tb00108.x
   FRANK RM, 1991, J APPL BIOMATER, V2, P243, DOI 10.1002/jab.770020405
   GARCIA R, 1992, J MATER SCI-MATER M, V3, P154, DOI 10.1007/BF00705285
   HAYASHI K, 1989, J BIOMED MATER RES, V23, P1247, DOI 10.1002/jbm.820231103
   INADOME T, 1995, J BIOMED MATER RES, V29, P19, DOI 10.1002/jbm.820290104
   IVARSSON B A, 1985, Colloids and Surfaces, V13, P169, DOI 10.1016/0166-6622(85)80015-9
   JANSEN JA, 1993, J BIOMED MATER RES, V27, P603, DOI 10.1002/jbm.820270507
   KASEMO B, 1991, BONE-BIOMATERIAL INTERFACE, P19
   KAY MI, 1964, NATURE, V204, P1050, DOI 10.1038/2041050a0
   KOTANI S, 1991, J BIOMED MATER RES, V25, P1303, DOI 10.1002/jbm.820251010
   MURA M J, 1990, Clinical Materials, V5, P285, DOI 10.1016/0267-6605(90)90028-T
   NELSON DGA, 1989, ANAT RECORD, V224, P265, DOI 10.1002/ar.1092240217
   OGILVIE A, 1987, J PERIODONTAL RES, V22, P270, DOI 10.1111/j.1600-0765.1987.tb01585.x
   OGISO M, 1992, J LONG-TERM EFF MED, V2, P137
   OGUCHI H, 1995, BIOMATERIALS, V16, P33, DOI 10.1016/0142-9612(95)91093-E
   ORLY I, 1989, CALCIFIED TISSUE INT, V45, P20, DOI 10.1007/BF02556656
   RADIN SR, 1993, J BIOMED MATER RES, V27, P35, DOI 10.1002/jbm.820270106
   STADELMANN PA, 1987, ULTRAMICROSCOPY, V21, P131, DOI 10.1016/0304-3991(87)90080-5
   TROMBE JC, 1972, THESIS U TOULOUSE FR
   VANHEEL M, 1981, ULTRAMICROSCOPY, V7, P113, DOI 10.1016/0304-3991(81)90001-2
   YAMAGUCHI K, 1995, BIOMATERIALS, V16, P983, DOI 10.1016/0142-9612(95)94905-Z
   YOSHINARI M, 1994, BIOMATERIALS, V15, P529, DOI 10.1016/0142-9612(94)90019-1
NR 29
TC 13
Z9 14
U1 0
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022-0345
EI 1544-0591
J9 J DENT RES
JI J. Dent. Res.
PD FEB
PY 1997
VL 76
IS 2
BP 682
EP 687
DI 10.1177/00220345970760020901
PG 6
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA WL793
UT WOS:A1997WL79300009
PM 9062562
DA 2018-10-19
ER

PT J
AU MattioliBelmonte, M
   Mengucci, P
   Specchia, N
   Gobbi, G
   Dubini, S
   Simonelli, L
   Greco, F
   Majni, G
   Biagini, G
   Rizzoli, C
AF MattioliBelmonte, M
   Mengucci, P
   Specchia, N
   Gobbi, G
   Dubini, S
   Simonelli, L
   Greco, F
   Majni, G
   Biagini, G
   Rizzoli, C
TI An experimental study in X-ray spectroscopy of the zirconium (Ca-PSZ) -
   Bone interface. Microanalytic evaluation of the osteogenetic response
SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE
LA English
DT Article
ID PARTIALLY-STABILIZED ZIRCONIA; MECHANICAL-PROPERTIES; INVITRO; CERAMICS;
   INVIVO; TIME
AB Ultrastructural difractometric and chemical evaluations of calcium partially stabilized zirconium (Ca-PSZ) implants were performed in an in vivo study on animals in order to evaluate its biological behaviour. The chemical-morphological investigations demonstrated the presence of an osteogenetic activity at the bone-biomaterial interface. The new-osteogenesis was preceded by the formation of a loose connective tissue around the implants. This mesenchymal-type tissue without a capsular organization, allowing modulation of the mechanical forces to which the implant is subject, could be considered a positive event in the osteogenetic process and not a sign of future failure of the implant. Finally, microanalytical investigations carried out on non-implanted and implanted Ca-PSZ tools suggested that the surface of this ceramic material,does not undergo modification once it has;been inserted in the biological environment (12 months).
C1 UNIV ANCONA,DEPT MAT SCI,I-60128 ANCONA,ITALY.
   UNIV ANCONA,ORTHOPAED CLIN,I-60128 ANCONA,ITALY.
   CATHOLIC UNIV ROME,ORTHOPAED CLIN,ROME,ITALY.
   UNIV BOLOGNA,HIST INST,BOLOGNA,ITALY.
RP MattioliBelmonte, M (reprint author), FAC MED,INST NORMAL HUMAN MORPHOL,VIA RANIERI MONTEDAGO,I-60131 ANCONA,ITALY.
RI Mattioli-Belmonte, Monica/J-5861-2012; MENGUCCI, PAOLO/M-7228-2016
OI MENGUCCI, PAOLO/0000-0001-9049-8524; SPECCHIA,
   Nicola/0000-0001-8710-378X; Majni, GIUSEPPE/0000-0002-8965-5016
CR AGAWAKA Y, 1993, J PROSTHET DENT, V69, P599
   AOBA T, 1992, CALCIFIED TISSUE INT, V51, P143, DOI 10.1007/BF00298503
   BARTIN S, 1994, ORTHOP RES, V12, P375
   BRUNSKI JB, 1979, J DENT RES, V58, P1953, DOI 10.1177/00220345790580100201
   CALES B, 1994, J BIOMED MATER RES, V28, P619, DOI 10.1002/jbm.820280512
   CALES B, 1994, J MATER SCI-MATER M, V5, P376, DOI 10.1007/BF00058967
   CHRISTEL P, 1989, J BIOMED MATER RES, V23, P45, DOI 10.1002/jbm.820230105
   DERBISHYRE B, 1994, MED ENG PHYS, V6, P299
   DRUMMOND JL, 1989, J AM CERAM SOC, V72, P675, DOI 10.1111/j.1151-2916.1989.tb06194.x
   GARVIE RC, 1984, J MATER SCI, V19, P3224, DOI 10.1007/BF00549808
   GEESINK RGT, 1987, CLIN ORTHOP RELAT R, V225, P147
   GROTE JJ, 1984, ARCH OTOLARYNGOL, V110, P197
   HARDY DCR, 1991, J BONE JOINT SURG BR, V73, P732
   HASTINGS GW, 1994, IMAGING TECHNIQUES B, P11
   HATANAKA S, 1993, IN VIVO, V7, P11
   HUIKSEN R, 1991, P S US HYDR COAT PRO
   KAWAUCHI K, 1984, ORTHOPAEDIC CERAMIC, P253
   KIRKPATRICK CJ, 1990, J MATER SCI-MATER M, V1, P9, DOI 10.1007/BF00705347
   KOBAYASHI K, 1981, SOLID STATE IONICS, V3-4, P489, DOI 10.1016/0167-2738(81)90138-7
   LIPP KK, 1993, AM REV RESPIR DIS, V148, P1089
   Lum L B, 1991, Int J Oral Maxillofac Implants, V6, P456
   MATSUHASHI T, 1971, J AM CERAM SOC, V60, P97
   POLACK FM, 1980, OPHTHALMOLOGY, V87, P693
   PORTER DL, 1977, J AM CERAM SOC, V60, P280, DOI 10.1111/j.1151-2916.1977.tb14128.x
   RAISZ LG, 1992, METABOLIC BONE DIS, P1
   RECK R, 1981, CLIN OTOLARYNGOL, V6, P63, DOI 10.1111/j.1365-2273.1981.tb01786.x
   RICHARDS RR, 1980, CLIN ORTHOPAEDICS, V150, P263
   SANDAHUS S, 1969, NOVEAOUX ASPECTS IMP
   Sedel L., 1991, BIOCERAMICS, V4, P27
   SHIMIZU K, 1993, J BIOMED MATER RES, V27, P729, DOI 10.1002/jbm.820270605
   SKERRY TM, 1990, CALCIFIED TISSUE INT, V46, P318, DOI 10.1007/BF02563823
   SKURIKHIN IM, 1993, J AOAC INT, V72, P257
   SMITH DC, 1993, INT J PROSTHODONT, V2, P106
   SWAT JGN, 1980, DENTAL IMPLANTS, P97
   TOMSEN P, 1993, BONE BIOMATERIAL INT, P153
NR 35
TC 7
Z9 7
U1 0
U2 0
PU CHAPMAN HALL LTD
PI LONDON
PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8HN
SN 0957-4530
J9 J MATER SCI-MATER M
JI J. Mater. Sci.-Mater. Med.
PD FEB
PY 1997
VL 8
IS 2
BP 85
EP 90
DI 10.1023/A:1018554715962
PG 6
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA WG209
UT WOS:A1997WG20900004
PM 15348775
DA 2018-10-19
ER

PT J
AU Silverstein, B
   Witkin, KM
   Frankos, VH
   Terr, AI
AF Silverstein, B
   Witkin, KM
   Frankos, VH
   Terr, AI
TI Assessing the role of the biomaterial aquavene in patient reactions to
   landmark midline catheters
SO REGULATORY TOXICOLOGY AND PHARMACOLOGY
LA English
DT Article
ID POLYETHYLENE GLYCOLS; CONTACT SENSITIVITY
AB Landmark midline catheters (Menlo Care, Inc., Palo Alto, CA) provide peripheral venous access for the infusion of medications or fluids. They are constructed of an inner layer of polyurethane and an outer layer of the biomaterial Aquavene, a blend of polyurethane and polyethylene oxide to which butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), and triallyl-s-triazine trione (TTT) are added. Once inside the vein, the Aquavene material becomes hydrated and the catheter swells resulting in minimal trauma to the vein. It is well recognized that some patients experience reactions to catheterization. Recent reports of hypersensitivity-like reactions in some patients catheterized with Landmark catheters have prompted the manufacturer to reexamine biocompatibility data and clinical data to assess whether Aquavene was the source of the patient responses. None of the biocompatibility studies provided by Menlo Care in support of U.S. registration and marketing of Aquavene-based catheters demonstrated any tendency for Aquavene or material extracted from Aquavene to invoke an immunological or toxicological response. Examination of potential catheter residuals revealed that significant amounts of BHA and BHT were unlikely to be released from the catheters during expected use. The amounts of polyethylene oxide and TTT expected to be released during the first few minutes after catheter insertion (when most of the patient reactions were reported) are almost 92,500 and 270,000 times lower, respectively, than non-toxic animal exposures. These analyses do not support chemically mediated toxicity as an explanation for the adverse events experienced by some patients. A review of the postmarket surveillance data on Aquavene-based catheters revealed that the reported events were not consistent with a hypersensitivity (immunogenic) response to the biomaterial. The rare reported adverse events tend to occur quickly, most often after hushing of the catheter, and resolve quickly, even when the catheter remains in place. Determining the frequency and severity of adverse events reported in association with the use of Landmark catheters will ultimately require a controlled prospective study, preferably one with a concurrent control group using alternative products. (C) 1997 Academic Press.
C1 ENVIRON,ARLINGTON,VA 22203.
   STANFORD UNIV,MED CTR,SAN FRANCISCO,CA 94305.
RP Silverstein, B (reprint author), WEINBERG GRP INC,WASHINGTON,DC 20036, USA.
CR BAJAJ AK, 1990, CONTACT DERMATITIS, V22, P291, DOI 10.1111/j.1600-0536.1990.tb01602.x
   CARPENTER CP, 1971, TOXICOL APPL PHARM, V18, P35, DOI 10.1016/0041-008X(71)90312-7
   *CLIN SKILLB, 1991, IV THER
   *DEP HLTH HUM SERV, 1995, ISO10993 DEP HLTH HU
   *DOW CHEM CO, 1992, UNPUB AC TOX PROP IN
   FISHER AA, 1978, CONTACT DERMATITIS, V4, P135, DOI 10.1111/j.1600-0536.1978.tb03759.x
   Fontaine P J, 1991, J Intraven Nurs, V14, P91
   GRAHAM DT, 1961, CIRCULATION, V23, P901, DOI 10.1161/01.CIR.23.6.901
   HADAWAY LC, 1990, CARING MAGAZINE  MAY, P45
   HARWOOD IR, 1992, PEDIATR PULM, V12, P233, DOI 10.1002/ppul.1950120407
   *INT STAND ORG, 1993, 10993 ISO
   KAPLAN NM, 1992, ARCH INTERN MED, V152, P413
   KOMSTA E, 1989, B ENVIRON CONTAM TOX, V43, P87, DOI 10.1007/BF01702242
   LEUNG PSC, 1993, ALLERG IMMUNOL, V25, P2
   LEVY JH, 1992, ANAPHYLACTIC REACTIO
   Maibach H I, 1975, Contact Dermatitis, V1, P247, DOI 10.1111/j.1600-0536.1975.tb05400.x
   *MENL CAR, 1988, UNPUB 90 DAY PIG IMP
   *MENL CAR, 1993, UNPUB IN VITR CYT ST
   *MENL CAR, 1993, UNPUB SUBCHR INTR TO
   *MENL CAR, 1992, UNPUB SURG SUBC IMPL
   *MENL CAR, 1993, UNPUB AM MUT STUD SA
   *MENL CAR, 1988, UNPUB CERT COMPL USP
   *MENL CAR, 1988, UNPUB HEM TEST
   *MENL CAR, 1988, UNPUB LIM AM LYS
   *MENL CAR, 1988, UNPUB PRIM SKIN IRR
   *MENL CAR, 1988, UNPUB CYT AG OV TEST
   *MENL CAR, 1992, UNPUB AQ UR STENT PI
   MERMEL LA, 1995, ANN INTERN MED, V123, P841, DOI 10.7326/0003-4819-123-11-199512010-00005
   *MINL CAR, 1991, UNPUB DERM SENS STUD
   PAVLIN DJ, 1993, ANESTH ANALG, V76, P931
   RADY MY, 1994, ANESTH ANALG, V78, P761
   RASOR JS, 1991, JVAN, V1, P8
   RICHTER AW, 1983, INT ARCH ALLER A IMM, V70, P124, DOI 10.1159/000233309
   RUETZ PP, 1967, MEDICINE, V46, P363, DOI 10.1097/00005792-196709000-00001
   SMEED C, 1990, J INTRAV NURS, V14, P91
   SMYTH HF, 1950, J AM PHARM ASSOC SCI, V39, P349, DOI 10.1002/jps.3030390615
   SMYTH HF, 1947, J AM PHARM ASSOC SCI, V36, P157, DOI 10.1002/jps.3030360508
   SMYTH HF, 1945, J AM PHARM ASSOC SCI, V34, P172, DOI 10.1002/jps.3030340606
   SMYTH HF, 1970, TOXICOL APPL PHARM, V16, P442, DOI 10.1016/0041-008X(70)90016-5
   SMYTH HF, 1955, J AM PHARM ASSOC, V44, P27, DOI 10.1002/jps.3030440111
   STENVELD HJ, 1994, CONTACT DERMATITIS, V30, P184, DOI 10.1111/j.1600-0536.1994.tb00712.x
   TUSSING TW, 1954, J AM PHARM ASSOC, V43, P489
   *UN CARB, 1988, TOX SUMM POLYOX WAT
   *USP NF, 1990, US PHARM CONV INC RO
   WATKINS J, 1979, BRIT J ANAESTH, V51, P51, DOI 10.1093/bja/51.1.51
   MORBIDITY MORTA 0209, P100
NR 46
TC 5
Z9 5
U1 1
U2 7
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0273-2300
J9 REGUL TOXICOL PHARM
JI Regul. Toxicol. Pharmacol.
PD FEB
PY 1997
VL 25
IS 1
BP 60
EP 67
DI 10.1006/rtph.1996.1057
PG 8
WC Medicine, Legal; Pharmacology & Pharmacy; Toxicology
SC Legal Medicine; Pharmacology & Pharmacy; Toxicology
GA WK540
UT WOS:A1997WK54000006
PM 9056501
DA 2018-10-19
ER

PT J
AU Lundberg, F
   Tegenfeldt, JO
   Montelius, L
   Ransjo, U
   Appelgren, P
   Siesjo, P
   Ljungh, A
AF Lundberg, F
   Tegenfeldt, JO
   Montelius, L
   Ransjo, U
   Appelgren, P
   Siesjo, P
   Ljungh, A
TI Protein depositions on one hydrocephalus shunt and on fifteen temporary
   ventricular catheters
SO ACTA NEUROCHIRURGICA
LA English
DT Article
DE shunt; protein; ventricular catheter
ID COAGULASE-NEGATIVE STAPHYLOCOCCI; ACUTE INFLAMMATORY RESPONSES;
   HUMAN-PLASMA; AFFINITY-CHROMATOGRAPHY; SURFACE HEPARINIZATION; POLYMER
   SURFACES; BINDING-SITES; FIBRONECTIN; FIBRINOGEN; VITRONECTIN
AB Biomaterials are commonly used in modem medicine. Proteins are adsorbed to the surface of the biomaterial immediately after insertion. This report demonstrates the presence of adsorbed proteins in one infected cerebrospinal shunt from a child with hydrocephalus and on fifteen temporary ventricular catheters from adult patients with spontaneous or traumatic brain injuries. Depositions of vitronectin, fibrinogen and thrombospondin-fibronectin to some extent - on the shunt surface was imaged by field-emission scanning electron microscopy. Vitronectin, fibronectin, fibrinogen, and thrombospondin on the ventricular catheters were shown with radio-actively labelled antibodies. Furthermore, protein adsorption from human cerebrospinal fluid to heparinized and unheparinized polymers was studied under flowing conditions in vitro. On heparinized polymer, significantly reduced levels of vitronectin, fibronectin, and thrombospondin were exposed, as measured after 4 hours in vitro perfusion. After 24 hours perfusion, the differences in protein exposition between heparinized and unheparinized polymers were substantially reduced.
C1 LUND UNIV, DEPT MED MICROBIOL, S-22362 LUND, SWEDEN.
   LUND INST TECHNOL, DEPT SOLID STATE PHYS, LUND, SWEDEN.
   KAROLINSKA HOSP, DEPT LAB MED, S-10401 STOCKHOLM, SWEDEN.
   KAROLINSKA HOSP, DEPT MED, S-10401 STOCKHOLM, SWEDEN.
   UNIV LUND HOSP, DEPT NEUROSURG, S-22185 LUND, SWEDEN.
RI Tegenfeldt, Jonas/B-9506-2008; Montelius, Lars/B-9071-2008
OI Tegenfeldt, Jonas/0000-0002-3695-6886; Montelius,
   Lars/0000-0001-9563-2307
CR AMMIRATI M, 1987, CHILD NERV SYST, V3, P106, DOI 10.1007/BF00271135
   Appelgren P, 1996, CRIT CARE MED, V24, P1482, DOI 10.1097/00003246-199609000-00009
   APPLEYARD ME, 1991, BRIT J OPHTHALMOL, V75, P276, DOI 10.1136/bjo.75.5.276
   BARBUCCI R, 1994, BIOMATERIALS, V15, P955, DOI 10.1016/0142-9612(94)90075-2
   BAYSTON R, 1989, HYDROCEPHALUS SHUNT
   CHEUNG AL, 1990, J INFECT DIS, V161, P1177, DOI 10.1093/infdis/161.6.1177
   CLERI DJ, 1980, J INFECT DIS, V141, P781, DOI 10.1093/infdis/141.6.781
   FABRIZIUSHOMAN DJ, 1991, J BIOMAT SCI-POLYM E, V3, P27, DOI 10.1163/156856292X00060
   FROMAN G, 1987, J BIOL CHEM, V262, P6564
   Gardner P, 1988, Curr Clin Top Infect Dis, V9, P185
   GEBB C, 1986, J BIOL CHEM, V261, P6698
   GEORGE R, 1979, J NEUROSURG, V51, P804, DOI 10.3171/jns.1979.51.6.0804
   GYRING J, 1989, ALFRED BENZON SYMP S, V27, P80
   HERRMANN M, 1991, INFECT IMMUN, V59, P279
   HERRMANN M, 1988, J INFECT DIS, V158, P693, DOI 10.1093/infdis/158.4.693
   HOOK M, 1989, FIBRONECTIN, P295
   HWANG RQ, 1991, PHYS REV LETT, V67, P3279, DOI 10.1103/PhysRevLett.67.3279
   Hynes RO, 1990, FIBRONECTINS
   JACOBSEN RJ, 1983, J BIOMED MATER RES, V16, P199
   KOST C, 1992, J BIOL CHEM, V267, P12098
   LARM O, 1987, THROMB HAEMOSTASIS, V58, P84
   LINDON JN, 1986, BLOOD, V68, P355
   LJUNGH A, 1995, METHOD ENZYMOL, V253, P501
   Lundberg F, 1997, J MED MICROBIOL, V46, P285, DOI 10.1099/00222615-46-4-285
   Lundberg F, 1997, INFECT IMMUN, V65, P897
   LUNDBERG N, 1960, ACTA PSYCHIATR S149, V36, P7
   MAKI DG, 1977, NEW ENGL J MED, V296, P1305, DOI 10.1056/NEJM197706092962301
   PARISE LV, 1993, BIOCHEM J, V289, P445, DOI 10.1042/bj2890445
   PAULSSON M, 1992, J CLIN MICROBIOL, V30, P2006
   PEKNA M, 1993, BIOMATERIALS, V14, P189, DOI 10.1016/0142-9612(93)90022-T
   PITT WG, 1986, BIOMATERIALS, V7, P340, DOI 10.1016/0142-9612(86)90004-9
   PODACK ER, 1979, J BIOL CHEM, V254, P9908
   RAPOZA R, 1990, J BIOMED MATER RES, P1263
   RENIER D, 1984, J NEUROSURG, V61, P1072, DOI 10.3171/jns.1984.61.6.1072
   ROZALSKA B, 1995, FEMS IMMUNOL MED MIC, V11, P307, DOI 10.1111/j.1574-695X.1995.tb00161.x
   RUGE JR, 1993, BRAIN SURGERY COMPLI, P1463
   SANTERRE JP, 1992, J BIOMED MATER RES, V26, P39, DOI 10.1002/jbm.820260105
   STEELE JG, 1991, BIOMATERIALS, V12, P531, DOI 10.1016/0142-9612(91)90046-D
   TANG LP, 1993, J EXP MED, V178, P2147, DOI 10.1084/jem.178.6.2147
   Tang LP, 1996, J CLIN INVEST, V97, P1329, DOI 10.1172/JCI118549
   VAUDAUX P, 1993, J INFECT DIS, V167, P633, DOI 10.1093/infdis/167.3.633
   VROMAN L, 1986, J COLLOID INTERF SCI, V111, P391, DOI 10.1016/0021-9797(86)90042-1
   VUENTO M, 1979, BIOCHEM J, V183, P331, DOI 10.1042/bj1830331
   WOOD JM, 1985, NEUROSURGERY, V1, P161
   YABKOWITZ R, 1989, J BIOL CHEM, V264, P10888
   YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281
   YU J, 1994, BIOMATERIALS, V15, P805, DOI 10.1016/0142-9612(94)90035-3
   YU JL, 1995, J SURG RES, V59, P596, DOI 10.1006/jsre.1995.1210
   Yu JL, 1997, BIOMATERIALS, V18, P421, DOI 10.1016/S0142-9612(96)00154-8
   ZARDI L, 1980, J IMMUNOL METHODS, V34, P155, DOI 10.1016/0022-1759(80)90169-6
NR 50
TC 10
Z9 10
U1 0
U2 2
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0001-6268
J9 ACTA NEUROCHIR
JI Acta Neurochir.
PY 1997
VL 139
IS 8
BP 734
EP 742
DI 10.1007/BF01420046
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA XT967
UT WOS:A1997XT96700015
PM 9309288
DA 2018-10-19
ER

PT S
AU Canham, LT
   Reeves, CL
   Wallis, DJ
   Newey, JP
   Houlton, MR
   Sapsford, GJ
   Godfrey, RE
   Loni, A
   Simons, AJ
   Cox, TI
   Ward, MCL
AF Canham, LT
   Reeves, CL
   Wallis, DJ
   Newey, JP
   Houlton, MR
   Sapsford, GJ
   Godfrey, RE
   Loni, A
   Simons, AJ
   Cox, TI
   Ward, MCL
BE Collins, RW
   Fauchet, PM
   Shimizu, I
   Vial, JC
   Shimada, T
   Alivisatos, AP
TI Silicon as an active biomaterial
SO ADVANCES IN MICROCRYSTALLINE AND NANOCRYSTALLINE SEMICONDUCTORS - 1996
SE MATERIALS RESEARCH SOCIETY SYMPOSIUM PROCEEDINGS
LA English
DT Proceedings Paper
CT Symposium Q on Advances in Microcrystalline and Nanocrystalline
   Semiconductors - 1996, at the 1996 MRS Fall Meeting
CY DEC 02-06, 1996
CL BOSTON, MA
SP Mat Res Soc, Asahi Glass Co Ltd, Hitachi Europe Ltd, Hitachi Ltd, Kaneka Corp, Mitsui Toatsu Chem Incorp, Sanyo Elect Co Ltd, Sharp Corp, Xerox PARC
AB The response of a range of porous Si and poly Si films to storage in acellular simulated body fluids is summarised and its implications discussed. It is suggested that the combination of VLSI technology, micromachining and surface microstructuring achievable with silicon, could establish this prominent semiconductor as a very useful biomaterial by the next century. The 'biocompatibility' of a variety of silicon microstructures, and even bulk silicon has received surprisingly little study, but now warrants detailed in-vitro and in-vivo assessment.
RP Canham, LT (reprint author), DEF RES AGCY,ST ANDREWS RD,MALVERN WR14 3PS,WORCS,ENGLAND.
NR 0
TC 14
Z9 14
U1 0
U2 1
PU MATERIALS RESEARCH SOCIETY
PI WARRENDALE
PA 506 KEYSTONE DRIVE, WARRENDALE, PA 15088-7563
SN 0272-9172
BN 1-55899-356-8
J9 MATER RES SOC SYMP P
PY 1997
VL 452
BP 579
EP 590
PG 12
WC Materials Science, Multidisciplinary; Materials Science,
   Characterization & Testing; Materials Science, Coatings & Films; Optics
SC Materials Science; Optics
GA BH46M
UT WOS:A1997BH46M00088
DA 2018-10-19
ER

PT J
AU JorgeHerrero, E
AF JorgeHerrero, E
TI Biological biomaterials
SO ANALES DE QUIMICA-INTERNATIONAL EDITION
LA English
DT Article
ID BIOPROSTHETIC HEART-VALVES; CHEMICALLY MODIFIED COLLAGEN; BOVINE
   PERICARDIUM; FOLLOW-UP; CARDIAC BIOPROSTHESES; CONNECTIVE-TISSUE;
   VASCULAR GRAFTS; DRUG-DELIVERY; CALCIFICATION; GLUTARALDEHYDE
AB There are a number of situations in which substances of biological origin are employed as biomaterials. Most of them are macromolecules derived from isolated connective tissue or the connective tissue itself in membrane form; in both cases, the tissue can be used in its natural farm or be chemically treated. In other cases, certain blood vessels can be chemically pretreated and used as vascular prostheses. Proteins such as albumin, collagen and fibrinogen are employed to coat vascular prostheses. Certain polysaccharides have also been tested for use in controlled drug release systems. Likewise, a number of tissues, such as dura mater, bovine pericardium, porcine valves and human valves, are used in the preparation of cardiac prostheses. We also use veins from animals or humans in arterial replacement, In none of these cases are the tissues employed similar to the native tissues as they have been chemically modified, becoming a new biomaterial with different physical and biochemical properties.
   In short, we find that natural products are being utilized as biomaterials and must be considered as such; thus, it is necessary to study both their chemicobiological and physicomechanical properties. In the present report, we review the current applications, problems and future prospects of some of these biological biomaterials.
RP JorgeHerrero, E (reprint author), CLIN PUERTA HIERRO, SERV CIRUGIA EXPT, C SAN MARTIN PORRES 2, E-28035 MADRID, SPAIN.
CR AKOUM A, 1992, RES SURG, V1, P1
   ALKHAJA N, 1991, EUR J CARDIO-THORAC, V5, P635, DOI 10.1016/1010-7940(91)90119-5
   ALLEN DJ, 1982, J THORAC CARDIOV SUR, V84, P267
   ALLEN PR, 1987, BIOMATERIALS, V8, P146, DOI 10.1016/0142-9612(87)90105-0
   Andreani J. F., 1993, Revue de Stomatologie et de Chirurgie Maxillo-Faciale, V94, P21
   ANGELL WW, 1987, J THORAC CARDIOV SUR, V93, P815
   AQUAVELLA JV, 1988, J CATARACT REFR SURG, V14, P574
   Baldwin M T, 1991, ASAIO Trans, V37, pM170
   BOYCE ST, 1988, J BIOMED MATER RES, V22, P939, DOI 10.1002/jbm.820221008
   BURGESON RE, 1992, CLIN ORTHOP RELAT R, V282, P250
   CAVALLARO JF, 1994, BIOTECH BIOENGINEERI, P781
   Chandy T, 1996, BIOMATERIALS, V17, P61, DOI 10.1016/0142-9612(96)80756-3
   CHVAPIL M, 1987, J BIOMED MATER RES, V21, P1383, DOI 10.1002/jbm.820211204
   COHN LH, 1985, J THORAC CARDIOV SUR, V90, P872
   COHN LH, 1984, CHEST, V85, P387, DOI 10.1378/chest.85.3.387
   CZIPERLE DJ, 1992, J CARDIOVASC SURG, V33, P407
   ELMASSRY S, 1994, J VASC SURG, V19, P487, DOI 10.1016/S0741-5214(94)70076-1
   GABBAY S, 1988, J THORAC CARDIOV SUR, V95, P208
   Galbavy S, 1995, Bratisl Lek Listy, V96, P368
   GENDLER E, 1984, J BIOMED MATER RES, V18, P727, DOI 10.1002/jbm.820180703
   GIUSTI P, 1994, BIOMATERIALS, V15, P1229, DOI 10.1016/0142-9612(94)90274-7
   GOTT JP, 1992, ANN THORAC SURG, V53, P207, DOI 10.1016/0003-4975(92)91321-Y
   GRABENWOGER M, 1992, J THORAC CARDIOV SUR, V104, P14
   GRUNKEMEIER GL, 1990, ANNU REV MED, V41, P251
   GUIDOIN R, 1989, BIOMATERIALS, V10, P156, DOI 10.1016/0142-9612(89)90018-5
   Hench L L, 1973, Med Instrum, V7, P136
   HUC A, 1985, J AM LEATHER CHEM AS, V80, P195
   IONESCU MI, 1972, J THORAC CARDIOV SUR, V64, P340
   ISHIHARA T, 1981, AM J CARDIOL, V48, P665, DOI 10.1016/0002-9149(81)90145-4
   Jayakrishnan A, 1996, BIOMATERIALS, V17, P471, DOI 10.1016/0142-9612(96)82721-9
   JAYAKRISHNAN A, 1994, INT J PHARM, V106, P221, DOI 10.1016/0378-5173(94)90005-1
   JORGEHERRERO E, 1991, BIOMATERIALS, V12, P683, DOI 10.1016/0142-9612(91)90117-S
   JORGEHERRERO E, 1991, BIOMATERIALS, V12, P249, DOI 10.1016/0142-9612(91)90208-R
   JORGEHERRERO E, 1994, BIOMATERIALS, V15, P815, DOI 10.1016/0142-9612(94)90036-1
   JorgeHerrero E, 1996, BIOMATERIALS, V17, P571, DOI 10.1016/0142-9612(96)88707-2
   JORGEHERRERO E, 1991, RES SURG, V3, P62
   KATO YP, 1991, J BONE JOINT SURG AM, V73A, P561, DOI 10.2106/00004623-199173040-00013
   KAUFMAN HE, 1994, J OCUL PHARMACOL, V10, P17, DOI 10.1089/jop.1994.10.17
   Kjaergard H K, 1994, Cardiovasc Surg, V2, P45
   KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303
   LEVY RJ, 1983, ATHEROSCLEROSIS, V46, P49, DOI 10.1016/0021-9150(83)90163-6
   LEVY RJ, 1983, AM J PATHOL, V113, P143
   LEVY RJ, 1986, AM J PATHOL, V122, P71
   LEVY RJ, 1987, J THORAC CARDIOV SUR, V94, P551
   LEVY RJ, 1985, SCIENCE, V228, P190, DOI 10.1126/science.3919445
   MORIMOTO Y, 1983, CRC CRIT R THER DRUG, V2, P18
   NIMNI ME, 1987, J BIOMED MATER RES, V21, P741, DOI 10.1002/jbm.820210606
   OKAZAKI M, 1990, BIOMATERIALS, V11, P568, DOI 10.1016/0142-9612(90)90080-A
   OKOSHI T, 1988, T AM SOC ART INT ORG, V34, P532
   OLMO N, 1988, J BIOMED MATER RES, V22, P257, DOI 10.1002/jbm.820220402
   PAEZ JMG, 1990, J THORAC CARDIOV SUR, V100, P580
   PAEZ JMG, 1990, BIOMATERIALS, V11, P186, DOI 10.1016/0142-9612(90)90153-H
   PAEZ JMG, 1994, BIOMATERIALS, V15, P172, DOI 10.1016/0142-9612(94)90063-9
   PARK GB, 1978, BIOMATER ARTIF CELL, V6, P1
   PETITE H, 1994, J BIOMED MATER RES, V28, P159, DOI 10.1002/jbm.820280204
   POHUNKOVA H, 1995, BIOMATERIALS, V16, P67, DOI 10.1016/0142-9612(95)91098-J
   Reid D B, 1991, Ann Vasc Surg, V5, P320, DOI 10.1007/BF02015291
   ROSENBLATT J, 1994, BIOMATERIALS, V15, P985, DOI 10.1016/0142-9612(94)90079-5
   ROSENBLOOM J, 1993, FASEB J, V7, P1208
   RUBENS F, 1992, J BIOMED MATER RES, V26, P1651, DOI 10.1002/jbm.820261209
   SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499
   SANMARTIN AC, 1993, BIOMATERIALS, V14, P76
   SASAJIMA T, 1992, ARTIF ORGAN TODAY, V2, P9
   SAWYER PN, 1987, AM J SURG, V154, P533, DOI 10.1016/0002-9610(87)90272-8
   SCHOEN FJ, 1985, LAB INVEST, V52, P523
   SCHOEN FJ, 1985, HUM PATHOL, V16, P549, DOI 10.1016/S0046-8177(85)80103-9
   SCHOEN FJ, 1985, T SOC BIOMATER, V8, P13
   SEGESSER L, 1986, J THORAC CARDIOVASC, V34, P35
   SERRE CM, 1993, BIOMATERIALS, V14, P97, DOI 10.1016/0142-9612(93)90217-P
   SESTAFE JVG, 1994, J BIOMED MATER RES, V28, P755, DOI 10.1002/jbm.820280613
   SPEER DP, 1980, J BIOMED MATER RES, V14, P753, DOI 10.1002/jbm.820140607
   STANLEY JC, 1991, VASCULAR SURGERY COM, P275
   THUBRIKAR MJ, 1983, J THORAC CARDIOV SUR, V86, P115
   TILSTRA DJ, 1994, ANNU REV MED, V45, P149, DOI 10.1146/annurev.med.45.1.149
   TROWBRIDGE EA, 1989, CRIT REV BIOCOMPAT, V5, P105
   TROWBRIDGE EA, 1988, J THORAC CARDIOV SUR, V95, P577
   UCHIDA N, 1993, J BIOMED MATER RES, V27, P1269, DOI 10.1002/jbm.820271007
   VANWACHEM PB, 1994, J BIOMED MATER RES, V28, P353, DOI 10.1002/jbm.820280310
   WALLEY VM, 1987, J THORAC CARDIOV SUR, V93, P925
   WEADOCK KS, 1993, J LONG-TERM EFF MED, V3, P207
   Webb C L, 1990, ASAIO Trans, V36, P56, DOI 10.1097/00002480-199004000-00003
   WEBB CL, 1991, AM J PATHOL, V138, P971
   Xi T, 1992, J Biomater Appl, V7, P61
   ZHANG Z, 1994, BIOMATERIALS, V15, P483
NR 84
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER IBERICA
PI BARCELONA
PA PROVENZA 388, E-08025 BARCELONA, SPAIN
SN 1130-2283
J9 AN QUIM-INT
JI An. Quim.-Int. Ed.
PY 1997
VL 93
IS 1
SU 1
BP S32
EP S37
PG 6
WC Chemistry, Multidisciplinary
SC Chemistry
GA WW400
UT WOS:A1997WW40000008
DA 2018-10-19
ER

PT B
AU LewandowskaSzumiel, M
   Komender, J
   Kudelska, D
   Mazur, M
AF LewandowskaSzumiel, M
   Komender, J
   Kudelska, D
   Mazur, M
BE vanZutphen, LFM
   Balls, M
TI Biocompatibility of carbon composites: comparison of in vitro and in
   vivo observations
SO ANIMAL ALTERNATIVES, WELFARE, AND ETHICS
SE DEVELOPMENTS IN ANIMAL AND VETERINARY SCIENCES
LA English
DT Proceedings Paper
CT 2nd World Congress on Alternatives and Animal Use in the Life Sciences
CY OCT 20-24, 1996
CL UTRECHT, NETHERLANDS
SP Johns Hopkins Univ, Ctr Alternat Anim Testing, European Cosmet Toiletry & Perfumery Assoc, European Commiss DGXI, European Commiss ECVAM, L Oreal, Procter & Gamble, Solvay Duphar, Wella
AB There are both ethical and scientific reasons for replacing the traditional in vivo methods of biomaterials testing by the in vitro techniques. In this paper, carbon fibre reinforced carbon composites (CC), which are destined to be used for intrabone implantation in orthopaedic applications, were investigated in vitro. Correlations between the results of these tests and phenomena found after this intrabone implantation of these materials was looked for.
   3T3 mouse fibroblasts and mouse peritoneal macrophages were incubated with both solid and powdered samples of CC. Viability of cells incubated with CC, as compared to control, was measured by using the MTT assay. Morphological observation was conducted. Nitric oxide (NO) secretion in macrophage cultures was measured spectrophotometrically.
   Neither cytotoxicity nor macrophage activation by CC were found in vitro. The ability of macrophages to phagocytose CC particles was observed. The perforation of solid CC samples due to macrophage activity was found in cell culture.
   The in vitro observations confirm the biocompatibility of CC implants found in the animal experiments. They also explain the mechanism of tissue penetration into the implants which was found in vivo. Therefore, not only has the correlation between the results of in vitro and in vivo experiments been confirmed in the model of CC implantation, but it has also been shown that phenomena which occur after biomaterial implantation can be explained by in vitro examinations.
RP LewandowskaSzumiel, M (reprint author), SCH MED,INST BIOSTRUCT,DEPT TRANSPLANTOL,PL-02004 WARSAW,POLAND.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE PUBL B V
PI AMSTERDAM
PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
BN 0-444-82424-3
J9 DEV AN VET
PY 1997
VL 27
BP 927
EP 933
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy; Toxicology;
   Veterinary Sciences; Zoology
SC Research & Experimental Medicine; Pharmacology & Pharmacy; Toxicology;
   Veterinary Sciences; Zoology
GA BJ87M
UT WOS:A1997BJ87M00124
DA 2018-10-19
ER

PT B
AU Matsumura, T
AF Matsumura, T
BE Funatsu, K
   Shirai, Y
   Matsushita, T
TI A study for the development of human biomaterial research resources in
   Japan
SO ANIMAL CELL TECHNOLOGY: BASIC & APPLIED ASPECTS, VOL 8
LA English
DT Proceedings Paper
CT 8th Annual Meeting of the
   Japanese-Association-for-Animal-Cell-Technology
CY NOV 06-10, 1995
CL IIZUKA, JAPAN
SP Japanese Assoc Anim Cell Technol
RP Matsumura, T (reprint author), MEIJI INST HLTH SCI,MEIJI MILK PROD CO LTD,540 NARUDA,ODAWARA 250,JAPAN.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
BN 0-7923-4486-3
PY 1997
BP 107
EP 110
PG 4
WC Biotechnology & Applied Microbiology; Cell Biology
SC Biotechnology & Applied Microbiology; Cell Biology
GA BJ18J
UT WOS:A1997BJ18J00016
DA 2018-10-19
ER

PT J
AU Schierholz, JM
   Rump, A
   Pulverer, G
AF Schierholz, JM
   Rump, A
   Pulverer, G
TI New antiinfectious biomaterials - Ciprofloxacin containing polyurethanes
   as potential drug delivery systems to prevent foreign-body infections
SO ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH
LA English
DT Article
DE Bay o 9867; CAS 86393-32-0; ciprofloxacin, betaine, salt; infections,
   foreign-body induced; polymer-antibiotic combinations; polyurethanes,
   foreign-body infections
ID CSF SHUNT INFECTIONS; RELEASE
AB Device related infections are an increasing problem since foreign materials are used in modern medicine; Ciprofloxacin-HCl salt (CAS 86393;32-0) and lipophilic ciprofloxacin-betaine (Bay o 9867) incorporated into polyurethanes by solvent casting technique were studied in order to develop antiinfectious properties of this biomaterial. Drug release rates, bacterial colonization and morphological features of the polymer-ciprofloxacin combinations were studied and the physico-chemical mechanisms of the delivery were discussed. Ciprofloxacin salt showed a fast initial release rare, whereas ciprofloxacin-betaine was characterized by a more continuous release behaviour. A higher diffusity of the lipophilic ciprofloxacin-betaine in the polymer could be shown as compared to its salt incorporated into the polyurethane. The high initial burst effect of the hydrochloride antibiotic was caused by its high solubility in the elution medium. Bacterial colonization tb the antibiotic-loaded polyurethanes was inhibited effectively only by preparations showing a slower but more sustained drug release. Scanning electron microscopy (SEM) demonstrated that the polyurethane-antibiotic combination was most homogenous for ciprofloxacin-betaine. Polyurethane material loaded with ciprofloxacin salt showed crystals at the surface and a granular structure of the polymeric matrix. Crystalline structure of the drug on polymeric surfaces varied with loading concentration and lipophilicity. Physico-chemical similarity of the polymeric material and the antibiotics is important for the homogeneity of the polymer-antibiotic combinations. High homogeneity is required for a sustained and prolonged release and effective inhibition of bacterial colonization.
C1 UNIV TECHNOL,RHEIN WESTFAL TH AACHEN,DEPT ANESTHESIOL,D-5100 AACHEN,GERMANY.
   UNIV COLOGNE,INST MED MICROBIOL & HYG,D-5000 COLOGNE 41,GERMANY.
RP Schierholz, JM (reprint author), B BRAUN MELSUNGEN AG,FORSCH & ENTWICKLUNG,NURNBERGER STR 55,D-34212 MELSUNGEN,GERMANY.
CR BLOMSTEDT GC, 1985, ACTA NEUROCHIR, V78, P81, DOI 10.1007/BF01808684
   BROWN MRW, 1985, J ANTIMICROB CHEMOTH, V15, P7, DOI 10.1093/jac/15.suppl_A.7
   CHIEN YW, 1974, J PHARM SCI, V63, P515, DOI 10.1002/jps.2600630405
   HAMPL J, 1995, ACTA NEUROCHIR, V133, P147, DOI 10.1007/BF01420065
   HIGUCHI T, 1963, J PHARM SCI, V52, P1145, DOI 10.1002/jps.2600521210
   HOWARD BMA, 1993, ARZNEIMITTEL-FORSCH, V43-2, P1125
   KAISER AB, 1986, NEW ENGL J MED, V315, P1129
   Maki DG, 1989, INFECT ASS INDWELLIN, P161
   ODIO C, 1984, AM J DIS CHILD, V138, P1103, DOI 10.1001/archpedi.1984.02140500009004
   PEPPAS NA, 1984, ANN NY ACAD SCI, V5, P26
   RITGER P L, 1987, Journal of Controlled Release, V5, P23, DOI 10.1016/0168-3659(87)90034-4
   ROSIN H, 1977, INFECTION, V5, P51, DOI 10.1007/BF01639112
   SCHIERHOLZ J, 1994, BIOMATERIALS, V15, P996, DOI 10.1016/0142-9612(94)90080-9
   SCHIERHOLZ J, 1995, HOSPITALIS, V65, P403
   SCHIERHOLZ J, 1991, NEW POLYM MAT, V3, P61
   Schierholz JM, 1996, ZBL BAKT-INT J MED M, V284, P390
   SINGH P, 1967, J PHARM SCI-US, V56, P1542, DOI 10.1002/jps.2600561203
   Smith J, 1988, QUINOLONES, P23
   Sugarman B, 1989, Infect Dis Clin North Am, V3, P187
   SUGARMAN B, 1984, INFECTIONS ASSOCIATE, P1
NR 20
TC 22
Z9 22
U1 0
U2 4
PU ECV-EDITIO CANTOR VERLAG MEDIZIN NATURWISSENSCHAFTEN
PI AULENDORF
PA BANDELSTOCKWEG 20, POSTFACH 1255, D-88322 AULENDORF, GERMANY
SN 0004-4172
J9 ARZNEIMITTEL-FORSCH
JI Arzneimittelforschung
PD JAN
PY 1997
VL 47
IS 1
BP 70
EP 74
PG 5
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA WG945
UT WOS:A1997WG94500014
PM 9037447
DA 2018-10-19
ER

PT J
AU Valenta, J
   Hrus, T
   Sochor, M
   Cihak, R
   Povysil, C
   Steidl, J
AF Valenta, J
   Hrus, T
   Sochor, M
   Cihak, R
   Povysil, C
   Steidl, J
TI Residual stresses in the human aorta and their influences by growth and
   remodelling
SO BIO-MEDICAL MATERIALS AND ENGINEERING
LA English
DT Article
DE residual stress; media; adventitia; connective tissue; hyperplasia;
   hypertrophy; multilayer vessel; growth function; biological time
ID ARTERIES; STRAIN; STATE
AB The aim of the present work is to demonstrate of the influence of the adventitia on distribution of residual stresses in the human aorta. The biomaterial increase in media as well as in adventitia in the course of the aorta's growth is formed by an intussusceptive mechanism of growth. In children's aortas, formative elastin lamellae are wavy with high amplitude perpendicular to the aortic surface. In adults' aortas the waves become smoother (stepwise) towards the adventitia. Also introduced is the growth function, which characterizes the biomaterial growth and the interference between the media and adventitial layers. It is possible to expect an extraordinary variability in the formation of the aortic wall tissue in the course of its growth as a result of metabolic and humoral influences and magnitude of the residual stresses in the course of growth.
C1 CZECH TECH UNIV,FAC MECH ENGN,DEPT BIOMECH & STRENGTH MAT,CR-16635 PRAGUE,CZECH REPUBLIC.
   CHARLES UNIV,INST ANAT,FAC MED 3,PRAGUE,CZECH REPUBLIC.
   CZECH TECH UNIV,FAC MECH ENGN,DEPT MAT SCI,CR-16635 PRAGUE,CZECH REPUBLIC.
RI Povysil, Ctibor/H-7976-2017
OI Povysil, Ctibor/0000-0002-8457-0953
CR CHUONG CJ, 1986, J BIOMECH ENG-T ASME, V108, P189, DOI 10.1115/1.3138600
   DOBISIKOVA M, 1991, MED LEG QUAD CAM, V13, P127
   KONVICKOVA S, 1989, P INT C EXP STRESS A, P168
   LIN IE, 1995, J BIOMECH ENG-T ASME, V117, P343, DOI 10.1115/1.2794190
   LIU SQ, 1989, J BIOMECH ENG-T ASME, V111, P325, DOI 10.1115/1.3168386
   MATSUMOTO T, 1995, J BIOMECH, V28, P1207, DOI 10.1016/0021-9290(94)00179-8
   MICHALEC J, 1995, WORKSH 95 CVUT PRAG, P699
   PICMANOVA D, 1994, P INT C BIOM MAN 94, P179
   RODRIGUEZ EK, 1994, J BIOMECH, V27, P455, DOI 10.1016/0021-9290(94)90021-3
   RUZICKA M, 1992, P 30 C EXP STRESS AN, P271
   SAINI A, 1995, 2 WORLD C BIOM AMST
   SRAMEK BB, 1995, BIOMECHANICS CARDIOV, P382
   STREJC P, 1996, IN PRESS PCB HUMAN S
   VALENTA J, 1995, BIOMECHANICS, P148
   VALENTA J, 1994, P INT C BIOM ENG BIO, P68
   VALENTA J, 1995, ACTA POLYTECHNICA, V35, P49
   XIE JP, 1991, J BIOMECH ENG-T ASME, V113, P36, DOI 10.1115/1.2894083
   XIE JP, 1995, J BIOMECH ENG-T ASME, V117, P136, DOI 10.1115/1.2792261
   YOKOBORI A T JR, 1991, Bio-Medical Materials and Engineering, V1, P25
NR 19
TC 2
Z9 2
U1 0
U2 2
PU IOS PRESS
PI AMSTERDAM
PA VAN DIEMENSTRAAT 94, 1013 CN AMSTERDAM, NETHERLANDS
SN 0959-2989
J9 BIO-MED MATER ENG
JI Bio-Med. Mater. Eng.
PY 1997
VL 7
IS 3
BP 159
EP 169
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA XP636
UT WOS:A1997XP63600001
PM 9262829
DA 2018-10-19
ER

PT J
AU Kumaresan, S
   Yoganandan, N
   Pintar, FA
AF Kumaresan, S
   Yoganandan, N
   Pintar, FA
TI Finite element analysis of anterior cervical spine interbody fusion
SO BIO-MEDICAL MATERIALS AND ENGINEERING
LA English
DT Article
DE biomaterial; cervical spine; finite element analysis; fusion;
   discectomy; titanium and tantalum implants
ID INTERVERTEBRAL DISC; TECHNICAL NOTE; BONE-GRAFTS; DISCECTOMY; DISKECTOMY
AB The present study investigated the external and the internal biomechanical responses of anterior cervical discectomy coupled with fusion. Five different types of interbody fusion materials were used: titanium core, titanium cage, tricortical iliac crest, tantalum core, and tantalum cage. Two different types of surgical procedures were analyzed: Smith-Robinson and Bailey-Badgley. A validated three-dimensional anatomically accurate finite element model of the human cervical spine was used in the study. The finite element model was exercised in compression, flexion, extension, and lateral bending for the intact case and for the two surgical procedures with five implant materials, The external response in terms of the stiffness and angular rotation, and the internal response in terms of the disc and the vertebral stresses were determined. The Smith-Robinson technique resulted in the highest increase in external response under all modes of loading for all implant materials. In contrast, the Bailey-Badgley technique produced a higher increase in the disc and the vertebral body stresses than the Smith-Robinson technique. As experimental human cadaver tests can only determine the external response of the non-fused spine simulating immediate post-operative structure, the present finite element studies assist in the understanding of biomechanics of interbody fusion by delineating the changes in the extrinsic and intrinsic characteristics of the cervical spine components due to surgery.
C1 MED COLL WISCONSIN,DEPT NEUROSURG,MILWAUKEE,WI 53226.
   DEPT VET AFFAIRS MED CTR,MILWAUKEE,WI.
FU PHS HHS [R49CCR 507370]
CR ALEMOHAMMAD S, 1985, NEUROSURGERY, V17, P94, DOI 10.1227/00006123-198507000-00017
   BAILEY RW, 1960, J BONE JOINT SURG AM, V42, P565, DOI 10.2106/00004623-196042040-00001
   GORE DR, 1984, SPINE, V9, P667, DOI 10.1097/00007632-198410000-00002
   GORE DR, 1984, CLIN ORTHOP RELAT R, V188, P191
   KADEN B, 1995, NEUROSURG REV, V18, P25, DOI 10.1007/BF00416473
   Kumaresan S, 1997, J SPINAL DISORD, V10, P40
   LEONG JCY, 1994, CLIN ORTHOPAEDICS, V300, P52
   MUHLBAUER M, 1995, ACTA NEUROCHIR, V134, P207, DOI 10.1007/BF01417691
   PINTAR FA, 1994, SPINE, V19, P2524, DOI 10.1097/00007632-199411001-00006
   ROSENORN J, 1983, J NEUROSURG, V59, P252, DOI 10.3171/jns.1983.59.2.0252
   Simmons E H, 1969, J Bone Joint Surg Br, V51, P225
   SMITH GW, 1958, J BONE JOINT SURG AM, V40, P607, DOI 10.2106/00004623-195840030-00009
   SMITH MD, 1993, J BONE JOINT SURG AM, V75A, P1206, DOI 10.2106/00004623-199308000-00010
   STAUFFER ES, 1977, J BONE JOINT SURG AM, V59, P45, DOI 10.2106/00004623-197759010-00006
   TOTH JM, 1997, SOC BIOMATERIALS
   WHITE AA, 1973, J BONE JOINT SURG AM, VA 55, P525, DOI 10.2106/00004623-197355030-00008
   WHITE AA, 1971, ACTA ORTHOP SCAND, V42, P482, DOI 10.3109/17453677108989065
   WITTENBERG RH, 1990, SPINE, V15, P1073, DOI 10.1097/00007632-199015100-00017
   Yoganandan N, 1997, J BIOMECH ENG-T ASME, V119, P87, DOI 10.1115/1.2796070
   Yoganandan N, 1996, SPINE, V21, P1824, DOI 10.1097/00007632-199608010-00022
   Yoganandan N, 1996, MED ENG PHYS, V18, P569, DOI 10.1016/1350-4533(96)00013-6
   ZDEBLICK TA, 1993, SPINE, V18, P513
   ZHANG J, 1993, 39 ANN M ORTH RES SO, P15
NR 23
TC 38
Z9 52
U1 2
U2 4
PU IOS PRESS
PI AMSTERDAM
PA VAN DIEMENSTRAAT 94, 1013 CN AMSTERDAM, NETHERLANDS
SN 0959-2989
J9 BIO-MED MATER ENG
JI Bio-Med. Mater. Eng.
PY 1997
VL 7
IS 4
BP 221
EP 230
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA YH163
UT WOS:A1997YH16300001
PM 9408574
DA 2018-10-19
ER

PT J
AU Otsuka, M
   Nakahigashi, Y
   Matsuda, Y
   Kokubo, T
   Yoshihara, S
   Fujita, H
   Nakamura, T
AF Otsuka, M
   Nakahigashi, Y
   Matsuda, Y
   Kokubo, T
   Yoshihara, S
   Fujita, H
   Nakamura, T
TI The in vitro and in vivo indomethacin release from self-setting
   bioactive glass bone cement
SO BIO-MEDICAL MATERIALS AND ENGINEERING
LA English
DT Article
DE hydroxyapatite; biomaterial; artificial bone; self-setting bone cement;
   bioactive bone glass cement; a drug delivery system for skeletal tissue;
   in vivo drug release test
ID DRUG-DELIVERY SYSTEM; CALCIUM-PHOSPHATE CEMENT; PHYSICOCHEMICAL
   PROPERTIES; SKELETAL
AB The in vivo and in vitro drug release profiles from a self-setting bioactive CaO-SiO2-P2O5 glass bone cement containing indomethacin as a model drug were investigated. The cement containing 2% and 5% indomethacin (IMC) powder hardened within 5 min after mixing with ammonium phosphate buffer. After setting, in vitro drug release from drug-loaded cement pellets in a simulated body fluid (SBF) at pH 7.25 and 37 degrees C continued for two weeks. The hardened cement gradually formed low-crystallinity hydroxyapatite during the drug release test in SEE An IMC-loaded cement device (2% and 5% drug) was implanted in the subcutaneous tissue on the back of rats. The in vivo IMC release from the cement increased and attained maximum levels (C-max of 2% and 5% drug-loaded cements was 0.27 and 3.37 mu g/ml, respectively) at T-max, 3 acid 0.5 d, respectively, upon subcutaneous (s.c.) administration in rats. This suggested that the s.c, administration of the cement provided IMC release for a much longer period than s.c. administration of the solution, and the plasma IMC concentration was dependent on the drug concentration in the cement. The plasma IMC concentration and the area under the curve from 2% and 5% IMC-loaded cements in rats were dependent on the concentration of IMC in the cements. The in vivo IMC concentration in plasma obtained by the deconvolution method was much lower than that delivered in SBF in vitro. Scanning electron microscopy and photomicrographs of cross sections showed that the bioactive bone cement had excellent biocompatibility with the surrounding soft tissues.
C1 Kobe Pharmaceut Univ, Dept Pharmaceut Technol, Kobe, Hyogo 658, Japan.
   Kyoto Univ, Fac Engn, Kyoto 60601, Japan.
   Nippon Elect Glass Co, Ohtsu, Shiga 520, Japan.
   Kyoto Univ, Fac Med, Kyoto 606, Japan.
EM m-otsuka@kobepharma-u.ac.jp
CR AOKI H, 1991, SCI MED APPL HYDROXY, P1
   ARAR HH, 1992, BIOMED SCI INSTRUM, V28, P173
   BENGHUZZI HA, 1992, BIOMED SCI INSTRUM, V28, P129
   BENGHUZZI HA, 1992, BIOMED SCI INSTRUM, V28, P179
   Brown WE, 1986, United States patent, Patent No. [4612053, EP 4612053]
   Cannon M R, 1995, Biomed Sci Instrum, V31, P159
   DOI Y, 1987, J JPN SOC DENTAL MAT, V6, P53
   JANSEN JA, 1991, J BIOMED MATER RES, V25, P973, DOI 10.1002/jbm.820250805
   KOKUBO T, 1991, J AM CERAM SOC, V74, P1739, DOI 10.1111/j.1151-2916.1991.tb07176.x
   MATSUDA T, 1990, SEITAI KOROIDO, P777
   Mileti I F, 1995, Biomed Sci Instrum, V31, P177
   NISHIMURA N, 1991, J APPL BIOMATER, V2, P219, DOI 10.1002/jab.770020402
   OTSUKA M, 1994, J PHARM SCI, V83, P611, DOI 10.1002/jps.2600830502
   OTSUKA M, 1990, CHEM PHARM BULL, V38, P3500, DOI 10.1248/cpb.38.3500
   OTSUKA M, 1994, J PHARM SCI, V83, P255, DOI 10.1002/jps.2600830229
   OTSUKA M, 1994, J PHARM SCI, V83, P259, DOI 10.1002/jps.2600830230
   OTSUKA M, 1992, CHEM PHARM BULL, V40, P3344
   SAHA S, 1984, J BIOMED MATER RES, V18, P435, DOI 10.1002/jbm.820180411
   SALVATI EA, 1986, CLIN ORTHOP RELAT R, P83
   YAMAMURA K, 1991, DRUG DELIVERY SYST, V6, P103
   YAMAOKA K, 1981, J PHARMACOBIO-DYNAM, V4, P879, DOI 10.1248/bpb1978.4.879
   YOSHIHARA S, 1992, BIOCERAMICS, V3, P231
NR 22
TC 2
Z9 2
U1 0
U2 3
PU IOS PRESS
PI AMSTERDAM
PA VAN DIEMENSTRAAT 94, 1013 CN AMSTERDAM, NETHERLANDS
SN 0959-2989
J9 BIO-MED MATER ENG
JI Bio-Med. Mater. Eng.
PY 1997
VL 7
IS 5
BP 291
EP 302
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA YQ580
UT WOS:000071402100002
PM 9457380
DA 2018-10-19
ER

PT J
AU Assad, M
   Lemieux, N
   Rivard, CH
AF Assad, M
   Lemieux, N
   Rivard, CH
TI Immunogold electron microscopy in situ end-labeling (EM-ISEL): Assay for
   biomaterial DNA damage detection
SO BIO-MEDICAL MATERIALS AND ENGINEERING
LA English
DT Article
DE biocompatibility; genotoxicity; DNA damage; in situ end-labeling;
   immunogold; electron microscopy
ID METHYL METHANESULFONATE; METAL CARCINOGENESIS; EXONUCLEASE-III;
   MAMMALIAN-CELLS; STRAND BREAKS; APOPTOSIS; LYMPHOCYTES; MECHANISMS;
   DIGESTION; INSITU
AB We have evaluated a genotoxicity assay that combines in situ end-labeling, colloidal gold tagging and electron microscopy in order to adapt it to the measurement of in vitro biomaterial-induced genotoxicity. Human lymphocytes were cultured in semi-physiological medium which had been previously exposed to biomaterial extracts of commercially pure titanium following ISO standards. In order to visualize the location of induced DNA strand breaks, cells were then exposed to exonuclease III which partially digests and amplifies lesions by releasing nucleotides at free 3' hydroxyl ends from nicked double-stranded DNA. The resulting single-stranded DNA was allowed to hybridize with short oligonucleotides of random sequences including biotinylated dUTP. After random priming using Escherichia coli DNA polymerase I, incorporation of biotin-dUTP was detected by immunogold binding to the chromatin. Cells exposed to a mutagenic concentration of methyl methanesulfonate, as a positive control, showed a significantly higher and stronger gold staining than both titanium-exposed and unexposed specimens. This assay allows a precise localization and quantification of both in vitro DNA breakage and DNA repair. It could provide a powerful tool for rapid assessment of the genotoxic potential of new biomaterials.
C1 Univ Montreal, Pediat Res Ctr, Montreal, PQ H3T 1C5, Canada.
   Univ Montreal, Dept Surg, Montreal, PQ H3T 1C5, Canada.
   Univ Montreal, Dept Pathol, Montreal, PQ H3T 1C5, Canada.
   Hop St Justine, Montreal, PQ H3T 1C5, Canada.
EM assad@justine.umontreal.ca
CR [Anonymous], 1992, 109936 ISO INT ORG S, p[9, 17]
   ANSARI B, 1993, J PATHOL, V170, P1, DOI 10.1002/path.1711700102
   BEYERSMANN D, 1994, ARCH TOX S, V16, P192
   BRUNBORG G, 1995, MUTAT RES-GENET TOX, V342, P157, DOI 10.1016/0165-1218(95)90025-X
   CIAPETTI G, 1993, BIOMATERIALS, V14, P359, DOI 10.1016/0142-9612(93)90055-7
   COATES PJ, 1995, J PATHOL, V176, P19, DOI 10.1002/path.1711760105
   COHEN M, 1990, BIOL EFFECTS HEAVY M, V2, P19
   EDWARDS AJ, 1993, MUTAT RES, V289, P139, DOI 10.1016/0027-5107(93)90063-L
   FERNANDEZ JL, 1995, J MED GENET, V32, P32, DOI 10.1136/jmg.32.1.32
   Fernandez Jose Luis, 1993, Cytobios, V73, P189
   FLOYD RA, 1990, CARCINOGENESIS, V11, P1447, DOI 10.1093/carcin/11.9.1447
   GINGRAS D, 1995, CELL VISION, V2, P218
   GOSALVEZ J, 1993, GENOME, V36, P230, DOI 10.1139/g93-032
   GOSALVEZ J, 1993, TRENDS GENET, V9, P156, DOI 10.1016/0168-9525(93)90151-7
   GUILLE E, 1981, SYSTEMIC ASPECTS BIO, V2, P33
   HAAF T, 1989, CYTOGENET CELL GENET, V50, P141
   HARTWIG A, 1990, MUTAT RES, V241, P75, DOI 10.1016/0165-1218(90)90110-N
   HARTWIG A, 1991, METAL COMPOUNDS ENV, V4, P475
   *INT ORG STAND, 1992, 109935 ISO 5, P1
   KASPRZAK KS, 1995, CANCER INVEST, V13, P411, DOI 10.3109/07357909509031921
   KLEIN CB, 1991, CHEM RES TOXICOL, V4, P592, DOI 10.1021/tx00024a001
   LEMIEUX N, 1990, HUM GENET, V85, P261
   MAJNO G, 1995, AM J PATHOL, V146, P3
   MESSIER PE, 1986, CYTOGENET CELL GENET, V43, P207, DOI 10.1159/000132322
   MIGHELI A, 1995, J PATHOL, V176, P27, DOI 10.1002/path.1711760106
   NOSE K, 1983, BIOCHEM BIOPH RES CO, V111, P383, DOI 10.1016/0006-291X(83)90317-0
   SALVADORI DMF, 1994, MUTAGENESIS, V9, P53, DOI 10.1093/mutage/9.1.53
   SGOURAS D, 1990, J MATER SCI-MATER M, V1, P61, DOI 10.1007/BF00839070
   SNOW ET, 1992, PHARMACOL THERAPEUT, V53, P31, DOI 10.1016/0163-7258(92)90043-Y
   STEWART BW, 1994, J NATL CANCER I, V86, P1286, DOI 10.1093/jnci/86.17.1286
   SUNDERMAN FW, 1989, FUND APPL TOXICOL, V13, P205, DOI 10.1016/0272-0590(89)90257-1
   TAKAMURA K, 1994, J BIOMED MATER RES, V28, P583, DOI 10.1002/jbm.820280508
   THERMAN E, 1993, HUMAN CHROMOSOMES ST, P65
   TUBIANA M, 1986, RADIOBIOLOGIE, P67
   WAALKES MP, 1987, CANCER RES, V47, P2445
   WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741
   WOOD KA, 1993, NEURON, V11, P621, DOI 10.1016/0896-6273(93)90074-2
NR 37
TC 5
Z9 5
U1 0
U2 1
PU IOS PRESS
PI AMSTERDAM
PA VAN DIEMENSTRAAT 94, 1013 CN AMSTERDAM, NETHERLANDS
SN 0959-2989
J9 BIO-MED MATER ENG
JI Bio-Med. Mater. Eng.
PY 1997
VL 7
IS 6
BP 391
EP 400
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA ZP901
UT WOS:000073800000005
PM 9622107
DA 2018-10-19
ER

PT B
AU Bosetti, M
   Santin, M
   Mazzocchi, M
   Krajewski, A
   Rastellino, M
   Ravaglioli, A
   Cannas, M
AF Bosetti, M
   Santin, M
   Mazzocchi, M
   Krajewski, A
   Rastellino, M
   Ravaglioli, A
   Cannas, M
BE Sedel, L
   Rey, C
TI Characterization of zirconia coated by bioactive glass: Preliminary
   observations
SO BIOCERAMICS, VOL 10
LA English
DT Proceedings Paper
CT 10th International Symposium on Ceramics in Medicine
CY OCT 05-09, 1997
CL PARIS, FRANCE
SP European Soc Biomat, Soc Biomat (USA), European Soc Orthopaed Res, Japanese Soc Biomat, Ceram Soc Japan, Japanese Soc Orthopaed Ceram Implants, Natl Inst Sci & Med Res (INSERM France), Natl Ctr Sci Res (CNRS France)
DE Zirconia; in-vitro biocompatibility; glass coating
AB The cell/biomaterial interface is one of the fundamental aspects that should be studied to evaluate the biocompatibility of a new implantable material. Cell attachment and orientation in vitro depends on mechanical and physico-chemical characteristic of the biomaterial, influenced particularly by protein adsorption to the material itself.
   This abstract reports observations on serum protein adsorption, growth and adhesion of fibroblasts on Zirconia covered surfaces by two different phosphate vitreous substances (differing for Tantalium and Lantanium presence).
   The pattern of adsorption of serum proteins onto Zirconia surfaces was characterized by an increased presence of proteins in the molecular weight range of 20-90 kDa thus permitting to conferm that bioactive glass coating led to a drastic increase of adsorbed proteins.
   Cell cultures has defined an accettable biocompatibility with a significantly greater cell growth on AP40 and RKKP coated materials than on uncoated Zirconia.
   In conclusion, these coatings permit the combination of the mechanical qualities of Zirconia (elsewhere demonstrated), which is not very biocompatible, with the properties of new ceramics which are not mechanically resistant, but biocompatible.
C1 Univ Turin, Dept Med Sci, I-28100 Novara, Italy.
RP Bosetti, M (reprint author), Univ Turin, Dept Med Sci, I-28100 Novara, Italy.
RI Mazzocchi, Mauro/D-9631-2016
OI Mazzocchi, Mauro/0000-0002-0243-6890
CR BERGER G, 1992, 10 YEARS CLIN EXPERI, P33
   FERRARIS M, 1996, P 3 M SEM CER CELLS
   FERRARIS M, 1997, J AM CER SOC B
   HULERT SF, 1993, ADV SERIES CERAMICS, V1, P25
   KIRKPATRICK CJ, 1992, BIOMAT TISSUE INTERF, V10, P31
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
NR 6
TC 0
Z9 0
U1 0
U2 1
PU PERGAMON PRESS LTD
PI OXFORD
PA THE BOULEVARD LANGFORD LANE KIDLINGTON, OXFORD OX5 1GB, ENGLAND
BN 0-08-042692-1
PY 1997
BP 139
EP 142
DI 10.1016/B978-008042692-1/50033-9
PG 4
WC Engineering, Biomedical; Materials Science, Biomaterials; Orthopedics
SC Engineering; Materials Science; Orthopedics
GA BM24P
UT WOS:000078165600033
DA 2018-10-19
ER

PT B
AU Martinetti, R
   Dolcini, L
   Ravaglioli, A
   Krajewski, A
   Mangano, C
AF Martinetti, R
   Dolcini, L
   Ravaglioli, A
   Krajewski, A
   Mangano, C
BE Sedel, L
   Rey, C
TI Experimental study on hydroxyapatite N-Carboxymethyl chitosan fillers
SO BIOCERAMICS, VOL 10
LA English
DT Proceedings Paper
CT 10th International Symposium on Ceramics in Medicine
CY OCT 05-09, 1997
CL PARIS, FRANCE
SP European Soc Biomat, Soc Biomat (USA), European Soc Orthopaed Res, Japanese Soc Biomat, Ceram Soc Japan, Japanese Soc Orthopaed Ceram Implants, Natl Inst Sci & Med Res (INSERM France), Natl Ctr Sci Res (CNRS France)
DE N-Carboxymethyl chitosan coating; porous hydroxyapatite; bioactive
   fillers
AB Hydroxyapatite / N-Carboxymethyl chitosan (HA / N-CMC) fillers were prepared and studied as a new biomaterial for medical use.
   N-CMC could either be a suitable structure where calcium and phosphate ions could arrange to begin mineralisation process or to influence the metabolism of the cells, inducing the synthesis of specific protein able to control the natural mechanism of hydroxyapatite crystals growth and consequently the mineralisation of new osteoid tissue.
   Starting materials and final samples were characterised: morphology and microstructure were evaluated by SEM and IR spectroscopy was used to detect the typical bands.
   N-CMC solution used for the preparation of the fillers coating was also characterised from the reological point of view.
   This experimental work underlines the important role of N-CMC for biomedical application, when in association with hydroxyapatite.
C1 FAENZA Srl, CERAMICA, FIN, I-48018 Faenza, Italy.
RP Martinetti, R (reprint author), FAENZA Srl, CERAMICA, FIN, Via Ravegnana 186, I-48018 Faenza, Italy.
CR LOBIANCO F, 1993, DENT CADMOS, V10, P40
   MATTIOLIBELMONTE M, 1995, J BIOACT COMPAT POL, V10, P249, DOI 10.1177/088391159501000304
   RAVAGLIOLI A, 1996, BIOCERAMICS, V9, P185
   Takechi M, 1996, J MATER SCI-MATER M, V7, P317, DOI 10.1007/BF00154542
NR 4
TC 0
Z9 0
U1 0
U2 3
PU PERGAMON PRESS LTD
PI OXFORD
PA THE BOULEVARD LANGFORD LANE KIDLINGTON, OXFORD OX5 1GB, ENGLAND
BN 0-08-042692-1
PY 1997
BP 503
EP 506
DI 10.1016/B978-008042692-1/50119-9
PG 4
WC Engineering, Biomedical; Materials Science, Biomaterials; Orthopedics
SC Engineering; Materials Science; Orthopedics
GA BM24P
UT WOS:000078165600119
DA 2018-10-19
ER

PT B
AU Lopes, MA
   Knowles, JC
   Hing, KA
   Santos, JD
   Monteiro, FJ
   Olsen, I
AF Lopes, MA
   Knowles, JC
   Hing, KA
   Santos, JD
   Monteiro, FJ
   Olsen, I
BE Sedel, L
   Rey, C
TI Biological evaluation of glass reinforced hydroxyapatite by flow
   cytometry
SO BIOCERAMICS, VOL 10
LA English
DT Proceedings Paper
CT 10th International Symposium on Ceramics in Medicine
CY OCT 05-09, 1997
CL PARIS, FRANCE
SP European Soc Biomat, Soc Biomat (USA), European Soc Orthopaed Res, Japanese Soc Biomat, Ceram Soc Japan, Japanese Soc Orthopaed Ceram Implants, Natl Inst Sci & Med Res (INSERM France), Natl Ctr Sci Res (CNRS France)
DE flow cytometry; cell culture; biocompatibility; hydroxyapatite
AB Flow cytometry (FCM) was used for evalualting the biological response of human cells to direct contact with materials with potential medical applications. The osteoblast-like cell line MG63 was grown on hydroxyapatite (HA) and P2O5-based glass reinforced hydroxyapatite composites (GR-HA). Results suggested that the composites caused a delay in the progression of cells from G0/G1 into the S phase of the cell cycle. Moreover, although the cellular expression of collagen type I (COL I) was found to be similar in both materials, the level of osteocalcin (OC) was downregulated in the OR-HA compared with HA alone. The results of this study suggest that the FCM is a useful technique for assessing cell-biomaterial interactions.
C1 Univ London Queen Mary & Westfield Coll, IRC Biomed Mat, London E1 4NS, England.
RP Lopes, MA (reprint author), Univ London Queen Mary & Westfield Coll, IRC Biomed Mat, Mile End Rd, London E1 4NS, England.
RI Lopes, Maria A./P-4442-2014; Knowles, Jonathan Campbell/B-9019-2008
OI Lopes, Maria A./0000-0003-4105-8148; Knowles, Jonathan
   Campbell/0000-0003-3917-3446
CR ORMEROD MG, 1994, FLOW CYTOMETRY
   SANTOS JD, 1994, BIOMATERIALS, V15, P5, DOI 10.1016/0142-9612(94)90188-0
   Shapiro HM, 1995, PRATICAL FLOW CYTOME
NR 3
TC 1
Z9 1
U1 0
U2 0
PU PERGAMON PRESS LTD
PI OXFORD
PA THE BOULEVARD LANGFORD LANE KIDLINGTON, OXFORD OX5 1GB, ENGLAND
BN 0-08-042692-1
PY 1997
BP 575
EP 578
DI 10.1016/B978-008042692-1/50136-9
PG 4
WC Engineering, Biomedical; Materials Science, Biomaterials; Orthopedics
SC Engineering; Materials Science; Orthopedics
GA BM24P
UT WOS:000078165600136
DA 2018-10-19
ER

PT B
AU Midy, V
   Hollande, E
   Rey, C
   Dard, M
AF Midy, V
   Hollande, E
   Rey, C
   Dard, M
BE Sedel, L
   Rey, C
TI Calcium phosphate ceramics as controlled release systems for FGF-2
SO BIOCERAMICS, VOL 10
LA English
DT Proceedings Paper
CT 10th International Symposium on Ceramics in Medicine
CY OCT 05-09, 1997
CL PARIS, FRANCE
SP European Soc Biomat, Soc Biomat (USA), European Soc Orthopaed Res, Japanese Soc Biomat, Ceram Soc Japan, Japanese Soc Orthopaed Ceram Implants, Natl Inst Sci & Med Res (INSERM France), Natl Ctr Sci Res (CNRS France)
DE calcium phosphate ceramics; Fibroblastic Growth Factor-2; adsorption
ID FIBROBLAST GROWTH-FACTOR; INVITRO
AB The aim of our study was to determine the capacity of calcium phosphate ceramics to serve as carriers for Fibroblastic Growth Factor-2 (FGF-2), which is able to locally stimulate bone formation in vivo. Two different apatitic substrates were tested: stoichiometric hydroxyapatite (HA), widely used as an osteoconductive biomaterial, and nanocrystalline carbonated apatite (CA), very close to bone mineral crystals. Adsorption of the growth factor was quantified by I-125 and reached 85% of the initial concentration for CA, and 10%, for HA. Release of FGF-2 was about 20%, of the adsorbed amounts for both compounds. In fetal bovine aortic endothelial cell culture, the FGF-2 released showed a strong loss of bioactivity possibly due to the presence of ceramic particles and/or to conformational changes.
C1 UPRESA, CNRS 5071, Lab Mat & Interfaces Phosphates & Biomat, F-31400 Toulouse, France.
RP Midy, V (reprint author), UPRESA, CNRS 5071, Lab Mat & Interfaces Phosphates & Biomat, 38 Rue 36 Ponts, F-31400 Toulouse, France.
CR ALLIOTLICHT B, 1991, BIOMATERIALS, V12, P752, DOI 10.1016/0142-9612(91)90025-6
   CANALIS E, 1988, J CLIN INVEST, V81, P1572, DOI 10.1172/JCI113490
   FRENKEL SR, 1992, ACTA ANAT, V145, P265
   GLOBUS RK, 1988, ENDOCRINOLOGY, V123, P98, DOI 10.1210/endo-123-1-98
   Griffith DL, 1996, P NATL ACAD SCI USA, V93, P878, DOI 10.1073/pnas.93.2.878
   HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665
   KAWAGUCHI H, 1994, ENDOCRINOLOGY, V135, P774, DOI 10.1210/en.135.2.774
   MIDY V, UNPUB
   REY C, 1991, CALCIFIED TISSUE INT, V49, P251, DOI 10.1007/BF02556214
   REY C, 1990, Biomaterials, V11, P13
NR 10
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON PRESS LTD
PI OXFORD
PA THE BOULEVARD LANGFORD LANE KIDLINGTON, OXFORD OX5 1GB, ENGLAND
BN 0-08-042692-1
PY 1997
BP 591
EP 594
DI 10.1016/B978-008042692-1/50140-0
PG 4
WC Engineering, Biomedical; Materials Science, Biomaterials; Orthopedics
SC Engineering; Materials Science; Orthopedics
GA BM24P
UT WOS:000078165600140
DA 2018-10-19
ER

PT J
AU Park, KD
   Lee, WK
   Yun, JY
   Han, DK
   Kim, SH
   Kim, YH
   Kim, HM
   Kim, KT
AF Park, KD
   Lee, WK
   Yun, JY
   Han, DK
   Kim, SH
   Kim, YH
   Kim, HM
   Kim, KT
TI Novel anti-calcification treatment of biological tissues by grafting of
   sulphonated poly(ethylene oxide)
SO BIOMATERIALS
LA English
DT Article
DE tissue modification; sulphonated PEO; anti-calcification; tissue valve
ID CONTROLLED-RELEASE; VALVE; PREVENTION; BIOMATERIAL; PROSTHESES;
   INHIBITION; PU-PEO-SO3
AB Biological porcine tissue was modified by the direct coupling of sulphonated poly(ethylene oxide) (PEO-SO3) containing amino end groups after glutaraldehyde fixation. The calcification of the modified tissue [bioprosthetic tissue (BT)-PEO-SO3] and control (BT control) was investigated by in vivo rate subdermal, canine aorta-illiac shunt and right ventricle-pulmonary artery shunt implantation models. Less calcium deposition of BT-PEO-SO3 than of BT control was observed in in vivo tests. Such a reduced calcification of BT-PEO-SO3 can be explained by decreases of residual glutaraldehyde groups, a space filling effect and, therefore, improved biostability and synergistic blood-compatible effects of PEO and SO3 groups after the covalent binding of PEG-SO3 to tissue. This simple method can be a useful anti-calcification treatment for implantable tissue valves. (C) 1996 Elsevier Science Limited
C1 KOREA INST SCI & TECHNOL, POLYMER CHEM LAB, SEOUL 130650, SOUTH KOREA.
   KOREA UNIV, DEPT THORAC & CARDIOVASC SURG, SEOUL 136701, SOUTH KOREA.
OI Han, Dong Keun/0000-0003-4641-7883
CR BLITTERSWIJK CA, 1991, T SOC BIOMATER, V14, P11
   CHANDA J, 1994, BIOMATERIALS, V15, P465, DOI 10.1016/0142-9612(94)90226-7
   CHEN WL, 1994, CIRCULATION, V90, P323, DOI 10.1161/01.CIR.90.1.323
   COLEMAN DL, 1981, T AM SOC ART INT ORG, V27, P708
   FERRANS VJ, 1980, AM J CARDIOL, V46, P721, DOI 10.1016/0002-9149(80)90421-X
   FRAUTSCHI JF, 1995, T SOC BIOMATER, V18, P160
   GOLOMB G, 1991, J BIOMED MATER RES, V25, P85, DOI 10.1002/jbm.820250107
   Han D K, 1993, ASAIO J, V39, pM537
   HAN DK, 1995, BIOMATERIALS, V16, P467, DOI 10.1016/0142-9612(95)98819-Z
   HAN DK, 1993, J BIOMED MATER RES, V27, P1063, DOI 10.1002/jbm.820270812
   Han DK, 1996, J BIOMED MATER RES, V30, P23, DOI 10.1002/(SICI)1097-4636(199601)30:1<23::AID-JBM4>3.0.CO;2-T
   HARASAKI H, 1981, T AM SOC ART INT ORG, V27, P683
   HIRSCH D, 1993, J BIOMED MATER RES, V27, P1477, DOI 10.1002/jbm.820271203
   JOHNSTON TP, 1989, INT J PHARM, V52, P139, DOI 10.1016/0378-5173(89)90288-3
   LEVY RJ, 1983, ATHEROSCLEROSIS, V46, P49, DOI 10.1016/0021-9150(83)90163-6
   LEVY RJ, 1991, BIOMATERIALS, V12, P707, DOI 10.1016/0142-9612(91)90017-5
   LEVY RJ, 1983, AM J PATHOL, V113, P143
   LEVY RJ, 1986, CRIT REV BIOCOMPAT, V2, P147
   NANCOLLAS GH, 1977, J CRYST GROWTH, V42, P185, DOI 10.1016/0022-0248(77)90194-4
   NIMNI ME, 1987, J BIOMED MATER RES, V21, P741, DOI 10.1002/jbm.820210606
   Park K D, 1994, ASAIO J, V40, pM377, DOI 10.1097/00002480-199407000-00026
   PEREIRA CA, 1990, J BIOMED MATER RES, V24, P345, DOI 10.1002/jbm.820240307
   SCHOEN FJ, 1988, J BIOMED MATER RES-A, V22, P11
   SCHOEN FJ, 1987, J BIOMED MATER RES-A, V21, P91
   THUBRIKAR MJ, 1983, J THORAC CARDIOV SUR, V86, P115
   WEBB CL, 1992, AM J PATHOL, V141, P487
NR 26
TC 33
Z9 34
U1 1
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD JAN
PY 1997
VL 18
IS 1
BP 47
EP 51
DI 10.1016/S0142-9612(96)00096-8
PG 5
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA WA345
UT WOS:A1997WA34500009
PM 9003896
DA 2018-10-19
ER

PT J
AU Khor, E
AF Khor, E
TI Methods for the treatment of collagenous tissues for bioprostheses
SO BIOMATERIALS
LA English
DT Review
DE collagenous tissue; bioprostheses; porcine aortic valve; bovine
   pericardium; cross-linking
ID CARDIAC-VALVE BIOPROSTHESES; DERMAL SHEEP COLLAGEN; CROSS-LINKING;
   HEART-VALVES; MECHANICAL-PROPERTIES; BOVINE PERICARDIUM; POLYEPOXY
   COMPOUND; VALVULAR BIOPROSTHESES; VASCULAR GRAFT; AORTIC-VALVE
AB Collagenous tissue as a biomaterial possesses many favourable characteristics and advantages over synthetic materials. The resemblance to human tissue suggests that it has a performance advantage over alternative materials. This advantage has been exploited to produce clinical devices that have been implanted in patients for more than a quarter of a century. The method of treating collagenous tissue for bioprostheses has developed from crude exposure of tissue to chemicals to a sophisticated level of considering the biochemical, chemical, engineering and clinical aspects of the process. This review focuses on the various chemical and physical treatments that have made the bioprostheses possible, highlighting the chemical agents and the cross-linking mechanism involved. (C) 1996 Elsevier Science Limited.
RP Khor, E (reprint author), NATL UNIV SINGAPORE,DEPT CHEM,KENT RIDGE,SINGAPORE 119260,SINGAPORE.
CR ANGELL WW, 1989, ANN THORAC SURG, V48, pS89, DOI 10.1016/0003-4975(89)90654-1
   BARTOLOTTI U, 1982, J THORAC CARDIOVASC, V84, P451
   BASHEY RI, 1988, COLLAGEN, V1, P257
   BERNSTEIN PH, 1980, J BIOL CHEM, V255, P414
   BODNAR E, 1991, VALVES, P49
   BOWES JH, 1968, BIOCHIM BIOPHYS ACTA, V168, P341, DOI 10.1016/0005-2795(68)90156-6
   BROOM ND, 1979, THORAX, V34, P166, DOI 10.1136/thx.34.2.166
   BROOM ND, 1977, J BIOMECH, V10, P707, DOI 10.1016/0021-9290(77)90086-0
   BUCH WS, 1970, J THORAC CARDIOV SUR, V60, P673
   BURMAN SO, 1989, ANN THORAC SURG, V48, pS75, DOI 10.1016/0003-4975(89)90647-4
   BUTANY J, 1990, ASAIO T, V26, pM414
   BUTTERFIELD M, 1990, ADV BIOMAT, V9, P523
   CARPENTIER A, 1984, CIRCULATION, V70, P165
   CARPENTIER A, 1969, J THORAC CARDIOV SUR, V58, P467
   CARPENTIER A, 1989, ANN THORAC SURG, V48, pS73, DOI 10.1016/0003-4975(89)90646-2
   CARPENTIER A, 1977, J ASSOC ADV MED INST, V11, P98
   CHACHQUES JC, 1988, ANN NY ACAD SCI, V529, P184
   Chan-Myers H B, 1992, ASAIO J, V38, P116, DOI 10.1097/00002480-199204000-00010
   CHAUVAUD S, 1991, J THORAC CARDIOV SUR, V102, P171
   CHEUNG DT, 1982, CONNECT TISSUE RES, V10, P187, DOI 10.3109/03008208209034418
   CHEUNG DT, 1982, CONNECT TISSUE RES, V10, P201, DOI 10.3109/03008208209034419
   CHEUNG DT, 1985, CONNECT TISSUE RES, V13, P109, DOI 10.3109/03008208509152389
   CHVAPIL M, 1993, J BIOMED MATER RES, V27, P313, DOI 10.1002/jbm.820270305
   Chvapil M., 1992, USA Pat, Patent No. [5,078,744, 5078744]
   COLLINS D, 1977, BIOCHIM BIOPHYS ACTA, V495, P129, DOI 10.1016/0005-2795(77)90247-1
   Damink LHHO, 1996, BIOMATERIALS, V17, P765, DOI 10.1016/0142-9612(96)81413-X
   DAMINK LHHO, 1995, J MATER SCI-MATER M, V6, P429
   DAVID TE, 1990, J THORAC CARDIOV SUR, V99, P113
   DUNN MG, 1993, J BIOMED MATER RES, V27, P1545, DOI 10.1002/jbm.820271211
   FENTIE IH, 1986, J SUBMICR CYTOL PATH, V18, P53
   FERRANS VJ, 1991, EUR J CARDIO-THORAC, V5, P144, DOI 10.1016/1010-7940(91)90213-4
   FERRANS VJ, 1987, HUM PATHOL, V18, P586, DOI 10.1016/S0046-8177(87)80358-1
   FERRANS VJ, 1991, REPLACEMENT CARDIAC, P49
   FISHER J, 1987, LIFE SUPPORT SYST, V5, P189
   GENDLER E, 1984, J BIOMED MATER RES, V18, P727, DOI 10.1002/jbm.820180703
   GIRARDOT MN, 1995, J BIOMED MATER RES, V29, P793, DOI 10.1002/jbm.820290703
   GLIMCHER MJ, 1989, ANAT REC, V224, P139, DOI 10.1002/ar.1092240205
   GOLOMB G, 1987, AM J PATHOL, V127, P122
   GOTT JP, 1992, ANN THORAC SURG, V53, P207, DOI 10.1016/0003-4975(92)91321-Y
   HATA C, 1992, ARTIF ORGANS, V16, P263, DOI 10.1111/j.1525-1594.1992.tb00307.x
   HILBERT S J, 1988, Medical Progress Through Technology, V14, P115
   HIRASAKI H, 1980, J THORAC CARDIOVASC, V79, P125
   Imamura E., 1992, U.S. Patent, Patent No. [5,080,670, 5080670]
   IMAMURA E, 1988, JPN J ARTIF ORGANS, V17, P1101
   ISIHIRARA T, 1981, J THORAC CARDIOVASC, V81, P747
   Jayakrishnan A, 1996, BIOMATERIALS, V17, P471, DOI 10.1016/0142-9612(96)82721-9
   JORGEHERRERO E, 1991, BIOMATERIALS, V12, P683, DOI 10.1016/0142-9612(91)90117-S
   KATO YP, 1989, BIOMATERIALS, V10, P38, DOI 10.1016/0142-9612(89)90007-0
   KHOR E, INPRESS J MAT SCI MA
   KHOR E, UNPUB J MAT SCI MAT
   KORN AH, 1972, J MOL BIOL, V65, P525, DOI 10.1016/0022-2836(72)90206-9
   LEE JM, 1994, J BIOMED MATER RES, V28, P981, DOI 10.1002/jbm.820280903
   LEVY RJ, 1986, CRIT REV BIOCOMPAT, V2, P147
   LEVY RJ, 1990, J CONTROL RELEASE, V11, P245, DOI 10.1016/0168-3659(90)90137-I
   Liao K X, 1991, ASAIO Trans, V37, pM175
   LIVESEY SA, 1994, Patent No. 5336616
   LLOYD DR, 1979, J POLYM SCI POL CHEM, V17, P3475
   LOCKIE KJ, 1994, J THORAC CARDIOV SUR, V108, P1037
   Loke WK, 1996, BIOMATERIALS, V17, P2163, DOI 10.1016/0142-9612(96)00053-1
   LOKE WK, 1995, BIOMATERIALS, V16, P1003
   LOKE WK, 1996, THESIS NATL U SINGAP
   LOVE JW, 1993, AUTOLOGOUS TISSUE HE, P92
   MAGILLIGAN DJ, 1988, T AM SOC ART INT ORG, V34, P1031
   MCINTYRE J, 1991, 17 M SOC BIOM, P119
   MECHANIC GL, 1992, Patent No. 5147514
   Miller E. J., 1984, EXTRACELLULAR MATRIX, P41
   MISSIRLIS YF, 1977, ACTA ANAT, V98, P199
   MIYATA T, 1992, Clinical Materials, V9, P139, DOI 10.1016/0267-6605(92)90093-9
   Moczar M, 1994, ASAIO J, V40, pM697, DOI 10.1097/00002480-199407000-00088
   MOORE MA, 1994, J BIOMED MATER RES, V28, P611, DOI 10.1002/jbm.820280511
   NAIMARK WA, 1995, J MATER SCI-MATER M, V6, P235, DOI 10.1007/BF00146862
   NASHEF AS, 1984, Patent No. 4481009
   Naughton G K, 1995, Tissue Eng, V1, P211, DOI 10.1089/ten.1995.1.211
   Nimni M., 1992, CARDIOVASCULAR BIOMA, P81
   NIMNI ME, 1987, J BIOMED MATER RES, V21, P741, DOI 10.1002/jbm.820210606
   NISHI C, 1995, J BIOMED MATER RES, V29, P829, DOI 10.1002/jbm.820290707
   OKOSHI T, 1990, T AM SOC ART INT ORG, V36, pM411
   Park K D, 1994, ASAIO J, V40, pM377, DOI 10.1097/00002480-199407000-00026
   PEREIRA CA, 1990, J BIOMED MATER RES, V24, P345, DOI 10.1002/jbm.820240307
   PETITE H, 1995, BIOMATERIALS, V16, P1003, DOI 10.1016/0142-9612(95)94908-4
   PETITE H, 1994, J BIOMED MATER RES, V28, P159, DOI 10.1002/jbm.820280204
   PETITE H, 1990, J BIOMED MATER RES, V24, P179, DOI 10.1002/jbm.820240205
   PETITE H, 1990, SURG HEART VALVE DIS, P659
   PUIG LB, 1972, J THORAC CARDIOV SUR, V64, P154
   PUIGLB, 1977, J CARDIOVASC SURG, V18, P247
   RADJEMAN A, 1987, J FIZIK MAL, V8, P52
   Riddle J M, 1982, Henry Ford Hosp Med J, V30, P139
   ROSE AG, 1987, PATHOLOGY HEART VALV, P114
   ROSS D, 1989, ANN THORAC SURG, V48, pS69, DOI 10.1016/0003-4975(89)90644-9
   Sacks M S, 1994, ASAIO J, V40, pM632, DOI 10.1097/00002480-199407000-00075
   SENNING A, 1967, J THORAC CARDIOV SUR, V54, P465
   SIMMONS DM, 1993, BIOTECHNOL APPL BIOC, V17, P23
   Sung HW, 1996, J BIOMED MATER RES, V30, P361, DOI 10.1002/(SICI)1097-4636(199603)30:3<361::AID-JBM10>3.0.CO;2-N
   TAN WM, 1993, BIOMATERIALS, V14, P1003, DOI 10.1016/0142-9612(93)90193-6
   Thoma R J, 1995, J Heart Valve Dis, V4, P214
   Thompson J. I., 1995, Bio-Medical Materials and Engineering, V5, P37
   THUBRIKAR MJ, 1983, J THORAC CARDIOV SUR, V86, P115
   TU R, 1993, J BIOMED MATER RES, V27, P3, DOI 10.1002/jbm.820270103
   VANLUYN MJA, 1992, J BIOMED MATER RES, V26, P1091, DOI 10.1002/jbm.820260810
   VANLUYN MJA, 1995, J MATER SCI-MATER M, V6, P288, DOI 10.1007/BF00120273
   VANWACHEM PB, 1994, J BIOMED MATER RES, V28, P353, DOI 10.1002/jbm.820280310
   VISSER CE, 1992, BIOMATERIALS, V13, P34, DOI 10.1016/0142-9612(92)90092-3
   WANG E, 1993, INT J ARTIF ORGANS, V16, P530
   WANG MC, 1994, BIOMATERIALS, V15, P507
   WEADOCK K, 1983, BIOMATER ARTIF CELL, V11, P293, DOI 10.3109/10731198309118815
   WEADOCK KS, 1995, J BIOMED MATER RES, V29, P1373, DOI 10.1002/jbm.820291108
   WIEBE D, 1988, SURGERY, V104, P26
   WOODROOF EA, 1978, J BIOENG, V2, P1
   WOODROOF EA, 1979, TISSUE HEART VALVES, P347
   XI TF, 1992, J BIOMED MATER RES, V26, P1241
NR 110
TC 278
Z9 289
U1 0
U2 28
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD JAN
PY 1997
VL 18
IS 2
BP 95
EP 105
DI 10.1016/S0142-9612(96)00106-8
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA WB272
UT WOS:A1997WB27200001
PM 9022956
DA 2018-10-19
ER

PT J
AU Blonder, R
   BenDov, I
   Dagan, A
   Willner, I
   Zisman, E
AF Blonder, R
   BenDov, I
   Dagan, A
   Willner, I
   Zisman, E
TI Photochemically-activated electrodes: application in design of
   reversible immunosensors and antibody patterned interfaces
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE immunosensors; electrochemical immunosensors; piezoelectric
   immunosensors; reversible immunosensors; antigen monolayers; antigen
   electrodes; photoisomerizable antigens; photoisomerizable monolayers;
   photoregulated antigen-antibody interactions; antibody microstructures;
   biomaterial surface patterns; photolithography; antibody patterns
ID SELF-ASSEMBLED MONOLAYERS; RECORDED OPTICAL SIGNALS; GLUCOSE-OXIDASE;
   AMPEROMETRIC TRANSDUCTION; ENZYME ELECTRODE; AU-ELECTRODES; SURFACES;
   IMMUNOASSAY; BIOSENSOR; LIGHT
AB Antigen monolayers assembled onto Au electrodes associated with a quartz crystal act as electrochemical or microgravimetric quartz-crystal-microbalance (QCM) sensing interfaces for the complementary antibody. Electrochemical analysis of the antibody (Ab) is based on the insulation of the antigen monolayer electrode by the associated Ab towards a redox probe in the electrolyte solution. Ferrocene-modified glucose oxidase (Fc-GOx) and glucose are employed as redox probes for the amperometric transduction of the Ab association to the electrode. Bioelectrocatalyzed oxidation of glucose provides an electrochemical route to amplify the antigen-Ab complex formation. Electrochemical analysis of the dinitrophenyl antibody, DNP-Ab, by a dinitrophenyl-lysine monolayer electrode is presented. QCM analysis of the Ab is based on the frequency changes of the quartz crystal resulting from the association of the Ab to the crystal assembly. This method is discussed with the analysis of the fluorescein antibody, Flc-Ab, using a fluorescein monolayer-modified quartz crystal. A novel method to tailor reversible immunosensor devices by the application of photoisomerizable antigen monolayers on electrodes is presented. The antigen is modified by photoactive units exhibiting reversible photoisomerizable proper ties. In one photoisomer state, the antigen exhibits affinity for the Ab and enables its electrochemical or QCM analysis. Photoisomerization to the complementary state perturbs the antigen structure and the monolayer lacks affinity for the Ab. This enables the washing-off of the Ab and the regeneration of the actively sensing interface by a second illumination process that restores the antigen monolayer-modified surface. This method is exemplified by the development of a reversible DNP-Ab sensing electrode. N-Mercaptobutyl dinitrospiropyran ran was assembled as a photoisomerizable monolayer on a Au electrode. The dinitrospiropyran monolayer, SP-state, exhibits affinity for the DNP-Ab and enables the amperometric detection of the Ab using Fc-GOx and glucose as redox probe. The complementary photoisomerized protonated dinitromerocyanine monolayer, MRH+-state, lacks affinity for the DNP-Ab. By photoisomerization of the DNP-Ab associated with the SP-monolayer electrode to the MRH+-monolayer state, the DNP-Ab is washed-off, and by a second illumination process, the MRH+-monolayer is re-isomerized to the SP-monolayer assembly, which is the active interface for further analysis of the DNP-Ab. Cyclic amperometric detection of the DNP-Ab by the photoisomerizable dinitrospiropyran monolayer is demonstrated. The association of the DNP-Ab to the SP-monolayer electrode and the dissociation of the Ab from the MRH+-monolayer electrode are confirmed by QCM experiments using a dinitrospiropyran monolayer-modified quartz crystal.
   The insulating features of an antigen-Ab complex on a conductive surface and the photochemically controlled association of an antibody to a photoisomerizable monolayer assembled onto the surface were used to develop means for micropatterning of surfaces by the antibody. A dinitrospiropyran antigen monolayer was assembled onto conductive ITO glass. A DNP-Ab solution was used as 'ink solution' to pattern the surface. The Ab-pattern was imaged by electrochemical copper deposition onto the Ab-lacking surface domains. The dinitrospiropyran monolayer assembled onto ITO or Pyrex glass surfaces was employed as an active interface for the photolithographic patterning of the surface with the DNP-Ab. Irradiation of the dinitrospiropyran monolayer, SP-state, through a grid-mask generated surface domains of protonated dinitromerocyanine, MRH+-state, which lacks affinity for the DNP-Ab. The DNP-Ab covalently-linked to agarose beads (50 mu m) was selectively associated to the SP-monolayer sites and the micro-pattern of the resulting antibody was imaged. Methods for employing this photolithographic patterning of DNP-Ab to generate microstructures of any biomaterial, and, specifically, neural networks, are discussed. (C) 1997 Elsevier Science Limited.
C1 HEBREW UNIV JERUSALEM,FARKAS CTR LIGHT INDUCED PROC,IL-91904 JERUSALEM,ISRAEL.
   SAVYON DIAGNOST LTD,IL-77101 ASHDOD,ISRAEL.
RP Blonder, R (reprint author), HEBREW UNIV JERUSALEM,INST CHEM,IL-91904 JERUSALEM,ISRAEL.
RI Ben-Dov, Iddo/F-3282-2010
OI Ben-Dov, Iddo/0000-0002-9180-3604
CR AIZAWA M, 1977, ARCH BIOCHEM BIOPHYS, V182, P305, DOI 10.1016/0003-9861(77)90311-3
   BHATIA SK, 1993, ANAL BIOCHEM, V208, P197, DOI 10.1006/abio.1993.1027
   BIOTIEUX JL, 1984, ANAL CHIM ACTA, V163, P309
   BRESLER HS, 1992, ACS SYM SER, V511, P89
   Cohen Y, 1996, J ELECTROANAL CHEM, V417, P65, DOI 10.1016/S0022-0728(96)04760-2
   DAVIES J, 1994, LANGMUIR, V10, P2654, DOI 10.1021/la00020a026
   DEGANI Y, 1987, J PHYS CHEM-US, V91, P1285, DOI 10.1021/j100290a001
   DIAMANDIS EP, 1990, ANAL CHEM, V62, pA1149, DOI 10.1021/ac00221a001
   DULCEY CS, 1991, SCIENCE, V252, P551, DOI 10.1126/science.2020853
   Engvall E, 1980, Methods Enzymol, V70, P419
   FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438
   GARVEY JS, 1977, METHODS IMMUNOLOGY
   GUILBAULT GG, 1992, BIOSENS BIOELECTRON, V7, P411, DOI 10.1016/0956-5663(92)85040-H
   HAGE DS, 1991, ANAL CHEM, V63, P586, DOI 10.1021/ac00006a008
   HO WO, 1995, BIOSENS BIOELECTRON, V10, P683, DOI 10.1016/0956-5663(95)96959-3
   HUANG JY, 1994, LANGMUIR, V10, P626, DOI 10.1021/la00015a005
   KATZ E, 1993, J ELECTROANAL CHEM, V354, P129, DOI 10.1016/0022-0728(93)80329-G
   KONIG B, 1994, ANAL CHEM, V66, P341, DOI 10.1021/ac00075a005
   KOSSLINGER C, 1992, BIOSENS BIOELECTRON, V7, P397, DOI 10.1016/0956-5663(92)85038-C
   LOPEZ GP, 1993, J AM CHEM SOC, V115, P5877, DOI 10.1021/ja00066a087
   MRKSICH M, 1995, LANGMUIR, V11, P4383, DOI 10.1021/la00011a034
   NAMBA K, 1975, B CHEM SOC JPN, V48, P1323, DOI 10.1246/bcsj.48.1323
   NOG TT, 1987, ELECTROCHEMICAL SENS
   RISHPON J, 1992, IMMUNOASSAYS, V13, P231
   ROZSNYAI LF, 1994, J AM CHEM SOC, V116, P5993, DOI 10.1021/ja00092a070
   SHOHAM B, 1995, BIOSENS BIOELECTRON, V10, P341, DOI 10.1016/0956-5663(95)96852-P
   SINGHVI R, 1994, SCIENCE, V264, P696, DOI 10.1126/science.8171320
   SULEIMAN AA, 1994, ANALYST, V119, P2279, DOI 10.1039/an9941902279
   TSUJI I, 1990, BIOSENS BIOELECTRON, V5, P87, DOI 10.1016/0956-5663(90)80001-T
   Undenfriend S, 1972, SCIENCE, V178, P871
   VANEMON JM, 1992, ANAL CHEM, V64, pA79, DOI 10.1021/ac00026a001
   WEHMEYER KR, 1986, ANAL CHEM, V58, P135, DOI 10.1021/ac00292a033
   WILBUR JL, 1994, ADV MATER, V6, P600, DOI 10.1002/adma.19940060719
   WILLNER I, 1993, ADV MATER, V5, P912, DOI 10.1002/adma.19930051206
   WILLNER I, 1991, J AM CHEM SOC, V113, P3321, DOI 10.1021/ja00009a016
   WILLNER I, 1993, J AM CHEM SOC, V115, P4937, DOI 10.1021/ja00064a084
   Willner I, 1996, LANGMUIR, V12, P946, DOI 10.1021/la9507038
   WILLNER I, 1994, J AM CHEM SOC, V116, P9365, DOI 10.1021/ja00099a078
   WILLNER I, 1994, J AM CHEM SOC, V116, P3121, DOI 10.1021/ja00086a051
   WILLNER I, 1995, THIN SOLID FILMS, V266, P254, DOI 10.1016/0040-6090(96)80029-0
   WILLNER I, 1992, J AM CHEM SOC, V114, P10965, DOI 10.1021/ja00053a045
   WILLNER I, 1995, J AM CHEM SOC, V117, P6581, DOI 10.1021/ja00129a023
   Willner I, 1996, ANGEW CHEM INT EDIT, V35, P367, DOI 10.1002/anie.199603671
   WILLNER I, 1994, J AM CHEM SOC, V116, P1428, DOI 10.1021/ja00083a031
   WILLNER I, 1992, J AM CHEM SOC, V114, P3150, DOI 10.1021/ja00034a078
   WILLNER I, 1993, BIOORGANIC PHOTOCHEM, V2, P1
   WOODS R, 1978, ELECTROANALYTICAL CH, V9, P1
NR 47
TC 23
Z9 25
U1 1
U2 16
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD, OXON, ENGLAND OX5 1GB
SN 0956-5663
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PY 1997
VL 12
IS 7
BP 627
EP 644
DI 10.1016/S0956-5663(97)00022-5
PG 18
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA YD373
UT WOS:A1997YD37300009
PM 9366021
DA 2018-10-19
ER

PT J
AU Schmitt, VO
   Szpunar, J
   Donard, OFX
   Lobinski, R
AF Schmitt, VO
   Szpunar, J
   Donard, OFX
   Lobinski, R
TI Microwave accelerated sample preparation for speciation analysis of
   organotin compounds in biomaterials
SO CANADIAN JOURNAL OF ANALYTICAL SCIENCES AND SPECTROSCOPY
LA English
DT Article
DE butyltin; triphenyltin; microwave-assisted extraction; sample
   preparation
ID ATOMIC-ABSORPTION SPECTROMETRY; CAPILLARY GAS-CHROMATOGRAPHY; FLAME
   PHOTOMETRIC DETECTION; BUTYLTIN COMPOUNDS; EMISSION DETECTION;
   SEDIMENTS; EXTRACTION; OPTIMIZATION; TRIBUTYLTIN; MATRICES
AB One- and two-step protocols for microwave-assisted preparation of biomaterials in a low-power focused microwave field were developed for speciation analysis of organotin. The two-step procedure teas based on the alkaline hydrolysis of the biomaterial using 25% tetramethylammonium hydroxide, followed by the adjustment to pH 5, ethylation of ionic organotin compounds with sodium tetraethylborate (NaBEt4) and extraction into iso-octane. The one-step procedure involved the simultaneous dissolution of biomaterial in acetic acid, ethylation with NaBEt4 and extraction with nonane. Both procedures gave good agreement with the certified values for TBT in the NIES11 reference fish tissue. The content of TPhT determined in the NIES11 sample was close to the indicated value using the one- and two-step procedures. The procedure bused on the simultaneous sample dissolution-derivatization-extraction was found to be he fastest ever reported but suffers from the elevated consumption of NaBEt4.
C1 UNIV BORDEAUX 1,CNRS URA 348,PHOTOPHYS & PHOTOCHIM MOL LAB,F-33405 TALENCE,FRANCE.
   LAB CHIM BIOINORGAN & ENVIRONM,F-64000 PAU,FRANCE.
CR CAI Y, 1995, J CHROMATOGR SCI, V33, P89, DOI 10.1093/chromsci/33.3.89
   CEULEMANS M, 1994, APPL ORGANOMET CHEM, V8, P451, DOI 10.1002/aoc.590080505
   DIRKX W, 1993, ANAL SCI, V9, P273, DOI 10.2116/analsci.9.273
   DIRKX WMR, 1994, ANAL CHIM ACTA, V286, P309, DOI 10.1016/0003-2670(94)85077-1
   DONARD OFX, 1995, ANAL CHEM, V67, P4250, DOI 10.1021/ac00119a008
   FORSYTH DS, 1995, FRESEN J ANAL CHEM, V351, P403, DOI 10.1007/BF00322909
   HUGGETT RJ, 1992, ENVIRON SCI TECHNOL, V26, P232, DOI 10.1021/es00026a001
   INOUE Y, 1995, J ANAL ATOM SPECTROM, V10, P363, DOI 10.1039/ja9951000363
   KINGSTON HM, 1988, INTRO MICROWAVES SAM
   KUBALLA J, 1995, ANALYST, V120, P667, DOI 10.1039/an9952000667
   LALERE B, 1995, ANALYST, V120, P2665, DOI 10.1039/an9952002665
   LIU Y, 1994, ANAL CHEM, V66, P3788, DOI 10.1021/ac00093a040
   LOBINSKI R, 1994, ANALUSIS, V22, P37
   LOBINSKI R, 1992, ANAL CHEM, V64, P159, DOI 10.1021/ac00026a013
   LOBINSKI R, 1996, CANAS 95 C ANAL ATMO
   MORITA M, 1990, 11 NIES
   NAGASE M, 1993, ANAL SCI, V9, P517, DOI 10.2116/analsci.9.517
   Pannier F, 1996, ANAL CHIM ACTA, V327, P287, DOI 10.1016/0003-2670(96)00102-X
   PANNIER F, 1994, ANAL CHIM ACTA, V287, P17, DOI 10.1016/0003-2670(94)85096-8
   PANNIER F, 1994, APPL ORGANOMET CHEM, V8, P595, DOI 10.1002/aoc.590080708
   QUEVAUVILLER P, 1994, APPL ORGANOMET CHEM, V8, P715, DOI 10.1002/aoc.590080724
   Shawky S, 1996, ANAL COMMUN, V33, P107, DOI 10.1039/ac9963300107
   STAB JA, 1994, APPL ORGANOMET CHEM, V8, P577, DOI 10.1002/aoc.590080706
   Szpunar J, 1996, TRAC-TREND ANAL CHEM, V15, P181, DOI 10.1016/0165-9936(96)00004-0
   Szpunar J, 1996, J ANAL ATOM SPECTROM, V11, P193, DOI 10.1039/ja9961100193
   Szpunar J, 1996, ANAL CHIM ACTA, V332, P225, DOI 10.1016/0003-2670(96)00257-7
   TOLOSA I, 1991, FRESEN J ANAL CHEM, V339, P646, DOI 10.1007/BF00325552
   TSUDA T, 1995, J ASSOC OFF ANA CHEM, V79, P941
   WALDOCK MJ, 1994, APPL ORGANOMET CHEM, V8, P649, DOI 10.1002/aoc.590080716
NR 29
TC 14
Z9 14
U1 1
U2 6
PU POLYSCIENCE PUBLICATIONS INC
PI MORIN HEIGHTS
PA PO BOX 148, MORIN HEIGHTS PQ J0R 1H0, CANADA
SN 1205-6685
J9 CAN J ANAL SCI SPECT
JI Can. J. Anal. Sci. Spectrosc.
PY 1997
VL 42
IS 2
BP 41
EP 49
PG 9
WC Chemistry, Analytical; Spectroscopy
SC Chemistry; Spectroscopy
GA XE581
UT WOS:A1997XE58100002
OA DOAJ Gold
DA 2018-10-19
ER

PT J
AU Watari, F
   Yokoyama, A
   Saso, F
   Uo, M
   Kawasaki, T
AF Watari, F
   Yokoyama, A
   Saso, F
   Uo, M
   Kawasaki, T
TI Fabrication and properties of functionally graded dental implant
SO COMPOSITES PART B-ENGINEERING
LA English
DT Article; Proceedings Paper
CT FGM Symposium at the 2nd International Conference on Composites
   Engineerings (ICCE/2)
CY AUG 21-24, 1995
CL NEW ORLEANS, LA
DE implant; biomaterial; FGM
AB Dental implants with functionally graded structures composed of titanium (Ti) and ceramic hydroxyapatite (HAP) were fabricated to satisfy both mechanical and biocompatible property requirements. Specimens containing up to Ti/50%HAP functionally graded material (FGM) with the dimensions 6 phi x 15 mm were successfully fabricated by CIP and sintering process. Miniature (2 phi x 10 mm) specimens of Ti, Ti/20%HAP FGM and Ti/30%HAP FGM implants were then made and inserted into femora of ten week-old Wistar strain rats to evaluate their biocompatibility. After 1, 2 and 4 weeks of implantation, the rats were killed and tissue blocks containing the implant material were embedded in resin. Observation of bone formation around the implant was performed by both the conventional method by optical microscopy using specimens stained with toluidine blue and the EPMA mapping method using unstained specimens. The observed area of new bone formation was in good agreement for both the light microscopy and EPMA elemental mapping method. Pure Ti and Ti/HAP FGM specimens showed no inflammation. When pure Ti and Ti/HAP FGM specimens were compared, Ti/HAP FGM showed better biocompatibility. (C) 1997 Elsevier Science Limited. All rights reserved.
RP Watari, F (reprint author), HOKKAIDO UNIV,SCH DENT,SAPPORO,HOKKAIDO 060,JAPAN.
RI Yokoyama, Atsuro/F-6418-2012
CR AKOKI H, 1991, SCI MED APPL HYDROXY
   Aoki H, 1994, MED APPL HYDROXYAPAT
   Takahashi H., 1993, J JPN DENT MAT, V12, P595
   Takahashi H., 1992, J JPN SOC DENT MAT D, V11, P462
   TAKAHASHI W, 1992, P INT S TI DENT SOC, P64
   WATARI F, 1995, P 3 INT S STRUCT FUN, P703
   WATARI F, 1993, T 2 INT C DENT MAT A, P288
   WATARI F, 1992, T 8 S AP JAP ASS AP, P25
NR 8
TC 97
Z9 101
U1 2
U2 12
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 1359-8368
J9 COMPOS PART B-ENG
JI Compos. Pt. B-Eng.
PY 1997
VL 28
IS 1-2
BP 5
EP 11
DI 10.1016/S1359-8368(96)00021-2
PG 7
WC Engineering, Multidisciplinary; Materials Science, Composites
SC Engineering; Materials Science
GA WK899
UT WOS:A1997WK89900003
DA 2018-10-19
ER

PT S
AU Mann, S
AF Mann, S
BE Chadwick, DJ
   Cardew, G
TI The biomimetics of enamel: A paradigm for organized biomaterials
   synthesis
SO DENTAL ENAMEL
SE CIBA FOUNDATION SYMPOSIA
LA English
DT Article; Proceedings Paper
CT Symposium on Dental Enamel
CY APR 23-25, 1996
CL CIBA FDN, LONDON, ENGLAND
SP Ciba Fdn
HO CIBA FDN
ID MINERALIZED TISSUES; MATERIALS CHEMISTRY; BIOMINERALIZATION; PROTEINS;
   TECTONICS; GROWTH
AB The formation of enamel takes place through a sequence of processes that can be mimicked in inorganic materials chemistry. This chapter describes the generic features of enamel biomineralization in terms of a house-building analogy. Four stages are identified: supramolecular preorganization and spatial patterning; interfacial molecular recognition in inorganic nucleation; vectorial crystallization; and pattern evolution and hierarchy. Each of these concepts can be translated into synthetic approaches to the formation of inorganic materials with organized architectures. An example of applying this biomimetic paradigm is described. Supersaturated water-in-oil microemulsions have been used to synthesize microskeletal calcium phosphates by controlled nucleation and vectorial growth in constrained reaction environments. The results of these preliminary studies suggest that biomimetic concepts could be useful in the fabrication of biomaterial implants with controlled porosity and microstructure.
RP Mann, S (reprint author), UNIV BATH, SCH CHEM, CLAVERTON DOWN, BATH BA2 7AY, AVON, ENGLAND.
RI Mann, Stephen/D-1332-2012
OI Mann, Stephen/0000-0003-3012-8964
CR ARSENAULT AL, 1989, CALCIFIED TISSUE INT, V45, P111, DOI 10.1007/BF02561410
   HEYWOOD BR, 1994, ADV MATER, V6, P9, DOI 10.1002/adma.19940060103
   lijima M, 1991, J CRYST GROWTH, V112, P571
   LOWENSTAM HA, 1989, BIOMINERALISATION, V332, P119
   MANN S, 1988, NATURE, V332, P119, DOI 10.1038/332119a0
   MANN S, 1995, J MATER CHEM, V5, P935, DOI 10.1039/jm9950500935
   MANN S, 1993, NATURE, V365, P499, DOI 10.1038/365499a0
   MCKEE MD, 1995, MICROSC RES TECHNIQ, V31, P44, DOI 10.1002/jemt.1070310105
   NANCI A, 1994, ANAT RECORD, V238, P425, DOI 10.1002/ar.1092380402
   NANCI A, 1996, IN PRESS ADV DENT RE
   ROBINSON C, 1983, TRENDS BIOCHEM SCI, V8, P284, DOI 10.1016/0968-0004(83)90084-1
   SASAKI T, 1983, J ELECTRON MICROSC, V32, P163
   SMITH CE, 1995, CALCIFIED TISSUE INT, V57, P133, DOI 10.1007/BF00298434
   WALSH D, 1994, SCIENCE, V264, P1576, DOI 10.1126/science.264.5165.1576
   WALSH D, 1993, J CRYST GROWTH, V133, P1, DOI 10.1016/0022-0248(93)90097-G
   WEINER S, 1986, CRC CR REV BIOCH MOL, V20, P365, DOI 10.3109/10409238609081998
   WEINSTOCK M, 1973, J CELL BIOL, V56, P838, DOI 10.1083/jcb.56.3.838
NR 17
TC 19
Z9 22
U1 0
U2 7
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, WEST SUSSEX, ENGLAND
SN 0300-5208
BN 0-471-96872-2
J9 CIBA F SYMP
PY 1997
VL 205
BP 261
EP 274
PG 14
WC Dentistry, Oral Surgery & Medicine; Medicine, General & Internal
SC Dentistry, Oral Surgery & Medicine; General & Internal Medicine
GA BH80W
UT WOS:A1997BH80W00017
PM 9189630
DA 2018-10-19
ER

PT J
AU Keller, JC
   Collins, JG
   Niederauer, GG
   McGee, TD
AF Keller, JC
   Collins, JG
   Niederauer, GG
   McGee, TD
TI In vitro attachment of osteoblast-like cells to osteoceramic materials
SO DENTAL MATERIALS
LA English
DT Article
ID DENTAL IMPLANTS; IN-VITRO; TITANIUM; INTERFACE; OSSEOINTEGRATION;
   STERILIZATION; BIOMATERIAL; SURFACES; INVITRO
AB Objective. The objective of this work was to examine osteoblast-like cell attachment and morphology in vitro to osteoceramic materials with three different surface morphologies.
   Methods. Osteoceramic composite disks were fabricated from tricalcium phosphate and magnesium-aluminate spinel (MgAl2O4)in a 50 vol% ratio. The disks were prepared with three different surface morphologies, including as-fired (irregular), etched (rough), or polished through 1 mm diamond paste (smooth). Osteoblast-like cell cultures were plated onto the prepared disks for 2 h, and the number of attached cells was determined. ANOVA and Student Newman-Kuels tests were used to test for significant differences in cell attachment (p < 0.05). SEM was used to visually evaluate the nature of the cellular adaptation on the osteoceramic surfaces,
   Results. Some additional surface roughening resulted from the interaction between the osteoceramic disks and the biological culture media during the attachment assay. A statistically larger number of cells was found to be attached to the etched osteoceramic surfaces compared to the as-fired and polished osteoceramic surfaces or the tissue culture plastic control. Cellular adaptation was extensive on all three osteoceramic surfaces at 2 h.
   Significance. These results are consistent with previous in vivo work and continue to support the hypothesis that osteoceramic materials have potential for implants and bone substitute materials.
C1 IOWA STATE UNIV,AMES,IA 50011.
RP Keller, JC (reprint author), UNIV IOWA,COLL DENT,DOW INST DENT RES,IOWA CITY,IA 52242, USA.
FU NIDCR NIH HHS [DE08540]
CR ALBREKTSSON T, 1987, J PROSTHET DENT, V57, P597, DOI 10.1016/0022-3913(87)90344-1
   BAGAMBISA FB, 1990, BIOMATERIALS, V11, P50, DOI 10.1016/0142-9612(90)90052-R
   Baier R E, 1988, Int J Oral Maxillofac Implants, V3, P9
   Bowers K T, 1992, Int J Oral Maxillofac Implants, V7, P302
   BRANEMARK PI, 1983, J PROSTHET DENT, V50, P399, DOI 10.1016/S0022-3913(83)80101-2
   BUSER D, 1991, J BIOMED MATER RES, V25, P889, DOI 10.1002/jbm.820250708
   CAMERON HU, 1977, J BIOMED MATER RES, V11, P179, DOI 10.1002/jbm.820110204
   CHEHROUDI B, 1992, CELL MATER, V2, P89
   DAVIES JE, 1990, J BIOMED MATER RES, V24, P1289, DOI 10.1002/jbm.820241003
   DEBRUIJN JD, 1993, CELL MATER, V3, P115
   DOUNDOULAKIS JH, 1987, J PROSTHET DENT, V58, P471, DOI 10.1016/0022-3913(87)90279-4
   FERRARO JW, 1979, PLAST RECONSTR SURG, V63, P634, DOI 10.1097/00006534-197905000-00005
   FILBEY JA, 1987, J ADHESION, V20, P283, DOI 10.1080/00218468708074948
   GOMI K, 1993, CELL MATER, V3, P151
   GOODMAN SB, 1993, BIOMATERIALS, V14, P723, DOI 10.1016/0142-9612(93)90035-Z
   GRAVES AM, 1988, THESIS IOWA STATE U
   JANIKOWSKI T, 1969, P IOWA ACAD SCI, V76, P113
   JARCHO M, 1986, DENT CLIN N AM, V30, P25
   KARAGIANES MT, 1976, J DENT RES, V55, P85, DOI 10.1177/00220345760550013001
   Kasemo B, 1988, Int J Oral Maxillofac Implants, V3, P247
   KASEMO B, 1988, J BIOMED MATER RES-A, V22, P145, DOI 10.1002/jbm.820221307
   KELLER JC, 1995, T ACAD DENT MAT, V8, P110
   KIESWETTER K, 1994, J BIOMED MATER RES, V28, P281, DOI 10.1002/jbm.820280302
   KRAUSER JT, 1989, DENT CLIN N AM, V33, P879
   MCGEE TD, 1974, J BIOMED MAT RES S, V5, P137
   NIEDERAUER GG, 1994, BIOMATERIALS, V15, P342, DOI 10.1016/0142-9612(94)90246-1
   NIEDERAUER GG, 1990, THESIS IOWA STATE U
   REY C, 1990, Biomaterials, V11, P13
   STANFORD CM, 1994, J DENT RES, V73, P1061, DOI 10.1177/00220345940730050801
   Swart K M, 1992, J Oral Implantol, V18, P130
   TWEDEN KS, 1987, THESIS IOWA STATE U
NR 31
TC 36
Z9 36
U1 0
U2 2
PU ACAD DENTAL MATERIALS
PI DALLAS
PA BAYLOR COLLEGE DENTISTRY, 3302 GASTON AVE, DALLAS, TX 75266-0677
SN 0109-5641
J9 DENT MATER
JI Dent. Mater.
PD JAN
PY 1997
VL 13
IS 1
BP 62
EP 68
DI 10.1016/S0109-5641(97)80010-3
PG 7
WC Dentistry, Oral Surgery & Medicine; Materials Science, Biomaterials
SC Dentistry, Oral Surgery & Medicine; Materials Science
GA XD943
UT WOS:A1997XD94300010
PM 9467325
DA 2018-10-19
ER

PT B
AU Davies, MC
   Tendler, SJB
   Roberts, CJ
   Williams, PM
AF Davies, MC
   Tendler, SJB
   Roberts, CJ
   Williams, PM
BE Olefjord, I
   Nyborg, L
   Briggs, D
TI Probing surface biointeractions at biomaterial surfaces
SO ECASIA 97: 7TH EUROPEAN CONFERENCE ON APPLICATIONS OF SURFACE AND
   INTERFACE ANALYSIS
LA English
DT Proceedings Paper
CT 7th European Conference on Applications of Surface and Interface
   Analysis (ECASIA 97)
CY JUN 16-20, 1997
CL GOTHENBURG, SWEDEN
C1 Univ Nottingham, Dept Pharmaceut Sci, Lab Biophys & Surface Anal, Nottingham NG7 2RD, England.
RP Davies, MC (reprint author), Univ Nottingham, Dept Pharmaceut Sci, Lab Biophys & Surface Anal, Univ Pk, Nottingham NG7 2RD, England.
RI Williams, Philip/C-6947-2009; Roberts, Clive/C-6970-2009
OI Williams, Philip/0000-0002-1822-2133; Roberts, Clive/0000-0001-9443-3445
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, WEST SUSSEX, ENGLAND
BN 0-471-97827-2
PY 1997
BP 44
EP 49
PG 6
WC Chemistry, Physical; Engineering, Mechanical; Materials Science,
   Multidisciplinary; Materials Science, Biomaterials; Materials Science,
   Coatings & Films; Materials Science, Composites; Optics; Physics,
   Condensed Matter; Polymer Science
SC Chemistry; Engineering; Materials Science; Optics; Physics; Polymer
   Science
GA BL02X
UT WOS:000074082100006
DA 2018-10-19
ER

PT J
AU Matheickal, JT
   Yu, Q
   Feltham, J
AF Matheickal, JT
   Yu, Q
   Feltham, J
TI Cu(II) binding by E-radiata biomaterial
SO ENVIRONMENTAL TECHNOLOGY
LA English
DT Article
DE biosorbent; biosorption; copper removal; Ecklonia radiata; marine algae
ID RHIZOPUS-ARRHIZUS BIOMASS; HEAVY-METALS; BIOSORPTION; AGARDH,J.; COPPER
AB Experimental studies showed that a common brown marine algae (Ecklonia radiata) can be used for the development of an efficient biosorbent material for Cu2+ removal from waste water. At pH 5.0, the uptake capacity of E.radiata for copper is 1.11 mmol g(-1). The adsorption of copper increases as pH increases and reaches a plateau at pH 5 The copper uptake process was rapid, with 90% of the adsorption completed within 15 minutes. Presence of Light metal ions in solution did not affect copper adsorption significantly. The presence of 5 mM of EDTA in solution completely inhibited the metal uptake while the effect of acetate, nitrate and chloride on metal uptake was marginal even at 20 mM concentrations of these ions. The dominant mechanism of copper biosorption is ion exchange involving Ca2+ and Mg2+ counter ions present in the algal cells. The feasibility of removing copper using the biosorbent in a packed bed system was also examined.
C1 GRIFFITH UNIV,SCH ENVIRONM ENGN,BRISBANE,QLD 4111,AUSTRALIA.
RI Yu, Qiming/B-8657-2008
OI Yu, Qiming/0000-0002-5768-6133
CR CHENG MH, 1975, J WATER POLLUT CON F, V47, P362
   CLAYTON MN, 1981, MARINE BOT AUSTRALAS, P105
   DARNALL D W, 1986, P1
   HIGGINS HW, 1987, AUST J MAR FRESH RES, V38, P307
   HOLAN ZR, 1993, BIOTECHNOL BIOENG, V41, P819, DOI 10.1002/bit.260410808
   KIRKMAN H, 1984, J EXP MAR BIOL ECOL, V76, P119, DOI 10.1016/0022-0981(84)90060-1
   KUYUCAK N, 1989, BIOTECHNOL BIOENG, V33, P823, DOI 10.1002/bit.260330705
   LOBBAN CS, 1994, SEAWEED ECOLOGY PHIL, P146
   LOW KS, 1994, J ENVIRON SCI HEAL A, V29, P171, DOI 10.1080/10934529409376028
   MATHEICKAL JT, 1995, P 10 NAT CONV ROYAL
   MATHEICKAL KT, 1991, WATER POLL RES J CAN, V26, P187
   MURALEEDHARAN TR, 1995, APPL ENVIRON MICROB, V61, P3507
   MUZZARELI RAA, 1980, BIOTECH BIOENGG, V24, P206
   PERCIVAL E, 1979, BRIT PHYCOL J, V14, P103, DOI 10.1080/00071617900650121
   RAO CRN, 1993, J ENVIRON ENG-ASCE, V119, P369, DOI 10.1061/(ASCE)0733-9372(1993)119:2(369)
   Rome L., 1987, APPL MICROBIOL BIOT, V26, P84, DOI DOI 10.1007/BF00282153
   TOBIN JM, 1984, APPL ENVIRON MICROB, V47, P821
   TOBIN JM, 1987, BIOTECHNOL BIOENG, V30, P882, DOI 10.1002/bit.260300711
   VOLESKY B, 1987, TRENDS BIOTECHNOL, V5, P96, DOI 10.1016/0167-7799(87)90027-8
   Volesky B., 1990, BIOSORPTION HEAVY ME, P3
   XUE HB, 1988, WATER RES, V22, P917, DOI 10.1016/0043-1354(88)90029-2
   YU Q, 1995, P 20 ENV WORKSH MIN
NR 22
TC 56
Z9 60
U1 2
U2 4
PU SELPER LTD, PUBLICATIONS DIV
PI LONDON
PA 79 RUSTHALL AVENUE, LONDON, ENGLAND W4 1BN
SN 0959-3330
J9 ENVIRON TECHNOL
JI Environ. Technol.
PD JAN
PY 1997
VL 18
IS 1
BP 25
EP 34
DI 10.1080/09593331808616509
PG 10
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA WJ857
UT WOS:A1997WJ85700003
DA 2018-10-19
ER

PT B
AU GonzalezCarrasco, JL
   Escudero, ML
   Chao, J
   Rubio, JC
   GarciaAlonso, MC
   Lopez, MF
   Ruiz, J
   Cebollada, F
   Adeva, P
   Canahua, H
AF GonzalezCarrasco, JL
   Escudero, ML
   Chao, J
   Rubio, JC
   GarciaAlonso, MC
   Lopez, MF
   Ruiz, J
   Cebollada, F
   Adeva, P
   Canahua, H
BE Sarton, LAJ
   Zeedijk, HB
TI The MA 956 superalloy: a potential biomaterial for surgical implants.
SO EUROMAT 97 - PROCEEDINGS OF THE 5TH EUROPEAN CONFERENCE ON ADVANCED
   MATERIALS AND PROCESSES AND APPLICATIONS: MATERIALS, FUNCTIONALITY &
   DESIGN, VOL 3: SURFACE ENGINEERING AND FUNCTIONAL MATERIALS
LA English
DT Proceedings Paper
CT 5th European Conference on Advanced Materials and Processes and
   Applications (EUROMAT 97)
CY APR 21-23, 1997
CL MAASTRICHT, NETHERLANDS
SP Federat European Mat Soc, Netherlands Soc Mat Sci
AB Thermal oxidation treatment (1100 degrees C/100 h) of MA 956 produces on the surface a tightly adherent alpha-alumina scale, about 5 mu m thick. The scale/metal system resembles an alumina coated material with the advantage that the coating is easier to perform than by other conventional processes. In vitro experiments have proved that MA 956 with and without scale exhibits an excellent corrosion behaviour being the corrosion intensities lower than those of metallic biomaterials in use. It is worth to remark that scale decreases the corrosion intensity at least up to two orders of magnitude with respect to the uncoated material, which corrosion behaviour is also excellent. The elevated compressive residual stresses in the scale guarantee its integrity during tensile deformation and account for the good fatigue and wear behaviour. SEM examination of implanted samples reveals a bone response similar to that for other biomaterials. These promising results provides with a window of opportunity for preoxidized Ma 956 in biomedical applications.
RP GonzalezCarrasco, JL (reprint author), CSIC,CTR NACL INVEST MET,AVDA GREGORIO DEL AMO 8,E-28040 MADRID,SPAIN.
RI Escudero, Maria Lorenza/L-7113-2014
OI Escudero, Maria Lorenza/0000-0002-2181-448X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NETHERLANDS SOC MATERIALS SCIENCE
PI ZWIJNDRECHT
PA PO BOX 390, N-3330 ZWIJNDRECHT, NETHERLANDS
BN 90-803513-3-4
PY 1997
BP 597
EP 600
PG 4
WC Engineering, Multidisciplinary; Materials Science, Multidisciplinary
SC Engineering; Materials Science
GA BJ43N
UT WOS:A1997BJ43N00138
DA 2018-10-19
ER

PT B
AU Fisher, E
   vanderStelt, PF
   Dunn, SM
AF Fisher, E
   vanderStelt, PF
   Dunn, SM
BE Hansen, KM
TI 3D registration of surfaces for change detection in medical images
SO IMAGE PROCESSING - MEDICAL IMAGING 1997, PTS 1 AND 2
SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
   (SPIE)
LA English
DT Proceedings Paper
CT Medical Imaging 1997 Symposium - Image Processing
CY FEB 25-28, 1997
CL NEWPORT BEACH, CA
SP Soc Photo Opt Instrumentat Engineers, Amer Assoc Physicists Med, Amer Physiol Soc, US FDA, Ctr Devices & Radiol Hlth, Soc Imaging Sci & Technol, Natl Elect Manufacturers Assoc, Diagnost Imaging & Therapy Syst Div, Radiol Informat Syst Consortium, Radiol Soc N Amer, Soc Comp Applicat Radiol
DE registration; rigid-body motion; change quantification
AB Spatial registration of data sets is essential for quantifying changes that take place over time in cases where the position of a patient with respect to the sensor has been altered. Changes within the region of interest (e.g., biomaterial wear, tumor growth, or tissue swelling) can be problematic for automatic methods of registration. This research addresses the problem of automatic three-dimensional (3D) registration of surfaces derived from serial, single-modality images for the purpose of quantifying changes over time. The registration algorithm utilizes motion-invariant, curvature-based geometric properties to derive an approximation to an initial rigid transformation to align two image sets. Following the initial registration changed portions of the surface are detected and excluded before refining the transformation parameters. The performance of the algorithm was tested using simulation experiments. To quantitatively assess the registration, random noise at various levels, known rigid motion transformations, and analytically-defined volume changes were applied to the initial surface data acquired from models of teeth. These simulation experiments demonstrated that the calculated transformation parameters were accurate to within 1.2% of the total applied rotation and 2.9% of the total applied translation, even at the highest applied noise levels and simulated wear values.
RP Fisher, E (reprint author), RUTGERS STATE UNIV,DEPT BIOMED ENGN,PISCATAWAY,NJ 08855, USA.
OI van der Stelt, Paul/0000-0002-2501-2484
NR 0
TC 10
Z9 10
U1 0
U2 0
PU SPIE - INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA PO BOX 10, BELLINGHAM, WA 98227-0010
BN 0-8194-2445-5
J9 P SOC PHOTO-OPT INS
PY 1997
VL 3034
BP 599
EP 610
DI 10.1117/12.274146
PN 1&2
PG 12
WC Optics; Radiology, Nuclear Medicine & Medical Imaging
SC Optics; Radiology, Nuclear Medicine & Medical Imaging
GA BH84E
UT WOS:A1997BH84E00058
DA 2018-10-19
ER

PT B
AU Wickramasinghe, NC
   Hoyle, F
   Wallis, DH
AF Wickramasinghe, NC
   Hoyle, F
   Wallis, DH
BE Hoover, RB
TI Spectroscopic evidence for panspermia
SO INSTRUMENTS, METHODS, AND MISSIONS FOR THE INVESTIGATION OF
   EXTRATERRESTRIAL MICROORGANISMS
SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
   (SPIE)
LA English
DT Proceedings Paper
CT Conference on Instruments, Methods, and Missions for the Investigation
   of Extraterrestrial Microorganisms
CY JUL 29-AUG 01, 1997
CL SAN DIEGO, CA
SP Soc Photo Opt Instrumentat Engineers
AB Astronomical spectra over a wide range of wavelengths is reviewed and compared with predictions from organic models of interstellar and cometary grains. The data requires the widespread occurrence of functional groups involving H,O,C,N in the form of complex structures in the proportions that characterise biomaterial. We argue for the widespread occurrence of a microbiological system on a galaxy-wide scale.
RP Wickramasinghe, NC (reprint author), UNIV WALES COLL CARDIFF,SCH MATH,SENGHENNYDD RD,CARDIFF CF2 4AG,S GLAM,WALES.
NR 0
TC 6
Z9 6
U1 0
U2 3
PU SPIE - INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA PO BOX 10, BELLINGHAM, WA 98227-0010
BN 0-8194-2533-8
J9 P SOC PHOTO-OPT INS
PY 1997
VL 3111
BP 282
EP 295
DI 10.1117/12.278780
PG 14
WC Astronomy & Astrophysics; Geochemistry & Geophysics; Instruments &
   Instrumentation; Microbiology; Optics
SC Astronomy & Astrophysics; Geochemistry & Geophysics; Instruments &
   Instrumentation; Microbiology; Optics
GA BJ31K
UT WOS:A1997BJ31K00027
DA 2018-10-19
ER

PT J
AU Tomazic, VJ
   Merritt, K
   Umbreit, TH
AF Tomazic, VJ
   Merritt, K
   Umbreit, TH
TI Significance of the size and chemical composition of biomaterial
   particles on the deposition pattern and the host response in mice.
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
C1 US FDA,ROCKVILLE,MD 20857.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0091-6749
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD JAN
PY 1997
VL 99
IS 1
SU S
BP 1296
EP 1296
PN 2
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA WH142
UT WOS:A1997WH14201292
DA 2018-10-19
ER

PT J
AU Matsumaru, Y
   Hyodo, A
   Nose, T
   Hirano, T
   Ohashi, S
AF Matsumaru, Y
   Hyodo, A
   Nose, T
   Hirano, T
   Ohashi, S
TI Embolic materials for endovascular treatment of cerebral lesions
SO JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION
LA English
DT Review
DE embolization; embolic material; cerebral lesion; interventional
   neuroradiology; endovascular treatment
ID BRAIN ARTERIOVENOUS-MALFORMATIONS; VINYL ALCOHOL COPOLYMER; THERAPEUTIC
   EMBOLIZATION; PREOPERATIVE EMBOLIZATION; POLYVINYL-ALCOHOL; ISOBUTYL-2
   CYANOACRYLATE; DETACHABLE BALLOONS; SACCULAR ANEURYSMS; INTERVENTIONAL
   NEURORADIOLOGY; SUPERSELECTIVE ANGIOGRAPHY
AB Recently developed soft microcatheters can be maneuvered endovascularly into the brain, permitting treatment of lesions without conventional neurosurgery. Progress in biomaterial science has contributed significantly to the development of this new therapeutic modality termed intravascular neurosurgery or interventional neuroradiology. Although embolic materials play an important role, ideal materials have yet to be devised. Various embolic materials in clinical use are reviewed, such as cyanoacrylates, ethylene-vinyl alcohol copolymer mixtures, Ethibloc, ethanol, estrogen, poly(vinyl acetate), cellulose acetate polymer, poly(vinyl alcohol), gelatin sponges, microfibrillar collagen, surgical silk sutures, detachable balloons, and coils. The materials are reviewed in the context of treatment application for various brain lesions, such as arteriovenous malformations, cerebral aneurysms, and head and neck tumors. Further developments in biomaterial polymer science can bring about progress against brain diseases.
C1 NATL INST BIOSCI & HUMAN TECHNOL, TSUKUBA, IBARAKI 305, JAPAN.
   UNIV TSUKUBA, INST CLIN MED, DEPT NEUROSURG, TSUKUBA, IBARAKI 305, JAPAN.
CR BARTH KH, 1984, INVEST RADIOL, V19, P517, DOI 10.1097/00004424-198411000-00008
   BARTH KH, 1977, INVEST RADIOL, V12, P273, DOI 10.1097/00004424-197705000-00012
   BENATI A, 1989, AM J NEURORADIOL, V10, P579
   BENTSON JR, 1972, RADIOLOGY, V105, P65, DOI 10.1148/105.1.65
   BERENSTEIN A, 1984, SURG NEUROL, V21, P3, DOI 10.1016/0090-3019(84)90392-6
   BERENSTEIN A, 1981, RADIOLOGY, V141, P105, DOI 10.1148/radiology.141.1.7027309
   BERENSTEIN A, 1987, J NEUROSURG, V67, P318
   BROTHERS MF, 1989, AM J NEURORADIOL, V10, P777
   CHALOUPKA JC, 1994, AM J NEURORADIOL, V15, P1107
   CHOI IS, 1985, AM J NEURORADIOL, V6, P462
   CHUANG VP, 1981, AM J ROENTGENOL, V137, P809, DOI 10.2214/ajr.137.4.809
   CROMWELL LD, 1979, AM J ROENTGENOL, V132, P799, DOI 10.2214/ajr.132.5.799
   DEBRUN G, 1982, J NEUROSURG, V56, P615, DOI 10.3171/jns.1982.56.5.0615
   DEBRUN G, 1981, AM J NEURORADIOL, V2, P167
   Dion JE, 1992, INTERV NEURORADIOL, P1
   DJINDJIAN R, 1973, NEURORADIOLOGY, V6, P20, DOI 10.1007/BF00338854
   DUBOIS JM, 1991, RADIOLOGY, V180, P195, DOI 10.1148/radiology.180.1.2052693
   ELLMAN BA, 1984, INVEST RADIOL, V19, P416, DOI 10.1097/00004424-198409000-00014
   ESKRIDGE JM, 1989, RADIOLOGY, V172, P991, DOI 10.1148/172.3.991
   ESKRIDGE JM, 1989, AM J NEURORADIOL, V10, P882
   FOX AJ, 1987, J NEUROSURG, V66, P40, DOI 10.3171/jns.1987.66.1.0040
   GOLD RE, 1975, RADIOLOGY, V116, P575, DOI 10.1148/116.3.575
   GROMWELL LD, 1986, AM J ROENTGENOL, V147, P627
   GUGLIELMI G, 1991, J NEUROSURG, V75, P1, DOI 10.3171/jns.1991.75.1.0001
   GUGLIELMI G, 1991, J NEUROSURG, V75, P8, DOI 10.3171/jns.1991.75.1.0008
   GUGLIELMI G, 1992, J NEUROSURG, V77, P515, DOI 10.3171/jns.1992.77.4.0515
   HALBACH VV, 1992, INTERV NEURORADIOL, P17
   HERRERA M, 1982, RADIOLOGY, V144, P638, DOI 10.1148/radiology.144.3.7100485
   Higashida R T, 1986, Acta Radiol Suppl, V369, P594
   HIGASHIDA RT, 1991, RADIOLOGY, V178, P663, DOI 10.1148/radiology.178.3.1994399
   HIGASHIDA RT, 1990, RADIOLOGY, V174, P687, DOI 10.1148/radiology.174.3.2305050
   HOGEMAN KARL-ERIK, 1961, ACTA CHIR SCAND, V121, P83
   KAUFFMANN GW, 1981, AM J ROENTGENOL, V137, P1163, DOI 10.2214/ajr.137.6.1163
   KAUFMAN SL, 1978, INVEST RADIOL, V13, P200, DOI 10.1097/00004424-197805000-00005
   KERBER C, 1975, INVEST RADIOL, V10, P536, DOI 10.1097/00004424-197509000-00011
   KERBER C, 1976, RADIOLOGY, V120, P547, DOI 10.1148/120.3.547
   KERBER CW, 1978, AM J ROENTGENOL, V130, P1193, DOI 10.2214/ajr.130.6.1193
   KINUGASA K, 1992, J NEUROSURG
   KLARA PM, 1985, J NEUROSURG, V63, P421, DOI 10.3171/jns.1985.63.3.0421
   KUMAR AJ, 1982, AM J NEURORADIOL, V3, P163
   KUNSTLINGER F, 1981, AM J ROENTGENOL, V136, P151, DOI 10.2214/ajr.136.1.151
   LANMAN TH, 1988, NEURORADIOLOGY, V30, P1, DOI 10.1007/BF00341935
   Lasjaunias P., 1987, SURG NEUROANGIOGRAPH, V2
   LEHMAN RAW, 1967, SURGERY, V61, P915
   LIGHT RU, 1945, J NEUROSURG, V2, P435, DOI 10.3171/jns.1945.2.5.0435
   LUESSENHOP AJ, 1960, JAMA-J AM MED ASSOC, V172, P1153, DOI 10.1001/jama.1960.63020110001009
   MARCLK P A, 1982, Journal of Dental Research, V61, P288
   PELZ DM, 1988, AM J NEURORADIOL, V9, P757
   PEREGRIN JH, 1984, CARDIOVASC INTER RAD, V7, P97, DOI 10.1007/BF02552689
   PEVSNER PH, 1983, AM J NEURORADIOL, V4, P388
   PEVSNER PH, 1982, NEUROSURGERY, V10, P314, DOI 10.1227/00006123-198203000-00003
   PICARD L, 1977, J NEURORADIOLOGY, V4, P385
   PURDY PD, 1990, AM J NEURORADIOL, V11, P501
   QUISLING RG, 1984, AM J NEURORADIOL, V5, P101
   RAO VR, 1990, RADIOLOGY, V175, P407, DOI 10.1148/radiology.175.2.2326468
   RICHTER G, 1984, INVEST RADIOL, V19, P36, DOI 10.1097/00004424-198401000-00009
   Romodanov AP, 1982, ADV TECHNICAL STANDA, P25
   SAMSON D, 1986, J NEUROSURG, V65, P571
   SERBINENKO FA, 1974, J NEUROSURG, V41, P125, DOI 10.3171/jns.1974.41.2.0125
   SHIMIZU Y, 1987, SURG NEUROL, V28, P23, DOI 10.1016/0090-3019(87)90201-1
   SPEAKMAN TJ, 1964, J NEUROL SCI, V1, P303, DOI 10.3171/jns.1964.21.4.0303
   SPIEGEL SM, 1986, AM J NEURORADIOL, V7, P109
   STANDARD SC, 1995, NEUROSURG T, P1
   SU CC, 1991, SURG NEUROL, V36, P4, DOI 10.1016/0090-3019(91)90125-S
   SUGAWARA T, 1992, Neurologia Medico-Chirurgica, V32, P59, DOI 10.2176/nmc.32.59
   Sugawara Takayuki, 1993, Neurologia Medico-Chirurgica, V33, P71, DOI 10.2176/nmc.33.71
   TADAVARTHY SM, 1974, RADIOLOGY, V112, P13, DOI 10.1148/112.1.13
   TAKI W, 1980, SURG NEUROL, V13, P140
   TAKI W, 1990, AM J NEURORADIOL, V11, P163
   TERADA T, 1991, J NEUROSURG, V75, P655, DOI 10.3171/jns.1991.75.4.0655
   VINTERS HV, 1981, J NEUROSURG, V55, P819, DOI 10.3171/jns.1981.55.5.0819
   VINUELA F, 1986, AM J NEURORADIOL, V7, P919
   VINUELA F, 1983, AM J NEURORADIOL, V4, P1233
   VINUELA F, 1984, AM J NEURORADIOL, V5, P765
   VINUELA F, 1991, NEUROSURGERY UPDATE, V2, P142
   VINUELA FV, 1983, AM J NEURORADIOL, V4, P959
   WHITE RI, 1977, RADIOLOGY, V125, P677, DOI 10.1148/125.3.677
   WRIGHT KC, 1982, RADIOLOGY, V145, P339, DOI 10.1148/radiology.145.2.7134431
   YAKES WF, 1989, RADIOLOGY, V170, P1059, DOI 10.1148/radiology.170.3.2916057
   YAKES WF, 1990, RADIOGRAPHICS, V10, P787, DOI 10.1148/radiographics.10.5.2217971
   YAMASHITA K, 1994, AM J NEURORADIOL, V15, P1103
NR 81
TC 20
Z9 21
U1 0
U2 11
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0920-5063
EI 1568-5624
J9 J BIOMAT SCI-POLYM E
JI J. Biomater. Sci.-Polym. Ed.
PY 1997
VL 8
IS 7
BP 555
EP 569
DI 10.1163/156856297X00452
PG 15
WC Engineering, Biomedical; Materials Science, Biomaterials; Polymer
   Science
SC Engineering; Materials Science; Polymer Science
GA XC975
UT WOS:A1997XC97500005
PM 9195334
DA 2018-10-19
ER

PT J
AU Sung, HW
   Chen, WY
   Tsai, CC
   Hsu, HL
AF Sung, HW
   Chen, WY
   Tsai, CC
   Hsu, HL
TI In vitro study of enzymatic degradation of biological tissues fixed by
   glutaraldehyde or epoxy compound
SO JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION
LA English
DT Article
DE biological tissue; epoxy compound; glutaraldehyde; collagenase;
   microcalorimetry; degradation
ID DERMAL SHEEP COLLAGEN; MECHANICAL-PROPERTIES; VALVED CONDUIT;
   HEART-VALVE; BIOMATERIAL; CALCIFICATION; PREVENTION; INVITRO; INVIVO
AB The study, using bacterial collagenase, was to investigate the changes in characteristics of a collagen-rich tissue, porcine pericardium, fixed by glutaraldehyde or epoxy compound (ethylene glycol diglycidyl ether) during the course of degradation. Fresh porcine pericardium was used as a control. During degradation, the heat released by the reaction of collagenase with a test sample was monitored by a highly sensitive microcalorimeter. Also, the degree of degradation of each test sample was determined by measuring its increment in free amino group content and changes in denaturation temperature and tensile strength. Microcalorimetric analysis of collagenase degradation of fresh, epoxy-fixed, and glutaraldehyde-fixed tissues revealed that the heat released during degradation correlates well with the degree of tissue degraded. The cleaving of peptide bonds in biological tissue by collagenase degradation may increase its free amino group content and reduce its denaturation temperature and tensile strength. It was noted that the fresh tissue cannot resist bacterial collagenase degradation, while the glutaraldehyde fixed tissue had a relatively better resistance to degradation than its epoxy-fixed counterpart.
RP Sung, HW (reprint author), NATL CENT UNIV,DEPT CHEM ENGN,CHUNGLI 32054,TAIWAN.
CR DAMINK LHHO, 1995, J BIOMED MATER RES, V29, P139, DOI 10.1002/jbm.820290202
   DAMINK LHHO, 1995, J BIOMED MATER RES, V29, P149, DOI 10.1002/jbm.820290203
   DIAMOND AM, 1991, MATRIX, V11, P321, DOI 10.1016/S0934-8832(11)80203-9
   HARPER E, 1972, BIOPOLYMERS, V11, P1607, DOI 10.1002/bip.1972.360110807
   HATA C, 1992, ARTIF ORGANS, V16, P263, DOI 10.1111/j.1525-1594.1992.tb00307.x
   Imamura E, 1989, J Card Surg, V4, P50, DOI 10.1111/j.1540-8191.1989.tb00256.x
   LEE JM, 1995, MED ENG PHYS, V17, P115, DOI 10.1016/1350-4533(95)91882-H
   Lohre J M, 1993, ASAIO J, V39, P106, DOI 10.1097/00002480-199304000-00007
   LOHRE JM, 1992, ARTIF ORGANS, V16, P630
   MCCLAIN PE, 1972, J BIOL CHEM, V247, P692
   MURAYAMA Y, 1988, T AM SOC ART INT ORG, V34, P546
   Nimni ME, 1988, COLLAGEN, VIII, P1
   NISHI C, 1995, J BIOMED MATER RES, V29, P829, DOI 10.1002/jbm.820290707
   NOISHIKI Y, 1993, INT J ARTIF ORGANS, V16, P192
   NOISHIKI Y, 1986, T AM SOC ART INT ORG, V32, P114
   Noishiki Y., 1989, U. S. Patent, Patent No. [4,806,599, 4806599]
   SCHOEN FJ, 1988, J BIOMED MATER RES-A, V22, P11
   SPEER DP, 1980, J BIOMED MATER RES, V14, P753, DOI 10.1002/jbm.820140607
   STENZEL KH, 1974, ANNU REV BIOPHYS BIO, V3, P231, DOI 10.1146/annurev.bb.03.060174.001311
   Stryer L., 1988, BIOCHEMISTRY-US
   Sung H W, 1994, ASAIO J, V40, P192, DOI 10.1097/00002480-199404000-00013
   Sung H. W., 1993, ASIAN CARDIOVASC THO, V1, P104
   Sung HW, 1996, J BIOMED MATER RES, V31, P511, DOI 10.1002/(SICI)1097-4636(199608)31:4<511::AID-JBM11>3.0.CO;2-J
   Sung HW, 1996, J BIOMED MATER RES, V30, P361, DOI 10.1002/(SICI)1097-4636(199603)30:3<361::AID-JBM10>3.0.CO;2-N
   SUNG HW, 1993, INT J ARTIF ORGANS, V16, P199
   TU R, 1994, J BIOMED MATER RES, V28, P677, DOI 10.1002/jbm.820280604
   White M J, 1973, Biomater Med Devices Artif Organs, V1, P703
   WOODROOF EA, 1978, J BIOENG, V2, P1
   Xi T, 1992, J Biomater Appl, V7, P61
   XI TF, 1992, J BIOMED MATER RES, V26, P1241
   YANNAS IV, 1975, J BIOMED MATER RES, V9, P623, DOI 10.1002/jbm.820090608
NR 31
TC 1
Z9 1
U1 1
U2 3
PU VSP BV
PI ZEIST
PA PO BOX 346, 3700 AH ZEIST, NETHERLANDS
SN 0920-5063
J9 J BIOMAT SCI-POLYM E
JI J. Biomater. Sci.-Polym. Ed.
PY 1997
VL 8
IS 8
BP 587
EP 600
DI 10.1163/156856297X00191
PG 14
WC Engineering, Biomedical; Materials Science, Biomaterials; Polymer
   Science
SC Engineering; Materials Science; Polymer Science
GA XK638
UT WOS:A1997XK63800002
PM 9241583
DA 2018-10-19
ER

PT J
AU Zdanowski, Z
   Koul, B
   Hallberg, E
   Schalen, C
AF Zdanowski, Z
   Koul, B
   Hallberg, E
   Schalen, C
TI Influence of heparin coating on in vitro bacterial adherence to
   poly(vinyl chloride) segments
SO JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION
LA English
DT Article
DE poly(vinyl chloride); heparin; bacteria; adherence
ID COAGULASE-NEGATIVE STAPHYLOCOCCI; FOREIGN-BODY INFECTIONS; VASCULAR
   PROSTHESES; POLYMER SURFACES; PLASMA-PROTEINS; AUREUS; FIBRONECTIN;
   BINDING; LAMININ; BYPASS
AB End-point attached, covalently bound heparin has been shown to be effective in preventing activation of the coagulation cascade by biomaterials. Data concerning its possible influence on bacterial attachment and resistance to biomaterial-associated infection are, so far, lacking. In the present work, the in vitro adherence of Staphylococcus aureus, Staphylococcus epidermidis and Escherichia coli, one isolate of each species, to plain poly(vinyl chloride) (plain PVC) and heparin coated poly(vinyl chloride) (EPA-PVC) segments was compared. Also, the influence of precoating the segments with human normal plasma for 2 h was studied. S-35-Methionine was used to radiolabel bacteria. The segments were exposed to bacterial suspensions of approximately 10(7) colony forming units (CFU) per milliliter at 37 degrees C for 0.5-6 h. Following repeated washing in phosphate buffered saline (PBS), radioactivity associated with the segments was measured.
   Plain PVC as compared to EPA-PVC bound significantly more cells of all three tested species. Plasma precoating significantly decreased adherence of the tested species to plain PVC but did not affect the binding to EPA-PVC. However, after precoating with human plasma, EPA-PVC compared to plain PVC showed a higher binding of S. aureus which might possibly be due to bridging effects of fibronectin or other plasma proteins, interacting with S. aureus.
C1 LUND UNIV, DEPT THORAC SURG, S-22100 LUND, SWEDEN.
   LUND UNIV, DEPT ZOOL, S-22100 LUND, SWEDEN.
   LUND UNIV, DEPT MED MICROBIOL, S-22100 LUND, SWEDEN.
RP Zdanowski, Z (reprint author), LUND UNIV, DEPT SURG, S-22100 LUND, SWEDEN.
CR APPELGREN P, 1995, LANCET, V345, P130, DOI 10.1016/S0140-6736(95)90097-7
   BERTILSSON L, 1991, MOL ENG, V1, P49
   Bindslev L, 1991, Acta Anaesthesiol Scand Suppl, V95, P125
   CHRISTENSEN GD, 1983, INFECT IMMUN, V40, P407
   DOUGHERTY SH, 1990, PATHOGENESIS WOUND B
   GATTINONI L, 1988, INTENSIVE CARE WORLD, V5, P42
   HERRMANN M, 1991, INFECT IMMUN, V59, P279
   HERRMANN M, 1988, J INFECT DIS, V158, P693, DOI 10.1093/infdis/158.4.693
   HOGT AH, 1985, J GEN MICROBIOL, V131, P2385
   HOLDERBAUM D, 1985, COLLAGEN REL RES, V5, P261
   JOHNSON JA, 1988, ARCH SURG-CHICAGO, V123, P859
   KAUL B, 1991, SCAND J THORAC CARD, V25, P199
   KNOCH M, 1992, INT J ARTIF ORGANS, V15, P103
   KOUL B, 1992, ANN THORAC SURG, V53, P1046, DOI 10.1016/0003-4975(92)90386-I
   LARM O, 1983, BIOMATER ARTIF CELL, V11, P161, DOI 10.3109/10731198309118804
   LIANG OD, 1992, INFECT IMMUN, V60, P899
   LOPES JD, 1985, SCIENCE, V229, P275, DOI 10.1126/science.3160113
   LUDWICKA A, 1984, ZBL BAKT-INT J MED M, V256, P479, DOI 10.1016/S0174-3031(84)80024-4
   MAXE I, 1986, INFECT IMMUN, V54, P695
   MOLLNES TE, 1991, ANN THORAC SURG, V52, P92, DOI 10.1016/0003-4975(91)91426-V
   PAULSSON M, 1994, J BIOMED MATER RES, V28, P311, DOI 10.1002/jbm.820280305
   PAULSSON M, 1993, THESIS U LUND
   PORTOLES M, 1993, J CATARACT REFR SURG, V19, P755, DOI 10.1016/S0886-3350(13)80345-8
   ROSSAINT R, 1992, INT J ARTIF ORGANS, V15, P29
   RUGGIERI MR, 1987, J UROLOGY, V138, P423, DOI 10.1016/S0022-5347(17)43177-6
   RUSSELL PB, 1987, J CLIN MICROBIOL, V25, P1083
   VERCELLOTTI GM, 1985, AM J PATHOL, V120, P13
   VIDEM V, 1992, J THORAC CARDIOV SUR, V103, P806
   WADSTROM T, 1987, ZBL BAKT-INT J MED M, V266, P191
   WADSTROM T, 1992, KOAGULASNEGATIVA STA, P31
   YU J, 1994, BIOMATERIALS, V15, P805, DOI 10.1016/0142-9612(94)90035-3
   ZAPOL WM, 1979, JAMA-J AM MED ASSOC, V242, P2193, DOI 10.1001/jama.242.20.2193
   ZDANOWSKI Z, 1993, APMIS, V101, P926, DOI 10.1111/j.1699-0463.1993.tb00203.x
   ZDANOWSKI Z, 1993, EUR J VASCULAR SURG, V7, P277, DOI 10.1016/S0950-821X(05)80009-X
   ZIMMERLI W, 1982, J INFECT DIS, V146, P487, DOI 10.1093/infdis/146.4.487
NR 35
TC 13
Z9 14
U1 0
U2 4
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0920-5063
EI 1568-5624
J9 J BIOMAT SCI-POLYM E
JI J. Biomater. Sci.-Polym. Ed.
PY 1997
VL 8
IS 11
BP 825
EP 832
DI 10.1163/156856297X00029
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials; Polymer
   Science
SC Engineering; Materials Science; Polymer Science
GA XZ521
UT WOS:A1997XZ52100002
PM 9342649
DA 2018-10-19
ER

PT J
AU Lens, JP
   Harmsen, PFH
   TerSchegget, EM
   Terlingen, JGA
   Engbers, GHM
   Feijen, J
AF Lens, JP
   Harmsen, PFH
   TerSchegget, EM
   Terlingen, JGA
   Engbers, GHM
   Feijen, J
TI Immobilization of functionalized alkyl-poly(ethylene oxide) surfactants
   on poly(ethylene) surfaces by means of an argon plasma treatment
SO JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION
LA English
DT Article
DE surface modification; argon plasma treatment; poly(ethylene); PEO
   surfactants; sulfate groups; carboxylate groups; XPS
ID GLOW-DISCHARGE TREATMENT; CONTACT-ANGLE HYSTERESIS; OXIDE)-GRAFTED
   POLYURETHANE; MODIFIED POLYETHYLENE; BIOMATERIAL SURFACES; BLOOD
   COMPATIBILITY; PROTEIN ADSORPTION; CARBOXYLIC-ACID; HEPARIN; PEO
AB Alkyl-poly(ethylene oxide) (PEO) surfactants containing a terminal hydroxyl, sulfate, or carboxylate group were grafted at the surface-of poly(ethylene) (PE) samples to improve their blood compatibility. Grafting was achieved by immobilizing PEO surfactants on PE using an argon plasma treatment. The sulfate group containing PEO surfactant was synthesized by sulfating polyoxyethylene(20)stearylether (Brij78(R); B) with chlorosulfonic acid. A carboxylate-terminated surfactant was synthesized by a substitution reaction of the sodium alkoxide form, of B with sodium iodoacetate. XPS analysis of the modified PE samples showed that at short plasma treatment times of up to 5 a the structure of the immobilized surfactants is largely retained. When plasma treatment times longer than 30 s were applied, the PEO chains of the surfactants were degraded. The wettability of the modified PE samples was improved compared to the unmodified PE samples. The wettability of the modified samples did not change when they were stored in air at room temperature for at least 12 weeks.
C1 UNIV TWENTE,DEPT CHEM ENGN,SECT POLYMER TECHNOL & BIOMAT,NL-7500 AE ENSCHEDE,NETHERLANDS.
   UNIV TWENTE,INST BIOMED TECHNOL,NL-7500 AE ENSCHEDE,NETHERLANDS.
CR AMEEN AP, 1993, POLYMER, V34, P1795, DOI 10.1016/0032-3861(93)90418-A
   AMIJI M, 1993, J BIOMAT SCI-POLYM E, V4, P217, DOI 10.1163/156856293X00537
   BINKS BP, 1992, THIN SOLID FILMS, V207, P273, DOI 10.1016/0040-6090(92)90137-Z
   CHATELIER RC, 1995, LANGMUIR, V11, P4122, DOI 10.1021/la00010a078
   CHILKOTI A, 1991, CHEM MATER, V3, P51, DOI 10.1021/cm00013a016
   CHILKOTI A, 1991, SURF INTERFACE ANAL, V17, P567, DOI 10.1002/sia.740170805
   DESAI NP, 1991, J BIOMED MATER RES, V25, P829, DOI 10.1002/jbm.820250704
   DICKIE RA, 1982, ANAL CHEM, V54, P2045, DOI 10.1021/ac00249a031
   ENGBERS GH, 1991, INT J ARTIF ORGANS, V14, P199
   Ferguson G. S., 1992, MODERN APPROACHES WE, P143
   FERGUSON GS, 1993, MACROMOLECULES, V26, P5870, DOI 10.1021/ma00074a007
   GOMBOTZ WR, 1989, J APPL POLYM SCI, V37, P91, DOI 10.1002/app.1989.070370108
   GOODE R, 1993, COMMERCIAL AND CONSUMER LAW, P3
   GRASEL TG, 1989, J BIOMED MATER RES, V23, P311, DOI 10.1002/jbm.820230304
   HAN DK, 1989, J BIOMED MATER RES-A, V23, P87, DOI 10.1002/jbm.820231309
   HAN DK, 1993, J BIOMAT SCI-POLYM E, V4, P401
   HAN DK, 1995, BIOMATERIALS, V16, P467, DOI 10.1016/0142-9612(95)98819-Z
   HAN DK, 1991, J BIOMED MATER RES, V25, P561, DOI 10.1002/jbm.820250502
   Han DK, 1996, J BIOMED MATER RES, V30, P23, DOI 10.1002/(SICI)1097-4636(199601)30:1<23::AID-JBM4>3.0.CO;2-T
   HAN DK, 1993, J BIOMAT SCI-POLYM E, V4, P579
   HANSEN RH, 1966, J POLYM SCI POL LETT, V4, P203, DOI 10.1002/pol.1966.110040309
   HOLMESFARLEY SR, 1987, LANGMUIR, V3, P62, DOI 10.1021/la00073a012
   HOLMESFARLEY SR, 1988, LANGMUIR, V4, P920
   HUDIS M, 1972, J POLYM SCI POL LETT, V10, P179, DOI 10.1002/pol.1972.110100305
   ISHIHARA K, 1993, BIOMEDICAL APPL POLY, P89
   ITO Y, 1986, J BIOMED MATER RES, V20, P1157, DOI 10.1002/jbm.820200808
   JOUBERT O, 1991, J APPL PHYS, V69, P1697, DOI 10.1063/1.347214
   JOZEFONVICZ J, 1990, Journal of Biomaterials Science Polymer Edition, V1, P147
   LABARRE DJ, 1990, INT J ARTIF ORGANS, V13, P651
   LENS JP, 1997, UNPUB J POLYM SCI PC
   LENS JP, 1997, UNPUB J FAC SCI TE A
   LENS JP, 1997, UNPUB J BIOMATER SCI
   LENS JP, 1997, IN PRESS LANGMUIR
   LENS JP, 1997, IN PRESS POLYMER
   LENS JP, 1997, UNPUB LANGMUIR
   LENS JP, 1997, UNPUB J BIOMED MAT R
   LI D, 1992, COLLOID POLYM SCI, V270, P498, DOI 10.1007/BF00665995
   LLANOS GR, 1993, J BIOMAT SCI-POLYM E, V4, P381
   NEUMANN AW, 1972, J COLLOID INTERF SCI, V38, P341, DOI 10.1016/0021-9797(72)90251-2
   SANTERRE JP, 1992, J BIOMED MATER RES, V26, P39, DOI 10.1002/jbm.820260105
   SCHONHORN H, 1967, J APPL POLYM SCI, V11, P1461, DOI 10.1002/app.1967.070110809
   SCHWARTZ LW, 1985, J COLLOID INTERF SCI, V106, P422, DOI 10.1016/S0021-9797(85)80016-3
   SHEU MS, 1993, CLIN MATER, V13, P41, DOI 10.1016/0267-6605(93)90088-O
   SHEU MS, 1994, APPL POLYM SYMP SER, V54, P29
   SHEU MS, 1993, J ADHES SCI TECHNOL, V7, P1065, DOI 10.1163/156856193X00583
   SHEU MS, 1992, J ADHES SCI TECHNOL, V6, P995, DOI 10.1163/156856192X00890
   SILVER JH, 1993, BIOMATERIALS, V14, P834, DOI 10.1016/0142-9612(93)90005-M
   TAKENS GAJ, 1997, UNPUB SURFACE INTERF
   TAKENS GAJ, 1997, UNPUB LANGMUIR
   TERLINGEN JGA, 1995, J APPL POLYM SCI, V57, P969, DOI 10.1002/app.1995.070570809
   TERLINGEN JGA, 1993, J COLLOID INTERF SCI, V155, P55, DOI 10.1006/jcis.1993.1009
   TERLINGEN JGA, 1993, J BIOMAT SCI-POLYM E, V4, P165, DOI 10.1163/156856293X00500
   TERLINGEN JGA, 1993, J APPL POLYM SCI, V50, P1529, DOI 10.1002/app.1993.070500906
   TERLINGEN JGA, 1995, P 12 INT S PLASM CHE, P215
   TERLINGEN JGA, 1982, J BIOMAT SCI-POLYM E, V4, P31
   VANDAMME HS, 1986, J COLLOID INTERF SCI, V114, P167, DOI 10.1016/0021-9797(86)90248-1
   VANDELDEN CJ, 1997, IN PRESS J BIOMATER
   Wagner C.D., 1990, PRACTICAL SURFACE AN, V1, P595
   WANG J, 1992, J PHYS CHEM-US, V96, P5224, DOI 10.1021/j100192a010
NR 59
TC 23
Z9 25
U1 1
U2 10
PU VSP BV
PI ZEIST
PA PO BOX 346, 3700 AH ZEIST, NETHERLANDS
SN 0920-5063
J9 J BIOMAT SCI-POLYM E
JI J. Biomater. Sci.-Polym. Ed.
PY 1997
VL 8
IS 12
BP 963
EP 982
DI 10.1163/156856297X00128
PG 20
WC Engineering, Biomedical; Materials Science, Biomaterials; Polymer
   Science
SC Engineering; Materials Science; Polymer Science
GA YH309
UT WOS:A1997YH30900005
PM 9399145
DA 2018-10-19
ER

PT J
AU Sun, XL
   Ito, A
   Tateishi, T
   Hoshino, A
AF Sun, XL
   Ito, A
   Tateishi, T
   Hoshino, A
TI Fretting corrosion resistance and fretting corrosion product
   cytocompatibility of ferritic stainless steel
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
ID COBALT; CARCINOGENICITY; PROSTHESES; TOXICITY
AB To avoid nickel ion release from SUS317L as an implant material, a new type of nickel, commercially free, of high purity, and high chromium ferritic stainless steel, was developed. The new stainless steel (FJ) was studied for aspects of fretting corrosion and cytocompatibility compared with SUS317L. A pin-on-plate fretting corrosion test in an artificial physiologic solution, and cell culture in media with the addition of the artificial physiologic solution used for fretting was conducted. Resistance to the fretting induced crevice corrosion of FJ was higher than that of SUS317L because of the favorable electrochemical stability of the FJ alloy. The amount of iron ion or colloidal fine particles released from FJ was about a quarter of that from SUS317L, although the weight loss of a pin of FJ was almost 5/3 that of SUS317L. The artificial physiologic solution used for SUS317L fretting was more harmful to the growth of L929 and MC3T3-E1 cells than that used for FJ fretting. FJ was therefore superior to SUS317L as a biomaterial, judging from the resistance to fretting-induced crevice corrosion, electrochemical stability, and the cytocompatibility of fretting corrosion products. (C) 1997 John Wiley & Sons, Inc.
C1 MINIST INT TRADE & IND, NATL INST ADV INTERDISCIPLINARY RES, TSUKUBA, IBARAKI 305, JAPAN.
   NATL RES INST MET, TSUKUBA, IBARAKI 305, JAPAN.
RI Ito, Atsuo/M-6785-2018
OI Ito, Atsuo/0000-0003-3318-040X
CR BEYERSMANN D, 1992, TOXICOL APPL PHARM, V115, P137, DOI 10.1016/0041-008X(92)90377-5
   BROWN SA, 1981, J BIOMED MATER RES, V15, P867, DOI 10.1002/jbm.820150611
   BROWN SA, 1985, ASTM STP, V859, P105
   CIGADA A, 1993, J APPL BIOMATER, V4, P39, DOI 10.1002/jab.770040105
   CIGADA A, 1979, STP, V684, P144
   COOGAN TP, 1989, CRC CR REV TOXICOL, V19, P341, DOI 10.3109/10408448909029327
   DOMINGO JL, 1989, REV ENVIRON CONTAM T, V108, P105
   EVANS EJ, 1987, BIOMATERIALS, V8, P377, DOI 10.1016/0142-9612(87)90009-3
   HAYNES DR, 1993, J BONE JOINT SURG AM, V75A, P825, DOI 10.2106/00004623-199306000-00004
   HOSHINO A, 1993, ZAIRYO TO KANKYO, V42, P291
   HOSHINO A, 1992, ZAIRYO TO KANKYO, V41, P465
   HOSHINO A, 1992, CORROSION ENG, V41, P465
   HOSHINO A, 1993, CORROSION ENG, V42, P341
   Ito A., 1993, Clinical Materials, V12, P203, DOI 10.1016/0267-6605(93)90074-H
   LOMBARDI AV, 1989, J BONE JOINT SURG AM, V71A, P1337, DOI 10.2106/00004623-198971090-00009
   MATHIESEN EB, 1991, J BONE JOINT SURG BR, V73, P569
   Mears D C, 1966, J Bone Joint Surg Br, V48, P567
   OKAYAMA S, 1992, 80 ANN WORLD DENT C
   PELTONEN L, 1979, CONTACT DERMATITIS, V5, P27, DOI 10.1111/j.1600-0536.1979.tb05531.x
   ROSTOKER G, 1987, J BONE JOINT SURG AM, V69A, P1408
   SIMPSON JP, 1981, NBS SP, V601, P395
   SUNDERMAN FW, 1989, FUND APPL TOXICOL, V13, P205, DOI 10.1016/0272-0590(89)90257-1
   SYRETT BC, 1978, CORROSION, V34, P379
NR 23
TC 4
Z9 4
U1 1
U2 4
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD JAN
PY 1997
VL 34
IS 1
BP 9
EP 14
PG 6
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA VY898
UT WOS:A1997VY89800002
DA 2018-10-19
ER

PT J
AU Rao, SB
   Sharma, CP
AF Rao, SB
   Sharma, CP
TI Use of chitosan as a biomaterial: Studies on its safety and hemostatic
   potential
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
ID ENZYMATIC DEGRADATION; POLYGLYCOLIC ACID
AB Chitosan, a mucopolysaccharide of marine origin, was studied for its safety and hemostatic potential. Its surface was treated with glutaraldehyde, carbodiimide, and plasma glow discharge to elicit effects of enzyme degradation. Of the seven enzymes used, leucine amino peptidase caused maximum degradation. Autoclaving appeared to be an ideal sterilizing method as it caused least decrease in tensile strength and effected a negligible rate of hemolysis. Sterilizing with glutaraldehyde with a physiologic pH retained the maximum tensile strength of chitosan. In vivo toxicity tests indicated that it is nontoxic, and the sterilized films were free of pyrogen. Coagulation and hemagglutination tests showed that the hemostatic mechanism of chitosan seems to be independent of the classical coagulation cascade and appears to be an interaction between the cell membrane of erythrocytes and chitosan. (C) 1997 John Wiley & Sons, Inc.
C1 SREE CHITRA TIRUNAL INST MED SCI & TECHNOL,BIOMED TECHNOL WING,TRIVANDRUM 695012,KERALA,INDIA.
RI Sharma, Chandra/A-4140-2009
OI Sharma, Chandra/0000-0002-6982-0926
CR ARAI K, 1968, B TOKAI REGIONAL FIS, V56, P89
   BRANDENBERG G, 1984, NEUROSURGERY, V15, P9, DOI 10.1227/00006123-198407000-00004
   *CAN STAND ASS, 1989, 3Z3106M84 CAN CAN ST
   CHANDY T, 1991, BIOMATERIALS, V12, P677, DOI 10.1016/0142-9612(91)90116-R
   CHU CC, 1983, J BIOMED MATER RES, V17, P1029, DOI 10.1002/jbm.820170612
   DACIE JV, 1975, PRACTICAL HAEMATOLOG
   DUTKIEWICZ J, 1989, P 4 INT C CHIT CHIT, V4, P719
   ERNST RR, 1968, BIOTECHNOL BIOENG, V10, P1, DOI 10.1002/bit.260100102
   EVANS EE, 1962, J HISTOCHEM CYTOCHEM, V10, P24, DOI 10.1177/10.1.24
   HILLYARD IW, 1964, P SOC EXP BIOL MED, V115, P1108
   Hoppe-Seiler F., 1994, BER DTSCH CHEM GES, V27, P3329
   LANDES DR, 1976, B ENVIRON CONTAM TOX, V15, P555, DOI 10.1007/BF01685704
   MADHAVAN P, 1992, CHITIN CHITOSAN THEI
   MALETTE WG, 1983, ANN THORAC SURG, V36, P55, DOI 10.1016/S0003-4975(10)60649-2
   MOGABGAB WJ, 1986, AM J HYG, V73, P273
   MOISEEV YV, 1979, J POLYM SCI PS, V66, P269
   Olsen R., 1989, P 4 INT C CHIT CHIT, V4, P813
   PAVAN A, 1979, J BIOMED MATER RES, V13, P477, DOI 10.1002/jbm.820130312
   Radhakrishnan VV, 1991, BIOMEDICINE, V2, P3
   RAO SB, 1995, BIOMATER APPL, V10, P136
   ROUGET G, 1959, CR HEBD ACAD SCI, V48, P792
   SAPOZHNIKOV A M, 1984, Biophysics (English Translation of Biofizika), V29, P300
   Sharma C P, 1987, J Biomater Appl, V1, P533
   *US PHARM CONV INC, 1985, USP
   WEINER ML, 1991, P 5 INT C CHIT CHIT, V5, P663
   WILLIAMS DF, 1977, J BIOENG, V1, P231
NR 26
TC 455
Z9 486
U1 7
U2 151
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD JAN
PY 1997
VL 34
IS 1
BP 21
EP 28
DI 10.1002/(SICI)1097-4636(199701)34:1<21::AID-JBM4>3.0.CO;2-P
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA VY898
UT WOS:A1997VY89800004
PM 8978649
DA 2018-10-19
ER

PT J
AU Benahmed, M
   Heymann, D
   Pilet, P
   Bienvenu, J
   Daculsi, G
AF Benahmed, M
   Heymann, D
   Pilet, P
   Bienvenu, J
   Daculsi, G
TI LPS increases biomaterial degradation by human monocytes in vitro
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
ID INDUCED CYTOKINES; LIPOPOLYSACCHARIDE; OSTEOCLAST; CELLS;
   DIFFERENTIATION; MACROPHAGES; EXPRESSION; IL-1-BETA; TNF
AB Different cell lines are involved during an immunological reaction, principally lymphocytes and monocytes. Monocyte/macrophage cells, which are among the first to appear in wound-healing and infection sites, are largely implicated in phagocytosis and could be involved in calcium-phosphate degradation. Their role in these processes may relate to cytokine secretions and/or their sensitivity to certain cytokines. We tested the behavior of human monocytes placed on the surface of biphasic calcium-phosphate (BCP) tablets in the presence of two lipopolysaccharide (LPS) concentrations. After short-term culture (48 h), cytokine release (IL-(1 beta), IL-6) was measured by ELISA, and morphological cell events and biomaterial degradation were observed in scanning electron microscopy. BCP surface pits were noted near cells stimulated by 0.5 mu g/mL LPS but were not apparent with 10 mu g/mL LPS. The number of lacunae on BCP was increased after LPS treatment of human monocytes. An upmodulation of IL-(1 beta) and IL-(6) (in culture medium) released by LPS-activated human monocytes was observed, indicating good cell stimulation. This study demonstrates that LPS-activated human monocytes can degrade the surface of calcium-phosphate ceramic and confirms the role of human monocytes in biomaterial degradation. (C) 1997 John Wiley & Sons, Inc.
C1 CTR HOSP LYON SUD,IMMUNOL LAB,F-69495 PIERRE BENITE,FRANCE.
RP Benahmed, M (reprint author), FAC CHIRURG DENT,CTR RECH MAT INTERETS BIOL,1 PL A RICORDEAU,F-44042 NANTES,FRANCE.
RI Paul, Pilet/A-3755-2015; Daculsi, Guy/P-1320-2014
OI Daculsi, Guy/0000-0003-1030-3446
CR AGARWAL S, 1995, J DENT RES, V74, P1057, DOI 10.1177/00220345950740040501
   ATHANNASSOU NA, 1988, J EXP PATHOL, V69, P309
   BARON R, 1989, ANAT RECORD, V224, P317, DOI 10.1002/ar.1092240220
   BENAHMED M, 1994, BIOMATERIALS, V15, P25, DOI 10.1016/0142-9612(94)90191-0
   BLIFELD C, 1991, TRANSPLANTATION, V51, P498, DOI 10.1097/00007890-199102000-00043
   BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77
   Daculsi G., 1992, BIOMATER TISSUE INT, V10, P296
   EGGESBO JB, 1993, THROMB RES, V70, P161, DOI 10.1016/0049-3848(93)90157-J
   FLAD HD, 1993, IMMUNOBIOLOGY, V187, P303, DOI 10.1016/S0171-2985(11)80346-3
   GALLAY P, 1993, J IMMUNOL, V150, P5086
   GESSANI S, 1993, J IMMUNOL, V151, P3758
   KODAMA H, 1991, J EXP MED, V173, P1291, DOI 10.1084/jem.173.5.1291
   Legeros Racquel Z., 1993, Clinical Materials, V14, P65, DOI 10.1016/0267-6605(93)90049-D
   MARCKS SC, 1988, AM J ANAT, V183, P1
   NAJAR HM, 1990, J LEUKOCYTE BIOL, V47, P429
   ORCEL P, 1990, ANAT REC, V226, P1, DOI 10.1002/ar.1092260102
   ORCEL P, 1993, AM PHYSL SOC, V93, P391
   ROODMAN GD, 1993, CALCIFIED TISSUE INT, V53, P594
   SATO T, 1993, ENDOCRINOLOGY, V133, P397, DOI 10.1210/en.133.1.397
   SCHELLER M, 1995, CYTOKINE, V7, P331, DOI 10.1006/cyto.1995.0042
   TOBIAS PS, 1993, IMMUNOBIOLOGY, V187, P227, DOI 10.1016/S0171-2985(11)80341-4
NR 21
TC 23
Z9 23
U1 0
U2 2
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD JAN
PY 1997
VL 34
IS 1
BP 115
EP 119
DI 10.1002/(SICI)1097-4636(199701)34:1<115::AID-JBM15>3.0.CO;2-J
PG 5
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA VY898
UT WOS:A1997VY89800015
PM 8978660
DA 2018-10-19
ER

PT J
AU Kazimiroff, J
   Frankel, SR
   LeGeros, RZ
AF Kazimiroff, J
   Frankel, SR
   LeGeros, RZ
TI Autoradiographic assessment of bone/biomaterial interface.
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Meeting Abstract
C1 NYU,HOSP JOINT DIS,SCH MED,NEW YORK,NY 10003.
   NYU,COLL DENT,NEW YORK,NY.
   DENTSPLY CAULK,NEW YORK,NY.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC DENTAL RESEARCH
PI ALEXANDRIA
PA 1619 DUKE ST, ALEXANDRIA, VA 22314
SN 0022-0345
J9 J DENT RES
JI J. Dent. Res.
PY 1997
VL 76
SI SI
BP 263
EP 263
PG 1
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA WB680
UT WOS:A1997WB68000258
DA 2018-10-19
ER

PT J
AU Nagahara, K
   Yamaguchi, K
   Kanematsu, N
   Doi, Y
AF Nagahara, K
   Yamaguchi, K
   Kanematsu, N
   Doi, Y
TI Evaluation of carbonate-containing apatites as a biomaterial with basic
   study.
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Meeting Abstract
C1 ASAHI UNIV,SCH DENT,DEPT ORAL & MAXILLOFACIAL SURG,GIFU,JAPAN.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC DENTAL RESEARCH
PI ALEXANDRIA
PA 1619 DUKE ST, ALEXANDRIA, VA 22314
SN 0022-0345
J9 J DENT RES
JI J. Dent. Res.
PY 1997
VL 76
SI SI
BP 1233
EP 1233
PG 1
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA WB680
UT WOS:A1997WB68001230
DA 2018-10-19
ER

PT J
AU Suzuki, T
   Mizushima, Y
AF Suzuki, T
   Mizushima, Y
TI Characteristics of silica-chitosan complex membrane and their
   relationships to the characteristics of growth and adhesiveness of L-929
   cells cultured on the biomembrane
SO JOURNAL OF FERMENTATION AND BIOENGINEERING
LA English
DT Article
DE silica; chitosan; wet contact angle; zeta potential; cell adhesion
ID DEPENDENT ANIMAL-CELLS; WOUND MANAGEMENT; BIOCERAMICS
AB The relationships between the chemical and physical characteristics of a silica-chitosan complex membrane (SiCM) and the characteristics of growth and adhesion of fibroblast-like L-929 cells cultured on the surface of SiCM were investigated for development of a novel implant biomaterial for use as artificial skin. Silicon ethoxide was used to cross-link the chitosan complex membrane to enhance its oxygen permeability. The composition of the SiCM was stepwise controlled by adjustment of the mixing ratio between silica and chitosan, for silica contents of 20, 33, 43, and 50 wt%. The zeta potential of the SiCM varied negatively according to the silica content, from +20 mV for chitosan membrane (0%-SiCM) to -0.6 mV for 43%-SiCM. Similarly, the wet contact angle decreased from 68 degrees to 41 degrees according to the increase in the silica content up to 43%. However, significant increases in the wet contact angle and the zeta potential occurred upon further increase of the silica content to 50%. The adhesion and growth characteristics of L-929 cells on SiCM were found to be related to the surface properties of the SiCMs. The cell proliferation rate was higher on the 0, 20 and 50%-SiCMs than on a typical polystyrene culture dish. The strongest cell adhesion was obtained on 50%-SiCM among the complex membranes. Thus, the surface wet contact angle and the zeta potential of 50%-SiCM, which is highly permeable to oxygen, were found to be suitable for L-929 cell adhesion and growth, and therefore to promote tissue culture on the SiCM in vitro.
C1 NGK SPARK PLUG CO LTD,KOMAKI 485,JAPAN.
RP Suzuki, T (reprint author), SCI UNIV TOKYO,DEPT BIOL SCI & TECHNOL,2641 YAMAZAKI,NODA,CHIBA 278,JAPAN.
CR AZUMA SI, 1992, BIOCHEM BIOPH RES CO, V168, P350
   BERSCHT PC, 1994, BIOMATERIALS, V15, P593, DOI 10.1016/0142-9612(94)90209-7
   BIAGINI G, 1991, BIOMATERIALS, V12, P281, DOI 10.1016/0142-9612(91)90035-9
   CHUNG LY, 1994, J BIOMED MATER RES, V28, P463, DOI 10.1002/jbm.820280409
   HOU W, 1989, CHEM PHARM BULL, V33, P3986
   IMAI Y, 1985, CHEM SOC JPN, P1259
   KNAPCZYK J, 1992, INT J PHARM, V80, P33, DOI 10.1016/0378-5173(92)90259-5
   KUBO K, 1993, J JPN SOC BIOMATER, V11, P85
   LAPORTE S, 1992, BIOCHEM BIOPH RES CO, V187, P1510, DOI 10.1016/0006-291X(92)90473-X
   Lefroy DC, 1996, J MOL CELL CARDIOL, V28, P429, DOI 10.1006/jmcc.1996.0039
   MIZUSHIMA Y, 1992, J NON-CRYST SOLIDS, V144, P305, DOI 10.1016/S0022-3093(05)80414-4
   MUZZARELLI R, 1990, ANTIMICROB AGENTS CH, V34, P2019, DOI 10.1128/AAC.34.10.2019
   NIKI M, 1994, J JPN SOC BIOMATER, V12, P5
   NISHIMURA K, 1986, VACCINE, V4, P151, DOI 10.1016/0264-410X(86)90002-2
   NISHIZAWA K, 1993, J FERMENT BIOENG, V75, P435, DOI 10.1016/0922-338X(93)90091-L
   Suzuki T, 1996, J FERMENT BIOENG, V81, P226, DOI 10.1016/0922-338X(96)82213-6
   SUZUKI T, 1990, J FERMENT BIOENG, V70, P164, DOI 10.1016/0922-338X(90)90177-X
   SUZUKI T, 1991, J FERMENT BIOENG, V72, P450, DOI 10.1016/0922-338X(91)90053-J
   Suzuki T, 1997, J BIOMED MATER RES, V34, P507, DOI 10.1002/(SICI)1097-4636(19970315)34:4<507::AID-JBM11>3.3.CO;2-P
   SUZUKI T, 1997, IN PRESS BIOCERAMICS, V10
   WALSH DA, 1994, BRIT J PHARMACOL, V112, P435, DOI 10.1111/j.1476-5381.1994.tb13091.x
   WANG E, 1988, Biotechnology Techniques, V2, P133, DOI 10.1007/BF01876164
   YOSHIOKA T, 1990, BIOTECHNOL BIOENG, V35, P66, DOI 10.1002/bit.260350110
NR 23
TC 23
Z9 24
U1 0
U2 3
PU SOC FERMENTATION BIOENGINEERING, JAPAN
PI OSAKA
PA OSAKA UNIV, FACULTY ENGINEERING, 2-1 YAMADAOKA, SUITA, OSAKA 565, JAPAN
SN 0922-338X
J9 J FERMENT BIOENG
JI J. Ferment. Bioeng.
PY 1997
VL 84
IS 2
BP 128
EP 132
DI 10.1016/S0922-338X(97)82541-X
PG 5
WC Biotechnology & Applied Microbiology; Food Science & Technology
SC Biotechnology & Applied Microbiology; Food Science & Technology
GA YB526
UT WOS:A1997YB52600006
DA 2018-10-19
ER

PT J
AU Sastry, TP
   Madhavan, V
   Nazer, MN
   Gomathinayagam, S
   Rose, C
   Rao, NM
AF Sastry, TP
   Madhavan, V
   Nazer, MN
   Gomathinayagam, S
   Rose, C
   Rao, NM
TI Graft copolymerization of glycidylmethacrylate onto fibrin prepared from
   slaughter-house waste
SO JOURNAL OF MACROMOLECULAR SCIENCE-PURE AND APPLIED CHEMISTRY
LA English
DT Article
DE fibrin; polyglycidylmethacrylate; graft-copolymerisation; percentage
   grafting; thermal decomposition
ID GLUE
AB Fibrin collected from the slaughter house in crude form was purified. The purified fibrin was graft copolymerised with poly-glycidylmethacrylate (PGMA) and characterised for the percentage of grafting. The infrared spectroscopy and thermogravimetric analysis, of the composite were studied. This biomaterial could be used as a drug delivery system after coupling the suitable antibiotic through the epoxy functional groups introduced by PGMA.
RP Sastry, TP (reprint author), CENT LEATHER RES INST,BIOPROD LAB,MADRAS 600020,TAMIL NADU,INDIA.
CR Bergel S, 1909, DEUT MED WOCHENSCHR, V35, P663, DOI 10.1055/s-0029-1201395
   BLOCKER SH, 1986, J PEDIATR SURG, V21, P369, DOI 10.1016/S0022-3468(86)80207-X
   COUTO J, 1987, SURGERY          MAR, P354
   DAHLSTROM KK, 1992, PLAST RECONSTR SURG, V89, P968, DOI 10.1097/00006534-199205000-00034
   Holmqvist N, 1986, J SPORT SCI, V4, P123, DOI 10.1080/02640418608732108
   KRAM HB, 1989, UROLOGY, V33, P215, DOI 10.1016/0090-4295(89)90395-6
   KRAM HB, 1990, J TRAUMA, V30, P97, DOI 10.1097/00005373-199001000-00016
   Laki K., 1968, FIBRINOGEN
   PERS M, 1987, PARAPLEGIA, V25, P275, DOI 10.1038/sc.1987.51
   PIECHOTTA FU, 1983, AESTHET PLAST SURG, V17, P263
   PLENK A, 1940, ARCH KLIN CHIR, V198, P402
   Rao K.P., 1969, LEATHER SCI, V16, P401
   SASTRY TP, 1989, DEV EVALUATION COLLA
   STYER L, 1988, BIOCHEMISTRY
NR 14
TC 4
Z9 4
U1 0
U2 1
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016
SN 1060-1325
J9 J MACROMOL SCI PURE
JI J. Macromol. Sci.-Pure Appl. Chem.
PY 1997
VL A34
IS 5
BP 915
EP 925
DI 10.1080/10601329708014341
PG 11
WC Polymer Science
SC Polymer Science
GA WX142
UT WOS:A1997WX14200014
DA 2018-10-19
ER

PT J
AU Clarke, SA
   Revell, PA
AF Clarke, SA
   Revell, PA
TI CD11a and CD11b are expressed by cells at the bone-biomaterial
   interface.
SO JOURNAL OF PATHOLOGY
LA English
DT Meeting Abstract
C1 ROYAL FREE HOSP,SCH MED,DEPT HISTOPATHOL,LONDON NW3 2PF,ENGLAND.
   ROYAL FREE HOSP,SCH MED,UK IRC BIOMED MAT,LONDON NW3 2PF,ENGLAND.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU JOHN WILEY & SONS LTD
PI W SUSSEX
PA BAFFINS LANE CHICHESTER, W SUSSEX, ENGLAND PO19 1UD
SN 0022-3417
J9 J PATHOL
JI J. Pathol.
PY 1997
VL 181
SU S
BP A45
EP A45
PG 1
WC Oncology; Pathology
SC Oncology; Pathology
GA WK188
UT WOS:A1997WK18800180
DA 2018-10-19
ER

PT J
AU Zhang, XK
   Chen, SF
   Li, B
AF Zhang, XK
   Chen, SF
   Li, B
TI Effect of heat-treatment and TiO2 addition on the crystallization
   features of bioactive glass ceramics
SO JOURNAL OF TRACE AND MICROPROBE TECHNIQUES
LA English
DT Article; Proceedings Paper
CT 14th International Congress on X-ray Optics and Microanalysis (ICXOM)
CY AUG 29-SEP 02, 1995
CL GUANGZHOU, PEOPLES R CHINA
DE phase separation; nucleation; crystallization; bioactivity
AB In this work, phase separation, nucleation and crystallization of the glass in the system K2O-MgO-Al2O3-B2O3-SiO2-CaO-P2O5-F were observed and analysed. Glass ceramics with two main crystalline phases were prepared by selecting suitable glass compositions and program of heat treatment. The multiple phase separation of the parent glasses can play an important role in nucleation and crystallization. XRD analysis indicated that the two main cryatlline phases were fluorapatite and fluorophlogopite, which are very important for bioactivity and applicability. This glass ceramic is considered as a very promising biomaterial.
C1 Shandong Normal Univ, Anal & Testing Ctr, Jinan 250014, Peoples R China.
   Shandong Inst Light Ind, Dept Inorgan Mat, Jinan 250100, Peoples R China.
   Shandong Med Univ, Jinan 250012, Peoples R China.
RP Chen, SF (reprint author), Shandong Inst Light Ind, Dept Inorgan Mat, Jinan 250100, Peoples R China.
CR Chen X.F., 1993, J CHIN CERAM SOC, V21, P247
   ZHANG XK, 1992, GLASS TECHNOL, V3, P1
NR 2
TC 4
Z9 4
U1 0
U2 0
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016 USA
SN 0733-4680
J9 J TRACE MICROPROBE T
JI J. Trace Microprobe Tech.
PY 1997
VL 15
IS 4
BP 713
EP 716
PG 4
WC Chemistry, Analytical
SC Chemistry
GA YL896
UT WOS:000071005400058
DA 2018-10-19
ER

PT B
AU Jacques, SL
   Barofsky, A
   Shangguan, HQ
   Prahl, SA
   Gregory, KW
AF Jacques, SL
   Barofsky, A
   Shangguan, HQ
   Prahl, SA
   Gregory, KW
BE Jacques, SL
   Katzir, A
TI Laser welding of biomaterials stained with indocyanine green to tissues.
SO LASER-TISSUE INTERACTION VIII, PROCEEDINGS OF
SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
   (SPIE)
LA English
DT Proceedings Paper
CT Conference on Laser-Tissue Interaction VIII
CY FEB 09-12, 1997
CL SAN JOSE, CA
SP USA Off Sci Res, Int Biomed Opt Soc, Soc Photo Opt Instrumentat Engineers, Amer Soc Laser Med & Surg Inc
AB This paper considers some issues pertinent to laser welding of elastin-based biomaterials to tissues using a pulsed diode laser (10-mu s pulse) and indocyanine green (ICG) as an absorbing chromophore to localize laser heating to the ''weld surface'', the elastin/tissue interface where welding occurs. Experiments involved laser welding of elastin heterographs to the intimal surface of the carotid artery (in vitro, porcine) as a similar to 4x5 mm(2) spot weld, then determining the breaking strength when the two tissues were pulled in a direction parallel to the plane of the spot weld while submerged in water. The questions answered are:
   WHAT IS THE PEAK TEMPERATURE REQUIRED FOR WELDING ELASTIN HETEROGRAPH TO THE INTIMAL SURFACE OF CAROTID ARTERY?
   ANSWER: similar to 300 degrees C threshold, similar to 600 degrees C for maximum strength. This estimate is based on optical measurements of dye accumulation in stain laver and measurements of thickness of stain layer via fluorescence microscope examination.
   WHAT IS THE DEPENDENCE OF WELD STRENGTH ON THE LASER EXPOSURE?
   ANSWER: Breaking force (g) = Max*(1-exp(-(E-p-E-th)/U-67)), where Max is the maximum strength achievable by laser welding, expressed as the breaking force in g when elastin heterograph and tissue are pulled. E-p is the laser pulse energy. E-th is the apparent threshold laser pulse energy that will break the weld. U-67 is the laser energy above threshold which achieves 67% of Max. Max was about 15 g for the similar to 20 mm(2) weld area of our experiments. E-th was 0.8 J. U-67 was 1.44 J.
   DOES WELD STRENGTH DEPEND ON HYDRATION CONDITIONS?
   ANSWER: Not on the amount of excess unbound water. There was no significant difference in weld strength between welding dripping wet tissues vs well blotted tissues.
   WHAT DIFFERENCE IS THERE BETWEEN IRRADIATING THE WELD SURFACE THROUGH THE BIOMATERIAL VS THROUGH THE TISSUE, WHEN THE BIOMATERIAL IS PARTIALLY STAINED WITH ICG?
   ANSWER: There is a difference if the stain layer is heavily stained. Irradiation through the tissue allows direct irradiation on the weld surface which achieves the highest peak temperatures for the least laser pulse energy. irradiation through the elastin heterograph causes direct irradiation of the rear surface of the stain layer, within the biomaterial and away from the weld surface, and thermal diffusion must bring the heat to the weld surface. This difference occurs only when the absorption by the stain layer is sufficiently high that little laser energy directly reaches the weld surface.
RP Jacques, SL (reprint author), OREGON MED LASER CTR,PORTLAND,OR 97225, USA.
NR 0
TC 7
Z9 7
U1 0
U2 1
PU SPIE - INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA PO BOX 10, BELLINGHAM, WA 98227-0010
BN 0-8194-2386-6
J9 P SOC PHOTO-OPT INS
PY 1997
VL 2975
BP 54
EP 61
DI 10.1117/12.275511
PG 8
WC Engineering, Biomedical; Optics
SC Engineering; Optics
GA BJ12Q
UT WOS:A1997BJ12Q00006
DA 2018-10-19
ER

PT B
AU Prahl, SA
   Pearson, SD
AF Prahl, SA
   Pearson, SD
BE Jacques, SL
   Katzir, A
TI Rate process models for thermal welding
SO LASER-TISSUE INTERACTION VIII, PROCEEDINGS OF
SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
   (SPIE)
LA English
DT Proceedings Paper
CT Conference on Laser-Tissue Interaction VIII
CY FEB 09-12, 1997
CL SAN JOSE, CA
SP USA Off Sci Res, Int Biomed Opt Soc, Soc Photo Opt Instrumentat Engineers, Amer Soc Laser Med & Surg Inc
DE indocyanine green; biomaterial
AB Laser tissue welding is a thermal process for binding two tissues together. Optical and thermal models exist to calculate the temperatures of laser irradiated tissues. However, a rate process model is required to relate the time-temperature history to a weld strength. This paper proposes a first-order rate process model based on contraction during heating. The entropy and enthalpy associated with contraction of porcine intestine in a water bath was measured and used to calculate the fraction of altered molecules for both water bath and laser welding. Intestine was welded to intestine in a water bath at 60-80 degrees C for seven minutes. Pulsed laser welding used 10-30 pulses and an exogenous chromophore. The yield strengths of the welds were measured and found to roughly correlate with the fraction of altered molecules estimated for both the water bath and laser welds.
RP Prahl, SA (reprint author), OREGON MED LASER CTR,9205 SW BARNES RD,PORTLAND,OR 97225, USA.
NR 0
TC 5
Z9 6
U1 0
U2 1
PU SPIE - INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA PO BOX 10, BELLINGHAM, WA 98227-0010
BN 0-8194-2386-6
J9 P SOC PHOTO-OPT INS
PY 1997
VL 2975
BP 245
EP 252
DI 10.1117/12.275486
PG 8
WC Engineering, Biomedical; Optics
SC Engineering; Optics
GA BJ12Q
UT WOS:A1997BJ12Q00028
DA 2018-10-19
ER

PT B
AU Starodub, NF
   Torbicz, W
   Starodub, VM
   Kanjuk, MI
   Ternovoj, KS
AF Starodub, NF
   Torbicz, W
   Starodub, VM
   Kanjuk, MI
   Ternovoj, KS
BE Chau, K
   French, PJ
TI Stabilization of activity and repeated usage of biomaterial during
   integration with transducers and analysis of irreversible inhibitors
SO MICROMACHINED DEVICES AND COMPONENTS III
SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
   (SPIE)
LA English
DT Proceedings Paper
CT 3rd Conference on Micromachined Devices and Components
CY SEP   29, 1997
CL AUSTIN, TX
SP Soc Photo Opt Instrumentat Engineers, Semiconductor Equipment & Mat Int, NIST, Solid State Technol
DE biosensors; biomaterial; immobilization; reactivation; repeated usage;
   irreversible inhibitors; analysis
AB At the creation and application of biosensors it is appeared a number of problems the main of which are: 1) optimization of process connected with stabilization of the structure of biomolecules at the integration with the transducers to preserve their maximum activity and 2) search of approaches to accomplish repeated analysis of substances which are irreversible inhibitors of activity of above mentioned molecules. Tn this article the results obtained in time of solving of these problems at the usage of enzymes as sensitive biolayer of biosensors are analysed. For stabilization of the structure of such enzymes as:beta-glucose oxydase, urease, cholinesterases during their immobilization the following approaches were examined: 1) usage of one or combination of chemical substances: protein, saccharose, ethylendiamine tetraacetic acid (EDTA), glycerol, ditiotrietole (DTT) and specific substrates or their homologues; 2) variation of covalent crosslinking methods including usage of bifunctional reagents in aqueous and vaporous phases; 3) change of time of the influence of this reagent. Optimization of these parameters can allow to preserve about 70-80% of initial enzyme activity at the usage of such bifunctional reagent as glutaraldehyde. For repeated analysis of phosphororganic pesticides and heavy metal ions which are irreversible inhibitors of enzymes the following approaches were applied: 1) treatment of enzyme membrane by special reactivating substances (for analysis: phosphororganic pesticides-pyridine-2-aldoxime methiodide (PAM-2 iodide); heavy metal ions -EDTA or DTT); 2) usage of easily replaceable enzymatic membrane. It was shown that the last way is more preferable, particularly if alginate gel or nitrocellulose is used for direct enzyme immobilization or preparation of separated biomembrane respectively. Standard deviation of sensor responses for different membrane castings did not exceed 10%. At the same time this parameter changed more strongly after even one use of reactivating reagents.
RP Starodub, NF (reprint author), NATL ACAD SCI,AV PALLADIN BIOCHEM INST,9 LEONTOVICHA STR,UA-252030 KIEV,UKRAINE.
NR 0
TC 2
Z9 2
U1 0
U2 3
PU SPIE - INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA PO BOX 10, BELLINGHAM, WA 98227-0010
BN 0-8194-2656-3
J9 P SOC PHOTO-OPT INS
PY 1997
VL 3224
BP 273
EP 282
DI 10.1117/12.284524
PG 10
WC Engineering, Electrical & Electronic; Engineering, Mechanical; Optics
SC Engineering; Optics
GA BJ87J
UT WOS:A1997BJ87J00030
DA 2018-10-19
ER

PT S
AU Perry, WL
   Lemons, JE
   Meyer, RD
   Clark, L
AF Perry, WL
   Lemons, JE
   Meyer, RD
   Clark, L
BE Bumgardner, JD
   Puckett, AD
TI Stainless steel particulate and human tissue responses
SO PROCEEDINGS OF THE 1997 16TH SOUTHERN BIOMEDICAL ENGINEERING CONFERENCE
SE SOUTHERN BIOMEDICAL ENGINEERING CONFERENCE. PROCEEDINGS
LA English
DT Proceedings Paper
CT 16th Southern Biomedical Engineering Conference
CY APR 04-06, 1997
CL BILOXI, MS
SP Mississippi State Univ, Dept Agr & Biol Engn, Univ Mississippi Med Ctr, Dept Restorat Dent Biomat Orthopaed Surg, Whitaker Fdn, Natl Sci Fdn, IEEE Engn Med & Biol Soc, Biomed Engn Soc, Inst Biol Engn, Soc Biomat
AB Biomaterial particulate properties, such as chemistry, size, shape, and number, are key factors in determining biological performance of implants. Debris has been shown to elicit inflammatory responses and possibly lead to osteolysis. One objective of this study is to provide a more in-depth understanding of human tissue responses to 316L, stainless steel particulates. The histological interactions and overall metallic contents of tissues collected from cross-screw stabilized, explanted intramedullary rods were qualitatively analyzed via light microscopy. More metallic debris was detected at sites near locking screws, where metal-on-metal motion existed. However, no direct correlations were observed between debris amounts and inflammatory response scores. There was also no direct correlation observed between inflammatory response scores in tissues near locking screws when compared to tissues away from sites of mechanical motion and debris generation. The results of this study represent responses over a relatively short period of time, typically less than three years, as the IM nails were utilized as temporary fixation devices.
RP Perry, WL (reprint author), UNIV ALABAMA,DEPT SURG,DIV ORTHOPAED,BIRMINGHAM,AL 35294, USA.
NR 0
TC 0
Z9 1
U1 0
U2 0
PU I E E E
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017
SN 1086-4105
BN 0-7803-3869-3
J9 SO BIOMM ENGN CONF P
PY 1997
BP 283
EP 284
DI 10.1109/SBEC.1997.583286
PG 2
WC Engineering, Biomedical
SC Engineering
GA BH56F
UT WOS:A1997BH56F00064
DA 2018-10-19
ER

PT B
AU DoLuu, HM
   Hutter, JC
AF DoLuu, HM
   Hutter, JC
BE Anderson, JG
   Katzper, M
TI A PBPK model to investigate the fate of 2,4-toluenediamine
SO SIMULATION IN THE MEDICAL SCIENCES
LA English
DT Proceedings Paper
CT Simulation in the Medical Sciences Conference, at the 1997 Western
   MultiConference
CY JAN 12-15, 1997
CL PHOENIX, AZ
SP Soc Comp Simulat Int
DE pharmacokinetic; polymer degradation; polyurethanes
AB Physiologically-based pharmacokinetic modeling, also known as PBPK, has been widely used in the study of drugs. Little progress has been made in applying this approach to assess the hazard(s) of medical devices. 2,4-Toluenediamine (2,4-TDA), a known mutagen and rodent carcinogen, was found as a degration product of the polyesterurethane (PU) foam cover of Memen(TM) breast implants in vivo. The carcinogenicity of 2,4-TDA was studied in mice and rats and found both dose-dependent and to vary with the route and species tested. PBPK modeling is used to describe the fate of 2,4-TDA in the rat. The PBPK model was calibrated with data derived from studies of 2,4-TDA related to the biodegradation of the PU foam. This computer based PBPK model was used to predict chemical exposure from biomaterial degradation, and help assess the risk from the implant degradation products leached into the body. The model of ordinary differential equations was solved using Mathcad PLUS 6.0 (MathSoft, Cambridge MA).
RP DoLuu, HM (reprint author), US FDA,CTR DEVICES & RADIOL HLTH,12200 WILKINS AVE,ROCKVILLE,MD 20852, USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SOC COMPUTER SIMULATION INT
PI SAN DIEGO
PA PO BOX 17900, SAN DIEGO, CA 92177
BN 1-56555-105-2
PY 1997
BP 113
EP 121
PG 9
WC Computer Science, Information Systems; Computer Science,
   Interdisciplinary Applications; Medical Informatics
SC Computer Science; Medical Informatics
GA BH94Q
UT WOS:A1997BH94Q00020
DA 2018-10-19
ER

PT B
AU Mitura, S
AF Mitura, S
BE Rogalski, A
   Rutkowski, J
   Majchrowski, A
   Zielinski, J
TI Nanocrystalline diamond for medicine
SO SOLID STATE CRYSTALS IN OPTOELECTRONICS AND SEMICONDUCTOR TECHNOLOGY
SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
   (SPIE)
LA English
DT Proceedings Paper
CT Conference on Solid State Crystals in Optoelectronics and Semiconductor
   Technology
CY OCT 07-11, 1996
CL ZAKOPANE, POLAND
SP Mil Univ Technol, Inst Appl Phys, Warsaw, State Comm Sci Res, Poland, Soc Photo Opt Instrumentat Engineers, SPIE, Poland Chapter, TU Lodz, Inst Phys, Polish Acad Sci, Comm Crystallog
DE amorphous carbon; nanocrystalline diamond; biomaterial; PA CVD
   synthesis; medicine
AB The unique properties of thin amorphous diamond layers make them perspective candidates for producing advanced microelectronic devices, coatings for cutting tools and optics. Moreover, due to the highest biocompatibility of carbon resulting from the presence of this element in human body, it appears to be a potential biomaterial.
   Until present the amorphous diamond has found industrial applications in some areas. One of the applications of the carbon layers are coatings for medical implants. The studies of carbon films as coatings for implants in surgery were aimed on the investigations of biological resistance of implants, histopathological investigations on laboratory animals, tests of corrosion resistance, measurements of mechanical properties and a breakdown test in Tyrod solution.
   The current state of published work in the subject is reviewed in the paper together with a discussion concerning classification of this material.
RP Mitura, S (reprint author), TECH UNIV LODZ,INST MAT SCI & ENGN,STEFANOWSKIEGO 1,PL-90924 LODZ,POLAND.
RI Mitura, Stanislaw/L-6013-2014
OI Mitura, Stanislaw/0000-0001-9280-3748
NR 0
TC 2
Z9 2
U1 0
U2 6
PU SPIE - INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA PO BOX 10, BELLINGHAM, WA 98227-0010
BN 0-8194-2605-9
J9 P SOC PHOTO-OPT INS
PY 1997
VL 3179
BP 79
EP 86
DI 10.1117/12.276200
PG 8
WC Crystallography; Optics; Physics, Applied
SC Crystallography; Optics; Physics
GA BJ06Y
UT WOS:A1997BJ06Y00014
DA 2018-10-19
ER

PT J
AU Nan, H
   Chen, YR
   Cai, GJ
   Lin, CG
   Wang, ZG
   Guo, Y
   Huehe, S
   Liu, XH
   Zhen, ZH
AF Nan, H
   Chen, YR
   Cai, GJ
   Lin, CG
   Wang, ZG
   Guo, Y
   Huehe, S
   Liu, XH
   Zhen, ZH
TI Research on the fatigue behavior of titanium based biomaterial coated
   with titanium nitride film by ion beam enhanced deposition
SO SURFACE & COATINGS TECHNOLOGY
LA English
DT Article
DE ion beam enhanced deposition; TiN film; titanium biomaterial; fatigue
ID TIN; COATINGS
AB In the present study, three-point bending fatigue tests in Ringer solution were performed using unnotched specimens of Ti6Al4V coated with TiN him by ion beam enhanced deposition (IBED). For comparison, uncoated samples were also investigated. The applied stresses on the tension side of the samples were 850-1100 MPa. The frequency was 60 Hz. The number of cycles to fatigue failure under different loads ranged from 3 x 10(4) to 1 x 10(7). The coated and uncoated samples had different fatigue behaviors. The fracture mechanisms of the samples were also studied using scanning electron microscopy (SEM) and transmission electron microscopy (TEM). Energy dispersive X-ray spectrometry (EDX) revealed segregation of aluminum from the matrix to the TiN surface area during the fatigue process. It was concluded that a TiN film coated by IBED could improve the fatigue properties of Ti6Al4V under low stress.
C1 CHINESE ACAD SCI,INST MET,FATIGUE & FRACTURE LAB,SHENYANG 110015,PEOPLES R CHINA.
   CHINESE ACAD SCI,INST MET,ION BEAM LAB,SHANGHAI 200050,PEOPLES R CHINA.
RP Nan, H (reprint author), SW JIAOTONG UNIV,DEPT MAT ENGN,CHENGDU 610031,PEOPLES R CHINA.
CR BULL SJ, 1990, SURF COAT TECH, V41, P269, DOI 10.1016/0257-8972(90)90138-3
   Collings E.W., 1988, ADV CRYO ENG, V34, P867
   DILLICH SA, 1991, J TRIBOL-T ASME, V113, P214, DOI 10.1115/1.2920592
   DION I, 1992, INT J ARTIF ORGANS, V15, P617
   DION I, 1993, BIOMATERIALS, V14, P712, DOI 10.1016/0142-9612(93)90070-I
   DUCHATEAU D, 1991, CETIM INFORMATION, V22, P42
   MITAMURA Y, 1990, Artificial Organs, V14, P94
   MITAMURA Y, 1986, T AM SOC ART INT ORG, V32, P444
   NARAYAN J, 1994, MAT SCI ENG B-SOLID, V25, P5, DOI 10.1016/0921-5107(94)90193-7
   RICKERBY DS, 1990, SURF COAT TECH, V41, P63, DOI 10.1016/0257-8972(90)90130-5
   VARDIMAN RG, 1982, J APPL PHYS, V53, P690, DOI 10.1063/1.329977
   WANG X, 1991, IONICS, V9, P39
NR 12
TC 5
Z9 5
U1 0
U2 4
PU ELSEVIER SCIENCE SA LAUSANNE
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0257-8972
J9 SURF COAT TECH
JI Surf. Coat. Technol.
PD JAN
PY 1997
VL 88
IS 1-3
BP 127
EP 131
DI 10.1016/S0257-8972(96)02891-5
PG 5
WC Materials Science, Coatings & Films; Physics, Applied
SC Materials Science; Physics
GA WB394
UT WOS:A1997WB39400018
DA 2018-10-19
ER

PT B
AU Ekbatani, AR
   Mirzadeh, H
   Katbab, AA
AF Ekbatani, AR
   Mirzadeh, H
   Katbab, AA
BE Sudarshan, TS
   Khor, KA
   Jeandin, M
TI Surface modification of ethylene propylene rubber by laser grafting of
   acrylic acid
SO SURFACE MODIFICATION TECHNOLOGIES X
LA English
DT Proceedings Paper
CT 10th International Conference on Surface Modification Technologies
CY SEP 02-04, 1996
CL SINGAPORE, SINGAPORE
SP Nanyang Technol Univ, Sch Mech & Prod Engn, Singapore, Inst Mat, Mat Minerals & Meta Soc, US, ASM Int, Natl Sci Fdn, US
AB In spite of the good bulk mechanical properties of ethylene propylene rubber (EPR) the low surface water compatibility is the main difficulty with this polymer to be used as a biomaterial. Peroxides formation on the surface by CO2-pulsed laser treatment through peroxidation method has been found as a successful technique to initiate the graft copolymerization of hydrophilic acrylic acid onto the surface of this rubber. The fractal type of morphology formed by the grafted chains enables the control of the hydrophobic to hydrophilic site ratio which is the main key in the extent of biocompatibility of polymer surfaces. Grafting occurred successfully and was found to be dependent upon laser pulse number. EDXA and ATR-IR has been employed to characterize the surface chemical compositions. Modified surfaces showed significant improved water compatibility the degree of which depends upon the surface morphology and graft level.
RP Ekbatani, AR (reprint author), AMIR KABIR UNIV TECHNOL,DEPT POLYMER ENGN,TEHRAN,IRAN.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ASHGATE PUBLISHING LTD
PI ALDERSHOT
PA GOWER HOUSE, CROFT ROAD, ALDERSHOT, ENGLAND
BN 1-86125-022-3
PY 1997
BP 256
EP 264
PG 9
WC Engineering, Mechanical; Materials Science, Coatings & Films
SC Engineering; Materials Science
GA BJ63U
UT WOS:A1997BJ63U00020
DA 2018-10-19
ER

PT J
AU Lin, S
   Drake, LR
   Rayson, GD
AF Lin, S
   Drake, LR
   Rayson, GD
TI Applications of frontal affinity chromatography to the study of
   interactions between metal ions and a complex biomaterial
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID BINDING-SITES; EU(III) LUMINESCENCE; ALGAL BIOMASS; URANIUM; ADSORPTION;
   RECOVERY; EXCHANGE; REMOVAL; DISTRIBUTIONS; SPECTROMETRY
AB The use of frontal affinity chromatography for the study of metal-biomaterial interactions is described. Both normal frontal affinity chromatography and a modification of this methodology were used to generate metal binding isotherms to a biomaterial. This modification enabled the acquisition of binding isotherms with extended concentration ranges at the expense of time-dependent binding information. Comparison between normal and modified mode was made by using a well-defined commercial resin. Similar performance of these two modes was obtained. The biomaterial investigated was composed of cell fragments from the plant Datura innoxia which were immobilized within a polysilicate matrix. The application of a regularized least-squares method indicated the existence of two classes of sites on this biosorbent involved in the binding of Ag+, a total metal-ion binding affinity order at solution pH 3-5 was determined to be Cu2+ > Cd2+ approximate to Ag+ > Ca2+.
C1 NEW MEXICO STATE UNIV,DEPT CHEM & BIOCHEM,LAS CRUCES,NM 88003.
CR ARNOLD FH, 1986, J CHROMATOGR, V355, P1, DOI 10.1016/S0021-9673(01)97299-1
   ARNOLD FH, 1985, CHEM ENG J BIOCH ENG, V30, pB9, DOI 10.1016/0300-9467(85)80016-2
   BENEDETTI MF, 1995, ENVIRON SCI TECHNOL, V29, P446, DOI 10.1021/es00002a022
   BUFFLE J, 1990, GEOCHIM COSMOCHIM AC, V54, P1535, DOI 10.1016/0016-7037(90)90389-3
   CERNIK M, 1995, ENVIRON SCI TECHNOL, V29, P413, DOI 10.1021/es00002a018
   CHAIKEN IM, 1986, J CHROMATOGR, V376, P11, DOI 10.1016/S0378-4347(00)80821-X
   CRIST RH, 1992, ENVIRON SCI TECHNOL, V26, P496, DOI 10.1021/es00027a007
   CRIST RH, 1981, ENVIRON SCI TECHNOL, V15, P1212, DOI 10.1021/es00092a010
   CRIST RH, 1992, ENVIRON SCI TECHNOL, V26, P1523, DOI 10.1021/es00032a004
   DARNALL DW, 1986, ENVIRON SCI TECHNOL, V20, P206, DOI 10.1021/es00144a018
   DARNALL DW, 1989, TRACE METAL REMOVAL, P1
   DRAKE LR, UNPUB APPL SPECTROSC
   DZOMBAK DA, 1986, ENVIRON SCI TECHNOL, V20, P669, DOI 10.1021/es00149a004
   FASSINA G, 1987, ADV CHROMATOGRAPHY, V27
   FERGUSON J, 1974, CHEM GEOL, V13, P163, DOI 10.1016/0009-2541(74)90018-7
   GALUN M, 1984, WATER AIR SOIL POLL, V21, P411, DOI 10.1007/BF00163640
   GARDEATORRESDEY JL, 1990, ENVIRON SCI TECHNOL, V24, P1372, DOI 10.1021/es00079a011
   GARNHAM GW, 1992, ENVIRON SCI TECHNOL, V26, P1764, DOI 10.1021/es00033a008
   GARNHAM GW, 1992, ENVIRON SCI TECHNOL, V26, P1784
   GOLSHANSHIRAZI S, 1988, ANAL CHEM, V60, P2630, DOI 10.1021/ac00174a019
   GREENE B, 1986, ENVIRON SCI TECHNOL, V20, P627, DOI 10.1021/es00148a014
   JAULMES A, 1988, ADV CHROMATOGRAPHY, V28
   KASAI K, 1986, J CHROMATOGR, V376, P33, DOI 10.1016/S0378-4347(00)80822-1
   KATTI AM, 1990, ADV CHROMATOGRAPHY, V31
   KE HY, 1992, APPL SPECTROSC, V47, P44
   KE HYD, 1992, APPL SPECTROSC, V46, P1168, DOI 10.1366/0003702924124178
   KE HYD, 1992, APPL SPECTROSC, V46, P1376, DOI 10.1366/0003702924123782
   KE HYD, 1992, ENVIRON SCI TECHNOL, V26, P782, DOI 10.1021/es00028a018
   KE HYD, 1992, APPL SPECTROSC, V46, P479, DOI 10.1366/0003702924125258
   KE HYD, 1994, ENVIRON SCI TECHNOL, V28, P586, DOI 10.1021/es00053a009
   KE HYD, 1992, ENVIRON SCI TECHNOL, V26, P1202, DOI 10.1021/es50002a609
   LOWE CR, 1974, AFFINITY CHROMATOGRA, pCH2
   MAHAN CA, 1989, ANAL CHEM, V61, P624, DOI 10.1021/ac00181a026
   MAJIDI V, 1990, ENVIRON SCI TECHNOL, V24, P1309, DOI 10.1021/es00079a002
   MONCRIEF RM, 1995, SEPAR SCI TECHNOL, V30, P2421, DOI 10.1080/01496399508013120
   NAKAJIMA A, 1993, J CHEM TECHNOL BIOT, V57, P321
   NAKAJIMA A, 1990, BIOMASS, V21, P55, DOI 10.1016/0144-4565(90)90047-N
   NEDERLOF MM, 1990, J COLLOID INTERF SCI, V135, P410, DOI 10.1016/0021-9797(90)90011-C
   NEDERLOF MM, 1992, ENVIRON SCI TECHNOL, V26, P763, DOI 10.1021/es00028a015
   SCHIEWER S, 1995, ENVIRON SCI TECHNOL, V29, P3049, DOI 10.1021/es00012a024
   SCOTT CD, 1992, BIOTECHNOL BIOENG, V39, P1064, DOI 10.1002/bit.260391011
   STARK PC, 1994, THESIS NEW MEXICO ST
   TREENSEARS ME, 1984, BIOTECHNOL BIOENG, V26, P1323, DOI 10.1002/bit.260261109
   TSEZOS M, 1983, BIOTECHNOL BIOENG, V25, P2025, DOI 10.1002/bit.260250812
   TSEZOS M, 1982, BIOTECHNOL BIOENG, V24, P385, DOI 10.1002/bit.260240211
   Volesky Bohumil, 1990, BIOSORPTION HEAVY ME
   WOOD JM, 1984, ENVIRON SCI TECHNOL, V18, P106
   YOZA N, 1973, ANAL LETT, V6, P595, DOI 10.1080/00032717308058709
NR 48
TC 16
Z9 16
U1 0
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0003-2700
J9 ANAL CHEM
JI Anal. Chem.
PD DEC 1
PY 1996
VL 68
IS 23
BP 4087
EP 4093
DI 10.1021/ac960569b
PG 7
WC Chemistry, Analytical
SC Chemistry
GA VV333
UT WOS:A1996VV33300009
PM 21619317
DA 2018-10-19
ER

PT J
AU Kanagaraja, S
   Lundstrom, I
   Nygren, H
   Tengvall, P
AF Kanagaraja, S
   Lundstrom, I
   Nygren, H
   Tengvall, P
TI Platelet binding and protein adsorption to titanium and gold after short
   time exposure to heparinized plasma and whole blood
SO BIOMATERIALS
LA English
DT Article
DE protein adsorption; protein mixture; platelet activation; microvesicle
   secretion
ID MOLECULAR-WEIGHT KININOGEN; ARTIFICIAL SURFACES; ADSORBED PROTEIN;
   FIBRINOGEN; ACTIVATION; ADHESION; BIOMATERIALS; ELLIPSOMETRY
AB Protein adsorption from human plasma and platelet binding and activation were studied at short blood-titanium/gold contact times. The protein adsorption was studied by ellipsometry-antibody techniques in situ, and adhering platelets were visualized with fluorescein isothiocyanate-labelled anti-CD 61 antibodies. Adhering platelets were quantified by counting labelled cells in microscopic image fields. The spreading of platelets was studied by scanning electron microscopy. The results show that after 1 min of plasma exposure, fibrinogen, IgG and albumin were detectable with antibodies on both surfaces. The amount of deposited fibrinogen and complement decreased with time on titanium, and the amount of adsorbed anti-high molecular weight kininogen increased. No complement was detected on gold surfaces after plasma incubation, and the antibody binding pattern also remained unchanged after prolonged plasma exposure. The surface-bound platelets were found to spread on the gold but not on titanium surfaces. C1q has been shown to induce the expression of P-selectin, i.e. cause secretion reactions in platelets. In this study secreted platelet-microvesicles were found on gold, but not on the titanium surfaces that bound significant amounts of C1q. Thus, the results of the present study indicate that the mixture of fibrinogen, C1q and kininogens, whilst causing adhesion and aggregation, does not result in the activation and microvesicle secretion of platelets. Platelet activation on biomaterial surfaces thus seems to be governed by the mixture of proteins present on that surface, and no one particular protein need cause a known reaction in platelets as obtained when platelets are exposed only to that particular protein. (C) 1996 Elsevier Science Limited.
C1 LINKOPING UNIV, APPL PHYS LAB, S-58183 LINKOPING, SWEDEN.
RP Kanagaraja, S (reprint author), GOTHENBURG UNIV, DEPT ANAT & CELL BIOL, MEDICINAREGATAN 3-5, S-41390 GOTHENBURG, SWEDEN.
CR ANDERSON JM, 1990, INT J ARTIF ORGANS, V13, P375
   ANDRADE JD, 1987, ANN NY ACAD SCI, V516, P158, DOI 10.1111/j.1749-6632.1987.tb33038.x
   BLACK J, 1992, BIOL PERFORMANCE MAT, P125
   COLMAN RW, 1987, ANN NY ACAD SCI, V516, P253, DOI 10.1111/j.1749-6632.1987.tb33046.x
   CUYPERS PA, 1987, ACS SYM SER, V343, P208
   DEFEIJTER JA, 1978, BIOPOLYMERS, V17, P1759, DOI 10.1002/bip.1978.360170711
   ELAM JH, 1993, BIOMATERIALS, V14, P233, DOI 10.1016/0142-9612(93)90029-2
   FEUERSTEIN IA, 1993, BIOMATERIALS, V14, P137, DOI 10.1016/0142-9612(93)90228-T
   GAEBEL K, 1991, BIOMATERIALS, V12, P597, DOI 10.1016/0142-9612(91)90058-I
   GOODMAN SL, 1993, J BIOMED MATER RES, V27, P683, DOI 10.1002/jbm.820270516
   GUSTAFSON EJ, 1989, J CELL BIOL, V109, P377, DOI 10.1083/jcb.109.1.377
   HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868
   HAWIGER J, 1983, ANN NY ACAD SCI, V408, P521, DOI 10.1111/j.1749-6632.1983.tb23270.x
   HORBETT TA, 1987, ACS SYM SER, V343, P1
   IVARSSON B, 1986, CRIT REV BIOCOMPAT, V2, P1
   KO TM, 1993, BIOMATERIALS, V14, P657
   KUNAPULI SP, 1993, PLATELETS, V4, P61, DOI 10.3109/09537109309013197
   LAW SKA, 1988, COMKPLEMENT
   MCCRAKIN FL, 1969, 479 NBS
   MCKENZIE R, 1975, THROMB RES, V6, P1, DOI 10.1016/0049-3848(75)90145-0
   NIEUWENHUIZEN W, 1983, ANN NY ACAD SCI, V408, P92, DOI 10.1111/j.1749-6632.1983.tb23236.x
   NYGREN H, 1988, ACTA PHYSIOL SCAND, V133, P573, DOI 10.1111/j.1748-1716.1988.tb08443.x
   PEERSCHKE EIB, 1994, J IMMUNOL, V152, P5896
   PEERSCHKE EIB, 1993, J EXP MED, V178, P579, DOI 10.1084/jem.178.2.579
   ROSENFELD SI, 1989, PLATELET IMMUNOBIOLO, P337
   SALZMAN EW, 1977, ANN NY ACAD SCI, V283, P114, DOI 10.1111/j.1749-6632.1977.tb41760.x
   SALZMAN EW, 1987, ANN NY ACAD SCI, V516, P184, DOI 10.1111/j.1749-6632.1987.tb33040.x
   SENIOR RM, 1986, J CLIN INVEST, V77, P1014, DOI 10.1172/JCI112353
   TANG LP, 1993, J EXP MED, V178, P2147, DOI 10.1084/jem.178.6.2147
   VROMAN L, 1980, BLOOD, V55, P156
NR 30
TC 68
Z9 70
U1 0
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD DEC
PY 1996
VL 17
IS 23
BP 2225
EP 2232
DI 10.1016/0142-9612(95)00311-8
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA VV856
UT WOS:A1996VV85600003
PM 8968516
DA 2018-10-19
ER

PT J
AU Yoshimine, Y
   Sumi, M
   Isobe, R
   Anan, H
   Maeda, K
AF Yoshimine, Y
   Sumi, M
   Isobe, R
   Anan, H
   Maeda, K
TI In vitro interaction between tetracalcium phosphate-based cement and
   calvarial osteogenic cells
SO BIOMATERIALS
LA English
DT Article
DE tetracalcium phosphate; osteogenic cells; dental cement; rat; electron
   microscopy
ID NODULES FORMED INVITRO; HYDROXYAPATITE INTERFACE; BONE; BIOMATERIALS;
   CULTURES
AB Newly-developed tetracalcium phosphate-based cement (4CP cement) and cells derived from neonatal rat calvaria were cocultured to study the in vitro reaction of osteoblastic cells to the biomaterial at light and electron microscopic levels. Three-dimensional nodular structures covered with active osteoblastic cells were formed in the periphery of the test material and they contained a mineralized tissue that exhibited features closely resembling bone formed in vivo. Ultrastructurally, the test material was circumscribed with an electron-dense structure, and was immediately adjacent to elongated cyoplasmic processes with intact morphology or collagen fibrils with periodic structures. Furthermore, the mineralization of the extracellular collagenous matrix occurred directly on the surface of the material. These in vitro findings suggest the ability of 4CP cement to bind directly with newly-formed hard tissues. (C) 1996 Elsevier Science Limited.
C1 NAGASAKI UNIV,SCH DENT,DEPT RADIOL,NAGASAKI 852,JAPAN.
RP Yoshimine, Y (reprint author), KYUSHU UNIV,FAC DENT,DEPT PERIODONTOL & ENDODONTOL,FUKUOKA 81282,JAPAN.
CR ALBREKTSSON T, 1986, BIOMATERIALS, V7, P201, DOI 10.1016/0142-9612(86)90103-1
   BELLOWS CG, 1986, CALCIFIED TISSUE INT, V38, P143, DOI 10.1007/BF02556874
   BHARGAVA U, 1988, BONE, V9, P155, DOI 10.1016/8756-3282(88)90005-1
   BROOK IM, 1992, BIOMATERIALS, V13, P721, DOI 10.1016/0142-9612(92)90134-A
   BROOK IM, 1991, BIOMATERIALS, V12, P179, DOI 10.1016/0142-9612(91)90197-I
   BROWN WE, 1983, J DENT RES, V62, P672
   DEBRUIJN JD, 1992, J BIOMED MATER RES, V26, P1365, DOI 10.1002/jbm.820261008
   DELANGE GL, 1990, J BIOMED MATER RES, V24, P829, DOI 10.1002/jbm.820240704
   GALANTE JO, 1991, J ORTHOPAED RES, V9, P760, DOI 10.1002/jor.1100090516
   GARVEY BT, 1995, J BIOMED MATER RES, V29, P987, DOI 10.1002/jbm.820290810
   Heller A L, 1975, J Endod, V1, P95, DOI 10.1016/S0099-2399(75)80025-2
   MANDAI Y, 1987, J JPN DENT MAT, V6, P403
   NAKAJIMA H, 1986, J DENT RES, V65, P778
   Olsson B, 1981, J Endod, V7, P355, DOI 10.1016/S0099-2399(81)80057-X
   ROBERTS SC, 1975, J ENDODONT, V1, P262
   SAUTIER JM, 1994, CALCIFIED TISSUE INT, V55, P458, DOI 10.1007/BF00298560
   SAUTIER JM, 1992, CALCIFIED TISSUE INT, V50, P527, DOI 10.1007/BF00582168
   SAUTIER JM, 1992, BIOMATERIALS, V13, P400, DOI 10.1016/0142-9612(92)90046-Q
   SERRE CM, 1993, BIOMATERIALS, V14, P97, DOI 10.1016/0142-9612(93)90217-P
   VANBLITTERSWIJK CA, 1985, BIOMATERIALS, V6, P243, DOI 10.1016/0142-9612(85)90020-1
   WATTS A, 1987, INT ENDOD J, V20, P169, DOI 10.1111/j.1365-2591.1987.tb00610.x
   YOSHIMINE Y, 1995, ORAL SURG ORAL MED O, V79, P351, DOI 10.1016/S1079-2104(05)80229-X
   YOSHIMINE Y, 1993, BIOMATERIALS, V14, P403, DOI 10.1016/0142-9612(93)90141-N
NR 23
TC 8
Z9 14
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD DEC
PY 1996
VL 17
IS 23
BP 2241
EP 2245
DI 10.1016/0142-9612(96)00045-2
PG 5
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA VV856
UT WOS:A1996VV85600005
PM 8968518
DA 2018-10-19
ER

PT J
AU Bellon, JM
   Contreras, LA
   Bujan, J
   Martin, ACS
AF Bellon, JM
   Contreras, LA
   Bujan, J
   Martin, ACS
TI Experimental assay of a Dual Mesh(R) polytetrafluoroethylene prosthesis
   (non-porous on one side) in the repair of abdominal wall defects
SO BIOMATERIALS
LA English
DT Article
DE polytetrafluoroethylene prosthesis; abdominal wall defects; macrophages;
   abdominal wall repair
ID EXPANDED POLYTETRAFLUOROETHYLENE; POLYPROPYLENE MESH; MACROPHAGE;
   MARLEX; PATCH; RAT
AB The porosity of the prosthetic biomaterials used to repair defects in the abdominal wall seems to influence the tissue repair process insofar as tissue integration of the prosthetic material and the formation of adhesions with abdominal viscera are concerned. We studied the behaviour of a new type of polytetrafluoroethylene prosthesis used for the repair of abdominal wall defects, Dual Mesh(R) (DM), which has two different faces; one face has a porosity between 30 and 60 mu m, while the other is nonporous. In 20 New Zealand White rabbits, a full-thickness (except skin) 7 cm x 5 cm defect was created in the anterior abdominal wall that was repaired with DM. At 14, 30, 60 and 90 days, samples were obtained and studied by light and scanning electron microscopy. An immunohistochemical study was made with antibody anti-rabbit macrophages (RAM-11). Tensile strength was measured with an Instron tensiometer using 2-cm-wide strips obtained parallel to the shorter axis of the implant. DM induced little tissue adhesion to the material on the visceral peritoneum interface and was surrounded by organized repair tissue. The biomaterial was integrated in the repair tissue on the subcutaneous interface, but not on the peritoneal interface. The macrophage response decreased between days 14 and 90 (P < 0.001). Tensile strength increased significantly (P < 0.05) at every study period. We conclude that the DM prosthesis has little tendency to formation of visceral adhesions, the DM prosthesis was well tolerated by the receptor organism and the tensile strength of the prosthesis/receptor tissue interface increased with time. (C) 1996 Elsevier Science Limited
RP Bellon, JM (reprint author), UNIV ALCALA DE HENARES, FAC MED, SURG RES LAB, DEPT MORPHOL SCI & SURG, ALCALA DE HENARES 28871, MADRID, SPAIN.
OI BELLON, JUAN M./0000-0002-6071-5011
CR AMID PK, 1994, J BIOMED MATER RES, V28, P373, DOI 10.1002/jbm.820280312
   BELLON J, 1995, EUR SURG RES S1, V27, P11
   BELLON JM, 1995, BIOMATERIALS, V16, P381, DOI 10.1016/0142-9612(95)98855-8
   BELLON JM, 1994, EUR SURG RES, V26, P46, DOI 10.1159/000129317
   BELLON JM, 1994, SOC ITALIANO FISIOPA, P85
   BELLON JM, 1994, BRIT J SURG, V81, P69
   BJURSTEN LM, 1991, 9 EUR C BIOM CHEST S
   BLEICHRODT RP, 1993, SURG GYNECOL OBSTET, V176, P18
   CONTRERAS L, 1995, BRIT J SURG, V82, P55
   CONTRERAS LA, 1996, EUR SURG RES S1, V28, P45
   DABROWIECKI S, 1991, EUR SURG RES, V23, P240, DOI 10.1159/000129159
   JENKINS SD, 1983, SURGERY, V94, P392
   Law NW, 1988, CLIN MATER, V3, P95
   LEIBOVICH SJ, 1975, AM J PATHOL, V78, P71
   MOLLOY RG, 1991, BRIT J SURG, V78, P242, DOI 10.1002/bjs.1800780237
   MURPHY JL, 1989, CAN J SURG, V32, P244
   PANS A, 1992, EUR SURG RES, V24, P54, DOI 10.1159/000129188
   SIMMERMACHER RKJ, 1991, BIOMATERIALS, V12, P22, DOI 10.1016/0142-9612(91)90126-U
   TYRELL J, 1989, SURG GYNECOL OBSTET, V168, P227
   VANDERLEI B, 1989, BRIT J SURG, V76, P803, DOI 10.1002/bjs.1800760813
   WALKER AP, 1993, J SURG RES, V55, P32, DOI 10.1006/jsre.1993.1104
NR 21
TC 26
Z9 27
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD DEC
PY 1996
VL 17
IS 24
BP 2367
EP 2372
DI 10.1016/S0142-9612(96)00080-4
PG 6
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA VY445
UT WOS:A1996VY44500009
PM 8982477
DA 2018-10-19
ER

PT J
AU Kapur, R
   Spargo, BJ
   Chen, MS
   Calvert, JM
   Rudolph, AS
AF Kapur, R
   Spargo, BJ
   Chen, MS
   Calvert, JM
   Rudolph, AS
TI Fabrication and selective surface modification of 3-dimensionally
   textured biomedical polymers from etched silicon substrates
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
ID MICROTEXTURED SILICONE; DEPOSITION; GROWTH; CELLS; LASER; FILMS
AB A new method is described for producing biomedically relevant polymers with precisely defined micron scale surface texture in the x, y, and z planes, Patterned Si templates were fabricated using photolithography to create a relief pattern in photoresist with lateral dimensions as small as 1 mu m. Electroless Ni was selectively deposited in the trenches of the patterned substrate, The Ni served as a resilient mask for transferring the patterns onto the Si substrate to depths of up to 8.5 mu m by anisotropic reactive ion etching with a fluorine-based plasma, The 3-dimensional (3-D) textured silicon substrates were used as robust, reusable molds for pattern transfer onto poly(dimethyl siloxane), low density poly(ethylene), poly(L-lactide), and poly(glycolide) by either casting or injection molding, The fidelity of the pattern transfer from the silicon substrates to the polymers was 90 to 95% in all three planes for ail polymers for more than 60 transfers from a single wafer, as determined by scanning electron microscopy and atomic force microscopy, Further, the 3-D textured polymers were selectively modified to coat proteins either in the trenches or on the mesas by capillary modification or selective coating techniques, These selectively patterned 3-D polymer substrates may be useful for a variety of biomaterial applications. (C) 1996 John Wiley & Sons, Inc.
C1 GEORGETOWN UNIV,DEPT BIOCHEM,WASHINGTON,DC.
   GEOCENTERS INC,FT WASHINGTON,MD 20744.
RP Kapur, R (reprint author), USN,RES LAB,CTR BIOMOL SCI & ENGN,CODE 6900,WASHINGTON,DC 20375, USA.
CR BANKS BA, 1982, Patent No. 4344996
   BRITLAND S, 1992, BIOTECHNOL PROGR, V8, P155, DOI 10.1021/bp00014a010
   BRUCK SD, 1980, PROPERTIES BIOMATERI
   BRUNETTE DM, 1983, J DENT RES, V62, P1045, DOI 10.1177/00220345830620100701
   CALVERT JM, 1994, J VAC SCI TECHNOL B, V12, P3884, DOI 10.1116/1.587568
   CHEHROUDI B, 1990, J BIOMED MATER RES, V24, P1203, DOI 10.1002/jbm.820240906
   Chehroudi B., 1990, J BIOMED MATER RES, V24, P1067
   CHESMEL KD, 1995, J BIOMED MATER RES, V29, P1089, DOI 10.1002/jbm.820290909
   CLARK P, 1987, DEVELOPMENT, V99, P439
   CURTIS ASG, 1990, CRIT REV BIOCOMPAT, V5, P344
   DENBRABER ET, 1995, J BIOMED MATER RES, V29, P511, DOI 10.1002/jbm.820290411
   DRESSICK WJ, 1994, J ELECTROCHEM SOC, V141, P210, DOI 10.1149/1.2054686
   GREEN AM, 1994, J BIOMED MATER RES, V28, P647, DOI 10.1002/jbm.820280515
   GRIGOROPOULOUS S, 1995, ELECTROCHEM SOC P, V95, P275
   Harrison RG, 1914, J EXP ZOOL, V17, P521, DOI 10.1002/jez.1400170403
   JELLINEK HHG, 1984, J PHYS CHEM-US, V88, P3048, DOI 10.1021/j150658a024
   Marchant Roger E., 1994, P13
   McCormick M., 1994, Engineering Science and Education Journal, V3, P255, DOI 10.1049/esej:19940604
   NAKAYAMA Y, 1995, J BIOMED MATER RES, V29, P1295, DOI 10.1002/jbm.820291017
   SCHMIDT JA, 1992, BIOMATERIALS, V13, P1059, DOI 10.1016/0142-9612(92)90138-E
   WEISS P, 1956, ANAT REC, V124, P381
   Wu S. Y., 1989, Potentialities of agricultural engineering in rural development. Proceedings of the international symposium on agricultural engineering (89-ISAE), Beijing, China, 12-15 September 1989., P411
NR 22
TC 40
Z9 40
U1 0
U2 8
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD WIN
PY 1996
VL 33
IS 4
BP 205
EP 216
DI 10.1002/(SICI)1097-4636(199624)33:4<205::AID-JBM1>3.0.CO;2-T
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA VW322
UT WOS:A1996VW32200001
PM 8953387
DA 2018-10-19
ER

PT J
AU Peluso, G
   Petillo, O
   Mazzarella, L
   LaCara, F
   Sada, A
   Melone, MAB
   Davies, PJA
   Gentile, V
AF Peluso, G
   Petillo, O
   Mazzarella, L
   LaCara, F
   Sada, A
   Melone, MAB
   Davies, PJA
   Gentile, V
TI Cell-biomaterial interactions: Role of transglutaminase enzyme
SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE
LA English
DT Article
ID TISSUE TRANSGLUTAMINASE; ENDOTHELIAL-CELLS; CROSS-LINKING; FIBRONECTIN;
   VITRONECTIN; FIBRINOGEN; MECHANISM; COMPLEXES; GROWTH; SHAPE
AB Cell interaction(s) with biomaterial undergo a multistep-step paradigm of adhesion, contact, attachment, and spreading. However, the molecular mechanism(s) underlying the cell anchorage on a material surface is not yet well understood. Transglutaminases, a family of calcium-dependent enzymes, has been implicated in the interactions between cells and extracellular matrix. To investigate the functions of this enzyme in cell-material interactions, Balb-C 3T3 fibroblasts were cultured, stably expressing high levels of tissue transglutaminase (TGase), on dishes precoated with thin layers of the hydrophilic hydrogel poly (2-hydroxyethyl methacrylate) (polyHEMA). Results suggest that in the presence of a relatively high poly (HEMA) dilution, the transfected cells showed a more complex morphologic pattern, characterized by many spread and flattened cells, in comparison with a control culture. These studies support the hypothesis that the overexpression of tissue transglutaminase may contribute both to changes in cellular morphology and adhesiveness.
C1 UNIV NAPLES 2,DIV NEUROL,NAPLES,ITALY.
   UNIV TEXAS,HLTH SCI CTR,SCH MED,DEPT PHARMACOL,HOUSTON,TX.
   UNIV NAPLES 2,SCH MED,DEPT BIOCHEM & BIOPHYS,NAPLES,ITALY.
RP Peluso, G (reprint author), INST PROT BIOCHEM & ENZYMOL,VIA TOIANO 6,I-80072 ARCO,NAPLES,ITALY.
RI Gentile, Vittorio/A-3045-2008; Melone, Mariarosa/N-6788-2015;
   TERRACCIANO, CHIARA/C-2955-2018
OI Gentile, Vittorio/0000-0001-7792-8294; Melone,
   Mariarosa/0000-0002-7213-9277; TERRACCIANO, CHIARA/0000-0002-1853-5578
CR ACHYUTHAN KE, 1988, J BIOL CHEM, V263, P14296
   AESCHLIMANN D, 1991, J BIOL CHEM, V266, P15308
   BARSIGIAN C, 1991, J BIOL CHEM, V266, P22501
   CAI D, 1991, BIOCHEM BIOPH RES CO, V175, P1119, DOI 10.1016/0006-291X(91)91681-2
   CULLEN BR, 1987, METHOD ENZYMOL, V152, P684
   FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505
   FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0
   GREENBERG CS, 1991, FASEB J, V5, P3071
   GRINNEL F, 1990, CELL, V19, P517
   HOWLETT CR, 1994, BIOMATERIALS, V15, P213, DOI 10.1016/0142-9612(94)90070-1
   INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579
   KLEBE RJ, 1981, J CELL PHYSIOL, V109, P481, DOI 10.1002/jcp.1041090314
   KNOX P, 1980, J CELL SCI, V46, P97
   LINDON MJ, 1985, BIOMATERIALS, V6, P396
   MARTINEZ J, 1989, J IBOL CHEM, V264, P2052
   MOSY EK, 1992, J BIOL CHEM, V267, P7880
   NARA K, 1989, J BIOL CHEM, V264, P19308
   SANE DC, 1988, BIOCHEM BIOPH RES CO, V157, P115, DOI 10.1016/S0006-291X(88)80020-2
   SANE DC, 1991, BIOCHEM BIOPH RES CO, V174, P465, DOI 10.1016/0006-291X(91)91439-J
   SEVASTIANOV VI, 1988, CRIT REV BIOCOMPAT, V4, P109
   SHEPPARD JI, 1994, J BIOMED MATER RES, V28, P1175, DOI 10.1002/jbm.820281008
   ZIATS NP, 1988, BIOMATERIALS, V9, P5, DOI 10.1016/0142-9612(88)90063-4
NR 22
TC 2
Z9 2
U1 0
U2 3
PU CHAPMAN HALL LTD
PI LONDON
PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8HN
SN 0957-4530
J9 J MATER SCI-MATER M
JI J. Mater. Sci.-Mater. Med.
PD DEC
PY 1996
VL 7
IS 12
BP 707
EP 711
DI 10.1007/BF00121405
PG 5
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA VX921
UT WOS:A1996VX92100001
DA 2018-10-19
ER

PT J
AU Delforge, D
   Art, M
   Gillon, B
   Dieu, M
   Delaive, E
   Raes, M
   Remacle, J
AF Delforge, D
   Art, M
   Gillon, B
   Dieu, M
   Delaive, E
   Raes, M
   Remacle, J
TI Automated solid-phase synthesis of cyclic peptides bearing a side-chain
   tail designed for subsequent chemical grafting
SO ANALYTICAL BIOCHEMISTRY
LA English
DT Article
ID COUPLING REAGENTS; IIB-IIIA; POTENT; RGD; CONFORMATION; CYCLIZATION;
   CONJUGATION; INTEGRIN; PROTEINS; LIGANDS
AB Recent developments in allyl chemistry and palladium solubilization allow automated continuous-flow solid-phase synthesis of cyclic or branched peptides, with specific side-chain cleavage and on-line cyclization. In this paper, we adapted the method to the synthesis of cyclic peptides bearing an anchoring tail on a side chain of the cycle, Side products were obtained with the standard procedure and an additional washing step had to be introduced in the synthesis protocol to remove side products resulting from the palladium allyl cleavage step. The method is illustrated by the automated synthesis of cyclo[-DVal-Arg-Gly-Asp-Glu (-epsilon Ahx-Cys-NH2)-] which contains the Arg-Gly-Asp adhesion motif (RGD) recognized by cellular integrins. The tail of the peptide was designed with a thiol at the carboxylic end to allow subsequent grafting by covalent attachment. Such tailed cyclic peptides can be grafted on different supports for new applications in biomaterial design, cell adhesion assays, affinity chromatography, immunization, vaccine development, ELISA kits, and the building of libraries of conformationally constrained peptides. (C) 1996 Academic Press, Inc.
RP Delforge, D (reprint author), FAC UNIV NOTRE DAME PAIX,LAB CELLULAR BIOCHEM,61 RUE BRUXELLES,B-5000 NAMUR,BELGIUM.
CR ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345
   ALBERICIO F, 1990, J ORG CHEM, V55, P3730, DOI 10.1021/jo00299a011
   Atherton E, 1989, SOLID PHASE PEPTIDE
   BRADY SF, 1983, PEPTIDES STRUCTURE F, P127
   CARLSSON J, 1978, BIOCHEM J, V173, P723, DOI 10.1042/bj1730723
   CARPINO LA, 1994, J CHEM SOC CHEM COMM, P201, DOI 10.1039/c39940000201
   CARPINO LA, 1993, J AM CHEM SOC, V115, P4397, DOI 10.1021/ja00063a082
   CASTRO B, 1975, TETRAHEDRON LETT, P1219
   CAVELIER F, 1989, B SOC CHIM FR, P788
   Delforge D, 1996, LETT PEPT SCI, V3, P89, DOI 10.1007/BF00126738
   GILON C, 1991, BIOPOLYMERS, V31, P745, DOI 10.1002/bip.360310619
   GURRATH M, 1992, EUR J BIOCHEM, V210, P911, DOI 10.1111/j.1432-1033.1992.tb17495.x
   He John X., 1994, Letters in Peptide Science, V1, P25, DOI 10.1007/BF00132759
   HEATH TG, 1993, J CHROMATOGR, V638, P9, DOI 10.1016/0021-9673(93)85002-O
   HOFFMANN E, 1991, LIEBIGS ANN CHEM, P585
   HRUBY VJ, 1990, BIOCHEM J, V268, P249, DOI 10.1042/bj2680249
   HYDE C, 1994, INT J PEPT PROT RES, V43, P431
   IZUMIYA N, 1981, BIOPOLYMERS, V20, P175
   JACKSON S, 1994, J AM CHEM SOC, V116, P3220, DOI 10.1021/ja00087a007
   KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6
   KATES SA, 1993, ANAL BIOCHEM, V212, P303, DOI 10.1006/abio.1993.1334
   KESSLER H, 1982, ANGEW CHEM INT EDIT, V21, P512, DOI 10.1002/anie.198205121
   KESSLER H, 1989, COMPUTER AIDED DRUG, P461
   KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3
   KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205
   Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8
   PALLIN TD, 1995, J CHEM SOC CHEM COMM, P2021, DOI 10.1039/c39950002021
   Raes M., 1994, V6, P67
   RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619
   RUOSLAHTI E, 1994, KIDNEY INT, V45, P17
   SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P7369, DOI 10.1021/bi00244a003
   SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066
   Sonnenberg A, 1993, Curr Top Microbiol Immunol, V184, P7
   TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409
   TONIOLO C, 1990, INT J PEPT PROT RES, V35, P287, DOI 10.1111/j.1399-3011.1990.tb00052.x
   Wang Rong, 1994, Current Opinion in Biotechnology, V5, P77, DOI 10.1016/S0958-1669(05)80074-6
   YOSHITAKE S, 1979, EUR J BIOCHEM, V101, P395, DOI 10.1111/j.1432-1033.1979.tb19731.x
NR 37
TC 16
Z9 17
U1 0
U2 10
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0003-2697
J9 ANAL BIOCHEM
JI Anal. Biochem.
PD NOV 15
PY 1996
VL 242
IS 2
BP 180
EP 186
DI 10.1006/abio.1996.0451
PG 7
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA VV318
UT WOS:A1996VV31800003
PM 8937560
DA 2018-10-19
ER

PT J
AU Cristoforoni, PM
   Kim, YB
   Preys, Z
   Lay, RY
   Montz, FJ
AF Cristoforoni, PM
   Kim, YB
   Preys, Z
   Lay, RY
   Montz, FJ
TI Adhesion formation after incisional hernia repair: A randomized porcine
   trial
SO AMERICAN SURGEON
LA English
DT Article
ID MESH
AB Adhesion formation involving intraperitoneal contents is a significant complication of incisional hernia repair. We evaluated the rate of peritoneal adhesion formation following closure of experimentally induced large ventral fascial defects using selected synthetic prosthetic materials in a well standardized porcine model. Sixty 25 kg hogs had a 4 x 6 cm ventral fascial defect induced and were randomized to repair with either interrupted O-Prolene(R) suture, Marlex(R) surgical mesh (Mx), GoreTex Dual Mesh(R) (Gore-DM), or an experimental version of the latter having multiple 0.4 mm fenestrations (Gore-DMH). Mr mesh induced significantly more adhesions than did Gore-DM when the two materials were placed in a comparable manner (P < 0.001). Those animals whose defects were closed primarily with Prolene(R) suture alone developed significantly fewer adhesions than either Mr or Gore-DM (with or without holes) when these materials were sutured in an overlaying (i.e., extraperitoneal) manner (Mx, P < 0.0001; Gore-DM, P < 0.05; Gore-DMH, P < 0.01). The intraperitoneal placement of the Gore-DM materials (i.e., underlay manner) resulted in a rate of adhesion formation that was not statistically different from that induced by closure with Prolene(R) alone (P = 0.08 for Gore-DM and P = 0.07 for Gore-DMH). Our findings support the use of Gore-DM biomaterial as the preferred material in the repair of large abdominal fascial defects when the use of a synthetic prosthetic material is necessitated by the defect size.
C1 UNIV CALIF LOS ANGELES,SCH MED,GYNECOL ONCOL SERV,LOS ANGELES,CA 90095.
CR BAUER JJ, 1987, ANN SURG, V206, P765, DOI 10.1097/00000658-198712000-00013
   BOYERS SP, 1988, FERTIL STERIL, V49, P1066
   GEORGE CD, 1986, ANN ROY COLL SURG, V68, P185
   GRACE RH, 1976, AM J SURG, V131, P210, DOI 10.1016/0002-9610(76)90099-4
   HOUCK JP, 1989, SURG GYNECOL OBSTET, V169, P397
   LANGER S, 1985, ACTA CHIR SCAND, V151, P217
   LARSON GM, 1978, AM J SURG, V135, P559, DOI 10.1016/0002-9610(78)90037-5
   LAW NW, 1994, PROSTHESES ABDONMINA, P290
   March C, 1993, GYNECOLOGIC SURG ADH, P253
   MONTZ FJ, 1993, GYNECOL ONCOL, V48, P247, DOI 10.1006/gyno.1993.1042
   MUDGE M, 1985, BRIT J SURG, V72, P70, DOI 10.1002/bjs.1800720127
   SANTORA TA, 1993, SURG CLIN N AM, V73, P557
   TYRELL J, 1989, SURG GYNECOL OBSTET, V168, P227
   *US DEP HHS, 1985, GUID CAR US LAB AN
NR 14
TC 15
Z9 15
U1 0
U2 1
PU SOUTHEASTERN SURGICAL CONGRESS
PI ATLANTA
PA 1776 PEACHTREE RD, NW., SUITE 410N, ATLANTA, GA 30309-2352
SN 0003-1348
J9 AM SURGEON
JI Am. Surg.
PD NOV
PY 1996
VL 62
IS 11
BP 935
EP 938
PG 4
WC Surgery
SC Surgery
GA VP511
UT WOS:A1996VP51100012
PM 8895716
DA 2018-10-19
ER

PT J
AU Loke, WK
   Khor, E
   Wee, A
   Teoh, SH
   Chian, KS
AF Loke, WK
   Khor, E
   Wee, A
   Teoh, SH
   Chian, KS
TI Hybrid biomaterials based on the interaction of polyurethane oligomers
   with porcine pericardium
SO BIOMATERIALS
LA English
DT Article
DE polyurethane oligomers; cross-linking; bioprostheses; hybrid
   biomaterial; porcine pericardium fixation
ID CROSS-LINKING; TISSUE; GLUTARALDEHYDE; CALCIFICATION; PREVENTION;
   IMPLANTS; COLLAGEN; DESIGN
AB Hybrid biomaterials have been produced by the interaction of polyurethane oligomers with both fresh and glutaraldehyde-fixed porcine pericardium. The hybrid biomaterials so formed were translucent with occasional white streaks and/or spots, had increased stiffness (to touch) but remained pliable. No shrinkage temperature was detected for fresh porcine pericardium hybrid up to 100 degrees C compared to porcine pericardium (similar to 67 degrees C) and glutaraldehyde-fixed porcine pericardium (similar to 87 degrees C). Amino acid analysis of the fresh porcine pericardium hybrid showed a reduction in lysine content after active isocyanate-terminated polyurethane oligomers exposure, indicating cross-linking between the polymer and tissue. Histological examination of the hybrid material shows a thin grey coating on both surfaces of the tissue, implying at least surface cross-linking oi the tissue with polyurethane. The results suggest that fresh porcine pericardium can he reacted with active isocyanate-terminated polyurethane oligomers to produce hybrid biomaterials with covalent bonding. (C) 1996 Elsevier Science Limited
C1 NATL UNIV SINGAPORE, DEPT CHEM, SINGAPORE 117548, SINGAPORE.
   NATL UNIV SINGAPORE, DEPT PATHOL, SINGAPORE 117548, SINGAPORE.
   NATL UNIV SINGAPORE, DEPT MECH & PROD ENGN, SINGAPORE 117548, SINGAPORE.
   NANYANG TECHNOL UNIV, SCH APPL SCI, DIV MAT ENGN, SINGAPORE 2236, SINGAPORE.
RI Chian, Kerm Sin/B-4771-2008
CR ASTLEY JP, 1976, J PHARM SCI, V65, P210, DOI 10.1002/jps.2600650210
   CHEUNG DT, 1982, CONNECT TISSUE RES, V10, P201, DOI 10.3109/03008208209034419
   CORTESE TA, 1971, DIMETHYL SULFOXIDE, V1, P337
   DAGALAKIS N, 1980, J BIOMED MATER RES, V14, P511, DOI 10.1002/jbm.820140417
   FELDMANN RJ, 1966, ARCH DERMATOL, V94, P649, DOI 10.1001/archderm.94.5.649
   FERRANS VJ, 1991, EUR J CARDIO-THORAC, V5, P144, DOI 10.1016/1010-7940(91)90213-4
   FERRANS VJ, 1991, REPLACEMENT CARDIAC, P49
   GRIES G, 1971, EFFECTS DMSO CONNECT, V1, P325
   Imamura E., 1992, U.S. Patent, Patent No. [5,080,670, 5080670]
   Jamieson W. R. E., 1991, REPLACEMENT CARDIAC, P229
   JORGEHERRERO E, 1991, BIOMATERIALS, V12, P249, DOI 10.1016/0142-9612(91)90208-R
   LEVY RJ, 1990, J CONTROL RELEASE, V11, P245, DOI 10.1016/0168-3659(90)90137-I
   LOKE WK, 1995, BIOMATERIALS, V16, P251, DOI 10.1016/0142-9612(95)92125-P
   LOKE WK, 1995, THESIS NATL U SINAGP
   MOORE MA, 1994, J BIOMED MATER RES, V28, P611, DOI 10.1002/jbm.820280511
   NAIMARK WA, 1995, J MATER SCI-MATER M, V6, P235, DOI 10.1007/BF00146862
   PATHAK YV, 1990, BIOMATERIALS, V11, P718, DOI 10.1016/0142-9612(90)90034-N
   PETITE H, 1990, J BIOMED MATER RES, V24, P179, DOI 10.1002/jbm.820240205
   ROSENTHAL GA, CHEM BIOCHEMISTRY AM, pCH20
   SCHOEN FJ, 1988, J BIOMED MATER RES-A, V22, P11
NR 20
TC 8
Z9 8
U1 2
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD NOV
PY 1996
VL 17
IS 22
BP 2163
EP 2172
DI 10.1016/0142-9612(96)00053-1
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA VQ135
UT WOS:A1996VQ13500007
PM 8922602
DA 2018-10-19
ER

PT J
AU Benahmed, M
   Bouler, JM
   Heymann, D
   Gan, O
   Daculsi, G
AF Benahmed, M
   Bouler, JM
   Heymann, D
   Gan, O
   Daculsi, G
TI Biodegradation of synthetic biphasic calcium phosphate by human
   monocytes in vitro: A morphological study
SO BIOMATERIALS
LA English
DT Article
DE monocytes; calcium phosphates; hydroxyapatite; vitamin D-3; interferons
ID COLONY-STIMULATING FACTOR; OSTEOCLAST FORMATION; INTERFERON-GAMMA;
   BONE-RESORPTION; CELLS; DIFFERENTIATION; MACROPHAGES; EXPRESSION;
   CERAMICS; CULTURES
AB Biodegradation processes (both intra- and extracellular) occur immediately after implantation of calcium phosphate (CaP) ceramics. Monocytes and macrophages, among the first cells to appear in wound healing, are largely implicated in phagocytosis and may be involved in CaP degradation because of their sensitivity to secreted cytokines. We tested the behaviour of human monocytes placed on the surface of hydroxyapatite (HA) and biphasic calcium phosphate (BCP) tablets in the presence of vitamin D-3 (VD3) and interferon gamma (INF gamma). After short-term culture (6 days), morphological events were observed in histological and scanning electron microscopy studies, and degradation lacunae were characterized. There were cell prints but no pits on the HA surface, but pits appeared near cells on the BCP surface. Preincubation of biomaterial in culture medium was essential. Variations in cell morphology were observed in different culture types. In the presence of VD3, degradation was greater than in the control, and cells were more polarized and rounded. With INF gamma, cells were extensively spread out on the sample surface, and the biomaterial seemed to be extracted from the surface by cells. Thus, monocytes are clearly influenced by soluble factors (vitamins, cytokines) and could be key cells in initiating the degradation of biomaterial. (C) 1996 Elsevier Science Limited
RP Benahmed, M (reprint author), FAC CHIRURG DENTAIRE,CTR RECH INTERDISCIPLINAIRE TISSUS CALCIFIES & BI,PL A RICORDEAU,F-44042 NANTES,FRANCE.
RI Daculsi, Guy/P-1320-2014
OI Daculsi, Guy/0000-0003-1030-3446; BOULER,
   Jean-Michel/0000-0001-9784-5584
CR BARON R, 1989, ANAT RECORD, V224, P317, DOI 10.1002/ar.1092240220
   BASLE MF, 1993, J MATER SCI-MATER M, V4, P273, DOI 10.1007/BF00122280
   BENAHMED M, 1994, BIOMATERIALS, V15, P25, DOI 10.1016/0142-9612(94)90191-0
   BLIFELD C, 1991, TRANSPLANTATION, V51, P498, DOI 10.1097/00007890-199102000-00043
   BLOTTIERE HM, 1995, BIOMATERIALS, V16, P497, DOI 10.1016/0142-9612(95)98824-X
   BOYDE A, 1991, CALCIFIED TISSUE INT, V49, P65, DOI 10.1007/BF02565123
   BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77
   CHAMBERS TJ, 1985, J CLIN PATHOL, V38, P241, DOI 10.1136/jcp.38.3.241
   Daculsi G., 1992, BIOMATER TISSUE INT, V10, P296
   DALCUSI G, 1992, BIOMATER TISSUE INT, V10, P299
   HAYES ME, 1991, J STEROID BIOCHEM, V38, P301, DOI 10.1016/0960-0760(91)90101-A
   KEY LL, 1962, INT J TISS RES, V6, P295
   KODAMA H, 1991, J EXP MED, V173, P1291, DOI 10.1084/jem.173.5.1291
   KREUTZ M, 1993, BLOOD, V82, P1300
   Legeros Racquel Z., 1993, Clinical Materials, V14, P65, DOI 10.1016/0267-6605(93)90049-D
   MARCKS SC, 1988, AM J ANAT, V183, P1
   MURRILLS RJ, 1993, J CELL PHYSIOL, V154, P511, DOI 10.1002/jcp.1041540309
   NAJAR HM, 1990, J LEUKOCYTE BIOL, V47, P429
   ORCEL P, 1990, ANAT REC, V226, P1, DOI 10.1002/ar.1092260102
   PASSUTI N, 1989, CLIN ORTHOP RELAT R, V248, P169
   RODRIGUIZ RM, 1993, PEDIATR RES, V33, P384
   ROODMAN GD, 1993, CALCIFIED TISSUE INT, V53, P594
   SATO T, 1993, ENDOCRINOLOGY, V133, P397, DOI 10.1210/en.133.1.397
   SCHLAG N, INFLAMMATION REPAIR, V2, pCH29
   SHIBUTANI T, 1993, J BONE MINER RES, V8, P331
NR 25
TC 35
Z9 36
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD NOV
PY 1996
VL 17
IS 22
BP 2173
EP 2178
DI 10.1016/0142-9612(96)00046-4
PG 6
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA VQ135
UT WOS:A1996VQ13500008
PM 8922603
DA 2018-10-19
ER

PT J
AU ScottBurden, T
   Tock, CL
   Schwarz, JJ
   Casscells, SW
   Engler, DA
AF ScottBurden, T
   Tock, CL
   Schwarz, JJ
   Casscells, SW
   Engler, DA
TI Genetically engineered smooth muscle cells as linings to improve the
   biocompatibility of cardiovascular prostheses
SO CIRCULATION
LA English
DT Article
DE heart-assist device; muscle, smooth; genes
ID VENTRICULAR ASSIST DEVICE; NITRIC-OXIDE; ENDOTHELIAL-CELLS
AB Background The seeding of the blood-contacting surfaces of cardiovascular prostheses with autologous endothelial cells to improve their biocompatibility has had little success. In most instances, cells have sloughed off under flow conditions. The performance of left ventricular assist devices (LVADs) designed to stabilize patients awaiting donor hearts for transplantation has been remarkably good. After prolonged implantation, pump surfaces become covered with a pannus of smooth muscle-like cells (myofibroblasts). Occasional islands of endothelial cells have been identified on top of such cell layers. Therefore, in an attempt to accelerate the beneficial conditioning and improve biomaterial-blood compatibility of LVAD internal surfaces, their seeding with autologous, genetically engineered smooth muscle cells (SMCs) was investigated.
   Methods and Results Since routine testing of the Thermo-cardiosystems HeartMate LVAD is carried out in calves, SMCs were isolated from calves, propagated in culture, and transduced with NO synthase genes to yield stable production of NO. Previous studies had demonstrated that SMCs attached strongly to the biomaterials that compose the internal surfaces of LVADs. Transduction of NO synthase gene expression in the SMCs was achieved by electroporation and antibiotic (G418) selection. Inhibition of smooth muscle cell proliferation by NO has been documented, and the same molecule has been shown to inhibit platelet adhesion to cell surfaces. Cells transduced with NO synthase expressed enzyme protein at consistently high levels for several passages in culture; however, NO production was dependent on the supplementation of culture medium with a source of tetrahydrobiopterin (sepiapterin). Under such conditions, transduced cells were growth-inhibited compared with mock-transfected controls. Induction of GTP cyclohydrolase (the rate-limiting enzyme for the production of tetrahydrobiopterin) expression also resulted in NO production by NO synthase-transduced cells.
   Conclusions Preliminary studies have shown that SMCs form strong attachments to the surface materials of LVADs and that their proliferation rates could be controlled after transformation with NO synthase under conditions that support production of NO. Therefore, genetically engineered SMCs may provide an improved blood-biomaterial interface for cardiovascular prostheses.
RP ScottBurden, T (reprint author), TEXAS MED CTR,TEXAS HEART INST,VASC CELL BIOL LAB,POB 20345,HOUSTON,TX 77225, USA.
FU NHLBI NIH HHS [HL-53233]
CR FRAZIER OH, 1993, TEX HEART I J, V20, P78
   FRAZIER OH, 1995, ANN SURG, V222, P327, DOI 10.1097/00000658-199509000-00010
   FRAZIER OH, 1992, ANN THORAC SURG, V53, P1080, DOI 10.1016/0003-4975(92)90393-I
   SCOTTBURDEN T, 1995, CIRCULATION, V91, P248, DOI 10.1161/01.CIR.91.1.248
   SCOTTBURDEN T, 1994, MOL PHARMACOL, V46, P274
   SCOTTBURDEN T, 1992, CIRC RES, V71, P1088, DOI 10.1161/01.RES.71.5.1088
   SCOTTBURDEN T, 1989, HYPERTENSION, V13, P295, DOI 10.1161/01.HYP.13.4.295
   SCOTTBURDEN T, IN PRESS ANN THORAC
   SINZINGER H, 1992, BRIT J CLIN PHARMACO, V33, P289, DOI 10.1111/j.1365-2125.1992.tb04037.x
   VONDERLEYEN HE, 1995, P NATL ACAD SCI USA, V92, P1137, DOI 10.1073/pnas.92.4.1137
   XU XM, 1993, J CLIN INVEST, V91, P1843, DOI 10.1172/JCI116398
   YAO SK, 1992, CIRCULATION, V86, P1302, DOI 10.1161/01.CIR.86.4.1302
   YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0
NR 13
TC 12
Z9 12
U1 0
U2 0
PU AMER HEART ASSOC
PI DALLAS
PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 1
PY 1996
VL 94
IS 9
SU S
BP 235
EP 238
PG 4
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA VP690
UT WOS:A1996VP69000043
PM 8901752
DA 2018-10-19
ER

PT J
AU Karlsson, C
   Nygren, H
   Braide, M
AF Karlsson, C
   Nygren, H
   Braide, M
TI Exposure of blood to biomaterial surfaces liberates substances that
   activate polymorphonuclear granulocytes
SO JOURNAL OF LABORATORY AND CLINICAL MEDICINE
LA English
DT Article
ID TUMOR-NECROSIS-FACTOR; HUMAN-NEUTROPHILS; PLATELET ACTIVATION;
   WHOLE-BLOOD; P-SELECTIN; CARDIOPULMONARY BYPASS; HEPARIN INHIBITION;
   INDUCED LUNG; CALCIUM; RELEASE
AB Human whole blood, anticoagulated or not, was exposed to hydrophilic glass surfaces or methylated hydrophobic glass surfaces under saline cover. Platelet-poor plasma or serum was prepared after 10 minutes of exposure, measured in respect to complement activation, and transferred to a suspension of granulocytes, which acted as bioprobes. The granulocytes were prepared from blood, anticoagulated with ethylenediaminetetraacetic acid, and evaluated regarding intracellular Ca2+ concentration (Calcium Green-1 fluorescence), integrin expression (CD-11b immunohistochemistry), respiratory burst (chemiluminescence), and priming (increase in N-formyl-methionyl-leucyl-phenylalanine-induced respiratory burst). The results indicate that humoral factors formed during the surface exposure of blood were able to activate the probe granulocytes. The exposure to hydrophilic surfaces led to a calcium transient three times the magnitude of that of hydrophobic surfaces. This response could be blocked by the presence of heparin during the blood-surface exposure but was not affected by the addition of heparin to the probe granulocytes. Hirudin, a specific thrombin blocker, had no effect. The exposure to hydrophobic surfaces led to complement activation in serum that induced priming and respiratory burst of the probe granulocytes. In conclusion, the study provides evidence that hydrophilic-hydrophobic surface treatment significantly affects the immediate inflammatory response of a blood-biomaterial interaction that is moderated by the presence of heparin.
C1 GOTHENBURG UNIV, DEPT ANAT & CELL BIOL, S-41390 GOTHENBURG, SWEDEN.
CR AGACE W, 1993, INFECT IMMUN, V61, P602
   BENGTSSON T, 1986, EUR J CELL BIOL, V42, P338
   BERGER M, 1985, J IMMUNOL, V135, P1342
   BERNARD GR, 1984, J CLIN INVEST, V73, P1772, DOI 10.1172/JCI111386
   BETZ M, 1988, KIDNEY INT, V34, P67, DOI 10.1038/ki.1988.146
   BRAIDE M, 1986, J IMMUNOL METHODS, V93, P183, DOI 10.1016/0022-1759(86)90187-0
   CHEUNG AK, 1990, J AM SOC NEPHROL, V1, P150
   CHONG BH, 1994, BLOOD, V83, P1535
   DORE M, 1990, INFLAMMATION, V14, P71, DOI 10.1007/BF00914031
   DRI P, 1991, INT J TISSUE REACT, V13, P193
   ELAM JH, 1992, BIOMATERIALS, V13, P3, DOI 10.1016/0142-9612(92)90086-4
   GEE MH, 1993, ANNU REV PHYSIOL, V55, P227, DOI 10.1146/annurev.ph.55.030193.001303
   GEMMELL CH, 1995, J LAB CLIN MED, V125, P276
   ISHIHARA Y, 1990, J LEUKOCYTE BIOL, V48, P89
   JACONI MEE, 1990, J CELL BIOL, V110, P1555, DOI 10.1083/jcb.110.5.1555
   JONSSON U, 1985, THIN SOLID FILMS, V124, P117, DOI 10.1016/0040-6090(85)90253-6
   JORDAN RE, 1987, SCIENCE, V237, P777, DOI 10.1126/science.3649921
   KASAHARA K, 1994, J INFECT DIS, V170, P1238, DOI 10.1093/infdis/170.5.1238
   KESTIN AS, 1993, BLOOD, V82, P107
   KJELLSTRAND P, 1991, INT J ARTIF ORGANS, V14, P698
   KUWAHARA T, 1988, NEPHROL DIAL TRANSPL, V3, P661, DOI 10.1093/oxfordjournals.ndt.a091724
   LABROUCHE S, 1992, THROMB HAEMOSTASIS, V68, P556
   LEW PD, 1990, AM REV RESPIR DIS, V141, pS127, DOI 10.1164/ajrccm/141.3_Pt_2.S127
   MORISAKI T, 1991, CLIN IMMUNOL IMMUNOP, V61, P365, DOI 10.1016/S0090-1229(05)80008-X
   MULLIGAN MS, 1992, J IMMUNOL, V149, P331
   MULLIGAN MS, 1993, J IMMUNOL, V150, P2401
   NAGATA K, 1993, J IMMUNOL, V151, P3267
   NELSON RM, 1993, BLOOD, V82, P3253
   NYGREN H, 1995, J VAC SCI TECHNOL A, V13, P2613, DOI 10.1116/1.579459
   POENIE M, 1986, SCIENCE, V233, P886, DOI 10.1126/science.3755550
   REDMOND JM, 1993, ANN THORAC SURG, V56, P474, DOI 10.1016/0003-4975(93)90882-I
   RENESTO P, 1991, ANN NY ACAD SCI, V624, P321
   RINDER CS, 1992, BLOOD, V79, P1201
   Siegel S, 1988, NONPARAMETRIC STAT B
   SUEMATSU M, 1989, J BIOCHEM-TOKYO, V106, P355, DOI 10.1093/oxfordjournals.jbchem.a122857
   TERADA LS, 1992, AM J PHYSIOL, V263, pL394
   TUFANO MA, 1994, RES MICROBIOL, V145, P297, DOI 10.1016/0923-2508(94)90185-6
   WALKER BAM, 1991, J IMMUNOL, V146, P3124
   WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158
   WEBER MH, 1994, CLIN NEPHROL, V41, P245
   WEST BC, 1985, P SOC EXP BIOL MED, V178, P373
   WINDSOR ACJ, 1993, BRIT J SURG, V80, P10, DOI 10.1002/bjs.1800800106
   YOU A, 1993, BIOCHIM BIOPHYS ACTA, V1156, P197
   YUO A, 1991, BLOOD, V78, P2708
NR 44
TC 11
Z9 11
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-2143
J9 J LAB CLIN MED
JI J. Lab. Clin. Med.
PD NOV
PY 1996
VL 128
IS 5
BP 496
EP 505
DI 10.1016/S0022-2143(96)90047-5
PG 10
WC Medical Laboratory Technology; Medicine, General & Internal; Medicine,
   Research & Experimental
SC Medical Laboratory Technology; General & Internal Medicine; Research &
   Experimental Medicine
GA VR632
UT WOS:A1996VR63200009
PM 8900293
DA 2018-10-19
ER

PT J
AU Canham, LT
   Newey, JP
   Reeves, CL
   Houlton, MR
   Loni, A
   Simons, AJ
   Cox, TI
AF Canham, LT
   Newey, JP
   Reeves, CL
   Houlton, MR
   Loni, A
   Simons, AJ
   Cox, TI
TI The effects of DC electric currents on the in-vitro calcification of
   bioactive silicon wafers
SO ADVANCED MATERIALS
LA English
DT Article
ID BONE; BIOMATERIALS; STIMULATION
AB That silicon could become an important tissue-compatible biomaterial is suggested by recent results. First observations are reported here of the significant effects that electrical bias has on the calcification process under simulated acellular physiological conditions. Cathodic current flow through porous silicon is shown to accelerate the kinetics of calcium phosphate deposition. Reasons why formation is restricted to the cathodically biased region and why calcium phosphate is not formed within the silicon layer are discussed.
RP Canham, LT (reprint author), DEF RES AGCY,ST ANDREWS RD,MALVERN WR14 3PS,WORCS,ENGLAND.
CR BEHARI J, 1991, CRIT REV BIOMED ENG, V18, P235
   CAMPBELL PK, 1991, IEEE T BIO-MED ENG, V38, P758, DOI 10.1109/10.83588
   CANHAM LT, 1991, J APPL PHYS, V70, P422, DOI 10.1063/1.350293
   CANHAM LT, 1992, MATER RES SOC SYMP P, V256, P63
   Canham LT, 1995, ADV MATER, V7, P1033, DOI 10.1002/adma.19950071215
   CANHAM LT, 1992, J APPL PHYS, V72, P1588
   CANHAM LT, 1996, IN PRESS MAT RES SOC, V414
   DeAza PN, 1996, J MATER SCI-MATER M, V7, P399, DOI 10.1007/BF00122007
   DIEGLE RB, 1978, J ELECTROCHEM SOC, V125, P1244, DOI 10.1149/1.2131657
   EARES ED, 1976, CALCIF TISSUE RES, V20, P75
   ELWOOD WK, 1990, J BIOELECTRICITY, V9, P19, DOI 10.3109/15368379009027757
   FRIEDENB.ZB, 1971, J BONE JOINT SURG AM, VA 53, P1400, DOI 10.2106/00004623-197153070-00018
   GOLOMB G, 1992, J MATER SCI-MATER M, V3, P272, DOI 10.1007/BF00705292
   HENCH LL, 1995, ADV CHEM SER, V245, P523
   KIM CY, 1989, J NON-CRYST SOLIDS, V113, P195, DOI 10.1016/0022-3093(89)90011-2
   LI PJ, 1994, J BIOMED MATER RES, V28, P7, DOI 10.1002/jbm.820280103
   MORTENSEN BT, 1982, J BIOMED ENG, V4, P103, DOI 10.1016/0141-5425(82)90069-3
   REGEHR WG, 1988, IEEE T BIO-MED ENG, V35, P1023, DOI 10.1109/10.8687
   SINGH S, 1986, J BIOELECTRICITY, V5, P285, DOI 10.1080/15368378609006062
   SMITH RL, 1986, IEEE T BIO-MED ENG, V33, P83, DOI 10.1109/TBME.1986.325881
   SPADARO JA, 1979, MED BIOL ENG COMPUT, V17, P769, DOI 10.1007/BF02441560
   TAMZIWA Y, 1991, J CHEM SOC FARADAY T, V87, P2235
   WATSON J, 1979, P IEEE, V67, P1339, DOI 10.1109/PROC.1979.11452
NR 23
TC 43
Z9 43
U1 0
U2 3
PU VCH PUBLISHERS INC
PI DEERFIELD BEACH
PA 303 NW 12TH AVE, DEERFIELD BEACH, FL 33442-1788
SN 0935-9648
J9 ADV MATER
JI Adv. Mater.
PD OCT
PY 1996
VL 8
IS 10
BP 847
EP &
DI 10.1002/adma.19960081019
PG 4
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA VM082
UT WOS:A1996VM08200017
DA 2018-10-19
ER

PT J
AU Zhang, Z
   King, MW
   How, TV
   Laroche, G
   Guidoin, R
AF Zhang, Z
   King, MW
   How, TV
   Laroche, G
   Guidoin, R
TI Chemical and morphological analysis of explanted polyurethane vascular
   prostheses: The challenge of removing fixed adhering tissue
SO BIOMATERIALS
LA English
DT Article
DE vascular prostheses; polyurethanes; cleaning method; tissue removal;
   surface characterization; polymer analysis
ID VASCUGRAFT(R) ARTERIAL PROSTHESIS; SURFACE
AB During in vivo experiments to evaluate the biocompatibility and biostability of alternative biomaterials, the ideal protocol for the handling and preservation of the explanted material is often compromised in order to meet the needs of both the pathologist and the materials scientist. Explants surrounded by tissue are often fixed in formalin or glutaraldehyde to facilitate later pathological and histological analysis, but the subsequent removal of such fixed tissue from thermally sensitive and less chemically stable polymers, such as polyurethanes, poses major problems for the materials scientist, who does not wish to modify the chemical, physical or morphological characteristics of the underlying biomaterial. The present study has attempted to find a solution to this problem by exposing virgin specimens of the microporous polyurethane Vascugraft(R) vascular prosthesis to six different cleaning conditions, all known to be effective in removing fixed tissue. These conditions included the use of 20% aqueous potassium hydroxide solution for 48 h at room temperature, 5% sodium bicarbonate solution for 5 min at the boil, and 9, 10, 11 and 12 N hydrochloric acid for 48 h at room temperature. The appearance and chemical properties of the virgin and treated specimens were compared using electron spectroscopy for chemical analysis, Fourier transform infrared spectroscopy, gel permeation chromatography for molecular weight and differential scanning calorimetry techniques. The use of temperatures close to the boil resulted in the formation of a translucent, rubbery material with gross changes in the microporous and microfibrous structure. The strongly acidic and alkaline conditions caused a loss in the surface carbonate group content. In addition, 12 N hydrochloric acid reduced the molecular weight and urethane content. Consequently, 9 N hydrochloric acid is recommended as the cleaning agent of choice for removing fixed tissue from this type of microporous polyurethane. Control experiments on virgin material should also be included in any cleaning protocol. (C) 1996 Elsevier Science Limited
C1 UNIV LAVAL,EXPT SURG LAB,DEPT SURG,QUEBEC CITY,PQ G1K 7P4,CANADA.
   ST FRANCIS ASSISI HOSP,QUEBEC BIOMAT INST,QUEBEC CITY,PQ G1K 7P4,CANADA.
RI Zhang, Ze/A-7902-2008
CR BRAUN D, 1986, EUR POLYM J, V22, P1, DOI 10.1016/0014-3057(86)90205-3
   BRUNNSCHWEILER D, 1993, POLYESTER 50 YEARS A
   DILKS A, 1980, DEV POLYM CHARACTERI, V2, P145
   GUIDOIN R, 1981, IMPLANT RETRIEVAL MA, P29
   KING M, 1984, ASAIO J, V7, P114
   KING MW, 1994, BIOMATERIALS, V15, P621, DOI 10.1016/0142-9612(94)90213-5
   PAYNTER RW, 1987, BIOMATERIALS, V8, P94, DOI 10.1016/0142-9612(87)90096-2
   Seferis J. C., 1989, POLYM HDB
   THERRIEN M, 1989, BIOMATERIALS, V10, P517, DOI 10.1016/0142-9612(89)90056-2
   WILLARD HH, 1974, INSTRUMENTAL METHODS, P150
   ZHANG Z, 1994, BIOMATERIALS, V15, P483
   ZHANG Z, 1994, BIOMATERIALS, V15, P1129, DOI 10.1016/0142-9612(94)90233-X
   ZHANG Z, 1995, BIOMATERIALS, V16, P369, DOI 10.1016/0142-9612(95)93854-7
NR 13
TC 4
Z9 5
U1 2
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD OCT
PY 1996
VL 17
IS 19
BP 1843
EP 1848
DI 10.1016/0142-9612(95)00246-4
PG 6
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA VH744
UT WOS:A1996VH74400002
PM 8889063
DA 2018-10-19
ER

PT J
AU Keogh, JR
   Wolf, MF
   Overend, ME
   Tang, LP
   Eaton, TW
AF Keogh, JR
   Wolf, MF
   Overend, ME
   Tang, LP
   Eaton, TW
TI Biocompatibility of sulphonated polyurethane surfaces
SO BIOMATERIALS
LA English
DT Article
DE polyurethanes; inflammation; thrombosis; heparin; biocompatibility
ID POLY(SODIUM VINYL SULFONATE); CARDIOPULMONARY BYPASS; COMPLEMENT
   ACTIVATION; ANTITHROMBIN-III; ARTIFICIAL SURFACES; PROTEIN ADSORPTION;
   FACTOR-XII; HEPARIN; PLATELETS; MECHANISM
AB Surfaces of medical devices made of polymeric materials may promote thrombosis and inflammation. Therefore, in an attempt to produce surfaces which might diminish biomaterial-mediated thrombosis and inflammation, surface derivatization with 2-acrylamido-2-methylpropanesulphonic acid (AMPS(R)) was carried out. The derivatization procedure generates free radicals which initiate the copolymerization of AMPS monomers directly to a polyurethane surface. In an in vitro blood loop study using non-anticoagulated human blood, the resulting AMPS-derivatized material completely abrogates the generation of fibrinopeptide A, decreases the production of beta-thromboglobulin and C3a, and decreases the adherence of platelets. The derivatized material also attracts fewer adherent neutrophils when implanted in mice. However, AMPS derivatization unexpectedly increases the recruitment of macrophages to implanted material and promotes the formation of adherent sleeve thrombi on central venous catheters indwelling in non-anticoagulated canine femoral veins. Thus, AMPS derivatization has highly variable effects on inflammatory and thrombotic systems. Further investigation is clearly required to determine the mechanisms underlying both desired and adverse effects. (C) 1996 Elsevier Science Limited.
C1 ALBANY MED COLL, DIV EXPT PATHOL, ALBANY, NY 12208 USA.
RP Keogh, JR (reprint author), MEDTRONIC INC, CTR BIOMAT RES, MINNEAPOLIS, MN 55430 USA.
CR ABSOLOM DR, 1987, J BIOMED MATER RES, V21, P161, DOI 10.1002/jbm.820210202
   ARNANDER C, 1989, J BIOMED MATER RES, V23, P285, DOI 10.1002/jbm.820230302
   BARBUCCI R, 1987, J BIOMED MATER RES, V21, P443, DOI 10.1002/jbm.820210405
   BARBUCCI R, 1991, INT J ARTIF ORGANS, V14, P499
   BICK RL, 1994, MED CLIN N AM, V78, P635, DOI 10.1016/S0025-7125(16)30151-1
   BIZIOS R, 1986, J CELL PHYSIOL, V128, P485, DOI 10.1002/jcp.1041280318
   BJORK I, 1982, MOL CELL BIOCHEM, V48, P161, DOI 10.1007/BF00421226
   BRESTEL EP, 1983, J IMMUNOL, V131, P2515
   BROWN DL, 1975, BRIT J HAEMATOL, V30, P377, DOI 10.1111/j.1365-2141.1975.tb01851.x
   CHENOWETH DE, 1981, NEW ENGL J MED, V304, P497, DOI 10.1056/NEJM198102263040901
   COLLINS WE, 1987, ANN NY ACAD SCI, V516, P291, DOI 10.1111/j.1749-6632.1987.tb33049.x
   DEWANJEE MK, 1992, ASAIO J, V38, P88
   Eloy R, 1988, J Biomater Appl, V2, P475
   ENGELBERG H, 1984, PHARMACOL REV, V36, P91
   FENG XD, 1985, MACROMOLECULES, V18, P2105, DOI 10.1021/ma00153a004
   FUKUMURA H, 1987, BIOMATERIALS, V8, P74, DOI 10.1016/0142-9612(87)90035-4
   GALLAGHER JT, 1985, BIOCHEM J, V230, P665, DOI 10.1042/bj2300665
   GEMMELL CH, 1994, SOC BIOMATER T, P73
   GRASEL TG, 1989, J BIOMED MATER RES, V23, P311, DOI 10.1002/jbm.820230304
   HAN DK, 1993, J BIOMAT SCI-POLYM E, V4, P401
   HAN DK, 1994, SOC BIOMATER T, V292
   HASDAI D, 1994, CORONARY ARTERY DIS, V5, P81, DOI 10.1097/00019501-199401000-00011
   HAYCOX CL, 1993, J BIOMED MATER RES, V27, P1181, DOI 10.1002/jbm.820270909
   HERZLINGER GA, 1980, T AM SOC ART INT ORG, V26, P165
   HOCKING DC, 1991, J APPL PHYSIOL, V70, P1121
   HOLMER E, 1980, THROMB RES, V18, P861, DOI 10.1016/0049-3848(80)90208-X
   HORBETT TA, 1982, ADV CHEM SER, P233
   ITO Y, 1991, J BIOMED MATER RES, V25, P1347, DOI 10.1002/jbm.820251104
   ITO Y, 1991, J BIOMED MATER RES, V25, P99, DOI 10.1002/jbm.820250108
   KANMANGNE FM, 1985, BIOMATERIALS, V6, P297, DOI 10.1016/0142-9612(85)90085-7
   KARGES HE, 1944, DRUG RES, V44, P793
   KAZATCHKINE MD, 1981, J CLIN INVEST, V67, P223, DOI 10.1172/JCI110017
   KEOGH JR, 1994, J LAB CLIN MED, V124, P537
   KIM SW, 1979, J POLYM SCI PS, V66, P429
   KIRKLIN JK, 1983, J THORAC CARDIOV SUR, V86, P845
   LARM O, 1983, BIOMATER ARTIF CELL, V11, P161, DOI 10.3109/10731198309118804
   LEININGER RI, 1987, ANN NY ACAD SCI, V516, P173, DOI 10.1111/j.1749-6632.1987.tb33039.x
   LINDON JN, 1985, J LAB CLIN MED, V105, P219
   LINDSAY RM, 1980, T AM SOC ART INT ORG, V26, P603
   LINHARDT RJ, 1986, APPL BIOCHEM BIOTECH, V12, P135
   LINHARDT RJ, 1988, J BIOL CHEM, V263, P13090
   MACHOVICH R, 1986, THROMB HAEMOSTASIS, V56, P397
   MARCHANT RE, 1986, J ADHESION, V20, P211, DOI 10.1080/00218468608071237
   MAROSSY K, 1981, BIOCHIM BIOPHYS ACTA, V659, P351, DOI 10.1016/0005-2744(81)90061-9
   MASON R G, 1971, Journal of Biomedical Materials Research, V5, P121, DOI 10.1002/jbm.820050109
   MIGONNEY V, 1988, BIOMATERIALS, V9, P413, DOI 10.1016/0142-9612(88)90005-1
   MOORE FD, 1988, ANN SURG, V208, P95, DOI 10.1097/00000658-198807000-00014
   NILSSON L, 1990, ARTIF ORGANS, V14, P46
   NOISHIKI Y, 1986, J BIOMED MATER RES, V20, P337, DOI 10.1002/jbm.820200306
   OKKEMA AZ, 1991, J BIOMED MATER RES, V25, P1371, DOI 10.1002/jbm.820251106
   PACKHAM MA, 1977, BLOOD, V50, P555
   PARK KD, 1992, J BIOMED MATER RES, V26, P739, DOI 10.1002/jbm.820260605
   PASINI FL, 1984, THROMB RES, V35, P527, DOI 10.1016/0049-3848(84)90284-6
   PIXLEY RA, 1985, BLOOD, V66, P198
   REDINI F, 1988, BIOCHEM J, V252, P515, DOI 10.1042/bj2520515
   ROITT I, 1987, IMMUNOLOGY
   SALZMAN EW, 1987, ANN NY ACAD SCI, V516, P184, DOI 10.1111/j.1749-6632.1987.tb33040.x
   SANTERRE JP, 1992, J BIOMED MATER RES, V26, P39, DOI 10.1002/jbm.820260105
   SHARATH MD, 1985, IMMUNOPHARMACOLOGY, V9, P73, DOI 10.1016/0162-3109(85)90002-5
   SHIBUYA Y, 1994, BBA-PROTEIN STRUCT M, V1206, P63, DOI 10.1016/0167-4838(94)90073-6
   SILVER JH, 1992, BIOMATERIALS, V13, P339, DOI 10.1016/0142-9612(92)90037-O
   SILVER JH, 1993, BIOMATERIALS, V14, P834, DOI 10.1016/0142-9612(93)90005-M
   SONNE O, 1988, SCAND J CLIN LAB INV, V48, P831, DOI 10.3109/00365518809088768
   TANG LP, 1993, J EXP MED, V178, P2147, DOI 10.1084/jem.178.6.2147
   TANZI MC, 1985, BIOMATERIALS, V6, P273, DOI 10.1016/0142-9612(85)90025-0
   WEILER JM, 1992, J IMMUNOL, V148, P3210
   WEILER JM, 1989, IMMUNOPHARMACOLOGY, V17, P65, DOI 10.1016/0162-3109(89)90051-9
   WOLF MF, 1992, IMPL RETR S SOC BIOM
   WOLF MF, 1991, 49 ANN M EL MICR SOC
   WOLF MF, 1993, Patent No. 5271898
   ZUCKER MB, 1969, P SOC EXP BIOL MED, V131, P318
NR 71
TC 29
Z9 29
U1 0
U2 12
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD OCT
PY 1996
VL 17
IS 20
BP 1987
EP 1994
DI 10.1016/0142-9612(96)00005-1
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA VJ535
UT WOS:A1996VJ53500011
PM 8894093
DA 2018-10-19
ER

PT J
AU Linnola, RJ
   Happonen, RP
   Andersson, OH
   Vedel, E
   YliUrpo, AU
   Krause, U
   Laatikainen, L
AF Linnola, RJ
   Happonen, RP
   Andersson, OH
   Vedel, E
   YliUrpo, AU
   Krause, U
   Laatikainen, L
TI Titanium and bioactive glass-ceramic coated titanium as materials for
   keratoprosthesis
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE keratoprosthesis; glass-ceramic; titanium; bioactive glass; biomaterial
ID FLUOROCARBON; IMPLANTATION; ACCEPTANCE; PROSTHESES; SURGERY
AB The current problem with keratoprosthesis is the ingrowth of corneal or conjunctival epithelium into the anterior chamber. This may lead to infections and extrusion of the prosthesis as well as to the development of retroprosthetic membrane and secondary glaucoma. Glass-ceramic coated and uncoated titanium has been tested as material for the keratoprosthesis to prevent epithelial ingrowth. Twenty-two Supra-Descemet's membrane keratoprostheses were inserted in the eyes of 22 rabbits for 1, 2, 4, 8, or 12 months. The prosthesis had an optic part made of polymethylmetacrylate (PMMA). The support for the optic part and the flange of the prosthesis were made of titanium. Eleven of the prostheses were coated with glass-ceramic. The histological sections of the enucleated eyes were prepared through the central part of the cornea and the prosthesis using a cutting-grinding method. The histological analysis was made on both halves of the implants separately giving two analysis areas in each eye. All 11 titanium prostheses were retained for the time period planned. Two glass-ceramic coated prostheses were lost at 2 and 4 weeks. respectively. This was caused by difficulties at surgery due to a thick coating. These eyes were excluded from the histological analysis. No significant ingrowth of epithelium was seen in 15/18 (83%) and in 16/22 (73%) of the analysed areas of the glass-ceramic coated and titanium prostheses, respectively. Titanium appears to be a suitable material for the keratoprosthesis. The ingrowth of the epithelium may be hindered further by coating the titanium with bioactive glass-ceramic. (C) 1996 Academic Press Limited
C1 OULU UNIV HOSP, DEPT OPHTHALMOL, FIN-90220 OULU, FINLAND.
   UNIV TURKU, INST DENT, DEPT ORAL SURG, FIN-20520 TURKU, FINLAND.
   ABO AKAD UNIV, DEPT CHEM ENGN, FIN-20520 TURKU, FINLAND.
   TURKU UNIV, INST DENT, DEPT PROSTHET, FIN-20520 TURKU, FINLAND.
CR Andersson OH, 1994, BIOCERAMICS, VOL 7, P67
   ANDERSSON OH, 1992, J MATER SCI-MATER M, V3, P145, DOI 10.1007/BF00705283
   ANDERSSON OH, 1990, HDB BIOACTIVE IMPLAN, V1, P143
   AQUAVELLA JV, 1983, CORNEA, V2, P177
   BARBER JC, 1988, INT OPHTHALMOL CLIN, V28, P103, DOI 10.1097/00004397-198802820-00002
   BARBER JC, 1980, INVEST OPHTH VIS SCI, V19, P182
   BLENCKE BA, 1978, OPHTHALMOLOGICA, V176, P105, DOI 10.1159/000308701
   Branemark P I, 1977, Scand J Plast Reconstr Surg Suppl, V16, P1
   CARDONA H, 1967, AM J OPHTHALMOL, V64, P228, DOI 10.1016/0002-9394(67)92516-0
   CARDONA H, 1962, AM J OPHTHALMOL, V54, P284, DOI 10.1016/0002-9394(62)93291-9
   CARDONA H, 1983, CORNEA, V2, P179
   CHOYCE DP, 1977, OPHTHALMIC SURG LAS, V8, P117
   CUPERUS PL, 1989, DOC OPHTHALMOL, V71, P29, DOI 10.1007/BF00155130
   DOHLMAN CH, 1974, AM J OPHTHALMOL, V77, P694, DOI 10.1016/0002-9394(74)90534-0
   DOHLMAN CH, 1994, CORNEA, V13, P214, DOI 10.1097/00003226-199405000-00004
   DONATH K, 1982, J ORAL PATHOL MED, V11, P318, DOI 10.1111/j.1600-0714.1982.tb00172.x
   ER U, 1978, BER DTSCH OPHTHALMOL, V75, P215
   Girard L J, 1977, Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol, V83, P252
   GIRARD LJ, 1983, CORNEA, V2, P207
   GULLAPALLI NR, 1979, AM J OPHTHALMOL, V88, P190
   HEIMKE G, 1983, CORNEA, V2, P197
   HENCH LL, 1975, J NON-CRYST SOLIDS, V19, P27, DOI 10.1016/0022-3093(75)90067-8
   KAIN HL, 1990, KLIN MONATSBL AUGENH, V197, P386, DOI 10.1055/s-2008-1046298
   KIRKHAM SM, 1991, OPHTHALMIC SURG LAS, V22, P455
   KOZARSKY AM, 1987, OPHTHALMOLOGY, V94, P904
   Krause A, 1992, CONTACTOLOGIA, V14E, P28
   LEGEAIS JM, 1995, ARCH OPHTHALMOL-CHIC, V113, P757, DOI 10.1001/archopht.1995.01100060083038
   LEGEAIS JM, 1992, CORNEA, V11, P538, DOI 10.1097/00003226-199211000-00010
   OGINO M, 1980, J NON-CRYST SOLIDS, V38-9, P673, DOI 10.1016/0022-3093(80)90514-1
   Osborn J. F., 1980, DENT IMPLANTS MAT SY, P111
   PAJAMAKI KJJ, 1995, J MATER SCI-MATER M, V5, P4
   PINTUCCI S, 1995, BRIT J OPHTHALMOL, V79, P825, DOI 10.1136/bjo.79.9.825
   POLACK FM, 1980, OPHTHALMOLOGY, V87, P693
   Polack FM, 1983, CORNEA, V2, P185
   SANDERS DM, 1973, J AM CERAM SOC, V56, P373, DOI 10.1111/j.1151-2916.1973.tb12689.x
   SLETTEBERG O, 1990, ACTA OPHTHALMOL, V68, P375
   SLETTEBERG O, 1990, ACTA OPHTHALMOL, V68, P369
   Strampelli B, 1970, Ann Ottalmol Clin Ocul, V96, P1
   THYLEFORS B, 1985, WHO CHRON, V39, P149
   WHITE JH, 1988, OPHTHALMIC SURG LAS, V19, P331
   WILSON J, 1990, HDB BIOACTIVE CERAMI, V1, P283
   Yakimenko S, 1993, REFRACT CORNEAL SURG, V9, P197
NR 42
TC 19
Z9 24
U1 0
U2 2
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD OCT
PY 1996
VL 63
IS 4
BP 471
EP 478
DI 10.1006/exer.1996.0137
PG 8
WC Ophthalmology
SC Ophthalmology
GA VQ440
UT WOS:A1996VQ44000013
PM 8944554
DA 2018-10-19
ER

PT J
AU Preston, CAK
   Khoury, AE
   Reid, G
   Bruce, AW
   Costerton, JW
AF Preston, CAK
   Khoury, AE
   Reid, G
   Bruce, AW
   Costerton, JW
TI Pseudomonas aeruginosa biofilms are more susceptible to ciprofloxacin
   than to tobramycin
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
DE biofilms; Pseudomonas; ciprofloxacin; tobramycin
ID GROWTH-RATE; INFECTION; RESISTANCE; CELLS
AB The objective of this study was to determine and compare the biofilm elimination concentrations (BEG: the concentration which reduced the viability of biofilm organisms by at least 99.9%) of ciprofloxacin and tobramycin for Pseudomonas aeruginosa, a common cause of nosocomial biomaterial-related infections. Bacterial biofilms were produced in the modified Bobbins device using continuous culture flow at 60 ml/h for 40-44 h, and the sessile organisms were then exposed to either ciprofloxacin or tobramycin at a range of concentrations for 12 or 36h. The BEC of ciprofloxacin was 5 mu g/ml for the 12 and 36 h treatments, a value 10 x greater than the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC). In contrast, the BEC of tobramycin was >100 mu g/ml after 12h and 75 mu g/ml following 36 h of drug exposure, that is 75-100 x the MIC and MBC. The results demonstrated that the BEC is a more suitable indicator of the antibiotic susceptibility of P. aeruginosa biofilms than the MIC and MBC. Ciprofloxacin was significantly more effective than tqbramycin in the treatment of P. aeruginosa adherent to biomaterials. With respect to clinical application, if the intention of antibiotic use is to eradicate bacteria adherent to devices, only biofilm-active agents should be used. Copyright (C) 1996 Elsevier Science B.V.
C1 CTR BIOMAT INFECT RES,TORONTO GEN DIV,TORONTO,ON M5G 2C4,CANADA.
   HOSP SICK CHILDREN,DIV UROL,TORONTO,ON M5G 1X8,CANADA.
   UNIV WESTERN ONTARIO,DEPT MICROBIOL & IMMUNOL,TORONTO,ON,CANADA.
   ST JOSEPHS HLTH CTR,LAWSON RES INST,LONDON,ON,CANADA.
   MONTANA STATE UNIV,BUTTE,MT.
CR Andriole VT, 1990, PRINCIPLES PRACTICE, P334
   ANWAR H, 1989, ANTIMICROB AGENTS CH, V33, P1824, DOI 10.1128/AAC.33.10.1824
   COSTERTON JW, 1981, ANNU REV MICROBIOL, V35, P299, DOI 10.1146/annurev.mi.35.100181.001503
   COSTERTON JW, 1987, ANNU REV MICROBIOL, V41, P435, DOI 10.1146/annurev.mi.41.100187.002251
   EVANS DJ, 1991, J ANTIMICROB CHEMOTH, V27, P177, DOI 10.1093/jac/27.2.177
   FURUSAWA T, 1986, J ANTIMICROB CHEMOTH, V17, P755, DOI 10.1093/jac/17.6.755
   GILBERT P, 1990, ANTIMICROB AGENTS CH, V34, P1865, DOI 10.1128/AAC.34.10.1865
   HUSTINX WNM, 1994, INT J ANTIMICROB AG, V4, P117, DOI 10.1016/0924-8579(94)90044-2
   MCCOY WF, 1982, DEV IND MICROBIOL, V23, P551
   Murray B E, 1989, Infect Dis Clin North Am, V3, P423
   NICKEL JC, 1985, ANTIMICROB AGENTS CH, V27, P619, DOI 10.1128/AAC.27.4.619
   PEARSON RD, 1980, ANTIMICROB AGENTS CH, V18, P699, DOI 10.1128/AAC.18.5.699
   REID G, 1994, PARAPLEGIA, V32, P468, DOI 10.1038/sc.1994.74
   WARREN JW, 1981, J UROLOGY, V125, P1
   ZUFFEREY J, 1988, J CLIN MICROBIOL, V26, P175
NR 15
TC 21
Z9 22
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0924-8579
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD OCT
PY 1996
VL 7
IS 4
BP 251
EP 256
DI 10.1016/S0924-8579(96)00330-5
PG 6
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA WB883
UT WOS:A1996WB88300005
PM 18611764
DA 2018-10-19
ER

PT J
AU Mikulec, LJ
   Puleo, DA
AF Mikulec, LJ
   Puleo, DA
TI Use of p-nitrophenyl chloroformate chemistry to immobilize protein on
   orthopedic biomaterials
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
ID ADHESION; PEPTIDE; ALLOY
AB Biochemical surface modification involves covalently immobilizing biomolecules onto biomaterial surfaces to induce specific biological responses. This approach may be useful for enhancing the fixation of orthopedic implants. p-Nitrophenyl chloroformate (p-NPC) was used to immobilize protein on bulk samples of Co-Cr-Mo and Ti-6Al-4V. Activation of both materials was dependent on the concentration of p-NPC, with a maximum of approximately 1.5 active groups/nm(2) of nominal surface area. Trypsin was used as a model protein because much is known about its structure and mode of action. Derivatization with 0.65 mg p-NPC/cm(2) resulted in significantly greater enzymatic activity (7.4 BAEE [N-(alpha)-benzoyl-L-arginine ethyl ester hydrochloride] units) on the Co-Cr-Mo samples compared with higher concentrations of p-NPC (5 BAEE units) and with simple adsorption of trypsin (1.5 BAEE units). An activity of 10.5 BAEE units was measured on both adsorbed and p-NPC-activated Ti-6Al-4V, with the exception of samples derivatized with 1.95 mg p-NPC/cm(2), on which activity was significantly lower (4 BAEE units). In probing the linkages between trypsin and biomaterial by treatment with chaotropic agents, guanidine hydrochloride (GuHCl) was observed to eliminate more enzymatic activity than was urea. On Co-Cr-Mo samples, GuHCl removed nearly all the trypsin activity, while urea significantly decreased the activity only at a concentration of 0.65 mg r-NPC/cm(2). Treatment of Ti-6Al-4V samples with GuHCl caused a trend of decreasing activity with increasing concentration of p-NPC, whereas urea had no effect on immobilized trypsin activity. (C) 1996 John Wiley & Sons, Inc.
C1 UNIV KENTUCKY,CTR BIOMED ENGN,WERNER GREN RES LAB 205,LEXINGTON,KY 40506.
CR Baier R. E., 1970, ADHESION BIOL SYSTEM, P15
   BIER M, 1951, ARCH BIOCHEM BIOPHYS, V33, P320, DOI 10.1016/0003-9861(51)90112-9
   Brunette D M, 1988, Int J Oral Maxillofac Implants, V3, P231
   DICKIE RA, 1982, ANAL CHEM, V54, P2045, DOI 10.1021/ac00249a031
   HERMODSON MA, 1973, BIOCHEMISTRY-US, V12, P3146, DOI 10.1021/bi00741a002
   ITO Y, 1991, J BIOMED MATER RES, V25, P1325, DOI 10.1002/jbm.820251102
   KASEMO B, 1986, CRIT REV BIOCOMPAT, V2, P335
   KLEIN CPAT, 1991, J BIOMED MATER RES, V25, P53, DOI 10.1002/jbm.820250105
   LIN HB, 1992, J BIOMAT SCI-POLYM E, V3, P217, DOI 10.1163/156856292X00132
   MASSIA SP, 1991, J BIOMED MATER RES, V25, P223, DOI 10.1002/jbm.820250209
   MATHEWS CK, 1990, BIOCHEMISTRY
   NOZAKI Y, 1970, J BIOL CHEM, V245, P1648
   NOZAKI Y, 1963, J BIOL CHEM, V238, P4074
   PARKS GA, 1965, CHEM REV, V65, P177, DOI 10.1021/cr60234a002
   PIMENTEL E, 1994, HDB GROWTH FACTORS, V1
   PULEO DA, 1995, J BIOMED MATER RES, V29, P951, DOI 10.1002/jbm.820290806
   RICK W, 1963, METHOD ENZYMAT AN, P807
   SIMMONS GW, 1987, J PHYS CHEM-US, V91, P1143, DOI 10.1021/j100289a025
   SPECTOR M, 1982, BIOCOMPATIBILITY ORT, P89
   STROUD RM, 1974, SCI AM, V231, P74, DOI 10.1038/scientificamerican0774-74
   Vollhardt K., 1987, ORGANIC CHEM
   Weltlaufer DB, 1964, J AM CHEM SOC, V86, P508
   WILCHEK M, 1982, BIOCHEM INT, V4, P629
   WILLIAMS JM, 1985, MATER SCI ENG, V69, P237, DOI 10.1016/0025-5416(85)90398-2
NR 24
TC 31
Z9 32
U1 1
U2 3
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD OCT
PY 1996
VL 32
IS 2
BP 203
EP 208
DI 10.1002/(SICI)1097-4636(199610)32:2<203::AID-JBM8>3.0.CO;2-X
PG 6
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA VG920
UT WOS:A1996VG92000009
PM 8884496
DA 2018-10-19
ER

PT J
AU Moon, IS
   Chai, JK
   Cho, KS
   Wikesjo, UM
   Kim, CK
AF Moon, IS
   Chai, JK
   Cho, KS
   Wikesjo, UM
   Kim, CK
TI Effects of polyglactin mesh combined with resorbable calcium carbonate
   or replamineform hydroxyapatite on periodontal repair in dogs
SO JOURNAL OF CLINICAL PERIODONTOLOGY
LA English
DT Article
DE polyglactin mesh; calcium carbonate; replamineform HA;
   periodontal/bone/cementum regeneration
ID CONNECTIVE-TISSUE ATTACHMENT; EARLY HEALING EVENTS; COLLAGEN MEMBRANES;
   REGENERATION; DEFECTS; BONE; CORAL; LIGAMENT; IMPLANTS
AB This study evaluates periodontal repair and biomaterial reaction following implantation of a polyglactin mesh with or without porous resorbable calcium carbonate (RCC) or porous replamineform hydroxyapatite (RHA) in conjunction with reconstructive surgery. Ligature- and surgically-induced interproximal periodontal defects of left and right mandibular premolar teeth in 7 dogs were used. Bilaterally mesial defects of the 2nd, 3rd and 4th premolar teeth were treated with polyglactin mesh, polyglactin mesh and RHA, or polyglactin mesh and RCC, respectively. The polyglactin mesh, shaped according to the contour of the defect, was adapted to the experimental teeth; its coronal margin positioned immediately apical to the cemento-enamel junction. Gingival flap margins were adapted and sutured to cover the polyglactin mesh completely. Clinical healing was generally uneventful. The dogs were sacrificed to provide block sections for histologic evaluation at 1, 3, 6, 12, 26, 32 and 56 weeks following wound closure. Generally, cementum regeneration was observed beginning at week 6 in all groups. Bone regeneration was observed from week 3 in polyglactin mesh-treated groups, and from week 6 in polyglactin mesh+RCC or polyglactin mesh+RHA treated groups. Bone regeneration appeared enhanced in polyglactin mesh+RCC or polyglactin mesh+RHA treated defects at week 12 and 26, with little difference between the three experimental conditions at week 56. Polyglactin mesh degradation was observed at week 3 and appeared complete at week 12. The RHA did not appear to resorb, while the RCC was gradually replaced by bone from week 3. Within limitations of the study conditions, periodontal regeneration was observed following implantation of a polyglactin mesh with or without RCC or RHA in conjunction with reconstructive surgery. As a conclusion, there seems to be no significant difference in periodontal regeneration after 12 months of healing between the group treated with the membrane only, and the group treated with the membrane and the bone substitution material. Changes in connective fiber orientation over the 1st 12 weeks of healing may suggest that ''fibrous encapsulation'' observed in earlier studies may only represent a transient stage in periodontal regeneration.
C1 YONSEI UNIV,COLL DENT,DEPT PERIODONTOL,SEODAEMOON KU,SEOUL 120752,SOUTH KOREA.
   LOMA LINDA UNIV,SCH DENT,ADV EDUC PROGRAM PERIODONT,LOMA LINDA,CA 92350.
RI Wikesjo, Ulf/A-4159-2009
OI Wikesjo, Ulf/0000-0003-1607-0583
CR BLUMENTHAL NM, 1988, J PERIODONTOL, V59, P830, DOI 10.1902/jop.1988.59.12.830
   CARRANZA FA, 1987, J PERIODONTOL, V58, P68
   CHO KS, 1987, J KOREAN ACAD PERIOD, V17, P57
   DOH HK, 1992, J KOREAN ACAD PERIOD, V22, P68
   DRAGOO MR, 1981, REGENERATION PERIODO
   FLEISHER N, 1988, INT J PERIODONT REST, V8, P45
   GOTTLOW J, 1984, J CLIN PERIODONTOL, V11, P494, DOI 10.1111/j.1600-051X.1984.tb00901.x
   GOTTLOW J, 1986, J CLIN PERIODONTOL, V13, P604, DOI 10.1111/j.1600-051X.1986.tb00854.x
   GUILLEMIN G, 1989, J BIOMED MATER RES, V23, P765, DOI 10.1002/jbm.820230708
   GUILLEMIN G, 1987, J BIOMED MATER RES, V21, P557, DOI 10.1002/jbm.820210503
   HANEY JM, 1993, IN PRESS J PERIODONT
   HARDWICK R, 1993, IN PRESS GUIDED BONE
   HIATT WH, 1968, J PERIODONTOL, V39, P11, DOI 10.1902/jop.1968.39.1.11
   HOLMES RE, 1979, PLAST RECONSTR SURG, V63, P626, DOI 10.1097/00006534-197905000-00004
   IGLHAUT J, 1988, J PERIODONTAL RES, V23, P107, DOI 10.1111/j.1600-0765.1988.tb01342.x
   KARRING T, 1985, J CLIN PERIODONTOL, V12, P51, DOI 10.1111/j.1600-051X.1985.tb01353.x
   MELCHER AH, 1976, J PERIODONTOL, V47, P256, DOI 10.1902/jop.1976.47.5.256
   NYGAARDOSTBY P, 1993, UNPUB J PERIODONTOL
   NYMAN S, 1982, J CLIN PERIODONTOL, V9, P257, DOI 10.1111/j.1600-051X.1982.tb02065.x
   NYMAN S, 1982, J CLIN PERIODONTOL, V9, P290, DOI 10.1111/j.1600-051X.1982.tb02095.x
   PFEIFER J, 1989, INT J PERIODONT REST, V9, P263
   PITARU S, 1988, J PERIODONTOL, V59, P380, DOI 10.1902/jop.1988.59.6.380
   PITARU S, 1989, J PERIODONTAL RES, V24, P247, DOI 10.1111/j.1600-0765.1989.tb01789.x
   SAPKOS SW, 1986, J PERIODONTOL, V57, P7, DOI 10.1902/jop.1986.57.1.7
   SCHALLHORN RG, 1977, J PERIODONTOL, V48, P570, DOI 10.1902/jop.1977.48.9.570
   SIGURDSSON TJ, 1993, IN PRESS J PERIODONT
   SOUYRIS F, 1985, J MAXILLOFAC SURG, V13, P64, DOI 10.1016/S0301-0503(85)80018-7
   STAHL SS, 1987, J PERIODONTOL, V58, P689, DOI 10.1902/jop.1987.58.10.689
   WEST TL, 1985, J PERIODONTOL, V56, P348, DOI 10.1902/jop.1985.56.6.348
   WHITE E, 1986, DENT CLIN N AM, V30, P49
   WIKESJO UME, 1992, J PERIODONTOL, V63, P158, DOI 10.1902/jop.1992.63.3.158
   WIKESJO UME, 1991, J PERIODONTOL, V62, P5, DOI 10.1902/jop.1991.62.1.5
   WIKESJO UME, 1992, J PERIODONTOL, V63, P107, DOI 10.1902/jop.1992.63.2.107
   WIKESJO UME, 1990, J PERIODONTOL, V61, P719, DOI 10.1902/jop.1990.61.12.719
   WIKESJO UME, 1991, J CLIN PERIODONTOL, V18, P49, DOI 10.1111/j.1600-051X.1991.tb01119.x
NR 35
TC 19
Z9 19
U1 0
U2 3
PU MUNKSGAARD INT PUBL LTD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 0303-6979
J9 J CLIN PERIODONTOL
JI J. Clin. Periodontol.
PD OCT
PY 1996
VL 23
IS 10
BP 945
EP 951
DI 10.1111/j.1600-051X.1996.tb00516.x
PG 7
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA VQ171
UT WOS:A1996VQ17100009
PM 8915024
DA 2018-10-19
ER

PT J
AU Benahmed, MD
   Heymann, D
   Berreur, M
   Cottrel, M
   Godard, A
   Daculsi, G
   Pradal, G
AF Benahmed, MD
   Heymann, D
   Berreur, M
   Cottrel, M
   Godard, A
   Daculsi, G
   Pradal, G
TI Ultrastructural study of degradation of calcium phosphate ceramic by
   human monocytes and modulation of this activity by HILDA/LIF cytokine
SO JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
LA English
DT Article
DE biphasic calcium phosphate ceramic; monocytes; HILDA/LIF; cytokines;
   cytotic phenomena; cell-crystal interaction; transmission electron
   microscopy
ID LEUKEMIA INHIBITORY FACTOR; HUMAN INTERLEUKIN; CELL-LINES; DA-CELLS;
   BONE-RESORPTION; DIFFERENTIATION; BIODEGRADATION; OSTEOCLASTS;
   EXPRESSION; CULTURE
AB Biodegradation of ceramics in vivo is achieved essentially by monocytes and multinuclear cells (osteoclasts). Monocytes are the key element in this process because they intervene first at the biomaterial implantation site during inflammatory reaction. In this work, in vitro studies were conducted on an ultrastructural scale to determine the specific behavior of these cells with regard to a calcium phosphate (CaP) ceramic. Two types of phagocytosis were observed when cells came into contact with the biomaterial: either CaP crystals were taken up alone and then dissolved in the cytoplasm after disappearance of the phagosome membrane or they were incorporated together with large quantities of culture medium, in which case dissolution occurred after the formation of heterophagosomes. Phagocytosis of CaP coincided with autophagy and the accumulation of residual bodies in the cells. Addition of HILDA/LIF factor to these cultures induced a very marked decrease in phagocytotic activity directed at the capture of CaP crystals and culture medium. Autophagy was reduced, and residual bodies were rare or absent. This study specifies the role of monocytes in CaP biodegradation and demonstrates for the first time that HILDA/LIF has a biological effect on this cell line.
C1 FAC MED,LAB HISTOL & EMBRYOL,REIMS,FRANCE.
   INST BIOL,REIMS,FRANCE.
   CTR REG MICROSCOPIE ELECT & MICROANAL LENSEMBLE S,REIMS,FRANCE.
RP Benahmed, MD (reprint author), FAC CHIRURG DENT,CTR RECH INTERDISCIPLINAIRE TISSUS CALCIFIES & BI,PL A RICORDEAUZ,F-44042 NANTES,FRANCE.
RI Daculsi, Guy/P-1320-2014
OI Daculsi, Guy/0000-0003-1030-3446
CR ABE E, 1988, J BONE MINER RES, V3, P635
   ANEGON I, 1990, CELL IMMUNOL, V130, P50, DOI 10.1016/0008-8749(90)90161-J
   BASLE MF, 1993, J MATER SCI-MATER M, V4, P273, DOI 10.1007/BF00122280
   BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6
   BAUMANN H, 1994, IMMUNOL TODAY, V15, P47
   BENAHMED M, 1994, BIOMATERIALS, V15, P25, DOI 10.1016/0142-9612(94)90191-0
   BENAHMED M, 1996, IN PRESS BIOMATERIAL
   BLIFELD C, 1991, TRANSPLANTATION, V51, P498, DOI 10.1097/00007890-199102000-00043
   BLOTTIERE HM, 1995, BIOMATERIALS, V16, P497, DOI 10.1016/0142-9612(95)98824-X
   BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77
   Daculsi G., 1992, BIOMATER TISSUE INT, V10, P296
   DARNELL J, 1986, MOL CELL BIOL, P165
   GASCAN H, 1990, J IMMUNOL, V144, P2592
   GODARD A, 1992, J BIOL CHEM, V267, P3214
   GOMI K, 1993, BIOMATERIALS, V14, P91, DOI 10.1016/0142-9612(93)90216-O
   KREUTZ M, 1993, BLOOD, V82, P1300
   Legeros Racquel Z., 1993, Clinical Materials, V14, P65, DOI 10.1016/0267-6605(93)90049-D
   LOWE C, 1991, CALCIFIED TISSUE INT, V49, P394, DOI 10.1007/BF02555849
   MAEKAWA T, 1990, INT J CANCER, V45, P353, DOI 10.1002/ijc.2910450224
   METCALF D, 1989, P NATL ACAD SCI USA, V86, P5948, DOI 10.1073/pnas.86.15.5948
   MOREAU JF, 1987, J IMMUNOL, V138, P3844
   MOREAU JF, 1986, ANN INST PASTEUR IMM, VC137, P25, DOI 10.1016/S0771-050X(86)80003-1
   MOREAU JF, 1988, NATURE, V336, P690, DOI 10.1038/336690a0
   PASSUTI N, 1989, CLIN ORTHOP RELAT R, V248, P169
   PITT D, 1975, LYSOSOMES CELL FUNCT
   REID IR, 1990, ENDOCRINOLOGY, V126, P1416, DOI 10.1210/endo-126-3-1416
   ROODMAN CD, 1993, CALCIFIED TISSUE INT, V53, P594
   SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0
   SOUEIDAN A, 1995, CELL MATER, V5, P31
   TOMIDA M, 1984, J BIOL CHEM, V259, P978
   VANBEEK E, 1993, J BONE MINER RES, V8, P191
   YAMADA S, 1994, CELL MATER, V4, P347
NR 32
TC 19
Z9 19
U1 0
U2 0
PU HISTOCHEMICAL SOC INC
PI NEW YORK
PA MT SINAI MEDICAL CENTER 19 EAST 98TH ST SUTIE 9G, NEW YORK, NY 10029
SN 0022-1554
J9 J HISTOCHEM CYTOCHEM
JI J. Histochem. Cytochem.
PD OCT
PY 1996
VL 44
IS 10
BP 1131
EP 1140
DI 10.1177/44.10.8813078
PG 10
WC Cell Biology
SC Cell Biology
GA VK549
UT WOS:A1996VK54900007
PM 8813078
DA 2018-10-19
ER

PT J
AU Verran, J
   Taylor, RL
   Lees, GC
AF Verran, J
   Taylor, RL
   Lees, GC
TI Bacterial adhesion to inert thermoplastic surfaces
SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE
LA English
DT Article
ID ESCHERICHIA-COLI; IMAGE-ANALYSIS; MICROBIAL ADHESION; EPITHELIAL-CELLS;
   FREE-ENERGY; HYDROPHOBICITY; ADHERENCE; STAPHYLOCOCCUS; ENUMERATION;
   ATTACHMENT
AB The adhesion of four bacterial species, two strains of each, to four hydrophobic thermoplastics was observed. Image analysis of adherent cells stained with acridine orange provided a rapid, direct and objective means of measuring adhesion to clear, translucent and opaque surfaces by calculating the percentage area of a microscopic field covered by cells (percentage coverage). There was a highly significant correlation (P > 0.05) between percentage coverage value and adherent cell count (obtained manually) for both rods and cocci. Bacterial adhesion to thermoplastics appeared to be strain specific and was not related to polymer composition. Highest percentage coverage values were obtained using hydrophobic bacteria, and lowest using hydrophilic bacteria. There was no relationship between the origin of the organisms (culture collections or isolates from biomaterial-associated infections) and their ability to adhere, after cultivation in brain heart infusion broth. Many factors influence this ability: an awareness of all experimental variables is essential.
C1 MANCHESTER METROPOLITAN UNIV,DEPT MAT TECHNOL,MANCHESTER M1 5GD,LANCS,ENGLAND.
RP Verran, J (reprint author), MANCHESTER METROPOLITAN UNIV,DEPT BIOL SCI,JOHN DALTON BLDG,CHESTER ST,MANCHESTER M1 5GD,LANCS,ENGLAND.
CR BAIER RE, 1980, DENT PLAQUE SURFACE, P31
   BEECH IB, 1989, J APPL BACTERIOL, V67, P201, DOI 10.1111/j.1365-2672.1989.tb03396.x
   BUSSCHER HJ, 1992, FEMS MICROBIOL LETT, V88, P199, DOI 10.1111/j.1574-6968.1992.tb04988.x
   BUSSCHER HJ, 1984, COLLOID SURFACE, V9, P319, DOI 10.1016/0166-6622(84)80175-4
   BUSSCHER HJ, 1991, MICROBIAL CELL HYDRO, P335
   Carballo J, 1992, J Biomater Appl, V7, P130, DOI 10.1177/088532829200700203
   DANKERT J, 1986, CRIT REV BIOCOMPAT, V2, P219
   ENER B, 1992, FEMS MICROBIOL LETT, V99, P37
   ESPERSEN F, 1994, J MED MICROBIOL, V40, P37, DOI 10.1099/00222615-40-1-37
   EVANSHURRELL JA, 1993, FEMS MICROBIOL LETT, V107, P77
   FLETCHER M, 1982, APPL ENVIRON MICROB, V44, P184
   GILBERT P, 1991, J APPL BACTERIOL, V71, P72
   GIMMOUR A, 1993, SOC APPL BACT TECHNI, V30
   GRISTINA AG, 1987, SCIENCE, V237, P1588, DOI 10.1126/science.3629258
   HARKES G, 1991, BIOMATERIALS, V12, P853, DOI 10.1016/0142-9612(91)90074-K
   HOGT AH, 1986, J GEN MICROBIOL, V131, P2485
   KEPNER RL, 1994, MICROBIOL REV, V58, P603
   LAMBE DW, 1994, MICROBIOS, V78, P133
   LINDAHL M, 1981, BIOCHIM BIOPHYS ACTA, V677, P471, DOI 10.1016/0304-4165(81)90261-0
   MARSHALL KC, 1971, J GEN MICROBIOL, V68, P337, DOI 10.1099/00221287-68-3-337
   MCELDOWNEY S, 1986, APPL ENVIRON MICROB, V52, P460
   MCFETERS GA, 1991, J MICROBIOL METH, V13, P87, DOI 10.1016/0167-7012(91)90009-F
   PEDERSON K, 1990, WATER RES, V24, P224
   PRATTTERPSTRA IH, 1988, CURR MICROBIOL, V16, P311, DOI 10.1007/BF01568537
   ROSENBERG M, 1986, ADV MICROB ECOL, V9, P353
   ROSENBERG M, 1980, FEMS MICROBIOL LETT, V9, P29, DOI 10.1111/j.1574-6968.1980.tb05599.x
   SAMARANAYAKE LP, 1980, ARCH ORAL BIOL, V25, P603, DOI 10.1016/0003-9969(80)90075-8
   SHAKESPEARE AP, 1988, LETT APPL MICROBIOL, V6, P79, DOI 10.1111/j.1472-765X.1988.tb01219.x
   SPEERT DP, 1986, INFECT IMMUN, V22, P462
   VANDERMEI HC, 1987, J MICROBIOL METH, V6, P277, DOI 10.1016/0167-7012(87)90065-0
   VANDERMEI HC, 1991, MICROBIAL CELL SURFA, P263
   VANLOOSDRECHT MCM, 1987, APPL ENVIRON MICROB, V53, P1893
   Verran J., 1991, Biofouling, V3, P183
   VERRAN J, 1980, MICROBIOS, V29, P161
   VERRAN J, 1995, LIFE DEATH BIOFILM, P53
   WEERKAMP AH, 1988, J DENT RES, V67
NR 36
TC 28
Z9 29
U1 0
U2 2
PU CHAPMAN HALL LTD
PI LONDON
PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8HN
SN 0957-4530
J9 J MATER SCI-MATER M
JI J. Mater. Sci.-Mater. Med.
PD OCT
PY 1996
VL 7
IS 10
BP 597
EP 601
DI 10.1007/BF00058198
PG 5
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA VL466
UT WOS:A1996VL46600003
DA 2018-10-19
ER

PT J
AU Kveton, JF
AF Kveton, JF
TI Obliteration of the eustachian tube using hydroxyapatite cement: A
   permanent technique
SO LARYNGOSCOPE
LA English
DT Article; Proceedings Paper
CT Meeting of the Southern-Section of the
   American-Laryngological-Rhinological-and-Otological-Society-Inc
CY JAN   05, 1996
CL NAPLES, FL
SP Amer Laryngol Rhinol & Otol Soc, So Sect
ID RECONSTRUCTION
AB Permanent obliteration of the eustachian tube via the middle ear traditionally has met with limited success. Combinations of muscle, fascia, adipose tissue, bone fragments, and inert material such as Proplast have been used to seal the middle ear from the nasopharynx by inciting a fibrous reaction within the lumen of the eustachian tube. Long-term follow-up has demonstrated repneumatization of the middle ear cleft in the majority of cases, indicating failure of the obliteration technique. This report describes a technique for successful long-term obliteration using hydroxyapatite cement. This new biomaterial possesses osseointegrative and osseoconductive properties that result in permanent obliteration by producing new bone formation within the lumen of the eustachian tube. This technique eliminates the complication of cerebrospinal fluid rhinorrhea in lateral skull base procedures that expose the eustachian tube to cerebrospinal fluid.
RP Kveton, JF (reprint author), YALE UNIV,SCH MED,DEPT SURG,OTOLARYNGOL SECT,333 CEDAR ST,POB 208041,NEW HAVEN,CT 06520, USA.
CR COSTANTINO PD, 1991, ARCH OTOLARYNGOL, V117, P379
   FRIEDMAN CD, 1991, ARCH OTOLARYNGOL, V117, P385
   KVETON JF, 1995, LARYNGOSCOPE, V105, P156, DOI 10.1288/00005537-199502000-00008
   KVETON JF, 1995, AM J OTOL, V16, P288
NR 4
TC 15
Z9 15
U1 0
U2 1
PU LARYNGOSCOPE CO
PI ST LOUIS
PA 10 S BROADWAY 14TH FLOOR, ST LOUIS, MO 63102-1741
SN 0023-852X
J9 LARYNGOSCOPE
JI Laryngoscope
PD OCT
PY 1996
VL 106
IS 10
BP 1241
EP 1243
DI 10.1097/00005537-199610000-00014
PG 3
WC Medicine, Research & Experimental; Otorhinolaryngology
SC Research & Experimental Medicine; Otorhinolaryngology
GA VL057
UT WOS:A1996VL05700014
PM 8849794
DA 2018-10-19
ER

PT J
AU Wennerberg, A
   Ohlsson, R
   Rosen, BG
   Andersson, B
AF Wennerberg, A
   Ohlsson, R
   Rosen, BG
   Andersson, B
TI Characterizing three-dimensional topography of engineering and
   biomaterial surfaces by confocal laser scanning and stylus techniques
SO MEDICAL ENGINEERING & PHYSICS
LA English
DT Article
DE 3D surface topography; stylus profilometer; confocal laser scanner;
   engineering and biomaterial surfaces
ID TITANIUM IMPLANTS; SPECTROSCOPIC CHARACTERIZATION; BONE; ROUGHNESS
AB Three-dimensional measurements of surface topography were performed using a confocal laser scanner and a contact stylus instrument. Three surfaces known to be difficult to evaluate were chosen to be measured on the same area with the two instruments. The measurements from the optical and the contact stylus profilometer were compared with each other and with measurements obtained from high-resolution atomic force microscopy, which served as a reference instrument. Six implants manufactured from commonly used biomaterials were also measured on the same part of the implant, but not on the same area, with the optical and the contact profilometer in order to stimulate the measurements that would be performed wizen different laboratories measure similarly treated surfaces. The numerical and visual differences achieved when measuring the same area with the two instruments investigated were compared. In general, we found an underestimation of the surface features with the contact stylus measurement and an overestimation with the confocal scanner The stylus readings are mainly influenced by the radius of the stylus tip, the pressure of the stylus tip on the surface, and the hardness of the material the optical profilometer has a tendency for creating spikes when surfaces with deep slopes are measured. For relatively soft metallic biomaterials, we found that using the optical instrument is the most appropriate method for surface roughness characterization, particularly when screw-shaped implants are analysed, whereas the stylus is preferred when larger areas with substantial slopes within the surface structure are to be evaluated. Copy right (C) 1996 Elsevier Science Ltd for IPEMB.
C1 CHALMERS UNIV TECHNOL,DEPT PROD ENGN,CHALMERS SURFACE GEOMETRY GRP,S-41296 GOTHENBURG,SWEDEN.
RP Wennerberg, A (reprint author), GOTHENBURG UNIV,INST SURG SCI,DEPT BIOMAT HANDICAP RES,BIOMAT GRP,MEDICINAREGATAN 8,S-41390 GOTHENBURG,SWEDEN.
CR ALBREKTSSON T, 1981, ACTA ORTHOP SCAND, V52, P155, DOI 10.3109/17453678108991776
   ASK M, 1988, APPL SURF SCI, V35, P283
   BAGUET J, 1993, BIOMATERIALS, V14, P279, DOI 10.1016/0142-9612(93)90118-L
   BENGTSSON A, 1991, THESIS CHALMERS U TE
   BIANCO PD, 1992, J MATER SCI-MATER M, V3, P28, DOI 10.1007/BF00702941
   BLUNT L, 1994, P 6 NORD S TRIB NORD, P359
   Bowers K T, 1992, Int J Oral Maxillofac Implants, V7, P302
   BUSER D, 1991, J BIOMED MATER RES, V25, P889, DOI 10.1002/jbm.820250708
   Deutsche Norm, 1990, 4776 DIN
   *DIN, 1990, 4777 DIN
   HELSINGEN AL, 1994, INT J ORAL MAXILLOF, V9, P422
   JOHANSSON CB, 1991, THESIS U GOTEBORG GO
   KELLER JC, 1994, J BIOMED MATER RES, V28, P939, DOI 10.1002/jbm.820280813
   Klauber C, 1990, Int J Oral Maxillofac Implants, V5, P264
   LAUSMAA J, 1990, APPL SURF SCI, V44, P133, DOI 10.1016/0169-4332(90)90100-E
   MEYLE J, 1994, Z ZAHNARZTL IMPLANTO, V10, P51
   MORBERG P, 1991, THESIS U GOTEBORG GO
   MULLERMAI CM, 1990, SCANNING MICROSCOPY, V4, P613
   NENTWIG GH, 1994, Z ZAHNARZTL IMPLANTO, V10, P150
   OHLSSON R, 1993, P ASPE 1993 ANN M
   Olefjord I, 1993, Int J Oral Maxillofac Implants, V8, P32
   QUIRYNEN M, 1990, J CLIN PERIODONTOL, V17, P138, DOI 10.1111/j.1600-051X.1990.tb01077.x
   RATNR BD, 1987, J BIOMED MATER RES-A, V21, P59
   SCHMIDT JA, 1992, BIOMATERIALS, V13, P675
   Smith D C, 1993, Int J Prosthodont, V6, P106
   SOBALLE K, 1993, ACTA ORTHOP SCAND S, V255, P64
   Stout K., 1990, ATLAS MACHINED SURFA
   STOUT KJ, 1992, PROPOSAL PARAMETERS
   TRICOT C, 1993, WEAR, V172, P127
   Wennerberg A, 1993, Int J Oral Maxillofac Implants, V8, P622
   Wennerberg A, 1996, BIOMATERIALS, V17, P15, DOI 10.1016/0142-9612(96)80750-2
   WENNERBERG A, 1995, J MATER SCI-MATER M, V6, P302, DOI 10.1007/BF00120275
   WENNERBERG A, 1995, CLIN ORAL IMPLAN RES, V6, P24, DOI 10.1034/j.1600-0501.1995.060103.x
   Whitehouse D.J., 1994, HDB SURFACE METROLOG
   Wilson T., 1990, CONFOCAL MICROSCOPY
NR 35
TC 60
Z9 60
U1 1
U2 8
PU BUTTERWORTH-HEINEMANN LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 1350-4533
J9 MED ENG PHYS
JI Med. Eng. Phys.
PD OCT
PY 1996
VL 18
IS 7
BP 548
EP 556
DI 10.1016/1350-4533(95)00005-4
PG 9
WC Engineering, Biomedical
SC Engineering
GA VK301
UT WOS:A1996VK30100004
PM 8892239
DA 2018-10-19
ER

PT J
AU Lin, JC
   Cooper, SL
AF Lin, JC
   Cooper, SL
TI In vitro fibrinogen adsorption from various dilutions of human blood
   plasma on glow discharge modified polyethylene
SO JOURNAL OF COLLOID AND INTERFACE SCIENCE
LA English
DT Article
DE surface modification; plasma treatment; protein adsorption; fibrinogen;
   Vroman effect; ammonia plasma; hexamethyldisiloxane plasma; sulfur
   dioxide plasma
ID MOLECULAR-WEIGHT KININOGEN; SOLID-SURFACES; TRANSIENT ADSORPTION;
   SEGMENTED POLYURETHANES; PROTEINS; ELUTABILITY; CHEMISTRY; BEHAVIOR;
   ALBUMIN
AB Studies have suggested that the adsorption of fibrinogen onto a biomaterial's surface plays an important role in determining a material's blood compatibility. In this study, fibrinogen adsorption from various dilutions of human blood plasma was measured on various radio frequency glow discharge (RFGD) modified surfaces. In addition, the relative binding strength of adsorbed fibrinogen on these surfaces was assessed by subsequent sodium dodecyl sulfate (SDS) elution. More fibrinogen was adsorbed on the hydrophilic surfaces modified by an ammonia plasma, a sulfur dioxide plasma, and an ammonia plasma with propane sultone post treatment than on the untreated polyethylene control. These three hydrophilic surfaces also exhibited higher fibrinogen retention values than the untreated polyethylene control did. The high in vitro fibrinogen adsorption results observed on these hydrophilic surfaces are closely parallel to those obtained previously in ex vivo canine shunt experiments. Transient fibrinogen adsorption, also known as the ''Vroman Effect,'' was not observed on the surfaces modified by the ammonia plasma and the ammonia plasma with propane sultone post treatment. In contrast, maxima in fibrinogen adsorption were noticed on the surface modified by the sulfur dioxide plasma. Despite the variations in surface chemistry, similar fibrinogen adsorption and SDS elution results were noticed on a Silastic control surface and surfaces modified by various plasma polymerized siloxanes. (C) 1996 Academic Press, Inc.
C1 UNIV WISCONSIN, DEPT CHEM ENGN, MADISON, WI 53706 USA.
RI Lin, Jui-Che/C-8230-2012
OI Lin, Jui-Che/0000-0003-4436-655X
CR Bennett JS, 1985, PLATELET MEMBRANE GL
   BRASH JL, 1989, J BIOMED MATER RES, V23, P157, DOI 10.1002/jbm.820230203
   BRASH JL, 1984, THROMB HAEMOSTASIS, V51, P326
   BRASH JL, 1988, BLOOD, V71, P932
   CLAUSS A., 1957, ACTA HAEMATOL, V17, P237
   COLLER BS, 1979, BLOOD, V53, P325
   ELWING H, 1987, J BIOMED MATER RES, V21, P1023, DOI 10.1002/jbm.820210808
   ERTEL SI, 1991, J COLLOID INTERF SCI, V147, P433, DOI 10.1016/0021-9797(91)90176-9
   GOODMAN SL, 1990, J COLLOID INTERF SCI, V139, P561, DOI 10.1016/0021-9797(90)90129-C
   HOFFMAN AS, 1982, ADV CHEM SER, P3
   HOFFMAN AS, 1986, J BIOMED MATER RES, V20, pR9, DOI 10.1002/jbm.820200903
   HOMAN DJ, 1990, THESIS U WISCONSIN M
   HORBETT TA, 1984, THROMB HAEMOSTASIS, V51, P174
   LIN JC, 1995, BIOMATERIALS, V16, P1017
   LIN JC, 1994, APPL POLYM SYMP SER, V54, P157
   LIN YS, 1992, BIOMATERIALS, V13, P497
   RAPOZA R J, 1989, Journal of Biomaterials Science Polymer Edition, V1, P99, DOI 10.1163/156856289X00091
   RAPOZA RJ, 1990, J COLLOID INTERF SCI, V136, P480, DOI 10.1016/0021-9797(90)90395-5
   SANTERRE JP, 1992, J BIOMED MATER RES, V26, P1003, DOI 10.1002/jbm.820260804
   SANTERRE JP, 1992, J BIOMED MATER RES, V26, P39, DOI 10.1002/jbm.820260105
   SLACK S M, 1991, Journal of Biomaterials Science Polymer Edition, V2, P227
   SLACK SM, 1987, ANN NY ACAD SCI, V516, P223, DOI 10.1111/j.1749-6632.1987.tb33044.x
   SLACK SM, 1989, J COLLOID INTERF SCI, V133, P148, DOI 10.1016/0021-9797(89)90288-9
   SLACK SM, 1992, J BIOMED MATER RES, V26, P1633, DOI 10.1002/jbm.820261208
   Vroman L, 1969, J Biomed Mater Res, V3, P43, DOI 10.1002/jbm.820030106
   VROMAN L, 1980, BLOOD, V55, P156
   WOJCIECHOWSKI PW, 1993, COLLOID SURFACE B, V1, P107, DOI 10.1016/0927-7765(93)80041-V
   YOUNG BR, 1988, J COLLOID INTERF SCI, V124, P28, DOI 10.1016/0021-9797(88)90321-9
   YOUNG BR, 1982, ADV CHEM SER, P317
   YOUNG BR, 1984, THESIS U WISCONSIN M
NR 30
TC 20
Z9 20
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0021-9797
EI 1095-7103
J9 J COLLOID INTERF SCI
JI J. Colloid Interface Sci.
PD SEP 25
PY 1996
VL 182
IS 2
BP 315
EP 325
DI 10.1006/jcis.1996.0470
PG 11
WC Chemistry, Physical
SC Chemistry
GA VL089
UT WOS:A1996VL08900001
DA 2018-10-19
ER

PT J
AU Baumgartner, JN
   Cooper, SL
AF Baumgartner, JN
   Cooper, SL
TI Bacterial adhesion on polyurethane surfaces conditioned with thrombus
   components
SO ASAIO JOURNAL
LA English
DT Article
ID STAPHYLOCOCCUS-AUREUS; MEDIATED ADHESION; FIBRONECTIN; INFECTION;
   ADHERENCE; EPIDERMIDIS; FIBRINOGEN; FLOW
AB Thrombosis and infection are two major complications associated with cardiovascular devices such as ventricular assist devices, total artificial hearts, vascular grafts, and catheters. When blood contacts an artificial biomaterial, protein deposition occurs, as do activation of the blood coagulation cascade, platelet adhesion, activation, and aggregation, all of which lead to thrombus formation. An increased incidence of bacterial infection also has been seen clinically with indwelling biomaterial devices. Some evidence suggests a possible association between thrombosis and infection, in that adherent bacteria may provide a nidus for thrombus formation, or adherent thrombi composed of platelets and fibrin may form sheltered sites for bacterial adhesion.(1,2) In the current study, the authors examined Staphylococcus aureus adhesion to sulfonated, aminated, and phosphonated polyurethane surfaces that had been preadsorbed with solutions of increasing complexity, in an effort to approach and simulate clot formation on the surface. These solutions included various combinations of fibrinogen, albumin, plasma, thrombin, and isolated platelets. Bacterial adhesion was observed in a radial flow chamber mounted on the motorized stage of a video microscopy system, with image processing software used to perform automated data collection and image analysis. Scanning electron microscopy also was used to visualize cross-linked fibrin and bacterial adhesion on these surfaces. Bacterial adhesion was found to be lowest on the phosphonated polyurethane. The presence of fibrin or isolated platelets significantly increased bacterial adhesion compared to surfaces pre-adsorbed with albumin.
C1 UNIV DELAWARE,DEPT CHEM ENGN,NEWARK,DE 19716.
CR ARCIOLA CR, 1993, BIOMATERIALS, V14, P1161, DOI 10.1016/0142-9612(93)90161-T
   COZENSROBERTS C, 1990, BIOPHYS J, V58, P107, DOI 10.1016/S0006-3495(90)82357-2
   DANKERT J, 1986, CRIT REV BIOCOMPAT, V2, P219
   DICKINSON RB, 1995, INFECT IMMUN, V63, P3143
   DICKINSON RB, 1995, AICHE J, V41, P2160, DOI 10.1002/aic.690410915
   DOUGHERTY SH, 1988, REV INFECT DIS, V10, P1102
   FOSTER TJ, 1994, FEMS MICROBIOL LETT, V118, P199, DOI 10.1016/0378-1097(94)90504-5
   GODDARD RJ, 1994, J POLYM SCI POL PHYS, V32, P1557, DOI 10.1002/polb.1994.090320827
   GRASEL TG, 1989, J BIOMED MATER RES, V23, P311, DOI 10.1002/jbm.820230304
   HERRMANN M, 1988, J INFECT DIS, V158, P693, DOI 10.1093/infdis/158.4.693
   MAKI DG, 1992, EPIDEMIOLOGY PREVENT, P27
   Mohammad S F, 1994, ASAIO J, V40, P226, DOI 10.1097/00002480-199404000-00019
   MOHAMMAD SF, 1988, T AM SOC ART INT ORG, V34, P573
   MOLLER PS, 1963, AERONAUT QUART, V14, P163, DOI 10.1017/S0001925900002742
   RUOSLAHTI E, 1982, METHOD ENZYMOL, V82, P803
   TOY PTCY, 1985, INFECT IMMUN, V48, P83
   Vaudaux P, 1990, J Biomater Appl, V5, P134, DOI 10.1177/088532829000500204
   VERHEYEN CCPM, 1993, BIOMATERIALS, V14, P383, DOI 10.1016/0142-9612(93)90059-B
   VOET D, 1990, BIOCHEMISTRY
   WANG I, 1993, J BIOMED MATER RES, V27, P1119, DOI 10.1002/jbm.820270902
NR 20
TC 14
Z9 14
U1 0
U2 6
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 1058-2916
J9 ASAIO J
JI Asaio J.
PD SEP-OCT
PY 1996
VL 42
IS 5
BP M476
EP M479
DI 10.1097/00002480-199609000-00033
PG 4
WC Engineering, Biomedical; Transplantation
SC Engineering; Transplantation
GA VP508
UT WOS:A1996VP50800032
PM 8944926
OA Bronze
DA 2018-10-19
ER

PT J
AU Kruft, MAB
   Benzina, A
   Blezer, R
   Koole, LH
AF Kruft, MAB
   Benzina, A
   Blezer, R
   Koole, LH
TI Studies on radio-opaque polymeric biomaterials with potential
   applications to endovascular prostheses
SO BIOMATERIALS
LA English
DT Article
DE radio-opacity; haemocompatibility; processability; stents; radio-opaque
   biomaterials
ID BLOOD
AB A new polymeric biomaterial, which uniquely combines radio-opacity (X-ray visibility) and low thrombogenicity, is described. First, preparation, purification, and identification of the essential monomeric building block, 2-[2'-iodobenzoyl]-ethyl methacrylate (3), are outlined. Second,
   3
   [GRAPHICS]
   the synthesis of the biomaterial, a terpolymer with composition MMA:HEMA:3 = 65:15:20 (mole/mole/mole) is described. Third, the physico-chemical characteristics of the polymer (e.g. NMR spectroscopy, thermal behaviour) are given. Fourth, the in vitro thrombogenicity of the material was characterized by means of recent test assay. The combined results reveal that the terpolymer is very suitable for prosthetic applications in the cardiovascular system. A new prototype of an endovascular stent, made from the terpolymer, is presented. Stents find clinical use in interventional cardiology, in conjunction with percutaneous transluminal coronary angioplasty (PTCA). It is put forward that the stent prototype presented herein has, at least in principle, some advantages over existing (metallic) stents; these advantages are primarily owing to the unique combination of X-ray visibility and haemocompatibility which is presently achieved. (C) 1996 Elsevier Science Limited.
C1 EINDHOVEN UNIV TECHNOL,EINDHOVEN POLYMER LABS,NL-5600 MB EINDHOVEN,NETHERLANDS.
RP Kruft, MAB (reprint author), UNIV LIMBURG,MAASTRICHT CTR BIOMAT RES,POB 616,NL-6200 MD MAASTRICHT,NETHERLANDS.
CR BENZINA A, 1994, BIOMATERIALS, V15, P1122, DOI 10.1016/0142-9612(94)90232-1
   BLACK J, 1988, ORTHOPAEDIC BIOMATER, P133
   BRANDRUP J, 1989, POLYM HDB, V6, P218
   DAVIES JP, 1989, J BIOMED MATER RES, V23, P379, DOI 10.1002/jbm.820230402
   Fox T.G., 1956, B AM PHYS SOC, V1, P123
   HEMKER HC, 1986, THROMB HAEMOSTASIS, V56, P9
   JAYAKRISHNAN A, 1992, J APPL POLYM SCI, V44, P743, DOI 10.1002/app.1992.070440421
   KRUFT MAB, 1994, J BIOMED MATER RES, V28, P1259, DOI 10.1002/jbm.820281103
   LANGENBACH L, 1993, CAN REV AM STUD, V23, P61, DOI 10.3138/CRAS-023-04-03
   LINDHOUT T, 1995, J MATER SCI-MATER M, V6, P367, DOI 10.1007/BF00120306
   MARK HF, 1988, ENCY POLYM SCI ENG, V14, P1
   MARK HF, 1988, ENCY POLYM SCI ENG, V5, P299
   MARK HF, 1988, ENCY POLYM SCI ENG, V1, P260
   NIMB L, 1993, J BIOMED MATER RES, V27, P565, DOI 10.1002/jbm.820270503
   PEPPAS NA, 1994, SCIENCE, V263, P1715, DOI 10.1126/science.8134835
   RATNER BD, 1993, J BIOMED MATER RES, V27, P837, DOI 10.1002/jbm.820270702
   SAKARIASSEN KS, 1983, J LAB CLIN MED, V102, P522
   SIGWART UC, 1992, CORONARY STENTS, P5
NR 18
TC 41
Z9 44
U1 1
U2 20
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD SEP
PY 1996
VL 17
IS 18
BP 1803
EP 1812
DI 10.1016/0142-9612(95)00339-8
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA VF340
UT WOS:A1996VF34000010
PM 8879520
DA 2018-10-19
ER

PT J
AU Dies, F
   Etienne, D
   Abboud, NB
   Ouhayoun, JP
AF Dies, F
   Etienne, D
   Abboud, NB
   Ouhayoun, JP
TI Bone regeneration in extraction sites after immediate placement of an
   e-PTFE membrane with or without a biomaterial - A report on 12
   consecutive cases
SO CLINICAL ORAL IMPLANTS RESEARCH
LA English
DT Article
DE guided bone regeneration; e PTFE membranes; extraction sockets with
   buccal dehiscence; demineralized freeze dried bone; Bio Oss(R); bone
   healing
ID GUIDED TISSUE REGENERATION; IMPLANTS; DEFECTS
AB The efficacy in restoring a buccal dehiscence after tooth extraction has been studied in 12 consecutive cases using guided bone regeneration with (6 patients) or without (6 patients) a biomaterial (DFDBA or Bio Oss(R)) beneath an e-PTFE membrane. A correlation between the clinical impression of density at drilling time and the histological signs of bone formation has been evaluated too. The membrane was removed after 6 or 9 months and a biopsy was performed. Clinically, GBR was highly predictable for regeneration of the alveolar bone after tooth extraction with buccal dehiscence. The histology fully confirmed the clinical and radiographical results, showing bone formation in all cases with individual variations in the amount of bone formed. 6-month biopsies from the membrane sites had lamellar bone with large medullary spaces, while a good bone density was observed at 9 months. The membrane/biomaterial sites demonstrated mineralization and large amounts of allograft at 6 months. Thus, bone regeneration seems to take more time when grafting material is used.
RP Dies, F (reprint author), UNIV PARIS 07, FAC DENT SURG, DEPT PERIODONTOL, 5 RUE GARANCIERE, F-75006 PARIS, FRANCE.
CR AMLER M H, 1960, J Am Dent Assoc, V61, P32
   ATWOOD DA, 1963, J PROSTHET DENT, V13, P810, DOI 10.1016/0022-3913(63)90225-7
   Becker W, 1994, Int J Oral Maxillofac Implants, V9, P31
   BECKER W, 1990, INT J PERIODONT REST, V10, P377
   BECKER W, 1994, INT J ORAL MAXILLOF, V9, P305
   BOWERS GM, 1988, INT J PERIODONT REST, V8, P35
   BUSER D, 1995, INT J PERIODONT REST, V15, P11
   Buser D, 1993, Int J Periodontics Restorative Dent, V13, P29
   Buser D, 1990, CLIN ORAL IMPLAN RES, V1, P22, DOI 10.1034/j.1600-0501.1990.010104.x
   BUSER D, 1994, GUIDED BONE REGENERA, P189
   CARLSSON GE, 1967, ACTA ODONTOL SCAND, V25, P1
   CENTRELLA M, 1992, BONE, V4, P47
   CORTELLINI P, 1993, CLIN ORAL IMPLAN RES, V4, P203, DOI 10.1034/j.1600-0501.1993.040406.x
   DAHLIN C, 1991, J NEUROSURG, V74, P487, DOI 10.3171/jns.1991.74.3.0487
   DAHLIN C, 1988, PLAST RECONSTR SURG, V81, P672, DOI 10.1097/00006534-198805000-00004
   DAHLIN C, 1993, OSTEOPROMOTION, P51
   DONATH K, 1982, J ORAL PATHOL MED, V11, P318, DOI 10.1111/j.1600-0714.1982.tb00172.x
   Donath K., 1987, PREPARATION HISTOLOG, P1
   Fugazzotto P A, 1993, Int J Oral Maxillofac Implants, V8, P335
   Gher M. E., 1994, INT J PERIODONT REST, V14, P333
   GOLDBERG VM, 1987, CLIN ORTHOP RELAT R, V225, P7
   Gotfredsen K, 1991, CLIN ORAL IMPLAN RES, V2, P172, DOI 10.1034/j.1600-0501.1991.020403.x
   Hjorting-Hansen E, 1971, Br J Oral Surg, V9, P33, DOI 10.1016/S0007-117X(71)80006-9
   JOVANOVIC S A, 1992, International Journal of Oral and Maxillofacial Implants, V7, P233
   JOVANOVIC SA, 1995, INT J PERIODONT REST, V15, P57
   JOVANOVIC SA, 1992, QUINTESSENCE, P321
   LANDSBERG CJ, 1994, INT J ORAL MAXILLOF, V9, P586
   LANG NP, 1994, CLIN ORAL IMPLAN RES, V5, P92, DOI 10.1034/j.1600-0501.1994.050205.x
   Lazzere RJ, 1989, INT J PERIODONT REST, V9, P333
   LEKHOLM U, 1986, INT J ORAL MAX SURG, V15, P53, DOI 10.1016/S0300-9785(86)80011-4
   LEKHOLM U, 1993, CLIN ORAL IMPLAN RES, V4, P121, DOI 10.1034/j.1600-0501.1993.040302.x
   MATTOUT P, 1995, CLIN ORAL IMPLAN RES, V6, P189, DOI 10.1034/j.1600-0501.1995.060308.x
   MECALL RA, 1991, INT J PERIODONT REST, V11, P9
   MELLONIG JT, 1993, INT J PERIODONT REST, V13, P109
   NEVINS M, 1994, INT J PERIODONT REST, V14, P97
   NEVINS M, 1992, INT J PERIODONT REST, V12, P97
   Nowzari H, 1995, Int J Oral Maxillofac Implants, V10, P67
   NYMAN S, 1990, International Journal of Oral and Maxillofacial Implants, V5, P9
   OBRIEN TP, 1994, J PERIODONTOL, V65, P17, DOI 10.1902/jop.1994.65.1.17
   Ohta Y, 1993, J Oral Implantol, V19, P184
   Schenk R K, 1994, Int J Oral Maxillofac Implants, V9, P13
   SHANAMAN RH, 1992, INT J PERIODONT REST, V12, P257
   SHANAMAN RH, 1994, INT J PERIODONT REST, V14, P293
   SIMION M, 1994, INT J PERIODONT REST, V14, P497
   SIMION M, 1994, INT J PERIODONT REST, V14, P199
   SIMION M, 1994, INT J PERIODONT REST, V14, P167
   SIMION M, 1991, RIV ITAL OSSEOINTEGR, V1, P40
   WACHTEL H C, 1991, International Journal of Oral and Maxillofacial Implants, V6, P127
   Werbitt MJ, 1992, INT J PERIODONT REST, V12, P207
   Wilson T G Jr, 1992, Int J Periodontics Restorative Dent, V12, P185
NR 50
TC 97
Z9 100
U1 1
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0905-7161
EI 1600-0501
J9 CLIN ORAL IMPLAN RES
JI Clin. Oral Implant. Res.
PD SEP
PY 1996
VL 7
IS 3
BP 277
EP 285
DI 10.1034/j.1600-0501.1996.070310.x
PG 9
WC Dentistry, Oral Surgery & Medicine; Engineering, Biomedical
SC Dentistry, Oral Surgery & Medicine; Engineering
GA VU668
UT WOS:A1996VU66800011
PM 9151592
DA 2018-10-19
ER

PT J
AU Wang, XD
   Subramanian, A
   Dhanda, R
   Agrawal, CM
AF Wang, XD
   Subramanian, A
   Dhanda, R
   Agrawal, CM
TI Testing of bone-biomaterial interfacial bonding strength: A comparison
   of different techniques
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
ID PUSH-OUT TEST; FINITE-ELEMENT ANALYSIS; BEHAVIOR; TOUGHNESS; APATITE;
   GLASS
C1 UNIV TEXAS,CTR HLTH SCI,DEPT ORTHOPAED,SAN ANTONIO,TX 78284.
CR ANDERSSON OH, 1992, J MATER SCI-MATER M, V3, P145, DOI 10.1007/BF00705283
   *ASTM, 1993, 1993 ANN BOOK ASTM S
   BLACK J, 1989, J BIOMED MATER RES, V23, P1243, DOI 10.1002/jbm.820231102
   de Groot K, 1989, J Biomed Mater Res, V23, P1367, DOI 10.1002/jbm.820231112
   DHERT WJA, 1992, J BIOMED MATER RES, V26, P119, DOI 10.1002/jbm.820260111
   FUJIU T, 1984, J BIOMED MATER RES, V18, P845, DOI 10.1002/jbm.820180714
   HARRIGAN TP, 1990, J ORTHOPAED RES, V8, P678, DOI 10.1002/jor.1100080509
   KITSUGI T, 1986, J BIOMED MATER RES, V20, P1295, DOI 10.1002/jbm.820200906
   KRAUSE WR, 1982, CLIN ORTHOP RELAT R, V163, P290
   LIN H, 1992, J BIOMED MATER RES, V26, P7
   LIN KY, 1976, INT J FRACTURE, V12, P521, DOI 10.1007/BF00034638
   MAK AF, 1980, THESIS NW U
   OHASHI KL, 1996, T 42 ANN M ORTH RES, P521
   PILLIAR RM, 1991, MRS BULL, V16, P55
   SHIRAZIADL A, 1992, J BIOMECH ENG-T ASME, V114, P111, DOI 10.1115/1.2895434
   Spector M, 1987, J Arthroplasty, V2, P163, DOI 10.1016/S0883-5403(87)80024-4
   SUO ZG, 1989, MAT SCI ENG A-STRUCT, V107, P135, DOI 10.1016/0921-5093(89)90382-1
   TAKATSUKA K, 1995, J BIOMED MATER RES, V29, P157, DOI 10.1002/jbm.820290204
   WANG X, 1995, 21 ANN M SOC BIOM SA
   WANG X, 1995, 41 ANN M ORTH RES SO, P755
   WANG XD, 1994, J APPL BIOMATER, V5, P315, DOI 10.1002/jab.770050406
NR 21
TC 14
Z9 14
U1 0
U2 3
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD FAL
PY 1996
VL 33
IS 3
BP 133
EP 138
DI 10.1002/(SICI)1097-4636(199623)33:3<133::AID-JBM2>3.3.CO;2-P
PG 6
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA VC840
UT WOS:A1996VC84000002
PM 8864884
DA 2018-10-19
ER

PT J
AU Chapekar, MS
AF Chapekar, MS
TI Regulatory concerns in the development of biologic-biomaterial
   combinations
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
ID PROTEINS
AB Several biologic-biomaterial combinations are currently under development in an attempt to modulate tissue or organ function in patients, The FDA regulations on combination products and the intercenter agreements among the Center for Biologics Evaluation and Research (CBER), the Center for Devices and Radiological Health (CDRH), and the Center for Drugs Evaluation and Research (CDER) provide further guidance on center jurisdiction of combination products and other products where there are jurisdictional concerns. The biological component of biologic-biomaterial combinations raises a number of issues that relate to the safety and bioactivity of the final product, For example, transmission of adventitious agents to patients via somatic cells, tissue, or cell-derived products is a major safety concern as are in vivo inflammatory responses elicited by the biomaterial component, CBER has drafted a number of ''Points to Consider'' documents to provide further guidance in the development of biological products, The intent of this article is to provide the highlights of the FDA regulations for combination products and the intercenter agreement between CBER and CDRH delineating the responsibilities of each center for medical device activities. In addition, the article focuses on the CBER's concerns related to the development of somatic cell-biomaterial combinations for therapeutic use. (C) 1996 John Wiley & Sons, Inc.
RP Chapekar, MS (reprint author), US FDA,CTR BIOL EVALUAT & RES,DIV APPLICAT REVIEW & POLICY,OFF THERAPEUT RES & REVIEW,HFM 591,ROCKVILLE,MD 20852, USA.
CR AEBISCHER P, 1991, EXP NEUROL, V111, P269, DOI 10.1016/0014-4886(91)90093-R
   AKAGAWA Y, 1985, J PROSTHET DENT, V53, P681, DOI 10.1016/0022-3913(85)90023-X
   ARNAUD E, 1994, CALCIFIED TISSUE INT, V54, P493, DOI 10.1007/BF00334331
   *CDRH, 1995, G951 CDRH BLUE BOOK
   *HHS, 1989, HHS PUBL FDA, P172
   *HHS, 1989, HHS PUBL FDA, P43
   KOSSOVSKY N, 1991, J BIOMED MATER RES, V25, P1287, DOI 10.1002/jbm.820251009
   MCGRATH KP, 1992, J AM CHEM SOC, V114, P727, DOI 10.1021/ja00028a048
   MOORE JC, 1990, INT J ORAL MAX SURG, V19, P172, DOI 10.1016/S0901-5027(05)80139-0
   SULLIVAN SJ, 1991, SCIENCE, V252, P718, DOI 10.1126/science.2024124
   TORIUMI DM, 1991, ARCH OTOLARYNGOL, V117, P1101
   1993, FED REGISTER, V58, P53248
   1991, FED REGISTER, V56, P58754
NR 13
TC 15
Z9 15
U1 1
U2 2
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD FAL
PY 1996
VL 33
IS 3
BP 199
EP 203
DI 10.1002/(SICI)1097-4636(199623)33:3<199::AID-JBM10>3.0.CO;2-C
PG 5
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA VC840
UT WOS:A1996VC84000010
PM 8864892
DA 2018-10-19
ER

PT J
AU Kao, WJ
   Sapatnekar, S
   Hiltner, A
   Anderson, JM
AF Kao, WJ
   Sapatnekar, S
   Hiltner, A
   Anderson, JM
TI Complement-mediated leukocyte adhesion on poly(etherurethane ureas)
   under shear stress in vitro
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
ID PROTEIN ADSORPTION; CELL-ADHESION; FLOW; ACTIVATION; BIOINCOMPATIBILITY;
   SURFACES; POLYURETHANE; MONOCYTES
AB Blood-contacting biomaterials may activate the complement cascade, thus promoting leukocyte adhesion to the biomaterial surface. We hypothesize that the extent of complement activation is modulated by biomaterial formulation and the presence of fluid shear stress. To investigate this hypothesis, we tested base poly(etherurethane ureas) formulated with or without Santowhite(R) antioxidant, a nucleophilic additive. We found that adherent leukocyte densities decreased with increasing shear stress. Moreover, leukocyte adhesion was decreased significantly further by Santowhite(R) additive under shear stress but not under static conditions. Monocytes showed a higher propensity for adhesion than did neutrophils under shear and static conditions. Under static conditions, adherent cells on the Santowhite(R)-containing polyurethane had a slightly more activated morphology than those on the base polyurethane. Cell adhesion under shear stress was significantly decreased when C3 or fibronectin was depleted from the suspension medium. Santowhite(R) additive increased Factor B adsorption to the test surface while shear stress increased Factor H adsorption. The combination of Santowhite(R) additive and shear stress increased the adsorption of both Factor B and Factor H and the serum protein S-terminal complement complex levels, but it did not further increase the state of activation of adherent cells. We conclude the leukocyte adhesion on poly(etherurethane urea) surfaces is sensitive to the levels of shear stress and that both C3 and fibronectin are required to maintain adhesion in the presence of shear stress. The low state of cellular activation and increased Factor H adsorption may explain the decreased adherent leukocyte density on the Santowhite(R)-containing polyurethane. (C) 1996 John Wiley & Sons, Inc.
C1 CASE WESTERN RESERVE UNIV,INST PATHOL,CLEVELAND,OH 44106.
   CASE WESTERN RESERVE UNIV,DEPT MACROMOL SCI,CLEVELAND,OH 44106.
FU NHLBI NIH HHS [HL25239, HL47300, HL33849]
CR AKERSTROM B, 1985, J IMMUNOL, V135, P2589
   ARNAOUT MA, 1990, BLOOD, V75, P1037
   BELLISSIMO JA, 1984, T AM SOC ART INT ORG, V30, P359
   BENTON ER, 1966, J FLUID MECH, V24, P781, DOI 10.1017/S0022112066001009
   BRUIL A, 1994, J BIOMAT SCI-POLYM E, V5, P263, DOI 10.1163/156856294X00013
   CHENOWETH DE, 1984, ASAIO J, V7, P44
   COURY AJ, 1988, J BIOMATER APPL, V3, P131
   DAILY JW, 1960, J BASIC ENG, V3, P217
   DEPPISCH R, 1990, KIDNEY INT, V37, P696, DOI 10.1038/ki.1990.36
   DEPPISCH R, 1994, KIDNEY INT, V45, pS77
   GIDDENS DP, 1993, CARDIOVASC PATHOL, V2, pS167
   GOLDSTEIN IM, 1992, INFLAMMATION BASIC P, P63
   HAKIM RM, 1993, CARDIOVASC PATHOL, V2, pS187
   HAMMER DA, 1993, BLOOD CELLS, V19, P261
   Jahns Gerlinde, 1993, Clinical Materials, V14, P303, DOI 10.1016/0267-6605(93)90017-2
   JOHNSON RJ, 1990, BLOOD PURIFICAT, V8, P318, DOI 10.1159/000169986
   JOHNSON RJ, 1994, NEPHROL DIAL TRANSPL, V9, P36
   KAO WYJ, 1994, J BIOMED MATER RES, V28, P819, DOI 10.1002/jbm.820280709
   KUIJPERS TW, 1990, J IMMUNOL, V145, P2588
   LAWRENCE MB, 1987, BLOOD, V70, P1284
   LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D
   LAZARUS JM, 1994, AM J KIDNEY DIS, V24, P1019, DOI 10.1016/S0272-6386(12)81077-8
   Levich VG, 1962, PHYSICOCHEM HYDRODYN, P57
   LIM F, 1993, BIOMATERIALS, V14, P537, DOI 10.1016/0142-9612(93)90243-U
   Liszewski M. Kathryn, 1993, P917
   MARDER SR, 1985, J IMMUNOL, V134, P3325
   MCNALLY AK, 1994, P NATL ACAD SCI USA, V91, P10119, DOI 10.1073/pnas.91.21.10119
   MOHANDAS N, 1974, J BIOMED MATER RES, V8, P119, DOI 10.1002/jbm.820080203
   *NAT HEART LUNG VA, 1979, 802185 NIH, P68
   PETSCHEK H, 1968, T AM SOC ART INT ORG, V14, P256
   RUGGERI ZM, 1993, THROMB HAEMOSTASIS, V70, P119
   Ryu G H, 1993, ASAIO J, V39, pM332
   SLACK SM, 1993, THROMB HAEMOSTASIS, V70, P129
   SLACK SM, 1993, CARDIOVASC PATHOL, V2, pS11
   STEELE JG, 1993, J BIOMED MATER RES, V27, P927, DOI 10.1002/jbm.820270712
   STOSSEL TP, 1971, J CLIN INVEST, V50, P1745, DOI 10.1172/JCI106664
   WANG I, 1993, J BIOMED MATER RES, V27, P1119, DOI 10.1002/jbm.820270902
   WEILER JM, 1992, J IMMUNOL, V148, P3210
   WILLEMS GM, 1993, BLOOD, V82, P497
   ZIATS NP, 1990, J LAB CLIN MED, V116, P687
NR 40
TC 21
Z9 21
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD SEP
PY 1996
VL 32
IS 1
BP 99
EP 109
DI 10.1002/(SICI)1097-4636(199609)32:1<99::AID-JBM12>3.3.CO;2-E
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA VC839
UT WOS:A1996VC83900013
PM 8864878
DA 2018-10-19
ER

PT J
AU Habal, MB
AF Habal, MB
TI Triad of system applications for absorbable rigid fixation of the
   craniofacial skeleton
SO JOURNAL OF CRANIOFACIAL SURGERY
LA English
DT Article
DE absorbable rigid fixation
ID BONE
AB A new generation of absorbable plating systems is used in a clinical setting. This new system represents state of the art innovation in biomaterial experimental design, demonstrating total absorption in one year, and well-achieved fixation of the skeleton.
RP Habal, MB (reprint author), TAMPA BAY CRANIOFACIAL CTR,801 W DR MARTIN LUTHER KING,JR BLVD,TAMPA,FL 33603, USA.
CR EPPLEY BL, 1996, CLIN PLAST SURG, V23, P139
   HABAL MB, 1994, CLIN PLAST SURG, V21, P349
   Habal MB, 1996, CLIN PLAST SURG, V23, P93
   HABAL MB, 1994, CLIN PLAST SURG, V21, P525
   HABAL MB, 1996, ADV PLAST RECONSTR S, V12, P47
   HABAL MB, 1995, ENCY HDB BIOMATERI A, V1, P95
   HABAL MB, 1992, BONE GRAFTS BONE SUB
NR 7
TC 32
Z9 33
U1 0
U2 2
PU LITTLE BROWN CO
PI BOSTON
PA 34 BEACON STREET, BOSTON, MA 02108-1493
SN 1049-2275
J9 J CRANIOFAC SURG
JI J. Craniofac. Surg.
PD SEP
PY 1996
VL 7
IS 5
BP 394
EP 398
DI 10.1097/00001665-199609000-00014
PG 5
WC Surgery
SC Surgery
GA VH348
UT WOS:A1996VH34800014
PM 9133853
DA 2018-10-19
ER

PT J
AU Vogler, EA
AF Vogler, EA
TI On the biomedical relevance of surface spectroscopy
SO JOURNAL OF ELECTRON SPECTROSCOPY AND RELATED PHENOMENA
LA English
DT Article
DE biocompatibility; biomaterials; interface; spectroscopy; surface
ID BLOOD COMPATIBILITY; POLYMER SURFACES; CELL-ATTACHMENT; HYDROXYL-GROUPS;
   ADHESION; BIOMATERIALS; FORCES; WATER; ACTIVATION; GROWTH
AB Practical utility of surface spectroscopy in biomaterials is viewed from an abstract analytical science perspective in which the desired target information is compared to that obtained through spectroscopic probes. Through a five step reasoning process it is concluded that much of the information obtained by surface spectroscopy is not directly relevant to biomaterial end-use properties. A context is proposed to make more effective use of the indirect, but still very useful, analytical information derived from surface spectroscopy in biomaterials research.
RP Vogler, EA (reprint author), BECTON DICKINSON RES CTR,21 DAVIS DR,POB 12016,RES TRIANGLE PK,NC 27709, USA.
CR AVEYARD R, 1973, INTRO PRINCIPLES SUR, P1
   BAIER RE, 1976, P 8 SCI C GES DTSCH, P159
   BENEDICT RW, 1979, BIOMATER ARTIF CELL, V7, P477, DOI 10.3109/10731197909118963
   CHINN JA, 1989, J COLLOID INTERF SCI, V127, P67, DOI 10.1016/0021-9797(89)90008-8
   CLAESSON PM, 1986, J COLLOID INTERF SCI, V114, P234, DOI 10.1016/0021-9797(86)90257-2
   CONWAY R, 1987, NATURE, V329, P467, DOI 10.1038/329467a0
   CURTIS ASG, 1983, J CELL BIOL, V97, P1500, DOI 10.1083/jcb.97.5.1500
   DWEZ JL, 1991, INT NEW MAT WORKSH P, P84
   GOOD RJ, 1990, J ADHES SCI TECHNOL, V4, P607
   HAYCOX CL, 1993, J BIOMED MATER RES, V27, P1181, DOI 10.1002/jbm.820270909
   HEIMENZ PC, 1986, PRINCIPLES COLLOID S, P611
   HERZLINGER GA, 1983, BIOCOMPATIBLE POLYM, P89
   Ho W, 1993, PHYSICAL METHODS C A, V9, P209
   HUNTER RJ, 1989, F COLLOID SCI, V1, P244
   ISRAELACHVILI J, 1982, NATURE, V300, P341, DOI 10.1038/300341a0
   LEE JH, 1991, BIOMATERIALS, V12, P443
   LEE JH, 1992, POLYMER, V16, P680
   LELAH MD, 1986, POLYURETHANES MED, P201
   MARRA J, 1986, J COLLOID INTERF SCI, V109, P11, DOI 10.1016/0021-9797(86)90276-6
   MCAUSLAN BR, 1987, J BIOMED MATER RES, V21, P921, DOI 10.1002/jbm.820210708
   MEYER AE, 1990, THESIS LUND U MALMO
   OWENS NF, 1988, J CELL SCI, V91, P269
   PASHLEY RM, 1985, SCIENCE, V229, P1088, DOI 10.1126/science.4035349
   RAMSEY WS, 1984, IN VITRO CELL DEV B, V20, P802
   Ratner B. D., 1984, CONT BIOMATERIALS MA, P193
   RATNER BD, 1990, J VAC SCI TECHNOL A, V8, P2306, DOI 10.1116/1.576755
   RATNER BD, 1993, J BIOMED MATER RES, V27, P283, DOI 10.1002/jbm.820270302
   RATNER BD, 1993, J BIOMED MATER RES, V27, P837, DOI 10.1002/jbm.820270702
   RATNER BD, 1988, SURFACE CHARACTERIZA
   RATZSCH M, 1990, ADV COLLOID INTERFAC, V31, P225, DOI 10.1016/0001-8686(90)80007-M
   SCHAKENRAAD JM, THESIS U GRONINGEN N
   SPECTOR M, 1992, J BIOMED MATER RES, V26, P1, DOI 10.1002/jbm.820260102
   VOGLER EA, 1987, J BIOMED MATER RES, V21, P1197, DOI 10.1002/jbm.820211004
   VOGLER EA, 1993, SURFACTANT SCI SERIE, V49, P183
   WARD CA, 1989, MED PROG TECHNOL, V15, P63
   WEISS R, 1991, SCIENCE, V252, P1059, DOI 10.1126/science.252.5009.1059
   WIGGINS PM, 1990, MICROBIOL REV, V54, P432
   WILLIAMS DF, 1987, DEFINITIONS BIOMEDIC, V4, P66
NR 38
TC 22
Z9 22
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0368-2048
J9 J ELECTRON SPECTROSC
JI J. Electron Spectrosc. Relat. Phenom.
PD SEP
PY 1996
VL 81
IS 3
BP 237
EP 247
DI 10.1016/0368-2048(96)02526-1
PG 11
WC Spectroscopy
SC Spectroscopy
GA VT919
UT WOS:A1996VT91900003
DA 2018-10-19
ER

PT J
AU Leggett, GJ
   Davies, MC
   Jackson, DE
   Tendler, SJB
AF Leggett, GJ
   Davies, MC
   Jackson, DE
   Tendler, SJB
TI Scanning probe microscopy of biomolecules and polymeric biomaterials
SO JOURNAL OF ELECTRON SPECTROSCOPY AND RELATED PHENOMENA
LA English
DT Article
DE adsorption; biomaterial; macromolecule; self-assembled monolayer; STM;
   TEM
ID 2-IMINOTHIOLANE METHYL 4-MERCAPTOBUTYRIMIDATE; TRANSMISSION
   ELECTRON-MICROSCOPY; BACTERIAL SURFACE PROTEIN; ATOMIC FORCE MICROSCOPY;
   TUNNELING-MICROSCOPY; GOLD SURFACES; DNA; GRAPHITE; MOLECULES; WATER
AB Critical problems associated with the analysis of biological macromolecules and polymeric biomaterials by scanning probe microscopy are identified. The problems of molecular immobilisation and distribution and data validation are discussed. A number of solutions are described, including the application of a conductive coating and the covalent attachment of biomolecules to suitable substrates. Recent work in the authors' laboratory is described. The conductive coating approach has been employed to study helical macromolecules (including polysaccharides and DNA) and protein molecules. A variety of covalent attachment procedures have been examined, including the adsorption of thiolated proteins onto gold surfaces, the coupling of proteins to self-assembled monolayers, and the attachment of biotinylated molecules to streptavidin-coated polystyrene surfaces. Studies of polymeric biomaterials are also described. Scanning tunnelling microscopy and transmission electron microscopy have been compared in studies of poly(ethylene oxide), and the interactions of ferritin with a ferritin antibody immobilised on a polystyrene surface have been examined.
C1 UNIV NOTTINGHAM,DEPT PHARMACEUT SCI,LAB BIOPHYS & SURFACE ANAL,NOTTINGHAM NG7 2RD,ENGLAND.
OI Davies, Martyn/0000-0001-7695-0596; Leggett, Graham/0000-0002-4315-9076
CR AMREIN M, 1988, SCIENCE, V240, P514, DOI 10.1126/science.3358130
   ARSCOTT PG, 1989, NATURE, V339, P484, DOI 10.1038/339484a0
   BINNIG G, 1983, PHYS REV LETT, V50, P120, DOI 10.1103/PhysRevLett.50.120
   BONNELL DA, 1993, SCANNING TUNNELLING
   BOTTOMLEY LA, 1992, J VAC SCI TECHNOL A, V10, P591, DOI 10.1116/1.577735
   BUTLER JE, 1992, J IMMUNOL METHODS, V150, P77, DOI 10.1016/0022-1759(92)90066-3
   CLEMMER CR, 1991, SCIENCE, V251, P640, DOI 10.1126/science.1992517
   CLEMMER CR, 1992, SCANNING MICROSCOPY, V6, P319
   DAVIES J, UNPUB LANGMUIR
   DRISCOLL RJ, 1990, NATURE, V346, P294, DOI 10.1038/346294a0
   FURUNO T, 1992, MICROSC RES TECHNIQ, V21, P32, DOI 10.1002/jemt.1070210105
   GUCKENBERGER R, 1989, ULTRAMICROSCOPY, V31, P327, DOI 10.1016/0304-3991(89)90055-7
   HALLMARK VM, 1987, PHYS REV LETT, V59, P2879, DOI 10.1103/PhysRevLett.59.2879
   HECKL WM, 1992, ULTRAMICROSCOPY, V42, P1073, DOI 10.1016/0304-3991(92)90404-8
   HECNK WM, 1989, LANGMUIR, V5, P1433
   JUE R, 1978, BIOCHEMISTRY-US, V17, P5399, DOI 10.1021/bi00618a013
   LAMBERT JM, 1978, BIOCHEMISTRY-US, V17, P5406, DOI 10.1021/bi00618a014
   LEGGETT GJ, 1993, J PHYS CHEM-US, V97, P8852, DOI 10.1021/j100137a006
   LEGGETT GJ, 1993, LANGMUIR, V9, P2356, DOI 10.1021/la00033a018
   LEGGETT GJ, 1993, J PHYS CHEM-US, V97, P5348, DOI 10.1021/j100122a028
   LEGGETT GJ, 1993, LANGMUIR, V9, P1115, DOI 10.1021/la00028a039
   LINDSAY SM, 1989, SCIENCE, V244, P1063, DOI 10.1126/science.2727694
   LINDSAY SM, 1992, BIOPHYS J, V61, P1570, DOI 10.1016/S0006-3495(92)81961-6
   LINDSAY SM, 1993, SCANNING TUNNELLING, P355
   LUTTRULL DK, 1992, LANGMUIR, V8, P765, DOI 10.1021/la00039a006
   LYUBCHENKO YL, 1991, J VAC SCI TECHNOL B, V9, P1288, DOI 10.1116/1.585223
   MARTI O, 1993, STM SFM BIOL
   MCGONIGAL GC, 1990, APPL PHYS LETT, V57, P28, DOI 10.1063/1.104234
   MURTHY MRN, 1981, J MOL BIOL, V152, P465, DOI 10.1016/0022-2836(81)90254-0
   ROBERTS CJ, 1992, BIOCHEM J, V283, P181, DOI 10.1042/bj2830181
   SALMERON M, 1990, J VAC SCI TECHNOL A, V8, P635, DOI 10.1116/1.576361
   SCHNEIR J, 1988, J APPL PHYS, V63, P717, DOI 10.1063/1.340062
   SONNENFELD R, 1986, SCIENCE, V232, P211, DOI 10.1126/science.232.4747.211
   TERSOFF J, 1985, PHYS REV B, V31, P805, DOI 10.1103/PhysRevB.31.805
   THUNDAT T, 1992, SCANNING MICROSCOPY, V6, P903
   TSUKADA M, 1991, SURF SCI REP, V13, P265
   WIEGRABE W, 1991, J MICROSC-OXFORD, V163, P79, DOI 10.1111/j.1365-2818.1991.tb03161.x
   WILKINS MJ, 1992, APPL PHYS LETT, V60, P1436, DOI 10.1063/1.107289
   WILKINS MJ, 1993, ULTRAMICROSCOPY, V48, P197, DOI 10.1016/0304-3991(93)90182-W
   WILKINS MJ, 1993, J MICROSC-OXFORD, V172, P215, DOI 10.1111/j.1365-2818.1993.tb03415.x
   WILKINS MJ, IN PRESS POLYM PREP
   YANG J, 1992, FEBS LETT, V301, P173, DOI 10.1016/0014-5793(92)81241-D
   YANG X, 1992, ANN PHYS-LEIPZIG, V1, P3
   YUAN JY, 1991, PHYS REV LETT, V67, P863, DOI 10.1103/PhysRevLett.67.863
NR 44
TC 8
Z9 8
U1 0
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0368-2048
J9 J ELECTRON SPECTROSC
JI J. Electron Spectrosc. Relat. Phenom.
PD SEP
PY 1996
VL 81
IS 3
BP 249
EP 268
DI 10.1016/0368-2048(95)02527-8
PG 20
WC Spectroscopy
SC Spectroscopy
GA VT919
UT WOS:A1996VT91900004
DA 2018-10-19
ER

PT J
AU Sodhi, RNS
AF Sodhi, RNS
TI Application of surface analytical and modification techniques to
   biomaterial research
SO JOURNAL OF ELECTRON SPECTROSCOPY AND RELATED PHENOMENA
LA English
DT Article
DE adsorbate; biomaterial; plasma technique; SSIMS; surface modification;
   XPS
ID SCANNING-TUNNELING-MICROSCOPY; NEURONAL CELL ATTACHMENT; ATOMIC-FORCE
   MICROSCOPY; X-RAY PHOTOELECTRON; ADHESION; PLASMA;
   POLY(TETRAFLUOROETHYLENE); TEFLON; FILMS; POLYTETRAFLUOROETHYLENE
AB The development of suitable materials for biomedical applications requires a thorough understanding of the structure and chemistry of the solid-liquid interface when such a material is placed in the biological environment. The held is made complex by the diversity of materials used, the different applications one has to consider, and the complexity of the various biological environments the implanted material may find itself in. To understand the interactions which may occur, it is important to have information on the structure and composition of the top few atomic layers. Concepts from surface science, such as surface analysis and modification techniques prove to be valuable aids in the development of suitable biomaterials. These methods are not new or unique but are well established in other technologies. In this paper, several areas of surface modification techniques will be chosen to illustrate how they are being applied in the biomaterial field, stressing the interdisciplinary nature of the work as well as the surface analytical techniques involved.
RP Sodhi, RNS (reprint author), UNIV TORONTO,CTR BIOMAT,170 COLL ST,TORONTO,ON M5S 3E3,CANADA.
CR American Society for Testing and Materials (ASTM), 1992, ANN BOOK ASTM STAND, V11.04
   ANDERS PA, 1989, J APPL PHYS, V66, P3548
   Andrade J. D., 1985, SURFACE INTERFACIAL, V1, P105
   BAIER RE, 1984, J BIOMED MATER RES, V18, P337, DOI 10.1002/jbm.820180404
   Beamson G., 1992, HIGH RESOLUTION XPS
   Briggs D., 1989, HDB STATIC SECONDARY
   BROWNE M, 1994, BIOMATERIALS, V15, P894, DOI 10.1016/0142-9612(94)90113-9
   BUSSCHER HJ, 1991, CELL MATER, V1, P243
   CADMAN P, 1979, J MATER SCI, V14, P2672, DOI 10.1007/BF00610638
   CALLEN BW, 1995, J VAC SCI TECHNOL A, V13, P2023, DOI 10.1116/1.579647
   CALLEN BW, 1993, J BIOMED MATER RES, V27, P851, DOI 10.1002/jbm.820270703
   CALLEN BW, 1995, J BIOMED MATER RES, V29, P279, DOI 10.1002/jbm.820290302
   CALLEN BW, 1994, T 20 M SOC BIOM BOST, P342
   CASTNER DG, 1992, T 4 WORLD BIOM C BER, P194
   CHAKRABARTI N, 1988, MACROMOLECULES, V21, P3011, DOI 10.1021/ma00188a020
   CHANEY R, 1987, FRESEN Z ANAL CHEM, V329, P143, DOI 10.1007/BF00469126
   CHANG CA, 1987, APPL PHYS LETT, V51, P1236, DOI 10.1063/1.98741
   CLARK DT, 1986, J ELECTRON SPECTROSC, V41, P399, DOI 10.1016/0368-2048(86)85017-4
   CLARK DT, 1987, J POLYM SCI POL CHEM, V25, P2643, DOI 10.1002/pola.1987.080251002
   Clark DT, 1978, POLYM SURFACES, P185
   CURTIS ASG, 1986, J CELL SCI, V86, P9
   DAVIES M, 1996, J ELECT SPECTROSC RE, V81, P249
   DAVIES MC, 1990, CRIT REV BIOCOMPAT, V5, P297
   ERTEL SI, 1991, J BIOMAT SCI-POLYM E, V3, P63
   Formichi M J, 1988, Ann Vasc Surg, V2, P14, DOI 10.1016/S0890-5096(06)60773-5
   GJERMO P, 1989, J DENT RES, V68, P1602
   GOMBOTZ WR, 1989, J APPL POLYM SCI, V37, P91, DOI 10.1002/app.1989.070370108
   HANSMA PK, 1988, SCIENCE, V242, P209, DOI 10.1126/science.3051380
   HAQUE Y, 1986, J APPL POLYM SCI, V32, P4369, DOI 10.1002/app.1986.070320407
   JANSTA J, 1975, J APPL POLYM SCI, V19, P3201, DOI 10.1002/app.1975.070191206
   JOHANSSON C, 1989, J BIOMED ENG, V11, P3, DOI 10.1016/0141-5425(89)90158-1
   Johnston EE, 1996, J ELECTRON SPECTROSC, V81, P303, DOI 10.1016/0368-2048(95)02666-5
   KASEMO B, 1986, CRIT REV BIOCOMPAT, V2, P335
   KIAEI D, 1992, J BIOMAT SCI-POLYM E, V4, P35
   KNUTSON K, 1985, SURFACE INTERFACIAL, V1, P197
   Lausmaa J, 1996, J ELECTRON SPECTROSC, V81, P343, DOI 10.1016/0368-2048(95)02530-8
   LINDSAY SM, 1993, J VAC SCI TECHNOL A, V11, P808, DOI 10.1116/1.578309
   MAEUSLI PA, 1986, BIOL BIOMECHANICAL P, P57
   MCKEOWN NB, 1991, LANGMUIR, V7, P2146, DOI 10.1021/la00058a029
   MICHAEL R, 1986, J VAC SCI TECHNOL A, V4, P1861, DOI 10.1116/1.573778
   Morosoff N., 1990, PLASMA DEPOSITION TR, P1, DOI 10.1016/13978-0-12-200430-8.50007-5
   RANIERI JP, 1994, INT J DEV NEUROSCI, V12, P725, DOI 10.1016/0736-5748(94)90052-3
   RANIERI JP, 1995, J BIOMED MATER RES, V29, P779, DOI 10.1002/jbm.820290614
   RATNER BD, 1990, J VAC SCI TECHNOL A, V8, P2306, DOI 10.1116/1.576755
   RATNER BD, 1993, J BIOMED MATER RES, V27, P837, DOI 10.1002/jbm.820270702
   Ratner BD, 1990, PLASMA DEPOSITION TR, P463
   RATNR BD, 1987, J BIOMED MATER RES-A, V21, P59
   ROBERTS RF, 1976, J APPL POLYM SCI, V20, P255, DOI 10.1002/app.1976.070200121
   RYE RR, 1987, APPL SURF SCI, V29, P397, DOI 10.1016/0169-4332(87)90045-6
   RYE RR, 1990, LANGMUIR, V6, P338, DOI 10.1021/la00092a008
   Sabbatini L, 1996, J ELECTRON SPECTROSC, V81, P285, DOI 10.1016/0368-2048(95)02528-6
   SACHER E, 1988, SURFACE CHARACTERISA
   Sherwood PMA, 1996, J ELECTRON SPECTROSC, V81, P319, DOI 10.1016/0368-2048(95)02529-4
   SODHI RNS, 1992, J DENT RES, V71, P1493, DOI 10.1177/00220345920710080601
   SODHI RNS, 1992, T 4 WORLD BIOM C BER, P172
   VARGO TG, 1992, LANGMUIR, V8, P130, DOI 10.1021/la00037a025
   VARGO TG, 1995, J BIOMED MATER RES, V29, P767, DOI 10.1002/jbm.820290613
   VARGO TG, 1991, J POLYM SCI POL CHEM, V29, P555, DOI 10.1002/pola.1991.080290412
   WERTHEIMER MR, 1985, J VAC SCI TECHNOL A, V3, P2643, DOI 10.1116/1.572805
   ZHOU XL, 1990, J CHEM PHYS, V92, P5612, DOI 10.1063/1.458493
NR 60
TC 38
Z9 39
U1 0
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0368-2048
J9 J ELECTRON SPECTROSC
JI J. Electron Spectrosc. Relat. Phenom.
PD SEP
PY 1996
VL 81
IS 3
BP 269
EP 284
DI 10.1016/0368-2048(95)02665-7
PG 16
WC Spectroscopy
SC Spectroscopy
GA VT919
UT WOS:A1996VT91900005
DA 2018-10-19
ER

PT J
AU Sabbatini, L
   Zambonin, PG
AF Sabbatini, L
   Zambonin, PG
TI XPS and SIMS surface chemical analysis of some important classes of
   polymeric biomaterials
SO JOURNAL OF ELECTRON SPECTROSCOPY AND RELATED PHENOMENA
LA English
DT Article
DE biomaterial; polymer; SIMS; XPS
ID COPOLYMER LATEX FILMS; MICROPHASE SEPARATED STRUCTURE; POLYURETHANE
   BLOCK COPOLYMERS; O-PHENYLENEDIAMINE FILM; ION MASS-SPECTROMETRY; SOFT
   CONTACT-LENSES; BLOOD COMPATIBILITY; QUANTITATIVE-DETERMINATION;
   SEGMENTED POLY(URETHANEUREAS); AMPEROMETRIC BIOSENSOR
AB Biocompatibility of materials, whatever their nature, starts at their surfaces. Chemical composition and structure, the presence of contamination, segregation of elements and molecules, microdomain distribution, functional group orientation and molecular mobility at the top layer of a biomaterial strongly influence its biological response and determine its long-term performances. The understanding of surfaces, however, is an intrinsically complex issue which needs to be addressed by many independent physical and chemical investigations.
   Several methods are available today for the characterization of surfaces, each possessing different potential and complementary characteristics. The present paper reviews some recent applications of surface analysis of polymeric biomaterials. In this particular field XPS and SIMS have been far more widely employed than other surface techniques. The subject matter has been confined to a few representative classes of biopolymers: polyurethanes, polymethacrylates, polyethylene and some miscellanea. Case studies are selected in which the correlation between surface characterization and bio- and blood-compatibility has been more clearly addressed. Among other issues, some emphasis is given to some studies dealing with the phenomenon of reorientation and restructuring of polymer surfaces under different experimental conditions.
RP Sabbatini, L (reprint author), UNIV BARI,DIPARTIMENTO CHIM,VIA ORBANA 4,I-70126 BARI,ITALY.
OI Sabbatini, Luigia/0000-0002-5099-2242
CR Andrade J. D., 1985, SURFACE INTERFACIAL, V1, P105
   BEAMSON G, 1991, SURF INTERFACE ANAL, V17, P105, DOI 10.1002/sia.740170206
   BORETOS JW, 1975, J BIOMED MATER RES, V9, P327, DOI 10.1002/jbm.820090308
   Briggs D., 1992, PRACTICAL SURFACE AN, V1, P437
   BRIGGS D, 1992, PRACTICAL SURFACE AN, V2, P367
   CASTNER DG, 1992, J BIOMAT SCI-POLYM E, V3, P463, DOI 10.1163/156856292X00448
   CASTNER DG, 1988, SURFACE CHARACTERIZA, P65
   CENTONZE D, 1992, FRESEN J ANAL CHEM, V342, P729, DOI 10.1007/BF00321865
   CENTONZE D, 1994, ELECTROANAL, V6, P423, DOI 10.1002/elan.1140060511
   CENTONZE D, 1992, ANN CHIM-ROME, V82, P219
   CENTONZE D, 1993, ECASIA 93 CAT IT
   CHOU NJ, 1990, NEW CHARACTERIZATION, P289
   DAVIES MC, 1990, CRIT REV BIOCOMPAT, V5, P297
   DEGIGLIO E, 1994, GNOSEIS, V1, P24
   FAKES DW, 1988, SURF INTERFACE ANAL, V13, P233, DOI 10.1002/sia.740130411
   FENCIL DA, 1989, T SOC BIOMATER, V15, P233
   GALLETTI PM, 1983, J BIOMED MATER RES, V17, P589
   GARBASSI F, 1993, POLYM SURFACES PHYSI, P395
   GARDELLA JA, 1990, ANAL CHEM, V62, pA645, DOI 10.1021/ac00210a002
   GARDELLA JA, 1986, J POLYM SCI POL LETT, V24, P649, DOI 10.1002/pol.1986.140241206
   GRAHAM SW, 1981, J BIOMED MATER RES, V15, P349, DOI 10.1002/jbm.820150307
   GRAHAM SW, 1981, J BIOMED MATER RES, V15, P465, DOI 10.1002/jbm.820150403
   GRASEL TG, 1987, J BIOMED MATER RES, V21, P815, DOI 10.1002/jbm.820210702
   Griesser HJ, 1990, J BIOACT COMPAT POLY, V5, P179
   GUERRIERI A, 1995, BIOMATERIALS, V16, P1025, DOI 10.1016/0142-9612(95)94911-4
   HANSMA PK, 1988, SCIENCE, V242, P209, DOI 10.1126/science.3051380
   HANSON SR, 1980, J LAB CLIN MED, V95, P289
   HANSON SR, 1982, ADV BIOMATER, V3, P519
   HAYAT U, 1992, BIOMATERIALS, V13, P801, DOI 10.1016/0142-9612(92)90022-G
   HAYWARD JA, 1986, BIOMATERIALS, V7, P252, DOI 10.1016/0142-9612(86)90045-1
   HOOK TJ, 1986, ANAL CHEM, V58, P1285, DOI 10.1021/ac00298a004
   Hu C. B., 1980, AM CHEM SOC DIV POLY, V21, P156
   ITO Y, 1988, CRC CRIT R BIOCOMP, V5, P45
   KANG IK, 1993, BIOMATERIALS, V14, P787, DOI 10.1016/0142-9612(93)90045-4
   KO TM, 1993, BIOMATERIALS, V14, P657
   Lelah M. D., 1986, POLYURETHANES MED
   LEWIS KB, 1993, J COLLOID INTERF SCI, V159, P77, DOI 10.1006/jcis.1993.1299
   LIN HB, 1993, J BIOMAT SCI-POLYM E, V4, P183, DOI 10.1163/156856293X00519
   LIN JN, 1990, LANGMUIR, V6, P509, DOI 10.1021/la00092a036
   LINDON JN, 1978, J LAB CLIN MED, V92, P904
   LYMAN DJ, 1977, T AM SOC ART INT ORG, V23, P253
   MAHMUD NA, 1983, PHYSICOCHEMICAL ASPE, V2, P953
   MAHMUD NA, 1986, POLYM MAT SCI ENG, V55, P751
   MALITESTA C, 1990, ANAL CHEM, V62, P2735, DOI 10.1021/ac00223a016
   MILLER DR, 1986, J MACROMOL SCI R M C, VC26, P33
   MORRA M, 1993, SPECTROSC EUR, V5, P10
   *NAT HEAT LUNG BLO, 1985, N8511185 NIH NAT HEA
   PALMISANO F, 1994, BIOSENS BIOELECTRON, V9, P471, DOI 10.1016/0956-5663(94)90009-4
   PALMISANO F, 1993, BIOSENS BIOELECTRON, V8, P393, DOI 10.1016/0956-5663(93)80023-I
   PAYNTER RW, 1986, TECHNIQUES BIOCOMPAT, V2, P49
   PIJPERS AP, 1986, J POLYM SCI POL LETT, V24, P653, DOI 10.1002/pol.1986.140241207
   PIJPERS AP, 1985, J POLYM SCI POL CHEM, V23, P453, DOI 10.1002/pol.1985.170230219
   PIJPERS AP, 1987, J ELECTRON SPECTROSC, V43, P131, DOI 10.1016/0368-2048(87)80025-7
   RATNER BD, 1993, J BIOMED MATER RES, V27, P283, DOI 10.1002/jbm.820270302
   RATNER BD, 1993, BIOMATERIALS, V14, P148, DOI 10.1016/0142-9612(93)90229-U
   RATNER BD, 1993, J BIOMED MATER RES, V27, P837, DOI 10.1002/jbm.820270702
   RATNER BD, 1988, PROG BIOMED ENG, V5, P87
   RATNER BD, 1983, PHYSICOCHEMICAL ASPE, V2, P969
   RICHARDSON RR, 1993, BIOMATERIALS, V14, P627, DOI 10.1016/0142-9612(93)90183-3
   SABBATINI L, 1992, CLAO J, V18, P101
   SABBATINI L, 1992, P INT S SURF PROP BI, P58
   Sabbatini L., 1993, SURFACE CHARACTERIZA
   SABBATINI L, 1988, P 2 INC SPETTR AN IT, pG13
   STUPP SI, 1977, J BIOMED MATER RES, V11, P237, DOI 10.1002/jbm.820110209
   SUNG CSP, 1979, J BIOMED MATER RES, V13, P161
   SUZUKI M, 1983, PHYSICOCHEMICAL ASPE, V2, P923
   TAKAHARA A, 1985, POLYMER, V26, P978, DOI 10.1016/0032-3861(85)90217-4
   TAKAHARA A, 1985, POLYMER, V26, P987, DOI 10.1016/0032-3861(85)90218-6
   TAKAHARA A, 1990, PROGRESS IN BIOMEDICAL POLYMERS, P217
   TINGEY KG, 1991, LANGMUIR, V7, P2471, DOI 10.1021/la00059a013
   TRIPATHI R, 1978, SOFT CONTACT LENSES, P299
   TYLER BJ, 1993, J BIOMED MATER RES, V27, P327, DOI 10.1002/jbm.820270306
   TYLER BJ, 1992, J BIOMED MATER RES, V26, P273, DOI 10.1002/jbm.820260302
   VARGO TG, 1989, J VAC SCI TECHNOL A, V7, P1733, DOI 10.1116/1.576036
   Vickerman J. C., 1989, SECONDARY ION MASS S
   WEDLER FC, 1977, J BIOMED MATER RES, V11, P525, DOI 10.1002/jbm.820110408
   YAMASHITA I, 1986, KOBUNSHI KAKO, V35, P158
   ZAMBONIN PG, 1992, CONTACTOLOGIA E, V14, P175
   ZHOU C, 1986, FENXI HU AXNE, V14, P667
NR 79
TC 41
Z9 43
U1 1
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0368-2048
J9 J ELECTRON SPECTROSC
JI J. Electron Spectrosc. Relat. Phenom.
PD SEP
PY 1996
VL 81
IS 3
BP 285
EP 301
DI 10.1016/0368-2048(95)02528-6
PG 17
WC Spectroscopy
SC Spectroscopy
GA VT919
UT WOS:A1996VT91900006
DA 2018-10-19
ER

PT J
AU Lausmaa, J
AF Lausmaa, J
TI Surface spectroscopic characterization of titanium implant materials
SO JOURNAL OF ELECTRON SPECTROSCOPY AND RELATED PHENOMENA
LA English
DT Article
DE biomaterial; implant; surface analysis; surface preparation; surface
   properties; titanium
ID X-RAY PHOTOELECTRON; SCANNING TUNNELING MICROSCOPY; OXIDE-FILMS;
   PREPARATIVE PROCEDURES; BIOMATERIAL SURFACES; OXIDIZED TITANIUM; TISSUE
   INTERFACE; BONE; ADSORPTION; TI-6AL-4V
AB Titanium is a relatively widely and successfully used biomaterial, especially in the dental and orthopaedic fields. The surface oxide which almost always covers titanium is considered to be an important factor for the favourable tissue response obtained with Ti implants. This paper describes the properties of surface oxides on Ti by discussing some selected examples of surface spectroscopy analyses of Ti surfaces prepared by different methods, including; clinical procedures (machining, solvent cleaning, sterilization), electrochemical methods (electropolishing and anodic oxidation), thermal oxidation in air, and nitrogen-ion implantation. The main analytical techniques are scanning AES and XPS (ESCA). Complementary information is obtained from secondary ion mass spectrometry (SIMS), Rutherford backscattering (RES), and nuclear reaction analysis (NRA). Selected spectroscopic results are discussed with reference to microstructural studies published elsewhere. Comparison between pure Ti and Ti6Al4V alloy shows many similarities, but also some significant differences between the two materials. The paper also comments briefly on surface contamination and cleaning, and discusses some selected examples of biological studies on different titanium surfaces.
C1 GOTHENBURG UNIV,S-41296 GOTHENBURG,SWEDEN.
RP Lausmaa, J (reprint author), CHALMERS UNIV TECHNOL,DEPT APPL PHYS,S-41296 GOTHENBURG,SWEDEN.
CR ADELL R, 1990, International Journal of Oral and Maxillofacial Implants, V5, P347
   ALADJEM A, 1973, J MATER SCI, V8, P688, DOI 10.1007/BF00561225
   ALBREKTSSON T, 1985, Critical Reviews in Biocompatibility, V1, P53
   ALBREKTSSON T, 1983, ANN BIOMED ENG, V11, P1, DOI 10.1007/BF02363944
   AMEEN AP, 1993, CLIN ORAL IMPLAN RES, V4, P144, DOI 10.1034/j.1600-0501.1993.040305.x
   ANDRADE JD, 1987, T AM SOC ART INT ORG, V33, P75
   ASK M, 1990, J MATER RES, V5, P1662, DOI 10.1557/JMR.1990.1662
   ASK M, 1988, APPL SURF SCI, V35, P283
   ASSEFPOURDEZFULY M, 1984, J MATER SCI, V19, P3626
   Baier R E, 1988, Int J Oral Maxillofac Implants, V3, P9
   BAIER RE, 1984, J BIOMED MATER RES, V18, P337, DOI 10.1002/jbm.820180404
   BAIER RE, 1982, BIOMATERIALS, V3, P241, DOI 10.1016/0142-9612(82)90027-8
   BAIER RE, 1992, TISSUE INTEGRATION IN ORAL, ORTHOPEDIC, AND MAXILLOFACIAL RECONSTRUCTION, P240
   BARO AM, 1986, BIOMATERIALS, V7, P463, DOI 10.1016/0142-9612(86)90036-0
   Binon P P, 1992, Int J Oral Maxillofac Implants, V7, P168
   Boehm HP, 1971, DISCUSS FARADAY SOC, V52, P264
   Bowers K T, 1992, Int J Oral Maxillofac Implants, V7, P302
   BRANEMARK PI, 1985, TISSUE INTEGRATED PR
   BUSER D, 1991, J BIOMED MATER RES, V25, P889, DOI 10.1002/jbm.820250708
   CLARSSON L, 1988, INT J ORAL MAXILLOF, V3, P21
   DAVIS GD, 1983, APPL SURF SCI, V15, P321, DOI 10.1016/0378-5963(83)90026-0
   Davis L. E., 1978, HDB AUGER ELECT SPEC
   DAWSON PT, 1985, SURF SCI, V149, P105, DOI 10.1016/S0039-6028(85)80016-9
   DELPLANCKE JL, 1988, ELECTROCHIM ACTA, V33, P1539, DOI 10.1016/0013-4686(88)80223-8
   DOUNDOULAKIS JH, 1987, J PROSTHET DENT, V58, P471, DOI 10.1016/0022-3913(87)90279-4
   GARDELLA JA, 1988, SURFACE CHARACTERIZA, P145
   GOPEL W, 1984, SURF SCI, V139, P333, DOI 10.1016/0039-6028(84)90054-2
   HAZAN R, 1993, BIOMATERIALS, V14, P570, DOI 10.1016/0142-9612(93)90172-X
   Henrich V. E., 1994, SURFACE SCI METAL OX
   HENRICH VE, 1983, PROG SURF SCI, V14, P175, DOI 10.1016/0079-6816(83)90002-3
   JANSEN JA, 1991, BIOMATERIALS, V12, P25, DOI 10.1016/0142-9612(91)90127-V
   JOBIN M, 1992, ULTRAMICROSCOPY, V42, P637, DOI 10.1016/0304-3991(92)90335-H
   JOBIN M, 1991, J VAC SCI TECHNOL B, V9, P1263, DOI 10.1116/1.585217
   JOHANSSON CB, 1993, J MATER SCI-MATER M, V4, P132, DOI 10.1007/BF00120382
   KASEMO B, 1986, CRIT REV BIOCOMPAT, V2, P335
   KASEMO B, 1991, BONE-BIOMATERIAL INTERFACE, P19
   Kasemo B, 1988, Int J Oral Maxillofac Implants, V3, P247
   KASEMO B, 1994, MAT SCI ENG C-BIOMIM, V1, P115, DOI 10.1016/0928-4931(94)90041-8
   KASEMO B, 1988, J BIOMED MATER RES-A, V22, P145, DOI 10.1002/jbm.820221307
   KELLER J C, 1990, International Journal of Oral and Maxillofacial Implants, V5, P360
   KELLER JC, 1994, J BIOMED MATER RES, V28, P939, DOI 10.1002/jbm.820280813
   Klauber C, 1990, Int J Oral Maxillofac Implants, V5, P264
   KONONEN M, 1992, J BIOMED MATER RES, V26, P1325
   KURTZ RL, 1989, SURF SCI, V218, P178, DOI 10.1016/0039-6028(89)90626-2
   KURTZ RL, 1986, SURF SCI, V177, P526, DOI 10.1016/0039-6028(86)90031-2
   LANDOLT D, 1987, ELECTROCHIM ACTA, V32, P1, DOI 10.1016/0013-4686(87)87001-9
   LANFORD WA, 1978, NUCL INSTRUM METHODS, V149, P1, DOI 10.1016/0029-554X(78)90832-7
   LARSSON C, 1994, BIOMATERIALS, V15, P1062, DOI 10.1016/0142-9612(94)90092-2
   LARSSON C, IN PRESS BIOMATERIAL
   LARSSON C, UNPUB BIOMATERIALS
   LAUSMAA J, 1990, SURF INTERFACE ANAL, V15, P328, DOI 10.1002/sia.740150506
   Lausmaa J., 1991, Surface Engineering, V7, P311
   LAUSMAA J, 1985, BIOMATERIALS, V6, P23, DOI 10.1016/0142-9612(85)90033-X
   LAUSMAA J, 1990, APPL SURF SCI, V45, P189, DOI 10.1016/0169-4332(90)90002-H
   LAUSMAA J, 1990, APPL SURF SCI, V44, P133, DOI 10.1016/0169-4332(90)90100-E
   LAUSMAA J, 1989, MATER RES SOC S P, V110, P647
   Lausmaa J, 1986, MATER RES SOC S P, V55, P351
   Lausmaa J., 1991, THESIS U GOTHENBURG
   LAUSMAA J, 1988, THESIS U GOTHENBURG
   LAUSMAA J, 1988, SURFACE CHARACTERIZA, P161
   LEWIS G, 1993, J VAC SCI TECHNOL A, V11, P325, DOI 10.1116/1.578733
   MAEUSLI PA, 1986, BIOL BIOMECHANICAL P, P57
   MATHIEU HJ, 1977, J VAC SCI TECHNOL, V14, P1023, DOI 10.1116/1.569313
   MATHIEU JB, 1978, J ELECTROCHEM SOC, V125, P1039, DOI 10.1149/1.2131617
   MATTSSON L, 1985, 264 GIPR CHALM U TEC
   MCKELLOP HA, 1990, J BIOMED MATER RES, V24, P1413, DOI 10.1002/jbm.820241102
   McQueen D, 1982, CLIN APPL BIOMATERIA, P179
   Moulder J. F., 1992, HDB XRAY PHOTOELECTR
   Olefjord I, 1993, Int J Oral Maxillofac Implants, V8, P32
   OLIN H, 1992, ULTRAMICROSCOPY, V42, P567, DOI 10.1016/0304-3991(92)90325-E
   PAMLER W, 1988, SURF INTERFACE ANAL, V13, P55, DOI 10.1002/sia.740130112
   RADEGRAN G, 1991, J ELECTRON MICR TECH, V19, P99, DOI 10.1002/jemt.1060190110
   RADEGRAN G, IN PRESS BIOMATERIAL
   RATNER BD, 1993, J BIOMED MATER RES, V27, P837, DOI 10.1002/jbm.820270702
   RATNR BD, 1987, J BIOMED MATER RES-A, V21, P59
   ROCKER G, 1987, SURF SCI, V181, P530, DOI 10.1016/0039-6028(87)90204-4
   ROSTLUND T, 1990, J BIOMED MATER RES, V24, P847, DOI 10.1002/jbm.820240705
   Samsonov G, 1973, OXIDE HDB
   SAYERS CN, 1978, SURF SCI, V77, P301, DOI 10.1016/0039-6028(78)90008-0
   SCOFIELD JH, 1976, J ELECTRON SPECTROSC, V8, P129, DOI 10.1016/0368-2048(76)80015-1
   SERRUYS Y, 1983, SURF SCI, V282, P279
   SHAM TK, 1979, CHEM PHYS LETT, V68, P426, DOI 10.1016/0009-2614(79)87231-0
   SMITH DC, 1991, J BIOMED MATER RES, V25, P1045, DOI 10.1002/jbm.820250902
   SMITH DC, 1991, J BIOMED MATER RES, V25, P1069, DOI 10.1002/jbm.820250903
   SMITH PB, 1987, SURF SCI, V188, P241, DOI 10.1016/S0039-6028(87)80155-3
   SODHI RNS, 1991, J VAC SCI TECHNOL A, V9, P1329, DOI 10.1116/1.577621
   STANFORD C, 1992, Journal of Dental Research, V71, P183
   STANFORD CM, 1994, J DENT RES, V73, P1061, DOI 10.1177/00220345940730050801
   Swart K M, 1992, J Oral Implantol, V18, P130
   THOMAS S, 1976, SURF SCI, V55, P754, DOI 10.1016/0039-6028(76)90279-X
   TORBERNTSSON LO, 1989, 292 GIPR U GOTH
   VIG JR, 1985, J VAC SCI TECHNOL A, V3, P1027, DOI 10.1116/1.573115
   VONSTEENBERGHE D, 1986, TISSUE INTEGRATION O, P509
   Wagner C. D., 1979, HDB XRAY PHOTOELECTR
   WALIVAARA B, 1994, BIOMATERIALS, V15, P827, DOI 10.1016/0142-9612(94)90038-8
   Wennerberg A, 1993, Int J Oral Maxillofac Implants, V8, P622
   WILLIAMS RL, 1988, BIOMATERIALS, V9, P206, DOI 10.1016/0142-9612(88)90085-3
NR 97
TC 166
Z9 168
U1 1
U2 53
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0368-2048
J9 J ELECTRON SPECTROSC
JI J. Electron Spectrosc. Relat. Phenom.
PD SEP
PY 1996
VL 81
IS 3
BP 343
EP 361
DI 10.1016/0368-2048(95)02530-8
PG 19
WC Spectroscopy
SC Spectroscopy
GA VT919
UT WOS:A1996VT91900009
DA 2018-10-19
ER

PT J
AU DaCostaNoble, R
   Soustre, EC
   Cadot, S
   Lauverjat, Y
   Lefebvre, F
   Rabaud, M
AF DaCostaNoble, R
   Soustre, EC
   Cadot, S
   Lauverjat, Y
   Lefebvre, F
   Rabaud, M
TI Evaluation of bioabsorbable elastin-fibrin matrix as a barrier in
   surgical periodontal treatment
SO JOURNAL OF PERIODONTOLOGY
LA English
DT Article
DE guided tissue regeneration; membranes, artificial; membranes, barriers;
   biodegradable matrix
ID EXPANDED POLYTETRAFLUOROETHYLENE MEMBRANES; II FURCATION DEFECTS; TISSUE
   REGENERATION; COLLAGEN; BIOMATERIAL; SURGERY; MONOMERS; DISEASE;
   THERAPY; HUMANS
AB THE PURPOSE OF THIS INVESTIGATION was to test clinically the efficiency of a recently described bioabsorbable matrix as a guided tissue regeneration membrane. This matrix was prepared from an original reaction between elastin and fibrin monomers and is now extensively used in several domains of surgery. The study group was composed of 26 patients, with a total of 35 lesions (22 intrabony defects, 8 Class II furcations and 5 Class III furcations) presenting moderate to advanced adult periodontitis. After initial therapy, measurements were made with a calibrated periodontal probe. Probing depth (PD) and gingival margin location (GM) measurements were taken twice: immediately before surgery and after 6 months before re-entry. Clinical attachment level (GAL), vertical osseous level (VOL) and alveolar crest location (AC) measurements were taken during surgery and after 6 months with re-entry procedures for all the patients. Color change of the gingival margin was only observed in 4 defects and device exposure occurred in the proportion of 2 out of the 35 defects. No foreign body reaction was observed in any case. At the intrabony defects mean PD reduction was 5 mm (P < 0.001) and mean gain of CAL was 4 mm (P < 0.001). Mean VOL was 4.3 mm (P < 0.001), mean gingival recession was 0.9 mm (P < 0.05) and mean AC was 0.2 mm (NS). At the Class II furcation defects the mean PD reduction was 4.5 mm (P < 0.001), mean gain CAL vertical was 3.2 mm and CAL horizontal was 4.5 mm (P < 0.001). Gingival recession averaged 1 mm (NS). A complete closure was observed in 2 out of the 8 defects. At the Class III furcation defects the mean PD reduction was 3.6 mm (P < 0.05) and mean CAL-V gain was 1.5 mm (P < 0.02). However the 5 sites showed no horizontal attachment gain and none were unchanged. A very low gingival recession, gingival reaction, crestal bone loss, and device exposure occurred during this study. This preliminary study suggests that the use of a biosynthetic barrier may have beneficial effects in the treatment of intrabony defects and Class II furcation defects. Randomized controlled trials are necessary to evaluate the efficacy and safety of this bioabsorbable membrane in periodontal therapy.
C1 UNIV BORDEAUX 2,DEPT PARODONTOL,F-33076 BORDEAUX,FRANCE.
CR APRAHAMIAN M, 1987, J BIOMED MATER RES, V21, P965, DOI 10.1002/jbm.820210803
   BARBIE C, 1989, BIOMATERIALS, V10, P445, DOI 10.1016/0142-9612(89)90084-7
   BLACK BS, 1994, J PERIODONTOL, V65, P598, DOI 10.1902/jop.1994.65.6.598
   BLUMENTHAL NM, 1993, J PERIODONTOL, V64, P925, DOI 10.1902/jop.1993.64.10.925
   BONZON N, 1995, BIOMATERIALS, V16, P881, DOI 10.1016/0142-9612(95)94151-A
   BOUCHARD P, 1993, J PERIODONTOL, V64, P1193, DOI 10.1902/jop.1993.64.12.1193
   CATON J, 1994, J PERIODONTOL, V65, P1037, DOI 10.1902/jop.1994.65.11.1037
   COLLET D, 1991, BIOMATERIALS, V12, P763, DOI 10.1016/0142-9612(91)90027-8
   COLLET D, 1992, J MATER SCI-MATER M, V3, P382, DOI 10.1007/BF00705372
   CORTELLINI P, 1993, J PERIODONTOL, V64, P254, DOI 10.1902/jop.1993.64.4.254
   FALK H, 1993, J SWED DENT ASS, V85, P673
   GOTTLOW J, 1993, J PERIODONTOL, V64, P1157, DOI 10.1902/jop.1993.64.11s.1157
   LAURELL L, 1994, J PERIODONTOL, V65, P967, DOI 10.1902/jop.1994.65.10.967
   LINDHE J, 1982, J CLIN PERIODONTOL, V9, P115, DOI 10.1111/j.1600-051X.1982.tb01227.x
   MATTSON JS, 1995, J PERIODONTOL, V66, P635, DOI 10.1902/jop.1995.66.7.635
   MELCHER AH, 1976, J PERIODONTOL, V47, P256, DOI 10.1902/jop.1976.47.5.256
   NYMAN S, 1982, J CLIN PERIODONTOL, V9, P290, DOI 10.1111/j.1600-051X.1982.tb02095.x
   PRATO GPP, 1988, J PERIODONTOL, V59, P679
   Rabaud M, 1992, J Biomater Appl, V7, P20, DOI 10.1177/088532829200700102
   RABAUD M, 1987, BIOMATERIALS, V8, P217, DOI 10.1016/0142-9612(87)90067-6
   RENVERT S, 1985, J CLIN PERIODONTOL, V12, P619, DOI 10.1111/j.1600-051X.1985.tb00933.x
   RIQUET M, 1990, BIOMATERIALS, V1, P518
   SANGALLI F, 1996, IN PRESS BIOMATERIAL, P16
   SELVIG KA, 1990, J PERIODONTOL, V61, P515, DOI 10.1902/jop.1990.61.8.515
   VANSWOL RL, 1993, J PERIODONTOL, V64, P622, DOI 10.1902/jop.1993.64.7.622
NR 25
TC 3
Z9 3
U1 0
U2 0
PU AMER ACAD PERIODONTOLOGY
PI CHICAGO
PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611-2690
SN 0022-3492
J9 J PERIODONTOL
JI J. Periodont.
PD SEP
PY 1996
VL 67
IS 9
BP 927
EP 934
DI 10.1902/jop.1996.67.9.927
PG 8
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA VJ491
UT WOS:A1996VJ49100013
PM 8884651
DA 2018-10-19
ER

PT J
AU Won, CY
   Chu, CC
   Yu, TJ
AF Won, CY
   Chu, CC
   Yu, TJ
TI Novel amine-containing biodegradable polyester via copolymerization of
   aspartic anhydride and 1,4-cyclohexanedimethanol
SO MACROMOLECULAR RAPID COMMUNICATIONS
LA English
DT Article
ID ACID
AB A novel biodegradable polyester having pendant amine functional groups was snythesized from N-(benzyloxycarbonyl)-L-aspartic anhydride (2) and 1,4-cyclohexanedimethanol (3) by polycondensation reaction using p-toluenesulfonic acid as a catalyst. The synthesized polymer 4 shows the characteristic eater carbonyl absorption peak at 1732 cm(-1) in the LR spectrum, and the NMR spectra were consistent with the IR data. Also, the elemental analysis showed that the experimental and calculated values were very close to each other. The weight-average molecular weight of the polymers ranged from 1140 to 5050 and increased with increasing reaction time. This new polymer would have the potential of a drug delivery biomaterial.
C1 VET GEN HOSP TAIPEI,TAIPEI,TAIWAN.
   NATL YANG MING UNIV,TAIPEI 112,TAIWAN.
RP Won, CY (reprint author), CORNELL UNIV,DEPT TEXT & APPAREL,FIBER & POLYMER SCI PROGRAM,ITHACA,NY 14853, USA.
CR ANDERSON GW, 1992, J AM CHEM SOC, V74, P5309
   BRAUD C, 1985, POLYM PREPR AM CHEM, V24, P71
   FELIX AM, 1978, J ORG CHEM, V43, P4194, DOI 10.1021/jo00415a045
   FIETIER I, 1990, POLYM BULL, V24, P349, DOI 10.1007/BF00294086
   GUERIN P, 1985, POLYM BULL, V14, P187, DOI 10.1007/BF00708479
   Lenz R. W., 1981, [No title captured], Patent No. [4265247, US 4265247 A 19810505]
   LUTZ WB, 1959, J AM CHEM SOC, V81, P167, DOI 10.1021/ja01510a039
   NOSHAY A, 1977, BLOCK COPOLYMERS, pCH7
   OUCHI T, 1989, MAKROMOL CHEM, V190, P1523
   SWINDLER R, 1993, Patent No. 5219980
   VELD PJAI, 1992, MAKROMOL CHEM, V193, P2713
   WATANABE T, 1995, CHEM PHARM BULL, V43, P529
   ZHOU QX, 1990, MACROMOLECULES, V23, P3399, DOI 10.1021/ma00216a002
NR 13
TC 10
Z9 10
U1 1
U2 7
PU HUTHIG & WEPF VERLAG
PI BASEL
PA AUF DEM WOLF 4 FX#001-41-61-317-94-11, CH-4052 BASEL, SWITZERLAND
SN 1022-1336
J9 MACROMOL RAPID COMM
JI Macromol. Rapid Commun.
PD SEP
PY 1996
VL 17
IS 9
BP 653
EP 659
DI 10.1002/marc.1996.030170907
PG 7
WC Polymer Science
SC Polymer Science
GA VH786
UT WOS:A1996VH78600008
DA 2018-10-19
ER

PT J
AU Yoo, JJ
   Atala, A
AF Yoo, JJ
   Atala, A
TI Bladder augmentation using a new biomaterial composed of allogenic
   bladder submucosa.
SO PEDIATRICS
LA English
DT Meeting Abstract
C1 CHILDRENS HOSP,DIV UROL,BOSTON,MA.
   HARVARD UNIV,SCH MED,BOSTON,MA.
NR 0
TC 9
Z9 9
U1 0
U2 0
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD, ELK GROVE VILLAGE, IL 60007-1098
SN 0031-4005
J9 PEDIATRICS
JI Pediatrics
PD SEP
PY 1996
VL 98
IS 3
SU S
BP F52
EP F52
PG 1
WC Pediatrics
SC Pediatrics
GA VG265
UT WOS:A1996VG26500193
DA 2018-10-19
ER

PT J
AU Sioshansi, P
   Tobin, EJ
AF Sioshansi, P
   Tobin, EJ
TI Surface treatment of biomaterials by ion beam processes
SO SURFACE & COATINGS TECHNOLOGY
LA English
DT Article; Proceedings Paper
CT 9th International Conference on Surface Modification of Metals by Ion
   Beams (SMMIB 95)
CY SEP 04-08, 1995
CL SAN SEBASTIAN, SPAIN
SP INASMET
DE surface treatment; ion beams; biocompatibility; biomaterial; coating
ID TITANIUM-ALLOYS; IMPLANTATION; IMPROVEMENT; METALS
AB Surface treatment of biomaterials is becoming an increasingly popular method of improving device function and biocompatibility without the expense and time required to develop new materials. Ion-beam-based processes, such as ion implantation and ion-beam-assisted deposition (IBAD), have proven particularly successful in this area because they offer a wide array of beneficial surface property modifications without adversely affecting bulk properties. For instance, orthopedic prostheses are made harder and more wear resistant by ion implanting their articulating surfaces. Many other devices, such as orthodontic appliances, surgical instruments and venous catheters, are treated to improve friction, fretting resistance and biocompatibility. IBAD is used to apply antimicrobial coatings to catheters and other devices, to apply sealant coatings to prevent oxygen or water vapor permeation, and to create metallized traces on polymers for use in flexible circuitry. This paper reviews the major medical device applications of ion beam-based technologies.
RP Sioshansi, P (reprint author), SPIRE CORP,PATRIOTS PK,BEDFORD,MA 01730, USA.
CR AGINS HJ, 1988, J BONE JOINT SURG AM, V70A, P347, DOI 10.2106/00004623-198870030-00005
   CROWNINSHIELD R, 1990, T 36 ANN M ORTH RES, V15, P470
   DEARNALEY G, 1978, THIN SOLID FILMS, V54, P215, DOI 10.1016/0040-6090(78)90201-8
   DRESCHER D, 1989, AM J ORTHOD DENTOFAC, V96, P397, DOI 10.1016/0889-5406(89)90324-7
   HARRIS WH, 1990, NEW ENGL J MED, V323, P725, DOI 10.1056/NEJM199009133231106
   *HLTH IND MAN ASS, 1994, 941 HIMA
   KURTZ SM, 1993, T ORTHOP RES SOC, V18, P434
   LEE EH, 1994, J MATER RES, V9, P1043, DOI 10.1557/JMR.1994.1043
   LEE EH, 1993, NUCL INSTRUM METH B, V74, P326, DOI 10.1016/0168-583X(93)95070-L
   LOMBARDI AV, 1989, J BONE JOINT SURG AM, V71A, P1337, DOI 10.2106/00004623-198971090-00009
   MATTOX DM, 1989, J VAC SCI TECHNOL A, V7, P1105, DOI 10.1116/1.576238
   MRAZ S, 1989, MACH DES, V61, P88
   OLIVER WC, 1984, METALL TRANS A, V15, P2221, DOI 10.1007/BF02647105
   PUTTERMAN C, 1990, RESUSCITATION, V20, P1, DOI 10.1016/0300-9572(90)90081-O
   SIOSHANSI P, 1987, NUCL INSTRUM METH B, V24-5, P767, DOI 10.1016/S0168-583X(87)80243-4
   SIOSHANSI P, 1985, J VAC SCI TECHNOL A, V3, P2670, DOI 10.1116/1.572811
   Sioshansi P., 1991, ORTHOPEDICS TODAY, V11, P24
   SUZUKI Y, 1988, NUCL INSTRUM METH B, V32, P120, DOI 10.1016/0168-583X(88)90193-0
   SUZUKI Y, 1990, Japanese Journal of Artificial Organs, V19, P1092
   TAYLOR SK, 1993, T 39 ANN M ORTH RES, V18, P503
   Uldall PR, 1993, DIALYSIS THERAPY, P5
   VENKATESAN T, 1985, NUCL INSTRUM METH B, V7-8, P461, DOI 10.1016/0168-583X(85)90413-6
   WILLERT HG, 1977, J BIOMED MATER RES, V11, P157, DOI 10.1002/jbm.820110202
   WILLIAMS JM, 1985, MATER SCI ENG, V69, P237, DOI 10.1016/0025-5416(85)90398-2
   ZALM PC, 1989, HDB ION BEAM PROCESS, P78
   ZIMMERMAN J, 1992, HLTH CARE MED TECHNO
   Zisman W. A., 1964, ADV CHEM SER, V43, P1
NR 27
TC 71
Z9 72
U1 1
U2 10
PU ELSEVIER SCIENCE SA LAUSANNE
PI LAUSANNE 1
PA PO BOX 564, 1001 LAUSANNE 1, SWITZERLAND
SN 0257-8972
J9 SURF COAT TECH
JI Surf. Coat. Technol.
PD SEP
PY 1996
VL 83
IS 1-3
BP 175
EP 182
DI 10.1016/0257-8972(95)02838-2
PG 8
WC Materials Science, Coatings & Films; Physics, Applied
SC Materials Science; Physics
GA VE213
UT WOS:A1996VE21300033
DA 2018-10-19
ER

PT J
AU Tse, M
   Uludag, H
   Sefton, MV
   Chang, PL
AF Tse, M
   Uludag, H
   Sefton, MV
   Chang, PL
TI Secretion of recombinant proteins from hydroxyethyl methacrylate-methyl
   methacrylate capsules
SO BIOTECHNOLOGY AND BIOENGINEERING
LA English
DT Article
DE immuno-isolation; fibroblasts; gene therapy; beta-glucuronidase;
   beta-hexosaminidase; Matrigel
ID BASEMENT-MEMBRANE MATRIX; HEMA-MMA MICROCAPSULES; HEPATOMA HEPG2 CELLS;
   IN-VIVO; GENE-THERAPY; FACTOR-IX; BETA-GLUCURONIDASE; RAT HEPATOCYTES;
   HEMOPHILIA-B; TRANSPLANTATION
AB Current human gene therapy relies on genetic modification of the patient's own cells. An alternate nonautologous approach is to use universal cell lines engineered to secrete therapeutic products. Protection with immunoisolation devices before implantation would allow the use of the same recombinant cell line for treating different patients, thus potentially lowering the cost of treatment. To study the properties of a mechanically stable synthetic biomaterial, hydroxyethyl methyacrylate-methyl methacrylate (HEMA-MMA) as the immune-isolation device, we encapsulated recombinant mouse fibroblast cells engineered to secrete products ranging from 27 to 300 kDa in size (human growth hormone, mouse beta-hexosaminidase and beta-glucuronidase) in the presence or absence of the extracellular matrix Matrigel. Both viability and cell number in the microcapsules increased with time after encapsulation and cell morphology indicated viable cell growth, thus showing that the capsule membrane barrier was compatible with nutrient/waste exchange necessary for normal metabolic activity.
   The intracellular levels of these recombinant gene products were constant throughout the experimental period of 22 days in the presence or absence of Matrigel, thus demonstrating that the microenvironment did not lead to downregulation of the transgenes. However, the extracellular levels of the gene products secreted from the cells and trapped within the microcapsules were dependent on the molecular size of the product and presence of Matrigel. With the 27-kDa human growth hormone, the presence of Matrigel caused its retention within this intracapsular space, but its release from the microcapsules to the culture medium was not impeded. With the 120-kDa beta-hexosaminidase or the 300-kDa beta-glucuronidase, they were retained within the microcapsule space regardless of the presence or absence of Matrigel, and their passage from the microcapsules to the media was totally blocked. In conclusion, the HEMA-MMA microcapsules are supportive of recombinant cell growth and maintained their molecular cutoff at similar to 100 kDa. Inclusion of extracellular matrix was unable to improve cell growth and may impede the exit of some gene products. (C) 1996 John Wiley & Sons, Inc.
C1 MCMASTER UNIV, DEPT PEDIAT, HLTH SCI CTR 3N18, HAMILTON, ON L8N 3Z5, CANADA.
   MCMASTER UNIV, DEPT BIOMED SCI, HAMILTON, ON L8N 3Z5, CANADA.
   MCMASTER UNIV, DEPT BIOL, HAMILTON, ON, CANADA.
   UNIV TORONTO, DEPT CHEM ENGN & APPL CHEM, TORONTO, ON, CANADA.
CR AEBISCHER P, 1991, J BIOMECH ENG-T ASME, V113, P178, DOI 10.1115/1.2891231
   AEBISCHER P, 1991, BIOMATERIALS, V12, P50, DOI 10.1016/0142-9612(91)90132-T
   AEBISCHER P, 1995, EUR NEUROL, V35, P65, DOI 10.1159/000117095
   AEBISCHER P, 1986, T AM SOC ART INT ORG, V32, P134
   ALHENDY A, 1995, HUM GENE THER, V6, P165, DOI 10.1089/hum.1995.6.2-165
   ALTMAN JJ, 1986, DIABETES, V35, P635
   ANDERSON WF, 1995, SOMATIC GENE THERAPY
   BABENSEE JE, 1992, J BIOMED MATER RES, V26, P1401, DOI 10.1002/jbm.820261102
   BASTEDO LK, 1995, THESIS MCMASTER U ON
   BISSELL DM, 1990, MOL BIOL MED, V7, P187
   BLAESE RM, 1993, PEDIATR RES, V33, pS49, DOI 10.1203/00006450-199304001-00010
   CHANG PL, 1994, BIOTECHNOL BIOENG, V43, P925, DOI 10.1002/bit.260431005
   CHANG PL, 1993, HUM GENE THER, V4, P433, DOI 10.1089/hum.1993.4.4-433
   CHANG PL, 1990, MOL BIOL MED, V7, P461
   CHANG PL, 1979, ANAL BIOCHEM, V97, P36, DOI 10.1016/0003-2697(79)90323-3
   CHANG PL, 1995, SOMATIC GENE THERAPY, P203
   CROOKS CA, 1990, J BIOMED MATER RES, V24, P1241, DOI 10.1002/jbm.820240908
   GAVAGHAN H, 1995, NATURE, V374, P393, DOI 10.1038/374393a0
   GLASER JH, 1973, J LAB CLIN MED, V82, P969
   GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3
   GRUBB JH, 1993, FASEB J, V7, pA1255
   HADLEY MA, 1985, J CELL BIOL, V101, P1511, DOI 10.1083/jcb.101.4.1511
   HOFFMAN D, 1993, EXP NEUROL, V122, P100, DOI 10.1006/exnr.1993.1111
   HORTELANO G, IN PRESS BLOOD
   HUGHES JR, 1994, IN PRESS J MEMBR SCI, V5, P1445
   HWANG JR, IN PRESS J MEMBR SCI
   KAY MA, 1994, P NATL ACAD SCI USA, V91, P2353, DOI 10.1073/pnas.91.6.2353
   KAY MA, 1993, SCIENCE, V262, P117, DOI 10.1126/science.8211118
   KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025
   KLOCK G, 1994, APPL MICROBIOL BIOT, V40, P638
   LIU HW, 1993, HUM GENE THER, V4, P291, DOI 10.1089/hum.1993.4.3-291
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MOULLIER P, 1993, NAT GENET, V4, P154, DOI 10.1038/ng0693-154
   OKADA S, 1969, SCIENCE, V165, P698, DOI 10.1126/science.165.3894.698
   OTTERLEI M, 1991, J IMMUNOTHER, V10, P286, DOI 10.1097/00002371-199108000-00007
   PERALES JC, 1994, P NATL ACAD SCI USA, V91, P4086, DOI 10.1073/pnas.91.9.4086
   SAGOT Y, 1995, EUR J NEUROSCI, V7, P1313, DOI 10.1111/j.1460-9568.1995.tb01122.x
   SCHUETZ EG, 1988, J CELL PHYSIOL, V134, P309, DOI 10.1002/jcp.1041340302
   SEFTON MV, 1982, BIOCHIM BIOPHYS ACTA, V717, P473, DOI 10.1016/0304-4165(82)90290-2
   SEFTON MV, 1994, PANCREATIC ISLET TRA, V3
   SOONSHIONG P, 1994, LANCET, V343, P950, DOI 10.1016/S0140-6736(94)90067-1
   STEVENSON WTK, 1987, J APPL POLYM SCI, V34, P65, DOI 10.1002/app.1987.070340106
   ULUDAG H, 1993, CELL TRANSPLANT, V2, P175, DOI 10.1177/096368979300200210
   ULUDAG H, 1993, J BIOMED MATER RES, V27, P1213, DOI 10.1002/jbm.820271002
   ULUDAG H, 1994, BIOTECHNOL BIOENG, V44, P1199, DOI 10.1002/bit.260441007
   ULUDAG H, 1995, J CONTROL RELEASE, V33, P273, DOI 10.1016/0168-3659(94)00094-B
   ULUDAG H, 1992, CELL TRANSPLANT, V35, P1
   ULUDAG H, 1993, ADV DRUG DELIV REV, V10, P1
   WELLS GDM, 1993, BIOMATERIALS, V14, P615, DOI 10.1016/0142-9612(93)90181-Z
NR 49
TC 28
Z9 28
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0006-3592
EI 1097-0290
J9 BIOTECHNOL BIOENG
JI Biotechnol. Bioeng.
PD AUG 5
PY 1996
VL 51
IS 3
BP 271
EP 280
DI 10.1002/(SICI)1097-0290(19960805)51:3<271::AID-BIT3>3.3.CO;2-T
PG 10
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA UX081
UT WOS:A1996UX08100003
PM 18624360
DA 2018-10-19
ER

PT J
AU Santin, M
   Huang, SJ
   Iannace, S
   Ambrosio, L
   Nicolais, L
   Peluso, G
AF Santin, M
   Huang, SJ
   Iannace, S
   Ambrosio, L
   Nicolais, L
   Peluso, G
TI Synthesis and characterization of a new interpenetrated
   poly(2-hydroxyethylmethacrylate)-gelatin composite polymer
SO BIOMATERIALS
LA English
DT Article
DE poly(2-hydroxyethylmethacrylate); gelatin; interpenetrating polymer
   network; biocompatibility; cell adhesion
ID IMPLANTATION; INVITRO; INVIVO
AB Poly(2-hydroxyethylmethacrylate) [poly(HEMA)] is a widely used biomaterial which does not allow cell adhesion and growth on its surface, limiting its use in biomedical applications in which cell cohesion is detrimental. We have prepared a poly(HEMA)-gelatin composite hydrogel using a sequential interpenetrating polymer network technique. The properties of this material were compared with poly(HEMA) freeze-dried sponges in terms of morphology, mechanical properties and biocompatibility. Moreover, in vivo biocompatibility experiments highlighted the occurrence of cellular interactions on the surface of the poly(HEMA)-gelatin interpenetrating polymer network, which are usually absent when unmodified poly(HEMA) hydrogels are implanted in the same host organism. These tests also showed a progressive gelatin degradation from the surface to the bulk of the poly(HEMA)-gelatin specimens during short-term (7 d) implantation. Finally, in vitro tests confirmed an improved ability of this composite to scaffold for the cells. (C) 1996 Elsevier Science Limited.
C1 CNR,INST PROT BIOCHEM & ENZYMOL,I-80072 ARCO,NAPLES,ITALY.
   UNIV CONNECTICUT,INST MAT SCI,STORRS,CT 06269.
   UNIV NAPLES,DEPT MAT & PROD ENGN,I-80125 NAPLES,ITALY.
OI AMBROSIO, LUIGI/0000-0002-8367-2405; Iannace,
   Salvatore/0000-0003-1487-4983
CR ALI SAM, 1993, BIOMATERIALS, V14, P648, DOI 10.1016/0142-9612(93)90063-8
   AMUDESWARI S, 1984, EUR POLYM J, V20, P91, DOI 10.1016/0014-3057(84)90230-1
   ANDERSON JM, 1988, ASAIO, V11
   BADWEY JA, 1980, ANNU REV BIOCHEM, V49, P695, DOI 10.1146/annurev.bi.49.070180.003403
   CHIRILA TV, 1993, BIOMATERIALS, V14, P26, DOI 10.1016/0142-9612(93)90072-A
   CIVERCHIAPEREZ L, 1980, P NATL ACAD SCI-BIOL, V77, P2064, DOI 10.1073/pnas.77.4.2064
   COLEMAN DL, 1974, J BIOMED MATER RES, V8, P65, DOI 10.1002/jbm.820080308
   COLEMAN DL, 1974, J BIOMED MATER RES, V8, P199, DOI 10.1002/jbm.820080503
   GORHAM SD, 1991, BIOMATERIALS NOVEL M
   JAYANTHI R, 1990, BIOMATERIALS, V11, P238
   KUMAR GS, 1981, J POLYM SCI POL CHEM, V9, P1265
   Pulapura S, 1992, J Biomater Appl, V6, P216, DOI 10.1177/088532829200600303
   RATNER BD, 1993, J BIOMED MATER RES, V27, P837, DOI 10.1002/jbm.820270702
   REMES A, 1992, BIOMATERIALS, V13, P731, DOI 10.1016/0142-9612(92)90010-L
   RICHES D, 1988, MOL CELLULAR BIOL WO
   SMETANA K, 1992, BIOMATERIALS, V13, P639, DOI 10.1016/0142-9612(92)90033-K
   Sperling L.H., 1981, INTERPENETRATING POL
   STOL M, 1991, BIOMATERIALS, V12, P454, DOI 10.1016/0142-9612(91)90142-W
   STOL M, 1985, BIOMATERIALS, V6, P193, DOI 10.1016/0142-9612(85)90009-2
   WOERLY S, 1990, BIOMATERIALS, V11, P97, DOI 10.1016/0142-9612(90)90123-8
   ZHAO QH, 1992, J BIOMED MATER RES, V26, P1019, DOI 10.1002/jbm.820260805
NR 21
TC 67
Z9 69
U1 0
U2 20
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD AUG
PY 1996
VL 17
IS 15
BP 1459
EP 1467
DI 10.1016/0142-9612(96)89769-9
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA UZ139
UT WOS:A1996UZ13900001
PM 8853115
DA 2018-10-19
ER

PT J
AU Takaoka, T
   Okumura, M
   Ohgushi, H
   Inoue, K
   Takakura, Y
   Tamai, S
AF Takaoka, T
   Okumura, M
   Ohgushi, H
   Inoue, K
   Takakura, Y
   Tamai, S
TI Histological and biochemical evaluation of osteogenic response in porous
   hydroxyapatite coated alumina ceramics
SO BIOMATERIALS
LA English
DT Article
DE hydroxyapatite coating; porous alumina ceramics; osteogenic response;
   alkaline phosphatase; bone specific bone gla protein
ID CELL INDUCED OSTEOGENESIS; PRIMARY BONE-FORMATION; MARROW-CELLS;
   COATINGS; IMPLANTS
AB We compared the osteogenic response in porous alumina (Al) and hydroxyapatite coated porous alumina ceramic (HA/Al) by grafting rat bone marrow cells with these implants subcutaneously in the back of syngeneic rats. The ceramics did not show any bone formation without marrow, but did when combined with marrow cells. The osteogenesis in HA/Al began directly on the ceramic surface, but in Al began away from the ceramic surface, and fibrous tissue interposition was seen between the de novo bone and its surface. Alkaline phosphatase activity and bone specific bone gla protein content in HA/Al with marrow were both about three times higher than in Al with marrow. These results indicate that HA/Al has excellent osteoconductive properties and that a composite of marrow and HA/Al is a clinically applicable osteogenic biomaterial. (C) 1996 Elsevier Science Limited.
RP Takaoka, T (reprint author), NARA MED UNIV, DEPT ORTHOPAED SURG, KASHIHARA, NARA 634, JAPAN.
CR BOUTIN P, 1988, J BIOMED MATER RES, V22, P1203, DOI 10.1002/jbm.820221210
   BURWELL RG, 1985, CLIN ORTHOP RELAT R, V200, P125
   CHRISTEL PS, 1992, CLIN ORTHOP RELAT R, P10
   COOK SD, 1988, CLIN ORTHOP RELAT R, V232, P225
   COOK SD, 1988, CLIN ORTHOP RELAT R, V230, P303
   Cooke F W, 1992, Clin Orthop Relat Res, P135
   DHERT WJA, 1991, J BIOMED MATER RES, V25, P1183, DOI 10.1002/jbm.820251002
   FURLONG RJ, 1991, J BONE JOINT SURG BR, V73, P741
   GEESINK RGT, 1988, J BONE JOINT SURG BR, V70, P17
   GEESINK RGT, 1990, CLIN ORTHOP RELAT R, V261, P39
   GRISS P, 1975, J BIOMED MATER RES, V9, P177, DOI 10.1002/jbm.820090421
   HEIMKE G, 1990, BIOCERAMICS, V3, P19
   HULBERT SF, 1990, BIOCERAMICS, V3, P1
   INOUE K, 1992, BIOCERAMICS, V5, P125
   NIEDZWIEDZKI T, 1993, BIOMATERIALS, V14, P115, DOI 10.1016/0142-9612(93)90221-M
   Ohashi T., 1988, BIOCERAMICS, P278
   OHGUSHI H, 1989, J ORTHOPAED RES, V7, P568, DOI 10.1002/jor.1100070415
   OHGUSHI H, 1990, J BIOMED MATER RES, V24, P1563, DOI 10.1002/jbm.820241202
   OHGUSHI H, 1990, ACTA ORTHOP SCAND, V61, P431, DOI 10.3109/17453679008993556
   OHGUSHI H, 1992, BIOCERAMICS, V5, P119
   OKUMURA M, 1991, CELL MATER, V1, P29
   OKUMURA M, 1991, BIOMATERIALS, V12, P411, DOI 10.1016/0142-9612(91)90010-8
   OKUMURA M, 1991, BIOCERAMICS, V4, P213
   Okumura Motoaki, 1992, Bio-Medical Materials and Engineering, V2, P191
   OONISHI H, 1989, J BONE JOINT SURG BR, V71, P213
   OONISHI H, 1988, BIOCERAMICS, P272
   Salama R, 1973, J Bone Joint Surg Br, V55, P402
   SALAMA R, 1983, CLIN ORTHOP RELAT R, V174, P113
   SEDEL L, 1990, J BONE JOINT SURG BR, V72, P658
   Sedel L., 1991, BIOCERAMICS, V4, P27
   SOBALLE K, 1989, CLIN ORTHOP RELAT R, V272, P255
   TAKAGI H, 1989, J BIOMED MATER RES-A, V23, P161
   TAKAKURA Y, 1990, CLIN ORTHOPAEDICS, V252, P209
   TAKAKURA Y, 1992, BIOCERAMICS, V5, P459
   WITVOET J, 1988, BIOCERAMICS, P314
   YOSHIKAWA T, 1992, CALCIFIED TISSUE INT, V50, P184, DOI 10.1007/BF00298798
NR 36
TC 52
Z9 54
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD AUG
PY 1996
VL 17
IS 15
BP 1499
EP 1505
DI 10.1016/0142-9612(96)89774-2
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA UZ139
UT WOS:A1996UZ13900006
PM 8853120
DA 2018-10-19
ER

PT J
AU Rovira, A
   Amedee, J
   Bareille, R
   Rabaud, M
AF Rovira, A
   Amedee, J
   Bareille, R
   Rabaud, M
TI Colonization of a calcium phosphate elastin-solubilized peptide-collagen
   composite material by human osteoblasts
SO BIOMATERIALS
LA English
DT Article
DE artificial connective matrix; hydroxyapatite; osteoblast; bone
ID BONE-MARROW; HYDROXYAPATITE; BIOMATERIALS; ATTACHMENT; INTERFACE;
   DEFECTS; INVITRO; MATRIX; CELLS
AB The evaluation of the suitability of a new biomaterial as a possible substitute for bone tissue is described here. This biomaterial is based on calcium phosphate particles linked to an artificial connective matrix, the elastin-solubilized peptides (ESP) associated with type I and III collagens. This work demonstrates the feasibility of shaping this composite material into discs, describes its microstructural characteristics, and evaluates its capacity as a substrate for the proliferation of human osteoblasts without loss of their phenotypic expression. (C) 1996 Elsevier Science Limited.
C1 CTR IND SANTIGA,CIDA,E-08130 STA PERPETUA MOG,BARCELONA,SPAIN.
   UNIV BORDEAUX 2,INSERM,U443,F-33076 BORDEAUX,FRANCE.
RI VILAMITJANA AMEDEE, Joelle/F-3369-2013
CR AMEDEE J, 1994, BIOMATERIALS, V15, P1029, DOI 10.1016/0142-9612(94)90086-8
   DAMIEN CJ, 1991, J APPL BIOMATER, V2, P187, DOI 10.1002/jab.770020307
   EVELAND ES, 1992, 4 WORLD BIOM C BERL, P26
   FAUCHEUX C, 1994, J MATER SCI-MATER M, V5, P635, DOI 10.1007/BF00120345
   GANELES J, 1986, J PERIODONTOL, V57, P133, DOI 10.1902/jop.1986.57.3.133
   GORHAM SD, 1993, J MATER SCI-MATER M, V4, P40, DOI 10.1007/BF00122976
   GOSHIMA J, 1991, CLIN ORTHOP RELAT R, V269, P274
   HARMAND MF, 1985, VITAMIN D CHEM BIOCH, P197
   HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665
   Hench L L, 1988, Ann N Y Acad Sci, V523, P54, DOI 10.1111/j.1749-6632.1988.tb38500.x
   Iwano T., 1991, CLIN ORTHOPAEDICS, V268, P243
   JARCHO M, 1981, CLIN ORTHOP RELAT R, V157, P259
   KAPLOW LS, 1968, ANN NY ACAD SCI, V155, P911, DOI 10.1111/j.1749-6632.1968.tb55077.x
   LEFEBVRE F, 1992, BIOMATERIALS, V13, P28, DOI 10.1016/0142-9612(92)90091-2
   MALIK MA, 1992, BIOMATERIALS, V13, P123, DOI 10.1016/0142-9612(92)90008-C
   NAJI A, 1991, BIOMATERIALS, V12, P692
   OKUMURA M, 1991, BIOMATERIALS, V12, P411, DOI 10.1016/0142-9612(91)90010-8
   PULEO DA, 1991, J BIOMED MATER RES, V25, P711, DOI 10.1002/jbm.820250603
   RABAUD M, 1991, BIOMATERIALS, V12, P313, DOI 10.1016/0142-9612(91)90040-H
   RIPAMONTI U, 1992, PLAST RECONSTR SURG, V90, P382, DOI 10.1097/00006534-199209000-00004
   Robert L, 1985, FRONTIERS MATRIX BIO, V10, P92
   ROVIRA A, 1993, J MATER SCI-MATER M, V4, P372, DOI 10.1007/BF00122195
   SAUTIER JM, 1992, BIOMATERIALS, V13, P400, DOI 10.1016/0142-9612(92)90046-Q
   VANBLITTERSWIJK CA, 1985, BIOMATERIALS, V6, P243, DOI 10.1016/0142-9612(85)90020-1
   Verrier S, 1996, J MATER SCI-MATER M, V7, P46, DOI 10.1007/BF00121189
NR 25
TC 17
Z9 17
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD AUG
PY 1996
VL 17
IS 15
BP 1535
EP 1540
DI 10.1016/0142-9612(96)89779-1
PG 6
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA UZ139
UT WOS:A1996UZ13900011
PM 8853125
DA 2018-10-19
ER

PT J
AU Tunney, MM
   Keane, PF
   Jones, DS
   Gorman, SP
AF Tunney, MM
   Keane, PF
   Jones, DS
   Gorman, SP
TI Comparative assessment of ureteral stent biomaterial encrustation
SO BIOMATERIALS
LA English
DT Article
DE ureteral stents; encrustation; polyurethanes; silicones; artificial
   urine
ID CATHETER MATERIALS; URINARY CATHETERS; IN-VITRO; BIOFILM; INVITRO;
   CIPROFLOXACIN; ADHERENCE; ADHESION; HYDROGEL
AB Long-term use of ureteral stents is hindered by the inherent problem of biomaterial encrustation which may lead to stone formation and attendant problems. The wide variety of polymeric biomaterials currently used for stent fabrication suggests that no single material is significantly superior to the others at resisting encrustation. A model representing upper urinary tract conditions was employed to compare the long-term struvite and hydroxyapatite encrustation of five materials currently used in the fabrication of ureteral stents. Silicone was least prone to struvite encrustation, followed by polyurethane, silitek, percuflex and hydrogel-coated polyurethane, in rank order. Similarly, silicone was least prone to hydroxyapatite encrustation, followed by silitek, polyurethane, percuflex and hydrogel-coated polyurethane. This study has shown that the problem of encrustation may limit the long-term use of ureteral stent biomaterials and suggests directions for improvement of biomaterials in this regard. (C) 1996 Eisevier Science Limited.
C1 QUEENS UNIV BELFAST,SCH PHARM,BELFAST BT9 7BL,ANTRIM,NORTH IRELAND.
   BELFAST CITY HOSP,DEPT UROL,BELFAST BT9 7BL,ANTRIM,NORTH IRELAND.
CR Adams James, 1994, Emergency Medicine Clinics of North America, V12, P749
   AXELSSON H, 1977, SCAND J UROL NEPHROL, V11, P283, DOI 10.3109/00365597709179966
   BASSETT J, 1978, VOGELS TXB QUANTITAT, P837
   Bonner M. C., 1993, Journal of Pharmacy and Pharmacology, V45, P1145
   BRUCE AW, 1974, CAN MED ASSOC J, V111, P238
   COX AJ, 1990, BRIT J UROL, V65, P55, DOI 10.1111/j.1464-410X.1990.tb14662.x
   COX AJ, 1989, UROL RES, V17, P353, DOI 10.1007/BF00510524
   COX AJ, 1988, BRIT J UROL, V61, P156, DOI 10.1111/j.1464-410X.1988.tb05067.x
   COX AJ, 1989, UROL RES, V17, P349, DOI 10.1007/BF00510523
   DENYER SP, 1990, J CLIN MICROBIOL, V28, P1813
   FARBER BF, 1992, J INFECT DIS, V166, P861, DOI 10.1093/infdis/166.4.861
   GORDON NSI, 1989, BRIT J UROL, V64, P195, DOI 10.1111/j.1464-410X.1989.tb05987.x
   GORMAN SP, 1991, P 10 PHARM TECH C, V2, P649
   HEDELIN H, 1984, BRIT J UROL, V56, P250, DOI 10.1111/j.1464-410X.1984.tb05382.x
   KEANE PF, 1994, BRIT J UROL, V73, P687, DOI 10.1111/j.1464-410X.1994.tb07557.x
   KUNIN CM, 1987, J UROLOGY, V138, P899, DOI 10.1016/S0022-5347(17)43412-4
   Liedberg H, 1991, Scand J Urol Nephrol Suppl, V138, P239
   MACKINNON A E, 1991, British Journal of Urology, V68, P431, DOI 10.1111/j.1464-410X.1991.tb15369.x
   MILLER JM, 1975, J UROLOGY, V113, P530, DOI 10.1016/S0022-5347(17)59518-X
   REID G, 1994, ANTIMICROB AGENTS CH, V38, P1490, DOI 10.1128/AAC.38.7.1490
   REID G, 1992, J UROLOGY, V148, P1592, DOI 10.1016/S0022-5347(17)36976-8
   RHIND JR, 1989, BRIT J UROL, V63, P644, DOI 10.1111/j.1464-410X.1989.tb05264.x
   SCHULZE KA, 1985, UROLOGY, V25, P616, DOI 10.1016/0090-4295(85)90293-6
   SRINIVASAN V, 1972, J UROLOGY, V108, P473, DOI 10.1016/S0022-5347(17)60777-8
   STICKLER DJ, 1994, CELL MATER, V4, P387
   Tunney M. M., 1995, Journal of Pharmacy and Pharmacology, V47, P1096
   TUNNEY MM, 1995, PHARMACOTHERAPY, V15, P379
   TUNNEY MM, 1996, IN PRESS BIOMATERIAL
NR 28
TC 69
Z9 70
U1 2
U2 14
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD AUG
PY 1996
VL 17
IS 15
BP 1541
EP 1546
DI 10.1016/0142-9612(96)89780-8
PG 6
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA UZ139
UT WOS:A1996UZ13900012
PM 8853126
DA 2018-10-19
ER

PT J
AU Huebsch, JB
   Fields, GB
   Triebes, TG
   Mooradian, DL
AF Huebsch, JB
   Fields, GB
   Triebes, TG
   Mooradian, DL
TI Photoreactive analog of peptide FN-C/H-V from the carboxy-terminal
   heparin-binding domains of fibronectin supports endothelial cell
   adhesion and spreading on biomaterial surfaces
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
LA English
DT Article
ID EXTRACELLULAR-MATRIX; SYNTHETIC PEPTIDES; VASCULAR GRAFTS; INSULIN
   RECEPTOR; SMALL-DIAMETER; SMOOTH-MUSCLE; GROWTH-FACTOR; PATENCY;
   ATTACHMENT; IMMOBILIZATION
AB The extracellular matrix protein fibronectin (FN) plays an important role in cell adhesion, spreading, and motility. Several cell-adhesion promoting domains exist within fibronectin, and peptide sequences from these domains have been shown to play an important role in cell interactions with fibronectin. Recently, a peptide sequence (FN-C/H-V) from the 33/66 kD carboxy-terminal heparin-binding domains of fibronectin was shown to promote the adhesion and spreading of vascular endothelial cells in vitro. Endothelial cell spreading on this peptide was followed by cytoskeletal reorganization, focal contact formation, and, ultimately, cell migration. In the current study, a photoreactive analog of FN-C/H-V (ASD-V) was generated using a heterobifunctional photoreactive crosslinking agent, sulfosuccinimidyl 2-(p-azidosalicylamido) ethyl-1,3'-dithio-propionate. ASD-V was then covalently coupled to polystyrene (PS) and polyethylene terephthalate film (PET) in order to assess the utility of ASD-V for preparing biomaterial surfaces with endothelial cell-adhesion promoting properties. The effects of pre-adsorption time and initial coating concentration on the efficiency of ASD-V coupling to PS and to PET were examined. Contact angle measurements and atomic force microscopy were used to characterize ASD-V-modified surfaces. Finally, the adhesion and spreading of vascular endothelial cells on ASD-V-modified surfaces was assessed. Our results suggest that photoreactive peptides are an effective and convenient means of modifying biomaterial surfaces to impart adhesion-promoting properties and that ASD-V, when coupled to PS and PET, promotes endothelial cell adhesion and spreading and may therefore be useful as a biomaterial surface modification in applications where re-endothelialization is desired (e.g., autologous endothelial seeding of vascular grafts, or transplantation of genetically engineered endothelial cells via polymer-coated stents). (C) 1996 John Wiley & Sons, Inc.
C1 UNIV MINNESOTA,DEPT LAB MED & PATHOL,CTR BIOMED ENGN,MINNEAPOLIS,MN 55455.
CR ALLCOCK HR, 1991, CHEM MATER, V3, P450, DOI 10.1021/cm00015a018
   ALLEN BT, 1984, J VASC SURG, V1, P224, DOI 10.1067/mva.1984.avs0010224
   Andrade J. D., 1985, SURFACE INTERFACIAL, P249
   CHOWDHRY V, 1979, ANNU REV BIOCHEM, V48, P293, DOI 10.1146/annurev.bi.48.070179.001453
   CLOWES AW, 1986, AM J PATHOL, V123, P220
   DAS M, 1977, P NATL ACAD SCI USA, V74, P2790, DOI 10.1073/pnas.74.7.2790
   DEJANA E, 1988, J CELL BIOL, V107, P1215, DOI 10.1083/jcb.107.3.1215
   DELDEN T, 1982, T AM SOC ART INT ORG, V28, P173
   DIGLIO CA, 1988, TISSUE CELL, V20, P477, DOI 10.1016/0040-8166(88)90051-1
   FIELDS CG, 1993, PEPTIDE RES, V6, P39
   FLEET GWJ, 1969, NATURE, V224, P511, DOI 10.1038/224511a0
   FURCHT LT, 1986, LAB INVEST, V55, P505
   HAUGEN PK, 1990, J CELL BIOL, V111, P2733, DOI 10.1083/jcb.111.6.2733
   HOFMANN C, 1981, J SUPRAMOL STR CELL, V15, P1, DOI 10.1002/jsscb.1981.380150102
   HUEBSCH JC, 1995, CIRC RES, V77, P43, DOI 10.1161/01.RES.77.1.43
   IWAMOTO Y, 1987, SCIENCE, V238, P1132, DOI 10.1126/science.2961059
   JACOBS S, 1979, P NATL ACAD SCI USA, V76, P4918, DOI 10.1073/pnas.76.10.4918
   KAEHLER J, 1989, J VASC SURG, V9, P535, DOI 10.1067/mva.1989.vs0090535
   KAELBLE DH, 1974, J ADHESION, V6, P23, DOI 10.1080/00218467408072237
   KESLER KA, 1986, J VASC SURG, V3, P58
   KRAMER RH, 1985, BIOCHEMISTRY-US, V24, P7423, DOI 10.1021/bi00346a059
   LARSSON PH, 1987, J IMMUNOL METHODS, V98, P129, DOI 10.1016/0022-1759(87)90446-7
   LIN HB, 1992, BIOMATERIALS, V13, P905, DOI 10.1016/0142-9612(92)90113-3
   MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375
   MASSIA SP, 1990, ANAL BIOCHEM, V187, P292, DOI 10.1016/0003-2697(90)90459-M
   MATSUDA T, 1989, T AM SOC ART INT ORG, V35, P677
   MCCARTHY JB, 1988, BIOCHEMISTRY-US, V27, P1380, DOI 10.1021/bi00404a044
   MCCARTHY JB, 1990, J CELL BIOL, V110, P777, DOI 10.1083/jcb.110.3.777
   MCCARTHY JB, 1986, J CELL BIOL, V102, P179, DOI 10.1083/jcb.102.1.179
   MOORADIAN DL, 1993, INVEST OPHTH VIS SCI, V34, P153
   MOORADIAN DL, 1992, INVEST OPHTH VIS SCI, V33, P3034
   MOORADIAN DL, 1992, J SURG RES, V53, P74, DOI 10.1016/0022-4804(92)90016-S
   NICHOLS WK, 1981, T AM SOC ART INT ORG, V27, P208
   PANTANO P, 1991, J AM CHEM SOC, V113, P1832, DOI 10.1021/ja00005a058
   PERKINS ME, 1979, CELL, V16, P941, DOI 10.1016/0092-8674(79)90109-0
   PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0
   Rutherford R B, 1988, J Vasc Surg, V8, P236
   SACHER E, 1983, J COLLOID INTERF SCI, V92, P275, DOI 10.1016/0021-9797(83)90140-6
   Sacher E, 1988, SURFACE CHARACTERIZA, P53
   SANK A, 1992, AM J SURG, V164, P199, DOI 10.1016/S0002-9610(05)81070-0
   SCHMIDT SP, 1984, J VASC SURG, V1, P434, DOI 10.1067/mva.1984.avs0010434
   SCHNEIDER A, 1992, J VASC SURG, V15, P649, DOI 10.1016/0741-5214(92)90010-6
   SCHNEIDER PA, 1988, J VASC SURG, V8, P229, DOI 10.1067/mva.1988.avs0080229
   SEEGER JM, 1988, J VASC SURG, V8, P476
   SHEPHARD EG, 1988, ANAL BIOCHEM, V168, P306, DOI 10.1016/0003-2697(88)90323-5
   SHINDO S, 1987, J VASC SURG, V6, P325, DOI 10.1067/mva.1987.avs0060325
   SIGRIST H, 1992, BIO-TECHNOL, V10, P1026, DOI 10.1038/nbt0992-1026
   STANLEY JC, 1982, SURGERY, V92, P994
   SZYCHER M, 1983, BIOCOMPATIBLE POLYM, P1
   VISSER MR, 1989, AM J PATHOL, V134, P223
   WESLOWSKI SA, 1982, THORAC CARDIOVASC SU, V30, P196
   WILKE MS, 1991, J INVEST DERMATOL, V97, P573, DOI 10.1111/1523-1747.ep12481915
   WU S, 1969, J COLLOID INTERF SCI, V31, P153, DOI 10.1016/0021-9797(69)90321-X
   YAN MD, 1993, J AM CHEM SOC, V115, P814, DOI 10.1021/ja00055a078
   YIP CC, 1978, J BIOL CHEM, V253, P1743
NR 55
TC 16
Z9 16
U1 0
U2 4
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-9304
J9 J BIOMED MATER RES
JI J. Biomed. Mater. Res.
PD AUG
PY 1996
VL 31
IS 4
BP 555
EP 567
DI 10.1002/(SICI)1097-4636(199608)31:4<555::AID-JBM16>3.0.CO;2-F
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA UY924
UT WOS:A1996UY92400016
PM 8836853
DA 2018-10-19
ER

PT J
AU Mercier, P
   Bellavance, F
   Cholewa, J
   Djokovic, S
AF Mercier, P
   Bellavance, F
   Cholewa, J
   Djokovic, S
TI Long-term stability of atrophic ridges reconstructed with
   hydroxylapatite: A prospective study
SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
LA English
DT Article
ID ALVEOLAR RIDGE; HISTOLOGIC EVALUATION; MANDIBULAR RIDGE;
   TISSUE-RESPONSE; HYDROXYAPATITE PARTICLES; DIFFERENT SHAPES; AUTOGENOUS
   BONE; AUGMENTATION; INTERFACE; VESTIBULOPLASTY
AB Purpose: This article reports the results of an investigation of the long-term efficacy and stability oi reconstructive surgery of atrophic ridges using dense hydroxylapatite (HA).
   Patients and Methods: Subperiosteal HA was used as a first stage of reconstruction in 678 ridges, 645 mandibular and 35 maxillary, followed after 4 to 5 weeks by a total lowering of the floor of the mouth, vestibuloplasty, and skin graft in the mandible: a same-stage submucous vestibuloplasty was done in the maxilia. Patients were followed for an average of 5.3 +/- 2.7 years by the same surgical and prosthodontic team. The presence of severe or moderate radiographic change was analyzed in relation to gender, age, severity of atrophy, postoperative complications, clinical changes, patient satisfaction, and type of KA particles used alone or with a binder.
   Results: Seventy-seven percent of cases had no observable radiographic changes, 13% had moderate changes, and 10% had severe changes, of which fewer than half also had severe clinical changes. Relationships were established between the presence of radiographic change and certain parameters, especially postoperative delay in healing, severe or moderate clinical changes, and type of HE particles used.
   Conclusion: Hydroxylapatite, when used alone or with binding agents, and in association with basic techniques of reconstructive surgery and soft tissue handling, is a predictable and stable biomaterial for ridge reconstruction.
C1 MCGILL UNIV,DEPT BIOSTAT & EPIDEMIOL,MONTREAL,PQ H3A 2T5,CANADA.
   MCGILL UNIV,DEPT CLIN EPIDEMIOL,MONTREAL,PQ H3A 2T5,CANADA.
RP Mercier, P (reprint author), ST MARYS HOSP,MAXILLARY ATROPHY CLIN,3830 LACOMBE ST,MONTREAL,PQ H3T 1M5,CANADA.
CR ASSAEL L, 1994, J DENT RES, V73
   BARSON RE, 1984, ORAL SURG ORAL MED O, V59, P113
   BEIRNE OR, 1985, J DENT RES, V64, P1152, DOI 10.1177/00220345850640091201
   BLIJDORP PA, 1988, INT J ORAL MAX SURG, V17, P354, DOI 10.1016/S0901-5027(88)80062-6
   BLOCK MS, 1985, J ORAL MAXIL SURG, V43, P3, DOI 10.1016/S0278-2391(85)80005-7
   BROOK IM, 1989, J ORAL MAXIL SURG, V47, P331, DOI 10.1016/0278-2391(89)90332-7
   BRUNSKI JB, 1991, BONE BIOMATERIAL INT, pCH36
   CHANG CS, 1983, J ORAL MAXIL SURG, V41, P729, DOI 10.1016/0278-2391(83)90190-8
   CHAO SY, 1987, J ORAL MAXIL SURG, V45, P359, DOI 10.1016/0278-2391(87)90361-2
   CHEUNG HS, 1993, STP PHARMA SCI, V3, P1
   DONATH K, 1987, ORAL SURG ORAL MED O, V63, P651, DOI 10.1016/0030-4220(87)90362-8
   DROBECK HP, 1986, J ORAL MAXILLOFAC SU, V44, P618
   ELDEEB M, 1988, J ORAL MAXIL SURG, V46, P758
   FRAME JW, 1987, J ORAL MAXIL SURG, V45, P771, DOI 10.1016/0278-2391(87)90200-X
   JARCHO M, 1977, J BIOENG, V1, P79
   JENSEN OT, 1985, ORAL SURG ORAL MED O, V60, P349, DOI 10.1016/0030-4220(85)90254-3
   KENT JN, 1986, J ORAL MAXIL SURG, V44, P37, DOI 10.1016/0278-2391(86)90012-1
   KENT JN, 1982, J AM DENT ASSOC, V105, P993, DOI 10.14219/jada.archive.1982.0405
   LAMBERT PM, 1986, J ORAL MAXIL SURG, V44, P329, DOI 10.1016/0278-2391(86)90086-8
   LEE DR, 1989, P 15 ANN M SOC BIOM
   LEHTINEN R, 1990, J ORAL MAXIL SURG, V48, P1075, DOI 10.1016/0278-2391(90)90292-A
   LEW D, 1986, J ORAL MAXIL SURG, V44, P516, DOI 10.1016/S0278-2391(86)80091-X
   MAROUF H A, 1990, International Journal of Oral and Maxillofacial Implants, V5, P148
   MEHLISCH DR, 1990, ORAL SURG ORAL MED O, V70, P685, DOI 10.1016/0030-4220(90)90001-9
   MERCIER P, 1992, J ORAL MAXIL SURG, V50, P210, DOI 10.1016/0278-2391(92)90314-P
   MERCIER P, 1985, ORAL SURG ORAL MED O, V60, P235, DOI 10.1016/0030-4220(85)90304-4
   MERCIER P, 1988, ORAL SURG ORAL MED O, V65, P641, DOI 10.1016/0030-4220(88)90001-1
   MERCIER P, 1988, ORAL SURG ORAL MED O, V65, P505, DOI 10.1016/0030-4220(88)90129-6
   MERCIER P, 1994, CONTROVERSIES ORAL M, pCH34
   MISIEK DJ, 1984, J ORAL MAXIL SURG, V42, P150, DOI 10.1016/S0278-2391(84)80025-7
   PAGE DG, 1987, J ORAL MAXIL SURG, V45, P356, DOI 10.1016/0278-2391(87)90360-0
   WIESE KG, 1993, INT J ORAL MAX SURG, V22, P306, DOI 10.1016/S0901-5027(05)80522-3
   WITTKAMPF ARM, 1988, J ORAL MAXIL SURG, V46, P1019, DOI 10.1016/0278-2391(88)90344-8
NR 33
TC 12
Z9 13
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0278-2391
J9 J ORAL MAXIL SURG
JI J. Oral Maxillofac. Surg.
PD AUG
PY 1996
VL 54
IS 8
BP 960
EP 968
DI 10.1016/S0278-2391(96)90392-4
PG 9
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA VC593
UT WOS:A1996VC59300008
PM 8765385
DA 2018-10-19
ER

PT J
AU Kaminski, W
   Strumillo, P
   Tomczak, E
   Zbicinski, I
AF Kaminski, W
   Strumillo, P
   Tomczak, E
   Zbicinski, I
TI Modelling of thermal degradation process dynamics of bioproducts using
   artificial neural networks
SO JOURNAL OF SYSTEMS ENGINEERING
LA English
DT Article
DE bioproduct degradation; drying; neural networks; non-linear system
   identification
AB A preliminary study aimed at applying artificial neural networks (ANN) to the modelling of thermal degradation process dynamics of labile materials is presented. Experimental data of process parameters gathered from the vibro-fluidised bed dryer was rued for network training. A feedforward ANN was trained to predict inactivation kinetics of the dried thermolabile material (saccharolytic activity was used as a biomaterial quality index). It was shown that a small-size network is capable of predicting this quality index in the limited range of drying process parameters (constant static height of the bed, fixed composition of the material).
C1 TECH UNIV LODZ,INST ELECTR,PL-90924 LODZ,POLAND.
RP Kaminski, W (reprint author), TECH UNIV LODZ,FAC PROC & ENVIRONM ENGN,WOLCZANSKA 175,PL-90924 LODZ,POLAND.
RI Strumillo, Pawel/R-5553-2017
OI Strumillo, Pawel/0000-0003-2757-9828
CR BULSARI AB, 1995, NEURAL NETWORKS CHEM, P231
   HERTZ J, 1991, INTRO THEORY NEURAL
   KAMINSKI W, 1992, CHEM ENG PROCESS, V31, P125, DOI 10.1016/0255-2701(92)85006-N
   KAREL M, 1992, DRYING 92 A, P3
   Kerkhof P. J. A. M., 1974, ADV PRECONCENTRATION, P349
   MORRIS AJ, 1994, T ICHEME A, V72, P3
   Narendra K S, 1990, IEEE Trans Neural Netw, V1, P4, DOI 10.1109/72.80202
   QIN SZ, 1992, IEEE T NEURAL NETWOR, V3, P122, DOI 10.1109/72.105425
   STRUMILLO C, 1995, BIOCH ENG J, V58, P197
NR 9
TC 4
Z9 4
U1 0
U2 2
PU SPRINGER-VERLAG LONDON LTD
PI GODALMING
PA SWEETAPPLE HOUSE CATTESHALL ROAD, GODALMING, SURREY, ENGLAND GU7 3DJ
SN 0938-7706
J9 J SYST ENG
JI J. Syst. Eng.
PD AUG
PY 1996
VL 6
IS 3
BP 159
EP 165
PG 7
WC Operations Research & Management Science
SC Operations Research & Management Science
GA UP381
UT WOS:A1996UP38100005
DA 2018-10-19
ER

PT J
AU Zhou, BL
AF Zhou, BL
TI Some progress in the biomimetic study of composite materials
SO MATERIALS CHEMISTRY AND PHYSICS
LA English
DT Article
DE composites; biomimetic design and processing; fractal-tree structure;
   crack healing
ID FIBERS
AB Some progress in the biomimetic design and processing of composite materials has been achieved on the basis of biomimetic analyses. The excellent structures and characteristics of biomaterials, such as adapting to stress conditions by form modulation, compensating for lacking material by composite structures, and healing injuries by material and energy supplements, are analyzed. Some examples of biomimetic design and processing are further illustrated: multilayer coating simulating the fine structure of plant fibers; dumbbell-like whiskers imitating animal bone; fractal-tree reinforcement by mimicry of branched roots in soil; biomaterial reinforcement and its modification; and fatigue-crack healing and lifetime prolongation of materials. The methodology of biomimetic study is described briefly in the last part of this paper.
C1 ACAD SINICA,INT CTR MAT PHYS,SHENYANG 110015,PEOPLES R CHINA.
RP Zhou, BL (reprint author), ACAD SINICA,INST MET RES,72 WENHUA RD,SHENYANG 110015,PEOPLES R CHINA.
CR FU SY, 1993, SCRIPTA METALL MATER, V29, P1541, DOI 10.1016/0956-716X(93)90274-V
   FUNG YC, 1983, BIOMECHANICS, P246
   Fut S. Y., 1992, SMART MATER STRUCT, V1, P180
   Gerard JT, 1978, LIFE SCI, P313
   GUO Y, 1991, CHIN J MET SCI TECHN, V7, P353
   JIA X, 1994, 94 FALL S CHIN MAT R
   LI SH, 1994, 94 FALL S CHIN MAT R
   LI SH, 1994, J MATER SCI TECHNOL, V10, P355
   LI SH, 1992, 6 INT WORKSH MAT PHY
   MA HZ, 1986, INTRO BIOMECHANICS, P133
   Tian Xiaobin, 1994, Acta Metallurgica Sinica, V30, pB180
   WAI NN, 1985, WOOD SCI TECHNOL, V19, P211, DOI 10.1007/BF00392050
   WANG YO, 1994, J MATER SCI LETT, V13, P245, DOI 10.1007/BF00571764
   XIAO YL, 1994, 94 FALL S CHIN MAT R
   Zeng Q, 1992, P 1 PAC RIM INT C AD, P943
   ZENG QY, 1994, SCI SILVAE SIN, V30, P253
   Zhao Xiaopeng, 1994, Acta Metallurgica Sinica, V30, pB187
   Zhou B., 1993, J MATER SCI TECHNOL, V9, P9
   ZHOU BL, 1994, JOM, V2, P57
   ZHOU BL, 1991, C MRS INT 90, P137
NR 20
TC 21
Z9 27
U1 0
U2 16
PU ELSEVIER SCIENCE SA LAUSANNE
PI LAUSANNE 1
PA PO BOX 564, 1001 LAUSANNE 1, SWITZERLAND
SN 0254-0584
J9 MATER CHEM PHYS
JI Mater. Chem. Phys.
PD AUG
PY 1996
VL 45
IS 2
BP 114
EP 119
DI 10.1016/0254-0584(96)80087-3
PG 6
WC Materials Science, Multidisciplinary
SC Materials Science
GA UY279
UT WOS:A1996UY27900004
DA 2018-10-19
ER

PT J
AU Carenza, M
   Lora, S
   Palma, G
   Pezzin, G
   Caliceti, P
AF Carenza, M
   Lora, S
   Palma, G
   Pezzin, G
   Caliceti, P
TI Enhanced biocompatibility of polyphosphazenes achieved by radiation
   grafting
SO RADIATION PHYSICS AND CHEMISTRY
LA English
DT Article
ID POLY(VINYL CHLORIDE) SHEETS; NATURAL-RUBBER TUBES; HYDROPHILIC MONOMERS;
   2-HYDROXYETHYL METHACRYLATE; BIOMATERIAL APPLICATIONS; BIOMEDICAL
   APPLICATIONS; MECHANICAL-PROPERTIES; N-VINYLPYRROLIDONE;
   SILICONE-RUBBER; FILMS
AB This paper reviews the work recently carried out in the authors' laboratory on the radiation graft copolymerization of hydrophilic monomers onto polyphosphazenes. Kinetics of grafting by the mutual irradiation method at room temperature of monomer-solvent mixtures were followed. Hydrophilicity, structure, mechanical properties, biocompatibility and anticoagulating properties of the modified samples were reported. Some experiments on the grafted polymer, to which heparin was ionically bonded with a high yield, were also carried out. Copyright (C) 1996 Elsevier Science Ltd.
C1 UNIV PADUA,DIPARTIMENTO CHIM FIS,I-35131 PADUA,ITALY.
   UNIV PADUA,DIPARTIMENTO SCI FARMACEUT,CTR STUDIO CHIM FARMACO & PROD BIOL ATTIVI,CNR,I-35131 PADUA,ITALY.
RP Carenza, M (reprint author), CNR,IST FOTOCHIM & RADIAZ ALTA ENERGIA,I-35020 LEGNANO,ITALY.
CR ALLCOCK HR, 1990, BIODEGRADABLE POLYM, P163
   BAMFORD CH, 1987, PLAST RUBBER PROCESS, V7, P155
   CARENZA M, 1994, PHYS MEDICA, V10, P36
   CARENZA M, 1992, RADIAT PHYS CHEM, V39, P485
   CHAPIRO A, 1983, EUR POLYM J, V19, P1117, DOI 10.1016/0014-3057(83)90006-X
   CHAPIRO A, 1980, RADIAT PHYS CHEM, V15, P423, DOI 10.1016/0146-5724(80)90163-6
   COHN D, 1984, J APPL POLYM SCI, V29, P2645, DOI 10.1002/app.1984.070290819
   COHN D, 1987, J APPL POLYM SCI, V33, P1, DOI 10.1002/app.1987.070330101
   CROMMEN J, 1993, J CONTROL RELEASE, V24, P167, DOI 10.1016/0168-3659(93)90176-6
   DWORJANYN PA, 1992, RAD PROCESSING POLYM, P93
   FAUCITANO A, 1991, RADIAT PHYS CHEM, V37, P573
   GOEDEMOED JH, 1990, POLYPHOSPHOZENES DRU, P9
   GUPTA BD, 1990, J MACROMOL SCI CHEM, VA27, P831, DOI 10.1080/10601329008544808
   HA HF, 1985, RADIAT PHYS CHEM, V25, P501
   HOFFMAN AS, 1984, ADV POLYM SCI, V57, P141
   JANSEN B, 1984, J BIOMED MATER RES, V18, P655, DOI 10.1002/jbm.820180607
   JANSEN B, 1985, J BIOMED MATER RES, V19, P1085, DOI 10.1002/jbm.820190918
   Jansen B, 1987, J Biomater Appl, V1, P502
   KABANOV VY, 1991, RADIAT PHYS CHEM, V37, P175
   KRISHNAN VK, 1990, J MATER SCI-MATER M, V1, P185, DOI 10.1007/BF00701075
   KRISHNAN VK, 1991, J MATER SCI-MATER M, V2, P56, DOI 10.1007/BF00701688
   KRUL LP, 1990, RUSS CHEM REV, V59, P469
   LAURENCIN CT, 1993, J BIOMED MATER RES, V27, P963, DOI 10.1002/jbm.820270716
   LORA S, 1994, BIOMATERIALS, V15, P937, DOI 10.1016/0142-9612(94)90121-X
   LORA S, 1990, RADIAT PHYS CHEM, V35, P117
   LORA S, 1991, BIOMATERIALS, V12, P275, DOI 10.1016/0142-9612(91)90034-8
   LORA S, 1988, RADIAT PHYS CHEM, V31, P629
   LORA S, 1987, Patent No. 19435
   PEZZIN G, 1991, CHEM IND MILAN, V73, P185
   POTIN P, 1991, EUR POLYM J, V27, P341, DOI 10.1016/0014-3057(91)90185-Q
   RATNER BD, 1974, J APPL POLYM SCI, V18, P3183, DOI 10.1002/app.1974.070181101
   RATNER BD, 1993, J BIOMAT SCI-POLYM E, V4, P155, DOI 10.1163/156856293X00492
   RAZZAK MT, 1988, J APPL POLYM SCI, V36, P645, DOI 10.1002/app.1988.070360315
   RAZZAK MT, 1993, RADIAT PHYS CHEM, V42, P57, DOI 10.1016/0969-806X(93)90202-6
   RAZZAK MT, 1989, J APPL POLYM SCI, V38, P829, DOI 10.1002/app.1989.070380506
   SINGH J, 1990, BIOMATERIALS, V11, P473, DOI 10.1016/0142-9612(90)90060-4
   STANNETT VT, 1990, RADIAT PHYS CHEM, V35, P82
   SUN YH, 1986, J BIOACT COMPAT POL, V1, P316
NR 38
TC 16
Z9 16
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
J9 RADIAT PHYS CHEM
JI Radiat. Phys. Chem.
PD AUG
PY 1996
VL 48
IS 2
BP 231
EP 236
DI 10.1016/0969-806X(95)00421-S
PG 6
WC Chemistry, Physical; Nuclear Science & Technology; Physics, Atomic,
   Molecular & Chemical
SC Chemistry; Nuclear Science & Technology; Physics
GA VA385
UT WOS:A1996VA38500009
DA 2018-10-19
ER

PT J
AU Ciapetti, G
   Granchi, D
   Verri, E
   Savarino, L
   Cavedagna, D
   Pizzoferrato, A
AF Ciapetti, G
   Granchi, D
   Verri, E
   Savarino, L
   Cavedagna, D
   Pizzoferrato, A
TI Application of a combination of neutral red and amido black staining for
   rapid, reliable cytotoxicity testing of biomaterials
SO BIOMATERIALS
LA English
DT Article
DE cells; viability; neutral red; amido black; cytotoxicity
ID COLORIMETRIC ASSAY; CELL; BIOCOMPATIBILITY; GROWTH; MTT
AB Cell viability and growth for cytotoxicity evaluation of materials for prosthetic devices has been tested using Various methods. The aim of this study was to extend the choice of reliable methods to quantify cytotoxicity of materials in vitro. By measuring both viability and growth of cells exposed to biomaterials in vitro, two different parameters are analysed and quantified upon reading of the absorbance of coloured solutions in a spectrophotometer. Neutral red uptake and amido black staining of cells have been used for cell viability and cell number measurement, respectively: they have been found to be well correlated with the number of surviving cells. These methods have been adjusted to a 96-well microplate cell culture system and re-evaluated as simple and reliable methods for the quantitative assessment of biomaterial effect on cells. Copyright (C) 1996 Elsevier Science Limited
RP Ciapetti, G (reprint author), IST ORTOPED RIZZOLI,LAB BIOCOMPATIBIL RES IMPLANT MAT,VIA BARBIANO 1-10,I-40136 BOLOGNA,ITALY.
RI Granchi, Donatella/J-3647-2016
OI Granchi, Donatella/0000-0001-7225-0023; Ciapetti,
   Gabriela/0000-0001-6740-0357; savarino, lucia/0000-0002-3177-3546
CR Allen Matthew, 1994, Clinical Materials, V16, P189, DOI 10.1016/0267-6605(94)90116-3
   [Anonymous], 1992, 10993 ISO
   BUMGARDNER JD, 1994, J APPL BIOMATER, V5, P203, DOI 10.1002/jab.770050305
   CIAPETTI G, 1993, BIOMATERIALS, V14, P359, DOI 10.1016/0142-9612(93)90055-7
   EVANS EJ, 1994, BIOMATERIALS, V15, P713, DOI 10.1016/0142-9612(94)90170-8
   EVERITT E, 1987, ANAL BIOCHEM, V162, P122, DOI 10.1016/0003-2697(87)90016-9
   FINTER NB, 1969, J GEN VIROL, V5, P419, DOI 10.1099/0022-1317-5-3-419
   HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   *NORM EXP ASS FRAN, 1988, 90702 S AFNOR NORM E
   PAPATHEOFANIS FJ, 1991, J BIOMED MATER RES, V25, P761, DOI 10.1002/jbm.820250606
   PATEL BCM, 1991, BIOMATERIALS, V12, P722, DOI 10.1016/0142-9612(91)90019-7
   SCHMALZ G, 1990, J MATER SCI-MATER M, V1, P228, DOI 10.1007/BF00701081
   SCHULZ J, 1994, J IMMUNOL METHODS, V167, P1, DOI 10.1016/0022-1759(94)90069-8
   SGOURAS D, 1990, J MATER SCI-MATER M, V1, P61, DOI 10.1007/BF00839070
   VANSLIEDREGT A, 1994, BIOMATERIALS, V15, P251, DOI 10.1016/0142-9612(94)90047-7
   WAN H, 1994, J MATER SCI-MATER M, V5, P154, DOI 10.1007/BF00053336
   WATAHA JC, 1994, J BIOMED MATER RES, V28, P427, DOI 10.1002/jbm.820280404
   WENNBERG A, 1983, J BIOMED MATER RES, V17, P23, DOI 10.1002/jbm.820170103
NR 20
TC 76
Z9 79
U1 1
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD JUL
PY 1996
VL 17
IS 13
BP 1259
EP 1264
DI 10.1016/0142-9612(96)88670-4
PG 6
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA UT734
UT WOS:A1996UT73400001
PM 8805972
DA 2018-10-19
ER

PT J
AU Bellon, JM
   Bujan, J
   Contreras, LA
   CarrerasSanMartin, A
   Hernando, A
   Jurado, F
AF Bellon, JM
   Bujan, J
   Contreras, LA
   CarrerasSanMartin, A
   Hernando, A
   Jurado, F
TI Improvement of the tissue integration of a new modified
   polytetrafluoroethylene prosthesis: Mycro Mesh(R)
SO BIOMATERIALS
LA English
DT Article
DE prosthetic patch; PTFE; abdominal wall defects; macrophages; abdominal
   wall repair
ID ABDOMINAL-WALL DEFECTS; EXPANDED POLYTETRAFLUOROETHYLENE; POLYPROPYLENE
   MESH; HERNIA REPAIR; GROWTH-FACTOR; MARLEX MESH; PATCH; MACROPHAGE; RAT
AB We studied the behaviour of the different tissue interfaces formed on a new type of prosthesis used for the repair of abdominal wall defects, Mycro Mesh(R) (W. L. Gore and Ass., Flagstaff, AZ, USA), which consists of perforated layers of polytetrafluoroethylene (PTFE). In 20 New Zealand white rabbits, a full-thickness (except skin) 7 cm x 5 cm defect was created in the anterior abdominal wall. The defects were repaired with a prosthetic implant (Mycro Mesh(R)) that was placed in direct contact with abdominal viscera and subcutaneous tissue. At 14, 30, 60 and 90 d post-implantation, samples were obtained from the tissue interfaces formed between the prosthesis and subcutaneous tissue, visceral peritoneum and receptor tissue, respectively. Samples were studied by optical microscopy and scanning electron microscopy. The immunohistological study was made with RAM-11, a monoclonal antibody specific for rabbit macrophages. Tensile strength was measured with an Instron tensiometer using 2 cm wide strips obtained parallel to the shorter axis of the implant. Strips included the prosthesis and two anchor zones on the receptor tissue. Macroscopically, the prosthesis induced little adhesion formation on the Visceral peritoneum interface. Microscopically, an organized neoperitoneum and abundant tissue formed on the subcutaneous interface. In the prosthesis perforations, bridges of tissue linked the peritoneal and subcutaneous sides. The macrophage response decreased significantly in intensity between day 14 and day 90 (Student-Newman-Keuls test, P = 0.01). Tensile strength increased significantly (Wilcoxon test, P < 0.05) at every study period. To conclude: the Mycro Mesh(R) prosthesis proved suitable for implantation in sites where it comes in contact with abdominal viscera and it provided good support for the formation of an organized neoperitoneum; the perforations in the prosthetic material improved implant integration; the macrophage response was not altered by the biomaterial and the tensile strength of the prosthesis increased as scar tissue formation and tissular integration of the prosthesis progressed. Copyright (C) 1996 Elsevier Science Limited
RP Bellon, JM (reprint author), UNIV ALCALA DE HENARES, DEPT MORPHOL SCI & SURG, SURG RES LAB, E-28871 MADRID, SPAIN.
RI Hernando, Antonio/E-2105-2015
OI Hernando, Antonio/0000-0001-7856-3768; BELLON, JUAN
   M./0000-0002-6071-5011; bujan, Julia/0000-0003-2419-2476
CR AMID PK, 1994, J BIOMED MATER RES, V28, P373, DOI 10.1002/jbm.820280312
   AMID PK, 1993, AM J SURG, V165, P369, DOI 10.1016/S0002-9610(05)80847-5
   BELLON JM, 1995, BIOMATERIALS, V16, P381, DOI 10.1016/0142-9612(95)98855-8
   BELLON JM, 1994, EUR SURG RES, V26, P46, DOI 10.1159/000129317
   BELLON JM, 1995, BRIT J SURG, V82, P69
   BERLINER SD, 1993, SURG GYNECOL OBSTET, V176, P323
   BJURSTEN LM, 1991, 9 EUR C BIOM CHEST U, P39
   BLEICHRODT RP, 1993, SURG GYNECOL OBSTET, V176, P18
   BROWDER W, 1988, SURGERY, V104, P224
   BROWN GL, 1985, ANN SURG, V201, P705, DOI 10.1097/00000658-198506000-00006
   CAPOZZI JA, 1988, SURG GYNECOL OBSTET, V167, P124
   DABROWIECKI S, 1991, EUR SURG RES, V23, P240, DOI 10.1159/000129159
   ELLIOTT MP, 1979, AM J SURG, V137, P342, DOI 10.1016/0002-9610(79)90063-1
   Gilbert AI, 1991, PERSPECT GEN SURG, V2, P113
   JENKINS SD, 1983, SURGERY, V94, P392
   LAW NW, 1991, SURGERY, V109, P652
   LAW NW, 1990, ACTA CHIR SCAND, V156, P759
   Law NW, 1988, CLIN MATER, V3, P95
   LEBLANC KA, 1994, INGUINAL HERNIA ADV, P501
   LEIBOVICH SJ, 1975, AM J PATHOL, V78, P71
   LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0
   MOLLOY RG, 1991, BRIT J SURG, V78, P242, DOI 10.1002/bjs.1800780237
   MURPHY JL, 1989, CAN J SURG, V32, P244
   MUSTOE TA, 1987, SCIENCE, V237, P1333, DOI 10.1126/science.2442813
   ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6
   SIMMERMACHER RJK, 1989, 2 S EXP OND HEELK SP
   SIMMERMACHER RKJ, 1991, BIOMATERIALS, V12, P22, DOI 10.1016/0142-9612(91)90126-U
   TYRELL J, 1989, SURG GYNECOL OBSTET, V168, P227
   WALKER AP, 1993, J SURG RES, V55, P32, DOI 10.1006/jsre.1993.1104
NR 29
TC 18
Z9 18
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD JUL
PY 1996
VL 17
IS 13
BP 1265
EP 1271
DI 10.1016/0142-9612(96)88671-6
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA UT734
UT WOS:A1996UT73400002
PM 8805973
DA 2018-10-19
ER

PT J
AU Braye, F
   Irigaray, JL
   Jallot, E
   Oudadesse, H
   Weber, G
   Deschamps, N
   Deschamps, C
   Frayssinet, P
   Tourenne, P
   Tixier, H
   Terver, S
   Lefaivre, J
   Amirabadi, A
AF Braye, F
   Irigaray, JL
   Jallot, E
   Oudadesse, H
   Weber, G
   Deschamps, N
   Deschamps, C
   Frayssinet, P
   Tourenne, P
   Tixier, H
   Terver, S
   Lefaivre, J
   Amirabadi, A
TI Resorption kinetics of osseous substitute: Natural coral and synthetic
   hydroxyapatite
SO BIOMATERIALS
LA English
DT Article
DE bone substitutes; interface; biomaterial resorption; coral;
   hydroxyapatite
AB Coral and hydroxyapatite may be used as substitution biomaterials for bone grafts. In this work, we extracted the implants from the femora to study the kinetics of elementary mineral transformation of the osseous substitutes. The use of physical analysis methods such as PIXE (particle-induced X-ray emission) shows that coral and hydroxyapatite, after their implantation in vivo, reach a mineral composition comparable with that of bone. For the first time we have measured the concentration of mineral elements, at different time intervals after implantation, along a cross-section. The distribution according to mineral elements (Ca, P, Sr, Zn, Fe) in the implant, in the receiver site and also at the interface, showed that the kinetics of coral resorption was faster than that of hydroxyapatite; in the same way, the osseous attack was not global but, rather, centripetal. (C) 1996 Elsevier Science Limited
C1 UNIV CLERMONT FERRAND,F-63177 CLERMONT FERRAN,FRANCE.
   INST PHYS NUCL EXPT,B-4000 LIEGE,BELGIUM.
   LAB PIERRE SUE,F-91190 GIF SUR YVETTE,FRANCE.
   SOC IND BIOLAND,F-31100 TOULOUSE,FRANCE.
   SERV PROFESSEUR TERVER,F-63000 CLERMONT FERRAN,FRANCE.
   INRA,F-63122 ST GENES CHAMPANE,FRANCE.
   ATOM ENERGY ORG IRAN,TEHRAN,IRAN.
RP Braye, F (reprint author), CNRS,IN2P3,LAB PHYS CORPUSCULAIRE CLERMONT FERRAND,F-63177 CLERMONT FERRAN,FRANCE.
CR BRAITTER P, 1977, J RADIOANAL CHEM, V37, P393
   BRAYE F, 1994, THESIS U BLAISEPASCA
   GUILLEMIN G, 1987, J BIOMED MATER RES, V21, P557, DOI 10.1002/jbm.820210503
NR 3
TC 49
Z9 57
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD JUL
PY 1996
VL 17
IS 13
BP 1345
EP 1350
DI 10.1016/0142-9612(96)88682-0
PG 6
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA UT734
UT WOS:A1996UT73400013
PM 8805984
DA 2018-10-19
ER

PT J
AU Tomczok, J
   SliwaTomczok, W
   Klein, CL
   vanKooten, TG
   Kirkpatrick, CJ
AF Tomczok, J
   SliwaTomczok, W
   Klein, CL
   vanKooten, TG
   Kirkpatrick, CJ
TI Biomaterial-induced alterations of human neutrophils under fluid shear
   stress: Scanning electron microscopical study in vitro
SO BIOMATERIALS
LA English
DT Article
DE neutrophil-biomaterial interactions; neutrophils; shear stress; flow
   chamber; scanning electron microscope
ID FOREIGN-BODY INFECTION; POLYMORPHONUCLEAR LEUKOCYTES; ACTIN
   POLYMERIZATION; HUMAN FIBROBLASTS; ENDOTHELIAL-CELL; FEP-TEFLON;
   ADHESION; SURFACES; PROTEIN; ATTACHMENT
AB Morphological changes of human polymorphonuclear neutrophils (PMN) adhering to hydrophilic (glass) and hydrophobic (FEP-Teflon, polyethylene, polypropylene) surfaces were studied in a parallel-plate flow chamber at the light and scanning electron microscopical levels. The PMN were exposed to a shear stress of 0.19 Pa (1.9 dynes cm(-2)) or were allowed to adhere without the stress component (static control) during 30 min for all four biomaterials. Observation by light microscopy was performed in situ in the flow chamber at 1, 5, 10, 15, 20, 25 and 30 min. The total number of adherent cells as a function of time and the activation status of the population on the basis of morphological criteria were determined. On the hydrophilic material adhesion of activated PMN was significantly higher (P < 0.05) than on the more hydrophobic surfaces. This effect was most pronounced for the adhesion of neutrophils to glass and polypropylene (PP). Polyethylene (PE) showed only minor adhesion rates. Scanning electron microscopy revealed details of cell shape changes and permitted a more precise classification of populations of neutrophils based on distinctive shapes. As PMN were exposed to shear stress on glass, the majority of cells exhibited surface veils, ridges and ruffles, suggesting a high level of cell migration. In this case, on polymeric surfaces the presence of filopodial networks (FEP-Teflon) and ameoboid cell shapes (PP and PE) was noted. The results suggest that a low shear stress, as well as various chemical and physical properties of biomaterial surfaces, are together responsible for differentiation of PMN populations on solid substrata. (C) 1996 Elsevier Science Limited
C1 UNIV MAINZ,INST PATHOL,D-55101 MAINZ,GERMANY.
CR ABSOLOM DR, 1988, J BIOMED MATER RES, V22, P215, DOI 10.1002/jbm.820220306
   BLAAUW EH, 1989, BIOMATERIALS, V10, P356, DOI 10.1016/0142-9612(89)90079-3
   CASTNER DG, 1992, REFERENCE MATERIALS OF THE EUROPEAN COMMUNITIES, P3
   COZENSROBERTS C, 1990, BIOPHYS J, V58, P841, DOI 10.1016/S0006-3495(90)82430-9
   CURTIS ASG, 1983, J CELL BIOL, V97, P1500, DOI 10.1083/jcb.97.5.1500
   DOOLEY DC, 1982, EXP HEMATOL, V10, P591
   FEHR J, 1985, J CLIN INVEST, V76, P535, DOI 10.1172/JCI112003
   GINGELL D, 1992, J CELL SCI, V100, P255
   Goodman S L, 1989, Scanning Microsc Suppl, V3, P285
   HAKKINEN L, 1988, J BIOMED MATER RES, V22, P1043, DOI 10.1002/jbm.820221108
   JESAITIS AJ, 1988, J CELL BIOL, V107, P921, DOI 10.1083/jcb.107.3.921
   KAPLAN SS, 1992, J BIOMED MATER RES, V26, P1039, DOI 10.1002/jbm.820260806
   KLEIN CL, 1994, COLLOID SURFACE B, V3, P229
   KUCIK DF, 1991, J CELL BIOL, V114, P1029, DOI 10.1083/jcb.114.5.1029
   LEE J, 1990, SCIENCE, V247, P1229, DOI 10.1126/science.2315695
   MASSIA SP, 1991, J CELL BIOL, V114, P1089, DOI 10.1083/jcb.114.5.1089
   MASSIA SP, 1991, J BIOMED MATER RES, V25, P223, DOI 10.1002/jbm.820250209
   MORLEY DJ, 1989, THROMB HAEMOSTASIS, V62, P1023
   NOLLERT MU, 1990, BIOCHEM BIOPH RES CO, V170, P281, DOI 10.1016/0006-291X(90)91271-S
   OMANN GM, 1989, J BIOL CHEM, V264, P16355
   RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8
   RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7
   ROOS D, 1970, BIOCHIM BIOPHYS ACTA, V222, P565, DOI 10.1016/0304-4165(70)90182-0
   SARNDAHL E, 1989, J CELL BIOL, V109, P2791, DOI 10.1083/jcb.109.6.2791
   SCHAKENRAAD JM, 1991, CELL MATER, V1, P35
   SCHAKENRAAD JM, 1986, BIOL BIOMECHANICAL P, P263
   SHANBHAG A, 1992, J BIOMED MATER RES, V26, P185, DOI 10.1002/jbm.820260205
   SOUTHWICK FS, 1990, J CELL BIOL, V110, P1965, DOI 10.1083/jcb.110.6.1965
   SOUTHWICK FS, 1989, J CELL BIOL, V109, P1561, DOI 10.1083/jcb.109.4.1561
   VANKOOTEN TG, 1992, BIOMATERIALS, V13, P897, DOI 10.1016/0142-9612(92)90112-2
   VANKOOTEN TG, 1991, CELL MATER, V1, P307
   VANKOOTEN TG, 1993, CELLULAR ADHESION DE, P101
   WILLIAMS SK, 1990, SCANNING MICROSCOPY, V4, P181
   YANG J, 1992, J BIOMED MATER RES, V26, P1217, DOI 10.1002/jbm.820260911
   ZIMMERLI W, 1984, J CLIN INVEST, V73, P1191, DOI 10.1172/JCI111305
   ZIMMERLI W, 1982, J INFECT DIS, V146, P487, DOI 10.1093/infdis/146.4.487
NR 36
TC 18
Z9 19
U1 1
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD JUL
PY 1996
VL 17
IS 14
BP 1359
EP 1367
DI 10.1016/0142-9612(96)87275-9
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA UW737
UT WOS:A1996UW73700001
PM 8830960
DA 2018-10-19
ER

PT J
AU Bellon, JM
   Contreras, LA
   Bujan, J
   Jurado, F
AF Bellon, JM
   Contreras, LA
   Bujan, J
   Jurado, F
TI Effect of phosphatidylcholine on the process of peritoneal adhesion
   following implantation of a polypropylene mesh prosthesis
SO BIOMATERIALS
LA English
DT Article
DE phosphatidylcholine; adhesion; polypropylene mesh; implants
ID EXPANDED POLYTETRAFLUOROETHYLENE PATCH; ABDOMINAL-WALL DEFECTS; REPAIR;
   MACROPHAGE; CELLS; RAT
AB The postimplantation peritoneal adhesions formed with some biomaterials continue to represent a serious problem when these biomaterials are placed in contact with the organs of the abdominal cavity. The objective was to test the effects of phosphatidylcholine (PC) in the attempt to modulate the adhesive process, thus improving the biomaterial/visceral peritoneum interface. We have carried out an experimental study using the New Zealand white rabbit, implanting a 7 x 5 cm(2) polypropylene prosthesis into the anterior abdominal wall in such a way that it replaced all the tissue layers and was in contact with the intestinal loops. Three study groups were established: group I (control), in which only implantation of the biomaterial was performed; group II, in which the prosthesis was pretreated with a solution of PC; and group III, in which the implants were treated as in group II and the animals underwent intraperitoneal administration of 10 ml of the same solution. The animals were killed on postimplantation day 14. The total surface of the prosthesis occupied by adhesions was measured and light and scanning electron microscopy were performed to analyse the healing process. In comparison with the controls, groups II and III did not present significant differences with respect to the resistance or extension of the adhesions. The microscopic results showed a rapid formation of disorderly and well-vascularised scar tissue enveloping the entire prosthesis. Thus, PC was unable to modulate the process of adhesion formation between the prosthesis and the organs of the abdominal cavity; nor did it induce changes in the cells of sufficient importance to alter the results of the healing process in the presence of this biomaterial. (C) 1996 Elsevier Science Limited
RP Bellon, JM (reprint author), UNIV ALCALA DE HENARES, DEPT MORPHOL SCI & SURG, SURG RES LAB, E-28871 ALCALA DE HENARES, MADRID, SPAIN.
OI bujan, Julia/0000-0003-2419-2476; BELLON, JUAN M./0000-0002-6071-5011
CR ARRAJAB A, 1991, J SURG RES, V50, P212, DOI 10.1016/0022-4804(91)90180-T
   BELLON JM, 1995, BIOMATERIALS, V16, P381, DOI 10.1016/0142-9612(95)98855-8
   BELLON JM, 1994, EUR SURG RES, V26, P46, DOI 10.1159/000129317
   BELLON JM, 1995, BRIT J SURG, V82, P69
   BLEICHRODT RP, 1993, SURG GYNECOL OBSTET, V176, P18
   BREBOROWICZ A, 1993, NEPHRON, V63, P15, DOI 10.1159/000187138
   ESKELAND GUNNAR, 1963, ACTA CHIR SCAND, V125, P91
   GAGNON RF, 1990, NEPHRON, V56, P201, DOI 10.1159/000186133
   GRAHAME GR, 1985, PERITON DIALYSIS B, V5, P109
   HEMADEH O, 1993, SURGERY, V114, P907
   JAMES DCO, 1965, J PATHOL BACTERIOL, V90, P279, DOI 10.1002/path.1700900132
   JENKINS SD, 1983, SURGERY, V94, P392
   LAW NW, 1991, SURGERY, V109, P652
   LAW NW, 1990, ACTA CHIR SCAND, V156, P759
   LEIBOVICH SJ, 1975, AM J PATHOL, V78, P71
   MILLIGAN DW, 1974, BRIT J SURG, V61, P274, DOI 10.1002/bjs.1800610406
   MYHREJENSEN O, 1969, ARCH PATHOL, V88, P623
   ROZGA J, 1990, NEPHRON, V54, P134, DOI 10.1159/000185833
   SNOJ M, 1992, BRIT J SURG, V79, P427, DOI 10.1002/bjs.1800790518
NR 19
TC 24
Z9 24
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD JUL
PY 1996
VL 17
IS 14
BP 1369
EP 1372
DI 10.1016/0142-9612(96)87276-0
PG 4
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA UW737
UT WOS:A1996UW73700002
PM 8830961
DA 2018-10-19
ER

EF